PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	RP	EM	RI	OI	FU	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	D2	EA	PG	WC	SC	GA	UT	PM	OA	HC	HP	DA
J	Xu, HH; Bratton, L; Nead, M; Russell, D; Zhou, ZR				Xu, Huihong; Bratton, Laura; Nead, Michael; Russell, Donna; Zhou, Zhongren			Comparison of programmed death-ligand 1 (PD-L1) immunostain for nonsmall cell lung carcinoma between paired cytological and surgical specimens	CYTOJOURNAL			English	Article						Cytological samples; lung adenocarcinoma; lung squamous cell carcinoma; paired surgical samples; programmed death-ligand 1 expression; PD-L1; PD-1	WUCHERERIA-BANCROFTI; MICROFILARIAE; URINE	Background: programmed death-ligand 1 (PD-L1) is a ligand for the inhibitory programmed cell death protein 1 (PD-L1), which are targeted by several anti-PD-1 and PD-L1 drugs for lung cancer treatment. In clinical practice, many lung cancer cases only have cytology samples available to test PD-L1. Our current study compared the PD-L1 immunohistochemistry (IHC) between paired cytological and surgical samples. Materials and Methods: Formalin-fixed lung cancer tissue microarray and paired cell blocks and surgical specimens from the same patients with a confirmed diagnosis of lung squamous cell carcinoma (SCC, n = 29) and adenocarcinoma (AC, n = 23) were sectioned for PD-L1 IHC. Results: PD-L1 was expressed on tumor cells in 16 of 29 (55%) SCC surgical specimens and 18 of 29 (62%) paired cytologic specimens with 83% matched immunostains. PD-L1 was expressed on tumor cells in 13 of 23 (57%) AC surgical specimens and in 17 of 23 (74%) paired cytologic specimens with 79% matched immunostains. The PD-L1 was expressed on inflammatory cells in 20 of 23 (87%) AC surgical specimens and in 15 of 23 (65%) paired cytologic specimens with 70% matched immunostains. The PD-L1 was expressed on inflammatory cells in 18 of 29 (62%) SCC surgical specimens and in 12 of 29 (41%) paired cytologic specimens with 79% matched immunostains. Conclusions: PD-L1 immunostain in cytology samples matched very well with paired surgical samples in both SCC and AC cases. The cytologic samples present slightly higher sensitivity for PD-L1 immunostain on tumor cells as compared to surgical biopsies.	[Xu, Huihong] VA Boston Healthcare Syst, Dept Pathol, Boston, MA USA; [Bratton, Laura; Russell, Donna] Univ Rochester, Med Ctr, Dept Pathol & Lab Med, Rochester, NY 14642 USA; [Nead, Michael] Univ Rochester, Med Ctr, Dept Med, Div Pulm Dis, Rochester, NY 14642 USA; [Zhou, Zhongren] Washington Univ, Dept Pathol & Immunol, St Louis, MO 63130 USA	Zhou, ZR (reprint author), Washington Univ, Dept Pathol & Immunol, St Louis, MO 63130 USA.	xuhh01@hotmail.com; lebratton1@gmail.com; michael_nead@urmc.rochester.edu; donna_mulford@urmc.rochester.edu; zzhouli7@hotmail.com					Ahuja A, 2012, J CYTOL, V29, P147, DOI 10.4103/0970-9371.97163; Devasia A, 1998, J UROLOGY, V159, P1637, DOI 10.1097/00005392-199805000-00062; Gourlay WA, 1999, J UROLOGY, V161, P603, DOI 10.1016/S0022-5347(01)61963-3; Jain S, 2015, J CYTOL, V32, P124, DOI 10.4103/0970-9371.160569; Roy Indranil, 2004, Nepal Med Coll J, V6, P64; Vankalakunti M, 2008, ACTA CYTOL, V52, P639, DOI 10.1159/000325614; Verma R, 2011, DIAGN CYTOPATHOL, V39, P847, DOI 10.1002/dc.21562; WEBBER CA, 1982, ACTA CYTOL, V26, P837	8	2	2	0	2	WOLTERS KLUWER MEDKNOW PUBLICATIONS	MUMBAI	WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA	0974-5963	1742-6413		CYTOJOURNAL	CytoJournal	DEC 24	2018	15								29	10.4103/cytojournal.cytojournal_2_18			12	Pathology	Pathology	HI1AQ	WOS:000456176500001	30662515	DOAJ Gold, Green Published			2019-10-28	
J	Abbaszadegan, MR; Moghbeli, M				Abbaszadegan, Mohammad Reza; Moghbeli, Meysam			Genetic and molecular origins of colorectal Cancer among the Iranians: an update	DIAGNOSTIC PATHOLOGY			English	Review						Colorectal Cancer; Marker; Diagnosis; Iran; Genetic	EPITHELIAL-MESENCHYMAL TRANSITION; GLUTATHIONE-S-TRANSFERASE; GROWTH-FACTOR RECEPTOR; NITRIC-OXIDE; MICROSATELLITE INSTABILITY; CLINICOPATHOLOGICAL FEATURES; DIFFERENTIAL EXPRESSION; OXIDATIVE STRESS; PROGNOSTIC VALUE; REGULATORY ROLE	BackgroundColorectal cancer (CRC) is one the leading causes of cancer related deaths among Iranians. Despite the various progresses in new therapeutic methods, it has still a low rate of survival. This high ratio of mortality is mainly related to the late diagnosis, in which the patients refer for treatment in advanced stages of tumor.Main bodycolorectal cancer progression is largely associated with molecular and genetic bases. Although Iran has a high ratio of CRC mortality, there is not an efficient genetic panel for detection and prognosis. Therefore, it is critical to introduce new diagnostic markers with ability to detect in early stages.ConclusionPresent review summarizes all of the genetic and epigenetic factors which are reported in CRC until now among the Iranian patients to pave the way of incorporation of new ethnic specific markers into the clinical practice and development of new targeted therapeutic methods.	[Abbaszadegan, Mohammad Reza] Mashhad Univ Med Sci, Med Genet Res Ctr, Mashhad, Iran; [Moghbeli, Meysam] Mashhad Univ Med Sci, Dept Modern Sci & Technol, Fac Med, Mashhad, Iran	Moghbeli, M (reprint author), Mashhad Univ Med Sci, Dept Modern Sci & Technol, Fac Med, Mashhad, Iran.	abbaszadeganmr@mums.ac.ir; moghbelim@mums.ac.ir	Moghbeli, Meysam/Q-7916-2019; Moghbeli, Meysam/Q-6582-2016	Moghbeli, Meysam/0000-0001-9680-0309			Abtahi S, 2017, J CANCER RES THER, V13, P252, DOI 10.4103/0973-1482.199448; Ahangari F, 2014, MED ONCOL, V31, DOI 10.1007/s12032-014-0173-7; Akbari Z, 2014, ASIAN PAC J CANCER P, V15, P4437, DOI 10.7314/APJCP.2014.15.11.4437; Akouchekian M, 2009, DIS COLON RECTUM, V52, P526, DOI 10.1007/DCR.0b013e31819acb99; Al-Samadi A, 2016, TUMOR BIOL, V37, P1609, DOI 10.1007/s13277-015-3941-x; Albanell J, 2001, CANCER RES, V61, P6500; Amirghofran Z, 2009, CANCER GENET CYTOGEN, V190, P21, DOI 10.1016/j.cancergencyto.2008.11.010; Ansari R, 2006, CANCER LETT, V240, P143, DOI 10.1016/j.canlet.2005.09.004; ARCECI RJ, 1993, BLOOD, V81, P2215; Asadi Milad, 2018, Asian Pac J Cancer Prev, V19, P1277; Atoum MF, 2014, ASIAN PAC J CANCER P, V15, P7337, DOI 10.7314/APJCP.2014.15.17.7337; Aukrust P, 2005, ANN MED, V37, P74, DOI 10.1080/07853890510007232; Ayoubi HA, 2017, J GASTROINTEST ONCOL, V8, P64, DOI 10.21037/jgo.2016.12.12; Azimzadeh Pedram, 2013, Gastroenterol Hepatol Bed Bench, V6, P86; Azimzadeh P, 2011, J GASTROINTEST LIVER, V20, P371; Basati G, 2016, TUMOR BIOL, V37, P1781, DOI 10.1007/s13277-015-3967-0; Basati G, 2014, MED ONCOL, V31, DOI 10.1007/s12032-014-0205-3; Bassermann F, 2010, CELL DEATH DIFFER, V17, P78, DOI 10.1038/cdd.2009.104; Bastaminejad Saiyad, 2017, Iranian Biomedical Journal, V21, P106, DOI 10.18869/acadpub.ibj.21.2.106; Bian XH, 2018, BIOCHEM PHARMACOL, V147, P30, DOI 10.1016/j.bcp.2017.11.008; Boland CR, 1998, CANCER RES, V58, P5248; Brim H, 2008, MOL CANCER, V7, DOI 10.1186/1476-4598-7-68; Cottonham CL, 2010, J BIOL CHEM, V285, P35293, DOI 10.1074/jbc.M110.160069; Damavand Behzad, 2015, Asian Pac J Cancer Prev, V16, P41; Dawson MA, 2012, CELL, V150, P12, DOI 10.1016/j.cell.2012.06.013; Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001-117; Ebrahimkhani S, 2012, PATHOL ONCOL RES, V18, P651, DOI 10.1007/s12253-011-9490-8; Eslamizadeh S, 2018, CELL J, V20, P220, DOI 10.22074/cellj.2018.5366; Estey MP, 2011, CURR BIOL, V21, pR384, DOI 10.1016/j.cub.2011.03.067; Faghani M, 2012, GASTROENT RES PRACT, DOI 10.1155/2012/756263; Fang JY, 2005, LANCET ONCOL, V6, P322, DOI 10.1016/S1470-2045(05)70168-6; Farzanehfar M, 2013, DNA CELL BIOL, V32, P371, DOI 10.1089/dna.2012.1949; Feghali Carol A., 1997, Frontiers in Bioscience (online), V2, pD12; Frank D, 2003, GENE, V312, P135, DOI 10.1016/S0378-1119(03)00609-7; Fransen K, 2004, CARCINOGENESIS, V25, P527, DOI 10.1093/carcin/bgh049; Ghavam-Nasiri MR, 2007, ARCH IRAN MED, V10, P38; Giles RH, 2003, BBA-REV CANCER, V1653, P1, DOI 10.1016/S0304-419X(03)00005-2; Glozak MA, 2007, ONCOGENE, V26, P5420, DOI 10.1038/sj.onc.1210610; Golmohammadi R, 2013, GUT LIVER, V7, P295, DOI 10.5009/gnl.2013.7.3.295; Greene SB, 2010, J CELL SCI, V123, P606, DOI 10.1242/jcs.056812; Guedes JG, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-169; Habibollahi P, 2010, PATHOL ONCOL RES, V16, P327, DOI 10.1007/s12253-009-9239-9; Hadinia A, 2007, J GASTROEN HEPATOL, V22, P2283, DOI 10.1111/j.1440-1746.2007.04862.x; Haghighi MM, 2008, ASIAN PAC J CANCER P, V9, P659; Haghighi MM, 2009, INT J COLORECTAL DIS, V24, P885, DOI 10.1007/s00384-009-0731-1; Hamzehzadeh L, 2018, CURR PROB CANCER, V42, P572, DOI 10.1016/j.currproblcancer.2018.05.001; Hosseini Sayed Mostafa, 2018, Middle East J Dig Dis, V10, P174, DOI 10.15171/mejdd.2018.107; Hosseini SV, 2004, ANZ J SURG, V74, P547, DOI 10.1111/j.1445-2197.2004.03064.x; Hua FF, 2017, EUR REV MED PHARMACO, V21, P5342, DOI 10.26355/eurrev_201712_13919; Hur K, 2013, GUT, V62, P1315, DOI 10.1136/gutjnl-2011-301846; Hutvagner G, 2008, NAT REV MOL CELL BIO, V9, P22, DOI 10.1038/nrm2321; Jaiswal M, 2001, AM J PHYSIOL-GASTR L, V281, pG626; Jamhiri I, 2017, MOL BIOL RES COMMUN, V6, P85; Jang CW, 2015, GENE DEV, V29, P1377, DOI 10.1101/gad.264150.115; John T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067876; Jovov B, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030168; Khales SA, 2015, J CANCER RES CLIN, V141, P229, DOI 10.1007/s00432-014-1808-y; Khalili Mitra, 2015, J Gastrointest Cancer, V46, P251, DOI 10.1007/s12029-015-9695-2; Khatami F, 2009, ASIAN PAC J CANCER P, V10, P1183; Khedri A, 2011, MOL BIOL REP, V38, P2939, DOI 10.1007/s11033-010-9957-9; KIHARA M, 1995, CARCINOGENESIS, V16, P2331, DOI 10.1093/carcin/16.10.2331; Kim PKM, 2001, INT IMMUNOPHARMACOL, V1, P1421, DOI 10.1016/S1567-5769(01)00088-1; Kim YI, 1999, J NUTR BIOCHEM, V10, P66, DOI 10.1016/S0955-2863(98)00074-6; Kimelman D, 2006, ONCOGENE, V25, P7482, DOI 10.1038/sj.onc.1210055; KOBZIK L, 1994, NATURE, V372, P546, DOI 10.1038/372546a0; Koochak Aghigh, 2016, Asian Pac J Cancer Prev, V17, P603; Landi D, 2008, CARCINOGENESIS, V29, P579, DOI 10.1093/carcin/bgm304; Larsson SC, 2005, J NATL CANCER I, V97, P1679, DOI 10.1093/jnci/dji375; Lee S, 2008, PATHOL INT, V58, P104, DOI 10.1111/j.1440-1827.2007.02197.x; Leonard GD, 2003, ONCOLOGIST, V8, P411, DOI 10.1634/theoncologist.8-5-411; Li SL, 2016, ONCOL REP, V36, P1917, DOI 10.3892/or.2016.5042; Limburg PJ, 2006, CLIN GASTROENTEROL H, V4, P1514, DOI 10.1016/j.cgh.2006.09.014; Liu L, 2004, CANCER RES, V64, P3491, DOI 10.1158/0008-5472.CAN-03-2106; Luqmani YA, 2005, MED PRIN PRACT, V14, P35, DOI 10.1159/000086183; Mahdavinezhad A, 2015, INT J MOL CELL MED, V4, P32; Mahmoudi T, 2016, META GENE, V9, P210, DOI 10.1016/j.mgene.2016.07.008; Mahmoudi T, 2016, INT J BIOL MARKER, V31, pE68, DOI 10.5301/jbm.5000159; Mahmoudi T, 2010, DIGEST DIS SCI, V55, P2008, DOI 10.1007/s10620-009-0989-8; Massague J, 2008, CELL, V134, P215, DOI 10.1016/j.cell.2008.07.001; Mazraehshah MK, 2018, J CELL BIOCHEM, V119, P10005, DOI 10.1002/jcb.27330; McCann SE, 2000, CANCER CAUSE CONTROL, V11, P965, DOI 10.1023/A:1026551309873; Micalizzi DS, 2009, FUTURE ONCOL, V5, P1129, DOI [10.2217/fon.09.94, 10.2217/FON.09.94]; Mirzaei A, 2015, TUMOR BIOL, V36, P4801, DOI 10.1007/s13277-015-3132-9; Moghbeli M, 2011, GENET MOL RES, V10, P3520, DOI 10.4238/2011.December.14.4; Moghbeli M, 2016, J CELL COMMUN SIGNAL, V10, P49, DOI 10.1007/s12079-015-0314-6; Moghbeli M, 2014, MED ONCOL, V31, DOI 10.1007/s12032-014-0069-6; Mohammed FMA, 2015, DIAGN PATHOL, V10, DOI 10.1186/s13000-015-0337-6; Mojarad EN, 2016, J ONCOL, DOI 10.1155/2016/2196703; Mokarram Pooneh, 2015, Asian Pac J Cancer Prev, V16, P8247; Monk M, 2001, ONCOGENE, V20, P8085, DOI 10.1038/sj.onc.1205088; Monk M, 2008, MOL HUM REPROD, V14, P347, DOI 10.1093/molehr/gan025; Moossavi M, 2018, J CELL BIOCHEM, V119, P8190, DOI 10.1002/jcb.26826; Morimoto LM, 2002, CANCER EPIDEM BIOMAR, V11, P1012; Motlagh A, 2007, ARCH IRAN MED, V10, P301; Naghibalhossaini F, 2012, MOL BIOL REP, V39, P6171, DOI 10.1007/s11033-011-1434-6; Naghibalhossaini F, 2010, CANCER GENET CYTOGEN, V197, P142, DOI 10.1016/j.cancergencyto.2009.11.014; Naini M Alizade, 2016, Asian Pac J Cancer Prev, V17, P2185; Nebert DW, 1996, DNA CELL BIOL, V15, P273, DOI 10.1089/dna.1996.15.273; Nemati K, 2015, GENE, V561, P88, DOI 10.1016/j.gene.2015.02.014; Nemati M, 2018, ADV CLIN EXP MED, V27, P305, DOI 10.17219/acem/66207; Niknami Z, 2017, EXCLI J, V16, P1009, DOI 10.17179/excli2017-481; Nishida M, 2007, MED MOL MORPHOL, V40, P55, DOI 10.1007/s00795-007-0366-7; Nomani H, 2005, CLIN BIOCHEM, V38, P621, DOI 10.1016/j.clinbiochem.2005.04.004; Ogrodnik M, 2014, P NATL ACAD SCI USA, V111, P8049, DOI 10.1073/pnas.1324035111; Omidifar N, 2015, IRAN J MED SCI, V40, P454; Orang AV, 2014, ASIAN PAC J CANCER P, V15, P6685, DOI 10.7314/APJCP.2014.15.16.6685; Orang AV, 2014, ASIAN PAC J CANCER P, V15, P4033, DOI 10.7314/APJCP.2014.15.9.4033; Paterson EL, 2013, NEOPLASIA, V15, P180, DOI 10.1593/neo.121828; PETERS WHM, 1991, GUT, V32, P408, DOI 10.1136/gut.32.4.408; Petrova DT, 2008, J CANCER RES CLIN, V134, P317, DOI 10.1007/s00432-007-0279-9; Poudyal D, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075034; Qin AY, 2013, EUR J CELL BIOL, V92, P54, DOI 10.1016/j.ejcb.2012.11.002; Raeisossadati R, 2014, TUMOR BIOL, V35, P5299, DOI 10.1007/s13277-014-1690-x; Raeisossadati R, 2011, INT J COLORECTAL DIS, V26, P1265, DOI 10.1007/s00384-011-1230-8; Rakoff-Nahoum Seth, 2006, Yale J Biol Med, V79, P123; Rampersaud GC, 2000, AM J CLIN NUTR, V72, P998; Reuveni H, 2013, CANCER RES, V73, P4383, DOI 10.1158/0008-5472.CAN-12-3385; Samaei NM, 2014, J BIOMED SCI, V21, DOI 10.1186/s12929-014-0073-3; Samanian S, 2011, ASIAN PAC J CANCER P, V12, P3141; Sandrock K, 2011, BIOL CHEM, V392, P751, DOI 10.1515/BC.2011.081; Seto AG, 2007, MOL CELL, V26, P603, DOI 10.1016/j.molcel.2007.05.021; Shafaei S, 2013, CASP J INTERN MED, V4, P768; Shahmoradi S, 2012, FAM CANCER, V11, P13, DOI 10.1007/s10689-011-9478-2; Sharif SB, 2016, ONCOL LETT, V12, P5335, DOI 10.3892/ol.2016.5327; Shi YP, 2013, CANCER BIOTHER RADIO, V28, P429, DOI 10.1089/cbr.2012.1396; Shrubsole MJ, 2001, CANCER RES, V61, P7136; Singhal SS, 1999, INVEST OPHTH VIS SCI, V40, P2652; Soreide K, 2006, BRIT J SURG, V93, P395, DOI 10.1002/bjs.5328; Spillane JB, 2007, ANZ J SURG, V77, P464, DOI 10.1111/j.1445-2197.2007.04096.x; Sternberg D, 1998, HUM MOL GENET, V7, P33, DOI 10.1093/hmg/7.1.33; Sternberg MJE, 1999, CURR OPIN STRUC BIOL, V9, P368, DOI 10.1016/S0959-440X(99)80050-5; Sugiyama M, 2009, INT J ONCOL, V34, P339, DOI 10.3892/ijo_00000156; Sun DF, 2013, J BIOL CHEM, V288, P9508, DOI 10.1074/jbc.M112.367763; Tavakoli Koudehi Ameneh, 2018, Asian Pac J Cancer Prev, V19, P463; Tavangar S, 2005, MED SCI MONITOR, V11, pCR123; Thorstensen L, 2005, NEOPLASIA, V7, P99, DOI 10.1593/neo.04448; Tian Y, 2010, INT J COLORECTAL DIS, V25, P161, DOI 10.1007/s00384-009-0809-9; Ting WC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056196; TIVOL EA, 1995, IMMUNITY, V3, P541, DOI 10.1016/1074-7613(95)90125-6; Valeri N, 2014, CANCER CELL, V25, P469, DOI 10.1016/j.ccr.2014.03.006; van Horssen R, 2006, ONCOLOGIST, V11, P397, DOI 10.1634/theoncologist.11-4-397; van Wijk SJL, 2010, FASEB J, V24, P981, DOI 10.1096/fj.09-136259; Vanhaecke T, 2000, BIOCHEM PHARMACOL, V60, P1491, DOI 10.1016/S0006-2952(00)00446-9; Walunas TL, 1996, J EXP MED, V183, P2541, DOI 10.1084/jem.183.6.2541; Wei YH, 2002, EXP BIOL MED, V227, P671; Weinberg JB, 2000, IMMUNOL RES, V22, P319, DOI 10.1385/IR:22:2-3:319; Xiao L, 2013, MOL BIOL CELL, V24, P3038, DOI 10.1091/mbc.E13-05-0287; Xu T, 2015, EXP THER MED, V10, P683, DOI 10.3892/etm.2015.2538; Yokota T, 2012, ANTI-CANCER AGENT ME, V12, P163, DOI 10.2174/187152012799014968; You JS, 2012, CANCER CELL, V22, P9, DOI 10.1016/j.ccr.2012.06.008; Zhang GJ, 2014, MOL MED REP, V10, P283, DOI 10.3892/mmr.2014.2144; Zhao BS, 2013, ASIAN PAC J CANCER P, V14, P139, DOI 10.7314/APJCP.2013.14.1.139; Zhao RB, 2000, GENE DEV, V14, P981; Zheng HC, 2003, WORLD J GASTROENTERO, V9, P1415, DOI 10.3748/wjg.v9.i7.1415	154	0	0	0	1	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1746-1596			DIAGN PATHOL	Diagn. Pathol.	DEC 22	2018	13								97	10.1186/s13000-018-0774-0			13	Pathology	Pathology	HF5BB	WOS:000454246500003	30579343	DOAJ Gold, Green Published			2019-10-28	
J	Kirishima, M; Yamada, S; Shinya, M; Onishi, S; Goto, Y; Kitazono, I; Hiraki, T; Higashi, M; Hida, AI; Tanimoto, A				Kirishima, Mari; Yamada, Sohsuke; Shinya, Mitsuhisa; Onishi, Shun; Goto, Yuko; Kitazono, Ikumi; Hiraki, Tsubasa; Higashi, Michiyo; Hida, Akira I.; Tanimoto, Akihide			An autopsy case of epignathus (immature teratoma of the soft palate) with intracranial extension but without brain invasion: case report and literature review	DIAGNOSTIC PATHOLOGY			English	Review						Epignathus; Intracranial extension; Immature teratoma; Hypoxia	PRENATAL-DIAGNOSIS; CONGENITAL TERATOMA; KARYOTYPE	BackgroundEpignathus is a rare congenital orofacial teratoma infrequently associated with intracranial extension. Intracranial extension of an epignathus indicates a poor prognosis; however, only a small number of such cases have been reported. While there have been some studies reporting cases of epignathus expanding directly into the cranium, others have reported no communication between an epignathus and an intracranial tumor.Case presentationA fetus at gestational week 27 was suspected of having an epignathus with intracranial tumor as shown by ultrasonographic and magnetic resonance imaging. The fetus was stillborn and an autopsy was performed. An epignathus measuring 12x6x6cm and weighing 270g protruded from the mouth, with its base on the soft palate. An intracranial tumor weighing 14g was located at the middle intracranial fossa and connected to the epignathus through the right side of the sella turcica. The intracranial tumor was encapsulated, and there was no invasion into the brain. Histologically, both the epignathus and intracranial tumor were immature teratomas, with neural and pulmonary components that were especially immature as compared to those of the internal organs and brain tissues of the fetus.ConclusionThere have been several reports of epignathus and intracranial tumors that did not communicate; therefore, careful evaluation is needed when a fetus is suspected of having an epignathus extending into an intracranial lesion. Our case supports the findings that an epignathus can directly expand into the cranium. Moreover, this is a rare case of an epignathus in which the intracranial lesion was encapsulated and did not invade the brain. These rare but important findings will provide additional, potential therapeutic strategies for gynecologists, neurosurgeons, and pathologists.	[Kirishima, Mari; Goto, Yuko; Kitazono, Ikumi; Hida, Akira I.; Tanimoto, Akihide] Kagoshima Univ, Grad Sch Med & Dent Sci, Dept Pathol, Field Oncol, 8-35-1 Sakuragaoka, Kagoshima 8908544, Japan; [Kirishima, Mari; Hiraki, Tsubasa; Higashi, Michiyo] Kagoshima Univ, Dept Pathol, 8-35-1 Sakuragaoka, Kagoshima 8908544, Japan; [Yamada, Sohsuke] Kanazawa Med Univ, Dept Pathol & Lab Med, 1-1 Daigaku, Kahoku, Ishikawa 9200293, Japan; [Shinya, Mitsuhisa] Kagoshima Univ Hosp, Dept Obstet & Gynecol, 8-35-1 Sakuragaoka, Kagoshima 8908544, Japan; [Onishi, Shun] Kagoshima Univ, Dept Pediat Surg, Res Field Med & Hlth Sci, Med & Dent Area,Res & Educ Assembly, 8-35-1 Sakuragaoka, Kagoshima 8908544, Japan	Kirishima, M (reprint author), Kagoshima Univ, Grad Sch Med & Dent Sci, Dept Pathol, Field Oncol, 8-35-1 Sakuragaoka, Kagoshima 8908544, Japan.; Kirishima, M (reprint author), Kagoshima Univ, Dept Pathol, 8-35-1 Sakuragaoka, Kagoshima 8908544, Japan.	k3324879@kadai.jp		Kirishima, Mari/0000-0002-6997-8336			Becker S, 2007, BRIT J ORAL MAX SURG, V45, P326, DOI 10.1016/j.bjoms.2005.11.007; Benson RE, 2009, BRIT J ORAL MAX SURG, V47, P46, DOI 10.1016/j.bjoms.2007.12.015; Calda P, 2011, J CLIN ULTRASOUND, V39, P164, DOI 10.1002/jcu.20762; Carvalho Cyntia Helena Pereira de, 2017, Braz. Dent. J., V28, P256, DOI 10.1590/0103-6440201701368; Chauhan DS, 2011, J MAXILLOFAC ORAL SU, V10, P253, DOI 10.1007/s12663-010-0140-6; Dakpe S, 2014, INT J ORAL MAX SURG, V43, P433, DOI 10.1016/j.ijom.2013.09.004; Ernst LM, 2011, COLOR ATLAS FETAL NE, P70; Gilbert-Barness E, 2013, HDB PEDIAT AUTOPSY P, P67; HOSODA YASUHIRO, 1963, KEIO JOUR MED, V12, P61; Isaacs H, 2002, PEDIATR NEUROL, V27, P333, DOI 10.1016/S0887-8994(02)00459-9; Johnston JM, 2007, J NEUROSURG, V106, P232, DOI 10.3171/ped.2007.106.3.232; Ng Hweena, 1993, Annals Academy of Medicine Singapore, V22, P823; SCHWARTZ S, 1992, TERATOLOGY, V46, P399, DOI 10.1002/tera.1420460410; SMITH NM, 1993, PRENATAL DIAG, V13, P945, DOI 10.1002/pd.1970131008; Staboulidou I, 2008, FETAL DIAGN THER, V24, P313, DOI 10.1159/000160219; Wang AC, 2017, CHINESE MED J-PEKING, V130, P2386, DOI 10.4103/0366-6999.215343; Witters I, 2001, ANN GENET-PARIS, V44, P179, DOI 10.1016/S0003-3995(01)01090-5	17	0	0	1	1	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1746-1596			DIAGN PATHOL	Diagn. Pathol.	DEC 22	2018	13								99	10.1186/s13000-018-0776-y			8	Pathology	Pathology	HF5BB	WOS:000454246500001	30579363	DOAJ Gold, Green Published			2019-10-28	
J	Orsini, P; Impera, L; Parciante, E; Cumbo, C; Minervini, CF; Minervini, A; Zagaria, A; Anelli, L; Coccaro, N; Casieri, P; Tota, G; Brunetti, C; Ricco, A; Carluccio, P; Specchia, G; Albano, F				Orsini, Paola; Impera, Luciana; Parciante, Elisa; Cumbo, Cosimo; Minervini, Crescenzio F.; Minervini, Angela; Zagaria, Antonella; Anelli, Luisa; Coccaro, Nicoletta; Casieri, Paola; Tota, Giuseppina; Brunetti, Claudia; Ricco, Alessandra; Carluccio, Paola; Specchia, Giorgina; Albano, Francesco			Droplet digital PCR for the quantification of Alu methylation status in hematological malignancies	DIAGNOSTIC PATHOLOGY			English	Article						Alu repeats; DNA methylation; ddPCR; Hematological malignancies; Hypomethylating agents	CHRONIC-MYELOID-LEUKEMIA; DNA METHYLATION; ABSOLUTE QUANTIFICATION; LINE-1 METHYLATION; HYPOMETHYLATION; AZACITIDINE; TRANSCRIPT; MUTATIONS; REPEATS; NUMBER	BackgroundAlu repeats, belonging to the Short Interspersed Repetitive Elements (SINEs) class, contain about 25% of CpG sites in the human genome. Alu sequences lie in gene-rich regions, so their methylation is an important transcriptional regulation mechanism. Aberrant Alu methylation has been associated with tumor aggressiveness, and also previously discussed in hematological malignancies, by applying different approaches. Moreover, today different techniques designed to measure global DNA methylation are focused on the methylation level of specific repeat elements.In this work we propose a new method of investigating Alu differential methylation, based on droplet digital PCR (ddPCR) technology.MethodsForty-six patients with hematological neoplasms were included in the study: 30 patients affected by chronic lymphocytic leukemia, 7 patients with myelodysplastic syndromes at intermediate/high risk, according with the International Prognostic Scoring System, and 9 patients with myelomonocytic leukemia. Ten healthy donors were included as controls. Acute promyelocytic leukemia-derived NB4 cell line, either untreated or treated with decitabine (DEC) hypomethylating agent, was also analyzed.DNA samples were investigated for Alu methylation level by digestion of genomic DNA with isoschizomers with differential sensitivity to DNA methylation, followed by ddPCR.ResultsUsing ddPCR, a significant decrease of the global Alu methylation level in DNA extracted from NB4 cells treated with DEC, as compared to untreated cells, was observed. Moreover, comparing the global Alu methylation levels at diagnosis and after azacytidine (AZA) treatment in MDS patients, a statistically significant decrease of Alu sequences methylation after therapy as compared to diagnosis was evident. We also observed a significant decrease of the Alu methylation level in CLL patients compared to HD, and, finally, for CMML patients, a decrease of Alu sequences methylation was observed in patients harboring the SRSF2 hotspot gene mutation c.284C>D.ConclusionsIn our work, we propose a method to investigate Alu differential methylation based on ddPCR technology. This assay introduces ddPCR as a more sensitive and immediate technique for Alu methylation analysis. To date, this is the first application of ddPCR to study DNA repetitive elements. This approach may be useful to profile patients affected by hematologic malignancies for diagnostic/prognostic purpose.	[Orsini, Paola; Impera, Luciana; Parciante, Elisa; Cumbo, Cosimo; Minervini, Crescenzio F.; Minervini, Angela; Zagaria, Antonella; Anelli, Luisa; Coccaro, Nicoletta; Casieri, Paola; Tota, Giuseppina; Brunetti, Claudia; Ricco, Alessandra; Carluccio, Paola; Specchia, Giorgina; Albano, Francesco] Univ Bari, Hematol Sect, Dept Emergency & Organ Transplantat, Pzza G Cesare 11, I-70124 Bari, Italy	Albano, F (reprint author), Univ Bari, Hematol Sect, Dept Emergency & Organ Transplantat, Pzza G Cesare 11, I-70124 Bari, Italy.	paolaorsini86@gmail.com; francesco.albano@uniba.it	; Albano, Francesco/J-2352-2016	CUMBO, Cosimo/0000-0002-2509-6200; Albano, Francesco/0000-0001-7926-6052	Associazione Italiana contro le Leucemie (AIL) BARI	This work was supported by "Associazione Italiana contro le Leucemie (AIL) BARI".	Albano F, 2015, ONCOTARGET, V6, P13269, DOI 10.18632/oncotarget.3773; Anelli L, 2016, ANN HEMATOL, V95, P1559, DOI 10.1007/s00277-016-2739-2; Bagacean C, 2017, CLIN EPIGENETICS, V9, DOI 10.1186/s13148-017-0422-7; Baker M, 2012, NAT METHODS, V9, P541, DOI 10.1038/nmeth.2027; Barault L, 2015, ANN ONCOL, V26, P1994, DOI 10.1093/annonc/mdv272; Barry KH, 2015, PROSTATE, V75, P1718, DOI 10.1002/pros.23053; Buj R, 2016, ONCOTARGET, V7, P10536, DOI 10.18632/oncotarget.7233; Cashen AF, 2008, CANCER CHEMOTH PHARM, V61, P759, DOI 10.1007/s00280-007-0531-7; Chen J, 2016, ONCOTARGET, V7, P26099, DOI 10.18632/oncotarget.8318; Chim CS, 2005, LEUKEMIA, V19, P2241, DOI 10.1038/sj.leu.2403937; Deininger P, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-12-236; Delia M, 2015, LEUKEMIA RES, V39, P1166, DOI 10.1016/j.leukres.2015.08.005; Fabris S, 2011, EPIGENETICS-US, V6, P188, DOI 10.4161/epi.6.2.13528; Fackenthal JD, 2008, DIS MODEL MECH, V1, P37, DOI 10.1242/dmm.000331; Ferguson LR, 2015, SEMIN CANCER BIOL, V35, pS5, DOI 10.1016/j.semcancer.2015.03.005; Golenkov A., 2014, BLOOD, V124; Goyama S, 2017, CANCER SCI, V108, P553, DOI 10.1111/cas.13168; Greenberg P, 1997, BLOOD, V89, P2079, DOI 10.1182/blood.V89.6.2079; Guillamot M, 2016, TRENDS CANCER, V2, P70, DOI 10.1016/j.trecan.2015.12.006; Hindson CM, 2013, NAT METHODS, V10, P1003, DOI 10.1038/nmeth.2633; Hu DQ, 2016, GENE DEV, V30, P2021, DOI 10.1101/gad.284109.116; Inamura K, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/dju195; Jorda M, 2017, GENOME RES, V27, P118, DOI 10.1101/gr.207522.116; Lisanti S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079044; Luo YT, 2014, BIOMED RES INT, DOI 10.1155/2014/784706; Marcucci G, 2005, J CLIN PHARMACOL, V45, P597, DOI 10.1177/0091270004271947; Nielsen HM, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-07057-3; Nouzova M, 2004, J PHARMACOL EXP THER, V311, P968, DOI 10.1124/jpet.104.072488; Patchsung M, 2018, EPIGENOMICS-UK, V10, P175, DOI 10.2217/epi-2017-0096; Patnaik MM, 2016, BLOOD CANCER J, V6, DOI 10.1038/bcj.2016.5; Pinheiro LB, 2012, ANAL CHEM, V84, P1003, DOI 10.1021/ac202578x; Puiggros A, 2014, BIOMED RES INT, DOI 10.1155/2014/435983; ROBLEDO M, 1995, LEUKEMIA, V9, P960; Roman-Gomez J, 2008, LEUKEMIA RES, V32, P487, DOI 10.1016/j.leukres.2007.07.021; Saied MH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033213; Salas LA, 2014, EPIGENETICS-US, V9, P1532, DOI 10.4161/15592294.2014.983377; Specchia G, 2004, LEUKEMIA LYMPHOMA, V45, P689, DOI 10.1080/10428190310001623900; Storlazzi CT, 2006, LEUKEMIA, V20, P2190, DOI 10.1038/sj.leu.2404418; SYKES PJ, 1992, BIOTECHNIQUES, V13, P444; Tajuddin SM, 2014, BRIT J CANCER, V110, P2123, DOI 10.1038/bjc.2014.67; Cedena MT, 2017, ONCOTARGET, V8, P106948, DOI 10.18632/oncotarget.22157; Thol F, 2011, J CLIN ONCOL, V29, P2499, DOI 10.1200/JCO.2010.33.4938; Torano EG, 2012, CLIN CHEM LAB MED, V50, P1733, DOI 10.1515/cclm-2011-0902; Van Wesenbeeck L, 2018, EPIGENETICS-US, V13, P207, DOI 10.1080/15592294.2018.1448679; Weisenberger DJ, 2005, NUCLEIC ACIDS RES, V33, P6823, DOI 10.1093/nar/gki987; Xie HH, 2009, NUCLEIC ACIDS RES, V37, P4331, DOI 10.1093/nar/gkp393; Yang AS, 2006, CANCER RES, V66, P5495, DOI 10.1158/0008-5472.CAN-05-2385; Yang LB, 2015, NAT REV CANCER, V15, P152, DOI 10.1038/nrc3895; Zagaria A, 2015, VIRCHOWS ARCH, V467, P357, DOI 10.1007/s00428-015-1802-z	49	0	0	0	0	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1746-1596			DIAGN PATHOL	Diagn. Pathol.	DEC 22	2018	13								98	10.1186/s13000-018-0777-x			11	Pathology	Pathology	HF5BB	WOS:000454246500002	30579366	DOAJ Gold, Green Published			2019-10-28	
J	Zai, JJ; Yi, K; Xie, LL; Zhu, JP; Feng, XT; Li, YM				Zai, Junjie; Yi, Kai; Xie, Lilan; Zhu, Jiping; Feng, Xiaoting; Li, Yaoming			Dual monoclonal antibody-based sandwich ELISA for detection of in vitro packaged Ebola virus	DIAGNOSTIC PATHOLOGY			English	Article						Monoclonal antibody; Ebola virus; GP; Detection; ELISA	RT-QPCR ASSAY; INFECTION; AFRICA	BackgroundRapid transmission and high mortality of Ebola virus disease (EVD) highlight a urgent need of large scale, convenient and effective measure for Ebola virus screening. Application of monoclonal antibodies (mAbs) are crucial for establishment of an enzyme-linked immunosorbent assay (ELISA) with high sensitivity and specificity.MethodsThe traditional cell fusion technique was used to generate a panel of hybridomas. Two mAbs were characterized by SDS-PAGE, Western blot, Indirect immunofluorescence assay (IFA). A sandwich ELISA was established using the two mAbs. The detection capability of the ELISA was evaluated.ResultsIn the current study, we produced two murine-derived mAbs (designated as 6E3 and 3F21) towards Zaire Ebola virus glycoprotein (GP), the major viral transmembrane spike protein associated with viral attachment. It was shown that 6E3 and 3F21 recognized GP1 and GP2 subunits of the GP respectively. Furthermore, 6E3 and 3F21 bound to corresponding epitopes on GP without reciprocal topographical interpretation. Subsequently, a sandwich ELISA based on the two mAbs were established and evaluated. The detection limit was 3.6ng/ml, with a linear range of 3.6-100ng/ml. More importantly, Ebola virus like particles (eVLPs) were able to be detected by this established virus detection measure.ConclusionsWe produced and characterized two murine-derived mAbs (designated as 6E3 and 3F21) towards Zaire Ebola virus glycoprotein (GP), and established a sandwich ELISA based on the mAbs. It was suggested that the sandwich ELISA provided an alternative method for specific and sensitive detection of Ebola virus in the field setting.	[Zai, Junjie; Yi, Kai; Xie, Lilan; Zhu, Jiping; Feng, Xiaoting; Li, Yaoming] Wuhan Univ Bioengn, Hubei Engn Res Ctr Viral Vector, Appl Biotechnol Res Ctr, Wuhan 430400, Hubei, Peoples R China; [Li, Yaoming] Wuhan Univ Bioengn, Coll Life Sci & Technol, Wuhan 430400, Hubei, Peoples R China	Li, YM (reprint author), Wuhan Univ Bioengn, Hubei Engn Res Ctr Viral Vector, Appl Biotechnol Res Ctr, Wuhan 430400, Hubei, Peoples R China.; Li, YM (reprint author), Wuhan Univ Bioengn, Coll Life Sci & Technol, Wuhan 430400, Hubei, Peoples R China.	limeming@webmail.hzau.edu.cn			Hubei Provincial Natural Science Foundation of ChinaNational Natural Science Foundation of China [2018CFB449]; High-level Scientific Research Foundation for the introduction of talent of Wuhan Institute of Bioengineering [2017KQ01]; National Natural Science Foundation of ChinaNational Natural Science Foundation of China [81202381]	This work was supported by grants from Hubei Provincial Natural Science Foundation of China 2018CFB449, High-level Scientific Research Foundation for the introduction of talent of Wuhan Institute of Bioengineering (2017KQ01), and National Natural Science Foundation of China (81202381).	Biava M, 2018, J VIROL METHODS, V252, P70, DOI 10.1016/j.jviromet.2017.11.009; Changula K, 2014, MICROBIOL IMMUNOL, V58, P483, DOI 10.1111/1348-0421.12181; Chen YQ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034947; Chertow DS, 2014, NEW ENGL J MED, V371, P2054, DOI 10.1056/NEJMp1413084; Cross RW, 2016, J INFECT DIS, V214, pS210, DOI 10.1093/infdis/jiw293; Dedkov VG, 2018, HEALTH SECUR, V16, P14, DOI 10.1089/hs.2017.0027; ELLIOTT LH, 1985, VIROLOGY, V147, P169, DOI 10.1016/0042-6822(85)90236-3; Pose AG, 2018, J IMMUNOL METHODS, V459, P70, DOI 10.1016/j.jim.2018.05.008; Han BS, 2018, CLIN EXP VACCINE RES, V7, P119, DOI 10.7774/cevr.2018.7.2.119; Huang WJ, 2012, J IMMUNOL, V188, P6247, DOI 10.4049/jimmunol.1103706; Kumar D, 2018, VIRAL IMMUNOL; Lee JE, 2008, NATURE, V454, P177, DOI 10.1038/nature07082; Li YM, 2012, HYBRIDOMA, V31, P60, DOI 10.1089/hyb.2011.0083; Li YM, 2010, J VIROL METHODS, V168, P51, DOI 10.1016/j.jviromet.2010.04.015; Marzi A, 2014, EXPERT REV VACCINES, V13, P521, DOI 10.1586/14760584.2014.885841; Medaglini D, 2018, SEMIN IMMUNOL; Qiu XG, 2011, CLIN IMMUNOL, V141, P218, DOI 10.1016/j.clim.2011.08.008; Sheng MM, 2014, SCI CHINA LIFE SCI, V57, P959, DOI 10.1007/s11427-014-4742-y; Takada A, 2012, FRONT MICROBIOL, V3, DOI 10.3389/fmicb.2012.00034; Towner JS, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000212; Wu CJ, 2006, MICROBES INFECT, V8, P2578, DOI 10.1016/j.micinf.2006.06.010; Xie Lilan, 2018, Monoclonal Antibodies in Immunodiagnosis and Immunotherapy, V37, P175, DOI 10.1089/mab.2018.0021; Xue JC, 2015, VIROL SIN, V30, P146, DOI 10.1007/s12250-014-3555-2; Yi F, 2018, VACCINE; Yoshida R, 2016, J INFECT DIS, V214, pS185, DOI 10.1093/infdis/jiw252; Zhang MD, 2015, J IMMUNOL, V194, P3102, DOI 10.4049/jimmunol.1401538; Zhang Y, 2018, DIAGN PATHOL, V13, DOI 10.1186/s13000-018-0727-7	27	0	0	2	7	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1746-1596			DIAGN PATHOL	Diagn. Pathol.	DEC 19	2018	13								96	10.1186/s13000-018-0773-1			8	Pathology	Pathology	HF0ZQ	WOS:000453894900001	30567559	DOAJ Gold, Green Published			2019-10-28	
J	Smith, CC; Conran, RM				Smith, Christina C.; Conran, Richard Michael			Educational Case: Membranous Nephropathy	ACADEMIC PATHOLOGY			English	Article						pathology competencies; organ system pathology; kidney; glomerular disorder; nephrotic syndrome; nephritic syndrome; membranous nephropathy	NEPHROTIC SYNDROME; DIAGNOSIS	The following fictional case is intended as a learning tool within the Pathology Competencies for Medical Education (PCME), a set of national standards for teaching pathology. These are divided into three basic competencies: Disease Mechanisms and Processes, Organ System Pathology, and Diagnostic Medicine and Therapeutic Pathology. For additional information, and a full list of learning objectives for all three competencies, see .	[Smith, Christina C.; Conran, Richard Michael] Eastern Virginia Med Sch, 700 West Olney, Norfolk, VA 23501 USA	Conran, RM (reprint author), Eastern Virginia Med Sch, 700 West Olney, Norfolk, VA 23501 USA.	conranrm@evms.edu					Alpers CE, 2015, ROBBINS COTRAN PATHO, P897; Cattran DC, 2018, UPTODATE; Fervenza FC, 2008, CLIN J AM SOC NEPHRO, V3, P905, DOI 10.2215/CJN.04321007; Jennette JC, 2015, RUBINS PATHOLOGY CLI, P903; Johnson RJ, 2015, COMPREHENSIVE CLIN N, P198; Kerlin BA, 2012, CLIN J AM SOC NEPHRO, V7, P513, DOI 10.2215/CJN.10131011; Kodner C, 2016, AM FAM PHYSICIAN, V93, P479; Neilson EG, 2015, HARRISONS PRINCIPLES; Teitelbaum I, 2009, CURRENT DIAGNOSIS TR, P211	9	0	0	1	1	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	2374-2895			ACAD PATHOL	Acad. Pathol.	DEC 16	2018	5								2374289518813673	10.1177/2374289518813673			6	Pathology	Pathology	HE8UI	WOS:000453722700001	30574541	DOAJ Gold, Green Published			2019-10-28	
J	Cai, W; Kesavan, DK; Wan, J; Abdelaziz, MH; Su, ZL; Xu, HX				Cai, Wei; Kesavan, Dinesh Kumar; Wan, Jie; Abdelaziz, Mohamed Hamed; Su, Zhaoliang; Xu, Huaxi			Bacterial outer membrane vesicles, a potential vaccine candidate in interactions with host cells based	DIAGNOSTIC PATHOLOGY			English	Review						Outer membrane vesicles; Host cells; Vaccines; Bacterium; Immunity	ESCHERICHIA-COLI; NEISSERIA-MENINGITIDIS; PORPHYROMONAS-GINGIVALIS; EXTRACELLULAR VESICLES; IMMUNE-RESPONSES; VIRULENCE FACTOR; IN-VITRO; B-CELL; SALMONELLA; IMMUNOGENICITY	Both Gram-Positive and Gram-Negative bacteria can secrete outer membrane vesicles (OMVs) in their growth and metabolism process. Originally, OMVs were considered as a by-product of bacterial merisis. However, many scientists have reported the important role of OMVs in many fields recently. In this review, we briefly introduce OMVs biological functions and then summarize the findings about the OMVs interactions with host cells. At last, we will make an expectation about the prospects of the application of OMVs as vaccines.	[Cai, Wei; Kesavan, Dinesh Kumar; Wan, Jie; Abdelaziz, Mohamed Hamed; Su, Zhaoliang; Xu, Huaxi] Jiangsu Univ, Dept Immunol, Zhenjiang 212013, Jiangsu, Peoples R China; [Su, Zhaoliang] Fourth Affiliated Jiangsu Univ, Cent Lab, Zhenjiang 212001, Peoples R China	Xu, HX (reprint author), Jiangsu Univ, Dept Immunol, Zhenjiang 212013, Jiangsu, Peoples R China.	1528664879@qq.com; xuhx@ujs.edu.cn			National Natural Science Foundation of ChinaNational Natural Science Foundation of China [81771756]; Social development project of Jiangsu Province [BE2016716]; Postdoctoral Foundation of Jiangsu Province [1601002C]	This work was supported by National Natural Science Foundation of China (grant no. 81771756), Social development project of Jiangsu Province (grant no. BE2016716), the Postdoctoral Foundation of Jiangsu Province (grant no. 1601002C).	Adriani R, 2018, VACCINE, V36, P322, DOI 10.1016/j.vaccine.2017.09.004; Alaniz RC, 2007, J IMMUNOL, V179, P7692, DOI 10.4049/jimmunol.179.11.7692; Alvarez CS, 2016, FRONT MICROBIOL, V7, DOI 10.3389/fmicb.2016.01981; Arntzen MO, 2017, ENVIRON MICROBIOL, V19, P2701, DOI 10.1111/1462-2920.13770; Aschtgen MS, 2016, J BACTERIOL, V198, P2156, DOI 10.1128/JB.00101-16; Aschtgen MS, 2016, CELL MICROBIOL, V18, P488, DOI 10.1111/cmi.12525; Bauwens A, 2017, ENV MICROBIOL REP, V9, P626, DOI 10.1111/1758-2229.12562; Bauwens A, 2017, ANTIMICROB AGENTS CH, V61, DOI [10.1128/AAC.00937-17, 10.1128/aac.00937-17]; Berleman JE, 2014, FRONT MICROBIOL, V5, DOI 10.3389/fmicb.2014.00474; Bielaszewska M, 2018, INT J MED MICROBIOL, V308, P882, DOI 10.1016/j.ijmm.2018.06.004; Bielaszewska M, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006159; Bitto NJ, 2018, IMMUNOL CELL BIOL, V96, P1120, DOI 10.1111/imcb.12190; Bitto NJ, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-07288-4; Bonnington KE, 2016, MBIO, V7, DOI 10.1128/mBio.01532-16; Bottero D, 2018, APPL ENVIRON MICROB, V84, DOI 10.1128/AEM.01877-17; Bottero D, 2016, VACCINE, V34, P3303, DOI [10.1016/j.vaccine.2016.04.07, 10.1016/j.vaccine.2016.04.079]; Brown L, 2014, MOL MICROBIOL, V93, P183, DOI 10.1111/mmi.12650; Cahill BK, 2015, MICROBIOL RES, V180, P1, DOI 10.1016/j.micres.2015.06.012; Canas MA, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.00498; Canas MA, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0160374; Cecil JD, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01017; Chatterjee S, 2017, J ANTIMICROB CHEMOTH, V72, P2201, DOI 10.1093/jac/dkx131; Chen L, 2016, P NATL ACAD SCI USA, V113, pE3609, DOI 10.1073/pnas.1518311113; Chen Q, 2017, CHEM COMMUN, V53, P7569, DOI 10.1039/c7cc04246a; Chen Y, 2014, BIOCHEM BIOPH RES CO, V453, P696, DOI 10.1016/j.bbrc.2014.09.142; Choi HI, 2017, BIOCHEM BIOPH RES CO, V490, P991, DOI 10.1016/j.bbrc.2017.06.152; Choi JW, 2017, J DENT RES, V96, P458, DOI 10.1177/0022034516685071; Davis JM, 2006, INFECT IMMUN, V74, P4401, DOI 10.1128/IAI.00637-06; Santos FAD, 2018, IMMUNOBIOLOGY, V223, P750, DOI 10.1016/j.imbio.2018.07.021; Deo P, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1006945; Devos S, 2017, ENVIRON MICROBIOL, V19, P3930, DOI 10.1111/1462-2920.13793; Elhenawy W, 2016, MBIO, V7, DOI 10.1128/mBio.00940-16; Elmi A, 2016, CELL MICROBIOL, V18, P561, DOI 10.1111/cmi.12534; Fernandez-Rojas MA, 2014, MICROBIOLOGYOPEN, V3, P711, DOI 10.1002/mbo3.201; Finethy R, 2017, MBIO, V8, DOI 10.1128/mBio.01188-17; Fingermann M, 2018, HUM VACC IMMUNOTHER, V14, P2208, DOI 10.1080/21645515.2018.1490381; Fleetwood AJ, 2017, FRONT CELL INFECT MI, V7, DOI 10.3389/fcimb.2017.00351; Florez C, 2017, MBIO, V8, DOI 10.1128/mBio.01034-17; Fulsundar S, 2015, MICROB PATHOGENESIS, V83-84, P12, DOI 10.1016/j.micpath.2015.04.005; Gamalier JP, 2017, MICROBIOL RES, V194, P38, DOI 10.1016/j.micres.2016.08.002; Gao XJ, 2018, DRUG METAB DISPOS, V46, P292, DOI 10.1124/dmd.117.079046; Gasperini G, 2018, MOL CELL PROTEOMICS, V17, P205, DOI 10.1074/mcp.RA117.000045; Grandi A, 2017, FRONT ONCOL, V7, DOI 10.3389/fonc.2017.00253; Gu L, 2019, SHOCK, V51, P256, DOI 10.1097/SHK.0000000000001129; Hampton CM, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.02177; Hickey CA, 2015, CELL HOST MICROBE, V17, P672, DOI 10.1016/j.chom.2015.04.002; Ho MH, 2016, FRONT CELL INFECT MI, V6, DOI 10.3389/fcimb.2016.00139; Hock BD, 2017, PATHOG DIS, V75, DOI 10.1093/femspd/ftx034; Horspool AM, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-28042-4; Jager J, 2015, CELL MICROBIOL, V17, P607, DOI 10.1111/cmi.12392; Jha C, 2017, MICROB PATHOGENESIS, V111, P218, DOI 10.1016/j.micpath.2017.08.048; Jung AL, 2017, JOVE-J VIS EXP, DOI 10.3791/55146; Jung AL, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005592; Kaparakis-Liaskos M, 2015, NAT REV IMMUNOL, V15, P375, DOI 10.1038/nri3837; Kaur Gagandeep, 2016, J Immunoassay Immunochem, V37, P261, DOI 10.1080/15321819.2015.1132231; Kim JH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059276; Kim SW, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-23656-0; Kim YS, 2013, CLIN EXP ALLERGY, V43, P443, DOI 10.1111/cea.12085; Kim YJ, 2016, PATHOG DIS, V74, DOI 10.1093/femspd/ftw104; Ko SH, 2016, INFECT IMMUN, V84, P2162, DOI 10.1128/IAI.00190-16; Ko SH, 2015, MEDIAT INFLAMM, DOI 10.1155/2015/301716; Koeppen K, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005672; Kothary MH, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.00134; Kunsmann L, 2015, SCI REP-UK, V5, DOI 10.1038/srep13252; Lapinet JA, 2000, INFECT IMMUN, V68, P6917, DOI 10.1128/IAI.68.12.6917-6923.2000; Lappann M, 2013, MOL MICROBIOL, V89, P433, DOI 10.1111/mmi.12288; Laughlin RC, 2015, VACCINE, V33, P5012, DOI 10.1016/j.vaccine.2015.05.014; Lee DH, 2011, VACCINE, V29, P8293, DOI 10.1016/j.vaccine.2011.08.102; Lee WH, 2015, EXP MOL MED, V47, DOI 10.1038/emm.2015.59; Li J, 2016, ENVIRON MICROBIOL, V18, P3850, DOI 10.1111/1462-2920.13344; Liu Q, 2017, J MICROBIOL BIOTECHN, V27, P1519, DOI 10.4014/jmb.1705.05028; Liu Q, 2016, INT J MED MICROBIOL, V306, P697, DOI 10.1016/j.ijmm.2016.08.004; Heredia RM, 2016, MICROBIOL-SGM, V162, P813, DOI 10.1099/mic.0.000265; McCaig WD, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0149132; Metruccio MME, 2016, FRONT MICROBIOL, V7, DOI 10.3389/fmicb.2016.00871; Mitra S, 2016, VACCINE, V34, P1839, DOI 10.1016/j.vaccine.2016.02.018; Mondal A, 2016, INFECT IMMUN, V84, P1478, DOI 10.1128/IAI.01365-15; Murase K, 2016, J INFECT DIS, V213, P856, DOI 10.1093/infdis/jiv506; Nakao R, 2016, VACCINE, V34, P4626, DOI 10.1016/j.vaccine.2016.06.016; Nakayama-Imaohji H, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0148887; Nho JS, 2015, MICROB PATHOGENESIS, V81, P39, DOI 10.1016/j.micpath.2015.03.012; Nieves W, 2014, CLIN VACCINE IMMUNOL, V21, P747, DOI 10.1128/CVI.00119-14; O'Donoghue EJ, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006760; Oftung F, 2016, CLIN VACCINE IMMUNOL, V23, P353, DOI 10.1128/CVI.00666-15; Ojima Y, 2018, BIOTECHNOL PROGR, V34, P51, DOI 10.1002/btpr.2536; Pilsczek FH, 2010, J IMMUNOL, V185, P7413, DOI 10.4049/jimmunol.1000675; Premjani V, 2014, FEMS MICROBIOL LETT, V355, P185, DOI 10.1111/1574-6968.12463; Rasti ES, 2018, CELL MICROBIOL, V20, DOI 10.1111/cmi.12828; Reyes-Robles T, 2018, J BACTERIOL; Roier S, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10515; Rumbo C, 2014, INFECT IMMUN, V82, P4666, DOI 10.1128/IAI.02034-14; Sevestre J, 2017, VACCINE, V35, P4029, DOI 10.1016/j.vaccine.2017.05.065; Sinha R, 2015, MICROBES INFECT, V17, P215, DOI 10.1016/j.micinf.2014.10.011; Stentz R, 2015, J ANTIMICROB CHEMOTH, V70, P701, DOI 10.1093/jac/dku466; Tavano R, 2009, J LEUKOCYTE BIOL, V86, P143, DOI [10.1189/JLB.0109030, 10.1189/jlb.0109030]; Thay B, 2014, INFECT IMMUN, V82, P4034, DOI 10.1128/IAI.01980-14; Tunheim G, 2016, APMIS, V124, P996, DOI 10.1111/apm.12589; Turner KL, 2016, ANTIMICROB AGENTS CH, V60, P1360, DOI 10.1128/AAC.01627-15; Turner L, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01466; Urashima A, 2017, CELL MICROBIOL, V19, DOI 10.1111/cmi.12758; Valeru Soni Priya, 2014, Int J Microbiol, V2014, P610190, DOI 10.1155/2014/610190; Vanaja SK, 2016, CELL, V165, P1106, DOI 10.1016/j.cell.2016.04.015; Vanhove AS, 2015, ENVIRON MICROBIOL, V17, P1152, DOI 10.1111/1462-2920.12535; Vaughan AT, 2010, J IMMUNOL, V185, P3652, DOI 10.4049/jimmunol.0902468; Vaughan AT, 2009, J IMMUNOL, V182, P2231, DOI 10.4049/jimmunol.0802531; Vida A, 2011, INFLAMM RES, V60, P801, DOI 10.1007/s00011-011-0344-3; Vidakovics MLAP, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000724; Waller T, 2016, INFECT IMMUN, V84, P1194, DOI 10.1128/IAI.01390-15; Winter J, 2014, INFECT IMMUN, V82, P1372, DOI 10.1128/IAI.01443-13; Xu K, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0191286; Yang WW, 2016, FEBS OPEN BIO, V6, P1310, DOI 10.1002/2211-5463.12151; Youssef AR, 2009, INFECT IMMUN, V77, P5170, DOI 10.1128/IAI.00355-09; Zakharzhevskaya NB, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-05264-6; Zakharzhevskaya NB, 2017, FRONT CELL INFECT MI, V7, DOI 10.3389/fcimb.2017.00002; Zariri A, 2016, INFECT IMMUN, V84, P3024, DOI 10.1128/IAI.00635-16; Zhang L, 2016, VACCINE, V34, P4250, DOI 10.1016/j.vaccine.2016.05.049; Zhu WY, 2018, J BIOL CHEM, V293, P11218, DOI 10.1074/jbc.RA117.001209	117	0	0	4	6	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1746-1596			DIAGN PATHOL	Diagn. Pathol.	DEC 11	2018	13								95	10.1186/s13000-018-0768-y			12	Pathology	Pathology	HD9BF	WOS:000452854500001	30537996	DOAJ Gold, Green Published			2019-10-28	
J	Otani, T; Hatakeyama, K; Ohtani, E; Nakayama, S; Fujimoto, T; Ohbayashi, C				Otani, Tomoyuki; Hatakeyama, Kinta; Ohtani, Emi; Nakayama, Susumu; Fujimoto, Takashi; Ohbayashi, Chiho			A Colonic Perineurioma	CLINICAL MEDICINE INSIGHTS- PATHOLOGY			English	Article						Perineurioma; benign fibroblastic polyp; colon; polypoid; mesenchymal tumor	FIBROBLASTIC POLYP	Perineurioma is a mesenchymal neoplasm best known in soft-tissue pathology. A colonic perineurioma is a relatively recently described entity and sometimes encountered in specimens from the large intestine, especially distal colon. Without its recognition, a perineurioma can be misdiagnosed as other more common gastrointestinal spindle cell neoplasms. Here, we describe a case of colonic perineurioma with polypoid growth extruding into the intestinal lumen. Case. A woman in her seventh decade of life underwent a follow-up colonoscopy after an uneventful resection of a benign colonic polyp. A previously undetected 6-mm polyp was found in the sigmoid colon and was resected endoscopically. Microscopic examination of the lesion revealed a proliferation of bland spindle cells in the lamina propria mucosae, which were immunohistochemically positive for epithelial membrane antigen, claudin 1, and glucose transporter-1. A colonic perineurioma was diagnosed.	[Otani, Tomoyuki; Hatakeyama, Kinta; Ohbayashi, Chiho] Nara Med Univ, Dept Diagnost Pathol, Kashihara, Nara 6348521, Japan; [Otani, Tomoyuki; Hatakeyama, Kinta; Ohtani, Emi] Minami Nara Gen Med Ctr, Dept Diagnost Pathol, Yoshino, Japan; [Ohtani, Emi] Minami Nara Gen Med Ctr, Dept Gastroenterol, Yoshino, Japan; [Nakayama, Susumu] Minami Nara Gen Med Ctr, Dept Gen Internal Med, Yoshino, Japan; [Fujimoto, Takashi] Minami Nara Gen Med Ctr, Dept Orthoped, Yoshino, Japan	Ohbayashi, C (reprint author), Nara Med Univ, Dept Diagnost Pathol, Kashihara, Nara 6348521, Japan.	ohbayashi@naramed-u.ac.jp					Agaimy A, 2010, AM J SURG PATHOL, V34, P1663, DOI 10.1097/PAS.0b013e3181f4a458; Eslami-Varzaneh F, 2004, AM J SURG PATHOL, V28, P374, DOI 10.1097/00000478-200403000-00010; Groisman GM, 2008, AM J SURG PATHOL, V32, P1088, DOI 10.1097/PAS.0b013e318160df3f; Groisman GM, 2006, HISTOPATHOLOGY, V48, P431, DOI 10.1111/j.1365-2559.2006.02357.x; Hornick JL, 2005, AM J SURG PATHOL, V29, P859, DOI 10.1097/01.pas.0000154130.87219.2c; Pai RK, 2011, AM J SURG PATHOL, V35, P1373, DOI 10.1097/PAS.0b013e318224d9df; van Wyk AC, 2018, DIAGN PATHOL, V13, DOI 10.1186/s13000-018-0694-z	7	0	0	0	0	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	1179-5557	2632-010X		CLIN MED INSIGHTS-PA	Clin. Med. Insights-Pathol.	DEC 6	2018	11								UNSP 1179555718815918	10.1177/1179555718815918			2	Pathology	Pathology	HG1OY	WOS:000454728900001	30574002	DOAJ Gold, Green Published			2019-10-28	
J	Kothari, T; Jensen, K; Mallon, D; Brogan, G; Crawford, J				Kothari, Tarush; Jensen, Kendal; Mallon, Debbie; Brogan, Gerard; Crawford, James			Impact of Daily Electronic Laboratory Alerting on Early Detection and Clinical Documentation of Acute Kidney Injury in Hospital Settings	ACADEMIC PATHOLOGY			English	Article						acute kidney injury; clinical documentation; KDIGO: Kidney Disease Improving Global Outcomes; clinical decision support; electronic laboratory alerting	SERUM CREATININE; DECISION-SUPPORT; DEFINITIONS; DISEASE; TIME; AKI; CLASSIFICATION; PROGNOSIS; OUTCOMES	Acute kidney injury, especially early-stage disease, is a common hospital comorbidity requiring timely recognition and treatment. We investigated the effect of daily laboratory alerting of patients at risk for acute kidney injury as measured by documented International Classification of Diseases diagnoses. A quasi-experimental study was conducted at 8 New York hospitals between January 1, 2014, and June 30, 2017. Education of clinical documentation improvement specialists, physicians, and nurses was conducted from July 1, 2014, to December 31, 2014, prior to initiating daily hospital-wide laboratory acute kidney injury alerting on January 1, 2015. Incidence based on documented International Classification of Diseases diagnosis of acute kidney injury and acute tubular necrosis during the intervention periods (3 periods of 6 months each: January 1 to June 30 of 2015, 2016, and 2017) were compared to one preintervention period (January 1, 2014, to June 30, 2014). The sample consisted of 269 607 adult hospital discharges, among which there were 39 071 episodes based on laboratory estimates and 27 660 episodes of documented International Classification of Diseases diagnoses of acute kidney injury or acute tubular necrosis. Documented incidence improved significantly from the 2014 preintervention period (5.70%; 95% confidence interval: 5.52%-5.88%) to intervention periods in 2015 (9.89%; 95% confidence interval, 9.66%-10.12%; risk ratio = 1.73, P < .001), 2016 (12.76%; 95% confidence interval, 12.51%-13.01%; risk ratio = 2.24, P < .001), and 2017 (12.49%; 95% confidence interval, 12.24%-12.74%; risk ratio = 2.19, P < .001). A multifactorial intervention comprising daily laboratory alerting and education of physicians, nurses, and clinical documentation improvement specialists led to increased recognition and clinical documentation of acute kidney injury.	[Kothari, Tarush; Jensen, Kendal; Crawford, James] Donald & Barbara Zucker Sch Med Hofstra Northwell, Dept Pathol & Lab Med, Hempstead, NY USA; [Mallon, Debbie] Northwell Hlth, Clin Documentat Improvement, Lake Success, NY USA; [Brogan, Gerard] Donald & Barbara Zucker Sch Med Hofstra Northwell, Dept Emergency Med, Hempstead, NY USA	Kothari, T (reprint author), 5 Dakota Dr,Suite 308, Hempstead, NY 11042 USA.	tkothari@northwell.edu					Baron JM, 2015, AM J CLIN PATHOL, V143, P42, DOI 10.1309/AJCP05XBCQPHTLGQ; Chawla LS, 2014, NEW ENGL J MED, V371, P58, DOI 10.1056/NEJMra1214243; Chertow GM, 2005, J AM SOC NEPHROL, V16, P3365, DOI 10.1681/ASN.2004090740; Connell Alistair, 2017, F1000Res, V6, P1033, DOI 10.12688/f1000research.11637.2; Garner AE, 2012, ANN CLIN BIOCHEM, V49, P59, DOI 10.1258/acb.2011.011125; Goitein L, 2016, JAMA INTERN MED, V176, P835, DOI 10.1001/jamainternmed.2016.1641; Goldstein SL, 2015, CURR OPIN CRIT CARE, V21, P485, DOI 10.1097/MCC.0000000000000250; Grams ME, 2014, CLIN J AM SOC NEPHRO, V9, P682, DOI 10.2215/CJN.07650713; Handler SM, 2014, NEPHROL DIAL TRANSPL, V29, P1802, DOI 10.1093/ndt/gfu211; Harris AD, 2006, J AM MED INFORM ASSN, V13, P16, DOI 10.1197/jamia.M1749; Hoste Eric A J, 2016, Can J Kidney Health Dis, V3, P10, DOI 10.1186/s40697-016-0101-1; James Matthew T, 2016, Can J Kidney Health Dis, V3, P9, DOI 10.1186/s40697-016-0100-2; Joslin J, 2015, CLIN MED, V15, P431, DOI 10.7861/clinmedicine.15-5-431; Kashani K, 2016, BLOOD PURIFICAT, V42, P323, DOI 10.1159/000450722; Kashani K, 2015, NEPHRON, V131, P92, DOI 10.1159/000437311; Kerr M, 2014, NEPHROL DIAL TRANSPL, V29, P1362, DOI 10.1093/ndt/gfu016; Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group, 2012, KDIGO CLIN PRACT GUI; Ko S, 2018, INTERN MED J, V48, P310, DOI 10.1111/imj.13729; Kolhe NV, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132279; Kolhe NV, 2014, NEPHRON CLIN PRACT, V126, P51, DOI 10.1159/000358435; Lachance P, 2017, NEPHROL DIAL TRANSPL, V32, P265, DOI 10.1093/ndt/gfw424; Levante C, 2016, BLOOD PURIFICAT, V42, pI, DOI 10.1159/000447988; Lu RH, 2014, BLOOD PURIFICAT, V38, P89, DOI 10.1159/000362865; do Nascimento RAM, 2016, REV ESC ENFERM USP, V50, P399, DOI 10.1590/S0080-623420160000400004; Oh J, 2016, CLIN KIDNEY J, V9, P567, DOI 10.1093/ckj/sfw054; Porter CJ, 2014, NEPHROL DIAL TRANSPL, V29, P1888, DOI 10.1093/ndt/gfu082; Sawhney S, 2017, ADV CHRONIC KIDNEY D, V24, P194, DOI 10.1053/j.ackd.2017.05.001; Selby NM, 2015, NEPHRON, V131, P113, DOI 10.1159/000439146; Selby NM, 2012, CLIN J AM SOC NEPHRO, V7, P533, DOI 10.2215/CJN.08970911; Siew Edward D, 2016, Can J Kidney Health Dis, V3, P12, DOI 10.1186/s40697-016-0098-5; Siew ED, 2015, KIDNEY INT, V87, P46, DOI 10.1038/ki.2014.293; Siew ED, 2013, CLIN J AM SOC NEPHRO, V8, P10, DOI 10.2215/CJN.00200112; Siew ED, 2012, CLIN J AM SOC NEPHRO, V7, P712, DOI 10.2215/CJN.10821011; Siew ED, 2010, KIDNEY INT, V77, P536, DOI 10.1038/ki.2009.479; Tso Geoffrey J, 2016, AMIA Annu Symp Proc, V2016, P1189; Wald R, 2012, CLIN J AM SOC NEPHRO, V7, P697, DOI 10.2215/CJN.03020312; Wang HE, 2013, NEPHROL DIAL TRANSPL, V28, P1447, DOI 10.1093/ndt/gfs533; Wilson FP, 2013, CLIN NEPHROL, V80, P417, DOI 10.5414/CN108072; Xu G, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2013-004388; Zeng XX, 2014, CLIN J AM SOC NEPHRO, V9, P12, DOI 10.2215/CJN.02730313	40	0	0	0	0	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	2374-2895			ACAD PATHOL	Acad. Pathol.	DEC 4	2018	5								2374289518816502	10.1177/2374289518816502			10	Pathology	Pathology	HE1AQ	WOS:000453002800001	30547082	DOAJ Gold, Green Published			2019-10-28	
J	Chokoshvili, D; Vears, DF; Borry, P				Chokoshvili, Davit; Vears, Danya F.; Borry, Pascal			Reproductive autonomy in expanded carrier screening: more than meets the eye?	EXPERT REVIEW OF MOLECULAR DIAGNOSTICS			English	Editorial Material						ELSI; ethics; expanded carrier screening; reproductive autonomy; reproductive genetics	IMPLEMENTATION		[Chokoshvili, Davit; Borry, Pascal] Univ Leuven, Dept Publ Hlth & Primary Care, Ctr Biomed Eth & Law, Kapucijnenvoer 35, B-3000 Leuven, Belgium; [Vears, Danya F.] Univ Melbourne, Melbourne Law Sch, Parkville, Vic, Australia; [Vears, Danya F.] Murdoch Childrens Res Inst, Parkville, Vic, Australia	Borry, P (reprint author), Univ Leuven, Dept Publ Hlth & Primary Care, Ctr Biomed Eth & Law, Kapucijnenvoer 35, B-3000 Leuven, Belgium.	pascal.borry@med.kuleuven.be	Borry, Pascal/B-5836-2012	Borry, Pascal/0000-0002-4931-9560	Victorian State Government through the Operational Infrastructure Support (OIS) Program	Danya Vears acknowledges the infrastructure funding received from the Victorian State Government through the Operational Infrastructure Support (OIS) Program.	Beauchamp KA, 2018, BIORXIV, DOI [10.1101/372334, DOI 10.1101/372334]; Bosslet GT, 2011, J MED ETHICS, V37, P280, DOI 10.1136/jme.2010.039230; Bruni T, 2012, MED HEALTH CARE PHIL, V15, P321, DOI 10.1007/s11019-011-9347-7; Chokoshvili D, 2018, PRENATAL DIAG, V38, P59, DOI 10.1002/pd.5109; Edwards JG, 2015, OBSTET GYNECOL, V125, P653, DOI 10.1097/AOG.0000000000000666; Henneman L, 2016, EUR J HUM GENET, V24, pE1, DOI 10.1038/ejhg.2015.271; Lazarin GA, 2016, SEMIN PERINATOL, V40, P29, DOI 10.1053/j.semperi.2015.11.005; Massie J, 2014, LANCET, V383, P923, DOI 10.1016/S0140-6736(13)61092-2; Wilfond BS, 2015, MOL GENET GENOM MED, V3, P239, DOI 10.1002/mgg3.130	9	1	1	0	0	TAYLOR & FRANCIS AS	OSLO	KARL JOHANS GATE 5, NO-0154 OSLO, NORWAY	1473-7159	1744-8352		EXPERT REV MOL DIAGN	Expert Rev. Mol. Diagn.	DEC 2	2018	18	12					993	994		10.1080/14737159.2018.1544496			2	Pathology	Pathology	HC7TN	WOS:000452004600001	30394810				2019-10-28	
J	Yang, RF; Wei, L				Yang, Ruifeng; Wei, Lai			Profile of the VERSANT HCV genotype 2.0 assay	EXPERT REVIEW OF MOLECULAR DIAGNOSTICS			English	Article						Hepatitis C virus (HCV); genotype; subtype; recombinant; direct acting antivirals (DAAs); next-generation sequencing (NGS); versant HCV genotype 2.0 assay	HEPATITIS-C-VIRUS; LINE PROBE ASSAY; SEQUENCE-ANALYSIS; CORE REGION; INNO-LIPA; PHYLOGENETIC ANALYSIS; GLOBAL EPIDEMIOLOGY; HIGH PREVALENCE; NS5B REGION; II ASSAY	Introduction: Hepatitis C virus (HCV) is divided into 7 genotypes and 67 subtypes. HCV genotype studies reflect the viral transmission patterns as well as human migration routes. In a clinical setting, HCV genotype is a baseline predictor for the sustained virological response (SVR) in chronic hepatitis C patients treated with peginterferon or some direct acting antivirals (DAAs). The Versant HCV genotype 2.0 assay has been globally used for HCV genotyping over a decade. Areas covered: The assay is based on reverse hybridization principle. It is evolved from its former versions, and the accuracy and successful genotyping/subtyping rate are substantially improved. It shows an accuracy of 99-100% for genotypes 1-6. It can also reliably identify subtypes 1a and 1b. However, the assay does not allow a high resolution for many other subtypes. Reasons for indeterminate or inaccurate genotyping/subtyping results are discussed. Expert commentary: Genotyping helps to find the most efficacious and cost-effective treatment regimen. The rapid development of anti-HCV treatment regimens, however, is greatly simplifying laboratory tests. In the near future, the need for HCV genotyping and frequent serial on-treatment HCV RNA tests will decrease along with the wide use of the more potent and pan-genotypic DAA regimens.	[Yang, Ruifeng; Wei, Lai] Peking Univ, Peoples Hosp, Hepatol Inst, Beijing Key Lab Hepatitis & Immunotherapy Liver D, Xizhimen South St 11, Beijing 100044, Peoples R China	Wei, L (reprint author), Peking Univ, Peoples Hosp, Hepatol Inst, Beijing Key Lab Hepatitis & Immunotherapy Liver D, Xizhimen South St 11, Beijing 100044, Peoples R China.	weilai@pkuph.edu.cn			China National Science and Technology Major Project for Infectious Diseases Control [2017ZX10202202]; China-Singapore International S&T Cooperation Program [2016YFE0116800]; Beijing Medical & Health Technology Promotion Project [2018-TG-19]	This work was supported by grants from the China National Science and Technology Major Project for Infectious Diseases Control during the 13th Five-Year Plan Period (2017ZX10202202), China-Singapore International S&T Cooperation Program (2016YFE0116800) and Beijing Medical & Health Technology Promotion Project (2018-TG-19).	AASLD-IDSA HCV Guidance Panel, 2018, CLIN INFECT DIS; Abergel A, 2007, ALIMENT PHARM THERAP, V26, P1437, DOI 10.1111/j.1365-2036.2007.03530.x; Akkarathamrongsin S, 2010, J MED VIROL, V82, P257, DOI 10.1002/jmv.21680; Al-Ahdal MN, 1997, ANN SAUDI MED, V17, P601, DOI 10.5144/0256-4947.1997.601; Asselah T, 2018, CLIN GASTROENTEROL H, V16, P417, DOI 10.1016/j.cgh.2017.09.027; Avo AP, 2013, J MED VIROL, V85, P815, DOI 10.1002/jmv.23545; Borgia SM, 2018, J INFECT DIS; Bouchardeau F, 2007, J CLIN MICROBIOL, V45, P1140, DOI 10.1128/JCM.01982-06; Cai QX, 2013, INT J MOL MED, V31, P347, DOI 10.3892/ijmm.2012.1209; Chen ZY, 2002, J CLIN MICROBIOL, V40, P3127, DOI 10.1128/JCM.40.9.3127-3134.2002; Chevaliez S, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008209; Chinchai T, 2006, INTERVIROLOGY, V49, P224, DOI 10.1159/000091469; Chinchai T, 2003, J VIROL METHODS, V109, P195, DOI 10.1016/S0166-0934(03)00071-5; Choudhary MC, 2014, INFECT GENET EVOL, V28, P87, DOI 10.1016/j.meegid.2014.09.009; Ciotti M, 2010, J VIROL METHODS, V167, P205, DOI 10.1016/j.jviromet.2010.03.017; Craxi A, 2011, J HEPATOL, V55, P245, DOI 10.1016/j.jhep.2011.02.023; De Keukeleire S, 2015, DIAGN MICR INFEC DIS, V82, P201, DOI 10.1016/j.diagmicrobio.2015.04.001; del Campo JA, 2018, INT J INFECT DIS, V67, P114, DOI 10.1016/j.ijid.2017.12.016; Doring M, 2018, NUCL ACIDS RES; European Ass Study Liver, 2017, J HEPATOL, V66, P153, DOI 10.1016/j.jhep.2016.09.001; European Assoc Study Liver, 2018, J HEPATOL, V69, P461, DOI 10.1016/j.jhep.2018.03.026; Feld JJ, 2015, NEW ENGL J MED, V373, P2599, DOI 10.1056/NEJMoa1512610; Foster GR, 2015, NEW ENGL J MED, V373, P2608, DOI 10.1056/NEJMoa1512612; Germer JJ, 1999, J CLIN MICROBIOL, V37, P2625; Germer JJ, 2003, J CLIN MICROBIOL, V41, P4855, DOI 10.1128/JCM.41.10.4855-4857.2003; Ghaderi-Zefrehi H, 2016, HEPAT MON, V16, DOI 10.5812/hepatmon.40357; Gonzalez V, 2013, J CLIN VIROL, V58, P249, DOI 10.1016/j.jcv.2013.05.005; Gonzalez-Candelas F, 2011, VIRUSES-BASEL, V3, P2006, DOI 10.3390/v3102006; Gower E, 2014, J HEPATOL, V61, pS45, DOI 10.1016/j.jhep.2014.07.027; Hadziyannis SJ, 2004, ANN INTERN MED, V140, P346, DOI 10.7326/0003-4819-140-5-200403020-00010; Halfon P, 2001, J CLIN MICROBIOL, V39, P1771, DOI 10.1128/JCM.39.5.1771-1773.2001; Han MS, 2017, CLIN CHEM LAB MED, V55, P1122, DOI 10.1515/cclm-2016-0130; Hedskog C, 2015, HEPATOLOGY, V61, P471, DOI 10.1002/hep.27361; Jacka B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067073; Karatapanis S, 2012, J MED VIROL, V84, P223, DOI 10.1002/jmv.22249; Katayama Y, 1996, MICROBIOL IMMUNOL, V40, P525, DOI 10.1111/j.1348-0421.1996.tb01104.x; Kessler HH, 2017, EXPERT REV MOL DIAGN, V17, P311, DOI 10.1080/14737159.2017.1293526; Ku KS, 2016, J CLIN MICROBIOL, V54, P1835, DOI 10.1128/JCM.00238-16; Kuiken C, 2006, HEPATOLOGY, V44, P1355, DOI 10.1002/hep.21377; Kwo PY, 2017, J HEPATOL, V67, P263, DOI 10.1016/j.jhep.2017.03.039; Laperche S, 2005, J CLIN MICROBIOL, V43, P733, DOI 10.1128/JCM.43.2.733-739.2005; Larrat S, 2013, J CLIN MICROBIOL, V51, P2815, DOI 10.1128/JCM.00586-13; Lawitz E, 2013, NEW ENGL J MED, V368, P1878, DOI 10.1056/NEJMoa1214853; Liu CH, 2015, J CLIN MICROBIOL, V53, P1754, DOI 10.1128/JCM.03548-14; Lu L, 2016, VIROLOGY, V492, P25, DOI 10.1016/j.virol.2016.01.028; Lu L, 2015, VIROLOGY, V482, P111, DOI 10.1016/j.virol.2015.03.038; Lwin AA, 2007, HEPATOL RES, V37, P337, DOI 10.1111/j.1872-034X.2007.00053.x; Manee N, 2017, J VIROL METHODS, V249, P31, DOI 10.1016/j.jviromet.2017.08.017; McNaughton AL, 2018, J VIRAL HEPATITIS, V25, P524, DOI 10.1111/jvh.12849; Mesbahi Z, 2018, J MED VIROL, V90, P1352, DOI 10.1002/jmv.25191; Miura M, 2013, J VIROL, V87, P12541, DOI 10.1128/JVI.00826-13; Mokhtari C, 2016, J CLIN MICROBIOL, V54, P296, DOI 10.1128/JCM.02264-15; Murphy DG, 2007, J CLIN MICROBIOL, V45, P1102, DOI 10.1128/JCM.02366-06; Nemoz B, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0194396; Noppornpanth S, 2006, J CLIN MICROBIOL, V44, P3969, DOI 10.1128/JCM.01122-06; Ntagirabiri R, 2014, PAN AFR MED J, V19, DOI 10.11604/pamj.2014.19.69.4580; OKAMOTO H, 1993, J GEN VIROL, V74, P2385, DOI 10.1099/0022-1317-74-11-2385; Ordeig L, 2018, J GEN VIROL, V99, P97, DOI 10.1099/jgv.0.000996; Pedersen MS, 2018, J CLIN VIROL, V105, P49, DOI 10.1016/j.jcv.2018.05.012; Pham LV, 2018, GASTROENTEROLOGY, V154, P2194, DOI 10.1053/j.gastro.2018.02.017; Pham VH, 2011, JPN J INFECT DIS, V64, P537; Pybus OG, 2001, SCIENCE, V292, P2323, DOI 10.1126/science.1058321; Pybus OG, 2009, J VIROL, V83, P1071, DOI 10.1128/JVI.01501-08; Qiu P, 2002, BMC MICROBIOL, V2, DOI 10.1186/1471-2180-2-29; Rao HY, 2012, J GASTROEN HEPATOL, V27, P526, DOI 10.1111/j.1440-1746.2011.06880.x; Rao HY, 2014, J GASTROEN HEPATOL, V29, P545, DOI 10.1111/jgh.12398; Rodriguez C, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-22614-0; Ross RS, 2007, J VIROL METHODS, V143, P153, DOI 10.1016/j.jviromet.2007.03.006; Shier MK, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0184163; Shinol RC, 2012, J CLIN MICROBIOL, V50, P3099, DOI 10.1128/JCM.01249-12; Simmonds P, 2005, HEPATOLOGY, V42, P962, DOI 10.1002/hep.20819; SIMMONDS P, 1994, J GEN VIROL, V75, P1053, DOI 10.1099/0022-1317-75-5-1053; SIMMONDS P, 1993, J GEN VIROL, V74, P2391, DOI 10.1099/0022-1317-74-11-2391; Smith D, 2018, HEPATOLOGY; SMITH DB, 1995, J GEN VIROL, V76, P1749, DOI 10.1099/0022-1317-76-7-1749; Smith DB, 2014, HEPATOLOGY, V59, P318, DOI 10.1002/hep.26744; SMUTS HM, 1995, J CLIN MICROBIOL, V33, P1679; Sohn YH, 2010, CLIN CHEM LAB MED, V48, P469, DOI 10.1515/CCLM.2010.093; Stelzl E, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0181273; Stelzl E, 2017, CLIN CHEM LAB MED, V55, P517, DOI 10.1515/cclm-2016-0620; Stuyver L, 1996, J CLIN MICROBIOL, V34, P2259; Tang HL, 2009, CLIN SCI, V117, P49, DOI 10.1042/CS20080631; Tapper EB, 2013, J VIRAL HEPATITIS, V20, P669, DOI 10.1111/jvh.12168; Thomson E, 2016, J CLIN MICROBIOL, V54, P2470, DOI 10.1128/JCM.00330-16; Trimbitas RD, 2016, J MED VIROL, V88, P1376, DOI 10.1002/jmv.24470; Verbeeck J, 2008, J CLIN MICROBIOL, V46, P1901, DOI 10.1128/JCM.02390-07; Wantuck JM, 2014, ALIMENT PHARM THER, V39, P137, DOI 10.1111/apt.12551; Wei Jun-feng, 2010, Nan Fang Yi Ke Da Xue Xue Bao, V30, P2270; Wei L, 2018, ANTIVIR RES, V158, P178, DOI 10.1016/j.antiviral.2018.08.001; Wei L, 2014, GASTROENTEROLOGY, V146, P1145, DOI 10.1053/j.gastro.2014.03.008; Welzel TM, 2017, J HEPATOL, V67, P224, DOI 10.1016/j.jhep.2017.03.014; Wyles DL, 2014, J VIRAL HEPATITIS, V21, P229, DOI 10.1111/jvh.12230; Yang RF, 2017, J CLIN LAB ANAL, V31, DOI 10.1002/jcla.22014; Yang RF, 2014, J CLIN MICROBIOL, V52, P3685, DOI 10.1128/JCM.00882-14; Yun AB, 1996, J MED VIROL, V49, P155, DOI 10.1002/(SICI)1096-9071(199607)49:3<155::AID-JMV1>3.0.CO;2-3; Zekri ARN, 2005, J MED VIROL, V75, P412, DOI 10.1002/jmv.20293; Zhang EZ, 2013, VIROL J, V10, DOI 10.1186/1743-422X-10-53; Zheng XT, 2003, J CLIN VIROL, V28, P214, DOI 10.1016/S1386-6532(03)00076-3	98	1	1	0	0	TAYLOR & FRANCIS AS	OSLO	KARL JOHANS GATE 5, NO-0154 OSLO, NORWAY	1473-7159	1744-8352		EXPERT REV MOL DIAGN	Expert Rev. Mol. Diagn.	DEC 2	2018	18	12					995	1004		10.1080/14737159.2018.1541740			10	Pathology	Pathology	HC7TN	WOS:000452004600002	30372355				2019-10-28	
J	Choy, ATF; Carnevale, I; Coppola, S; Meijer, LL; Kazemier, G; Zaura, E; Deng, DM; Giovannetti, E				Choy, Arthur T. F.; Carnevale, Ilaria; Coppola, Stefano; Meijer, Laura L.; Kazemier, Geert; Zaura, Egija; Deng, Dongmei; Giovannetti, Elisa			The microbiome of pancreatic cancer: from molecular diagnostics to new therapeutic approaches to overcome chemoresistance caused by metabolic inactivation of gemcitabine	EXPERT REVIEW OF MOLECULAR DIAGNOSTICS			English	Article						Aggregatibacter actinomycetemcomitans; chronic periodontitis; cytidine deaminase; Notch-1; Notch-1; Porphyromonas gingivalis	COLORECTAL-CANCER; TUMOR; RESISTANCE; BACTERIA	Introduction: Pancreatic cancer is a complex disease, with an extremely poor response to chemotherapy. Emerging evidence indicates that the tumor microenvironment (TME) might play an important role in mediating chemoresistance. Areas covered: The evaluated study by Geller and collaborators describes several bacterial species within pancreatic tumor tissues and TME and investigated their roles in gemcitabine chemoresistance. Intratumor bacteria express the enzyme cytidine deaminase (CDD), whose long form (CDDL) was shown to metabolize gemcitabine into its inactive metabolite. CDDL is mostly expressed by Gammaproteobacteria and this was among the most common species in pancreatic cancer tissues. Interestingly, mouse models of colorectal cancer injected with bacterial CDDL displayed a reduced response to gemcitabine, but this resistance was neutralized by the antibiotic ciprofloxacin. Expert Commentary: The increased knowledge on the microbiome in pancreatic tissues, as well as its role in chemoresistance, will provide innovative prognostic and therapeutic strategies.	[Choy, Arthur T. F.; Carnevale, Ilaria; Zaura, Egija; Deng, Dongmei] Acad Ctr Dent Amsterdam ACTA, Dept Prevent Dent, Amsterdam, Netherlands; [Carnevale, Ilaria; Meijer, Laura L.; Giovannetti, Elisa] Vrije Univ Amsterdam, Amsterdam UMC, Canc Ctr Amsterdam, Dept Med Oncol, Amsterdam, Netherlands; [Carnevale, Ilaria; Giovannetti, Elisa] Univ Pisa, AIRC Start UP Unit, Canc Pharmacol Lab, Pisa, Italy; [Coppola, Stefano] Leiden Univ, Huygens Kamerlingh Onnes Lab, Phys Life Proc, Leiden, Netherlands; [Meijer, Laura L.; Kazemier, Geert] Vrije Univ Amsterdam, Amsterdam UMC, Canc Ctr Amsterdam, Dept Surg, Amsterdam, Netherlands	Giovannetti, E (reprint author), Univ Amsterdam, VU Univ, Med Ctr, Lab Med Oncol,Dept Med Oncol,Canc Ctr Amsterdam, CCA Room 1-52,Boelelaan 1117, NL-1081 HV Amsterdam, Netherlands.	e.giovannetti@vumc.nl	Coppola, Stefano/D-4031-2014	Coppola, Stefano/0000-0002-1539-364X	Cancer Center Amsterdam Foundation; Bennink Foundation; Italian Association for Cancer ResearchAssociazione Italiana per la Ricerca sul Cancro (AIRC); Associazione Italiana per la Ricerca sul Cancro Start-Up GrantAssociazione Italiana per la Ricerca sul Cancro (AIRC)	This work was partly supported by Cancer Center Amsterdam Foundation grant 2016 [GK, EG], Bennink Foundation (EG, LM, GK) and Italian Association for Cancer Research, Associazione Italiana per la Ricerca sul Cancro Start-Up Grant [EG]. SC is beneficiary of an AXA Research Fund Post-doctoral grant.	Amrutkar M, 2017, CANCERS, V9, DOI 10.3390/cancers9110157; Avan A, 2013, CANCER RES, V73, P6745, DOI 10.1158/0008-5472.CAN-13-0837; Caparello C, 2016, WORLD J GASTROENTERO, V22, P6987, DOI 10.3748/wjg.v22.i31.6987; Castillo ED, 2017, BIORXIV; Ciccolini J, 2016, CANCER CHEMOTH PHARM, V78, P1, DOI 10.1007/s00280-016-3003-0; Coppola S, 2017, DRUG RESIST UPDATE, V31, P43, DOI 10.1016/j.drup.2017.07.001; Fan XZ, 2018, GUT, V67, P120, DOI 10.1136/gutjnl-2016-312580; Farrell JJ, 2012, GUT, V61, P582, DOI 10.1136/gutjnl-2011-300784; Geller LT, 2017, SCIENCE, V357, P1156, DOI 10.1126/science.aah5043; Giovannetti E, 2017, SEMIN CANCER BIOL, V44, P43, DOI 10.1016/j.semcancer.2017.04.006; Hanage WP, 2014, NATURE, V512, P247, DOI 10.1038/512247a; Jettte L, 2008, ANTICANCER RES, V28, P2175; Katsowich N, 2017, SCIENCE, V355, P735, DOI 10.1126/science.aah4886; Klemm F, 2015, TRENDS CELL BIOL, V25, P198, DOI 10.1016/j.tcb.2014.11.006; Lam SY, 2017, BEST PRACT RES CL GA, V31, P607, DOI 10.1016/j.bpg.2017.09.010; Le Large TYS, 2016, EXPERT REV MOL DIAGN, V16, P733, DOI 10.1080/14737159.2016.1175940; Lehouritis P, 2015, SCI REP-UK, V5, DOI 10.1038/srep14554; Michaud DS, 2007, JNCI-J NATL CANCER I, V99, P171, DOI 10.1093/jnci/djk021; Michaud DS, 2014, CANCER J, V20, P203, DOI 10.1097/PPO.0000000000000046; Michaud DS, 2013, GUT, V62, P1764, DOI 10.1136/gutjnl-2012-303006; Mielgo A, 2013, BMB REP, V46, P131, DOI 10.5483/BMBRep.2013.46.3.036; Ogrendik M, 2017, GASTROINTEST TUMORS, V3, P125, DOI 10.1159/000452708; Olive KP, 2015, CLIN CANCER RES, V21, P3366, DOI 10.1158/1078-0432.CCR-15-0416; Panebianco C, 2018, MICROBIOME, V6, DOI 10.1186/s40168-018-0483-7; Pushalkar S, 2018, CANCER DISCOV, V8, P403, DOI 10.1158/2159-8290.CD-17-1134; Vande Voorde J, 2014, J BIOL CHEM, V289, P13054, DOI 10.1074/jbc.M114.558924; Voorde JV, 2014, EXCLI J, V13, P300; Weizman N, 2014, ONCOGENE, V33, P3812, DOI 10.1038/onc.2013.357; Woo BH, 2017, ONCOTARGET, V8, P46981, DOI 10.18632/oncotarget.16550; Yu TC, 2017, CELL, V170, P548, DOI 10.1016/j.cell.2017.07.008	30	1	1	6	12	TAYLOR & FRANCIS AS	OSLO	KARL JOHANS GATE 5, NO-0154 OSLO, NORWAY	1473-7159	1744-8352		EXPERT REV MOL DIAGN	Expert Rev. Mol. Diagn.	DEC 2	2018	18	12					1005	1009		10.1080/14737159.2018.1544495			5	Pathology	Pathology	HC7TN	WOS:000452004600003	30392417				2019-10-28	
J	Andersen, RF				Andersen, Rikke Fredslund			Tumor-specific methylations in circulating cell-free DNA as clinically applicable markers with potential to substitute mutational analyses	EXPERT REVIEW OF MOLECULAR DIAGNOSTICS			English	Review						Circulating tumor DNA; DNA methylation; mutation analyses; plasma; biomarker; tumor monitoring	PLASMA DNA; COLORECTAL-CANCER; DIGITAL PCR; QUANTITATIVE-ANALYSIS; ADJUVANT THERAPY; LIQUID BIOPSIES; NUCLEIC-ACIDS; GENOME-WIDE; SERUM; BLOOD	Introduction: Analysis of circulating tumor DNA is a promising approach to guide the treatment of cancer patients but despite large efforts it has not been broadly applied in the clinic. Technical obstacles and lack of standardization have hampered the process and it has proved challenging to make highly sensitive analyses available for all patients. Research has focused on the use of somatic mutations but because of large mutational diversity among patients the setup becomes unmanageable for daily routine use. Areas covered: Methylations are key events in cancer development and can be used as markers for the presence of circulating tumor DNA similar to how mutations have been used. This review focuses on analytical aspects and possible clinical applications of methylated ctDNA in plasma from cancer patients. Expert commentary: Technical and clinical challenges of mutation and methylation analyses are similar. However, the possibility to analyze a limited number of methylations present in all tumors of a certain type allows for proper validation and standardization of the analyses. Tumor-specific methylation analyses could supplement or substitute mutation analyses for certain clinical applications and assist the progress of the clinical use of circulating tumor DNA.	[Andersen, Rikke Fredslund] Vejle Hosp, Dept Biochem & Immunol, Beriderbakken 4, DK-7100 Vejle, Denmark	Andersen, RF (reprint author), Vejle Hosp, Dept Biochem & Immunol, Beriderbakken 4, DK-7100 Vejle, Denmark.	rikke.fredslund.andersen@rsyd.dk					Akbani R, 2015, CELL, V161, P1681, DOI 10.1016/j.cell.2015.05.044; Allison KH, 2014, ONCOLOGY-NY, V28, P772; Andersen RF, 2015, CLIN CHIM ACTA, V439, P97, DOI 10.1016/j.cca.2014.10.011; Avraham A, 2012, INT J CANCER, V131, pE1166, DOI 10.1002/ijc.27526; Barault L, 2015, ANN ONCOL, V26, P1994, DOI 10.1093/annonc/mdv272; Barault L, 2018, GUT, V67, P1995, DOI 10.1136/gutjnl-2016-313372; Baylin Stephen B, 2005, Nat Clin Pract Oncol, V2 Suppl 1, pS4, DOI 10.1038/ncponc0354; Bediaga NG, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2721; Bergheim J, 2018, BRIT J CANCER, V118, P1217, DOI 10.1038/s41416-018-0035-8; Berman BP, 2012, NAT GENET, V44, P40, DOI 10.1038/ng.969; Boeckx N, 2018, CLIN COLORECTAL CANC, V17, pE369, DOI 10.1016/j.clcc.2018.02.006; Bromberg JS, 2017, J APPL LAB MED, V2, P309, DOI DOI 10.1373/JALM.2016.022731; Buj R, 2016, ONCOTARGET, V7, P10536, DOI 10.18632/oncotarget.7233; Chandrananda D, 2015, BMC MED GENOMICS, V8, DOI 10.1186/s12920-015-0107-z; Chatterjee A, 2017, METHODS MOL BIOL, V1537, P249, DOI 10.1007/978-1-4939-6685-1_15; Chodavarapu RK, 2010, NATURE, V466, P388, DOI 10.1038/nature09147; Cohen JD, 2018, SCIENCE, V359, P926, DOI 10.1126/science.aar3247; Costello JF, 2000, NAT GENET, V24, P132, DOI 10.1038/72785; Crowley E, 2013, NAT REV CLIN ONCOL, V10, P472, DOI 10.1038/nrclinonc.2013.110; Davis A, 2017, BBA-REV CANCER, V1867, P151, DOI 10.1016/j.bbcan.2017.01.003; De Mattos-Arruda L, 2016, NAT REV CLIN ONCOL, V13, P566, DOI 10.1038/nrclinonc.2016.35; de Vos L, 2017, CLIN EPIGENETICS, V9, DOI 10.1186/s13148-017-0425-4; Deng DJ, 2010, ADV GENET, V71, P125, DOI [10.1016/S0065-2660(10)71005-1, 10.1016/B978-0-12-380864-6.00005-5]; Diaz LA, 2014, J CLIN ONCOL, V32, P579, DOI 10.1200/JCO.2012.45.2011; Dietrich D, 2016, LABORATORIUMSMEDIZIN, V40, P335, DOI 10.1515/labmed-2016-0039; Duffy MJ, 2013, CLIN CHEM, V59, P1447, DOI 10.1373/clinchem.2012.200477; Fackler MJ, 2014, CANCER RES, V74, P2160, DOI 10.1158/0008-5472.CAN-13-3392; Feldman R, 2017, ANN TRANSL MED, V5, DOI 10.21037/atm.2017.07.34; Fiegl H, 2005, CANCER RES, V65, P1141, DOI 10.1158/0008-5472.CAN-04-2438; Fleischhacker M, 2007, BBA-REV CANCER, V1775, P181, DOI 10.1016/j.bbcan.2006.10.001; Fu B, 2018, DIS MARKERS, DOI 10.1155/2018/6437104; Gainetdinov IV, 2016, LUNG CANCER, V99, P127, DOI 10.1016/j.lungcan.2016.07.005; Garlan F, 2017, CLIN CANCER RES, V23, P5416, DOI 10.1158/1078-0432.CCR-16-3155; Garrigou S, 2016, CLIN CHEM, V62, P1129, DOI 10.1373/clinchem.2015.253609; Gerlinger M, 2012, NEW ENGL J MED, V366, P883, DOI 10.1056/NEJMoa1113205; Gormally E, 2006, CANCER RES, V66, P6871, DOI 10.1158/0008-5472.CAN-05-4556; Guo SC, 2017, NAT GENET, V49, P635, DOI 10.1038/ng.3805; Hansen KD, 2011, NAT GENET, V43, P768, DOI 10.1038/ng.865; Heitzer E, 2015, CLIN CHEM, V61, P112, DOI 10.1373/clinchem.2014.222679; Hendriks RJ, 2018, PROSTATE, V78, P336, DOI 10.1002/pros.23477; Herbst A, 2017, INT J CANCER, V140, P2134, DOI 10.1002/ijc.30625; Heyn H, 2012, NAT REV GENET, V13, P679, DOI 10.1038/nrg3270; Hoffmann AC, 2009, J CANCER RES CLIN, V135, P1231, DOI 10.1007/s00432-009-0564-x; Hoshimoto S, 2012, J INVEST DERMATOL, V132, P1689, DOI 10.1038/jid.2012.36; Jiang PY, 2015, P NATL ACAD SCI USA, V112, pE1317, DOI 10.1073/pnas.1500076112; Johnson AA, 2012, REJUV RES, V15, P483, DOI 10.1089/rej.2012.1324; Kint S, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0199091; Knudson AG, 2001, NAT REV CANCER, V1, P157, DOI 10.1038/35101031; Langevin SM, 2014, EPIGENETICS-US, V9, P884, DOI 10.4161/epi.28575; Lehmann-Werman R, 2016, P NATL ACAD SCI USA, V113, pE1826, DOI 10.1073/pnas.1519286113; Li M, 2009, NAT BIOTECHNOL, V27, P858, DOI 10.1038/nbt.1559; Li WS, 2017, CELL RES, V27, P1243, DOI 10.1038/cr.2017.121; Liggett TE, 2011, INT J CANCER, V128, P492, DOI 10.1002/ijc.25363; Loree JM, 2016, FUTURE ONCOL, V12, P2021, DOI 10.2217/fon-2016-0109; Lui YNYN, 2002, CLIN CHEM, V48, P421; Mahon KL, 2014, BRIT J CANCER, V111, P1802, DOI 10.1038/bjc.2014.463; Martinez-Cardus A, 2016, GASTROENTEROLOGY, V151, P961, DOI 10.1053/j.gastro.2016.08.001; McGranahan N, 2017, CELL, V168, P613, DOI 10.1016/j.cell.2017.01.018; Mossman David, 2006, Hered Cancer Clin Pract, V4, P75, DOI 10.1186/1897-4287-4-2-75; Nagai Y, 2017, ONCOTARGET, V8, P11906, DOI 10.18632/oncotarget.14439; O'Connor ES, 2011, J CLIN ONCOL, V29, P3381, DOI 10.1200/JCO.2010.34.3426; Orntoft MBW, 2017, EPIGENETICS-US, V12, P626, DOI 10.1080/15592294.2017.1334024; Pallisgaard N, 2015, CLIN CHIM ACTA, V446, P141, DOI 10.1016/j.cca.2015.04.015; Pharo HD, 2016, SCI REP-UK, V6, DOI 10.1038/srep33936; Ponomaryova AA, 2013, LUNG CANCER, V81, P397, DOI 10.1016/j.lungcan.2013.05.016; Postel M, 2018, EXPERT REV MOL DIAGN, V18, P7, DOI 10.1080/14737159.2018.1400384; Rykova EY, 2018, TRANSL CANCER RES, V7, pS153, DOI 10.21037/tcr.2018.02.08; Sakakura C, 2009, ANTICANCER RES, V29, P2619; Salazar F, 2011, LUNG CANCER, V72, P84, DOI 10.1016/j.lungcan.2010.07.008; Schmidt B, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0118195; Schmitt MW, 2016, NAT REV CLIN ONCOL, V13, P335, DOI 10.1038/nrclinonc.2015.175; Schrock A, 2017, CLIN CHEM, V63, P1288, DOI 10.1373/clinchem.2016.270207; Sharma G, 2012, TUMOR BIOL, V33, P1837, DOI 10.1007/s13277-012-0443-y; Siravegna G, 2015, NAT MED, V21, P795, DOI 10.1038/nm.3870; Siravegna G, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0449-4; Spindler KG, 2013, BRIT J CANCER, V109, P3067, DOI 10.1038/bjc.2013.633; Spindler KLG, 2017, ONCOLOGIST, V22, P1049, DOI 10.1634/theoncologist.2016-0178; Strickler JH, 2018, CANCER DISCOV, V8, P164, DOI 10.1158/2159-8290.CD-17-1009; Struhl K, 2013, NAT STRUCT MOL BIOL, V20, P267, DOI 10.1038/nsmb.2506; Sun K, 2015, P NATL ACAD SCI USA, V112, pE5503, DOI 10.1073/pnas.1508736112; Swarup V, 2007, FEBS LETT, V581, P795, DOI 10.1016/j.febslet.2007.01.051; Symonds EL, 2018, CLIN EPIGENETICS, V10, DOI 10.1186/s13148-018-0500-5; Takahashi H, 2017, CLIN BREAST CANCER, V17, P61, DOI 10.1016/j.clbc.2016.06.006; Thomas ML, 2018, CANCERS, V10; VanderLaan PA, 2017, LUNG CANCER, V106, P17, DOI 10.1016/j.lungcan.2017.01.011; Vaughn CP, 2011, GENE CHROMOSOME CANC, V50, P307, DOI 10.1002/gcc.20854; Visvanathan K, 2017, J CLIN ONCOL, V35, P751, DOI 10.1200/JCO.2015.66.2080; Vogelstein B, 2013, SCIENCE, V339, P1546, DOI 10.1126/science.1235122; Volckmar AL, 2018, GENE CHROMOSOME CANC, V57, P123, DOI 10.1002/gcc.22517; Wan JCM, 2017, NAT REV CANCER, V17, P223, DOI 10.1038/nrc.2017.7; Warton K, 2016, ENDOCR-RELAT CANCER, V23, pR157, DOI 10.1530/ERC-15-0369; Warton Kristina, 2015, Front Mol Biosci, V2, P13, DOI 10.3389/fmolb.2015.00013; Weller M, 2010, NAT REV NEUROL, V6, P39, DOI 10.1038/nrneurol.2009.197; Whale AS, 2018, METHODS MOL BIOL, V1768, P45, DOI 10.1007/978-1-4939-7778-9_4; Whale AS, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058177; Wong IHN, 2003, CLIN CANCER RES, V9, P1047; Yates LR, 2012, NAT REV GENET, V13, P795, DOI 10.1038/nrg3317	97	2	2	1	7	TAYLOR & FRANCIS AS	OSLO	KARL JOHANS GATE 5, NO-0154 OSLO, NORWAY	1473-7159	1744-8352		EXPERT REV MOL DIAGN	Expert Rev. Mol. Diagn.	DEC 2	2018	18	12					1011	1019		10.1080/14737159.2018.1545576			9	Pathology	Pathology	HC7TN	WOS:000452004600004	30411633				2019-10-28	
J	Cimadamore, A; Scarpelli, M; Santoni, M; Cheng, L; Lopez-Beltran, A; Montironi, R				Cimadamore, Alessia; Scarpelli, Marina; Santoni, Matteo; Cheng, Liang; Lopez-Beltran, Antonio; Montironi, Rodolfo			Upper urinary tract urothelial carcinoma and its variants: transition from morphology to personalized molecular characterization in diagnosis, prognosis, and therapy	EXPERT REVIEW OF MOLECULAR DIAGNOSTICS			English	Review						Upper tract urothelial carcinoma; cancer variants; molecular characterization; predictive models; personalized approach	CLEAR-CELL ADENOCARCINOMA; ICUD-SIU CONSULTATION; RADICAL NEPHROURETERECTOMY; HISTOLOGICAL VARIANTS; RENAL PELVIS; NEOADJUVANT CHEMOTHERAPY; CLINICAL-SIGNIFICANCE; NESTED VARIANT; TUMOR NECROSIS; BLADDER	Introduction: Upper tract urothelial carcinoma (UTUC) accounts for 5% of urothelial carcinomas (UCs), the estimated annual incidence being 1-2 cases per 100,000 inhabitants. The aim of this review was to summarize the main morphologic features of UTUC as well as the current status and future role of its molecular characterization in diagnosis, prognosis, and therapy. Areas covered: Several studies on the UTUCs have shown the diagnostic, prognostic, and therapeutic significance of standard pathological features, such as tumor stage, grade, and lymph node metastasis. Investigations have also identified novel factors, in particular, variant histologies, and molecular biomarkers. Based on these, predictive tools have been developed. Expert commentary: The morphology of the UTUC has been considered to be the same as that of Bladder Urothelial carcinoma (BUC). Molecular characterization studies, including genomics, have shown changes in UTUC occurring at differing frequencies in comparison with BUC, the former with unique molecular subtypes and different responses to treatment.	[Cimadamore, Alessia; Scarpelli, Marina; Montironi, Rodolfo] Polytech Univ Marche Reg, United Hosp, Sch Med, Sect Pathol Anat, Ancona, Italy; [Santoni, Matteo] Macerata Hosp, Oncol Unit, Macerata, Italy; [Cheng, Liang] Indiana Univ Sch Med, Dept Pathol & Lab Med, Indianapolis, IN 46202 USA; [Lopez-Beltran, Antonio] Cordoba Univ, Med Sch, Dept Surg, Cordoba, Spain	Montironi, R (reprint author), Polytech Univ Marche Reg, United Hosp, Sch Med, Pathol Anat, Via Conca 71, I-60126 Ancona, Italy.	r.montironi@univpm.it		CIMADAMORE, ALESSIA/0000-0001-5981-3514			Agaimy A, 2016, VIRCHOWS ARCH, V469, P321, DOI 10.1007/s00428-016-1977-y; Al-Ahmadie HA, 2016, NAT GENET, V48, P356, DOI 10.1038/ng.3503; Aziz A, 2017, WORLD J UROL, V35, P1401, DOI 10.1007/s00345-016-1995-z; Bagrodia A, 2018, EUR UROL FOCUS; Bagrodia A, 2016, J UROLOGY, V195, P1684, DOI 10.1016/j.juro.2016.01.006; Choi W, 2017, EUR UROL, V72, P354, DOI 10.1016/j.eururo.2017.03.010; Chowdhury S, 2017, J CLIN ONCOL, V35, DOI 10.1200/JCO.2017.35.15_suppl.5028; Donahue TF, 2018, JCO PRECIS ONCOL, V2, P1; EBLE JN, 2004, PATHOLOGY GENETICS T, P89; Fajkovic H, 2012, J UROLOGY, V187, P845, DOI 10.1016/j.juro.2011.10.158; Favaretto RL, 2018, INT BRAZ J UROL, V44, P22, DOI [10.1590/S1677-5538.IBJU.2017.0204, 10.1590/s1677-5538.ibju.2017.0204]; Favaretto RL, 2017, WORLD J UROL, V35, P113, DOI 10.1007/s00345-016-1835-1; Gakis G, 2017, WORLD J UROL, V35, P327, DOI 10.1007/s00345-016-1819-1; Green DA, 2013, J UROLOGY, V189, P1214, DOI 10.1016/j.juro.2012.05.079; Guo CC, 2009, ARCH PATHOL LAB MED, V133, P62, DOI 10.1043/1543-2165-133.1.62; Gupta R, 2008, ADV ANAT PATHOL, V15, P127, DOI 10.1097/PAP.0b013e31817145a9; Habuchi T, 2005, INT J UROL, V12, P709, DOI 10.1111/j.1442-2042.2005.01155.x; Hafner C, 2001, ONCOGENE, V20, P4910, DOI 10.1038/sj.onc.1204671; Hensley Patrick J, 2017, J Endourol Case Rep, V3, P165, DOI 10.1089/cren.2017.0103; Hoglund M, 2007, EUR UROL, V51, P1185, DOI 10.1016/j.eururo.2006.11.025; Jibril A, 2018, AM J CASE REP, V19, P158, DOI 10.12659/AJCR.906679; Kang CH, 2003, CANCER, V98, P1620, DOI 10.1002/cncr.11691; Kauffman EC, 2008, EXPERT REV ANTICANC, V8, P75, DOI 10.1586/14737140.8.1.75; Keck B, 2012, UROL INT, V89, P120, DOI 10.1159/000335519; Khene ZE, 2016, TRANSL ANDROL UROL, V5, P711, DOI 10.21037/tau.2016.09.05; Krabbe LM, 2015, J UROLOGY, V193, P1486, DOI 10.1016/j.juro.2014.11.007; Lau SK, 2009, PATHOL RES PRACT, V205, P508, DOI 10.1016/j.prp.2008.12.006; Lee HY, 2015, ANN SURG ONCOL, V22, P1392, DOI 10.1245/s10434-014-4103-x; Leow JJ, 2014, EUR UROL, V66, P529, DOI 10.1016/j.eururo.2014.03.003; Liu KW, 2013, POL J PATHOL, V64, P308, DOI 10.5114/PJP.2013.30341; Lopez-Beltran A, 2017, VIRCHOWS ARCH, V470, P703, DOI 10.1007/s00428-017-2117-z; Lu W, 2017, ONCOL LETT, V13, P1331, DOI 10.3892/ol.2017.5575; Mandalapu RS, 2017, WORLD J UROL, V35, P355, DOI 10.1007/s00345-016-1859-6; Masson-Lecomte A, 2014, WORLD J UROL, V32, P531, DOI 10.1007/s00345-013-1141-0; Matin SF, 2015, EUR UROL, V68, P978, DOI 10.1016/j.eururo.2015.08.009; Mbeutcha A, 2017, WORLD J UROL, V35, P337, DOI 10.1007/s00345-016-1826-2; McCash SI, 2010, APMIS, V118, P407, DOI 10.1111/j.1600-0463.2010.02608.x; Moch H, 2016, EUR UROL, V70, P93, DOI 10.1016/j.eururo.2016.02.029; Moktefi A, 2018, MODERN PATHOL, V31, P1270, DOI 10.1038/s41379-018-0023-9; Moschini M, 2017, NAT REV UROL, V14, P651, DOI 10.1038/nrurol.2017.125; Moss TJ, 2017, EUR UROL, V72, P641, DOI 10.1016/j.eururo.2017.05.048; Mostofi FK, 1973, HISTOLOGICAL TYPING; Nguyen D, 2016, VIRCHOWS ARCH, V469, P427, DOI 10.1007/s00428-016-2001-2; Paner GP, 2018, EUR UROL, V73, P560, DOI 10.1016/j.eururo.2017.12.018; Patriarca C, 2011, INT J SURG PATHOL, V19, P11, DOI 10.1177/1066896909356106; Perez-Montiel D, 2006, MODERN PATHOL, V19, P494, DOI 10.1038/modpathol.3800559; Pham MN, 2017, WORLD J UROL, V35, P367, DOI 10.1007/s00345-016-1885-4; Porten S, 2014, CANCER-AM CANCER SOC, V120, P1794, DOI 10.1002/cncr.28655; Rink M, 2012, J UROLOGY, V188, P398, DOI 10.1016/j.juro.2012.04.009; Roupret M, 2005, BJU INT, V96, P489, DOI 10.1111/j.1464-410X.2005.05671.x; Roupret M, 2018, EUR UROL, V73, P111, DOI 10.1016/j.eururo.2017.07.036; Sanford T, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0137141; Seitz C, 2010, J UROLOGY, V184, P1895, DOI 10.1016/j.juro.2010.06.106; Sfakianos JP, 2015, EUR UROL, V68, P970, DOI 10.1016/j.eururo.2015.07.039; Shao IH, 2019, INT J UROL, V26, P148, DOI 10.1111/iju.13826; Shariat SF, 2017, WORLD J UROL, V35, P325, DOI 10.1007/s00345-017-2016-6; Shih CM, 2010, J CHIN MED ASSOC, V73, P40, DOI 10.1016/S1726-4901(10)70020-4; Siegel RL, 2016, CA-CANCER J CLIN, V66, P7, DOI 10.3322/caac.21332; Sood Akshay, 2016, J Endourol Case Rep, V2, P204; Soria F, 2017, WORLD J UROL, V35, P379, DOI 10.1007/s00345-016-1928-x; Sung HH, 2014, J CLIN PATHOL, V67, P49, DOI 10.1136/jclinpath-2013-201799; Terada T, 2010, PATHOL RES PRACT, V206, P379, DOI 10.1016/j.prp.2009.07.021; Tripodi S, 2011, ANAL QUANT CYTOL, V33, P340; Vashistha V, 2013, ARCH PATHOL LAB MED, V137, P400, DOI 10.5858/arpa.2012-0136-OA; Wang XY, 2017, FUTURE ONCOL, V13, P705, DOI 10.2217/fon-2016-0414; Wang YX, 2018, WORLD J SURG ONCOL, V16, DOI 10.1186/s12957-018-1383-9; Wang YD, 2013, SPRINGERPLUS, V2, DOI 10.1186/2193-1801-2-412; Wang ZH, 2012, INT J CLIN EXP PATHO, V5, P601; Wheat JC, 2012, UROL ONCOL-SEMIN ORI, V30, P252, DOI 10.1016/j.urolonc.2010.01.001; Xylinas E, 2013, EUR J CANCER, V49, P1889, DOI 10.1016/j.ejca.2013.02.001; Yates DR, 2012, BRIT J CANCER, V106, P1083, DOI 10.1038/bjc.2012.64; Zhang B, 2017, MED ONCOL, V34, DOI 10.1007/s12032-017-0941-2; Zhong MH, 2015, AM J SURG PATHOL, V39, P127, DOI 10.1097/PAS.0000000000000305; Zhou HJ, 2014, AM J CLIN EXP UROL, V2, P156; Zigeuner R, 2010, EUR UROL, V57, P575, DOI 10.1016/j.eururo.2009.11.035	75	1	1	0	2	TAYLOR & FRANCIS AS	OSLO	KARL JOHANS GATE 5, NO-0154 OSLO, NORWAY	1473-7159	1744-8352		EXPERT REV MOL DIAGN	Expert Rev. Mol. Diagn.	DEC 2	2018	18	12					1021	1028		10.1080/14737159.2018.1549490			8	Pathology	Pathology	HC7TN	WOS:000452004600005	30452305				2019-10-28	
J	Whiteside, TL				Whiteside, Theresa L.			The potential of tumor-derived exosomes for noninvasive cancer monitoring: an update	EXPERT REVIEW OF MOLECULAR DIAGNOSTICS			English	Review						Extracellular vesicles; tumor-derived exosomes; cancer; non-invasive biomarkers	EXTRACELLULAR VESICLES; PLASMA; MICROVESICLES; MELANOMA; HEAD	Introduction: Liquid biopsy platforms are being actively developed in the biomarker field. Extracellular vesicles (EVs), especially the tumor-derived exosome (TEX) subsets of EVs, represent a platform that allows for molecular and genetic profiling of parent tumor cells. TEX are ubiquitous in body fluids of cancer patients and are promising clinically relevant surrogates of cancer cells. Areas covered: Isolation from body fluids of cancer patients and subsetting of exosomes based on immunoaffinity capture offers a means of evaluating proteins, lipids, nucleic acids and other molecular contents that are a characteristic of TEX and exosomes produced by reprogrammed normal cells. The same liquid biopsy can inform about the status of a tumor and simultaneously evaluate the competency of immune cells to mediate anti-tumor activities. Expert commentary: TEX and reprogrammed non-TEX isolated from plasma of cancer patients have the potential to become non-invasive biomarkers of cancer diagnosis, prognosis and response to therapies.	[Whiteside, Theresa L.] Univ Pittsburgh, Sch Med, Dept Pathol, Pittsburgh, PA USA; [Whiteside, Theresa L.] Univ Pittsburgh, Sch Med, Dept Immunol, Pittsburgh, PA USA; [Whiteside, Theresa L.] Univ Pittsburgh, Sch Med, Dept Otolaryngol, Pittsburgh, PA USA; [Whiteside, Theresa L.] UPMC Hillman Canc Ctr, 5117 Ctr Ave,Suite 1-27, Pittsburgh, PA 15213 USA	Whiteside, TL (reprint author), UPMC Hillman Canc Ctr, 5117 Ctr Ave,Suite 1-27, Pittsburgh, PA 15213 USA.	whitesidetl@upmc.edu			NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [RO-1 CA168628, R-21 CA205644]	The author acknowledges partial support from NIH grants RO-1 CA168628 and R-21 CA205644.	Abels ER, 2016, CELL MOL NEUROBIOL, V36, P301, DOI 10.1007/s10571-016-0366-z; Atay Safinur, 2014, Commun Integr Biol, V7, pe28231, DOI 10.4161/cib.28231; Boyiadzis M, 2017, LEUKEMIA, V31, P1259, DOI 10.1038/leu.2017.91; Burz Claudia, 2018, Oncotarget, V9, P24561, DOI 10.18632/oncotarget.25337; Cramer DW, 2010, CLIN CHEM, V56, P1889, DOI 10.1373/clinchem.2010.153122; Fanini F, 2017, SEMIN CELL DEV BIOL, V67, P23, DOI 10.1016/j.semcdb.2016.12.004; Ferracin M, 2016, ADV EXP MED BIOL, V937, P171, DOI 10.1007/978-3-319-42059-2_9; Frediani JN, 2016, MOL CANCER, V15, DOI 10.1186/s12943-016-0525-3; Hanash S, 2018, CLIN CHEM, V64, P743, DOI 10.1373/clinchem.2017.273466; Heitzer E, 2015, CLIN CHEM, V61, P112, DOI 10.1373/clinchem.2014.222679; Hong CS, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-14661-w; Hong CS, 2016, J EXTRACELL VESICLES, V5, DOI 10.3402/jev.v5.29289; Iero M, 2008, CELL DEATH DIFFER, V15, P80, DOI 10.1038/sj.cdd.4402237; Ishiba T, 2018, BIOCHEM BIOPH RES CO, V500, P621, DOI 10.1016/j.bbrc.2018.04.120; Kowal J, 2016, P NATL ACAD SCI USA, V113, pE968, DOI 10.1073/pnas.1521230113; Li P, 2017, THERANOSTICS, V7, P789, DOI 10.7150/thno.18133; Lucchetti D, 2019, BIOTECHNOL J, V14, DOI 10.1002/biot.201700716; Ludwig S, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00445; Ludwig S, 2017, CLIN CANCER RES, V23, P4843, DOI 10.1158/1078-0432.CCR-16-2819; Meehan B, 2016, J EXTRACELL VESICLES, V5, DOI 10.3402/jev.v5.33109; Melo SA, 2015, NATURE, V523, P177, DOI 10.1038/nature14581; Mrizak D, 2015, JNCI-J NATL CANCER I, V107, DOI 10.1093/jnci/dju363; Mulcahy LA, 2014, J EXTRACELL VESICLES, V3, DOI 10.3402/jev.v3.24641; Oppenheim JJ, 2018, CSH PERSPECT BIOL, V10, DOI 10.1101/cshperspect.a028498; Pavlou MP, 2010, J PROTEOMICS, V73, P1896, DOI 10.1016/j.jprot.2010.04.003; Peinado H, 2012, NAT MED, V18, P883, DOI 10.1038/nm.2753; Raposo G, 2013, J CELL BIOL, V200, P373, DOI 10.1083/jcb.201211138; Sharma P, 2018, J CLIN ONCOL INSIGHT; Sharma P, 2018, J EXTRACELL VESICLES, V7, DOI 10.1080/20013078.2018.1435138; Szajnik M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011469; Theodoraki MN, 2018, CLIN EXP IMMUNOL, V192, P271, DOI 10.1111/cei.13113; Theodoraki MN, 2017, J IMMUNOTHER CANCER, V5; Theodoraki Marie-Nicole, 2018, Oncoscience, V5, P75, DOI 10.18632/oncoscience.410; Theodoraki MN, 2018, CLIN CANCER RES, V24, P896, DOI 10.1158/1078-0432.CCR-17-2664; Wang YY, 2014, METHODS MOL BIOL, V1102, P523, DOI 10.1007/978-1-62703-727-3_28; Whiteside TL, 2018, SEMIN IMMUNOL, V35, P69, DOI 10.1016/j.smim.2017.12.003; Whiteside TL, 2017, FUTURE ONCOL, V13, P2583, DOI 10.2217/fon-2017-0343; Whiteside TL, 2016, CLIN CANCER RES, V22, P1845, DOI 10.1158/1078-0432.CCR-16-0049; Whiteside TL, 2016, J CLIN INVEST, V126, P1216, DOI 10.1172/JCI81136; Wieckowski EU, 2009, J IMMUNOL, V183, P3720, DOI 10.4049/jimmunol.0900970; Yang KS, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aal3226; Zhang HY, 2018, NAT CELL BIOL, V20, P332, DOI 10.1038/s41556-018-0040-4; Zhang HG, 2016, ONCOTARGET, V7, P41346, DOI 10.18632/oncotarget.9325; Zijlstra A, 2018, NAT CELL BIOL, V20, P228, DOI 10.1038/s41556-018-0049-8	44	1	1	1	10	TAYLOR & FRANCIS AS	OSLO	KARL JOHANS GATE 5, NO-0154 OSLO, NORWAY	1473-7159	1744-8352		EXPERT REV MOL DIAGN	Expert Rev. Mol. Diagn.	DEC 2	2018	18	12					1029	1040		10.1080/14737159.2018.1544494			12	Pathology	Pathology	HC7TN	WOS:000452004600006	30406709				2019-10-28	
J	Picca, A; Berzero, G; Di Stefano, AL; Sanson, M				Picca, Alberto; Berzero, Giulia; Di Stefano, Anna Luisa; Sanson, Marc			The clinical use of IDH1 and IDH2 mutations in gliomas	EXPERT REVIEW OF MOLECULAR DIAGNOSTICS			English	Review						IDH1and IDH2 mutations; gliomagenesis; grade II and III gliomas; biomarkers; target therapy	MAGNETIC-RESONANCE-SPECTROSCOPY; ISOCITRATE DEHYDROGENASE 1; CENTRAL-NERVOUS-SYSTEM; LOWER-GRADE GLIOMAS; INTEGRATED GENOMIC ANALYSIS; ACUTE MYELOID-LEUKEMIA; DNA-REPAIR ENZYMES; MUTANT IDH1; ONCOMETABOLITE 2-HYDROXYGLUTARATE; DIFFUSE GLIOMAS	Introduction: Mutations in the genes isocitrate dehydrogenase (IDH) 1 and 2 have been reported in a limited number of tumors. In gliomas, IDH mutations are primarily detected in WHO grade II-III tumors and represent a major biomarker with diagnostic, prognostic, and predictive implications. The recent development of IDH inhibitors and vaccines suggests that the IDH mutation is also an appealing target for therapy. Areas covered: This review focuses on the role of IDH mutations in diffuse gliomas. Besides discussing their role in gliomagenesis, we will emphasize the role of IDH mutations in clinical practice as a diagnostic, prognostic and predictive biomarker, and as a potential therapeutic target. Noninvasive detection of the IDH mutation by means of liquid biopsy and MR spectroscopy will also be discussed. Expert commentary: While IDH mutation is a consolidated diagnostic and prognostic biomarker in clinical practice, its role in oncogenesis is far from being elucidated, and there are several pending issues. The routine use of noninvasive techniques for detection and monitoring of the IDH status remains challenging. Although the IDH mutation is a very early alteration in gliomagenesis, it may then be omitted during tumor progression. This observation has important implications when designing targeted clinical trials.	[Picca, Alberto] Univ Pavia, Neurosci Consortium, Pavia, Italy; [Berzero, Giulia] IRCCS Mondino Fdn, Neuroncol Unit, Pavia, Italy; [Berzero, Giulia] Univ Pavia, Biomed Sci, Pavia, Italy; [Di Stefano, Anna Luisa; Sanson, Marc] Sorbonne Univ, Paris, France; [Di Stefano, Anna Luisa] Foch Hosp, Dept Neurol, Paris, France; [Sanson, Marc] Hop La Pitie Salpetriere, AP HP, Serv Neurol 2, Paris, France	Sanson, M (reprint author), GH Pitie Salpetriere, Serv Neurol 2, 47 Bd Hop, F-75013 Paris, France.	marc.sanson@psl.aphp.fr	Berzero, Giulia/AAA-4424-2019	Picca, Alberto/0000-0001-7807-5393			Abdel-Wahab O, 2009, BLOOD, V114, P144, DOI 10.1182/blood-2009-03-210039; Alentorn A, 2015, NEUROLOGY, V85, P1325, DOI 10.1212/WNL.0000000000002014; Amankulor NM, 2017, GENE DEV, V31, P774, DOI 10.1101/gad.294991.116; Amary MF, 2011, J PATHOL, V224, P334, DOI 10.1002/path.2913; Andronesi OC, 2016, CLIN CANCER RES, V22, P1632, DOI 10.1158/1078-0432.CCR-15-0656; Andronesi OC, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3002693; Archer GE, 2014, NEURO-ONCOLOGY, V16, piii40; Bardella C, 2016, CANCER CELL, V30, P578, DOI 10.1016/j.ccell.2016.08.017; Beiko J, 2014, NEURO-ONCOLOGY, V16, P81, DOI 10.1093/neuonc/not159; Berghoff AS, 2017, NEURO-ONCOLOGY, V19, P1460, DOI 10.1093/neuonc/nox054; Best MG, 2015, ACTA NEUROPATHOL, V129, P849, DOI 10.1007/s00401-015-1399-y; Bleeker FE, 2010, ACTA NEUROPATHOL, V119, P487, DOI 10.1007/s00401-010-0645-6; Boisselier B, 2012, NEUROLOGY, V79, P1693, DOI 10.1212/WNL.0b013e31826e9b0a; Boisselier B, 2010, HUM MUTAT, V31, P1360, DOI 10.1002/humu.21365; Borger DR, 2014, CLIN CANCER RES, V20, P1884, DOI 10.1158/1078-0432.CCR-13-2649; Borger DR, 2012, ONCOLOGIST, V17, P72, DOI 10.1634/theoncologist.2011-0386; Borodovsky A, 2013, ONCOTARGET, V4, P1737, DOI 10.18632/oncotarget.1408; Branzoli F, 2018, NEURO-ONCOLOGY, V20, P907, DOI 10.1093/neuonc/nox214; Brat DJ, 2015, NEW ENGL J MED, V372, P2481, DOI 10.1056/NEJMoa1402121; Broen MPG, 2018, NEURO-ONCOLOGY, V20, P1393, DOI 10.1093/neuonc/noy048; Buckner JC, 2016, NEW ENGL J MED, V374, P1344, DOI 10.1056/NEJMoa1500925; Bunse L, 2018, NAT MED, V24, P1192, DOI 10.1038/s41591-018-0095-6; Cairncross JG, 2014, J CLIN ONCOL, V32, P783, DOI 10.1200/JCO.2013.49.3726; Capper D, 2018, NATURE, V555, P469, DOI 10.1038/nature26000; Capper D, 2012, INT J CANCER, V131, P766, DOI 10.1002/ijc.26425; Capper D, 2010, BRAIN PATHOL, V20, P245, DOI 10.1111/j.1750-3639.2009.00352.x; Catteau A, 2014, ACTA NEUROPATHOL COM, V2, DOI 10.1186/2051-5960-2-58; Chan AKY, 2015, ONCOTARGET, V6, P20885, DOI 10.18632/oncotarget.4928; Chen FY, 2017, CHEM RES TOXICOL, V30, P1102, DOI 10.1021/acs.chemrestox.7b00009; Chen H, 2017, NEUROLOGY, V88, P1805, DOI 10.1212/WNL.0000000000003911; Chen WW, 2013, MOL THER-NUCL ACIDS, V2, DOI 10.1038/mtna.2013.28; Chiang S, 2016, CANCER RES, V76, P7118, DOI 10.1158/0008-5472.CAN-16-0298; Cho YS, 2017, ACS MED CHEM LETT, V8, P1116, DOI 10.1021/acsmedchemlett.7b00342; Choi CH, 2016, J CLIN ONCOL, V34, P4030, DOI 10.1200/JCO.2016.67.1222; Choi C, 2012, NAT MED, V18, P624, DOI 10.1038/nm.2682; Chowdhury R, 2011, EMBO REP, V12, P463, DOI 10.1038/embor.2011.43; Coffelt SB, 2016, NAT REV CANCER, V16, P431, DOI 10.1038/nrc.2016.52; Cruz GR, 2014, J NEURO-ONCOL, V117, P235, DOI 10.1007/s11060-014-1398-1; Dang L, 2009, NATURE, V462, P739, DOI 10.1038/nature08617; de la Fuente MI, 2016, NEURO-ONCOLOGY, V18, P283, DOI 10.1093/neuonc/nov307; DiNardo CD, 2018, NEW ENGL J MED, V378, P2386, DOI 10.1056/NEJMoa1716984; Dubbink HJ, 2016, NEURO-ONCOLOGY, V18, P388, DOI 10.1093/neuonc/nov182; Emir UE, 2016, CANCER RES, V76, P43, DOI 10.1158/0008-5472.CAN-15-0934; Fathi AT, 2016, ONCOLOGIST, V21, P214, DOI 10.1634/theoncologist.2015-0342; Felsberg J, 2010, ACTA NEUROPATHOL, V119, P501, DOI 10.1007/s00401-010-0647-4; Feng J, 2016, BIOMED RES INT, DOI 10.1155/2016/1450843; Figarella-Branger D, 2016, NEURO-ONCOLOGY, V18, P888, DOI 10.1093/neuonc/now085; Figueroa ME, 2010, CANCER CELL, V18, P553, DOI 10.1016/j.ccr.2010.11.015; Flavahan WA, 2016, NATURE, V529, P110, DOI 10.1038/nature16490; Fontanilles M, 2018, CURR NEUROL NEUROSCI, V18, DOI 10.1007/s11910-018-0820-z; Green CL, 2011, BLOOD, V118, P409, DOI 10.1182/blood-2010-12-322479; Gupta R, 2013, MODERN PATHOL, V26, P619, DOI 10.1038/modpathol.2012.210; Hegi ME, 2005, NEW ENGL J MED, V352, P997, DOI 10.1056/NEJMoa043331; Horbinski C, 2013, ACTA NEUROPATHOL, V125, P621, DOI 10.1007/s00401-013-1106-9; Horbinski C, 2010, J MOL DIAGN, V12, P487, DOI 10.2353/jmoldx.2010.090228; Houillier C, 2010, NEUROLOGY, V75, P1560, DOI 10.1212/WNL.0b013e3181f96282; Intlekofer AM, 2015, CELL METAB, V22, P304, DOI 10.1016/j.cmet.2015.06.023; Janin M, 2014, J CLIN ONCOL, V32, P297, DOI 10.1200/JCO.2013.50.2047; Jin CH, 2016, ONCOTARGETS THER, V9, P1571, DOI 10.2147/OTT.S96762; Jin GL, 2013, CANCER RES, V73, P496, DOI 10.1158/0008-5472.CAN-12-2852; Johannessen TCA, 2016, MOL CANCER RES, V14, P976, DOI 10.1158/1541-7786.MCR-16-0141; Johnson BE, 2014, SCIENCE, V343, P189, DOI 10.1126/science.1239947; Kalinina J, 2016, CLIN CANCER RES, V22, P6256, DOI 10.1158/1078-0432.CCR-15-2965; Kanamori M, 2014, J NEUROSURG, V120, P1288, DOI 10.3171/2014.3.JNS131505; Karpel-Massler G, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00984-9; Kato Y, 2009, BIOCHEM BIOPH RES CO, V390, P547, DOI 10.1016/j.bbrc.2009.10.001; Khurshed M, 2017, ONCOTARGET, V8, P49165, DOI 10.18632/oncotarget.17106; Kickingereder P, 2015, SCI REP-UK, V5, DOI 10.1038/srep16238; Kohanbash G, 2017, J CLIN INVEST, V127, P1425, DOI 10.1172/JCI90644; Kolker S, 2002, EUR J NEUROSCI, V16, P21, DOI 10.1046/j.1460-9568.2002.02055.x; Kopinja J, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-14065-w; Kranendijk M, 2012, J INHERIT METAB DIS, V35, P571, DOI 10.1007/s10545-012-9462-5; Labreche K, 2018, ACTA NEUROPATHOL, V135, P743, DOI 10.1007/s00401-018-1825-z; Labussiere M, 2010, NEUROLOGY, V74, P1886, DOI 10.1212/WNL.0b013e3181e1cf3a; Lai A, 2011, J CLIN ONCOL, V29, P4482, DOI 10.1200/JCO.2010.33.8715; Lasocki A, 2018, AM J NEURORADIOL, V39, P687, DOI 10.3174/ajnr.A5572; Leather T, 2017, METABOLITES, V7, DOI 10.3390/metabo7020029; Lemonnier F, 2016, P NATL ACAD SCI USA, V113, P15084, DOI 10.1073/pnas.1617929114; Leu K, 2017, J NEURO-ONCOL, V134, P177, DOI 10.1007/s11060-017-2506-9; Linos K, 2018, HISTOPATHOLOGY, V73, P963, DOI 10.1111/his.13707; Lombardi G, 2015, ONCOLOGIST, V20, P562, DOI 10.1634/theoncologist.2014-0266; Longuespee R, 2018, ACTA NEUROPATHOL COM, V6, DOI 10.1186/s40478-018-0523-3; Louis DN, 2016, ACTA NEUROPATHOL, V131, P803, DOI 10.1007/s00401-016-1545-1; Lu C, 2012, NATURE, V483, P474, DOI 10.1038/nature10860; Lu YX, 2017, CANCER RES, V77, P1709, DOI 10.1158/0008-5472.CAN-16-2773; Machida Y, 2016, CANCER RES, V76, DOI 10.1158/1538-7445.AM2016-3101; Mardis ER, 2009, NEW ENGL J MED, V361, P1058, DOI 10.1056/NEJMoa0903840; Martinez-Ricarte F, 2018, CLIN CANCER RES, V24, P2812, DOI 10.1158/1078-0432.CCR-17-3800; Mazor T, 2017, P NATL ACAD SCI USA, V114, P10743, DOI 10.1073/pnas.1708914114; Melin BS, 2017, NAT GENET, V49, P789, DOI 10.1038/ng.3823; Mellinghoff I, 2018, J CLIN ONCOL, V36; Mellinghoff IK, 2016, NEURO-ONCOLOGY, V18, P12; Modrek AS, 2017, CELL REP, V21, P1267, DOI 10.1016/j.celrep.2017.10.009; Molenaar RJ, 2015, CANCER RES, V75, P4790, DOI 10.1158/0008-5472.CAN-14-3603; Molenaar RJ, 2014, BBA-REV CANCER, V1846, P326, DOI 10.1016/j.bbcan.2014.05.004; Moroni I, 2004, NEUROLOGY, V62, P1882, DOI 10.1212/01.WNL.0000125335.21381.87; Nikiforova MN, 2016, NEURO-ONCOLOGY, V18, P379, DOI 10.1093/neuonc/nov289; Noushmehr H, 2010, CANCER CELL, V17, P510, DOI 10.1016/j.ccr.2010.03.017; Park YW, 2018, AM J NEURORADIOL, V39, P37, DOI 10.3174/ajnr.A5421; Parsons DW, 2008, SCIENCE, V321, P1807, DOI 10.1126/science.1164382; Patay Z, 2012, AM J NEURORADIOL, V33, P940, DOI 10.3174/ajnr.A2869; Patay Z, 2015, J INHERIT METAB DIS, V38, P273, DOI 10.1007/s10545-014-9782-8; Patel SH, 2017, CLIN CANCER RES, V23, P6078, DOI 10.1158/1078-0432.CCR-17-0560; Paugh BS, 2010, J CLIN ONCOL, V28, P3061, DOI 10.1200/JCO.2009.26.7252; Pellegatta S, 2015, ACTA NEUROPATHOL COM, V3, DOI 10.1186/s40478-014-0180-0; Perizzolo M, 2012, BRAIN PATHOL, V22, P619, DOI 10.1111/j.1750-3639.2012.00579.x; Phan K, 2018, WORLD NEUROSURG, V111, pE539, DOI [10.1016/J.WNEU.2017.12.112, 10.1016/j.wneu.2017.12.112]; Pirro V, 2017, P NATL ACAD SCI USA, V114, P6700, DOI 10.1073/pnas.1706459114; PLATTEN M, 2018, J CLIN ONCOL S, V36; Platten M, 2016, J CLIN ONCOL, V34, DOI 10.1200/JCO.2016.34.15_suppl.TPS2082; Pope WB, 2012, J NEURO-ONCOL, V107, P197, DOI 10.1007/s11060-011-0737-8; Popovici-Muller J, 2018, ACS MED CHEM LETT, V9, P300, DOI 10.1021/acsmedchemlett.7b00421; Pusch S, 2011, NEUROPATH APPL NEURO, V37, P428, DOI 10.1111/j.1365-2990.2010.01127.x; Pusch S, 2017, ACTA NEUROPATHOL, V133, P629, DOI 10.1007/s00401-017-1677-y; Ramkissoon SH, 2015, NEURO-ONCOLOGY, V17, P1344, DOI 10.1093/neuonc/nov015; Reuss DE, 2015, ACTA NEUROPATHOL, V129, P133, DOI 10.1007/s00401-014-1370-3; Rover LK, 2018, EBIOMEDICINE, V28, P97, DOI 10.1016/j.ebiom.2018.01.016; Rohle D, 2013, SCIENCE, V340, P626, DOI 10.1126/science.1236062; Sahm F, 2016, ACTA NEUROPATHOL, V131, P903, DOI 10.1007/s00401-015-1519-8; Sanson M, 2009, J CLIN ONCOL, V27, P4150, DOI 10.1200/JCO.2009.21.9832; Santagata S, 2014, P NATL ACAD SCI USA, V111, P11121, DOI 10.1073/pnas.1404724111; Sasaki M, 2012, GENE DEV, V26, P2038, DOI 10.1101/gad.198200.112; Schumacher T, 2014, NATURE, V512, P324, DOI 10.1038/nature13387; Schwartzentruber J, 2012, NATURE, V482, P226, DOI 10.1038/nature10833; Seltzer MJ, 2010, CANCER RES, V70, P8981, DOI 10.1158/0008-5472.CAN-10-1666; Setty P, 2010, J MOL DIAGN, V12, P750, DOI 10.2353/jmoldx.2010.090237; Shankar GM, 2015, JAMA ONCOL, V1, P662, DOI 10.1001/jamaoncol.2015.0917; Shirahata M, 2018, ACTA NEUROPATHOL, V136, P153, DOI 10.1007/s00401-018-1849-4; Sturm D, 2012, CANCER CELL, V22, P425, DOI 10.1016/j.ccr.2012.08.024; Sulkowski PL, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aal2463; Suzuki H, 2015, NAT GENET, V47, P458, DOI 10.1038/ng.3273; Tabouret E, 2016, ACTA NEUROPATHOL, V132, P625, DOI 10.1007/s00401-016-1611-8; Tateishi K, 2015, CANCER CELL, V28, P773, DOI 10.1016/j.ccell.2015.11.006; Tietze A, 2018, J NEUROSURG, V128, P391, DOI 10.3171/2016.10.JNS161793; Turcan S, 2018, NAT GENET, V50, P62, DOI 10.1038/s41588-017-0001-z; Turcan S, 2013, ONCOTARGET, V4, P1729, DOI 10.18632/oncotarget.1412; Turcan S, 2012, NATURE, V483, P479, DOI 10.1038/nature10866; Uckermann O, 2018, J NEURO-ONCOL, V139, P261, DOI 10.1007/s11060-018-2883-8; Uckermann O, 2018, CLIN CANCER RES, V24, P2530, DOI 10.1158/1078-0432.CCR-17-1795; van den Bent MJ, 2013, J CLIN ONCOL, V31, P344, DOI 10.1200/JCO.2012.43.2229; van Lith SAM, 2016, SCI REP-UK, V6, DOI 10.1038/srep30486; van Lith SAM, 2014, BBA-REV CANCER, V1846, P66, DOI 10.1016/j.bbcan.2014.04.004; Verhaak RGW, 2010, CANCER CELL, V17, P98, DOI 10.1016/j.ccr.2009.12.020; Villanueva-Meyer JE, 2018, AM J ROENTGENOL, V210, P621, DOI 10.2214/AJR.17.18457; Wakimoto H, 2014, CLIN CANCER RES, V20, P2898, DOI 10.1158/1078-0432.CCR-13-3052; Wang J, 2015, ONCOTARGET, V6, P39651, DOI 10.18632/oncotarget.5630; Wang P, 2015, CELL REP, V13, P2353, DOI 10.1016/j.celrep.2015.11.029; Ward PS, 2012, ONCOGENE, V31, P2491, DOI 10.1038/onc.2011.416; Ward PS, 2010, CANCER CELL, V17, P225, DOI 10.1016/j.ccr.2010.01.020; Watanabe T, 2009, AM J PATHOL, V174, P1149, DOI 10.2353/ajpath.2009.080958; Wu G, 2012, NAT GENET, V44, P251, DOI 10.1038/ng.1102; Xu W, 2011, CANCER CELL, V19, P17, DOI 10.1016/j.ccr.2010.12.014; Yan H, 2009, NEW ENGL J MED, V360, P765, DOI 10.1056/NEJMoa0808710; Zacher A, 2017, BRAIN PATHOL, V27, P146, DOI 10.1111/bpa.12367; Zhang LJ, 2018, CLIN CANCER RES, V24, P5381, DOI 10.1158/1078-0432.CCR-17-3855; Zhang XR, 2016, NEURO-ONCOLOGY, V18, P1402, DOI 10.1093/neuonc/now061; Zou YJ, 2015, NEURO-ONCOLOGY, V17, P477, DOI 10.1093/neuonc/nou351	157	0	0	2	10	TAYLOR & FRANCIS AS	OSLO	KARL JOHANS GATE 5, NO-0154 OSLO, NORWAY	1473-7159	1744-8352		EXPERT REV MOL DIAGN	Expert Rev. Mol. Diagn.	DEC 2	2018	18	12					1041	1051		10.1080/14737159.2018.1548935			11	Pathology	Pathology	HC7TN	WOS:000452004600007	30427756				2019-10-28	
J	Huppertz, B				Huppertz, Berthold			An updated view on the origin and use of angiogenic biomarkers for preeclampsia	EXPERT REVIEW OF MOLECULAR DIAGNOSTICS			English	Review						Angiogenic biomarkers; PGF; placenta; preeclampsia; sFlt-1	ENDOTHELIAL GROWTH-FACTOR; EXTRAVILLOUS TROPHOBLAST INVASION; UTERINE ARTERY DOPPLER; ALPHA-FETOPROTEIN; FACTOR RECEPTOR-1; HYPERTENSIVE DISORDERS; BIOCHEMICAL MARKERS; SOLUBLE ENDOGLIN; MATERNAL SERUM; HUMAN PLACENTA	Introduction: The last decade has seen massive efforts towards the identification and the potential use of predictive biomarkers for the pregnancy pathology preeclampsia. The angiogenic factors sFlt-1 and placental growth factor (PGF) have been in focus and have been massively supported. Areas covered: This review describes preeclampsia and intra-uterine growth restriction (IUGR), focusing on sFlt-1 and PGF, their sources during and outside pregnancy and the application of these markers in diseases outside pregnancy. Finally, the specificity of the angiogenic markers for preeclampsia is discussed. Expert commentary: The admixture of the two independent syndromes preeclampsia and IUGR has not helped in identifying the etiologies of either. Rather, it has made the search for new markers and pathways much more complicated as has the constriction on the angiogenic markers. The current markers sFlt-1 and PGF have a clear value once an adverse outcome is diagnosed but are not specific for preeclampsia. Also, they are mostly derived from the maternal vascular system rather than the placenta and are already in use as markers outside pregnancy. A new holistic approach using disease maps and interoperable workflows based on topic-related big data will help in broadening our understanding of the etiology of preeclampsia and hence, develop new markers and therapies.	[Huppertz, Berthold] Med Univ Graz, Gottfried Schatz Res Ctr, Div Cell Biol Histol & Embryol, Neue Stiftingtalstr 6-2, A-8010 Graz, Austria	Huppertz, B (reprint author), Med Univ Graz, Gottfried Schatz Res Ctr, Div Cell Biol Histol & Embryol, Neue Stiftingtalstr 6-2, A-8010 Graz, Austria.	berthold.huppertz@medunigraz.at		Huppertz, Berthold/0000-0003-4814-2158			Alisi A, 2011, LAB INVEST, V91, P283, DOI 10.1038/labinvest.2010.166; Amorim MG, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-14264-5; Andersson MK, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-249; Autiero M, 2003, J THROMB HAEMOST, V1, P1356, DOI 10.1046/j.1538-7836.2003.00263.x; Barleon B, 1996, BLOOD, V87, P3336, DOI 10.1182/blood.V87.8.3336.bloodjournal8783336; Bellamy L, 2007, BMJ-BRIT MED J, V335, P974, DOI 10.1136/bmj.39335.385301.BE; Benirschke K, 2006, PATHOLOGY HUMAN PLAC; Bianconi E, 2013, ANN HUM BIOL, V40, P463, DOI 10.3109/03014460.2013.807878; Chafetz I, 2007, AM J OBSTET GYNECOL, V197, DOI 10.1016/j.ajog.2007.02.025; Chau K, 2017, J HUM HYPERTENS, V31, P782, DOI 10.1038/jhh.2017.61; Chelli D, 2016, CLIN LAB, V62, P1927, DOI 10.7754/Clin.Lab.2016.151004; Cianfarani F, 2006, AM J PATHOL, V169, P1167, DOI 10.2353/ajpath.2006.051314; Clark DE, 1998, J ENDOCRINOL, V159, P459, DOI 10.1677/joe.0.1590459; Clark DE, 1998, BIOL REPROD, V59, P1540, DOI 10.1095/biolreprod59.6.1540; Cureton N, 2017, THERANOSTICS, V7, P3715, DOI 10.7150/thno.19678; De Ceuninck F, 2004, BIOCHEM BIOPH RES CO, V323, P960, DOI 10.1016/j.bbrc.2004.08.184; De Falco S, 2012, EXP MOL MED, V44, P1, DOI 10.3858/emm.2012.44.1.025; Di Martino D, 2016, EUR J OBSTET GYN R B, V206, P70, DOI 10.1016/j.ejogrb.2016.08.036; Dymara-Konopka W, 2018, CURR PHARM BIOTECHNO, V19, P797, DOI [10.1174/1389101019666180915115559, 10.2174/1389201019666180925115559]; Ehrlich L, 2017, HYPERTENS PREGNANCY, V36, P175, DOI 10.1080/10641955.2017.1291673; GAROFF L, 1973, J OBSTET GYN BR COMM, V80, P695; Gerber HP, 1999, NAT MED, V5, P623, DOI 10.1038/9467; GILLIM DL, 1954, OBSTET GYNECOL, V4, P264; Gonzales SK, 2018, PREGNANCY HYPERTENS, V12, P40, DOI 10.1016/j.preghy.2018.02.006; Gordijn SJ, 2016, ULTRASOUND OBST GYN, V48, P333, DOI 10.1002/uog.15884; Green CJ, 2001, CANCER RES, V61, P2696; HAWKES N, 2018, BMJ-BRIT MED J, V362, DOI DOI 10.1136/BMJ.K3247; He NN, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0169849; Helske S, 2001, MOL HUM REPROD, V7, P205, DOI 10.1093/molehr/7.2.205; Herraiz I, 2018, FETAL DIAGN THER, V43, P81, DOI 10.1159/000477903; Hod T, 2015, CSH PERSPECT MED, V5, DOI 10.1101/cshperspect.a023473; Hoeller A, 2017, HYPERTENS PREGNANCY, V36, P151, DOI 10.1080/10641955.2016.1273363; Holme AM, 2016, AM J OBSTET GYNECOL, V215, DOI 10.1016/j.ajog.2016.07.056; Huppertz B, 2018, BIOCH BIOPHYS ACTA; Huppertz B, 2008, HYPERTENSION, V51, P970, DOI 10.1161/HYPERTENSIONAHA.107.107607; Huppertz B, 2018, CURR PHARM BIOTECHNO, V19, P771, DOI [10.1174/1389101019666180417110547, 10.2174/1389201019666180427110547]; Imudia AN, 2009, HUM REPROD, V24, P2086, DOI 10.1093/humrep/dep206; Ishida A, 2001, J CELL PHYSIOL, V188, P359, DOI 10.1002/jcp.1121; Iwasaki H, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024872; Karumanchi SA, 2018, BJOG-INT J OBSTET GY, V125, P1396, DOI 10.1111/1471-0528.15180; KRIEGER V I, 1947, Med J Aust, V1, P417; Krussel JS, 1999, MOL HUM REPROD, V5, P452, DOI 10.1093/molehr/5.5.452; Kumara HMCS, 2011, SURG ENDOSC, V25, P2153, DOI 10.1007/s00464-010-1514-z; Lesmes C, 2015, ULTRASOUND OBST GYN, V46, P341, DOI 10.1002/uog.14899; Levine RJ, 2004, NEW ENGL J MED, V350, P672, DOI 10.1056/NEJMoa031884; Litwinska E, 2017, ADV CLIN EXP MED, V26, P439, DOI 10.17219/acem/62214; Luft FC, 2006, NEPHROL DIAL TRANSPL, V21, P3052, DOI 10.1093/ndt/gfl439; Maynard SE, 2003, J CLIN INVEST, V111, P649, DOI 10.1172/JCI200317189; Medinger M, 2015, ANTICANCER RES, V35, P1085; Meng Q, 2018, TOHOKU J EXP MED, V244, P291, DOI 10.1620/tjem.244.291; Mohammed KA, 2007, AM J PHYSIOL-LUNG C, V292, pL559, DOI 10.1152/ajplung.00075.2006; Moser G, 2010, HUM REPROD, V25, P1127, DOI 10.1093/humrep/deq035; Moser G, 2018, HUM REPROD UPDATE, V24, P484, DOI 10.1093/humupd/dmy008; Moser G, 2017, PLACENTA, V56, P19, DOI 10.1016/j.placenta.2017.02.007; Moser G, 2017, HISTOCHEM CELL BIOL, V147, P353, DOI 10.1007/s00418-016-1509-5; Ness RB, 2006, AM J OBSTET GYNECOL, V195, P40, DOI 10.1016/j.ajog.2005.07.049; Perry H, 2018, TRENDS CARDIOVAS MED, V28, P505, DOI 10.1016/j.tcm.2018.04.009; Poon LC, 2015, ULTRASOUND OBST GYN, V46, P437, DOI 10.1002/uog.14904; Reuvekamp A, 1999, BRIT J OBSTET GYNAEC, V106, P1019, DOI 10.1111/j.1471-0528.1999.tb08107.x; Roberts JM, 2013, OBSTET GYNECOL, V122, P1122, DOI 10.1097/01.AOG.0000437382.03963.88; RODECK CH, 1976, BRIT J OBSTET GYNAEC, V83, P24, DOI 10.1111/j.1471-0528.1976.tb00725.x; Rolnik DL, 2017, NEW ENGL J MED, V377, P613, DOI 10.1056/NEJMoa1704559; Romero R, 2008, J MATERN-FETAL NEO M, V21, P9, DOI 10.1080/14767050701830480; Rosenberger C, 2007, J INVEST DERMATOL, V127, P2445, DOI 10.1038/sj.jid.5700874; Saleh L, 2018, ULTRASOUND OBST GYN, V51, P751, DOI 10.1002/uog.17547; Satagopam V, 2016, BIG DATA-US, V4, P97, DOI 10.1089/big.2015.0057; Scheufler KM, 2003, J CEREBR BLOOD F MET, V23, P99, DOI 10.1097/01.WCB.0000037547.46809.83; Schimanski CC, 2010, INT J COLORECTAL DIS, V25, P181, DOI 10.1007/s00384-009-0843-7; Sharp A, 2018, LANCET CHILD ADOLESC, V2, P93, DOI 10.1016/S2352-4642(17)30173-6; Shear RM, 2005, AM J OBSTET GYNECOL, V192, P1119, DOI 10.1016/j.ajog.2004.10.621; Staff AC, 2013, HYPERTENSION, V61, P932, DOI 10.1161/HYPERTENSIONAHA.111.00250; Surmon Laura, 2014, BMC Res Notes, V7, P154, DOI 10.1186/1756-0500-7-154; Thilaganathan B, 2018, ULTRASOUND OBST GYN, V51, P714, DOI 10.1002/uog.19081; Toi M, 2002, INT J CANCER, V98, P14, DOI 10.1002/ijc.10121; Townsend R, 2016, INTEGR BLOOD PRESS C, V9, P79, DOI 10.2147/IBPC.S77344; Tsatsaris V, 2003, J CLIN ENDOCR METAB, V88, P5555, DOI 10.1210/jc.2003-030528; Ukah UV, 2017, HYPERTENSION, V70, P1228, DOI 10.1161/HYPERTENSIONAHA.117.10150; Verlohren S, 2014, ULTRASOUND OBST GYN, V44, P293, DOI 10.1002/uog.13310; Verrax J, 2011, MOL PHARMACEUT, V8, P701, DOI 10.1021/mp100268t; WALTERS BNJ, 1985, BRIT J OBSTET GYNAEC, V92, P341, DOI 10.1111/j.1471-0528.1985.tb01106.x; Wei SC, 2005, GUT, V54, P666, DOI 10.1136/gut.2004.050831; Weller K, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023931; Windsperger K, 2017, HUM REPROD, V32, P1208, DOI 10.1093/humrep/dex058; WOLFF F, 1973, REV FR GYNECOL OBSTE, V68, P93; Yao YG, 2005, FEBS LETT, V579, P1227, DOI 10.1016/j.febslet.2005.01.017; Yokoi A, 2017, ONCOTARGET, V8, P89811, DOI 10.18632/oncotarget.20688	86	0	0	2	8	TAYLOR & FRANCIS AS	OSLO	KARL JOHANS GATE 5, NO-0154 OSLO, NORWAY	1473-7159	1744-8352		EXPERT REV MOL DIAGN	Expert Rev. Mol. Diagn.	DEC 2	2018	18	12					1053	1061		10.1080/14737159.2018.1546579			9	Pathology	Pathology	HC7TN	WOS:000452004600008	30413130				2019-10-28	
J	Bretzel, G; Beissner, M				Bretzel, Gisela; Beissner, Marcus			PCR detection of Mycobacterium ulcerans-significance for clinical practice and epidemiology	EXPERT REVIEW OF MOLECULAR DIAGNOSTICS			English	Review						Buruli ulcer disease; epidemiology; IS2404; laboratory confirmation; LAMP; viability testing; quantification; real-time (q)PCR; 16S rRNA RT qPCR	FINE-NEEDLE-ASPIRATION; INFECTION BURULI ULCER; LABORATORY DIAGNOSIS; DNA EXTRACTION; RISK-FACTORS; DISEASE; GHANA; BENIN; SENSITIVITY; SPECIMENS	Introduction: Buruli ulcer (BU) is a neglected disease which has been reported from mostly impoverished, remote rural areas from 35 countries worldwide. BU affects skin, subcutaneous tissue, and bones, and may cause massive tissue destruction and life-long disabilities if not diagnosed and treated early. Without laboratory confirmation diagnostic and treatment errors may occur. This review describes the application of IS2404 PCR, the preferred diagnostic test, in the area of individual patient management and clinico-epidemiological studies. Areas covered: A Medline search included publications on clinical sample collection, DNA extraction, and PCR detection formats of the past and present, potential and limitations of clinical application, as well as clinico-epidemiological studies. Expert commentary: A global network of reference laboratories basically provides the possibility for PCR confirmation of 70% of all BU cases worldwide as requested by the WHO. Keeping laboratory confirmation on a constant level requires continuous outreach activities. Among the potential measures to maintain sustainability of laboratory confirmation and outreach activities are decentralized or mobile diagnostics available at point of care, such as IS2404-based LAMP, which complement the standard IS2404-based diagnostic tools available at central level.	[Bretzel, Gisela; Beissner, Marcus] Ludwigs Maximilians Univ, Univ Hosp, Div Infect Dis & Trop Med, Leopoldstr 5, D-80802 Munich, Germany	Bretzel, G (reprint author), Ludwigs Maximilians Univ, Univ Hosp, Div Infect Dis & Trop Med, Leopoldstr 5, D-80802 Munich, Germany.	bretzel@lrz.uni-muenchen.de					Ablordey A, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001590; Adu EJK, 2015, INT J MYCOBACT, V4, P138, DOI 10.1016/j.ijmyco.2015.03.006; Affolabi D, 2012, J CLIN MICROBIOL, V50, P1195, DOI 10.1128/JCM.05592-11; Al Ramahi JW, 2017, INT J INFECT DIS, V58, P77, DOI 10.1016/j.ijid.2017.02.014; Amofah G, 2002, EMERG INFECT DIS, V8, P167, DOI 10.3201/eid0802.010119; Babonneau J, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003606; Bafende AE, 2004, TROP DOCT, V34, P82, DOI 10.1177/004947550403400207; Bar W, 1998, TROP MED INT HEALTH, V3, P189; Beissner M, 2017, 10 EUR C TROP MED IN; Beissner M, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0004219; Beissner M, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0004170; Beissner M, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002011; Beissner M, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001756; Beissner M, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001747; Beissner M, 2010, FUTURE MICROBIOL, V5, P363, DOI 10.2217/FMB.10.3; Boyd SC, 2012, MED J AUSTRALIA, V196, P341, DOI 10.5694/mja12.10087; Bratschi MW, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002252; Bretzel G, 2007, TROP MED INT HEALTH, V12, P89, DOI 10.1111/j.1365-3156.2006.01761.x; Bretzel G, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0001228; Chauty A, 2007, ANTIMICROB AGENTS CH, V51, P4029, DOI 10.1128/AAC.00175-07; Chauty A, 2011, CLIN INFECT DIS, V52, P94, DOI 10.1093/cid/ciq072; de Souza DK, 2012, BMC INFECT DIS, V12, DOI 10.1186/1471-2334-12-8; Debacker M, 2004, TROP MED INT HEALTH, V9, P1297, DOI 10.1111/j.1365-3156.2004.01339.x; Debacker M, 2004, EMERG INFECT DIS, V10, P1391, DOI 10.3201/eid1008.030886; Debacker M, 2006, EMERG INFECT DIS, V12, P1325, DOI 10.3201/eid1209.050598; Doig KD, 2012, BMC GENOMICS, V13, DOI 10.1186/1471-2164-13-258; Douine Maylis, 2017, Lancet Planet Health, V1, pe65, DOI [10.1016/S2542-5196(17)30009-8, 10.1016/s2542-5196(17)30009-8]; Durnez L, 2009, J MICROBIOL METH, V76, P152, DOI 10.1016/j.mimet.2008.10.002; Eddyani M, 2008, J CLIN MICROBIOL, V46, P69, DOI 10.1128/JCM.00301-07; Eddyani M, 2018, CLIN INFECT DIS, V67, P827, DOI 10.1093/cid/ciy197; Eddyani M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089407; Eddyani M, 2009, J CLIN MICROBIOL, V47, P1700, DOI 10.1128/JCM.00197-09; Faber WR, 2015, EMERG INFECT DIS, V21, P497, DOI 10.3201/eid2103.141237; Faber WR, 2000, T ROY SOC TROP MED H, V94, P277, DOI 10.1016/S0035-9203(00)90320-1; Fyfe JAM, 2007, APPL ENVIRON MICROB, V73, P4733, DOI 10.1128/AEM.02971-06; Guarner J, 2018, J CLIN MICROBIOL, V56, DOI 10.1128/JCM.01507-17; Guerra H, 2008, EMERG INFECT DIS, V14, P373, DOI 10.3201/eid1403.070904; Guimaraes-Peres A, 1999, J CLIN MICROBIOL, V37, P206; Herbinger KH, 2010, J CLIN MICROBIOL, V48, P3732, DOI 10.1128/JCM.01549-10; Herbinger KH, 2009, CLIN INFECT DIS, V48, P1055, DOI 10.1086/597398; Hospers IC, 2005, T ROY SOC TROP MED H, V99, P196, DOI 10.1016/j.trstmh.2004.05.004; Johnson PDR, 2007, MED J AUSTRALIA, V186, P64, DOI 10.5694/j.1326-5377.2007.tb00802.x; Kibadi K, 2014, MED SANTE TROP, V24, P420, DOI 10.1684/mst.2014.0385; Kibadi K, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000736; Lamelas A, 2016, PLOS NEGLECT TROP D, V19, P10; Lavender CJ, 2012, J CLIN MICROBIOL, V50, P3717, DOI 10.1128/JCM.01324-12; Lehman L, 2006, BURULI ULCER PREVENT; Maman I, 2018, BMC INFECT DIS, V18, DOI 10.1186/s12879-018-2958-3; Manou LSB, 2013, MED SANTE TROP, V23, P450, DOI 10.1684/mst.2013.0259; Meka AO, 2016, T ROY SOC TROP MED H, V110, P502, DOI 10.1093/trstmh/trw065; Mensah-Quainoo E, 2008, TROP MED INT HEALTH, V13, P191, DOI 10.1111/j.1365-3156.2007.01990.x; Mueller YK, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004593; N'krumah RTAS, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004327; Nienhuis WA, 2010, LANCET, V375, P664, DOI 10.1016/S0140-6736(09)61962-0; Njiru ZK, 2012, J CLIN MICROBIOL, V50, P1737, DOI 10.1128/JCM.06460-11; Noeske J, 2004, AM J TROP MED HYG, V70, P520, DOI 10.4269/ajtmh.2004.70.520; O'Brien DP, 2017, EMERG INFECT DIS, V23, P837, DOI 10.3201/eid2305.160809; O'Brien DP, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0004253; O'Brien DP, 2014, MED J AUSTRALIA, V200, P267, DOI 10.5694/mja13.11331; O'Brien DP, 2009, MED J AUSTRALIA, V191, P564, DOI 10.5694/j.1326-5377.2009.tb03313.x; Phanzu DM, 2006, AM J TROP MED HYG, V75, P311, DOI 10.4269/ajtmh.2006.75.311; Phanzu DM, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002563; Phanzu DM, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0001402; Phillips R, 2005, J CLIN MICROBIOL, V43, P3650, DOI 10.1128/JCM.43.8.3650-3656.2005; Phillips RO, 2009, J CLIN MICROBIOL, V47, P924, DOI 10.1128/JCM.01842-08; Phillips RO, 2014, ANTIMICROB AGENTS CH, V58, P6341, DOI 10.1128/AAC.03874-14; Phillips RO, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003457; Pommelet V, 2014, CLIN INFECT DIS, V59, P1256, DOI 10.1093/cid/ciu584; Portaels F, 1997, J CLIN MICROBIOL, V35, P1097; Portaels F, 2014, LAB DIAGNOSIS BURULI; Portaels F, 2001, BURULI ULCER DIAGNOS; Quek TYJ, 2007, EMERG INFECT DIS, V13, P1661, DOI 10.3201/eid1311.061206; Robert B, 1997, J CLIN MICROBIOL, V35, P2709; Roltgen K, 2015, RES REP TROP MED, V6, P59, DOI 10.2147/RRTM.S62026; Roltgen K, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000751; Roltgen K, 2010, GENOME ANNOUNC, V4, pe751; Rondini S, 2006, J PATHOL, V208, P119, DOI 10.1002/path.1864; Rondini S, 2003, J CLIN MICROBIOL, V41, P4231, DOI 10.1128/JCM.41.9.4231-4237.2003; Rondini S, 2006, J CLIN MICROBIOL, V44, P4273, DOI 10.1128/JCM.00970-06; Ross BC, 1997, J CLIN MICROBIOL, V35, P1696; Ruf MT, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004767; Ruf MT, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0001252; Rusch- Gerdes S, 1998, EMERG INFECT DIS, V3, P189; Sakyi SA, 2016, CAN J INFECT DIS MED, DOI 10.1155/2016/5310718; Sarfo FS, 2016, CELL MICROBIOL, V18, P17, DOI 10.1111/cmi.12547; Sarfo FS, 2010, ANTIMICROB AGENTS CH, V54, P3678, DOI 10.1128/AAC.00299-10; Sarpong-Duah M, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0005695; SAXEGAARD F, 1985, J CLIN MICROBIOL, V22, P312; Shinoda Noriko, 2016, Trop Med Health, V44, P28, DOI 10.1186/s41182-016-0028-3; Siegmund V, 2005, J CLIN MICROBIOL, V43, P271, DOI 10.1128/JCM.43.1.271-276.2005; Siegmund V, 2007, CLIN INFECT DIS, V45, P68, DOI 10.1086/518604; Sopoh GE, 2007, EMERG INFECT DIS, V13, P1374, DOI 10.3201/eid1309.061338; Steffen CM, 2010, ANZ J SURG, V80, P732, DOI 10.1111/j.1445-2197.2010.05338.x; Stienstra Y, 2003, J CLIN MICROBIOL, V41, P794, DOI 10.1128/JCM.41.2.794-797.2003; Stinear T, 1999, J CLIN MICROBIOL, V37, P1018; Tabah EN, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004224; Tai AYC, 2018, EMERG INFECT DIS, V24, P58, DOI 10.3201/eid2401.171070; Thomas BS, 2014, EMERG INFECT DIS, V20, P1876, DOI 10.3201/eid2011.131534; Ukwaja KN, 2016, INFECT DIS POVERTY, V5, DOI 10.1186/s40249-016-0119-8; van der Werf TS, 2018, CLIN INFECT DIS, V67, P835, DOI 10.1093/cid/ciy203; Veitch MGK, 1997, EPIDEMIOL INFECT, V119, P313, DOI 10.1017/S0950268897008273; Vincent QB, 2014, LANCET GLOB HEALTH, V2, pE422, DOI 10.1016/S2214-109X(14)70223-2; Walsh DS, 2010, CURR OPIN INFECT DIS, V23, P445, DOI 10.1097/QCO.0b013e32833c2209; WHO, 2017, BIENN M GLOB BUR ULC; Williamson H, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088007; World Health Organization, 2012, TREATM MYC ULC DIS B; World Health Organization, 2013, WHO FIND CONS M DIAG; World Health Organization, 2007, WHO ANN M BUR ULC 2; World Health Organization, 2004, WEEKLY EPIDEMIOLOGIC, V15, p[145, 79]; World Health Organization, 2010, GUID SAMPL TECHN LAB; Yeboah-Manu D, 2011, AM J TROP MED HYG, V85, P900, DOI 10.4269/ajtmh.2011.11-0362; Yerramilli A, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0005800; Yotsu RR, 2015, J DERMATOL, V42, P1033, DOI 10.1111/1346-8138.13049	113	0	0	2	6	TAYLOR & FRANCIS AS	OSLO	KARL JOHANS GATE 5, NO-0154 OSLO, NORWAY	1473-7159	1744-8352		EXPERT REV MOL DIAGN	Expert Rev. Mol. Diagn.	DEC 2	2018	18	12					1063	1074		10.1080/14737159.2018.1543592			12	Pathology	Pathology	HC7TN	WOS:000452004600009	30381977				2019-10-28	
J	Liao, PH; Chou, SC; Huang, WT; Su, YZ; Wang, MC; Chuang, SS				Liao, Pi-Han; Chou, Shih-Cheng; Huang, Wan-Ting; Su, Ying-Zhen; Wang, Ming-Chung; Chuang, Shih-Sung			Recurrent monomorphic epitheliotropic intestinal T-cell lymphoma with aberrant CD20 expression: An implication for anti-CD20 (rituximab) antibody therapy?	PATHOLOGY INTERNATIONAL			English	Letter									[Liao, Pi-Han; Wang, Ming-Chung] Kaohsiung Chang Gung Mem Hosp, Kaohsiung Med Ctr, Dept Internal Med, Div Hematol Oncol, Kaohsiung, Taiwan; [Chou, Shih-Cheng] Yuans Gen Hosp, Dept Pathol, Kaohsiung, Taiwan; [Huang, Wan-Ting] Kaohsiung Chang Gung Mem Hosp, Kaohsiung Med Ctr, Dept Pathol, Kaohsiung, Taiwan; [Huang, Wan-Ting] Coll Med, Kaohsiung, Taiwan; [Huang, Wan-Ting] Chang Gung Univ, Kaohsiung, Taiwan; [Su, Ying-Zhen; Chuang, Shih-Sung] Chi Mei Med Ctr Tainan, Dept Pathol, Tainan, Taiwan	Liao, PH (reprint author), Kaohsiung Chang Gung Mem Hosp, Kaohsiung Med Ctr, Dept Internal Med, Div Hematol Oncol, Kaohsiung, Taiwan.						Buckner CL, 2007, ANN CLIN LAB SCI, V37, P263; Hirata Yuji, 2009, Leuk Res, V33, pe13, DOI 10.1016/j.leukres.2008.09.034; Huang YH, 2015, J CLIN PATHOL, V68, P943, DOI 10.1136/jclinpath-2015-203188; Rahemtullah A, 2008, AM J SURG PATHOL, V32, P1593, DOI 10.1097/PAS.0b013e31817d7452; Yao X, 2001, MODERN PATHOL, V14, P105, DOI 10.1038/modpathol.3880265	5	0	0	1	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1320-5463	1440-1827		PATHOL INT	Pathol. Int.	DEC	2018	68	12					712	714		10.1111/pin.12730			3	Pathology	Pathology	HE9GF	WOS:000453756100008	30402988				2019-10-28	
J	Holecek, M; Vodenicarovova, M				Holecek, Milan; Vodenicarovova, Melita			Muscle wasting and branched-chain amino acid, alpha-ketoglutarate, and ATP depletion in a rat model of liver cirrhosis	INTERNATIONAL JOURNAL OF EXPERIMENTAL PATHOLOGY			English	Article						ammonia detoxification; cachexia; glutamine; liver cirrhosis	SKELETAL-MUSCLE; PROTEIN-METABOLISM; NUTRITIONAL SUPPORT; PLASMA; HYPERAMMONEMIA; LEUCINE; AMMONIA; CATAPLEROSIS; ADAPTATION; CATABOLISM	The aim of the study was to examine whether a rat model of liver cirrhosis induced by carbon tetrachloride (CCl4) is a suitable model of muscle wasting and alterations in amino acid metabolism in cirrhotic humans. Rats were treated by intragastric gavage of CCl4 or vehicle for 45 days. Blood plasma and different muscle types-tibialis anterior (mostly white fibres), soleus (red muscle) and extensor digitorum longus (white muscle)-were analysed at the end of the study. Characteristic biomarkers of impaired hepatic function were found in the plasma of cirrhotic animals. The weights and protein contents of all muscles of CCl4-treated animals were lower when compared with controls. Increased concentrations of glutamine (GLN) and aromatic amino acids (phenylalanine and tyrosine) and decreased concentrations of branched-chain amino acids (BCAA), glutamate (GLU), alanine and aspartate were found in plasma and muscles. In the soleus muscle, GLN increased more and GLU and BCAA decreased less than in the extensor digitorum and tibialis muscles. Increased chymotrypsin-like activity (indicating enhanced proteolysis) and decreased a-ketoglutarate and ATP levels were found in muscles of cirrhotic animals. ATP concentration also decreased in blood plasma. It is concluded that a rat model of CCl4-induced cirrhosis is a valid model for the investigation of hepatic cachexia that exhibits alterations in line with a theory of role of ammonia in pathogenesis of BCAA depletion, citric cycle and mitochondria dysfunction, and muscle wasting in cirrhotic subjects. The findings indicate more effective ammonia detoxification to GLN in red than in white muscles.	[Holecek, Milan; Vodenicarovova, Melita] Charles Univ Prague, Fac Med Hradec Kralove, Dept Physiol, Hradec Kralove, Czech Republic	Holecek, M (reprint author), Charles Univ Prague, Fac Med Hradec Kralove, Hradec Kralove, Czech Republic.	holecek@lfhk.cuni.cz			Charles University [Progres Q40/02]	Charles University, Grant/Award Number: Progres Q40/02	BLONDECYNOBER F, 1994, ANN NUTR METAB, V38, P238, DOI 10.1159/000177817; Bosoi CR, 2017, METAB BRAIN DIS, V32, P513, DOI 10.1007/s11011-016-9937-4; Campollo O, 2017, WORLD J HEPATOL, V9, P667, DOI 10.4254/wjh.v9.i14.667; Dam G, 2015, SCAND J CLIN LAB INV, V75, P674, DOI 10.3109/00365513.2015.1074276; Dasarathy S, 2016, J HEPATOL, V65, P1232, DOI 10.1016/j.jhep.2016.07.040; Davuluri G, 2016, J PHYSIOL-LONDON, V594, P7341, DOI 10.1113/JP272796; Davuluri G, 2016, J HEPATOL, V65, P929, DOI 10.1016/j.jhep.2016.06.004; Giusto M, 2017, PHYSIOL REP, V5, DOI 10.14814/phy2.13153; Gomes-Marcondes MCC, 2002, CANCER LETT, V180, P69, DOI 10.1016/S0304-3835(02)00006-X; Hanai T, 2016, HEPATOL RES, V46, P743, DOI 10.1111/hepr.12616; HERNANDEZMUNOZ R, 1991, ALCOHOL CLIN EXP RES, V15, P500, DOI 10.1111/j.1530-0277.1991.tb00550.x; Holecek M, 1996, J HEPATOL, V24, P209, DOI 10.1016/S0168-8278(96)80031-6; Holecek M, 2000, METABOLISM, V49, P1330, DOI 10.1053/meta.2000.9531; Holecek M, 2017, PHYSIOL RES, V66, P959; Holecek M, 1995, ANN NUTR METAB, V39, P346, DOI 10.1159/000177884; Holecek M, 1999, AMINO ACIDS, V16, P1; Holecek M, 1996, AMINO ACIDS, V10, P229, DOI 10.1007/BF00807325; Holecek M, 2018, J PHYSIOL BIOCHEM, V74, P523, DOI 10.1007/s13105-018-0646-9; Holecek M, 2017, NUTRITION, V41, P80, DOI 10.1016/j.nut.2017.04.003; Holecek M, 2011, AMINO ACIDS, V40, P575, DOI 10.1007/s00726-010-0679-z; Honda T, 2004, J HEPATOL, V40, P439, DOI 10.1016/j.jhep.2003.11.003; IOB V, 1967, J SURG RES, V7, P41, DOI 10.1016/0022-4804(67)90008-X; Kadlcikova J, 2004, INT J EXP PATHOL, V85, P365, DOI 10.1111/j.0959-9673.2004.00405.x; KOOHMARAIE M, 1990, J ANIM SCI, V68, P2362; Leweling H, 1996, J HEPATOL, V25, P756, DOI 10.1016/S0168-8278(96)80249-2; MOLLER P, 1984, SCAND J GASTROENTERO, V19, P267; MONTANARI A, 1988, HEPATOLOGY, V8, P1034, DOI 10.1002/hep.1840080509; Nardelli S, 2017, CLIN GASTROENTEROL H, V15, P934, DOI 10.1016/j.cgh.2016.10.028; NG EH, 1991, HEMATOL ONCOL CLIN N, V5, P161; Peng S, 2007, AM J CLIN NUTR, V85, P1257; PLAUTH M, 1990, HEPATO-GASTROENTEROL, V37, P135; Plauth M, 2011, CURR OPIN CLIN NUTR, V14, P61, DOI 10.1097/MCO.0b013e3283413726; RUBIN E, 1967, MEDICINE, V46, P163, DOI 10.1097/00005792-196703000-00009; SCHAUDER P, 1984, HEPATOLOGY, V4, P667, DOI 10.1002/hep.1840040417; SCHOTT K, 1984, J NEUROCHEM, V42, P644, DOI 10.1111/j.1471-4159.1984.tb02730.x; SHAW JHF, 1989, ANN SURG, V209, P63, DOI 10.1097/00000658-198901000-00010; STREAT SJ, 1987, J TRAUMA, V27, P262, DOI 10.1097/00005373-198703000-00006; WAGENMAKERS AJM, 1990, INT J SPORTS MED, V11, pS101, DOI 10.1055/s-2007-1024861; WEBER FL, 1992, GASTROENTEROLOGY, V102, P1700, DOI 10.1016/0016-5085(92)91733-K; Yang Q, 1997, NUTRITION, V13, P640	40	2	1	5	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0959-9673	1365-2613		INT J EXP PATHOL	Int. J. Exp. Pathol.	DEC	2018	99	6					274	281		10.1111/iep.12299			8	Pathology	Pathology	HM4TP	WOS:000459467900139	30637824				2019-10-28	
J	Watanabe, S; Kumazaki, S; Yamamoto, S; Sato, I; Kitamori, K; Mori, M; Yamori, Y; Hirohata, S				Watanabe, Shogo; Kumazaki, Shota; Yamamoto, Shusei; Sato, Ikumi; Kitamori, Kazuya; Mori, Mari; Yamori, Yukio; Hirohata, Satoshi			Non-alcoholic steatohepatitis aggravates nitric oxide synthase inhibition-induced arteriosclerosis in SHRSP5/Dmcr rat model	INTERNATIONAL JOURNAL OF EXPERIMENTAL PATHOLOGY			English	Article						atherosclerosis; endothelial function; myocardial ischaemia; non-alcoholic steatohepatitis; SHRSP5/Dmcr	FATTY LIVER-DISEASE; VENTRICULAR DIASTOLIC DYSFUNCTION; MYOCARDIAL-INFARCTION; ANIMAL-MODEL; CARDIOVASCULAR-DISEASE; RISK; ACID; INFLAMMATION; ATHEROSCLEROSIS; HYPERTENSION	Non-alcoholic steatohepatitis (NASH) is linked to increased cardiovascular risk, independent of the broad spectrum of metabolic syndrome risk factors. Stroke-prone (SP) spontaneously hypertensive rats (SHRSP5/Dmcr) fed a high-fat and high-cholesterol (HFC) diet developed hepatic lesions similar to those in human NASH pathology. These rats simultaneously developed lipid deposits in the mesenteric arteries, cardiac fibrosis, endothelial dysfunction and left ventricle (LV) diastolic dysfunction. However, the intermediary factors between NASH and cardiovascular disease are still unknown. We investigated whether NASH aggravates nitric oxide (NO) synthase inhibition-induced arteriosclerosis in SHRSP5/Dmcr rats. Wistar Kyoto and SHRSP5/Dmcr rats were divided into 4 groups of 5 and fed the stroke-prone (SP) or HFC diets for 8 weeks. To induce NO synthase inhibition, N-omega-nitro-L-arginine methyl ester hydrochloride (L-NAME) mixed with drinking water was administered in the final 2 weeks. The NASH+ L-NAME group demonstrated the following characteristics related to arteriosclerosis and myocardial ischaemia: (a) LV systolic dysfunction with asynergy, (b) replacement fibrosis caused by the shedding of cardiomyocytes and (c) arterial lipid deposition and coronary occlusion secondary to endothelial dysfunction. These characteristics were not observed in the NASH or non-NASH+ L-NAME groups. The SHRSP5/Dmcr rat model demonstrates that NASH significantly aggravates cardiovascular risk.	[Watanabe, Shogo; Kumazaki, Shota; Yamamoto, Shusei; Sato, Ikumi; Hirohata, Satoshi] Okayama Univ, Grad Sch Hlth Sci, Dept Med Technol, Okayama, Japan; [Kitamori, Kazuya] Kinjo Gakuin Univ, Coll Human Life & Environm, Nagoya, Aichi, Japan; [Mori, Mari] Tokai Univ, Sch Hlth Studies, Dept Hlth Management, Tokyo, Kanagawa, Japan; [Yamori, Yukio] Mukogawa Womens Univ, Inst World Hlth Dev, Nishinomiya, Hyogo, Japan	Watanabe, S (reprint author), Okayama Univ, Grad Sch Hlth Sci, Dept Med Technol, Kita Ku, Okayama, Japan.	watanabe1224@okayama-u.ac.jp			Japan Society for the Promotion of ScienceMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science [15K19178, 18K10993]	This work was supported by grants from the Japan Society for the Promotion of Science Grant-in-Aid for Young Scientists (B), Grant Number 15K19178, and Grant-in-Aid for Scientific Research (C), Grant Number 18K10993 to S. Watanabe.	Athyros Vasilios G, 2017, Metabolism, V66, pe6, DOI 10.1016/j.metabol.2016.10.011; Athyros VG, 2014, CURR MED RES OPIN, V30, P229, DOI 10.1185/03007995.2013.855192; Bonapace S, 2012, DIABETES CARE, V35, P389, DOI 10.2337/dc11-1820; Brea A, 2013, INT J CARDIOL, V167, P1109, DOI 10.1016/j.ijcard.2012.09.085; Fargion S, 2014, WORLD J GASTROENTERO, V20, P13306, DOI 10.3748/wjg.v20.i37.13306; Fracanzani AL, 2008, AM J MED, V121, P72, DOI 10.1016/j.amjmed.2007.08.041; GLAGOV S, 1987, NEW ENGL J MED, V316, P1371, DOI 10.1056/NEJM198705283162204; Gordts PLSM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038330; Hagstrom H, 2018, HEPATOL COMMUN, V2, P48, DOI 10.1002/hep4.1124; Horai Y, 2016, INT J EXP PATHOL, V97, P75, DOI 10.1111/iep.12169; Hosoo S, 2015, MOLECULES, V20, P21971, DOI 10.3390/molecules201219826; Ikeda K, 1997, CLIN EXP PHARMACOL P, V24, P344, DOI 10.1111/j.1440-1681.1997.tb01199.x; Imprialos K, 2017, HELLENIC J ATHEROSCL, V8, P111; Iwamoto M, 2010, HYPERTENS RES, V33, P1305, DOI 10.1038/hr.2010.189; Jia XF, 2013, DIGEST DIS SCI, V58, P2212, DOI 10.1007/s10620-013-2747-1; Jia XF, 2012, LIFE SCI, V90, P934, DOI 10.1016/j.lfs.2012.04.029; Kim D, 2012, HEPATOLOGY, V56, P605, DOI 10.1002/hep.25593; Kitamori Kazuya, 2012, Environmental Health and Preventive Medicine, V17, P173, DOI 10.1007/s12199-011-0235-9; Kozaki Y, 2015, J PHYSIOL SCI, V65, P417, DOI 10.1007/s12576-015-0380-9; Kumar S, 2016, SCI REP-UK, V6, DOI 10.1038/srep31130; Kunimasa K, 2010, CLIN EXP PHARMACOL P, V37, P1102, DOI 10.1111/j.1440-1681.2010.05440.x; Lefebvre P, 2009, PHYSIOL REV, V89, P147, DOI 10.1152/physrev.00010.2008; Li WX, 2016, SCI REP-UK, V6, DOI 10.1038/srep24580; Marchesini G, 2001, DIABETES, V50, P1844, DOI 10.2337/diabetes.50.8.1844; Matsuura N, 2015, AM J PHYSIOL-HEART C, V308, pH1275, DOI 10.1152/ajpheart.00906.2014; Naghavi M, 2003, CIRCULATION, V108, P1664, DOI 10.1161/01.CIR.0000087480.94275.97; NAKAMUTA M, 1995, J BIOL CHEM, V270, P13042, DOI 10.1074/jbc.270.22.13042; Oni ET, 2013, ATHEROSCLEROSIS, V230, P258, DOI 10.1016/j.atherosclerosis.2013.07.052; Ono K, 2002, J AM SOC ECHOCARDIOG, V15, P109, DOI 10.1067/mje.2002.115034; Ono Y, 1999, HYPERTENSION, V34, P609, DOI 10.1161/01.HYP.34.4.609; Reid AE, 2001, GASTROENTEROLOGY, V121, P710, DOI 10.1053/gast.2001.27126; SAHN DJ, 1978, CIRCULATION, V58, P1072, DOI 10.1161/01.CIR.58.6.1072; Shiomi M, 2003, ARTERIOSCL THROM VAS, V23, P1239, DOI 10.1161/01.ATV.0000075947.28567.50; Shiomi M, 2009, ATHEROSCLEROSIS, V207, P1, DOI 10.1016/j.atherosclerosis.2009.03.024; Sookoian S, 2008, J HEPATOL, V49, P600, DOI 10.1016/j.jhep.2008.06.012; Stefan N, 2008, ENDOCR REV, V29, P939, DOI 10.1210/er.2008-0009; Sweet JG, 2015, J APPL PHYSIOL, V119, P817, DOI 10.1152/japplphysiol.00467.2015; Tada Y, 2010, BIOL PHARM BULL, V33, P1971, DOI 10.1248/bpb.33.1971; TANZAWA K, 1980, FEBS LETT, V118, P81, DOI 10.1016/0014-5793(80)81223-3; Targher G, 2005, DIABETES, V54, P3541, DOI 10.2337/diabetes.54.12.3541; Targher G, 2010, NEW ENGL J MED, V363, P1341, DOI 10.1056/NEJMra0912063; Targher G, 2009, SEMIN THROMB HEMOST, V35, P277, DOI 10.1055/s-0029-1222606; Tilg H, 2008, TRENDS ENDOCRIN MET, V19, P371, DOI 10.1016/j.tem.2008.08.005; Watanabe S, 2018, J ATHEROSCLER THROMB, V25, P439, DOI 10.5551/jat.40956; YAMORI Y, 1981, JPN CIRC J, V45, P1068, DOI 10.1253/jcj.45.1068; YAMORI Y, 1976, STROKE, V7, P120, DOI 10.1161/01.STR.7.2.120	46	2	2	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0959-9673	1365-2613		INT J EXP PATHOL	Int. J. Exp. Pathol.	DEC	2018	99	6					282	294		10.1111/iep.12301			13	Pathology	Pathology	HM4TP	WOS:000459467900140	30680827				2019-10-28	
J	Zhang, J; Qiu, HM; Huang, JJ; Ding, SM; Huang, B; Wu, Q; Jiang, QS				Zhang, Jie; Qiu, Hongmei; Huang, Jiajun; Ding, Shumei; Huang, Bo; Wu, Qin; Jiang, Qingsong			Establishment of a diabetic myocardial hypertrophy model in Mus musculus castaneus mouse	INTERNATIONAL JOURNAL OF EXPERIMENTAL PATHOLOGY			English	Article						animal model; diabetic cardiomyopathy; Mus musculus castaneus mice; myocardial hypertrophy		The aim of this study was to establish a robust model of diabetic myocardial hypertrophy in Mus musculus castaneus mice. Mice were fed a high-fat diet for four weeks and then given streptozotocin (STZ, 40 mg kg(-1) d(-1) for 5 days, intraperitoneally) and fasting blood glucose (FBG) levels were tested after seven days. Mice with FBG levels above 11.1 mmol/L were considered diabetic. Diabetic mice continued to have access to the high-fat diet until cardiac hypertrophy developed. FBG and body weight (BW) were measured weekly. Myocardial hypertrophy was confirmed by left ventricle (LV) hypertrophy index (LVHI), LV/BW, LV histopathological observation and atrial natriuretic factor (ANF) mRNA expression. Serum insulin and plasma haemoglobin A1c (HbA1c) levels, total cholesterol (TCH) and triglyceride (TG) were measured, and then an insulin resistance index (HOMA.IR) was calculated. The level of FBG in the model group remained above 11.1 mmol/L, and the BW showed significant weight loss, compared with the control group (P<0.01). The high levels of HbA1c, HOME.IR, TCH and TG, and the low level of insulin suggested that glucose metabolism was not balanced with insulin resistance; meanwhile, higher TCH and TG showed that dyslipidaemia had also developed. After the diabetic mice were kept on the high-energy diet for another four weeks, histopathological observation showed myocardial injuries, much more surface area and collagen fibres, higher LVHI and LV/BW, and elevated expression of ANF mRNA (P<0.01), suggesting that myocardial hypertrophy had appeared in Mus musculus castaneus mice under the current experimental conditions. Thus a robust model of diabetic myocardial hypertrophy was established four weeks after confirmation of diabetes, which was induced by feeding a high-fat diet for four weeks combined with a repeated low-dose STZ exposure, in Mus musculus castaneus mice.	[Zhang, Jie; Qiu, Hongmei; Huang, Jiajun; Ding, Shumei; Jiang, Qingsong] Chongqing Med Univ, Chongqing Key Lab Biochem & Mol Pharmacol, Dept Pharmacol, Chongqing, Peoples R China; [Huang, Bo; Wu, Qin] Zunyi Med Univ, Minist Educ, Key Lab Basic Pharmacol, Zunyi, Guizhou, Peoples R China; [Huang, Bo; Wu, Qin] Zunyi Med Univ, Minist Educ, Joint Int Res Lab Ethnomed, Zunyi, Guizhou, Peoples R China	Jiang, QS (reprint author), Chongqing Med Univ, Dept Pharmacol, Chongqing, Peoples R China.	cqjiangqs@163.com			National Natural Science Foundation of ChinaNational Natural Science Foundation of China [81471334, 81871002]; Opening Foundation of Key Laboratory of Basic Pharmacology of Ministry of Education, Zunyi Medical University, Guizhou, China [JCYL-K-007]; Guizhou Traditional Chinese Medicine Administration Bureau, Guizhou, China [QZYY-2016-004]; Natural Science Foundation of Chongqing, ChinaNatural Science Foundation of Chongqing [cstc2017jcjAX0211]	The National Natural Science Foundation of China, Grant/Award Number: 81471334 and 81871002; Opening Foundation of Key Laboratory of Basic Pharmacology of Ministry of Education, Zunyi Medical University, Guizhou, China, Grant/Award Number: JCYL-K-007; Guizhou Traditional Chinese Medicine Administration Bureau, Guizhou, China, Grant/Award Number: QZYY-2016-004; Natural Science Foundation of Chongqing, China, Grant/Award Number: cstc2017jcjAX0211	Barriere DA, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-017-18896-5; Brainard RE, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0083174; Earl PL, 2015, VIROLOGY, V475, P150, DOI 10.1016/j.virol.2014.11.015; FEIN FS, 1980, CIRC RES, V47, P922, DOI 10.1161/01.RES.47.6.922; Fisher SJ, 2001, J ENDOCRINOL, V168, P49, DOI 10.1677/joe.0.1680049; Fuentes-Antras J, 2015, J DIABETES RES, DOI 10.1155/2015/656795; Furman BL, 2015, CURR PROTOC PHARM, V70, DOI [10.1002/0471141755.ph0547s70, DOI 10.1002/0471141755.PH0547S70]; Graham ML, 2011, COMPARATIVE MED, V61, P356; He SR, 2011, EXP BIOL MED, V236, P212, DOI 10.1258/ebm.2010.010208; Huynh K, 2014, PHARMACOL THERAPEUT, V142, P375, DOI 10.1016/j.pharmthera.2014.01.003; Kawamura M, 2017, CARDIOVASC DIABETOL, V16, DOI 10.1186/s12933-017-0625-4; Kern TS, 2010, MOL VIS, V16, P2121; Lacombe VA, 2007, AM J PHYSIOL-REG I, V293, pR1787, DOI 10.1152/ajpregu.00059.2007; Liu P, 2017, BIOCHEM BIOPH RES CO, V493, P1573, DOI 10.1016/j.bbrc.2017.10.027; Mellert J, 1998, TRANSPLANTATION, V66, P200, DOI 10.1097/00007890-199807270-00010; Mostafavinia Ataroalsadat, 2016, Lab Anim Res, V32, P160; Nayor M, 2018, JACC-HEART FAIL, P30050; Rabinovitch A, 1996, DIABETES, V45, P749, DOI 10.2337/diabetes.45.6.749; Schilling JD, 2012, HEART FAIL CLIN, V8, P619, DOI 10.1016/j.hfc.2012.06.007; TREMBLEAU S, 1995, J EXP MED, V181, P817, DOI 10.1084/jem.181.2.817; von Herrath M, 2011, J MED VIROL, V83, P1672, DOI 10.1002/jmv.22063; Wild S, 2004, DIABETES CARE, V27, P1047, DOI 10.2337/diacare.27.5.1047; Yang L, 2018, MOL MED REP, V17, P4099, DOI 10.3892/mmr.2017.8342; Yu LY, 2017, CELL J, V19, P469, DOI 10.22074/cellj.2017.4509; Zheng GY, 2016, CHIN J BIOCH PHARM, V1, P20	25	1	1	3	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0959-9673	1365-2613		INT J EXP PATHOL	Int. J. Exp. Pathol.	DEC	2018	99	6					295	303		10.1111/iep.12296			9	Pathology	Pathology	HM4TP	WOS:000459467900141	30614094				2019-10-28	
J	Toropova, YG; Pechnikova, NA; Zelinskaya, IA; Zhuravsky, SG; Kornyushin, OV; Gonchar, AI; Ivkin, DY; Leonova, YV; Karev, VE; Karabak, IA				Toropova, Yana G.; Pechnikova, Nadezdha A.; Zelinskaya, Irina A.; Zhuravsky, Sergey G.; Kornyushin, Oleg V.; Gonchar, Alina I.; Ivkin, Dmitry Y.; Leonova, Yulia V.; Karev, Vadim E.; Karabak, Irina A.			Nicotinamide riboside has protective effects in a rat model of mesenteric ischaemia-reperfusion	INTERNATIONAL JOURNAL OF EXPERIMENTAL PATHOLOGY			English	Article						acute mesenteric ischaemia; ischaemia-reperfusion injury; microcirculation; nicotinamide riboside; wire myography	NAD(+) PRECURSOR; ISCHEMIA/REPERFUSION; METABOLISM; NEUROPATHY; INTESTINE; INJURY	Acute mesenteric ischaemia is a syndrome caused by inadequate blood flow through the mesenteric vessels, resulting in ischaemia and eventual gangrene of the bowel wall. Although relatively rare, it is a potentially life-threatening condition. The maintenance of haemodynamic stability, along with adequate oxygen saturation, and the correction of any electrolyte imbalance, are of the utmost importance. However, nicotinamide adenine dinucleotide (NAD) biosynthesis modulation by precursor introduction can also be a powerful tool for preventing injury. Nicotinamide riboside is a pyridine-nucleoside form of vitamin B3 that functions as a precursor to NAD(+). The present study investigated nicotinamide riboside's effect on endothelium functional state, microcirculation and intestinal morphology in acute mesenteric ischaemia and reperfusion. Mesenteric ischaemia was simulated after the adaptation period (15 minutes) by occluding the superior mesenteric artery for 60 minutes, followed by a reperfusion period of 30 minutes. The functional state of intestinal microcirculation was evaluated by laser Doppler flowmetry. Endothelial functional activity was studied by using wire myography. Intestinal samples were stained with haematoxylin and eosin for histological analysis. The results revealed that nicotinamide riboside protects the intestinal wall from ischaemia-reperfusion injury, as well as improving the relaxation function of mesenteric vessels. Nicotinamide riboside's protective effect in small intestine ischaemia-reperfusion can be used to reduce ischaemia-reperfusion injury, as well as to preserve intestinal grafts until transplant.	[Toropova, Yana G.; Pechnikova, Nadezdha A.; Zelinskaya, Irina A.; Zhuravsky, Sergey G.; Kornyushin, Oleg V.; Gonchar, Alina I.; Leonova, Yulia V.] Minist Hlth Russian Federat, VA Almazov Natl North West Med Res Ctr, St Petersburg, Russia; [Pechnikova, Nadezdha A.; Ivkin, Dmitry Y.] St Petersburg State Chem Pharmaceut Univ, St Petersburg, Russia; [Zelinskaya, Irina A.] St Petersburg Natl Res Univ Informat Technol Mech, St Petersburg, Russia; [Zhuravsky, Sergey G.] Pavlov First St Petersburg State Med Univ, Minist Hlth Russian Federat, St Petersburg, Russia; [Zhuravsky, Sergey G.; Leonova, Yulia V.] Minist Hlth Russian Federat, Res Inst Influenza, St Petersburg, Russia; [Karev, Vadim E.; Karabak, Irina A.] Fed Med & Biol Agcy, Childrens Sci & Clin Ctr Infect Dis, St Petersburg, Russia; [Pechnikova, Nadezdha A.] Russian Acad Sci, Zool Inst, Univ Skaya Embankment 1, St Petersburg 199034, Russia	Pechnikova, NA (reprint author), Minist Hlth Russian Federat, VA Almazov Natl North West Med Res Ctr, St Petersburg, Russia.	nadya-pechnikova@mail.ru	Zhuravskii, Sergei/F-6563-2019	Zhuravskii, Sergei/0000-0002-5960-068X; pechnikova, nadya/0000-0002-3485-8545			Bieganowski P, 2004, CELL, V117, P495, DOI 10.1016/S0092-8674(04)00416-7; Canto C, 2012, CELL METAB, V15, P838, DOI 10.1016/j.cmet.2012.04.022; Crafts TD, 2015, CYTOKINE, V71, P385, DOI 10.1016/j.cyto.2014.08.005; Hamity MV, 2017, PAIN, V158, P962, DOI 10.1097/j.pain.0000000000000862; Heuser M, 2000, J SURG RES, V92, P186, DOI 10.1006/jsre.2000.5898; Hosgorler FU, 2010, J SURG RES, V159, P603, DOI 10.1016/j.jss.2009.03.028; Kourtzidis IA, 2016, J INT SOC SPORT NUTR, V13, DOI 10.1186/s12970-016-0143-x; Mallick IH, 2004, DIGEST DIS SCI, V49, P1359, DOI 10.1023/B:DDAS.0000042232.98927.91; Mastoraki Aikaterini, 2016, World J Gastrointest Pathophysiol, V7, P125, DOI 10.4291/wjgp.v7.i1.125; Menger MD, 1997, SHOCK, V8, P2, DOI 10.1097/00024382-199707000-00002; MULVANY MJ, 1977, CIRC RES, V41, P19, DOI 10.1161/01.RES.41.1.19; Sauve AA, 2008, J PHARMACOL EXP THER, V324, P883, DOI 10.1124/jpet.107.120758; Trammell SAJ, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12948; Trammell SAJ, 2016, SCI REP-UK, V6, DOI 10.1038/srep26933; Vollmar B, 2011, LANGENBECK ARCH SURG, V396, P13, DOI 10.1007/s00423-010-0727-x; Yang Y, 2016, BBA-PROTEINS PROTEOM, V1864, P1787, DOI 10.1016/j.bbapap.2016.06.014; Zhang F, 2015, MOL MED REP, V11, P269, DOI 10.3892/mmr.2014.2679	17	0	0	1	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0959-9673	1365-2613		INT J EXP PATHOL	Int. J. Exp. Pathol.	DEC	2018	99	6					304	311		10.1111/iep.12302			8	Pathology	Pathology	HM4TP	WOS:000459467900142	30793416				2019-10-28	
J	Zhang, Y; He, Y; Zhang, D; Zhang, M; Wang, MY; Ma, TY; Chen, JH				Zhang, Ying; He, Ying; Zhang, Dan; Zhang, Meng; Wang, Mengying; Ma, Tianyou; Chen, Jinghong			Death of chondrocytes in Kashin-Beck disease: Apoptosis, necrosis or necroptosis?	INTERNATIONAL JOURNAL OF EXPERIMENTAL PATHOLOGY			English	Article						apoptosis; chondrocyte; Kashin-Beck disease; necroptosis; necrosis	CELL-DEATH; T-2 TOXIN; ARTICULAR-CARTILAGE; OXIDATIVE STRESS; KINASE; INHIBITION; FAS	The purpose of this paper was to investigate chondrocyte distribution and death in the cartilage in Kashin-Beck disease (KBD). Apoptotic chondrocytes were detected by TUNEL assay. Ultrastructural changes were examined by transmission electron microscope (TEM). Biochemical markers associated with apoptosis (eg, caspase-3) and necroptosis (eg, RIP3) were investigated by immunohistochemistry. In KBD cartilage chondrocyte death was characterized by paler staining of the cells. Multiple chondral cell clusters surrounded the areas lacking cells in the deep zone. The per cent of TUNEL-positive and RIP3-positive chondrocytes were higher in the middle zones of KBD samples; however, there was some positive staining for TUNEL but negative staining for caspase-3. Immunohistochemistry failed to detect significant differences in caspase-3 levels in KBD children compared to controls, suggesting that beside apoptosis necroptosis dominates as a cell death mechanism in the middle zone of cartilage from KBD children. To clarify further the presence of chondrocyte necroptosis in KBD, we performed TUNEL, caspase-3 and RIP3 staining in a rat KBD model which is based upon T-2 toxin treatment under selenium-deficient conditions. Apoptosis and necroptosis co-existed in the middle zone in this rat KBD model. Ultrastructural analysis of chondrocyte from deep cartilage revealed abnormal cells with numerous morphological changes, such as plasma membrane breakdown, generalized swelling of the cytoplasm and loss of identifiable organelles. Chondrocyte death by necrosis in the deep zone of cartilages in KBD may be a result of exposure to T-2 toxin from bone marrow or bloodstream under selenium-deficient nutrition status in KBD endemic areas. Chondrocyte death plays a key role in either the initiation or the progression of KBD pathogenesis.	[Zhang, Ying; He, Ying; Zhang, Dan; Zhang, Meng; Wang, Mengying; Ma, Tianyou; Chen, Jinghong] Xi An Jiao Tong Univ, Sch Publ Hlth, Key Lab Trace Elements & Endem Dis, Hlth Sci Ctr,Natl Hlth Commiss, Xian 710061, Shaanxi, Peoples R China	Chen, JH (reprint author), Xi An Jiao Tong Univ, Key Lab Trace Elements & Endem Dis, Natl Hlth & Family Planning Commiss, Sch Publ Hlth,Hlth Sci Ctr, Xian, Shaanxi, Peoples R China.	jixiang46@163.com			National Natural Science Foundation of ChinaNational Natural Science Foundation of China [81573102, 81872565]; China Scholarship CouncilChina Scholarship Council [201706280086]	National Natural Science Foundation of China, Grant/Award Number: 81573102 and 81872565; China Scholarship Council, Grant/Award Number: 201706280086	ALLANDER E, 1994, SCAND J RHEUMATOL, P1; Bush PG, 2003, OSTEOARTHR CARTILAGE, V11, P242, DOI 10.1053/S1063-4584-(02)00369-2; Chen JH, 2012, J ORTHOP RES, V30, P1229, DOI 10.1002/jor.22073; Cho Y, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023209; Conrad M, 2016, NAT REV DRUG DISCOV, V15, P348, DOI 10.1038/nrd.2015.6; Degterev A, 2005, NAT CHEM BIOL, V1, P112, DOI 10.1038/nchembio711; Degterev A, 2008, NAT CHEM BIOL, V4, P313, DOI 10.1038/nchembio.83; Del Carlo Marcello Jr, 2008, Curr Rheumatol Rep, V10, P37; Dianjun Sun YL, 1997, CHIN J EPIDEM, V16, P207; Elmore S, 2007, TOXICOL PATHOL, V35, P495, DOI 10.1080/01926230701320337; Galluzzi L, 2015, CELL DEATH DIFFER, V22, P58, DOI 10.1038/cdd.2014.137; Guan F, 2013, RHEUMATOL INT, V33, P157, DOI 10.1007/s00296-011-2335-7; He SD, 2016, CELL MOL LIFE SCI, V73, P2177, DOI 10.1007/s00018-016-2192-3; He Y, 2018, BIOMED PHARMACOTHER, V106, P1696, DOI 10.1016/j.biopha.2018.07.128; Hinsenkamp M, 2001, INT ORTHOP, V25, P133, DOI 10.1007/s002640000177; Holler N, 2000, NAT IMMUNOL, V1, P489, DOI 10.1038/82732; Kaiser WJ, 2013, CURR OPIN VIROL, V3, P296, DOI 10.1016/j.coviro.2013.05.019; KOLSTEREN P, 1992, ANN SOC BELG MED TR, V72, P81; KUETTNER KE, 1992, CLIN BIOCHEM, V25, P155, DOI 10.1016/0009-9120(92)90224-G; Lee YS, 2013, FEBS LETT, V587, P266, DOI 10.1016/j.febslet.2012.12.004; Linkermann A, 2014, NEW ENGL J MED, V370, P455, DOI 10.1056/NEJMra1310050; Los M, 2002, MOL BIOL CELL, V13, P978, DOI 10.1091/mbc.01-05-0272; Mo D, 1990, ZHONGHUA FANG SHE XU, V12, P90; Mo D, 1992, CHIN J EPIDEM, V1, P116; Mo D, 1997, J XI MED U, V9, P11; Pasteels JL, 2001, INT ORTHOP, V25, P151, DOI 10.1007/s002640000190; Skulachev VP, 2006, APOPTOSIS, V11, P473, DOI 10.1007/s10495-006-5881-9; Trichonas G, 2010, P NATL ACAD SCI USA, V107, P21695, DOI 10.1073/pnas.1009179107; Van Herreweghe F, 2010, CELL MOL LIFE SCI, V67, P1567, DOI 10.1007/s00018-010-0283-0; Vanlangenakker N, 2011, CELL DEATH DIS, V2, DOI 10.1038/cddis.2011.111; Wang G. Y., 1985, Acta Nutrimenta Sinica, V7, P39; Wang SH, 2006, J RHEUMATOL, V33, P615; Wang W, 2013, OSTEOARTHR CARTILAGE, V21, P1781, DOI 10.1016/j.joca.2013.08.002; Yamamuro T, 2001, INT ORTHOP, V25, P134, DOI 10.1007/s002640000178; Yang HJ, 2017, BIOMED ENVIRON SCI, V30, P351, DOI 10.3967/bes2017.046; Yang J. B., 1998, CHIN J EPIDEM, V17, P201; Ying He JC, 2016, CHIN J EPIDEM, V35, P351; Yongmin Xiong SZ, 1997, CHIN J EPIDEM, V12, P4; Zhou XR, 2014, RHEUMATOL INT, V34, P995, DOI 10.1007/s00296-013-2862-5	39	1	1	3	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0959-9673	1365-2613		INT J EXP PATHOL	Int. J. Exp. Pathol.	DEC	2018	99	6					312	322		10.1111/iep.12297			11	Pathology	Pathology	HM4TP	WOS:000459467900143	30680829				2019-10-28	
J	Asiri, A; Raposo, TP; Alfahed, A; Ilyas, M				Asiri, Abdulaziz; Raposo, Teresa Pereira; Alfahed, Abdulaziz; Ilyas, Mohammad			TGF beta 1-induced cell motility but not cell proliferation is mediated through Cten in colorectal cancer	INTERNATIONAL JOURNAL OF EXPERIMENTAL PATHOLOGY			English	Article						cell invasion; cell motility; colorectal cancer; epithelial-mesenchymal transition; transforming growth factor beta	EPITHELIAL-MESENCHYMAL TRANSITION; TENSIN-LIKE PROTEIN; TUMOR PROGRESSION; MIGRATION; METASTASIS; EXPRESSION; ONCOGENE; ADHESION; INVASION; SNAIL	Cten (C-terminal tensin-like) is a member of the tensin protein family found in complex with integrins at focal adhesions. It promotes epithelial-mesenchymal transition (EMT) and cell motility. The precise mechanisms regulating Cten are unknown, although we and others have shown that Cten could be under the regulation of several cytokines and growth factors. Since transforming growth factor beta 1 (TGF-beta 1) regulates integrin function and promotes EMT/cell motility, we were prompted to investigate whether TGF-beta 1 induces EMT and cell motility through Cten signalling in colorectal cancer. TGF-beta 1 signalling was modulated by either stimulation with TGF-beta 1 or knockdown of TGF-beta 1 in the CRC cell lines SW620 and HCT116. The effect of this modulation on expression of Cten, EMT markers and on cellular function was tested. The role of Cten as a direct mediator of TGF-beta 1 signalling was investigated in a CRC cell line in which the Cten gene had been deleted (SW620(Delta Cten)). When TGF-beta 1 was stimulated or inhibited, this resulted in, respectively, upregulation and downregulation of Cten expression and EMT markers (Snail, Rock, N-cadherin, Src). Cell migration and cell invasion were significantly increased following TGF-beta 1 stimulation and lost by TGF-beta 1 knockdown. TGF-beta 1 stimulation of the SW620(Delta Cten) cell line resulted in selective loss of the effect of TGF-beta 1 signalling pathway on EMT and cell motility while the stimulatory effect on cell proliferation was retained. These data suggested Cten may play an essential role in mediating TGF-beta 1-induced EMT and cell motility and may therefore play a role in metastasis in CRC.	[Asiri, Abdulaziz; Raposo, Teresa Pereira; Alfahed, Abdulaziz; Ilyas, Mohammad] Univ Nottingham, Sch Med, Queens Med Ctr, Div Canc & Stem Cells, Nottingham, England; [Asiri, Abdulaziz; Raposo, Teresa Pereira; Alfahed, Abdulaziz; Ilyas, Mohammad] Univ Nottingham, Queens Med Ctr, Nottingham Mol Pathol Node, Nottingham, England; [Alfahed, Abdulaziz] Prince Sattam Bin Abdulaziz Univ, Coll Appl Med Sci, Dept Med Lab, Al Kharj 11942, Saudi Arabia	Raposo, TP (reprint author), Univ Nottingham, Div Canc & Stem Cells, Nottingham, England.	msztp2@nottingham.ac.uk		Raposo, Teresa/0000-0003-4033-8498	Saudi Arabian Cultural Bureau in Britain [S3555]	This work was supported by the Saudi Arabian Cultural Bureau in Britain: (S3555).	Al-Ghamdi S, 2013, PANCREAS, V42, P135, DOI 10.1097/MPA.0b013e3182557ceb; Al-Ghamdi S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020919; Albasri A, 2011, ONCOGENE, V30, P2997, DOI 10.1038/onc.2011.26; Albasri A, 2011, BREAST CANCER RES TR, V126, P47, DOI 10.1007/s10549-010-0890-3; Albasri A, 2009, J PATHOL, V218, P57, DOI 10.1002/path.2508; Araki S, 2010, J CLIN INVEST, V120, P290, DOI 10.1172/JCI39194; Bakin AV, 2000, J BIOL CHEM, V275, P36803, DOI 10.1074/jbc.M005912200; Bennett DT, 2015, J THORAC CARDIOV SUR, V149, P369, DOI 10.1016/j.jtcvs.2014.08.087; Bhowmick NA, 2001, MOL BIOL CELL, V12, P27, DOI 10.1091/mbc.12.1.27; Bu JQ, 2017, EUR REV MED PHARMACO, V21, P2137; Cao X, 2012, P NATL ACAD SCI USA, V109, P1455, DOI 10.1073/pnas.1114368109; Cho HJ, 2007, BIOCHEM BIOPH RES CO, V353, P337, DOI 10.1016/j.bbrc.2006.12.035; Choi HJ, 2017, BMB REP, V50, P429, DOI 10.5483/BMBRep.2017.50.8.097; Chui MH, 2013, INT J CANCER, V132, P1487, DOI 10.1002/ijc.27745; Cicchini C, 2008, EXP CELL RES, V314, P143, DOI 10.1016/j.yexcr.2007.09.005; Guinney J, 2015, NAT MED, V21, P1350, DOI 10.1038/nm.3967; Hung SY, 2014, MOL CARCINOGEN, V53, P787, DOI 10.1002/mc.22034; Janda E, 2002, J CELL BIOL, V156, P299, DOI 10.1083/jcb.200109037; Katz M, 2007, NAT CELL BIOL, V9, P961, DOI 10.1038/ncb1622; Lee YI, 2004, BIOCHEM BIOPH RES CO, V316, P997, DOI 10.1016/j.bbrc.2004.02.150; Liu RY, 2014, INT J ONCOL, V44, P1643, DOI 10.3892/ijo.2014.2310; Lo SH, 2002, CANCER RES, V62, P4217; Nagaraj NS, 2010, EXPERT OPIN INV DRUG, V19, P77, DOI 10.1517/13543780903382609; Pang MF, 2016, ONCOGENE, V35, P748, DOI 10.1038/onc.2015.133; Peinado H, 2007, NAT REV CANCER, V7, P415, DOI 10.1038/nrc2131; Sasaki H, 2003, LUNG CANCER-J IASLC, V40, P151, DOI 10.1016/S0169-5002(03)00037-0; Silginer M, 2016, ONCOGENE, V35, P3260, DOI 10.1038/onc.2015.387; Thorpe H, 2017, MOL CARCINOGEN, V56, P2601, DOI 10.1002/mc.22704; Thorpe H, 2015, INT J EXP PATHOL, V96, P362, DOI 10.1111/iep.12154; Yuan Y, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031802; Zavadil J, 2004, EMBO J, V23, P1155, DOI 10.1038/sj.emboj.7600069	31	1	1	1	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0959-9673	1365-2613		INT J EXP PATHOL	Int. J. Exp. Pathol.	DEC	2018	99	6					323	330		10.1111/iep.12300			8	Pathology	Pathology	HM4TP	WOS:000459467900144	30648319				2019-10-28	
J	Schirmacher, P; Moch, H				Schirmacher, Peter; Moch, Holger			Statute of the Rudolf-Virchow Foundation for Pathology	PATHOLOGE			German	Editorial Material																	0	0	0	2	2	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	0172-8113	1432-1963		PATHOLOGE	Pathologe	DEC	2018	39			2			S364	S365		10.1007/s00292-018-0554-3			2	Pathology	Pathology	HK9RR	WOS:000458330000002					2019-10-28	
J	[Anonymous]				[Anonymous]			Statute of the German Society for Pathology e.V.	PATHOLOGE			German	Editorial Material																	0	0	0	0	0	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	0172-8113	1432-1963		PATHOLOGE	Pathologe	DEC	2018	39			2			S361	S363		10.1007/s00292-018-0553-4			3	Pathology	Pathology	HK9RR	WOS:000458330000001	30406432				2019-10-28	
J	Karamchandani, DM; Chetty, R				Karamchandani, Dipti M.; Chetty, Runjan			Apoptotic colopathy: a pragmatic approach to diagnosis	JOURNAL OF CLINICAL PATHOLOGY			English	Review							VERSUS-HOST-DISEASE; GASTROINTESTINAL MUCOSAL BIOPSIES; COMMON VARIABLE IMMUNODEFICIENCY; HISTOLOGIC FEATURES; GRAFT; MYCOPHENOLATE; PATHOLOGY; COLITIS; CYTOMEGALOVIRUS; IMMUNOHISTOCHEMISTRY	'Apoptotic colopathy' is an umbrella term signifying a pattern of injury where the gastrointestinal biopsy shows a colitic picture with apoptosis as the predominant histological feature. Although the entities within apoptotic colopathy share a common histological feature-'apoptosis', there is a list of varied clinical differential diagnoses that produce this similar histological pattern of injury. These include graft-versus-host disease, drug-induced injury due to multiple drugs (in particular, mycophenolate mofetil, check point inhibitor therapy and some others), infections (particularly cytomegalovirus, adenovirus and some others), immune disorders and other miscellaneous causes. However, the management of these varied differentials is strikingly different, thus necessitating an algorithmic approach for accurate diagnosis and optimal patient management. A definitive diagnosis requires interpretation of varied histological findings in the appropriate clinical context including clinical history, drug history and laboratory findings. This review will focus on the histopathological findings of varied entities that can manifest as 'apoptotic colopathy' on assessment of colonic biopsies.	[Karamchandani, Dipti M.] Penn State Hlth Milton S Hershey Med Ctr, Dept Pathol, Div Anat Pathol, 500 Univ Dr,H179, Hershey, PA 17033 USA; [Chetty, Runjan] Univ Hlth Network, Lab Med Program, Dept Pathol, Toronto, ON, Canada	Karamchandani, DM (reprint author), Penn State Hlth Milton S Hershey Med Ctr, Dept Pathol, Div Anat Pathol, 500 Univ Dr,H179, Hershey, PA 17033 USA.	dkaramchandani@pennstatehealth.psu.edu		Chetty, Runjan/0000-0002-2124-515X			Assarzadegan N, 2018, VIRCHOWS ARCH, V472, P125, DOI 10.1007/s00428-017-2267-z; Daniels JA, 2007, AM J SURG PATHOL, V31, P1800, DOI 10.1097/PAS.0b013e3180cab60c; EPSTEIN RJ, 1980, GASTROENTEROLOGY, V78, P764; Iqbal N, 2000, AM J GASTROENTEROL, V95, P3034; Juric-Sekhar G, 2017, HUM PATHOL, V60, P11, DOI 10.1016/j.humpath.2016.09.009; Kambham N, 2004, AM J SURG PATHOL, V28, P365, DOI 10.1097/00000478-200403000-00009; Karamchandani DM, 2018, J CLIN PATHOL, V71, P665, DOI 10.1136/jclinpath-2018-205143; LAMPERT IA, 1985, HISTOPATHOLOGY, V9, P875, DOI 10.1111/j.1365-2559.1985.tb02872.x; Lee S, 2013, J CLIN PATHOL, V66, P8, DOI 10.1136/jclinpath-2012-200888; LERNER KG, 1974, TRANSPLANT P, V6, P367; Lin JM, 2013, AM J SURG PATHOL, V37, P539, DOI 10.1097/PAS.0b013e318272c62a; Louie CY, 2015, AM J SURG PATHOL, V39, P1653, DOI 10.1097/PAS.0000000000000525; Marginean EC, 2016, ARCH PATHOL LAB MED, V140, P748, DOI 10.5858/arpa.2015-0451-RA; Masia R, 2014, AM J SURG PATHOL, V38, P1319, DOI 10.1097/PAS.0000000000000317; Mccoy MH, 2014, HUM PATHOL, V45, P48, DOI 10.1016/j.humpath.2013.07.040; McCurdy JD, 2015, INFLAMM BOWEL DIS, V21, P2833, DOI 10.1097/MIB.0000000000000556; Mills AM, 2013, AM J SURG PATHOL, V37, P995, DOI 10.1097/PAS.0b013e31827fcc33; Panarelli NC, 2018, MODERN PATHOL, V31, P844, DOI 10.1038/s41379-018-0015-9; Papadimitriou JC, 2003, INT J SURG PATHOL, V11, P295, DOI 10.1177/106689690301100406; Papadimitriou JC, 2001, TRANSPLANT P, V33, P2237, DOI 10.1016/S0041-1345(01)01951-0; Parfitt JR, 2008, AM J SURG PATHOL, V32, P1367, DOI 10.1097/PAS.0b013e31816bf3fe; Patil DT, 2018, VIRCHOWS ARCH, V472, P67, DOI 10.1007/s00428-017-2274-0; SALE GE, 1979, AM J SURG PATHOL, V3, P291, DOI 10.1097/00000478-197908000-00001; Schulenburg A, 2004, ANN HEMATOL, V83, P101, DOI 10.1007/s00277-003-0756-4; Selbst MK, 2009, MODERN PATHOL, V22, P737, DOI 10.1038/modpathol.2009.44; Shulman HM, 2006, BIOL BLOOD MARROW TR, V12, P31, DOI 10.1016/j.bbmt.2005.10.023; SNOVER DC, 1985, TRANSPLANTATION, V39, P95, DOI 10.1097/00007890-198501000-00017; Soldini D, 2014, J CLIN PATHOL, V67, P582, DOI 10.1136/jclinpath-2014-202199; Star KV, 2013, AM J SURG PATHOL, V37, P1319, DOI 10.1097/PAS.0b013e31829ab1ef; Villanacci V, 2011, DIGEST LIVER DIS, V43, P523, DOI 10.1016/j.dld.2010.12.016; Wang MH, 2000, SCAND J GASTROENTERO, V35, P667; Washington K, 1996, AM J SURG PATHOL, V20, P1240, DOI 10.1097/00000478-199610000-00010; Washington K, 2009, HUM PATHOL, V40, P909, DOI 10.1016/j.humpath.2009.04.001; Weidner AS, 2015, AM J SURG PATHOL, V39, P1661, DOI 10.1097/PAS.0000000000000522; Wong NACS, 2015, HISTOPATHOLOGY, V66, P467, DOI 10.1111/his.12542	35	0	0	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0021-9746	1472-4146		J CLIN PATHOL	J. Clin. Pathol.	DEC	2018	71	12					1033	1040		10.1136/jclinpath-2018-205388			8	Pathology	Pathology	HK2ND	WOS:000457748300001	30275102				2019-10-28	
J	Godber, IM; Benton, SC; Fraser, CG				Godber, Ian M.; Benton, Sally C.; Fraser, Callum G.			Setting up a service for a faecal immunochemical test for haemoglobin (FIT): a review of considerations, challenges and constraints	JOURNAL OF CLINICAL PATHOLOGY			English	Review							PERFORMANCE; SYMPTOMS; SEX; AGE	Quantitative faecal immunochemical tests for haemoglobin (FIT) have now been advocated by the National Institute for Care and Health Excellence (NICE: DG30) to assist in the triage of patients presenting with symptoms that suggest a low risk of colorectal (bowel) cancer. The evidence is that FIT provides a good rule out test for significant bowel disease. However, a small number of cases will be missed, and robust safety-netting procedures are required to follow up some FIT-negative patients. A range of diagnostic pathways are possible, and there is no best approach at present. Introduction of FIT requires careful consideration of the logistics of supply of devices and information to requesting sites and of transport to the laboratory. A number of FIT analytical systems are available. Three are documented as appropriate for use in assessment of patients with symptoms. However, preanalytical, analytical and postanalytical challenges remain. The methods have different specimen collection devices. The methods use polyclonal antibodies and there is no primary reference material or method to which FIT methods are standardised. Third-party internal quality control is lacking, and external quality assessment schemes have many difficulties in providing appropriate materials. Reporting of results should be done using mu g Hb/g faeces units and with knowledge of the limit of detection and limit of quantitation of the analytical system used. FIT can be used successfully in an agreed diagnostic pathway, along with other clinical and laboratory information: this requires a multidisciplinary approach, providing opportunities for professionals in laboratory medicine involvement.	[Godber, Ian M.] Monklands Hosp, NHS Lanarkshire, Dept Clin Biochem, Airdrie, Lanark, Scotland; [Benton, Sally C.] Royal Surrey Cty Hosp, Berkshire & Surrey Pathol Serv, Guildford, Surrey, England; [Benton, Sally C.] Bowel Canc Screening Hub, Guildford, Surrey, England; [Fraser, Callum G.] Univ Dundee, Ninewells Hosp & Med Sch, Ctr Res Canc Prevent & Screening, Dundee, Scotland	Godber, IM (reprint author), Monklands Hosp, Dept Clin Biochem, Airdrie ML60JS, Scotland.	Godber@lanarkshire.scot.nhs.uk					Auge JM, 2018, CLIN CHEM LAB MED, V56, P625, DOI 10.1515/cclm-2017-0605; Brown LF, 2008, ANN CLIN BIOCHEM, V45, P604, DOI 10.1258/acb.2008.008024; Carroll MR, 2018, ANN CLIN BIOCHEM, V1; Carroll MRR, 2013, EVALUATION QUANTITAT; Clinical and Laboratory Standards Institute, 2012, EV DET CAP CLIN LAB; Cubiella J, 2017, INT J CANCER, V140, P2201, DOI 10.1002/ijc.30639; Cubiella J, 2016, BMC MED, V14, DOI 10.1186/s12916-016-0668-5; Digby J, 2014, J MED SCREEN, V21, P95, DOI 10.1177/0969141314535388; Digby J, 2013, J CLIN PATHOL, V66, P415, DOI 10.1136/jclinpath-2013-201445; Fraser CG, 2008, ANN CLIN BIOCHEM, V45, P117, DOI 10.1258/acb.2008.007223; Fraser CG, 2018, SURG-J R COLL SURG E, V16, P302, DOI 10.1016/j.surge.2018.01.004; Fraser CG, 2014, CLIN CHEM LAB MED, V52, P1211, DOI 10.1515/cclm-2014-0115; Fraser CG, 2012, JNCI-J NATL CANCER I, V104, P810, DOI 10.1093/jnci/djs190; Fraser CG, 2018, CLIN CHEM LAB MED, V2018; Gies A, 2018, GASTROENTEROLOGY, V154, P93, DOI 10.1053/j.gastro.2017.09.018; Godber IM, 2016, CLIN CHEM LAB MED, V54, P595, DOI 10.1515/cclm-2015-0617; Juul JS, 2018, BRIT J CANCER, V119, P471, DOI 10.1038/s41416-018-0178-7; Kinns H, 2013, J CLIN PATHOL, V66, P1027, DOI 10.1136/jclinpath-2013-201661; Mellen S, 2018, ANN CLIN BIOCHEM, V1; National Institute for Health and Care Excellence, 2015, SUSP CANC REC REF; NICE, 2017, QUANT FAEC IMM TESTS; Nieuwenburg SAV, 2019, GUT, V68, P866, DOI 10.1136/gutjnl-2018-316344; Piggott C, 2018, ANN CLIN BIOCHEM, V1; Quyn AJ, 2018, ANN CLIN BIOCHEM, V55, P69, DOI 10.1177/0004563217707981; Rapi S, 2017, INT J BIOL MARKER, V32, pE261, DOI 10.5301/ijbm.5000265; Rees CJ, 2016, GUT, V65, P1923, DOI 10.1136/gutjnl-2016-312044; Rodriguez-Alonso L, 2015, DIGEST LIVER DIS, V47, P797, DOI 10.1016/j.dld.2015.05.004; Spiteri N, 2018, J LAB PRECIS MED, V3, P52; Steele RJC, 2018, TIMELY DIAGNOSIS COL; Symonds EL, 2015, J MED SCREEN, V22, P187, DOI 10.1177/0969141315584783; Westwood M, 2017, BMC MED, V15, DOI 10.1186/s12916-017-0944-z	31	2	2	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0021-9746	1472-4146		J CLIN PATHOL	J. Clin. Pathol.	DEC	2018	71	12					1041	1045		10.1136/jclinpath-2018-205047			5	Pathology	Pathology	HK2ND	WOS:000457748300002	30275098				2019-10-28	
J	Arun, AK; Senthamizhselvi, A; Hemamalini, S; Edison, ES; Korula, A; Fouzia, NA; George, B; Mathews, V; Balasubramanian, P				Arun, A. Kumar; Senthamizhselvi, Anandan; Hemamalini, Suresh; Edison, Eunice S.; Korula, Anu; Fouzia, N. A.; George, Biju; Mathews, Vikram; Balasubramanian, Poonkuzhali			Spectrum of ELANE mutations in congenital neutropenia: a single-centre study in patients of Indian origin	JOURNAL OF CLINICAL PATHOLOGY			English	Article							ACUTE MYELOID-LEUKEMIA; ELASTASE; GENE; MOSAICISM; PROTEASES; RISK; HAX1; GFI1	Aims Congenital and cyclical neutropenia are rare inherited diseases that result in recurrent life-threatening bacterial infections due to a deficiency of mature neutrophils. Cyclical neutropenia is usually caused by heterozygous ELANE mutations while congenital neutropenia is genetically heterogeneous with mutations in genes like ELANE, HAX-1, G6PC3 and GFI1. The presence of ELANE mutation aids in the establishment of diagnosis and rules out other secondary causes of neutropenia such as autoimmune cytopenia and evolving aplasia. Further, patients with ELANE mutations are also at a high risk of developing myelodysplasia or acute myeloid leukaemia. Hence it is important to screen for these mutations in patients presenting with neutropenia early in life. Methods The study included 52 patients who were evaluated for inherited neutropenia. Genomic DNA was extracted from peripheral blood leucocytes and mutation analysis was done by bidirectional Sanger sequencing. Results Ten different missense, frameshift or splice site variants in ELANE gene were identified in 11 patients: c. 125C>T (p.Pro42Leu), c. 164G>A (p.Cys55Tyr), c. 169G>A (p.Ala57Thr), c. 179T>C (p.Ile60Thr), c. 770C>T (p.Pro257Leu), c. 367-8C>A, c. 597+1G>A along with three novel mutations c. 302T>A (p.Val101Glu), c. 468G>T (p.Try156Cys) and c. 596delT (Phe199Ser fs* 13). Family studies were available for three patients and, in all three instances, the mutation had a de novo origin. Conclusion The widespread distribution of mutations suggests the need to screen all the exons in ELANE gene for proper characterisation of the genotype.	[Arun, A. Kumar; Senthamizhselvi, Anandan; Hemamalini, Suresh; Edison, Eunice S.; Korula, Anu; Fouzia, N. A.; George, Biju; Mathews, Vikram; Balasubramanian, Poonkuzhali] Christian Med Coll & Hosp, Dept Haematol, Vellore 632004, Tamil Nadu, India	Balasubramanian, P (reprint author), Christian Med Coll & Hosp, Dept Haematol, Vellore 632004, Tamil Nadu, India.	bpoonkuzhali@cmcvellore.ac.in	SOUNDRARAJAN, JOYSON/I-1779-2019	Kumar, A.Arun/0000-0002-0362-0278	Department of Biotechnology, Government of IndiaDepartment of Biotechnology (DBT) IndiaGovernment of India [BT/MB/ 04/2004]	This study was supported by grant BT/MB/ 04/2004 from the Department of Biotechnology, Government of India.	Adzhubei IA, 2010, NAT METHODS, V7, P248, DOI 10.1038/nmeth0410-248; Ancliff PJ, 2002, BLOOD, V100, P707, DOI 10.1182/blood-2002-01-0060; Ancliff PJ, 2001, BLOOD, V98, P2645, DOI 10.1182/blood.V98.9.2645; Armistead PM, 2010, BRIT J HAEMATOL, V150, P716, DOI 10.1111/j.1365-2141.2010.08274.x; Bellanne-Chantelot C, 2004, BLOOD, V103, P4119, DOI 10.1182/blood-2003-10-3518; Benson KF, 2003, NAT GENET, V35, P90, DOI 10.1038/ng1224; Benson KF, 2002, BRIT J HAEMATOL, V118, P923, DOI 10.1046/j.1365-2141.2002.03631_3.x; Borregaard N, 1997, BLOOD, V89, P3503, DOI 10.1182/blood.V89.10.3503.3503_3503_3521; Boxer LA, 2006, J PEDIATR-US, V148, P633, DOI 10.1016/j.jpeds.2005.12.029; Carlsson G, 2012, BRIT J HAEMATOL, V158, P363, DOI 10.1111/j.1365-2141.2012.09171.x; Dale DC, 2000, BLOOD, V96, P2317, DOI 10.1182/blood.V96.7.2317.h8002317_2317_2322; Dale DC, 2002, SEMIN HEMATOL, V39, P89, DOI 10.1053/shem.2002.31917; Donadieu J, 2005, HAEMATOLOGICA, V90, P45; DONG F, 1995, NEW ENGL J MED, V333, P487, DOI 10.1056/NEJM199508243330804; Freedman MH, 2000, BLOOD, V96, P429; Germeshausen M, 2013, HUM MUTAT, V34, P905, DOI 10.1002/humu.22308; Germeshausen M, 2010, HAEMATOL-HEMATOL J, V95, P1207, DOI 10.3324/haematol.2009.017665; Grenda DS, 2007, BLOOD, V110, P4179, DOI 10.1182/blood-2006-11-057299; Hirata O, 2015, J CLIN IMMUNOL, V35, P512, DOI 10.1007/s10875-015-0165-1; Horwitz M, 1999, NAT GENET, V23, P433, DOI 10.1038/70544; Horwitz MS, 2013, HEMATOL ONCOL CLIN N, V27, P19, DOI 10.1016/j.hoc.2012.10.004; Kearse M, 2012, BIOINFORMATICS, V28, P1647, DOI 10.1093/bioinformatics/bts199; Klein C, 2007, NAT GENET, V39, P86, DOI 10.1038/ng1940; Kollner I, 2006, BLOOD, V108, P493, DOI 10.1182/blood-2005-11-4689; KOSTMANN R, 1975, ACTA PAEDIATR SCAND, V64, P362, DOI 10.1111/j.1651-2227.1975.tb03847.x; KOSTMANN R, 1956, Acta Paediatr Suppl, V45, P1; LANGE RD, 1983, EXP HEMATOL, V11, P435; Makaryan V, 2015, CURR OPIN HEMATOL, V22, P3, DOI 10.1097/MOH.0000000000000105; Nayak RC, 2015, J CLIN INVEST, V125, P3103, DOI 10.1172/JCI80924; Ng PC, 2003, NUCLEIC ACIDS RES, V31, P3812, DOI 10.1093/nar/gkg509; Pham CTN, 2006, NAT REV IMMUNOL, V6, P541, DOI 10.1038/nri1841; Rosenberg PS, 2010, BR J HAEMATOL, V150; Salipante SJ, 2007, HUM MUTAT, V28, P874, DOI 10.1002/humu.20529; Schwarz JM, 2010, NAT METHODS, V7, P575, DOI 10.1038/nmeth0810-575; Tidwell T, 2014, BLOOD, V123, P562, DOI 10.1182/blood-2013-07-513242; Xia J, 2008, CURR OPIN HEMATOL, V15, P1, DOI 10.1097/MOH.0b013e3282f13cd2; Xia J, 2009, BRIT J HAEMATOL, V147, P535, DOI 10.1111/j.1365-2141.2009.07888.x; Zlotogora J, 1998, HUM GENET, V102, P381, DOI 10.1007/s004390050708	38	0	0	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0021-9746	1472-4146		J CLIN PATHOL	J. Clin. Pathol.	DEC	2018	71	12					1046	1050		10.1136/jclinpath-2018-205235			5	Pathology	Pathology	HK2ND	WOS:000457748300003	30171085				2019-10-28	
J	Dannheim, KC; Pozdnyakova, O; Dal Cin, P; Weinberg, OK				Dannheim, Katelyn C.; Pozdnyakova, Olga; Dal Cin, Paola; Weinberg, Olga K.			Immunophenotypic dysplasia and aberrant T-cell antigen expression in acute myeloid leukaemia with complex karyotype and TP53 mutations	JOURNAL OF CLINICAL PATHOLOGY			English	Article							MYELODYSPLASTIC SYNDROMES; FLOW-CYTOMETRY; STANDARDIZATION; IMPLEMENTATION; VALIDATION; GENE	Aims Cytogenetic and molecular aberrations are the strongest factors in determining outcome in acute myeloid leukaemia (AML). AML with complex karyotype confers a particularly poor prognosis and is associated with morphologic dysplasia. Flow cytometric immunophenotyping (FCI) has been investigated in defining dysplasia within myelodysplastic syndromes, but little is known about immunophenotypic dysplasia in AML and correlation with genetic abnormalities. This study aimed to explore differences in antigen expression by FCI in AML with complex karyotype (AML-CK) and AML with complex karyotype and TP53 mutations (AML-TP53) compared with AML with normal karyotype (AML-NK). Methods Twenty-five cases of AML-CK, 13 of which had abnormalities of TP53, were compared with 83 cases of AML-NK using FCI. Results Our findings demonstrated brighter expression of CD34 with decreased CD33 and aberrant expression of CD5 in blasts of AML-CK, while AML-TP53 blasts exhibited brighter expression of CD13. Granulocytes in AML-CK exhibited brighter expression of CD5, CD7, CD10 and CD14, with brighter CD3 also seen in AML-TP53. Conclusions Our results suggest that immunophenotypic dysplasia correlates with complex karyotype and TP53 mutation, including increased expression of T-cell antigens.	[Dannheim, Katelyn C.] Beth Israel Deaconess Med Ctr, Dept Pathol, 330 Brookline Ave, Boston, MA 02215 USA; [Pozdnyakova, Olga; Dal Cin, Paola] Brigham & Womens Hosp, Dept Pathol, 75 Francis St, Boston, MA 02115 USA; [Weinberg, Olga K.] Boston Childrens Hosp, Dept Pathol, Boston, MA 02115 USA	Weinberg, OK (reprint author), Boston Childrens Hosp, Dept Pathol, Boston, MA 02115 USA.	olga.weinberg@childrens.harvard.edu					Bowen D, 2009, LEUKEMIA, V23, P203, DOI 10.1038/leu.2008.173; Della Porta MG, 2015, LEUKEMIA, V29, P66, DOI 10.1038/leu.2014.161; Dohner H, 2010, BLOOD, V115, P453, DOI 10.1182/blood-2009-07-235358; Grimwade D, 2001, BEST PRACT RES CL HA, V14, P497, DOI 10.1053/beha.2001.0152; Grimwade D, 2010, BLOOD, V116, P354, DOI 10.1182/blood-2009-11-254441; Haferlach C, 2008, LEUKEMIA, V22, P1539, DOI 10.1038/leu.2008.143; Kluk MJ, 2016, J MOL DIAGN, V18, P507, DOI 10.1016/j.jmoldx.2016.02.003; Mrozek K, 2004, BLOOD REV, V18, P115, DOI 10.1016/S0268-960X(03)00040-7; Mrozek K, 2008, SEMIN ONCOL, V35, P365, DOI 10.1053/j.seminoncol.2008.04.007; Schoch C, 2001, BRIT J HAEMATOL, V112, P118, DOI 10.1046/j.1365-2141.2001.02511.x; Scott BL, 2008, BLOOD, V112, P2681, DOI 10.1182/blood-2008-05-153700; Stetler-Stevenson M, 2001, BLOOD, V98, P979, DOI 10.1182/blood.V98.4.979; Stirewalt DL, 2001, BLOOD, V97, P3589, DOI 10.1182/blood.V97.11.3589; Swerdlow SH, 2008, WHO CLASSIFICATION T; Swerdlow SH, 2017, WHO CLASSIFICATION T; van de Loosdrecht AA, 2008, BLOOD, V111, P1067, DOI 10.1182/blood-2007-07-098764; van de Loosdrecht AA, 2009, HAEMATOL-HEMATOL J, V94, P1124, DOI 10.3324/haematol.2009.005801; Weinberg OK, 2017, J CLIN PATHOL, V70, P109, DOI 10.1136/jclinpath-2016-203863; Weinberg OK, 2015, MODERN PATHOL, V28, P965, DOI 10.1038/modpathol.2015.55; Welch JS, 2016, NEW ENGL J MED, V375, P2023, DOI 10.1056/NEJMoa1605949; Wells DA, 2003, BLOOD, V102, P394, DOI 10.1182/blood-2002-09-2768; Westers TM, 2012, LEUKEMIA, V26, P1730, DOI 10.1038/leu.2012.30	22	0	0	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0021-9746	1472-4146		J CLIN PATHOL	J. Clin. Pathol.	DEC	2018	71	12					1051	1059		10.1136/jclinpath-2018-205348			9	Pathology	Pathology	HK2ND	WOS:000457748300004	30171088				2019-10-28	
J	El-Balat, A; Schmeil, I; Gasimli, K; Sanger, N; Karn, T; Ahr, A; Becker, S; Arsenic, R; Holtrich, U; Engels, K				El-Balat, Ahmed; Schmeil, Iryna; Gasimli, Khayal; Saenger, Nicole; Karn, Thomas; Ahr, Andre; Becker, Sven; Arsenic, Ruza; Holtrich, Uwe; Engels, Knut			Claudin-1 is linked to presence of implants and micropapillary pattern in serous borderline epithelial tumours of the ovary	JOURNAL OF CLINICAL PATHOLOGY			English	Article							ACTIVATED PROTEIN-KINASE; STRATIFICATION MARKER; PROGNOSTIC-FACTORS; CANCER; EXPRESSION; TARGETS; RECURRENCE; JUNCTIONS; EMPHASIS; INVASION	Aims Expression of Claudin-1 has been associated with prognosis in several cancers. Here we investigated the expression pattern of Claudin-1 in borderline tumours of the ovary (BOT). Methods We analysed a cohort of 114 cases of borderline tumour (BOT). Claudin-1 expression was studied by immunohistochemistry using a polyclonal antibody and was compared with clinical and histopathological characteristics. Results Strong Claudin-1 expression was found in 30 cases (26.3%) independent of histological subtype. Expression was significantly less frequent in International Federation of Gynecology and Obstetrics (FIGO) stage I (p=0.045), while the presence of microinvasion did not correlate with Claudin-1 expression. In contrast, we detected a highly significant association of Claudin-1 expression with the presence of peritoneal implants (p=0.003) and micropapillary pattern (p=0.047), which are features exclusively seen in serous BOT. Moreover, when we restricted our analysis to the subtype of serous BOT, the association of Claudin-1 expression with peritoneal implants (p<0.001) and micropapillary pattern (p=0.003) remained highly significant. Conclusions In conclusion, Claudin-1 expression is associated with the presence of peritoneal implants and micropapillary pattern, which have been shown to be associated with poor prognosis. We speculate that overexpression of Claudin-1 might be linked to the mitogen-activated protein kinase pathway activation in BOT and suggest further studies to define its prognostic and potential therapeutic value.	[El-Balat, Ahmed; Schmeil, Iryna; Gasimli, Khayal; Saenger, Nicole; Karn, Thomas; Ahr, Andre; Becker, Sven; Holtrich, Uwe] Univ Hosp Frankfurt, Dept Obstet & Gynecol, D-60590 Frankfurt, Germany; [Arsenic, Ruza] Charite, Inst Pathol, Berlin, Germany; [Engels, Knut] Ctr Pathol Cytol & Mol Pathol, Neuss, Germany	El-Balat, A (reprint author), Univ Hosp Frankfurt, Dept Obstet & Gynecol, D-60590 Frankfurt, Germany.	ahmed.el-balat@kgu.de	; Karn, Thomas/C-7452-2013	El-Balat, Ahmed/0000-0002-0560-8395; Karn, Thomas/0000-0002-3264-6573	Margarete-Bonifer-Stiftung, Bad Soden; HW&J Hector-Stiftung, Mannheim [M82]; BANSS-Stiftung, Biedenkopf	This work was supported by grants from the Margarete-Bonifer-Stiftung, Bad Soden, the HW&J Hector-Stiftung, Mannheim (grant number: M82), and the BANSS-Stiftung, Biedenkopf.	Ayhan A, 2005, GYNECOL ONCOL, V98, P439, DOI 10.1016/j.ygyno.2005.05.033; Bell DA, 2004, HUM PATHOL, V35, P934, DOI 10.1016/j.humpath.2004.03.005; BOSTWICK DG, 1986, CANCER, V58, P2052, DOI 10.1002/1097-0142(19861101)58:9<2052::AID-CNCR2820580916>3.0.CO;2-5; du Bois A, 2013, EUR J CANCER, V49, P1905, DOI 10.1016/j.ejca.2013.01.035; El-Balat A, 2018, PATHOL ONCOL RES, V24, P277, DOI 10.1007/s12253-017-0240-4; El-Balat A, 2016, J CLIN PATHOL, V69, P142, DOI 10.1136/jclinpath-2015-203224; Harhaj NS, 2004, INT J BIOCHEM CELL B, V36, P1206, DOI 10.1016/j.biocel.2003.08.007; Hsu CY, 2004, CLIN CANCER RES, V10, P6432, DOI 10.1158/1078-0432.CCR-04-0893; KAERN J, 1993, INT J GYNECOL CANCER, V3, P349, DOI 10.1046/j.1525-1438.1993.03060349.x; KATZENSTEIN ALA, 1978, AM J SURG PATHOL, V2, P339, DOI 10.1097/00000478-197812000-00001; Kim B, 2016, BIOL REPROD, V94, DOI 10.1095/biolreprod.115.134965; Knust E, 2002, SCIENCE, V298, P1955, DOI 10.1126/science.1072161; Kominsky Scott L., 2006, Expert Reviews in Molecular Medicine, V8, P1, DOI 10.1017/S1462399406000056; Kurman RJ, 2005, HISTOPATHOLOGY, V47, P310, DOI 10.1111/j.1365-2559.2005.02186.x; Kurman RJ, 2004, WHO CLASSIFICATION T; Kurman RJ, 2016, AM J PATHOL, V186, P733, DOI 10.1016/j.ajpath.2015.11.011; Kwon MJ, 2013, INT J MOL SCI, V14, P18148, DOI 10.3390/ijms140918148; Lenhard MS, 2009, EUR J OBSTET GYN R B, V145, P189, DOI 10.1016/j.ejogrb.2009.04.031; Longacre TA, 2005, AM J SURG PATHOL, V29, P707, DOI 10.1097/01.pas.0000164030.82810.db; McKenney JK, 2006, AM J SURG PATHOL, V30, P1209, DOI 10.1097/01.pas.0000213299.11649.fa; McKenney JK, 2016, AM J SURG PATHOL, V40, P1155, DOI 10.1097/PAS.0000000000000692; McShane LM, 2005, JNCI-J NATL CANCER I, V97, P1180, DOI 10.1093/jnci/dji237; Morice P, 2003, ANN ONCOL, V14, P592, DOI 10.1093/annonc/mdg173; Morin PJ, 2005, CANCER RES, V65, P9603, DOI 10.1158/0008-5472.CAN-05-2782; Pohl G, 2005, CANCER RES, V65, P1994, DOI 10.1158/0008-5472.CAN-04-3625; Qin WX, 2013, FEBS LETT, V587, P1434, DOI 10.1016/j.febslet.2013.03.023; Ren J, 2008, GYNECOL ONCOL, V110, P162, DOI 10.1016/j.ygyno.2008.03.019; Seidman JD, 2000, HUM PATHOL, V31, P539, DOI 10.1053/hp.2000.8048; Seidman JD, 2004, HUM PATHOL, V35, P918, DOI 10.1016/j.humpath.2004.03.004; Shih IM, 2010, GYNECOL ONCOL, V117, P1, DOI 10.1016/j.ygyno.2010.02.016; Silva EG, 2010, INT J GYNECOL PATHOL, V29, P507, DOI 10.1097/PGP.0b013e3181e31f74; Singer G, 2003, J NATL CANCER I, V95, P484, DOI 10.1093/jnci/95.6.484; Singh AB, 2010, J ONCOL, V2010, P1, DOI DOI 10.1155/2010/541957; Singh AB, 2015, SEMIN CELL DEV BIOL, V42, P58, DOI 10.1016/j.semcdb.2015.05.001; Swisshelm K, 2005, ADV DRUG DELIVER REV, V57, P919, DOI 10.1016/j.addr.2005.01.006; TAYLOR HC, 1929, SURG GYNECOL OBSTET, V48, P204; Tinelli R, 2006, GYNECOL ONCOL, V100, P185, DOI 10.1016/j.ygyno.2005.09.021; Vang R, 2017, AM J SURG PATHOL, V41, P725, DOI 10.1097/PAS.0000000000000824	38	0	0	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0021-9746	1472-4146		J CLIN PATHOL	J. Clin. Pathol.	DEC	2018	71	12					1060	1064		10.1136/jclinpath-2018-205292			5	Pathology	Pathology	HK2ND	WOS:000457748300005	30171086				2019-10-28	
J	Fanshawe, TR; Ordonez-Mena, JM; Turner, PJ; Van den Bruel, A; Shine, B; Hayward, GN				Fanshawe, Thomas R.; Ordonez-Mena, Jose M.; Turner, Philip J.; Van den Bruel, Ann; Shine, Brian; Hayward, Gail N.			Frequencies and patterns of laboratory test requests from general practice: a service evaluation to inform point-of-care testing	JOURNAL OF CLINICAL PATHOLOGY			English	Article							POCT	Aims The demand for test requests from general practice to laboratory services remains high. Tests performed at the point of care could reduce turnaround time and speed up clinical decision making. Replicating laboratory testing in the community would require panels of tests to be performed simultaneously, which is now approaching technological feasibility. We assessed frequencies and combinations of test requests from community settings to inform the potential future development of multiplex point-of-care panels. Methods We assessed all laboratory test requests made from general practice in Oxfordshire, UK, from January 2014 to March 2017. We summarised test request frequency overall and in combination, using heatmaps and hierarchical cluster analysis. Results are also presented by age/sex subgroups. We further assessed patterns of tests requested within 7 and 14 days after an initial test request. Results 11 763 473 test requests were made for 413 073 individuals (28% age >65). Of more than 500 test types, 62 were requested at least 5000 times, most commonly renal function tests (approximately 296 000/year), full blood count (278 000/year) and liver function tests (237 000/year). Cluster analysis additionally identified a clear grouping of tests commonly used to investigate anaemia. Follow-up test frequency was much lower than the frequency of multiple tests ordered at initial presentation. Conclusions The current high volume of single and combination test requests highlights an opportunity for reliable multiplex point-of-care panels to cover a core set of frequently requested tests. The impact on test use of introducing such panels to general practice requires additional research.	[Fanshawe, Thomas R.; Ordonez-Mena, Jose M.; Turner, Philip J.; Van den Bruel, Ann; Hayward, Gail N.] Univ Oxford, Nuffield Dept Primary Care Hlth Sci, Oxford OX2 6GG, England; [Van den Bruel, Ann] Univ Leuven, Acad Ctr Gen Practice, Leuven, Belgium; [Shine, Brian] John Radcliffe Hosp, Clin Biochem, Oxford, England	Fanshawe, TR (reprint author), Univ Oxford, Nuffield Dept Primary Care Hlth Sci, Oxford OX2 6GG, England.	thomas.fanshawe@phc.ox.ac.uk	Ordonez-Mena, Jose M./I-6787-2017; Van den Bruel, Ann/P-6041-2017	Ordonez-Mena, Jose M./0000-0002-8965-104X; Turner, Philip/0000-0001-7299-8939; Van den Bruel, Ann/0000-0001-9012-2009	National Institute for Health Research (NIHR) Community Healthcare Medtech and In Vitro Diagnostics Cooperative (MIC); NIHR Biomedical Research Centre, OxfordNational Institute for Health Research (NIHR)	This article presents independent research funded by the National Institute for Health Research (NIHR) Community Healthcare Medtech and In Vitro Diagnostics Cooperative (MIC). JMO-M is partly supported by the NIHR Biomedical Research Centre, Oxford.	Abbott, 2018, I STAT SYST PROD SER; Alere, 2018, AL AF LIP PAN; [Anonymous], 2016, AL AF CRP C REACT PR; Cooper MS, 2008, BRIT MED J, V336, P1298, DOI 10.1136/bmj.39582.589433.BE; El-Osta A, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2016-015494; Everitt B.S., 2011, CLUSTER ANAL; Finch H, 2005, J DATA SCI, V3, P85; Florkowski C, 2017, CRIT REV CL LAB SCI, V54, P471, DOI 10.1080/10408363.2017.1399336; Gu ZG, 2016, BIOINFORMATICS, V32, P2847, DOI 10.1093/bioinformatics/btw313; Gu ZG, 2014, BIOINFORMATICS, V30, P2811, DOI 10.1093/bioinformatics/btu393; Guthrie B., 2001, EUR J GEN PRACT, V7, P138; Hawker CD, 2017, CLIN CHEM, V63, P1074, DOI 10.1373/clinchem.2017.272047; Houben PHH, 2010, SCAND J PRIM HEALTH, V28, P18, DOI 10.3109/02813430903281758; Howick J, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2014-005611; Jones CHD, 2016, BMC HEALTH SERV RES, V16, DOI 10.1186/s12913-016-1834-3; Jones CHD, 2013, BMC FAM PRACT, V14, DOI 10.1186/1471-2296-14-117; Jung WE, 2015, MICROELECTRON ENG, V132, P46, DOI 10.1016/j.mee.2014.09.024; Khunti K, 2010, BRIT J GEN PRACT, V60, P157, DOI 10.3399/bjgp10X483454; National Institute for Health Care and Excellence, 2015, TIR FAT AD; NHS, 2016, WHAT IS NHS HLTH CHE; O'Kane MJ, 2011, ANN CLIN BIOCHEM, V48, P155, DOI 10.1258/acb.2010.010214; O'Neill J, 2016, REV ANTIMICROBIAL RE; Office for National Statistics, 2017, POP EST UK ENGL WAL; Price CP, 2017, FAM PRACT; Public Health England, 2018, NAT GEN PRACT PROF; R Core Team, 2016, R LANG ENV STAT COMP; Renier W, 2018, EUR J EMERG MED, V25, P3, DOI 10.1097/MEJ.0000000000000429; Seamark D, 1999, J ROY SOC MED, V92, P339, DOI 10.1177/014107689909200703; Sharma P, 2015, HEALTH TECHNOL ASSES, V19, pI, DOI 10.3310/hta19480; Sinclair D, 2003, J CLIN PATHOL, V56, P385, DOI 10.1136/jcp.56.5.385; St John Andrew, 2014, Clin Biochem Rev, V35, P155; Turner PJ, 2016, FAM PRACT, V33, P388, DOI 10.1093/fampra/cmw018; Verbakel JY, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2016-015760; Verbakel JY, 2016, BMC MED, V14, DOI 10.1186/s12916-016-0679-2; Violan C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102149; Watson J, 2017, FAM PRACT, V34, P735, DOI 10.1093/fampra/cmx051; World Health Organization (WHO), 2015, GLOB ACT PLAN ANT RE	37	1	1	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0021-9746	1472-4146		J CLIN PATHOL	J. Clin. Pathol.	DEC	2018	71	12					1065	1071		10.1136/jclinpath-2018-205242			7	Pathology	Pathology	HK2ND	WOS:000457748300006	30228215				2019-10-28	
J	Marks, E; Wang, YH; Shi, Y; Susa, J; Jacobson, M; Goldstein, DY				Marks, Etan; Wang, Yanhua; Shi, Yang; Susa, Joseph; Jacobson, Mark; Goldstein, D. Yitzchak			Specific TCR gene rearrangements in mycosis fungoides: does advanced clinical stage show a preference?	JOURNAL OF CLINICAL PATHOLOGY			English	Article							POLYMERASE-CHAIN-REACTION; CELL-RECEPTOR GENES; SEZARY-SYNDROME; PROGNOSTIC-FACTORS; UNITED-STATES; SURVIVAL; IMMUNOGLOBULIN; LYMPHOMA; BIOMED-2; RECOMBINATIONS	Aims The relationship between the presence of specific T-cell receptor (TCR) gene rearrangements and clinical stage in mycosis fungoides (MF) has not been studied. We analysed a cohort of patients with a diagnosis of MF to determine the different types of specific TCR gene rearrangements present and their relationship to disease stage. Methods A retrospective chart review was used to select patients with a diagnosis of MF who had a skin biopsy and a positive TCR gene rearrangement study in either blood or tissue and at least 2 years of clinical follow-up. Results 43 patients were identified and divided into two groups. The first group consisted of 23 patients with early stage disease (IA-IIA) that was either stable or went into partial or complete remission with minimal intervention. None of these patients advanced to late stage disease. The second group consisted of 20 patients who had either late stage disease at diagnosis or progressed to late stage disease at some point in time. In the first group, only 4/23 (17%) patients had a single TCR gene rearrangement in the V(sic)1-8 region. In contrast, the second group had 13/20 (65%) patients with a single TCR gene rearrangement in the V(sic)1-8 region (p=0.002). Conclusion The presence of a single TCR gene rearrangement in the V(sic)1-8 region could possibly be related to a more advanced stage of MF. However, more comprehensive studies, such as next generation sequencing, with a larger cohort is necessary for a more definitive conclusion.	[Marks, Etan] NYU, Dept Pathol, Langone Med Ctr, 550 1St Ave, New York, NY 10016 USA; [Wang, Yanhua; Shi, Yang; Jacobson, Mark; Goldstein, D. Yitzchak] Montefiore Med Ctr, Albert Einstein Coll Med, Dept Pathol, Bronx, NY 10467 USA; [Susa, Joseph] Cockerell Dermatopathol, Div Dermatopathol, Dallas, TX USA	Marks, E (reprint author), NYU, Langone Med Ctr, New York, NY 10016 USA.	et565@aol.com	Marks, Etan/M-5056-2019	Marks, Etan/0000-0002-4601-0285; Goldstein, D. Yitzchak/0000-0001-6367-8335			Agar NS, 2010, J CLIN ONCOL, V28, P4730, DOI 10.1200/JCO.2009.27.7665; Alberti-Violetti Silvia, 2015, Clin Lymphoma Myeloma Leuk, V15, pe105, DOI 10.1016/j.clml.2015.02.027; Chitgopeker P, 2014, J INVEST DERMATOL, V134, P1, DOI 10.1038/jid.2014.73; Criscione VD, 2007, ARCH DERMATOL, V143, P854, DOI 10.1001/archderm.143.7.854; Desai M, 2015, J AM ACAD DERMATOL, V72, P276, DOI 10.1016/j.jaad.2014.10.019; Girardi M, 2004, NEW ENGL J MED, V350, P1978, DOI 10.1056/NEJMra032810; Gra OA, 2007, J MOL DIAGN, V9, P249, DOI 10.2353/jmoldx.2007.060087; Hosler GA, 2008, J CUTAN PATHOL, V35, P1063, DOI 10.1111/j.1600-0560.2007.00931.x; Jawed SI, 2014, J AM ACAD DERMATOL, V70, DOI 10.1016/j.jaad.2013.07.049; Kim EJ, 2005, J CLIN INVEST, V115, P798, DOI 10.1172/JCI200524826; Langerak AW, 2012, LEUKEMIA, V26, P2159, DOI 10.1038/leu.2012.246; Langerak Anton W, 2007, Expert Opin Med Diagn, V1, P451, DOI 10.1517/17530059.1.4.451; Lawnicki LC, 2003, J MOL DIAGN, V5, P82, DOI 10.1016/S1525-1578(10)60456-4; Ly B, 2013, ARCH PATHOL LAB MED, V137, P1654, DOI 10.5858/arpa.2012-0666-OA; Patel KP, 2010, J MOL DIAGN, V12, P226, DOI 10.2353/jmoldx.2010.090042; Scarisbrick JJ, 2015, J CLIN ONCOL, V33, P3766, DOI 10.1200/JCO.2015.61.7142; Schrijver I., 2011, DIAGNOSTIC MOL PATHO; Signoretti S, 1999, AM J PATHOL, V154, P67, DOI 10.1016/S0002-9440(10)65252-2; Sufficool KE, 2015, J AM ACAD DERMATOL, V73, P228, DOI 10.1016/j.jaad.2015.04.030; Szczepanski T, 2000, LEUKEMIA, V14, P1208, DOI 10.1038/sj.leu.2401765; Talpur R, 2012, CLIN CANCER RES, V18, P5051, DOI 10.1158/1078-0432.CCR-12-0604; Tobisawa S, 2013, J DERMATOL SCI, V71, P160, DOI 10.1016/j.jdermsci.2013.04.020; Toro JR, 2003, BLOOD, V101, P3407, DOI 10.1182/blood-2002-05-1597; van Dongen JJM, 2003, LEUKEMIA, V17, P2257, DOI 10.1038/sj.leu.2403202; VANDONGEN JJM, 1991, CLIN CHIM ACTA, V198, P93; VANDONGEN JJM, 1991, CLIN CHIM ACTA, V198, P1; Wang LH, 2015, NAT GENET, V47, P1426, DOI 10.1038/ng.3444; Wilcox RA, 2016, AM J HEMATOL, V91, P152, DOI [10.1002/ajh.24233, 10.1002/ajh.24462]; WOOD GS, 1994, J INVEST DERMATOL, V103, P34, DOI 10.1111/1523-1747.ep12389114; Yamanaka K, 2005, CLIN CANCER RES, V11, P5748, DOI 10.1158/1078-0432.CCR-04-2514; Yawalkar N, 2003, BLOOD, V102, P4059, DOI 10.1182/blood-2003-04-1044	31	0	0	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0021-9746	1472-4146		J CLIN PATHOL	J. Clin. Pathol.	DEC	2018	71	12					1072	1077		10.1136/jclinpath-2018-205324			6	Pathology	Pathology	HK2ND	WOS:000457748300007	30171087				2019-10-28	
J	Batenchuk, C; Albitar, M; Zerba, K; Sudarsanam, S; Chizhevsky, V; Jin, C; Burns, V				Batenchuk, Cory; Albitar, Maher; Zerba, Kim; Sudarsanam, Sucha; Chizhevsky, Vladislav; Jin, Chelsea; Burns, Virginia			A real-world, comparative study of FDA-approved diagnostic assays PD-L1 IHC 28-8 and 22C3 in lung cancer and other malignancies	JOURNAL OF CLINICAL PATHOLOGY			English	Article							IMMUNOHISTOCHEMICAL ASSAYS; CHECKPOINT INHIBITORS; OPEN-LABEL; NIVOLUMAB; PEMBROLIZUMAB; MULTICENTER; CARCINOMA; DOCETAXEL	Aims At the time of analysis, two widely used, drug-specific, tumour-cell programmed death ligand 1 (PD-L1) assays were approved by the US Food and Drug Administration for anti-PD-1 therapies: the Dako PD-L1 immunohistochemistry (IHC) 28-8 pharmDx assay and the Dako PD-L1 IHC 22C3 pharmDx assay. Given that the majority of current PD-L1 testing in US clinical practice is performed at commercial reference laboratories, we aimed to evaluate the concordance of the 28-8 and 22C3 assays in a real-world setting. Methods Matched PD-L1 IHC 28-8 and 22C3 results from routine assessment were obtained from 1930 patients, including 412 confirmed to have lung cancer, submitted from hospitals in over 38 US states/territories. Biopsies were stained, reviewed and scored by trained/certified pathologists at a single cancer reference laboratory between 2015 and 2017. Rate of concordance between assay findings was assessed by Bland-Altman analysis; overall per cent agreement (OPA), positive per cent agreement and negative per cent agreement; and Cohen's kappa. Results PD-L1 IHC 28-8 and 22C3 displayed strong correlation across all samples and in samples with a confirmed lung cancer diagnosis irrespective of biopsy site. The OPA was 97%-98% for all samples, depending on the expression level defining PD-L1 positivity. In the Bland-Altman analysis, the mean difference in percentage of tumour cells positively stained for PD-L1 between the paired assay findings was -0.80% for all samples and -0.93% in samples with a confirmed lung cancer diagnosis. Conclusions These data, in conjunction with recent findings, support the analytical concordance of the PD-L1 IHC 28-8 and 22C3 assays for assessing per cent tumour-cell membrane PD-L1 expression.	[Batenchuk, Cory; Zerba, Kim; Jin, Chelsea; Burns, Virginia] Bristol Myers Squibb, Princeton, NJ 08648 USA; [Albitar, Maher; Sudarsanam, Sucha; Chizhevsky, Vladislav] NeoGen Labs, Aliso Viejo, CA USA	Burns, V (reprint author), Bristol Myers Squibb, Princeton, NJ 08648 USA.	Virginia.Burns@bms.com			Bristol-Myers SquibbBristol-Myers Squibb	This study was supported by Bristol-Myers Squibb.	[Anonymous], 2017, PD L1 IHC 28 8 PHARM; Ansell SM, 2015, NEW ENGL J MED, V372, P311, DOI 10.1056/NEJMoa1411087; AstraZeneca, 2018, IMFINZI; Borghaei H, 2015, NEW ENGL J MED, V373, P1627, DOI 10.1056/NEJMoa1507643; Brahmer J, 2015, NEW ENGL J MED, V373, P123, DOI 10.1056/NEJMoa1504627; Brunnstrom H, 2017, MODERN PATHOL, V30, P1411, DOI 10.1038/modpathol.2017.59; Dako, 2017, PD L1 IHC 22C3 PHARM; El-Khoueiry AB, 2017, LANCET, V389, P2492, DOI 10.1016/S0140-6736(17)31046-2; EMD Serono, 2017, BAVENCIO; FDA, 2007, STAT GUID REP RES ST; Ferris RL, 2016, NEW ENGL J MED, V375, P1856, DOI 10.1056/NEJMoa1602252; Garon EB, 2015, NEW ENGL J MED, V372, P2018, DOI 10.1056/NEJMoa1501824; Gaule P, 2017, JAMA ONCOL, V3, P256, DOI 10.1001/jamaoncol.2016.3015; Genentech, 2018, TECENTRIQ; Hendry S, 2018, J THORAC ONCOL, V13, P367, DOI 10.1016/j.jtho.2017.11.112; Hirsch FR, 2017, J THORAC ONCOL, V12, P208, DOI 10.1016/j.jtho.2016.11.2228; Jorgensen JT, 2016, EXPERT REV MOL DIAGN, V16, P131, DOI 10.1586/14737159.2016.1117389; Kim H, 2017, ONCOTARGET, V8, P98524, DOI 10.18632/oncotarget.21567; Merck, 2018, KEYTRUDA; Motzer RJ, 2015, NEW ENGL J MED, V373, P1803, DOI 10.1056/NEJMoa1510665; Overman MJ, 2017, LANCET ONCOL, V18, P1182, DOI 10.1016/S1470-2045(17)30422-9; Ratcliffe MJ, 2017, CLIN CANCER RES, V23, P3585, DOI 10.1158/1078-0432.CCR-16-2375; Rimm DL, 2017, JAMA ONCOL, V3, P1051, DOI 10.1001/jamaoncol.2017.0013; Roach C, 2016, APPL IMMUNOHISTO M M, V24, P392, DOI 10.1097/PAI.0000000000000408; Robert C, 2015, NEW ENGL J MED, V372, P320, DOI 10.1056/NEJMoa1412082; Romano RC, 2016, AM J CLIN PATHOL, V146, P727, DOI [10.1093/ajcp/aqw186, 10.1093/AJCP/AQW186]; Scheel AH, 2018, HISTOPATHOLOGY, V72, P449, DOI 10.1111/his.13375; Sharma P, 2016, LANCET ONCOL, V17, P1590, DOI 10.1016/S1470-2045(16)30496-X; Squibb Bristol-Myers, 2018, OPDIVO; Tamura T, 2015, MOL CLIN ONCOL, V3, P217, DOI 10.3892/mco.2014.410; Tsao M. S., 2018, J THORAC ONCOL; Zitvogel L, 2012, ONCOIMMUNOLOGY, V1, P1223, DOI 10.4161/onci.21335	32	0	0	1	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0021-9746	1472-4146		J CLIN PATHOL	J. Clin. Pathol.	DEC	2018	71	12					1078	1083		10.1136/jclinpath-2018-205362			6	Pathology	Pathology	HK2ND	WOS:000457748300008	30275099	Green Published			2019-10-28	
J	Liu, M; Tang, SX; Tsang, JYS; Shi, YJ; Ni, YB; Law, BKB; Tse, GMK				Liu, Ming; Tang, Shao-Xian; Tsang, Julia Y. S.; Shi, Yu-Jie; Ni, Yun-Bi; Law, Bonita K. B.; Tse, Gary M. K.			Core needle biopsy as an alternative to whole section in IHC4 score assessment for breast cancer prognostication	JOURNAL OF CLINICAL PATHOLOGY			English	Article							HER2 STATUS; ESTROGEN-RECEPTOR; CLINICAL-PRACTICE; INTRATUMORAL HETEROGENEITY; PROGESTERONE-RECEPTOR; DIAGNOSTIC-ACCURACY; EXCISIONAL BIOPSY; SURGICAL EXCISION; AMERICAN SOCIETY; ER	Aims IHC4 score, based on expression of four routine markers (oestrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2) and proliferation marker, Ki67), is a recently developed, cost-effective prognostic tool in breast cancer. Possibly, the score may be useful also in advanced diseases where only core needle biopsy (CNB) is available and neoadjuvant therapy. However, its studies on CNB are scant. This study examined whether IHC4 score assessment on CNB is comparable to that from whole section (WS). Methods Immunohistochemical (IHC) analysis was performed for ER, PR, HER2 and Ki67 on 108 paired CNB and WS to evaluate IHC4 score (with follow-up range 1-230 months and 5 relapse/death). Concordance between the two was examined. Factors that affected the concordance were analysed. Additionally, IHC4 score was compared with Nottingham Prognostic Index (NPI). Results There was moderate concordance between IHC4 score on CNB and WS (all cases: kappa=0.699, p<0.001; ER+ cases: kappa=0.595, p<0.001). Among the IHC4 components, concordance for HER2 was the poorest (kappa=0.178, p<0.001 in all cases; ER+ cases: kappa=0.082, p<0.097). Significant factors affecting concordance between CNB and WS included number of cores, total core length and percentage of tumour cells in cores (p <= 0.030), indicating the importance of sufficient sampling. Interestingly, the concordance was also affected by patients' age (p=0.039). There was poor agreement between IHC4 score and NPI (kappa <= 0.160). Conclusion Our results suggested that IHC4 score can be used on adequately sampled CNB. Its poor agreement with NPI highlights the independence of the two factors.	[Liu, Ming] Xin Jiang Med Univ, Affiliated Hosp 1, Dept Pathol, Xin Jiang, Peoples R China; [Tang, Shao-Xian] Fudan Univ, Shanghai Canc Ctr, Dept Pathol, Shanghai, Peoples R China; [Tsang, Julia Y. S.; Ni, Yun-Bi; Tse, Gary M. K.] Chinese Univ Hong Kong, Prince Wales Hosp, Dept Anat & Cellular Pathol, Hong Kong, Peoples R China; [Shi, Yu-Jie] Henan Prov Peoples Hosp, Dept Pathol, Zhengzhou, Henan, Peoples R China; [Law, Bonita K. B.] Union Hosp, Union Breast Ctr, Hong Kong, Peoples R China	Tse, GMK (reprint author), Prince Wales Hosp, Dept Anat & Cellular Pathol, Shatin, Hong Kong, Peoples R China.	garytse@cuhk.edu.hk					Apple SK, 2009, MODERN PATHOL, V22, P1151, DOI 10.1038/modpathol.2009.82; Arnedos M, 2009, ANN ONCOL, V20, P1948, DOI 10.1093/annonc/mdp234; Arnone P, 2010, UPDATES SURG-ITALY, V62, P75, DOI 10.1007/s13304-010-0014-y; Barton S, 2012, BRIT J CANCER, V106, P1760, DOI 10.1038/bjc.2012.166; Bilous M, 2010, MODERN PATHOL, V23, pS36, DOI 10.1038/modpathol.2010.34; Brunelli M, 2009, AM J CLIN PATHOL, V131, P678, DOI 10.1309/AJCP09VUTZWZXBMJ; Cassano E, 2007, BREAST CANCER RES TR, V102, P103, DOI 10.1007/s10549-006-9305-x; Chen XS, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-390; Coates AS, 2015, ANN ONCOL, V26, P1533, DOI 10.1093/annonc/mdv221; Cuzick J, 2011, J CLIN ONCOL, V29, P4273, DOI 10.1200/JCO.2010.31.2835; Dekker TJA, 2013, ANN ONCOL, V24, P931, DOI 10.1093/annonc/mds599; Di Nubila B, 2006, BREAST, V15, P744, DOI 10.1016/j.breast.2006.02.006; Dowsett M, 2011, J NATL CANCER I, V103, P1656, DOI 10.1093/jnci/djr393; ELSTON CW, 1991, HISTOPATHOLOGY, V19, P403, DOI 10.1111/j.1365-2559.1991.tb00229.x; GALEA MH, 1992, BREAST CANCER RES TR, V22, P207, DOI 10.1007/BF01840834; Green AR, 2016, BREAST CANCER RES TR, V157, P65, DOI 10.1007/s10549-016-3804-1; Gyorffy B, 2015, BREAST CANCER RES, V17, DOI 10.1186/s13058-015-0514-2; Hammond MEH, 2010, J CLIN ONCOL, V28, P2784, DOI 10.1200/JCO.2009.25.6529; Harris LN, 2016, J CLIN ONCOL, V34, P1134, DOI 10.1200/JCO.2015.65.2289; Kim HS, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0151054; Lorgis V, 2011, BREAST, V20, P284, DOI 10.1016/j.breast.2010.12.007; Loubeyre P, 2013, BREAST J, V19, P605, DOI 10.1111/tbj.12181; Munch-Petersen HD, 2014, APMIS, V122, P750, DOI 10.1111/apm.12213; Petrau C, 2015, AM J CLIN PATHOL, V144, P555, DOI 10.1309/AJCP9KFVM2GZMNDV; Pijnappel RM, 1997, EUR J RADIOL, V24, P120, DOI 10.1016/S0720-048X(96)01140-0; Ricci MD, 2012, REV ASSOC MED BRAS, V58, P532, DOI 10.1590/S0104-42302012000500008; Shi YJ, 2017, ONCOLOGIST, V22, P487, DOI 10.1634/theoncologist.2016-0352; Si CS, 2014, INT J CLIN EXP PATHO, V7, P6800; Tamaki K, 2010, CANCER SCI, V101, P2074, DOI 10.1111/j.1349-7006.2010.01630.x; Tsuda H, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-534; Verkooijen HM, 2000, BRIT J CANCER, V82, P1017; Viale G, 2008, J CLIN ONCOL, V26, P5569, DOI 10.1200/JCO.2008.17.0829; Wolff AC, 2013, J CLIN ONCOL, V31, P3997, DOI 10.1200/JCO.2013.50.9984	33	1	1	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0021-9746	1472-4146		J CLIN PATHOL	J. Clin. Pathol.	DEC	2018	71	12					1084	1089		10.1136/jclinpath-2018-205228			6	Pathology	Pathology	HK2ND	WOS:000457748300009	30228212				2019-10-28	
J	Cao, K; Dong, YT; Xiang, J; Xu, Y; Hong, W; Song, H; Guan, ZZ				Cao, Kun; Dong, Yang-Ting; Xiang, Jie; Xu, Yi; Hong, Wei; Song, Hui; Guan, Zhi-Zhong			Reduced expression of SIRT1 and SOD-1 and the correlation between these levels in various regions of the brains of patients with Alzheimer's disease	JOURNAL OF CLINICAL PATHOLOGY			English	Article							OXIDATIVE STRESS; CELL-DEATH; PATHOGENESIS; PROGRESSION; PATHOLOGY; OLIGOMERS; TOXICITY; PROTECTS; BANKING; NEURONS	Aims This study was designed to explore the expression and distribution of silent information regulator 1 (SIRT1) and superoxide dismutase 1 (SOD-1) in various regions of the brains of patients with Alzheimer's disease (AD), as well as to assess potential correlations between the levels of these proteins and also between these proteins and the Braak stage of AD. Methods In the temporal and frontal cortices, hippocampus and cerebellum of 10 patients with AD and 10 age-matched control subjects, expression of SIRT1 and SOD-1, together with histopathology, were assessed by immunohistochemical and immunofluorescent stainings. Relationships between variables were examined with the Pearson correlation test. Results The numbers of both SIRT1-positive and SOD-1-positive neurons and integrated optical density of immunohistochemical staining for these proteins in the temporal and frontal cortices, and hippocampus of patients with AD were significantly decreased than those in corresponding controls. In the case of the cerebellum, very weak expression of SIRT1 and obvious expression of SOD-1 were observed in granule cells, with no significant difference between AD and the control group. Interestingly, the protein levels between SIRT1 and SOD-1, as well as the level of SIRT1 or SOD-1 and Braak stage, were significantly correlated in neurons in all regions of the AD brains investigated except for the cerebellum. Conclusions These findings indicate that the reduced level of SIRT1 in the brains of patients with AD may be related to the decline in SOD-1 and neuropathological changes of this disorder.	[Cao, Kun; Dong, Yang-Ting; Xiang, Jie; Xu, Yi; Guan, Zhi-Zhong] Guizhou Med Univ, Affiliated Hosp, Dept Pathol, Guiyang 550004, GZ, Peoples R China; [Cao, Kun; Dong, Yang-Ting; Xiang, Jie; Xu, Yi; Hong, Wei; Song, Hui; Guan, Zhi-Zhong] Guizhou Med Univ, Minist Educ, Key Lab Endem & Ethn Dis, Guiyang, Guizhou, Peoples R China; [Hong, Wei; Song, Hui; Guan, Zhi-Zhong] Key Lab Med Mol Biol, Guiyang, Guizhou, Peoples R China	Guan, ZZ (reprint author), Guizhou Med Univ, Affiliated Hosp, Dept Pathol, Guiyang 550004, GZ, Peoples R China.	1457658298@qq.com			Chinese National Natural Science FoundationNational Natural Science Foundation of China [81760571]; Foundation of the Ministry of Education of P. R. China [IRT13058]; Scientific Foundations in Guizhou Province of China [[2014]06, [2014]4010, [2014]6008, [2016]161]	This work was supported financially by grants from the Chinese National Natural Science Foundation (81760571); the Foundation of the Ministry of Education of P. R. China (IRT13058); and the Scientific Foundations in Guizhou Province of China ([2014]06, [2014]4010, [2014]6008 and [2016]161). The postmortem human brain samples were unselfishly provided by the Netherlands Brain Bank (Amsterdam, the Netherlands).	Ansari MA, 2010, J NEUROPATH EXP NEUR, V69, P155, DOI 10.1097/NEN.0b013e3181cb5af4; Ballard C, 2011, LANCET, V377, P1019, DOI 10.1016/S0140-6736(10)61349-9; Beduer A, 2015, J NEURAL ENG, V12, DOI 10.1088/1741-2560/12/2/024001; Bhattacharyya A, 2014, PHYSIOL REV, V94, P329, DOI 10.1152/physrev.00040.2012; Braak H, 1997, NEUROBIOL AGING, V18, pS85, DOI 10.1016/S0197-4580(97)00062-6; BRAAK H, 1991, ACTA NEUROPATHOL, V82, P239, DOI 10.1007/BF00308809; Celsi F, 2004, NEUROCHEM INT, V44, P25, DOI 10.1016/S0197-0186(03)00101-3; Chan-Palay V, 1982, CYTOCHMICAL METHODS, P423; Chen J, 2005, J BIOL CHEM, V280, P40364, DOI 10.1074/jbc.M509329200; Corpas R, 2017, MOL NEUROBIOL, V54, P5604, DOI 10.1007/s12035-016-0087-9; Dong YT, 2018, J ALZHEIMERS DIS, V63, P283, DOI 10.3233/JAD-171020; Fischer LR, 2010, ACTA NEUROPATHOL, V119, P249, DOI 10.1007/s00401-009-0631-z; FLIERS E, 1985, BRAIN RES, V342, P45, DOI 10.1016/0006-8993(85)91351-4; Hu W, 2017, FRONT AGING NEUROSCI, V9, DOI 10.3389/fnagi.2017.00311; Islam MT, 2017, NEUROL RES, V39, P73, DOI 10.1080/01616412.2016.1251711; Jesko H, 2017, NEUROCHEM RES, V42, P876, DOI 10.1007/s11064-016-2110-y; Karuppagounder SS, 2009, NEUROCHEM INT, V54, P111, DOI 10.1016/j.neuint.2008.10.008; Kaur SJ, 2016, GENE, V577, P109, DOI 10.1016/j.gene.2015.11.049; Lalla R, 2013, FRONT AGING NEUROSCI, V5, DOI 10.3389/fnagi.2013.00016; Lattanzio F, 2016, EXP TOXICOL PATHOL, V68, P271, DOI 10.1016/j.etp.2016.02.001; Li HY, 2017, LIFE SCI, V190, P84, DOI 10.1016/j.lfs.2017.09.037; Lovell MA, 2007, J NEUROSCI RES, V85, P3036, DOI 10.1002/jnr.21346; Lutz MI, 2014, NEUROMOL MED, V16, P405, DOI 10.1007/s12017-014-8288-8; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; Michan S, 2010, J NEUROSCI, V30, P9695, DOI 10.1523/JNEUROSCI.0027-10.2010; Murakami K, 2011, J BIOL CHEM, V286, P44557, DOI 10.1074/jbc.M111.279208; Oku Y, 2017, CELL STRUCT FUNCT, V42, P71, DOI 10.1247/csf.17006; Polito L, 2017, NEUROPROT ALZHEIMERS; Postina R, 2004, J CLIN INVEST, V113, P1456, DOI 10.1172/JCI200420864; Ramadori G, 2008, J NEUROSCI, V28, P9989, DOI 10.1523/JNEUROSCI.3257-08.2008; RAVID R, 1992, PROG BRAIN RES, V93, P83; Ravid R, 1993, J Neural Transm Suppl, V39, P143; Ravid R, 2008, CELL TISSUE BANK, V9, P121, DOI 10.1007/s10561-007-9055-y; REISBERG B, 1982, AM J PSYCHIAT, V139, P1136; Salminen A, 2013, INT J MOL SCI, V14, P3834, DOI 10.3390/ijms14023834; Scuderi C, 2014, FRONT PHARMACOL, V5, DOI 10.3389/fphar.2014.00089; Singh P, 2017, BMC NEUROSCI, V18, DOI 10.1186/s12868-017-0364-1; Tafuri F, 2015, FRONT CELL NEUROSCI, V9, DOI 10.3389/fncel.2015.00336; Tang QH, 2018, CARDIOVASC THER, V36, DOI 10.1111/1755-5922.12318; Vachharajani VT, 2016, J IMMUNOL RES, DOI 10.1155/2016/8167273; Viola KL, 2015, ACTA NEUROPATHOL, V129, P183, DOI 10.1007/s00401-015-1386-3; Wong SY, 2016, REV NEUROSCIENCE, V27, P813, DOI 10.1515/revneuro-2016-0023; YAMAMOTO T, 1986, NEUROPATH APPL NEURO, V12, P3, DOI 10.1111/j.1365-2990.1986.tb00677.x; Yang L, 2018, ENVIRON TOXICOL PHAR, V57, P70, DOI 10.1016/j.etap.2017.11.011; Yu JW, 2016, J NEUROCHEM, V137, P371, DOI 10.1111/jnc.13587; Yu WF, 2005, EXP NEUROL, V192, P215, DOI 10.1016/j.expneurol.2004.12.015; Zakhary SM, 2010, ANAT REC, V293, P1024, DOI 10.1002/ar.21116; Zeng Y, 2016, EXP EYE RES, V151, P203, DOI 10.1016/j.exer.2016.05.002	48	2	2	1	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0021-9746	1472-4146		J CLIN PATHOL	J. Clin. Pathol.	DEC	2018	71	12					1090	1099		10.1136/jclinpath-2018-205320			10	Pathology	Pathology	HK2ND	WOS:000457748300010	30185534				2019-10-28	
J	Brierley, DJ; Farthing, PM; Zijlstra-Shaw, S				Brierley, Daniel J.; Farthing, Paula M.; Zijlstra-Shaw, Sandra			Assessors' and trainees' perceptions of workplace-based assessments in histopathology	JOURNAL OF CLINICAL PATHOLOGY			English	Article							NATIONAL EVALUATION; MEDICAL-EDUCATION; DOCTORS; SKILLS; RELIABILITY; CHALLENGES; VIEWS	Aim Workplace-based assessments (WBAs) are an integral part of specialist medical and dental training in the UK. Histopathology represents a very different training environment to the surgical specialities so it is important to know that the current WBAs are fit for purpose. A literature search revealed very little evidence regarding the perception of WBAs in histopathology. The aim of this study was therefore to assess the current perception of WBAs in histopathology by assessors and trainees. Methods A questionnaire was sent to all histopathology assessors and trainees on the Royal College of Pathologists database. Data were analysed using basic descriptive statistics. Free text comments were analysed by thematic analysis. Results The questionnaire was completed by 242/2175 assessors (response rate 11.1%) and 91/519 trainees (response rate 17.5%). There was no significantly different perception of WBAs between trainers and trainees (p>0.05). Key findings included respondents stating that they strongly disagreed or disagreed WBAs identify diagnostic competence (68% of trainees; 62% of assessors), identify trainees in difficulty (69% of trainees; 64% of assessors) or accurately reflect trainee progress (62% of trainees; 59% of assessors). Analysis of free text comments identified three main issues related to WBAs: their utilisation, purpose and design. Conclusion There was an overall negative perception of WBAs, particularly their perceived regulatory nature. It appears that the current WBAs do not always meet the criteria of a useful test in that they are perceived as being applied variably, produce results with questionable validity and have little apparent educational value.	[Brierley, Daniel J.; Farthing, Paula M.] Univ Sheffield, Sch Clin Dent, Acad Unit Oral & Maxillofacial Med Pathol & Surg, Sheffield S10 2TA, S Yorkshire, England; [Zijlstra-Shaw, Sandra] Univ Sheffield, Sch Clin Dent, Acad Unit Oral Hlth Dent & Soc, Sheffield, S Yorkshire, England	Brierley, DJ (reprint author), Univ Sheffield, Sch Clin Dent, Acad Unit Oral & Maxillofacial Med Pathol & Surg, Sheffield S10 2TA, S Yorkshire, England.	d.j.brierley@sheffield.ac.uk					Ali JM, 2013, SURG-J R COLL SURG E, V11, P286, DOI 10.1016/j.surge.2013.03.001; Barrett A, 2016, MED TEACH, V38, P1188, DOI 10.1080/0142159X.2016.1215413; Beard JD, 2008, ANN ROY COLL SURG, V90, P282, DOI 10.1308/003588408X286017; Bindal T, 2011, MED TEACH, V33, P919, DOI 10.3109/0142159X.2011.558140; Black D, 2009, CLIN TEACH, V6, P79, DOI 10.1111/j.1743-498X.2009.00273.x; Daniel W.W., 1999, BIOSTATISTICS FDN AN; Department of Health, 2007, GUID POSTGR SPEC TRA; Finall A, 2012, J CLIN PATHOL, V65, P538, DOI 10.1136/jclinpath-2012-200682; General Medical Council, 2011, LEARN ASS CLIN ENV W; Homer M, 2013, MED TEACH, V35, P684, DOI 10.3109/0142159X.2013.801548; Kane M. T., 2006, ED MEASUREMENT, P17, DOI DOI 10.1037/0033-2909.114.3.533; Kirton JA, 2013, BRIT DENT J, V214, P305, DOI 10.1038/sj.bdj.2013.302; Marriott J, 2011, BRIT J SURG, V98, P450, DOI 10.1002/bjs.7342; Massie J, 2016, ADV HEALTH SCI EDUC, V21, P455, DOI 10.1007/s10459-015-9614-0; Miller A, 2010, BMJ-BRIT MED J, V341, DOI 10.1136/bmj.c5064; MILLER GE, 1990, ACAD MED, V65, pS63, DOI 10.1097/00001888-199009000-00045; Mitchell C, 2011, MED EDUC, V45, P1190, DOI 10.1111/j.1365-2923.2011.04056.x; Murphy DJ, 2009, ADV HEALTH SCI EDUC, V14, P219, DOI 10.1007/s10459-008-9104-8; Pereira EAC, 2009, J ROY SOC MED, V102, P287, DOI 10.1258/jrsm.2009.080398; Powell H, 2014, B R COLL SURG ENGL, V96, P160; Prescott LE, 2002, MED EDUC, V36, P92, DOI 10.1046/j.1365-2923.2002.01099.x; Royal College of Pathologists, 2018, WORKPL BAS ASS; Ryland I, 2006, CLIN MED, V6, P378, DOI 10.7861/clinmedicine.6-4-378; Saedon H, 2012, BMC MED EDUC, V12, DOI 10.1186/1472-6920-12-25; Tooke J., 2008, ASPIRING EXCELLENCE; Torsney KM, 2015, WORLD J SURG, V39, P623, DOI 10.1007/s00268-014-2875-6	26	0	0	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0021-9746	1472-4146		J CLIN PATHOL	J. Clin. Pathol.	DEC	2018	71	12					1100	1107		10.1136/jclinpath-2018-205361			8	Pathology	Pathology	HK2ND	WOS:000457748300011	30196274				2019-10-28	
J	Miller, TE; Yang, M; Bajor, D; Friedman, JD; Chang, RYC; Dowlati, A; Willis, JE; Sadri, N				Miller, Tyler E.; Yang, Michael; Bajor, David; Friedman, Judah D.; Chang, Richard Y. C.; Dowlati, Afshin; Willis, Joseph E.; Sadri, Navid			Clinical utility of reflex testing using focused next-generation sequencing for management of patients with advanced lung adenocarcinoma	JOURNAL OF CLINICAL PATHOLOGY			English	Article							CANCER; CRIZOTINIB; CHEMOTHERAPY; VALIDATION; DABRAFENIB; TRAMETINIB	Aims The growing number of genomically targeted therapies has made genomic testing an important part of the care for patients with non-small cell lung cancer. However, limited tissue availability, cost and long turnaround times can create barriers to efficient genomic testing and subsequent treatment. Effective approaches to reduce these barriers are needed. Methods 302 advanced lung adenocarcinomas from consecutive patients seen at University Hospitals Cleveland Medical Center (UHCMC) were tested inhouse using a hybrid DNA/RNA next-generation sequencing (NGS) panel. Sample testing was reflexed from pathology for all stage III or IV tumours. Genomic alterations were tiered according to their clinical relevance and reported with guideline-recommended therapies. Clinical implications of genomic testing results were assessed by manual chart review. Results With a sample cohort consisting of 64% biopsies, 16% excisions/resections and 20% fine needle aspirations, the assay was reliable with a 95% success rate. The average turnaround time from receipt of unstained formalin-fixed paraffin embedded slides to reporting was 4.8 +/- 2.1 days, half of the recommended 10 days and similar to single-gene testing. Alterations with Food and Drug Administration-approved or the National Cancer Center Network guideline-recommended targeted therapies were found in 18% of cases. Within this group, 60% of patients went on genomically driven therapies. Conclusions We found our reflexed inhouse NGS assay to be reliable, cost-effective and efficient. Incorporation of reflex testing with our NGS assay led to an expansion of successful genomic profiling for all guideline-recommended alterations, and by including an expanded number of alterations within our panel we obtained clinically useful information outside the guidelines without changing cost or efficiency. This approach has enabled UHCMC clinicians to efficiently initiate genomically driven therapies for patients with lung adenocarcinoma.	[Miller, Tyler E.] Case Western Reserve Univ, Sch Med, Dept Pathol, Cleveland, OH 44106 USA; [Yang, Michael; Willis, Joseph E.; Sadri, Navid] Univ Hosp Cleveland Med Ctr, Dept Pathol, Cleveland, OH 44103 USA; [Bajor, David; Friedman, Judah D.; Chang, Richard Y. C.; Dowlati, Afshin] Univ Hosp Seidman Canc Ctr, Div Hematol & Oncol, Cleveland, OH USA	Sadri, N (reprint author), Univ Hosp Cleveland Med Ctr, Dept Pathol, Cleveland, OH 44103 USA.	navid.sadri@uhhospitals.org		sadri, navid/0000-0001-5051-717X; Miller, Tyler E/0000-0002-1269-1895	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [GM007250]; National Cancer InstituteUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [CA183510]	TEM training and education was funded by the National Institutes of Health (Grant Number: GM007250) and the National Cancer Institute (Grant Number: CA183510). Other authors have no competing interests to declared.	Blumenthal GM, 2015, J CLIN ONCOL, V33, P1008, DOI 10.1200/JCO.2014.59.0489; Borghaei H, 2015, NEW ENGL J MED, V373, P1627, DOI 10.1056/NEJMoa1507643; Ettinger DS, 2017, J NATL COMPR CANC NE, V15, P504, DOI 10.6004/jnccn.2017.0050; Frampton GM, 2013, NAT BIOTECHNOL, V31, P1023, DOI 10.1038/nbt.2696; Hovelson DH, 2015, NEOPLASIA, V17, P385, DOI 10.1016/j.neo.2015.03.004; Jordan EJ, 2017, CANCER DISCOV, V7, P596, DOI 10.1158/2159-8290.CD-16-1337; Kazandjian D, 2016, ONCOLOGIST, V21, P974, DOI 10.1634/theoncologist.2016-0101; Khozin S, 2017, CLIN CANCER RES, V23, P2131, DOI 10.1158/1078-0432.CCR-16-1773; Kwak EL, 2010, NEW ENGL J MED, V363, P1693, DOI 10.1056/NEJMoa1006448; Lindeman NI, 2018, ARCH PATHOL LAB MED, V142, P321, DOI 10.5858/arpa.2017-0388-CP; Mok TS, 2017, NEW ENGL J MED, V376, P629, DOI 10.1056/NEJMoa1612674; Noone AM, 2017, CANCER EPIDEM BIOMAR, V26, P632, DOI 10.1158/1055-9965.EPI-16-0520; Odogwu L, 2018, ONCOLOGIST, V23, P740, DOI 10.1634/theoncologist.2017-0642; Planchard D, 2016, LANCET ONCOL, V17, P984, DOI 10.1016/S1470-2045(16)30146-2; Reck M, 2016, NEW ENGL J MED, V375, P1823, DOI 10.1056/NEJMoa1606774; Shaw AT, 2014, NEW ENGL J MED, V371, P1963, DOI 10.1056/NEJMoa1406766; Shaw AT, 2013, NEW ENGL J MED, V368, P2385, DOI 10.1056/NEJMoa1214886; Sholl LM, 2015, J THORAC ONCOL, V10, P768, DOI 10.1097/JTO.0000000000000516	18	2	2	1	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0021-9746	1472-4146		J CLIN PATHOL	J. Clin. Pathol.	DEC	2018	71	12					1108	1115		10.1136/jclinpath-2018-205396			8	Pathology	Pathology	HK2ND	WOS:000457748300012	30228211				2019-10-28	
J	Reed, LJ; Attarian, S; Olson, TR; Singh, S; Shestopalov, A; Friedman, EW				Reed, Loius J.; Attarian, Shirin; Olson, Todd R.; Singh, Shashi; Shestopalov, Alexander; Friedman, Ellen W.			Feasibility and safety of targeting the anterior superior iliac spine to perform a bone marrow procedure: a prospective, clinical study	JOURNAL OF CLINICAL PATHOLOGY			English	Article							BIOPSY NEEDLE; ASPIRATION; MORBIDITY	Aims The bone marrow procedure (BMP) has been performed worldwide for years. Nonetheless, no generally accepted standards or guidelines for the performance of the BMP exist. Recent studies suggested that the lateral angulation technique (LAT), targeting the anterior superior iliac spine (ASIS) after penetration of the posterior superior iliac spine, yields longer biopsy cores and is safer for patients. We assessed the feasibility and safety of targeting the ASIS in the prone and lateral decubitus positions. Methods We first observed the BMP needle tracks on cadavers. Our cadaver study revealed that the LAT is feasible and safe but requires different operator techniques. Next, we studied 25 adult haematology patients undergoing elective BMP via the LAT approach. Patients returned 5 days after the BMP for a haemoglobin assessment, pain questionnaire and low-dose non-contract CT. Results 8% of patients reported persistent pain. No fall in haemoglobin and no pelvic haematomas or neurovascular injuries were detected. 88% of BMPs were successfully accomplished by targeting the ASIS. 12% required a back-up traditional angulation technique (TAT), directing the needle straight in, perpendicular to the coronal plane of the back. All three demonstrated inadvertent, but asymptomatic, penetration of the sacrum. Biopsy lengths were compared with a historical TAT control demonstrating that specimens obtained by LAT are significantly longer. Imaging studies showed that a seven-degree change in needle direction can convert a TAT to a LAT. Conclusion The LAT approach is feasible, safe and more productive than the TAT, and may be the preferred standard for training haematologists.	[Reed, Loius J.] Jacobi Med Ctr, Dept Oncol, Bronx, NY USA; [Attarian, Shirin] Montefiore Med Ctr, Albert Einstein Coll Med, Dept Med, Div Oncol, Bronx, NY 10467 USA; [Attarian, Shirin] Northwell Hlth, Monter Canc Ctr, Lake Success, NY USA; [Olson, Todd R.] Albert Einstein Coll Med, Dept Anat & Struct Biol, Bronx, NY 10467 USA; [Singh, Shashi; Shestopalov, Alexander] Jacobi Med Ctr, Dept Radiol, Bronx, NY USA; [Friedman, Ellen W.] Montefiore Med Ctr, Albert Einstein Coll Med, Dept Med, Div Hematol, Bronx, NY 10467 USA	Attarian, S (reprint author), Northwell Hlth, Dept Oncol, Monter Canc Ctr, 450 Lakeville Rd, Lake Success, NY 11042 USA.	sattarian@northwell.edu					Attarian S, 2018, AM J HEMATOL, V93, pE60, DOI 10.1002/ajh.24985; Bain BJ, 2006, HAEMATOL-HEMATOL J, V91, P1293; Bain BJ, 2003, BRIT J HAEMATOL, V121, P949, DOI 10.1046/j.1365-2141.2003.04329.x; Fischbach FT, 2009, MANUAL LAB DIAGNOSTI; HIRTE WE, 1963, CAN MED ASSOC J, V89, P203; Islam A., 2013, MANUAL BONE MARROW E; Islam A, 2007, J CLIN PATHOL, V60, P212, DOI 10.1136/jcp.2006.037341; Konda B, 2014, AM J HEMATOL, V89, P943, DOI 10.1002/ajh.23790; Malempati Suman, 2009, N Engl J Med, V361, pe28, DOI 10.1056/NEJMvcm0804634; Reed L, 2018, J CLIN PATHOL, V71, P172, DOI 10.1136/jclinpath-2017-204686; Reed LJ, 2011, HEMATOL REP, V3, P60, DOI 10.4081/hr.2011.e21; Singh AP, 2017, HEMATOL REP, V9, P118, DOI 10.4081/hr.2017.7131	12	0	0	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0021-9746	1472-4146		J CLIN PATHOL	J. Clin. Pathol.	DEC	2018	71	12					1116	1119		10.1136/jclinpath-2018-205309			4	Pathology	Pathology	HK2ND	WOS:000457748300013	30352912				2019-10-28	
J	Ko, CJ; Myung, P; Leffell, DJ; Bourdon, JC				Ko, Christine J.; Myung, Peggy; Leffell, David J.; Bourdon, Jean-Christophe			Cutaneous immunohistochemical staining pattern of p53 beta isoforms	JOURNAL OF CLINICAL PATHOLOGY			English	Article							SQUAMOUS-CELL CARCINOMAS; P53 ISOFORMS; DIFFERENTIATION; FEATURES	p53 is considered the guardian of the genome and as such has numerous functions. The TP53 gene is the most commonly mutated gene in cancer, and yet the exact biological significance of such mutations remains unclear. There are at least 12 different isoforms of p53, and the complexity of the p53 pathway may be in part related to these isoforms. Prior research has often not teased out what isoforms of p53 are being studied, and there is evidence in the literature that p53 isoforms are expressed differently. In this paper, we document the staining pattern of p53 beta isoforms in the skin and correlate it with mutational status in a subgroup of squamous proliferations of the skin. p53 beta isoforms are present in the cytoplasm of the differentiated layer of the epidermis and hair follicles (granular layer, infundibular and isthmus-catagen). p53 beta isoforms are diffusely expressed within the cytoplasm of well-differentiated squamous tumours with tetramerisation (C-terminal) domain mutations in TP53. Our results lend support to p53 beta isoforms being a marker of differentiation in keratinocytes.	[Ko, Christine J.; Myung, Peggy; Leffell, David J.] Yale Univ, Sch Med, Dept Dermatol, New Haven, CT 06510 USA; [Bourdon, Jean-Christophe] Univ Dundee, Sch Med, Dept Dermatol, Dundee, Scotland	Ko, CJ (reprint author), Yale Univ, Sch Med, 333 Cedar St, New Haven, CT 06511 USA.	christine.ko@yale.edu		Ko, Christine/0000-0003-2270-2524	Women's Health Research at Yale	This study was funded by Women's Health Research at Yale.	Avery-Kiejda KA, 2014, CARCINOGENESIS, V35, P586, DOI 10.1093/carcin/bgt411; Bourdon JC, 2005, GENE DEV, V19, P2122, DOI 10.1101/gad.1339905; Freije A, 2014, CELL REP, V9, P1349, DOI 10.1016/j.celrep.2014.10.012; Fujita K, NAT CELL BIOL; Kim C, 2014, J AM ACAD DERMATOL, V70, P70, DOI 10.1016/j.jaad.2013.09.026; Ko CJ, 2017, J AM ACAD DERMATOL, V77, P1126, DOI 10.1016/j.jaad.2017.04.1119; Ko CJ, 2010, CLIN DERMATOL, V28, P254, DOI 10.1016/j.clindermatol.2009.06.010; Mondal AM, 2013, J CLIN INVEST, V123, P5247, DOI 10.1172/JCI70355; Munday WR, 2016, J CUTAN PATHOL, V43, P759, DOI 10.1111/cup.12738; Murray-Zmijewski F, 2006, CELL DEATH DIFFER, V13, P962, DOI 10.1038/sj.cdd.4401914; SPANDAU DF, 1994, ONCOGENE, V9, P1861; Tang Y, 2013, ONCOGENE, V32, P2792, DOI 10.1038/onc.2012.288; Tanikawa C, 2017, EBIOMEDICINE, V20, P109, DOI 10.1016/j.ebiom.2017.05.017	13	0	0	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0021-9746	1472-4146		J CLIN PATHOL	J. Clin. Pathol.	DEC	2018	71	12					1120	1122		10.1136/jclinpath-2018-205098			3	Pathology	Pathology	HK2ND	WOS:000457748300014	30305316				2019-10-28	
J	Scimia, M; Du, JW; Pepe, F; Bianco, MA; Spena, SR; Patell-Socha, F; Sun, Q; Powell, MJ; Malapelle, U; Troncone, G				Scimia, Mauro; Du, Jinwei; Pepe, Francesco; Bianco, Maria Antonia; Spena, Silvana Russo; Patell-Socha, Farah; Sun, Qing; Powell, Michael J.; Malapelle, Umberto; Troncone, Giancarlo			Evaluation of a novel liquid biopsy-based ColoScape assay for mutational analysis of colorectal neoplasia and triage of FIT plus patients: a pilot study	JOURNAL OF CLINICAL PATHOLOGY			English	Article							SOCIETY; DNA	Circulating cell free tumour derived nucleic acids are becoming recognised as clinically significant and extremely useful biomarkers for detection of cancer and for monitoring the progression of targeted drug therapy and immunotherapy. Screening programmes for colorectal cancer in Europe use the Fetal Immunochemical Test (FIT) test as a primary screener. FIT+ patients are referred to immediate colonoscopy and the positive predictive value (PPV) is usually 25%. In this article, we report a study employing the ColoScape assay panel to detect mutations in the APC, KRAS, BRAF and CTNNB1 genes, in order to collect preliminary performance indicators and plan a future, larger population study. The assay was evaluated on 52 prospectively collected whole-blood samples obtained from FIT+ patients enrolled in the CRC screening programme of ASL NAPOLI 3 SUD, using colonoscopy as confirmation. The assay's sensitivity for advanced adenomas was 53.8% and the specificity was 92.3%. The PPV was 70.0% and negative predicitive value (NPV) was 85.7%. Workflow optimisation is essential to maximise sensitivity. Of note, four of the six positive cases missed by ColoScape had a less than suboptimal DNA input (data not shown). Had they been ruled out as inadequate, sensitivity would have increased from 53.8% to 69%. However, as stated previously, this is not a clinical trial, but rather an initial, preliminary technical evaluation. In conclusion this study shows that ColoScape is a promising tool and further studies are warranted in order to validate its use for the triage of FIT+ patients.	[Scimia, Mauro; Du, Jinwei; Patell-Socha, Farah; Sun, Qing; Powell, Michael J.] DiaCarta Inc, Richmond, CA USA; [Pepe, Francesco; Malapelle, Umberto; Troncone, Giancarlo] Univ Federico II Naples, Dept Publ Hlth, I-80131 Naples, Italy; [Bianco, Maria Antonia; Spena, Silvana Russo] ASL NAPOLI 3 SUD, Gastroenterol & Digest Endoscopy Unit, Nola, Italy	Malapelle, U (reprint author), Univ Federico II Naples, Dept Publ Hlth, I-80131 Naples, Italy.	umberto.malapelle@unina.it	pepe, francesco/X-2551-2019	Malapelle, Umberto/0000-0003-3211-9957			Goldberg RM, 2018, ESMO OPEN, V3, DOI 10.1136/esmoopen-2018-000353; Gruppo Italiano Screening Colorettale, 2014, GISCOR SURV CCR; Imperiale TF, 2014, NEW ENGL J MED, V371, P187, DOI 10.1056/NEJMc1405215; Luchtenborg M, 2005, BMC CANCER, V5, DOI 10.1186/1471-2407-5-160; Malapelle U, 2017, BRIT J CANCER, V116, P802, DOI 10.1038/bjc.2017.8; Myers MB, 2016, NEOPLASIA, V18, P253, DOI 10.1016/j.neo.2016.03.002; Nian JY, 2017, CLIN TRANSL GASTROEN, V8, DOI 10.1038/ctg.2016.66; Powell MJ, 2018, J CLIN ONCOL, V36, DOI 10.1200/JCO.2018.36.15_suppl.e24189; Powell MJ, 2015, BAOJ CANC; Robertson DJ, 2017, GASTROENTEROLOGY, V152, P1217, DOI 10.1053/j.gastro.2016.08.053; Schneider M, 2011, CANCERS, V3, P91; Scholtka B, 2009, CANCER EPIDEMIOL, V33, P123, DOI 10.1016/j.canep.2009.05.001; Sepulveda AR, 2017, ARCH PATHOL LAB MED, V141, P625, DOI 10.5858/arpa.2016-0554-CP; Sparks AB, 1998, CANCER RES, V58, P1130; Steinberg P, 2007, US Patent, Patent No. [0,172,823 A1, 0172823]; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; Yan WX, 2016, CHIN J CANCER, V35, DOI 10.1186/s40880-016-0131-1	17	0	0	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0021-9746	1472-4146		J CLIN PATHOL	J. Clin. Pathol.	DEC	2018	71	12					1123	1126		10.1136/jclinpath-2018-205412			4	Pathology	Pathology	HK2ND	WOS:000457748300015	30315134				2019-10-28	
J	Chong, VCL; Tan, CL; Chee, YL; De Mel, S				Chong, Vanessa Cui-Lian; Tan, Char Loo; Chee, Yen-Lin; De Mel, Sanjay			A young patient with a lytic skull lesion	JOURNAL OF CLINICAL PATHOLOGY			English	Editorial Material									[Chong, Vanessa Cui-Lian; Chee, Yen-Lin; De Mel, Sanjay] Natl Univ Hlth Syst, Natl Univ Canc Inst Singapore, Dept Haematol Oncol, Singapore, Singapore; [Tan, Char Loo] Natl Univ Hlth Syst, Dept Pathol, Singapore, Singapore	De Mel, S (reprint author), Natl Univ Hlth Syst, Natl Univ Canc Inst, Dept Haematol Oncol, Singapore 119074, Singapore.	sanjay_widanalage@nuhs.edu.sg					Caponetti GC, 2012, HUM PATHOL, V43, P2223, DOI 10.1016/j.humpath.2012.03.014; Girschikofsky M, 2013, ORPHANET J RARE DIS, V8, DOI 10.1186/1750-1172-8-72; Grois N, 2006, PEDIATR BLOOD CANCER, V46, P228, DOI 10.1002/pbc.20425; Haroche J, 2015, J CLIN ONCOL, V33, P411, DOI 10.1200/JCO.2014.57.1950; KILPATRICK SE, 1995, CANCER, V76, P2471, DOI 10.1002/1097-0142(19951215)76:12<2471::AID-CNCR2820761211>3.0.CO;2-Z	5	0	0	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0021-9746	1472-4146		J CLIN PATHOL	J. Clin. Pathol.	DEC	2018	71	12					1128	1129		10.1136/jclinpath-2018-205016			2	Pathology	Pathology	HK2ND	WOS:000457748300016	30257852				2019-10-28	
J	Selves, J; Terris, B; Cazals-Hatem, D; Flejou, JF				Selves, Janick; Terris, Benoit; Cazals-Hatem, Dominique; Flejou, Jean-Francois			Guidelines for the management of malignant colo-rectal polyps (pTis and pT1) treated by endoscopic resection	ANNALES DE PATHOLOGIE			French	Article						Colorectal cancer; Endoscopic resection; Standardized report; Malignant polyp; pT1; Superficial cancer		The therapeutic management of malignant colorectal polyp with endoscopic resectionis mainly based on specific histopathological criteria. The quality of these criteria is strongly linked to the management of the endoscopic specimen. The French Pathology Society drafted a standardized pathological report with guidelines for the macroscopic management of the endoscopic specimen and explanatory notes for each histopathological criteria. These guidelines are based on the TNM AJCC/UICC classification, 8th edition and the WHO 2010 classification of colorectal tumors, the recommendations of the French Society of Digestive Endoscopy, the synthesis of the literature and on international consensus for prognostic criteria. The pathological report of a malignant colorectal polyp must clearly mention: the histological type and the size of the polyp, the pT stage and the following five prognostic criteria: the value of the resection margins, the level of tumor invasion into the submucosa, the grade of the tumor, the absence or presence of vascular emboli and of tumor budding. Published by Elsevier Masson SAS.	[Selves, Janick] IUCT Oncopole, Dept Anat Pathol, 1 Ave Irene Joliot Curie, F-31059 Toulouse, France; [Terris, Benoit] Hop Cochin, AP HP, Serv Pathol, 27 Rue Faubourg St Jacques, F-75679 Paris 14, France; [Cazals-Hatem, Dominique] Hop Beaujon, Dept Anat Pathol, 100 Blvd Gen Leclerc, F-92110 Clichy, France; [Flejou, Jean-Francois] Sorbonne Univ, Hop St Antoine, Serv Anat & Cytol Pathol, Fac Med,AP HP, 184 Rue Faubourg St Antoine, F-75571 Paris 12, France	Selves, J (reprint author), IUCT Oncopole, Dept Anat Pathol, 1 Ave Irene Joliot Curie, F-31059 Toulouse, France.	selves.j@chu-toulouse.fr					Axon A, 2005, ENDOSCOPY, V37, P570, DOI 10.1055/s-2005-861352; Barret M, 2017, ACTA ENDOSC, DOI [10.1007/510190-017-0595-4, DOI 10.1007/510190-017-0595-4]; Brierley James D., TNM CLASSIFICATION M; Brown IS, 2016, J CLIN PATHOL, V69, P292, DOI 10.1136/jclinpath-2015-203203; Dessain A, 2017, VIRCHOWS ARCH, V470, P165, DOI 10.1007/s00428-016-2055-1; Dixon MF, 2002, GUT, V51, P130, DOI 10.1136/gut.51.1.130; HAGGITT RC, 1985, GASTROENTEROLOGY, V89, P326; Hamilton SR, 2010, WHO CLASSIFICATION T, P132; Heresbach D, 2011, ACTA ENDOSC, V41, P222, DOI 10.1007/s10190-011-0179-3; Lugli A., 2017, MODERN PATHOL, P1; Selves J., 2017, ACTA ENDOSC, V47, P154; Ueno H, 2004, GASTROENTEROLOGY, V127, P385, DOI 10.1053/S0016-5085(04)00717-6; Wang LM, 2015, COLORECTAL DIS, V17, P674, DOI 10.1111/codi.12910	13	0	0	0	0	MASSON EDITEUR	MOULINEAUX CEDEX 9	21 STREET CAMILLE DESMOULINS, ISSY, 92789 MOULINEAUX CEDEX 9, FRANCE	0242-6498			ANN PATHOL	Ann. Pathol.	DEC	2018	38	6					331	337		10.1016/j.annpat.2018.04.007			7	Pathology	Pathology	HJ9JW	WOS:000457515700001	30056944				2019-10-28	
J	Papouin, B; Mussini, C; De Martin, E; Guettier, C				Papouin, Barbara; Mussini, Charlotte; De Martin, Eleonora; Guettier, Catherine			Hepatic and digestive adverse events of immune checkpoint inhibitors (anti-CTLA-4 and, anti-PD-1/PD-L1): A clinico-pathological review	ANNALES DE PATHOLOGIE			French	Review						Immune checkpoint inhibitors; Anti-CTLA-4; Anti-PD-1; Immune related adverse events; Hepatitis; Colitis	ADVANCED MELANOMA; PREEXISTING AUTOIMMUNE; IPILIMUMAB; COLITIS; ANTIBODIES; BLOCKADE; THERAPY; CANCER; SAFETY; IMMUNOTHERAPY	Immune checkpoint inhibitors (anti-CTLA-4 and anti-PD-1/PD-L1) have recently revolutionized anti-cancer therapy and are nowadays used in different metastatic cancers. These treatments may induce immune-related adverse events which frequently involve the digestive tract and, to a less extent the liver. The tissular injuries, which are still poorly characterized from a morphological and physiopathological point of view, may lead on one side to the interruption of a life-saving treatment and on the other side to the development of severe complications, if not death. Therefore, it is crucial to diagnose as early as possible and treat these digestive and hepatic adverse effects in an optimal way. This article aims to describe the clinical and pathological presentations of digestive and hepatic adverse events induced by these immunotherapies. (C) 2018 Elsevier Masson SAS. All rights reserved.	[Papouin, Barbara; Mussini, Charlotte; Guettier, Catherine] Hop Bicetre, AP HP, Serv Anat & Cytol Pathol, 78,Rue Gen Leclerc, F-94270 Le Kremlin Bicetre, France; [De Martin, Eleonora] Hop Paul Brousse, AP HP, Ctr Hepatobiliaire, 12,Ave Paul Valliant Couturier, F-94800 Villejuif, France; [Guettier, Catherine] Univ Paris Saclay, Fac Med Paris Sud, F-94276 Le Kremlin Bicetre, France; [Guettier, Catherine] Hop Paul Brousse, Inserm 1193, F-94800 Villejuif, France	Papouin, B (reprint author), Hop Bicetre, AP HP, Serv Anat & Cytol Pathol, 78,Rue Gen Leclerc, F-94270 Le Kremlin Bicetre, France.	barbara.papouin@aphp.fr					Amode R, 2017, MELANOMA RES, V27, P110, DOI 10.1097/CMR.0000000000000313; Attia P, 2005, J CLIN ONCOL, V23, P6043, DOI 10.1200/JCO.2005.06.205; Baroudjian B, 2016, MELANOMA RES, V26, P308, DOI 10.1097/CMR.0000000000000252; Beck KE, 2006, J CLIN ONCOL, V24, P2283, DOI 10.1200/JCO.2005.04.5716; Berman David, 2010, Cancer Immun, V10, P11; Bertrand A, 2015, BMC MED, V13, DOI 10.1186/s12916-015-0455-8; Brahmer JR, 2012, NEW ENGL J MED, V366, P2455, DOI 10.1056/NEJMoa1200694; Brahmer JR, 2010, J CLIN ONCOL, V28, P3167, DOI 10.1200/JCO.2009.26.7609; Carbonnel F, 2017, SEMIN IMMUNOPATHOL, V39, P327, DOI 10.1007/s00281-016-0613-x; Chen JH, 2017, AM J SURG PATHOL, V41, P643, DOI 10.1097/PAS.0000000000000829; Collins M, 2017, ANN ONCOL, V28, P2860, DOI 10.1093/annonc/mdx403; Coutzac C, 2017, J CROHNS COLITIS, V11, P1238, DOI 10.1093/ecco-jcc/jjx081; Danlos FX, 2018, EUR J CANCER, V91, P21, DOI 10.1016/j.ejca.2017.12.008; De Martin E, 2018, J HEPATOL, V68, P1181, DOI 10.1016/j.jhep.2018.01.033; Downey SG, 2007, CLIN CANCER RES, V13, P6681, DOI 10.1158/1078-0432.CCR-07-0187; Everett J, 2017, AM J SURG PATHOL, V41, P134, DOI 10.1097/PAS.0000000000000759; Garcia-Varona A, 2013, INFLAMM BOWEL DIS, V19, pE15, DOI 10.1002/ibd.22846; Gupta A, 2015, ALIMENT PHARM THER, V42, P406, DOI 10.1111/apt.13281; Hodi FS, 2016, LANCET ONCOL, V17, P1558, DOI 10.1016/S1470-2045(16)30366-7; Hodi FS, 2010, NEW ENGL J MED, V363, P711, DOI 10.1056/NEJMoa1003466; Hofmann L, 2016, EUR J CANCER, V60, P190, DOI 10.1016/j.ejca.2016.02.025; Johncilla M, 2015, AM J SURG PATHOL, V39, P1075, DOI 10.1097/PAS.0000000000000453; Johnson DB, 2016, JAMA ONCOL, V2, P234, DOI 10.1001/jamaoncol.2015.4368; Kaehler KC, 2010, SEMIN ONCOL, V37, P485, DOI 10.1053/j.seminoncol.2010.09.003; Kim KW, 2013, INVEST NEW DRUG, V31, P1071, DOI 10.1007/s10637-013-9939-6; Kleiner DE, 2012, DIGEST DIS SCI, V57, P2233, DOI 10.1007/s10620-012-2140-5; Kuehn HS, 2014, SCIENCE, V345, P1623, DOI 10.1126/science.1255904; Larkin J, 2015, NEW ENGL J MED, V373, P1270, DOI [10.1056/NEJMoa1504030, 10.1056/NEJMc1509660]; Lord JD, 2010, DIGEST DIS SCI, V55, P1396, DOI 10.1007/s10620-009-0839-8; Marthey L, 2016, J CROHNS COLITIS, V10, P395, DOI 10.1093/ecco-jcc/jjv227; Menzies AM, 2017, ANN ONCOL, V28, P368, DOI 10.1093/annonc/mdw443; Michot JM, 2016, EUR J CANCER, V54, P139, DOI 10.1016/j.ejca.2015.11.016; Mitchell KA, 2013, J CLIN GASTROENTEROL, V47, P781, DOI 10.1097/MCG.0b013e31828f1d51; Nishimura H, 2001, SCIENCE, V291, P319, DOI 10.1126/science.291.5502.319; Oble DA, 2008, AM J SURG PATHOL, V32, P1130, DOI 10.1097/PAS.0b013e31817150e3; Phan GQ, 2003, P NATL ACAD SCI USA, V100, P8372, DOI 10.1073/pnas.1533209100; Robert C, 2015, NEW ENGL J MED, V372, P2521, DOI 10.1056/NEJMoa1503093; Samaan MA, 2018, NAT REV GASTRO HEPAT, V15, P222, DOI 10.1038/nrgastro.2018.14; Schubert D, 2014, NAT MED, V20, P1410, DOI 10.1038/nm.3746; Simonelli M, 2016, IMMUNOTHERAPY-UK, V8, P1363, DOI 10.2217/imt-2016-0057; TIVOL EA, 1995, IMMUNITY, V3, P541, DOI 10.1016/1074-7613(95)90125-6; Topalian SL, 2012, NEW ENGL J MED, V366, P2443, DOI 10.1056/NEJMoa1200690; Verschuren EC, 2016, CLIN GASTROENTEROL H, V14, P836, DOI 10.1016/j.cgh.2015.12.028; Villadolid J, 2015, TRANSL LUNG CANCER R, V4, P576, DOI 10.3978/j.issn.2218-6751.2015.10.01; Voskens CJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053745; Weber J, 2009, CLIN CANCER RES, V15, P5591, DOI 10.1158/1078-0432.CCR-09-1024; Weber JS, 2016, ONCOLOGIST, V21, P1230, DOI 10.1634/theoncologist.2016-0055; Weber JS, 2015, LANCET ONCOL, V16, P375, DOI 10.1016/S1470-2045(15)70076-8; Weber JS, 2012, J CLIN ONCOL, V30, P2691, DOI 10.1200/JCO.2012.41.6750; Zen Y, 2018, MODERN PATHOL, V31, P965, DOI 10.1038/s41379-018-0013-y	50	0	0	5	7	MASSON EDITEUR	MOULINEAUX CEDEX 9	21 STREET CAMILLE DESMOULINS, ISSY, 92789 MOULINEAUX CEDEX 9, FRANCE	0242-6498			ANN PATHOL	Ann. Pathol.	DEC	2018	38	6					338	351		10.1016/j.annpat.2018.07.005			14	Pathology	Pathology	HJ9JW	WOS:000457515700002	30143243				2019-10-28	
J	Attencourt, C; Sabbagh, C; Meynier, J; Grados, L; Regimbeau, JM; Chatelain, D				Attencourt, Christophe; Sabbagh, Charles; Meynier, Jonathan; Grados, Lucien; Regimbeau, Jean-Marc; Chatelain, Denis		Assoc Picarde Cancerologie Digesti	Venous invasions in colonic adenocarcinoma: Value of elastic stain	ANNALES DE PATHOLOGIE			French	Article						Venous invasion; Vascular invasion; Colonic adenocarcinoma; Colorectal cancer; Elastic stain; Prognostic factor	COLORECTAL-CANCER; PROGNOSTIC-FACTOR; CARCINOMA; IDENTIFICATION; FEATURES; RECTUM; IMPACT; VEINS; TUMOR	The aim of our study was to assess the value of Elastic stain in the diagnosis of venous invasion (VI) in colonic adenocarcinoma. Material and methods.- All patients who undergone surgery for colonic adenocarcinoma at the University Hospital of Amiens, between 2004 and 2007, were included. Hematein-phloxinsaffron (HPS) stained slides of colectomy specimens were reviewed by two pathologists. Tumor blocks were stained with Elastic Stain (Roche - Ventane (R)). The presence or absence of VI, their number and localization were correlated with overall survival. Results. - Two hundred and thirty-one cases were investigated and 3274 slides were examined. VI were more often diagnosed by Elastic Stain than HPS stain (66% vs. 40%). Ninety percent of VI were revealed within the first 6 HPS slides, and from the first 5 in Elastic Stain. The presence of VI revealed by Elastic Stain and/or HPS was significantly associated with decreased overall survival in multivariate analysis (P=0.029), especially for stage IIA tumors (P= 0.016). Tumor differentiation (P= 0.006) and pTNM stage (P= 0.001) were also independent prognostic factors. The localization and the number of Vi were not prognostic factors. Conclusion. - Our study confirms the prognostic value of VI, revealed by an elastic stain, in colonic adenocarcinoma. A systematic elastic stain of all tumor blocks (number at least 5) could be considered in the future, during pathological examination of colectomy for adenocarcinoma. (C) 2018 Elsevier Masson SAS. All rights reserved.	[Attencourt, Christophe; Grados, Lucien; Chatelain, Denis] CHU Amiens, Serv Anat Pathol, Chemin Longpre, F-80080 Amiens, France; [Sabbagh, Charles; Regimbeau, Jean-Marc] CHU Amiens, Serv Chirurg Digest, Chemin Longpre, F-80080 Amiens, France; [Meynier, Jonathan] CHU Amiens, Delegat Rech Clin & Innovat, Chemin Longpre, F-80080 Amiens, France	Attencourt, C (reprint author), Ctr Hosp Univ, Chemin Longpre, F-80080 Amiens, France.	attencourt.christophe@chu-amiens.fr					Baumhoer D, 2010, INT J COLORECTAL DIS, V25, P741, DOI 10.1007/s00384-010-0890-0; BROWN CE, 1938, SURG GYNECOL OBSTET, V66, P611; Dawson H, 2015, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00354; Desolneux G, 2010, INT J COLORECTAL DIS, V25, P829, DOI 10.1007/s00384-010-0934-5; Fujii T, 2014, ANTICANCER RES, V34, P3147; Howlett CJ, 2009, J CLIN PATHOL, V62, P1021, DOI 10.1136/jcp.2009.065615; Kirsch R, 2013, AM J SURG PATHOL, V37, P200, DOI 10.1097/PAS.0b013e31826a92cd; Liang P, 2007, ANN SURG ONCOL, V14, P470, DOI 10.1245/s10434-006-9189-3; Lourghrey MB, 2014, DATASET COLORECTAL C; Matsumoto K, 2007, DIS COLON RECTUM, V50, P308, DOI 10.1007/s10350-006-0792-y; Maughan NJ, 2007, BRIT J CANCER, V97, P1393, DOI 10.1038/sj.bjc.6604036; Messenger DE, 2012, HUM PATHOL, V43, P965, DOI 10.1016/j.humpath.2011.11.015; Mori D, 2009, HISTOPATHOLOGY, V55, P654, DOI 10.1111/j.1365-2559.2009.03428.x; Morris M, 2007, INT J COLORECTAL DIS, V22, P887, DOI 10.1007/s00384-006-0262-y; Ouchi K, 1996, CANCER, V78, P2313, DOI 10.1002/(SICI)1097-0142(19961201)78:11<2313::AID-CNCR7>3.0.CO;2-N; Petersen VC, 2002, GUT, V51, P65, DOI 10.1136/gut.51.1.65; Quirke P, 2007, HISTOPATHOLOGY, V50, P103, DOI 10.1111/j.1365-2559.2006.02543.x; Roxburgh CSD, 2011, J CLIN PATHOL, V64, P1142, DOI 10.1136/jclinpath-2011-200284; Sato T, 2010, AM J SURG PATHOL, V34, P454, DOI 10.1097/PAS.0b013e3181d296ef; Seefeld PH, 1943, ANN SURG, V119, P76; Sejben I, 2010, J CLIN PATHOL, V63, P575, DOI 10.1136/jcp.2010.075846; Shinto E, 2014, WORLD J SURG, V38, P3257, DOI 10.1007/s00268-014-2734-5; Stephen A, 2012, COLORECTAL CANC STRU; Stewart CJR, 2007, HISTOPATHOLOGY, V51, P372, DOI 10.1111/j.1365-2559.2007.02787.x; Suzuki A, 2009, AM J SURG PATHOL, V33, P1601, DOI 10.1097/PAS.0b013e3181ae29d6; TALBOT IC, 1981, HISTOPATHOLOGY, V5, P141, DOI 10.1111/j.1365-2559.1981.tb01774.x; Ueno H, 2004, GASTROENTEROLOGY, V127, P385, DOI 10.1053/S0016-5085(04)00717-6; van de Velde CJH, 2014, EUR J CANCER, V50, DOI 10.1016/j.ejca.2013.06.048	28	0	0	0	0	MASSON EDITEUR	MOULINEAUX CEDEX 9	21 STREET CAMILLE DESMOULINS, ISSY, 92789 MOULINEAUX CEDEX 9, FRANCE	0242-6498			ANN PATHOL	Ann. Pathol.	DEC	2018	38	6					352	362		10.1016/j.annpat.2018.02.003			11	Pathology	Pathology	HJ9JW	WOS:000457515700003	29843970				2019-10-28	
J	Benoit, A; Hoyeau, N; Flejou, JF				Benoit, Anais; Hoyeau, Nadia; Flejou, Jean-Francois			Diagnosis of Helicobacter pylori infection on gastric biopsies: Standard stain, special stain or immunohistochemistry?	ANNALES DE PATHOLOGIE			French	Article						Helicobacter pylori; Cresyl violet; Immunohistochemical stain for Helicobacter pylori; Active chronic gastritis	ANCILLARY STAINS; SPECIMENS	Introduction. - There is no consensus on the benefit of performing a systematic complementary technique for the diagnosis of Helicobacter pylori infection. In our laboratory, a cresyl violet was carried out systematically until July 2014; since that date, a cresyl violet or immunohistochemistry is only made on request. We evaluated the value of cresyl violet staining of gastric biopsies to diagnose H. pylori infection by comparing a period of systematic staining to a time when it was made on demand. Material and methods. - We retrospectively studied the gastric biopsy of 786 consecutive patients from April to November 2014, taken in the absence of focal endoscopic lesion. During the first period, hematoxytin-eosin and cresyl violet were performed on all biopsies. During the second period, hematoxylin-eosin was performed and then, if necessary, cresyl violet or immunohistochemistry. All hematoxylin-eosin stained slides were revised to identify H. pylori. We performed immunohistochemistry in cases of active chronic gastritis without H. pylori identified on hematoxylin-eosin or cresyl violet. Results. - We have shown that gastric biopsy performed in the absence of focal mucosal lesion are normal in 55% of cases. The percentage of H. pylori infection was similar in both groups. In cases of active chronic gastritis, H. pylori infection is visible, in most cases, on hematoxyt-ineosin (94 %). Immunohistochemistry should be prescribed only in case of chronic active gastritis without H. pylori identified on standard staining, with bacteria rare or atypically located. Conclusion. - In our experiment, H. pylori is present only in case of active gastritis (33% of the biopsies in our series) and being almost always identifiable on the standard staining with H-E (in 94% of the cases), it is not It is not necessary to systematically perform, on all gastric biopsies, a complementary histo- or immunohistochemical technique. (C) 2018 Elsevier Masson SAS. All rights reserved.	[Benoit, Anais; Hoyeau, Nadia; Flejou, Jean-Francois] Hop St Antoine, AP HP, Serv Anat & Cytol Pathol, 184 Rue Faubourg St Antoine, F-75012 Paris, France	Benoit, A (reprint author), Ctr Hosp Intercommunal Poissy St Germain en Laye, Serv Anat & Cytol Pathol, 20 Rue Armagis, F-78100 St Germain En Laye, France.	Anaisdz123@gmail.com					Batts KP, 2013, AM J SURG PATHOL, V37, pE12, DOI 10.1097/PAS.0000000000000097; BURNETT RA, 1987, J CLIN PATHOL, V40, P353, DOI 10.1136/jcp.40.3.353-b; Chitkara Y, 2015, AM J CLIN PATHOL, V143, P84, DOI 10.1309/AJCP0G6INEDBSXCN; Decker L, 2017, PATHOL RES PRACT, V213, P23, DOI 10.1016/j.prp.2016.09.003; Faigel DO, 1996, DIGEST DIS SCI, V41, P937, DOI 10.1007/BF02091534; GENTA RM, 1994, HUM PATHOL, V25, P221, DOI 10.1016/0046-8177(94)90191-0; Glickman JN, 2015, DIGEST LIVER DIS, V47, P549, DOI 10.1016/j.dld.2015.04.005; Hartman DJ, 2012, AM J CLIN PATHOL, V137, P255, DOI 10.1309/AJCPD8FFBJ5LSLTE; Laine L, 1997, GASTROINTEST ENDOSC, V45, P463, DOI 10.1016/S0016-5107(97)70174-3; Lash R, 2014, INFLAMMATORY DISORDE, P352; Lash RH, 2016, HELICOBACTER, V21, P581, DOI 10.1111/hel.12315; Megraud F, 2016, HELICOBACTER, V21, P8, DOI 10.1111/hel.12333; Pittman ME, 2016, HUM PATHOL, V58, P90, DOI 10.1016/j.humpath.2016.07.031; Smith SB, 2012, AM J CLIN PATHOL, V137, P733, DOI 10.1309/AJCP8DGTAVG7MBMT; Tankovic J, 2010, ANTIBIOTIQUES, V12, P137, DOI 10.1016/j.antib.2010.02.001; Wang XH, 2010, ANN DIAGN PATHOL, V14, P256, DOI 10.1016/j.anndiagpath.2010.05.002; WARREN JR, 1983, LANCET, V1, P1273; Yang YX, 2015, GASTROENTEROLOGY, V149, P1082, DOI 10.1053/j.gastro.2015.07.039	18	1	1	0	2	MASSON EDITEUR	MOULINEAUX CEDEX 9	21 STREET CAMILLE DESMOULINS, ISSY, 92789 MOULINEAUX CEDEX 9, FRANCE	0242-6498			ANN PATHOL	Ann. Pathol.	DEC	2018	38	6					363	369		10.1016/j.annpat.2018.03.009			7	Pathology	Pathology	HJ9JW	WOS:000457515700004	29853336				2019-10-28	
J	Toquet, C; Normand, A; Guihard, G				Toquet, Claire; Normand, Adeline; Guihard, Gilles			Learning pathologic anatomy during medical formation: Understanding the contribution of the motivation	ANNALES DE PATHOLOGIE			French	Article						Pathological anatomy; Medical formation; Motivation; Self-determination theory; Health care	SELF-DETERMINATION THEORY; ONLINE COURSE MOOC; ACADEMIC-PERFORMANCE; INTRINSIC MOTIVATION; INTEGRATION	Introduction. - The motivations of medical students for Pathologic Anatomy are little known although they can strongly influence their academic performance. Our work focused on the analysis of the relationship between performance and motivation for Pathologic Anatomy. Materials and methods. - Second-year students (n=268) from the University of Nantes were contacted to complete a motivation questionnaire and to provide indicators of performance and attendance. The responses were analyzed in order to establish the psychometric reliability and the factorial structure of the questionnaire. The relationship between motivation and performance was explored by correlation and by linear regression studies. A cluster analysis was performed to specify the distribution of the two variables in our sample. Results. - The sample corresponded to 168 respondents with a F/M ratio similar to that of our population. Our data demonstrated the reliability of the questionnaire and a structure described by 5 motivation factors (self-determination, self-efficacy, career, grade and intrinsic motivation). The academic performance was not significantly correlated with the overall motivation or with student attendance. However, it was predicted by self-determination and self-efficacy. Our work revealed gender differences as well as the existence of two distinct clusters defined by the motivation and performance of the students. Discussion/Conclusion. - This work constitutes the first study of the motivations of French medical students for cyto-pathology. It validates a quantitative assessment tool for motivation. Finally, it explores the heterogeneity of the distribution of motivation and academic performance within a population of learners. (C) 2018 Elsevier Masson SAS. All rights reserved.	[Toquet, Claire; Normand, Adeline] CHU Nantes, Dept Pathol, F-44000 Nantes, France; [Toquet, Claire] Univ Nantes, Ctr Rech Transplantat & Immunol, UMR Inserm 1064, F-44000 Nantes, France; [Guihard, Gilles] Univ Nantes, Fac Med, Lab Neurophysiol Expt, F-44000 Nantes, France; [Guihard, Gilles] Univ Nantes, CREN EA 2661, F-44312 Nantes 3, France	Guihard, G (reprint author), Fac Med, 1 Rue Gaston Veil, F-44000 Nantes, France.	gilles.guihard@univ-nantes.fr					Afzal H, 2010, INT J BUSINESS MANAG, V5, P80, DOI DOI 10.5539/IJBM.V5N4P80; Alves M., 2012, PROCEDIA SOCIAL BEHA, V6-7, P781, DOI DOI 10.1016/J.SBSPR0.2010.03.793; Amrai K, 2011, PROCD SOC BEHV, V15, P399, DOI 10.1016/j.sbspro.2011.03.111; Artino AR, 2012, PERSPECT MED EDUC, V1, P76, DOI 10.1007/s40037-012-0012-5; Bandura A., 2007, AUTO EFFICACITE SENT; Campos-Sanchez A, 2014, BMC MED EDUC, V14, DOI 10.1186/1472-6920-14-46; Chung G. K. W. K., 2012, J ED DATA MINING, V4, P144; Cortright RN, 2013, ADV PHYSIOL EDUC, V37, P227, DOI 10.1152/advan.00018.2013; Crutzen R, 2017, HEALTH PSYCHOL REV, V11, P242, DOI [10.1080/17437199.2013.848409, 10.1080/17437199.2015.1124240]; Darcan O. N., 2012, J E LEARN HIGH ED, V2012, P1; De Wellis RF, 2003, APPL SOCIAL RES METH, V26; Demiroren M, 2016, MED EDUC ONLINE, V21, DOI 10.3402/meo.v21.30049; Diderichsen S, 2013, BMC MED EDUC, V13, DOI 10.1186/1472-6920-13-39; Everaert P, 2017, ACCOUNT EDUC, V26, P78, DOI 10.1080/09639284.2016.1274911; Fabry Gotz, 2012, GMS Z Med Ausbild, V29, pDoc56, DOI 10.3205/zma000826; Gardair C, 2016, ANN PATHOL, V36, P305, DOI 10.1016/j.annpat.2016.08.013; Gbollie C, 2017, EDUC RES INT, DOI 10.1155/2017/1789084; Glynn SM, 2011, J RES SCI TEACH, V48, P1159, DOI 10.1002/tea.20442; Goodman S, 2011, S AFR J PSYCHOL, V41, P373, DOI 10.1177/008124631104100311; Guihard G, 2017, LENCEPHALE; Haider SA, 2015, J RES DEV MANAG, V8, P9; Kusurkar RA, 2013, ADV HEALTH SCI EDUC, V18, P57, DOI 10.1007/s10459-012-9354-3; Kusurkar R, 2013, MED TEACH, V35, P173, DOI 10.3109/0142159X.2012.737056; Kusurkar R, 2010, ADV HEALTH SCI EDUC, V15, P303, DOI 10.1007/s10459-009-9198-7; Kusurkar RA, 2013, BMC MED EDUC, V13, DOI 10.1186/1472-6920-13-87; Kusurkar RA, 2012, ACAD MED, V87, P735, DOI 10.1097/ACM.0b013e318253cc0e; Liyanagunawardena TR, 2014, J MED INTERNET RES, V16, DOI 10.2196/jmir.3439; Lucieer SM, 2016, MED TEACH, V38, P585, DOI 10.3109/0142159X.2015.1073240; Oriahi Cl, 2009, SOC SCI, V4, P30; Osborne J. W., 2012, PRACTICAL ASSESSMENT, V17, P1; Panayides P, 2013, EUR J PSYCHOL, V9, P687, DOI 10.5964/ejop.v9i4.653; Peters G-JY, 2014, EUROPEAN HLTH PSYCHO, V16, P56, DOI DOI 10.1017/CB09781107415324.004; Rourke L, 2015, JAMA DERMATOL, V151, P293, DOI 10.1001/jamadermatol.2014.3300; Ryan RM, 2000, CONTEMP EDUC PSYCHOL, V25, P54, DOI 10.1006/ceps.1999.1020; Ryan RM, 2000, AM PSYCHOL, V55, P68, DOI 10.1037/0003-066X.55.1.68; Sahota M, 2016, BMC MED EDUC, V16, DOI 10.1186/s12909-016-0831-x; Samulski TD, 2016, ADV ANAT PATHOL, V23, P112, DOI 10.1097/PAP.0000000000000108; Short EJ, 1989, TRIPLE ALLIANCE LEAR; Swinnerton BJ, 2017, ANAT SCI EDUC, V10, P53, DOI 10.1002/ase.1625; Tamannaeifar MR, 2011, ED STRATEG MED SCI, V4, P15; ten Cate TJ, 2011, MED TEACH, V33, P961, DOI 10.3109/0142159X.2011.595435; Vermunt JD, 1996, HIGH EDUC, V31, P25, DOI 10.1007/BF00129106; Webb AL, 2014, ANAT SCI EDUC, V7, P350, DOI 10.1002/ase.1428; Zhang GY, 2016, ACAD PATHOL, V3, DOI 10.1177/2374289516685323	44	0	0	2	3	MASSON EDITEUR	MOULINEAUX CEDEX 9	21 STREET CAMILLE DESMOULINS, ISSY, 92789 MOULINEAUX CEDEX 9, FRANCE	0242-6498			ANN PATHOL	Ann. Pathol.	DEC	2018	38	6					370	380		10.1016/j.annpat.2018.02.004			11	Pathology	Pathology	HJ9JW	WOS:000457515700005	29843971				2019-10-28	
J	Regragui, M; Karkouri, M; Ibahioin, K; El Azhari, A				Regragui, Meriem; Karkouri, Mehdi; Ibahioin, Khadija; El Azhari, Abdessamad			Astroblastoma: A rare glial tumor	ANNALES DE PATHOLOGIE			French	Article						Astroblastoma; Cerebral tumor; Glial; Pseudorosettes; Grading	NEURORADIOLOGIC CHARACTERISTICS; FEATURES	Astroblastoma is a rare neuroepithelial tumor most commonly seen in children and young adults. Due to its rarity, this tumor can be easily misdiagnosed as its classification, histogenesis and therapeutic management are still being discussed. We report the case of a 21 year old man, who presented at the Emergency Room for loss of consciousness. He reported a history of headaches, vomiting and decreased visual acuity. The CT and MRI showed a left temporoparietal solid-cystic mass with heterogeneous enhancement and peritesional edema. The patient underwent a total mass resection. On histopathological examination, tumor cells were organized in perivascular pseudorosettes which are typically encountered in astroblastoma, without neither necrosis nor endothelial hyperplasia. They had broad processes and rounded nuclei without any mitotic activity. Immunochemistry stains confirmed the diagnosis by showing a positive reactivity for GFAP, EMA, vimentin and S100. Astroblastoma is a rare glial tumor of uncertain origin. Clinical presentation and imaging are nonspecific. Therefore, its diagnosis is based on histopathologic findings: typical perivascular pseudorosettes. However, similar histological pattern may be seen in other glial neoplasms. In the 2016 WHO Classification, astroblastoma is among the "other glial neoplasms" without a grading system. So far; there are no reliable prognosis factors for this tumor; however, two entities have been described: well differenciated astroblastoma (considered as low grade) and anaplastic/malignant astroblastomas (considered as high grade). Gross total resection is the treatment of choice for astroblastomas. Adjuvant therapy is still controversial. This case illustrates a cerebral tumor which is rarely encountered in practice and that can cause diagnostic problems and subsequently, inadequate treatment. (C) 2018 Elsevier Masson SAS. All rights reserved.	[Regragui, Meriem; Karkouri, Mehdi] Ctr Hosp Univ Lbn Rochd, Lab Anat & Cytol Pathol, 1 Rue Hop, Casablanca, Morocco; [Ibahioin, Khadija; El Azhari, Abdessamad] Ctr Hosp Univ Lbn Rochd, Serv Neurochirurg, 1 Rue Hop, Casablanca, Morocco	Regragui, M (reprint author), Ctr Hosp Univ Lbn Rochd, Lab Anat & Cytol Pathol, 1 Rue Hop, Casablanca, Morocco.	mls.meriem@gmail.com					Ahmed KA, 2014, WORLD NEUROSURG, V82, pE291, DOI 10.1016/j.wneu.2013.10.035; Bailey P, 1926, CLASSIFICATION TUMOR, p[83, 133]; Bailey P, 1930, ACTA PSYCH NEUROL, V5, P439, DOI 10.1111/j.1600-0447.1930.tb08230.x; Bell JW, 2007, NEURORADIOLOGY, V49, P203, DOI 10.1007/s00234-006-0182-0; BONNIN JM, 1989, NEUROSURGERY, V25, P6, DOI 10.1227/00006123-198907000-00002; Brat DJ, 2000, BRAIN PATHOL, V10, P342; Burger P.C., 1994, ATLAS TUMOR PATHOLOG; Cunningham DA, 2016, PEDIATR RADIOL, V46, P1301, DOI 10.1007/s00247-016-3607-x; GROTTS B F, 1949, Arch Pediatr, V66, P283; Lehman NL, 2017, NEURO-ONCOLOGY, V19, P31, DOI 10.1093/neuonc/now118; Louis DN, 2016, WHO CLASSIFICATION T; Mangano F T, 2007, J Neurosurg Sci, V51, P21; Mellai M, 2015, ONCOTARGETS THER, V8, P451, DOI 10.2147/OTT.S71384; Mierau GW, 1999, ULTRASTRUCT PATHOL, V23, P325; Navarro R, 2005, CHILD NERV SYST, V21, P211, DOI 10.1007/s00381-004-1055-7; Notarianni C, 2008, SURG NEUROL, V69, P201, DOI 10.1016/j.surneu.2006.12.045; PIZER BL, 1995, J NEUROSURG, V83, P550, DOI 10.3171/jns.1995.83.3.0550; Port JD, 2002, AM J NEURORADIOL, V23, P243; Richard A, 2012, VOLUME SERIES FDN DI; Salvati M, 2009, J NEURO-ONCOL, V93, P369, DOI 10.1007/s11060-008-9789-9; Sughrue ME, 2011, J CLIN NEUROSCI, V18, P750, DOI 10.1016/j.jocn.2010.11.007; Sugita Y, 2002, NEUROPATHOLOGY, V22, P200, DOI 10.1046/j.1440-1789.2002.00435.x; Thiessen B, 1998, J NEURO-ONCOL, V40, P59, DOI 10.1023/A:1006025000409; Yuzawa S, 2016, BRAIN TUMOR PATHOL, V33, P63, DOI 10.1007/s10014-015-0241-5	24	0	0	0	0	MASSON EDITEUR	MOULINEAUX CEDEX 9	21 STREET CAMILLE DESMOULINS, ISSY, 92789 MOULINEAUX CEDEX 9, FRANCE	0242-6498			ANN PATHOL	Ann. Pathol.	DEC	2018	38	6					381	385		10.1016/j.annpat.2018.06.003			5	Pathology	Pathology	HJ9JW	WOS:000457515700006	30487065				2019-10-28	
J	Tauziede-Espariat, A; Raffoul, J; Sun, SR; Lassabe, C; Monnin, C				Tauziede-Espariat, Arnault; Raffoul, Johnny; Sun, Shan Rong; Lassabe, Catherine; Monnin, Christine			A cutaneous case of angiolymphoid hyperplasia with eosinophilia: Presentation of a rare entity	ANNALES DE PATHOLOGIE			French	Article						Angiolymphoid hyperplasia; Eosinophils	EPITHELIOID HEMANGIOMA	We report the case of a Caucasian 73-year-old woman, without medical history, who is operated of two lesions of the forehead and the scalp measuring 0.4 and 1 cm. There is no adenopathy. Histopathological examination revealed a diffuse vascular proliferation of the dermis and the hypodermis composed of small vessels bordered of plump "epthelioid" endothelial cells. There is no mitotic figure. The stroma is slightly fibrous accompanied by a polymorphic inflammatory infiltrate rich in lymphocytes, sometimes arranged in lymphoid follicles, plasma cells and eosinophils. The proposed diagnosis is angiolymphoid hyperplasia with eosinophilia. This is a rare vascular tumor, benign according with the OMS classification and preferentially observed in the skin. We report a cutaneous case, clinical and histopathological data of the reported cases and present the main differential diagnoses. (C) 2018 Elsevier Masson SAS. All rights reserved.	[Tauziede-Espariat, Arnault; Raffoul, Johnny; Sun, Shan Rong; Lassabe, Catherine; Monnin, Christine] Ctr Hosp Montbeliard, Serv Pathol, 12 Rue Docteur Flamand, F-25200 Montbeliard, France	Tauziede-Espariat, A (reprint author), Ctr Hosp Montbeliard, Serv Anat & Cytol Pathol, 12 Rue Docteur Flamand, F-25200 Montbeliard, France.	arnault.tauziedeespariat@gmail.com					Adler BL, 2016, J AM ACAD DERMATOL, V74, P506, DOI 10.1016/j.jaad.2015.10.011; Calderaro J, 2011, ANN PATHOL, V31, P312, DOI 10.1016/j.annpat.2011.05.008; Chen H, 2004, AM J SURG PATHOL, V28, P505, DOI 10.1097/00000478-200404000-00010; Ennibi K, 2007, REV MED INTERNE, V28, P346, DOI 10.1016/j.revmed.2007.01.014; FETSCH JF, 1991, MODERN PATHOL, V4, P449; Gyulai R, 1996, LANCET, V347, P1837, DOI 10.1016/S0140-6736(96)91658-X; Hung T, 2001, J OTOLARYNGOL, V30, P359, DOI 10.2310/7070.2001.19425; Kempf W, 2002, HUM PATHOL, V33, P1023, DOI 10.1053/hupa.2002.128247; Lebbe C, 1997, ARCH DERMATOL, V133, P919, DOI 10.1001/archderm.133.7.919; Requena L, 1997, J AM ACAD DERMATOL, V37, P887, DOI 10.1016/S0190-9622(97)70065-3; Rodriguez-Lomba E, 2016, J AM ACAD DERMATOL, V75, pE19, DOI 10.1016/j.jaad.2016.02.1145; ROSAI J, 1979, HUM PATHOL, V10, P707, DOI 10.1016/S0046-8177(79)80114-8; Wang Su-xia, 2007, Zhonghua Nei Ke Za Zhi, V46, P827; WELLS GC, 1969, BRIT J DERMATOL, V81, P1, DOI 10.1111/j.1365-2133.1969.tb15914.x; Zarrin-Khameh N, 2005, ARCH PATHOL LAB MED, V129, P1168	15	0	0	0	0	MASSON EDITEUR	MOULINEAUX CEDEX 9	21 STREET CAMILLE DESMOULINS, ISSY, 92789 MOULINEAUX CEDEX 9, FRANCE	0242-6498			ANN PATHOL	Ann. Pathol.	DEC	2018	38	6					386	390		10.1016/j.annpat.2018.06.002			5	Pathology	Pathology	HJ9JW	WOS:000457515700007	30119962				2019-10-28	
J	Duchesne, M; Nguyen, QD; Guyot, A; Pommepuy, I; Caire, F; Labrousse, F				Duchesne, Mathilde; Nguyen, Quoc Dat; Guyot, Anne; Pommepuy, Isabelle; Caire, Francois; Labrousse, Francois			Calcifying pseudoneoplasm of the neuraxis	ANNALES DE PATHOLOGIE			French	Article						Pseudoneoplasm; Calcification; Central nervous system		Calcifying pseudoneoplasms of the neuraxis (CAPNON) are rare lesions of the central nervous system. To date, about 60 cases have been reported in literature. We present a case that had the peculiarity to occur in a pregnant woman. At 32 weeks of gestation, a 26-year-old woman was hospitalized to explore nocturnal epigastralgia. During the hospitalisation, the patient presented generalised seizures. As an eclampsia had been suspected, a caesarean delivery was performed. Post-operatively, the patient harboured memory disorders and neuroimaging explorations were done. They showed an intracerebral calcified mass located in the left frontal lobe and surrounded by an oedema. A complete surgical resection was performed. Histological examination of the surgical specimen showed a calcified tissue containing a fibrillary or granular material. A dense and hyalinised eosinophilic material focally surrounded the calcifications and contained regular fusiform cells of fibroblastic type. Foci of lipomatous and osseous metaplasia were present. Immunohistochemical staining for EMA and STAT6 was negative. There was no associated meningioangiomatosis nor tumour proliferation. Forty-five months after surgery, the patient did not present any seizures and had no sequelae. CAPNON are rare lesions occurring at any age. Their location in the central nervous system is ubiquitous and they can be intra or extra axial. The treatment is surgical and the prognosis excellent. CAPNON must be recognized and distinguished from the other calcified lesions, tumoural or non-tumoural, to avoid an inadequate and potentially harmful treatment. (C) 2018 Elsevier Masson SAS. All rights reserved.	[Duchesne, Mathilde; Nguyen, Quoc Dat; Guyot, Anne; Pommepuy, Isabelle; Labrousse, Francois] CHU Dupuytren, Serv Anat Pathol, 2 Ave Martin Luther King, F-87042 Limoges, France; [Caire, Francois] CHU Dupuytren, Serv Neurochirurg, 2 Ave Martin Luther King, F-87042 Limoges, France	Labrousse, F (reprint author), CHU Dupuytren, Serv Anat Pathol, 2 Ave Martin Luther King, F-87042 Limoges, France.	mathilde.duchesne@unilim.fr; datnguyen20987@gmail.com; anne.guyot@chu-limoges.fr; isabelle.pommepuy@chu-limoges.fr; francois.caire@chu-limoges.fr; labrousse@unilim.fr					Abdaljaleel M, 2017, NEUROPATHOLOGY, V37, P233, DOI 10.1111/neup.12349; Alshareef M, 2016, W NEUROSURG, V364, P11; Bartanusz V, 2013, J NEUROSURG-SPINE, V18, P367, DOI 10.3171/2013.1.SPINE12810; BERTONI F, 1990, J NEUROSURG, V72, P42, DOI 10.3171/jns.1990.72.1.0042; Duque SG, 2016, CLIN NEUROL NEUROSUR, V143, P116, DOI 10.1016/j.clineuro.2016.02.025; Higa N, 2017, NEUROPATHOLOGY, V37, P446, DOI 10.1111/neup.12384; Hubbard M, 2015, NEUROPATHOLOGY, V35, P452, DOI 10.1111/neup.12198; Miller EA, 1922, SURG GYNECOL OBSTET, V34, P786; Qian J, 1999, AM J SURG PATHOL, V23, P1270, DOI 10.1097/00000478-199910000-00013; RHODES RH, 1978, HUM PATHOL, V9, P309, DOI 10.1016/S0046-8177(78)80088-4; Rodriguez FJ, 2008, ACTA NEUROPATHOL, V115, P363, DOI 10.1007/s00401-007-0286-6	11	1	1	1	1	MASSON EDITEUR	MOULINEAUX CEDEX 9	21 STREET CAMILLE DESMOULINS, ISSY, 92789 MOULINEAUX CEDEX 9, FRANCE	0242-6498			ANN PATHOL	Ann. Pathol.	DEC	2018	38	6					391	394		10.1016/j.annpat.2018.04.006			4	Pathology	Pathology	HJ9JW	WOS:000457515700008	29858103				2019-10-28	
J	Thierry, S; El Alami-Thomas, W; Cazin, S; Chiforeanu, DC; Medane, S; Dugay, F; Kammerer-Jacquet, SF; Argani, P; Laguerre, B; Rioux-Leclercq, N				Thierry, Sixte; El Alami-Thomas, Wassila; Cazin, Sebastien; Chiforeanu, Dan Christian; Medane, Sarah; Dugay, Frederic; Kammerer-Jacquet, Solene-Florence; Argani, Pedram; Laguerre, Brigitte; Rioux-Leclercq, Nathalie			Low-grade eosinophilic unclassified renal cell carcinoma, a recently proposed entity in the spectrum of eosinophilic renal cells tumors: Report of one case and discussion	ANNALES DE PATHOLOGIE			French	Article						Renal tumor; Rena oncocytoma; Low-grade eosinophilic unclassified renal cell carcinoma; CCND1		Low-grade eosinophilic unclassified renal cell carcinoma is a rare kidney tumor recently described, not included in the WHO classification, which is very close to oncocytoma. It is unknown to most pathologists and clinicians. From a histopathological point of view, this tumor is composed of oncocytic cells arranged in a diffuse and solid pattern, without cell nests, that makes it possible to differentiate it from oncocytoma, and expresses cytokeratin 7 (CK7) heterogeneously. We report a case with a cranial vault metastasis, and present the features to differentiate this entity from oncocytoma. Furthemore, we discuss about unclassified renal cell carcinomas with oncocytic cells. (C) 2018 Elsevier Masson SAS. All rights reserved.	[Thierry, Sixte; Chiforeanu, Dan Christian; Medane, Sarah; Kammerer-Jacquet, Solene-Florence; Rioux-Leclercq, Nathalie] CHU Pontchaillou, Serv Anat & Cytol Pathol, 2 Rue Henri Le Guilloux, F-35000 Rennes, France; [El Alami-Thomas, Wassila] Inst Histopathol, 55 Rue Amiral du Chaffault, F-44100 Nantes, France; [Cazin, Sebastien] Ctr Med Erdre St Augustin, 1 Rue Eugene Tessier, F-44000 Nantes, France; [Dugay, Frederic] CHU Pontchaillou, Serv Cytogenet & Biot Cellulaire, 2 Rue Henri Le Guilloux, F-35000 Rennes, France; [Argani, Pedram] Johns Hopkins Med Inst, Dept Pathol, 1800 Orleans St, Baltimore, MD 21287 USA; [Laguerre, Brigitte] Ctr Eugene Marquis, Serv Oncol Med, Ave Bataille Flandres Dunkerque, F-35000 Rennes, France	Thierry, S (reprint author), CHU Pontchaillou, Serv Anat & Cytol Pathol, 2 Rue Henri Le Guilloux, F-35000 Rennes, France.	sixtethierry@hotmail.com					Couturier J, 2008, ANN PATHOL, V28, P402, DOI 10.1016/j.annpat.2008.06.032; Joshi S, 2015, CELL REP, V13, P1895, DOI 10.1016/j.celrep.2015.10.059; Klatte T, 2012, CANCER-AM CANCER SOC, V118, P5777, DOI 10.1002/cncr.27607; Kryvenko ON, 2014, ARCH PATHOL LAB MED, V138, P1531, DOI 10.5858/arpa.2013-0653-RA; Moch H, 2016, WHO CLASSIFICATION T; Perrino CM, 2018, HISTOPATHOLOGY, V72, P305, DOI 10.1111/his.13362; Qin LX, 2002, WORLD J GASTROENTERO, V8, P769, DOI 10.3748/wjg.v8.i5.769; Sukov WR, 2009, HUM PATHOL, V40, P1296, DOI 10.1016/j.humpath.2009.01.016; Trpkov K, 2010, HISTOPATHOLOGY, V57, P893, DOI 10.1111/j.1365-2559.2010.03726.x; Yusenko MV, 2010, INT J UROL, V17, P592, DOI 10.1111/j.1442-2042.2010.02558.x	10	0	0	1	2	MASSON EDITEUR	MOULINEAUX CEDEX 9	21 STREET CAMILLE DESMOULINS, ISSY, 92789 MOULINEAUX CEDEX 9, FRANCE	0242-6498			ANN PATHOL	Ann. Pathol.	DEC	2018	38	6					395	400		10.1016/j.annpat.2018.05.013			6	Pathology	Pathology	HJ9JW	WOS:000457515700009	30077423				2019-10-28	
J	Robinet, G; Renaudineau, E; Lamaison, C; Cam, G; Rioux-Leclercq, N				Robinet, Gwladys; Renaudineau, Eric; Lamaison, Claire; Cam, Gerard; Rioux-Leclercq, Nathalie			Renal amyloidosis revealing a cryopyrin associated periodic syndrome	ANNALES DE PATHOLOGIE			French	Article						Cryopyrin associated periodic syndrome; Muckle-Wells syndrome; AA amyloidosis; IgA nephropathy		Introduction. - Cryopyrin associated periodic syndrome is a rare auto inflammatory disease including three clinical entities with a common genetic cause. Among these three entities, Muckle-Wells syndrome is described as an intermediate phenotype associated with a progressive sensorineural hearing loss and AA amyloidosis. The present case reports a renal AA amyloidosis associated with an IgA nephropathy, revealing a Muckle-Wells syndrome. Observation. - The case is reported of a 38-years-old patient who presented a renal failure revealed concomitantly with a macroscopic hematuria exploration. Urological investigations were performed with negative results. The patient had no particular background except urticarial rashes, unlabeled inflammatory rheumatism and a grandmother's amyloidosis. Renal biopsy revealed glomerular, vascular and interstitial AA amyloidosis associated to an IgA nephropathy. This amyloidosis was known to be a part of Muckle-Wells syndrome, and a NLRP3 gene study confirmed the diagnosis. Conclusion. - Cryopyrin associated periodic syndrome is a rare disease and the clinical diagnosis suspicion need genetic confirmation. AA amyloidosis is known to happen in Muckle-Wells syndrome. Other occasional renal impairments are described in this syndrome whereas the IgA nephropathy association remains poorly characterized. (C) 2018 Elsevier Masson SAS. All rights reserved.	[Robinet, Gwladys; Lamaison, Claire; Rioux-Leclercq, Nathalie] CHU Pontchaillou, Serv Anat & Cytol Pathol, 2 Rue Henri le Guilloux, F-35033 Rennes 9, France; [Renaudineau, Eric; Cam, Gerard] Ctr Hosp St Malo, Serv Nephrol, 1 Rue Marne, F-35400 St Malo, France	Robinet, G (reprint author), CHU Pontchaillou, Serv Anat & Cytol Pathol, 2 Rue Henri le Guilloux, F-35033 Rennes 9, France.	gwladys.robinet@chu-rennes.fr					ALAMARTINE E, 1991, AM J KIDNEY DIS, V18, P12, DOI 10.1016/S0272-6386(12)80284-8; Giat E, 2014, ISR MED ASSOC J, V16, P659; Gicquel T, 2016, PRESSE MED, V45, P438, DOI 10.1016/j.lpm.2016.01.006; Kuemmerle-Deschner JB, 2015, SEMIN IMMUNOPATHOL, V37, P377, DOI 10.1007/s00281-015-0491-7; Lachmann HJ, 2007, NEW ENGL J MED, V356, P2361, DOI 10.1056/NEJMoa070265; Pepys-Vered ME, 2014, ISR MED ASSOC J, V16, P277; Radford MG, 1997, J AM SOC NEPHROL, V8, P199; SAID R, 1992, KIDNEY INT, V41, P414, DOI 10.1038/ki.1992.57; Topaloglu R, 2016, PEDIATR NEPHROL, V31, P633, DOI 10.1007/s00467-015-3249-5; Tsai YL, 2017, SCI REP-UK, V7, DOI 10.1038/srep41123; Verine J, 2008, ATLAS PATHOLOGIE REN, P345	11	0	0	0	1	MASSON EDITEUR	MOULINEAUX CEDEX 9	21 STREET CAMILLE DESMOULINS, ISSY, 92789 MOULINEAUX CEDEX 9, FRANCE	0242-6498			ANN PATHOL	Ann. Pathol.	DEC	2018	38	6					401	406		10.1016/j.annpat.2018.07.001			6	Pathology	Pathology	HJ9JW	WOS:000457515700010	30236822				2019-10-28	
J	Bailly, A; Sartelet, H				Bailly, Adeline; Sartelet, Herve			Bicolour placenta: An illustration of the twin to twin transfusion syndrome	ANNALES DE PATHOLOGIE			French	Editorial Material									[Bailly, Adeline; Sartelet, Herve] CHU Grenoble Alpes, Serv Anat & Cytol Pathol, CS10217, Ave Maquis du Gresivaudan, F-38043 Grenoble 9, France	Bailly, A (reprint author), CHU Grenoble Alpes, Serv Anat & Cytol Pathol, CS10217, Ave Maquis du Gresivaudan, F-38043 Grenoble 9, France.	baillya@hotmail.fr						0	0	0	0	0	MASSON EDITEUR	MOULINEAUX CEDEX 9	21 STREET CAMILLE DESMOULINS, ISSY, 92789 MOULINEAUX CEDEX 9, FRANCE	0242-6498			ANN PATHOL	Ann. Pathol.	DEC	2018	38	6					407	407		10.1016/j.annpat.2018.07.002			1	Pathology	Pathology	HJ9JW	WOS:000457515700011	30119960				2019-10-28	
J	Mesa, H; Rawal, A; Gupta, P				Mesa, Hector; Rawal, Ajay; Gupta, Pankaj			Diagnosis of Lymphoid Lesions in Limited Samples A Guide for the General Surgical Pathologist, Cytopathologist, and Cytotechnologist	AMERICAN JOURNAL OF CLINICAL PATHOLOGY			English	Review						Lymphoma; Biopsy; Fine needle; Classification; Immunohistochemistry; In situ hybridization	B-CELL LYMPHOMA; FINE-NEEDLE-ASPIRATION; PREDOMINANT HODGKIN LYMPHOMA; MYD88 L265P; MOLECULAR SUBTYPES; STRONG PREDICTOR; ZONE LYMPHOMA; CORE BIOPSY; MYC; IMMUNOHISTOCHEMISTRY	Objectives: Advances in interventional techniques allow obtaining samples from most body sites through minimally invasive procedures that yield limited samples. We provide practical guidelines for diagnosis of lymphoid lesions in these samples. Methods: Guidelines for selection of biopsy site and triage of the specimen according to results of rapid on-site evaluation (ROSE), and description of the advantages and limitations of currently available ancillary studies are described, based on the experience of the authors, complemented by a comprehensive review of the literature. Results: Five diagnostic categories are observed at ROSE: (1) preponderance of small cells, (2) large cells, (3) mixed small and large cells, (4) blast-like cells, and (5) rare large pleomorphic cells. Detailed description of the diagnostic work-up and subsequent classification for each of these groups is provided. Conclusions: A definitive diagnosis of lymphoid neoplasms in limited samples is possible in most cases through correlation of morphology, ancillary studies, and clinical scenario.	[Mesa, Hector] Vet Adm Hlth Care Serv, Dept Pathol, Minneapolis, MN USA; [Gupta, Pankaj] Vet Adm Hlth Care Serv, Dept Hematol Oncol, Minneapolis, MN USA; [Rawal, Ajay] Methodist Hosp, Dept Pathol, St Louis Pk, MN USA	Mesa, H (reprint author), Minneapolis VA Hlth Care Serv Off, BB-104,One Vet Dr, Minneapolis, MN 55417 USA.	Hector.Mesa@va.gov					Agarwal R, 2016, J CLIN PATHOL, V69, P266, DOI 10.1136/jclinpath-2015-203002; Amador-Ortiz C, 2011, AM J CLIN PATHOL, V135, P516, DOI 10.1309/AJCP3WZ8ZDRJQDOU; Anderson MA, 2016, HEMATOL ONCOL CLIN N, V30, P1317, DOI 10.1016/j.hoc.2016.07.012; Baseggio L, 2010, HAEMATOL-HEMATOL J, V95, P604, DOI 10.3324/haematol.2009.011049; Benharroch D, 2015, J CANCER, V6, P1155, DOI 10.7150/jca.13107; Boerma EG, 2009, LEUKEMIA, V23, P225, DOI 10.1038/leu.2008.281; CARBONE A, 1992, VIRCHOWS ARCH A, V420, P527, DOI 10.1007/BF01600258; Chase ML, 2018, BRIT J HAEMATOL, V180, P177, DOI 10.1111/bjh.14996; Choi WWL, 2009, CLIN CANCER RES, V15, P5494, DOI 10.1158/1078-0432.CCR-09-0113; Criel A, 1999, LEUKEMIA LYMPHOMA, V33, P33, DOI 10.3109/10428199909093723; Dabbs DJ, 2010, DIAGNOSTIC IMMUNOHIS, P189; Davis TA, 1999, CLIN CANCER RES, V5, P611; DiMaio CJ, 2016, ENDOSC INT OPEN, V4, pE974, DOI 10.1055/s-0042-112581; Dunphy CH, 2000, CYTOMETRY, V42, P296, DOI 10.1002/1097-0320(20001015)42:5<296::AID-CYTO7>3.0.CO;2-X; Fan Z, 2003, AM J SURG PATHOL, V27, P1346, DOI 10.1097/00000478-200310000-00007; Garcia JF, 2005, HISTOPATHOLOGY, V47, P101, DOI 10.1111/j.1365-2559.2005.02175.x; Gong JZ, 2004, DIAGN CYTOPATHOL, V31, P23, DOI 10.1002/dc.20082; Gong JZ, 2002, AM J CLIN PATHOL, V117, P880; Green TM, 2012, J CLIN ONCOL, V30, P3460, DOI 10.1200/JCO.2011.41.4342; Grygalewicz B, 2018, AM J CLIN PATHOL, V149, P17, DOI [10.1093/AJCP/AQX139, 10.1093/ajcp/aqx139]; Hans CP, 2004, BLOOD, V103, P275, DOI 10.1182/blood-2003-05-1545; Hu QL, 2013, AM J CLIN PATHOL, V140, P238, DOI 10.1309/AJCP9ZAGKVJ8PDAX; Hu SM, 2013, BLOOD, V121, P4021, DOI 10.1182/blood-2012-10-460063; Jaso JM, 2013, AM J CLIN PATHOL, V140, P693, DOI 10.1309/AJCPEMVXES72DUIF; Jimenez C, 2013, LEUKEMIA, V27, P1722, DOI 10.1038/leu.2013.62; Johl A, 2016, ANN HEMATOL, V95, P1281, DOI 10.1007/s00277-016-2704-0; Karamchandani JR, 2012, APPL IMMUNOHISTO M M, V20, P445, DOI 10.1097/PAI.0b013e318244ff4b; Kluk MJ, 2016, AM J CLIN PATHOL, V145, P166, DOI 10.1093/ajcp/aqv028; Kussick SJ, 2004, AM J CLIN PATHOL, V121, P464, DOI 10.1309/4EJ8T3R2ERKQ61WH; Li SY, 2015, MODERN PATHOL, V28, P208, DOI 10.1038/modpathol.2014.95; Liu QY, 2013, AM J SURG PATHOL, V37, P333, DOI 10.1097/PAS.0b013e31826b9b57; Long NM, 2011, INSIGHTS IMAGING, V2, P679, DOI 10.1007/s13244-010-0062-3; Lorsbach RB, 2011, AM J CLIN PATHOL, V136, P168, DOI 10.1309/AJCPENJ68FFBRIYB; Lu TX, 2015, ONCOTARGET, V6, P18374, DOI 10.18632/oncotarget.4073; Nguyen L, 2017, GENES-BASEL, V8, DOI 10.3390/genes8040116; Matsubayashi H, 2016, WORLD J GASTROENTERO, V22, P628, DOI 10.3748/wjg.v22.i2.628; National Comprehensive Cancer Network (NCCN), 2018, NCCN CLIN PRACT GUID; O'Connell FP, 2004, AM J CLIN PATHOL, V121, P254, DOI 10.1309/617DWB5GNFWXHW4L; Pan ZG, 2017, AM J SURG PATHOL, V41, P25, DOI 10.1097/PAS.0000000000000753; Pellegrini W, 2007, HAEMATOL-HEMATOL J, V92, P708, DOI 10.3324/haematol.11002; Petrich AM, 2014, BLOOD, V124, P2354, DOI 10.1182/blood-2014-05-578963; Pileri SA, 2002, J CLIN PATHOL, V55, P162, DOI 10.1136/jcp.55.3.162; Pillai RK, 2013, AM J SURG PATHOL, V37, P323, DOI 10.1097/PAS.0b013e31826cebad; Sandoval-Sus JD, 2016, CURR CANCER DRUG TAR, V16, P305, DOI 10.2174/1568009615666151030102539; Sarkozy Clementine, 2015, Lancet Oncol, V16, pe555, DOI 10.1016/S1470-2045(15)00005-4; Sesques P, 2017, BLOOD, V129, P280, DOI 10.1182/blood-2016-02-636316; Shalabi H, 2018, HAEMATOLOGICA, V103, pE215, DOI 10.3324/haematol.2017.183459; Shih AR, 2017, J HEMATOP, V10, P49, DOI 10.1007/s12308-017-0292-0; Sibon D, 2012, J CLIN ONCOL, V30, P3939, DOI 10.1200/JCO.2012.42.2345; Smith LB, 2010, ARCH PATHOL LAB MED, V134, P1434, DOI 10.1043/2010-0207-OA.1; Soleimani A, 2016, BLOOD, V128, DOI 10.1182/blood.V128.22.3048.3048; Swerdlow SH, 2017, WHO CLASSIFICATION T; Traverse-Glehen A, 2005, AM J SURG PATHOL, V29, P1411, DOI 10.1097/01.pas.0000180856.74572.73; Treon SP, 2012, NEW ENGL J MED, V367, P826, DOI 10.1056/NEJMoa1200710; van den Brand M, 2013, HAEMATOLOGICA, V98, P1003, DOI 10.3324/haematol.2012.083386; vonWasielewski R, 1997, AM J PATHOL, V151, P1123; Yang G, 2013, BLOOD, V122, P1222, DOI 10.1182/blood-2012-12-475111; Yu H, 2017, AM J HEMATOL, V92, pE11, DOI 10.1002/ajh.24594	58	0	0	0	0	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0002-9173	1943-7722		AM J CLIN PATHOL	Am. J. Clin. Pathol.	DEC	2018	150	6					471	484		10.1093/AJCP/AQY077			14	Pathology	Pathology	HI6KS	WOS:000456564300001	30084952	Bronze			2019-10-28	
J	Lewandrowski, K; Keegan, A; Makarenko, V; Maryamchak, E; Mata, DA; Palte, MJ; Rudolf, JW; Safdar, N; Schmidt, RJ; Stuart, L; Xiong, YQ; Rao, L; Melanson, SEF; Snyder, LM				Lewandrowski, Kent; Keegan, Alissa; Makarenko, Vladislav; Maryamchak, Elena; Mata, Douglas A.; Palte, Michael J.; Rudolf, Joseph W.; Safdar, Nida; Schmidt, Ryan J.; Stuart, Lena; Xiong, Yiqin; Rao, Lokinendi; Melanson, Stacy E. F.; Snyder, L. Michael			Development of a Commercial Reference Laboratory Elective Rotation for Residents in Clinical Pathology	AMERICAN JOURNAL OF CLINICAL PATHOLOGY			English	Article						Reference laboratory; Resident training; Clinical pathology elective rotation; Laboratory management	CURRICULUM; FELLOWS	Objectives: To develop a curriculum for a commercial reference laboratory clinical pathology training elective. Methods: A 4-day elective at Quest Diagnostics was developed. The elective included 32 sessions composed of interactive didactic sessions and laboratory tours/demonstrations. Ten residents who attended the elective completed a written evaluation and scored each component of the curriculum. Results: Written comments were very positive and demonstrated the goals of the elective were achieved. Laboratory tours and one-on-one sessions with the medical directors were especially well received. Most of the residents stated that the rotation gave them exposure to an area of laboratory medicine that they were not familiar with. Conclusions: The elective provided a resident training experience that was highly regarded and exposed residents to an area of laboratory medicine not encountered in most pathology training programs. Our curriculum could serve as a model for establishing a similar elective in other training programs.	[Lewandrowski, Kent; Maryamchak, Elena; Safdar, Nida; Stuart, Lena] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA; [Lewandrowski, Kent; Keegan, Alissa; Maryamchak, Elena; Mata, Douglas A.; Palte, Michael J.; Safdar, Nida; Schmidt, Ryan J.; Stuart, Lena; Melanson, Stacy E. F.] Harvard Med Sch, Dept Pathol, Boston, MA USA; [Keegan, Alissa; Mata, Douglas A.; Palte, Michael J.; Schmidt, Ryan J.; Melanson, Stacy E. F.] Brigham & Womens Hosp, Dept Pathol, 75 Francis St, Boston, MA 02115 USA; [Makarenko, Vladislav; Xiong, Yiqin; Rao, Lokinendi; Snyder, L. Michael] UMass Mem Med Ctr, Worcester, MA USA; [Rudolf, Joseph W.] Univ Minnesota, Sch Med, Dept Pathol, Minneapolis, MN 55455 USA; [Rao, Lokinendi; Snyder, L. Michael] Quest Diagnost, Marlborough, MA USA	Lewandrowski, K (reprint author), Massachusetts Gen Hosp, 55 Fruit St,Gray 5 Chem, Boston, MA 02114 USA.	klewandrowski@partners.org	Mata, Douglas A./P-1040-2019	Mata, Douglas A./0000-0002-8059-8668			Ardisson L, 2007, LABMEDICINE, V38, P472, DOI 10.1309/G2MM69T9C4C97W0W; Beyer G, 2002, CLIN CHEM LAB MANAGE, P316; Hemmer PR, 2007, ARCH PATHOL LAB MED, V131, P610; Horowitz RE, 2004, ARCH PATHOL LAB MED, V128, P59; MacMillan Donna, 2004, Clin Leadersh Manag Rev, V18, P216; Otte KK, 2010, ARCH PATHOL LAB MED, V134, P1029, DOI 10.1043/2009-0251-OA.1	6	0	0	0	0	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0002-9173	1943-7722		AM J CLIN PATHOL	Am. J. Clin. Pathol.	DEC	2018	150	6					485	490		10.1093/AJCP/AQY070			6	Pathology	Pathology	HI6KS	WOS:000456564300002	30053105				2019-10-28	
J	Hou, YJ; Moosavi, HS; Wei, L; Parwani, AV; Li, XX; Li, ZB				Hou, Yanjun; Moosavi, Harrison S.; Wei, Lai; Parwani, Anil V.; Li, Xiaoxian (Bill); Li, Zaibo			Magee Equation Recurrence Score Is Associated With Distal Metastatic Risk in Male Breast Carcinomas Experience From Two Institutions	AMERICAN JOURNAL OF CLINICAL PATHOLOGY			English	Article						Male breast cancer; Magee equation; Recurrence score	ONCOTYPE DX; ESTROGEN-RECEPTOR; CANCER STATISTICS; PREDICTION; BIOMARKERS; FEATURES; GUIDE; ASSAY	Objectives: To conduct a clinicopathologic study of male breast carcinoma with Magee equation recurrence score (RS). Methods: Seventy-four cases of male invasive breast cancers (MBCs) were studied, including 63 hormone receptor (HR)-positive, 10 human epidermal growth factor receptor 2-positive, and one triple-negative breast cancers. Results: Among 63 HR-positive MBC patients, nine patients developed distal metastasis. Statistical analysis demonstrated distal metastasis was significantly associated with positive lymph node, high Nottingham grade, and increased Magee equation RS. All HR-positive MBCs were further stratified into two categories (low RS < 18; intermediate/ high RS >= 18). There was a significantly increased risk for distal metastasis in MBCs with intermediate/high Magee equation RS, but no increased risk for lymph node metastasis. Conclusions: Our data suggest Magee equation RS may be useful to predict distal metastatic risk in MBC patients.	[Hou, Yanjun; Parwani, Anil V.; Li, Zaibo] Ohio State Univ, Wexner Med Ctr, Dept Pathol, 410 W 10th Ave, Columbus, OH 43210 USA; [Wei, Lai] Ohio State Univ, Dept Biomed Informat, Ctr Biostat, Columbus, OH 43210 USA; [Moosavi, Harrison S.; Li, Xiaoxian (Bill)] Emory Univ, Dept Pathol & Lab Med, Atlanta, GA 30322 USA	Li, ZB (reprint author), Ohio State Univ, Wexner Med Ctr, Dept Pathol, 410 W 10th Ave, Columbus, OH 43210 USA.	Zaibo.Li@osumc.edu					Abreu MH, 2016, INT J CANCER, V139, P1715, DOI 10.1002/ijc.30225; Anderson WF, 2010, J CLIN ONCOL, V28, P232, DOI 10.1200/JCO.2009.23.8162; Auerbach J, 2010, ARCH PATHOL LAB MED, V134, P1697, DOI 10.1043/2009-0439-OAR.1; Bystricky B, 2016, ONCOL LETT, V12, P1615, DOI 10.3892/ol.2016.4807; Cardoso F, 2018, ANN ONCOL, V29, P405, DOI 10.1093/annonc/mdx651; Cuzick J, 2011, J CLIN ONCOL, V29, P4273, DOI 10.1200/JCO.2010.31.2835; Flanagan MB, 2008, MODERN PATHOL, V21, P1255, DOI 10.1038/modpathol.2008.54; Giordano SH, 2004, CANCER, V101, P51, DOI 10.1002/cncr.20312; Giordano SH, 2002, ANN INTERN MED, V137, P678, DOI 10.7326/0003-4819-137-8-200210150-00013; Hagemann IS, 2016, ARCH PATHOL LAB MED, V140, P815, DOI 10.5858/arpa.2016-0051-RA; Harris LN, 2016, J CLIN ONCOL, V34, P1134, DOI 10.1200/JCO.2015.65.2289; Hong JH, 2016, CANCER RES TREAT, V48, P1389, DOI 10.4143/crt.2015.410; Hou YJ, 2017, AM J CLIN PATHOL, V148, P167, DOI [10.1093/AJCP/AQX059, 10.1093/ajcp/aqx059]; Hou YJ, 2017, AM J CLIN PATHOL, V147, P541, DOI [10.1093/AJCP/AQX008, 10.1093/ajcp/aqx008]; Humphries MP, 2017, SCI REP-UK, V7, DOI 10.1038/srep45293; Klein ME, 2013, MODERN PATHOL, V26, P658, DOI 10.1038/modpathol.2013.36; Kraus JA, 2012, MODERN PATHOL, V25, P869, DOI 10.1038/modpathol.2011.219; Lecarpentier J, 2017, J CLIN ONCOL, V35, P2240, DOI 10.1200/JCO.2016.69.4935; Li XX, 2017, CLIN BREAST CANCER, V17, P356, DOI 10.1016/j.clbc.2017.03.005; Losurdo A, 2017, CRIT REV ONCOL HEMAT, V113, P283, DOI 10.1016/j.critrevonc.2017.03.013; Nilsson C, 2013, ACTA ONCOL, V52, P102, DOI 10.3109/0284186X.2012.711952; Pritzlaff M, 2017, BREAST CANCER RES TR, V161, P575, DOI 10.1007/s10549-016-4085-4; Ruddy KJ, 2013, ANN ONCOL, V24, P1434, DOI 10.1093/annonc/mdt025; Serdy KM, 2017, AM J CLIN PATHOL, V147, P110, DOI [10.1093/ajcp/aqw207, 10.1093/AJCP/AQW207]; Shaaban AM, 2012, BREAST CANCER RES TR, V133, P949, DOI 10.1007/s10549-011-1856-9; Siegel R, 2014, CA-CANCER J CLIN, V64, P9, DOI 10.3322/caac.21208; Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387; Vermeulen MA, 2017, EUR J CANCER, V82, P219, DOI 10.1016/j.ejca.2017.01.034; Yu E, 2015, CUREUS, V7, DOI 10.7759/cureus.355; Zbytek B, 2013, APPL IMMUNOHISTO M M, V21, P48, DOI 10.1097/PAI.0b013e3182427cda; Zografos E, 2016, CANCER GENOM PROTEOM, V13, P183	31	0	0	0	0	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0002-9173	1943-7722		AM J CLIN PATHOL	Am. J. Clin. Pathol.	DEC	2018	150	6					491	498		10.1093/AJCP/AQY078			8	Pathology	Pathology	HI6KS	WOS:000456564300003	30084931				2019-10-28	
J	Anderson, KR; Onken, A; Heidinger, BH; Chen, YG; Bankier, AA; VanderLaan, PA				Anderson, Kevin R.; Onken, Allison; Heidinger, Benedikt H.; Chen, Yigu; Bankier, Alexander A.; VanderLaan, Paul A.			Pathologic T Descriptor of Nonmucinous Lung Adenocarcinomas Now Based on Invasive Tumor Size How Should Pathologists Measure Invasion?	AMERICAN JOURNAL OF CLINICAL PATHOLOGY			English	Article						Lung adenocarcinoma; Measurement; Invasive; Part-solid; Staging	RESOLUTION COMPUTED-TOMOGRAPHY; AMERICAN-JOINT-COMMITTEE; GLASS OPACITY COMPONENT; 8TH EDITION; PULMONARY ADENOCARCINOMAS; TNM CLASSIFICATION; SOLID COMPONENT; LEPIDIC GROWTH; NODULES; CANCER	Objectives: The eighth edition of the American Joint Committee on Cancer staging manual now stratifies nonmucinous lung adenocarcinomas (nmLACAs) by the size of the invasive component only. This is determined by direct gross or microscopic measurement; however, a calculated invasive size based on the percentage of invasive growth patterns has been proposed as an alternative option. Methods: To compare radiologic with different pathologic assessments of invasive tumor size, we retrospectively reviewed a cohort of resected nmLACAs with a part-solid appearance on computed tomography (CT) scan (n = 112). Results: The median direct microscopic pathologic invasive measurements were not significantly different from the median calculated pathologic invasive measurements; however, the median CT invasive measurements were 0.26 cm larger than the median direct pathologic measurements (P < .001). Conclusions: Our results show that pathologic calculated invasive tumor measurements are comparable to direct microscopic measurements of invasive tumor, thereby supporting the recommendation for use of calculated invasive tumor size by the pathologist if necessary.	[Anderson, Kevin R.; Onken, Allison; Chen, Yigu; VanderLaan, Paul A.] Harvard Med Sch, Beth Israel Deaconess Med Ctr, Dept Pathol, Boston, MA USA; [Heidinger, Benedikt H.; Bankier, Alexander A.] Harvard Med Sch, Beth Israel Deaconess Med Ctr, Dept Radiol, Boston, MA USA	VanderLaan, PA (reprint author), Beth Israel Deaconess Med Ctr, Dept Pathol, 330 Brookline Ave, Boston, MA 02215 USA.	pvanderl@bidmc.harvard.edu		Heidinger, Benedikt/0000-0002-4827-2457; VanderLaan, Paul/0000-0002-7234-5652			Anderson KR, 2017, AM J CLIN PATHOL, V147, P641, DOI [10.1093/AJCP/AQX036, 10.1093/ajcp/aqx036]; Aokage K, 2017, J THORAC ONCOL, V12, P1403, DOI 10.1016/j.jtho.2017.06.003; Bankier AA, 2017, RADIOLOGY, V285, P584, DOI 10.1148/radiol.2017162894; Borczuk AC, 2012, MODERN PATHOL, V25, pS1, DOI 10.1038/modpathol.2011.151; Burt BM, 2015, ANN SURG ONCOL, V22, pS1318, DOI 10.1245/s10434-015-4780-0; Chen KZ, 2017, CLIN LUNG CANCER, V18, pE457, DOI 10.1016/j.cllc.2017.04.001; Cohen J., 1988, STAT POWER ANAL BEHA; Faul F, 2007, BEHAV RES METHODS, V39, P175, DOI 10.3758/BF03193146; Heidinger BH, 2017, ACAD RADIOL, V24, P1422, DOI 10.1016/j.acra.2017.05.013; Heidinger BH, 2017, J THORAC ONCOL, V12, P1288, DOI 10.1016/j.jtho.2017.05.017; Heidinger BH, 2017, ACAD RADIOL, V24, P851, DOI 10.1016/j.acra.2017.01.009; Hsu PK, 2007, ANN THORAC SURG, V84, P1825, DOI 10.1016/j.athoracsur.2007.07.016; Hwang EJ, 2015, EUR RADIOL, V25, P558, DOI 10.1007/s00330-014-3441-1; Ko JP, 2016, RADIOLOGY, V280, P931, DOI 10.1148/radiol.2016142975; Lampen-Sachar K, 2012, LUNG CANCER, V75, P332, DOI 10.1016/j.lungcan.2011.08.001; Lee KH, 2014, J THORAC ONCOL, V9, P74, DOI 10.1097/JTO.0000000000000019; Maeyashiki T, 2013, EUR J CARDIO-THORAC, V43, P915, DOI 10.1093/ejcts/ezs516; Murakawa T, 2013, EUR J CARDIO-THORAC, V43, P925, DOI 10.1093/ejcts/ezs467; Nemec U, 2018, EUR RADIOL, V28, P235, DOI 10.1007/s00330-017-4937-2; Rami-Porta R, 2016, AJCC CANC STAGING MA, P431; Rami-Porta R, 2017, CA-CANCER J CLIN, V67, P138, DOI 10.3322/caac.21390; Strand TE, 2015, DIAGN PATHOL, V10, DOI 10.1186/s13000-015-0335-8; Thunnissen E, 2012, MODERN PATHOL, V25, P1574, DOI 10.1038/modpathol.2012.106; Travis WD, 2016, J THORAC ONCOL, V11, P1204, DOI 10.1016/j.jtho.2016.03.025; Tsutani Y, 2013, ANN ONCOL, V24, P2376, DOI 10.1093/annonc/mdt230; Tsutani Y, 2013, J THORAC CARDIOV SUR, V146, P580, DOI 10.1016/j.jtcvs.2013.04.032; Tsutani Y, 2013, J THORAC CARDIOV SUR, V146, P17, DOI 10.1016/j.jtcvs.2012.11.019; Tsutani Y, 2012, J THORAC CARDIOV SUR, V143, P607, DOI 10.1016/j.jtcvs.2011.10.037; Warth A, 2012, EUR RESPIR J, V40, P1221, DOI 10.1183/09031936.00219211; Warth A, 2012, VIRCHOWS ARCH, V461, P185, DOI 10.1007/s00428-012-1263-6; Warth A, 2012, J CLIN ONCOL, V30, P1438, DOI 10.1200/JCO.2011.37.2185	31	0	0	2	3	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0002-9173	1943-7722		AM J CLIN PATHOL	Am. J. Clin. Pathol.	DEC	2018	150	6					499	506		10.1093/AJCP/AQY080			8	Pathology	Pathology	HI6KS	WOS:000456564300004	30084917				2019-10-28	
J	Gumus, A				Gumus, Alper			Evaluation of Ethanol Interference on Routine Biochemical Tests	AMERICAN JOURNAL OF CLINICAL PATHOLOGY			English	Article						Ethanol; Interference; Coefficient of variation (CV); Bias; Total error (TE); Allowable total error (aTE)	ALCOHOL	Objectives: Ethanol is a widely consumed drug in almost every society. In this study, the potential interfering effect of ethanol on routine biochemical tests was evaluated. Methods: Serum pools were prepared from blood samples collected from patients seeking treatment at the emergency department. Five separate groups were formed by adding ethanol to the samples, so the final concentrations were negative: 50 mg/dL, 100 mg/dL, 200 mg/dL, and 400 mg/dL. Each group was divided into 20 portions, and routine biochemical tests were measured from each portion. The coefficient of variation (CV), bias, and total error values were calculated for the measured parameters. Results: Alanine aminotransferase (ALT; EC 2.6.1.2) and lactate dehydrogenase (LDH; EC 1.1.1.27) activities decreased in proportion to the ethanol level. High negative biases were observed, suggesting a dose-dependent negative interference. The total error values calculated for direct bilirubin and urea were higher than the allowable total error reported in the Clinical Laboratory Improvement Amendments of 1988. For direct bilirubin, it was observed that the cause of this shift was due to the increase in CV values. Conclusions: We conclude that ethanol may cause interference in the measurement of some biochemical tests, whereas the most prominent effect was observed for LDH and ALT.	[Gumus, Alper] Haseki Training & Res Hosp, Med Biochem Lab, Istanbul, Turkey	Gumus, A (reprint author), Haseki Training & Res Hosp, Millet St, TR-34096 Istanbul, Turkey.	dralpergumus@gmail.com		Gumus, Alper/0000-0002-4453-6339			Cederbaum AI, 2012, CLIN LIVER DIS, V16, P667, DOI 10.1016/j.cld.2012.08.002; Clinical and Laboratory Standards Institute (CLSI), 2005, EP7P CLSI; Dimeski G., 2008, CLIN BIOCHEM REV, V29, P43; Giltlow S., 2001, SUBSTANCE USE DISORD, P61; Higgins T, 2015, TIETZ FUNDAMENTALS C, P518; Koseoglu M, 2011, BIOCHEM MEDICA, V21, P79; Mukherjee S, 2013, CURR NEUROVASC RES, V10, P256, DOI 10.2174/15672026113109990004; Oscar-Berman M, 2007, NEUROPSYCHOL REV, V17, P239, DOI 10.1007/s11065-007-9038-6; Romo AJ, 2011, BBA-PROTEINS PROTEOM, V1814, P1534, DOI 10.1016/j.bbapap.2011.02.003; Sandoval C, 2017, INT J MORPHOL, V35, P942; Theodorsson E, 2014, BIOANALYSIS, V6, P2855, DOI [10.4155/BIO.14.249, 10.4155/bio.14.249]; Vairappan B., 2016, ALCOHOLIC LIVER DIS, P187; Wians EH, 2009, LABMEDICINE, V40, P105, DOI 10.1309/KN404L0HHUTWWUDD; Zakhari S, 2006, ALCOHOL RES HEALTH, V29, P245	14	0	0	0	0	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0002-9173	1943-7722		AM J CLIN PATHOL	Am. J. Clin. Pathol.	DEC	2018	150	6					507	511		10.1093/AJCP/AQY081			5	Pathology	Pathology	HI6KS	WOS:000456564300005	30169725				2019-10-28	
J	McMenamin, M; McKenna, M; McDowell, A				McMenamin, Mary; McKenna, Michael; McDowell, Andrew			Clinical Utility of CINtec PLUS Triage in Equivocal Cervical Cytology and Human Papillomavirus Primary Screening	AMERICAN JOURNAL OF CLINICAL PATHOLOGY			English	Article						CINtec PLUS cytology; Equivocal cytology; HPV triage; HPV primary screening	CANCER PRECURSORS; MILD DYSKARYOSIS; PAP CYTOLOGY; YOUNG-WOMEN; PERFORMANCE; RISK; BORDERLINE; HPV16; AGE	Objectives: While cervical cytology is accepted triage for human papillomavirus (HPV)-positive women, the efficiency of cervical screening could be improved by exploiting disease markers with higher specificity. Methods: CINtec PLUS triage alone and combined with HPV 16/18 genotyping was performed on ThinPrep samples from HPV-positive women. Clinical performance and the potential to reduce or expedite colposcopy referrals were evaluated. Results: The 2-year sensitivity and specificity for cervical intraepithelial neoplasia grade 3 or worse (CIN3+) were 90% and 42%, respectively. Specificity was improved over HPV testing in equivocal cytology and could cut the referral rate by about 40%. When combined with HPV 16/18 genotyping, CINtec PLUS triage of the 12 other high-risk HPV genotypes generally demonstrated better sensitivity for CIN3+ than separate triage of non-type-specific HPV-positive women. This strategy could reduce colposcopy referrals by 31%. Conclusions: These findings highlight the potential of CINtec PLUS to improve management pathways in HPV-positive women. CINtec PLUS cytology represents a sensitive and efficient triage in HPV-positive women. The clinical performance of the dual-stain was most notable in women younger than 25 years and could potentially improve management pathways.	[McMenamin, Mary; McKenna, Michael] Western Hlth & Social Care Trust, Altnagelvin Hosp, Cytopathol Dept, Derry BT47 6SB, Londonderry, North Ireland; [McDowell, Andrew] Ulster Univ, Sch Biomed Sci, Northern Ireland Ctr Stratified Med, Derry, Londonderry, North Ireland	McMenamin, M (reprint author), Western Hlth & Social Care Trust, Altnagelvin Hosp, Cytopathol Dept, Derry BT47 6SB, Londonderry, North Ireland.	mary.mcmenamin2@westhealth.n-i.nhs.uk			Roche Molecular Diagnostics	We thank Roche Molecular Diagnostics for its support with this study by providing CINtec PLUS cytology kits and the Departments of Cytology at Altnagelvin and Belfast City Hospitals for technical support.	Agorastos T, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0119755; Arbyn M, 2011, BRIT J CANCER, V105, P877, DOI 10.1038/bjc.2011.351; Arbyn M, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008054.pub2; Castle PE, 2005, J NATL CANCER I, V97, P1066, DOI 10.1093/jnci/dji186; Castle PE, 2011, LANCET ONCOL, V12, P880, DOI 10.1016/S1470-2045(11)70188-7; Castle PE, 2007, AM J OBSTET GYNECOL, V197, DOI 10.1016/j.ajog.2007.07.049; Ikenberg H, 2013, JNCI-J NATL CANCER I, V105, P1550, DOI 10.1093/jnci/djt235; McKenna M, 2016, CYTOPATHOLOGY, V27, P261, DOI 10.1111/cyt.12316; McKenna M, 2014, CANCER CYTOPATHOL, V122, P702, DOI 10.1002/cncy.21444; McMenamin M, 2017, CYTOPATHOLOGY, V28, P284, DOI 10.1111/cyt.12426; Moss S, 2015, HPV PRIMARY SCREENIN; National Health Service Cancer Screening Programmes, 2012, ACH STAND BENCHM REP, V1; NHS Cancer Screening Programmes, 2013, HPV PRIM SCREEN ALG; Palmer TJ, 2016, BRIT J CANCER, V114, P582, DOI 10.1038/bjc.2015.474; Petry KU, 2011, GYNECOL ONCOL, V121, P505, DOI 10.1016/j.ygyno.2011.02.033; Roche, CINTEC PLUS CYT KIT; Rodriguez AC, 2008, JNCI-J NATL CANCER I, V100, P513, DOI 10.1093/jnci/djn044; Ronco G, 2014, LANCET, V383, P524, DOI 10.1016/S0140-6736(13)62218-7; Schmidt D, 2011, CANCER CYTOPATHOL, V119, P158, DOI 10.1002/cncy.20140; Solomon D, 2002, JAMA-J AM MED ASSOC, V287, P2114, DOI 10.1001/jama.287.16.2114; Stoler MH, 2012, AM J CLIN PATHOL, V137, P295, DOI 10.1309/AJCPGW1V2BBWMOCX; Uijterwaal MH, 2014, BRIT J CANCER, V110, P1579, DOI 10.1038/bjc.2014.34; Uijterwaal MH, 2015, INT J CANCER, V136, P2361, DOI 10.1002/ijc.29290; Wentzensen N, 2007, DIS MARKERS, V23, P315, DOI 10.1155/2007/678793; Wentzensen N, 2015, JNCI-J NATL CANCER I, V107, DOI 10.1093/jnci/djv257; Wentzensen N, 2012, CLIN CANCER RES, V18, P4154, DOI 10.1158/1078-0432.CCR-12-0270; Wright TC, 2011, AM J CLIN PATHOL, V136, P578, DOI 10.1309/AJCPTUS5EXAS6DKZ	27	0	0	0	0	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0002-9173	1943-7722		AM J CLIN PATHOL	Am. J. Clin. Pathol.	DEC	2018	150	6					512	521		10.1093/AJCP/AQY073			10	Pathology	Pathology	HI6KS	WOS:000456564300006	30169728	Bronze			2019-10-28	
J	Stram, MN; Suciu, CN; Seheult, JN; McCullough, MA; Kader, M; Wells, A; Pasculle, AW; Rinaldo, CR; Ismail, N				Stram, Michelle N.; Suciu, Christopher N.; Seheult, Jansen N.; McCullough, Melissa A.; Kader, Muhamuda; Wells, Alan; Pasculle, A. William; Rinaldo, Charles R.; Ismail, Nahed			Herpes Simplex Virus-1 qPCR in the Diagnosis of Lower Respiratory Tract Infections in Organ Transplant Recipients and Critically Ill Patients	AMERICAN JOURNAL OF CLINICAL PATHOLOGY			English	Article						Herpes simplex virus-1; Bronchoalveolar lavage; Quantitative polymerase chain reaction; Viral culture; Herpes lower respiratory tract infection; Herpes pneumonia; Organ transplant recipients; Critically ill patients	BRONCHOALVEOLAR LAVAGE; TYPE-1; PNEUMONIA	Objectives: To determine a quantitative herpes simplex virus (HSV) DNA threshold in lower respiratory tract specimens that correlates with positive viral culture and clinical outcomes. Methods: Bronchoalveolar lavage and bronchial wash samples from 53 HSV culture-positive and 61 culture-negative matched controls were tested using HSV-1 and HSV-2 quantitative polymerase chain reaction (qPCR). Results: Median viral culture turnaround time was 21.8 days and 9.9 days for culture-negative and culturepositive specimens, respectively. Using an HSV-1 viral load threshold of 1.62 x 103 copies/mL, there was 93% agreement with viral culture. An HSV-1 viral load >= 1.3 x 10(4) copies/mL was associated with worse clinical outcome compared to a viral load < 1.3 x 10(4) copies/mL (hazard ratio [HR] = 4.27, P =.017), and there was a trend of worse outcome compared to patients with undetectable HSV-1 DNA (HR = 1.60, P =.056). Conclusions: qPCR has clinical utility for rapid accurate identification of HSV-1 in lower respiratory tract specimens.	[Stram, Michelle N.; Suciu, Christopher N.; Seheult, Jansen N.; Kader, Muhamuda; Wells, Alan; Pasculle, A. William; Rinaldo, Charles R.; Ismail, Nahed] Univ Pittsburgh, Med Ctr, Dept Pathol, Pittsburgh, PA USA; [McCullough, Melissa A.; Pasculle, A. William; Rinaldo, Charles R.; Ismail, Nahed] Univ Pittsburgh, Med Ctr, Clin Microbiol Lab, Pittsburgh, PA USA; [McCullough, Melissa A.] Butler Hlth Syst, Clin Microbiol Lab, Butler, PA USA; [Ismail, Nahed] Univ Illinois, Chicago, IL 60612 USA	Ismail, N (reprint author), Univ Illinois, Dept Pathol, 840 South Wood St,265F CMET, Chicago, IL 60612 USA.	ismail7@uic.edu		Seheult, Jansen/0000-0002-6850-7495			Baughman RP, 2007, SEMIN RESP CRIT CARE, V28, P475, DOI 10.1055/s-2007-991520; Bruynseels P, 2003, LANCET, V362, P1536, DOI 10.1016/S0140-6736(03)14740-X; Bursac Z, 2008, SOURCE CODE BIOL MED, V3, DOI 10.1186/1751-0473-3-17; BUSS DH, 1979, AM J MED, V66, P457, DOI 10.1016/0002-9343(79)91068-4; Byers RJ, 1996, EUR RESPIR J, V9, P2313, DOI 10.1183/09031936.96.09112313; Carroll KC, 2002, J CLIN MICROBIOL, V40, P3115, DOI 10.1128/JCM.40.9.3115-3120.2002; Costa C, 2012, CLIN MICROBIOL INFEC, V18, pE305, DOI 10.1111/j.1469-0691.2012.03882.x; Franquet T, 2011, RADIOLOGY, V260, P18, DOI 10.1148/radiol.11092149; Frobert E, 2013, J CLIN VIROL, V58, P265, DOI 10.1016/j.jcv.2013.04.019; HEROUT V, 1966, AM J CLIN PATHOL, V46, P411; Kabadayi S, 2017, BJA EDUC, V17, P48, DOI 10.1093/bjaed/mkw040; Karimi R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034232; Leland DS, 2007, CLIN MICROBIOL REV, V20, P49, DOI 10.1128/CMR.00002-06; Lepiller Q, 2015, J INFECTION, V71, P93, DOI 10.1016/j.jinf.2015.02.013; Linssen CFM, 2008, INTENS CARE MED, V34, P2202, DOI 10.1007/s00134-008-1231-4; MERCHANT RK, 1992, AM REV RESPIR DIS, V146, P448, DOI 10.1164/ajrccm/146.2.448; PUGIN J, 1991, AM REV RESPIR DIS, V143, P1121, DOI 10.1164/ajrccm/143.5_Pt_1.1121; RAMSEY PG, 1982, ANN INTERN MED, V97, P813, DOI 10.7326/0003-4819-97-6-813; SCHULLER D, 1994, CHEST, V106, pS3, DOI 10.1378/chest.106.1_Supplement.3S; Simoons-Smit AM, 2006, CLIN MICROBIOL INFEC, V12, P1050, DOI 10.1111/j.1469-0691.2006.01475.x; Stevenson HL, 2006, INFECT IMMUN, V74, P4856, DOI 10.1128/IAI.00246-06; TIMSIT JF, 1995, CHEST, V108, P1632, DOI 10.1378/chest.108.6.1632; Torres A, 2000, CHEST, V117, p198S, DOI 10.1378/chest.117.4_suppl_2.198S; Traen S, 2014, J CLIN VIROL, V60, P215, DOI 10.1016/j.jcv.2014.04.010; Wald A, 2007, HUMAN HERPESVIRUSES: BIOLOGY, THERAPY, AND IMMUNOPROPHYLAXIS, P656; Watson S, 2007, VIROL J, V4, DOI 10.1186/1743-422X-4-130; Witt Matthias N, 2009, BMC Pulm Med, V9, P22, DOI 10.1186/1471-2466-9-22; Xu FJ, 2006, JAMA-J AM MED ASSOC, V296, P964, DOI 10.1001/jama.296.8.964	28	0	0	0	0	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0002-9173	1943-7722		AM J CLIN PATHOL	Am. J. Clin. Pathol.	DEC	2018	150	6					522	532		10.1093/AJCP/AQY088			11	Pathology	Pathology	HI6KS	WOS:000456564300007	30212869				2019-10-28	
J	Vidarsdottir, H; Tran, L; Nodin, B; Jirstrom, K; Planck, M; Mattsson, JSM; Botling, J; Micke, P; Jonsson, P; Brunnstrom, H				Vidarsdottir, Halla; Tran, Lena; Nodin, Bjorn; Jirstrom, Karin; Planck, Maria; Mattsson, Johanna S. M.; Botling, Johan; Micke, Patrick; Jonsson, Per; Brunnstrom, Hans			Comparison of Three Different TTF-1 Clones in Resected Primary Lung Cancer and Epithelial Pulmonary Metastases	AMERICAN JOURNAL OF CLINICAL PATHOLOGY			English	Article						8G7G3/1; Immunohistochemistry; SP141; SPT24; Tissue microarray	TRANSCRIPTION FACTOR-I; MONOCLONAL-ANTIBODIES; EXPRESSION; ADENOCARCINOMA; NAPSIN; DIAGNOSTICS; CARCINOMA; FACTOR-1; IMMUNOHISTOCHEMISTRY; ENDOMETRIAL	Objectives: Immunohistochemical staining against thyroid transcription factor 1 (TTF-1) is often used to distinguish lung adenocarcinoma from squamous cell carcinoma and pulmonary metastasis. Methods: TTF-1 expression was examined using the antibody clones 8G7G3/1, SPT24, and SP141 on tissue microarrays from 665 cases of resected lung cancers and 428 pulmonary metastases. Results: Most lung adenocarcinomas, 89%, 93%, and 93%, were positive with TTF-1 clones 8G7G3/1, SPT24, and SP141, respectively. The corresponding figures for lung squamous cell carcinomas were 0%, 6%, and 8%. In total, five (2%), 19 (7%), and 21 (8%) of the pulmonary metastases from colorectal adenocarcinomas were positive with clones 8G7G3/1, SPT24, and SP141, respectively. Other TTF-1-positive pulmonary metastases (n = 8) were thyroid, urothelial, pancreatic, small bowel, and cervix carcinomas. Conclusions: TTF-1 expression in lung cancer and pulmonary metastases differs between clones, with 8G7G3/1 being more specific but less sensitive compared with SPT24 and SP141.	[Vidarsdottir, Halla] Helsingborg Hosp, Dept Surg, Helsingborg, Sweden; [Vidarsdottir, Halla; Nodin, Bjorn; Jirstrom, Karin; Planck, Maria; Brunnstrom, Hans] Lund Univ, Dept Clin Sci Lund, Div Oncol & Pathol, Lund, Sweden; [Jonsson, Per] Lund Univ, Div Thorac Surg, Lund, Sweden; [Tran, Lena; Jirstrom, Karin; Brunnstrom, Hans] Dept Genet & Pathol, Lab Med, Solvegatan 25, SE-22185 Lund, Sweden; [Planck, Maria] Skane Univ Hosp, Dept Oncol, Lund, Sweden; [Jonsson, Per] Skane Univ Hosp, Dept Thorac Surg, Lund, Sweden; [Mattsson, Johanna S. M.; Botling, Johan; Micke, Patrick] Uppsala Univ, Dept Immunol Genet & Pathol, Uppsala, Sweden	Brunnstrom, H (reprint author), Dept Genet & Pathol, Lab Med, Solvegatan 25, SE-22185 Lund, Sweden.	hans.brunnstrom@med.lu.se		Brunnstrom, Hans/0000-0001-7402-138X	Mrs Berta Kamprad Foundation; Regional Agreement on Medical Training and Clinical Research (ALF, Swedish government)	This study was supported by the Mrs Berta Kamprad Foundation (nonprofit organization) and the Regional Agreement on Medical Training and Clinical Research (ALF, Swedish government funding).	Alkushi A, 2003, VIRCHOWS ARCH, V442, P271, DOI 10.1007/s00428-002-0752-4; Bae JM, 2018, HISTOPATHOLOGY, V72, P423, DOI 10.1111/his.13398; Bejarano PA, 1996, MODERN PATHOL, V9, P445; Bishop JA, 2010, HUM PATHOL, V41, P20, DOI 10.1016/j.humpath.2009.06.014; Brunnstrom H, 2013, AM J CLIN PATHOL, V140, P37, DOI 10.1309/AJCP50RDXSCSBTBO; Choi SM, 2016, APPL IMMUNOHISTO M M, V24, P603, DOI 10.1097/PAI.0000000000000244; Comperat E, 2005, MODERN PATHOL, V18, P1371, DOI 10.1038/modpathol.3800422; Ericson-Lindquist K, 2017, DIAGN PATHOL, V12, DOI 10.1186/s13000-017-0621-8; Fujiwara S, 2010, HUM PATHOL, V41, P560, DOI 10.1016/j.humpath.2009.09.010; Galloway M, 2007, VIRCHOWS ARCH, V451, P109, DOI 10.1007/s00428-007-0432-5; Graham AD, 2006, HISTOPATHOLOGY, V48, P764, DOI 10.1111/j.1365-2559.2006.02365.x; Gremel G, 2014, HISTOPATHOLOGY, V64, P293, DOI 10.1111/his.12255; Kadota K, 2015, AM J SURG PATHOL, V39, P1170, DOI 10.1097/PAS.0000000000000439; Kristensen MH, 2011, APPL IMMUNOHISTO M M, V19, P437, DOI 10.1097/PAI.0b013e31820e6baf; Lim TKH, 2007, J CLIN PATHOL, V60, P941, DOI 10.1136/jcp.2007.047829; Manjer J, 2001, EUR J CANCER PREV, V10, P489, DOI 10.1097/00008469-200112000-00003; Manjer J, 2002, SCAND J PUBLIC HEALT, V30, P103, DOI 10.1080/14034940210133771; Matoso A, 2010, APPL IMMUNOHISTO M M, V18, P142, DOI 10.1097/PAI.0b013e3181bdf4e7; Micke P, 2016, J THORAC ONCOL, V11, P862, DOI 10.1016/j.jtho.2016.01.020; Ordonez NG, 2012, APPL IMMUNOHISTO M M, V20, P429, DOI 10.1097/PAI.0b013e31825439bc; Penman D, 2006, J CLIN PATHOL, V59, P663, DOI 10.1136/jcp.2005.030064; Robens J, 2010, AM J SURG PATHOL, V34, P1881, DOI 10.1097/PAS.0b013e3181f884e8; Sakurai A, 2011, HISTOPATHOLOGY, V59, P145, DOI 10.1111/j.1365-2559.2011.03869.x; Siami K, 2007, AM J SURG PATHOL, V31, P1759, DOI 10.1097/PAS.0b013e3181131e21; Surrey LF, 2014, AM J SURG PATHOL, V38, P224, DOI 10.1097/PAS.0000000000000138; Tran L, 2016, APPL IMMUNOHISTO M M, V24, P648, DOI 10.1097/PAI.0000000000000235; Travis WD, 2015, WHO CLASSIFICATION T; Turner BM, 2012, ARCH PATHOL LAB MED, V136, P163, DOI 10.5858/arpa.2011-0320-OA; Xu B, 2010, APPL IMMUNOHISTO M M, V18, P244, DOI 10.1097/PAI.0b013e3181c29407; Ye J, 2012, BIOTECH HISTOCHEM, V87, P30, DOI 10.3109/10520295.2011.591838; Zamecnik J, 2004, J CLIN PATHOL, V57, P1111, DOI 10.1136/jcp.2004.017467; Zhang PJ, 2009, INT J GYNECOL PATHOL, V28, P10, DOI 10.1097/PGP.0b013e3181804bc6	32	5	5	0	0	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0002-9173	1943-7722		AM J CLIN PATHOL	Am. J. Clin. Pathol.	DEC	2018	150	6					533	544		10.1093/AJCP/AQY083			12	Pathology	Pathology	HI6KS	WOS:000456564300008	30169783				2019-10-28	
J	Klee, GG; Ichihara, K; Ozarda, Y; Baumann, NA; Straseski, J; Bryant, SC; Wood-Wentz, CM				Klee, George G.; Ichihara, Kiyoshi; Ozarda, Yesim; Baumann, Nikola A.; Straseski, Joely; Bryant, Sandra C.; Wood-Wentz, Christina M.			Reference Intervals Comparison of Calculation Methods and Evaluation of Procedures for Merging Reference Measurements From Two US Medical Centers	AMERICAN JOURNAL OF CLINICAL PATHOLOGY			English	Article						Reference values; Normal values; Merging reference data; Method comparison; Serum panel; Parametric method; Nonparametric method; Box-Cox power transformation; Latent abnormal values exclusion (LAVE)	GLOBAL MULTICENTER; WORLDWIDE MULTICENTER; DERIVATION; PANEL	Objectives: To analyze consistency of reference limits and widths of reference intervals (RIs) calculated by six procedures and evaluate a protocol for merging intrainstitutional reference data. Methods: The differences between reference limits were compared with "optimal" bias goals. Also, widths of the RIs were compared. RIs were calculated using Mayo-SAS quantile, EP Evaluator, and four International Federation of Clinical Chemistry and Laboratory Medicine methods: parametric and nonparametric (NP) with and without latent abnormal values exclusion (LAVE). Regression parameters from cotested samples were evaluated for harmonizing intrainstitutional reference data. Results: Mayo-SAS quintile, LAVE(-) NP, and EP Evaluator generated similar RIs, but these RIs often were wider than RIs from parametric procedures. LAVE procedures generated narrower RIs for nutritional and inflammatory markers. Transformation with regression parameters did not ensure homogeneity of merged data. Conclusions: Parametric methods are recommended when inappropriate values cannot be excluded. The nonparametric procedures may generate wider RIs. Data sets larger than 200 are recommended for robust estimates. Caution should be exercised when merging intrainstitutional data.	[Klee, George G.; Baumann, Nikola A.] Mayo Clin, Dept Lab Med & Pathol, Rochester, MN USA; [Bryant, Sandra C.; Wood-Wentz, Christina M.] Mayo Clin, Div Biomed Stat & Informat, Rochester, MN USA; [Ichihara, Kiyoshi] Yamaguchi Univ, Grad Sch Med, Ube, Yamaguchi, Japan; [Ozarda, Yesim] Uludag Univ, Bursa, Turkey; [Straseski, Joely] Univ Utah, Dept Pathol, Salt Lake City, UT USA	Klee, GG (reprint author), Mayo Fdn, 200 First St SW, Rochester, MN 55905 USA.	klee.george@mayo.edu					Budd JR, 2013, MEASUREMENT PROCEDUR, V30; Chen LC, INTRO QUANTILE REGRE; Data Innovations, EP EV QUAL ASS SIMPL; Essermeant L., NORMAL RANGES DETERM; Horowitz GL, 2010, EP28A3C CLSI, P28; Ichihara K, 2017, CLIN CHIM ACTA, V467, P70, DOI 10.1016/j.cca.2016.09.016; Ichihara K, 2017, CLIN CHIM ACTA, V467, P83, DOI 10.1016/j.cca.2016.09.015; Ichihara K, 2014, CLIN CHIM ACTA, V432, P108, DOI 10.1016/j.cca.2014.01.025; Ichihara K, 2013, CLIN CHEM LAB MED, V51, P1443, DOI 10.1515/cclm-2012-0422; Ichihara K, 2013, CLIN CHEM LAB MED, V51, P1007, DOI 10.1515/cclm-2013-0248; Ichihara K, 2010, CLIN CHEM LAB MED, V48, P1537, DOI 10.1515/CCLM.2010.319; Koenker R, 2001, J ECON PERSPECT, V15, P143, DOI 10.1257/jep.15.4.143; Ozarda Y, 2017, BIOCHEM MEDICA, V27, P350, DOI 10.11613/BM.2017.038; Ozarda Y, 2013, CLIN CHEM LAB MED, V51, P1027, DOI 10.1515/cclm-2013-0249; Ricos C, OPTIMAL BIOL VAR DAT; Ricos C, DESIRABLE SPECIFICAT	16	0	0	0	0	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0002-9173	1943-7722		AM J CLIN PATHOL	Am. J. Clin. Pathol.	DEC	2018	150	6					545	554		10.1093/AJCP/AQY082			10	Pathology	Pathology	HI6KS	WOS:000456564300009	30169553				2019-10-28	
J	Rosenbaum, MW; Baron, JM				Rosenbaum, Matthew W.; Baron, Jason M.			Using Machine Learning-Based Multianalyte Delta Checks to Detect Wrong Blood in Tube Errors	AMERICAN JOURNAL OF CLINICAL PATHOLOGY			English	Article						Delta check; WBIT; Wrong blood in tube; Preanalytic error; Machine learning; Patient safety	PERFORMANCE; OUTCOMES	Objectives: An unfortunate reality of laboratory medicine is that blood specimens collected from one patient occasionally get mislabeled with identifiers from a different patient, resulting in so-called "wrong blood in tube" (WBIT) errors and potential patient harm. Here, we sought to develop a machine learning-based, multianalyte delta check algorithm to detect WBIT errors and mitigate patient harm. Methods: We simulated WBIT errors within sets of routine inpatient chemistry test results to develop, train, and evaluate five machine learning-based WBIT detection algorithms. Results: The best-performing WBIT detection algorithm we developed was based on a support vector machine and incorporated changes in test results between consecutive collections across 11 analytes. This algorithm achieved an area under the curve of 0.97 and considerably outperformed traditional single-analyte delta checks. Conclusions: Machine learning-based multianalyte delta checks may offer a practical strategy to identify WBIT errors prior to test reporting and improve patient safety.	[Rosenbaum, Matthew W.; Baron, Jason M.] Harvard Med Sch, Massachusetts Gen Hosp, Dept Pathol, Boston, MA USA	Baron, JM (reprint author), Massachusetts Gen Hosp, Gray 554,55 Fruit St, Boston, MA 02114 USA.	jmbaron@partners.org					[Anonymous], 2012, 2012 AUD BLOOD SAMPL; Baron JM, 2015, AM J CLIN PATHOL, V143, P42, DOI 10.1309/AJCP05XBCQPHTLGQ; Baron JM, 2014, CLIN CHIM ACTA, V427, P196, DOI 10.1016/j.cca.2013.09.027; Bastanlar Y, 2014, METHODS MOL BIOL, V1107, P105, DOI 10.1007/978-1-62703-748-8_7; Bolton-Maggs PHB, 2015, BRIT J HAEMATOL, V168, P3, DOI 10.1111/bjh.13137; Carli D, 2018, JMIR MED INF, V6, DOI 10.2196/medinform.7170; Dickerson JA, 2014, ARCH PATHOL LAB MED, V138, P110, DOI 10.5858/arpa.2012-0726-OA; Dzik WH, 2003, VOX SANG, V85, P40, DOI 10.1046/j.1423-0410.2003.00313.x; HOUWEN B, 1989, LAB MED, V20, P410, DOI 10.1093/labmed/20.6.410; IIZUKA Y, 1982, CLIN CHEM, V28, P2244; Laposata M, 2007, CLIN CHEM LAB MED, V45, P712, DOI 10.1515/CCLM.2007.173; Lewandrowski K, 2014, CLIN CHIM ACTA, V427, P107, DOI 10.1016/j.cca.2013.11.011; Makary MA, 2016, BMJ-BRIT MED J, V353, DOI 10.1136/bmj.i2139; Meyer D, 2015, MISC FUNCTIONS DEP S; National Center for Health Statistics, 2017, HLTH US 2016 CHARTB; NOSANCHUK JS, 1974, AM J CLIN PATHOL, V62, P707; Ovens Katie, 2012, J Pathol Inform, V3, P5, DOI 10.4103/2153-3539.93402; Park SH, 2012, ANN LAB MED, V32, P345, DOI 10.3343/alm.2012.32.5.345; R Core Team, 2013, R LANG ENV STAT COMP; Rheem I, 1998, ST HEAL T, V52, P859; Schifman RB, 2017, ARCH PATHOL LAB MED, V141, P813, DOI 10.5858/arpa.2016-0161-CP; Strathmann FG, 2011, CLIN CHIM ACTA, V412, P1973, DOI 10.1016/j.cca.2011.07.007; The Joint Commission, 2015, NAT PAT SAF GOALS EF; Topaz M, 2016, J AM MED INFORM ASSN, V23, P601, DOI 10.1093/jamia/ocv143	24	2	2	4	4	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0002-9173	1943-7722		AM J CLIN PATHOL	Am. J. Clin. Pathol.	DEC	2018	150	6					555	566		10.1093/AJCP/AQY085			12	Pathology	Pathology	HI6KS	WOS:000456564300010	30169595				2019-10-28	
J	Foschini, MP; Eusebi, V				Foschini, Maria P.; Eusebi, Vincenzo			Microglandular adenosis of the breast: a deceptive and still mysterious benign lesion	HUMAN PATHOLOGY			English	Article						Microglandular adenosis; Breast; Nasal cavity; Acinic cell carcinoma; Tibular carcinoma; Microglandular amartoma	MOLECULAR EVIDENCE; CARCINOMA; ADENOMYOEPITHELIOMA; TRANSITION	Microglandular adenosis (MA) of the breast, a benign glandular proliferation, was originally described approximately 35 years ago. The lesion is constituted by small glands, all of the same size. Glands are lined by one layer of cuboidal epithelial cells encircled by basal lamina without any evidence of inter-posed myoepithelial elements. Cells are positive for low-weight keratins and S-100 protein and negative for estrogen receptor, progesterone receptor, and HER-2. Since then, in the years that followed, several malignant lesions all showing microglandular architecture have been regarded either as a precursor or as an equivalent manifestation of MA. The latter has been associated with a large number of malignancies that include ductal carcinoma in situ, lobular carcinoma in situ, ademyoepithelioma, high-grade basal-like carcinoma, adenoid cystic carcinoma, matrix-producing carcinoma, invasive duct carcinoma not otherwise specified, and spindle cell carcinoma, not to mention acinic cell carcinoma. None of the above tumors were identical to MA. Differences mainly rested not only on the specific structure of the small glands but also on the cytological composition and immunohistochemical features of different lesions. Here, a review of the features of MA together with the differential diagnosis with lesions showing microglandular structure is discussed. MA shows similarities to a lesion named microglandular hamartoma/adenosis of the nasal cavity. The relation of the 2 similar lesions is discussed. (C) 2018 Elsevier Inc. All rights reserved.	[Foschini, Maria P.; Eusebi, Vincenzo] Univ Bologna, Sect Anat Pathol, Bellaria Hosp, Dept Biomed & Neuromotor Sci, I-40139 Bologna, Italy	Foschini, MP (reprint author), Bellaria Hosp, Anat Pathol, Via Altura 3, I-40139 Bologna, Italy.	mariapia.foschini@unibo.it	Foschini, Maria P./A-6306-2016	Foschini, Maria P./0000-0001-7079-7260			Ambrosini-Spaltro A, 2010, VIRCHOWS ARCH, V457, P727, DOI 10.1007/s00428-010-0984-7; BAILLIE EE, 1974, ORAL SURG ORAL MED O, V38, P760, DOI 10.1016/0030-4220(74)90397-1; Chuang SS, 2000, HISTOPATHOLOGY, V36, P376; CLEMENT PB, 1983, HISTOPATHOLOGY, V7, P169, DOI 10.1111/j.1365-2559.1983.tb02233.x; Damiani S, 2000, VIRCHOWS ARCH, V437, P74, DOI 10.1007/s004280000206; DIAZ NM, 1991, ARCH PATHOL LAB MED, V115, P578; EUSEBI V, 1979, HISTOPATHOLOGY, V3, P407, DOI 10.1111/j.1365-2559.1979.tb03022.x; EUSEBI V, 1987, HISTOPATHOLOGY, V11, P305, DOI 10.1111/j.1365-2559.1987.tb02635.x; EUSEBI V, 1993, AM J SURG PATHOL, V17, P99, DOI 10.1097/00000478-199302000-00001; Geyer FC, 2017, MODERN PATHOL, V30, P69, DOI 10.1038/modpathol.2016.161; Geyer FC, 2012, HISTOPATHOLOGY, V60, pE115, DOI 10.1111/j.1365-2559.2012.04207.x; Geyer FC, 2009, HISTOPATHOLOGY, V55, P732, DOI 10.1111/j.1365-2559.2009.03432.x; Geza A, 2003, AM J SURG PATHOL, V27, P1052, DOI 10.1097/00000478-200308000-00002; Guerini-Rocco E, 2016, J PATHOL, V238, P677, DOI 10.1002/path.4691; JAMES BA, 1993, AM J CLIN PATHOL, V100, P507, DOI 10.1093/ajcp/100.5.507; Khalifeh IM, 2008, AM J SURG PATHOL, V32, P544, DOI 10.1097/PAS.0b013e31815a87e2; KIAER H, 1984, VIRCHOWS ARCH A, V405, P55, DOI 10.1007/BF00694925; Koenig C, 2000, INT J SURG PATHOL, V8, P303, DOI 10.1177/106689690000800409; Martincorena I, 2015, SCIENCE, V349, P1483, DOI 10.1126/science.aab4082; McDivitt RW, 1976, TUMORS BREAST ATLAS; Millis RR, 1995, ADV ANAT PATHOL, V2, P10; Roncaroli F, 1996, VIRCHOWS ARCH, V429, P69; ROSEN PP, 1983, AM J SURG PATHOL, V7, P137, DOI 10.1097/00000478-198303000-00003; ROSENBLUM MK, 1986, AM J SURG PATHOL, V10, P237, DOI 10.1097/00000478-198604000-00002; Shin SJ, 2009, AM J SURG PATHOL, V33, P496, DOI 10.1097/PAS.0b013e31818af361; TAVASSOLI FA, 1983, AM J SURG PATHOL, V7, P731, DOI 10.1097/00000478-198307080-00002; TAVASSOLI FA, 1993, MODERN PATHOL, V6, P318	27	1	1	1	4	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	DEC	2018	82						1	9		10.1016/j.humpath.2018.06.025			9	Pathology	Pathology	HG4TV	WOS:000454968800001	29949742				2019-10-28	
J	Weinstein, RS				Weinstein, Ronald S.			On being a pathologist: a pathway to pathology practice; the added value of supplemental vocational training and mentoring in college and medical school	HUMAN PATHOLOGY			English	Article						Pathology; Careers; Medical education; Vocational training; Interdisciplinary education; STEM; Entrepreneurship	TELEMEDICINE; TELEPATHOLOGY; HEALTH; NEXUS	Traditionally, vocational training and liberal arts (and premedical) curricula have been separate education tracks. This personal profile describes a program that evolved from the partial fusion of vocational training and a premedical education track. My personal health issue, visual impairment, which presumably resulted as a complication of congenital toxoplasmosis, hampered my ability to read in grammar school and necessitated my placement in remedial reading classes until eighth grade. My father created an independent home-based vocational training program that ran in parallel to my traditional school education all the way through college. In this case study, I provide an overview of this hybrid education program, which we refer to as the Vocational Training/Medical College Curriculum of the Future (VTMC). This term implies that the education of a student from K-12 school through medical college is a continuum. I find it useful to conceptualize a single education continuum beginning with vocational training and ending with medical education, with a large overlap area in the middle. In this paper, 1 describe a set of my work experiences that leveraged and reinforced my didactic education experiences. Mentors who supported aspects of the VTMC program have included a college president, a US Congressman, a Nobel Laureate, and a Massachusetts General Hospital leader in academic pathology. Elements of this innovative VTMC program have been used in K-12 public schools and in nonmedical graduate school programs. (C) 2018 Published by Elsevier Inc.	[Weinstein, Ronald S.] Univ Arizona, Coll Med, Dept Pathol, Tucson, AZ 85724 USA	Weinstein, RS (reprint author), Univ Arizona, Coll Med, Dept Pathol, Tucson, AZ 85724 USA.	rweinstcin@telemedicine.arizona.cdu					Bashshur RL, 2014, TELEMED E-HEALTH, V20, P769, DOI 10.1089/tmj.2014.9981; Blendon RJ, 2002, NEW ENGL J MED, V347, P1933, DOI 10.1056/NEJMsa022151; BRANTON D, 1975, SCIENCE, V190, P54, DOI 10.1126/science.1166299; Briehl MM, 2016, ACAD PATHOL, V3, DOI 10.1177/2374289516680217; BRYANT DC, 1962, BIOL BULL, V123, P479; BULLIVANT S, 1966, J CELL BIOL, V29, P435, DOI 10.1083/jcb.29.3.435; Cross W, 1964, STRATTON STORY POLIT; Flegr J, 2014, MOL ECOL, V23, P5934, DOI 10.1111/mec.13006; HILL RB, 1984, HUM PATHOL, V15, P602, DOI 10.1016/S0046-8177(84)80282-8; INGELFINGER FJ, 1974, NEW ENGL J MED, V291, P250, DOI 10.1056/NEJM197408012910510; Johnson SK, 2018, P ROY SOC B-BIOL SCI, V285, DOI 10.1098/rspb.2018.0822; Kasha M, 1977, SEARCH DISCOVERY TRI, P339; Krupinski EA, 2013, TELEMED E-HEALTH, V19, P349, DOI 10.1089/tmj.2012.0285; Leaf A, 1976, BIOGRAPHICAL MEMOIRS, P2; Lopez AM, 2009, HUM PATHOL, V40, P1082, DOI 10.1016/j.humpath.2009.04.005; McNutt N S, 1970, Am J Cardiol, V25, P169, DOI 10.1016/0002-9149(70)90577-1; McNutt N S, 1973, Prog Biophys Mol Biol, V26, P45; MCNUTT NS, 1971, J CELL BIOL, V51, P805, DOI 10.1083/jcb.51.3.805; MCNUTT NS, 1969, SCIENCE, V165, P597, DOI 10.1126/science.165.3893.597; MCNUTT NS, 1970, J CELL BIOL, V47, P666, DOI 10.1083/jcb.47.3.666; Samojlowicz D, 2017, FORENSIC SCI INT, V280, P49, DOI 10.1016/j.forsciint.2017.09.009; Schmitt MH, 2013, AM J MED, V126, P284, DOI 10.1016/j.amjmed.2012.10.015; Scully R E, 1982, N Engl J Med, V307, P370, DOI 10.1056/NEJM198208053070610; STECK TL, 1970, SCIENCE, V168, P255, DOI 10.1126/science.168.3928.255; SZENTGYORGYI A, 1963, ANNU REV BIOCHEM, V32, P1, DOI 10.1146/annurev.bi.32.070163.000245; Weinstein JB, 2015, AM J MED, V128, P672, DOI 10.1016/j.amjmed.2015.01.041; Weinstein RS, 2007, IBM SYST J, V46, P69, DOI 10.1147/sj.461.0069; Weinstein R S, 1976, Adv Cancer Res, V23, P23, DOI 10.1016/S0065-230X(08)60543-6; Weinstein Ronald S, 2007, J Interprof Care, V21 Suppl 2, P51, DOI 10.1080/13561820701349321; Weinstein RS, 2017, ACAD PATHOL, V4, DOI 10.1177/2374289517718872; Weinstein RS, 2016, ACAD PATHOL, V3, DOI 10.1177/2374289516636132; Weinstein RS, 2015, AM J MED, V128, pE1, DOI 10.1016/j.amjmed.2015.05.045; Weinstein RS, 2014, HEALTH AFFAIR, V33, P1103, DOI 10.1377/hlthaff.2014.0396; Weinstein RS, 2014, AM J MED, V127, P183, DOI 10.1016/j.amjmed.2013.09.032; Weinstein Ronald S, 2010, J Allied Health, V39 Suppl 1, P238; Weinstein RS, 2009, HUM PATHOL, V40, P1057, DOI 10.1016/j.humpath.2009.04.006; Weinstein RS, 2004, HUM PATHOL, V35, P1303, DOI 10.1016/j.humpath.2004.09.002; WEINSTEIN RS, 1986, HUM PATHOL, V17, P433, DOI 10.1016/S0046-8177(86)80028-4; Weinstein RS, 2000, HUM PATHOL, V31, P1, DOI 10.1016/S0046-8177(00)80190-2; WEINSTEIN RS, 1969, NEW ENGL J MED, V281, P86, DOI 10.1056/NEJM196907102810206; WEINSTEIN RS, 1983, HUM PATHOL, V14, P6, DOI 10.1016/S0046-8177(83)80041-0; WEINSTEIN RS, 1972, NEW ENGL J MED, V286, P521, DOI 10.1056/NEJM197203092861006; Weinstein RS, 1990, HUM PATHOL, V21, P462; Weinstein RS, 1969, RED CELL MEMBRANE ST, P36; Weinstein RS, 1997, TELEMEDICINE THEORY, P179; Wikipedia, TELEPATHOLOGY	46	0	0	1	3	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	DEC	2018	82						10	19		10.1016/j.humpath.2018.08.035			10	Pathology	Pathology	HG4TV	WOS:000454968800002	30267777				2019-10-28	
J	Meiss, AE; Thomas, M; Modesitt, SC; Ring, KL; Atkins, KA; Mills, AM				Meiss, Alice E.; Thomas, Martha; Modesitt, Susan C.; Ring, Kari L.; Atkins, Kristen A.; Mills, Anne M.			Clinicopathologic characterization of breast carcinomas in patients with non-BRCA germline mutations: results from a single institution's high-risk population	HUMAN PATHOLOGY			English	Article; Proceedings Paper	107th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP)	MAR 17-23, 2018	Vancouver, CANADA	US & Canadian Acad Pathol		Breast carcinoma; Breast cancer; Germline mutations; Familial cancer; Non-BRCA mutations	CANCER-RISK; HISTOPATHOLOGICAL FEATURES; EARLY-ONSET; WOMEN; SUSCEPTIBILITY; SPECTRUM; CARRIERS; TUMORS; PALB2; PANEL	As multigene panel testing for hereditary cancer syndromes becomes commonplace, germline mutations in genes other than BRCA112 are increasingly identified in breast cancer patients. While histopathologic features of BRCA-mutated breast cancers have been well-characterized, less is known about non-BRCA-related hereditary cancers. We herein investigate the clinicopathologic characteristics of breast cancers in women with non-BRCA germline mutations. Out of 612 women who underwent germline testing, 16 (2.6%) women with 18 cancers had mutations in non-BRCA genes: ATM, CHEK2, PALB2, TP53, BMPRIA, BRIP1, MUTYH, and RADS. An additional 2 cancers were identified in a woman with a diagnosis of Bloom syndrome (BLM mutation) who was not germline tested. Average age at diagnosis was 50 (range: 27-77), and 65% had no personal cancer history. The majority (79%) of tumors were grade 1 to 2; 35% were either lobular or ductal with lobular features. Stromal responses varied from absent to desmoplastic to sclerotic; 69% of cases had an in situ component. With the exception of a brisk lymphocytic response in BLM- and TP53-mutated cancers, lymphocytic infiltration was mild or absent. In summary, the majority of non BRCA-related hereditary breast cancers represent the patient's sentinel malignancy. Lobular features were seen in a subset, and high-grade, immunogenic carcinomas were uncommon except in the setting ofBLM and TP53 mutations. Overall, these findings demonstrate a range of involved genes in non-BRCA mutation carriers with breast cancer and histopathologic heterogeneity in the associated cancers, arguing against use of histomorphology to infonn panel testing algorithms. (C) 2018 Elsevier Inc. All rights reserved.	[Meiss, Alice E.] Univ Virginia, Sch Med, Charlottesville, VA 22908 USA; [Thomas, Martha] Univ Virginia, Canc Ctr, Div Genet Counseling, Charlottesville, VA USA; [Modesitt, Susan C.; Ring, Kari L.] Univ Virginia, Dept Obstet & Gynecol, Charlottesville, VA USA; [Atkins, Kristen A.; Mills, Anne M.] Univ Virginia, Dept Pathol, Charlottesville, VA 22903 USA	Mills, AM (reprint author), Univ Virginia, Dept Pathol, Charlottesville, VA 22903 USA.	amm7r@virginia.edu					Antoniou AC, 2014, NEW ENGL J MED, V371, P497, DOI 10.1056/NEJMoa1400382; Aretz S, 2007, J MED GENET, V44, P702, DOI 10.1136/jmg.2007.052506; Arps DP, 2013, BREAST CANCER RES TR, V138, P719, DOI 10.1007/s10549-013-2493-2; Aytac E, 2015, BRIT J SURG, V102, P114, DOI 10.1002/bjs.9693; Balleine RL, 2006, HISTOPATHOLOGY, V49, P523, DOI 10.1111/j.1365-2559.2006.02538.x; Buys SS, 2017, CANCER-AM CANCER SOC, V123, P1721, DOI 10.1002/cncr.30498; CALLAHAN R, 1992, CANCER, V69, P1582, DOI 10.1002/1097-0142(19920315)69:6+<1582::AID-CNCR2820691313>3.0.CO;2-Y; Cobain EF, 2016, SEMIN ONCOL, V43, P528, DOI 10.1053/j.seminoncol.2016.10.001; Couch FJ, 2017, JAMA ONCOL, V3, P1190, DOI 10.1001/jamaoncol.2017.0424; Cunniff C, 2017, MOL SYNDROMOL, V8, P4, DOI 10.1159/000452082; Dossus L, 2015, BREAST CANCER RES, V17, DOI 10.1186/s13058-015-0546-7; Eerola H, 2005, BREAST CANCER RES, V7, pR465, DOI 10.1186/bcr1025; Eerola H, 2005, BREAST CANCER RES, V7, pR93, DOI 10.1186/bcr953; Huszno J, 2016, ONCOLOGY-BASEL, V90, P193, DOI 10.1159/000444326; Keeney MG, 2017, PATHOLOGY, V49, P363, DOI 10.1016/j.pathol.2017.03.002; Kleibl Z, 2016, BREAST, V28, P136, DOI 10.1016/j.breast.2016.05.006; Li CI, 2003, JAMA-J AM MED ASSOC, V289, P1421, DOI 10.1001/jama.289.11.1421; Malkin D, 2011, CANCER, V2, P475, DOI [10.1177/1947601911413466, DOI 10.1177/1947601911413466]; Masciari S, 2007, J MED GENET, V44, P726, DOI 10.1136/jmg.2007.051268; Masciari S, 2012, BREAST CANCER RES TR, V133, P1125, DOI 10.1007/s10549-012-1993-9; Nichols KE, 2001, CANCER EPIDEM BIOMAR, V10, P83; O'Shea AM, 2008, HISTOPATHOLOGY, V53, P184, DOI 10.1111/j.1365-2559.2008.03071.x; Palacios J, 2003, CLIN CANCER RES, V9, P3606; Plasilova ML, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000004614; Rahman N, 2007, NAT GENET, V39, P165, DOI 10.1038/ng1959; Rath MG, 2013, BREAST CANCER RES TR, V139, P193, DOI 10.1007/s10549-012-2375-z; Reeves GK, 2006, LANCET ONCOL, V7, P910, DOI 10.1016/S1470-2045(06)70911-1; Rennert G, 2012, CANCER-AM CANCER SOC, V118, P1989, DOI 10.1002/cncr.26506; Schmidt MK, 2016, J CLIN ONCOL, V34, P2750, DOI 10.1200/JCO.2016.66.5844; Schrader KA, 2011, J MED GENET, V48, P64, DOI 10.1136/jmg.2010.079814; Schrader KA, 2008, FAM CANCER, V7, P73, DOI 10.1007/s10689-007-9172-6; Southey MC, 2016, J MED GENET, V53, P800, DOI 10.1136/jmedgenet-2016-103839; Stefansson OA, 2011, EPIGENETICS-US, V6, P638, DOI 10.4161/epi.6.5.15667; Teo ZL, 2013, BRIT J CANCER, V109, P154, DOI 10.1038/bjc.2013.295; Tung N, 2015, CANCER-AM CANCER SOC, V121, P25, DOI 10.1002/cncr.29010; Vahteristo P, 2006, EUR J HUM GENET, V14, P167, DOI 10.1038/sj.ejhg.5201542; Wilson JRF, 2010, J MED GENET, V47, P771, DOI 10.1136/jmg.2010.078113; Win AK, 2016, INT J CANCER, V139, P1557, DOI 10.1002/ijc.30197	38	0	0	0	1	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	DEC	2018	82						20	31		10.1016/j.humpath.2018.06.024			12	Pathology	Pathology	HG4TV	WOS:000454968800003	29958926				2019-10-28	
J	Johnson, DN; Sadow, PM				Johnson, Daniel N.; Sadow, Peter M.			Exploration of BRAFV600E as a diagnostic adjuvant in the non-invasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP)	HUMAN PATHOLOGY			English	Article						Thyroid; Follicular; Non-invasive; Neoplasm; BRAF; HBME1; NIFTP	BRAF V600E MUTATION; IMMUNOHISTOCHEMICAL DETECTION; CARCINOMA; VARIANT; EXPRESSION; PROTEIN; PROFILE	The non-invasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP) and encapsulated follicular variant of papillary thyroid carcinoma (EFVPTC) are distinguished from classical papillary thyroid carcinoma with predominantly follicular architecture (CPTCPFA) by distinct histomorphologic and molecular features. CPTCPFA frequently harbor the oncogenic variant BRAFV600E while NIFTP and EFVPTC are largely RAS driven. CPTCPFA have rare papillae and intranuclear pseudoinclusions that may distinguish them from NIFTP or EFVPTC. We evaluated for BRAFV600E mutation using mutation-specific BRAF (VE1) antibody immunohistochemistry (BRAFVE) as part of an immunomorphologic tumor panel, often including HBME1, for follicular-patterned lesions with nuclear atypia. An archival search identified cases of NIFTP, CPTCPFA, or EFVPTC between 2015-2017, and demographic data, tumor characteristics, molecular data, and metastases were documented. Our search yielded 275 tumors across categories, and 208 were tested with BRAFVE. Sixty-one NIFTP and 31 sub-centimeter NIFTP were tested, and none (0/92) were positive for BRAFVE. Nineteen CPTCPFA and 14 sub-centimeter CPTCPFA were tested with 18 of 33 (54.5%) BRAFVE positive. Sixty-one EFVPTC and 21 sub-centimeter EFVPTC were tested, with 12 of 81 (14.8%) positive. Mean follow-up time was 1.5 years. Six (4.6%) patients with concurrent classical papillary thyroid carcinoma had local lymph node metastases at time of NIFTP diagnosis, as did 15 of 111 (13.5%) EFVPTC. Six of 34 (14.7%) CPTCPFA had local nodal metastases with five being considered the primary lesion. One EFVPTC (0.9%), BRAFVE negative, metastasized to femur. The findings indicate that BRAFVE used in conjunction with routine sampling of follicular-patterned tumors is a useful diagnostic adjuvant. (C) 2018 Elsevier Inc. All rights reserved.	[Johnson, Daniel N.; Sadow, Peter M.] Massachusetts Gen Hosp, Pathol Serv, WRN219,55 Fruit St, Boston, MA 02114 USA; [Johnson, Daniel N.; Sadow, Peter M.] Harvard Med Sch, Dept Pathol, Boston, MA 02115 USA; [Sadow, Peter M.] Massachusetts Eye & Ear, Dept Otolaryngol, Boston, MA 02114 USA	Sadow, PM (reprint author), Massachusetts Gen Hosp, Pathol Serv, WRN219,55 Fruit St, Boston, MA 02114 USA.	psadow@mgh.harvard.edu					Afkhami M, 2016, THYROID, V26, P242, DOI 10.1089/thy.2015.0227; Agrawal N, 2014, CELL, V159, P676, DOI 10.1016/j.cell.2014.09.050; Baloch Z, 2018, ENDOCR PATHOL, V29, P91, DOI 10.1007/s12022-018-9532-9; Capper D, 2011, ACTA NEUROPATHOL, V122, P11, DOI 10.1007/s00401-011-0841-z; Cho U, 2017, MODERN PATHOL, V30, P810, DOI 10.1038/modpathol.2017.9; Cracolici V, 2018, HEAD NECK PATHOL, V12, P522, DOI 10.1007/s12105-018-0905-7; Daniels GH, 2011, ENDOCR PRACT, V17, P768, DOI 10.4158/EP10407.RA; Dankner M, 2018, ONCOGENE, V37, P3183, DOI 10.1038/s41388-018-0171-x; Diniz MG, 2017, ORAL ONCOL, V72, P165, DOI 10.1016/j.oraloncology.2017.07.021; Feller JK, 2013, MODERN PATHOL, V26, P414, DOI 10.1038/modpathol.2012.168; Glomski K, 2017, ENDOCR PATHOL, V28, P177, DOI 10.1007/s12022-017-9483-6; Gucer H, 2016, ENDOCR PATHOL, V27, P224, DOI 10.1007/s12022-016-9433-8; Howitt BE, 2013, THYROID, V23, P1256, DOI 10.1089/thy.2013.0018; Hung YP, 2018, HISTOPATHOLOGY, V72, P53, DOI 10.1111/his.13363; Ilie MI, 2014, THYROID, V24, P858, DOI 10.1089/thy.2013.0302; Johnson DN, 2018, ARCH PATHOL LAB MED, V142, P838, DOI 10.5858/arpa.2017-0118-OA; Koperek O, 2012, AM J SURG PATHOL, V36, P844, DOI 10.1097/PAS.0b013e318246b527; Lloyd RV, 2017, WHO CLASSIFICATION T; Nikiforov YE, 2018, JAMA ONCOL, V4, P1125, DOI 10.1001/jamaoncol.2018.1446; Nikiforov YE, 2016, JAMA ONCOL, V2, P1023, DOI 10.1001/jamaoncol.2016.0386; Pearlstein MV, 2014, J CUTAN PATHOL, V41, P724, DOI 10.1111/cup.12364; Rivera M, 2009, THYROID, V19, P119, DOI 10.1089/thy.2008.0303; Routhier CA, 2013, HUM PATHOL, V44, P2563, DOI 10.1016/j.humpath.2013.06.018; Schulten HJ, 2013, ANTICANCER RES, V33, P4779; Seethala RR, 2018, MODERN PATHOL, V31, P39, DOI 10.1038/modpathol.2017.130; Seethala RR, 2016, NON TRADITIONAL REF; Tallini G, 2017, J CLIN ENDOCR METAB, V102, P15, DOI 10.1210/jc.2016-2976; Tiacci E, 2017, J CLIN ONCOL, V35, P1002, DOI 10.1200/JCO.2016.71.1556; Torregrossa L, 2016, J CLIN ENDOCR METAB, V101, P4413, DOI 10.1210/jc.2016-1775; Wilmott JS, 2013, BRIT J CANCER, V108, P924, DOI 10.1038/bjc.2013.29; Xu B, 2018, ENDOCRINE, V59, P143, DOI 10.1007/s12020-017-1484-1; Xu B, 2015, ENDOCR PATHOL, V26, P191, DOI 10.1007/s12022-015-9376-5; Zhu ZW, 2003, AM J CLIN PATHOL, V120, P71, DOI 10.1309/ND8D9LAJTRCTG6QD	33	4	4	0	2	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	DEC	2018	82						32	38		10.1016/j.humpath.2018.06.033			7	Pathology	Pathology	HG4TV	WOS:000454968800004	30146440				2019-10-28	
J	Devereaux, KA; Charu, V; Zhao, SC; Charville, GW; Bangs, CD; van de Rijn, M; Cherry, AM; Natkunam, Y				Devereaux, Kelly A.; Charu, Vivek; Zhao, Shuchun; Charville, Gregory W.; Bangs, Charles D.; van de Rijn, Matt; Cherry, Athena M.; Natkunam, Yasodha			Immune checkpoint blockade as a potential therapeutic strategy for undifferentiated malignancies	HUMAN PATHOLOGY			English	Article						Undifferentiated malignancy; Undifferentiated carcinoma; PD-L1; Checkpoint inhibitors; Immune checkpoint; 9p24.1 alterations	LIGAND 1 PD-L1; GENE AMPLIFICATION; EXPRESSION; CANCER; NIVOLUMAB; PEMBROLIZUMAB; HETEROGENEITY; CARCINOMAS; DOCETAXEL; ANTIBODY	Undifferentiated malignancies (UMs) encompass a diverse set of aggressive tumors that pose not only a diagnostic challenge but also a challenge for clinical management. Most tumors in this category are currently treated empirically with nonspecific chemotherapeutic agents that yield extremely poor clinical response. Given that UMs are inherently genetically unstable neoplasms with the potential for immune dysregulation and increased neoantigen production, they are likely to be particularly amenable to immune checkpoint inhibitors, which target programmed cell death protein 1 (PD-1) or its ligands, PD-L1 and PD-L2, to promote T-cell antitumor activity. Aberrant expression of PD-L1 and, more recently, chromosomal 9p24.1/CD274(PD-L1)/PDCD1LG2(PD-L2) alterations can be used as biomarkers to predict responsiveness to checkpoint inhibitors. Here we evaluated 93 cases previously diagnosed as an "undifferentiated" malignancy and found that 56% (52/93) of UMs moderately to strongly express PD-L1 by immunohistochemistry (IHC). Concurrent CD274(PD-L1) and PDCD I LG2(PD-L2) fluorescence in situ hybridization (FISH) was performed on 24 of these cases and demonstrates a genetic gain at both loci in 62.5% of UMs. Genetic alterations at the CD274(PD-L1) and PDCD1LG2(PD-L2) loci were found to be completely concordant by FISH. Overall, we found that a significant proportion of UMs express PD-L1 and provide molecular support for using checkpoint inhibitors as a treatment approach for this class of tumors. (C) 2018 Elsevier Inc. All rights reserved.	[Devereaux, Kelly A.; Charu, Vivek; Zhao, Shuchun; Charville, Gregory W.; Bangs, Charles D.; van de Rijn, Matt; Cherry, Athena M.; Natkunam, Yasodha] Stanford Univ, Sch Med, Dept Pathol, L235,300 Pasteur Dr, Stanford, CA 94305 USA	Natkunam, Y (reprint author), Stanford Univ, Sch Med, Dept Pathol, L235,300 Pasteur Dr, Stanford, CA 94305 USA.	yaso@stanford.edu			Department of Pathology Trainee Mentored Award at Stanford University School of Medicine	This study was supported by the Department of Pathology Trainee Mentored Award at Stanford University School of Medicine.	Ansell SM, 2015, NEW ENGL J MED, V372, P311, DOI 10.1056/NEJMoa1411087; Barrett MT, 2015, ONCOTARGET, V6, P26483, DOI 10.18632/oncotarget.4494; Borghaei H, 2015, NEW ENGL J MED, V373, P1627, DOI 10.1056/NEJMoa1507643; Brahmer J, 2015, NEW ENGL J MED, V373, P123, DOI 10.1056/NEJMoa1504627; Budczies J, 2017, ONCOIMMUNOLOGY, V6, DOI 10.1080/2162402X.2017.1279777; Budczies J, 2016, GENE CHROMOSOME CANC, V55, P626, DOI 10.1002/gcc.22365; Chen MX, 2017, MODERN PATHOL, V30, P1516, DOI 10.1038/modpathol.2017.86; Garon EB, 2015, NEW ENGL J MED, V372, P2018, DOI 10.1056/NEJMoa1501824; Gatalica Z, 2014, ONCOTARGET, V5, P12440, DOI 10.18632/oncotarget.2574; Groschel S, 2016, CSH MOL CASE STUD, V2, DOI 10.1101/mcs.a001180; Herbst RS, 2014, NATURE, V515, P563, DOI 10.1038/nature14011; Howitt BE, 2016, JAMA ONCOL, V2, P518, DOI 10.1001/jamaoncol.2015.6326; Ilie M, 2016, ANN ONCOL, V27, P147, DOI 10.1093/annonc/mdv489; Inoue Y, 2016, ONCOTARGET, V7, P32113, DOI 10.18632/oncotarget.8528; Keung EZ, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2017.1385689; Kitazono S, 2015, CLIN LUNG CANCER, V16, P385, DOI 10.1016/j.cllc.2015.03.008; Kostine M, 2016, MODERN PATHOL, V29, P1028, DOI 10.1038/modpathol.2016.108; Le DT, 2015, NEW ENGL J MED, V372, P2509, DOI 10.1056/NEJMoa1500596; Lehrke HD, 2017, AM J CLIN PATHOL, V148, P441, DOI [10.1093/ajcp/aqx092, 10.1093/AJCP/AQX092]; Lin ZY, 2016, ONCOTARGET, V7, P15033, DOI 10.18632/oncotarget.7590; Marinelli RJ, 2008, NUCLEIC ACIDS RES, V36, pD871, DOI 10.1093/nar/gkm861; McLaughlin J, 2016, JAMA ONCOL, V2, P46, DOI 10.1001/jamaoncol.2015.3638; Rehman JA, 2017, MODERN PATHOL, V30, P340, DOI 10.1038/modpathol.2016.186; Rimm DL, 2017, JAMA ONCOL, V3, P1051, DOI 10.1001/jamaoncol.2017.0013; Rizvi NA, 2015, SCIENCE, V348, P124, DOI 10.1126/science.aaa1348; Roemer MGM, 2016, J CLIN ONCOL, V34, P2690, DOI 10.1200/JCO.2016.66.4482; Ross JS, 2015, JAMA ONCOL, V1, P40, DOI 10.1001/jamaoncol.2014.216; Saito R, 2017, MODERN PATHOL, V30, P427, DOI 10.1038/modpathol.2016.202; Straub M, 2016, ONCOTARGET, V7, P12024, DOI 10.18632/oncotarget.7593; Taube JM, 2014, CLIN CANCER RES, V20, P5064, DOI 10.1158/1078-0432.CCR-13-3271; Tawbi HA, 2017, LANCET ONCOL, V18, P1493, DOI 10.1016/S1470-2045(17)30624-1; Topalian SL, 2015, CANCER CELL, V27, P450, DOI 10.1016/j.ccell.2015.03.001; Topalian SL, 2012, NEW ENGL J MED, V366, P2443, DOI 10.1056/NEJMoa1200690; Tothill RW, 2013, J PATHOL, V231, P413, DOI 10.1002/path.4251; Varadhachary GR, 2014, NEW ENGL J MED, V371, P757, DOI 10.1056/NEJMra1303917	35	0	0	0	1	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	DEC	2018	82						39	45		10.1016/j.humpath.2018.06.034			7	Pathology	Pathology	HG4TV	WOS:000454968800005	30539796				2019-10-28	
J	Lu, ZC; Al-Obaidy, K; Cheng, L; Perry, KD; Grignon, DJ; Williamson, SR				Lu, Zhichun; Al-Obaidy, Khaleel; Cheng, Liang; Perry, Kyle D.; Grignon, David J.; Williamson, Sean R.			Immunohistochemical characteristics of renomedullary interstitial cell tumor: a study of 41 tumors with emphasis on differential diagnosis of mesenchymal neoplasms	HUMAN PATHOLOGY			English	Article						Renomedullary interstitial cell tumor; Kidney; Renal mesenchymal tumors; Medullary fibroma; Solitary fibrous tumor; Mixed epithelial and stromal tumor	FEATURES; FIBROMA	Renomedullary interstitial cell tumors (RMICTs) are almost always incidentally identified either at autopsy or upon resection of the kidney for other reasons. However, rare cases that are large, resulting in a clinical mass, have been reported. The immunohistochemical phenotype of usual, incidental RMICT using modem soft tissue tumor markers is largely unknown, however, providing little information to aid in classification of larger or atypical tumors. We retrieved 41 RMICTs from 36 patients and studied pathologic characteristics including morphology, immunohistochemistry (S100, keratin AE1/AE3, smooth muscle actin, desmin, estrogen and progesterone receptors, calponin, CD34, CD35), and histochemical staining. Data collected included age, sex, tumor size, laterality, and indication for kidney examination. RMICTs (n = 41) were identified in 23 men and 13 women, with a mean age of 57 years (range, 24-83 years); tumor sizes ranged from less than 1 to 13 mm (median, 4 mm). Kidneys were resected for 32 tumors, 1 chronic pyelonephritis, 1 trauma, and 2 autopsies. All (41; 100%) had entrapped renal tubules, 5 (12%) of which included cystic or dilated tubules. Most (35; 85%) had collagenous fibers, all of which were negative for Congo red. RMICT demonstrates a largely negative immunohistochemical phenotype with weak-to-moderate labeling for smooth muscle actin and calponin that is substantially less than myofibroblastic lesions. Positive staining for estrogen and progesterone receptors is common (61%), which could overlap with mixed epithelial and stromal tumor and other entities; however, staining is typically weak. CD34 is usually negative, with occasional weak labeling, in contrast to solitary fibrous tumor. (C) 2018 Elsevier Inc. All rights reserved.	[Lu, Zhichun; Perry, Kyle D.; Williamson, Sean R.] Henry Ford Hlth Syst, Dept Pathol & Lab Med, Detroit, MI 48202 USA; [Al-Obaidy, Khaleel; Cheng, Liang; Grignon, David J.] Indiana Univ Sch Med, Dept Pathol & Lab Med, Indianapolis, IN 46202 USA	Williamson, SR (reprint author), Henry Ford Hosp, Dept Pathol, K6,2799 West Grand Blvd, Detroit, MI 48202 USA.	swilli25@hths.org		Al-Obaidy, Khaleel/0000-0001-9890-8751			Bazzi WM, 2014, UROLOGY, V83, P1104, DOI 10.1016/j.urology.2014.01.008; Calio A, 2016, AM J SURG PATHOL, V40, P1693, DOI 10.1097/PAS.0000000000000739; Dall'era M, 2000, J UROLOGY, V164, P2018, DOI 10.1016/S0022-5347(05)66943-1; Faris G, 2009, ISR MED ASSOC J, V11, P509; Kuroda N, 2002, ONCOL REP, V9, P745; Kuroda N, 2014, INT J CLIN EXP PATHO, V7, P2737; LERMAN RJ, 1972, HUM PATHOL, V3, P559, DOI 10.1016/S0046-8177(72)80006-6; MAI KT, 1994, J UROLOGY, V151, P986, DOI 10.1016/S0022-5347(17)35143-1; Ohkawa M., 1993, International Urology and Nephrology, V25, P45, DOI 10.1007/BF02552253; Tickoo SK, 2008, MODERN PATHOL, V21, P60, DOI 10.1038/modpathol.3800958	10	0	0	0	0	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	DEC	2018	82						46	50		10.1016/j.humpath.2018.07.010			5	Pathology	Pathology	HG4TV	WOS:000454968800006	30031100				2019-10-28	
J	Gurung, A; Assis, DN; McCarty, TR; Mitchell, KA; Boyer, JL; Jain, D				Gurung, Ananta; Assis, David N.; McCarty, Thomas R.; Mitchell, Kisha A.; Boyer, James L.; Jain, Dhanpat			Histologic features of autoimmune hepatitis: a critical appraisal	HUMAN PATHOLOGY			English	Article						Autoimmune hepatitis; Histologic features; Kupffer cell hyaline globules (KcHG); Plasma-lymphocytic inflammation; Plasma cell clusters	HEPATOCELLULAR-CARCINOMA; SIMPLIFIED CRITERIA; DIAGNOSIS; CELLS	We speculate that the "typical" histologic features (lymphoplasmacytic interface hepatitis, emperipolesis, and hepatocyte rosettes) of autoimmune hepatitis (AIH) are related to severity of hepatitis rather than etiology. We critically appraised various histologic features of AIH and compared them with cases of chronic hepatitis with similar inflammatory grade and fibrosis stage. Fifty-one patients with clinically confirmed AIH were identified at our institution, of which 43 biopsies (from 42 patients) were taken before initiation of therapy and formed the study group. Hepatitis C biopsies with similar grade and stage served as controls. Kupffer cell hyaline globules (KcHGs; P =.03), prominence of plasma cells in portal tracts (P =.003), "plasma-lymphocytic" inflammation (defined as plasma cells > lymphocytes), or as clusters (defined as >= 5) within portal tracts (P =.002) or lobules (P =.001) were significantly associated with AIH. Rosettes and emperipolesis lacked significance when controlled for inflammatory grade (rosettes, P = 1; emperipolesis, P =.4), supporting our hypothesis. Based on our findings, we developed a modified scoring system in which typical features require the presence of both (1) prominent plasma cells (plasma cells comprise >= 20% of inflammatory cells or presence of plasma cell clusters) and (2) KcHG. "Compatible" features include prominent plasma cells but lack KcHG, and "atypical" features include the presence of another disease process. Although application of this scoring system in our patients decreased the sensitivity to 77% (from 100%), it increased the specificity to 67% (from 0%). Further studies with different control groups are needed to validate these findings. (C) 2018 Elsevier Inc. All rights reserved.	[Gurung, Ananta; Mitchell, Kisha A.; Jain, Dhanpat] Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06520 USA; [Gurung, Ananta] Royal Columbian Hosp, Dept Pathol, 330 E Columbia St, New Westminster, BC V3L 3W7, Canada; [Assis, David N.; McCarty, Thomas R.; Boyer, James L.] Yale Univ, Sch Med, Internal Med, New Haven, CT 06520 USA	Gurung, A (reprint author), Royal Columbian Hosp, Dept Pathol, 330 E Columbia St, New Westminster, BC V3L 3W7, Canada.	ananta.gurung@fraserhealth.ca					Alvarez E, 1999, J HEPATOL, V31, P929, DOI 10.1016/S0168-8278(99)80297-9; Balitzer D, 2017, MODERN PATHOL, V30, P773, DOI 10.1038/modpathol.2016.267; Bedossa P, 1996, HEPATOLOGY, V24, P289, DOI 10.1002/hep.510240201; de Boer YS, 2015, HISTOPATHOLOGY, V66, P351, DOI 10.1111/his.12558; Dyson JK, 2016, J HEPATOL, V64, P234, DOI 10.1016/j.jhep.2015.07.041; Fujii Y, 2015, HEPATOLOGY, V61, P400, DOI 10.1002/hep.27559; Hennes EM, 2008, HEPATOLOGY, V48, P169, DOI 10.1002/hep.22322; Iwai M, 2008, HEPATOL RES, V38, P784, DOI 10.1111/j.1872-034X.2008.00347.x; JOHNSON PJ, 1993, HEPATOLOGY, V18, P998, DOI 10.1002/hep.1840180435; Krawitt EL, 2006, NEW ENGL J MED, V354, P54, DOI 10.1056/NEJMra050408; Kumari N, 2013, EUR J GASTROEN HEPAT, V25, P333, DOI 10.1097/MEG.0b013e32835a68a1; Miao Q, 2015, CLIN REV ALLERG IMMU, V48, P226, DOI 10.1007/s12016-014-8432-0; Pant M, 2015, USCAP ANN M MARCH 12; Suzuki A, 2011, HEPATOLOGY, V54, P931, DOI 10.1002/hep.24481; Tucker SM, 2015, AM J SURG PATHOL, V39, P772, DOI 10.1097/PAS.0000000000000395; Waldenstrom J, 1950, DTSCH GES VERDAU STO, V15, P113; Wong RJ, 2011, DIGEST DIS SCI, V56, P578, DOI 10.1007/s10620-010-1444-6; Yeoman AD, 2008, HEPATOLOGY, V48, P863, DOI 10.1002/hep.22432	18	1	1	0	0	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	DEC	2018	82						51	60		10.1016/j.humpath.2018.07.014			10	Pathology	Pathology	HG4TV	WOS:000454968800007	30041025				2019-10-28	
J	Li, SQ; Zhang, YS; Wang, ZY; Yang, YF; Gao, WS; Li, DS; Wei, JX				Li, Shuqiang; Zhang, Yushi; Wang, Zhiyong; Yang, Yanfeng; Gao, Wansheng; Li, Dongsheng; Wei, Jinxing			Genotype-phenotype correlation of patients with tuberous sclerosis complex-associated renal angiomyolipoma: a descriptive study	HUMAN PATHOLOGY			English	Article						Tuberous sclerosis complex; Renal angiomyolipoma; Genotype; Phenotype; High-throughput sequencing	SPORADIC LYMPHANGIOLEIOMYOMATOSIS; MTOR; TSC1; MANIFESTATIONS; IDENTIFICATION; PATHOGENESIS; DISEASE	TSC2 gene mutation was repeatedly reported to be associated with a more severe phenotype in patients with tuberous sclerosis complex (TSC). Our current study aims to further explore whether there is such a correlation in patients with TSC-associated renal angiomyolipoma (TSC-RAML). TSC1/TSC2 gene mutation was screened by high-throughput sequencing in 25 TSC-RAML patients from 2 medical centers. Clinical data were also carefully collected. Linear regression analysis and Student t-test were conducted by IBM SPSS Statistics Version 21.0 to analyze the genotypic-phenotypic relationship. The results indicated a high level of TSC gene mutation (80%; 20/25) in TSC-RAML patients, with higher frequency of TSC2 mutation (68%; 17/25) than TSCI mutation (12%; 3/25). Seven novel mutation sites were detected in this study. In general, there were no significant correlations between tumor size and age (r = 0.134, P =.522), hemoglobin (r = 0.255, P =.219), and serum creatinine (r = 0.043, P =.839). Patients with larger tumor size have higher risk of bleeding. Specially, it was higher hemoglobin level in patients with TSC1 mutation than ones with TSC2 mutation and without TSC mutation (P <.05). However, no difference was found in either tumor size or serum creatinine by TSC mutation genes (P >.05). Furthermore, no difference was found in tumor size, hemoglobin, and serum creatinine by TSC mutation types (P >.05). In conclusion, TSC-RAML is TSC2 mutation dominant, with the individual differences varying greatly. No definite genotype-phenotype correlation exists in patients with TSC-RAML, and it needs to be further explored. (C) 2018 Elsevier Inc. All rights reserved.	[Li, Shuqiang; Wang, Zhiyong; Yang, Yanfeng; Gao, Wansheng; Li, Dongsheng; Wei, Jinxing] Zhengzhou Univ, Affiliated Hosp 1, Dept Urol, 1 Jianshe East Rd, Zhengzhou 450052, Henan, Peoples R China; [Zhang, Yushi] Chinese Acad Med Sci, Peking Union Med Coll Hosp, Dept Urol, Beijing 100730, Peoples R China; [Zhang, Yushi] Peking Union Med Coll, Beijing 100730, Peoples R China	Li, SQ (reprint author), Zhengzhou Univ, Affiliated Hosp 1, Dept Urol, 1 Jianshe East Rd, Zhengzhou 450052, Henan, Peoples R China.	lishugiang235@163.com					Bissler JJ, 2013, LANCET, V381, P817, DOI 10.1016/S0140-6736(12)61767-X; Brakemeier S, 2017, PEDIATR NEPHROL, V32, P1137, DOI 10.1007/s00467-016-3474-6; Chan JA, 2004, J NEUROPATH EXP NEUR, V63, P1236, DOI 10.1093/jnen/63.12.1236; Crino PB, 2006, NEW ENGL J MED, V355, P1345, DOI 10.1056/NEJMra055323; Curatolo P, 2008, LANCET, V372, P657, DOI 10.1016/S0140-6736(08)61279-9; Dunlop EA, 2014, SEMIN CELL DEV BIOL, V36, P121, DOI 10.1016/j.semcdb.2014.08.006; Harabayashi T, 2004, J UROLOGY, V171, P102, DOI 10.1097/01.ju.0000100100.36354.61; Henske EP, 2016, NAT REV DIS PRIMERS, V2, DOI 10.1038/nrdp.2016.35; Jang MA, 2012, PEDIATR NEUROL, V46, P222, DOI 10.1016/j.pediatrneurol.2012.02.002; Jozwiak J, 2008, LANCET ONCOL, V9, P73, DOI 10.1016/S1470-2045(07)70411-4; Kingswood JC, 2016, J MED ECON, V19, P1116, DOI 10.1080/13696998.2016.1202254; Kothare SV, 2014, EPILEPSIA, V55, P1025, DOI 10.1111/epi.12680; Kristof AS, 2010, LYMPHAT RES BIOL, V8, P33, DOI 10.1089/lrb.2009.0019; Kwiatkowski DJ, 2003, CANCER BIOL THER, V2, P471, DOI 10.4161/cbt.2.5.446; Li SQ, 2017, ONCOL LETT, V14, P7085, DOI 10.3892/ol.2017.7079; Muhlebner A, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0157396; NELLIST M, 1993, CELL, V75, P1305; Niida Y, 2013, J HUM GENET, V58, P216, DOI 10.1038/jhg.2013.3; Northrup H, 2013, PEDIATR NEUROL, V49, P243, DOI 10.1016/j.pediatrneurol.2013.08.001; Orlova KA, 2010, ANN NY ACAD SCI, V1184, P87, DOI 10.1111/j.1749-6632.2009.05117.x; OSBORNE JP, 1991, ANN NY ACAD SCI, V615, P125; Peng ZF, 2014, J UROLOGY, V192, P1424, DOI 10.1016/j.juro.2014.04.096; Rentz AM, 2015, PEDIATR NEUROL, V52, P435, DOI 10.1016/j.pediatrneurol.2014.11.013; Rouviere O, 2013, Diagn Interv Imaging, V94, P225, DOI 10.1016/j.diii.2013.01.003; SAMPSON JR, 1989, J MED GENET, V26, P28, DOI 10.1136/jmg.26.1.28; Sampson JR, 1997, AM J HUM GENET, V61, P843, DOI 10.1086/514888; Tee AR, 2003, CURR BIOL, V13, P1259, DOI 10.1016/S0960-9822(03)00506-2; Tsai V, 2014, CEREB CORTEX, V24, P315, DOI 10.1093/cercor/bhs310; vanSlegtenhorst M, 1997, SCIENCE, V277, P805	29	0	0	0	1	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	DEC	2018	82						61	67		10.1016/j.humpath.2018.07.017			7	Pathology	Pathology	HG4TV	WOS:000454968800008	30036593				2019-10-28	
J	Roth, LM; Michal, M; Michal, M; Cheng, L				Roth, Lawrence M.; Michal, Michal; Michal, Michael, Jr.; Cheng, Liang			Protein expression of the transcription factors DMRT1, TCLF5, and OCT4 in selected germ cell neoplasms of the testis	HUMAN PATHOLOGY			English	Article						Testis; Mixed genn cell-sex cord stromal tumor; Spermatocytic tumor; Seminoma; DMRT1; OCT4	CORD-STROMAL TUMOR; HUMAN SPERMATOCYTIC SEMINOMAS; OVARY; MARKER	In the present study, we investigated protein expression of the transcription factors mammalian doublesex and mab-3 related transcription factor 1 (DMRT1), basic helix-loop-helix transcription factor-like 5 (TCLF5), and octamer-binding transcription factor 4 (OCT4) in normal human spermatogenesis, testicular mixed germ cell-sex cord stromal tumor (MGC-SCST), spermatocytic tumor, and seminoma. In normal human spermatogenesis, DMRT1 is expressed in the nuclei of spermatogonia but not in those of more mature germ cells. By way of contrast, TCLF5 is expressed in the nuclei of some clusters of primary spennatocytes that have entered meiosis 1, in secondary spennatocytes, and in round (early) spermatids in the seminiferous tubules of adults during the reproductive years. OCT4 is expressed in primordial germ cells but not in the seminiferous tubules of the normal adult testis during the reproductive years. DMRT1 is expressed in the germ cells of both testicular MGC-SCST and spermatocytic tumor, whereas TCLF5 is not expressed in either neoplasm. These low-grade neoplasms, however, differ histologically in that all the germ cell nuclei of testicular MGC-SCST resemble spermatogonia, whereas in spermatocytic tumor, the nuclei of the medium-sized and large cells resemble those of primary spennatocytes. Both neoplasms lack expression of OCT4. By way of contrast, in seminoma, a fully malignant testicular germ cell tumor, the germ cell nuclei express OCT4 but do not express either DMRT1 or TCLF5. (C) 2018 Elsevier Inc. All rights reserved.	[Roth, Lawrence M.; Cheng, Liang] Indiana Univ Sch Med, Dept Pathol, Van Nuys Med Sci Bldg 128,635 Barnhill Dr, Indianapolis, IN 46202 USA; [Michal, Michal; Michal, Michael, Jr.] Charles Univ Prague, Fac Med Pilsen, Dept Pathol, Plzen 30460, Czech Republic; [Michal, Michael, Jr.] Charles Univ Prague, Fac Med Pilsen, Biomed Ctr, Plzen 30460, Czech Republic; [Cheng, Liang] Indiana Univ Sch Med, Dept Urol, Indianapolis, IN 46202 USA	Roth, LM (reprint author), Indiana Univ Sch Med, Dept Pathol, Van Nuys Med Sci Bldg 128,635 Barnhill Dr, Indianapolis, IN 46202 USA.	lroth@iupui.edu					Abiko K, 2010, AM J SURG PATHOL, V34, P1842, DOI 10.1097/PAS.0b013e3181fcd707; BOLEN JW, 1981, AM J CLIN PATHOL, V75, P565; Cheng L, 2007, J PATHOL, V211, P1, DOI 10.1002/path.2105; Giannoulatou E, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0178169; Jacobsen GK, 1989, ATLAS GERM CELL TUMO; Jones TD, 2004, AM J SURG PATHOL, V28, P935, DOI 10.1097/00000478-200407000-00014; Jones TD, 2006, CLIN CANCER RES, V12, P5377, DOI 10.1158/1078-0432.CCR-06-0444; Jorgensen A, 2012, MOL HUM REPROD, V18, P523, DOI 10.1093/molehr/gas030; Looijenga LHJ, 2006, CANCER RES, V66, P290, DOI 10.1158/0008-5472.CAN-05-2936; Maruyama O, 1998, CYTOGENET CELL GENET, V82, P41, DOI 10.1159/000015061; Masson P., 1946, REV CAN BIOL, V15, P480; MATOSKA J, 1989, CANCER-AM CANCER SOC, V64, P2146, DOI 10.1002/1097-0142(19891115)64:10<2146::AID-CNCR2820641029>3.0.CO;2-T; Matson CK, 2010, DEV CELL, V19, P612, DOI 10.1016/j.devcel.2010.09.010; Michal M, 2006, VIRCHOWS ARCH, V448, P612, DOI 10.1007/s00428-006-0155-z; Moch H, 2016, CLASSIFICATION TUMOU; Rajpert-De Meyts E, 2003, HISTOPATHOLOGY, V42, P217; RAMES RA, 1995, J UROLOGY, V154, P1479, DOI 10.1016/S0022-5347(01)66901-5; ROSAI J, 1969, CANCER-AM CANCER SOC, V24, P103, DOI 10.1002/1097-0142(196907)24:1<103::AID-CNCR2820240114>3.0.CO;2-1; Rosenberg C, 1998, GENE CHROMOSOME CANC, V23, P286, DOI 10.1002/(SICI)1098-2264(199812)23:4<286::AID-GCC2>3.0.CO;2-6; Roth LM, 2018, HISTOPATHOLOGY, V72, P545, DOI 10.1111/his.13387; Roth LM, 2017, HUM PATHOL, V65, P1, DOI 10.1016/j.humpath.2017.04.009; Roth LM, 2017, J CLIN PATHOL, V70, P222, DOI 10.1136/jclinpath-2016-203902; Siep M, 2004, NUCLEIC ACIDS RES, V32, P6425, DOI 10.1093/nar/gkh979; TALERMAN A, 1972, OBSTET GYNECOL, V40, P473; TALERMAN A, 1972, CANCER, V30, P1219, DOI 10.1002/1097-0142(197211)30:5<1219::AID-CNCR2820300512>3.0.CO;2-U; Talerman A, 2007, INT J GYNECOL PATHOL, V26, P313, DOI 10.1097/01.pgp.0000250148.52215.ce; Trainer D. T., 2012, HISTOLOGY PATHOLOGIS, P1003; Ulbright TM, 2000, AM J SURG PATHOL, V24, P535, DOI 10.1097/00000478-200004000-00007	28	2	2	0	0	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	DEC	2018	82						68	75		10.1016/j.humpath.2018.07.019			8	Pathology	Pathology	HG4TV	WOS:000454968800009	30067948				2019-10-28	
J	Cloutier, J; Thompson, ED; Cimino-Mathews, A; Rooper, LM; Matoso, A; Argani, P				Cloutier, Jeffrey; Thompson, Elizabeth D.; Cimino-Mathews, Ashley; Rooper, Lisa M.; Matoso, Andres; Argani, Pedram			Metastatic breast cancer simulating well-differentiated neuroendocrine neoplasms of visceral organs	HUMAN PATHOLOGY			English	Article						Neuroendocrine; Metastatic; Breast carcinoma; Well-differentiated; Visceral	ENETS CONSENSUS GUIDELINES; PROGNOSTIC-SIGNIFICANCE; CARCINOMA; EXPRESSION; TUMOR; DISEASE; LIVER; MAMMAGLOBIN; MANAGEMENT; DIAGNOSIS	A series of metastatic breast carcinoma (MBC) mimicking visceral well-differentiated neuroendocrine neoplasms has not previously been reported. We identified 5 consultation cases originally submitted as neuroendocrine neoplasms in women but that were found to be MBC on subsequent review. All 5 neoplasms demonstrated nested architecture and relatively uniform nuclei. Four patients had a known history of breast cancer (remote in 3 and concurrent in 1), but the metastases (3 liver, 1 lung) labeled for chromogranin and/or synaptophysin, prompting misdiagnosis as neuroendocrine neoplasm. In a fifth case, a liver metastasis in a patient with a known pancreatic endocrine neoplasm was originally thought to be of pancreatic origin; an occult concurrent primary breast cancer (PBC) was subsequently identified as the source. On further immunohistochemistry (BC), all metastases evaluated were diffusely, strongly positive for estrogen receptor (5/5 cases) and GATA3 (4/4 cases). Three patients had previously received ineffective treatment for neuroendocrine carcinoma. Based on the consultation diagnosis, all 4 patients with follow-up received hormone therapy, which was effective in 3. In a separate tissue microarray cohort of paired PBCs and hematogenous MBCs, chromogranin and/or synaptophysin 1HC labeling was typically negative and increased from the PBC to the MBC in only 5% of cases. In conclusion, although neuroendocrine differentiation is uncommon in breast cancer and does not commonly increase in metastases, MBC with neuroendocrine differentiation should be considered in patients with visceral neuroendocrine neoplasms of unknown primary site. Diffuse IHC labeling for estrogen receptor and GATA3 helps establish the correct diagnosis. (C) 2018 Elsevier Inc. All rights reserved.	[Cloutier, Jeffrey] Stanford Univ, Dept Pathol, Stanford, CA 94305 USA; [Thompson, Elizabeth D.; Cimino-Mathews, Ashley; Rooper, Lisa M.; Matoso, Andres; Argani, Pedram] Johns Hopkins Med Inst, Dept Pathol, Baltimore, MD 21231 USA; [Thompson, Elizabeth D.; Cimino-Mathews, Ashley; Rooper, Lisa M.; Matoso, Andres; Argani, Pedram] Johns Hopkins Med Inst, Dept Oncol, Baltimore, MD 21231 USA	Argani, P (reprint author), Johns Hopkins Univ Hosp, Surg Pathol, Weinberg Bldg,Rm 2242,401 N Broadway, Baltimore, MD 21231 USA.	pargani@jhmi.edu		Rooper, Lisa/0000-0001-5636-9753			Bellizzi AM, 2013, ADV ANAT PATHOL, V20, P285, DOI 10.1097/PAP.0b013e3182a2dc67; Bhargava R, 2007, AM J CLIN PATHOL, V127, P103, DOI 10.1309/TDP92PQLDE2HLEET; Bogina G, 2016, HISTOPATHOLOGY, V68, P422, DOI 10.1111/his.12766; Bussolati G, 2012, WHO CLASSIFICATION T, P62; Catena L, 2011, TUMORI, V97, P564, DOI 10.1700/989.10712; Christensen L, 2016, INT J SURG PATHOL, V24, P463, DOI 10.1177/1066896916632909; Cimino-Mathews A, 2013, HUM PATHOL, V44, P1341, DOI 10.1016/j.humpath.2012.11.003; Darvishian F, 2006, HUM PATHOL, V37, P839, DOI 10.1016/j.humpath.2006.02.005; Ellis CL, 2013, AM J SURG PATHOL, V37, P1756, DOI 10.1097/PAS.0b013e31829cdba7; Ellis IO, 2003, WHO CLASSIFICATION T, P32; Farley HA, 2016, SURG ONCOL CLIN N AM, V25, P217, DOI 10.1016/j.soc.2015.08.010; Grandhi MS, 2015, J GASTROINTEST SURG, V19, P2273, DOI 10.1007/s11605-015-2931-z; Hennessy BT, 2007, CLIN BREAST CANCER, V7, P892, DOI 10.3816/CBC.2007.n.056; Inno A, 2016, ONCOLOGIST, V21, P28, DOI 10.1634/theoncologist.2015-0309; Judson K, 2006, AM J SURG PATHOL, V30, P912, DOI 10.1097/01.pas.0000206220.08232.2d; Koo J, 2015, SEMIN DIAGN PATHOL, V32, P456, DOI 10.1053/j.semdp.2015.09.013; Kwon SY, 2014, HISTOPATHOLOGY, V64, P647, DOI 10.1111/his.12306; Lewis GH, 2011, AM J CLIN PATHOL, V135, P587, DOI 10.1309/AJCPMFR6OA8ICHNH; Makretsov N, 2003, HUM PATHOL, V34, P1001, DOI 10.1053/S0046-8177(03)00411-8; Manes K, 2014, INT J SURG CASE REP, V5, P540, DOI 10.1016/j.ijscr.2014.05.006; Mclntire M, 2008, DIAGN CYTOPATHOL, V36, P54, DOI [10.1002/dc.20946, 10.1002/dc.20753]; Miettinen M, 2014, AM J SURG PATHOL, V38, P13, DOI 10.1097/PAS.0b013e3182a0218f; Miremadi A, 2002, HISTOPATHOLOGY, V40, P215, DOI 10.1046/j.1365-2559.2002.01336.x; Pavel M, 2016, NEUROENDOCRINOLOGY, V103, P172, DOI [10.1159/000446025, 10.1159/000443167]; Pavel M, 2012, NEUROENDOCRINOLOGY, V95, P157, DOI 10.1159/000335597; Perry KD, 2011, HISTOPATHOLOGY, V59, P619, DOI 10.1111/j.1365-2559.2011.03940.x; Righi L, 2010, SEMIN DIAGN PATHOL, V27, P69, DOI 10.1053/j.semdp.2009.12.003; Shin SJ, 2000, AM J SURG PATHOL, V24, P1231, DOI 10.1097/00000478-200009000-00006; Sica G, 2008, ARCH PATHOL LAB MED, V132, P1889, DOI 10.1043/1543-2165-132.12.1889; Takeda Y, 2008, ARCH PATHOL LAB MED, V132, P239, DOI 10.1043/1543-2165(2008)132[239:AOEPOB]2.0.CO;2; Tang F, 2011, HISTOPATHOLOGY, V59, P106, DOI 10.1111/j.1365-2559.2011.03880.x; Tian Z, 2011, HUM PATHOL, V42, P1169, DOI 10.1016/j.humpath.2010.11.014; VIALE G, 1992, CANCER-AM CANCER SOC, V70, P2268, DOI 10.1002/1097-0142(19921101)70:9<2268::AID-CNCR2820700910>3.0.CO;2-X; Wachter DL, 2014, BIOMED RES INT, DOI 10.1155/2014/408459; Yang ZH, 2017, AM J SURG PATHOL, V41, P915, DOI 10.1097/PAS.0000000000000876	35	1	1	0	0	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	DEC	2018	82						76	86		10.1016/j.humpath.2018.07.011			11	Pathology	Pathology	HG4TV	WOS:000454968800010	30031098				2019-10-28	
J	Koshiol, J; Bellolio, E; Vivallo, C; Cook, P; Roa, JC; McGee, EE; Losada, H; Van Dyke, AL; Van De Wyngard, V; Prado, R; Villaseca, M; Riquelme, P; Acevedo, J; Olivo, V; Pettit, K; Hildesheim, A; Medina, K; Memis, B; Adsay, V; Ferreccio, C; Araya, JC				Koshiol, Jill; Bellolio, Enrique; Vivallo, Carolina; Cook, Paz; Carlos Roa, Juan; McGee, Emma E.; Losada, Hector; Van Dyke, Alison L.; Van De Wyngard, Vanessa; Prado, Rodrigo; Villaseca, Miguel; Riquelme, Pia; Acevedo, Johanna; Olivo, Vanessa; Pettit, Karen; Hildesheim, Allan; Medina, Katie; Memis, Bahar; Adsay, Volkan; Ferreccio, Catterina; Carlos Araya, Juan			Distribution of dysplasia and cancer in the gallbladder: an analysis from a high cancer-risk population	HUMAN PATHOLOGY			English	Article						Dysplasia; Invasive carcinoma; Gallbladder cancer; Sampling; Histopathology	PRIMARY SCLEROSING CHOLANGITIS; CHOLECYSTECTOMY; CARCINOMA; ROUTINE; BILIARY; LESIONS; HISTOPATHOLOGY; METAPLASIA	Gallbladder dysplasia can progress to cancer and may be associated with increased cancer risk at other biliary tract sites. Thus, its accurate identification is relevant both for etiologic understanding and for clinical purposes. Data on the frequency and distribution of gallbladder dysplasia are lacking owing to limited gallbladder sampling and inability to visualize dysplasia grossly. An expert pathology group used consensus criteria to review 140 totally sampled consecutive cholecystectomy specimens from Chilean women. Three cases (2%) revealed incidental invasive carcinoma, all T2, along with high-grade dysplasia (HGD). The surface areas covered by dysplasia or cancer in these cases were 9%, 37%, and 87%. Although the first longitudinal ("diagnostic") section of the whole gallbladder captured HGD or cancer in all 3 cases, the deepest focus of invasive carcinoma was not present in this section. Fourteen additional cases (10%) had low-grade dysplasia (LGD), which was typically very focal (covering <5% of the surface) and most often occurred in the fundus. LGD was not present in the diagnostic section of 5 cases (38%) and would have been missed without additional sampling. None of the cancers or dysplasias were grossly visible. Although HGD and carcinoma are likely to be identified in "diagnostic" sections, accurate staging requires total sampling. LGD is typically very focal and would often be missed in routine practice. To identify cancer precursors, additional sampling, particularly of the fundus, may be warranted. The predominance of LGD in the fundus also provides etiologic insight, supporting the contribution of gallstones and chronic inflammation. Published by Elsevier Inc.	[Koshiol, Jill; McGee, Emma E.; Van Dyke, Alison L.; Hildesheim, Allan] NCI, Infect & Immunoepidemiol Branch, Div Canc Epidemiol & Genet, Rockville, MD 20850 USA; [Bellolio, Enrique; Vivallo, Carolina; Losada, Hector; Villaseca, Miguel; Medina, Katie; Carlos Araya, Juan] Hosp Dr Hernan Henriquez Aravena, Temuco 4780000, Chile; [Bellolio, Enrique; Vivallo, Carolina; Villaseca, Miguel; Medina, Katie; Carlos Araya, Juan] Univ La Frontera, Dept Pathol, Fac Med, Temuco 4780000, Chile; [Cook, Paz; Van De Wyngard, Vanessa; Riquelme, Pia; Acevedo, Johanna; Ferreccio, Catterina] Pontificia Univ Catolica Chile, Sch Med, Dept Publ Hlth, Santiago 8330077, Chile; [Carlos Roa, Juan] Pontificia Univ Catolica Chile, Sch Med, Dept Pathol, Santiago 8330024, Chile; [Prado, Rodrigo] Hosp Curico, Serv Salud Maule, Pathol Serv, Curico 3342629, Chile; [Cook, Paz; Van De Wyngard, Vanessa; Acevedo, Johanna; Ferreccio, Catterina; Carlos Araya, Juan] FONDAP, Adv Ctr Chron Dis ACCDiS, Santiago 8380492, Chile; [Olivo, Vanessa; Pettit, Karen] Westat Corp, Rockville, MD 20850 USA; [Memis, Bahar] Emory Univ, Sch Med, Dept Pathol, Atlanta, GA 30322 USA; [Adsay, Volkan] Koc Univ, Sch Med, Dept Pathol, Istanbul, Turkey; [Losada, Hector] Univ La Frontera, Fac Med, Dept Surg, Temuco 4780000, Chile; [Van Dyke, Alison L.] NCI, Div Canc Control & Populat Sci, Surveillance Res Program, Rockville, MD 20850 USA; [Memis, Bahar] SBU Mehmet Akif Inan Training & Res Hosp, Sanliurfa, Turkey; [Adsay, Volkan] KOC Univ Hosp, Istanbul, Turkey	Koshiol, J (reprint author), NCI, Infect & Immunoepidemiol Branch, Div Canc Epidemiol & Genet, NIH, 9609 Med Ctr Dr,Rm 6-E212, Rockville, MD 20850 USA.	koshiolj@mail.nih.gov	Adsay, Volkan/N-7130-2017	Adsay, Volkan/0000-0002-1308-3701	Intramural Research Program of the National Institutes of Health, National Cancer Institute, Division of Cancer Epidemiology and GeneticsUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)NIH National Cancer Institute- Division of Cancer Epidemiology & Genetics; Office of Research on Women's Health, National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Office of Research on Women's Health (ORWH)	This work was supported by general funds from the Intramural Research Program of the National Institutes of Health, National Cancer Institute, Division of Cancer Epidemiology and Genetics, and the Office of Research on Women's Health, National Institutes of Health.	Adsay NV, 2012, SEMIN DIAGN PATHOL, V29, P127, DOI 10.1053/j.semdp.2012.08.010; Adsay V, 2016, LAB INVEST, V96, p438A; Adsay V, 2013, AM J CLIN PATHOL, V140, P278, DOI 10.1309/AJCPUJPGQIZ6DC6A; Aloia TA, 2015, HPB, V17, P681, DOI 10.1111/hpb.12444; Bertran E, 2010, INT J CANCER, V127, P2446, DOI 10.1002/ijc.25421; De Aretxabala X, 2009, J SURG ONCOL, V100, P589, DOI 10.1002/jso.21389; Dix FP, 2003, SURG J R COLL SURG E, V1, P233, DOI 10.1016/S1479-666X(03)80023-9; DUARTE I, 1993, CANCER-AM CANCER SOC, V72, P1878, DOI 10.1002/1097-0142(19930915)72:6<1878::AID-CNCR2820720615>3.0.CO;2-2; Emmett CD, 2015, ANN ROY COLL SURG, V97, P526, DOI 10.1308/rcsann.2015.0013; Espinoza JA, 2016, BBA-REV CANCER, V1865, P245, DOI 10.1016/j.bbcan.2016.03.004; Hayes BD, 2014, ANN DIAGN PATHOL, V18, P181, DOI 10.1016/j.anndiagpath.2014.03.004; Henson DE, 2009, ARCH PATHOL LAB MED, V133, P67, DOI 10.1043/1543-2165-133.1.67; Jayasundara JASB, 2013, ANN ROY COLL SURG, V95, P317, DOI 10.1308/003588413X13629960046471; Karlsen TH, 2008, CURR OPIN GASTROEN, V24, P395, DOI 10.1097/MOG.0b013e3282f5727a; Keshav S, 2011, GASTROENTEROLOGY CLI; Koshiol J, 2017, CANC EPIDEMIOLOGY PR, P661; Lewis JT, 2007, AM J SURG PATHOL, V31, P907, DOI 10.1097/01.pas.0000213435.99492.8a; Mao K, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000000596; Patel K, 2016, WORLD J GASTRO SURG, V8, P685, DOI 10.4240/wjgs.v8.i10.685; Randi G, 2009, ANN ONCOL, V20, P146, DOI 10.1093/annonc/mdn533; Renshaw AA, 2012, AM J CLIN PATHOL, V138, P374, DOI 10.1309/AJCPB0ZTXXIF6MOF; ROA I, 1993, REV MED CHILE, V121, P21; Serra S, 2014, J CLIN PATHOL, V67, P875, DOI 10.1136/jclinpath-2014-202435; Shukla PJ, 2008, HPB, V10, P48, DOI 10.1080/13651820701867802; Siddiqui FG, 2013, BMC SURG, V13, DOI 10.1186/1471-2482-13-26; Takano A, 2016, INT J SURG CASE REP, V28, P325, DOI 10.1016/j.ijscr.2016.10.042; Tayeb Muhammad, 2015, Asian Pac J Cancer Prev, V16, P1535	27	1	1	1	1	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	DEC	2018	82						87	94		10.1016/j.humpath.2018.07.015			8	Pathology	Pathology	HG4TV	WOS:000454968800011	30036595				2019-10-28	
J	Zheng, W; Fung, KM; Cheng, H; Osunkoya, AO				Zheng, Wei; Fung, Kar-Ming; Cheng, Hang; Osunkoya, Adeboye O.			Benign vascular tumors, cysts, and pseudocysts of the adrenal gland: a contemporary multi-institutional clinicopathological analysis of 55 cases	HUMAN PATHOLOGY			English	Article						Adrenal gland; Vascular tumor, cyst, pseudocyst; Hemangioma; Lymphangioma; Angiomatous endothelial cyst; Vascular malformation	RARE CAVERNOUS HEMANGIOMA; ADENOMATOID TUMOR; ENDOTHELIAL CYST; MIMICKING; LESIONS	Benign adrenal vascular tumors, cysts, and pseudocysts are a heterogeneous group of relatively uncommon entities that may pose diagnostic challenges radiologically and pathologically. However, there are only a few small cases series systematically characterizing the clinicopathological features of these lesions. We identified 55 cases of benign adrenal vascular tumors, cysts, and pseudocysts (23 pseudocysts, 17 hemangiomas, 8 lymphangiomas, 6 angiomatous endothelial cysts, and 1 arteriovenous malformation) from a multi-institutional urologic pathology database between 2000 and 2017 and retrospectively analyzed their clinicopathological features. We found that these lesions have a female predominance and most are right sided. These lesions may occur simultaneously with other adrenal tumors associated with hormonal hypersecretion. A substantial portion of pseudocysts were semisolid or solid with no fluid collection, mimicking a solid adrenal tumor and resulting in adrenalectomy. In addition, a small proportion of benign vascular lesions may have coexisting epithelial tumors, requiring extensive specimen sampling and thorough microscopic examination. (C) 2018 Elsevier Inc. All rights reserved.	[Zheng, Wei; Osunkoya, Adeboye O.] Emory Univ, Sch Med, Dept Pathol, Suite H174,1364 Clifton Rd NE, Atlanta, GA 30322 USA; [Fung, Kar-Ming] Univ Oklahoma, Hlth Sci Ctr, Dept Pathol, Oklahoma City, OK 73104 USA; [Fung, Kar-Ming] Univ Oklahoma, Hlth Sci Ctr, Stephenson Canc Ctr, Oklahoma City, OK 73104 USA; [Fung, Kar-Ming] Vet Affairs Med Ctr, Dept Pathol, Oklahoma City, OK 73014 USA; [Cheng, Hang] Indiana Univ Sch Med, Dept Pathol, Indianapolis, IN 46202 USA; [Osunkoya, Adeboye O.] Emory Univ, Sch Med, Dept Urol, Atlanta, GA 30322 USA; [Osunkoya, Adeboye O.] Vet Affairs Med Ctr, Dept Pathol, Decatur, GA 30033 USA; [Osunkoya, Adeboye O.] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA	Osunkoya, AO (reprint author), Emory Univ, Sch Med, Dept Pathol, Suite H174,1364 Clifton Rd NE, Atlanta, GA 30322 USA.	adeboye.osunkoya@emory.edu					Bisceglia M, 2009, ADV ANAT PATHOL, V16, P424, DOI 10.1097/PAP.0b013e3181bb6c09; Carvounis E, 2006, ARCH PATHOL LAB MED, V130, P1722; Diolombi ML, 2016, HUM PATHOL, V53, P63, DOI 10.1016/j.humpath.2016.02.017; Edwards JP, 2014, INT J SURG CASE REP, V5, P52, DOI 10.1016/j.ijscr.2013.11.003; Ellis CL, 2011, HUM PATHOL, V42, P1013, DOI 10.1016/j.humpath.2010.10.023; Erickson LA, 2004, CANCER, V101, P1537, DOI 10.1002/cncr.20555; Fernandez-Vega I, 2014, ENDOCR PATHOL, V25, P443, DOI 10.1007/s12022-014-9331-x; GAFFEY MJ, 1989, AM J SURG PATHOL, V13, P740, DOI 10.1097/00000478-198909000-00003; Hirota S, 1999, ABDOM IMAGING, V24, P511, DOI 10.1007/s002619900551; Isono M, 2017, AM J CASE REP, V18, P1034, DOI 10.12659/AJCR.905063; Lykoudis PM, 2015, J BUON, V20, P1630; MEDEIROS LJ, 1989, HUM PATHOL, V20, P660, DOI 10.1016/0046-8177(89)90153-6; Narayana SM, 2010, ANZ J SURG, V80, P761, DOI 10.1111/j.1445-2197.2010.05474.x; Pang C, 2015, UROL CASE REP, V3, P120, DOI 10.1016/j.eucr.2015.03.009; Ross M, 2012, UROLOGY, V80, pE27, DOI 10.1016/j.urology.2012.05.032; Sebastiano C, 2013, HUM PATHOL, V44, P1797, DOI 10.1016/j.humpath.2013.02.002; Siddiqi AJ, 2009, J MAGN RESON IMAGING, V29, P949, DOI 10.1002/jmri.21430; Torres C, 1997, MODERN PATHOL, V10, P530; Wang L, 2014, SAO PAULO MED J, V132, P249, DOI 10.1590/1516-3180.2014.1324715; Yamada Takayuki, 2002, Radiat Med, V20, P51; Zhao M, 2013, INT J CLIN EXP PATHO, V6, P943	21	1	1	0	0	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	DEC	2018	82						95	102		10.1016/j.humpath.2018.07.013			8	Pathology	Pathology	HG4TV	WOS:000454968800012	30041023				2019-10-28	
J	Zhang, XM; Song, LJ; Shen, J; Yue, H; Han, YQ; Yang, CL; Liu, SY; Deng, JW; Jiang, Y; Fu, GH; Shen, WW				Zhang, Xue-Mei; Song, Ling-Jun; Shen, Juan; Yue, Hao; Han, Ya-Qin; Yang, Chen-Ling; Liu, Shi-Yun; Deng, Jia-Wen; Jiang, Yue; Fu, Guo-Hui; Shen, Wei-Wei			Prognostic and predictive values of immune infiltrate in patients with head and neck squamous cell carcinoma	HUMAN PATHOLOGY			English	Article						Tumor-infiltrating lymphocytes; Immunoscore; Head and neck squamous cell carcinoma; Prognosis; Predictive	IMMUNOSCORE; CANCER; LYMPHOCYTES; SURVIVAL; DENSITY; TUMORS	This study sought to determine whether the in situ tumor-infiltrating immune lymphocytes, as a novel companion to the Immunoscore analysis, could be a promising, valuable prognostic and predictive marker in patients with head and neck squamous cell carcinoma (HNSCC). Total (CD3+) and cytotoxic (CD8+) T lymphocytes were assessed using immunohistochemistty in tumor nests and stroma obtained from patient surgical specimens. The "Immunoscore" methodology has been defined to quantify the amount of in situ immune infiltrate (from 10 to 14). Survival curves were measured using the Kaplan Meier method, and differences in survival and response to therapy between the groups were estimated using the log-rank test. The prognostic value of the Immunoscore was determined using Cox multivariate analysis. The density and location of CD3+ and CD8+ lymphocytes and the associated Immunoscore correlated significantly with differences in disease-free survival (DFS) and overall survival (OS) (all P <.005). Compared with tumor-node-metastasis (TNM) staging, the Immunoscore was found to have an advantage in predicting survival (P =.000). In addition, a high Immunoscore was associated with the tumors of advanced-stage patients who underwent different treatment regimens. The Immunoscore could be a useful prognostic marker. The measurement of CD3+ and CD8+ cell infiltration may be beneficial in HNSCC patients and may help determine which patients may benefit most from definitive chemoradiotherapy. (C) 2018 Elsevier Inc. All rights reserved.	Shanghai Jiao Tong Univ, Sch Med, Fac Basic Med, Shanghai Gen Hosp,Pathol Ctr, Shanghai 200080, Peoples R China; Shanghai Jiao Tong Univ, Sch Med, Inst Med Sci, Key Lab Cell Differentiat & Apoptosis,Chinese Min, Shanghai 200080, Peoples R China	Fu, GH; Shen, WW (reprint author), Shanghai Jiao Tong Univ, Sch Med, Fac Basic Med, Shanghai Gen Hosp,Pathol Ctr, 280 South Chong Qing Rd, Shanghai 200025, Peoples R China.	fuguhu@263.net; weiweishen@126.com			National Natural Science Foundation of ChinaNational Natural Science Foundation of China [81372637]; National Basic Research Program of China (973 Program)National Basic Research Program of China [2013CB910903]; National Key Technology R&D Program of ChinaNational Key Technology R&D Program [2014BAI09B03]; Key Projects in Shanghai Science & Technology Pillar Program for Biomedicine [14431904700]; Shanghai Pujiang ProgramShanghai Pujiang Program [16PJ1405300]; Shanghai Hospital Development Center Emerging Advanced Technology Joint Research Project [SHDC1214105]	This work was supported in part by the National Natural Science Foundation of China (NO81372637), National Basic Research Program of China (973 Program) (NO2013CB910903), National Key Technology R&D Program of China (NO2014BAI09B03), Key Projects in Shanghai Science & Technology Pillar Program for Biomedicine (NO14431904700), Shanghai Pujiang Program (NO16PJ1405300) and Shanghai Hospital Development Center Emerging Advanced Technology Joint Research Project (NOSHDC1214105).	Akhlaghi Fahimeh, 2014, J Dent (Tehran), V11, P290; Anitei MG, 2014, CLIN CANCER RES, V20, P1891, DOI 10.1158/1078-0432.CCR-13-2830; Balermpas P, 2014, BRIT J CANCER, V110, P501, DOI 10.1038/bjc.2013.640; Berghoff AS, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2015.1057388; Bowles DW, 2016, SEMIN RADIAT ONCOL, V26, P299, DOI 10.1016/j.semradonc.2016.05.004; Donnem T, 2016, ANN ONCOL, V27, P226, DOI 10.1093/annonc/mdv560; Donnem T, 2015, CLIN CANCER RES, V21, P2635, DOI 10.1158/1078-0432.CCR-14-1905; Gabrielson A, 2016, CANCER IMMUNOL RES, V4, P419, DOI 10.1158/2326-6066.CIR-15-0110; Galon J, 2006, SCIENCE, V313, P1960, DOI 10.1126/science.1129139; Galon J, 2014, J PATHOL, V232, P199, DOI 10.1002/path.4287; Galon J, 2012, J TRANSL MED, V10, DOI 10.1186/1479-5876-10-205; Gupta B, 2016, ONCOLOGY-BASEL, V91, P13, DOI 10.1159/000446117; Hoesli Rebecca C, 2016, Curr Oral Health Rep, V3, P74; Kirilovsky A, 2016, INT IMMUNOL, V28, P373, DOI 10.1093/intimm/dxw021; Mlecnik B, 2011, CANCER METAST REV, V30, P5, DOI 10.1007/s10555-011-9270-7; Nagtegaal ID, 2012, NAT REV CLIN ONCOL, V9, P119, DOI 10.1038/nrclinonc.2011.157; Newman JR, 2015, LARYNGOSCOPE, V125, P624, DOI 10.1002/lary.24915; Pages F, 2010, ONCOGENE, V29, P1093, DOI 10.1038/onc.2009.416; Paulsen EE, 2015, NEOPLASIA, V17, P839, DOI 10.1016/j.neo.2015.11.004; Pfister DG, 2015, J NATL COMPR CANC NE, V13, P847, DOI 10.6004/jnccn.2015.0102; Rancoule C, 2016, ORAL ONCOL, V62, P153, DOI 10.1016/j.oraloncology.2016.09.002; Salgado R, 2015, ANN ONCOL, V26, P259, DOI 10.1093/annonc/mdu450; Schmitz S, 2016, CURR TREAT OPTION ON, V17, DOI 10.1007/s11864-016-0412-6; Sun C, 2015, ONCOTARGET, V6, P35602, DOI 10.18632/oncotarget.5801; Uppaluri Ravindra, 2008, Cancer Immun, V8, P16; Vos T, 2016, LANCET, V388, P1545, DOI 10.1016/S0140-6736(16)31678-6; Wang HD, 2016, LANCET, V388, P1459, DOI 10.1016/S0140-6736(16)31012-1; Watanabe Y, 2010, ORAL SURG ORAL MED O, V109, P744, DOI 10.1016/j.tripleo.2009.12.015	28	2	2	0	3	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	DEC	2018	82						104	112		10.1016/j.humpath.2018.07.012			9	Pathology	Pathology	HG4TV	WOS:000454968800013	30036594				2019-10-28	
J	Lobo, J; Costa, AL; Vilela-Salgueiro, B; Rodrigues, A; Guimaraes, R; Cantante, M; Lopes, P; Antunes, L; Jeronimo, C; Henrique, R				Lobo, Joao; Costa, Ana Laura; Vilela-Salgueiro, Barbara; Rodrigues, Angelo; Guimaraes, Rita; Cantante, Mariana; Lopes, Paula; Antunes, Luis; Jeronimo, Carmen; Henrique, Rui			Testicular germ cell tumors: revisiting a series in light of the new WHO classification and AJCC staging systems, focusing on challenges for pathologists	HUMAN PATHOLOGY			English	Article						Testicular cancer; Germ cell tumors; Histopathology; Prognosis; AJCC; WHO	CLINICAL STAGE; CONTEMPORARY MANAGEMENT; PROGNOSTIC-FACTORS; DIAGNOSIS; SEMINOMA; SURVEILLANCE; EPIGENETICS; SPECIMENS; CONSENSUS; RELAPSE	Testicular germ cell tumors (TGCTs) are strikingly heterogeneous, reflecting a complex tumor model, posing serious challenges for pathologists. Accurate classification and staging, according to most recent systems, is fundamental. We aimed to revise a series of consecutively diagnosed TGCTs (20052016) in light of the new World Health Organization (WHO) classification and American Joint Committee on Cancer (AJCC) staging systems, discussing dilemmas imposed to pathologists. All 164 patients' clinical files/histological slides were reviewed. Follow-up was last updated on November 2017. Statistical analysis was performed with SPSS (v24). P < 0.05 was considered significant. Non-seminomatous tumors (NSTs) showed more frequently cysts, necrosis, hemorrhage, lymphovascular invasion (LVI) and higher stage than seminomas (SEs) (P < .001, P = .015, P < .001, P = .001, P = .007). Embryonal carcinoma (EC), yolk sac tumor (YST) and teratoma (TE) were the most frequent components in mixed tumors (82.5%, 82.5% and 80.7%). SEs with "atypical features" showed more LVI, higher mitotic count and more extensive necrosis (P = .030, P < .001, P = .016). LVI and >50%EC component, but not rete testis invasion, were associated with higher stage (P < .001, P = .009). Regarding SEs, there was an association between tumor size and both stage (P = .004) and LVI (P < .001). Only four patients disclosed altered stage group when AJCC 8th Edition was employed. Disease recurrence/progression occurred in 5.4% of cases. In two cases, tumor components in metastasectomy specimens were not present in the primary TGCT. Overall survival at 5 years was 98.6%. TGCTs are challenging neoplasms, and pathologists and clinicians alike must be aware of recent updates in classification and staging for adequately tailoring treatment strategies. (C) 2018 Elsevier Inc. All rights reserved.	[Lobo, Joao; Rodrigues, Angelo; Guimaraes, Rita; Cantante, Mariana; Lopes, Paula; Henrique, Rui] Portuguese Oncol Inst Porto IPOP, Dept Pathol, P-4200072 Porto, Portugal; [Lobo, Joao; Costa, Ana Laura; Vilela-Salgueiro, Barbara; Rodrigues, Angelo; Jeronimo, Carmen; Henrique, Rui] Portuguese Oncol Inst Porto GEBC CI IPOP, Res Ctr, Canc Biol & Epigenet Grp, P-4200072 Porto, Portugal; [Lobo, Joao; Rodrigues, Angelo; Jeronimo, Carmen; Henrique, Rui] Univ Porto ICBAS UP, Dept Pathol & Mol Immunol, Inst Biomed Sci Abel Salazar, Rua Jorge Viterbo Ferreira 228, P-4050513 Porto, Portugal; [Antunes, Luis] Portuguese Oncol Inst Porto IPOP, Dept Epidemiol, P-4200072 Porto, Portugal	Henrique, R (reprint author), Portuguese Oncol Inst Porto, Dept Pathol, Rua Dr Antonio Bernardino de Almeida, P-4200072 Porto, Portugal.	henrique@ipoporto.min-saude.pt	; Antunes, Luis/A-8572-2014	Lobo, Joao/0000-0001-6829-1391; Antunes, Luis/0000-0002-3098-0711	Fundacao para a Ciencia e Tecnologia [POCI-01-0145-FEDER-29043]; FCT - Fundacao para a Ciencia e Tecnologia - fellowship [SFRH/BD/132751/2017]	This work was funded by Fundacao para a Ciencia e Tecnologia (POCI-01-0145-FEDER-29043). J.L. is supported by an FCT - Fundacao para a Ciencia e Tecnologia - fellowship (SFRH/BD/132751/2017).	Amin MB, 2017, AJCC CANC STAGING MA; [Anonymous], 1997, J Clin Oncol, V15, P594; Berney DM, 2015, HISTOPATHOLOGY, V67, P313, DOI 10.1111/his.12657; Beyer J, 2013, ANN ONCOL, V24, P878, DOI 10.1093/annonc/mds579; Cheng L, 2017, HUM PATHOL, V59, P10, DOI 10.1016/j.humpath.2016.08.002; Chung P, 2015, CANCER MED-US, V4, P155, DOI 10.1002/cam4.324; Costa AL, 2017, EPIGENOMICS-UK, V9, P155, DOI 10.2217/epi-2016-0081; Daugaard G, 2006, BJU INT, V97, P724, DOI 10.1111/j.1464-410X.2006.06017.x; David S, 2017, PATHOL ONCOL RES, V23, P513, DOI 10.1007/s12253-016-0120-3; Divrik RT, 2006, J UROLOGY, V176, P1424, DOI 10.1016/j.juro.2006.06.012; Ehara H, 2011, PEDIATR INT, V53, P72, DOI 10.1111/j.1442-200X.2010.03189.x; Ehrlich Y, 2010, ANN ONCOL, V21, P1846, DOI 10.1093/annonc/mdq045; Feldman DR, 2014, J CLIN ONCOL, V32, P3797, DOI 10.1200/JCO.2014.56.8006; Ghazarian AA, 2015, ANDROLOGY-US, V3, P13, DOI 10.1111/andr.288; Gilbert DC, 2016, CLIN CANCER RES, V22, P1265, DOI 10.1158/1078-0432.CCR-15-1186; Heberle H, 2015, BMC BIOINFORMATICS, V16, DOI 10.1186/s12859-015-0611-3; Henrique R, 2017, EUR UROL, V71, P221, DOI 10.1016/j.eururo.2016.08.013; Howitt Brooke E, 2015, Surg Pathol Clin, V8, P687, DOI 10.1016/j.path.2015.07.007; Moch H, 2016, WHO CLASSIFICATION T; Mosharafa AA, 2004, J UROLOGY, V171, P1471, DOI 10.1097/01.ju.0000116841.30826.85; O'Shaughnessy MJ, 2015, UROL CLIN N AM, V42, P359, DOI 10.1016/j.ucl.2015.04.010; Purshouse K, 2017, CLIN GENITOURIN CANC, V15, P152, DOI [10.1016/j.clgc.2016.05.005, 10.10164/j.clgc.2016.05.005]; Rice KR, 2014, J UROLOGY, V192, P1403, DOI 10.1016/j.juro.2014.05.118; Ritchey M, 2002, J UROLOGY, V168, P1678; Ross JH, 2002, J UROLOGY, V168, P1675, DOI 10.1097/01.ju.0000030749.27823.f5; Sharma P, 2015, AM J CLIN PATHOL, V144, P289, DOI 10.1309/AJCPJTX8R6CVWSRW; Silverio PC, 2015, ANN DIAGN PATHOL, V19, P99, DOI 10.1016/j.anndiagpath.2014.12.006; Stevenson SM, 2015, UROL CLIN N AM, V42, P269, DOI 10.1016/j.ucl.2015.04.001; Tickoo SK, 2002, INT J SURG PATHOL, V10, P23, DOI 10.1177/106689690201000105; Trabert B, 2015, ANDROLOGY-US, V3, P4, DOI 10.1111/andr.293; Ulbright TM, 2018, PATHOLOGY, V50, P88, DOI 10.1016/j.pathol.2017.07.013; Ulbright TM, 2005, MODERN PATHOL, V18, pS61, DOI 10.1038/modpathol.3800310; Vergouwe Y, 2003, J CLIN ONCOL, V21, P4092, DOI 10.1200/JCO.2003.01.094; Verrill C, 2017, AM J SURG PATHOL, V41, pE22, DOI 10.1097/PAS.0000000000000844; Warde P, 2002, J CLIN ONCOL, V20, P4448, DOI 10.1200/JCO.2002.01.038; Wei Y, 2014, WORLD J SURG ONCOL, V12, DOI 10.1186/1477-7819-12-400; Yilmaz A, 2013, MODERN PATHOL, V26, P579, DOI 10.1038/modpathol.2012.189	37	6	6	2	4	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	DEC	2018	82						113	124		10.1016/j.humpath.2018.07.016			12	Pathology	Pathology	HG4TV	WOS:000454968800014	30041024				2019-10-28	
J	Maloney, N; Giannikou, K; Lefferts, J; Bridge, JA; Linos, K				Maloney, Nolan; Giannikou, Krinio; Lefferts, Joel; Bridge, Julia A.; Linos, Konstantinos			Expanding the histomorphologic spectrum of TFE3-rearranged perivascular epithelioid cell tumors	HUMAN PATHOLOGY			English	Article						PEComa; Perivascular epithelioid cell; tumor; TFE3; TSC1; TSC2; Tuberous sclerosis complex	PECOMAS; GENE	Perivascular epithelioid cell tumors (PEComas) are a family of mesenchymal neoplasms that have smooth muscle and melanocytic differentiation. They can be sporadic or associated with tuberous sclerosis complex and commonly present in the kidney as angiomyolipoma or in the lung as pulmonary clear cell sugar tumors or lymphangioleiomyomatosis. However, they can present at any visceral or soft tissue site. They usually have a benign clinical course, but rarely can behave in a malignant fashion. Most PEComas demonstrate abnormalities of TSC2, but a recently described subset harbor TFE3 rearrangements that seem to be mutually exclusive of TSC2 alterations. TFE3-rearranged PEComas demonstrate a distinct alveolar morphology that lacks spindle cells and smooth muscle differentiation. Distinction between these may have important therapeutic consequences. Herein, we present a case of a TFE3-rearranged PEComa without the customary morphology that required ancillary investigation with TFE3 immunohistochemistry and break apart fluorescence in situ hybridization for proper categorization. (C) 2018 Elsevier Inc. All rights reserved.	[Maloney, Nolan; Lefferts, Joel; Linos, Konstantinos] Dartmouth Hitchcock Med Ctr, Dept Pathol & Lab Med, One Med Ctr Dr, Lebanon, NH 03756 USA; [Maloney, Nolan; Lefferts, Joel; Linos, Konstantinos] Geisel Sch Med Dartmouth, Lebanon, NH 03756 USA; [Giannikou, Krinio] Harvard Med Sch, Brigham & Womens Hosp, Dept Pulm & Crit Care Med & Genet, Boston, MA 02115 USA; [Bridge, Julia A.] Univ Nebraska Med Ctr, Dept Pathol & Microbiol, 983135 Nebraska Med Ctr, Omaha, NE 68198 USA	Linos, K (reprint author), Dartmouth Hitchcock Med Ctr, Dept Pathol & Lab Med, One Med Ctr Dr, Lebanon, NH 03756 USA.	Konstantinos.Linos@Hitchcock.org			The Engles Fund for TSC and LAM Research	This study was funded partially by The Engles Fund for TSC and LAM Research.	Agaram NP, 2015, AM J SURG PATHOL, V39, P813, DOI 10.1097/PAS.0000000000000389; Argani P, 2010, AM J SURG PATHOL, V34, P1395, DOI 10.1097/PAS.0b013e3181f17ac0; Bleeker Jonathan S., 2012, Sarcoma, P541626, DOI 10.1155/2012/541626; Broad Institute, BAS QUAL SCOR REC BQ; Dibble CC, 2012, MOL CELL, V47, P535, DOI 10.1016/j.molcel.2012.06.009; Dickson MA, 2013, INT J CANCER, V132, P1711, DOI 10.1002/ijc.27800; Folpe AL, 2005, AM J SURG PATHOL, V29, P1558, DOI 10.1097/01.pas.0000173232.22117.37; Giannikou K, 2016, PLOS GENET, V12, DOI 10.1371/journal.pgen.1006242; HENSKE EP, 1995, GENE CHROMOSOME CANC, V13, P295, DOI 10.1002/gcc.2870130411; Hornick JL, 2006, HISTOPATHOLOGY, V48, P75, DOI 10.1111/j.1365-2559.2005.02316.x; Jones E, 2017, TRANSL CANCER RES, V6, pS234, DOI 10.21037/tcr.2017.09.31; Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324; Malinowska I, 2012, AM J SURG PATHOL, V36, P783, DOI 10.1097/PAS.0b013e31824a8a37; McGregor SM, 2017, AM J SURG PATHOL, V41, P717, DOI 10.1097/PAS.0000000000000778; McKenna A, 2010, GENOME RES, V20, P1297, DOI 10.1101/gr.107524.110; Pan CC, 2008, J PATHOL, V214, P387, DOI 10.1002/path.2289; Rao Q, 2015, AM J SURG PATHOL, V39, P1181, DOI 10.1097/PAS.0000000000000502; Slade L, 2017, MOL CANCER RES, V15, P1637, DOI 10.1158/1541-7786.MCR-17-0320	18	1	1	0	0	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	DEC	2018	82						125	130		10.1016/j.humpath.2018.03.023			6	Pathology	Pathology	HG4TV	WOS:000454968800015	29626599				2019-10-28	
J	Wang, CY; Hahn, E; Slodkowska, E; Eskander, A; Enepekides, D; Higgins, K; Vesprini, D; Liu, SK; Downes, MR; Xu, B				Wang, Chiyun; Hahn, Elan; Slodkowska, Elzbieta; Eskander, Antoine; Enepekides, Danny; Higgins, Kevin; Vesprini, Danny; Liu, Stanley K.; Downes, Michelle R.; Xu, Bin			Reproducibility of PD-L1 immunohistochemistry interpretation across various types of genitourinary and head/neck carcinomas, antibody clones, and tissue types	HUMAN PATHOLOGY			English	Article						PD-L1 immunohistochemistry assay; Assay comparison; Head and neck carcinoma; Urothelial carcinoma; Prostatic carcinoma	CELL LUNG-CANCER; SQUAMOUS-CELL; EXPRESSION; IMMUNOTHERAPY; HEAD	Programmed death-ligand 1 (PD-L1) expression by tumor cells is a mechanism for down-regulation of antitumor T-cell responses and is a target for immunotherapy in various cancers. PD-L1 status as a predictor of treatment response has led to the development of multiple platforms with different reference cutoffs. We studied 128 cases of genitourinary and head/neck carcinomas, aiming to assess the frequency of PD-L1 positivity, interobserver reliability of PD-L1 interpretation, and the concordance of PD-L1 scoring between small samples from tissue microarray and whole sections using SP263 and SP142 clones. No prostatic carcinoma (0/21) was PD-L1 positive compared with 15% to 24% PD-L1 positivity in urothelial carcinoma (UC), hypo pharyngeal squamous cell carcinoma (HP-SCC), and high-grade salivary gland carcinoma. There was substantial interobserver agreement in determining overall PD-L1 positivity in UC and HP-SCC using SP263 (kappa = 0.702) and SP142 (kappa = 0.757) antibodies. Subgroup analysis for both antibodies showed excellent agreement in UC (kappa = 0.812 and 0.827) and moderate agreement in HP-SCC (kappa = 0.469 and 0.591). Moderate to substantial agreement between tissue microarray and whole sections was achieved using SP263 (overall, kappa = 0.573; UC, kappa = 0.424; and HP-SCC, kappa = 0.667) and SP142 (UC, kappa = 0.493). PD-L1 interpretation in genitourinary and head/neck carcinomas is reliable and reproducible among pathologists and across different tissue preparations. Tumor PD-L1 staining heterogeneity may lead to discrepant PD-L1 results between small biopsies and large sections from surgical resection in a subset of tumors (19% of UC and 15% of HP-SCC). Retesting in such cases may be required to determine patient suitability for anti PD-1/PD-L1 therapy. (C) 2018 Elsevier Inc. All rights reserved.	[Wang, Chiyun; Hahn, Elan; Slodkowska, Elzbieta; Downes, Michelle R.; Xu, Bin] Sunnybrook Hlth Sci Ctr, Dept Lab Med & Mol Diagnost, Toronto, ON M4N 3M5, Canada; [Wang, Chiyun; Hahn, Elan; Slodkowska, Elzbieta; Downes, Michelle R.; Xu, Bin] Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON M4N 3M5, Canada; [Eskander, Antoine; Enepekides, Danny; Higgins, Kevin] Sunnybrook Hlth Sci Ctr, Dept Otolaryngol Head & Neck Surg, Toronto, ON M4N 3M5, Canada; [Vesprini, Danny; Liu, Stanley K.] Univ Toronto, Dept Radiat Oncol, Toronto, ON M4N 3M5, Canada	Downes, MR (reprint author), Sunnybrook Hlth Sci Ctr, Anat Pathol, Room E417,2075 Bayview Ave, Toronto, ON M4N 3M5, Canada.; Xu, B (reprint author), Sunnybrook Hlth Sci Ctr, Anat Pathol, Room E428,2075 Bayview Ave, Toronto, ON M4N 3M5, Canada.	michelle.downes@sunnybrook.ca; bin1.xu@sunnybrook.ca		Liu, Stanley/0000-0001-6851-0857; Xu, Bin/0000-0003-4638-9835	Sunnybrook Health Sciences Centre departmental educational grant courtesy of AstraZeneca	The SP263 antibody was purchased using a Sunnybrook Health Sciences Centre departmental educational grant courtesy of AstraZeneca.	Berger KN, 2018, GENE, V638, P20, DOI 10.1016/j.gene.2017.09.050; Brunnstrom H, 2017, MODERN PATHOL, V30, P1411, DOI 10.1038/modpathol.2017.59; Chen YP, 2017, THERANOSTICS, V7, P3585, DOI 10.7150/thno.21471; Cho YA, 2011, ORAL ONCOL, V47, P1148, DOI 10.1016/j.oraloncology.2011.08.007; Cohen RB, 2018, AM J CLIN ONCOL-CANC, V41, P1083, DOI 10.1097/COC.0000000000000429; Cooper WA, 2017, CLIN CANCER RES, V23, P4569, DOI 10.1158/1078-0432.CCR-17-0151; De Meulenaere A, 2017, ONCOTARGET, V8, P80443, DOI 10.18632/oncotarget.19045; Diggs LP, 2017, BIOMARK RES, V5, DOI 10.1186/s40364-017-0093-8; El-Naggar A, 2017, WHO CLASSIFICATION H; Fankhauser Christian D, 2018, Oncotarget, V9, P10284, DOI 10.18632/oncotarget.22888; Graff JN, 2016, ONCOTARGET, V7, P52810, DOI 10.18632/oncotarget.10547; Harada K, 2018, BMC CANCER, V18, DOI 10.1186/s12885-018-4069-3; Hirsch FR, 2017, J THORAC ONCOL, V12, P208, DOI 10.1016/j.jtho.2016.11.2228; Hodgson A, 2018, AM J SURG PATHOL, V42, P1059, DOI 10.1097/PAS.0000000000001084; Koshkin VS, 2018, CURR ONCOL REP, V20, DOI 10.1007/s11912-018-0693-y; Li C, 2017, J THORAC ONCOL, V12, P1536, DOI 10.1016/j.jtho.2017.07.015; Mukaigawa T, 2016, J SURG ONCOL, V114, P36, DOI 10.1002/jso.24266; Ning YM, 2017, ONCOLOGIST, V22, P743, DOI 10.1634/theoncologist.2017-0087; Notsuda H, 2017, J THORAC ONCOL, V12, P422, DOI 10.1016/j.jtho.2017.01.007; Outh-Gauer S, 2018, CANCER TREAT REV, V65, P54, DOI 10.1016/j.ctrv.2018.02.008; Powles T, 2017, JAMA ONCOL, V3, DOI 10.1001/jamaoncol.2017.2411; Ratcliffe MJ, 2017, CLIN CANCER RES, V23, P3585, DOI 10.1158/1078-0432.CCR-16-2375; Rebelatto MC, 2016, DIAGN PATHOL, V11, DOI 10.1186/s13000-016-0545-8; Rehman JA, 2017, MODERN PATHOL, V30, P340, DOI 10.1038/modpathol.2016.186; Rimm DL, 2017, JAMA ONCOL, V3, P1051, DOI 10.1001/jamaoncol.2017.0013; Rosenberg JE, 2016, LANCET, V387, P1909, DOI 10.1016/S0140-6736(16)00561-4; Russell-Goldman E, 2018, CANCER CYTOPATHOL, V126, P253, DOI 10.1002/cncy.21973; Satgunaseelan L, 2016, PATHOLOGY, V48, P574, DOI 10.1016/j.pathol.2016.07.003; Scheel AH, 2016, MODERN PATHOL, V29, P1165, DOI 10.1038/modpathol.2016.117; Strome SE, 2003, CANCER RES, V63, P6501; Tretiakova M, 2018, MODERN PATHOL, V31, P623, DOI 10.1038/modpathol.2017.188; Tsao MS, 2017, INT ASS STUDY LUNG C; Velho PI, 2018, EXPERT REV CLIN PHAR, V11, P475, DOI 10.1080/17512433.2018.1464388; Ventana Medical Systems, 2017, VENTANA PD L1 SP263; Ventana Medical Systems, 2016, VENTANA PD L1 SP142	35	4	4	0	1	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	DEC	2018	82						131	139		10.1016/j.humpath.2018.07.024			9	Pathology	Pathology	HG4TV	WOS:000454968800016	30075156				2019-10-28	
J	Deeken-Draisey, A; Yang, GY; Gao, JH; Alexiev, BA				Deeken-Draisey, Audrey; Yang, Guang-Yu; Gao, Juehua; Alexiev, Borislav A.			Anaplastic thyroid carcinoma: an epidemiologic, histologic, immunohistochemical and molecular single-institution study	HUMAN PATHOLOGY			English	Article						Anaplastic thyroid carcinoma; Pathology; Immunohistochemistry; Gene mutations; Differential diagnosis	PAUCICELLULAR VARIANT; GIANT-CELLS; CANCER; TUMORS	Anaplastic thyroid carcinoma (ATC) is a highly aggressive form of thyroid cancer. A single institution thyroid cancer cohort of ATC was identified within the last 10 years at our institution. Retrospective analysis revealed that the frequency of ATC was 0.5% (11/2106 thyroid carcinomas). The average age at diagnosis of ATC was 74 years, and the female-to-male ratio was 1.2:1. ATC presented as a rapidly enlarging neck mass involving predominantly the left thyroid lobe (7/11; 64%). Cervical adenopathy was present in 7 (64%) of 11 cases. Fifty-five percent (6/11) of patients had distant metastases at the time of diagnosis. Histologically, ATC closely simulated a large variety of soft tissue sarcomas; osteoclast-like giant cell rich tumors; squamous cell, spindle cell, and small cell carcinomas; and anaplastic/large cell lymphomas. Four tumors (4/11; 36%) showed heterologous elements, including rhabdoid and chondroid differentiation. Immunohistochemical studies showed that all ATCs lost TTF-1 and thyroglobulin expression, whereas PAX-8 expression was identified in 36% (4/11) of tumors. Intense and extensive nuclear staining of p53 (>50%) and high Ki-67 proliferative rate (>30%) were seen in all ATCs (11/11; 100%). Next-generation sequencing revealed recurrent BRAF V600E and TP53 gene mutations. Individual examples of a BRAF G469A mutation in ATC with follicular carcinoma component, EGFR, PTEN, PIK3CA, and FGFR3 mutations, were also identified, whereas 1 case of ATC showed wild-type sequencing with no identifiable alterations. (C) 2018 Elsevier Inc. All rights reserved.	[Deeken-Draisey, Audrey; Yang, Guang-Yu; Gao, Juehua; Alexiev, Borislav A.] Northwestern Univ, Feinberg Sch Med, Northwestern Mem Hosp, Dept Pathol, Chicago, IL 60611 USA	Alexiev, BA (reprint author), Northwestern Univ, Feinberg Sch Med, Northwestern Mem Hosp, Dept Pathol, Chicago, IL 60611 USA.	Borislav.Alexiev@northwestern.edu					Albores-Saavedra J, 2007, AM J SURG PATHOL, V31, P729, DOI 10.1097/01.pas.0000213417.00386.74; ALDINGER KA, 1978, CANCER-AM CANCER SOC, V41, P2267, DOI 10.1002/1097-0142(197806)41:6<2267::AID-CNCR2820410627>3.0.CO;2-7; Amin MB, 2017, AJCC CANC STAGING MA; Aschebrook-Kilfoy B, 2011, THYROID, V21, P125, DOI 10.1089/thy.2010.0021; Baloch ZW, 2018, HISTOPATHOLOGY, V72, P40, DOI 10.1111/his.13348; Bishop JA, 2011, HUM PATHOL, V42, P1873, DOI 10.1016/j.humpath.2011.02.004; Canos JC, 2001, ENDOCR PATHOL, V12, P157, DOI 10.1385/EP:12:2:157; CARCANGIU ML, 1985, AM J CLIN PATHOL, V83, P135, DOI 10.1093/ajcp/83.2.135; Forbes SA, 2017, NUCLEIC ACIDS RES, V45, pD777, DOI 10.1093/nar/gkw1121; GAFFEY MJ, 1991, AM J SURG PATHOL, V15, P160, DOI 10.1097/00000478-199102000-00009; Gauchotte G, 2011, PATHOLOGY, V43, P447, DOI 10.1097/PAT.0b013e3283486178; Haddad RI, 2015, J NATL COMPR CANC NE, V13, P1140, DOI 10.6004/jnccn.2015.0139; Hundahl SA, 2000, CANCER, V89, P202, DOI 10.1002/1097-0142(20000701)89:1<202::AID-CNCR27>3.0.CO;2-A; KOBAYASHI S, 1987, ACTA PATHOL JAPON, V37, P807; Lancia I, 2016, J CLIN INVEST, V126, P1052, DOI 10.1172/JCI85271; Lim SM, 2012, YONSEI MED J, V53, P352, DOI 10.3349/ymj.2012.53.2.352; LIVOLSI VA, 1987, AM J CLIN PATHOL, V87, P434, DOI 10.1093/ajcp/87.4.434; Lloyd RV, 2017, WHO CLASSIFICATION T; Nagaiah G, 2011, J ONCOL, DOI 10.1155/2011/542358; Njim L, 2008, ANN PATHOL, V28, P221, DOI 10.1016/j.annpat.2008.06.006; Olthof M, 2008, ENDOCR PATHOL, V19, P62, DOI 10.1007/s12022-008-9017-3; ORDONEZ NG, 1991, AM J CLIN PATHOL, V96, P15, DOI 10.1093/ajcp/96.1.15; Ragazzi M, 2014, INT J ENDOCRINOL, DOI 10.1155/2014/790834; Rivera M, 2010, ACTA CYTOL, V54, P668, DOI 10.1159/000325230; Robinson JT, 2011, NAT BIOTECHNOL, V29, P24, DOI 10.1038/nbt.1754; SHVERO J, 1988, CANCER-AM CANCER SOC, V62, P319, DOI 10.1002/1097-0142(19880715)62:2<319::AID-CNCR2820620216>3.0.CO;2-T; Siironen P, 2010, ONCOLOGY-BASEL, V79, P400, DOI 10.1159/000322640; Smallridge RC, 2009, ENDOCR-RELAT CANCER, V16, P17, DOI 10.1677/ERC-08-0154; Sugitani I, 2012, WORLD J SURG, V36, P1247, DOI 10.1007/s00268-012-1437-z; Sun CZ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080011; Thorvaldsdottir H, 2013, BRIEF BIOINFORM, V14, P178, DOI 10.1093/bib/bbs017; Troch M, 2010, J CLIN ENDOCR METAB, V95, pE54, DOI 10.1210/jc.2009-2827; VENKATESH YSS, 1990, CANCER-AM CANCER SOC, V66, P321, DOI 10.1002/1097-0142(19900715)66:2<321::AID-CNCR2820660221>3.0.CO;2-A; Wan SK, 1996, AM J CLIN PATHOL, V105, P388; Xu B, 2016, ENDOCR PATHOL, V27, P205, DOI 10.1007/s12022-016-9445-4; Yau T, 2008, ANN SURG ONCOL, V15, P2500, DOI 10.1245/s10434-008-0005-0	36	2	2	0	0	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	DEC	2018	82						140	148		10.1016/j.humpath.2018.07.027			9	Pathology	Pathology	HG4TV	WOS:000454968800017	30075157				2019-10-28	
J	Malgulwar, PB; Nambirajan, A; Pathak, P; Rajeshwari, M; Suri, V; Sarkar, C; Singh, M; Sharma, MC				Malgulwar, Prit Benny; Nambirajan, Aruna; Pathak, Pankaj; Rajeshwari, Madhu; Suri, Vaishali; Sarkar, Chitra; Singh, Manmohan; Sharma, Mehar Chand			Epithelial-to-mesenchymal transition related transcription factors are up-regulated in ependymomas and correlate with a poor prognosis	HUMAN PATHOLOGY			English	Article						Ependymomas; EMT; Snail/SNA11; Slug/SNA12; Twist1; Molecular subgroups	C11ORF95-RELA FUSION PRESENT; E-CADHERIN; SUPRATENTORIAL EPENDYMOMA; DIFFERENTIAL EXPRESSION; BETA-CATENIN; N-CADHERIN; PATHWAY; GLIOBLASTOMA; COMPARTMENTS; INVASION	Epithelial-to-mesenchymal transition (EMT) plays an important role in invasion and metastasis of various cancers including gliomas. EMT has also been linked to cancer stem cells and resistance to chemotherapy. An initial in-silico data mining in a published ependymoma (EPN) patient series (GSE21687) revealed up-regulation of EMT transcription factors in tumor samples. Furthermore, quantitative real-time polymerase chain reaction based gene expression analysis of EMT transcription factors in 96 EPNs showed significant up-regulation of SNAI1, SNAI2,ZEB1, and TWIST] as compared with normal brain, associated with up-regulation of CDH2/N-cadherin and down-regulation of CDH1/E-cadherin. Although this was observed in varying degrees in all clinicopathological-molecular subgroups of EPNs, it was most evident in supratentorial EPNs harboring fusions of RELA (v-rel avian reticuloendotheliosis viral oncogene homolog A) gene and in posterior fossa EPNs. Immunohistochemistry performed in 60 of the above cases corroborated with gene expression patterns, and immunopositivity for Snail, Slug, Zeb1, and Twist1 was observed in 80%, 80%, 81%, and 63% of all EPNs. Immunopositivity for N-cadherin and E-cadherin was observed in 76.6% and 2% of the cases, respectively. Univariate Cox regression analysis showed that low expression of CDH1/E-cadherin (P =.002) and high expression levels of CDH2/N-cadherin (P<.001), SNAl1/Snail (P =.023), SNAI2/Slug (P <.001), and ZEB1 (P <.001) were associated with shorter progression-free survival. Here, we report for the first time the existence of EMT-like phenotype in EPNs. These factors could represent new prognostic and therapeutic targets in EPN. (C) 2018 Elsevier Inc. All rights reserved.	[Malgulwar, Prit Benny; Nambirajan, Aruna; Pathak, Pankaj; Rajeshwari, Madhu; Suri, Vaishali; Sarkar, Chitra; Sharma, Mehar Chand] All India Inst Med Sci, Dept Pathol, New Delhi 110029, India; [Singh, Manmohan] All India Inst Med Sci, Dept Neurosurg, New Delhi 110029, India	Sharma, MC (reprint author), All India Inst Med Sci, Dept Pathol, New Delhi 110029, India.	sharmamehar@yahoo.co.in			AIIMS Intramural Research grants; Science and Engineering Research Board [EMR/2016/003365]; Indian Council of Medical Research, IndiaIndian Council of Medical Research [3/2/3/284/2014/NCD-III]; Neurosciences Centre, AIIMS	The authors are thankful to Neurosciences Centre, AIIMS; AIIMS Intramural Research grants; and Science and Engineering Research Board (EMR/2016/003365) for financial support of the work. Prit Benny Malgulwar is a Senior Research Fellowship awardee (No. 3/2/3/284/2014/NCD-III) from the Indian Council of Medical Research, India.	Nieto MA, 2011, ANNU REV CELL DEV BI, V27, P347, DOI 10.1146/annurev-cellbio-092910-154036; Buehler D, 2013, MODERN PATHOL, V26, P54, DOI 10.1038/modpathol.2012.137; Cachia D, 2015, BRAIN TUMOR PATHOL, V32, P105, DOI 10.1007/s10014-014-0205-1; Ellison DW, 2011, J NEGAT RESULTS BIOM, V10, DOI 10.1186/1477-5751-10-7; Ellison DW, 2016, WHO CLASSIFICATION T, P106; FIGARELLABRANGER D, 1995, ACTA NEUROPATHOL, V89, P248; Glickman MH, 2002, PHYSIOL REV, V82, P373, DOI 10.1152/physrev.00027.2001; Han SP, 2011, CELL MOL NEUROBIOL, V31, P489, DOI 10.1007/s10571-010-9643-4; Johnson RA, 2010, NATURE, V466, P632, DOI 10.1038/nature09173; Kahlert UD, 2013, CANCER LETT, V331, P131, DOI 10.1016/j.canlet.2012.12.010; Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104; Kim SI, 2017, J PATHOL TRANSL MED, V51, P588, DOI 10.4132/jptm.2017.08.10; Malgulwar PB, 2018, J NEURO-ONCOL, V138, P29, DOI 10.1007/s11060-018-2767-y; Mikheeva SA, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-194; Motta FJN, 2008, GENET MOL RES, V7, P295, DOI 10.4238/vol7-2gmr424; Myung JK, 2014, INT J CLIN EXP PATHO, V7, P1977; Nagaishi M, 2012, BRAIN PATHOL, V22, P670, DOI 10.1111/j.1750-3639.2012.00571.x; Nambirajan A, 2014, NEUROPATH APPL NEURO, V40, P714, DOI 10.1111/nan.12097; Nambirajan A, 2016, NEUROPATHOLOGY, V36, P490, DOI 10.1111/neup.12299; Nomura A, 2016, LAB INVEST, V96, P1268, DOI 10.1038/labinvest.2016.109; Nordfors K, 2013, HISTOL HISTOPATHOL, V28, P1137, DOI 10.14670/HH-28.1137; Pajtler KW, 2017, ACTA NEUROPATHOL, V133, P5, DOI 10.1007/s00401-016-1643-0; Pajtler KW, 2015, CANCER CELL, V27, P728, DOI 10.1016/j.ccell.2015.04.002; Parker M, 2014, NATURE, V506, P451, DOI 10.1038/nature13109; Pires BRB, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0169622; Qi ST, 2012, HISTOPATHOLOGY, V61, P711, DOI 10.1111/j.1365-2559.2012.04297.x; Rajeshwari M, 2016, J NEURO-ONCOL, V127, P271, DOI 10.1007/s11060-015-2047-z; Schwechheimer K, 1998, VIRCHOWS ARCH, V432, P163, DOI 10.1007/s004280050151; Siebzehnrubl FA, 2013, EMBO MOL MED, V5, P1196, DOI 10.1002/emmm.201302827; Utsuki S, 2002, J NEURO-ONCOL, V57, P187, DOI 10.1023/A:1015720220602; Witt H, 2011, CANCER CELL, V20, P143, DOI 10.1016/j.ccr.2011.07.007; Wu WH, 2013, INT J NEUROSCI, V123, P318, DOI 10.3109/00207454.2012.758123; Yang HW, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-301; Yokoi K, 2007, CHILD NERV SYST, V23, P237, DOI 10.1007/s00381-006-0197-1; Zarkoob H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064169	35	1	1	0	2	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	DEC	2018	82						149	157		10.1016/j.humpath.2018.07.018			9	Pathology	Pathology	HG4TV	WOS:000454968800018	30067950				2019-10-28	
J	Hoskoppal, D; Reisenbichler, ES				Hoskoppal, Deepthi; Reisenbichler, Emily S.			Can tumor-associated macrophages in ductal carcinoma in situ on biopsy predict invasive carcinoma on excision?	HUMAN PATHOLOGY			English	Article						Ductal carcinoma in situ (DCIS); CD163; Active surveillance; Invasion upgrade; Macrophages	BREAST-CANCER; LOW-RISK; EXPRESSION; POPULATION; RECURRENCE; DISEASE	Recent trials have explored surveillance of ductal carcinoma in situ (DCIS) without complete excision, but it is difficult to fully exclude an associated, unsampled invasive focus. Tumor microenvironment, including tumor-associated macrophages, may play a role in the transition from in situ to invasive carcinoma, and the presence of CD163-positive cells with DCIS has been associated with increased risk of progression to invasive carcinoma. We aimed to evaluate the role of DCIS-associated CD163-positive cells on biopsy in predicting associated invasion on excision. Immunohistochemistry for CD163 was performed on 57 total biopsy cases of DCIS of low (n=13), intermediate (n=21), and high (n=23) nuclear grade, 27 (47%) of which showed invasion on the subsequent excision specimen. Positive intratumoral and stromal cells were quantified independently by 2 observers based on the percentage of cells staining. Intratumoral CD163 scores ranged from 0 to 2 (mean, 0.7). Stromal CD163 scores ranged from 0 to 3 (mean, 1.3). lntratumoral and stromal CD163 levels were not significantly associated with the presence of subsequent invasion when evaluated as a whole group (P=.36 and P=.47) or when subdivided into low (P=.36 and P=.17), intermediate (P=.82 and P=.82), or high (P=.09 and P=.68) nuclear grades. There was no correlation between intratumoral CD163 content and DCIS grade (P=.257). A trend for higher stromal CD163 expression was seen with higher-grade DCIS, although not statistically significant (P=.178). In conclusion, CD163 on breast core biopsy does not help select patients who may safely forgo excision of DCIS. (C) 2018 Elsevier Inc. All rights reserved.	[Hoskoppal, Deepthi] Vanderbilt Univ, Med Ctr, Dept Pathol Microbiol & Immunol, Nashville, TN 37232 USA; [Reisenbichler, Emily S.] Yale Univ, Dept Pathol, New Haven, CT 06520 USA	Reisenbichler, ES (reprint author), Yale Univ, POB 208023, New Haven, CT 06520 USA.	emily.reisenbichler@yale.edu		Reisenbichler, Emily/0000-0002-1570-6538			Acerbi I, 2015, INTEGR BIOL-UK, V7, P1120, DOI 10.1039/c5ib00040h; Allegra Carmen J, 2009, NIH Consens State Sci Statements, V26, P1; Collins LC, 2004, AM J SURG PATHOL, V28, P126, DOI 10.1097/00000478-200401000-00015; Dillon MF, 2006, J SURG ONCOL, V93, P559, DOI 10.1002/jso.20445; Ding JX, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041942; Fortis SP, 2017, J IMMUNOTHER CANCER, V5, DOI 10.1186/s40425-017-0240-7; Francis A, 2015, CLIN ONCOL-UK, V27, P6, DOI 10.1016/j.clon.2014.09.015; Hussein MR, 2006, J CLIN PATHOL, V59, P972, DOI 10.1136/jcp.2005.031252; Lindsten T, 2017, INT J ONCOL, V51, P104, DOI 10.3892/ijo.2017.3996; Medrek C, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-306; Nolte DA, 2017, MODERN PATHOL, V30, p62A; Pilewskie M, 2016, ANN SURG ONCOL, V23, P3487, DOI 10.1245/s10434-016-5268-2; Podoll MB, 2018, ARCH PATHOL LAB MED, V142, P1120, DOI 10.5858/arpa.2017-0268-OA; Shabo I, 2008, INT J CANCER, V123, P780, DOI 10.1002/ijc.23527; Sharma M, 2010, BREAST CANCER RES TR, V123, P397, DOI 10.1007/s10549-009-0654-0; Sica A, 2006, EUR J CANCER, V42, P717, DOI 10.1016/j.ejca.2006.01.003; Silverstein MJ, 2015, BREAST J, V21, P127, DOI 10.1111/tbj.12368; Solin LJ, 2013, JNCI-J NATL CANCER I, V105, P701, DOI 10.1093/jnci/djt067; Sousa S, 2015, BREAST CANCER RES, V17, DOI 10.1186/s13058-015-0621-0; Virnig BA, 2010, J NATL CANCER I, V102, P170, DOI 10.1093/jnci/djp482; Wang L, 2017, INT J CLIN EXP PATHO, V10, P7743; Youngwirth Linda M, 2017, Bull Am Coll Surg, V102, P62	22	0	0	0	1	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	DEC	2018	82						158	162		10.1016/j.humpath.2018.07.023			5	Pathology	Pathology	HG4TV	WOS:000454968800019	30067949				2019-10-28	
J	Birkman, EM; Avoranta, T; Algars, A; Korkeila, E; Lintunen, M; Lahtinen, L; Kuopio, T; Ristamaki, R; Carpen, O; Sundstrom, J				Birkman, Eva-Maria; Avoranta, Tuulia; Algars, Annika; Korkeila, Eija; Lintunen, Minnamaija; Lahtinen, Laura; Kuopio, Teijo; Ristamaki, Raija; Carpen, Olli; Sundstrom, Jari			EGFR gene copy number decreases during anti-EGFR antibody therapy in colorectal cancer	HUMAN PATHOLOGY			English	Article						Colorectal cancer; Epidermal growth factor receptor; Gene copy number; Silver in situ hybridization; Monoclonal antibody	ACQUIRED-RESISTANCE; CETUXIMAB THERAPY; PREDICTS RESPONSE; RAS MUTATIONS; WILD-TYPE; KRAS; HETEROGENEITY; METAANALYSIS; BLOCKADE; BENEFIT	Epidermal growth factor receptor (EGFR) gene copy number (GCN) increase is associated with a favorable anti-EGFR antibody treatment response in RAS wild-type metastatic colorectal cancer. However, there are limited and comparative data regarding the EGFR GCN in primary colorectal cancer tumors and corresponding metastases or the effect of anti-EGFR antibody treatment on EGFR GCN in recurrent disease. In addition, little is known about the potential EGFR GCN changes during anti-EGFR therapy in comparison with other treatment regimens. EGFR GCN was analyzed by EGFR immunohistochemistry-guided silver in situ hybridization in primary and corresponding recurrent local or metastatic tumors from 80 colorectal cancer patients. GCN levels were compared between KRAS wild-type patients having received antiEGFR therapy and patients having received other forms of treatment after primary surgery. The EGFR GCN decrease between primary and recurrent tumors was more pronounced among the anti EGFR-treated patients than among patients not treated with anti-EGFR therapy (P=.047). None of the patients experiencing an EGFR GCN increase of at least 1.0 between the primary and recurrent tumors were treated with antiEGFR antibodies. When including only patients with distant metastases, an EGFR GCN decrease of at least 1.0 was more common among the anti EGFR-treated patients than among patients not treated with anti-EGFR therapy (P=.028). Our results suggest that anti-EGFR antibody treatment is associated with EGFR GCN decrease between the primary and recurrent colorectal adenocarcinomas, whereas no GCN change is observed among patients receiving other forms of treatment after primary surgery. (C) 2018 The Authors. Published by Elsevier Inc.	[Birkman, Eva-Maria; Avoranta, Tuulia; Sundstrom, Jari] Univ Turku, Dept Pathol, FIN-20520 Turku, Finland; [Birkman, Eva-Maria; Lintunen, Minnamaija; Sundstrom, Jari] Turku Univ Hosp, Dept Pathol, FIN-20520 Turku, Finland; [Avoranta, Tuulia; Algars, Annika; Korkeila, Eija; Ristamaki, Raija] Turku Univ Hosp, Dept Oncol, Turku 20521, Finland; [Algars, Annika] Univ Turku, MediC Res Lab, FIN-20520 Turku, Finland; [Lahtinen, Laura; Kuopio, Teijo] Cent Finland Cent Hosp, Dept Pathol, Jyvaskyla 40620, Finland; [Kuopio, Teijo] Univ Jyvaskyla, Dept Biol & Environm Sci, Jyvaskyla 40014, Finland; [Carpen, Olli] Univ Helsinki, Pathol, Res Programs Unit, FIN-00014 Helsinki, Finland; [Carpen, Olli] Univ Helsinki, HUSLAB, FIN-00014 Helsinki, Finland; [Carpen, Olli] Helsinki Univ Hosp, Helsinki 00014, Finland; [Carpen, Olli] Univ Turku, Auria Biobank, Turku, Finland; [Carpen, Olli] Turku Univ Hosp, Turku 20521, Finland	Birkman, EM (reprint author), Univ Turku, Kiinamyllynkatu 10, FIN-20520 Turku, Finland.	emabir@utu.fi		Lahtinen, Laura/0000-0001-7559-2168	Turku University Foundation; Finnish Medical Foundation; Cancer Society of Southwest Finland; Research Foundation of Clinical Chemistry, Finland	This study was supported by the Turku University Foundation, The Finnish Medical Foundation, The Cancer Society of Southwest Finland, and The Research Foundation of Clinical Chemistry, Finland. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Algars A, 2011, BRIT J CANCER, V105, P255, DOI 10.1038/bjc.2011.223; Algars A, 2017, INT J CANCER, V140, P922, DOI 10.1002/ijc.30507; Algars A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099590; Allegra CJ, 2016, J CLIN ONCOL, V34, P179, DOI 10.1200/JCO.2015.63.9674; Altman DG, 2012, BMC MED, V10, DOI 10.1186/1741-7015-10-51; Amado RG, 2008, J CLIN ONCOL, V26, P1626, DOI 10.1200/JCO.2007.14.7116; Atreya CE, 2015, J CLIN ONCOL, V33, P682, DOI 10.1200/JCO.2014.58.9325; Bardelli A, 2013, CANCER DISCOV, V3, P658, DOI 10.1158/2159-8290.CD-12-0558; Bertotti A, 2015, NATURE, V526, P263, DOI 10.1038/nature14969; Bronte G, 2015, ONCOTARGET, V6, P24780, DOI 10.18632/oncotarget.4959; Cappuzzo F, 2008, ANN ONCOL, V19, P717, DOI 10.1093/annonc/mdm492; Ciardiello F, 2008, NEW ENGL J MED, V358, P1160, DOI 10.1056/NEJMra0707704; Diaz LA, 2012, NATURE, V486, P537, DOI 10.1038/nature11219; Eisenhauer EA, 2009, EUR J CANCER, V45, P228, DOI 10.1016/j.ejca.2008.10.026; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Lievre A, 2006, CANCER RES, V66, P3992, DOI 10.1158/0008-5472.CAN-06-0191; Linardou H, 2008, LANCET ONCOL, V9, P962, DOI 10.1016/S1470-2045(08)70206-7; Misale S, 2014, CANCER DISCOV, V4, P1269, DOI 10.1158/2159-8290.CD-14-0462; Misale S, 2012, NATURE, V486, P532, DOI 10.1038/nature11156; Molinari F, 2009, BRIT J CANCER, V100, P1087, DOI 10.1038/sj.bjc.6604848; Moroni M, 2005, LANCET ONCOL, V6, P279, DOI 10.1016/S1470-2045(05)70102-9; Park JH, 2011, CANCER CHEMOTH PHARM, V68, P1045, DOI 10.1007/s00280-011-1586-z; Personeni N, 2008, CLIN CANCER RES, V14, P5869, DOI 10.1158/1078-0432.CCR-08-0449; Pietrantonio F, 2017, CLIN CANCER RES, V23, P2414, DOI 10.1158/1078-0432.CCR-16-1863; Sartore-Bianchi A, 2007, J CLIN ONCOL, V25, P3238, DOI 10.1200/JCO.2007.11.5956; Scartozzi M, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-303; Sorich MJ, 2015, ANN ONCOL, V26, P13, DOI 10.1093/annonc/mdu378; Vakiani E, 2017, ONCOTARGET, V8, P42487, DOI 10.18632/oncotarget.17200; Yonesaka K, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002442	29	0	0	1	1	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	DEC	2018	82						163	171		10.1016/j.humpath.2018.07.028			9	Pathology	Pathology	HG4TV	WOS:000454968800020	30096327	Green Published			2019-10-28	
J	Shinozaki-Ushiku, A; Higashihara, T; Ikemura, M; Sato, J; Nangaku, M; Ushiku, T; Fukayama, M				Shinozaki-Ushiku, Aya; Higashihara, Takaaki; Ikemura, Masako; Sato, Junichiro; Nangaku, Masaomi; Ushiku, Tetsuo; Fukayama, Masashi			Glomeruloid hemangioma associated with TAFRO syndrome	HUMAN PATHOLOGY			English	Article						Glomeruloid hemangioma; TAFRO syndrome; Multicentric Castleman disease; POEMS syndrome; Immunoglobulin		Glomeruloid hemangioma is a rare cutaneous lesion that has been considered as a specific cutaneous marker of POEMS syndrome. Herein, we present the first case of glomeruloid hemangioma associated with TAFRO syndrome, a unique variant of idiopathic multicentric Castleman disease. The patient is a 74-year-old woman presented with fever, cervical lymphadenopathy, thrombocytopenia, bilateral pleural effusions and ascites. Biopsy of the lymph node revealed multicentric Castleman disease-like histology and bone marrow biopsy showed mild reticulin fibrosis, consistent with TAFRO syndrome. The patient simultaneously developed multiple skin lesions, which were histologically confirmed as glomeruloid hemangioma. Multiple immunoglobulin-positive granules were detected in the proliferating endothelial cells. Glomeruloid hemangioma is not specific to POEMS syndrome and can be a manifestation of TAFRO syndrome. (C) 2018 Elsevier Inc. All rights reserved.	[Shinozaki-Ushiku, Aya; Ikemura, Masako; Ushiku, Tetsuo; Fukayama, Masashi] Univ Tokyo, Grad Sch Med, Dept Pathol, Tokyo 1130033, Japan; [Higashihara, Takaaki; Sato, Junichiro; Nangaku, Masaomi] Univ Tokyo, Grad Sch Med, Dept Nephrol & Endocrinol, Tokyo 1130033, Japan	Fukayama, M (reprint author), Univ Tokyo, Grad Sch Med, Dept Pathol, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1130033, Japan.	mfiikayama-tky@umin.ac.jp					CHAN JKC, 1990, AM J SURG PATHOL, V14, P1036, DOI 10.1097/00000478-199011000-00005; Flatley EM, 2015, AM J SURG PATHOL, V39, P864, DOI 10.1097/PAS.0000000000000406; Forman SB, 2007, J CUTAN PATHOL, V34, P956, DOI 10.1111/j.1600-0560.2007.00742.x; Gonzalez-Guerra E, 2009, CLIN EXP DERMATOL, V34, P800, DOI 10.1111/j.1365-2230.2008.02997.x; Gupta V, 2016, INDIAN J DERMATOL VE, V82, P442, DOI 10.4103/0378-6323.181461; Iwaki N, 2016, AM J HEMATOL, V91, P220, DOI 10.1002/ajh.24242; Kawabata H, 2013, J CLIN EXP HEMATOP, V53, P57, DOI 10.3960/jslrt.53.57; Lee H, 2008, AM J DERMATOPATH, V30, P539, DOI 10.1097/DAD.0b013e318182c800; RONGIOLETTI F, 1994, AM J DERMATOPATH, V16, P175, DOI 10.1097/00000372-199404000-00013; Takai Kazue, 2010, Rinsho Ketsueki, V51, P320; Velez D, 2005, J CUTAN PATHOL, V32, P449, DOI 10.1111/j.0303-6987.2005.00353.x; Yamamoto T, 2007, J EUR ACAD DERMATOL, V21, P417, DOI 10.1111/j.1468-3083.2006.01905.x; Yang SG, 1998, AM J DERMATOPATH, V20, P266, DOI 10.1097/00000372-199806000-00008; Yuri T, 2008, PATHOL INT, V58, P390, DOI 10.1111/j.1440-1827.2008.02241.x	14	1	1	0	0	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	DEC	2018	82						172	176		10.1016/j.humpath.2018.04.011			5	Pathology	Pathology	HG4TV	WOS:000454968800021	29702119				2019-10-28	
J	Lee, HE; Churg, A; Ryu, JH; Bilawich, AM; Larsen, BT; Tazelaar, HD; Yi, ES				Lee, Hee Eun; Churg, Andrew; Ryu, Jay H.; Bilawich, Ana Maria; Larsen, Brandon T.; Tazelaar, Henry D.; Yi, Eunhee S.			Histopathologic findings in lung biopsies from patients with primary biliary cholangitis	HUMAN PATHOLOGY			English	Article						Primary biliary cirrhosis; Primary biliary cholangitis; Interstitial lung disease; Connective tissue disease; Autoimmune disease; Lung; Histopathologic findings	PULMONARY INVOLVEMENT; DISEASE; CIRRHOSIS	Primary biliary cholangitis (PBC) is a progressive autoimmune disease of the liver causing destruction of intrahepatic bile ducts, associated with lymphocytic and granulomatous inflammation. PBC has been associated with many extrahepatic manifestations including interstitial lung disease. However, comprehensive pulmonary histopathology in PBC has not been well documented. Sixteen PBC patients who underwent lung biopsies were identified from surgical pathology files in three institutions. Histopathologic review was performed. Patient age ranged 41 to 79 years (median 55 years) and 15 patients (94%) were women. Specimens consisted of lobectomy (n = 1), surgical biopsies (n = 12), transthoracic needle biopsy (n = 1) and transbronchial biopsy (n = 2). Fifteen of 16 (94%) cases showed lymphocytic inflammation, mainly localized to peribronchiolar stroma and alveolar septa. Thirteen (81%) cases revealed non-necrotizing granulomas, most of which were poorly formed, reminiscent of those seen in liver biopsies from PBC patients. Six cases also showed eosinophilic infiltrates. Organizing pneumonia was seen in 7 cases. Four cases showed diffuse interstitial fibrosis with nonspecific interstitial pneumonia and usual interstitial pneumonia patterns. One patient underwent lobectomy for a mass lesion and was diagnosed with light chain deposition disease with underlying kappa-restricted extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue. In summary, PBC-associated histopathologic changes in the lung include lymphocytic inflammation predominantly around small airways and non-necrotizing granulomas in multiple compartments of lung tissue, which parallel PBC-associated histopathology in liver biopsies, often associated with other common patterns of diffuse lung disease. (C) 2018 Elsevier Inc. All rights reserved.	[Lee, Hee Eun; Yi, Eunhee S.] Mayo Clin, Div Anat Pathol, Rochester, MN 55905 USA; [Churg, Andrew] Univ British Columbia, Dept Pathol, Vancouver, BC V6T 2B5, Canada; [Ryu, Jay H.] Mayo Clin, Div Pulm & Crit Care Med, Rochester, MN 55905 USA; [Bilawich, Ana Maria] Univ British Columbia, Dept Radiol, Vancouver, BC V6T 2B5, Canada; [Larsen, Brandon T.; Tazelaar, Henry D.] Mayo Clin, Div Anat Pathol, Scottsdale, AZ 85259 USA	Yi, ES (reprint author), Mayo Clin, Div Anat Pathol, Rochester, MN 55905 USA.	Yi.Joanne@mayo.edu					Bartosiewicz Malgorzata, 2012, Pneumonol Alergol Pol, V80, P471; Bates CA, 2004, J ALLERGY CLIN IMMUN, V114, P415, DOI 10.1016/j.jaci.2004.05.057; Cavazza A, 2010, PATHOLOGY, V42, P596, DOI 10.3109/00313025.2010.508779; Churg A, 2017, AM J SURG PATHOL, V41, P1403, DOI 10.1097/PAS.0000000000000885; COSTA C, 1995, LIVER, V15, P196; Franco I, 2015, REV PORT PNEUMOL, V21, P214, DOI 10.1016/j.rppnen.2015.02.008; Kaplan MM, 2005, NEW ENGL J MED, V353, P1261, DOI 10.1056/NEJMra043898; Kayser K., 1993, Zentralblatt fuer Pathologie, V139, P377; KROWKA MJ, 1989, CLIN CHEST MED, V10, P593; Liu B, 2008, CLIN RHEUMATOL, V27, P1299, DOI 10.1007/s10067-008-0917-x; Rao N, 2015, HUM PATHOL, V46, P1306, DOI 10.1016/j.humpath.2015.05.011; RODRIGUEZROISIN R, 1981, THORAX, V36, P208, DOI 10.1136/thx.36.3.208; Shen M, 2009, J CLIN GASTROENTEROL, V43, P676, DOI 10.1097/MCG.0b013e31818aa11e; WALLACE JG, 1987, J CLIN GASTROENTEROL, V9, P431, DOI 10.1097/00004836-198708000-00015; WEISSMAN E, 1983, AM J MED SCI, V285, P21, DOI 10.1097/00000441-198305000-00004	15	0	0	0	1	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	DEC	2018	82						177	186		10.1016/j.humpath.2018.07.021			10	Pathology	Pathology	HG4TV	WOS:000454968800022	30067952				2019-10-28	
J	Pezhouh, MK; Miller, JA; Sharma, R; Borzik, D; Eze, O; Waters, K; Westerhoff, MA; Parian, AM; Lazarev, MG; Voltaggio, L				Pezhouh, Maryam Kherad; Miller, James Adam; Sharma, Rajni; Borzik, David; Eze, Ogechukwu; Waters, Kevin; Westerhoff, Maria A.; Parian, Alyssa M.; Lazarev, Mark G.; Voltaggio, Lysandra			Refractory inflammatory bowel disease: is there a role for Epstein-Barr virus? A case-controlled study using highly sensitive Epstein-Barr virus encoded small RNA1 in situ hybridization	HUMAN PATHOLOGY			English	Article						Inflammatory bowel disease; Epstein-Barr virus; Refractory; Ulcerative colitis; Crohn Disease	HUMAN CYTOMEGALOVIRUS; INFECTION; EXACERBATION; REPLICATION; SURGERY; THERAPY; LATENT; CELLS; DNA	A potential role for viral infections has been implicated in inflammatory bowel disease (IBD) unresponsive to medical treatment. It is well known that Epstein-Barr virus (EBV) infection can elicit a brisk mononuclear response in the gastrointestinal tract. The aim of this study was to further evaluate the role of EBV in patients with refractory IBD and compare them with nonrefractory IBD cases. Surgically resected colonic specimens from 67 patients with refractory IBD (62 with ulcerative colitis, 3 patients with Crohn disease, and 2 patients with indeterminate colitis) were retrieved. Twelve colectomy specimens from patients with ulcerative colitis who had undergone resections for dysplasia or endometriosis were included as controls. Highly sensitive EBV-encoded small RNA1 (EBER-1) in situ hybridization was performed on a representative block from each specimen. EBER-1 reactivity was graded as absent, focal, or diffuse. EBV was detected in 60% (40/67) of patients with refractory 1BD compared with 25% (3/12) of the control group (P < .05). Focal EBER-1 positivity was present in 45% of cases of refractory 1BD compared with 25% of controls. Diffuse EBER-1 reactivity was seen in 15% of cases of refractory IBD (10/67); none of the samples from the control group contained diffuse EBER-1 positivity. There was a positive correlation between EBER positivity and depth of inflammation and mucosal ulceration in patients with refractory IBD. Our findings suggest a potential role for EBV infection in patients with refractory 1BD. (C) 2018 Elsevier Inc. All rights reserved.	[Pezhouh, Maryam Kherad] Northwestern Univ, Feinberg Sch Med, Dept Pathol, 251 East Huron St,Feinberg 7-334, Chicago, IL 60611 USA; [Miller, James Adam; Sharma, Rajni; Borzik, David; Eze, Ogechukwu; Waters, Kevin; Voltaggio, Lysandra] Johns Hopkins Med Inst, Dept Pathol, Baltimore, MD 21287 USA; [Westerhoff, Maria A.] Univ Michigan, Dept Pathol, Ann Arbor, MI 48109 USA; [Parian, Alyssa M.; Lazarev, Mark G.] Johns Hopkins Med Inst, Dept Gastroenterol, Baltimore, MD 21287 USA	Pezhouh, MK (reprint author), Northwestern Univ, Feinberg Sch Med, Dept Pathol, 251 East Huron St,Feinberg 7-334, Chicago, IL 60611 USA.	maryam.kheradpezhouh@nm.org					Borza CM, 2002, NAT MED, V8, P594, DOI 10.1038/nm0602-594; Ciccocioppo R, 2016, IMMUNOL RES, V64, P191, DOI 10.1007/s12026-015-8737-y; Ciccocioppo R, 2015, WORLD J GASTROENTERO, V21, P1915, DOI 10.3748/wjg.v21.i6.1915; Dayharsh GA, 2002, GASTROENTEROLOGY, V122, P72, DOI 10.1053/gast.2002.30328; Decker LL, 1996, J VIROL, V70, P3286; Dimitroulia E, 2013, DIS COLON RECTUM, V56, P322, DOI 10.1097/DCR.0b013e31827cd02c; Ferrari L, 2016, WORLD J GASTRO SURG, V8, P363, DOI 10.4240/wjgs.v8.i5.363; Ghoshal Uday C, 2015, Trop Gastroenterol, V36, P80; Juan A, 2017, DIGEST LIVER DIS, V49, P934, DOI 10.1016/j.dld.2017.03.011; Lapsia S, 2016, J MED VIROL, V88, P312, DOI 10.1002/jmv.24331; Lidar M, 2009, ISR MED ASSOC J, V11, P558; Loewendorf A, 2010, J INTERN MED, V267, P483, DOI 10.1111/j.1365-2796.2010.02220.x; Malik TA, 2015, SURG CLIN N AM, V95, P1105, DOI 10.1016/j.suc.2015.07.006; MILLER G, 1990, J INFECT DIS, V161, P833, DOI 10.1093/infdis/161.5.833; Murata T, 2014, REV MED VIROL, V24, P142, DOI 10.1002/rmv.1780; Sandborn WJ, 2008, GASTROENTEROLOGY, V135, P1442, DOI 10.1053/j.gastro.2008.09.053; Sankaran-Walters S, 2011, J CLIN VIROL, V50, P31, DOI 10.1016/j.jcv.2010.09.011; Spieker T, 2000, AM J PATHOL, V157, P51, DOI 10.1016/S0002-9440(10)64516-6; Tangye SG, 2017, J EXP MED, V214, P269, DOI 10.1084/jem.20161846; Vester-Andersen MK, 2014, AM J GASTROENTEROL, V109, P705, DOI 10.1038/ajg.2014.45; Vogl BA, 2012, J MED VIROL, V84, P119, DOI 10.1002/jmv.22258; WAKEFIELD AJ, 1993, J MED VIROL, V39, P345, DOI 10.1002/jmv.1890390415; WAKEFIELD AJ, 1992, J MED VIROL, V38, P183, DOI 10.1002/jmv.1890380306; Yanai H, 1999, AM J GASTROENTEROL, V94, P1582; Young LS, 2004, NAT REV CANCER, V4, P757, DOI 10.1038/nrc1452	25	1	2	0	0	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	DEC	2018	82						187	192		10.1016/j.humpath.2018.08.001			6	Pathology	Pathology	HG4TV	WOS:000454968800023	30120969				2019-10-28	
J	Zheng, Q; Luo, RK; Jin, Y; Shen, XX; Shan, L; Shen, L; Hou, YY; Li, Y				Zheng, Qiang; Luo, Rongkui; Jin, Yan; Shen, Xuxia; Shan, Ling; Shen, Lei; Hou, Yingyong; Li, Yuan			So-called "non-classic" ciliated muconodular papillary tumors: a comprehensive comparison of the clinicopathological and molecular features with classic ciliated muconodular papillary tumors	HUMAN PATHOLOGY			English	Article						Ciliated muconodular papillary tumor (CMPT); Histopathology; Molecular genetics; Driver mutation; Differential diagnosis	LUNG; MUTATIONS; BRAF	Ciliated muconodular papillary tumors (CMPTs) are characterized by tripartite cellular components of ciliated columnar cells, mucinous cells, and basal cells with predominantly papillary architecture. Some peripheral lung nodules may not demonstrate papillary architecture and tripartite cells that show bronchiolar differentiation; these nodules are termed "CMPTs with non-classic morphology" by some authors. To validate the rationality of "non-classic" CMPTs and to analyze the clinicopathological features of CMPTs, we enrolled 21 cases of lung nodules, comprising classic CMPTs (n = 11) and so-called non-classic CMPTs (n = 10). The status of driver mutations, including those in EGFR, BRAF, ALK, and KRAS, was examined by molecular tests. Clinical and radiological follow-up was performed (3-27 months). Cilia as well as the mucinous and papillary components are usually present throughout classic CMPTs but may be absent in their non-classic counterparts. However, both entities present a bi-layer architecture with evidence of bronchiolar differentiation. Driver mutations involved the BRAF (n = 6), EGFR (n = 1) and ALK (n = 1), were identified in 8 of 11 (73%) classic CMPTs, whereas driver mutations, comprising BRAF (n = 2), EGFR (n = 1) and KRAS (n = 1), were identified in 4 of 10 (40%) non-classic lesions. Since it contains the largest series of Chinese patients with CMPTs, this study may expand the morphologic and molecular spectrum of CMPTs: a hallmark of CMPTs is bi-layer architecture with a continuous basal layer that can harbor high-frequency driver mutations. Recognition of the non-classic morphology of CMPTs may be helpful to avoid misdiagnosis and unnecessary treatment. (C) 2018 Elsevier Inc. All rights reserved.	[Zheng, Qiang; Jin, Yan; Shen, Xuxia; Shan, Ling; Shen, Lei; Li, Yuan] Fudan Univ, Shanghai Canc Ctr, Dept Pathol, Shanghai 200030, Peoples R China; [Zheng, Qiang; Jin, Yan; Shen, Xuxia; Shan, Ling; Shen, Lei; Li, Yuan] Fudan Univ, Shanghai Med Coll, Dept Oncol, Shanghai 200030, Peoples R China; [Luo, Rongkui; Hou, Yingyong] Fudan Univ, Zhongshan Hosp, Dept Pathol, Shanghai 200030, Peoples R China	Li, Y (reprint author), Fudan Univ, Shanghai Canc Ctr, Dept Pathol, Shanghai 200030, Peoples R China.	lumoxuan2009@163.com			National Natural Science Foundation of ChinaNational Natural Science Foundation of China [81472173]; Foundation for Distinctive Youth of FUSCC	This study was supported by the National Natural Science Foundation of China [grant number 81472173] and Foundation for Distinctive Youth of FUSCC.	Chang JC, 2017, PULMONARY CILIATED M; Chuang HW, 2014, PATHOL INT, V64, P352, DOI 10.1111/pin.12179; Flieder DB, 1998, AM J SURG PATHOL, V22, P1328, DOI 10.1097/00000478-199811000-00003; Hata Y, 2013, JPN J CLIN ONCOL, V43, P205, DOI 10.1093/jjco/hys218; Inamura K, 2011, PATHOL INT, V61, P252, DOI 10.1111/j.1440-1827.2011.02659.x; Ishikawa Y., 2002, PATHOL CLIN MED, V20, P964; Jin Y, 2017, PATHOL INT, V67, P171, DOI 10.1111/pin.12512; Kamata T, 2016, J THORAC ONCOL, V11, P261, DOI 10.1016/j.jtho.2015.10.021; Kamata T, 2015, AM J SURG PATHOL, V39, P753, DOI 10.1097/PAS.0000000000000414; Kon T, 2016, PATHOL INT, V66, P633, DOI 10.1111/pin.12460; Lau KW, 2016, HUM PATHOL, V49, P22, DOI 10.1016/j.humpath.2015.09.038; Liu LP, 2016, AM J SURG PATHOL, V40, P1631, DOI 10.1097/PAS.0000000000000707; Matsuoka Shunichiro, 2017, Asian Cardiovasc Thorac Ann, V25, P391, DOI 10.1177/0218492317713100; Sato S, 2010, INTERACT CARDIOV TH, V11, P685, DOI 10.1510/icvts.2009.229989; Segawa Masataka, 2017, Kyobu Geka, V70, P782; Sugase T, 2016, SURG CASE REP, V2, DOI 10.1186/s40792-016-0266-y; Taguchi R, 2017, PATHOL INT, V67, P99, DOI 10.1111/pin.12504; Udo E, 2017, DIAGN PATHOL, V12, DOI 10.1186/s13000-017-0651-2	18	1	2	0	4	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	DEC	2018	82						193	201		10.1016/j.humpath.2018.07.029			9	Pathology	Pathology	HG4TV	WOS:000454968800024	30092236				2019-10-28	
J	Olson, NJ; Addante, RR; de Abreu, FB; Memoli, VA				Olson, Nicholas J.; Addante, Rocco R.; de Abreu, Francine B.; Memoli, Vincent A.			Central. xanthoma of the jaw in association with Noonan syndrome	HUMAN PATHOLOGY			English	Article						Central xanthoma; Noonan syndrome; Giant cell lesion; Reparative granuloma; Histiocytic neoplasms	PTPN11 MUTATIONS; LESIONS	Xanthomas are histiocytic lesions of the skin, soft tissue, and bone and are generally considered to be reactive in nature. When they arise in the bones of the jaw, they are referred to as central xanthomas. New evidence supports the hypothesis that central xanthomas are a separate and distinct entity from their extragnathic counterparts. Noonan syndrome (NS) is an autosomal dominant disorder that has been associated with giant cell lesions, which also commonly occur in the jaw. We present a case of a 15-year-old boy with NS who presented with a radiolucent lesion of the mandible that on excision was found to be a central xanthoma. Although giant cell lesions have been well described in NS, xanthomas of the jaw have not been reported. We will also discuss the entities that must be excluded before making a diagnosis of central xanthoma, as this can affect both treatment and follow-up. (C) 2018 Elsevier Inc. All rights reserved.	[Olson, Nicholas J.; Addante, Rocco R.; de Abreu, Francine B.; Memoli, Vincent A.] 1 Med Ctr Dr, Lebanon, NH 03756 USA	Olson, NJ (reprint author), 1 Med Ctr Dr, Lebanon, NH 03756 USA.	nicholas.j.olson@hitchcock.org					Alawi F, 2006, ORAL SURG ORAL MED O, V102, P506, DOI 10.1016/j.tripleo.2005.10.071; Beneteau C, 2009, EUR J HUM GENET, V17, P1216, DOI 10.1038/ejhg.2009.44; Czerniak B, 2015, DORFMAN CZERNIAKS BO; Daley T, 2015, OR SURG OR MED OR PA, V119, P92, DOI 10.1016/j.oooo.2014.09.018; Diamond EL, 2016, CANCER DISCOV, V6, P154, DOI [10.1158/2159-8290.CD-15-0913, 10.1158/2159-8290.CD-NB2016-001]; Emile JF, 2016, BLOOD, V127, P2672, DOI [10.1182/blood-2016-01-690636, 10.1182/blood-2016-01690636]; Flaitz C, 2002, ORAL SURG ORAL MED O, V94, P345, DOI 10.1067/moe.2002.122340; HARSANYI BB, 1988, ORAL SURG ORAL MED O, V65, P551, DOI 10.1016/0030-4220(88)90138-7; Lee SE, 2012, HUM PATHOL, V43, P1234, DOI 10.1016/j.humpath.2011.09.012; Linari S, 2015, CLIN CASES MINER BON, V12, P157, DOI 10.11138/ccmbm/2015.12.2.157; Nelson J F, 1978, J Oral Med, V33, P94; Neumann TE, 2009, EUR J HUM GENET, V17, P420, DOI 10.1038/ejhg.2008.188; NORA JJ, 1974, AM J DIS CHILD, V127, P48, DOI 10.1001/archpedi.1974.02110200050007; Rawal YB, 2017, HEAD NECK PATHOL, V11, P192, DOI 10.1007/s12105-016-0764-z; Remotti F, 2012, ARCH PATHOL LAB MED, V136, P772, DOI 10.5858/arpa.2011-0557-RA; Tartaglia M, 2010, MOL SYNDROMOL, V1, P2, DOI 10.1159/000276766; Tartaglia M, 2002, AM J HUM GENET, V70, P1555, DOI 10.1086/340847; Zak A, 2014, BIOMED PAP, V158, P181, DOI 10.5507/bp.2014.016	18	1	1	0	1	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	DEC	2018	82						202	205		10.1016/j.humpath.2018.04.020			4	Pathology	Pathology	HG4TV	WOS:000454968800025	29727697				2019-10-28	
J	Yang, S; Leone, DA; Biswas, A; Deng, A; Jukic, D; Singh, R; Sundram, U; Mahalingam, M				Yang, Shi; Leone, Dominick A.; Biswas, Asok; Deng, April; Jukic, Drazen; Singh, Rajendra; Sundram, Uma; Mahalingam, Meera			Concordance of somatic mutation profiles (BRAF, NRAS, and TERT) and tumoral PD-L1 in matched primary cutaneous and metastatic melanoma samples	HUMAN PATHOLOGY			English	Article						BRAF; NRAS; TERT; PD-L1; Melanoma; Metastasis	PROMOTER MUTATIONS; DESMOPLASTIC MELANOMA; EXPRESSION; FREQUENCY; INSIGHTS	Despite the efficacy of BRAF-targeted and PD-L1 related immune therapies in tackling metastatic melanoma, a significant number of patients exhibit resistance. Given this, the objective of the current study was to ascertain concordance of somatic mutations in BRAFINRAS/TERT and immunohistochemical PD-L1 and CD8 in matched primary cutaneous and metastatic melanoma. A total of 43 archival paired samples with sufficient material for genetic and immunohistochemical analyses met the criteria for inclusion in the study. Immunohistochemistry was performed for PD-L1 and CD8 and direct-DNA Sanger sequencing for BRAFINRAS/TERT promoter mutational analyses. Agreement between paired samples was assessed using Cohen kappa. Poor concordance among primary and corresponding metastases was noted in BRAF (9/42 cases discordant, kappa = 0.49; 95% confidence interval [CI], 0.21-0.77; P = .0013), TERT promoter mutations (13/41 cases discordant, kappa = 0.33; 95% CI, 0.04-0.62; P = .033), tumoral PD-L1 immunoexpression (9/43 cases discordant, kappa = 0.39; 95% CI, 0.07-0.72; P = .0099), and immunoexpression of CD8(+) T lymphocytes (12/43 cases discordant kappa = 0.44; 95% CI, 0.19-0.69; P = .002). Although NRAS1 and NRAS2 were highly concordant (42/43 and 39/43 cases, respectively), discordant NRAS2 mutational status was associated with a median time to metastasis of 90 versus 455 days for pairs with concordant status (P = .07). Although limited by sample size, our findings suggest that consideration be given to mutational analysis of metastatic tissue rather than the primary to guide BRAF-targeted therapy and question the roles of TERT promoter mutations and PD-L1 as predictive biomarkers in malignant melanoma. (C) 2018 Elsevier Inc. All rights reserved.	[Yang, Shi] Boston Univ, Sch Med, Dept Pathol, Boston, MA 02118 USA; [Leone, Dominick A.] Boston Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02118 USA; [Leone, Dominick A.] Brigham & Womens Hosp, Channing Div Network Med, 75 Francis St, Boston, MA 02115 USA; [Biswas, Asok] Western Gen Hosp, Dept Pathol, Edinburgh EH1, Midlothian, Scotland; [Biswas, Asok] Univ Edinburgh, Edinburgh EH1, Midlothian, Scotland; [Deng, April] Univ Massachusetts, Med Sch, Dept Pathol, Worcester, MA 01606 USA; [Jukic, Drazen] Univ Florida, Dept Dermatol, Gainesville, FL 32601 USA; [Jukic, Drazen] Mercer Univ, Sch Med, Macon, GA 31201 USA; [Jukic, Drazen] James A Haley VA Ctr PLMS, Tampa, FL 33612 USA; [Singh, Rajendra] Icahn Sch Med Mt Sinai, Dept Pathol & Dermatol, New York, NY 11766 USA; [Sundram, Uma] Oakland Univ, William Beaumont Sch Med, Dept Anat Pathol, Royal Oak, MI 48017 USA; [Sundram, Uma] Beaumont Hlth Syst, Royal Oak, MI 48017 USA; [Mahalingam, Meera] VA Integrated Syst Network VISN1, Dept Pathol & Lab Med, Dermatopathol Sect, West Roxbury, MA 02132 USA	Mahalingam, M (reprint author), VA Integrated Syst Network VISN1, Dept Pathol & Lab Med 113, Dermatopathol Sect, 1400 VFW PKWY, West Roxbury, MA 02132 USA.	me@meeramahalingam.com					Akslen LA, 2005, J INVEST DERMATOL, V125, P312, DOI 10.1111/j.0022-202X.2005.23788.x; Boursault L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070826; Cheng L, 2018, MODERN PATHOL, V31, P24, DOI 10.1038/modpathol.2017.104; Choi DY, 2014, EWHA MED J, V37, P30, DOI 10.12771/emj.2014.37.1.30; Colombino M, 2014, J TRANSL MED, V12, DOI 10.1186/1479-5876-12-117; Colombino M, 2013, J TRANSL MED, V11, DOI 10.1186/1479-5876-11-202; Colombino M, 2012, J CLIN ONCOL, V30, P2522, DOI 10.1200/JCO.2011.41.2452; Danilova L, 2016, P NATL ACAD SCI USA, V113, pE7769, DOI 10.1073/pnas.1607836113; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Egberts F, 2016, J MOL DIAGN, V18, P75, DOI 10.1016/j.jmoldx.2015.07.010; Egberts F, 2014, MELANOMA RES, V24, P131, DOI 10.1097/CMR.0000000000000048; Ekedahl H, 2016, PIGM CELL MELANOMA R, V29, P598, DOI 10.1111/pcmr.12500; Frydenlund N, 2017, HUM PATHOL, V66, P13, DOI 10.1016/j.humpath.2017.06.012; Frydenlund N, 2017, MODERN PATHOL, V30, P357, DOI 10.1038/modpathol.2016.210; Griewank KG, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/dju246; Heidenreich B, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4401; Heinzerling L, 2013, BRIT J CANCER, V109, P2833, DOI 10.1038/bjc.2013.622; Hino R, 2010, CANCER-AM CANCER SOC, V116, P1757, DOI 10.1002/cncr.24899; Horn S, 2013, SCIENCE, V339, P959, DOI 10.1126/science.1230062; Huang FW, 2013, SCIENCE, V339, P957, DOI 10.1126/science.1229259; Hugdahl E, 2018, BRIT J CANCER, V118, P98, DOI 10.1038/bjc.2017.384; Jang S, 2014, CLIN PHARMACOL THER, V95, P24, DOI 10.1038/clpt.2013.197; Jung Juliana Elizabeth, 2010, J. Bras. Patol. Med. Lab., V46, P487, DOI 10.1590/S1676-24442010000600009; Macerola E, 2015, VIRCHOWS ARCH, V467, P177, DOI 10.1007/s00428-015-1784-x; Mahalingam M, 2018, METHODS MOL BIOL, V1723, P1, DOI 10.1007/978-1-4939-7558-7_1; Nagore E, 2016, PIGM CELL MELANOMA R, V29, P236, DOI 10.1111/pcmr.12441; Ofner R, 2017, J CANCER RES CLIN, V143, P613, DOI 10.1007/s00432-016-2322-1; Omholt K, 2003, CLIN CANCER RES, V9, P6483; R Core Team, 2016, R LANG ENV STAT COMP; Robert C, 2015, NEW ENGL J MED, V372, P2521, DOI 10.1056/NEJMoa1503093; Robert C, 2015, NEW ENGL J MED, V372, P320, DOI 10.1056/NEJMoa1412082; Sunshine JC, 2017, CLIN CANCER RES, V23, P4938, DOI 10.1158/1078-0432.CCR-16-1821; Taube JM, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003689; Varada S, 2015, HISTOL HISTOPATHOL, V30, P763, DOI 10.14670/HH-11-584; Vinagre J, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3185; Yancovitz M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029336; Yang S, 2016, MELANOMA RES, V26, P361, DOI 10.1097/CMR.0000000000000272; Zebary A, 2013, J DERMATOL SCI, V72, P284, DOI 10.1016/j.jdermsci.2013.07.013	38	2	2	1	1	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	DEC	2018	82						206	214		10.1016/j.humpath.2018.08.002			9	Pathology	Pathology	HG4TV	WOS:000454968800026	30120967				2019-10-28	
J	Garces, S; Khoury, JD; Kanagal-Shamanna, R; Salem, A; Wang, SA; Ok, CY; Hu, SM; Patel, KP; Routbort, MJ; Luthra, R; Tang, GL; Schlette, EJ; Bueso-Ramos, CE; Medeiros, LJ; Loghavi, S				Garces, Sofia; Khoury, Joseph D.; Kanagal-Shamanna, Rashmi; Salem, Alireza; Wang, Sa A.; Ok, Chi Young; Hu, Shimin; Patel, Keyur P.; Routbort, Mark J.; Luthra, Rajyalakshmi; Tang, Guilin; Schlette, Ellen J.; Bueso-Ramos, Carlos E.; Medeiros, L. Jeffrey; Loghavi, Sanam			Chronic lymphocytic leukemia with proliferation centers in bone marrow is associated with younger age at initial presentation, complex karyotype, and TP53 disruption	HUMAN PATHOLOGY			English	Article						Chronic lymphocytic leukemia/small lymphocytic lymphoma; Bone marrow; Proliferation centers; TP53; Complex karyotype	LYMPHOMA; EXPRESSION; CLL; TRANSFORMATION; MARKERS; PROTEIN	The presence of expanded proliferation centers (PCs) in lymph nodes involved by chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma has been associated with adverse clinical outcomes, but the frequency and significance of PCs in bone marrow (BM) remain unclear. The study group included 36 patients with BM involvement by CLL in which PCs were present. We compared this group with 110 randomly selected BM samples involved by CLL without morphologically discernable PCs. Patients with PCs in BM were younger (median age, 53 years [range,18-71 years] versus 58 years [range, 31-82 years]; P = .007), more frequently experienced B symptoms (27.8% versus 8.2%, P = .0076), more often had Rai stage IV disease (30.6% versus 17.3%, P = .02) and higher serum lactate dehydrogenase (P = .0037) and beta(2)-microglobulin (P = .0001) levels, and lower hemoglobin (P = .026) and platelet counts (P = .0422). TP53 alterations were more common in patients with PCs in BM (45.4% versus 18.7%; P = .0049), as was a complex karyotype (26.4% versus 9%; P = .019). There were no significant differences in the frequency of ZAP70 or CD38 positivity or IGHV mutation status. The median time to first treatment was shorter in patients with PCs in BM (7 months versus 19 months, P = .047), and the frequency of Richter syndrome was higher (14% versus 4%, P = .041). Patients with PCs in BM had significantly shorter overall survival compared with the control group (median, 249.3 months versus undefined; P = .0241). These data suggest that identification of PCs in BM samples involved by CLL is associated with adverse prognostic features. (C) 2018 Elsevier Inc. All rights reserved.	[Garces, Sofia; Khoury, Joseph D.; Kanagal-Shamanna, Rashmi; Wang, Sa A.; Ok, Chi Young; Hu, Shimin; Patel, Keyur P.; Routbort, Mark J.; Luthra, Rajyalakshmi; Tang, Guilin; Schlette, Ellen J.; Bueso-Ramos, Carlos E.; Medeiros, L. Jeffrey; Loghavi, Sanam] Univ Texas MD Anderson Canc Ctr, Dept Hematopathol, Houston, TX 77030 USA; [Salem, Alireza] Baylor Univ, Med Ctr, Dept Pathol, Dallas, TX 75246 USA	Loghavi, S (reprint author), Dept Hematopathol, Unit 72,1515 Holcombe Blvd, Houston, TX 77030 USA.	SLoghavi@mdanderson.org	Hu, Shimin/H-3427-2019; Medeiros, L. Jeffrey/AAB-1018-2019	Ok, Chi Young/0000-0002-6822-7880			Agbay RLMC, 2016, AM J HEMATOL, V91, P1036, DOI 10.1002/ajh.24473; Baliakas P, 2015, LEUKEMIA, V29, P329, DOI 10.1038/leu.2014.196; Balogh Z, 2011, LEUKEMIA LYMPHOMA, V52, P1080, DOI 10.3109/10428194.2011.555889; BENEZRA J, 1989, BLOOD, V73, P579; Campo E. G. P., 2017, WHO CLASSIFICATION T, P216; Chabot-Richards D, 2016, HEMATOPATHOLOGY, P261; Chang JC, 2016, ANN DIAGN PATHOL, V25, P15, DOI 10.1016/j.anndiagpath.2016.07.011; Ciccone M, 2012, LEUKEMIA, V26, P499, DOI 10.1038/leu.2011.247; Damle RN, 1999, BLOOD, V94, P1840; Delgado J, 2014, HAEMATOLOGICA, V99, P4, DOI 10.3324/haematol.2013.096297; ENNO A, 1979, BRIT J HAEMATOL, V41, P9, DOI 10.1111/j.1365-2141.1979.tb03676.x; Falchi L, 2014, BLOOD, V123, P2783, DOI 10.1182/blood-2013-11-536169; Gibson SE, 2016, BRIT J HAEMATOL, V175, P173, DOI 10.1111/bjh.13844; Gine E, 2010, HAEMATOL-HEMATOL J, V95, P1526, DOI 10.3324/haematol.2010.022277; Gradowski JF, 2012, AM J CLIN PATHOL, V138, P132, DOI 10.1309/AJCPIVKZRMPF93ET; Jaffe E. S., 2017, WHO CLASSIFICATION T, P190; JULIUSSON G, 1990, NEW ENGL J MED, V323, P720, DOI 10.1056/NEJM199009133231105; Khoury JD, 2018, CLIN CANCER RES, V24, P521, DOI 10.1158/1078-0432.CCR-17-1597; Lampert IA, 1999, HUM PATHOL, V30, P648, DOI 10.1016/S0046-8177(99)90089-8; Malcikova J, 2018, LEUKEMIA, V32, P1070, DOI 10.1038/s41375-017-0007-7; Montserrat E, 1996, BRIT J HAEMATOL, V93, P111, DOI 10.1046/j.1365-2141.1996.449988.x; Oscier D, 2016, BRIT J HAEMATOL, V174, P767, DOI 10.1111/bjh.14132; Parikh SA, 2014, HAEMATOLOGICA, V99, P140, DOI 10.3324/haematol.2013.086066; Ratterman M, 2014, LEUKEMIA RES, V38, P299, DOI 10.1016/j.leukres.2013.08.009; Retter I, 2005, NUCLEIC ACIDS RES, V33, pD671, DOI 10.1093/nar/gki088; Rigolin GM, 2017, BLOOD, V129, P3495, DOI 10.1182/blood-2017-03-772285; Rosenquist R, 2016, HAEMATOLOGICA, V101, P1002, DOI 10.3324/haematol.2015.134510; SCHMID C, 1994, HISTOPATHOLOGY, V24, P445, DOI 10.1111/j.1365-2559.1994.tb00553.x; Shaffer LG, 2013, ISCN 2013 INT SYSTEM; Shankey TV, 2006, CYTOM PART B-CLIN CY, V70B, P259, DOI 10.1002/cyto.b.20135; Soma LA, 2006, HUM PATHOL, V37, P152, DOI 10.1016/j.humpath.2005.09.029; Stilgenbauer Stephan, 2015, Am Soc Clin Oncol Educ Book, P164, DOI 10.14694/EdBook_AM.2015.35.164; Stilgenbauer S, 2014, BLOOD, V123, P3247, DOI 10.1182/blood-2014-01-546150; Yin CC, 2015, MODERN PATHOL, V28, P1130, DOI 10.1038/modpathol.2015.58	34	1	1	1	2	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	DEC	2018	82						215	231		10.1016/j.humpath.2018.07.030			17	Pathology	Pathology	HG4TV	WOS:000454968800027	30086334				2019-10-28	
J	Pasternak, S; Carter, MD; Ly, TY; Doucette, S; Walsh, NM				Pasternak, Sylvia; Carter, Michael D.; Thai Yen Ly; Doucette, Steve; Walsh, Noreen M.			Immunohistochemical profiles of different subsets of Merkel cell carcinoma	HUMAN PATHOLOGY			English	Article						Merkel cell carcinoma; Cutaneous neuroendocrine carcinoma; Immunohistochemistry; Combined Merkel cell carcinoma; Pure Merkel cell carcinoma; MCPyV	NEUROENDOCRINE CARCINOMA; POLYOMAVIRUS EXPRESSION; PROGNOSTIC MARKER; TTF-1 EXPRESSION; P63 EXPRESSION; TUMORS; PURE	The literature records many examples of Merkel cell carcinoma (MCC) exhibiting aberrant immunohistochemical profiles. These can lead to diagnostic difficulty. The objectives of the current study were (1) to examine the immunohistochemical profile of different subsets of MCC to determine whether predictable subset-specific patterns exist and (2) to establish whether shared immunophenotypic patterns might reveal links between individual subsets, as demonstrated previously at a genetic level. In 52 cases of MCC, stratified by viral status and morphology, we studied 5 markers commonly used in the diagnostic evaluation of these tumors (CK20, CK7, chromogranin, neurofilament and TTF-1). Expression of these proteins was recorded as quantitative (H-scores) and absolute (positive vs negative) variables. In general, our data indicate that the "classical" or expected panel (CK20+, NF+, Chromo+, TTF-1, CK7-) is observed significantly more often in pure Merkel cell polyomavirns (MCPyV)-positive than in MCPyV-negative cases (78% vs 25%; P=.002). Neurofilament was less frequently encountered in MCPyV-negative than in MCPyV-positive tumors (66.7% vs 100%; P = .001) and expression of TTF-1 (37.5% vs 3.6%; P = .003) and CK7 (45.8 vs 14.3; P = .02) was more frequent. No significant immonophenotypic differences were observed between pure and combined MCPyV-negative tumors. Recognition of the more aberrant immunohistochemical profile of MCPyV-negative MCC should inform the diagnostic approach to this tumor. Moreover, the shared aberrant immunophenotype in pure and combined MCPyV-negative tumors supports a link between these entities and serves to separate them from MCPyV-positive tumors. (C) 2018 Elsevier Inc. All rights reserved.	[Pasternak, Sylvia; Carter, Michael D.; Thai Yen Ly; Walsh, Noreen M.] Nova Scotia Hlth Author, Queen Elizabeth II Hlth Sci Ctr, Dept Pathol, Halifax, NS B3H 1V8, Canada; [Pasternak, Sylvia; Carter, Michael D.; Thai Yen Ly; Doucette, Steve; Walsh, Noreen M.] Dalhousie Univ, Halifax, NS B3H 1V8, Canada; [Pasternak, Sylvia; Walsh, Noreen M.] Nova Scotia Hlth Author, Queen Elizabeth II Hlth Sci Ctr, Dept Med, Halifax, NS B3H 1V8, Canada; [Doucette, Steve] Capital Dist Hlth Author, Res Methods Unit, Halifax, NS B3H 1V7, Canada	Pasternak, S (reprint author), Div Anat Pathol, Rm 727,Mackenzie Bldg, Halifax, NS B3H 1V8, Canada.	Sylvia.Pastemak@nshealth.ca			Nova Scotia Health Authority Research Fund	This study was supported by a research grant from the Nova Scotia Health Authority Research Fund	Asioli S, 2007, CANCER-AM CANCER SOC, V110, P640, DOI 10.1002/cncr.22828; Beer TW, 2009, J CUTAN PATHOL, V36, P385, DOI 10.1111/j.1600-0560.2008.01062.x; Busam KJ, 2009, AM J SURG PATHOL, V33, P1378, DOI 10.1097/PAS.0b013e3181aa30a5; Calder KB, 2007, J CUTAN PATHOL, V34, P918, DOI 10.1111/j.1600-0560.2007.00759.x; Carter MD, 2018, HUM PATHOL, V71, P117, DOI 10.1016/j.humpath.2017.10.014; Czapiewski P, 2016, AM J DERMATOPATH, V38, P513, DOI 10.1097/DAD.0000000000000464; Feng HC, 2008, SCIENCE, V319, P1096, DOI 10.1126/science.1152586; Fleming KE, 2014, HUM PATHOL, V45, P952, DOI 10.1016/j.humpath.2013.12.008; Garneski KM, 2009, J INVEST DERMATOL, V129, P246, DOI 10.1038/jid.2008.229; Iliadis A, 2015, POL J PATHOL, V66, P200, DOI 10.5114/PJP.2015.53017; Koba S, 2011, J DERMATOL SCI, V64, P77, DOI 10.1016/j.jdermsci.2011.06.011; Lai JH, 2015, HUM PATHOL, V46, P1290, DOI 10.1016/j.humpath.2015.05.008; Ly TY, 2012, HUM PATHOL, V43, P557, DOI 10.1016/j.humpath.2011.06.005; McCalmont TH, 2010, J CUTAN PATHOL, V37, P822, DOI [10.1111/j.1600-0560.2010.01567_2.x, DOI 10.1111/J.1600-0560.2010.01567_2.X]; Miner AG, 2015, MODERN PATHOL, V28, P498, DOI 10.1038/modpathol.2014.148; Moshiri AS, 2017, J INVEST DERMATOL, V137, P819, DOI 10.1016/j.jid.2016.10.028; Pilloni L, 2009, EUR J HISTOCHEM, V53, P275; Pulitzer MP, 2015, MODERN PATHOL, V28, P1023, DOI 10.1038/modpathol.2015.60; Reddi DM, 2013, J CUTAN PATHOL, V40, P431, DOI 10.1111/cup.12079; SHAH IA, 1993, MODERN PATHOL, V6, P3; VISSCHER D, 1989, MODERN PATHOL, V2, P331; Walsh NMG, 2001, HUM PATHOL, V32, P680, DOI 10.1053/hupa.2001.25904; Walsh NM, 2016, HUM PATHOL, V52, P190, DOI 10.1016/j.humpath.2016.02.002	23	1	1	0	0	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	DEC	2018	82						232	238		10.1016/j.humpath.2018.07.022			7	Pathology	Pathology	HG4TV	WOS:000454968800028	30067951				2019-10-28	
J	Wang, J; Gao, HY; Liu, GH; Gu, L; Yang, C; Zhang, FM; Liu, TB				Wang, Jing; Gao, Hongyu; Liu, Guohui; Gu, Lina; Yang, Chang; Zhang, Fengmin; Liu, Tianbo			Tumor necrosis factor alpha-induced protein 8 expression as a predictor of prognosis and resistance in patients with advanced ovarian cancer treated with neoadjuvant chemotherapy	HUMAN PATHOLOGY			English	Article						Neoadjuvant chemotherapy; Ovarian cancer; Platinum resistance; Survival; TNFAIP8	SQUAMOUS-CELL CARCINOMA; LYMPH-NODE METASTASIS; TNFAIP8 OVEREXPRESSION; POOR-PROGNOSIS; AUTOPHAGY; PROLIFERATION; CISPLATIN; RADIATION; SCC-S2; INHIBITION	We explored the correlation of tumor necrosis factor alpha-induced protein 8 (TNFAIP8) with platinum resistance in ovarian cancers treated with neoadjuvant chemotherapy (NACT). We observed a significant trend of decreased TNFAIP8 expression after NACT (P = .042), and the extent of decreased TNFAIP8 expression after NACT was positively associated with response to NACT (P = .013). Interestingly, in patients treated with NACT, the extent of decreased TNFAIP8 expression after NACT in tumor (change in immunohistochemistry scores <=-1 versus >= 0; P = .001) correlated significantly with overall survival. Furthermore, TNFAIP8 knockout inhibited tumor proliferation in a time-dependent manner and arrested the cell cycle in the G0/G1 phase in OVCAR-3 cells. In vitro, OVCAR-3 cells with down-regulated TNFAIP8 exhibited greater chemosensitivity as well as increased autophagy-related protein (Beclin 1 and LC II) expression. We propose that the degree of decreased TNFAIP8 expression is a biomarker for predicting NACT resistance, and TNFAIP8 may be involved in cisplatin-induced chemoresistance by interacting with autophagy-related proteins and may be a therapeutic target for ovarian cancer treatment. (C) 2018 Elsevier Inc. All rights reserved.	[Wang, Jing; Gu, Lina; Yang, Chang; Liu, Tianbo] Harbin Med Univ, Dept Gynecol, Canc Hosp, Harbin 150081, Heilongjiang, Peoples R China; [Gao, Hongyu] Harbin Med Univ, Dept Gastroenterol Surg, Canc Hosp, Harbin 150081, Heilongjiang, Peoples R China; [Liu, Guohui] Harbin Med Univ, Canc Hosp, Dept Radiat Oncol, Harbin 150081, Heilongjiang, Peoples R China; [Zhang, Fengmin] Harbin Med Univ, Dept Microbiol, Wu Lien Teh Inst, 157 Baojian Rd, Harbin 150081, Heilongjiang, Peoples R China; [Zhang, Fengmin] Harbin Med Univ, Heilongjiang Prov Key Lab Infect & Immun, 157 Baojian Rd, Harbin 150081, Heilongjiang, Peoples R China	Liu, TB (reprint author), Harbin Med Univ, Dept Gynecol, Canc Hosp, Harbin 150081, Heilongjiang, Peoples R China.; Zhang, FM (reprint author), Harbin Med Univ, Dept Microbiol, Wu Lien Teh Inst, 157 Baojian Rd, Harbin 150081, Heilongjiang, Peoples R China.; Zhang, FM (reprint author), Harbin Med Univ, Heilongjiang Prov Key Lab Infect & Immun, 157 Baojian Rd, Harbin 150081, Heilongjiang, Peoples R China.	fengminzhang@ems.hrbmu.edu.cn; skyliu_1030@163.com			National Natural Science Foundation of ChinaNational Natural Science Foundation of China [81502225]; Postdoctoral Foundation of ChinaChina Postdoctoral Science Foundation [2015M581480]; Postdoctoral Foundation of Heilongjiang Province of China [LBH-Z15123]; Haiyan Foundation of the Affiliated Tumor Hospital of Harbin Medical University [JJMS2016-01]; Fundamental Research Funds for the Provincial Universities [2017LCZX71, 20161czx77]; Youth Elite Training Foundation of the Affiliated Tumor Hospital of Harbin Medical University [JY2016-03]	This study was supported by grants from the National Natural Science Foundation of China (81502225), the Postdoctoral Foundation of China (2015M581480), the Postdoctoral Foundation of Heilongjiang Province of China (LBH-Z15123), the Haiyan Foundation of the Affiliated Tumor Hospital of Harbin Medical University (JJMS2016-01), the Fundamental Research Funds for the Provincial Universities (20161czx77), the Youth Elite Training Foundation of the Affiliated Tumor Hospital of Harbin Medical University (JY2016-03), and the Fundamental Research Funds for the Provincial Universities (2017LCZX71).	Boeckman HJ, 2005, MOL CANCER RES, V3, P277, DOI 10.1158/1541-7786.MCR-04-0032; Bookman MA, 2012, CLIN OBSTET GYNECOL, V55, P96, DOI 10.1097/GRF.0b013e31824b45da; Chen WQ, 2016, CA-CANCER J CLIN, V66, P115, DOI 10.3322/caac.21338; Day TF, 2017, METHODS MOL BIOL, V1513, P83, DOI 10.1007/978-1-4939-6539-7_7; Dong QZ, 2010, CANCER SCI, V101, P1562, DOI 10.1111/j.1349-7006.2010.01557.x; Glasgow MA, 2013, J SURG ONCOL, V107, P195, DOI 10.1002/jso.23171; Go RS, 1999, J CLIN ONCOL, V17, P409, DOI 10.1200/JCO.1999.17.1.409; Ha JY, 2014, J NEUROCHEM, V129, P527, DOI 10.1111/jnc.12643; Hadisaputri YE, 2012, ANN SURG ONCOL, V19, pS589, DOI 10.1245/s10434-011-2097-1; Harhaji-Trajkovic L, 2009, J CELL MOL MED, V13, P3644, DOI 10.1111/j.1582-4934.2009.00663.x; Hu RY, 2016, ONCOTARGETS THER, V9, P4473, DOI 10.2147/OTT.S100593; Kelland L, 2007, NAT REV CANCER, V7, P573, DOI 10.1038/nrc2167; Kumar D, 2004, ONCOGENE, V23, P612, DOI 10.1038/sj.onc.1207123; Li YS, 2015, MOL MED REP, V12, P2636, DOI 10.3892/mmr.2015.3690; Liu DL, 2011, MED ONCOL, V28, P105, DOI 10.1007/s12032-009-9397-3; Liu K, 2012, ASIAN PAC J CANCER P, V13, P847, DOI 10.7314/APJCP.2012.13.3.847; Liu T, 2013, BRIT J CANCER, V109, P1685, DOI 10.1038/bjc.2013.501; Liu TB, 2014, TUMOR BIOL, V35, P5805, DOI 10.1007/s13277-014-1770-y; Liu TB, 2014, HUM PATHOL, V45, P1251, DOI 10.1016/j.humpath.2014.02.005; Livesey KM, 2009, CURR OPIN INVEST DR, V10, P1269; Miao ZF, 2012, TUMOR BIOL, V33, P2099, DOI 10.1007/s13277-012-0469-1; Morgan RJ, 2009, NCCN CLIN PRACTICE G; PAPADOPOULOS NM, 1977, ANN CLIN LAB SCI, V7, P506; Patel S, 1997, ORAL ONCOL, V33, P197, DOI 10.1016/S0964-1955(96)00065-6; Periyasamy-Thandavan S, 2008, KIDNEY INT, V74, P631, DOI 10.1038/ki.2008.214; Shi TY, 2013, CARCINOGENESIS, V34, P770, DOI 10.1093/carcin/bgt001; Sun ZG, 2016, TUMOR BIOL, V37, P10923, DOI 10.1007/s13277-016-4978-1; Therasse P, 2000, J NATL CANCER I, V92, P205, DOI 10.1093/jnci/92.3.205; Vergote I, 2010, NEW ENGL J MED, V363, P943, DOI 10.1056/NEJMoa0908806; White E, 2009, CLIN CANCER RES, V15, P5308, DOI 10.1158/1078-0432.CCR-07-5023; Yang M, 2014, HISTOPATHOLOGY, V65, P517, DOI 10.1111/his.12413; Zhang CB, 2006, MOL THER, V13, P947, DOI 10.1016/j.ymthe.2005.11.020; Zhang CB, 2013, INT J CANCER, V133, P31, DOI 10.1002/ijc.27996	33	3	3	0	0	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	DEC	2018	82						239	248		10.1016/j.humpath.2018.02.031			10	Pathology	Pathology	HG4TV	WOS:000454968800029	30107189				2019-10-28	
J	Chou, A; Itchins, M; de Reuver, PR; Arena, J; Clarkson, A; Sheen, A; Sioson, L; Cheung, V; Perren, A; Nahm, C; Mittal, A; Samra, JS; Pajic, M; Gill, AJ				Chou, Angela; Itchins, Malinda; de Reuver, Philip R.; Arena, Jennifer; Clarkson, Adele; Sheen, Amy; Sioson, Loretta; Cheung, Veronica; Perren, Aurel; Nahm, Christopher; Mittal, Anubhav; Samra, Jaswinder S.; Pajic, Marina; Gill, Anthony J.			ATRX loss is an independent predictor of poor survival in pancreatic neuroendocrine tumors	HUMAN PATHOLOGY			English	Article						ATRX; DAXX; Pancreatic neuroendocrine tumor; PanNET; Prognosis	DAXX; PROGNOSIS	Pancreatic neuroendocrine tumors (PanNETs) are rare neoplasms accounting for 1% to 2% of all pancreatic tumors. The biological behavior of PanNETs is heterogeneous and unpredictable, adding to the difficulties of clinical management. The DAXX (death domain associated protein) and ATRX (alpha-thalassemia/mental retardation syndrome X-linked) genes encode proteins involved in SWI/SNF-like chromatin remodeling. Somatic inactivating mutations in DAXX and ATRX are frequent in PanNETs, mutually exclusive, and associated with telomere dysfunction, resulting in genomic instability and alternate lengthening of telomeres. We sought to assess the clinical significance of the loss of the ATRX and DAXX proteins as determined by immunohistochemistry (IHC) in patients with PanNET. From an unselected cohort of 105 patients, we found ATRX loss in 10 tumors (9.5%) and DAXX loss in 16 (15.2%). DAXX and ATRX losses were confirmed mutually exclusive and associated with other adverse clinicopathological variables and poor survival in univariate analysis. In addition, ATRX loss was also associated with higher AJCC stage and infiltrative tumor borders. However, only ATRX loss, lymphovascular invasion, and perineural spread were independent predictors of poor overall survival in multivariate analysis. In conclusion, loss of expression of ATRX as determined by IHC is a useful independent predictor of poor overall survival in PanNETs. Given its relative availability, ATRX loss as determined by MC may have a role in routine clinical practice to refine prognostication in patients with PanNET. (C) 2018 Elsevier Inc. All rights reserved.	[Chou, Angela; Clarkson, Adele; Sheen, Amy; Sioson, Loretta; Cheung, Veronica; Gill, Anthony J.] Royal North Shore Hosp, Kolling Inst Med Res, Canc Diag & Pathol Grp, St Leonards, NSW 2065, Australia; [Chou, Angela; Itchins, Malinda; Nahm, Christopher; Mittal, Anubhav; Samra, Jaswinder S.; Gill, Anthony J.] Univ Sydney, Sydney, NSW 2006, Australia; [Chou, Angela] St Vincents Hosp, Dept Anat Pathol, SYDPATH, Darlinghurst, NSW 2010, Australia; [Chou, Angela; Pajic, Marina] Kinghorn Canc Ctr, Darlinghurst, NSW 2010, Australia; [Chou, Angela; Pajic, Marina] Garvan Inst Med Res, Darlinghurst, NSW 2010, Australia; [Itchins, Malinda] Royal North Shore Hosp, Dept Med Oncol, St Leonards, NSW 2065, Australia; [de Reuver, Philip R.] Radboud Univ Nijmegen, Dept Surg, Med Ctr, NL-6525 Nijmegen, Netherlands; [de Reuver, Philip R.; Arena, Jennifer; Nahm, Christopher; Mittal, Anubhav; Samra, Jaswinder S.] Royal North Shore Hosp, Dept Upper Gastrointestinal Surg, St Leonards, NSW 2065, Australia; [Clarkson, Adele; Cheung, Veronica; Gill, Anthony J.] Royal North Shore Hosp, Dept Anat Pathol, NSW Hlth Pathol, St Leonards, NSW 2065, Australia; [Perren, Aurel] Univ Bern, Inst Pathol, CH-3012 Bern, Switzerland	Gill, AJ (reprint author), Royal North Shore Hosp, Dept Anat Pathol, St Leonards, NSW 2065, Australia.	affgill@med.usyd.edu.au	Perren, Aurel/A-9383-2018; de Reuver, Philip R/G-9657-2016	Perren, Aurel/0000-0002-6819-6092; de Reuver, Philip R/0000-0002-8566-4222; Pajic, Marina/0000-0002-3871-3829	Sydney Vital, Translational Cancer Research, through a Cancer Institute NSW competitive grant; Cancer Institute NSW Early Career Fellowship [AC00430]	This project was supported by the Sydney Vital, Translational Cancer Research, through a Cancer Institute NSW competitive grant. The views expressed herein are those of the authors and are not necessarily those of the Cancer Institute NSW. Dr Chou is supported by the Cancer Institute NSW Early Career Fellowship (AC00430).	Carrera S, 2017, HERED CANCER CLIN PR, V15, DOI 10.1186/s13053-017-0069-6; Clynes D, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8538; Ekeblad S, 2008, CLIN CANCER RES, V14, P7798, DOI 10.1158/1078-0432.CCR-08-0734; Fesinmeyer MD, 2005, CANCER EPIDEM BIOMAR, V14, P1766, DOI 10.1158/1055-9965.EPI-05-0120; Goldberg AD, 2010, CELL, V140, P678, DOI 10.1016/j.cell.2010.01.003; Halfdanarson TR, 2008, ANN ONCOL, V19, P1727, DOI 10.1093/annonc/mdn351; Hamilton NA, 2012, SURGERY, V152, P107, DOI 10.1016/j.surg.2012.02.011; Jiao YC, 2011, SCIENCE, V331, P1199, DOI 10.1126/science.1200609; Jilesen APJ, 2016, WORLD J SURG, V40, P715, DOI 10.1007/s00268-015-3341-9; Kim JY, 2017, CLIN CANCER RES, V23, P1598, DOI 10.1158/1078-0432.CCR-16-1147; Koschmann C, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aac8228; Lewis PW, 2010, P NATL ACAD SCI USA, V107, P14075, DOI 10.1073/pnas.1008850107; Lloyd RV, 2017, WHO CLASSIFICATION T; Lovejoy CA, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002772; Marinoni I, 2014, GASTROENTEROLOGY, V146, P453, DOI 10.1053/j.gastro.2013.10.020; Pan WW, 2013, J BIOL CHEM, V288, P13620, DOI 10.1074/jbc.M112.446369; Park JK, 2017, ONCOTARGET, V8, P49796, DOI 10.18632/oncotarget.17964; Pipinikas CP, 2015, ENDOCR-RELAT CANCER, V22, pL13, DOI 10.1530/ERC-15-0108; Puto LA, 2015, J BIOL CHEM, V290, P15406, DOI 10.1074/jbc.M115.658765; Roy S, 2018, GASTROENTEROLOGY, V154, P2060, DOI 10.1053/j.gastro.2018.02.026; Scarpa A, 2017, NATURE, V543, P65, DOI 10.1038/nature21063; Scarpa A, 2010, MODERN PATHOL, V23, P824, DOI 10.1038/modpathol.2010.58; Singhi AD, 2017, CLIN CANCER RES, V23, P600, DOI 10.1158/1078-0432.CCR-16-1113; Watson LA, 2015, EPIGENOMICS-UK, V7, P1365, DOI 10.2217/epi.15.82	24	0	0	2	3	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	DEC	2018	82						249	257		10.1016/j.humpath.2018.07.032			9	Pathology	Pathology	HG4TV	WOS:000454968800030	30081149	Green Published			2019-10-28	
J	Mizuno, H; Sekine, A; Oguro, M; Oshima, Y; Kawada, M; Sumida, K; Yamanouchi, M; Hayami, N; Suwabe, T; Hiramatsu, R; Hasegawa, E; Hoshino, J; Sawa, N; Fujii, T; Takaichi, K; Ohashi, K; Ubara, Y				Mizuno, Hiroki; Sekine, Akinari; Oguro, Masahiko; Oshima, Yoichi; Kawada, Masahiro; Sumida, Keiichi; Yamanouchi, Masayuki; Hayami, Noriko; Suwabe, Tatsuya; Hiramatsu, Rikako; Hasegawa, Eiko; Hoshino, Junichi; Sawa, Naoki; Fujii, Takashi; Takaichi, Kenmei; Ohashi, Kenichi; Ubara, Yoshifumi			Renal histology in a patient with TAFRO syndrome: a case report	HUMAN PATHOLOGY			English	Article						Multicentric Castleman disease; TAFRO syndrome; Thrombotic microangiopathy; Thrombocytopenia; Tocilizumab	DISEASE; CONSTELLATION	An 84-year-old Japanese man was admitted due to anasarca, thrombocytopenia, systemic inflammation, and progressive renal insufficiency, resistance to diuretics, glucocorticoid therapy, and plasma exchange. Renal biopsy showed diffuse endocapillary proliferation and mesangiolysis without any immune deposits. Tocilizumab suppressed systemic inflammation, resulting in improvement of anasarca and renal dysfunction, but thrombocytopenia persisted and platelet-associated IgG antibody was elevated. Although romiplostim was effective for thrombocytopenia, the patient died of aspiration pneumonia after cerebral hemorrhage. Autopsy showed hyaline vascular type Castleman disease like lymphadenopathy and reticulin myelofibrosis with an increase of megakaryocytes. Renal finding showed that endocapillary injury improved, and collapsed glomeruli were noted. This patient fitted the criteria for TAFRO (thrombocytopenia [T], anasarca [A], fever [F], reticulin myelofibrosis [R], and organomegaly [O]) syndrome. The clinical course suggests that 2 factors, including overproduction of interleukin 6 and autoimmune-mediated thrombocytopenia via thrombopoietin receptor, may have contributed to the pathogenesis of TAFRO syndrome in this patient. (C) 2018 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license.	[Mizuno, Hiroki; Sekine, Akinari; Oguro, Masahiko; Oshima, Yoichi; Kawada, Masahiro; Sumida, Keiichi; Yamanouchi, Masayuki; Hayami, Noriko; Suwabe, Tatsuya; Hiramatsu, Rikako; Hasegawa, Eiko; Hoshino, Junichi; Sawa, Naoki; Takaichi, Kenmei; Ubara, Yoshifumi] Toranomon Gen Hosp, Nephrol Ctr, Tokyo 1050001, Japan; [Fujii, Takashi; Ohashi, Kenichi] Toranomon Gen Hosp, Dept Pathol, Tokyo 1050001, Japan; [Takaichi, Kenmei; Ubara, Yoshifumi] Toranomon Gen Hosp, Okinaka Mem Inst Med Res, Tokyo 1050001, Japan; [Ohashi, Kenichi] Yokohama City Univ Med, Grad Sch Med, Dept Pathol, Yokohama, Kanagawa 2360004, Japan	Mizuno, H (reprint author), Toranomon Gen Hosp, Nephrol Ctr, Minato Ku, 2-2-2 Toranomon, Tokyo 1058470, Japan.	hilomiz@yahoo.co.jp		Oshima, Yoichi/0000-0003-1908-6329	Okinaka Memorial Institute for Medical Research	This study was funded by the Okinaka Memorial Institute for Medical Research.	Fujiki T, 2017, CEN CASE REP, V6, P105, DOI 10.1007/s13730-017-0253-6; Fujiwara S, 2016, INT J HEMATOL, V103, P718, DOI 10.1007/s12185-016-1978-2; Iwaki N, 2017, SCI REP-UK, V7, DOI 10.1038/srep42316; Iwaki N, 2016, AM J HEMATOL, V91, P220, DOI 10.1002/ajh.24242; Jose FF, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000006271; Kawabata H, 2013, J CLIN EXP HEMATOP, V53, P57, DOI 10.3960/jslrt.53.57; Masaki Y, 2016, INT J HEMATOL, V103, P686, DOI 10.1007/s12185-016-1979-1; Nakamoto Y, 1999, NEPHROL DIAL TRANSPL, V14, P2370, DOI 10.1093/ndt/14.10.2370; Neunert C, 2011, BLOOD, V117, P4190, DOI 10.1182/blood-2010-08-302984; Tadokoro A, 2016, AM J MED, V129, P938, DOI 10.1016/j.amjmed.2016.05.010; Yuan XG, 2011, CLIN EXP NEPHROL, V15, P921, DOI 10.1007/s10157-011-0499-9	11	1	1	0	0	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	DEC	2018	82						258	263		10.1016/j.humpath.2018.03.021			6	Pathology	Pathology	HG4TV	WOS:000454968800031	29626596	Other Gold			2019-10-28	
J	Hsieh, MS; Lee, YH; Jin, YT; Huang, WC				Hsieh, Min-Shu; Lee, Yi-Hsuan; Jin, Ying-Tai; Huang, Wen-Chih			Strong SOX10 expression in human papilloma virus-related multiphenotypic sinonasal carcinoma: report of 6 new cases validated by high-risk human papillomavirus mRNA in situ hybridization test	HUMAN PATHOLOGY			English	Article						HPV-related multipheno typic sinonasal carcinoma; Adenoid cystic carcinoma; P16; mRNA ISH; SOX10	ADENOID CYSTIC CARCINOMA; SALIVARY-GLAND TUMORS; SQUAMOUS-CELL CARCINOMA; MYB EXPRESSION; NECK-CANCER; HEAD; FEATURES; TRACT; HPV; MARKER	Human papillomavirus (HPV) related multiphenotypic sinonasal carcinoma (HMSC) is associated with high-risk HPV (HR-HPV) infection. Using HR-HPV messenger RNA (mRNA) in situ hybridization (ISH), we reported 6 new HMSC cases and compared their histopathology with that of sinonasal adenoid cystic carcinoma. Using p16 immunohistochemistry (IHC) and HR-HPV ISH, we retrospectively identified 6 HMSC cases. All HMSC cases were positive for HR-HPV mRNA ISH and p16 IHC. Two HMSC cases had overlying atypical squamous epithelium, and 1 had invasive squamous cell carcinoma (SCC). All HMSC cases were SOX10 positive, whereas the overlying atypical squamous epithelium and the SCC were SOX10 negative. One atypical HMSC-like case was also identified, which was positive for HR-HPV mRNA ISH, HR-HPV DNA ISH, and SOX10 IHC, but negative for p16 IHC. This study showed that HR-HPV mRNA ISH was a useful tool to diagnose HMSC and had stronger signals compared with HRHPV DNA ISH. HR-HPV E6/E7 mRNA could be identified in the overlying atypical squamous epithelium and the invasive SCC. A combination of p16 and SOX10 IHC will be a useful screening panel for HMSC followed by confirmatory HR-HPV mRNA ISH test. (C) 2018 Elsevier Inc. All rights reserved.	[Hsieh, Min-Shu; Lee, Yi-Hsuan] Natl Taiwan Univ Hosp, Dept Pathol, Taipei 10002, Taiwan; [Hsieh, Min-Shu; Lee, Yi-Hsuan] Natl Taiwan Univ, Coll Med, Taipei 10002, Taiwan; [Hsieh, Min-Shu] Natl Taiwan Univ, Coll Med, Grad Inst Pathol, Taipei 10002, Taiwan; [Jin, Ying-Tai] Taiwan Adventist Hosp, Dept Pathol, Taipei 10556, Taiwan; [Huang, Wen-Chih] Far Eastern Mem Hosp, Dept Anat Pathol, 21,Sect 2,Nanya South Rd, New Taipei 22060, Taiwan; Natl Taipei Univ Nursing & Hlth Sci, Coll Nursing, Taipei 11219, Taiwan	Huang, WC (reprint author), Far Eastern Mem Hosp, Dept Anat Pathol, 21,Sect 2,Nanya South Rd, New Taipei 22060, Taiwan.	pathology.taipei@gmail.com			National Taiwan University HospitalNational Taiwan University [106-M3739, 106-003612, 107-N3971, 107-N4038]	This study was supported by grants from National Taiwan University Hospital (Nos. 106-M3739, 106-003612, 107-N3971, and 107-N4038).	Bishop JA, 2017, WHO CLASSIFICATION H, P15; Bishop JA, 2017, AM J SURG PATHOL, V41, P1690, DOI 10.1097/PAS.0000000000000944; Bishop JA, 2016, HEAD NECK PATHOL, V10, P23, DOI 10.1007/s12105-016-0688-7; Bishop JA, 2013, AM J SURG PATHOL, V37, P836, DOI 10.1097/PAS.0b013e31827b1cd6; Bishop JA, 2013, AM J SURG PATHOL, V37, P185, DOI 10.1097/PAS.0b013e3182698673; Bishop JA, 2012, AM J SURG PATHOL, V36, P1874, DOI 10.1097/PAS.0b013e318265fb2b; Brainard JA, 1998, AM J SURG PATHOL, V22, P965, DOI 10.1097/00000478-199808000-00006; Brill LB, 2011, MODERN PATHOL, V24, P1169, DOI 10.1038/modpathol.2011.86; Hang JF, 2017, HISTOPATHOLOGY, V71, P887, DOI 10.1111/his.13301; Hsieh MS, 2016, HUM PATHOL, V56, P134, DOI 10.1016/j.humpath.2016.05.021; Hwang SJ, 2015, AURIS NASUS LARYNX, V42, P53, DOI 10.1016/j.anl.2014.07.005; Lai CH, 2007, INT J CANCER, V120, P1999, DOI 10.1002/ijc.22538; Leivo I, 2016, HEAD NECK PATHOL, V10, P68, DOI 10.1007/s12105-016-0694-9; Lewis JS, 2018, ARCH PATHOL LAB MED, V142, P559, DOI 10.5858/arpa.2017-0286-CP; Lewis JS, 2016, HEAD NECK PATHOL, V10, P60, DOI 10.1007/s12105-016-0692-y; Lewis JS, 2014, HEAD NECK PATHOL, V8, P241, DOI 10.1007/s12105-013-0514-4; Miettinen M, 2015, AM J SURG PATHOL, V39, P826, DOI 10.1097/PAS.0000000000000398; Mirghani H, 2015, MODERN PATHOL, V28, P1518, DOI 10.1038/modpathol.2015.113; Ohtomo R, 2013, MODERN PATHOL, V26, P1041, DOI 10.1038/modpathol.2013.54; Parwani AV, 2005, HUM PATHOL, V36, P82, DOI 10.1016/j.humpath.2004.08.015; Persson M, 2009, P NATL ACAD SCI USA, V106, P18740, DOI 10.1073/pnas.0909114106; Poling JS, 2017, AM J SURG PATHOL, V41, P973, DOI 10.1097/PAS.0000000000000878; Purgina B, 2015, HEAD NECK PATHOL, V9, P436, DOI 10.1007/s12105-015-0615-3; Thompson LDR, 2014, HEAD NECK PATHOL, V8, P88, DOI 10.1007/s12105-013-0487-3; Ukpo OC, 2011, AM J SURG PATHOL, V35, P1343, DOI 10.1097/PAS.0b013e318220e59d; West RB, 2011, AM J SURG PATHOL, V35, P92, DOI 10.1097/PAS.0b013e3182002777	26	2	2	2	2	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	DEC	2018	82						264	272		10.1016/j.humpath.2018.07.026			9	Pathology	Pathology	HG4TV	WOS:000454968800032	30071233				2019-10-28	
J	Ma, YY; Zhang, GH; Li, JJ; Wang, SB; Hu, ZM; Zhang, CW; Li, EG				Ma, Ying-Yu; Zhang, Guo-Hai; Li, Jingjing; Wang, Shi-Bing; Hu, Zhi-Ming; Zhang, Cheng-Wu; Li, Erguang			The correlation of NLRC3 expression with the progression and prognosis of hepatocellular carcinoma	HUMAN PATHOLOGY			English	Article						NLRC3; Progression; Prognosis; Tumor suppressor; Hepatocellular carcinoma	MESENCHYMAL TRANSITION; NLRP3 INFLAMMASOME; CANCER; SENSOR; PATHWAYS; IMMUNITY	NLRC3 is a member of the nucleotide-binding domain and leucine-rich repeat (NLR) family protein that plays a role in inflammation and immunity. Although chronic inflammation has been identified as a hallmark of cancer, NLRC3 expression correlation with the development and prognosis of hepatocellular carcinoma (HCC) is unclear. In the present study, we first used Oncomine and OncoLnc database to determine the clinical significance of NLRC3 in HCC. Then we performed quantitative real-time polymerase chain reaction, Western blot, and immunohistochemical staining (IHC) and analyzed the correlation between NLRC3 expression and clinicopathological features of HCC in a Chinese population. We found that high levels of NLRC3 messenger RNA (mRNA) correlated with a favorable clinical outcome; furthermore, expression of NLRC3 was significantly reduced in the cancer tissue in patients compared with noncancerous hepatic tissues. NLRC3 reduction was correlated with Edmondson grade and metastasis. Kaplan-Meier survival analysis revealed that HCC patients with high expression of NLRC3 have a more favorable prognosis compared with those with low expression of NLRC3. We then used short hairpin RNA to knock down NLRC3 expression in HCC cell lines and evaluated its effect on cell proliferation and apoptosis. Suppression of NLRC3 expression promoted cell proliferation and inhibited apoptosis in vitro. Genomic analysis of the OncoLnc database also showed that NLRC3 mRNA level was directly correlated with mRNA levels of inflammasome components caspase-1, IL-1 beta, and IL-18. Based on our present study, down-regulated expression of NLRC3 may play an important role in cancer progression and prognosis of HCC by acting as a tumor suppressor. (C) 2018 Elsevier Inc. All rights reserved.	[Ma, Ying-Yu; Zhang, Guo-Hai; Li, Jingjing; Li, Erguang] Nanjing Univ, Med Sch, State Key Lab Pharmaceut Biotechnol, Nanjing 210093, Jiangsu, Peoples R China; [Ma, Ying-Yu] Peoples Hosp Hangzhou, Zhejiang Prov Peoples Hosp, Med Coll, Key Lab Gastroenterol Zhejiang Prov, Hangzhou 310014, Zhejiang, Peoples R China; [Wang, Shi-Bing] Peoples Hosp Hangzhou, Zhejiang Prov Peoples Hosp, Med Coll, Key Lab Tumor Mol Diag & Individualized Med Zheji, Hangzhou 310014, Zhejiang, Peoples R China; [Hu, Zhi-Ming; Zhang, Cheng-Wu] Peoples Hosp Hangzhou, Zhejiang Prov Peoples Hosp, Med Coll, Dept Hepatobiliary Surg, Hangzhou 310014, Zhejiang, Peoples R China; [Li, Erguang] Nanjing Univ, Med Sch, Jiangsu Key Lab Mol Med, Nanjing 210093, Jiangsu, Peoples R China	Ma, YY; Li, EG (reprint author), Nanjing Univ, Med Sch, Nanjing 210093, Jiangsu, Peoples R China.	myy011525@163.com; erguang@nju.edu.cn			Natural Science Foundation of Zhejiang ProvinceNatural Science Foundation of Zhejiang Province [LQ16H160017]; Natural Science Foundation of ChinaNational Natural Science Foundation of China [81602706]	This work was supported by the Natural Science Foundation of Zhejiang Province (grant no. LQ16H160017) and the Natural Science Foundation of China (grant no. 81602706).	Allen IC, 2012, IMMUNITY, V36, P742, DOI 10.1016/j.immuni.2012.03.012; Allen IC, 2010, J EXP MED, V207, P1045, DOI 10.1084/jem.20100050; Eisenbarth SC, 2009, EMBO MOL MED, V1, P92, DOI 10.1002/emmm.200900014; Grivennikov SI, 2010, CELL, V140, P883, DOI 10.1016/j.cell.2010.01.025; Gultekin Y, 2015, J INNATE IMMUN, V7, P25, DOI 10.1159/000363602; Guo LT, 2017, INT J MOL MED, V40, P898, DOI 10.3892/ijmm.2017.3077; Karki R, 2017, CELL CYCLE, V16, P1243, DOI 10.1080/15384101.2017.1317414; Karki R, 2016, NATURE, V540, P583, DOI 10.1038/nature20597; Lee S, 2018, J HEPATOL, V69, P70, DOI 10.1016/j.jhep.2018.02.026; Liu C, 2018, BMC CANCER, V18, DOI 10.1186/s12885-018-4121-3; Liu RR, 2015, ONCOTARGET, V6, P33456, DOI 10.18632/oncotarget.5587; Lv Z, 2018, CRIT CARE MED, V46, pE49, DOI 10.1097/CCM.0000000000002799; Mantovani A, 2008, NATURE, V454, P436, DOI 10.1038/nature07205; Nikolaou K, 2013, CLIN CANCER RES, V19, P2810, DOI 10.1158/1078-0432.CCR-12-1961; Pang Q, 2018, EUR J GASTROEN HEPAT, V30, P60, DOI 10.1097/MEG.0000000000001021; Qiao L, 2014, CANCER LETT, V345, P150, DOI 10.1016/j.canlet.2013.10.013; Romano A, 2018, J HEPATOL, V69, P345, DOI 10.1016/j.jhep.2018.03.009; Schneider M, 2012, NAT IMMUNOL, V13, P823, DOI 10.1038/ni.2378; Shaw PJ, 2010, EUR J IMMUNOL, V40, P624, DOI 10.1002/eji.200940211; Tao HQ, 2011, HUM PATHOL, V42, P1401, DOI 10.1016/j.humpath.2010.08.023; Tokumitsu Y, 2018, ONCOL LETT, V15, P4411, DOI 10.3892/ol.2018.7821; Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262; Wang H, 2016, EXP CELL RES, V342, P184, DOI 10.1016/j.yexcr.2016.03.009; Wang YL, 2016, ONCOL REP, V35, P2053, DOI 10.3892/or.2016.4569; Wei Q, 2014, LAB INVEST, V94, P52, DOI 10.1038/labinvest.2013.126; Xia YJ, 2011, HUM PATHOL, V42, P1620, DOI 10.1016/j.humpath.2011.01.008; Yang HI, 2010, J CLIN ONCOL, V28, P2437, DOI 10.1200/JCO.2009.27.4456; Yuen MF, 2009, J GASTROEN HEPATOL, V24, P346, DOI 10.1111/j.1440-1746.2009.05784.x; Zhang L, 2014, IMMUNITY, V40, P329, DOI 10.1016/j.immuni.2014.01.010; Zhu QQ, 2015, ONCOTARGET, V6, P4440, DOI 10.18632/oncotarget.2913	30	1	1	2	5	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	DEC	2018	82						273	281		10.1016/j.humpath.2018.07.031			9	Pathology	Pathology	HG4TV	WOS:000454968800033	30081150				2019-10-28	
J	Coppock, JD; Volaric, AK; Mills, AM; Gru, AA				Coppock, Joseph D.; Volaric, Ashley K.; Mills, Anne M.; Gru, Alejandro A.			Concordance levels of PD-L1 expression by immunohistochemistry, mRNA in situ hybridization, and outcome in lung carcinomas	HUMAN PATHOLOGY			English	Article						Non-small cell lung carcinoma; PD-L1; lmmunohistochemistry; RNA in situ hybridization; Concordance	CANCER; ASSAYS; PEMBROLIZUMAB; NIVOLUMAB	Targeted inhibition of programmed cell death-1 (PD-1) and its ligand (PD-L1) has emerged as first-line therapy for advanced non small cell lung cancer. Although patients with high PD-LI expression have improved outcomes with anti PD-1/PD-L1 directed therapies, use as a predictive biomarker is complicated by robust responses in some patients with low-level expression. Furthermore, reported PD-L1 levels in lung cancers vary widely, and discrepancies exist with different antibodies. PD-L1 expression was thus compared by immunohistochemistry (IHC) versus RNA in situ hybridization (ISH) in 112 lung cancers by tissue microarray: 51 adenocarcinoma, 42 squamous cell carcinoma, 9 adenosquamous carcinoma, 5 carcinoid, 3 undifferentiated large cell carcinoma, 1 large cell neuroendocrine carcinoma, and 1 smaL1 cell carcinoma. At least 1% tumor cell staining was considered positive in each modality. A positive concordance of only 60% (67/112) was found between IHC and ISH. Fifty percent (56/112) were positive by IHC and 50% (56/112) by ISH; however, 20% (22/112) were ISH positive but IHC negative. Conversely, 21% (23/112) were IHC positive but ISH negative. There was no significant stratification of PD-L1 positivity by histologic subtype. A trend of more PD-L1 positive stage 1 cancers identified by ISH versus IHC was observed but was not statistically significant (50% [27/54] by IHC and 64% [35/55] by ISH, P = .18). No significant difference in survival was identified, with an average of 5.3 months in IHC versus 5.2 months in ISH-positive cases. The results demonstrate discordance between PD-L1 RNA levels and protein expression in non small cell lung cancers, warranting comparison as predictive biomarkers. (C) 2018 Elsevier Inc. All rights reserved.	[Coppock, Joseph D.; Volaric, Ashley K.; Mills, Anne M.; Gru, Alejandro A.] Univ Virginia, Dept Pathol, 1215 Lee St,HEP 3rd Floor, Charlottesville, VA 22908 USA	Coppock, JD (reprint author), Univ Virginia, Dept Pathol, 1215 Lee St,HEP 3rd Floor, Charlottesville, VA 22908 USA.	jdc5xc@hscmail.mcc.virginia.edu					Brahmer J, 2015, NEW ENGL J MED, V373, P123, DOI 10.1056/NEJMoa1504627; Brunnstrom H, 2017, MODERN PATHOL, V30, P1411, DOI 10.1038/modpathol.2017.59; Buttner R, 2017, J CLIN ONCOL, V35, P3867, DOI 10.1200/JCO.2017.74.7642; Chae YK, 2016, CLIN LUNG CANCER, V17, P350, DOI 10.1016/j.cllc.2016.03.011; Edge SB, 2010, AJCC CANC STAGING MA; Erber R, 2017, ANTICANCER RES, V37, P6771, DOI 10.21873/anticanres.12137; Gafeer MM, 2018, APPL IMMUNOHISTO M M, V26, pe86, DOI 10.1097/PAI.0000000000000595; Ilie M, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0183023; Kim HR, 2017, ONCOTARGET, V8, P87234, DOI 10.18632/oncotarget.20254; Langer CJ, 2016, LANCET ONCOL, V17, P1497, DOI 10.1016/S1470-2045(16)30498-3; Marchetti A, 2017, J THORAC ONCOL, V12, P1654, DOI 10.1016/j.jtho.2017.07.031; McLaughlin J, 2016, JAMA ONCOL, V2, P46, DOI 10.1001/jamaoncol.2015.3638; Parra ER, 2018, APPL IMMUNOHISTO M M, V26, P83, DOI 10.1097/PAI.0000000000000531; Patel SP, 2015, MOL CANCER THER, V14, P847, DOI 10.1158/1535-7163.MCT-14-0983; PDQ Adult Treatment Editorial Board PATE. Non Small Cell Lung Cancer Treatment (PDQ ), 2018, PDQ AD TREATM ED BOA; Reck M, 2016, NEW ENGL J MED, V375, P1823, DOI 10.1056/NEJMoa1606774; Rimm DL, 2017, JAMA ONCOL, V3, P1051, DOI 10.1001/jamaoncol.2017.0013; Rothschild SI, 2015, CANCERS, V7, P930, DOI 10.3390/cancers7020816; Schafer K, 2017, CHEM-EUR J, V23, P370, DOI 10.1002/chem.201603807; Shi XH, 2017, SCI REP-UK, V7, DOI 10.1038/srep46209; Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262; Yang X, 2018, NEW ENGL J MED, V379, DOI 10.1056/NEJMc1808251; Yu H, 2017, J THORAC ONCOL, V12, P110, DOI 10.1016/j.jtho.2016.09.002; Yu H, 2016, J THORAC ONCOL, V11, P964, DOI 10.1016/j.jtho.2016.04.014; Zarogoulidis P, 2018, TRANSL LUNG CANCER R, V7, pS28, DOI 10.21037/tlcr.2018.01.04	25	1	1	1	2	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	DEC	2018	82						282	288		10.1016/j.humpath.2018.07.025			7	Pathology	Pathology	HG4TV	WOS:000454968800034	30075155				2019-10-28	
J	Carpenter, PM; Ziogas, A; Markham, EM; Cantillep, AS; Yan, R; Anton-Culver, H				Carpenter, Philip M.; Ziogas, Argyrios; Markham, Emma M.; Cantillep, Alegria S.; Yan, Rui; Anton-Culver, Hoda			Laminin 332 expression and prognosis in breast cancer	HUMAN PATHOLOGY			English	Article						Laminin 332; Breast carcinoma; Triple-negative; Immunohistochemistry; Prognosis; siRNA; Tumor cell migration	TUMOR INVASION; GROWTH; METASTASIS; INTERFACE; CARCINOMA; TARGET	The purpose of this study was to determine the distribution of and potential significance of laminin 332 (LM332) in breast cancer. Specimens from a population-based cohort (N = 297) from 1994 to 1995 were stained for estrogen receptor (ER), progesterone receptor (PgR), HER2 and the LM332 beta 3 chain. Seventy-five tumors were LM332-positive and 222 were negative. LM332 beta 3 stained 16.0% of ER and/or PgR-positive tumors and 73.2% of triple-negative breast cancers (TNBC). Immunoblotting revealed LM332 in TNBC and HER2-positive samples, but not in an ER-positive breast carcinoma or a phyllodes tumor. After 20 years, 172 patients were alive, 43 had died of breast cancer and 82 of other causes. Patients with LM332-positive tumors had significantly worse 5 (P <.0001) and 10-year (P <.05) overall and breast cancer specific survival. Among patients with LM332 beta 3-expressing and ER/PgR-negative carcinomas, 10-year survival was significantly reduced (P <.0450). In a multivariate analysis LM332-positive patients had significant hazard ratios of 3.9 with 95% confidence intervals (CI) of 2.0-7.7 and 2.2 with 95% CI of 1.33.8 for 5 and 10-year overall survival, respectively. Because tumor cell motility is required for metastasis, the effect of LM332 on MDA-MB-231 migration was determined using siRNA. Knockdown of LM332-specific beta 3 and gamma 2 chains reduced motility without affecting viability. Our observation that LM332 in breast carcinoma is associated with decreased survival provides evidence that LM332 may have a role in the aggressive phenotype of some breast cancers. (C) 2018 Elsevier Inc. All rights reserved.	[Carpenter, Philip M.; Yan, Rui] Univ Southern Calif, Keck Sch Med, Dept Pathol, Los Angeles, CA 90033 USA; [Carpenter, Philip M.; Markham, Emma M.; Cantillep, Alegria S.] Univ Calif Orange, Dept Pathol, Orange, CA USA; [Ziogas, Argyrios; Markham, Emma M.; Anton-Culver, Hoda] Univ Calif Irvine, Dept Epidemiol, Irvine, CA 92697 USA; [Markham, Emma M.] Imperial Coll London, Hammersmith Hosp, Commonwealth Bldg,Du Cane Rd, London W12 0NN, England; [Cantillep, Alegria S.] Touro Univ, Coll Osteopath Med, Vallejo, CA USA	Carpenter, PM (reprint author), Univ Southern Calif, Dept Pathol, Keck Hosp, FIC4,Room 2420,1500 San Pablo St, Los Angeles, CA 90033 USA.	Philip.Carpenter@med.use.edu; aziogas@uci.edu; markhamemma@gmail.com; alegcantillep@gmail.com; ruiyan80@gmail.com; hantoncu@uci.edu			National Cancer InstituteUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [CA58860, CA-62203]; Lon V. Smith Foundation [LVS-18840]	The study was supported by the National Cancer Institute Support Grant CA-62203 to the Chao Family Cancer Center, Dr. Frank Meyskcns, Principal Investigator, National Cancer Institute Grant CA58860 and the Lon V. Smith Foundation Grant LVS-18840.	Agboola AOJ, 2016, MALAYS J PATHOL, V38, P83; ALLRED DC, 1990, ARCH SURG-CHICAGO, V125, P107; Anton-Culver H, 2000, EUR J CANCER, V36, P1200, DOI 10.1016/S0959-8049(00)00110-6; California Cancer Registry, CANC REP; Cao X, 2013, BIOMED OPT EXPRESS, V4, P1, DOI 10.1364/BOE.4.000001; Carpenter PM, 2008, AM J SURG PATHOL, V32, P345, DOI 10.1097/PAS.0b013e3181592201; Carpenter PM, 2009, MOL CANCER RES, V7, P462, DOI 10.1158/1541-7786.MCR-08-0148; D'Alfonso TM, 2015, J CLIN PATHOL, V68, P516, DOI 10.1136/jclinpath-2015-202923; Diaz LK, 2005, MODERN PATHOL, V18, P1165, DOI 10.1038/modpathol.3800411; Domogatskaya A, 2012, ANNU REV CELL DEV BI, V28, P523, DOI 10.1146/annurev-cellbio-101011-155750; Guess CM, 2009, MATRIX BIOL, V28, P445, DOI 10.1016/j.matbio.2009.07.008; Henning K, 1999, HISTOPATHOLOGY, V34, P305; Khoury T, 2009, MODERN PATHOL, V22, P1457, DOI 10.1038/modpathol.2009.117; Kim BG, 2011, AM J PATHOL, V178, P373, DOI 10.1016/j.ajpath.2010.11.028; Kwon SY, 2012, APPL IMMUNOHISTO M M, V20, P159, DOI 10.1097/PAI.0b013e3182329e8f; Lehmann BD, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0157368; Marinkovich MP, 2007, NAT REV CANCER, V7, P370, DOI 10.1038/nrc2089; Moon YW, 2015, CELL DEATH DIFFER, V22, P1341, DOI 10.1038/cdd.2014.228; Park HS, 2014, MODERN PATHOL, V27, P1212, DOI 10.1038/modpathol.2013.251; Patarroyo M, 2002, SEMIN CANCER BIOL, V12, P197, DOI 10.1016/S1044-579X(02)00023-8; Pietri E, 2016, ENDOCR-RELAT CANCER, V23, pR485, DOI 10.1530/ERC-16-0190; Press MF, 2016, J CLIN ONCOL, V34, P3518, DOI 10.1200/JCO.2016.66.6693; Rakha EA, 2007, CANCER-AM CANCER SOC, V109, P25, DOI 10.1002/cncr.22381; Salo S, 2009, INT J CANCER, V125, P1814, DOI 10.1002/ijc.24532; Sathyanarayana UG, 2004, CANCER RES, V64, P1425, DOI 10.1158/0008-5472.CAN-03-0701; Stipp CS, 2010, EXPERT REV MOL MED, V12, DOI 10.1017/S1462399409001355; STRACKE ML, 1991, EXP SUPPL, V59, P147; Tran M, 2008, CANCER RES, V68, P2885, DOI 10.1158/0008-5472.CAN-07-6160; Tsuruta D, 2008, CURR MED CHEM, V15, P1968, DOI 10.2174/092986708785132834; Wang H, 2004, J CELL BIOL, V164, P935, DOI 10.1083/jcb.200309112; Wolff AC, 2014, ARCH PATHOL LAB MED, V138, P241, DOI 10.5858/arpa.2013-0953-SA; Yan HHN, 2008, P NATL ACAD SCI USA, V105, P8950, DOI 10.1073/pnas.0711264105; Zhou B, 2014, MOL CANCER RES, V12, P143, DOI 10.1158/1541-7786.MCR-13-0184; Zhou Y, 2016, CANCER RES, V76, P5777, DOI 10.1158/0008-5472.CAN-15-2936; Ziogas A, 2000, CANCER EPIDEM BIOMAR, V9, P103	35	0	0	1	4	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	DEC	2018	82						289	296		10.1016/j.humpath.2018.08.003			8	Pathology	Pathology	HG4TV	WOS:000454968800035	30125583				2019-10-28	
J	Barresi, V				Barresi, Valeria			Conflicting IDH1/IDH2, ATRX, and 1p/19q results in diffuse gliomas: a commentary	HUMAN PATHOLOGY			English	Letter									[Barresi, Valeria] Univ Messina, Dept Human Pathol Adulthood & Evolut Age Gaetano, I-98125 Messina, Italy	Barresi, V (reprint author), Univ Messina, Dept Human Pathol Adulthood & Evolut Age Gaetano, I-98125 Messina, Italy.	vbarresi@unime.it					Ballester LY, 2017, HUM PATHOL, V69, P15, DOI 10.1016/j.humpath.2017.05.005; Barresi V, 2017, J NEUROPATH EXP NEUR, V76, P342, DOI 10.1093/jnen/nlx024; Jiao YC, 2012, ONCOTARGET, V3, P709, DOI 10.18632/oncotarget.588; Louis DN, 2016, WHO CLASSIFICATION T; Yoshimoto K, 2017, BRAIN TUMOR PATHOL, V34, P103, DOI 10.1007/s10014-017-0287-7	5	0	0	0	0	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	DEC	2018	82						297	298		10.1016/j.humpath.2018.04.034			2	Pathology	Pathology	HG4TV	WOS:000454968800036	30539794				2019-10-28	
J	Manley, P; Kirsch, R; Walla, JS; Riddell, R				Manley, Paul; Kirsch, Richard; Walla, Jagdeep S.; Riddell, Robert			Telocytes as possible precursors of PDGFRA-mutant gastrointestinal mesenchymal tumors	HUMAN PATHOLOGY			English	Letter									[Manley, Paul] Queens Univ, Kingston Hlth Sci Ctr Kingston, Dept Pathol & Mol Med, Kingston, ON K7L 3N6, Canada; [Kirsch, Richard; Riddell, Robert] Mt Sinai Hosp, Dept Pathol & Lab Med, Toronto, ON M5G 1X5, Canada; [Walla, Jagdeep S.] Kingston Hlth Sci Ctr, Dept Pediat, Div Med Genet, Kingston, ON K7L 2V7, Canada; [Walla, Jagdeep S.] Queens Univ, Kingston, ON K7L 2V7, Canada	Walla, JS (reprint author), Kingston Hlth Sci Ctr, Dept Pediat, Div Med Genet, Kingston, ON K7L 2V7, Canada.; Walla, JS (reprint author), Queens Univ, Kingston, ON K7L 2V7, Canada.	waliaj@kgh.kari.net					Faussone Pellegrini Maria-Simonetta, 2011, Biomol Concepts, V2, P481, DOI 10.1515/BMC.2011.039; Manley PN, 2018, HUM PATHOL, V76, P52, DOI 10.1016/j.humpath.2018.02.014; Ricci R, 2016, HERED CANCER CLIN PR, V14, DOI 10.1186/s13053-016-0055-4; Ricci R, 2015, MODERN PATHOL, V28, P954, DOI 10.1038/modpathol.2015.56; Vannucchi Maria Giuliana, 2016, BioMolecular Concepts, V7, P93, DOI 10.1515/bmc-2015-0034; Vannucchi MG, 2013, J CELL MOL MED, V17, P1099, DOI 10.1111/jcmm.12134	6	2	2	1	11	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	DEC	2018	82						298	300		10.1016/j.humpath.2018.04.035			3	Pathology	Pathology	HG4TV	WOS:000454968800037	29981769				2019-10-28	
J	Wang, QQ; Yong, L				Wang, Qianqian; Yong, Liu			Eps8, a therapeutic potential target for cancer	HUMAN PATHOLOGY			English	Letter									[Wang, Qianqian] Anhui Univ Chinese Med, Affiliated Hosp 1, Dept TCM Pharm, Hefei 230031, Anhui, Peoples R China; [Yong, Liu] Anhui Univ Chinese Med, Affiliated Hosp 1, Hefei 230031, Anhui, Peoples R China	Wang, QQ (reprint author), Anhui Univ Chinese Med, Affiliated Hosp 1, Dept TCM Pharm, Hefei 230031, Anhui, Peoples R China.	1154080308@qq.com					Chen YR, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0682-x; Huang R, 2018, ONCOL REP, V39, P119, DOI 10.3892/or.2017.6102; Nasri E, 2018, HUM PATHOL, V72, P45, DOI 10.1016/j.humpath.2017.10.021; Sun PP, 2018, BIOCHEM BIOPH RES CO, V497, P990, DOI 10.1016/j.bbrc.2018.02.128; Xie XL, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0420-5	5	1	1	0	0	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	DEC	2018	82						300	301		10.1016/j.humpath.2018.04.037			2	Pathology	Pathology	HG4TV	WOS:000454968800038	30539795				2019-10-28	
J	Elmore, SA; Carreira, V; Labriola, CS; Mahapatra, D; McKeag, SR; Rinke, M; Shackelford, C; Singh, B; Talley, A; Wallace, SM; Wancket, LM; Willson, CJ				Elmore, Susan A.; Carreira, Vinicius; Labriola, Caralyn S.; Mahapatra, Debabrata; McKeag, Sean R.; Rinke, Matthias; Shackelford, Cynthia; Singh, Bhanu; Talley, Ashley; Wallace, Shannon M.; Wancket, Lyn M.; Willson, Cynthia J.			Proceedings of the 2018 National Toxicology Program Satellite Symposium	TOXICOLOGIC PATHOLOGY			English	Article; Proceedings Paper	Annual National-Toxicology-Program Satellite Symposium on Pathology Potpourri at the 37th Annual Meeting of the the Society-of-Toxicologic-Pathology	2018	Indianapolis, IN	Natl Toxicol Program, Soc Toxicol Pathol		NTP Satellite Symposium; testis dysgenesis; ameloblast degeneration; intestinal leiomyositis; gallbladder mucinous hyperplasia; renal tubule basophilic granules; uterine choriocarcinoma; renal neoplasia; rete ovarii hyperplasia; fish larvae gross lesions; INHAND	EPITHELIOID TROPHOBLASTIC TUMOR; TESTICULAR DYSGENESIS SYNDROME; IN-UTERO EXPOSURE; CHRONIC INTESTINAL PSEUDOOBSTRUCTION; REPRODUCTIVE-TRACT LESIONS; NONPROLIFERATIVE LESIONS; DEVELOPMENTAL TOXICITY; PROLIFERATIVE LESIONS; CYSTIC HYPERPLASIA; RETE OVARII	The 2018 annual National Toxicology Program Satellite Symposium, entitled "Pathology Potpourri," was held in Indianapolis, Indiana, at the Society of Toxicologic Pathology's 37th annual meeting. The goal of this symposium was to present and discuss challenging diagnostic pathology and/or nomenclature issues. This article presents summaries of the speakers' talks along with select images that were used by the audience for voting and discussion. Various lesions and other topics covered during the symposium included seminiferous tubule dysgenesis in rats, ameloblast and odontoblast degeneration/necrosis in a Sprague Dawley rat, intestinal leiomyositis in a beagle dog, gallbladder mucinous hyperplasia, focus of hepatocellular alteration and bile duct alteration in otters, renal tubule cytoplasmic vacuolation with basophilic granules in mice treated swith antisense oligonucleotide therapy, a uterine choriocarcinoma in a rhesus macaque, and rete ovarii proliferative ovarian lesions in various aged rat strains. One particularly provocative lesion was a malignant neoplastic proliferation in the renal pelvic region of a cynomolgus macaque from a 21-day study. Additional challenging lesions included thyroid proliferative lesions in zebra fish and gross findings in fish larvae during routine chemical screening. The Rabbit and Minipig International Harmonization of Nomenclature and Diagnostic Criteria Organ Working Groups also presented a series of challenging lesions.	[Elmore, Susan A.] NIEHS, Cellular & Mol Pathol Branch, Natl Toxicol Program, NIH, 111 TW Alexander Dr, Res Triangle Pk, NC 27709 USA; [Carreira, Vinicius] Janssen Res & Dev, La Jolla, CA USA; [Labriola, Caralyn S.] Wake Forest Univ, Bowman Gray Sch Med, Winston Salem, NC USA; [Mahapatra, Debabrata; Willson, Cynthia J.] Integrated Lab Syst Inc, Res Triangle Pk, NC USA; [McKeag, Sean R.] Covance Labs, Harrogate, N Yorkshire, England; [Rinke, Matthias] Bayer AG, Wuppertal, Germany; [Shackelford, Cynthia] Expt Pathol Labs Inc, Res Triangle Pk, NC USA; [Singh, Bhanu] Janssen Res & Dev, Spring House, PA USA; [Talley, Ashley] Charles River Labs Inc, Durham, NC USA; [Wallace, Shannon M.] Expt Pathol Labs Inc, Sterling, VA USA; [Wancket, Lyn M.] NAMSA, Northwood, OH USA	Elmore, SA (reprint author), NIEHS, Cellular & Mol Pathol Branch, Natl Toxicol Program, NIH, 111 TW Alexander Dr, Res Triangle Pk, NC 27709 USA.	elmore@niehs.nih.gov		Carreira, Vinicius/0000-0003-4524-0510; , Cynthia/0000-0003-0942-3723	Intramural Research Program of the National Institute of Environmental Health Sciences, National Institutes of Health	The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This research was supported (in part) by the Intramural Research Program of the National Institute of Environmental Health Sciences, National Institutes of Health.	Abbas HH, 2012, LIFE SCI J, V9, P700; ADACHI TADASHI, 1957, BULL TOKYO MED AND DENTAL UNIV, V4, P215; ALLRICH RD, 1983, BIOL REPROD, V28, P902, DOI 10.1095/biolreprod28.4.902; Atkins HM, 2016, VET PATHOL, V53, P1252, DOI 10.1177/0300985816646433; Baker TR, 2013, TOXICOL SCI, V135, P241, DOI 10.1093/toxsci/kft144; Barlow NJ, 2004, TOXICOL PATHOL, V32, P79, DOI 10.1080/01926230490265894; Barlow NJ, 2003, TOXICOL PATHOL, V31, P397, DOI 10.1080/01926230390202335; Bentley RC, 2003, CLIN OBSTET GYNECOL, V46, P513, DOI 10.1097/00003081-200309000-00004; Billiard SM, 2006, TOXICOL SCI, V92, P526, DOI 10.1093/toxsci/kfl011; Bohm J, 2000, AM J SURG PATHOL, V24, P56, DOI 10.1097/00000478-200001000-00007; Bollen P, 2006, EXP TOXICOL PATHOL, V57, P347, DOI 10.1016/j.etp.2006.03.005; Bradley A. E., 2012, BACKGROUND LESIONS L, P87; BYSKOV AG, 1977, J ANAT, V123, P77; Carney SA, 2006, BIRTH DEFECTS RES A, V76, P7, DOI 10.1002/bdra.20216; Cesta MF, 2006, TOXICOL PATHOL, V34, P455, DOI 10.1080/01926230600867743; Chu D, 2007, J AM ASSOC LAB ANIM, V46, P92; Clewell RA, 2013, REPROD TOXICOL, V35, P70, DOI 10.1016/j.reprotox.2012.07.008; Cline JM, 2008, TOXICOL PATHOL, V36, p142S, DOI 10.1177/0192623308327117; Cooper TK, 2017, VET PATHOL, V54, P178, DOI 10.1177/0300985816658102; Cooper TK, 2005, J COMP PATHOL, V133, P218, DOI 10.1016/j.jcpa.2005.04.003; Couraud L, 2006, VET REC, V159, P86, DOI 10.1136/vr.159.3.86; Creasy D, 2012, TOXICOL PATHOL, V40, p40S, DOI 10.1177/0192623312454337; Crow GL, 2001, J AQUAT ANIM HEALTH, V13, P1, DOI 10.1577/1548-8667(2001)013<0001:HAOGIE>2.0.CO;2; Davis B., 2001, INT CLASSIFICATION R, P667; DEOLIVEIRANOGUEIRA T, 1981, SCAND J DENT RES, V89, P48; Dincer Z, 2012, MINIPIG IN BIOMEDICAL RESEARCH, P305; Dixon D, 2014, J TOXICOL PATHOL, V27, p1S, DOI 10.1293/tox.27.1S; Farman CA, 2005, VET PATHOL, V42, P226, DOI 10.1354/vp.42-2-226; FELL BF, 1983, J COMP PATHOL, V93, P171, DOI 10.1016/0021-9975(83)90003-8; Fisher JS, 2003, HUM REPROD, V18, P1383, DOI 10.1093/humrep/deg273; Fossey S, 2016, J TOXICOL PATHOL, V29, p49S, DOI [10.1293/tox.2016-I002, 10.1293/tox.29.3S-2]; Fournie JW, 2005, TOXICOL PATHOL, V33, P540, DOI 10.1080/01926230500214509; Giusti AMF, 2005, VET PATHOL, V42, P223, DOI 10.1354/vp.42-2-223; Glerup P, 2013, HASCHEK AND ROUSSEAUX'S HANDBOOK OF TOXICOLOGIC PATHOLOGY, VOL 1-3, 3RD EDITION, P461, DOI 10.1016/B978-0-12-415759-0.00013-3; Goudie DR, 2011, NAT GENET, V43, P365, DOI 10.1038/ng.780; Haley PJ, 2017, J TOXICOL PATHOL, V30, P111, DOI 10.1293/tox.2016-0075; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hanno K, 2010, CHEMOSPHERE, V78, P830, DOI 10.1016/j.chemosphere.2009.11.043; Helke KL, 2016, TOXICOL PATHOL, V44, P575, DOI 10.1177/0192623316639389; Helke KL, 2016, TOXICOL PATHOL, V44, P325, DOI 10.1177/0192623315611762; Henry TR, 1997, TOXICOL APPL PHARM, V142, P56, DOI 10.1006/taap.1996.8024; Herbertz S, 2015, DRUG DES DEV THER, V9, P4479, DOI 10.2147/DDDT.S86621; Hildebrand Joanna, 2011, Wiadomosci Parazytologiczne, V57, P151; Hinther Ashley, 2012, Frontiers in Genetics, V3, P51, DOI 10.3389/fgene.2012.00051; Honjo Y, 2007, CELL CYCLE, V6, P1360, DOI 10.4161/cc.6.11.4268; Howroyd PC, 2016, TOXICOL PATHOL, V44, P607, DOI 10.1177/0192623316642881; Hui P., 2014, WHO CLASSIFICATION T, V43, P155; Hutchison GR, 2008, INT J ANDROL, V31, P103, DOI 10.1111/j.1365-2605.2007.00816.x; Jain D., 2009, SURG PATHOLOGY GI TR, P125; Jeppesen G, 2015, TOXICOL PATHOL, V43, P257, DOI 10.1177/0192623314538344; Jiang J., 2004, J TOXICOL PATHOL, V17, P127; Johnson CS, 2007, VET PATHOL, V44, P106, DOI 10.1354/vp.44-1-106; Kalhor N, 2009, AM J SURG PATHOL, V33, P633, DOI 10.1097/PAS.0b013e318191f2eb; Kangawa A, 2016, TOXICOL PATHOL, V44, P1105, DOI 10.1177/0192623316673495; Kaspareit J, 2004, EXP TOXICOL PATHOL, V56, P9, DOI 10.1016/j.etp.2004.04.009; Kaste SC, 1997, LEUKEMIA, V11, P792, DOI 10.1038/sj.leu.2400670; Kim H K, 1982, J Osaka Dent Univ, V16, P157; Kommoss F, 2001, INT J GYNECOL PATHOL, V20, P380, DOI 10.1097/00004347-200110000-00011; Kon Y, 2007, ANAT HISTOL EMBRYOL, V36, P172, DOI 10.1111/j.1439-0264.2006.00728.x; Kuijpers MHM, 1996, TOXICOL PATHOL, V24, P346, DOI 10.1177/019262339602400311; Lara NLM, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-02684-2; Leininger J. R., 2018, BOORMANS PATHOLOGY R, P15; Long GG, 2002, TOXICOL PATHOL, V30, P592, DOI 10.1080/01926230290105785; Mahood IK, 2005, ENDOCRINOLOGY, V146, P613, DOI 10.1210/en.2004-0671; Marbaix E, 2008, VET PATHOL, V45, P375, DOI 10.1354/vp.45-3-375; Marr-Belvin AK, 2010, J MED PRIMATOL, V39, P170, DOI 10.1111/j.1600-0684.2010.00409.x; MAUDESLE.LE, 1967, VET REC, V80, P658; McInnes E. F., 2012, BACKGROUND LESIONS L, P81; MIKKELSEN HB, 1978, SCAND J DENT RES, V86, P313; Mione MC, 2010, DIS MODEL MECH, V3, P517, DOI 10.1242/dmm.004747; Morgan K. T., 1987, MONOGRAPHS PATHOLOGY, P42; Mulero-Navarro S, 2016, FRONT CELL DEV BIOL, V4, DOI 10.3389/fcell.2016.00045; Mylchreest E, 2002, REPROD TOXICOL, V16, P19, DOI 10.1016/S0890-6238(01)00201-5; Noussios G, 2011, EUR J ENDOCRINOL, V165, P375, DOI 10.1530/EJE-11-0461; Parks LG, 2000, TOXICOL SCI, V58, P339, DOI 10.1093/toxsci/58.2.339; Pasche Boris, 2014, Trans Am Clin Climatol Assoc, V125, P300; Patnaik A K, 2000, J Feline Med Surg, V2, P143, DOI 10.1053/jfms.2000.0085; Prasch AL, 2003, TOXICOL SCI, V76, P138, DOI 10.1093/toxsci/kfg202; REINDEL JF, 1987, J COMP PATHOL, V97, P601, DOI 10.1016/0021-9975(87)90011-9; Renne R, 2009, TOXICOL PATHOL, V37, p5S, DOI 10.1177/0192623309353423; Ruehl-Fehlert C, 2003, EXP TOXICOL PATHOL, V55, P91, DOI 10.1078/0940-2993-00311; Ruuska TH, 2002, GASTROENTEROLOGY, V122, P1133, DOI 10.1053/gast.2002.32396; Saggiorato E, 2001, J CLIN ENDOCR METAB, V86, P5152, DOI 10.1210/jc.86.11.5152; Sato J, 2012, J TOXICOL PATHOL, V25, P103, DOI 10.1293/tox.25.103; Schour I, 1949, RAT LABORATORY INVES, P104; Scott Eirwen M, 2012, Case Rep Obstet Gynecol, V2012, P862472, DOI 10.1155/2012/862472; Seckl MJ, 2000, LANCET, V356, P36, DOI 10.1016/S0140-6736(00)02432-6; Sellers RS, 2017, TOXICOL PATHOL, V45, P416, DOI 10.1177/0192623317700519; Sharpe Richard M, 2008, Fertil Steril, V89, pe33, DOI 10.1016/j.fertnstert.2007.12.026; Sharpe RM, 2006, BEST PRACT RES CL EN, V20, P91, DOI 10.1016/j.beem.2005.09.005; Shih IM, 1999, HUM PATHOL, V30, P687, DOI 10.1016/S0046-8177(99)90095-3; Shih IM, 2004, AM J SURG PATHOL, V28, P1177, DOI 10.1097/01.pas.0000130325.66448.a1; Simpson VR, 2005, VET REC, V157, P49, DOI 10.1136/vr.157.2.49; Skakkebaek NE, 2001, HUM REPROD, V16, P972, DOI 10.1093/humrep/16.5.972; Sorby R, 2005, J COMP PATHOL, V132, P313, DOI 10.1016/j.jcpa.2004.11.003; Stauber A. J., 2014, J CLIN PRACT, V4, P1; STENE T, 1979, SCAND J DENT RES, V87, P39; STEPHENS LC, 1982, VET PATHOL, V19, P669, DOI 10.1177/030098588201900612; Stockinger B, 2014, ANNU REV IMMUNOL, V32, P403, DOI 10.1146/annurev-immunol-032713-120245; Sun N, 2016, J CLIN MED, V5, DOI 10.3390/jcm5120109; Tan OL, 2005, J PATHOL, V205, P483, DOI 10.1002/path.1719; Thoolen B, 2010, TOXICOL PATHOL, V38, p5S, DOI 10.1177/0192623310386499; Tierney KB, 2011, BBA-MOL BASIS DIS, V1812, P381, DOI 10.1016/j.bbadis.2010.10.011; TODD GC, 1986, VET PATHOL, V23, P110, DOI 10.1177/030098588602300202; Toyosawa K, 2000, VET PATHOL, V37, P186, DOI 10.1354/vp.37-2-186; van den Driesche S, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.91204; VANSTRAATEN HWM, 1977, BIOL REPROD, V17, P467, DOI 10.1095/biolreprod17.4.467; Washabau R., 2013, CANINE FELINE GASTRO, P651; WENZEL JGW, 1987, ANAT HISTOL EMBRYOL, V16, P124, DOI 10.1111/j.1439-0264.1987.tb00731.x; Wiseman SM, 2007, ARCH SURG-CHICAGO, V142, P717, DOI 10.1001/archsurg.142.8.717; WISK JD, 1992, ARCH TOXICOL, V66, P245, DOI 10.1007/BF02307169; Yokouchi Y, 2011, TOXICOL PATHOL, V39, P553, DOI 10.1177/0192623311399787; Zacuto AC, 2016, J VET INTERN MED, V30, P132, DOI 10.1111/jvim.13652	113	0	0	1	4	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0192-6233	1533-1601		TOXICOL PATHOL	Toxicol. Pathol.	DEC	2018	46	8			SI		865	897		10.1177/0192623318800734			33	Pathology; Toxicology	Pathology; Toxicology	HF3NN	WOS:000454141900001	30282530				2019-10-28	
J	Cianciolo, RE; Jennette, JC				Cianciolo, Rachel E.; Jennette, J. Charles			Glomerulonephritis in Animal Models and Human Medicine: Discovery, Pathogenesis, and Diagnostics	TOXICOLOGIC PATHOLOGY			English	Article; Proceedings Paper	Annual National-Toxicology-Program Satellite Symposium on Pathology Potpourri at the 37th Annual Meeting of the the Society-of-Toxicologic-Pathology	2018	Indianapolis, IN	Natl Toxicol Program, Soc Toxicol Pathol		glomerulus; glomerulonephritis; transmission electron microscopy; immunofluorescence	BASEMENT-MEMBRANE; CLASSIFICATION; ANTIBODIES; DEPOSITS	Glomerulonephritis (GN) is inflammation of glomeruli. The four major categories that cause human GN are mediated by immunoglobulin or complement or both, and they include (1) immune complex-mediated GN, (2) anti-glomerular basement membrane-mediated GN, (3) antineutrophil cytoplasmic autoantibody-mediated GN, and (4) complement factor 3 glomerulopathy mediated by complement dysregulation. Initiating processes include infection, autoimmunity, exogenous antigens, and neoplasia. Often there are predisposing and modulating genetic, epigenetic, and/or environmental factors. Animal models facilitated the recognition and elucidation of the pathogeneses of all four categories of GN, and they continue to be used in preclinical studies to identify and validate therapies for all four types of GN. Advanced diagnostic modalities (e.g., transmission electron microscopy and immunofluorescence) are helpful and sometimes required for the correct categorization of GN in humans and animals. This review provides historical background on the discovery of the different GN pathogeneses, describes some of the animal models used to discover and understand each GN pathogenic category, reviews the diagnostic classification of each category of GN, and compares human GN to spontaneous forms of nonhuman GN.	[Cianciolo, Rachel E.] Ohio State Univ, 1925 Coffey Rd, Columbus, OH 43210 USA; [Jennette, J. Charles] Univ N Carolina, Chapel Hill, NC USA	Cianciolo, RE (reprint author), Ohio State Univ, 1925 Coffey Rd, Columbus, OH 43210 USA.	cianciolo.14@osu.edu					Beck L, 2013, AM J KIDNEY DIS, V62, P403, DOI 10.1053/j.ajkd.2013.06.002; Beck LH, 2009, NEW ENGL J MED, V361, P11, DOI 10.1056/NEJMoa0810457; Bomback AS, 2012, NAT REV NEPHROL, V8, P634, DOI 10.1038/nrneph.2012.213; Bonsib S. M., 2007, HEPTINSTALLS PATHOLO, V1, P1; Cianciolo RE, 2016, VET PATHOL, V53, P113, DOI 10.1177/0300985815579996; Cianciolo RE, 2013, J VET INTERN MED, V27, pS10, DOI 10.1111/jvim.12226; CIANCIOLO R. F., 2015, JUBB KENNEDY PALMER, V2, P376; DIXON FJ, 1961, J EXP MED, V113, P899, DOI 10.1084/jem.113.5.899; FALK RJ, 1988, NEW ENGL J MED, V318, P1651, DOI 10.1056/NEJM198806233182504; Frazier KS, 2012, TOXICOL PATHOL, V40, P14, DOI 10.1177/0192623312438736; GERMUTH FG, 1953, J EXP MED, V97, P257, DOI 10.1084/jem.97.2.257; Hogasen K, 1998, IMMUNOLOGIST, V6, P23; Holm LP, 2015, VET REC, V176, DOI 10.1136/vr.102892; ISKANDAR SS, 1983, AM J PATHOL, V112, P155; JANSEN JH, 1992, J VET MED A, V39, P582, DOI 10.1111/j.1439-0442.1992.tb00221.x; Jennette JC, 2007, HEPTINSTALLS PATHOLO, V1, P613; Keir L, 2011, PEDIATR NEPHROL, V26, P523, DOI 10.1007/s00467-010-1637-4; LERNER RA, 1967, J EXP MED, V126, P989, DOI 10.1084/jem.126.6.989; Mancho C, 2010, J VET DIAGN INVEST, V22, P553, DOI 10.1177/104063871002200409; Markowitz GS, 2007, KIDNEY INT, V71, P491, DOI 10.1038/sj.ki.5002118; MELLORS RC, 1955, J HISTOCHEM CYTOCHEM, V3, P284, DOI 10.1177/3.4.284; Nangaku Masaomi, 2005, Clin Exp Nephrol, V9, P183, DOI 10.1007/s10157-005-0357-8; OSBORNE C A, 1973, Journal of the American Animal Hospital Association, V9, P295; Richard ML, 2018, LUPUS SCI MED, V5, DOI 10.1136/lupus-2016-000199; Rousset-Rouviere C, 2014, PEDIATR NEPHROL, V29, P1107, DOI 10.1007/s00467-013-2711-5; Schneider SM, 2013, J VET INTERN MED, V27, pS67, DOI 10.1111/jvim.12247; Schroeder C, 1999, NEPHROL DIAL TRANSPL, V14, P1875, DOI 10.1093/ndt/14.8.1875; STEBLAY RW, 1962, J EXP MED, V116, P253, DOI 10.1084/jem.116.2.253; STILMANT MM, 1979, KIDNEY INT, V15, P184, DOI 10.1038/ki.1979.24; STURGILL BC, 1965, J AMER MED ASSOC, V194, P914, DOI 10.1001/jama.194.8.914; Suzuki Hitoshi, 2014, Drug Discov Today Dis Models, V11, P5; Volhard F, 1914, BRIGHTSCHE NIERENKRA; Weening JJ, 2004, KIDNEY INT, V65, P521, DOI 10.1111/j.1523-1755.2004.00443.x; Wyatt RJ, 2013, NEW ENGL J MED, V368, P2402, DOI 10.1056/NEJMra1206793	34	0	0	0	1	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0192-6233	1533-1601		TOXICOL PATHOL	Toxicol. Pathol.	DEC	2018	46	8			SI		898	903		10.1177/0192623318800714			6	Pathology; Toxicology	Pathology; Toxicology	HF3NN	WOS:000454141900002	30278837				2019-10-28	
J	Frazier, KS; Obert, LA				Frazier, Kendall S.; Obert, Leslie A.			Drug-induced Glomerulonephritis: The Spectre of Biotherapeutic and Antisense Oligonucleotide Immune Activation in the Kidney	TOXICOLOGIC PATHOLOGY			English	Article; Proceedings Paper	Annual National-Toxicology-Program Satellite Symposium on Pathology Potpourri at the 37th Annual Meeting of the the Society-of-Toxicologic-Pathology	2018	Indianapolis, IN	Natl Toxicol Program, Soc Toxicol Pathol		glomerulonephritis; antisense oligonucleotide; biotherapeutic; mouse; monkey; immune complex	COMPLEX-MEDIATED GLOMERULONEPHRITIS; NONSMALL MOLECULE THERAPEUTICS; VASCULAR INJURY; TNF-ALPHA; IN-VIVO; HYALINE GLOMERULOPATHY; MONOCLONAL-ANTIBODY; NONHUMAN-PRIMATES; SAFETY ASSESSMENT; NUCLEIC-ACID	Prevalence of immune-mediated glomerulonephritis has increased in preclinical toxicity studies, with more frequent use of biotherapeutic agents (especially antigenic humanized molecules) and antisense oligonucleotide (ASO) therapies. Immune complex disease affects a small number of study monkeys, often correlates with antidrug antibody (ADA) titers, and occurs at a dose that favors immune complex formation or impedes clearance. While preclinical glomerulonephritis often fails to correlate with evidence of glomerular or vascular injury in human clinical trials and is not considered predictive, additional animal investigative immunohistochemical work may be performed to substantiate evidence for immune complex pathogenesis. While ADA is most commonly encountered as a predisposing factor with biotherapeutic agents, complement activation may occur without circulating complexes, and other mechanisms of non-ADA immune-mediated glomerulonephritis have been observed including nonendogenous immune aggregates and immunoregulatory pharmacology. Although glomerulonephritis associated with oligonucleotide therapies has been noted occasionally in preclinical studies and more rarely with human patients, pathophysiologic mechanisms involved appear to be different between species and preclinical cases are not considered predictive for humans. ADA is not involved in oligonucleotide-associated cases, and complement fixation plays a more important role in monkeys. Recent screening of ASOs for proinflammatory activity appears to have decreased glomerulonephritis incidence preclinically.	[Frazier, Kendall S.; Obert, Leslie A.] GlaxoSmithKline, UE0376,709 Swedeland Rd, King Of Prussia, PA 19406 USA	Frazier, KS (reprint author), GlaxoSmithKline, UE0376,709 Swedeland Rd, King Of Prussia, PA 19406 USA.	kendall.s.frazier@gsk.com					Abbas A, 2015, TARGET ONCOL, V10, P487, DOI 10.1007/s11523-015-0368-7; ADAMS LE, 1993, INT J IMMUNOPHARMACO, V15, P887, DOI 10.1016/0192-0561(93)90006-K; ALEXANDER NJ, 1985, LAB ANIM SCI, V35, P465; Alpers C. E., 2009, PATHOLOGIC BASIS DIS, P930; Barbour TD, 2013, NEPHROL DIAL TRANSPL, V28, P1685, DOI 10.1093/ndt/gfs430; Bauer S, 2008, IMMUNOBIOLOGY, V213, P315, DOI 10.1016/j.imbio.2007.10.010; Birmingham DJ, 1999, CLIN IMMUNOL, V91, P99, DOI 10.1006/clim.1998.4677; Brinks V, 2011, PHARM RES-DORDR, V28, P2379, DOI 10.1007/s11095-011-0523-5; Burel SA, 2012, J PHARMACOL EXP THER, V342, P150, DOI 10.1124/jpet.112.193789; Chi X, 2017, DRUG DISCOV TODAY, V22, P823, DOI 10.1016/j.drudis.2017.01.013; Choi SS, 2010, J MICROBIOL, V48, P512, DOI 10.1007/s12275-010-0053-6; Clarke LA, 2010, ARTHRITIS RHEUM-US, V62, P1770, DOI 10.1002/art.27418; COCHRANE CG, 1968, J EXP MED, V127, P137, DOI 10.1084/jem.127.1.137; CORNACOFF JB, 1983, J CLIN INVEST, V71, P236, DOI 10.1172/JCI110764; COSIO FG, 1987, J IMMUNOL, V138, P2587; COSIO FG, 1990, J IMMUNOL, V145, P4198; COSIO FG, 1987, CLIN IMMUNOL IMMUNOP, V42, P1, DOI 10.1016/0090-1229(87)90167-X; Crooke ST, 2018, NUCLEIC ACID THER, V28, P10, DOI 10.1089/nat.2017.0693; Crooke ST, 2017, NUCLEIC ACID THER, V27, P121, DOI 10.1089/nat.2016.0650; Crooke ST, 2016, MOL THER, V24, P1771, DOI 10.1038/mt.2016.136; DAVIES KA, 1990, J IMMUNOL, V144, P4613; De Bandt M, 2005, ARTHRITIS RES THER, V7, pR545, DOI 10.1186/ar1715; del Conde I, 2005, J EXP MED, V201, P871, DOI 10.1084/jem.20041497; Demeule B, 2006, EUR J PHARM BIOPHARM, V62, P121, DOI 10.1016/j.ejpb.2005.08.008; Egashira K, 2002, CIRC RES, V90, P1167, DOI 10.1161/01.RES.0000020561.03244.7E; Engelhardt JA, 2016, NUCLEIC ACID THER, V26, P199, DOI 10.1089/nat.2015.0598; Engelhardt JA, 2015, TOXICOL PATHOL, V43, P935, DOI 10.1177/0192623315570341; Farman Cindy A., 2003, Toxicologic Pathology, V31, P119, DOI 10.1080/01926230390174995; FDA (Food and Drug Administration), 2012, EMDAC CLIN BRIEF DOC; Ferreira N, 2016, SCI REP-UK, V6, DOI 10.1038/srep26623; FRAZIER K.S., 2012, TOXICOL PATHOL, P421; Frazier KS, 2017, BIRTH DEFECTS RES, V109, P1243, DOI 10.1002/bdr2.1088; Frazier KS, 2015, TOXICOL PATHOL, V43, P915, DOI 10.1177/0192623315570340; Frazier KS, 2015, TOXICOL PATHOL, V43, P78, DOI 10.1177/0192623314551840; Frazier KS, 2014, TOXICOL PATHOL, V42, P923, DOI 10.1177/0192623313505781; Frazier KS, 2012, TOXICOL PATHOL, V40, P14, DOI 10.1177/0192623312438736; Frazier KS, 2000, VET PATHOL, V37, P328, DOI 10.1354/vp.37-4-328; GAUTHIER VJ, 1990, J IMMUNOL, V145, P3348; George JN, 2014, NEW ENGL J MED, V371, P654, DOI 10.1056/NEJMra1312353; GERMUTH FG, 1953, J EXP MED, V97, P257, DOI 10.1084/jem.97.2.257; Goncalves NP, 2014, EXP NEUROL, V257, P76, DOI 10.1016/j.expneurol.2014.04.030; Gonnet-Gracia C, 2008, CLIN EXP RHEUMATOL, V26, P401; Gonzalez-Quesada C, 2009, CURR ATHEROSCLER REP, V11, P131, DOI 10.1007/s11883-009-0021-y; Groseclose MR, 2015, J AM SOC MASS SPECTR, V26, P887, DOI 10.1007/s13361-015-1103-4; Guilpain P, 2005, PRESSE MED, V34, P1023, DOI 10.1016/S0755-4982(05)84105-3; Gurevich F, 2009, AM J MED, V122, P322, DOI 10.1016/j.amjmed.2008.11.025; Han C, 2015, DRUG METAB DISPOS, V43, P762, DOI 10.1124/dmd.114.062679; Hart SP, 2004, J IMMUNOL, V172, P1882, DOI 10.4049/jimmunol.172.3.1882; HEBERT LA, 1991, KIDNEY INT, V39, P44, DOI 10.1038/ki.1991.6; HEBERT LA, 1994, J AM SOC NEPHROL, V5, pS70; HEBERT LA, 1978, KIDNEY INT, V14, P452, DOI 10.1038/ki.1978.150; HEBERT LA, 1991, AM J KIDNEY DIS, V17, P352; HEBERT LA, 1994, KIDNEY INT, V45, P493, DOI 10.1038/ki.1994.64; HEDIN H, 1979, INT ARCH ALLER A IMM, V60, P286, DOI 10.1159/000232353; Henry S. P., 2008, ANTISENSE DRUG TECHN, V2, P327; Henry SP, 2012, TOXICOLOGY, V301, P13, DOI 10.1016/j.tox.2012.06.005; Henry SP, 1999, TOXICOL PATHOL, V27, P95, DOI 10.1177/019262339902700117; Henry SP, 2002, INT IMMUNOPHARMACOL, V2, P1657, DOI 10.1016/S1567-5769(02)00142-X; Henry SP, 1997, J PHARMACOL EXP THER, V281, P810; Hoane JS, 2016, TOXICOL PATHOL, V44, P687, DOI 10.1177/0192623316630625; Hogan JJ, 2015, CLIN J AM SOC NEPHRO, V10, P1300, DOI 10.2215/CJN.01910215; Hugli T E, 1978, Adv Immunol, V26, P1, DOI 10.1016/S0065-2776(08)60228-X; International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use, 2011, S6 R1 PRECL SAF EV B; Izzedine H, 2014, KIDNEY INT, V85, P457, DOI 10.1038/ki.2013.344; Izzedine H, 2010, EUR J CANCER, V46, P439, DOI 10.1016/j.ejca.2009.11.001; Joseph K, 2005, ADV IMMUNOL, V86, P159, DOI 10.1016/S0065-2776(04)86005-X; Kahook MY, 2010, RETINA-J RET VIT DIS, V30, P887, DOI 10.1097/IAE.0b013e3181d50cea; KAUFFMANN RH, 1980, CLIN EXP IMMUNOL, V41, P459; KAVAI M, 1988, SCAND J IMMUNOL, V28, P123, DOI 10.1111/j.1365-3083.1988.tb02423.x; Kinsell LW, 1941, J IMMUNOL, V42, P35; KNIKER WT, 1968, J EXP MED, V127, P119, DOI 10.1084/jem.127.1.119; Kopeloff N, 1941, J IMMUNOL, V40, P471; KRANT JD, 1989, CLIN IMMUNOL IMMUNOP, V50, P241, DOI 10.1016/0090-1229(89)90132-3; Kronenberg S, 2017, REGUL TOXICOL PHARM, V88, P125, DOI 10.1016/j.yrtph.2017.06.004; Lalowski M, 2013, NEPHROL DIAL TRANSPL, V28, P1648, DOI 10.1093/ndt/gft008; Leach MW, 2014, TOXICOL PATHOL, V42, P293, DOI 10.1177/0192623313510987; Leach MW, 2013, TOXICOL PATHOL, V41, P128, DOI 10.1177/0192623312451371; Lee HS, 2009, HISTOL HISTOPATHOL, V24, P901, DOI 10.14670/HH-24.901; Linder E., 1972, Clinical Immunology and Immunopathology, V1, P104, DOI 10.1016/0090-1229(72)90011-6; Liu L, 2011, INVEST OPHTH VIS SCI, V52, P1023, DOI 10.1167/iovs.10-6431; MAHAN JD, 1993, KIDNEY INT, V44, P716, DOI 10.1038/ki.1993.305; MANNIK M, 1980, J INVEST DERMATOL, V74, P333, DOI 10.1111/1523-1747.ep12543582; Markowitz GS, 2010, CLIN J AM SOC NEPHRO, V5, P607, DOI 10.2215/CJN.07311009; Marquis JK, 2000, CURR OPIN MOL THER, V2, P258; Martinez-Salgado C, 2007, TOXICOL APPL PHARM, V223, P86, DOI 10.1016/j.taap.2007.05.004; Matsuyama A, 2003, CIRCULATION, V108, P1469, DOI 10.1161/01.CIR.0000090689.69973.B1; McGavin M. D., 2005, PATHOLOGIC BASIS VET; MEDGYESI GA, 1981, IMMUNOLOGY, V43, P171; Michelin MA, 2002, INT J EXP PATHOL, V83, P105, DOI 10.1046/j.1365-2613.2002.00224.x; Monach PA, 2011, ARTHRITIS RHEUM-US, V63, P3988, DOI 10.1002/art.30615; Morgan WA, 1998, TOXICOL LETT, V94, P209, DOI 10.1016/S0378-4274(98)00024-1; Muller-Deile J, 2010, CLIN KIDNEY J, V3, P172, DOI 10.1093/ndtplus/sfp175; Nangaku Masaomi, 2005, Clin Exp Nephrol, V9, P183, DOI 10.1007/s10157-005-0357-8; Pabla N, 2008, KIDNEY INT, V73, P994, DOI 10.1038/sj.ki.5002786; Pai RM, 2016, TOXICOL SCI, V151, P245, DOI 10.1093/toxsci/kfw037; Perez-De-Lis M, 2017, EXPERT OPIN DRUG SAF, V16, P1255, DOI 10.1080/14740338.2017.1372421; Ponce R, 2009, REGUL TOXICOL PHARM, V54, P164, DOI 10.1016/j.yrtph.2009.03.012; POSKITT TR, 1974, AM J PATHOL, V76, P145; RADEGRAN K, 1972, ACTA ANAESTH SCAND, V16, P76, DOI 10.1111/j.1399-6576.1972.tb00573.x; Ramos-Casals M, 2007, MEDICINE, V86, P242, DOI 10.1097/MD.0b013e3181441a68; Rao S, 2004, ANN ONCOL, V15, P1413, DOI 10.1093/annonc/mdh359; RATNOFF WD, 1983, SPRINGER SEMIN IMMUN, V6, P361, DOI 10.1007/BF02116280; REMUZZI G, 1995, KIDNEY INT, V48, pS70; Revenas B, 1980, Acta Chir Scand Suppl, V499, P161; Richardt-Pargmann D, 2009, ANN NY ACAD SCI, V1175, P40, DOI 10.1111/j.1749-6632.2009.04971.x; Rihova Z, 2005, RENAL FAILURE, V27, P397, DOI 10.1081/JDI-200065304; Robbins S. L., 1999, ROBBINS PATHOLOGIC B; Rojas JR, 2005, J PHARMACOL EXP THER, V313, P578, DOI 10.1124/jpet.104.079277; Rojko JL, 2014, TOXICOL PATHOL, V42, P725, DOI 10.1177/0192623314526475; Rojko JL, 2008, PRECLINICAL SAFETY E, P241; ROMEN W, 1975, VIRCHOWS ARCH B, V19, P205; Rosenberg AS, 2006, AAPS J, V8, pE501; Rubin RL, 2015, EXPERT OPIN DRUG SAF, V14, P361, DOI 10.1517/14740338.2015.995089; SAMS WM, 1985, J INVEST DERMATOL, V85, pS144; Senn JJ, 2005, J PHARMACOL EXP THER, V314, P972, DOI 10.1124/jpet.105.084004; Shen LJ, 2014, J PHARMACOL EXP THER, V351, P709, DOI 10.1124/jpet.114.219378; Singh VK, 1999, IMMUNOL RES, V20, P147, DOI 10.1007/BF02786470; SMEDEGARD G, 1979, ACTA PHYSIOL SCAND, V106, P191, DOI 10.1111/j.1748-1716.1979.tb06389.x; SMEDEGARD G, 1980, INT ARCH ALLER A IMM, V61, P117, DOI 10.1159/000232424; Sousa MM, 2001, J NEUROSCI, V21, P7576; Stokes MB, 2005, NEPHROL DIAL TRANSPL, V20, P1400, DOI 10.1093/ndt/gfh832; Tarrant JM, 2010, TOXICOL SCI, V117, P4, DOI 10.1093/toxsci/kfq134; Theofilopoulos A N, 1979, Adv Immunol, V28, P89; van der Laken CJ, 2007, ANN RHEUM DIS, V66, P253, DOI 10.1136/ard.2006.057406; van Meer PJK, 2013, MABS-AUSTIN, V5, P810, DOI 10.4161/mabs.25234; Vazquez-Rey M, 2011, BIOTECHNOL BIOENG, V108, P1494, DOI 10.1002/bit.23155; WALLER SJ, 1981, ARTHRITIS RHEUM, V24, P651, DOI 10.1002/art.1780240504; Wener, 2007, SYSTEMIC LUPUS ERYTH, P214; WOJCINSKI ZW, 1991, TOXICOL PATHOL, V19, P224, DOI 10.1177/019262339101900304; Yamada N, 2013, TOXICOL PATHOL, V41, P1106, DOI 10.1177/0192623313478206; Zhou X. J., 2007, HEPTINSTALLS PATHOLO, P253; Zuber J, 2002, MEDICINE, V81, P321, DOI 10.1097/01.md.0000024572.33832.c8	132	4	4	0	2	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0192-6233	1533-1601		TOXICOL PATHOL	Toxicol. Pathol.	DEC	2018	46	8			SI		904	917		10.1177/0192623318789399			14	Pathology; Toxicology	Pathology; Toxicology	HF3NN	WOS:000454141900003	30089413				2019-10-28	
J	Crabbs, TA				Crabbs, Torrie A.			Acute Kidney Injury (AKI)-The Toxicologic Pathologist's Constant Companion	TOXICOLOGIC PATHOLOGY			English	Article; Proceedings Paper	Annual National-Toxicology-Program Satellite Symposium on Pathology Potpourri at the 37th Annual Meeting of the the Society-of-Toxicologic-Pathology	2018	Indianapolis, IN	Natl Toxicol Program, Soc Toxicol Pathol		acute kidney injury; INHAND; drug-induced kidney injury; immunopathology; hemodynamics		This article provides a brief overview of the second scientific session of the 37th Annual Symposium of the Society of Toxicologic Pathology in Indianapolis, Indiana, on June 18, 2018. The session was entitled "Acute Kidney Injury (AKI): The Toxicologic Pathologist's Constant Companion" and was co-chaired by Drs. Zaher Radi and Torrie Crabbs. The fundamentals of tubule and interstitial anatomy were covered by Dr. Kevin McDorman, followed by a review of International Harmonization of Nomenclature and Diagnostic Criteria, Standard for Exchange of Nonclinical Data, and Drug-Induced Kidney Injury terminology, which was presented by Dr. Torrie Crabbs. Dr. Bruce Molitoris gave a talk on renal hemodynamics, microcirculation, and ischemia. Advances and challenges on new therapies and clinical targets of AKI were presented by Dr. Brad Rovin, and the session ended with a review from Dr. Zaher Radi on immunopathology of AKI.	[Crabbs, Torrie A.] Expt Pathol Labs, POB 12766, Res Triangle Pk, NC 27709 USA	Crabbs, TA (reprint author), Expt Pathol Labs, POB 12766, Res Triangle Pk, NC 27709 USA.	tcrabbs@epl-inc.com						0	0	0	2	2	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0192-6233	1533-1601		TOXICOL PATHOL	Toxicol. Pathol.	DEC	2018	46	8			SI		918	919		10.1177/0192623318797055			2	Pathology; Toxicology	Pathology; Toxicology	HF3NN	WOS:000454141900004	30189797				2019-10-28	
J	Crabbs, TA; McDorman, KS				Crabbs, Torrie A.; McDorman, Kevin S.			Brief Synopsis: Review of Renal Tubule and Interstitial Anatomy and Physiology and Renal INHAND, SEND, and DIKI Nomenclature	TOXICOLOGIC PATHOLOGY			English	Article; Proceedings Paper	Annual National-Toxicology-Program Satellite Symposium on Pathology Potpourri at the 37th Annual Meeting of the the Society-of-Toxicologic-Pathology	2018	Indianapolis, IN	Natl Toxicol Program, Soc Toxicol Pathol		INHAND; SEND; drug induced kidney injury; historical control database	RAT	This article provides a synopsis of the first two presentations from the second scientific session of the 37th Annual Symposium of the Society of Toxicologic Pathology in Indianapolis, Indiana, on June 18, 2018; the session focused on acute kidney injury. The first presentation, given by Dr. Kevin McDorman, focused on "Fundamentals of Renal Tubule and Interstitial Anatomy and Physiology." Several common background findings from toxicity studies were additionally discussed. Lastly, factors that impact the relevance and usefulness of historical control data, such as quality and consistency of histopathology, were discussed. The second presentation, given by Dr. Torrie Crabbs, provided a review of International Harmonization of Nomenclature and Diagnostic Criteria (INHAND), Standard for Exchange of Nonclinical Data (SEND), and drug-induced kidney injury (DIKI) nomenclature. INHAND is a global collaborative project that provides internationally accepted standardized nomenclature and diagnostic criteria for proliferative and nonproliferative changes in laboratory animals in toxicity and carcinogenicity studies. SEND is currently a required standard for data submission to the Food and Drug Administration (FDA). Since the FDA has indicated its preference for INHAND nomenclature, SEND will predominately use INHAND terminology; thus, familiarity with INHAND terminology is critical for toxicologic pathologists. The diagnostic features of three common DIKI findings, in addition to several complicated INHAND terminologies, were reviewed.	[Crabbs, Torrie A.] Expt Pathology Labs Inc, POB 12766, Res Triangle Pk, NC 27709 USA; [McDorman, Kevin S.] Charles River Labs Inc, Frederick, MD USA	Crabbs, TA (reprint author), Expt Pathology Labs Inc, POB 12766, Res Triangle Pk, NC 27709 USA.	tcrabbs@epl-inc.com					Bauchet AL, 2011, TOXICOL PATHOL, V39, P1115, DOI 10.1177/0192623311425060; Crabbs TA, 2013, TOXICOL PATHOL, V41, P866, DOI 10.1177/0192623312467523; Frazier KS, 2012, TOXICOL PATHOL, V40, P14, DOI 10.1177/0192623312438736; Mann PC, 2012, TOXICOL PATHOL, V40, P7, DOI 10.1177/0192623312438738; Seely JC, 2015, TOXICOL PATHOL, V43, P457, DOI 10.1177/0192623315573044; Shen SS, 2012, ARCH PATHOL LAB MED, V136, P410, DOI 10.5858/arpa.2011-0472-RA; Souza NP, 2018, TOXICOL PATHOL, V46, P266, DOI 10.1177/0192623318762694; Young B, 2002, WHEATERS FUNCTIONAL	8	0	0	1	1	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0192-6233	1533-1601		TOXICOL PATHOL	Toxicol. Pathol.	DEC	2018	46	8			SI		920	924		10.1177/0192623318798758			5	Pathology; Toxicology	Pathology; Toxicology	HF3NN	WOS:000454141900005	30189790				2019-10-28	
J	Kang, R; Rovin, B				Kang, Rima; Rovin, Brad			Advances and Challenges on New Therapies and Clinical Targets of Acute Kidney Injury	TOXICOLOGIC PATHOLOGY			English	Article; Proceedings Paper	Annual National-Toxicology-Program Satellite Symposium on Pathology Potpourri at the 37th Annual Meeting of the the Society-of-Toxicologic-Pathology	2018	Indianapolis, IN	Natl Toxicol Program, Soc Toxicol Pathol		biomarkers; acute tubular necrosis; serum creatinine; TIMP-2; IGFBP-7	CELL-CYCLE	Acute kidney injury (AKI) is encountered in high-risk hospital settings where patients often suffer systemic illnesses, undergo surgery, or receive medications toxic to the kidneys. It is associated with high morbidity and mortality. Despite advances in understanding the pathophysiologic mechanisms involved in AKI, our ability to detect AKI early is limited, and outcomes remain unchanged. Once AKI is identified by the traditional markers of urine output and serum creatinine, the main therapeutic intervention is usually supportive care and/or renal replacement therapy until renal injury resolves. Urine biomarkers provide an optimistic future, offering the ability to identify patients at high risk for AKI such that preventative measures can be introduced. In this article, the etiologies of AKI are discussed, new biomarkers are assessed, and areas for further investigation are suggested.	[Kang, Rima; Rovin, Brad] Ohio State Univ, Med Ctr, Columbus, OH 43210 USA	Kang, R (reprint author), Ohio State Univ, Med Ctr, Dept Nephrol, 395 West 12th Ave,Ground Floor, Columbus, OH 43210 USA.	rima.kang@osumc.edu					Ali T, 2007, J AM SOC NEPHROL, V18, P1292, DOI 10.1681/ASN.2006070756; Bellomo R, 2012, LANCET, V380, P756, DOI 10.1016/S0140-6736(11)61454-2; Bonventre JV, 2011, J CLIN INVEST, V121, P4210, DOI 10.1172/JCI45161; Devarajan P, 2006, J AM SOC NEPHROL, V17, P1503, DOI 10.1681/ASN.2006010017; Johnson RJ, 2015, COMPREHENSIVE CLIN N; Kashani K, 2013, CRIT CARE, V17, DOI 10.1186/cc12503; Kellum JA, 2016, NEPHROL DIAL TRANSPL, V31, P16, DOI 10.1093/ndt/gfv130; Kellum JA, 2014, BIOMARK MED, V8, P1239, DOI [10.2217/BMM.14.82, 10.2217/bmm.14.82]; Khwaja A, 2012, NEPHRON CLIN PRACT, V120, pC179, DOI 10.1159/000339789; McCullough P. A., 2016, J AM HEART ASSOC, V5, P1; Meersch M, 2017, INTENS CARE MED, V43, P1551, DOI 10.1007/s00134-016-4670-3; Murray PT, 2014, KIDNEY INT, V85, P513, DOI 10.1038/ki.2013.374; Pickkers P, 2017, INTENS CARE MED, V43, P1198, DOI 10.1007/s00134-017-4687-2; Praga M, 2010, KIDNEY INT, V77, P956, DOI 10.1038/ki.2010.89; Price PM, 2009, KIDNEY INT, V76, P604, DOI 10.1038/ki.2009.224; Ronco C, 2017, NEPHROL DIAL TRANSPL, V32, P408, DOI 10.1093/ndt/gfx016; Sreedharan R., 2009, PEDIAT NEPHROLOGY, P1577; Susantitaphong P, 2013, CLIN J AM SOC NEPHRO, V8, P1482, DOI 10.2215/CJN.00710113; Thomas ME, 2015, KIDNEY INT, V87, P62, DOI 10.1038/ki.2014.328; Yap SC, 2012, ANESTHESIOLOGY, V116, P1139, DOI 10.1097/ALN.0b013e31824f951b	20	1	1	1	5	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0192-6233	1533-1601		TOXICOL PATHOL	Toxicol. Pathol.	DEC	2018	46	8			SI		925	929		10.1177/0192623318800688			5	Pathology; Toxicology	Pathology; Toxicology	HF3NN	WOS:000454141900006	30278835				2019-10-28	
J	Radi, ZA				Radi, Zaher A.			Immunopathogenesis of Acute Kidney Injury	TOXICOLOGIC PATHOLOGY			English	Article; Proceedings Paper	Annual National-Toxicology-Program Satellite Symposium on Pathology Potpourri at the 37th Annual Meeting of the the Society-of-Toxicologic-Pathology	2018	Indianapolis, IN	Natl Toxicol Program, Soc Toxicol Pathol		immunopathology; renal; acute kidney injury	ISCHEMIA-REPERFUSION INJURY; ACUTE-RENAL-FAILURE; COLONY-STIMULATING FACTOR; ACUTE TUBULAR-NECROSIS; HYPOXIA-INDUCIBLE FACTOR-1-ALPHA; COMPLEMENT REGULATORY PROTEINS; RESIDENT DENDRITIC CELLS; TOLL-LIKE RECEPTORS; KILLER T-CELLS; ISCHEMIA/REPERFUSION INJURY	Pathophysiologically, the classification of acute kidney injury (AKI) can be divided into three categories: (1) prerenal, (2) intrinsic, and (3) postrenal. Emerging evidence supports the involvement of renal tubular epithelial cells and the innate and adaptive arms of the immune system in the pathogenesis of intrinsic AKI. Pro-inflammatory damage-associated molecular patterns, pathogen-associated molecular patterns, hypoxia inducible factors, toll-like receptors, complement system, oxidative stress, adhesion molecules, cell death, resident renal dendritic cells, neutrophils, T and B lymphocytes, macrophages, natural killer T cells, cytokines, and secreted chemokines contribute to the immunopathogenesis of AKI. However, other immune cells and pathways such as M2 macrophages, regulatory T cells, progranulin, and autophagy exhibit anti-inflammatory properties and facilitate kidney tissue repair after AKI. Thus, therapies for AKI include agents such as anti-inflammatory (e.g., recombinant alkaline phosphatase), antioxidants (iron chelators), and apoptosis inhibitors. In preclinical toxicity studies, drug-induced kidney injury can be seen after exposure to a nephrotoxicant test article due to immune mechanisms and dysregulation of innate, and/or adaptive cellular immunity. The focus of this review will be on intrinsic AKI, as it relates to the immune and renal systems cross talks focusing on the cellular and pathophysiologic mechanisms of AKI.	[Radi, Zaher A.] Pfizer Worldwide Res & Dev, Drug Safety R&D, Cambridge, MA USA	Radi, ZA (reprint author), Pfizer Worldwide Res Dev, Drug Safety R&D, One Portland St, Cambridge, MA 02139 USA.	zaher.radi@pfizer.com	Radi, Zaher/K-9359-2019				Alikhan MA, 2011, AM J PATHOL, V179, P1243, DOI 10.1016/j.ajpath.2011.05.037; Anders HJ, 2004, J AM SOC NEPHROL, V15, P854, DOI 10.1097/01.ASN.0000121781.89599.16; Andringa KK, 2014, NEPHRON CLIN PRACT, V127, P70, DOI 10.1159/000363669; Arulkumaran N, 2018, CRIT CARE MED, V46, pE318, DOI 10.1097/CCM.0000000000002937; Arumugam TV, 2003, KIDNEY INT, V63, P134, DOI 10.1046/j.1523-1755.2003.00737.x; Ascon DB, 2006, J IMMUNOL, V177, P3380, DOI 10.4049/jimmunol.177.5.3380; Benoit SW, 2018, PEDIATR NEPHROL, V33, P779, DOI 10.1007/s00467-017-3695-3; BRENNER M, 1990, CHEST, V98, P170, DOI 10.1378/chest.98.1.170; Brooks C, 2009, J CLIN INVEST, V119, P1275, DOI 10.1172/JCI37829; Burne MJ, 2001, J CLIN INVEST, V108, P1283, DOI 10.1172/JCI12080; Bussolati B, 2002, INT J MOL MED, V10, P441; Tabara LC, 2014, EXPERT REV MOL MED, V16, DOI 10.1017/erm.2014.14; Celie JWAM, 2007, AM J PATHOL, V170, P1865, DOI 10.2353/ajpath.2007.070061; Chandraker A, 1997, KIDNEY INT, V52, P1678, DOI 10.1038/ki.1997.502; Cho SG, 2010, AM J PHYSIOL-RENAL, V299, pF199, DOI 10.1152/ajprenal.00716.2009; Chow JC, 1999, J BIOL CHEM, V274, P10689, DOI 10.1074/jbc.274.16.10689; Danobeitia JS, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0183701; Darisipudi MN, 2012, J AM SOC NEPHROL, V23, P1783, DOI 10.1681/ASN.2012040338; Davila J. C., 2018, COMPREHENSIVE TOXICO, P404; Day YJ, 2006, J IMMUNOL, V176, P3108, DOI 10.4049/jimmunol.176.5.3108; de Arriba G, 2013, TOXICOL LETT, V218, P30, DOI 10.1016/j.toxlet.2013.01.007; De Greef KE, 2001, KIDNEY INT, V60, P1415, DOI 10.1046/j.1523-1755.2001.00944.x; de Vries B, 2003, J IMMUNOL, V170, P3883, DOI 10.4049/jimmunol.170.7.3883; Deng B, 2017, KIDNEY INT, V92, P89, DOI 10.1016/j.kint.2017.01.009; Dong X, 2007, KIDNEY INT, V71, P619, DOI 10.1038/sj.ki.5002132; El-Achkar TM, 2006, AM J PHYSIOL-RENAL, V290, pF1034, DOI 10.1152/ajprenal.00414.2005; Emma F, 2016, NAT REV NEPHROL, V12, P267, DOI 10.1038/nrneph.2015.214; Faubel S, 2007, J PHARMACOL EXP THER, V322, P8, DOI 10.1124/jpet.107.119792; Fearns C, 1997, INFECT IMMUN, V65, P4822; Friedewald JJ, 2004, KIDNEY INT, V66, P486, DOI 10.1111/j.1523-1755.2004.761_3.x; Fukuzawa N, 2009, TRANSPL IMMUNOL, V22, P62, DOI 10.1016/j.trim.2009.07.005; Funk JA, 2012, AM J PHYSIOL-RENAL, V302, pF853, DOI 10.1152/ajprenal.00035.2011; GOES N, 1995, TRANSPLANTATION, V59, P565; Gomez H, 2014, SHOCK, V41, P3, DOI 10.1097/SHK.0000000000000052; Hall AM, 2013, KIDNEY INT, V83, P72, DOI 10.1038/ki.2012.328; Han H. I., 2018, PEDIATR NEPHROL, P1; He ZB, 2009, AM J PHYSIOL-RENAL, V296, pF535, DOI 10.1152/ajprenal.90634.2008; Heidari R, 2018, NEPHROLOGY, V23, P351, DOI 10.1111/nep.13012; Herter JM, 2014, J INNATE IMMUN, V6, P597, DOI 10.1159/000358238; Hu C, 2017, CURR PROTEIN PEPT SC, V18, P1200, DOI 10.2174/1389203717666160909151725; ICHIDA S, 1994, KIDNEY INT, V46, P89, DOI 10.1038/ki.1994.247; Jang HR, 2016, AM J PHYSIOL-RENAL, V310, pF272, DOI 10.1152/ajprenal.00217.2015; Jang HR, 2015, NAT REV NEPHROL, V11, P88, DOI 10.1038/nrneph.2014.180; Jang HR, 2009, AM J PHYSIOL-RENAL, V297, pF1457, DOI 10.1152/ajprenal.90769.2008; Jiang ZZ, 2013, TOXICOL APPL PHARM, V266, P198, DOI 10.1016/j.taap.2012.07.008; Jo SK, 2006, NEPHROL DIAL TRANSPL, V21, P1231, DOI 10.1093/ndt/gfk047; Jones EA, 2000, J UROLOGY, V163, P999, DOI 10.1016/S0022-5347(05)67871-8; Justo P, 2003, J AM SOC NEPHROL, V14, P3072, DOI 10.1097/01.ASN.0000099383.57934.0E; Kalakeche R, 2011, J AM SOC NEPHROL, V22, P1505, DOI 10.1681/ASN.2011020203; Kato N, 2009, J AM SOC NEPHROL, V20, P1565, DOI 10.1681/ASN.2008090957; Kelly KJ, 1996, J CLIN INVEST, V97, P1056, DOI 10.1172/JCI118498; Khan KNM, 2012, RSC DRUG DISCOV, V12, P499; Kim MG, 2010, NEPHROL DIAL TRANSPL, V25, P2908, DOI 10.1093/ndt/gfq183; Kinsey GR, 2012, CRIT CARE, V16, DOI 10.1186/cc11228; Kowaltowski AJ, 1999, FREE RADICAL BIO MED, V26, P463, DOI 10.1016/S0891-5849(98)00216-0; Kurts C, 2013, NAT REV IMMUNOL, V13, P738, DOI 10.1038/nri3523; Langenberg C, 2014, CRIT CARE MED, V42, pE58, DOI 10.1097/CCM.0b013e3182a639da; Lau A, 2013, AM J TRANSPLANT, V13, P2805, DOI 10.1111/ajt.12447; Lech M, 2009, J IMMUNOL, V183, P4109, DOI 10.4049/jimmunol.0900118; Lee HT, 2007, AM J PHYSIOL-RENAL, V293, pF713, DOI 10.1152/ajprenal.00161.2007; Lee H, 2010, KIDNEY INT, V78, P1100, DOI 10.1038/ki.2010.139; Lee S, 2011, J AM SOC NEPHROL, V22, P317, DOI 10.1681/ASN.2009060615; Lenda DM, 2003, J IMMUNOL, V170, P3254, DOI 10.4049/jimmunol.170.6.3254; Li HM, 2018, AM J PHYSIOL-RENAL, V314, pF809, DOI 10.1152/ajprenal.00569.2017; Li L, 2007, J IMMUNOL, V178, P5899, DOI 10.4049/jimmunol.178.9.5899; Li L, 2010, SEMIN NEPHROL, V30, P268, DOI 10.1016/j.semnephrol.2010.03.005; Li L, 2010, J CLIN INVEST, V120, P331, DOI 10.1172/JCI38702; Linkermann A, 2011, KIDNEY INT, V79, P169, DOI 10.1038/ki.2010.317; Liu MC, 2006, J AM SOC NEPHROL, V17, P765, DOI 10.1681/ASN.2005010102; Lorz C, 2005, KIDNEY INT, V67, P592, DOI 10.1111/j.1523-1755.2005.67115.x; Lu LH, 2008, J PHARMACOL EXP THER, V324, P111, DOI 10.1124/jpet.107.130161; Luo CJ, 2016, ANN INTENSIVE CARE, V6, DOI 10.1186/s13613-016-0157-1; Maravitsa P, 2016, IMMUNOL LETT, V178, P68, DOI 10.1016/j.imlet.2016.08.002; Martensson J, 2016, CONTRIB NEPHROL, V187, P36, DOI 10.1159/000442363; Martina MN, 2014, NEPHRON CLIN PRACT, V127, P51, DOI 10.1159/000363719; McCullough JW, 2013, SEMIN NEPHROL, V33, P543, DOI 10.1016/j.semnephrol.2013.08.005; Menke J, 2009, J CLIN INVEST, V119, P2330, DOI 10.1172/JCI39087; Moore PK, 2018, AM J KIDNEY DIS, V72, P136, DOI 10.1053/j.ajkd.2017.11.021; Morrell ED, 2014, CRIT CARE, V18, DOI 10.1186/s13054-014-0501-5; Nangaku M, 1998, KIDNEY INT, V54, P1419, DOI 10.1046/j.1523-1755.1998.00130.x; Nangaku M, 2013, CLIN EXP PHARMACOL P, V40, P148, DOI 10.1111/1440-1681.12005; Nemoto T, 2001, KIDNEY INT, V60, P2205, DOI 10.1046/j.1523-1755.2001.00054.x; Niknahad H, 2017, RENAL FAILURE, V39, P745, DOI 10.1080/0886022X.2017.1399908; Ow CPC, 2018, ACTA PHYSIOL, V222, DOI 10.1111/apha.12999; PALLER MS, 1989, J LAB CLIN MED, V113, P379; Peng Q, 2012, J AM SOC NEPHROL, V23, P1474, DOI 10.1681/ASN.2011111072; Persy VP, 2003, KIDNEY INT, V63, P543, DOI 10.1046/j.1523-1755.2003.00767.x; Prowle JR, 2012, CRIT CARE MED, V40, P1768, DOI 10.1097/CCM.0b013e318246bd85; Rabb H, 2000, AM J PHYSIOL-RENAL, V279, pF525; Radi ZA, 2001, J VET INTERN MED, V15, P516, DOI 10.1892/0891-6640(2001)015<0516:CAMLTA>2.3.CO;2; Radi Zaher A, 2018, Curr Protoc Toxicol, V76, pe51, DOI 10.1002/cptx.51; Radi ZA, 2018, INT J TOXICOL, V37, P223, DOI 10.1177/1091581818763804; Radi ZA, 2011, AM J PATHOL, V179, P240, DOI 10.1016/j.ajpath.2011.03.029; Radi ZA, 2009, TOXICOL PATHOL, V37, P34, DOI 10.1177/0192623308329474; Rosenberger C, 2003, KIDNEY INT, V64, P874, DOI 10.1046/j.1523-1755.2003.00159.x; Rosenberger C, 2002, J AM SOC NEPHROL, V13, DOI 10.1097/01.ASN.0000017223.49823.2A; Rosenberger C, 2007, J AM SOC NEPHROL, V18, P343, DOI 10.1681/ASN.2006070792; Rossaint J, 2011, KIDNEY INT, V80, P493, DOI 10.1038/ki.2011.125; Rothfuchs AG, 2004, J IMMUNOL, V172, P6345, DOI 10.4049/jimmunol.172.10.6345; SAKR M, 1992, TRANSPLANTATION, V53, P987, DOI 10.1097/00007890-199205000-00004; Sanz AB, 2016, SEMIN NEPHROL, V36, P189, DOI 10.1016/j.semnephrol.2016.03.006; Sanz AB, 2008, J AM SOC NEPHROL, V19, P1634, DOI 10.1681/ASN.2007121336; Scholz J, 2008, J AM SOC NEPHROL, V19, P527, DOI 10.1681/ASN.2007060684; Servais H, 2005, TOXICOL APPL PHARM, V206, P321, DOI 10.1016/j.taap.2004.11.024; Shapouri-Moghaddam A, 2018, J CELL PHYSIOL, V233, P6425, DOI 10.1002/jcp.26429; Singbartl K, 2000, CRIT CARE MED, V28, P2507, DOI 10.1097/00003246-200007000-00053; Singbartl K, 2016, CRIT CARE MED, V44, pE492, DOI 10.1097/CCM.0000000000001472; SOLEZ K, 1979, MEDICINE, V58, P362, DOI 10.1097/00005792-197909000-00003; Soos TJ, 2006, KIDNEY INT, V70, P591, DOI 10.1038/sj.ki.5001567; STEIN JH, 1985, MINER ELECTROL METAB, V11, P256; Stribos EGD, 2015, MOL IMMUNOL, V64, P82, DOI 10.1016/j.molimm.2014.11.003; Su CM, 2016, CLIN CHIM ACTA, V457, P86, DOI 10.1016/j.cca.2016.04.008; Swaminathan S, 2015, SEMIN NEPHROL, V35, P38, DOI 10.1016/j.semnephrol.2015.01.005; Tadagavadi RK, 2015, TOXINS, V7, P3245, DOI 10.3390/toxins7083245; Tadagavadi RK, 2010, J AM SOC NEPHROL, V21, P53, DOI 10.1681/ASN.2009040407; Takada M, 1997, TRANSPLANT P, V29, P1324, DOI 10.1016/S0041-1345(96)00577-5; Takada M, 1997, J CLIN INVEST, V100, P1199, DOI 10.1172/JCI119632; Tanaka S, 2015, KIDNEY DIS-BASEL, V1, P80, DOI 10.1159/000381515; Tang WX, 2013, J NEPHROL, V26, P1073, DOI 10.5301/jn.5000268; Tecklenborg J, 2018, CLIN EXP IMMUNOL, V192, P142, DOI 10.1111/cei.13119; Thurman JM, 2006, J CLIN INVEST, V116, P357, DOI 10.1172/JCI24521; Thurman JM, 2005, KIDNEY INT, V67, P524, DOI 10.1111/j.1523-1755.2005.67109.x; Thurman JM, 2003, J IMMUNOL, V170, P1517, DOI 10.4049/jimmunol.170.3.1517; Tsuboi N, 2002, J IMMUNOL, V169, P2026, DOI 10.4049/jimmunol.169.4.2026; Walmsley SR, 2005, J EXP MED, V201, P105, DOI 10.1084/jem.20040624; Wang H., 2018, CLIN EXP PHARM PHYSL; Wang YQ, 2015, KIDNEY INT, V88, P1274, DOI 10.1038/ki.2015.295; West AP, 2006, ANNU REV CELL DEV BI, V22, P409, DOI 10.1146/annurev.cellbio.21.122303.115827; Wolfs TGAM, 2002, J IMMUNOL, V168, P1286, DOI 10.4049/jimmunol.168.3.1286; WRIGHT SD, 1990, SCIENCE, V249, P1431, DOI 10.1126/science.1698311; Xu YF, 2016, SEMIN NEPHROL, V36, P199, DOI 10.1016/j.semnephrol.2016.03.007; Xu YF, 2015, J AM SOC NEPHROL, V26, P2647, DOI 10.1681/ASN.2014080741; Yamada K, 2004, J IMMUNOL, V172, P3869, DOI 10.4049/jimmunol.172.6.3869; Yang SH, 2011, J AM SOC NEPHROL, V22, P1305, DOI 10.1681/ASN.2010080815; Yokota N, 2003, AM J PHYSIOL-RENAL, V285, pF319, DOI 10.1152/ajprenal.00432.2002; Ysebaert DK, 2000, NEPHROL DIAL TRANSPL, V15, P1562, DOI 10.1093/ndt/15.10.1562; Zhang BZ, 2008, J AM SOC NEPHROL, V19, P923, DOI 10.1681/ASN.2007090982; Zipfel PF, 2009, NAT REV IMMUNOL, V9, P729, DOI 10.1038/nri2620; Zonneveld R, 2014, CRIT CARE, V18, DOI 10.1186/cc13733; Zsengeller ZK, 2012, J HISTOCHEM CYTOCHEM, V60, P521, DOI 10.1369/0022155412446227	140	2	2	2	3	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0192-6233	1533-1601		TOXICOL PATHOL	Toxicol. Pathol.	DEC	2018	46	8			SI		930	943		10.1177/0192623318799976			14	Pathology; Toxicology	Pathology; Toxicology	HF3NN	WOS:000454141900007	30282524				2019-10-28	
J	Wang, JY; Zhong, JY; Yang, HC; Fogo, AB				Wang, Jiayi; Zhong, Jianyong; Yang, Hai-Chun; Fogo, Agnes B.			Cross Talk from Tubules to Glomeruli	TOXICOLOGIC PATHOLOGY			English	Article; Proceedings Paper	Annual National-Toxicology-Program Satellite Symposium on Pathology Potpourri at the 37th Annual Meeting of the the Society-of-Toxicologic-Pathology	2018	Indianapolis, IN	Natl Toxicol Program, Soc Toxicol Pathol		tubuloglomerular cross talk; atubular glomeruli; tubuloglomerular feedback; hypoxia; renin-angiotensin-aldosterone system	CHRONIC KIDNEY-DISEASE; PARIETAL EPITHELIAL-CELLS; HYPOXIA-INDUCIBLE FACTORS; RENIN-ANGIOTENSIN SYSTEM; ATUBULAR GLOMERULI; TUBULOGLOMERULAR FEEDBACK; BOWMANS CAPSULE; UP-REGULATION; INJURY; PROGRESSION	Tubular injury sensitizes glomeruli to injury. We review potential mechanisms of this tubuloglomerular cross talk. In the same nephron, tubular injury can cause stenosis of the glomerulotubular junction and finally result in atubular glomeruli. Tubular injury also affects glomerular filtration function through tubuloglomerular feedback. Progenitor cells, that is, parietal epithelial cells and renin positive cells, can be involved in repair of injured glomeruli and also may be modulated by tubular injury. Loss of nephrons induces additional workload and stress on remaining nephrons. Hypoxia and activation of the renin-angiotensin-aldosterone system induced by tubular injury also modulate tubuloglomerular cross talk. Therefore, effective therapies in chronic kidney disease may need to aim to interrupt this deleterious tubuloglomerular cross talk.	[Wang, Jiayi] Cent S Univ, Xiangya Hosp 2, Div Nephrol, Changsha, Hunan, Peoples R China; [Wang, Jiayi; Zhong, Jianyong; Yang, Hai-Chun; Fogo, Agnes B.] Vanderbilt Univ, Med Ctr, Dept Pathol Microbiol & Immunol, MCN C3310, Nashville, TN 37232 USA; [Zhong, Jianyong; Yang, Hai-Chun; Fogo, Agnes B.] Vanderbilt Univ, Med Ctr, Div Pediat Nephrol, Nashville, TN USA	Fogo, AB (reprint author), Vanderbilt Univ, Med Ctr, Dept Pathol Microbiol & Immunol, MCN C3310, Nashville, TN 37232 USA.	agnes.fogo@vanderbilt.edu	Yang, Haichun/D-6965-2014		NIH NIDDKUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [DK56942-09]	The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported in part by NIH NIDDK DK56942-09 (Agnes B. Fogo).	Allred AJ, 2000, AM J PHYSIOL-RENAL, V279, pF636; Araujo M, 2009, AM J PHYSIOL-RENAL, V296, pF790, DOI 10.1152/ajprenal.90446.2008; Asakura J, 2012, NEPHRON EXP NEPHROL, V122, P83, DOI 10.1159/000348661; Basile DP, 2016, J AM SOC NEPHROL, V27, P687, DOI 10.1681/ASN.2015030309; Berger K, 2014, P NATL ACAD SCI USA, V111, P1533, DOI 10.1073/pnas.1316177111; BREZIS M, 1995, NEW ENGL J MED, V332, P647, DOI 10.1056/NEJM199503093321006; Brunskill EW, 2011, J AM SOC NEPHROL, V22, P2213, DOI 10.1681/ASN.2011040401; Cao W, 2016, KIDNEY BLOOD PRESS R, V41, P746, DOI 10.1159/000450564; Chawla LS, 2014, NEW ENGL J MED, V371, P58, DOI 10.1056/NEJMra1214243; Chou YH, 2017, SCI REP-UK, V7, DOI 10.1038/srep46518; Coca SG, 2012, KIDNEY INT, V81, P442, DOI 10.1038/ki.2011.379; Crowley SD, 2011, AM J PHYSIOL-RENAL, V301, pF1124, DOI 10.1152/ajprenal.00305.2011; Ferenbach DA, 2015, NAT REV NEPHROL, V11, P264, DOI 10.1038/nrneph.2015.3; Forbes MS, 2011, AM J PHYSIOL-RENAL, V301, pF110, DOI 10.1152/ajprenal.00022.2011; Galarreta CI, 2015, AM J PHYSIOL-RENAL, V308, pF1155, DOI 10.1152/ajprenal.00591.2014; Galarreta CI, 2014, AM J PATHOL, V184, P1957, DOI 10.1016/j.ajpath.2014.03.007; Gurley SB, 2011, CELL METAB, V13, P469, DOI 10.1016/j.cmet.2011.03.001; Haase VH, 2006, AM J PHYSIOL-RENAL, V291, pF271, DOI 10.1152/ajprenal.00071.2006; Haase VH, 2009, ANN NY ACAD SCI, V1177, P57, DOI 10.1111/j.1749-6632.2009.05030.x; Hsu CY, 2016, J AM SOC NEPHROL, V27, P914, DOI 10.1681/ASN.2014111114; Johnson RJ, 2002, NEW ENGL J MED, V346, P913, DOI 10.1056/NEJMra011078; Kapitsinou PP, 2014, J CLIN INVEST, V124, P2396, DOI 10.1172/JCI69073; Kaverina NV, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0173891; Kontogiannis J, 1998, AM J PHYSIOL-RENAL, V274, pF79; Kurtz L, 2007, J AM SOC NEPHROL, V18, P1103, DOI 10.1681/ASN.2006090953; Lan RP, 2016, J AM SOC NEPHROL, V27, P3356, DOI 10.1681/ASN.2015020177; Lasagni L, 2010, J AM SOC NEPHROL, V21, P1612, DOI 10.1681/ASN.2010010048; Lim BJ, 2017, KIDNEY INT, V92, P1395, DOI 10.1016/j.kint.2017.04.010; Lubbers DW, 1997, KIDNEY INT, V51, P372, DOI 10.1038/ki.1997.49; Mahoney CP, 2000, PEDIATR NEPHROL, V15, P50, DOI 10.1007/PL00013448; Majmundar AJ, 2010, MOL CELL, V40, P294, DOI 10.1016/j.molcel.2010.09.022; Manotham K, 2004, KIDNEY INT, V65, P871, DOI 10.1111/j.1523-1755.2004.00461.x; Mimura I, 2010, NAT REV NEPHROL, V6, P667, DOI 10.1038/nrneph.2010.124; Morrell ED, 2014, NEPHROL DIAL TRANSPL, V29, P1312, DOI 10.1093/ndt/gft503; Najafian B, 2006, J AM SOC NEPHROL, V17, pS53, DOI 10.1681/ASN.2005121342; NATH KA, 1992, AM J KIDNEY DIS, V20, P1; Nordquist L, 2015, J AM SOC NEPHROL, V26, P328, DOI 10.1681/ASN.2013090990; Palant CE, 2017, CURR OPIN ANESTHESIO, V30, P100, DOI 10.1097/ACO.0000000000000428; Pippin JW, 2015, AM J PHYSIOL-RENAL, V309, pF341, DOI 10.1152/ajprenal.00438.2014; Pippin JW, 2013, AM J PATHOL, V183, P542, DOI 10.1016/j.ajpath.2013.04.024; Rodriguez-Romo R, 2016, KIDNEY INT, V89, P363, DOI 10.1038/ki.2015.320; Romagnani P, 2011, AM J PATHOL, V178, P490, DOI 10.1016/j.ajpath.2010.11.044; Sagrinati C, 2006, J AM SOC NEPHROL, V17, P2443, DOI 10.1681/ASN.2006010089; Schmidt C, 2007, CRIT CARE MED, V35, P2110, DOI 10.1097/01.ccm.0000281447.22966.8b; Schmidt C, 2007, J AM SOC NEPHROL, V18, P1072, DOI 10.1681/ASN.2006050454; Schulte K, 2014, J AM SOC NEPHROL, V25, P129, DOI 10.1681/ASN.2013040376; Shankland SJ, 2013, CURR OPIN NEPHROL HY, V22, P302, DOI 10.1097/MNH.0b013e32835fefd4; Singh P, 2011, CONTRIB NEPHROL, V174, P12, DOI 10.1159/000329229; Singh P, 2010, CURR OPIN NEPHROL HY, V19, P59, DOI 10.1097/MNH.0b013e3283331ffd; Siragy HM, 2010, AM J NEPHROL, V31, P541, DOI 10.1159/000313363; Smeets B, 2013, J PATHOL, V229, P645, DOI 10.1002/path.4125; Smeets B, 2012, SEMIN NEPHROL, V32, P357, DOI 10.1016/j.semnephrol.2012.06.007; Tanaka T, 2003, BIOCHEM BIOPH RES CO, V309, P222, DOI 10.1016/S0006-291X(03)01557-2; Venkatachalam MA, 2010, AM J PHYSIOL-RENAL, V298, pF1078, DOI 10.1152/ajprenal.00017.2010; Wang XXX, 2017, J BIOL CHEM, V292, P5335, DOI 10.1074/jbc.M117.779520; Weichert W, 2001, AM J PHYSIOL-RENAL, V280, pF706; White KE, 2008, NEPHROL DIAL TRANSPL, V23, P3539, DOI 10.1093/ndt/gfn351; Yang L, 2010, NAT MED, V16, P535, DOI 10.1038/nm.2144; Zhong JY, 2017, AM J PHYSIOL-RENAL, V312, pF375, DOI 10.1152/ajprenal.00266.2016	59	3	3	0	0	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0192-6233	1533-1601		TOXICOL PATHOL	Toxicol. Pathol.	DEC	2018	46	8			SI		944	948		10.1177/0192623318796784			5	Pathology; Toxicology	Pathology; Toxicology	HF3NN	WOS:000454141900008	30157700				2019-10-28	
J	Cohen, SM				Cohen, Samuel M.			Crystalluria and Chronic Kidney Disease	TOXICOLOGIC PATHOLOGY			English	Article; Proceedings Paper	Annual National-Toxicology-Program Satellite Symposium on Pathology Potpourri at the 37th Annual Meeting of the the Society-of-Toxicologic-Pathology	2018	Indianapolis, IN	Natl Toxicol Program, Soc Toxicol Pathol		calculi; urinary obstruction; retrograde nephropathy; pyelonephritis; hydronephrosis; end-stage kidney	URINARY-BLADDER CARCINOGENS; RENAL TOXICITY; UROLITHIASIS; MELAMINE	Crystalluria can involve the kidney and lower urinary tract, can produce acute and chronic effects, and occurs in all mammalian species. Most commonly urinary crystals contain calcium. Numerous other endogenous and exogenous substances can produce crystalluria. Crystals are identified in kidneys of many species, up to 100% in certain rat strains. More severe renal disease (acute tubular necrosis and chronic renal disease) can be secondary to crystal accumulation, such as observed with melamine-cyanuric acid in cats and dogs. Aggregation of crystals leads to calculi that act as urothelial abrasives with consequent regenerative proliferation. Accumulation in the kidney pelvis or bladder can lead to partial or complete obstruction and hydronephrosis. Long-term presence of urinary tract calculi in rodents leads to increased risk of urothelial tumors, but not in humans. Crystals in the lower urinary tract can act as irritants in rodents, but not in humans. It is critical that specific procedures are followed to optimize the presence of crystals in urine for diagnosis, including not fasting the animals. Numerous factors have been identified which can enhance or inhibit crystal formation. Extrapolation from animals for the threshold toxicity of crystals/calculi is appropriate but is not relevant for cancer risk assessment.	[Cohen, Samuel M.] Univ Nebraska Med Ctr, Dept Pathol & Microbiol, Oncol, Omaha, NE USA	Cohen, SM (reprint author), Univ Nebraska Med Ctr, Dept Pathol & Microbiol, 983135 Nebraska Med Ctr, Omaha, NE 68124 USA.	scohen@unmc.edu		Cohen, Samuel/0000-0002-5047-0962			Cesta MF, 2013, TOXICOL PATHOL, V41, P1068, DOI 10.1177/0192623313482057; Chen KC, 2009, TOXICOL PATHOL, V37, P959, DOI 10.1177/0192623309347910; CLAYSON DB, 1995, FOOD CHEM TOXICOL, V33, P771, DOI 10.1016/0278-6915(95)00044-3; Cohen SM, 2007, TOXICOL PATHOL, V35, P337, DOI 10.1080/01926230701197115; Cohen SM, 2018, TOXICOL RES-UK, V7, P565, DOI 10.1039/c7tx00294g; COHEN SM, 1995, FOOD CHEM TOXICOL, V33, P715, DOI 10.1016/0278-6915(95)00040-9; Cohen SM, 2002, FOOD CHEM TOXICOL, V40, P793, DOI 10.1016/S0278-6915(02)00020-0; Dapson S.C., 1993, CARCINOGENICITY PEER, P1; DESESSO JM, 1995, FOOD CHEM TOXICOL, V33, P705, DOI 10.1016/0278-6915(95)00039-5; Dobson RLM, 2008, TOXICOL SCI, V106, P251, DOI 10.1093/toxsci/kfn160; Dominick MA, 2006, TOXICOL PATHOL, V34, P903, DOI 10.1080/01926230601072327; Frazier KS, 2012, TOXICOL PATHOL, V40, P14, DOI 10.1177/0192623312438736; Gossner CME, 2009, ENVIRON HEALTH PERSP, V117, P1803, DOI 10.1289/ehp.0900949; Guan N, 2009, NEW ENGL J MED, V360, P1067, DOI 10.1056/NEJMoa0809550; Guo CG, 2007, TOXICOL LETT, V173, P8, DOI 10.1016/j.toxlet.2007.06.010; Hard GC, 2009, VET PATHOL, V46, P1248, DOI 10.1354/vp.08-VP-0317-F-FL; Karcher D. S., 2017, HENRYS CLIN DIAGNOSI, P441; Liapis H., 2015, HEPTISTALLS PATHOLOG, P1039; LORD GH, 1990, FOOD CHEM TOXICOL, V28, P449, DOI 10.1016/0278-6915(90)90092-2; Robinson MR, 2008, J UROLOGY, V179, P46, DOI 10.1016/j.juro.2007.08.123; Trump B. F., 1984, ADV MOD ENV TOXICOL, V7, P273	21	0	0	1	3	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0192-6233	1533-1601		TOXICOL PATHOL	Toxicol. Pathol.	DEC	2018	46	8			SI		949	955		10.1177/0192623318800711			7	Pathology; Toxicology	Pathology; Toxicology	HF3NN	WOS:000454141900009	30270758				2019-10-28	
J	Hard, GC				Hard, Gordon C.			Mechanisms of Rodent Renal Carcinogenesis Revisited	TOXICOLOGIC PATHOLOGY			English	Article; Proceedings Paper	Annual National-Toxicology-Program Satellite Symposium on Pathology Potpourri at the 37th Annual Meeting of the the Society-of-Toxicologic-Pathology	2018	Indianapolis, IN	Natl Toxicol Program, Soc Toxicol Pathol		kidney; modes of action; chemical carcinogenesis; renal tubule tumor; key events	CHRONIC PROGRESSIVE NEPHROPATHY; DNA ADDUCT FORMATION; HYALINE DROPLET NEPHROPATHY; RAT-KIDNEY DNA; OCHRATOXIN-A; POTASSIUM BROMATE; TUMOR-FORMATION; TUBULE TUMORS; FUMONISIN B-1; CHROMOSOMAL INSTABILITY	The important renal tumors that can be induced by exposure of rats to chemical carcinogens are renal tubule tumors (RTTs) derived from tubule epithelium; renal pelvic carcinoma derived from the urothelial lining of the pelvis; renal mesenchymal tumors (RMTs) derived from the interstitial connective tissue; and nephroblastoma derived from the metanephric primordia. However, almost all of our knowledge concerning mechanisms of renal carcinogenesis in the rodent pertains to the adenomas and carcinomas originating from renal tubule epithelium. Currently, nine mechanistic pathways can be identified in either the rat or mouse following chemical exposure. These include direct DNA reactivity, indirect DNA reactivity through free radical formation, multiphase bioactivation involving glutathione conjugation, mitotic disruption, sustained cell proliferation from direct cytotoxicity, sustained cell proliferation by disruption of a physiologic process (alpha 2u-globulin nephropathy), exaggerated pharmacologic response, species-dominant metabolic pathway, and chemical exacerbation of chronic progressive nephropathy. Spontaneous occurrence of RTTs in the rat will be included since one example is a confounder for interpreting kidney tumor results in chemical carcinogenicity studies in rats.		Hard, GC (reprint author), 203 Paku Dr, Tairua 3508, New Zealand.	gordonhard@msn.com					Adler M, 2009, CARCINOGENESIS, V30, P711, DOI 10.1093/carcin/bgp049; ALDEN CL, 1981, VET PATHOL, V18, P549, DOI 10.1177/030098588101800413; ANDERS MW, 1988, CRC CR REV TOXICOL, V18, P311, DOI 10.3109/10408448809037470; ANDERSON RL, 1981, FOOD COSMET TOXICOL, V19, P639, DOI 10.1016/0015-6264(81)90516-2; Baetcke K. P., 1991, ALPHA2U GLOBULIN ASS; Bakhoum SF, 2014, CURR BIOL, V24, pR148, DOI 10.1016/j.cub.2014.01.019; BANNASCH P, 1980, J CANCER RES CLIN, V98, P243, DOI 10.1007/BF00410788; BARNES JM, 1977, LANCET, V1, P671; Barone S, 2009, J BIOL CHEM, V284, P5056, DOI 10.1074/jbc.M808128200; Bevan RJ, 2017, REGUL TOXICOL PHARM, V88, P291, DOI 10.1016/j.yrtph.2017.01.003; Bogdanffy MS, 2014, INT J TOXICOL, V33, P436, DOI 10.1177/1091581814551648; Bomhard E. M., 1996, ORAL ANTIDIABETICS, P557; Bondy GS, 2015, TOXICOL PATHOL, V43, P715, DOI 10.1177/0192623314568391; BOORMAN GA, 1992, TOXICOL PATHOL, V20, P236, DOI 10.1177/019262339202000210; Borghoff S, 2015, TOXICOLOGY, V333, P1, DOI 10.1016/j.tox.2015.02.003; BORGHOFF SJ, 1991, TOXICOL APPL PHARM, V107, P228, DOI 10.1016/0041-008X(91)90205-S; Brown AL, 2007, EXP TOXICOL PATHOL, V59, P85, DOI 10.1016/j.etp.2007.05.001; Castegnaro M, 1998, INT J CANCER, V77, P70; Cohen SM, 1998, DRUG METAB REV, V30, P339, DOI 10.3109/03602539808996317; COHEN SM, 1990, SCIENCE, V249, P1007, DOI 10.1126/science.2204108; Czakai K, 2011, TOXICOL SCI, V122, P317, DOI 10.1093/toxsci/kfr110; De Jonghe S, 2014, CHEM-BIOL INTERACT, V224, P1, DOI 10.1016/j.cbi.2014.09.018; De Rijk EPCT, 2003, TOXICOL PATHOL, V31, P462, DOI 10.1080/01926230390213775; DeAngelo AB, 1998, TOXICOL PATHOL, V26, P587, DOI 10.1177/019262339802600501; DEES JH, 1980, J NATL CANCER I, V64, P1537; DEKANT W, 1993, TOXICOL LETT, V67, P151, DOI 10.1016/0378-4274(93)90052-Y; Dekant W, 1999, J CANCER RES CLIN, V125, P174, DOI 10.1007/s004320050260; Delatour T, 2008, MOL NUTR FOOD RES, V52, P472, DOI 10.1002/mnfr.200700276; DIETRICH DR, 1991, MUTAT RES, V248, P239, DOI 10.1016/0027-5107(91)90060-2; Dodd DE, 2013, ENVIRON TOXICOL PHAR, V36, P1227, DOI 10.1016/j.etap.2013.10.005; Domijan AM, 2006, TOXICOLOGY, V222, P53, DOI 10.1016/j.tox.2006.01.024; Dragan YP, 2001, TOXICOL SCI, V61, P6, DOI 10.1093/toxsci/61.1.6; EBINA Y, 1986, J NATL CANCER I, V76, P107; EKER R, 1954, ACTA PATHOL MIC SC, V34, P554; el Khoury A, 2010, TOXINS, V2, P461, DOI 10.3390/toxins2040461; Everitt JI, 1995, TOXICOL LETT, V82-3, P621, DOI 10.1016/0378-4274(95)03506-0; Faucet V, 2004, CHEM RES TOXICOL, V17, P1289, DOI 10.1021/tx049877s; Food and Drug Administration, 2013, FDA BRIEF DOC; Ganem NJ, 2007, CURR OPIN GENET DEV, V17, P157, DOI 10.1016/j.gde.2007.02.011; Gautier JC, 2001, CHEM RES TOXICOL, V14, P34, DOI 10.1021/tx000070j; GRAY JE, 1977, CRC CR REV TOXICOL, V5, P115, DOI 10.3109/10408447709003377; Hard G. C., 2010, CANC RISK ASSESSMENT, P248; Hard GC, 2005, TOXICOL PATHOL, V33, P641, DOI 10.1080/01926230500299716; Hard GC, 2004, TOXICOL PATHOL, V32, P171, DOI 10.1080/01926230490422574; Hard GC, 1998, TOXICOL PATHOL, V26, P104, DOI 10.1177/019262339802600112; HARD GC, 1970, CANCER RES, V30, P2806; Hard GC, 2001, TOXICOL PATHOL, V29, P379, DOI 10.1080/019262301316905345; HARD GC, 1994, TOXICOL PATHOL, V22, P489, DOI 10.1177/019262339402200503; Hard GC, 1999, CARCINOGENICITY, P439; HARD GC, 1993, ENVIRON HEALTH PERSP, V99, P313, DOI 10.2307/3431508; Hard GC, 2000, TOXICOL SCI, V53, P237, DOI 10.1093/toxsci/53.2.237; HARD GC, 1991, IARC SCI PUBL, V115, P113; Hard GC, 2007, FOOD CHEM TOXICOL, V45, P600, DOI 10.1016/j.fct.2006.10.018; Hard GC, 2006, TOXICOL PATHOL, V34, P941, DOI 10.1080/01926230601083381; Hard GC, 2013, TOXICOL SCI, V132, P268, DOI 10.1093/toxsci/kfs305; Hard GC, 2012, TOXICOL PATHOL, V40, P473, DOI 10.1177/0192623311431948; Hard GC, 2009, CRIT REV TOXICOL, V39, P332, DOI 10.1080/10408440802368642; Hard GC, 2008, TOXICOL PATHOL, V36, P388, DOI 10.1177/0192623308315829; Hard GC, 2008, TOXICOL PATHOL, V36, P1014, DOI 10.1177/0192623308327413; Hayashi MT, 2013, ONCOGENE, V32, P4593, DOI 10.1038/onc.2012.615; Hibi D, 2011, TOXICOL SCI, V122, P406, DOI 10.1093/toxsci/kfr139; Hino O, 2003, CANCER SCI, V94, P142, DOI 10.1111/j.1349-7006.2003.tb01410.x; Hollander P, 1992, Drugs, V44 Suppl 3, P47; Howard PC, 2001, ENVIRON HEALTH PERSP, V109, P309, DOI 10.2307/3435023; IZUMI K, 1994, JPN J CANCER RES, V85, P563, DOI 10.1111/j.1349-7006.1994.tb02396.x; JACKSON MR, 1974, J PATHOL, V113, P197, DOI 10.1002/path.1711130309; JAKOBY WB, 1990, J BIOL CHEM, V265, P20715; Kamp HG, 2005, MOL NUTR FOOD RES, V49, P1160, DOI 10.1002/mnfr.200500124; KASAI H, 1987, CARCINOGENESIS, V8, P1959, DOI 10.1093/carcin/8.12.1959; Kitaura K, 1999, JPN J CANCER RES, V90, P385, DOI 10.1111/j.1349-7006.1999.tb00759.x; Knight B., 2014, TOXICOLOGIST, V576; KOBAYASHI T, 1995, NAT GENET, V9, P70, DOI 10.1038/ng0195-70; KONISHI N, 1989, VET PATHOL, V26, P6, DOI 10.1177/030098588902600102; KUROKAWA Y, 1983, J NATL CANCER I, V71, P965; Lanzoni A, 2007, TOXICOL PATHOL, V35, P589, DOI 10.1080/01926230701383202; LASH LH, 1990, DRUG METAB DISPOS, V18, P50; LAU SS, 1990, TOXICOLOGY, V64, P291, DOI 10.1016/0300-483X(90)90122-W; LAU SS, 1995, DRUG METAB REV, V27, P125, DOI 10.3109/03602539509029819; LEHMANMCKEEMAN LD, 1990, TOXICOL APPL PHARM, V103, P539, DOI 10.1016/0041-008X(90)90326-P; Limbeck E, 2018, ARCH TOXICOL, V92, P995, DOI 10.1007/s00204-017-2107-6; Lock EA, 2006, TOXICOL SCI, V91, P313, DOI 10.1093/toxsci/kfj107; Lock EA, 2004, CRIT REV TOXICOL, V34, P211, DOI 10.1080/10408440490265210; LOCK EA, 1979, ARCH TOXICOL, V43, P47, DOI 10.1007/BF00695873; Lund F, 1994, MYCOLOGICAL RES, V98, P1317; LUZ A, 1991, TOXICOL PATHOL, V19, P670, DOI 10.1177/019262339101900410; Malir F, 2016, TOXINS, V8, DOI 10.3390/toxins8070191; Mally A, 2005, FOOD ADDIT CONTAM A, V22, P65, DOI 10.1080/02652030500317544; Mally A, 2005, CHEM RES TOXICOL, V18, P1253, DOI 10.1021/tx049650x; Mally A, 2012, TOXICOL SCI, V127, P315, DOI 10.1093/toxsci/kfs105; Mally A, 2009, MOL NUTR FOOD RES, V53, P467, DOI 10.1002/mnfr.200800149; Mamidi RNVS, 2014, CHEM-BIOL INTERACT, V221, P109, DOI 10.1016/j.cbi.2014.08.001; MANTLE PG, 1991, P ROY SOC B-BIOL SCI, V246, P251, DOI 10.1098/rspb.1991.0152; Mao CG, 2008, BBA-MOL CELL BIOL L, V1781, P424, DOI 10.1016/j.bbalip.2008.06.002; MAUNSBACH AB, 1966, J ULTRA MOL STRUCT R, V16, P239, DOI 10.1016/S0022-5320(66)80060-6; MONKS TJ, 1990, TOXICOL APPL PHARM, V106, P1, DOI 10.1016/0041-008X(90)90100-9; MONKS TJ, 1992, CRIT REV TOXICOL, V22, P243, DOI 10.3109/10408449209146309; Muller S, 2012, FOOD CHEM TOXICOL, V50, P3833, DOI 10.1016/j.fct.2012.06.053; National Toxicology Program, 1977, NIH PUBLICATION, V77-806; National Toxicology Program, 1989, NIH PUBLICATION, V89-2813; NICOLL JW, 1977, CHEM-BIOL INTERACT, V16, P301, DOI 10.1016/0009-2797(77)90109-0; Okimoto K, 2004, P NATL ACAD SCI USA, V101, P2023, DOI 10.1073/pnas.0308071100; Pfau SJ, 2012, EMBO REP, V13, P515, DOI 10.1038/embor.2012.65; PFOHLLESZKOWICZ A, 1991, IARC SCI PUBL, V115, P245; PFOHLLESZKOWICZ A, 1993, MUTAT RES, V289, P265, DOI 10.1016/0027-5107(93)90077-S; Pogribny IP, 2013, CANCER LETT, V334, P39, DOI 10.1016/j.canlet.2012.09.010; Qi XZ, 2014, TOXICOL APPL PHARM, V280, P543, DOI 10.1016/j.taap.2014.08.030; Rached E, 2007, TOXICOL SCI, V97, P288, DOI 10.1093/toxsci/kfm042; Rached E, 2006, TOXICOL SCI, V92, P78, DOI 10.1093/toxsci/kfj213; RILEY RT, 1994, J NUTR, V124, P594; Schlatter C, 1996, FOOD ADDIT CONTAM, V13, P43; Schlueter G, 1988, ACARBOSE TREATMENT D, P5; Shiao YH, 1998, JNCI-J NATL CANCER I, V90, P1720, DOI 10.1093/jnci/90.22.1720; SHORT BG, 1989, TOXICOL APPL PHARM, V101, P414, DOI 10.1016/0041-008X(89)90191-9; Smith JD, 2017, INT J TOXICOL, V36, P440, DOI 10.1177/1091581817735090; Stemmer K., 2008, TOXICOLOGIST, V102, P21; Swenberg JA, 1999, IARC SCI PUBL, P95; Tanaka K, 2016, BBA-REV CANCER, V1866, P64, DOI 10.1016/j.bbcan.2016.06.002; Taniai E, 2014, TOXICOL LETT, V224, P64, DOI 10.1016/j.toxlet.2013.10.001; Taub ME, 2015, CHEM RES TOXICOL, V28, P103, DOI 10.1021/tx500380t; Tennant RW, 1996, MUTAT RES-REV GENET, V365, P119, DOI 10.1016/S0165-1110(96)90016-0; THURMAN JD, 1995, VET PATHOL, V32, P419, DOI 10.1177/030098589503200412; TOYOKUNI S, 1994, INT J CANCER, V57, P123, DOI 10.1002/ijc.2910570122; TOYOKUNI S, 1994, P NATL ACAD SCI USA, V91, P2616, DOI 10.1073/pnas.91.7.2616; Travlos GS, 2011, TOXICOL PATHOL, V39, P381, DOI 10.1177/0192623310388432; Trump B. F., 1984, ADV MOD ENV TOXICOL, V7, P273; TSUDA H, 1983, CARCINOGENESIS, V4, P523, DOI 10.1093/carcin/4.5.523; Tsuda M, 1999, J PHARMACOL EXP THER, V289, P1301; Turesky RJ, 2005, CHEM RES TOXICOL, V18, P1082, DOI 10.1021/tx050076e; UMEMURA T, 1990, CARCINOGENESIS, V11, P345, DOI 10.1093/carcin/11.2.345; VANDOREN G, 1983, EUR J BIOCHEM, V134, P175, DOI 10.1111/j.1432-1033.1983.tb07548.x; Vogetseder A, 2008, AM J PHYSIOL-CELL PH, V294, pC22, DOI 10.1152/ajpcell.00227.2007; Ways K, 2015, TOXICOL PATHOL, V43, P48, DOI 10.1177/0192623314557179; WEEKES UY, 1975, J NATL CANCER I, V55, P1199, DOI 10.1093/jnci/55.5.1199; Wilkinson CF, 1996, REGUL TOXICOL PHARM, V24, P69, DOI 10.1006/rtph.1996.0065; WILSON NH, 1990, TOXICOL LETT, V53, P155, DOI 10.1016/0378-4274(90)90113-Z; WU JS, 1994, NAT GENET, V7, P541, DOI 10.1038/ng0894-541; Yamaguchi R, 1996, CARCINOGENESIS, V17, P2419, DOI 10.1093/carcin/17.11.2419; YEUNG RS, 1994, P NATL ACAD SCI USA, V91, P11413, DOI 10.1073/pnas.91.24.11413; Yoo HS, 1996, TOXICOL APPL PHARM, V138, P211, DOI 10.1006/taap.1996.0119; Zhao ZS, 1997, CHEM-BIOL INTERACT, V108, P107, DOI 10.1016/S0009-2797(97)00103-8	140	1	1	0	0	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0192-6233	1533-1601		TOXICOL PATHOL	Toxicol. Pathol.	DEC	2018	46	8			SI		956	969		10.1177/0192623318797071			14	Pathology; Toxicology	Pathology; Toxicology	HF3NN	WOS:000454141900010	30270795				2019-10-28	
J	Heinz-Taheny, KM; Harlan, SM; Qi, ZH; Heuer, JG				Heinz-Taheny, Kathleen M.; Harlan, Shannon M.; Qi, Zhonghua; Heuer, Josef G.			Synopsis of Sweet! Mouse Models of Diabetic Kidney Disease	TOXICOLOGIC PATHOLOGY			English	Article; Proceedings Paper	Annual National-Toxicology-Program Satellite Symposium on Pathology Potpourri at the 37th Annual Meeting of the the Society-of-Toxicologic-Pathology	2018	Indianapolis, IN	Natl Toxicol Program, Soc Toxicol Pathol		kidney; rodent models; diabetic kidney disease; chronic diabetic complications; diabetic glomerulopathy; diabetic nephropathy; hypertension		Diabetes mellitus (types 1 and 2) is the leading cause of glomerular disease and end-stage renal disease in most developed countries, with estimates that one-third of people living with diabetes will develop diabetic kidney disease (DKD). The current standard of care medications slow but do not arrest progression of kidney disease, and therefore, therapy for DKD is a highly unmet medical need for patients. To discover and test novel and durable new therapies, it is necessary to develop animal models of human DKD, which authentically recapitulate the human disease state and provide translatable efficacy to human patients. Here, we review selected mouse models of human DKD, which demonstrate many of the features of type 2 human DKD.	[Heinz-Taheny, Kathleen M.; Harlan, Shannon M.; Qi, Zhonghua; Heuer, Josef G.] Eli Lilly & Co, Indianapolis, IN 46285 USA	Heinz-Taheny, KM (reprint author), Eli Lilly & Co, Lilly Corp Ctr, Lilly Res Labs, Indianapolis, IN 46285 USA.	heinztahenykm@lilly.com					Centers for Disease Control and Prevention, 2018, CHRON KIDN DIS SURV; Harlan SM, 2018, J AM SOC NEPHROL, V29, P477, DOI 10.1681/ASN.2017040385; Hudkins KL, 2010, J AM SOC NEPHROL, V21, P1533, DOI 10.1681/ASN.2009121290; Lai FMM, 2004, MODERN PATHOL, V17, P1506, DOI 10.1038/modpathol.3800219; Meyza KZ, 2013, BEHAV BRAIN RES, V251, P25, DOI 10.1016/j.bbr.2012.07.021; Mooradian AD, 2009, NAT CLIN PRACT ENDOC, V5, P150, DOI 10.1038/ncpendmet1066; Reidy K, 2014, J CLIN INVEST, V124, P2333, DOI 10.1172/JCI72271; Sharma K, 2003, AM J PHYSIOL-RENAL, V284, pF1138, DOI 10.1152/ajprenal.00315.2002; Wang HD, 2016, LANCET, V388, P1459, DOI 10.1016/S0140-6736(16)31012-1; Zhao HJ, 2006, J AM SOC NEPHROL, V17, P2664, DOI 10.1681/ASN.2006070798	10	0	0	0	2	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0192-6233	1533-1601		TOXICOL PATHOL	Toxicol. Pathol.	DEC	2018	46	8			SI		970	975		10.1177/0192623318799995			6	Pathology; Toxicology	Pathology; Toxicology	HF3NN	WOS:000454141900011	30213245				2019-10-28	
J	Homer, BL; Dower, K				Homer, Bruce L.; Dower, Ken			41-Week Study of Progressive Diabetic Nephropathy in the ZSF1 fa/fa(CP) Rat Model	TOXICOLOGIC PATHOLOGY			English	Article; Proceedings Paper	Annual National-Toxicology-Program Satellite Symposium on Pathology Potpourri at the 37th Annual Meeting of the the Society-of-Toxicologic-Pathology	2018	Indianapolis, IN	Natl Toxicol Program, Soc Toxicol Pathol		diabetic nephropathy; ZSF1 rat model; diabetic kidney disease		This symposium synopsis summarizes key results from a 41-week study of diabetic nephropathy (DN) in the type 2 diabetic ZSF1 fa/fa(CP) rat model. During this study, we conducted longitudinal analysis of biomarkers, renal histopathology, ultrastructural assessment, renal quantitative image analysis, and transcriptome analysis of glomerular-enriched tissue. We concluded that there is translational value for using the ZSF1 rat model in mechanistic and therapeutic intervention efficacy studies for type 2 DN.	[Homer, Bruce L.] Pfizer Worldwide Res & Dev, Drug Safety, Cambridge, MA 02139 USA; [Dower, Ken] Pfizer Worldwide Res & Dev, Inflammat & Immunol, Cambridge, MA USA	Homer, BL (reprint author), Pfizer Worldwide Res & Dev, Drug Safety, Cambridge, MA 02139 USA.	bhomer52@gmail.com					Brosius FC, 2009, J AM SOC NEPHROL, V20, P2503, DOI 10.1681/ASN.2009070721; Dower K, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0181861; Hodgin JB, 2013, DIABETES, V62, P299, DOI 10.2337/db11-1667; Tofovic SP, 2000, RENAL FAILURE, V22, P387, DOI 10.1081/JDI-100100882	4	0	0	0	0	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0192-6233	1533-1601		TOXICOL PATHOL	Toxicol. Pathol.	DEC	2018	46	8			SI		976	977		10.1177/0192623318803278			2	Pathology; Toxicology	Pathology; Toxicology	HF3NN	WOS:000454141900012	30278832				2019-10-28	
J	McDuffie, JE				McDuffie, James E.			Brief Overview: Assessment of Compound-induced Acute Kidney Injury Using Animal Models, Biomarkers, and In Vitro Platforms	TOXICOLOGIC PATHOLOGY			English	Article; Proceedings Paper	Annual National-Toxicology-Program Satellite Symposium on Pathology Potpourri at the 37th Annual Meeting of the the Society-of-Toxicologic-Pathology	2018	Indianapolis, IN	Natl Toxicol Program, Soc Toxicol Pathol		biomarkers; animal models; rat; dog pathology; nonhuman primate; in vitro toxicology; clinical pathology	GENE-EXPRESSION ANALYSIS; ON-A-CHIP; INDUCED NEPHROTOXICITY; EARLY INDICATORS; NEXT-GENERATION; CELL-LINE; 2 STRAINS; CISPLATIN; KIM-1; QUALIFICATION	The inability to unequivocally predict translatable drug-induced kidney injury in nonclinical studies during pharmacological development is evidenced by drug attrition in human clinical trials. Eight urinary proteins have been qualified as renal safety biomarkers for limited context of use in nonclinical drug development studies in rats. Formal qualification of human renal safety biomarkers is pending the submission of data from prospective clinical trials and analyses of biomarker performance to the Food and Drug Administration and European Medicines Agency by the Foundation for the National Institutes of Health and Predictive Safety Testing Consortium's Nephrotoxicity Working Group. In vitro kidney platforms may be leveraged to investigate the potential risk of compound-induced acute kidney injury and/or dysfunction. The early assessment of drug-related kidney safety profiles using biomarker-level changes in animal models and in vitro platforms could significantly reduce renal safety-related drug attrition; yet, there are no well-validated in vitro systems to enable comprehensive investigations of compound-induced nephrotoxicity. Thus, histopathology remains the gold standard for diagnosing nephron-specific damage. Traditional and emerging biomarker panels should be combined with histopathology and/or cytopathology to enable early identification of compound-induced kidney injury.	[McDuffie, James E.] Janssen Res & Dev LLC, Mechanist & Invest Toxicol, San Diego, CA USA	McDuffie, JE (reprint author), Janssen Res & Dev LLC, 3210 Merryfield Row, San Diego, CA 92121 USA.	jmcduffi@its.jnj.com			C-Path's/PSTC	This article is based upon selected work supported by C-Path's/PSTC.	[Anonymous], 2016, EMA LETT SUPPORT DRU; [Anonymous], 2012, PROSPECTIVE OBSERVAT; [Anonymous], 2009, CPMPICH28695; [Anonymous], 2013, PROSPECTIVE OBSERVAT; [Anonymous], 1958, MDCK NBL 2 ATCC CCL; [Anonymous], 2012, EPAR SUMMARY PUBLIC; [Anonymous], 2013, BIOMARKERS CONSORTIU; [Anonymous], 2016, FDA LETT SUPPORT DRU; Awdishu L, 2017, BMC NEPHROL, V18, DOI 10.1186/s12882-017-0536-3; Bellomo R, 2004, CRIT CARE, V8, pR204, DOI 10.1186/cc2872; Bendele A, 1998, TOXICOL SCI, V42, P152, DOI 10.1006/toxs.1997.2396; Benjamin A, 2015, J PHARMACOL TOX MET, V75, P101, DOI 10.1016/j.vascn.2015.01.004; Brott DA, 2014, DRUG DES DEV THER, V8, P227, DOI 10.2147/DDDT.S54956; Chen Y., 2017, TOXICOL APPL PHARM, V268, P352; Chen YF, 2013, TOXICOL APPL PHARM, V268, P352, DOI 10.1016/j.taap.2013.01.032; Church RJ, 2014, TOXICOL RES-UK, V3, P384, DOI 10.1039/c4tx00051j; Davis JW, 2004, TOXICOL APPL PHARM, V200, P16, DOI 10.1016/j.taap.2004.02.001; de Larco J. E., 1987, J CELL PHYSL, V94, P335; Dehne EM, 2017, FUTUR SCI OA, V3, DOI 10.4155/fsoa-2017-0002; Dieterich C, 2009, TOXICOL SCI, V107, P258, DOI 10.1093/toxsci/kfn203; Dieterle F, 2010, NAT BIOTECHNOL, V28, P455, DOI 10.1038/nbt.1625; DUCNGUYEN H, 1966, J BACTERIOL, V92, P1133; Ennulat D, 2015, TOXICOL PATHOL, V43, P62, DOI 10.1177/0192623314554840; FLACH R, 1995, BBA-MOL CELL RES, V1268, P325, DOI 10.1016/0167-4889(95)00110-E; Frazier KS, 2012, TOXICOL PATHOL, V40, P14, DOI 10.1177/0192623312438736; Gautier JC, 2016, TOXICOL APPL PHARM, V303, P1, DOI 10.1016/j.taap.2016.04.012; Gautier JC, 2010, TOXICOL PATHOL, V38, P943, DOI 10.1177/0192623310379139; Glynne PA, 2000, METH MOLEC MED, V36, P197, DOI 10.1385/1-59259-216-3:197; Guha M, 2011, TOXICOL SCI, V120, P269, DOI 10.1093/toxsci/kfr013; Harpur E, 2011, TOXICOL SCI, V122, P235, DOI 10.1093/toxsci/kfr112; Ishihara M, 2013, AM J PHYSIOL-RENAL, V305, pF495, DOI 10.1152/ajprenal.00642.2012; Ivie SE, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017787; Jang KJ, 2013, INTEGR BIOL-UK, V5, P1119, DOI 10.1039/c3ib40049b; King SM, 2017, FRONT PHYSIOL, V8, DOI 10.3389/fphys.2017.00123; Kondo C, 2012, J TOXICOL SCI, V37, P723, DOI 10.2131/jts.37.723; Luo QH, 2016, KIDNEY BLOOD PRESS R, V41, P911, DOI 10.1159/000452592; Martensson J, 2012, BRIT J ANAESTH, V109, P843, DOI 10.1093/bja/aes357; McDuffie JE, 2016, TOXICOL RES-UK, V5, P1202, DOI 10.1039/c5tx00497g; McDuffie JE, 2010, CYTOKINE, V52, P156, DOI 10.1016/j.cyto.2010.06.005; McDuffie JE, 2016, J TOXICOL SCI, V41, P459, DOI 10.2131/jts.41.459; McDuffie JM, 2013, OPEN J MOL INTEGR PH, V3, P125; Mehta RL, 2007, CRIT CARE, V11, DOI 10.1186/cc5713; Nassirpour R, 2014, BMC GENOMICS, V15, DOI 10.1186/1471-2164-15-485; O'Brien LE, 2002, NAT REV MOL CELL BIO, V3, P531, DOI 10.1038/nrm859; Pavkovic M, 2016, TOXICOL SCI, V152, P205, DOI 10.1093/toxsci/kfw077; Periyasamy-Thandavan S, 2008, KIDNEY INT, V74, P631, DOI 10.1038/ki.2008.214; Quiros Y, 2011, TOXICOL SCI, V119, P245, DOI 10.1093/toxsci/kfq267; Rached E, 2008, TOXICOL SCI, V103, P371, DOI 10.1093/toxsci/kfn040; REDFERN WS, 2010, TOXICOLOGIST, V114, P1081; Rouse RL, 2011, KIDNEY INT, V79, P1186, DOI 10.1038/ki.2010.463; Rudmann DG, 2013, TOXICOL PATHOL, V41, P970, DOI 10.1177/0192623312474726; RYAN MJ, 1994, KIDNEY INT, V45, P48, DOI 10.1038/ki.1994.6; Sauer J-M, 2016, J MED DEV SCI, V1, P34, DOI 10.18063/JMDS.2015.01.007; Sharp CN, 2017, AM J PHYSIOL-RENAL, V313, pF835, DOI 10.1152/ajprenal.00285.2017; Shukla P, 2015, BMC GENOMICS, V16, DOI 10.1186/s12864-015-2036-9; Sohn SJ, 2013, TOXICOL LETT, V217, P235, DOI 10.1016/j.toxlet.2012.12.015; Suter-Dick L, 2018, AAPS J, V20, DOI 10.1208/s12248-018-0245-2; Thukral SK, 2005, TOXICOL PATHOL, V33, P343, DOI 10.1080/01926230590927230; Tonomura Y, 2009, HUM EXP TOXICOL, V28, P293, DOI 10.1177/0960327109105404; ULLRICH O, 1991, J BIOL CHEM, V266, P3518; Van Acker T, 2016, ANAL CHIM ACTA, V945, P23, DOI 10.1016/j.aca.2016.10.014; Veeranagouda Y, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0142708; Vinken P, 2012, TOXICOL PATHOL, V40, P1049, DOI 10.1177/0192623312444765; Wagoner MP, 2017, CURR TOP MED CHEM, V17, P2767, DOI 10.2174/1568026617666170713172331; Wei QQ, 2007, AM J PHYSIOL-RENAL, V293, pF1282, DOI 10.1152/ajprenal.00230.2007; Wieser M, 2008, AM J PHYSIOL-RENAL, V295, pF1365, DOI 10.1152/ajprenal.90405.2008; Wilmer MJ, 2016, TRENDS BIOTECHNOL, V34, P156, DOI 10.1016/j.tibtech.2015.11.001; Zhang J, 2009, TOXICOL PATHOL, V37, P629, DOI 10.1177/0192623309339605; Zhou XB, 2014, TOXICOL APPL PHARM, V280, P30, DOI 10.1016/j.taap.2014.07.002; 2000, CPMPICH53900	70	0	0	0	0	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0192-6233	1533-1601		TOXICOL PATHOL	Toxicol. Pathol.	DEC	2018	46	8			SI		978	990		10.1177/0192623318807679			13	Pathology; Toxicology	Pathology; Toxicology	HF3NN	WOS:000454141900013	30392454				2019-10-28	
J	Harlan, SM; Heinz-Taheny, KM; Overstreet, JM; Breyer, MD; Harris, RC; Heuer, JG				Harlan, Shannon M.; Heinz-Taheny, Kathleen M.; Overstreet, Jessica M.; Breyer, Matthew D.; Harris, Raymond C.; Heuer, Josef G.			Pathological and Transcriptome Changes in the ReninAAV db/db uNx Model of Advanced Diabetic Kidney Disease Exhibit Features of Human Disease	TOXICOLOGIC PATHOLOGY			English	Article; Proceedings Paper	Annual National-Toxicology-Program Satellite Symposium on Pathology Potpourri at the 37th Annual Meeting of the the Society-of-Toxicologic-Pathology	2018	Indianapolis, IN	Natl Toxicol Program, Soc Toxicol Pathol		animal models; mouse pathology; renal; diabetes	HYPERTENSION	The ReninAAV db/db uNx model of diabetic kidney disease (DKD) exhibits hallmarks of advanced human disease, including progressive elevations in albuminuria and serum creatinine, loss of glomerular filtration rate, and pathological changes. Microarray analysis of renal transcriptome changes were more similar to human DKD when compared to db/db eNOS(-/-) model. The model responds to treatment with arterial pressure lowering (lisinopril) or glycemic control (rosiglitazone) at early stages of disease. We hypothesized the ReninAAV db/db uNx model with advanced disease would have residual disease after treatment with lisinopril, rosiglitazone, or combination of both. To test this, ReninAAV db/db uNx mice with advanced disease were treated with lisinopril, rosiglitazone, or combination of both for 10 weeks. All treatment groups showed significant lowering of urinary albumin to creatinine ratio compared to baseline; however, only combination group exhibited lowering of serum creatinine. Treatment improved renal pathological scores compared to baseline values with residual disease evident in all treatment groups when compared to db/m controls. Gene expression analysis by TaqMan supported pathological changes with increased fibrotic and inflammatory markers. The results further validate this model of DKD in which residual disease is present when treated with agents to lower arterial pressure and glycemic control.	[Harlan, Shannon M.; Heinz-Taheny, Kathleen M.; Breyer, Matthew D.; Heuer, Josef G.] Eli Lilly & Co, Lilly Corp Ctr, Lilly Res Labs, Indianapolis, IN 46285 USA; [Overstreet, Jessica M.; Harris, Raymond C.] Vanderbilt Univ, Sch Med, Div Nephrol, Nashville, TN 37212 USA; [Breyer, Matthew D.] Indiana Univ, Dept Med, Indianapolis, IN USA	Heuer, JG (reprint author), Lilly Res Labs, Biotherapeut Discovery Res, 355 E Merrill St, Indianapolis, IN 46285 USA.	jheuer@lilly.com		Breyer, Matthew/0000-0003-1880-371X	Eli Lilly and CompanyEli Lilly	The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: J. Overstreet is a LIFA Postdoc funded by Eli Lilly and Company.	Harlan SM, 2018, J AM SOC NEPHROL, V29, P477, DOI 10.1681/ASN.2017040385; Harlan SM, 2015, AM J PHYSIOL-REG I, V309, pR467, DOI 10.1152/ajpregu.00106.2015; Hudkins KL, 2010, J AM SOC NEPHROL, V21, P1533, DOI 10.1681/ASN.2009121290; SAITO Y, 1988, KIDNEY INT, V34, P389, DOI 10.1038/ki.1988.193; Wanner C, 2016, NEW ENGL J MED, V375, P1801, DOI [10.1056/NEJMoa1515920, 10.1056/NEJMc1611290]; Zhang MZ, 2012, AM J PHYSIOL-RENAL, V302, pF433, DOI 10.1152/ajprenal.00292.2011	6	1	1	2	2	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0192-6233	1533-1601		TOXICOL PATHOL	Toxicol. Pathol.	DEC	2018	46	8			SI		991	998		10.1177/0192623318804986			8	Pathology; Toxicology	Pathology; Toxicology	HF3NN	WOS:000454141900014	30392455				2019-10-28	
J	Nabity, MB				Nabity, Mary B.			Traditional Renal Biomarkers and New Approaches to Diagnostics	TOXICOLOGIC PATHOLOGY			English	Article; Proceedings Paper	Annual National-Toxicology-Program Satellite Symposium on Pathology Potpourri at the 37th Annual Meeting of the the Society-of-Toxicologic-Pathology	2018	Indianapolis, IN	Natl Toxicol Program, Soc Toxicol Pathol		biomarkers; glomerular filtration rate; kidney; microRNA; proteinuria; proteomics; SDMA	SYMMETRIC DIMETHYLARGININE CONCENTRATION; KIDNEY-FUNCTION BIOMARKERS; SERUM CONCENTRATIONS; CREATININE; CATS; DISEASE; DOGS	Traditional biomarkers of renal disease have a number of limitations, whether evaluating veterinary patients or performing preclinical toxicity studies. Serum creatinine and urea nitrogen are affected by nonrenal influences that limit their usefulness for detecting small but significant decreases in glomerular filtration rate (GFR) in veterinary patients. These nonrenal influences can be more controlled in preclinical studies than in clinical patients; however, because of its high functional reserve, these estimates of GFR are insensitive for detecting kidney injury prior to loss of a substantial proportion of functioning nephrons. Urine biomarkers can be highly sensitive for tubular or glomerular injury that might lead to irreversible damage to the nephron. Several proteins are qualified by the Food and Drug Administration for nonclinical application as urinary biomarkers of drug-induced nephrotoxicity, and many of these also have preliminary data supporting their usefulness for kidney injury in dogs and cats. In addition to these relatively recently identified biomarkers, efforts are underway to discover new renal biomarkers using a variety of techniques including liquid chromatography-mass spectrometry and small RNA sequencing. Ultimately, the interplay between preclinical studies and clinical patients in discovery and validation of renal biomarkers is critical to their successful implementation.	[Nabity, Mary B.] Texas A&M Univ, Dept Vet Pathobiol, Coll Vet Med & Biomed Sci, 4467 TAMU, College Stn, TX 77843 USA	Nabity, MB (reprint author), Texas A&M Univ, Dept Vet Pathobiol, Coll Vet Med & Biomed Sci, 4467 TAMU, College Stn, TX 77843 USA.	mnabity@cvm.tamu.edu					Braff J, 2014, J VET INTERN MED, V28, P1699, DOI 10.1111/jvim.12446; Braun JP, 2008, VET REC, V162, P215, DOI 10.1136/vr.162.7.215; Cheetham SA, 2009, PHYSIOL BEHAV, V96, P253, DOI 10.1016/j.physbeh.2008.10.005; Cross J., 2017, TOXICOLOGIST SUPPLEM, V156; Dahlem DP, 2017, J VET INTERN MED, V31, P799, DOI 10.1111/jvim.14694; Delanaye P, 2017, NEPHRON, V136, P302, DOI 10.1159/000469669; Hall JA, 2016, J VET INTERN MED, V30, P794, DOI 10.1111/jvim.13942; Hall JA, 2014, VET J, V202, P588, DOI [10.1016/j.tvjl.2014.10.021, 10.1016/j.tvj1.2014.10.021]; Hall JA, 2014, J VET INTERN MED, V28, P1676, DOI 10.1111/jvim.12445; Ichii O, 2017, SCI REP-UK, V7, DOI 10.1038/srep40340; Imafidon Eseigbe Christian, 2016, Pathophysiology, V23, P51, DOI 10.1016/j.pathophys.2016.02.001; Jepson RE, 2008, J VET INTERN MED, V22, P317, DOI 10.1111/j.1939-1676.2008.0075.x; Kopke MA, 2018, J VET INTERN MED, V32, P736, DOI 10.1111/jvim.15050; Levey AS, 2014, AM J KIDNEY DIS, V63, P820, DOI 10.1053/j.ajkd.2013.12.006; Muckova P, 2015, J PROTEOME RES, V14, P5202, DOI 10.1021/acs.jproteome.5b00814; Nabity MB, 2015, J VET INTERN MED, V29, P1036, DOI 10.1111/jvim.12835; Tatematsu S, 2007, J AM SOC NEPHROL, V18, P741, DOI 10.1681/ASN.2006040367; Ulleberg T, 2011, ACTA VET SCAND, V53, DOI 10.1186/1751-0147-53-25	18	0	0	4	13	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0192-6233	1533-1601		TOXICOL PATHOL	Toxicol. Pathol.	DEC	2018	46	8			SI		999	1001		10.1177/0192623318800709			3	Pathology; Toxicology	Pathology; Toxicology	HF3NN	WOS:000454141900015	30270776				2019-10-28	
J	Nabity, MB; Polli, JW; Vaidya, V; Krolewski, A; Glaab, WE				Nabity, Mary B.; Polli, Joseph W.; Vaidya, Vishal; Krolewski, Andrzej; Glaab, Warren E.			New Frontiers: Approaches to Understand the Mechanistic Basis of Renal Toxicity	TOXICOLOGIC PATHOLOGY			English	Article; Proceedings Paper	Annual National-Toxicology-Program Satellite Symposium on Pathology Potpourri at the 37th Annual Meeting of the the Society-of-Toxicologic-Pathology	2018	Indianapolis, IN	Natl Toxicol Program, Soc Toxicol Pathol		diabetic nephropathy; drug transporters; kidney toxicity; microRNAs	DRUG TRANSPORTERS; KIDNEY INJURY; MICRORNAS; EXPRESSION; PROFILES; HUMANS	A scientific session entitled "New Frontiers: Approaches to Understand the Mechanistic Basis of Renal Toxicity" focused on novel biomarkers to monitor kidney injury both preclinically and clinically, as well as providing mechanistic insight of the induced injury. Further, the role and impact of kidney membrane transporters in drug-induced kidney toxicity provided additional considerations when understanding kidney injury and the complex role of drug transporters in either sensitivity or resistance to drug-induced injury. The onset of nephropathy in diabetic patients was also presented, focusing on the quest to discover novel biomarkers that would differentiate diabetic populations more susceptible to nephropathy and renal failure. The session highlighted exciting new research areas and novel biomarkers that will enhance our understanding of kidney injury and provide tools for ensuring patient safety clinically.	[Nabity, Mary B.] Texas A&M Univ, Coll Vet Med & Biomed Sci, Dept Vet Pathobiol, 4467 TAMU, College Stn, TX 77843 USA; [Polli, Joseph W.] GlaxoSmithKline, King Of Prussia, PA USA; [Vaidya, Vishal] Pfizer, Cambridge, MA USA; [Krolewski, Andrzej] Harvard Med Sch, Joslin Diabet Ctr, Boston, MA USA; [Glaab, Warren E.] Merck & Co Inc, West Point, PA USA	Nabity, MB (reprint author), Texas A&M Univ, Coll Vet Med & Biomed Sci, Dept Vet Pathobiol, 4467 TAMU, College Stn, TX 77843 USA.	mnabity@cvm.tamu.edu					Bleasby K, 2006, XENOBIOTICA, V36, P963, DOI 10.1080/00498250600861751; Cardenas-Gonzalez M, 2017, CLIN CHEM, V63, P1515, DOI 10.1373/clinchem.2017.274175; Chau BN, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003205; Chu Xiaoyan, 2016, Drug Metab Dispos, V44, P1498, DOI 10.1124/dmd.115.067694; Fallon JK, 2016, PHARM RES-DORDR, V33, P2280, DOI 10.1007/s11095-016-1966-5; Gerlach CV, 2017, ARCH TOXICOL, V91, P2781, DOI 10.1007/s00204-017-1974-1; Gomez IG, 2016, AM J PHYSIOL-RENAL, V310, pP931, DOI 10.1152/ajprenal.00523.2015; He JK, 2014, BIOPHARM DRUG DISPOS, V35, P253, DOI 10.1002/bdd.1890; Krolewski AS, 2015, DIABETES CARE, V38, P954, DOI 10.2337/dc15-0184; Kunin M, 2012, NEPHROL DIAL TRANSPL, V27, P1387, DOI 10.1093/ndt/gfr541; Pavkovic M, 2016, TOXICOL SCI, V152, P205, DOI 10.1093/toxsci/kfw077; Pavkovic M, 2016, PHARMACOL THERAPEUT, V163, P48, DOI 10.1016/j.pharmthera.2016.03.016; Pellegrini KL, 2016, TOXICOL APPL PHARM, V312, P42, DOI 10.1016/j.taap.2015.12.002; Pellegrini KL, 2014, TOXICOL SCI, V141, P484, DOI 10.1093/toxsci/kfu143; Prasad B, 2016, DRUG METAB DISPOS, V44, P1920, DOI 10.1124/dmd.116.072066; Ramachandran K, 2013, CLIN CHEM, V59, P1742, DOI 10.1373/clinchem.2013.210245; Saikumar J, 2014, CLIN CHEM, V60, P1158, DOI 10.1373/clinchem.2013.216044; Saikumar J, 2012, TOXICOL SCI, V129, P256, DOI 10.1093/toxsci/kfs210; Xu YJ, 2017, MOL MED REP, V15, P474, DOI 10.3892/mmr.2016.5970	19	0	0	0	0	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0192-6233	1533-1601		TOXICOL PATHOL	Toxicol. Pathol.	DEC	2018	46	8			SI		1002	1005		10.1177/0192623318798599			4	Pathology; Toxicology	Pathology; Toxicology	HF3NN	WOS:000454141900016	30189777				2019-10-28	
J	Choudhary, S; Walker, A; Funk, K; Keenan, C; Khan, I; Maratea, K				Choudhary, Shambhunath; Walker, Audrey; Funk, Kathleen; Keenan, Charlotte; Khan, Imran; Maratea, Kimberly			The Standard for the Exchange of Nonclinical Data (SEND): Challenges and Promises	TOXICOLOGIC PATHOLOGY			English	Article; Proceedings Paper	Annual National-Toxicology-Program Satellite Symposium on Pathology Potpourri at the 37th Annual Meeting of the the Society-of-Toxicologic-Pathology	2018	Indianapolis, IN	Natl Toxicol Program, Soc Toxicol Pathol		SEND; SDTM; nonclinical studies; drug approval; FDA		The Standard for the Exchange of Nonclinical Data (SEND) is an implementation of the Study Data Tabulation Model for nonclinical studies that enables the U.S. Food and Drug Administration (FDA) to modernize and streamline the review process. As a result, patients may benefit from speedier approval of new drugs. However, SEND implementation and compliance can be challenging and require effective cooperation between pharmaceutical companies and contract research organizations. In order to improve Society of Toxicologic Pathology (STP) members' awareness about SEND, including the steps, obstacles, and mistakes to avoid in its implementation while applying for FDA approval, the Career Development and Outreach Committee of the STP sponsored a career development lunchtime series panel discussion entitled "The Standard for the Exchange of Nonclinical Data (SEND): Challenges and Promise" in conjunction with the STP 37th Annual Symposium. The presentations and discussion at this workshop provided perspectives of experts including pathologists and information technology professionals familiar with the SEND submission process and FDA reviewers. This article is designed to provide brief summaries of their talks as well as the questions asked during this well-received panel discussion.	[Choudhary, Shambhunath] Charles River Labs, 640 North Elizabeth St, Spencerville, OH 45887 USA; [Walker, Audrey] Charles River Labs, Senneville, PQ, Canada; [Funk, Kathleen] Expt Pathol Labs, Sterling, VA USA; [Keenan, Charlotte] CM Keenan ToxPath Consulting, Doylestown, PA USA; [Khan, Imran] US FDA, Silver Spring, MD USA; [Maratea, Kimberly] AstraZeneca, IMED Biotech Unit, Pathol Drug Safety & Metab, Boston, MA USA	Choudhary, S (reprint author), Charles River Labs, 640 North Elizabeth St, Spencerville, OH 45887 USA.	shambhunath.choudhary@crl.com					[Anonymous], 2013, STUDY DATA TABULATIO; [Anonymous], 2016, STANDARD EXCHANGE NO; [Anonymous], 2017, STUDY DATA STANDARDS; Keenan CM, 2015, J TOXICOL PATHOL, V28, P48, DOI 10.1293/tox.28.2014-0049	4	0	0	0	2	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0192-6233	1533-1601		TOXICOL PATHOL	Toxicol. Pathol.	DEC	2018	46	8			SI		1006	1012		10.1177/0192623318805743			7	Pathology; Toxicology	Pathology; Toxicology	HF3NN	WOS:000454141900017	30295163				2019-10-28	
J	Vahle, JL				Vahle, John L.			Immunogenicity and Immune Complex Disease in Preclinical Safety Studies	TOXICOLOGIC PATHOLOGY			English	Article; Proceedings Paper	Annual National-Toxicology-Program Satellite Symposium on Pathology Potpourri at the 37th Annual Meeting of the the Society-of-Toxicologic-Pathology	2018	Indianapolis, IN	Natl Toxicol Program, Soc Toxicol Pathol		immunogenicity; toxicity; immune complex disease; nonhuman primate; biotherapeutics	HYPERSENSITIVITY REACTIONS; CYNOMOLGUS MONKEYS; ANTIBODIES	This article summarizes a continuing education presentation on immunogenicity that was part of a continuing education course entitled, "Clinical Pathology of Biotherapeutics." Immunogenicity of a biotherapeutic can have diverse impacts including altered systemic exposure and pharmacologic responses and, in a fraction of the cases, safety concerns including cross-reactive neutralization of endogenous proteins or sequela related to immune complex disease (ICD). In most cases, immune complexes are readily cleared from circulation; however, based on physiochemical properties, insoluble complexes form, activate complement, and deposit in tissues. Using published information and personal experience, a set of repeat-dose monkey toxicity studies with manifestations suggestive of ICD was reviewed to summarize the spectrum of clinical and pathology findings. The most common live-phase observation linked to ICD was an acute postdosing reaction following multiple dose administrations characterized by generalized collapse and attributed to acute complement activation. Less common live-phase observations were related to syndromes such as a consumptive coagulopathy or a protein losing nephropathy. The most common histologic change attributed to ICD was multi-organ vascular/perivascular inflammation followed by glomerulonephritis. The presentation concluded with a description of the challenges in assessing the relevance of immunogenicity-related reaction in monkey to human clinical use.	[Vahle, John L.] Lilly Res Labs, Indianapolis, IN USA	Vahle, JL (reprint author), Eli Lilly & Co, Lilly Corp Ctr, Indianapolis, IN 46285 USA.	jvahle@lilly.com		Vahle, John/0000-0001-7964-9133			Basser RL, 2002, BLOOD, V99, P2599, DOI 10.1182/blood.V99.7.2599; De Groot AS, 2007, TRENDS IMMUNOL, V28, P482, DOI 10.1016/j.it.2007.07.011; Heyen JR, 2014, TOXICOL PATHOL, V42, P765, DOI 10.1177/0192623314522559; Husar E, 2017, TOXICOL PATHOL, V45, P676, DOI 10.1177/0192623317723539; Krishna M, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00021; Kronenberg S, 2017, REGUL TOXICOL PHARM, V88, P125, DOI 10.1016/j.yrtph.2017.06.004; KUUSREICHEL K, 1994, CLIN DIAGN LAB IMMUN, V1, P365; Leach MW, 2014, TOXICOL PATHOL, V42, P293, DOI 10.1177/0192623313510987; Li JZ, 2001, BLOOD, V98, P3241, DOI 10.1182/blood.V98.12.3241; Mease Kirsten M., 2017, Current Opinion in Toxicology, V4, P1, DOI 10.1016/j.cotox.2017.03.005; Pierog P, 2015, J IMMUNOL METHODS, V416, P124, DOI 10.1016/j.jim.2014.11.007; Ponce R, 2009, REGUL TOXICOL PHARM, V54, P164, DOI 10.1016/j.yrtph.2009.03.012; Rojas JR, 2005, J PHARMACOL EXP THER, V313, P578, DOI 10.1124/jpet.104.079277; Rojko JL, 2014, TOXICOL PATHOL, V42, P725, DOI 10.1177/0192623314526475; Yin LS, 2015, CELL IMMUNOL, V295, P118, DOI 10.1016/j.cellimm.2015.03.002	15	0	0	0	1	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0192-6233	1533-1601		TOXICOL PATHOL	Toxicol. Pathol.	DEC	2018	46	8			SI		1013	1019		10.1177/0192623318797070			7	Pathology; Toxicology	Pathology; Toxicology	HF3NN	WOS:000454141900018	30157708				2019-10-28	
J	Assaf, BT; Whiteley, LO				Assaf, Basel T.; Whiteley, Laurence O.			Considerations for Preclinical Safety Assessment of Adeno-Associated Virus Gene Therapy Products	TOXICOLOGIC PATHOLOGY			English	Article; Proceedings Paper	Annual National-Toxicology-Program Satellite Symposium on Pathology Potpourri at the 37th Annual Meeting of the the Society-of-Toxicologic-Pathology	2018	Indianapolis, IN	Natl Toxicol Program, Soc Toxicol Pathol		study design; gene therapy; preclinical; adeno-associated virus; AAV	GERMLINE TRANSMISSION; HEPATIC GENOTOXICITY; AAV INTEGRATION; VECTOR; IMMUNITY	Progress in understanding the molecular bases of human health and disease in recent decades has flourished making it possible for the field of gene therapy (GT) to offer new possibilities for treating, and even curing, a plethora of medical conditions such as monogenic disorders and metabolic diseases. GT is a therapeutic intervention to genetically alter or modify living cells by means of gene delivery achieved using either viral vectors or nonviral vectors, with adeno-associated virus (AAV) vectors constituting market-share majority. Although GT is conceptually attractive, adverse and even fatal iatrogenic complications have marred the initial enthusiasm of clinical successes. The properties of investigational AAV-based GT may pose safety concerns unique from those of small molecule drugs and other macromolecular biologics, such as ectopic or unregulated expression of the transgene, long-term persistence, and off-target distribution. Herein, we discuss considerations in the design of a comprehensive preclinical safety program for AAV-based GT prior to administration in humans.	[Assaf, Basel T.; Whiteley, Laurence O.] Pfizer Inc, Drug Safety Res & Dev, 300 Technol Sq,3rd Floor, Cambridge, MA 02139 USA	Assaf, BT; Whiteley, LO (reprint author), Pfizer Inc, Drug Safety Res & Dev, 300 Technol Sq,3rd Floor, Cambridge, MA 02139 USA.	basel.assaf@pfizer.com; laurence.o.whiteley@pfizer.com	assaf, basel/V-7358-2019				Aiuti A, 2013, HUM GENE THER CL DEV, V24, P47, DOI 10.1089/humc.2013.119; Arruda VR, 2001, MOL THER, V4, P586, DOI 10.1006/mthe.2001.0491; Carter BJ, 2004, MOL THER, V10, P981, DOI 10.1016/j.ymthe.2004.09.011; Chandler RJ, 2015, J CLIN INVEST, V125, P870, DOI 10.1172/JCI79213; Colella P, 2018, MOL THER-METH CLIN D, V8, P87, DOI 10.1016/j.omtm.2017.11.007; Deyle DR, 2009, CURR OPIN MOL THER, V11, P442; Donsante A, 2007, SCIENCE, V317, P477, DOI 10.1126/science.1142658; Falese L, 2017, GENE THER, V24, P768, DOI 10.1038/gt.2017.95; Fitzpatrick Z, 2018, MOL THER-METH CLIN D, V9, P119, DOI 10.1016/j.omtm.2018.02.003; Gil-Farina I, 2016, MOL THER, V24, P1100, DOI 10.1038/mt.2016.52; Golebiowski D, 2017, HUM GENE THER, V28, P510, DOI 10.1089/hum.2016.109; Hastie E, 2015, HUM GENE THER, V26, P257, DOI 10.1089/hum.2015.025; Hinderer C, 2018, HUM GENE THER, V29, P285, DOI 10.1089/hum.2018.015; Hordeaux J, 2018, MOL THER, V26, P664, DOI 10.1016/j.ymthe.2018.01.018; Kaeppel C, 2013, NAT MED, V19, P889, DOI 10.1038/nm.3230; Karda R, 2014, FRONT MOL NEUROSCI, V7, DOI 10.3389/fnmol.2014.00089; Keeler AM, 2017, CTS-CLIN TRANSL SCI, V10, P242, DOI 10.1111/cts.12466; Lisowski L, 2014, NATURE, V506, P382, DOI 10.1038/nature12875; Manno CS, 2006, NAT MED, V12, P342, DOI 10.1038/nm1358; Masat E, 2013, DISCOV MED, V15, P379; Meliani A, 2015, HUM GENE THER METHOD, V26, P45, DOI 10.1089/hgtb.2015.037; Mingozzi F, 2017, ANNU REV VIROL, V4, P511, DOI 10.1146/annurev-virology-101416-041936; Mingozzi F, 2013, BLOOD, V122, P23, DOI 10.1182/blood-2013-01-306647; Naso MF, 2017, BIODRUGS, V31, P317, DOI 10.1007/s40259-017-0234-5; Penaud-Budloo M, 2018, MOL THER-METH CLIN D, V8, P166, DOI 10.1016/j.omtm.2018.01.002; Schuettrumpf J, 2006, MOL THER, V13, P1064, DOI 10.1016/j.ymthe.2006.03.002; Zincarelli C, 2008, MOL THER, V16, P1073, DOI 10.1038/mt.2008.76	27	0	0	0	1	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0192-6233	1533-1601		TOXICOL PATHOL	Toxicol. Pathol.	DEC	2018	46	8			SI		1020	1027		10.1177/0192623318803867			8	Pathology; Toxicology	Pathology; Toxicology	HF3NN	WOS:000454141900019	30295175				2019-10-28	
J	Pardo, ID; Rao, DB; Butt, MT; Jortner, BS; Valentine, WM; Arezzo, J; Sharma, AK; Bolon, B				Pardo, Ingrid D.; Rao, Deepa B.; Butt, Mark T.; Jortner, Bernard S.; Valentine, William M.; Arezzo, Joseph; Sharma, Alok K.; Bolon, Brad			Toxicologic Pathology of the Peripheral Nervous System (PNS): Overview, Challenges, and Current Practices	TOXICOLOGIC PATHOLOGY			English	Article; Proceedings Paper	Annual National-Toxicology-Program Satellite Symposium on Pathology Potpourri at the 37th Annual Meeting of the the Society-of-Toxicologic-Pathology	2018	Indianapolis, IN	Natl Toxicol Program, Soc Toxicol Pathol		peripheral nervous system; ganglia; nerve; autonomic; neuropathy; axonal degeneration; myelinopathy; neuronopathy	DORSAL-ROOT GANGLION; HYPOGLYCEMIC NEUROPATHY; RATS; POLYNEUROPATHY; NEUROTOXICITY; NECROSIS; PROTEIN; NERVES	Peripheral nervous system (PNS) toxicity is a frequent adverse effect encountered in patients treated with certain therapeutics (e.g., antiretroviral drugs, cancer chemotherapeutics), in occupational workers exposed to industrial chemicals (e.g., solvents), or during accidental exposures to household chemicals and/or environmental agents (e.g., pesticides). However, the literature and expertise needed for the effective design, conduct, analysis, and reporting of safety studies to identify and define PNS toxicity are hard to find. This half-day course familiarized participants with basic PNS biology; causes and mechanisms of PNS pathology; classic methods and current best practice recommendations for PNS sampling, preparation, and evaluation; and examples of commonly observed lesions and artifacts. Three concluding case presentations synthesized information from the prior technical lectures by presenting real-world examples of lesions caused by drugs and chemicals to demonstrate how PNS toxicity may be addressed in evaluating product safety during nonclinical studies. Topics emphasized comparative and correlative data among animal species used in toxicity studies and clinical evaluation in humans in order to facilitate the translation of animal data into human risk assessment with respect to PNS toxicologic pathology.	[Pardo, Ingrid D.] Pfizer, Groton, CT USA; [Rao, Deepa B.] US FDA, Ctr Drug Evaluat & Res, Silver Spring, MD USA; [Butt, Mark T.] Tox Path Specialists LLC, Frederick, MD USA; [Jortner, Bernard S.] Virginia Polytech Inst & State Univ, Virginia Maryland Reg Coll Vet Med, Blacksburg, VA 24061 USA; [Valentine, William M.] Cedar Bay Vet Clin, Winter Garden, FL USA; [Arezzo, Joseph] Albert Einstein Coll Med, Bronx, NY 10467 USA; [Sharma, Alok K.] Covance Labs Inc, Madison, WI USA; [Bolon, Brad] GEMpath Inc, 1100 East 17th Ave,Unit M202, Longmont, CO 80504 USA	Bolon, B (reprint author), GEMpath Inc, 1100 East 17th Ave,Unit M202, Longmont, CO 80504 USA.	bradgempath@aol.com			U.S. National Toxicology Program	The authors thank the staff and members of the Society of Toxicologic Pathology (STP) for selecting this continuing education course for presentation at the 2018 Annual STP Meeting and Ms. Beth Mahler for her aid in optimizing the resolution of the photomicrographs. Dr. Pardo acknowledges Dr. Georg Krinke for his scientific contribution in biomarkers for autonomic dysfunction. Dr. Rao acknowledges the contribution of Drs. Grace Kissling, David E. Malarkey, and Susan Elmore and support from the U.S. National Toxicology Program where the work for her case presentation was conducted.	Apostolidis L, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0183845; Arezzo JC, 2011, TOXICOL PATHOL, V39, P46, DOI 10.1177/0192623310390231; Behl M, 2013, TOXICOLOGY, V314, P84, DOI [10.1016/j.cox.2013.09.006, 10.1016/j.tox.2013.09.006]; Bolon B, 2018, TOXICOL PATHOL, V46, P372, DOI 10.1177/0192623318772484; Brienza M, 2014, J NEURORADIOLOGY, V41, P124, DOI 10.1016/j.neurad.2013.06.001; BURNSTOCK G, 1971, BRIT J PHARMACOL, V43, P295; COTARDBARTLEY MP, 1981, VET PATHOL, V18, P110, DOI 10.1177/030098588101800111; Eisenhofer G, 2004, PHARMACOL REV, V56, P331, DOI 10.1124/pr.56.3.1; Englander EW, 2013, DNA REPAIR, V12, P685, DOI 10.1016/j.dnarep.2013.04.020; GRAHAM DG, 1995, CRIT REV TOXICOL, V25, P91, DOI 10.3109/10408449509021609; Heckmann JG, 2000, MUSCLE NERVE, V23, P1891, DOI 10.1002/1097-4598(200012)23:12<1891::AID-MUS17>3.0.CO;2-Y; Hidmark AS, 2017, J NEUROIMMUNOL, V306, P76, DOI 10.1016/j.jneuroim.2017.03.008; Jamali R, 2006, J NEUROPATH EXP NEUR, V65, P1118, DOI 10.1097/01.jnen.0000248546.13176.d4; Jensen VFH, 2014, J NEUROENDOCRINOL, V26, P123, DOI 10.1111/jne.12133; Jensen VFH, 2016, J TOXICOL PATHOL, V29, P17, DOI 10.1293/tox.2015-0041; Lauria G, 2005, EUR J NEUROL, V12, P747, DOI 10.1111/j.1468-1331.2005.01260.x; Mangus LM, 2016, TOXICOL PATHOL, V44, P904, DOI 10.1177/0192623316650286; McMartin DN, 1997, GUIDES TOXICOLOGIC P; Mitsumori K., 1990, PATHOLOGY FISCHER RA, P183; Mohseni S, 2000, ACTA NEUROPATHOL, V100, P415, DOI 10.1007/s004010000204; Mohseni S, 2001, ACTA NEUROPATHOL, V102, P413; Mohseni Simin, 2014, Handb Clin Neurol, V126, P513, DOI 10.1016/B978-0-444-53480-4.00036-9; Morfini GA, 2012, BASIC NEUROCHEMISTRY: PRINCIPLES OF MOLECULAR, CELLULAR, AND MEDICAL NEUROBIOLOGY, 8THEDITION, P146; MUFSON EJ, 1980, EXP NEUROL, V70, P179, DOI 10.1016/0014-4886(80)90016-3; Ohana M, 2014, DIAGN INTERV IMAG, V95, P17, DOI 10.1016/j.diii.2013.05.008; Pettersen JC, 2014, TOXICOL PATHOL, V42, P696, DOI 10.1177/0192623314526006; Roberts RA, 2015, TOXICOL SCI, V148, P332, DOI 10.1093/toxsci/kfv188; Ronchi G, 2014, J PERIPHER NERV SYST, V19, P224, DOI 10.1111/jns.12090; SIMA AAF, 1989, DIABETES RES CLIN PR, V6, P279, DOI 10.1016/0168-8227(89)90068-5; Striano S, 2003, NEUROPHYSIOL CLIN, V33, P223, DOI 10.1016/j.neucli.2003.08.001; Sugimoto K, 2004, ACTA NEUROPATHOL, V108, P503, DOI 10.1007/s00401-004-0915-2; Takala RSK, 2016, WORLD NEUROSURG, V87, P8, DOI 10.1016/j.wneu.2015.10.066; Tirmenstein M, 2015, TOXICOL PATHOL, V43, P825, DOI 10.1177/0192623315581020; VALENTINE WM, 1995, CHEM RES TOXICOL, V8, P96, DOI 10.1021/tx00043a013; VanHam L, 1997, VET REC, V141, P98, DOI 10.1136/vr.141.4.98; Vernau W, 2011, FUNDAMENTAL NEUROPATHOLOGY FOR PATHOLOGISTS AND TOXICOLOGISTS: PRINCIPLES AND TECHNIQUES, P271; World Health Organization, 2016, WHO GLOB REP DIAB; Zahner MR, 2017, J PHARMACOL TOX MET, V88, P64, DOI 10.1016/j.vascn.2017.06.002; Zhuo M, 2018, FREE RADICAL BIO MED, V121, P9, DOI 10.1016/j.freeradbiomed.2018.04.570; Zotava E. G., 2013, PHYSL J, V2013, P11, DOI [10. 1155/2013/254789, DOI 10.1155/2013/254789]	40	2	2	1	2	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0192-6233	1533-1601		TOXICOL PATHOL	Toxicol. Pathol.	DEC	2018	46	8			SI		1028	1036		10.1177/0192623318800707			9	Pathology; Toxicology	Pathology; Toxicology	HF3NN	WOS:000454141900020	30295173				2019-10-28	
J	Carreira, V; Palanisamy, G; Quist, E; Nelson, K; Fossey, S; Zimmerman, B; Ramaiah, L; Schafer, KA				Carreira, Vinicius; Palanisamy, Gopinath; Quist, Erin; Nelson, Keith; Fossey, Stacey; Zimmerman, Bevin; Ramaiah, Lila; Schafer, Kenneth A.			Practical Strategies for Navigating Toxicologic Pathology in One's Early Career horizontal ellipsis and Beyond!	TOXICOLOGIC PATHOLOGY			English	Article; Proceedings Paper	Annual National-Toxicology-Program Satellite Symposium on Pathology Potpourri at the 37th Annual Meeting of the the Society-of-Toxicologic-Pathology	2018	Indianapolis, IN	Natl Toxicol Program, Soc Toxicol Pathol		career development; workshop; toxicologic pathology	VETERINARY CLINICAL PATHOLOGY; REGULATORY-TYPE; GUIDELINES	The toxicologic pathologist plays a vital role in the scientific community, using their unique blend of diagnostic and investigative skills to advance biomedical research, public health, drug discovery, or regulatory practices. But what exactly do toxicologic pathologists contribute? Where do these specialized professionals work? How can toxicologic pathologists maximize their efficiency and potential? To enlighten students and trainees, as well as early- or mid-career toxicologic pathologists, or even those approaching retirement, the Career Development and Outreach Committee of the Society of Toxicologic Pathology (STP) sponsored a career development workshop entitled "Practical Strategies for Navigating Toxicologic Pathology in One's Early Career horizontal ellipsis and Beyond!" in conjunction with the STP 37th annual symposium. The workshop featured toxicologic pathologists from contract research organizations and the pharmaceutical industry, who provided their perspectives on career preparation, evolving veterinary pathologist roles within various sectors of toxicologic pathology, the fundamentals of safety assessment, logistics of projects involving good laboratory practices, tools for effective interpretation and communication of anatomic and clinical pathology results, and a recap of scientific resources available to support the toxicologic pathologist in his or her journey. This article provides brief summaries of the talks presented during this career development workshop.	[Carreira, Vinicius] Janssen Res & Dev, 3210 Merryfield Row, La Jolla, CA 92122 USA; [Palanisamy, Gopinath] Theravance Biopharma, San Francisco, CA USA; [Quist, Erin] Expt Pathol Labs Inc, Durham, NC USA; [Nelson, Keith] MPI Res, Mattawan, MI USA; [Fossey, Stacey] AbbVie Inc, N Chicago, IL USA; [Zimmerman, Bevin] Charles River Labs, Ashland, OH USA; [Ramaiah, Lila] Bristol Myers Squibb, New Brunswick, NJ USA; [Schafer, Kenneth A.] Vet Path Serv Inc, Mason, OH USA	Carreira, V (reprint author), Janssen Res & Dev, 3210 Merryfield Row, La Jolla, CA 92122 USA.	vcarreir@its.jnj.com		Carreira, Vinicius/0000-0003-4524-0510			Bolon B, 2010, J TOXICOL PATHOL, V23, P171, DOI 10.1293/tox.23.171; Christopher MM, 2003, VET CLIN PATH, V32, P202, DOI 10.1111/j.1939-165X.2003.tb00337.x; Ettlin RA, 2009, TOXICOL PATHOL, V37, P553, DOI 10.1177/0192623309336156; Kidney BA, 2009, VET CLIN PATH, V38, P281, DOI 10.1111/j.1939-165X.2009.00172.x; Klens-Bigman D., 2002, FIGHTINGARTS MAGAZIN; Munson L, 2010, VET PATHOL, V47, P995, DOI 10.1177/0300985810377725; Ramaiah L, 2017, TOXICOL PATHOL, V45, P260, DOI 10.1177/0192623316681646; Sharkey L, 2006, VET CLIN PATH, V35, P382, DOI 10.1111/j.1939-165X.2006.tb00153.x; Takamura Y., 1986, AIKIDO J; Troth SP, 2018, TOXICOL PATHOL, V46, P476, DOI 10.1177/0192623318778733; Turner PV, 2015, VET PATHOL, V52, P7, DOI 10.1177/0300985813519652; van Tongeren S, 2011, INT J TOXICOL, V30, P568, DOI 10.1177/1091581811413304; Wells C., 1996, PRESENTING TOXICOLOG; Yokota K., 2014, J ED HUM DEV, V3, P167	14	0	0	1	1	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0192-6233	1533-1601		TOXICOL PATHOL	Toxicol. Pathol.	DEC	2018	46	8			SI		1037	1048		10.1177/0192623318805716			12	Pathology; Toxicology	Pathology; Toxicology	HF3NN	WOS:000454141900021	30352538				2019-10-28	
J	Sharp, CN				Sharp, Cierra N.			Cisplatin Effects in Lung Adenocarcinoma-bearing Mice, Alone and in Combination with Erlotinib	TOXICOLOGIC PATHOLOGY			English	Article; Proceedings Paper	Annual National-Toxicology-Program Satellite Symposium on Pathology Potpourri at the 37th Annual Meeting of the the Society-of-Toxicologic-Pathology	2018	Indianapolis, IN	Natl Toxicol Program, Soc Toxicol Pathol		cisplatin; nephrotoxicity; erlotinib; cancer	KIDNEY INJURY	Cisplatin causes nephrotoxicity that can lead to the development of acute kidney injury or chronic kidney disease. However, the current mouse model of cisplatin nephrotoxicity is neither physiologically nor clinically relevant. Our goal was to improve upon these deficits by developing a repeated, low-dose regimen of cisplatin and combining it with a transgenic mouse model of lung adenocarcinoma. This overview details how addressing these deficits have improved our understanding of cisplatin-induced kidney injury.	[Sharp, Cierra N.] Univ Louisville, Dept Pharmacol & Toxicol, 505 S Hancock St,252G, Louisville, KY 40202 USA	Sharp, CN (reprint author), Univ Louisville, Dept Pharmacol & Toxicol, 505 S Hancock St,252G, Louisville, KY 40202 USA.	cnshar01@louisville.edu					Chawla LS, 2014, NEW ENGL J MED, V371, P58, DOI 10.1056/NEJMra1214243; Ozkok A, 2014, BIOMED RES INT, DOI 10.1155/2014/967826; Sharp CN, 2018, AM J PHYSIOL-RENAL, V315, pF161, DOI 10.1152/ajprenal.00636.2017; Sharp CN, 2017, AM J PHYSIOL-RENAL, V313, pF835, DOI 10.1152/ajprenal.00285.2017; Sharp CN, 2016, AM J PHYSIOL-RENAL, V310, pF560, DOI 10.1152/ajprenal.00512.2015; Tang JH, 2013, AM J PATHOL, V183, P160, DOI 10.1016/j.ajpath.2013.04.005	6	0	0	0	0	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0192-6233	1533-1601		TOXICOL PATHOL	Toxicol. Pathol.	DEC	2018	46	8			SI		1049	1050		10.1177/0192623318798342			2	Pathology; Toxicology	Pathology; Toxicology	HF3NN	WOS:000454141900022	30189778				2019-10-28	
J	Zhu, LL; Deng, HY; Hu, J; Huang, SS; Xiong, JP; Deng, J				Zhu, Lingling; Deng, Hanyu; Hu, Jia; Huang, Shanshan; Xiong, Jianping; Deng, Jun			The promising role of miR-296 in human cancer	PATHOLOGY RESEARCH AND PRACTICE			English	Review						MiR-296; Cancer; Target genes	CELL LUNG-CANCER; ENDOTHELIAL GROWTH-FACTOR; MICRORNA EXPRESSION; BREAST-CANCER; HEPATOCELLULAR-CARCINOMA; DIFFERENTIAL EXPRESSION; GENE-EXPRESSION; TUMOR INVASION; GASTRIC-CANCER; PROLIFERATION	MicroRNAs (MiRNAs) are small non-protein-coding RNA molecules that silence mRNA translation; they have emerged as key players in nearly all biological processes in the past few decades. In particular, miRNAs are involved in carcinogenic processes, with either oncogenic or tumor suppressive roles in human cancers. The abnormal expression of miR-296 has important roles in various cellular processes inhuman malignancies, including cell proliferation, apoptosis, invasion, and epithelial-mesenchymal transition. Epigenetic mechanisms and upstream transcription factors are responsible for the regulation of miR-296 expression in cancer. In this review, we summarize and discuss the most recent findings regarding miR-296 in cancer, including its downstream targets, functional effects, underlying regulatory mechanisms, and therapeutic potentials.	[Zhu, Lingling; Deng, Hanyu; Hu, Jia] Sichuan Univ, West China Hosp, Lung Canc Ctr, Chengdu, Sichuan, Peoples R China; [Huang, Shanshan; Xiong, Jianping; Deng, Jun] Nanchang Univ, Affiliated Hosp 1, Dept Oncol, Nanchang, Jiangxi, Peoples R China	Xiong, JP; Deng, J (reprint author), Nanchang Univ, Affiliated Hosp 1, Dept Oncol, Nanchang, Jiangxi, Peoples R China.	junjungege@outlook.com; dengjun19871106@126.com			National Natural Science Foundation of ChinaNational Natural Science Foundation of China [81760432, 81572288, 81160281, 81441083, 81660405]; JiangXi Province Talent 555 Project [20152ACB20024]; National Natural Science Foundation of JiangXi Province [20151BBG70228]; JiangXi Province Postgraduate Special Innovation Fund [YC2016]; JiangXi Province General Project [20171BBG70121, 2017BBH80027]; Youth Scientific Funds-Youth Fund Project [20171BAB215041]; JiangXi Province Education Fund Project [700653002]; department of health of JiangXi Province Project [20181041]	This work was funded by the National Natural Science Foundation of China (grant numbers 81760432, 81572288, 81160281, 81441083, and 81660405), the JiangXi Province Talent 555 Project (grant number 20152ACB20024), the National Natural Science Foundation of JiangXi Province (grant number 20151BBG70228), the JiangXi Province Postgraduate Special Innovation Fund (grant number YC2016), the JiangXi Province General Project (grant number: 20171BBG70121 and 2017BBH80027), the Youth Scientific Funds-Youth Fund Project (grant number: 20171BAB215041), the JiangXi Province Education Fund Project (grant number: 700653002), and the department of health of JiangXi Province Project (grant number: 20181041).	Adlakha YK, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-33; Bai YF, 2013, EUR J CANCER, V49, P710, DOI 10.1016/j.ejca.2012.08.020; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; BECKER JC, 1991, J IMMUNOL, V147, P4398; Bouchie A, 2013, NAT BIOTECHNOL, V31, P577, DOI 10.1038/nbt0713-577; Brandao BB, 2017, REDOX BIOL, V12, P82, DOI 10.1016/j.redox.2017.01.020; Calin GA, 2006, NAT REV CANCER, V6, P857, DOI 10.1038/nrc1997; Carmeliet P, 2009, NAT REV CLIN ONCOL, V6, P315, DOI 10.1038/nrclinonc.2009.64; Chen Z, 2013, J CLIN INVEST, V123, P1057, DOI 10.1172/JCI65344; Chi JD, 2017, ONCOL LETT, V14, P7153, DOI 10.3892/ol.2017.7146; Cho WCS, 2010, INT J BIOCHEM CELL B, V42, P1273, DOI 10.1016/j.biocel.2009.12.014; Corbetta S, 2010, ENDOCR-RELAT CANCER, V17, P135, DOI 10.1677/ERC-09-0134; De Santa F, 2013, CURR PHARM DESIGN, V19, P745, DOI 10.2174/138161213804581846; Deng J, 2016, ONCOTARGET, V7, P10037, DOI 10.18632/oncotarget.7048; Deng J, 2014, BIOCHEM BIOPH RES CO, V443, P789, DOI 10.1016/j.bbrc.2013.11.064; Deng XJ, 2018, MOL THER, V26, P1066, DOI 10.1016/j.ymthe.2018.01.023; Dinami R, 2017, ONCOTARGET, V8, P95674, DOI 10.18632/oncotarget.21680; Dong F., 2017, ONCOTARGET; Feng J, 2015, MOL MED REP, V12, P8141, DOI 10.3892/mmr.2015.4436; Fu QF, 2017, CLIN CANCER RES, V23, P6336, DOI 10.1158/1078-0432.CCR-16-2813; Gerhardt H, 2003, J CELL BIOL, V161, P1163, DOI 10.1083/jcb.200302047; Guo CC, 2016, EUR UROL, V70, P611, DOI 10.1016/j.eururo.2016.02.056; Guo L, 2009, PHOTOCHEM PHOTOBIOL, V85, P765, DOI 10.1111/j.1751-1097.2008.00482.x; He Z, 2017, BMC CANCER, V17, DOI 10.1186/s12885-017-3121-z; Hermeking H, 2007, CANCER CELL, V12, P414, DOI 10.1016/j.ccr.2007.10.028; Ho JJD, 2012, J BIOL CHEM, V287, P29003, DOI 10.1074/jbc.M112.373365; Hong L, 2010, ANN SURG, V251, P1056, DOI 10.1097/SLA.0b013e3181dd4ea9; Huang N, 2012, FEBS LETT, V586, P884, DOI 10.1016/j.febslet.2012.02.017; Huang ZB, 2017, CANCER MED-US, V6, P109, DOI 10.1002/cam4.973; Iorio MV, 2012, CANCER J, V18, P215, DOI 10.1097/PPO.0b013e318250c001; Jafri M. A., 2017, SEMIN CANC BIOL; Janssen HLA, 2013, NEW ENGL J MED, V368, P1685, DOI 10.1056/NEJMoa1209026; Jiang J, 2008, CLIN CANCER RES, V14, P419, DOI 10.1158/1078-0432.CCR-07-0523; Gonzalez-Duarte RJ, 2015, BIOCHEM CELL BIOL, V93, P376, DOI 10.1139/bcb-2015-0010; Kakizaki T, 2017, ONCOL LETT, V14, P987, DOI 10.3892/ol.2017.6193; Karsy Michael, 2012, Genes Cancer, V3, P3, DOI 10.1177/1947601912448068; Kavitha N, 2014, ASIAN PAC J CANCER P, V15, P7489, DOI 10.7314/APJCP.2014.15.18.7489; Ko MA, 2012, ANN THORAC SURG, V94, P1094, DOI 10.1016/j.athoracsur.2012.04.145; Kushibiki T, 2010, J BIOPHOTONICS, V3, P368, DOI 10.1002/jbio.200900082; Kutanzi KR, 2011, CLIN EPIGENETICS, V2, P171, DOI 10.1007/s13148-011-0040-8; Kwekel JC, 2015, BIOL SEX DIFFER, V6, DOI 10.1186/s13293-014-0019-1; Langenkamp E, 2012, ANTI-CANCER DRUG, V23, P161, DOI 10.1097/CAD.0b013e32834dc279; Lee H., 2016, MOL CELLS; Lee H, 2016, BBA-GENE REGUL MECH, V1859, P599, DOI 10.1016/j.bbagrm.2016.02.010; Lee KH, 2014, BBA-MOL CELL RES, V1843, P2055, DOI 10.1016/j.bbamcr.2014.06.001; Li HL, 2017, MOL MED REP, V16, P466, DOI 10.3892/mmr.2017.6602; Li H, 2018, MOL MED, V24, DOI 10.1186/s10020-018-0012-y; Li PL, 2017, MOL THER-NUCL ACIDS, V8, P356, DOI 10.1016/j.omtn.2017.07.007; Li T, 2014, ONCOGENE, V33, P783, DOI 10.1038/onc.2012.637; Liu X, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.458; Liu Xiao-Si, 2018, Zhongguo Shi Yan Xue Ye Xue Za Zhi, V26, P437, DOI 10.7534/j.issn.1009-2137.2018.02.022; Lopez-Bertoni H, 2016, ONCOGENE, V35, P4903, DOI 10.1038/onc.2016.22; Lopez-Bertoni H, 2018, NANO LETT, V18, P4086, DOI 10.1021/acs.nanolett.8b00390; Lujambio A, 2007, CANCER RES, V67, P1424, DOI 10.1158/0008-5472.CAN-06-4218; Luo W, 2016, AM J TRANSL RES, V8, P1848; Lv CY, 2014, WORLD J GASTROENTERO, V20, P4428, DOI 10.3748/wjg.v20.i15.4428; Lv LL, 2018, ONCOL RES, V26, P775, DOI 10.3727/096504017X15132494420120; Ma SH, 2018, GENE DEV, V32, P737, DOI 10.1101/gad.316570.118; Maia D, 2015, J TRANSL MED, V13, DOI 10.1186/s12967-015-0621-y; Mao JY, 2010, INT J BIOCHEM CELL B, V42, P1536, DOI 10.1016/j.biocel.2010.06.006; Mei L. L., 2017, CANC BIOMARK; Meltzer PS, 2005, NATURE, V435, P745, DOI 10.1038/435745a; Motawi TK, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0137706; Mulrane L, 2013, CANCER RES, V73, P6554, DOI 10.1158/0008-5472.CAN-13-1841; Onyeagucha B, 2017, ONCOTARGET, V8, P85984, DOI 10.18632/oncotarget.20841; Paggetti J, 2015, BLOOD, V126, P1106, DOI 10.1182/blood-2014-12-618025; Peng W., 2018, CANC MED; Rupaimoole R, 2017, NAT REV DRUG DISCOV; Rupaimoole R, 2017, NAT REV DRUG DISCOV, V16, P203, DOI [10.1038/nrd.2016246, 10.1038/nrd.2016.246]; Rupaimoole R, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6202; Savi F, 2014, CLIN SCI, V127, P233, DOI 10.1042/CS20130580; Sebastiani G, 2017, J ENDOCRINOL INVEST, V40, P591, DOI 10.1007/s40618-017-0611-4; Severino P, 2015, BMC MED GENOMICS, V8, DOI 10.1186/s12920-015-0102-4; Shah MY, 2011, J CELL PHYSIOL, V226, P1868, DOI 10.1002/jcp.22517; Shen J, 2013, NATURE, V497, P383, DOI 10.1038/nature12080; Shivapurkar N, 2013, INT J COLORECTAL DIS, V28, P887, DOI 10.1007/s00384-012-1560-1; Siekmann AF, 2007, NATURE, V445, P781, DOI 10.1038/nature05577; Su YH, 2015, BBA-MOL CELL RES, V1853, P2261, DOI 10.1016/j.bbamcr.2015.05.012; Sun CC, 2017, MOL THER-NUCL ACIDS, V9, P100, DOI 10.1016/j.omtn.2017.08.015; Sun CC, 2016, MOL THER-NUCL ACIDS, V5, DOI 10.1038/mtna.2016.96; Sun CC, 2016, AGING-US, V8, P2509, DOI 10.18632/aging.101080; Sun CC, 2016, ONCOTARGET, V7, P51784, DOI 10.18632/oncotarget.10108; Sun CC, 2016, BIOCHEM BIOPH RES CO, V471, P82, DOI 10.1016/j.bbrc.2016.01.175; Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024; Tang XQ, 2007, RNA, V13, P1803, DOI 10.1261/rna.498607; Tang XQ, 2009, RNA, V15, P287, DOI 10.1261/rna.1211209; Toledo F, 2009, NATURE, V460, P466, DOI 10.1038/460466a; Tyagi N, 2016, J BIOMED NANOTECHNOL, V12, P28, DOI 10.1166/jbn.2016.2172; Vaira V, 2012, ONCOGENE, V31, P27, DOI 10.1038/onc.2011.209; Vaira V, 2013, CANCER RES, V73, P2695, DOI 10.1158/0008-5472.CAN-12-4232; van den Beucken T, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6203; van Jaarsveld MTM, 2014, MOL ONCOL, V8, P458, DOI 10.1016/j.molonc.2013.12.011; Verdelli C, 2015, J ENDOCRINOL INVEST, V38, P383, DOI 10.1007/s40618-014-0234-y; Wan LY, 2015, BIOCHEM BIOPH RES CO, V457, P125, DOI 10.1016/j.bbrc.2014.11.039; Wang LL, 2009, HUM REPROD, V24, P562, DOI 10.1093/humrep/den439; Wang LY, 2016, FEBS LETT, V590, P4252, DOI 10.1002/1873-3468.12442; Wang SS, 2009, CURR OPIN GENET DEV, V19, P205, DOI 10.1016/j.gde.2009.04.002; Wang XH, 2018, MOL CELL BIOCHEM, V445, P25, DOI 10.1007/s11010-017-3248-x; Wei JJ, 2011, CLIN CANCER RES, V17, P1297, DOI 10.1158/1078-0432.CCR-10-0993; Wei LM, 2015, ONCOL REP, V33, P615, DOI 10.3892/or.2014.3645; Wurdinger T, 2008, CANCER CELL, V14, P382, DOI 10.1016/j.ccr.2008.10.005; Xie CR, 2017, MOL THER-NUCL ACIDS, V9, P440, DOI 10.1016/j.omtn.2017.10.018; Xu C, 2016, ONCOL REP, V35, P497, DOI 10.3892/or.2015.4392; Yan W, 2016, AM J CANCER RES, V6, P260; Yan W, 2014, ONCOTARGET, V5, P12908, DOI 10.18632/oncotarget.2679; Yao YS, 2014, ONCOL LETT, V7, P541, DOI 10.3892/ol.2013.1697; Yates LA, 2013, CELL, V153, P516, DOI 10.1016/j.cell.2013.04.003; Yoon A, 2011, NUCLEIC ACIDS RES, V39, P8078, DOI 10.1093/nar/gkr492; Zhang Ying-Hui, 2016, Zhongguo Dang Dai Er Ke Za Zhi, V18, P1302; Zhang YJ, 2012, ONCOL REP, V27, P685, DOI 10.3892/or.2011.1561; Zhang ZW, 2018, GENE, V650, P60, DOI 10.1016/j.gene.2018.01.096; Zhao TS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043399; Zheng J, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-141	113	0	0	1	4	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	DEC	2018	214	12					1915	1922		10.1016/j.prp.2018.09.026			8	Pathology	Pathology	HG0YQ	WOS:000454675600001	30293950				2019-10-28	
J	Zhang, ZJ; Qin, WJ; Sun, YL				Zhang, Zhenjun; Qin, Wenjie; Sun, Yuling			Contribution of biomarkers for pancreatic cancer -associated new-onset diabetes to pancreatic cancer screening	PATHOLOGY RESEARCH AND PRACTICE			English	Review						Pancreatic cancer associated new-onset diabetes; Pancreatic cancer; Biomarkers; Early screening	N-TERMINAL PEPTIDE; OSTEOPROTEGERIN LEVELS; CIRCULATING MICRORNAS; CELL-PROLIFERATION; SERUM; DIAGNOSIS; ADRENOMEDULLIN; THROMBOSPONDIN-1; MELLITUS; CARCINOMA	Background: Pancreatic cancer (PaC) is one of the deadliest types of tumor, and it is regarded as a fatal disease, with a 5-year survival rate less than 10%. Most clinical diagnoses for PaC are made at an advanced stage because of the insidious onset of the disease, which leads to an extremely poor prognosis. Recent findings: The relationship between diabetes mellitus (DM) and PaC has been established by several decades of research, and the prevalence of DM in patients with PaC has been reported to be 40%, with half of the patients having developed new-onset DM within 2 years or less. Increasing evidence suggests that new-onset DM is associated with a high prevalence of PaC, and PaC resection ameliorates DM. Therefore, screening for PaC may be needed in patients with newly developed DM. Purpose: The objective of this review was to present our current understanding of biomarkers for PaC-associated new-onset DM (PCAND), to offer a perspective on the prospects and problems of using this strategy for early screening to differentiate PCAND from new-onset type 2 DM not associated with PaC and to suggest candidate biomarkers to use for PaC screening in patients with new-onset DM. Finding sensitive and specific biomarkers to manage these patients constitutes a challenge for the research community and for public health policies.	[Zhang, Zhenjun; Qin, Wenjie; Sun, Yuling] Zhengzhou Univ, Affiliated Hosp 1, Dept Hepatobiliary & Pancreat Surg, Inst Hepatobiliary & Pancreat Dis,Sch Med, 1 Jianshe Rd, Zhengzhou 450052, Henan, Peoples R China	Sun, YL (reprint author), Zhengzhou Univ, Affiliated Hosp 1, Dept Hepatobiliary & Pancreat Surg, Inst Hepatobiliary & Pancreat Dis,Sch Med, 1 Jianshe Rd, Zhengzhou 450052, Henan, Peoples R China.	ylsun@zzu.edu.cn					Aggarwal G, 2012, GASTROENTEROLOGY, V143, P1510, DOI 10.1053/j.gastro.2012.08.044; AurrandLions M, 1996, IMMUNITY, V5, P391, DOI 10.1016/S1074-7613(00)80496-3; Basso D, 2006, CLIN CHIM ACTA, V372, P120, DOI 10.1016/j.cca.2006.03.027; Basso D, 2011, J CELL PHYSIOL, V226, P456, DOI 10.1002/jcp.22355; Brand RE, 2011, CLIN CANCER RES, V17, P805, DOI 10.1158/1078-0432.CCR-10-0248; Callery MP, 2009, ANN SURG ONCOL, V16, P1727, DOI 10.1245/s10434-009-0408-6; CERSOSIMO E, 1991, CANCER, V67, P486, DOI 10.1002/1097-0142(19910115)67:2<486::AID-CNCR2820670228>3.0.CO;2-1; Chari ST, 2005, GASTROENTEROLOGY, V129, P504, DOI 10.1053/j.gastro.2005.05.007; Chari ST, 2001, GASTROENTEROLOGY, V121, P640, DOI 10.1053/gast.2001.27210; Chen X, 2008, CELL RES, V18, P997, DOI 10.1038/cr.2008.282; Dabritz J, 2005, BRIT J CANCER, V92, P405, DOI 10.1038/sj.bjc.6602319; Dai X, 2016, J DIABETES, V8, P422, DOI 10.1111/1753-0407.12313; Duffy MJ, 2010, ANN ONCOL, V21, P441, DOI 10.1093/annonc/mdp332; Evans JL, 2002, ENDOCR REV, V23, P599, DOI 10.1210/er.2001-0039; Firpo MA, 2009, WORLD J SURG, V33, P716, DOI 10.1007/s00268-008-9853-9; FOGAR P, 1994, ANTICANCER RES, V14, P2827; Gebhardt C, 2006, BIOCHEM PHARMACOL, V72, P1622, DOI 10.1016/j.bcp.2006.05.017; GREEN RC, 1958, DIABETES, V7, P308, DOI 10.2337/diab.7.4.308; Guo QQ, 2010, J CANCER RES CLIN, V136, P1627, DOI 10.1007/s00432-010-0820-0; Hinson JP, 2000, ENDOCR REV, V21, P138, DOI 10.1210/er.21.2.138; Javeed N, 2015, CLIN CANCER RES, V21, P1722, DOI 10.1158/1078-0432.CCR-14-2022; Jenkinson C, 2016, CLIN CANCER RES, V22, P1734, DOI 10.1158/1078-0432.CCR-15-0879; Jimeno A, 2006, MOL CANCER THER, V5, P787, DOI 10.1158/1535-7163.MCT-06-0005; Kang MX, 2016, CANCER LETT, V373, P241, DOI 10.1016/j.canlet.2015.12.031; Keleg S, 2007, INT J CANCER, V121, P21, DOI 10.1002/ijc.22596; Kim JE, 2004, J GASTROEN HEPATOL, V19, P182, DOI 10.1111/j.1440-1746.2004.03219.x; KITAMURA K, 1993, BIOCHEM BIOPH RES CO, V192, P553, DOI 10.1006/bbrc.1993.1451; Kolb A., 2014, CANCER BIOL THER, V8, P1527; Korc M, 2015, CLIN CANCER RES, V21, P1508, DOI 10.1158/1078-0432.CCR-14-2990; Krejs GJ, 2010, DIGEST DIS, V28, P355, DOI 10.1159/000319414; LAWLER JW, 1978, J BIOL CHEM, V253, P8609; Lawrie CH, 2008, BRIT J HAEMATOL, V141, P672, DOI 10.1111/j.1365-2141.2008.07077.x; Lipton A, 2002, CLIN CANCER RES, V8, P2306; Liu R, 2012, CLIN CHEM, V58, P610, DOI 10.1373/clinchem.2011.172767; Maithel SK, 2008, ANN SURG ONCOL, V15, P3512, DOI 10.1245/s10434-008-0134-5; Malyankar UM, 2000, J BIOL CHEM, V275, P20959, DOI 10.1074/jbc.C000290200; Martin F, 2001, IMMUNOGENETICS, V53, P296, DOI 10.1007/s002510100327; Mitchell PS, 2008, P NATL ACAD SCI USA, V105, P10513, DOI 10.1073/pnas.0804549105; Miyata Y, 2013, INT J MOL SCI, V14, P12249, DOI 10.3390/ijms140612249; Ng EKO, 2009, GUT, V58, P1375, DOI 10.1136/gut.2008.167817; Olerud J, 2011, DIABETES, V60, P1946, DOI 10.2337/db10-0277; Pannala R, 2009, LANCET ONCOL, V10, P88, DOI 10.1016/S1470-2045(08)70337-1; PERMERT J, 1993, BRIT J SURG, V80, P1047, DOI 10.1002/bjs.1800800841; PERMERT J, 1993, EUR J SURG, V159, P101; Raghow R, 2013, WORLD J DIABETES, V4, P234, DOI 10.4239/wjd.v4.i6.234; Ramachandran V, 2007, CANCER RES, V67, P2666, DOI 10.1158/0008-5472.CAN-06-3362; Rasmussen LM, 2006, EUR J ENDOCRINOL, V154, P75, DOI 10.1530/eje.1.02049; Sagar G, 2016, GUT, V65, P1165, DOI 10.1136/gutjnl-2014-308350; Sah RP, 2013, NAT REV GASTRO HEPAT, V10, P423, DOI 10.1038/nrgastro.2013.49; Secchiero P, 2006, AM J PATHOL, V169, P2236, DOI 10.2353/ajpath.2006.060398; Shi WC, 2014, BIOSCI TRENDS, V8, P322, DOI 10.5582/bst.2014.01092; Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387; Stathis A, 2010, NAT REV CLIN ONCOL, V7, P163, DOI 10.1038/nrclinonc.2009.236; Sun ZL, 2007, BBA-PROTEINS PROTEOM, V1774, P764, DOI 10.1016/j.bbapap.2007.04.001; Susanto H, 2016, ONCOTARGET, V7, P42330, DOI 10.18632/oncotarget.9815; Takeda K, 2002, J EXP MED, V195, P161, DOI 10.1084/jem.20011171; Tan KS, 2012, J CLIN INVEST, V122, P2289, DOI 10.1172/JCI57817; Toffoli B, 2011, MOL CELL ENDOCRINOL, V331, P136, DOI 10.1016/j.mce.2010.08.019; Varma V, 2008, DIABETES, V57, P432, DOI 10.2337/db07-0840; Wang K, 2009, P NATL ACAD SCI USA, V106, P4402, DOI 10.1073/pnas.0813371106; Yi P, 2013, CELL, V153, P747, DOI 10.1016/j.cell.2013.04.008	61	1	1	3	8	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	DEC	2018	214	12					1923	1928		10.1016/j.prp.2018.10.003			6	Pathology	Pathology	HG0YQ	WOS:000454675600002	30477640				2019-10-28	
J	Liu, W; Pan, HF; Wang, Q; Zhao, ZM				Liu, Wei; Pan, Hua-feng; Wang, Qi; Zhao, Zi-ming			The application of transgenic and gene knockout mice in the study of gastric precancerous lesions	PATHOLOGY RESEARCH AND PRACTICE			English	Review						Mouse model; Review; Intestinal metaplasia; Gastric dysplasia; Gastric cancer; Helicobacter pylori	METHYL-N-NITROSOUREA; POLYPEPTIDE-EXPRESSING METAPLASIA; HELICOBACTER-PYLORI INFECTION; INTESTINAL METAPLASIA; STEM-CELLS; OXYNTIC ATROPHY; PARIETAL-CELLS; CHIEF CELLS; GLANDULAR STOMACH; PROGENITOR CELLS	Gastric intestinal metaplasia is a precursor for gastric dysplasia, which is in turn, a risk factor for gastric adenocarcinoma. Gastric metaplasia and dysplasia are known as gastric precancerous lesions (GPLs), which are essential stages in the progression from normal gastric mucosa to gastric cancer (GC) or gastric adenocarcinoma. Genetically-engineered mice have become essential tools In various aspects of GC research, including mechanistic studies and drug discovery. Studies in mouse models have contributed significantly to our understanding of the pathogenesis and molecular mechanisms underlying GPLs and GC. With the development and improvement of gene transfer technology, investigators have created a variety of transgenic and gene knockout mouse models for GPLs, such as H/K-ATPase transgenic and knockout mutant mice and gastrin gene knockout mice. Combined with Helicobacter infection, and treatment with chemical carcinogens, these mice develop GPLs or GC and thus provide models for studying the molecular biology of GC, which may lead to the discovery and development of novel drugs. In this review, we discuss recent progress in the use of genetically-engineered mouse models for GPL research, with particular emphasis on the importance of examining the gastric mucosa at the histological level to investigate morphological changes of GPL and GC and associated protein and gene expression.	[Liu, Wei; Pan, Hua-feng] Guangzhou Univ Chinese Med, Inst Gastroenterol, Guangzhou 510006, Guangdong, Peoples R China; [Wang, Qi] Guangzhou Univ Chinese Med, Inst Clin Pharmacol, Guangzhou 510006, Guangdong, Peoples R China; [Zhao, Zi-ming] Guangdong Prov Engn Technol Res Inst TCM, Guangzhou 510095, Guangdong, Peoples R China	Liu, W (reprint author), Guangzhou Univ Chinese Med, Guangzhou 510405, Guangdong, Peoples R China.	gzzyydxliuwei@126.com			National Natural Science Foundation of ChinaNational Natural Science Foundation of China [81673946]; Natural Science Foundation of Guangdong Province ChinaNational Natural Science Foundation of Guangdong Province [2017A030313845]; High level university construction project of China [A1-AFD018171Z11034, A1-AFD018171Z11037]	This work was funded by grants from the National Natural Science Foundation of China (No.81673946); Project supported by the Natural Science Foundation of Guangdong Province China (No. 2017A030313845); High level university construction project of China (No. A1-AFD018171Z11034, No. A1-AFD018171Z11037).	Aida T, 2014, DEV GROWTH DIFFER, V56, P34, DOI 10.1111/dgd.12101; [Anonymous], 1994, IARC Monogr Eval Carcinog Risks Hum, V61, P1; Arnold K, 2011, CELL STEM CELL, V9, P317, DOI 10.1016/j.stem.2011.09.001; Arul GS, 2000, GUT, V47, P753, DOI 10.1136/gut.47.6.753; Arumugam A., 2012, STEROIDS, V77, P791; Barker N, 2010, CELL STEM CELL, V6, P25, DOI 10.1016/j.stem.2009.11.013; Bass AJ, 2014, NATURE, V513, P202, DOI 10.1038/nature13480; Biswas S, 2015, J PATHOL, V237, P135, DOI 10.1002/path.4563; Brembeck FH, 2003, CANCER RES, V63, P2005; Choi E, 2016, GASTROENTEROLOGY, V150, P918, DOI 10.1053/j.gastro.2015.11.049; Cobb S, 2004, CANCER-AM CANCER SOC, V100, P1311, DOI 10.1002/cncr.20094; CORREA P, 1992, CANCER RES, V52, P6735; Crabtree JE, 2004, J PATHOL, V202, P197, DOI 10.1002/path.1498; Davis PA, 2001, CRIT REV ONCOL HEMAT, V40, P77, DOI 10.1016/S1040-8428(00)00131-1; de Vries AC, 2007, HELICOBACTER, V12, P1; de Vries AC, 2008, GASTROENTEROLOGY, V134, P945, DOI 10.1053/j.gastro.2008.01.071; Deng NT, 2012, GUT, V61, P673, DOI 10.1136/gutjnl-2011-301839; DESMOND H, 1987, FEBS LETT, V210, P185, DOI 10.1016/0014-5793(87)81334-0; Dockray GJ, 2001, ANNU REV PHYSIOL, V63, P119, DOI 10.1146/annurev.physiol.63.1.119; Dong B, 2005, WORLD J GASTROENTERO, V11, P3595, DOI 10.3748/wjg.v11.i23.3595; Doyle A, 2012, TRANSGENIC RES, V21, P327, DOI 10.1007/s11248-011-9537-3; ECTORS N, 1986, HISTOPATHOLOGY, V10, P1271, DOI 10.1111/j.1365-2559.1986.tb02570.x; Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210; FILIPE MI, 1994, INT J CANCER, V57, P324, DOI 10.1002/ijc.2910570306; Fox JG, 2007, AM J PATHOL, V171, P1520, DOI 10.2353/ajpath.2007.070249; Fox JG, 2003, GASTROENTEROLOGY, V124, P1879, DOI 10.1016/S0016-5085(03)00406-2; Fox JG, 2003, CANCER RES, V63, P942; Fox JG, 2001, NEW ENGL J MED, V345, P829, DOI 10.1056/NEJM200109133451111; Frame S, 2000, CURR OPIN GENET DEV, V10, P106, DOI 10.1016/S0959-437X(99)00052-0; Franic TV, 2001, AM J PHYSIOL-GASTR L, V281, pG1502; Furuta T, 2004, J GASTROENTEROL, V39, P501, DOI 10.1007/s00535-004-1353-6; Giroux V, 2017, NAT REV CANCER, V17, P594, DOI 10.1038/nrc.2017.68; Goldenring JR, 2000, GASTROENTEROLOGY, V118, P1080, DOI 10.1016/S0016-5085(00)70361-1; Gut MO, 2002, GASTROENTEROLOGY, V123, P1889, DOI 10.1053/gast.2002.37052; Halldorsdottir AM, 2003, DIGEST DIS SCI, V48, P431, DOI 10.1023/A:1022564027468; Hamilton SR, 2000, WHO CLASSIFICATION T, V2; Han SU, 2002, J GASTROEN HEPATOL, V17, P253, DOI 10.1046/j.1440-1746.2002.02684.x; Hayakawa Y, 2017, CELL MOL GASTROENTER, V4, P89, DOI 10.1016/j.jcmgh.2017.02.009; Hayakawa Y, 2015, CANCER CELL, V28, P800, DOI 10.1016/j.ccell.2015.10.003; Hayakawa Y, 2015, GUT, V64, P544, DOI 10.1136/gutjnl-2014-307190; Hayakawa Yoku, 2013, Cancers (Basel), V5, P92, DOI 10.3390/cancers5010092; Hayakawa Y, 2011, P NATL ACAD SCI USA, V108, P780, DOI 10.1073/pnas.1011418108; HEILMANN KL, 1979, PATHOL RES PRACT, V164, P249, DOI 10.1016/S0344-0338(79)80047-3; HISAMICHI S, 1988, CANCER DETECT PREV, V11, P323; Hryniuk A, 2014, J BIOL CHEM, V289, P33343, DOI 10.1074/jbc.M114.583823; Huh WJ, 2012, GASTROENTEROLOGY, V142, P21, DOI 10.1053/j.gastro.2011.09.050; Humar B, 2009, CANCER RES, V69, P2050, DOI 10.1158/0008-5472.CAN-08-2457; Ito K, 2011, GASTROENTEROLOGY, V140, P1536, DOI 10.1053/j.gastro.2011.01.043; Jin GC, 2013, GASTROENTEROLOGY, V145, P820, DOI 10.1053/j.gastro.2013.07.034; Judd LM, 2005, J GASTROEN HEPATOL, V20, P1266, DOI 10.1111/j.1440-1746.2005.03867.x; Kapadia CR, 2003, J CLIN GASTROENTEROL, V36, pS29, DOI 10.1097/00004836-200305001-00006; KARAM SM, 1993, ANAT REC, V236, P259, DOI 10.1002/ar.1092360202; Karam SM, 1998, BRAZ J MED BIOL RES, V31, P271, DOI 10.1590/S0100-879X1998000200010; Kinoshita H., 2018, AM J PHYSIOL-GASTR L, P314; Kinoshita H., 2018, J PATHOL; Kinoshita H, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18102063; Koh TJ, 1997, GASTROENTEROLOGY, V113, P1015, DOI 10.1016/S0016-5085(97)70199-9; KOPIN AS, 1992, P NATL ACAD SCI USA, V89, P3605, DOI 10.1073/pnas.89.8.3605; Langhans N, 1997, GASTROENTEROLOGY, V112, P280, DOI 10.1016/S0016-5085(97)90000-7; LAUREN P, 1965, ACTA PATHOL MIC SC, V64, P31, DOI 10.1111/apm.1965.64.1.31; Lee CW, 2008, CANCER RES, V68, P3540, DOI 10.1158/0008-5472.CAN-07-6786; Lee Y., 2016, ONCOTARGET, V8; Leeson C., 1985, TXB HISTOLOGY, P597; Leung WK, 2008, CARCINOGENESIS, V29, P1648, DOI 10.1093/carcin/bgn156; Leushacke M., 2017, NAT CELL BIOL, P19; Leushacke M, 2017, NAT CELL BIOL, V19, P774, DOI 10.1038/ncb3541; Leushacke M, 2013, CELL REP, V5, P349, DOI 10.1016/j.celrep.2013.09.025; Li Q, 2012, GASTROENTEROLOGY, V142, P531, DOI 10.1053/j.gastro.2011.11.034; Li QT, 1996, J BIOL CHEM, V271, P3671; LI QT, 1995, J BIOL CHEM, V270, P15777, DOI 10.1074/jbc.270.26.15777; Li XN, 2014, NAT MED, V20, P769, DOI 10.1038/nm.3585; Lofgren JL, 2011, GASTROENTEROLOGY, V140, P210, DOI 10.1053/j.gastro.2010.09.048; LUETTEKE NC, 1994, GENE DEV, V8, P399, DOI 10.1101/gad.8.4.399; Luo GF, 2017, INT J CANCER, V141, P1333, DOI 10.1002/ijc.30835; Matsuo J, 2017, GASTROENTEROLOGY, V152, P218, DOI 10.1053/j.gastro.2016.09.018; Mills JC, 2017, CELL MOL GASTROENTER, V4, P85, DOI 10.1016/j.jcmgh.2017.03.006; Mills JC, 2011, GASTROENTEROLOGY, V140, P412, DOI 10.1053/j.gastro.2010.12.001; Mutoh H, 2004, CANCER RES, V64, P7740, DOI 10.1158/0008-5472.CAN-04-1617; Mutoh H, 2004, GUT, V53, P1416, DOI 10.1136/gut.2003.032482; Mutoh H, 2002, BIOCHEM BIOPH RES CO, V294, P470, DOI 10.1016/S0006-291X(02)00480-1; Nagata A, 1996, P NATL ACAD SCI USA, V93, P11825, DOI 10.1073/pnas.93.21.11825; Nakajima T, 2002, AM J PHYSIOL-GASTR L, V282, pG359, DOI 10.1152/ajpgi.00117.2001; Nam K. T., 2010, GASTROENTEROLOGY, V139, DOI [10.1053/j.gastro.2010.09.0052028-37.e9, DOI 10.1053/J.GASTRO.2010.09.0052028-37.E9]; Nam KT, 2007, GASTROENTEROLOGY, V132, P1804, DOI 10.1053/j.gastro.2007.03.040; Nam KT, 2010, GASTROENTEROLOGY, V139, P2028, DOI 10.1053/j.gastro.2010.09.005; Nomura S, 2005, AM J PHYSIOL-GASTR L, V288, pG362, DOI 10.1152/ajpgi.00160.2004; Nomura S, 2005, GASTROENTEROLOGY, V128, P1292, DOI 10.1053/j.gastro.2005.03.019; Nomura S, 2004, GASTROENTEROLOGY, V127, P582, DOI 10.1053/j.gastro.2004.05.029; Nozaki K, 2008, GASTROENTEROLOGY, V134, P511, DOI 10.1053/j.gastro.2007.11.058; Ogawa M, 2006, AM J PHYSIOL-GASTR L, V290, pG793, DOI 10.1152/ajpgi.00309.2005; Okumura T, 2010, CANCER RES, V70, P8435, DOI 10.1158/0008-5472.CAN-10-1506; Palli D, 2005, AM J GASTROENTEROL, V100, P1941, DOI 10.1111/j.1572-0241.2005.50084.x; PEMBERTON L, 1992, BIOCHEM BIOPH RES CO, V185, P167, DOI 10.1016/S0006-291X(05)80971-4; Perez GIP, 2005, CANCER EPIDEM BIOMAR, V14, P1869, DOI 10.1158/1055-9965.EPI-04-0889; Phesse TJ, 2017, NAT CELL BIOL, V19, P752, DOI 10.1038/ncb3567; Poh AR, 2016, J GASTROEN HEPATOL, V31, P1257, DOI 10.1111/jgh.13297; Radyk MD, 2018, GASTROENTEROLOGY, V154, P839, DOI 10.1053/j.gastro.2017.11.278; Ramanathan V, 2012, CANCER INVEST, V30, P275, DOI 10.3109/07357907.2012.657814; Ray K. C., 2017, PLOS ONE, V6; Reis CA, 1999, CANCER RES, V59, P1003; Rugge M, 2002, ALIMENT PHARM THERAP, V16, P1249, DOI 10.1046/j.1365-2036.2002.01301.x; Sakamoto K, 2010, GASTROENTEROLOGY, V139, P226, DOI 10.1053/j.gastro.2010.03.047; Sakitani K., 2017, ONCOTARGET, V8; Scarff KL, 1999, GASTROENTEROLOGY, V117, P605, DOI 10.1016/S0016-5085(99)70453-1; Schmidt PH, 1999, LAB INVEST, V79, P639; Schultheis PJ, 1998, J CLIN INVEST, V101, P1243, DOI 10.1172/JCI1249; Serizawa T, 2016, INFECT IMMUN, V84, P562, DOI 10.1128/IAI.01437-15; Sheh A, 2010, P NATL ACAD SCI USA, V107, P15217, DOI 10.1073/pnas.1009017107; Shibata W, 2008, CANCER RES, V68, P5031, DOI 10.1158/0008-5472.CAN-07-6332; Shimizu T, 2016, J PATHOL, V239, P399, DOI 10.1002/path.4735; Shiotani A, 2005, J GASTROENTEROL, V40, P337, DOI 10.1007/s00535-004-1549-9; Sigal M, 2017, NATURE, V548, P451, DOI 10.1038/nature23642; Silberg DG, 2002, GASTROENTEROLOGY, V122, P689, DOI 10.1053/gast.2002.31902; Singh P, 2000, GASTROENTEROLOGY, V119, P162, DOI 10.1053/gast.2000.8527; Spechler SJ, 2017, GASTROENTEROLOGY, V153, pE6, DOI 10.1053/j.gastro.2017.05.050; Spicer Z, 2000, J BIOL CHEM, V275, P21555, DOI 10.1074/jbc.M001558200; Stange DE, 2013, CELL, V155, P357, DOI 10.1016/j.cell.2013.09.008; Sun FJ, 2003, DIGEST DIS SCI, V48, P976, DOI 10.1023/A:1023068116934; Takaishi S, 2009, AM J PATHOL, V175, P365, DOI 10.2353/ajpath.2009.081165; Takasu S, 2008, CANCER SCI, V99, P2356, DOI 10.1111/j.1349-7006.2008.00983.x; TATEMATSU M, 1993, JPN J CANCER RES, V84, P1258, DOI 10.1111/j.1349-7006.1993.tb02831.x; TATEMATSU M, 1992, JPN J CANCER RES, V83, P915, DOI 10.1111/j.1349-7006.1992.tb01999.x; Teixeira A, 2002, J PATHOL, V197, P37, DOI 10.1002/path.1083; Tomita H, 2011, GASTROENTEROLOGY, V140, P879, DOI 10.1053/j.gastro.2010.11.037; Tu SP, 2011, CANCER RES, V71, P4247, DOI 10.1158/0008-5472.CAN-10-4009; Tu S, 2008, CANCER CELL, V14, P408, DOI 10.1016/j.ccr.2008.10.011; Wang BY, 2017, J MOL NEUROSCI, V63, P233, DOI 10.1007/s12031-017-0973-2; Wang TC, 1999, AM J PHYSIOL-GASTR L, V277, pG6, DOI 10.1152/ajpgi.1999.277.1.G6; WANG TC, 1992, YALE J BIOL MED, V65, P705; Wang TC, 1996, J CLIN INVEST, V98, P1918, DOI 10.1172/JCI118993; Wang TC, 2000, GASTROENTEROLOGY, V118, P36, DOI 10.1016/S0016-5085(00)70412-4; Wang XT, 2012, J EXP CLIN CANC RES, V31, DOI 10.1186/1756-9966-31-98; Waterston RH, 2002, NATURE, V420, P520, DOI 10.1038/nature01262; Wong WM, 1999, GASTROENTEROLOGY, V116, pA525; Yamachika T, 1998, JPN J CANCER RES, V89, P385, DOI 10.1111/j.1349-7006.1998.tb00575.x; Yamaguchi H, 2002, LAB INVEST, V82, P1045, DOI 10.1097/01.LAB.0000022225.45996.21; Yamamoto M, 2000, CARCINOGENESIS, V21, P1891, DOI 10.1093/carcin/21.10.1891; Yamamoto M, 2002, CANCER LETT, V179, P121, DOI 10.1016/S0304-3835(02)00013-7; Zavros Y, 2005, ONCOGENE, V24, P2354, DOI 10.1038/sj.onc.1208407	139	0	0	1	5	ELSEVIER GMBH	MUNICH	HACKERBRUCKE 6, 80335 MUNICH, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	DEC	2018	214	12					1929	1939		10.1016/j.prp.2018.10.022			11	Pathology	Pathology	HG0YQ	WOS:000454675600003	30477641				2019-10-28	
J	Helmo, FR; Etchebehere, RM; Bernardes, N; Meirelles, MF; Petrini, CG; Rocha, LP; Monteiro, MLGD; Guimaraes, CSD; Teixeira, VDA; dos Reis, MA; Machado, JR; Correa, RRM				Helmo, Fernanda Rodrigues; Etchebehere, Renata Margarida; Bernardes, Natalia; Meirelles, Maria Flavia; Petrini, Caetano Galvao; Rocha, Laura Penna; Goncalves dos Reis Monteiro, Maria Luiza; de Oliveira Guimaraes, Camila Souza; Antunes Teixeira, Vicente de Paula; dos Reis, Marlene Antonia; Machado, Juliana Reis; Miranda Correa, Rosana Rosa			Melatonin treatment in fetal and neonatal diseases	PATHOLOGY RESEARCH AND PRACTICE			English	Review						Melatonin; Oxidative stress; Fetal disease; Neonatal disease	EXTRACELLULAR-SUPEROXIDE DISMUTASE; OXIDATIVE MITOCHONDRIAL DAMAGE; DNA-DAMAGE; NECROTIZING ENTEROCOLITIS; INFLAMMATORY RESPONSE; ANTIOXIDANT ENZYMES; MATERNAL MELATONIN; CIRCADIAN-RHYTHMS; BIRTH-WEIGHT; ENDOTHELIAL DYSFUNCTION	This literature review aims to address the main scientific findings on oxidative stress activity in different gestational disorders, as well as the function and application of melatonin in the treatment of fetal and neonatal changes. Oxidative stress has been associated with the etiopathogenesis of recurrent miscarriages, preeclampsia, intrauterine growth restriction, and stillbirth. Both, the exacerbated consumption of the antioxidant enzymes superoxide dismutase, catalase and glutathione peroxidase, and the increased synthesis of reactive oxygen species, such as superoxide, peroxynitrite, and hydrogen peroxide, induce phospholipid peroxidation and endothelial dysfunction, impaired invasion and death of trophoblast cells, impaired decidualization, and remodeling of maternal spiral arteries. It has been postulated that melatonin induces specific biochemical responses that regulate cell proliferation in fetuses, and that its antioxidant action promotes bioavailability of nitric oxide and, thus, placental perfusion and also fetal nutrition and oxygenation. Therefore, the therapeutic action of melatonin has been the subject of major studies that aim to minimize or prevent different injuries affecting this pediatric age group, such as intrauterine growth restriction, encephalopathy, chronic lung diseases, retinopathy of prematurity Conclusion: the results antioxidant and indicate that melatonin is an important therapy for the clinical treatment of these diseases.	[Helmo, Fernanda Rodrigues; Bernardes, Natalia; Meirelles, Maria Flavia; Rocha, Laura Penna; Goncalves dos Reis Monteiro, Maria Luiza; Antunes Teixeira, Vicente de Paula; dos Reis, Marlene Antonia; Machado, Juliana Reis; Miranda Correa, Rosana Rosa] Univ Fed Triangulo Mineiro, Inst Biol & Nat Sci, Discipline Gen Pathol, Uberaba, MG, Brazil; [Etchebehere, Renata Margarida] Univ Fed Triangulo Mineiro, Clin Hosp, Surg Pathol Serv, Uberaba, MG, Brazil; [Petrini, Caetano Galvao] Univ Sao Paulo, Fac Med Ribeirao Preto, Ribeirao Preto, SP, Brazil; [de Oliveira Guimaraes, Camila Souza] Univ Fed Lavras, Discipline Gen Pathol, Dept Hlth Sci, Lavras, MG, Brazil	Correa, RRM (reprint author), Univ Fed Triangulo Mineiro, Disciplina Patol Geral, Inst Ciencias Biol & Nat, Rua Frei Paulino 30, BR-38025180 Uberaba, MG, Brazil.	rosana.correa@uftm.edu.br		Monteiro, Maria Luiza Goncalves dos Reis/0000-0002-7961-6996	Conselho Nacional de Desenvolvimento Cientifico e Tecnologic (CNPq)National Council for Scientific and Technological Development (CNPq); Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)CAPES; Fundacao de Amparo a Pesquisa do Estado de Minas Gerais (FAPEMIG)Minas Gerais State Research Foundation (FAPEMIG); Fundacao de Ensino e Pesquisa de Uberaba (FUNEPU)	We thank Conselho Nacional de Desenvolvimento Cientifico e Tecnologic (CNPq), Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES), Fundacao de Amparo a Pesquisa do Estado de Minas Gerais (FAPEMIG), and Fundacao de Ensino e Pesquisa de Uberaba (FUNEPU) for financial support.	Acuna-Castroviejo D., 2014, CELL MOL LIFE SCI; Al-Gubory KH, 2010, INT J BIOCHEM CELL B, V42, P1634, DOI 10.1016/j.biocel.2010.06.001; Alonso-Alconada D, 2013, INT J MOL SCI, V14, P9379, DOI 10.3390/ijms14059379; Amaral F. G., 2014, J NEUROENDOCRINOL; Anhe GF, 2004, J NEUROCHEM, V90, P559, DOI 10.1111/j.1471-4159.2004.02514.x; Bazavilvaso-Rodriguez MA, 2011, ARCH MED RES, V42, P195, DOI 10.1016/j.arcmed.2011.04.011; Auten RL, 2006, AM J PHYSIOL-LUNG C, V290, pL32, DOI 10.1152/ajplung.00133.2005; Aversa S, 2012, J MATERN-FETAL NEO M, V25, P207, DOI 10.3109/14767058.2011.573827; Baykan A, 2008, ANADOLU KARDIYOL DER, V8, P243; BECKERANDRE M, 1994, J BIOL CHEM, V269, P28531; Burton GJ, 2011, BEST PRACT RES CL OB, V25, P287, DOI 10.1016/j.bpobgyn.2010.10.016; Cai H, 2000, CIRC RES, V87, P840, DOI 10.1161/01.RES.87.10.840; Calvo JR, 2013, J PINEAL RES, V55, P103, DOI 10.1111/jpi.12075; Carloni S, 2008, J PINEAL RES, V44, P157, DOI 10.1111/j.1600-079X.2007.00503.x; Carrillo-Vico A, 2003, CELL MOL LIFE SCI, V60, P2272, DOI 10.1007/s00018-003-3207-4; Cekmez F, 2013, REGUL PEPTIDES, V184, P121, DOI 10.1016/j.regpep.2013.03.016; Cetinkaya M, 2011, NEONATOLOGY, V99, P302, DOI 10.1159/000320643; Chan KA, 2015, BIOL REPROD, V92, DOI 10.1095/biolreprod.114.124149; Chen YH, 2006, J PINEAL RES, V40, P40, DOI 10.1111/j.1600-079X.2005.00274.x; Chen YC, 2012, J FORMOS MED ASSOC, V111, P57, DOI 10.1016/j.jfma.2011.11.024; Chessex P, 2010, FREE RADICAL BIO MED, V49, P1380, DOI 10.1016/j.freeradbiomed.2010.07.018; Clerici G, 2012, J OBSTET GYNAECOL, V32, P124, DOI 10.3109/01443615.2011.637139; Clifford K, 1999, HUM REPROD, V14, P2727, DOI 10.1093/humrep/14.11.2727; Davis JM, 2010, SEMIN FETAL NEONAT M, V15, P191, DOI 10.1016/j.siny.2010.04.001; De Bont R, 2004, MUTAGENESIS, V19, P169, DOI 10.1093/mutage/geh025; Dennery PA, 2010, FREE RADICAL BIO MED, V49, P1147, DOI 10.1016/j.freeradbiomed.2010.07.011; Drury PP, 2014, J CEREBR BLOOD F MET, V34, P126, DOI 10.1038/jcbfm.2013.174; Dubocovich ML, 2005, ENDOCRINE, V27, P101, DOI 10.1385/ENDO:27:2:101; Esposito E, 2010, J PINEAL RES, V49, P321, DOI 10.1111/j.1600-079X.2010.00796.x; Fialova L, 2006, SCAND J CLIN LAB INV, V66, P121, DOI 10.1080/00365510500375230; FRANK L, 1987, J PEDIATR-US, V110, P9, DOI 10.1016/S0022-3476(87)80279-2; FRANK L, 1987, J PEDIATR-US, V110, P106, DOI 10.1016/S0022-3476(87)80300-1; Fujimaki A, 2011, PLACENTA, V32, P367, DOI 10.1016/j.placenta.2011.02.004; Fulia F, 2001, J PINEAL RES, V31, P343, DOI 10.1034/j.1600-079X.2001.310409.x; Furness DLF, 2011, J REPROD IMMUNOL, V89, P153, DOI 10.1016/j.jri.2011.02.004; Garcia JJ, 2014, J PINEAL RES, V56, P225, DOI 10.1111/jpi.12128; Ghulmiyyah LM, 2011, AM J OBSTET GYNECOL, V205, DOI 10.1016/j.ajog.2011.03.015; Ginsberg Y, 2012, J DEV ORIG HLTH DIS, V3, P358, DOI 10.1017/S204017441200027X; Gitto E, 2004, J PEDIATR SURG, V39, P184, DOI 10.1016/j.jpedsurg.2003.10.003; Gitto E, 2016, J PAEDIATR CHILD H, V52, P291, DOI 10.1111/jpc.13007; Gitto E, 2013, OXID MED CELL LONGEV, DOI 10.1155/2013/980374; Gitto E, 2012, J PINEAL RES, V52, P291, DOI 10.1111/j.1600-079X.2011.00941.x; Gitto E, 2011, J PINEAL RES, V50, P21, DOI 10.1111/j.1600-079X.2010.00814.x; Guerrero Juan M., 2002, Current Topics in Medicinal Chemistry, V2, P167, DOI 10.2174/1568026023394335; Guney M, 2011, BIOL TRACE ELEM RES, V143, P1091, DOI 10.1007/s12011-010-8951-3; Gupta S, 2007, OBSTET GYNECOL SURV, V62, P335, DOI 10.1097/01.ogx.0000261644.89300.df; Guven A, 2011, J PEDIATR SURG, V46, P2101, DOI 10.1016/j.jpedsurg.2011.06.040; Herrera E, 2014, CURR PHARM BIOTECHNO, V15, P24, DOI 10.2174/1389201015666140330192345; Hilali N, 2013, EUR J OBSTET GYN R B, V170, P377, DOI 10.1016/j.ejogrb.2013.07.031; Jarvie E, 2010, CLIN SCI, V119, P123, DOI 10.1042/CS20090640; Junovich G, 2013, AM J REPROD IMMUNOL, V70, P182, DOI 10.1111/aji.12132; Karacay O, 2010, DIABETES RES CLIN PR, V89, P231, DOI 10.1016/j.diabres.2010.04.015; Kaur C, 2013, J PINEAL RES, V54, P190, DOI 10.1111/jpi.12016; Kennaway DJ, 2000, SEMIN PERINATOL, V24, P258, DOI 10.1053/sper.2000.8594; Kvetnoy IM, 1999, HISTOCHEM J, V31, P1, DOI 10.1023/A:1003431122334; Kwak-Kim J, 2014, AM J REPROD IMMUNOL, V72, P129, DOI 10.1111/aji.12234; Lanoix D, 2008, J PINEAL RES, V45, P50, DOI 10.1111/j.1600-079X.2008.00555.x; Lanoix D, 2013, MOL CELL ENDOCRINOL, V381, P35, DOI 10.1016/j.mce.2013.07.010; Lanoix D, 2012, J PINEAL RES, V53, P417, DOI 10.1111/j.1600-079X.2012.01012.x; Lappas M, 2010, J ENDOCRINOL, V204, P75, DOI 10.1677/JOE-09-0321; Lemley CO, 2012, AM J PHYSIOL-REG I, V302, pR454, DOI 10.1152/ajpregu.00407.2011; LERNER AB, 1960, J BIOL CHEM, V235, P1992; Li HP, 2013, INT J CLIN EXP PATHO, V6, P650; Lima FB, 1998, AM J PHYSIOL-ENDOC M, V275, pE934; Longini M, 2007, CLIN BIOCHEM, V40, P793, DOI 10.1016/j.clinbiochem.2007.03.004; Macchi MM, 2004, FRONT NEUROENDOCRIN, V25, P177, DOI 10.1016/j.yfrne.2004.08.001; Malti N, 2014, PLACENTA, V35, P411, DOI 10.1016/j.placenta.2014.03.010; Gallardo JM, 2015, OBESITY, V23, P1650, DOI 10.1002/oby.21159; Marseglia L, 2016, REPROD SCI, V23, P970, DOI 10.1177/1933719115612132; Marseglia L, 2015, AM J PERINAT, V32, P905, DOI 10.1055/s-0035-1547328; Marseglia L, 2015, WOMEN BIRTH, V28, P81, DOI 10.1016/j.wombi.2014.12.007; Marseglia L, 2015, INT J MOL SCI, V16, P1209, DOI 10.3390/ijms16011209; Martinez-Cruz F, 2006, NEUROSCI LETT, V392, P1, DOI 10.1016/j.neulet.2005.02.073; MATALON S, 1990, BIOCHIM BIOPHYS ACTA, V1035, P121, DOI 10.1016/0304-4165(90)90105-6; Matsuzuka T, 2005, J PINEAL RES, V39, P217, DOI 10.1111/j.1600-079X.2005.00260.x; Menon R, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00567; Mert I, 2012, J OBSTET GYNAECOL RE, V38, P658, DOI 10.1111/j.1447-0756.2011.01771.x; Miller SL, 2005, DEV NEUROSCI-BASEL, V27, P200, DOI 10.1159/000085993; Mishra OP, 1999, BRAIN RES BULL, V48, P233, DOI 10.1016/S0361-9230(98)00170-1; Morris JM, 1998, BRIT J OBSTET GYNAEC, V105, P1195, DOI 10.1111/j.1471-0528.1998.tb09974.x; Murphy SR, 2013, AM J PHYSIOL-REG I, V304, pR130, DOI 10.1152/ajpregu.00069.2012; Nagai R, 2008, J PINEAL RES, V45, P271, DOI 10.1111/j.1600-079X.2008.00586.x; Nakamura Y, 2001, J PINEAL RES, V30, P29, DOI 10.1034/j.1600-079X.2001.300104.x; Naranjo MC, 2007, CELL MOL LIFE SCI, V64, P781, DOI 10.1007/s00018-007-6435-1; Negi R, 2012, J MATERN-FETAL NEO M, V25, P1338, DOI 10.3109/14767058.2011.633672; Negro S, 2017, J BIOL REG HOMEOS AG, V31, P221; Nogueira TC, 2011, ENDOCRINOLOGY, V152, P1253, DOI 10.1210/en.2010-1088; Nozik-Grayck E, 2000, AM J PHYSIOL-LUNG C, V279, pL977; Okatani Y, 2001, J PINEAL RES, V31, P173, DOI 10.1034/j.1600-079x.2001.310212.x; Ornoy A, 2015, BIRTH DEFECTS RES C, V105, P53, DOI 10.1002/bdrc.21090; Otto WR, 2002, J PATHOL, V197, P527, DOI 10.1002/path.1160; Olegario JGP, 2013, CLIN DEV IMMUNOL, DOI 10.1155/2013/340959; Pan L, 2009, WORLD J PEDIATR, V5, P216, DOI 10.1007/s12519-009-0041-2; Pandi-Perumal SR, 2008, PROG NEUROBIOL, V85, P335, DOI 10.1016/j.pneurobio.2008.04.001; Park Sang-Woo, 2012, Chonnam Med J, V48, P116, DOI 10.4068/cmj.2012.48.2.116; Pereira LHM, 2014, DIS MARKERS, DOI 10.1155/2014/252780; Perez MJ, 2007, J PINEAL RES, V43, P130, DOI 10.1111/j.1600-079X.2007.00453.x; Perrone S, 2012, J MATERN-FETAL NEO M, V25, P110, DOI 10.3109/14767058.2012.664344; Perrone S, 2010, J MATERN-FETAL NEO M, V23, P63, DOI 10.3109/14767058.2010.509940; Perrone S, 2010, EARLY HUM DEV, V86, P241, DOI 10.1016/j.earlhumdev.2010.03.008; Potdar N, 2009, BJOG-INT J OBSTET GY, V116, P637, DOI 10.1111/j.1471-0528.2008.02096.x; Redman CWG, 2003, PLACENTA, V24, pS21, DOI 10.1053/plac.2002.0930; Reiter RJ, 2014, HUM REPROD UPDATE, V20, P293, DOI 10.1093/humupd/dmt054; Revuelta M., 2015, BRAIN PATHOL; Richter HG, 2009, J PINEAL RES, V46, P357, DOI 10.1111/j.1600-079X.2009.00671.x; Rogerio F, 2002, BRAIN RES, V926, P33, DOI 10.1016/S0006-8993(01)03286-3; Saito S, 1999, CLIN EXP IMMUNOL, V117, P550; Saito S, 1999, AM J REPROD IMMUNOL, V41, P297; Sakata M, 2008, OBSTET GYNECOL SURV, V63, P651, DOI 10.1097/OGX.0b013e318181a79f; Sanchez-Aranguren LC, 2014, FRONT PHYSIOL, V5, DOI 10.3389/fphys.2014.00372; Sedelnikova OA, 2010, MUTAT RES-REV MUTAT, V704, P152, DOI 10.1016/j.mrrev.2009.12.005; Seron-Ferre M, 2001, SEMIN PERINATOL, V25, P363, DOI 10.1053/sper.2001.29037; Seron-Ferre M, 2012, MOL CELL ENDOCRINOL, V349, P68, DOI 10.1016/j.mce.2011.07.039; Seron-Ferre Maria, 2007, Birth Defects Research, V81, P204, DOI 10.1002/bdrc.20101; Shavali S, 2005, BRAIN RES BULL, V64, P471, DOI 10.1016/j.brainresbull.2004.09.008; Silvestri M, 2013, ITAL J PEDIATR, V39, DOI 10.1186/1824-7288-39-61; Singh M., 2014, DRUG DISCOV TODAY; Sisino G, 2013, BBA-MOL BASIS DIS, V1832, P1959, DOI 10.1016/j.bbadis.2013.07.009; Siu AW, 2006, J PINEAL RES, V40, P101, DOI 10.1111/j.1600-079X.2005.00304.x; Sivakumar V, 2011, J PATHOL, V224, P245, DOI 10.1002/path.2858; Slominski A, 2005, ENDOCRINE, V27, P137, DOI 10.1385/ENDO:27:2:137; Slominski A, 2007, MOL CELL ENDOCRINOL, V265, P143, DOI 10.1016/j.mce.2006.12.012; Slominski RM, 2012, MOL CELL ENDOCRINOL, V351, P152, DOI 10.1016/j.mce.2012.01.004; Smirnov AN, 2001, BIOCHEMISTRY-MOSCOW+, V66, P19, DOI 10.1023/A:1002821427018; Srivastava KK, 2015, INDIAN J CLIN BIOCHE, V30, P3, DOI 10.1007/s12291-014-0441-5; Stigger F, 2013, INT J DEV NEUROSCI, V31, P820, DOI 10.1016/j.ijdevneu.2013.10.003; Tain YL, 2014, J AM SOC HYPERTENS, V8, P216, DOI 10.1016/j.jash.2014.01.009; Tamura H, 2008, J PINEAL RES, V44, P335, DOI 10.1111/j.1600-079X.2007.00537.x; Tare M, 2014, J PHYSIOL-LONDON, V592, P2695, DOI 10.1113/jphysiol.2014.270934; Thakor AS, 2015, J PINEAL RES, V59, P80, DOI 10.1111/jpi.12242; Torres-Farfan C, 2006, ENDOCRINOLOGY, V147, P4618, DOI 10.1210/en.2006-0628; Tuckerman E, 2007, HUM REPROD, V22, P2208, DOI 10.1093/humrep/dem141; Tuckerman E, 2010, J REPROD IMMUNOL, V87, P60, DOI 10.1016/j.jri.2010.07.001; Tutunculer F, 2005, PEDIATR INT, V47, P434, DOI 10.1111/j.1442-200x.2005.02085.x; Vural H, 2001, J PINEAL RES, V31, P193, DOI 10.1034/j.1600-079X.2001.310301.x; Watanabe K, 2004, J PINEAL RES, V37, P276, DOI 10.1111/j.1600-079X.2004.00167.x; Welin AK, 2007, PEDIATR RES, V61, P153, DOI 10.1203/01.pdr.0000252546.20451.1a; Widmer M, 2007, OBSTET GYNECOL, V109, P168, DOI 10.1097/01.AOG.0000249609.04831.7c; Wilhelmsen M, 2011, J PINEAL RES, V51, P270, DOI 10.1111/j.1600-079X.2011.00895.x; Yang X, 2012, J MATERN-FETAL NEO M, V25, P884, DOI 10.3109/14767058.2011.601367; Yang Y, 2013, J PINEAL RES, V55, P275, DOI 10.1111/jpi.12070; Zanquetta MM, 2003, J PINEAL RES, V35, P141, DOI 10.1034/j.1600-079X.2003.00067.x; Zanuto R, 2013, J PINEAL RES, V55, P156, DOI 10.1111/jpi.12056; Zhao L, 2015, J PINEAL RES, V59, P230, DOI 10.1111/jpi.12254	144	1	1	3	6	ELSEVIER GMBH	MUNICH	HACKERBRUCKE 6, 80335 MUNICH, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	DEC	2018	214	12					1940	1951		10.1016/j.prp.2018.10.016			12	Pathology	Pathology	HG0YQ	WOS:000454675600004	30377024				2019-10-28	
J	Chen, DB; Shen, DH; Yang, SM; Fang, XZ				Chen, Ding-bao; Shen, Dan-hua; Yang, Shen-miao; Fang, Xin-zhi			Clinicopathological features of splenic tumours of lymphoid tissue	PATHOLOGY RESEARCH AND PRACTICE			English	Article						Splenic neoplasm; B cell lymphoma; Immunophenotype; Differential diagnosis	SPLEEN	Background: To study the effects of splenectomy on treatment and diagnosis of tumours of lymphoid tissue of the spleen. Methods: Fifty-three cases were reviewed from Peking University People's Hospital from 2002 to 2017. According to WHO classification of tumours of haematopoietic and lymphoid tissues (2008) and classification updated (2016), the cases were studied by microscopy, immunohistochemistry and in situ hybridization, combined with the bone marrow biopsy and clinical examination. Results: In 53 cases, the male to female ratio was 3.4:1, the mean age was 55.4 years old, the median survival time was 17.0 months, and all patients present with variable degree of splenomegaly. The elevated percentage of lymphocyte in peripheral blood can be seen in 22 cases, and elevated LDH level in 24 cases. Abnormal blood counts can be seen in 26 cases before operation, and 22 cases remission to normal level partly or completely after operation. The clinical symptoms included abdominal pain or distension, fatigue, fever, and weight loss, etc. Seventeen cases present with lymphoadenopathy of abdomen or other sites. Fourteen cases were stage I or II, whereas 6 were stage III, 28 were stage IV. Forty-three cases were splenic B-cell marginal zone lymphoma (SMZL)(48.8%,21/43), DLBCL(23.3%,10/43), splenic diffuse red pulp small B-cell lymphoma (SDRPSBL) (11.6%,5/43), mantle cell lymphoma (MCL)(9.3%,4/43), follicular lymphoma (FL)(4.7%,2/43), composite lymphoma (CL, DLBCL and classical Hodgkin lymphoma)(2.3%,1/43) in turn, and the remaining 10 cases were chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL) (n = 4), hairy cell leukaemia (HCL) (n = 1), hepatosplenic T-cell lymphoma (HSTL) (n = 5). The survival period of SMZL and DLBCL was 25.7, 18.6 months, respectively. Thirteen cases were dead (27.1%, 13/48). The chemotherapy protocol included Hyper-CVAD A/B with/without R (Rituximab), COP, CHOP with/without R etc. The prognosis of those with elevated LDH level, high clinical staging, B symptom, and older than 60 year old was obviously worse, and the prognosis of DLBCL was worse than that of SMZL. Conclusions: Most splenic lymphoid tumors present with splenomegaly and abnormal blood counts, and complete or part remission of blood counts can be seen after splenectomy, and splenectomy is also helpful for pathological diagnosis. The most common pathological types are SMZL and DLBCL. The definite diagnosis can be made by combining with clinical features, histopathology, immunophenotype, genetics, bone marrow biopsy and laboratory examination.	[Chen, Ding-bao; Shen, Dan-hua] Peking Univ, Peoples Hosp, Dept Pathol, Xizhimen South St 11, Beijing 100044, Peoples R China; [Yang, Shen-miao] Peking Univ, Peoples Hosp, Dept Hematol, Xizhimen South St 11, Beijing 100044, Peoples R China; [Fang, Xin-zhi] Xinjiang Med Univ, Canc Hosp, Dept Pathol, Suzhou St 789, Urumqi 830000, Peoples R China	Chen, DB (reprint author), Peking Univ, Peoples Hosp, Dept Pathol, Xizhimen South St 11, Beijing 100044, Peoples R China.	cdingbao@163.com			Xinjiang Uygur autonomous region Natural Science Foundation [2014211C107]	Supported by grants from the Xinjiang Uygur autonomous region Natural Science Foundation (2014211C107).	AHMANN DL, 1966, CANCER-AM CANCER SOC, V19, P461, DOI 10.1002/1097-0142(196604)19:4<461::AID-CNCR2820190402>3.0.CO;2-X; BROX A, 1991, AM J HEMATOL, V38, P95, DOI 10.1002/ajh.2830380205; [陈定宝 Chen Dingbao], 2010, [诊断病理学杂志, Chinese Journal of Diagnostic Pathology], V17, P405; [陈辉树 Chen Huishu], 2005, [中国肿瘤临床, Chinese Journal of Clinical Oncology], V32, P700; DASGUPTA T, 1965, SURG GYNECOL OBSTETR, V120, P947; Liu W, 2001, Zhonghua Bing Li Xue Za Zhi, V30, P93; Mollejo M, 2003, AM J SURG PATHOL, V27, P895, DOI 10.1097/00000478-200307000-00004; Ponzoni M, 2012, AM J SURG PATHOL, V36, P1609, DOI 10.1097/PAS.0b013e318271243d; Rosai J., 2011, ROSAI ACKERMANS SURG; Swerdlow SH, 2008, WHO CLASSIFICATION T, P285; Swerdlow SH, 2016, BLOOD, V127, P2375, DOI 10.1182/blood-2016-01-643569; Zhan Y. N., CHIN J PATHOL, V38	12	0	0	1	2	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	DEC	2018	214	12					1952	1958		10.1016/j.prp.2018.07.021			7	Pathology	Pathology	HG0YQ	WOS:000454675600005	30087035				2019-10-28	
J	Kang, YY; Liu, J; Zhang, Y; Sun, Y; Wang, JT; Huang, BY; Zhong, M				Kang, Yuanyuan; Liu, Jie; Zhang, Ying; Sun, Yan; Wang, Junting; Huang, Biying; Zhong, Ming			Upregulation of Periostin expression in the pathogenesis of ameloblastoma	PATHOLOGY RESEARCH AND PRACTICE			English	Article						Ameloblastoma; Periostin; Proliferation; Migration; Biomarker	CANCER; GROWTH; CELLS	Ameloblastoma(AB) is an aggressive and slow-growing tumor with high recurrence rate, which arises from odontogenic epithelium. AB mostly shows osteolytic growth, but the specific pathogenesis is not yet clear. Periostin is a considered a prominent oncogene, which was mainly produced by osteoblasts and their precursors cells, it have been proved that Periostin play an important role in bone lysis. However, the precise role of Periostin in AB progression remains unknown. In this article, the surgical specimens from cases of AB were collected, and the Periostin expression was tested and the results were analyzed for possible correlations with clinical characteristics. In addition, the proliferation, cell cycle and migration of AM-1 cells were evaluated after transfection of siPeriostin. The results showed that Periostin levels were significantly higher in patients with AB than in controls. Moreover, Periostin levels in patients with AB were significantly associated with the number of disease. Furthermore, the results suggested that Periostin expression significantly promoted the proliferation and migration, in addition to cell cycle progression of AM-1 cells. The present study demonstrated that Periostin may be important in the pathogenesis and progression of AB and indicated its potential therapeutic value.	[Kang, Yuanyuan; Zhang, Ying; Sun, Yan] China Med Univ, Sch Stomatol, Dept Emergency & Oral Med, Shenyang, Liaoning, Peoples R China; [Liu, Jie] China Med Univ, Dept Cent Lab, Shenyang, Liaoning, Peoples R China; [Wang, Junting; Huang, Biying; Zhong, Ming] China Med Univ, Sch Stomatol, Dept Oral Histopathol, 117 North Nanjing St, Shenyang 110002, Liaoning, Peoples R China	Zhong, M (reprint author), China Med Univ, Sch Stomatol, Dept Oral Histopathol, 117 North Nanjing St, Shenyang 110002, Liaoning, Peoples R China.	mzhong@cmu.edu.cn			National Natural Science Foundation of ChinaNational Natural Science Foundation of China [81072197, 81470758]; Natural Science Foundation of Liaoning ProvinceNatural Science Foundation of Liaoning Province [20170541012]	AM-1 cell was supplied by the professor of Hidemitsu Harada (School of Dentistry, Iwate Medical University). And this study was supported by the National Natural Science Foundation of China (81072197 and 81470758) and the Natural Science Foundation of Liaoning Province (20170541012).	Abtahi MA, 2018, J CURR OPHTHALMOL, V30, P23, DOI 10.1016/j.joco.2017.09.001; Bachem MG, 2005, GASTROENTEROLOGY, V128, P907, DOI 10.1053/j.gastro.2004.12.036; Bao SD, 2004, CANCER CELL, V5, P329, DOI 10.1016/S1535-6108(04)00081-9; Baril P, 2007, ONCOGENE, V26, P2082, DOI 10.1038/sj.onc.1210009; Chau E, 2013, OR SURG OR MED OR PA, V116, P214, DOI 10.1016/j.oooo.2013.05.008; Dong Li, 2016, PROG MODERN BIOMED, V16, P1562; Elliott CG, 2012, J CELL SCI, V125, P121, DOI 10.1242/jcs.087841; Erkan M, 2007, GASTROENTEROLOGY, V132, P1447, DOI 10.1053/j.gastro.2007.01.031; Fukushima N, 2008, MODERN PATHOL, V21, P1044, DOI 10.1038/modpathol.2008.77; Gonzalez-Gonzalez L, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00225; Kikuchi Y, 2014, AM J PATHOL, V184, P859, DOI 10.1016/j.ajpath.2013.11.012; Kim GE, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0187635; Kotobuki Y, 2014, PIGM CELL MELANOMA R, V27, DOI 10.1111/pcmr.12245; Kudo A, 2011, CELL MOL LIFE SCI, V68, P3201, DOI 10.1007/s00018-011-0784-5; Kudo Y, 2006, CANCER RES, V66, P6928, DOI 10.1158/0008-5472.CAN-05-4540; Li ZW, 2015, INT J MOL SCI, V16, P12108, DOI 10.3390/ijms160612108; Liu Y, 2017, ONCOTARGET, V8, P89552, DOI 10.18632/oncotarget.11533; Masthan KMK, 2015, J PHARM BIOALLIED SC, V7, pS167, DOI 10.4103/0975-7406.155891; Murakami Daigo, 2018, Kurume Med J, V64, P13, DOI 10.2739/kurumemedj.MS640012; Nuzzo PV, 2014, CLIN GENITOURIN CANC, V12, P301, DOI 10.1016/j.clgc.2014.02.005; Oh HJ, 2017, J PATHOL TRANSL MED, V51, P306, DOI 10.4132/jptm.2017.01.19; Puppin C, 2008, J ENDOCRINOL, V197, P401, DOI 10.1677/JOE-07-0618; REICHART PA, 1995, ORAL ONCOL, V31B, P86; Ruan K, 2009, CELL MOL LIFE SCI, V66, P2219, DOI 10.1007/s00018-009-0013-7; Snider P, 2008, CIRC RES, V102, P752, DOI 10.1161/CIRCRESAHA.107.159517; Tingle Samuel J, 2015, World J Gastrointest Pathophysiol, V6, P235, DOI 10.4291/wjgp.v6.i4.235; Vonlaufen A, 2008, CANCER RES, V68, P2085, DOI 10.1158/0008-5472.CAN-07-2477; Zwahlen RA, 2002, J CRANIO MAXILL SURG, V30, P273, DOI 10.1054/jcms.2002.0317	28	1	1	0	1	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	DEC	2018	214	12					1959	1965		10.1016/j.prp.2018.08.028			7	Pathology	Pathology	HG0YQ	WOS:000454675600006	30196986				2019-10-28	
J	Meng, JL; Wang, S; Shen, XF; Bai, ZM; Niu, QS; Ma, DY; Xu, YC; Liang, CZ				Meng, Jialin; Wang, Shuo; Shen, Xufeng; Bai, Zhengming; Niu, Qingsong; Ma, Dongyue; Xu, Yuchen; Liang, Chaozhao			Polymorphism of MMP-9 gene is not associated with the risk of urinary cancers: Evidence from an updated meta-analysis	PATHOLOGY RESEARCH AND PRACTICE			English	Article						MMP-9; Polymorphism; Cancer; Meta-analysis	BLADDER-CANCER; MATRIX METALLOPROTEINASES; MMP-9 EXPRESSION; PROGRESSION; METASTASIS; INVASION	Objective: Matrix metalloproteinases 9 (MMP-9) is a zinc-dependent gelatinase, which could decrease the expression of extracellular matrix proteins and influence the metastatic behavior of tumors. In order to draw a comprehensive and precise result about the relationship of MMP-9 and urinary cancers, we presented the current meta-analysis. Methods: We searched the PubMed, EMbase, Web of Science, CBM, CNKI and Wanfang databases, the cited references were also manually searched again, covering all the papers published until August 2018. Quality assessment was conducted using the Newcastle-Ottawa Scale. All the meta-analysis was conducted with Stata version 12.0 software to assess the strength of the association. Linkage disequilibrium (LD) analyses of gene polymorphisms and in-silico analysis of MMP-9 expression were also conducted to illustrate the relationship. Results: 17 case-control studies comprise of more than 6154 cases and 6330 controls were enrolled and analyzed. After analyzed, we found that there is no significant association between rs3918241, rs2250889, rs17576 and rs17577 of MMP-9 and urinary cancers. LD analysis uncovered a significant LD between rs3918241 and rs17577 in CEU, CHB&CHS, ESN, and JPT populations (CEU: r(2) = 1.0; CHB&CHS: r(2) = 1.0; ESN: r(2) = 0.74; JPT: r(2) = 0.77), as well as a remarkable LD between rs17576 and rs2250889 in CHB&CHS and JPT populations (CHB &CHS: r(2) = 0.81; JPT: r(2) = 0.82). Furthermore, in-silico results indicated that the expression of MMP-9 in cancer tissue was higher than that in normal tissue in prostate cancer (Transcripts Per Kilobase Million (TPM) = 7.14 vs. 1.36, P < 0.001), bladder cancer (TPM = 14.2 vs. 2.47, P < 0.001), kidney renal clear cell carcinoma (TPM = 7.43 vs. 1.61, P < 0.001), kidney renal papillary cell carcinoma (TPM = 5.52 vs. 1.74, P = 0.002). Conclusions: rs3918241, rs2250889, rs17576 and rs17577 polymorphisms of MMP-9 are not associated with altered risk of urinary cancer. More studies with large sample size focused on the combined effect of two or more polymorphisms of MMP-9 are necessary in the future.	[Meng, Jialin; Shen, Xufeng; Bai, Zhengming; Xu, Yuchen; Liang, Chaozhao] Anhui Med Univ, Inst Urol, Affiliated Hosp 1, Dept Urol, Hefei, Anhui, Peoples R China; [Meng, Jialin; Shen, Xufeng; Bai, Zhengming; Xu, Yuchen; Liang, Chaozhao] Anhui Med Univ, Anhui Prov Key Lab Genitourinary Dis, Hefei, Anhui, Peoples R China; [Wang, Shuo] Anhui Med Univ, Clin Coll 2, Hefei, Anhui, Peoples R China; [Meng, Jialin; Shen, Xufeng; Bai, Zhengming; Niu, Qingsong; Ma, Dongyue; Xu, Yuchen; Liang, Chaozhao] Anhui Prov PKD Ctr, Hefei, Anhui, Peoples R China	Liang, CZ (reprint author), Anhui Med Univ, Inst Urol, Affiliated Hosp 1, Dept Urol,Anhui Prov Key Lab Genitourinary Dis, 218 Jixi Rd, Hefei 230022, Anhui, Peoples R China.	liang_chaozhao@ahmu.edu.cn	Meng, Jialin/L-8480-2019	Meng, Jialin/0000-0002-4622-833X	National Natural Science Foundation of ChinaNational Natural Science Foundation of China [81630019]; Anhui Provincial Natural Science FoundationNatural Science Foundation of Anhui Province [1408085QH180]	This manuscript was supported by National Natural Science Foundation of China (81630019 to C Liang) and Anhui Provincial Natural Science Foundation (No. 1408085QH180).	Aalinkeel R, 2011, IMMUNOL INVEST, V40, P447, DOI 10.3109/08820139.2011.557795; Awakura Y, 2006, CANCER LETT, V241, P59, DOI 10.1016/j.canlet.2005.10.005; BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446; Bhatt JR, 2014, NAT REV UROL, V11, P517, DOI [10.1038/nruro1.2014.194, 10.1038/nrurol.2014.194]; Bonferroni C. E., 1936, COMM FIRENZE, V1936, P216; Cambier S, 2016, EUR UROL, V69, P60, DOI 10.1016/j.eururo.2015.06.045; Angosto MC, 2010, AN REAL ACAD NAC F, V76, P59; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; Dingerdissen HM, 2018, NUCLEIC ACIDS RES, V46, pD1128, DOI 10.1093/nar/gkx907; dos Reis ST, 2009, J UROLOGY, V181, P2320, DOI 10.1016/j.juro.2009.01.012; Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210; Gil Ugarteburu Rodrigo, 2010, Arch Esp Urol, V63, P125; Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186; Jacobs EJ, 2008, CANCER EPIDEM BIOMAR, V17, P972, DOI 10.1158/1055-9965.EPI-07-2787; Kader AK, 2006, CANCER RES, V66, P11644, DOI 10.1158/0008-5472.CAN-06-1212; Klassen LMB, 2018, GENE, V642, P461, DOI 10.1016/j.gene.2017.11.054; Lau J, 1997, ANN INTERN MED, V127, P820, DOI 10.7326/0003-4819-127-9-199711010-00008; Leal J, 2016, EUR UROL, V69, P438, DOI 10.1016/j.eururo.2015.10.024; Liabakk NB, 1996, CANCER RES, V56, P190; Ma F., 2017, MINERVA UROL NEFROL, V69; Mandel A, 2018, MOL MED, V24, P1, DOI 10.1186/s10020-018-0035-4; Mannello F, 2012, PROG HISTOCHEM CYTO, V47, P27, DOI 10.1016/j.proghi.2011.12.002; Mehner C, 2014, ONCOTARGET, V5, P2736, DOI 10.18632/oncotarget.1932; Moher D, 2009, ANN INTERN MED, V151, P264, DOI 10.7326/0003-4819-151-4-200908180-00135; Nabeshima K, 2002, PATHOL INT, V52, P255, DOI 10.1046/j.1440-1827.2002.01343.x; Niu HT, 2018, PEERJ, V6, DOI 10.7717/peerj.5050; Odedina Folakemi T, 2009, Infect Agent Cancer, V4 Suppl 1, pS2, DOI 10.1186/1750-9378-4-S1-S2; Pence S, 2017, CELL MOL BIOL, V63, P46, DOI 10.14715/cmb/2017.63.9.9; Protzel C, 2012, EUR UROL SUPPL, V11, P52, DOI 10.1016/j.eursup.2012.05.002; Pego ER, 2018, UROL ONCOL-SEMIN ORI, V36, P272, DOI 10.1016/j.urolonc.2018.03.009; Schveigert D, 2013, TUMORI, V99, P523, DOI 10.1700/1361.15105; Sfar S, 2007, CANCER GENET CYTOGEN, V172, P38, DOI 10.1016/j.cancergencyto.2006.07.014; Shay G, 2015, MATRIX BIOL, V44-46, P200, DOI 10.1016/j.matbio.2015.01.019; Siegel RL, 2018, CA-CANCER J CLIN, V68, P7, DOI 10.3322/caac.21442; Srivastava P, 2010, ANN SURG ONCOL, V17, P3068, DOI 10.1245/s10434-010-1153-6; Struckmann K, 2008, J PATHOL, V214, P464, DOI 10.1002/path.2310; Tang ZF, 2017, NUCLEIC ACIDS RES, V45, pW98, DOI 10.1093/nar/gkx247; Thakkinstian A, 2005, STAT MED, V24, P1291, DOI 10.1002/sim.2010; Tian TV, 2014, ONCOGENE, V33, P2204, DOI 10.1038/onc.2013.176; Tian W, 2018, DNA CELL BIOL, V37, P336, DOI 10.1089/dna.2017.4085; Tsai JP, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048164; Wells M, 2012, ALIMENT PHARM THER, V35, P1267, DOI 10.1111/j.1365-2036.2012.05088.x; Wieczorek E, 2013, BJU INT, V112, P1207, DOI 10.1111/bju.12230; Xie YQ, 2017, CELL DEATH DISCOV, V3, DOI 10.1038/cddiscovery.2017.36; Yoo YA, 2011, CANCER RES, V71, P7061, DOI 10.1158/0008-5472.CAN-11-1338; Zhang PP, 2017, J CANCER, V8, P2042, DOI 10.7150/jca.18852; Zhong A, 2005, J CLIN UROLOGY, V22, P461	47	0	0	0	1	ELSEVIER GMBH	MUNICH	HACKERBRUCKE 6, 80335 MUNICH, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	DEC	2018	214	12					1966	1973		10.1016/j.prp.2018.09.011			8	Pathology	Pathology	HG0YQ	WOS:000454675600007	30249503				2019-10-28	
J	Qu, XF; Yang, L; Shi, QQ; Wang, XF; Wang, DG; Wu, GY				Qu, Xianfeng; Yang, Li; Shi, Qingqing; Wang, Xiaofei; Wang, Dongguo; Wu, Guiyang			Lidocaine inhibits proliferation and induces apoptosis in colorectal cancer cells by upregulating mir-520a-3p and targeting EGFR	PATHOLOGY RESEARCH AND PRACTICE			English	Article						Lidocaine; Colorectal cancer; EGFR; MicroRNA; MiR-520a-3p	GROWTH-FACTOR RECEPTOR; MICRORNAS; METASTASIS; ANESTHESIA; EXPRESSION	Lidocaine is a conventional local anesthetic which is shown antiproliferative of colorectal cancer (CRC) in patients. MicroRNAs (miRNAs) have been consistently demonstrated to be involved in CRC, and miR-520a-3p could suppress CRC migration, promote apoptosis by targeting epidermal growth factor receptor (EGFR). However, the mechanism by which lidocaine regulated CRC proliferation and apoptosis remains unknown. In this study, quantitative RT-PCR were used to measure miR-520a-3p and EGFR expression levels, and western blotting assays ware performed to measure EGFR expression in CRC cells. Luciferase reporter assay was employed to validate the direct targeting of EGFR by miR-520a-3p. Cell proliferation and apoptosis assays ware utilized to analyze the role of lidocaine in CRC cells. The results indicated that 500 and 1000 mu M lidocaine over 24 h inhibited proliferation and induced apoptosis of CRC cells. Compared with the control group, the expression of EGFR was suppressed by lidocaine (500 mu M) in CRC cells. Furthermore, miR-520a-3p could directly targets EGFR in CRC cells. Lidocaine (500 mu M) increased the expression of miR-520a-3p and rescued the reduction of miR-520a-3p caused by miR-520a-3p inhibitor. The results suggested that lidocaine could suppress the expression of EGFR by upregulating miR-520a-3p, and it could induce apoptosis and inhibit proliferation in CRC cells. Lidocaine may serve as potential therapeutic regimen for colorectal cancer.	[Qu, Xianfeng; Yang, Li; Shi, Qingqing; Wang, Xiaofei] Taizhou Municipal Hosp, Dept Anesthesiol, Taizhou 318000, Zhejiang, Peoples R China; [Wang, Dongguo] Taizhou Municipal Hosp, Clin Lab, Taizhou 318000, Zhejiang, Peoples R China; [Wu, Guiyang] Taizhou Municipal Hosp, Dept Gastrointestinal Surg, Taizhou 318000, Zhejiang, Peoples R China	Wu, GY (reprint author), Taizhou Municipal Hosp, 381 Zhongshan East Rd, Taizhou 318000, Zhejiang, Peoples R China.	wuguiyang201807@outlook.com			Medical Science Foundation of Department of Public Health, Zhejiang Province [2018KY905]	The present study was supported by the Medical Science Foundation of Department of Public Health, Zhejiang Province (NO: 2018KY905).	Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Bundscherer AC, 2017, ANTICANCER RES, V37, P1941, DOI 10.21873/anticanres.11534; Cui J, 2014, TUMOR BIOL, V35, P11701, DOI 10.1007/s13277-014-2660-z; Di Leva G, 2013, CURR OPIN GENET DEV, V23, P3, DOI 10.1016/j.gde.2013.01.004; Flora M, 2012, CANCER GENET-NY, V205, P630, DOI 10.1016/j.cancergen.2012.10.005; Herbst RS, 2004, NAT REV CANCER, V4, P956, DOI 10.1038/nrc1506; Hirata M, 2004, ANESTHESIOLOGY, V100, P1206, DOI 10.1097/00000542-200405000-00024; Hodgson PS, 2001, ANESTHESIOLOGY, V94, P799, DOI 10.1097/00000542-200105000-00018; Huang JH, 1997, J PHARMACOL EXP THER, V282, P802; Italiano A, 2005, ANN ONCOL, V16, P1503, DOI 10.1093/annonc/mdi282; Kahokehr A, 2010, ANAESTH INTENS CARE, V38, P623, DOI 10.1177/0310057X1003800404; Koppert W, 2000, PAIN, V85, P217, DOI 10.1016/S0304-3959(99)00268-7; Kornmann M, 2008, EJSO-EUR J SURG ONC, V34, P1316, DOI 10.1016/j.ejso.2008.01.019; LAMBERT LA, 1994, ANESTHESIOLOGY, V80, P1082, DOI 10.1097/00000542-199405000-00017; Liu XB, 2016, CELL PHYSIOL BIOCHEM, V39, P617, DOI 10.1159/000445653; Martinsson T, 1999, J PHARMACOL EXP THER, V288, P660; Mlcochova J, 2013, J CANCER RES CLIN, V139, P1615, DOI 10.1007/s00432-013-1470-9; Padfield E, 2015, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00005; Sakaguchi M, 2006, ANESTH ANALG, V102, P1103, DOI 10.1213/01.ane.0000198330.84341.35; Sartore-Bianchi A, 2009, CANCER RES, V69, P1851, DOI 10.1158/0008-5472.CAN-08-2466; Shono A, 2003, BRIT J ANAESTH, V91, P825, DOI 10.1093/bja/aeg266; Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262; Wei W, 2016, CELL PHYSIOL BIOCHEM, V39, P1165, DOI 10.1159/000447823; Wu N, 2016, TUMOR BIOL, V37, P8271, DOI 10.1007/s13277-015-4730-2; Yan L, 2015, AM J CANCER RES, V5, P1447; Zhang R, 2017, CELL PHYSIOL BIOCHEM, V42, P1559, DOI 10.1159/000479397; Zlobec I, 2008, J CLIN PATHOL, V61, P561, DOI 10.1136/jcp.2007.054858	28	4	4	0	4	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	DEC	2018	214	12					1974	1979		10.1016/j.prp.2018.09.012			6	Pathology	Pathology	HG0YQ	WOS:000454675600008	30262429				2019-10-28	
J	Huang, B; Huang, MP; Li, Q				Huang, Bin; Huang, Manping; Li, Qin			MiR-137 suppresses migration and invasion by targeting EZH2-STAT3 signaling in human hepatocellular carcinoma	PATHOLOGY RESEARCH AND PRACTICE			English	Article						MiR-137; HCC; EZH2; STAT3; Metastasis	CELL-PROLIFERATION; EARLY RECURRENCE; METASTASIS; EZH2; PROMOTES; MICRORNA-137; ANGIOGENESIS; EXPRESSION	Background: Hepatocellular carcinoma (HCC) is one of the most common and aggressive human malignancies and many cell-intrinsic identities and extrinsic epigenetic factors influence the metastatic potential of HCC cells. MicroRNA-137 is often found to be acting as tumor suppressors, however, how miR-137 involved in the metastasis progression in human HCC remains unclear. Method: QPCR was performed to detect the miR-137 mRNA levels in HCC cell linesand normal liver cell line HL7702. Then transwell assay and wound-healing assay were determined to investigate the motility of HCC cells introduced into lentivirus to ectopically upregulate endogenous miR-137 and EAH2 expressions. Targeting of enhancer of zeste homolog 2 (EZH2) gene by miR-137 in HCC was assessed by dual-luciferase activity assay and qPCR. Western blot was applied to explore the mechanism. In vivo, lung metastasis were evaluated using a mice tail vein injection model. Results: In this study, we found that miR-137 is decreased in HCC cell lines and had an inhibitory effect on HCC migration and invasion in vitro. EZH2 was a direct downstream target gene of miR-137 in HCC and miR-137 suppressed invasion and migration by targeting EZH2-STAT3 signaling in HCC cells. Furthermore, EZH2 overexpression reversed the miR-137 mimics-induced inhibitory effects on migration and invasion of HCC cells. In addition, miR-137 inhibited lung metastasis of HCC in vivo by targeting EZH2-STAT3 signaling. Conclusion: MiR-137 suppressed migration and invasion by targeting EZH2-STAT3 signaling pathway in HCC cells in vitro and in vivo, suggesting miR-137-EZH2-STAT3 may be a potential therapeutic target for treatment of human hepatocellular carcinoma.	[Huang, Bin; Huang, Manping] Hunan Prov Canc Hosp, Dept Intervent, Changsha 410009, Hunan, Peoples R China; [Li, Qin] Affiliated Hosp, Hunan Inst Tradit Chinese Med, Dept Gynecol, Changsha 410009, Hunan, Peoples R China	Li, Q (reprint author), Affiliated Hosp, Hunan Inst Tradit Chinese Med, Dept Gynecol, Changsha 410009, Hunan, Peoples R China.	liqinlq2017123112@163.com					Au SLK, 2012, HEPATOLOGY, V56, P622, DOI 10.1002/hep.25679; Chen JX, 2016, GUT, V65, P1522, DOI 10.1136/gutjnl-2015-310625; Chen JX, 2015, J HEPATOL, V62, P1287, DOI 10.1016/j.jhep.2015.01.014; Chen Y, 2017, BRIT J CANCER, V117, P1192, DOI 10.1038/bjc.2017.265; El-Serag HB, 2012, GASTROENTEROLOGY, V142, P1264, DOI 10.1053/j.gastro.2011.12.061; Fidler IJ, 2003, NAT REV CANCER, V3, P453, DOI 10.1038/nrc1098; Gao M, 2015, ONCOL REP, V34, P2523, DOI 10.3892/or.2015.4261; Hammond SM, 2015, ADV DRUG DELIVER REV, V87, P3, DOI 10.1016/j.addr.2015.05.001; Italiano A, 2016, PHARMACOL THERAPEUT, V165, P26, DOI 10.1016/j.pharmthera.2016.05.003; Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI 10.3322/caac.20115; Kim E, 2013, CANCER CELL, V23, P839, DOI 10.1016/j.ccr.2013.04.008; Li JJ, 2017, CANCER CELL INT, V17, DOI 10.1186/s12935-017-0408-8; Liu LL, 2014, ONCOTARGET, V5, P5113, DOI 10.18632/oncotarget.2089; Liu M, 2014, PROTEIN CELL, V5, P673, DOI 10.1007/s13238-014-0065-9; Lu AQ, 2017, ONCOL REP, V37, P2071, DOI 10.3892/or.2017.5498; Luo CL, 2013, J INVEST DERMATOL, V133, P768, DOI 10.1038/jid.2012.357; Luo XL, 2014, CANCER DISCOV, V4, P640, DOI 10.1158/2159-8290.CD-14-0406; Mao BJ, 2015, ONCOL REP, V34, P2811, DOI 10.3892/or.2015.4275; Mierke CT, 2014, REP PROG PHYS, V77, DOI 10.1088/0034-4885/77/7/076602; Mohr AM, 2015, SEMIN LIVER DIS, V35, P3, DOI 10.1055/s-0034-1397344; Sakabe T, 2017, LIVER INT, V37, P271, DOI 10.1111/liv.13213; Smith AR, 2015, ONCOTARGET, V6, P12558, DOI 10.18632/oncotarget.3726; Sudo T, 2005, BRIT J CANCER, V92, P1754, DOI 10.1038/sj.bjc.6602531; Sun J, 2015, J NEURO-ONCOL, V122, P481, DOI 10.1007/s11060-015-1753-x; Wang HY, 2014, ONCOL REP, V32, P1465, DOI 10.3892/or.2014.3352; Wu LP, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0130124; Xu ZH, 2016, ONCOL REP, V35, P3630, DOI 10.3892/or.2016.4761; Yang F, 2015, WORLD J GASTROENTERO, V21, P13268, DOI 10.3748/wjg.v21.i47.13268; Yang YR, 2015, INT J CLIN EXP PATHO, V8, P10847; Yuan JH, 2014, CANCER CELL, V25, P666, DOI 10.1016/j.ccr.2014.03.010; Zhai R, 2016, ONCOTARGETS THER, V9, P6987, DOI 10.2147/OTT.S110985; Zhang HM, 2018, J CELL BIOCHEM, V119, P938, DOI 10.1002/jcb.26259; Zhang X, 2017, BIOCHIMIE, V137, P12, DOI 10.1016/j.biochi.2017.02.010	33	4	4	0	3	ELSEVIER GMBH	MUNICH	HACKERBRUCKE 6, 80335 MUNICH, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	DEC	2018	214	12					1980	1986		10.1016/j.prp.2018.08.005			7	Pathology	Pathology	HG0YQ	WOS:000454675600009	30274685				2019-10-28	
J	Wang, D; Zhang, XJ; Lu, YP; Wang, XT; Zhu, L				Wang, Dan; Zhang, Xiaojing; Lu, Yapeng; Wang, Xueting; Zhu, Li			Hypoxia inducible factor 1 alpha in hepatocellular carcinoma with cirrhosis: Association with prognosis	PATHOLOGY RESEARCH AND PRACTICE			English	Article						Hypoxia inducible factor 1 alpha; Hepatocellular carcinoma; Cirrhosis; Prognosis	CANCER; FACTOR-1-ALPHA; OVEREXPRESSION; HIF-1-ALPHA; BIOMARKERS; TUMOR; HIF-1	Background: Hypoxia inducible factor la (HIF-1 alpha) is a protein related with carcinogenesis and metastasis in many tumors. However, little is known about the prognostic value of HIP-1 alpha in hepatocellular carcinoma (HCC) patients with cirrhosis. Methods: Clinical-pathological information and follow-up data were collected from HCC (n = 419) and chronic hepatitis (n = 49) patients. HIF-1 alpha expression was scored based on the percentage of immunohistochemical staining. Correlations between HIF-1 alpha expression and clinical features were evaluated by Chi-square test. And survival analysis was performed by multivariate Cox regression analysis. Results: In cirrhosis patients, the frequency of HIP-1 alpha positive expression in HCC was higher than in chronic hepatitis (P = 0.002). HIF-1 alpha positive expression was significantly associated with vascular invasion (P = 0.002), TNM stage (P = 0.005), HBV infection (P = 0.005), tumor size (P = 0.025) and portal vein tumor thrombus (P = 0.001) in HCC with liver cirrhosis. While, in cirrhosis-free patients, HIP-1 alpha positive expression had a significant correlation with vascular invasion (P = 0.039) and AFP value (P = 0.001) in. HIF-1 alpha "positive" had decreased overall survival compared to HIP-1 alpha "negative" patients and this was an independent adverse prognostic factor (multivariable analysis P = 0.001) for HCC patients with cirrhosis, but not for cirrhosis-free patients. Conclusions: Our results suggested that HIP-1 alpha served as a poor prognostic factor for HCC patients with cirrhosis.	[Wang, Dan; Lu, Yapeng; Wang, Xueting; Zhu, Li] Nantong Univ, Inst Naut Med, Nantong 226019, Jiangsu, Peoples R China; [Zhang, Xiaojing] Nantong Univ, Affiliated Hosp, Dept Clin Pathol, Core Facil Mol Pathol & Biobanking, Nantong 226001, Jiangsu, Peoples R China; [Zhang, Xiaojing] Nantong Univ, Med Sch, Nantong 226001, Jiangsu, Peoples R China	Zhu, L (reprint author), 9 Se Yuan Rd, Nantong 226019, Jiangsu, Peoples R China.	zhulili65@126.com			Graduate Student Scientific Research Innovation Projects in Jiangsu province [YKC16059]; National Natural Science Foundation of ChinaNational Natural Science Foundation of China [31471141, 31671206, 31500965, 81702874]	The study was partially funded by Graduate Student Scientific Research Innovation Projects in Jiangsu province (YKC16059) and National Natural Science Foundation of China (Grant Nos. 31471141, 31671206, 31500965 & 81702874).	Beasley NJP, 2002, CANCER RES, V62, P2493; Bersten DC, 2013, NAT REV CANCER, V13, P827, DOI 10.1038/nrc3621; Bos R, 2003, CANCER, V97, P1573, DOI 10.1002/cncr.11246; Choudhry H, 2018, CELL METAB, V27, P281, DOI 10.1016/j.cmet.2017.10.005; Chua YL, 2010, J BIOL CHEM, V285, P31277, DOI 10.1074/jbc.M110.158485; Corpechot C, 2002, HEPATOLOGY, V35, P1010, DOI 10.1053/jhep.2002.32524; Cui CP, 2017, GUT, V66, P2149, DOI 10.1136/gutjnl-2016-313264; Forner A, 2018, LANCET, V391, P1301, DOI 10.1016/S0140-6736(18)30010-2; Ju C, 2016, J MOL MED, V94, P613, DOI 10.1007/s00109-016-1408-1; Keith B, 2012, NAT REV CANCER, V12, P9, DOI 10.1038/nrc3183; LaGory EL, 2016, NAT CELL BIOL, V18, P356, DOI 10.1038/ncb3330; Le QT, 2008, CANCER METAST REV, V27, P351, DOI 10.1007/s10555-008-9144-9; Ruan K, 2009, J CELL BIOCHEM, V107, P1053, DOI 10.1002/jcb.22214; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; Semenza GL, 2014, ANNU REV PATHOL-MECH, V9, P47, DOI 10.1146/annurev-pathol-012513-104720; Sia D, 2017, GASTROENTEROLOGY, V152, P745, DOI 10.1053/j.gastro.2016.11.048; Sivridis E, 2002, CANCER, V95, P1055, DOI 10.1002/cncr.10774; Strzyz P, 2016, NAT REV MOL CELL BIO, V17, P610, DOI 10.1038/nrm.2016.119; Sumiyoshi Y, 2006, CLIN CANCER RES, V12, P5112, DOI 10.1158/1078-0432.CCR-05-2382; Sun RW, 2014, ONCOTARGET, V5, P12398, DOI 10.18632/oncotarget.2643; Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262; Tsuchiya N, 2015, WORLD J GASTROENTERO, V21, P10573, DOI 10.3748/wjg.v21.i37.10573; Volm M, 2000, ANTICANCER RES, V20, P1527; Waypa GB, 2016, MOL ASPECTS MED, V47-48, P76, DOI 10.1016/j.mam.2016.01.002; Zheng SS, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065753	25	1	2	0	1	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	DEC	2018	214	12					1987	1992		10.1016/j.prp.2018.09.007			6	Pathology	Pathology	HG0YQ	WOS:000454675600010	30274686				2019-10-28	
J	Ding, Z; Lan, HT; Xu, R; Zhou, X; Pan, Y				Ding, Zhi; Lan, Haitao; Xu, Rui; Zhou, Xiang; Pan, Yong			LncRNA TP73-AS1 accelerates tumor progression in gastric cancer through regulating miR-194-5p/SDAD1 axis	PATHOLOGY RESEARCH AND PRACTICE			English	Article						TP73-AS1; miR-194-5; SDAD1; Proliferation; Gastric cancer	INHIBITS CELL-PROLIFERATION; COLORECTAL-CANCER; PROMOTE; VARIANT; EXPRESSION; ESOPHAGEAL; BIOMARKERS; APOPTOSIS	Background: Long noncoding RNAs (lncRNAs) have been considered as significant regulators in many cancer progression, such as proliferation, invasion and other path of evolution. Nevertheless, we have not had a grasp of the role of lncRNA TP73-AS1 in gastric cancer (GC). Methods: qRT-PCR analysis was first conducted to examine the TP73-AS1 level in both GC tissues and cell lines. Then gain or loss-of-function assays were carried out to detect the effect of TP73-AS1 on GC development. In mechanism, bioinformatics analysis and luciferase reporter assays were used to search and confirm the target gene of TP73-AS1. Finally, rescue assays were performed to confirm the influence of TP73-AS1-miR-194-5p-SDAD1 axis on GC development. Results: TP73-AS1 was upregulated in GC tissues and cell lines. Furthermore, TP73-AS1 exerted oncogenic role in GC through promoting cell growth and metastasis. In addition, TP73-AS1 was certified as a ceRNA by regulating miR-194-5p/SDAD1 axis. Conclusions: TP73-AS1 accelerates tumor progression in gastric cancer through regulating miR-194-5p/SDAD1 axis.	[Ding, Zhi; Xu, Rui; Zhou, Xiang] Sichuan Canc Hosp & Inst, Gastrointestinal Ctr, Chengdu 610041, Sichuan, Peoples R China; [Lan, Haitao] Sichuan Acad Med Sci, Oncol Ctr, Chengdu 610072, Sichuan, Peoples R China; [Lan, Haitao; Pan, Yong] Sichuan Prov Peoples Hosp, Chengdu 610072, Sichuan, Peoples R China; [Pan, Yong] Sichuan Acad Med Sci, Dept Gastrointestinal Surg, Chengdu 610072, Sichuan, Peoples R China	Pan, Y (reprint author), Sichuan Prov Peoples Hosp, Chengdu 610072, Sichuan, Peoples R China.; Pan, Y (reprint author), Sichuan Acad Med Sci, Dept Gastrointestinal Surg, Chengdu 610072, Sichuan, Peoples R China.	DrYongPan@163.com					Camargo MC, 2014, GUT, V63, P236, DOI 10.1136/gutjnl-2013-304531; Chen QY, 2015, CELL PHYSIOL BIOCHEM, V36, P622, DOI 10.1159/000430125; Coupland VH, 2013, GUT, V62, P961, DOI 10.1136/gutjnl-2012-303008; Duraes C, 2014, VIRCHOWS ARCH, V464, P367, DOI 10.1007/s00428-013-1533-y; Endo H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077070; Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210; Gibb EA, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-38; Hou CG, 2016, CELL PHYSIOL BIOCHEM, V39, P1512, DOI 10.1159/000447854; Jiang YG, 2016, AM J CANCER RES, V6, P1890; Khalil AM, 2009, P NATL ACAD SCI USA, V106, P11667, DOI 10.1073/pnas.0904715106; Li SL, 2017, J EXP CLIN CANC RES, V36, DOI 10.1186/s13046-017-0519-z; Li S, 2016, CELL PHYSIOL BIOCHEM, V40, P1303, DOI 10.1159/000453183; Li XP, 2015, CELL PHYSIOL BIOCHEM, V35, P2033, DOI 10.1159/000374010; Liu Y, 2015, CELL PHYSIOL BIOCHEM, V37, P1010, DOI 10.1159/000430227; Orfanelli U, 2015, ONCOGENE, V34, P2094, DOI 10.1038/onc.2014.144; Ponting CP, 2009, CELL, V136, P629, DOI 10.1016/j.cell.2009.02.006; Ren J, 2018, THERANOSTICS, V8, P3932, DOI 10.7150/thno.25541; Tuo ZY, 2018, BIOCHEM BIOPH RES CO, V499, P875, DOI 10.1016/j.bbrc.2018.04.010; Wang B, 2016, CELL PHYSIOL BIOCHEM, V40, P391, DOI 10.1159/000452554; Wang DH, 2015, CELL PHYSIOL BIOCHEM, V37, P1454, DOI 10.1159/000438514; Wang QX, 2015, CELL PHYSIOL BIOCHEM, V35, P933, DOI 10.1159/000369750; Wang XW, 2016, CELL PHYSIOL BIOCHEM, V38, P1796, DOI 10.1159/000443118; Xiang XJ, 2015, CELL PHYSIOL BIOCHEM, V36, P1382, DOI 10.1159/000430304; Xu J, 2017, CELL PHYSIOL BIOCHEM, V41, P635, DOI 10.1159/000457938; Yan XL, 2017, CANCER RES, V77, P6704, DOI 10.1158/0008-5472.CAN-17-1915; Yao J, 2018, J CELL BIOCHEM, V119, P680, DOI 10.1002/jcb.26231; Zang WQ, 2016, ONCOTARGET, V7, P19960, DOI 10.18632/oncotarget.6963; Zeng MX, 2017, CELL MOL BIOL LETT, V22, DOI 10.1186/s11658-017-0041-5; Zhang Q, 2016, ONCOGENE, V35, P3151, DOI 10.1038/onc.2015.365; Zhou Q, 2016, CELL PHYSIOL BIOCHEM, V39, P453, DOI 10.1159/000445638; Zhu P, 2015, CELL PHYSIOL BIOCHEM, V37, P1572, DOI 10.1159/000438524	31	4	5	0	8	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	DEC	2018	214	12					1993	1999		10.1016/j.prp.2018.09.006			7	Pathology	Pathology	HG0YQ	WOS:000454675600011	30279010				2019-10-28	
J	Tanaka, R; Tachibana, K; Suda, K; Kondo, H; Noguchi, M				Tanaka, Ryota; Tachibana, Keisei; Suda, Kazuharu; Kondo, Haruhiko; Noguchi, Masayuki			A severe combined immunodeficiency disease mouse model of human adenocarcinoma with lepidic-predominant growth	PATHOLOGY RESEARCH AND PRACTICE			English	Article						SCID mouse; lung cancer; lepidic adenocarcinoma; orthotopic implantation	ORTHOTOPIC PROPAGATION; CYTOLOGICAL SUBTYPES; LUNG ADENOCARCINOMA	Severe combined immunodeficiency disease (SCID) mice with human lepidic adenocarcinoma were established by the intrabronchial implantation of fresh surgically resected specimens. Human pulmonary adenocarcinoma tissue from 16 different cases was transplanted into SCID mice, and SCID mouse tumors were established from four of these cases (25%). Among the four tumors, the tumor cells of two SCID mice showed replacement lepidic growth of mouse alveolar structures accompanied by multiple intrapulmonary lesions. Human lung carcinoma cell lines showing lepidic growth are rare and the xenograft models using the SCID mouse model developed in the current study will be useful for analyzing the growth and/or progression patterns and clinical behavior of lepidic adenocarcinoma, the major histological subtype of human carcinoma of the lung.	[Tanaka, Ryota; Tachibana, Keisei; Suda, Kazuharu; Kondo, Haruhiko] Kyorin Univ, Sch Med, Dept Surg, 6-20-2 Shinkawa, Mitaka, Tokyo 1818611, Japan; [Tanaka, Ryota; Tachibana, Keisei; Noguchi, Masayuki] Univ Tsukuba, Grad Sch Comprehens Human Sci, Dept Pathol, Inst Basic Med Sci, Ibaraki, Japan	Tanaka, R (reprint author), Kyorin Univ, Sch Med, Dept Surg, 6-20-2 Shinkawa, Mitaka, Tokyo 1818611, Japan.	ryota@ks.kyorin-u.ac.jp					FURUKAWA T, 1993, CANCER RES, V53, P1204; Goldstraw P, 2016, J THORAC ONCOL, V11, P39, DOI 10.1016/j.jtho.2015.09.009; KIMULA Y, 1978, AM J SURG PATHOL, V2, P253, DOI 10.1097/00000478-197809000-00002; Maeshima AM, 2008, PATHOL INT, V58, P31, DOI 10.1111/j.1440-1827.2007.02185.x; MANZOTTI C, 1993, CLIN EXP METASTAS, V11, P5, DOI 10.1007/BF00880061; Mase K, 2002, LUNG CANCER-J IASLC, V36, P271, DOI 10.1016/S0169-5002(02)00004-1; MCLEMORE TL, 1987, CANCER RES, V47, P5132; NOGUCHI M, 1995, CANCER-AM CANCER SOC, V75, P2844, DOI 10.1002/1097-0142(19950615)75:12<2844::AID-CNCR2820751209>3.0.CO;2-#; PAGET S, 1889, LANCET, V1, P571, DOI DOI 10.1016/S0140-6736(00)49915-0; Shimosato Y., 2004, STERNBERGS DIAGNOSTI, P1173; Tanaka R, 2013, CLIN IMAG, V37, P876, DOI 10.1016/j.clinimag.2013.06.001; Travis W, 1999, HISTOLOGICAL TYPING; Travis WD, 2015, WHO CLASSIFICATION T	13	0	0	0	2	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	DEC	2018	214	12					2000	2003		10.1016/j.prp.2018.09.021			4	Pathology	Pathology	HG0YQ	WOS:000454675600012	30287185				2019-10-28	
J	Karagianni, F; Kataki, A; Koniaris, E; Karamagkiolas, S; Derventzi, A; Giotakis, E; Konstandoulakis, M; Zografos, G; Giotakis, I				Karagianni, Fani; Kataki, Agapi; Koniaris, Eythymios; Karamagkiolas, Sotirios; Derventzi, Anastasia; Giotakis, Evangelos; Konstandoulakis, Manousos; Zografos, George; Giotakis, Ioannis			Distinctive expression profiles of Caveolin-1 and Notch-1 protein in patients with nasal polyps or sinonasal inverted papillomas	PATHOLOGY RESEARCH AND PRACTICE			English	Article						Caveolin-1; Notch-1; Sinonasal inverted papilloma; Nasal polyps	MALIGNANT-TRANSFORMATION; INFLAMMATION; RECURRENCE	Background: Nasal polyposis (NP) and sinonasal inverted papillomas (SIP) are considered benign lesions capable of recurrence or malignant transformation although not with the same prevalence. Since fluctuations of Caveolin-1 and Notch-1 proteins expression have been reported in many pathologies, the current study aimed to investigate their involvement in the epithelial transformation observed in SIPs compared to NP. Methods: Immunohistochemical expression of Caveolin-1 and Notch-1 proteins was assessed in 104 patients with sinonasal lesions (45 NP, 45 SIP and 14 NP with SIP), semiquantively (percentage times intensity). Proteins expression profiles were evaluated statistically for their correlation with patients demographic and dinicopathological variables (grade of dysplasia, inflammation, recurrence) as well as with markers of proliferation (Ki67) and apoptosis (7-AAD) as determined by flow cytometry analysis. Results: SIP lesions presented increased Caveolin-1 immunopositivity compared to NP (62.2%, vs 40.9%; p = 0.045). Cytoplasmic staining was observed only in epithelium's basal and suprabasal layers. Caveolin-1 positivity was not related to Ki67 expression, apoptosis, inflammation or dysplasia, eventhough 81.8% of highly immunopositive lesions were dysplastic (p = 0.03). Also, smokers presented significantly increased immunopositivy (p = 0.03). In contrast SIP lesions presented reduced Notch-1 expression compared to NP (68.9% vs 100%; p < 0.001). Dysplastic lesions presented low Notch-1 immunopositivity (p < 0.001). Enhancement of Notch -1 gene expression was also associated with inflammation. Conclusions: The herein presented data suggest that the expression profiles of Caveolin-1 and Notch-1 proteins in sinonasal pathologies are distinctive and that could be explored as potential targets for the development of alternative therapeutic approaches.	[Karagianni, Fani; Kataki, Agapi; Derventzi, Anastasia; Konstandoulakis, Manousos; Zografos, George] Univ Athens, Athens Med Sch, Hippocration Hosp, Dept Propaedeut 1, 114 Queens Sofia Ave, Athens, Greece; [Koniaris, Eythymios] Univ Athens, Athens Med Sch, Hippocration Hosp Athens, Dept Pathol Anat, Athens, Greece; [Karamagkiolas, Sotirios; Giotakis, Evangelos] Univ Athens, Athens Med Sch, Hippocration Hosp Athens, Dept Otolaryngol 1, Athens, Greece; [Giotakis, Ioannis] Univ Athens, Sch Med, Attikon Univ Hosp, Otolaryngol Dept 2, Athens, Greece	Kataki, A (reprint author), Univ Athens, Athens Med Sch, Hippocration Hosp, Dept Propaedeut 1, 114 Queens Sofia Ave, Athens, Greece.	akataki@med.uoa.gr		karamagkiolas, sotirios/0000-0002-7013-2055	National and Kapodistrian University of Athens, Athens, Greece [8316, 4784]	This work was funded through the Special Account for Research Grants 8316 and 4784 of the National and Kapodistrian University of Athens, Athens, Greece, without being directly involved in either the study design; collection, analysis and interpretation of data; writing of the report; or in the decision to submit the article for publication.	Bernstein J M, 2001, Curr Allergy Asthma Rep, V1, P262, DOI 10.1007/s11882-001-0017-3; Bishop JA, 2017, HEAD NECK PATHOL, V11, P269, DOI 10.1007/s12105-017-0799-9; Chaaban MR, 2013, AM J RHINOL ALLERGY, V27, P473, DOI 10.2500/ajra.2013.27.3981; Chiappara G, 2017, EUR RESPIR J, V50, DOI 10.1183/1393003.congress-2017.PA1004; Chong L, 2014, INFLAMMATION, V37, P1476, DOI 10.1007/s10753-014-9873-6; Deitmer T, 1996, ACTA OTO-LARYNGOL, V116, P762, DOI 10.3109/00016489609137921; Frank PG, 2003, ARTERIOSCL THROM VAS, V23, P1161, DOI 10.1161/01.ATV.0000070546.16946.3A; Gvaramia D, 2013, MATRIX BIOL, V32, P307, DOI 10.1016/j.matbio.2013.03.005; Hung KF, 2003, J ORAL PATHOL MED, V32, P461, DOI 10.1034/j.1600-0714.2003.00185.x; Jaafari-Ashkavandi Z, 2017, PATHOL RES PRACT, V213, P809, DOI 10.1016/j.prp.2017.03.006; Jia GH, 2015, DIABETES, V64, P3645, DOI 10.2337/dbi15-0005; Joenvaard S., 2009, J ALLERGY CLIN IMMUN, V124; Kataki A, 2014, PATHOL RES PRACT, V210, P105, DOI 10.1016/j.prp.2013.10.006; Katori H, 2006, ACTA OTO-LARYNGOL, V126, P214, DOI 10.1080/00016480500312554; Liang Y, 2001, Zhonghua Er Bi Yan Hou Ke Za Zhi, V36, P94; Lin H, 2015, EUR ARCH OTO-RHINO-L, V272, P613, DOI 10.1007/s00405-014-3146-8; Liu X, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-04639-z; Massard C., 2018, ANN ONCOL; Memos N, 2011, J NEUROSCI RES, V89, P1409, DOI 10.1002/jnr.22673; Messaris E., SURG INFECT, V9; Minwook K., 2008, KOREAN J OTORHINOLAR, V51, P46; Newton Jonathan Ray, 2008, Ther Clin Risk Manag, V4, P507; Nguyen Kim Cuc Thi, 2017, Chonnam Med J, V53, P28, DOI 10.4068/cmj.2017.53.1.28; NIELSEN PL, 1991, LARYNGOSCOPE, V101, P1094; Sakamoto K, 2016, PATHOL INT, V66, P609, DOI 10.1111/pin.12461; Sakamoto K, 2012, LAB INVEST, V92, P688, DOI 10.1038/labinvest.2012.9; SCHMID I, 1994, J IMMUNOL METHODS, V170, P145, DOI 10.1016/0022-1759(94)90390-5; Shin JS, 2001, IMMUNOLOGY, V102, P2, DOI 10.1046/j.1365-2567.2001.01173.x; Sun QJ, 2017, ONCOL LETT, V13, P4585, DOI 10.3892/ol.2017.6089; Takeshita K, 2007, CIRC RES, V100, P70, DOI 10.1161/01.RES.0000254788.47304.6e; Volonte D, 2009, J BIOL CHEM, V284, P5462, DOI 10.1074/jbc.C800225200; Wang M. J., 2016, WORLD J OTORHINOLARY, V3, P54; Weng AP, 2004, SCIENCE, V306, P269, DOI 10.1126/science.1102160; Yamamoto S, 2014, METHODS MOL BIOL, V1187, P1, DOI 10.1007/978-1-4939-1139-4_1; Zemans R, 2008, AM J PHYSIOL-LUNG C, V294, pL175, DOI 10.1152/ajplung.00488.2007	35	0	0	0	1	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	DEC	2018	214	12					2004	2010		10.1016/j.prp.2018.09.029			7	Pathology	Pathology	HG0YQ	WOS:000454675600013	30297114				2019-10-28	
J	Xu, J; Tan, YH; Shao, XX; Zhang, CM; He, YL; Wang, J; Xi, YF				Xu, Jing; Tan, Yanhong; Shao, Xiaoxia; Zhang, Cuiming; He, Yanling; Wang, Jie; Xi, Yanfeng			Evaluation of NCAM and c-Kit as hepatic progenitor cell markers for intrahepatic cholangiocarcinomas	PATHOLOGY RESEARCH AND PRACTICE			English	Article						Intrahepatic cholangiocarcinomas; hepatic progenitor cells; neural cell adhesion molecule; c-Kit	TUMOR-INITIATING CELLS; STEM-CELLS; STEM/PROGENITOR CELLS; KERATIN 19; LIVER; CARCINOMA; DIFFERENTIATION; PHENOTYPES; INVASION; TARGET	Background: Intrahepatic cholangiocarcinomas (ICCs) are primary liver malignancies and are the second most common type of malignancy after hepatocellular carcinoma. ICCs are heterogeneous in clinical features, genotype, and biological behavior, suggesting that ICCs can initiate in different cell lineages. Aim: We investigated intrahepatic cholangiocarcinoma RBE cell lines for the markers neural cell adhesion molecule (NCAM) and c-Kit, which possess hepatic progenitor cells properties. Methods: NCAM + c-Kit + cells were tested for hepatic progenitor cell properties including proliferation ability, colony formation, spheroid formation, and invasiveness in NOD/SCID mice. The Agilent Whole Human Genome Microarray Kit was used to evaluate differences in gene expression related to stem cell signaling pathways between NCAM + c-Kit + and NCAM-c-Kit- subset cells. Microarray results were further confirmed by real-time RT-PCR. Results: NCAM + c-Kit + cells showed hepatic progenitor cell-like traits including the abilities to self-renew and differentiate and tumorigenicity in NOD/SCID mice. Differences were observed in the expression of 421 genes related to stem cell signaling pathways (fc >= 2 or fc <= 0.5), among which 231 genes were upregulated and 190 genes were downregulated. Conclusion: NCAM + c-Kit + subset cells in RBE may have properties of hepatic progenitor cells. NCAM combined with c-Kit may be a valuable marker for isolating and purifying ICC stem/progenitor cells.	[Xu, Jing; Shao, Xiaoxia; He, Yanling; Wang, Jie] Shanxi Med Univ, Dept Pathol, 56 Xinjian South Rd, Taiyuan 030001, Shanxi, Peoples R China; [Tan, Yanhong] Shanxi Med Univ, Affiliated Hosp 2, Inst Hematol, Taiyuan, Shanxi, Peoples R China; [Zhang, Cuiming] Shanxi Med Univ, Affiliated Hosp 2, Dept Ultrasound, Taiyuan, Shanxi, Peoples R China; [Xi, Yanfeng] Shanxi Med Univ, Affiliated Tumor Hosp, Dept Pathol, Taiyuan 030001, Shanxi, Peoples R China	Xu, J (reprint author), Shanxi Med Univ, Dept Pathol, 56 Xinjian South Rd, Taiyuan 030001, Shanxi, Peoples R China.; Xi, YF (reprint author), Shanxi Med Univ, Affiliated Tumor Hosp, Dept Pathol, Taiyuan 030001, Shanxi, Peoples R China.	xujing@sxmu.edu.cn; xiyanfeng1998@163.com			Science and Technology Innovation Fund of Shanxi Medical University [01201302]; Shanxi Scholarship Council of China [2011-046]; Fund Program for the Scientific Activities of Selected Returned Overseas Professionals in Shanxi Province [2011-762]; 331 Early Career Researcher Grant of the Basic Medical School, Shanxi Medical University Funding Statement [201407]	The Science and Technology Innovation Fund of Shanxi Medical University (01201302); Research Project Supported by Shanxi Scholarship Council of China (2011-046); Fund Program for the Scientific Activities of Selected Returned Overseas Professionals in Shanxi Province (2011-762); 331 Early Career Researcher Grant of the Basic Medical School, Shanxi Medical University Funding Statement (201407)	Bihari C, 2016, HEPATOLOGY, V64, P1273, DOI 10.1002/hep.28754; Chen Y, 2012, INT J BIOL SCI, V8, P992, DOI 10.7150/ijbs.4454; Chun HW, 2016, ONCOL LETT, V12, P1753, DOI 10.3892/ol.2016.4884; Coulouarn C, 2012, CARCINOGENESIS, V33, P1791, DOI 10.1093/carcin/bgs208; Ding XW, 2010, LIFE SCI, V86, P631, DOI 10.1016/j.lfs.2010.02.012; Dubois-Pot-Schneider H, 2014, HEPATOLOGY, V60, P2077, DOI 10.1002/hep.27353; Faiao-Flores F, 2017, ONCOGENE, V36, P1849, DOI 10.1038/onc.2016.348; Gonnissen A, 2016, ONCOTARGET, V7, P84286, DOI 10.18632/oncotarget.12483; Govaere O, 2014, GUT, V63, P674, DOI 10.1136/gutjnl-2012-304351; Jia SQ, 2013, GASTROENT RES PRACT, DOI 10.1155/2013/145253; Kasai K, 2016, PATHOL INT, V66, P653, DOI 10.1111/pin.12476; Katsuda T, 2017, CELL STEM CELL, V20, P41, DOI 10.1016/j.stem.2016.10.007; Kawai T, 2015, CLIN CANCER RES, V21, P3081, DOI 10.1158/1078-0432.CCR-14-1936; Kim H, 2004, J HEPATOL, V40, P298, DOI 10.1016/j.jhep.2003.10.023; Lara-Pezzi E, 2001, HEPATOLOGY, V33, P1270, DOI 10.1053/jhep.2001.1270; Lee JS, 2006, NAT MED, V12, P410, DOI 10.1038/nm1377; Lee TKW, 2011, CELL STEM CELL, V9, P50, DOI 10.1016/j.stem.2011.06.005; Li XY, 2017, CANCER LETT, V386, P35, DOI 10.1016/j.canlet.2016.10.044; Lubik AA, 2017, INT J CANCER, V140, P358, DOI 10.1002/ijc.30450; Ma S, 2008, MOL CANCER RES, V6, P1146, DOI 10.1158/1541-7786.MCR-08-0035; Malhi H, 2006, J HEPATOL, V45, P856, DOI 10.1016/j.jhep.2006.09.001; Murakami S, 2015, STEM CELLS, V33, P2652, DOI 10.1002/stem.2059; Oertel M, 2008, GASTROENTEROLOGY, V134, P823, DOI 10.1053/j.gastro.2008.01.007; Oikawa T, 2013, HEPATOLOGY, V57, P1469, DOI 10.1002/hep.26159; Roskams T, 2006, ONCOGENE, V25, P3818, DOI 10.1038/sj.onc.1209558; Schmelzer E, 2006, STEM CELLS, V24, P1852, DOI 10.1634/stemcells.2006-0036; Shan JJ, 2012, HEPATOLOGY, V56, P1004, DOI 10.1002/hep.25745; Shao J, 2016, MOL MED REP, V14, P4991, DOI 10.3892/mmr.2016.5899; Song LQ, 2016, ONCOL LETT, V12, P1027, DOI 10.3892/ol.2016.4722; Su RJ, 2016, HEPATOL RES, V46, P1380, DOI 10.1111/hepr.12687; Sureban SM, 2015, ONCOTARGET, V6, P37200, DOI 10.18632/oncotarget.5808; Tang CM, 2016, ONCOTARGET, V7, P78226, DOI 10.18632/oncotarget.12909; Wang RH, 2016, ONCOTARGET, V7, P5754, DOI 10.18632/oncotarget.6805; Wang T, 2016, SCI REP-UK, V6, DOI 10.1038/srep25183; Wolf B, 2016, CANCER RES, V76, P5550, DOI 10.1158/0008-5472.CAN-15-3453; Wu WD, 2016, ONCOTARGET, V7, P81144, DOI 10.18632/oncotarget.13214; Xu J, 2011, HISTOPATHOLOGY, V59, P1090, DOI 10.1111/j.1365-2559.2011.04058.x; Xu X, 2012, MOL CANCER THER, V11, P629, DOI 10.1158/1535-7163.MCT-11-0531; Yamashita T, 2013, HEPATOLOGY, V57, P1484, DOI 10.1002/hep.26168; Yamashita T, 2009, GASTROENTEROLOGY, V136, P1012, DOI 10.1053/j.gastro.2008.12.004; Ye F, 2014, CELL BIOSCI, V4, DOI 10.1186/2045-3701-4-50; Zhang F, 2008, HISTOPATHOLOGY, V52, P224, DOI 10.1111/j.1365-2559.2007.02929.x	42	0	0	1	3	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	DEC	2018	214	12					2011	2017		10.1016/j.prp.2018.09.005			7	Pathology	Pathology	HG0YQ	WOS:000454675600014	30301635				2019-10-28	
J	Samadaian, N; Salehipour, P; Ayati, M; Rakhshani, N; Najafi, A; Afsharpad, M; Yazarlou, F; Modarressi, MH				Samadaian, Niusha; Salehipour, Pouya; Ayati, Mohsen; Rakhshani, Naser; Najafi, Ali; Afsharpad, Mandana; Yazarlou, Fatemeh; Modarressi, Mohammad Hossein			A potential clinical significance of DAB2IP and SPRY2 transcript variants in prostate cancer	PATHOLOGY RESEARCH AND PRACTICE			English	Article						DAR2IP; SPRY2; Splice variants; Prostate cancer; Benign prostate hyperplasia	ABERRANT PROMOTER METHYLATION; PROTEIN HDAB2IP GENE; DOWN-REGULATION; CELL-PROLIFERATION; TUMOR-SUPPRESSOR; SPROUTY2; EXPRESSION; ACTIVATION; RESISTANCE; SURVIVAL	Deregulation of key signaling pathways is one of the primary phenomena in carcinogenesis. DAB2IP and SPRY2 are regulatory elements, which act as feedback inhibitors of receptor tyrosine kinases signaling in mitogen-activated protein kinase pathway. These elements have also been implicated in the pathophysiology of cancer. Therefore, this study is aimed to investigate the expression of all known splice variants of DAB2IP and SPRY2 in prostate tissue. Fresh Prostate tissue samples (50 prostate cancer/matched normal tissue and 30 BPH) were collected and total RNA was extracted followed by cDNA synthesis. The expression of DAB2IP and SPRY2 transcript variants were evaluated using RT-PCR and quantitative Real-time PCR. The results indicated significant down-regulation of DAB2IP transcript variant 1 in cancerous tissues compared to paired normal tissues (P = 0.001) as well as SPRY2 transcript variant 2 in cancerous tissues in comparison with the normal counterparts and BPH (P = 0.008 and P = 0.025, respectively). In addition, there was a significant negative correlation between DAB2IP.1 and SPRY2.2 expression with PSA levels in prostate cancer (P = 0.039 rho = -0.24 and P = 0.045 rho = -0.3, respectively). Interestingly, the down-regulation of DAB2IP.1 mRNA and SPRY2.2 mRNA was positively correlated in tumor samples (P = 0.002 rho = 0.434). For the first time, this experiment highlights the deregulation of DAB2IP and SPRY2 transcript variants in human prostate cancer. The present study confirms and extends the previous reports through indicating transcript-specific down-regulation and significant association of DAB2IP and SPRY2 in prostate tumorigenesis.	[Samadaian, Niusha; Salehipour, Pouya; Najafi, Ali; Yazarlou, Fatemeh; Modarressi, Mohammad Hossein] Univ Tehran Med Sci, Dept Med Genet, Tehran 1417613151, Iran; [Ayati, Mohsen] Univ Tehran Med Sci, Dept Urooncol, Res Ctr, Tehran 1417613151, Iran; [Rakhshani, Naser] Iran Univ Med Sci, Firoozgar Hosp, Gastrointestinal & Liver Dis Res Ctr, Tehran 1449614535, Iran; [Afsharpad, Mandana] Iran Univ Med Sci, Canc Control Res Ctr, Tehran 1449614535, Iran	Modarressi, MH (reprint author), Univ Tehran Med Sci, Dept Med Genet, Tehran 1417613151, Iran.	n-samadaian@razi.tums.ac.ir; P-Salehipour@razi.tums.ac.ir; drayati_mohsen@yahoo.com; n_rakhshani@yahoo.com; Alinajafi2006@gmail.com; m.afsharpad@gmail.com; f_yazarlou@razi.tums.ac.ir; Modaresi@tums.ac.ir		Modarressi, Mohammad hossein/0000-0003-2763-1964; Salehipour, Pouya/0000-0001-8247-0003	Tehran University of Medical SciencesTehran University of Medical Sciences [96-04-30-36452]	The authors would like to thank the Medical Genetics Department at Tehran University of Medical Sciences and the Mehr Hospital for providing assistance and prostate cancer samples, respectively. This study was supported by the Tehran University of Medical Sciences [96-04-30-364521.	Barbachano A, 2010, ONCOGENE, V29, P4800, DOI 10.1038/onc.2010.225; Bustin SA, 2009, CLIN CHEM, V55, P611, DOI 10.1373/clinchem.2008.112797; Chen H, 2003, J BIOL CHEM, V278, P3121, DOI 10.1074/jbc.M208230200; Climente-Gonzalez H, 2017, CELL REP, V20, P2215, DOI 10.1016/j.celrep.2017.08.012; Dote H, 2004, CLIN CANCER RES, V10, P2082, DOI 10.1158/1078-0432.CCR-03-0236; Dote H, 2005, BRIT J CANCER, V92, P1117, DOI 10.1038/sj.bjc.6602458; Faratian D, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023772; Feng YH, 2011, CANCER BIOL THER, V11, P111, DOI 10.4161/cbt.11.1.13965; Fong CW, 2006, CANCER RES, V66, P2048, DOI 10.1158/0008-5472.CAN-05-1072; Fritzsche S, 2006, ENDOCR-RELAT CANCER, V13, P839, DOI 10.1677/erc.1.01190; Jacobs C, 2015, CANCER MED-US, V4, P1844, DOI 10.1002/cam4.554; Katoh K, 2013, MOL BIOL EVOL, V30, P772, DOI 10.1093/molbev/mst010; Lee SA, 2008, HEPATOLOGY, V47, P1200, DOI 10.1002/hep.22169; Lee TY, 2012, BMC GENOMICS, V13, DOI 10.1186/1471-2164-13-S1-S3; Liao PH, 2018, ARCH ORAL BIOL, V87, P131, DOI 10.1016/j.archoralbio.2017.12.021; Lin CL, 2015, MOL MED REP, V11, P547, DOI 10.3892/mmr.2014.2700; Liu L, 2016, ONCOTARGET, V7, P3766, DOI 10.18632/oncotarget.6501; Lo TL, 2006, CANCER LETT, V242, P141, DOI 10.1016/j.canlet.2005.12.032; Maertens Ophelia, 2014, Advances in Biological Regulation, V55, P1, DOI 10.1016/j.jbior.2014.04.002; McKie AB, 2005, ONCOGENE, V24, P2166, DOI 10.1038/sj.onc.1208371; Patel R, 2013, J CLIN INVEST, V123, P1157, DOI 10.1172/JCI63672; Qiu GH, 2007, J HEPATOL, V46, P655, DOI 10.1016/j.jhep.2006.11.012; Qu Hongzhu, 2013, Genomics Proteomics & Bioinformatics, V11, P135, DOI 10.1016/j.gpb.2013.05.001; Schutzman JL, 2012, P NATL ACAD SCI USA, V109, P20023, DOI 10.1073/pnas.1217204109; Shen YJ, 2014, CANCER SCI, V105, P704, DOI 10.1111/cas.12407; Siegel RL, 2018, CA-CANCER J CLIN, V68, P7, DOI 10.3322/caac.21442; So WK, 2015, FEBS LETT, V589, P302, DOI 10.1016/j.febslet.2014.12.012; Wu K, 2014, ONCOGENE, V33, P1954, DOI 10.1038/onc.2013.143; Xie DX, 2010, P NATL ACAD SCI USA, V107, P2485, DOI 10.1073/pnas.0908133107; Xu YF, 2017, ONCOTARGET, V8, P4888, DOI 10.18632/oncotarget.13982; Yang C, 2016, MOL MED REP, V14, P567, DOI 10.3892/mmr.2016.5281; Yano M, 2005, INT J CANCER, V113, P59, DOI 10.1002/ijc.20531; Yao Y, 2016, EXP HEMATOL, V44, P474, DOI 10.1016/j.exphem.2016.02.009; Zhou J, 2016, ONCOGENE, V35, P4663, DOI 10.1038/onc.2016.4; Zhou J, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.289	35	1	1	0	2	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	DEC	2018	214	12					2018	2024		10.1016/j.prp.2018.09.019			7	Pathology	Pathology	HG0YQ	WOS:000454675600015	30301636				2019-10-28	
J	Fan, SC; Gao, HS; Sun, LZ; Zhu, FW; Zhou, R; Zhang, WX; Yan, YH; Gao, YL				Fan, Shaochen; Gao, Huasong; Sun, Lingzheng; Zhu, Fengwei; Zhou, Rui; Zhang, Weixun; Yan, Yaohua; Gao, Yilu			Knockdown of DSPP inhibits the migration and invasion of glioma cells	PATHOLOGY RESEARCH AND PRACTICE			English	Article						Glioma; DSPP; Migration; Knockdown; AKT/mTOR/p70S6K signaling pathway	EXPRESSION; PROTEINS; PROLIFERATION; OSTEOPONTIN; SURVIVAL; FAMILY	Dentin sialophosphoprotein (DSPP) is a member of the SIBLING (Small integrin-binding ligand N-linked glycoproteins) family of phosphoglycoproteins and has been proved to contribute to the migration of a variety of solid tumor cells. However, whether DSPP participates in the pathogenic process of glioma remains unknown. In this study, we aimed to investigate the expression and biological function of DSPP in human glioma cells. We demonstrated through Western blot that DSPP is overexpressed in glioma tissues comparing to normal brain tissues. To investigate the role of DSPP in glioma carcinogenesis, we reduced the DSPP expression by small interfering RNA (siRNA) and found that DSPP silencing significantly inhibited the migration and invasion of glioma cells, the critical characteristics of glioma. Furthermore, we showed that DSPP down-regulation significantly decreased the activation of the AKT/mTOR/p70S6K pathway in glioma cells. Taken together, these findings indicate that knockdown of DSPP inhibits glioma cells migration and invasion, suggesting that targeting DSPP might be a potentially effective therapeutic strategy for treating glioma.	[Fan, Shaochen; Sun, Lingzheng; Zhu, Fengwei; Zhou, Rui; Zhang, Weixun; Yan, Yaohua; Gao, Yilu] Nantong Univ, Affiliated Hosp, Dept Neurosurg, Nantong, Jiangsu, Peoples R China; [Gao, Huasong] Fudan Univ, Huashan Hosp, Dept Neurosurg, Shanghai, Peoples R China	Yan, YH; Gao, YL (reprint author), Nantong Univ, Affiliated Hosp, Dept Neurosurg, Nantong, Jiangsu, Peoples R China.	ntuyyh@126.com; yilugao2015@163.com			National Natural Science Foundation of ChinaNational Natural Science Foundation of China [81371335]; Postgraduate Research & Practice Innovation Program of Jiangsu Province [KYCX18_2407]	This work was supported by the National Natural Science Foundation of China (No. 81371335) and the Postgraduate Research & Practice Innovation Program of Jiangsu Province (KYCX18_2407).	Atai NA, 2011, IMMUNOLOGY, V132, P39, DOI 10.1111/j.1365-2567.2010.03335.x; Bellahcene A, 2008, NAT REV CANCER, V8, P212, DOI 10.1038/nrc2345; Butler WT, 2002, CONNECT TISSUE RES, V43, P301, DOI 10.1080/03008200290000682; Chaplet M, 2006, INT J CANCER, V118, P850, DOI 10.1002/ijc.21442; Clarke J, 2010, ARCH NEUROL-CHICAGO, V67, P279, DOI 10.1001/archneurol.2010.5; Eyler CE, 2011, CELL, V146, P53, DOI 10.1016/j.cell.2011.06.006; Fisher LW, 2004, CLIN CANCER RES, V10, P8501, DOI 10.1158/1078-0432.CCR-04-1072; Fisher LW, 2003, CONNECT TISSUE RES, V44, P33, DOI 10.1080/03008200390152061; GEORGE A, 1993, J BIOL CHEM, V268, P12624; Hunter GK, 1996, BIOCHEM J, V317, P59, DOI 10.1042/bj3170059; Joshi R, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013974; Krex D, 2007, BRAIN, V130, P2596, DOI 10.1093/brain/awm204; Lamour V, 2010, INT J CANCER, V126, P1797, DOI 10.1002/ijc.24751; Li XM, 2016, ONCOTARGET, V7, P33440, DOI [10.18632/oncotarget.7961, 10.18632/oncotarget.6497]; Manji HK, 2003, BIOL PSYCHIAT, V53, P707, DOI 10.1016/S0006-3223(03)00117-3; Martelli AM, 2010, ONCOTARGET, V1, P89, DOI 10.18632/oncotarget.114; Mitra A, 2012, CYTOKINE, V60, P38, DOI 10.1016/j.cyto.2012.06.316; Mrugala MM, 2013, DISCOV MED, V15, P221; Ogbureke KUE, 2007, J HISTOCHEM CYTOCHEM, V55, P403, DOI 10.1369/jhc.6A7075.2007; Ostrom QT, 2014, NEURO-ONCOLOGY, V16, P1, DOI 10.1093/neuonc/nou223; Qin C, 2004, CRIT REV ORAL BIOL M, V15, P126, DOI 10.1177/154411130401500302; Schultz CR, 2012, MOL CANCER, V11, DOI 10.1186/1476-4598-11-20; Song Y., 2014, MOL CANC, V13; Street A, 2004, J BIOL CHEM, V279, P12232, DOI 10.1074/jbc.M312245200; Stupp R, 2005, NEW ENGL J MED, V352, P987, DOI 10.1056/NEJMoa043330; Tian BQ, 2017, J DRUG TARGET, V25, P626, DOI 10.1080/1061186X.2017.1306535; Van Meir EG, 2010, CA-CANCER J CLIN, V60, P166, DOI 10.3322/caac.20069; Wen PY, 2008, NEW ENGL J MED, V359, P492, DOI 10.1056/NEJMra0708126	28	0	0	1	1	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	DEC	2018	214	12					2025	2030		10.1016/j.prp.2018.09.024			6	Pathology	Pathology	HG0YQ	WOS:000454675600016	30309696				2019-10-28	
J	Yan, YM; Yu, J; Liu, HC; Guo, SR; Zhang, Y; Ye, YF; Xu, LJ; Ming, L				Yan, Yunmeng; Yu, Jing; Liu, Hongchun; Guo, Shuren; Zhang, Yan; Ye, Yafei; Xu, Lijuan; Ming, Liang			Construction of a long non-coding RNA-associated ceRNA network reveals potential prognostic lncRNA biomarkers in hepatocellular carcinoma	PATHOLOGY RESEARCH AND PRACTICE			English	Article						Competitive endogenous RNA; Long non-coding RNAs; Liver hepatocellular carcinoma; Prognostic biomarker	POOR-PROGNOSIS; SNHG20 PREDICTS; RESOURCE; HYPOTHESIS; TARGETS	Objectives: Hepatocellular carcinoma (HCC) is the sixth leading cause of cancer-related mortality in the world. Accumulating evidence has highlighted the regulatory roles of long non-coding RNAs (lncRNAs) acting as competing endogenous RNAs (ceRNAs) in HCC. Methods: The lncRNA expression data and corresponding patient information were obtained from The Cancer Genome Atlas (TCGA) database. Competing lncRNA-mRNA interactions were identified using the hypergeometric test. Co-expression analysis was implemented using the Spearman correlation coefficient. Multivariate Cox regression survival analysis was utilized to extract prognostic lncRNAs in the network. Results: Based on the "ceRNA hypothesis", a global lncRNA-associated ceRNA network (LCeNET) in HCC was constructed. Nine lncRNAs were identified as hubs and found to be enriched in various cancer-related biological processes. In addition, ceRNA pairs associated with survival were screened to construct a lncRNA-miRNA-mRNA sub network. Finally, we developed a sixteen-lncRNA model that could classify patients into high- and low-risk subgroups with different survival outcomes, and MCM3AP-AS1 functioned as a hub in both LCeNET and prognostic model. Conclusions: Our work will improve the understanding of lncRNA-mediated ceRNA regulatory mechanisms in HCC pathogenesis and facilitate the identification of candidate prognostic biomarkers for HCC.	[Yan, Yunmeng; Yu, Jing; Liu, Hongchun; Guo, Shuren; Zhang, Yan; Ye, Yafei; Xu, Lijuan; Ming, Liang] Zhengzhou Univ, Affiliated Hosp 1, Dept Clin Lab, Key Clin Lab Henan Prov, Zhengzhou 450052, Henan, Peoples R China	Ming, L (reprint author), 1 Jianshe Rd East, Zhengzhou, Henan, Peoples R China.	medscience1@163.com					AKANO N, 1989, VIRCHOWS ARCH A, V414, P325, DOI 10.1007/BF00734087; Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002; Betel D, 2008, NUCLEIC ACIDS RES, V36, pD149, DOI 10.1093/nar/gkm995; Cao YZ, 2016, ONCOTARGET, V7, P41737, DOI 10.18632/oncotarget.9569; Dhanasekaran R, 2012, HEPATIC MED-EVID RES, V4, P19, DOI 10.2147/HMER.S16316; Hsu SD, 2011, NUCLEIC ACIDS RES, V39, pD163, DOI 10.1093/nar/gkq1107; Huang RY, 2016, CELL PHYSIOL BIOCHEM, V40, P707, DOI 10.1159/000452582; Jeggari A, 2012, BIOINFORMATICS, V28, P2062, DOI 10.1093/bioinformatics/bts344; Kataoka Masaharu, 2014, Cells, V3, P883, DOI 10.3390/cells3030883; Li T, 2016, ONCOGENE, V35, P1575, DOI 10.1038/onc.2015.223; Liu JX, 2017, BIOMED PHARMACOTHER, V89, P857, DOI 10.1016/j.biopha.2017.01.011; Liu Z, 2017, EJSO-EUR J SURG ONC, V43, P1697, DOI 10.1016/j.ejso.2017.06.013; Paraskevopoulou MD, 2016, NUCLEIC ACIDS RES, V44, pD231, DOI 10.1093/nar/gkv1270; Petrick JL, 2016, INT J CANCER, V139, P1534, DOI 10.1002/ijc.30211; Ponting CP, 2009, CELL, V136, P629, DOI 10.1016/j.cell.2009.02.006; Qi XL, 2015, J MED GENET, V52, P710, DOI 10.1136/jmedgenet-2015-103334; Qiu MT, 2013, TUMOR BIOL, V34, P613, DOI 10.1007/s13277-013-0658-6; Salmena L, 2011, CELL, V146, P353, DOI 10.1016/j.cell.2011.07.014; Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303; Tay Y, 2014, NATURE, V505, P344, DOI 10.1038/nature12986; Tian F, 2017, BIOSCIENCE REP, V37, DOI 10.1042/BSR20170301; Tomczak Katarzyna, 2015, Contemp Oncol (Pozn), V19, pA68, DOI 10.5114/wo.2014.47136; Villanueva A, 2010, ANNU REV MED, V61, P317, DOI 10.1146/annurev.med.080608.100623; Wong CM, 2018, NAT REV GASTRO HEPAT, V15, P137, DOI 10.1038/nrgastro.2017.169; Wong N, 2015, NUCLEIC ACIDS RES, V43, pD146, DOI 10.1093/nar/gku1104; Xiao FF, 2009, NUCLEIC ACIDS RES, V37, pD105, DOI 10.1093/nar/gkn851; Yang C, 2016, ONCOTARGET, V7, P13479, DOI 10.18632/oncotarget.7266; Yang Chunqing, 2017, Front Mol Neurosci, V10, P437, DOI 10.3389/fnmol.2017.00437; Zhang DY, 2016, J CANCER, V7, P608, DOI 10.7150/jca.13822; Zhang M, 2016, BIOMED PHARMACOTHER, V80, P73, DOI 10.1016/j.biopha.2016.02.036	30	3	4	2	7	ELSEVIER GMBH	MUNICH	HACKERBRUCKE 6, 80335 MUNICH, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	DEC	2018	214	12					2031	2038		10.1016/j.prp.2018.09.022			8	Pathology	Pathology	HG0YQ	WOS:000454675600017	30316688				2019-10-28	
J	Hu, JH; Ruan, JG; Liu, XH; Xiao, CJ; Xiong, JP				Hu, Jinhua; Ruan, Jiugen; Liu, Xiaohong; Xiao, Chijin; Xiong, Jianping			MicroRNA-301a-3p suppressed the progression of hepatocellular carcinoma via targeting VGLL4	PATHOLOGY RESEARCH AND PRACTICE			English	Article						miR-301a-3p; Hepatocellular carcinoma; VGLL4	CANCER; EXPRESSION; MIR-301A; ACTS	Dysregulation of microRNAs (miRNAs) is involved in a variety of biological process including tumorigenesis. miR-301a-3p has been reported to be an onco-miRNA in various types of cancer, like breast cancer, malignant melanoma, and pancreatic cancer. However, the role of miR-301a-3p in hepatocellular carcinoma (HCC) remains largely incomplete. In the present study, we found that miR-301a-3p was upregulated in HCC tissues and cell lines, and higher miR-301a-3p expression predicted poor prognosis in HCC patients. We also demonstrated that miR-301a-3p overexpression enhanced the ability of proliferation, invasion, and chemoresistance in HCC cell lines, and conversely, silencing miR-301a-3p expression induced the opposite effects. VGLL4, as the direct target of miR-301a-3p, was predicted by bioinformatic websites and confirmed by western blot, RT-PCR, and luciferase reporter assay. Enforced VGLL4 expression rescued the effects of miR-301a-3p mimics on cell proliferation, invasion and chemoresistance. Moreover, we found miR-301a-3p modulated the transcription activity of TEADs. Collectively, our findings suggested that the miR-301a-3p-VGLL4 signaling axis might be a potential therapeutic target for HCC.	[Hu, Jinhua; Liu, Xiaohong; Xiao, Chijin] Peoples Hosp Xinyu City, Dept Oncol, Xinyu 338000, Jiangxi, Peoples R China; [Hu, Jinhua; Xiong, Jianping] Nanchang Univ, Affiliated Hosp 1, Dept Oncol, Nanchang 330006, Jiangxi, Peoples R China; [Ruan, Jiugen] Peoples Hosp Xinyu City, Dept Radiol, Xinyu 338000, Jiangxi, Peoples R China	Xiong, JP (reprint author), Nanchang Univ, Affiliated Hosp 1, Dept Oncol, Nanchang 330006, Jiangxi, Peoples R China.	jpxiong610@sohu.com			National Natural Science Foundation of ChinaNational Natural Science Foundation of China [81160281, 81441083, 81660405]; National Natural Science Foundation of JiangXi Province [20152ACB20024, 20151BBG70228]	This work was supported by the National Natural Science Foundation of China (grant nos. 81160281, 81441083, and 81660405), the, and the National Natural Science Foundation of JiangXi Province (grant nos. 20152ACB20024 and 20151BBG70228).	Ambros V, 2004, NATURE, V431, P350, DOI 10.1038/nature02871; Cui L, 2016, CELL PHYSIOL BIOCHEM, V40, P230, DOI 10.1159/000452540; Garzon R, 2009, ANNU REV MED, V60, P167, DOI 10.1146/annurev.med.59.053006.104707; Guo T, 2013, CELL RES, V23, P1201, DOI 10.1038/cr.2013.120; He C, 2016, GUT, V65, P1938, DOI 10.1136/gutjnl-2015-309389; Jansson MD, 2012, MOL ONCOL, V6, P590, DOI 10.1016/j.molonc.2012.09.006; Jiao S, 2014, CANCER CELL, V25, P166, DOI 10.1016/j.ccr.2014.01.010; Jin HS, 2011, BIOCHEM BIOPH RES CO, V412, P454, DOI 10.1016/j.bbrc.2011.07.117; Koontz LM, 2013, DEV CELL, V25, P388, DOI 10.1016/j.devcel.2013.04.021; Lettlova S, 2018, CELL PHYSIOL BIOCHEM, V46, P2601, DOI 10.1159/000489687; Liu L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055532; Lu Y, 2015, J CANCER, V6, P1260, DOI 10.7150/jca.12659; Lu ZX, 2011, EMBO J, V30, P57, DOI 10.1038/emboj.2010.296; Ma FX, 2013, CYTOTHERAPY, V15, P1511, DOI 10.1016/j.jcyt.2013.06.007; Mycko MP, 2012, P NATL ACAD SCI USA, V109, pE1248, DOI 10.1073/pnas.1114325109; Peng Y, 2016, SIGNAL TRANSDUCT TAR, V1, DOI 10.1038/sigtrans.2015.4; Shi W, 2011, CANCER RES, V71, P2926, DOI 10.1158/0008-5472.CAN-10-3369; Sun KL, 2013, NAT REV GENET, V14, P535, DOI 10.1038/nrg3471; Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262; Wang M, 2013, J GASTROENTEROL, V48, P1023, DOI 10.1007/s00535-012-0733-6; Wang XF, 2018, CANCER RES, V78, P4586, DOI 10.1158/0008-5472.CAN-17-3841; Xia X, 2015, ONCOTARGET, V6, P21046, DOI 10.18632/oncotarget.4124; Zhang WJ, 2014, CELL RES, V24, P331, DOI 10.1038/cr.2014.10	23	4	4	1	1	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	DEC	2018	214	12					2039	2045		10.1016/j.prp.2018.09.008			7	Pathology	Pathology	HG0YQ	WOS:000454675600018	30322806				2019-10-28	
J	Song, XY; Zhao, CR; Jiang, LY; Lin, S; Bi, J; Wei, Q; Yu, LF; Zhao, L; Wei, MJ				Song, Xinyue; Zhao, Chaoran; Jiang, Longyang; Lin, Shu; Bi, Jia; Wei, Qian; Yu, Lifeng; Zhao, Lin; Wei, Minjie			High PITX1 expression in lung adenocarcinoma patients is associated with DNA methylation and poor prognosis	PATHOLOGY RESEARCH AND PRACTICE			English	Article						PITX1; Overall survival; DNA methylation; Lung adenocarcinoma	CANCER STATISTICS; CLINICOPATHOLOGICAL FEATURES; GENE-EXPRESSION; CELL CARCINOMA; EPIGENETICS; PROGRESSION; DIAGNOSIS; PROTEIN	Background: Pituitary homeobox 1 (PITX1) is a member of the PITX gene family which is vital to proper development of early embryo. However, the relationship of PITX1 expression and overall survival (OS) in non-small cell lung cancer (NSCLC) is not clear. Methods: In our study, bioinformatic analysis was performed using UCSC Xena Browser. We used data based on the Cancer Genome Atlas-lung cancer (TCGA-LUNG). Kaplan Meier curves of overall survival were used to investigate the association between PITX1 gene expression and OS in NSCLC patients by the UCSC Xena browser. Results: Compared with normal lung tissue, PITX gene family was upregulated in NSCLC. Furthermore, higher PITX1 expression was significantly associated with worse OS in 2 yrs., 5 yrs. and 10 yrs. OS (p = 0.004754, 0.01469, 0.02935 respectively) in lung adenocarcinoma (LUAD) patients, but not in lung squamous cell carcinoma (LUSC) patients. PITX1 expression increased in male patients, advanced TNM stage, advanced T stage and advanced regional lymph node status of LUAD patients. PITX1 expressed lowest in bronchioid subtype, meanwhile PITX1 expression was highest in squamoid and magnoid subtype. The high DNA methylation of PITX1 indicated the poor OS in LUAD patients. GSEA revealed that inflammatory response, TNF alpha signaling via NE kappa B, TGF beta signaling, IL6 JAK STAT3 signaling and interferon Gamma response were significantly enriched in high PITX1 expression. Conclusion: These findings suggested that PITX1 might serve as a potential biomarker for early detection and prognosis prediction of LUAD patients.	[Song, Xinyue; Zhao, Chaoran; Jiang, Longyang; Lin, Shu; Bi, Jia; Wei, Qian; Yu, Lifeng; Zhao, Lin; Wei, Minjie] China Med Univ, Dept Pharmacol, Sch Pharm, Shenyang North New Area, 77 Puhe Rd, Shenyang 110122, Liaoning, Peoples R China; [Song, Xinyue; Zhao, Chaoran; Jiang, Longyang; Lin, Shu; Bi, Jia; Wei, Qian; Yu, Lifeng; Zhao, Lin; Wei, Minjie] China Med Univ, Liaoning Key Lab Mol Targeted Antitumor Drug Dev, Shenyang North New Area, 77 Puhe Rd, Shenyang 110122, Liaoning, Peoples R China	Zhao, L; Wei, MJ (reprint author), China Med Univ, Dept Pharmacol, Sch Pharm, Shenyang North New Area, 77 Puhe Rd, Shenyang 110122, Liaoning, Peoples R China.	zl_cmu@163.com; weiminjiecmu@163.com			National Natural Science Foundation of ChinaNational Natural Science Foundation of China [81673475, 81601370, U1608281]; Liaoning Province Scientific Research Foundation [2014226033]; Key Laboratory Foundation from Shenyang ST Projects [F16-094-1-00]; Shenyang ST Projects [17-123-9-00]; National Natural Science Foundation of Liaoning [U1608281]	This work was supported by National Natural Science Foundation of China and Liaoning joint fund key program (No. U1608281), National Natural Science Foundation of China (No. 81673475, 81601370), Liaoning Province Scientific Research Foundation (2014226033), the Key Laboratory Foundation from Shenyang S&T Projects (F16-094-1-00) and Shenyang S&T Projects (17-123-9-00).	Ansari J, 2016, TRANSL LUNG CANCER R, V5, P155, DOI 10.21037/tlcr.2016.02.02; Ariyo EO, 2017, BIOCHEM BIOPH RES CO, V487, P274, DOI 10.1016/j.bbrc.2017.04.049; Barut F, 2016, KAOHSIUNG J MED SCI, V32, P494, DOI 10.1016/j.kjms.2016.08.001; Chen RH, 2017, ONCOL LETT, V14, P4989, DOI 10.3892/ol.2017.6824; Chen Y, 2007, LUNG CANCER, V55, P287, DOI 10.1016/j.lungcan.2006.11.001; Chen Z, 2014, NAT REV CANCER, V14, P535, DOI 10.1038/nrc3775; Forde PM, 2014, CLIN CANCER RES, V20, P2244, DOI 10.1158/1078-0432.CCR-13-2088; Herbst RS, 2008, NEW ENGL J MED, V359, P1367, DOI 10.1056/NEJMra0802714; Holland PWH, 2013, WIRES DEV BIOL, V2, P31, DOI 10.1002/wdev.78; Jazi MS, 2016, TUMOR BIOL, V37, P10329, DOI 10.1007/s13277-016-4901-9; Jezkova E, 2016, TUMOR BIOL, V37, P15707, DOI 10.1007/s13277-016-5324-3; Jones PA, 2012, NAT REV GENET, V13, P484, DOI 10.1038/nrg3230; Knosel T, 2012, INT J COLORECTAL DIS, V27, P1391, DOI 10.1007/s00384-012-1460-4; Koch A, 2015, BMC GENOMICS, V16, DOI 10.1186/s12864-015-1847-z; Kolfschoten IGM, 2005, CELL, V121, P849, DOI 10.1016/j.cell.2005.04.017; Lanctot C, 1999, DEVELOPMENT, V126, P1805; Lanctot C, 1997, DEVELOPMENT, V124, P2807; Li Y., 2017, ONCOTARGET, V8; Liu DX, 2007, CELL DEATH DIFFER, V14, P1893, DOI 10.1038/sj.cdd.4402209; Liu YN, 2018, CANCER BIOMARK, V21, P11, DOI 10.3233/CBM-170164; Mehta A, 2015, CANCER METAST REV, V34, P229, DOI 10.1007/s10555-015-9563-3; Ohira T, 2015, SCI REP-UK, V5, DOI 10.1038/srep08201; Pierceall WE, 2012, ANN ONCOL, V23, P2245, DOI 10.1093/annonc/mdr624; Sailer V, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0179412; Sailer V, 2017, CLIN EPIGENETICS, V9, DOI 10.1186/s13148-017-0317-7; Siegel RL, 2018, CA-CANCER J CLIN, V68, P7, DOI 10.3322/caac.21442; Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387; Suva ML, 2013, SCIENCE, V339, P1567, DOI 10.1126/science.1230184; Tai WT, 2016, HEPATOLOGY, V63, P1528, DOI 10.1002/hep.28478; Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262; Travis WD, 2011, J THORAC ONCOL, V6, P244, DOI 10.1097/JTO.0b013e318206a221; Travis WD, 2010, J THORAC ONCOL, V5, P411, DOI 10.1097/JTO.0b013e3181d57f6e; Um SW, 2017, CLIN EPIGENETICS, V9, DOI 10.1186/s13148-017-0432-5; Vizoso M, 2015, CARCINOGENESIS, V36, P1453, DOI 10.1093/carcin/bgv146; Wei JH, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9699; Yu ZH, 2014, INT J MOL MED, V34, P1409, DOI 10.3892/ijmm.2014.1923; Zhan C, 2015, J THORAC DIS, V7, P1398, DOI 10.3978/j.issn.2072-1439.2015.07.25; Zhou S., 2018, PLOS ONE, V12	38	0	0	0	3	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	DEC	2018	214	12					2046	2053		10.1016/j.prp.2018.09.025			8	Pathology	Pathology	HG0YQ	WOS:000454675600019	30322808				2019-10-28	
J	Lu, GH; Duan, J; Zhou, DW				Lu, Guohui; Duan, Jian; Zhou, Dongwei			Long-noncoding RNA IFNG-AS1 exerts oncogenic properties by interacting with epithelial splicing regulatory protein 2 (ESRP2) in pituitary adenomas	PATHOLOGY RESEARCH AND PRACTICE			English	Article						Pituitary adenoma (PA); Long noncoding RNA IFNG-AS1 (IFNG-AS1); Epithelial splicing regulatory protein 2 (ESRP2); Oncogene	EXPRESSION; INVASION; CANCER; HOTAIR; MEG3	Despite the enormous development of medical technologies in recent decades, pituitary adenoma (PA) remains among the most refractory cancers in the world. Elucidating the molecular mechanisms underlying the pathology of PA is essential to identify new treatments for PA. In the present study, we found that IFNG-AS1 expression was significantly higher in PA tissues than in nontumor tissues via qRT-PCR and RNA fluorescence in situ hybridization (FISH). shRNA-mediated IFNG-AS1 knockdown in HP75 cells significantly inhibited tumor progression, and IFNG-AS1 overexpression remarkably promoted tumor progression. Epithelial splicing regulatory protein 2 (ESRP2) was demonstrated to be a target protein of IFNG-AS1 in PA; knocking down ESRP2 reversed the tumor-inhibitory effects of IFNG-AS1 knockdown, and overexpressing ESRP2 abolished the tumor-promoting effects of IFNG-AS1 overexpression in HP75 cells. In conclusion, our findings suggested that IFNG-AS1 may function as an oncogene in PA by interacting with ESRP2.	[Lu, Guohui; Duan, Jian; Zhou, Dongwei] Nanchang Univ, Affiliated Hosp 1, Dept Neurosurg, 17 Yong Wai Zheng Jie, Nanchang 330006, Jiangxi, Peoples R China	Zhou, DW (reprint author), Nanchang Univ, Affiliated Hosp 1, Dept Neurosurg, 17 Yong Wai Zheng Jie, Nanchang 330006, Jiangxi, Peoples R China.	doc_zhoudw@21cn.com			National Natural Science Foundation of ChinaNational Natural Science Foundation of China [81560220]; Key Project of Jiangxi Youth Science Foundation [20171ACB21054]; Youth Science Fund of Jiangxi Province [20151BAB215014]; Jiangxi Provincial Department of Education Science and Technology Research Project [GJJ160133]	This work was supported by the National Natural Science Foundation of China (81560220); the Key Project of Jiangxi Youth Science Foundation (20171ACB21054); the Youth Science Fund of Jiangxi Province (20151BAB215014); Jiangxi Provincial Department of Education Science and Technology Research Project (GJJ160133).	Aflorei ED, 2014, J NEURO-ONCOL, V117, P379, DOI 10.1007/s11060-013-1354-5; Asa SL, 2009, ANNU REV PATHOL-MECH, V4, P97, DOI 10.1146/annurev.pathol.4.110807.092259; Bayega A, 2018, METHODS MOL BIOL, V1783, P121, DOI 10.1007/978-1-4939-7834-2_6; Bhate A, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9768; Binse I, 2014, HORM METAB RES, V46, P644, DOI 10.1055/s-0034-1383566; Chen BB, 2018, J CELL MOL MED, V22, P4751, DOI 10.1111/jcmm.13726; Cheng WS, 2014, EUR REV MED PHARMACO, V18, P3504; Deloria AJ, 2016, ONCOTARGET, V7, P73800, DOI 10.18632/oncotarget.12070; Di Ieva A, 2014, NAT REV ENDOCRINOL, V10, P423, DOI 10.1038/nrendo.2014.64; Fu DX, 2018, AM J CANCER RES, V8, P245; Han YX, 2015, BIOINFORM BIOL INSIG, V9, P29, DOI 10.4137/BBI.S28991; Jeong HM, 2017, ONCOGENESIS, V6, DOI 10.1038/oncsis.2017.89; Jeong HM, 2017, ONCOGENESIS, V6, DOI 10.1038/oncsis.2017.87; Johnsson P, 2014, BBA-GEN SUBJECTS, V1840, P1063, DOI 10.1016/j.bbagen.2013.10.035; Laws ER, 2019, J ENDOCRINOL INVEST, V42, P129, DOI 10.1007/s40618-018-0901-5; Li JY, 2017, ONCOTARGET, V8, P4595, DOI 10.18632/oncotarget.13948; Li LM, 2018, AM J PATHOL, V188, P1882, DOI 10.1016/j.ajpath.2018.04.012; Li ZY, 2015, PITUITARY, V18, P42, DOI 10.1007/s11102-014-0554-0; Lu CW, 2018, CANCER MED-US, V7, P3792, DOI 10.1002/cam4.1571; Meij BP, 2002, J NEUROSURG, V96, P195, DOI 10.3171/jns.2002.96.2.0195; Melmed S, 2011, NAT REV ENDOCRINOL, V7, P257, DOI 10.1038/nrendo.2011.40; Nagy Z, 2017, MED HYPOTHESES, V99, P40, DOI 10.1016/j.mehy.2016.12.007; Padua D, 2016, AM J PHYSIOL-GASTR L, V311, pG446, DOI 10.1152/ajpgi.00212.2016; Raverot G, 2012, CLIN ENDOCRINOL, V76, P769, DOI 10.1111/j.1365-2265.2012.04381.x; Trouillas J, 2018, EUR J ENDOCRINOL, V178, pC7, DOI 10.1530/EJE-18-0250; Wang JC, 2018, CLIN CHIM ACTA, V485, P229, DOI 10.1016/j.cca.2018.07.004; Warzecha CC, 2009, MOL CELL, V33, P591, DOI 10.1016/j.molcel.2009.01.025; Yu D, 2018, PEERJ, V6, DOI 10.7717/peerj.5011; Yu X, 2015, MOL MED REP, V12, P5611, DOI 10.3892/mmr.2015.4161; Zhong XT, 2018, J BUON, V23, P776	30	1	1	0	1	ELSEVIER GMBH	MUNICH	HACKERBRUCKE 6, 80335 MUNICH, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	DEC	2018	214	12					2054	2061		10.1016/j.prp.2018.09.023			8	Pathology	Pathology	HG0YQ	WOS:000454675600020	30322807				2019-10-28	
J	Yao, YY; Liu, Z; Guo, H; Huang, SS; Zhong, M; Deng, J; Xiong, JP				Yao, Yangyang; Liu, Zhen; Guo, Hui; Huang, Shanshan; Zhong, Min; Deng, Jun; Xiong, Jianping			Elevated TRIM23 expression predicts poor prognosis in Chinese gastric cancer	PATHOLOGY RESEARCH AND PRACTICE			English	Article						TRIM23; Gastric cancer; Biomarker; Prognosis	NF-KAPPA-B; PROTEINS; ROLES; PROLIFERATION; SURVIVAL; CELLS	The gene TRIM23 (tripartite motif containing 23) is a member of the tripartite motif (TRIM) family whose expression putatively participates in many pathophysiological processes. Nonetheless, the role of TRIM23 in gastric cancer (GC) remains uncertain. Our study evaluated the expression of TRIM23 in GC tissues and cell lines, and investigated an association between TRIM23 and survival. In the present study, our results demonstrated that TRIM23 mRNA and protein were frequently over-expressed in GC cell lines and GC tissues. High level of TRIM23 protein correlated with tumor size, tumor-node-metastasis (TNM) stage, depth of invasion, lymph node metastasis (LNM), tumor differentiation, and nerve invasion. Compared with the low TRIM23 protein group, the high TRIM23 protein group was significantly associated with worse prognosis of GC patients. Consistently, the KM-plot database suggested that high TRIM23 mRNA expression was also linked to a poor prognosis in GC patients both in positive and negative subgroups of human epidermal growth factor receptor 2 (HER2). But in the HER2 positive subgroup, the advantages of the low TRIM23 expression on overall survival were much more statistically significant. The univariate analysis indicated that TRIM23 expression correlated with overall survival. The multivariate analysis showed that independent factors of prognosis in GC were lymph node metastasis, vascular invasion, and depth of invasion. In summary, TRIM23 may be associated with progression of GC, and may be considered a therapeutic target for GC patients.	[Yao, Yangyang; Liu, Zhen; Guo, Hui; Huang, Shanshan; Zhong, Min; Deng, Jun; Xiong, Jianping] Nanchang Univ, Affiliated Hosp 1, Dept Oncol, Nanchang 330006, Jiangxi, Peoples R China	Deng, J; Xiong, JP (reprint author), Nanchang Univ, Affiliated Hosp 1, Dept Oncol, Nanchang 330006, Jiangxi, Peoples R China.	dengjun19871106@126.com; junjungege@outlook.com			National Natural Science Foundation of ChinaNational Natural Science Foundation of China [81860427, 81760432, 81660402, 81660405]; JiangXi Province General Project [20164BCD40097, 20171BBG70121, 2017BBH80027]; Youth Scientific Funds-Youth Fund Project [2018ACB21037, 20171BAB215041]; JiangXi Province Education Fund Project [700653002]; department of health of JiangXi Province Project [20181041]	This work was supported by the National Natural Science Foundation of China (grant numbers 81860427, 81760432, 81660402 and 81660405), the JiangXi Province General Project (grant numbers: 20164BCD40097, 20171BBG70121 and 2017BBH80027), the Youth Scientific Funds-Youth Fund Project (grant numbers: 2018ACB21037 and 20171BAB215041), the JiangXi Province Education Fund Project (grant number: 700653002), and the department of health of JiangXi Province Project (grant number: 20181041).	Arimoto K, 2010, P NATL ACAD SCI USA, V107, P15856, DOI 10.1073/pnas.1004621107; Bao CY, 2015, SCI SIGNAL, V8, DOI 10.1126/scisignal.aaa8441; Chua TC, 2012, INT J CANCER, V130, P2845, DOI 10.1002/ijc.26292; Fang ZL, 2017, ONCOL LETT, V13, P1797, DOI 10.3892/ol.2017.5604; Fang ZL, 2017, J EXP CLIN CANC RES, V36, DOI 10.1186/s13046-017-0489-1; Groner AC, 2016, CANCER CELL, V29, P846, DOI 10.1016/j.ccell.2016.04.012; Hatakeyama S, 2011, NAT REV CANCER, V11, P792, DOI 10.1038/nrc3139; Hou JM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036252; Ikeda K, 2012, ADV EXP MED BIOL, V770, P27; Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI 10.3322/caac.20115; Kashimoto K, 2012, CANCER SCI, V103, P2021, DOI 10.1111/j.1349-7006.2012.02407.x; Kim WH, 2009, EXP CELL RES, V315, P2154, DOI 10.1016/j.yexcr.2009.04.018; Liu X, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0085462; Liu Y, 2014, ONCOGENE, V33, P308, DOI 10.1038/onc.2012.596; Micale L, 2012, ADV EXP MED BIOL, V770, P11; Munoz JJ, 2015, J UROLOGY, V194, P245, DOI 10.1016/j.juro.2014.11.097; Nasarre P, 2013, CANCER RES, V73, P7111, DOI 10.1158/0008-5472.CAN-13-1755; Oba K, 2013, JNCI-J NATL CANCER I, V105, P1600, DOI 10.1093/jnci/djt270; Ozato K, 2008, NAT REV IMMUNOL, V8, P849, DOI 10.1038/nri2413; Poole E, 2009, J VIROL, V83, P3581, DOI 10.1128/JVI.02072-08; Rizzolio S, 2011, CURR MED CHEM, V18, P3563, DOI 10.2174/092986711796642544; Samuel S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023208; Sasaki K, 2015, IMMUNOL REV, V266, P175, DOI 10.1111/imr.12308; Sens-Abuazar C, 2012, TRANSL ONCOL, V5, P113, DOI 10.1593/tlo.11280; Sparrer KMJ, 2017, NAT MICROBIOL, V2, P1543, DOI 10.1038/s41564-017-0017-2; Teixeira LK, 2013, ANNU REV BIOCHEM, V82, P387, DOI 10.1146/annurev-biochem-060410-105307; Watanabe M, 2015, ELIFE, V4, DOI 10.7554/eLife.05615; Xue DW, 2015, TUMOR BIOL, V36, P6849, DOI 10.1007/s13277-015-3393-3; Zhang J, 2013, TUMOR BIOL, V34, P2397, DOI 10.1007/s13277-013-0789-9; Zhang WZ, 2011, BRAZ J MED BIOL RES, V44, P642, DOI [10.1590/S0100-879X2011007500072, 10.1590/S0100-879X2011000700005]; Zhou GX, 2013, ASIAN PAC J CANCER P, V14, P5199, DOI 10.7314/APJCP.2013.14.9.5199	31	2	2	0	3	ELSEVIER GMBH	MUNICH	HACKERBRUCKE 6, 80335 MUNICH, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	DEC	2018	214	12					2062	2068		10.1016/j.prp.2018.10.010			7	Pathology	Pathology	HG0YQ	WOS:000454675600021	30477642				2019-10-28	
J	Tanigawa, M; Naito, Y; Akiba, J; Kawahara, A; Okabe, Y; Ishida, Y; Ishikawa, H; Hisaka, T; Fujita, F; Yasunaga, M; Shigaki, T; Sudo, T; Mihara, Y; Nakayama, M; Kondo, R; Kusano, H; Shimamatsu, K; Okuda, K; Akagi, Y; Yano, H				Tanigawa, Masahiko; Naito, Yoshiki; Akiba, Jun; Kawahara, Akihiko; Okabe, Yoshinobu; Ishida, Yusuke; Ishikawa, Hiroto; Hisaka, Toru; Fujita, Fumihiko; Yasunaga, Masafumi; Shigaki, Takahiro; Sudo, Tomoya; Mihara, Yutaro; Nakayama, Masamichi; Kondo, Reiichiro; Kusano, Hironori; Shimamatsu, Kazuhide; Okuda, Koji; Akagi, Yoshito; Yano, Hirohisa			PD-L1 expression in pancreatic adenosquamous carcinoma: PD-L1 expression is limited to the squamous component	PATHOLOGY RESEARCH AND PRACTICE			English	Article						Pancreas; Pancreatic cancer; Pancreatic adenosquamous carcinoma; PD-L1; EUS-FNA; Immunohistochemistry	CLINICAL-SIGNIFICANCE; CELL CARCINOMA; ADENOCARCINOMA; IMMUNOTHERAPY; METAPLASIA; NIVOLUMAB; DIAGNOSIS; LIGAND-1; TRIALS	Aim: We examined the programmed death-ligand 1 (PD-L1) expression in surgically resected pancreatic adenosquamous carcinoma (PASC) samples. Furthermore, the detection rate was also assessed using biopsy cases obtained from endoscopic ultrasound-guided fine needle aspiration (EUS-FNA). Methods: Fifteen cases of PASC (six resected and nine EUS-FNA biopsied) from the Kurume University Hospital between 2009 and 2016 were used for the evaluation of PD-L1 expression. As a control group, 34 cases of pancreatic ductal adenocarcinomas (PDACs) were selected. To compare the positivity and intensity of PD-L1, two types of clones (SP263, E1L3N) were examined for immunostaining. Only the membrane expression of PD-L1 was regarded as positive. The PD-L1 expressions in the squamous cell carcinoma component (SCc), adenocarcinoma component (ACc), and immune cells were assessed separately. The ratio of PD-L1 expression was calculated by counting the positive tumor cells, and tumor proportion score (TPS) was applied (TPS; Null < 1%, low expression; 1 <= TPS <= 49% and high expression; >= 50%). Results: PD-L1 expression was observed in five surgical PASC samples (83%). This shows that SCc presented a high expression in these cases. However, the overall TPS indicated a low expression. In contrast, only one case (3%) was positive for PD-L1 in PDACs, and the TPS indicated a low expression. No differences in PD-L1 expression were observed between the two clones, SP263 and E1L3N. High PD-L1 expression in the EUS-FNA sample was found in only one case (11%). Discussion: Although assessment using the tumor cells of PASC samples obtained from EUS-FNA was difficult, this study suggests the selective expression of PD-L1 in the SCc of PASC. Furthermore, it was considered that immune checkpoint inhibitors could provide therapeutic effects selectively on the SCc for the entire range of TPSs, though the PD-L1 expression was low.	[Tanigawa, Masahiko; Naito, Yoshiki; Mihara, Yutaro; Nakayama, Masamichi; Kondo, Reiichiro; Kusano, Hironori; Yano, Hirohisa] Kurume Univ, Dept Pathol, Sch Med, Kurume, Fukuoka, Japan; [Naito, Yoshiki; Akiba, Jun; Kawahara, Akihiko] Kurume Univ Hosp, Dept Diagnost Pathol, 67 Asahimachi, Kurume, Fukuoka 8300011, Japan; [Okabe, Yoshinobu; Ishida, Yusuke] Kurume Univ, Sch Med, Dept Med, Div Gastroenterol, Kurume, Fukuoka, Japan; [Ishikawa, Hiroto; Hisaka, Toru; Fujita, Fumihiko; Yasunaga, Masafumi; Shigaki, Takahiro; Sudo, Tomoya; Okuda, Koji; Akagi, Yoshito] Kurume Univ, Sch Med, Dept Surg, Kurume, Fukuoka, Japan; [Shimamatsu, Kazuhide] Omuta City Hosp, Dept Pathol, Omuta, Japan	Naito, Y (reprint author), Kurume Univ Hosp, Dept Diagnost Pathol, 67 Asahimachi, Kurume, Fukuoka 8300011, Japan.	nyoshiki@med.kurume-u.ac.jp					Al-Hader A, 2017, WORLD J GASTROENTERO, V23, P7945, DOI 10.3748/wjg.v23.i45.7945; Amatatsu M., 2018, CANC SCI; Basturk O, 2005, MODERN PATHOL, V18, P1193, DOI 10.1038/modpathol.3800401; Blum V, 2018, EUR J DERMATOL, V28, P78, DOI 10.1684/ejd.2017.3209; Bolton SJ, 2009, RESP RES, V10, DOI 10.1186/1465-9921-10-118; Boyd CA, 2012, J SURG RES, V174, P12, DOI 10.1016/j.jss.2011.06.015; Brody JR, 2009, MODERN PATHOL, V22, P651, DOI 10.1038/modpathol.2009.15; Chen DS, 2013, IMMUNITY, V39, P1, DOI 10.1016/j.immuni.2013.07.012; Du CL, 2017, INT J CHRONIC OBSTR, V12, P3341, DOI 10.2147/COPD.S143279; Fang Y, 2017, J PATHOL, V243, P155, DOI 10.1002/path.4943; Fehrenbacher L, 2016, LANCET, V387, P1837, DOI 10.1016/S0140-6736(16)00587-0; Fukushima N., 2010, WHO CLASSIFICATION T; Garon EB, 2015, NEW ENGL J MED, V372, P2018, DOI 10.1056/NEJMoa1501824; Gong J, 2018, J IMMUNOTHER CANCER, V6, DOI 10.1186/s40425-018-0316-z; Herfs M, 2012, AM J RESP CELL MOL, V47, P67, DOI 10.1165/rcmb.2011-0353OC; Hirschowitz L, 2007, DIAGN PATHOL, V2, DOI 10.1186/1746-1596-2-40; Horiguchi M., 2018, J CLIN ONCOL; IEMURA A, 1992, CANCER, V70, P415; Kardon DE, 2001, MODERN PATHOL, V14, P443, DOI 10.1038/modpathol.3880332; Kieler M, 2018, PANCREAS, V47, P142, DOI 10.1097/MPA.0000000000000970; Layfield LJ, 2001, DIAGN CYTOPATHOL, V25, P38, DOI 10.1002/dc.1099; Lin G, 2017, ONCOTARGET, V8, P83986, DOI 10.18632/oncotarget.20233; Marcus R, 2017, J PATHOL, V243, P271, DOI 10.1002/path.4959; Naito Y, 2018, DIAGN CYTOPATHOL, V46, P198, DOI 10.1002/dc.23823; Naito Y, 2009, J HEPATO-BILIARY-PAN, V16, P478, DOI 10.1007/s00534-009-0078-6; Nomi T, 2007, CLIN CANCER RES, V13, P2151, DOI 10.1158/1078-0432.CCR-06-2746; O'Neil BH, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0189848; Ohigashi Y, 2005, CLIN CANCER RES, V11, P2947, DOI 10.1158/1078-0432.CCR-04-1469; Overman MJ, 2018, J CLIN ONCOL, V36, P773, DOI 10.1200/JCO.2017.76.9901; Rahib L, 2016, JAMA ONCOL, V2, P1209, DOI 10.1001/jamaoncol.2016.0585; Sakurai K, 2018, TOHOKU J EXP MED, V244, P33, DOI 10.1620/tjem.244.33; Sato F, 2018, J ORAL PATHOL MED, V47, P683, DOI 10.1111/jop.12722; Shi XH, 2017, SCI REP-UK, V7, DOI 10.1038/srep46209; Silvestris N, 2017, ONCOTARGET, V8, P95773, DOI 10.18632/oncotarget.21319; Simone Christine G, 2013, Gastrointest Cancer Res, V6, P75; Teo MY, 2018, EXPERT REV ANTICANC, V18, P215, DOI 10.1080/14737140.2018.1432357; Tessier-Cloutier B, 2017, BMC CANCER, V17, DOI 10.1186/s12885-017-3634-5; Ushijima T, 2014, MOL CLIN ONCOL, V2, P599, DOI 10.3892/mco.2014.277; Velcheti V, 2014, LAB INVEST, V94, P107, DOI 10.1038/labinvest.2013.130; Wang A, 2015, EJSO-EUR J SURG ONC, V41, P450, DOI 10.1016/j.ejso.2015.01.020; Wu QM, 2018, EUR REV MED PHARMACO, V22, P1397, DOI 10.26355/eurrev_201803_14485; Wu YH, 2017, ONCOTARGET, V8, P64066, DOI 10.18632/oncotarget.19318; Yokoyama S, 2016, CLIN CANCER RES, V22, P4727, DOI 10.1158/1078-0432.CCR-16-0434; Young RH, 2002, HISTOPATHOLOGY, V41, P185, DOI 10.1046/j.1365-2559.2002.01462.x	44	1	1	1	5	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	DEC	2018	214	12					2069	2074		10.1016/j.prp.2018.10.006			6	Pathology	Pathology	HG0YQ	WOS:000454675600022	30477643				2019-10-28	
J	Son, HJ; Jo, YS; Kim, MS; Yoo, NJ; Lee, SH				Son, Hyun Ji; Jo, Yun Sol; Kim, Min Sung; Yoo, Nam Jin; Lee, Sug Hyung			DAB2IP with tumor-inhibiting activities exhibits frameshift mutations in gastrointestinal cancers	PATHOLOGY RESEARCH AND PRACTICE			English	Article						DAB2; DAB2IP; Tumor suppressor gene; Frameshift mutation; GI cancer; Microsatellite instability	ABERRANT PROMOTER METHYLATION; PROTEIN HDAB2IP GENE; PROSTATE-CANCER; DOWN-REGULATION; MICROSATELLITE INSTABILITY; UROTHELIAL CARCINOMA; EXPRESSION; HETEROGENEITY; DOC-2/DAB2; AUTOPHAGY	A scaffold protein DAB2 and its interaction partner DAB2IP have putative tumor suppressor gene (TSG) functions. Previous studies identified that both DAB2 and DAB2IP genes were inactivated by promoter hypermethylation in human cancers, but their mutational alterations in cancers remain largely unknown. The aim of our study was to find whether DAB2 and DAB2IP were mutated in gastric (GCs) and colorectal cancers (CRCs) by DNA sequencing. Both DAB2 and DAB2IP have mononucleotide repeats in their coding sequence that could be mutation targets in high microsatellite instability (MSI-H) cancers. We analyzed GC and CRC tissues and found that 8 of 34 GCs (23.5%) and 15 of 79 CRCs (20.0%) with MSI-H harbored DAB2IP frameshift mutations. DAB2 frameshift mutations were found in 2 of 79 CRCs (2.5%) with MSI-H. These mutations were not detected in microsatellite stable (MSS) cancers. We also found intratumoral heterogeneity (ITH) of DAB2IP frameshift mutations in 7 of 16 CRCs (43.8%). Loss of DAB2IP protein expression was found in approximately 20% of GCs and CRCs irrespective of MSI and DAB2IP frameshift mutation status. Our study shows that the TSG DAB2IP harbored frameshift mutations and ITH as well as expression loss. Together these tumor alterations might play a role in tumorigenesis of GC and CRC with MSI-H by down-regulating the tumor-inhibiting activities of DAB2IP.	[Son, Hyun Ji; Jo, Yun Sol; Kim, Min Sung; Yoo, Nam Jin; Lee, Sug Hyung] Catholic Univ Korea, Dept Pathol, Coll Med, 505 Banpo Dong, Seoul 137701, South Korea	Lee, SH (reprint author), Catholic Univ Korea, Dept Pathol, Coll Med, 505 Banpo Dong, Seoul 137701, South Korea.	suhulee@catholic.ac.kr			National Research Foundation of KoreaNational Research Foundation of Korea [2012R1A5A2047939]	This study was supported by grants from National Research Foundation of Korea (2012R1A5A2047939).	Akiyama Y, 2003, MOL CELL BIOL, V23, P8429, DOI 10.1128/MCB.23.23.8429-8439.2003; Bellazzo A, 2017, CELL DEATH DIFFER, V24, P15, DOI 10.1038/cdd.2016.134; Chen H, 2005, J BIOL CHEM, V280, P22437, DOI 10.1074/jbc.M501379200; Dote H, 2005, BRIT J CANCER, V92, P1117, DOI 10.1038/sj.bjc.6602458; Finkielstein CV, 2016, BIOESSAYS, V38, pS45, DOI 10.1002/bies.201670907; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Imai K, 2008, CARCINOGENESIS, V29, P673, DOI 10.1093/carcin/bgm228; Jiang Y, 2009, ONCOGENE, V28, P2999, DOI 10.1038/onc.2009.157; Jou YC, 2016, VIRCHOWS ARCH, V468, P733, DOI 10.1007/s00428-016-1924-y; Kang MR, 2009, J PATHOL, V217, P702, DOI 10.1002/path.2509; Karam JA, 2007, CLIN CANCER RES, V13, P4400, DOI 10.1158/1078-0432.CCR-07-0287; Kim HS, 2003, GASTROENTEROLOGY, V125, P708, DOI 10.1016/S0016-5085(03)01059-X; Kim MS, 2008, HUM PATHOL, V39, P1059, DOI 10.1016/j.humpath.2007.11.013; Kim MS, 2015, PATHOLOGY, V47, P598, DOI 10.1097/PAT.0000000000000305; Kim TM, 2014, J PATHOL, V233, P425, DOI 10.1002/path.4380; Kleeff J, 2002, DIS COLON RECTUM, V45, P1242, DOI 10.1097/01.DCR.0000024310.21986.7E; Kong ZL, 2010, CANCER RES, V70, P2829, DOI 10.1158/0008-5472.CAN-09-2919; Li C, 2015, AM J MED SCI, V349, P425, DOI 10.1097/MAJ.0000000000000436; Liu L, 2016, ONCOTARGET, V7, P3766, DOI 10.18632/oncotarget.6501; Marusyk A, 2012, NAT REV CANCER, V12, P323, DOI 10.1038/nrc3261; McGranahan N, 2015, CANCER CELL, V27, P15, DOI 10.1016/j.ccell.2014.12.001; Mok SC, 1998, ONCOGENE, V16, P2381, DOI 10.1038/sj.onc.1201769; Murphy KM, 2006, J MOL DIAGN, V8, P305, DOI 10.2353/jmoldx.2006.050092; Oh HR, 2015, PATHOLOGY, V47, P101, DOI 10.1097/PAT.0000000000000212; Tong JH, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-253; Wang Z, 2002, J BIOL CHEM, V277, P12622, DOI 10.1074/jbc.M110568200; Yano M, 2005, INT J CANCER, V113, P59, DOI 10.1002/ijc.20531; Yu L, 2012, NEOPLASIA, V14, P1203, DOI 10.1593/neo.121310; Zhang XJ, 2012, J GASTROEN HEPATOL, V27, P1117, DOI 10.1111/j.1440-1746.2011.07049.x; Zhou J, 2001, J BIOL CHEM, V276, P27793, DOI 10.1074/jbc.M102803200	30	0	0	0	1	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	DEC	2018	214	12					2075	2080		10.1016/j.prp.2018.10.005			6	Pathology	Pathology	HG0YQ	WOS:000454675600023	30477644				2019-10-28	
J	Chen, FY; Zhou, H; Wu, CQZ; Yan, H				Chen, Fangyao; Zhou, Hui; Wu, Chenqiuzi; Yan, Hong			Identification of miRNA profiling in prediction of tumor recurrence and progress and bioinformatics analysis for patients with primary esophageal cancer: Study based on TCGA database	PATHOLOGY RESEARCH AND PRACTICE			English	Article						miRNA profiling; Esophageal cancer; Tumor recurrence and progress; LASSO; Bioinformatics analysis	SQUAMOUS-CELL CARCINOMA; WNT SIGNALING PATHWAY; PROMOTES PROLIFERATION; MICRORNA EXPRESSION; INVASION; PROGNOSIS; ONTOLOGY; RISK	Object This study focused on the identification of prognostic miRNAs for the prediction of tumor recurrence and progress in esophageal cancer. Methods: MiRNA profiling and clinical characteristics of esophageal cancer patients was downloaded from the TCGA database. Univariate analysis was performed to select potential prognostic miRNAs and covariates. LASSO based logistic regression was conducted to identify the prognostic miRNAs given covariates. Bioinformatics analysis including gene ontology, disease ontology and pathway enrichment analysis were performed. A nomogram was generated based on multivariate logistic regression to illustrate the association between the identified miRNAs and the risk of tumor recurrence and progress. Results: A total of 1881 miRNAs and 10 clinical characteristics were obtained from TCGA database. 18 miRNAs were finally identified in which 6 miRNAs were identified for the first time to be associated with the tumor recurrence and progress of esophageal cancer given covariates. Bioinformatics analysis suggested that the identified miRNAs were associated with the tumor recurrence and progress of esophageal cancer. The association between identified miRNAs and risk of tumor recurrence and progress were presented in a nomogram. Conclusion: The 6 newly identified miRNAs may be potential biomarkers for the prediction of tumor recurrence and progress of esophageal cancer.	[Chen, Fangyao; Yan, Hong] Xi An Jiao Tong Univ, Hlth Sci Ctr, Sch Publ Hlth, Dept Epidemiol & Hlth Stat, 76 Yanta Xilu Rd, Xian 710061, Shaanxi, Peoples R China; [Zhou, Hui] Xi An Jiao Tong Univ, Dept Pharm, Affiliated Hosp 1, Dept Epidemiol & Hlth Stat, 277 Yanta Xilu Rd, Xian 710061, Shaanxi, Peoples R China; [Wu, Chenqiuzi] Xi An Jiao Tong Univ, Affiliated Hosp 1, 277 Yanta Xilu Rd, Xian 710061, Shaanxi, Peoples R China	Yan, H (reprint author), Xi An Jiao Tong Univ, Hlth Sci Ctr, Sch Publ Hlth, Dept Epidemiol & Hlth Stat, 76 Yanta Xilu Rd, Xian 710061, Shaanxi, Peoples R China.	yanhxjtu@hotmail.com			National Natural Science Foundation of ChinaNational Natural Science Foundation of China [81703325]	This study has been supported by the National Natural Science Foundation of China (grant number 81703325).	Altermann E, 2005, BMC GENOMICS, V6, DOI 10.1186/1471-2164-6-60; Asano T, 2004, ONCOGENE, V23, P8571, DOI 10.1038/sj.onc.1207902; Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Brennecke J, 2003, CELL, V113, P25, DOI 10.1016/S0092-8674(03)00231-9; Calin GA, 2006, NAT REV CANCER, V6, P857, DOI 10.1038/nrc1997; Chou CH, 2017, NUCL ACIDS RES, V46; Chung CS, 2013, BMC GASTROENTEROL, V13, DOI 10.1186/1471-230X-13-154; Clement G, 2006, ONCOGENE, V25, P3084, DOI 10.1038/sj.onc.1209338; Collado M, 2007, CELL, V130, P223, DOI 10.1016/j.cell.2007.07.003; Coppola D., 2015, WIPO Patent Application, Patent No. [WO/2015/156964, 2015156964]; Dong XA, 1996, STAT SINICA, V6, P675; Gambari R, 2013, INT J MOL MED, V32, pS77; [高志奎 Gao Zhikui], 2016, [癌变·畸变·突变, Carcinogenesis, Teratogenesis and Mutagenesis], V28, P107; Garcia-Becerra R, 2013, INT J MOL SCI, V14, P108, DOI 10.3390/ijms14010108; Gastaldi C, 2014, CARCINOGENESIS, V35, P1110, DOI 10.1093/carcin/bgt490; Gordon S, 2006, ONCOGENE, V25, P1125, DOI 10.1038/sj.onc.1209080; Hill MM, 2002, CURR BIOL, V12, P1251, DOI 10.1016/S0960-9822(02)00973-9; Hu YB, 2017, ONCOL LETT, V14, P3001, DOI 10.3892/ol.2017.6471; Huang SD, 2012, MOL CANCER, V11, DOI 10.1186/1476-4598-11-51; Janssens V, 2005, CURR OPIN GENET DEV, V15, P34, DOI 10.1016/j.gde.2004.12.004; Kato J., 2015, INT J CANCER, V95, P92; Kibbe WA, 2015, NUCLEIC ACIDS RES, V43, pD1071, DOI 10.1093/nar/gku1011; Koivisto P, 1996, SCAND J CLIN LAB INV, V56, P57; Li C, 2016, CELL STEM CELL, V19, P120, DOI 10.1016/j.stem.2016.04.017; Li J, 2016, BIOCHEM BIOPH RES CO, V469, P15, DOI 10.1016/j.bbrc.2015.11.062; Lin CY, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5620; Liu Q, 2012, MOL BIOL REP, V39, P1239, DOI 10.1007/s11033-011-0854-7; Liu XR, 2017, ONCOL RES, V25, P427, DOI 10.3727/096504016X14747300207374; Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702; Luo W, 2017, J CELL BIOCHEM, V118, P3488, DOI 10.1002/jcb.26008; Maslennikova DA, 2017, SOVREM TEHNOL MED, V9, P29, DOI 10.17691/stm2017.9.2.03; Mathe EA, 2009, CLIN CANCER RES, V15, P6192, DOI 10.1158/1078-0432.CCR-09-1467; Mayo M., 2002, BIOCHIM BIOPHYS ACTA, V1470, pM55; Min H., 2016, CANCER RES, V76, P1112; Mirghasemi A, 2015, CANCER CELL INT, V15, DOI 10.1186/s12935-015-0237-6; Musgrove EA, 2009, NAT REV CANCER, V9, P631, DOI 10.1038/nrc2713; Niu HY, 2015, CELL PHYSIOL BIOCHEM, V36, P2263, DOI 10.1159/000430190; Ruffner H, 2001, P NATL ACAD SCI USA, V98, P5134, DOI 10.1073/pnas.081068398; Rustgi AK, 2014, NEW ENGL J MED, V371, P2499, DOI 10.1056/NEJMra1314530; Schriml L. M., 2015, MAMM GENOME, V26, P1; Seeling JM, 1999, SCIENCE, V283, P2089, DOI 10.1126/science.283.5410.2089; Shimizu Y, 2002, GENE CHROMOSOME CANC, V33, P73, DOI 10.1002/gcc.1226; Stewart DJ, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/djt356; Su HF, 2014, CELL BIOL INT, V38, P318, DOI 10.1002/cbin.10202; Tang SW, 2016, SCI REP-UK, V6, DOI 10.1038/srep24466; Tibshirani R, 1996, J ROY STAT SOC B MET, V58, P267; Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262; Wang ZQ, 2014, FEBS LETT, V588, P915, DOI 10.1016/j.febslet.2014.01.035; WHO/ICO Information Centre on HPV and Cervical Cancer, 2007, Vaccine, V25 Suppl 3, pC1; Wiseman BS, 2002, SCIENCE, V296, P1046, DOI 10.1126/science.1067431; Wolf D, 2005, CLIN CANCER RES, V11, P8326, DOI 10.1158/1078-0432.CCR-05-1244; Yang H, 2017, EUR REV MED PHARMACO, V21, P3200; Yang HS, 2009, CLIN CANCER RES, V15, P5744, DOI 10.1158/1078-0432.CCR-09-0385; Yang J, 2008, DEV CELL, V14, P818, DOI 10.1016/j.devcel.2008.05.009; Yang M, 2016, BIOMED PHARMACOTHER, V79, P153, DOI 10.1016/j.biopha.2016.01.011; Yang M, 2014, MOL CELLS, V37, P873, DOI 10.14348/molcells.2014.0147; Zhang BJ, 2014, INT J CLIN EXP PATHO, V7, P6213; Zhang L, 2016, LIFE SCI, V155, P110, DOI 10.1016/j.lfs.2016.05.014; Zhu G, 2012, DIS ESOPHAGUS, V25, P505, DOI 10.1111/j.1442-2050.2011.01273.x	60	0	0	2	4	ELSEVIER GMBH	MUNICH	HACKERBRUCKE 6, 80335 MUNICH, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	DEC	2018	214	12					2081	2086		10.1016/j.prp.2018.10.009			6	Pathology	Pathology	HG0YQ	WOS:000454675600024	30477645				2019-10-28	
J	Jakobsen, MR; Teerapakpinyo, C; Shuangshoti, S; Keelawat, S				Jakobsen, Morten Ragn; Teerapakpinyo, Chinachote; Shuangshoti, Shanop; Keelawat, Somboon			Comparison between digital image analysis and visual assessment of immunohistochemical HER2 expression in breast cancer	PATHOLOGY RESEARCH AND PRACTICE			English	Article						HER2; Breast cancer; Digital image analysis; Dual in-situ hybridization	IN-SITU HYBRIDIZATION; FISH; GENE	Background: Assessment of HER2 status is considered standard of care in the histopathologic workup of breast cancer and conveys prognostic and predictive information used to guide treatment decisions. The assessment is often carried out in a two-step approach where immunohistochemical expression of HER2 protein is first evaluated by conventional microscopy and equivocal cases are further analyzed by in-situ hybridization techniques to assess gene amplification status. In this study we compared conventional manual assessment of immunohistochemical HER2 expression with digital image analysis (DIA) and consensus manual assessment by a panel of three pathologists. Methods: From our archive we retrieved sections of 109 invasive breast carcinomas stained for HER2 with corresponding HER2 score from the original pathology report. The glass slides were assessed by three pathologists to reach a consensus score. Next, the slides were scanned into whole slide images and DIA was performed using Aperio Imagescope. The scoring results were then compared with gene amplification status evaluated by dual in-situ hybridization (DISH). Results: Comparing manual assessment with consensus assessment and DIA, good agreement was obtained with weighted kappa coefficients of 0.79 (manual vs. consensus) and 0.67 (manual vs. DIA). When compared with gene status assessment by DISH, agreement analysis yielded weighted kappa coefficients of 0.52 (manual vs. DISH), 0.58 (consensus vs. DISH) and 0.78 (DIA vs. DISH). There were no false negatives by any of the three methods and false positives ranging from 0.9 to 2.8%. The proportion of equivocal cases by each method was 44% (manual), 33.3% (consensus) and 14.7% (DIA). Application of DIA reduced the number of equivocal cases by 67% without increasing the proportion of false negatives. Conclusion: We conclude that DIA is an accurate method to reduce the number of HER2 equivocal cases without affecting the sensitivity of the HER2 assessment.	[Jakobsen, Morten Ragn; Shuangshoti, Shanop; Keelawat, Somboon] King Chulalongkorn Mem Hosp, Dept Pathol, Bangkok, Thailand; [Teerapakpinyo, Chinachote; Shuangshoti, Shanop] Chulalongkorn Univ, Chula GenePRO Ctr, Res Affairs, Fac Med, Bangkok, Thailand	Jakobsen, MR (reprint author), King Chulalongkorn Mem Hosp, Dept Pathol, Bangkok, Thailand.	morten@durian.dk			Rachadapiseksomphot Endowment Fund of the Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand; National Research Council of Thailand Grant under the Research University Network (RUN) Initiative	This research was supported by the Rachadapiseksomphot Endowment Fund of the Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand, and the National Research Council of Thailand Grant under the Research University Network (RUN) Initiative.	Brugmann A, 2011, APPL IMMUNOHISTO M M, V19, P203, DOI 10.1097/PAI.0b013e3181f7118e; Brugmann A, 2012, BREAST CANCER RES TR, V132, P41, DOI 10.1007/s10549-011-1514-2; Dekker TJA, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3208; Grogan T., 2018, INTERPRETATION GUIDE; Hammond MEH, 2010, J CLIN ONCOL, V28, P2784, DOI 10.1200/JCO.2009.25.6529; Hanna WM, 2014, MODERN PATHOL, V27, P4, DOI 10.1038/modpathol.2013.103; Helin HO, 2016, VIRCHOWS ARCH, V468, P191, DOI 10.1007/s00428-015-1868-7; Holten-Rossing H, 2015, BREAST CANCER RES TR, V152, P367, DOI 10.1007/s10549-015-3475-3; Imaging L. B., 2015, MEMBRANE ALGORITHMS; Koopman T, 2018, HISTOPATHOLOGY, V72, P191, DOI 10.1111/his.13322; Kurozumi S, 2016, BREAST CANCER RES TR, V158, P99, DOI 10.1007/s10549-016-3856-2; Layfield LJ, 2017, APPL IMMUNOHISTO M M, V25, P231, DOI 10.1097/PAI.0000000000000304; Nassar A, 2011, ARCH PATHOL LAB MED, V135, P896, DOI 10.1043/2010-0418-OAR1.1; Nitta H, 2008, DIAGN PATHOL, V3, DOI 10.1186/1746-1596-3-41; Perez EA, 2014, CANCER TREAT REV, V40, P276, DOI 10.1016/j.ctrv.2013.09.001; Press MF, 2002, J CLIN ONCOL, V20, P3095, DOI 10.1120/JCO.2002.09.094; Wolff A. C., 2018, ARCH PATHOL LAB MED; Wolff AC, 2013, J CLIN ONCOL, V31, P3997, DOI 10.1200/JCO.2013.50.9984	18	1	1	0	0	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	DEC	2018	214	12					2087	2092		10.1016/j.prp.2018.10.015			6	Pathology	Pathology	HG0YQ	WOS:000454675600025	30377025				2019-10-28	
J	Cha, YJ; Shim, HS; Han, J; Choi, YS				Cha, Yoon Jin; Shim, Hyo Sup; Han, Joungho; Choi, Yong Soo			Clinicopathologic analysis of 10 cases of pulmonary colloid adenocarcinoma and prognostic implication of invasive micropapillary component	PATHOLOGY RESEARCH AND PRACTICE			English	Article						Colloid adenocarcinoma; Lung; Micropapillary; Metaplasia; CDX2	MUCINOUS ADENOCARCINOMA; LUNG; GENE; DIFFERENTIATION; CYSTADENOMA; CARCINOMAS	Background: We aimed to investigate the clinicopathologic and histopathologic characteristics of colloid adenocarcinoma of the lung. Methods: We reviewed the data of 10 patients with colloid adenocarcinoma that met the definition and histopathologic criteria of the current classification of the World Health Organization. The clinicopathologic characteristics were analyzed. Comprehensive histologic review and immunohistochemical staining for TTF-1, ALK, CDX2, and MUC5AC as well as a molecular examination for EGFR and KRAS was performed. Results: Among 7 men and 3 women (mean age, 69.6 years), three patients had metastasis of the N2 lymph nodes; of these, two experienced recurrence, and one died of the disease. Remaining patients were all alive without metastasis or recurrence of disease. On gross examination, all tumors were circumscribed mucoid masses. Histologically, we observed the characteristic mucin pools that were distending and destroying the alveolar walls and low cellularity of tumor cells. Most tumor cells were tall columnar cells with basally-located bland-looking nuclei and intracytoplasmic mucin. CDX2 and TTF-1 were partially positive in all and four patients, respectively. MUC5AC was positive in all cases, at least focally. Seven cases showed peribronchiolar metaplasia-like, ciliated tumor cells. Three patients with N2 lymph node metastasis showed mild (N = 2) and moderate (N = 1) cytologic atypia in primary tumors. Presence of stromal invasion and/or micropapillary pattern was common findings of cases with N2 lymph metastasis. Conclusion: Colloid adenocarcinoma is a rare variant of lung adenocarcinoma with distinct clinicopathologic characteristics. The frequently seen ciliated tumor cells may suggest that this tumor might originate from a metaplastic process. Majority had indolent clinical course but presence of stromal invasion or micropapillary pattern may reflect aggressive behavior of colloid adenocarcinoma and may indicate poor prognosis.	[Cha, Yoon Jin; Shim, Hyo Sup] Yonsei Univ, Dept Pathol, Coll Med, Seoul, South Korea; [Han, Joungho] Sungkyunkwan Univ, Dept Pathol, Sch Med, Samsung Med Ctr, 81 Irwon Ro, Seoul 06351, South Korea; [Choi, Yong Soo] Sungkyunkwan Univ, Dept Thorac Surg, Sch Med, Samsung Med Ctr, Seoul, South Korea	Han, J (reprint author), Sungkyunkwan Univ, Dept Pathol, Sch Med, Samsung Med Ctr, 81 Irwon Ro, Seoul 06351, South Korea.	hanjho@skku.edu					Amin MB, 2017, AJCC CANC STAGING MA; Boudreau F, 2002, J BIOL CHEM, V277, P31909, DOI 10.1074/jbc.M204622200; Brownlee NA, 2005, ARCH PATHOL LAB MED, V129, P121; Cha YJ, 2016, PATHOLOGY, V48, P325, DOI 10.1016/j.pathol.2016.02.016; DAVISON AM, 1992, THORAX, V47, P129, DOI 10.1136/thx.47.2.129; DIXON AY, 1993, AM J SURG PATHOL, V17, P722, DOI 10.1097/00000478-199307000-00010; Fukuoka J, 2005, AM J SURG PATHOL, V29, P948, DOI 10.1097/01.pas.0000168177.71405.ac; Gaeta M, 2012, EUR J RADIOL, V81, P3587, DOI 10.1016/j.ejrad.2011.12.022; Gao ZH, 2005, AM J CLIN PATHOL, V124, P62, DOI 10.1309/52XXR6E6U0J2JX0F; GRAEMECOOK F, 1991, HUM PATHOL, V22, P185, DOI 10.1016/0046-8177(91)90041-M; HIGASHIYAMA M, 1992, CHEST, V101, P763, DOI 10.1378/chest.101.3.763; Ishibashi H, 2003, ANN THORAC SURG, V76, P1738, DOI 10.1016/S0003-4975(03)00657-X; Jung JI, 2001, BRIT J RADIOL, V74, P490, DOI 10.1259/bjr.74.882.740490; Kalhor N, 2014, SEMIN DIAGN PATHOL, V31, P265, DOI 10.1053/j.semdp.2014.06.003; Maeda Y, 2012, J CLIN INVEST, V122, P4388, DOI 10.1172/JCI64048; MORAN CA, 1992, MODERN PATHOL, V5, P634; Murai T, 2011, CLIN IMAG, V35, P151, DOI 10.1016/j.clinimag.2010.05.003; Ohba T, 2011, LUNG CANCER, V73, P375, DOI 10.1016/j.lungcan.2011.05.016; Papla Boleslaw, 1996, Polish Journal of Pathology, V47, P87; Rossi G, 2004, AM J SURG PATHOL, V28, P442, DOI 10.1097/00000478-200404000-00003; Sonzogni A, 2017, J PATHOL CLIN RES, V3, P139, DOI 10.1002/cjp2.67; Taylor MS, 2018, AM J PATHOL, V188, P1149, DOI 10.1016/j.ajpath.2018.01.021; TRAUB B, 1991, ARCH PATHOL LAB MED, V115, P740; Travis W. D., 2007, PATHOLOGY GENETICS T; Travis WD, 2015, WHO CLASSIFICATION T; Yoshida A, 2011, AM J SURG PATHOL, V35, P1226, DOI 10.1097/PAS.0b013e3182233e06	26	0	0	2	3	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	DEC	2018	214	12					2093	2098		10.1016/j.prp.2018.10.014			6	Pathology	Pathology	HG0YQ	WOS:000454675600026	30377026				2019-10-28	
J	Zhou, F; Huang, LL				Zhou, Feng; Huang, Lili			A typical postcesarean epithelioid trophoblastic lesion with placenta increta: Case report and literature review	PATHOLOGY RESEARCH AND PRACTICE			English	Review						Uterus; Epithelioid; Intermediate trophoblastic cells; Postcesarean delivery; Placenta increta	TUMOR; SECTION; CYST	We report an extremely rare case of unusual atypical epithelioid trophoblastic lesion from placenta increta. A 25 year-old Chinese woman with a history of 1 cesarean delivery was admitted to the hospital at 37 weeks' gestation. Magnetic resonance imaging (MRI) showed the feature of placenta increta. An elective primary cesarean section was scheduled and a healthy baby was born. The patient was suggestive of placenta increta and implantation site was resected. Histology indicated a lesion consisting of epithelioid trophoblastic cells with an intermediate pattern between a classical placental site nodule and an epithelioid trophoblastic tumor. This may be linked to her previous cesarean delivery, which supports the relationship between atypical epithelioid trophoblastic lesion formation and surgical interventions. Her serum human chorionic gonadotropin (hCG) was 352.4 IU/L after delivery and gradually decreased to normal level.	[Zhou, Feng] Zhejiang Univ, Sch Med, Womens Hosp, Dept Pathol, Hangzhou 310006, Zhejiang, Peoples R China; [Huang, Lili] Zhejiang Univ, Sch Med, Womens Hosp, Dept Obstet & Gynecol, Hangzhou 310006, Zhejiang, Peoples R China	Zhou, F (reprint author), Zhejiang Univ, Sch Med, Womens Hosp, Hangzhou 310006, Zhejiang, Peoples R China.	fungchew@zju.edu.cn			program for National Natural Science Foundation of ChinaNational Natural Science Foundation of China [81701502]	This work was supported by the program for National Natural Science Foundation of China (No.81701502).	Alvarado-Cabrero I, 2014, AM J SURG PATHOL, V38, P111, DOI 10.1097/PAS.0b013e3182a2926e; Hui P., 2014, WHO CLASSIFICATION T, P156; ISMAIL SM, 1995, AM J SURG PATHOL, V19, P1440, DOI 10.1097/00000478-199512000-00011; Kaur B, 2015, INT J GYNECOL PATHOL, V34, P152, DOI 10.1097/PGP.0000000000000128; Liang Y, 2012, INT J GYNECOL PATHOL, V31, P458, DOI 10.1097/PGP.0b013e31824a1dc9; Mao TL, 2006, AM J SURG PATHOL, V30, P1105; McCarthy W. A., 2017, INT J GYNECOL PATHOL, P1; O'Neill CJ, 2009, HUM PATHOL, V40, P1358, DOI 10.1016/j.humpath.2009.01.023; Shih IM, 2011, BLAUSTEIN'S PATHOLOGY OF THE FEMALE GENITAL TRACT, SIXTH EDITION, P1075, DOI 10.1007/978-1-4419-0489-8_20; Shih Ie-Ming, 2002, Current Molecular Medicine (Hilversum), V2, P1; Shih IM, 2001, INT J GYNECOL PATHOL, V20, P31, DOI 10.1097/00004347-200101000-00004; Shih IM, 1998, AM J SURG PATHOL, V22, P1393, DOI 10.1097/00000478-199811000-00010; YOUNG RH, 1990, AM J SURG PATHOL, V14, P1001, DOI 10.1097/00000478-199011000-00002; Zhou F, 2015, HUM PATHOL, V46, P1036, DOI 10.1016/j.humpath.2014.10.031	14	0	0	2	8	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	DEC	2018	214	12					2099	2102		10.1016/j.prp.2018.08.004			4	Pathology	Pathology	HG0YQ	WOS:000454675600027	30131186				2019-10-28	
J	Deng, HY; Liu, C; Zhang, GL; Wang, XL; Liu, YP				Deng, Huiyan; Liu, Chang; Zhang, Guoliang; Wang, Xiaoling; Liu, Yueping			Lung adenocarcinoma with concurrent ALK and ROS1 rearrangement: A case report and review of the literatures	PATHOLOGY RESEARCH AND PRACTICE			English	Review						Lung adenocarcinoma; ALK; ROS1; Co-mutation	FACTOR-RECEPTOR GENE; MUTATIONS; CANCER; CRIZOTINIB; FUSIONS; EGFR	ALK and ROS1 are prognostic and predictive tumor markers in non-small cell lung carcinoma (NSCLC), which are more often found in lung adenocarcinomas as with other oncogenes such as EGFR, KRAS, or C-MET. Their positivity is 2.6% and 1.3%, respectively, and patients who have mutations in both genes are extremely rare. Here, we report a 61-year-old male diagnosed with acinar adenocarcinoma, who was shown to have both ALK and ROS1 rearrangements but was EGFR-and C-MET mutation-negative. He was treated surgically and received targeted therapy. Our review of the literature revealed that few such cases of concurrent ALK and ROS1 rearrangements have been reported. This information furthers our understanding of the molecular biology underlying NSCLC which will aid the selection of optimal treatment for patients with more than one driver mutation.	[Deng, Huiyan; Liu, Chang; Wang, Xiaoling; Liu, Yueping] Hebei Med Univ, Hosp 4, Dept Pathol, 12 Jiankang Rd, Shijiazhuang 050011, Hebei, Peoples R China; [Zhang, Guoliang] Hebei Med Univ, Hosp 4, Dept Chest Surg, Shijiazhuang 050011, Hebei, Peoples R China	Liu, YP (reprint author), Hebei Med Univ, Hosp 4, Dept Pathol, 12 Jiankang Rd, Shijiazhuang 050011, Hebei, Peoples R China.	annama@163.com					Bergethon K, 2012, J CLIN ONCOL, V30, P863, DOI 10.1200/JCO.2011.35.6345; Davies KD, 2012, CLIN CANCER RES, V18, P4570, DOI 10.1158/1078-0432.CCR-12-0550; Desai A, 2016, CANCER BIOL MED, V13, P77, DOI 10.28092/j.issn.2095-3941.2016.0008; Gainor JF, 2013, CLIN CANCER RES, V19, P4273, DOI 10.1158/1078-0432.CCR-13-0318; Ju LX, 2016, LUNG CANCER, V95, P94, DOI 10.1016/j.lungcan.2016.03.005; Kim HR, 2013, ANN ONCOL, V24, P2364, DOI 10.1093/annonc/mdt220; Kosaka T, 2004, CANCER RES, V64, P8919, DOI 10.1158/0008-5472.CAN-04-2818; Li Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0052093; Liang W., 2016, METASTATIC EML4 ALK, V5, p[16, 62]; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; Mazieres J, 2015, J CLIN ONCOL, V33, P992, DOI 10.1200/JCO.2014.58.3302; Mescam-Mancini L, 2014, LUNG CANCER, V83, P168, DOI 10.1016/j.lungcan.2013.11.019; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; Rikova K, 2007, CELL, V131, P1190, DOI 10.1016/j.cell.2007.11.025; Rimkunas VM, 2012, CLIN CANCER RES, V18, P4449, DOI 10.1158/1078-0432.CCR-11-3351; Shaw AT, 2014, NEW ENGL J MED, V371, P1963, DOI 10.1056/NEJMoa1406766; Shigematsu H, 2005, JNCI-J NATL CANCER I, V97, P339, DOI 10.1093/jnci/dji055; Takeuchi K, 2012, NAT MED, V18, P378, DOI 10.1038/nm.2658; Wu SF, 2015, THORAC CANCER, V6, P413, DOI 10.1111/1759-7714.12191	19	2	2	0	7	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	DEC	2018	214	12					2103	2105		10.1016/j.prp.2018.09.028			3	Pathology	Pathology	HG0YQ	WOS:000454675600028	30327151				2019-10-28	
J	Pan, ST; Ko, YH; Tan, SY; Chuang, SS				Pan, Shien-Tung; Ko, Young-Hyeh; Tan, Soo-Yong; Chuang, Shih-Sung			Primary cutaneous peripheral T-cell lymphoma with a late relapse solely in the ileum mimicking monomorphic epitheliotropic intestinal T-cell lymphoma	PATHOLOGY RESEARCH AND PRACTICE			English	Article						Cutaneous T-cell lymphoma; Intestinal T-cell lymphoma; Monomorphic epitheliotropic intestinal T-cell lymphoma; Primary cutaneous T-cell lymphoma; Peripheral T-cell lymphoma, not otherwise specified; Relapse	NASAL TYPE; EXPRESSION	Background: Primary cutaneous peripheral T-cell lymphomas (PC-PTCLs) are classified into mycosis fungoides (MF) and other rare specific types; and those do not fit into any specific entities are designated as PTCL, not otherwise specified (NOS), an aggressive neoplasm. Monomorphic epitheliotropic intestinal T-cell lymphoma (MEITL) is an aggressive primary intestinal T-cell lymphoma with enteropathy in the non-neoplastic mucosa. We report a rare case of PC-PTCL-NOS with a late relapse solely in the ileum after complete remission. We discuss the importance of evaluating enteropathy, megakaryocyte-associated tyrosine kinase (MATK) immunostaining, and the implication of clonal relationship of metachronous lymphomas. Case report: We reviewed the histopathology and immunohistochemistry of the skin tumor from a 68-year-old female and the relapsed intestinal T-cell lymphoma. The tumor cells "trans-regressed" from large and pleomorphic in the skin to small/medium-sized cells with clear cytoplasm in the ileum; and furthermore, there was immunophenotypic alteration. However, there was no enteropathy in the non-tumoral ileal mucosa adjacent to the tumor proper and both the cutaneous and ileal tumors were negative for MATK. Clonality study showed clonal TRG and TRB rearrangement with identical band sizes of the amplicons, confirming primary cutaneous tumor with a late relapse in the ileum. Conclusions: Although PC-PTCL-NOS is an aggressive neoplasm, rare cases such as this might have a long-term survival. Furthermore, the late relapse mimicking MEITL is intriguing and exceptional, in spite the fact that MEITL is a primary intestinal T-cell lymphoma with a typical histopathology and immunophenotype. Detailed clinicopathological and molecular studies are mandatory to elucidate the clonal relationship of metachronous lymphomas, as this has important clinical implication for treatment. Evaluation of the non-tumoral intestinal mucosa for enteropathy and immunostaining for MATK might help to differentiate a mimicker from a true MEITL.	[Pan, Shien-Tung] Tungs Taichung MetroHarbor Hosp, Dept Pathol, Taichung, Taiwan; [Ko, Young-Hyeh] Sungkyunkwan Univ, Dept Pathol & Translat Genom, Samsung Med Ctr, Sch Med, Seoul, South Korea; [Tan, Soo-Yong] Singapore Natl Univ, Dept Pathol, Singapore, Singapore; [Chuang, Shih-Sung] Chi Mei Med Ctr, Dept Pathol, 901 Chung Hwa Rd, Tainan 71004, Taiwan; [Chuang, Shih-Sung] Natl Taiwan Univ, Sch Med, Dept Pathol, Coll Med, Taipei, Taiwan; [Chuang, Shih-Sung] Taipei Med Univ, Sch Med, Dept Pathol, Coll Med, Taipei, Taiwan	Chuang, SS (reprint author), Chi Mei Med Ctr, Dept Pathol, 901 Chung Hwa Rd, Tainan 71004, Taiwan.	cmh5301@mail.chimei.org.tw			Chi-Mei Medical Center, Tainan, Taiwan	Chi-Mei Medical Center, Tainan, Taiwan.	Chuang SS, 2009, APPL IMMUNOHISTO M M, V17, P77, DOI 10.1097/PAI.0b013e31817bb046; Gaulard P, 2017, WHO CLASSIFICATION T, P397; Hamada T, 2014, J DERMATOL, V41, P3, DOI 10.1111/1346-8138.12299; Huang YH, 2015, J CLIN PATHOL, V68, P943, DOI 10.1136/jclinpath-2015-203188; Isaacson PG, 2008, WHO CLASSIFICATION T, P289; Ishibashi H, 2016, DIAGN PATHOL, V11, DOI 10.1186/s13000-016-0519-x; Jaffe E. S., 2017, WHO CLASSIFICATION T, P372; Jaffe ES, 2017, WHO CLASSIFICATION T, P377; Lee SE, 2016, ONCOTARGET, V7, P12359, DOI 10.18632/oncotarget.7132; Liao JB, 2010, ARCH PATHOL LAB MED, V134, P996, DOI 10.1043/2009-0132-OA.1; Park JH, 2012, J AM ACAD DERMATOL, V67, P1200, DOI 10.1016/j.jaad.2012.02.033; Pileri SA, 2017, WHO CLASSIFICATION T, P403; Shioyama Y, 2000, Radiat Med, V18, P369; Tan SY, 2013, LEUKEMIA, V27, P1688, DOI 10.1038/leu.2013.41; Tan SY, 2011, LEUKEMIA, V25, P555, DOI 10.1038/leu.2010.295; Tolkachjov SN, 2016, J AM ACAD DERMATOL, V75, P992, DOI 10.1016/j.jaad.2016.06.011; Tse E, 2012, AM J HEMATOL, V87, P663, DOI 10.1002/ajh.23213	17	1	1	1	1	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	DEC	2018	214	12					2106	2109		10.1016/j.prp.2018.10.002			4	Pathology	Pathology	HG0YQ	WOS:000454675600029	30477646				2019-10-28	
J	Lionti, S; La Rocca, L; Nunnari, CM; Barresi, V				Lionti, Simona; La Rocca, Lilli; Nunnari, Carmela Mirella; Barresi, Valeria			Strong androgen receptor expression is not useful in distinguishing GATA3+metastases	PATHOLOGY RESEARCH AND PRACTICE			English	Article						GATA3; Androgen receptor; Breast carcinoma; Urothelial carcinoma; Metastasis	GATA3 IMMUNOHISTOCHEMISTRY; UROTHELIAL CARCINOMA; BREAST; MARKER; DIAGNOSIS; UTILITY; CANCER; BENIGN; TUMOR	GATA binding protein 3 (GATA3) immunohistochemical expression is commonly considered to be a sensitive and specific diagnostic marker for breast and urothelial carcinomas in surgical pathology practice. However, since its expression has been also demonstrated in other tumors, GATA3 should be better used in conjunction with other immunohistochemical markers to establish tumor primitivity in metastatic setting. Interestingly, GATA3 expression seems to be significantly correlated with androgen receptor (AR) expression in breast carcinoma. In addition, strong AR expression-defined as immunohistochemical positivity in more than 60% of tumor cells- was suggested to be 100% specific for breast origin in GATA3 + metastases. The aim of this study was to verify whether strong AR expression may actually be useful to determine primivity in GATA3 + metastatic setting. Thus, we investigated AR and GATA3 immuno-expression in a cohort of metastatic tumors derived from urothelial, breast, endometrial and salivary gland carcinomas. We did not find any GATA3 or AR expression in the metastases from endometrial or salivary gland carcinomas, while GATA3 expression was seen in the majority of metastases from urothelial or breast carcinomas. In addition, strong AR expression was seen in 73% and in 47% of metastatic breast and urothelial carcinomas, respectively. On the whole, our findings confirm that GATA3 is sensitive and specific for breast and urothelial origin in metastatic setting. According to our results, strong AR expression is not useful to distinguish breast from urothelial primitivity, as previously suggested.	[Lionti, Simona; La Rocca, Lilli; Nunnari, Carmela Mirella; Barresi, Valeria] Univ Messina, Dipartimento Patol Umana Adulto & Eta Evolut G Ba, Messina, Italy	Barresi, V (reprint author), Policlin G Martino, Dipartimento Patol Umana Adulto & Eta Evolut, Via Consolare Valeria, I-98125 Messina, Italy.	vbarresi@unime.it		Barresi, Valeria/0000-0001-7086-1920			Asselin-Labat ML, 2007, NAT CELL BIOL, V9, P201, DOI 10.1038/ncb1530; Boto A, 2018, HUM PATHOL, V75, P63, DOI 10.1016/j.humpath.2018.01.024; Bronte G, 2018, TRANSL ONCOL, V11, P950, DOI 10.1016/j.tranon.2018.05.006; Chang A, 2012, AM J SURG PATHOL, V36, P1472, DOI 10.1097/PAS.0b013e318260cde7; Chou J, 2010, J CELL PHYSIOL, V222, P42, DOI 10.1002/jcp.21943; Deftereos G, 2015, AM J SURG PATHOL, V39, P1282, DOI 10.1097/PAS.0000000000000505; Engelsen IB, 2008, AM J OBSTET GYNECOL, V199, DOI 10.1016/j.ajog.2008.04.043; Higgins J.P., 2007, AM J SURG PATHOL, V31, P1; Hoch RV, 1999, INT J CANCER, V84, P122; Hou YJ, 2017, ANN DIAGN PATHOL, V30, P21, DOI 10.1016/j.anndiagpath.2017.05.006; Howitt BE, 2015, AM J SURG PATHOL, V39, P1411, DOI 10.1097/PAS.0000000000000471; Inoue S, 2017, HUM PATHOL, V64, P83, DOI 10.1016/j.humpath.2017.04.003; KO LJ, 1991, MOL CELL BIOL, V11, P2778, DOI 10.1128/MCB.11.5.2778; Liu HY, 2012, AM J CLIN PATHOL, V138, P57, DOI 10.1309/AJCP5UAFMSA9ZQBZ; Mertens RB, 2015, AM J DERMATOPATH, V37, P885, DOI 10.1097/DAD.0000000000000306; Miettinen M, 2014, AM J SURG PATHOL, V38, P13, DOI 10.1097/PAS.0b013e3182a0218f; Miyamoto H, 2012, HUM PATHOL, V43, P2033, DOI 10.1016/j.humpath.2012.02.011; Ordonez NG, 2013, ADV ANAT PATHOL, V20, P352, DOI 10.1097/PAP.0b013e3182a28a68; Schwartz LE, 2013, HEAD NECK PATHOL, V7, P311, DOI 10.1007/s12105-013-0442-3; Yeoh CC, 2018, J ORAL PATHOL MED, V47, P691, DOI 10.1111/jop.12741; Zadeh SL, 2018, INT J GYNECOL PATHOL, V37, P167, DOI 10.1097/PGP.0000000000000401	21	0	0	0	2	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	DEC	2018	214	12					2110	2114		10.1016/j.prp.2018.09.027			5	Pathology	Pathology	HG0YQ	WOS:000454675600030	30293951				2019-10-28	
J	Leal, S; Rocha, L; Silva, A; Faria, J; Dinis-Oliveira, RJ; Sa, SI				Leal, Sandra; Rocha, Lidia; Silva, Ana; Faria, Juliana; Dinis-Oliveira, Ricardo Jorge; Sa, Susana I.			Evaluation of progressive hepatic histopathology in long-term tamoxifen therapy	PATHOLOGY RESEARCH AND PRACTICE			English	Article						Tamoxifen; Cycling female rats; Hepatotoxicity; Metabolic profile; Pilot study	NONALCOHOLIC STEATOHEPATITIS; ADJUVANT TAMOXIFEN; RAT; PREVENTION	Tamoxifen (TAM) therapy is the better treatment for breast cancer and the drug use the prophylaxis of this disease in young premenopausal women. Yet, the effects associated with this therapy are unknown. To better understand the extension of this problem, we developed an animal model to mimic this therapy, aiming to evaluate its potential biochemical and histopathological changes in the liver. Young cycling female rats were treated with TAM for one, two and three months and toxicological biomarkers and liver histomorphometry were evaluated. Starting at two months, TAM-treatment prevented the normal age-dependent increase in body weight, without inducing changes in food intake. Serum levels of cholesterol and of the metabolic enzymes creatine kinase and aspartate aminotransferase were reduced in all TAM treatment periods. Serum levels of the metabolic enzymes alkaline phosphatase and lactate dehydrogenase were increased after the first month but returned to control levels upon 3 months of drug exposition. Moderate microvesicular steatosis, classified only at the first month of TAM treatment, was reduced afterwards. Our model showed an adaptive response of liver upon 3 months of treatment, suggesting that at the stated conditions, TAM will not promote hepatotoxicity. In this way, the present model may be useful in the study of possible key endocrine effects of TAM use and the search for better clinical outcomes.	[Leal, Sandra; Faria, Juliana; Dinis-Oliveira, Ricardo Jorge] Inst Res & Adv Training Hlth Sci & Technol, CESPU, Gandra, Portugal; [Rocha, Lidia; Silva, Ana; Sa, Susana I.] Univ Porto, Fac Med, Unit Anat, Dept Biomed, Alameda Prof Hemani Monteiro, P-4200319 Porto, Portugal; [Dinis-Oliveira, Ricardo Jorge] Univ Porto, Fac Pharm, Dept Biol Sci, UCIBIO,REQUIMTE,Lab Toxicol, Porto, Portugal; [Dinis-Oliveira, Ricardo Jorge] Univ Porto, Fac Med, Dept Publ Hlth & Forens Sci & Med Educ, Porto, Portugal; [Leal, Sandra; Sa, Susana I.] Univ Porto, Fac Med, Ctr Hlth Technol & Serv Res CINTESIS, Porto, Portugal	Sa, SI (reprint author), Univ Porto, Fac Med, Unit Anat, Dept Biomed, Alameda Prof Hemani Monteiro, P-4200319 Porto, Portugal.	sasusana@med.up.pt	Leal, Sandra/V-5113-2019; Dinis-Oliveira, Ricardo Jorge/D-9186-2013; Sa, Susana Isabel/H-8781-2013	Leal, Sandra/0000-0002-6762-4534; Dinis-Oliveira, Ricardo Jorge/0000-0001-7430-6297; Sa, Susana Isabel/0000-0002-5078-980X; Faria, Juliana/0000-0001-7753-0219; , Lidia/0000-0001-6925-2386	FEDER - Programa Operacional Competitividade e Internacionalizacao - COMPETE2020; FCT - Fundacao para a Ciencia e a Tecnologia within CINTESIS, RD Unit [POCI-01-0145-FEDER-007746, UID/IC/4255/2013]; FCT - Fundacao para a Ciencia e a Tecnologia [IF/01147/2013]	This article was supported by FEDER through the operation funded by the Programa Operacional Competitividade e Internacionalizacao - COMPETE2020 and by National Funds through FCT - Fundacao para a Ciencia e a Tecnologia within CINTESIS, R&D Unit [grant numbers POCI-01-0145-FEDER-007746 and UID/IC/4255/2013]. Ricardo Dinis-Oliveira acknowledges FCT - Fundacao para a Ciencia e a Tecnologia [grant number IF/01147/2013].	Begriche K, 2013, HEPATOLOGY, V58, P1497, DOI 10.1002/hep.26226; Begriche K, 2011, J HEPATOL, V54, P773, DOI 10.1016/j.jhep.2010.11.006; Bland AE, 2009, GYNECOL ONCOL, V112, P150, DOI 10.1016/j.ygyno.2008.08.035; Bruno S, 2005, BRIT MED J, V330, P932, DOI 10.1136/bmj.38391.663287.E0; Cuzick J, 2015, LANCET ONCOL, V16, P67, DOI 10.1016/S1470-2045(14)71171-4; Davies C, 2013, LANCET, V381, P805, DOI 10.1016/S0140-6736(12)61963-1; Dutta S, 2016, LIFE SCI, V152, P244, DOI 10.1016/j.lfs.2015.10.025; Fujimura H, 2009, J APPL TOXICOL, V29, P356, DOI 10.1002/jat.1420; GREAVES P, 1993, CANCER RES, V53, P3919; Gudbrandsen OA, 2006, J LIPID RES, V47, P2223, DOI 10.1194/jlr.M600148-JLR200; Hesselbarth N., 2015, BIOCHEM BIOPH RES CO; JORDAN VC, 1990, BREAST CANCER RES TR, V15, P125, DOI 10.1007/BF01806350; Kirman CR, 2003, REGUL TOXICOL PHARM, V38, P345, DOI 10.1016/j.yrtph.2003.07.004; Lelliott CJ, 2005, FASEB J, V19, P1108, DOI 10.1096/fj.04-3196com; Liu L, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2014.553; Logan CA, 2001, J HIST BIOL, V34, P287, DOI 10.1023/A:1010398116188; Morice P, 2016, LANCET, V387, P1094, DOI 10.1016/S0140-6736(15)00130-0; Reagan-Shaw S, 2008, FASEB J, V22, P659, DOI 10.1096/fj.07-9574LSF; Ricciardi E, 2014, EUR J OBSTET GYN R B, V183, P121, DOI 10.1016/j.ejogrb.2014.10.021; Saphner T, 2009, CANCER-AM CANCER SOC, V115, P3189, DOI 10.1002/cncr.24374; Sengupta P, 2013, INT J PREVENTIVE MED, V4, P624; Shagufta, 2018, EUR J MED CHEM, V143, P515, DOI 10.1016/j.ejmech.2017.11.056; Thoolen B, 2010, TOXICOL PATHOL, V38, p5S, DOI 10.1177/0192623310386499; TURNER RT, 1988, ENDOCRINOLOGY, V122, P1146, DOI 10.1210/endo-122-3-1146; WADE GN, 1993, AM J PHYSIOL, V264, pR1219; Xu BB, 2016, BIOCHIMIE, V124, P92, DOI 10.1016/j.biochi.2015.06.018; Yang G, 2013, PHARMACOL THERAPEUT, V139, P392, DOI 10.1016/j.pharmthera.2013.05.005	27	2	2	0	4	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	DEC	2018	214	12					2115	2120		10.1016/j.prp.2018.09.030			6	Pathology	Pathology	HG0YQ	WOS:000454675600031	30314755				2019-10-28	
J	Fassan, M; Pennelli, G; Mastracci, L; Remo, A; Cappellesso, R; Lo Mele, M; Realdon, S; Munari, G; Lazzi, S; Rugge, M				Fassan, Matteo; Pennelli, Gianmaria; Mastracci, Luca; Remo, Andrea; Cappellesso, Rocco; Lo Mele, Marcello; Realdon, Stefano; Munari, Giada; Lazzi, Stefano; Rugge, Massimo			Clear cell dysplasia in a sessile serrated adenoma	PATHOLOGY RESEARCH AND PRACTICE			English	Letter							CARCINOMA		[Fassan, Matteo; Pennelli, Gianmaria; Cappellesso, Rocco; Lo Mele, Marcello; Munari, Giada; Rugge, Massimo] Univ Padua, Dept Med DIMED, Surg Pathol & Cytopathol Unit, Padua, PD, Italy; [Mastracci, Luca] Univ Genoa, Dept Surg & Diagnost Sci DISC, Genoa, GE, Italy; [Mastracci, Luca] IRCCS S Martino Polyclin Hosp, Genoa, GE, Italy; [Remo, Andrea] Mater Salutis Hosp, Dept Pathol, ULSS9, Legnago, VR, Italy; [Realdon, Stefano] Ist Oncol Veneto IOV IRCCS, Padua, PD, Italy; [Lazzi, Stefano] Univ Siena, Sect Pathol, Dept Med Biotechnol, Siena, SI, Italy	Fassan, M (reprint author), Univ Padua, Dept Med DIMED, Surg Pathol & Cytopathol Unit, Padua, PD, Italy.	matteo.fassan@unipd.it	Fassan, Matteo/F-5152-2012; Realdon, Stefano/K-8664-2016	Fassan, Matteo/0000-0001-6515-5482; Realdon, Stefano/0000-0001-6843-7637			Domoto H, 1999, HISTOPATHOLOGY, V34, P250; Eloy C, 2009, INT J SURG PATHOL, V17, P438, DOI 10.1177/1066896908319211; Liu C, 2017, MODERN PATHOL, V30, P1728, DOI 10.1038/modpathol.2017.92; Miyasaka C, 2018, PATHOL INT, V68, P256, DOI 10.1111/pin.12628; Pusztaszeri M, 2008, HUM PATHOL, V39, P1402, DOI 10.1016/j.humpath.2008.01.008; Remo A, 2017, PATHOL RES PRACT, V213, P447, DOI 10.1016/j.prp.2017.02.013; Shi CJ, 2010, AM J SURG PATHOL, V34, P1344, DOI 10.1097/PAS.0b013e3181ec0810	7	1	1	0	1	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	DEC	2018	214	12					2121	2122		10.1016/j.prp.2018.09.020			2	Pathology	Pathology	HG0YQ	WOS:000454675600032	30293952				2019-10-28	
J	Hu, JJ; Khalifa, RD; Roma, AA; Fadare, O				Hu, Jingjing; Khalifa, Raji D.; Roma, Andres A.; Fadare, Oluwole			The pathologic distinction of primary and metastatic mucinous tumors involving the ovary: A re-evaluation of algorithms based on gross features	ANNALS OF DIAGNOSTIC PATHOLOGY			English	Article						Ovary; Metastatic; Mucinous tumors; Mucinous borderline tumor	SECONDARY; ADENOCARCINOMAS; CARCINOMAS; NEOPLASIA; SIZE	The problems associated with the pathologic distinction of primary ovarian mucinous tumors from their metastatic counterparts are well-recognized. Herein, we systematically evaluate a variety of gross parameters to determine the combination of features that most optimally separate primary from secondary mucinous ovarian tumors, and to address the tumor types that are most frequently associated with exceptions. 129 consecutive mucinous tumors involving the ovary formed the study set, including 61 primary mucinous tumors (16 carcinomas, 45 borderline tumors), and 68 metastatic carcinomas (21 colon; 28 appendix; 5 breast; 3 lung; 3 pancreas; 3 cervix; 1 bladder; 4 stomach). Consistent with prior studies, we found that as compared with metastases, primary ovarian mucinous tumors tend to be larger, more frequently unilateral and were more likely to be predominantly cystic and devoid of surface nodules. 41 of the 68 cases in the metastatic group showed intraperitoneal disease, as compared with only 3 of the 61 cases in the primary group (p < 0.0001). In 21% (14/68) of the metastatic group, the ovarian tumor was the first clinical indication of the primary tumor, and 82% of those cases were of gastrointestinal tract primary; this group of cases showed significantly larger tumors than ovarian tumors for patients with an established diagnosis of cancer. Receiver operating curve analyses showed that a tumor size cut off of < 13 cm for metastatic disease yielded the maximal area under the curve of 0.877 (sensitivity 80%; specificity 80%); the most frequent exception to the size cut off of < 13 cm for metastases was colorectal carcinoma, 30% of which were >= 13 cm. An algorithm whereby a tumor >= 13 cm is considered primary unless it displays surface nodules or bilaterality, and a tumor < 13 cm is considered metastatic unless it is unilateral, correctly classified 94% (64/68) of the metastatic tumors and 98% (60/61) of the primary tumors. 3 of the 4 incorrectly classified cases in the metastatic group had intraperitoneal disease. We conclude that gross features are very useful in the distinction of primary from metastatic mucinous tumors in the ovary, and the presence of intraperitoneal disease provides additional diagnostic information. Although algorithms such as the one described herein are imperfect classifiers, they do provide baseline information on which additional findings, including microscopic features, can be added to ultimately provide the most accurate diagnostic classification.	[Hu, Jingjing; Khalifa, Raji D.; Roma, Andres A.; Fadare, Oluwole] Univ Calif San Diego, Dept Pathol, San Diego, CA 92103 USA	Fadare, O (reprint author), Univ Calif San Diego Hlth, Dept Pathol, Anat Pathol Div, 9300 Campus Point Dr,Suite 1-200,MC 7723, La Jolla, CA 92037 USA.	ofadare@ucsd.edu					Antila R, 2006, GYNECOL ONCOL, V101, P97, DOI 10.1016/j.ygyno.2005.09.046; Ayhan A, 1995, J SURG ONCOL, V60, P268, DOI 10.1002/jso.2930600411; Bruls J, 2015, VIRCHOWS ARCH, V467, P79, DOI 10.1007/s00428-015-1771-2; Pinto PBC, 2012, INT J GYNECOL PATHOL, V31, P313, DOI 10.1097/PGP.0b013e31823f844d; DEMOPOULOS RI, 1987, INT J GYNECOL PATHOL, V6, P166, DOI 10.1097/00004347-198706000-00008; Hart WR, 2005, PATHOL INT, V55, P231, DOI 10.1111/j.1440-1827.2005.01819.x; Hart WR, 2005, INT J GYNECOL PATHOL, V24, P4, DOI 10.1097/01.pgp.0000148335.39146.a7; Judson K, 2008, INT J GYNECOL PATHOL, V27, P182, DOI 10.1097/PGP.0b013e31815b9752; Khunamornpong S, 2006, GYNECOL ONCOL, V101, P152, DOI 10.1016/j.ygyno.2005.10.008; Khunamornpong S, 2006, INT J GYNECOL CANCER, V16, P132, DOI 10.1111/j.1525-1438.2006.00302.x; lavazzo C, 2011, ARCH GYNECOL OBSTET, P1; Lee KR, 2000, AM J SURG PATHOL, V24, P1447, DOI 10.1097/00000478-200011000-00001; Leen SLS, 2012, J CLIN PATHOL, V65, P591, DOI 10.1136/jclinpath-2011-200162; McCluggage WG, 2012, J CLIN PATHOL, V65, P596, DOI 10.1136/jcp.2010.085688; Moore RG, 2004, GYNECOL ONCOL, V93, P87, DOI 10.1016/j.ygyno.2003.12.039; Santesson L, 1968, UICC MONOGR SER, V11, P1; Seidman JD, 2003, AM J SURG PATHOL, V27, P985, DOI 10.1097/00000478-200307000-00014; Shi Yifu, 2002, Zhonghua Fu Chan Ke Za Zhi, V37, P97; Stewart CJR, 2005, INT J GYNECOL PATHOL, V24, P356, DOI 10.1097/01.pgp.0000168514.06429.c3; ULBRIGHT TM, 1984, CANCER, V53, P1164, DOI 10.1002/1097-0142(19840301)53:5<1164::AID-CNCR2820530523>3.0.CO;2-4; Wasinghon Pornsawan, 2008, Journal of the Medical Association of Thailand, V91, P1791; Yada-Hashimoto N, 2003, GYNECOL ONCOL, V89, P314, DOI 10.1016/S0090-8258(03)00075-1; YAKUSHIJI M, 1987, Acta Obstetrica et Gynaecologica Japonica (Japanese Edition), V39, P479; Yemelyanova AV, 2008, AM J SURG PATHOL, V32, P128, DOI 10.1097/PAS.0b013e3180690d2d; Young RH, 2006, ADV ANAT PATHOL, V13, P205, DOI 10.1097/01.pap.0000213038.85704.e4	25	2	2	3	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1092-9134	1532-8198		ANN DIAGN PATHOL	Ann. Diagn. Pathol.	DEC	2018	37						1	6		10.1016/j.anndiagpath.2018.07.001			6	Pathology	Pathology	HF9NS	WOS:000454569300001	30179792				2019-10-28	
J	Bosch, DE; Yeh, MM; Schmidt, RA; Swanson, PE; Truong, CD				Bosch, Dustin E.; Yeh, Matthew M.; Schmidt, Rodney A.; Swanson, Paul E.; Truong, Camtu D.			Gallbladder carcinoma and epithelial dysplasia: Appropriate sampling for histopathology	ANNALS OF DIAGNOSTIC PATHOLOGY			English	Article						Gallbladder carcinoma; Epithelial dysplasia; Histopathologic sampling	CANCER	Gallbladder carcinoma (GC) is an uncommon malignancy with an overall 5-year survival of < 5%. Due to overlap of clinical presentation with the more common cholecystitis, an estimated 50-65% of all GCs are found incidentally. Epithelial dysplasia is identified in similar to 50% of specimens with invasive carcinoma. Recent expert panel guidelines have recommended histologic examination of the entire gallbladder in cases where initial sampling reveals dysplasia. 89 cases of GC, 34 high grade dysplasia (HGD), and 60 low grade dysplasia (LGD) were identified in cholecystectomy specimens assessed at our institution over the last 15 years. Pre-operative imaging (either ultrasound or CT) only identified 52% of mass lesions in GC cases. Among gallbladder specimens with epithelial dysplasia only at initial sampling, additional sectioning was performed in 59% of HGD and 55% of LGD. Additional sectioning of gallbladder specimens with HGD had a higher yield (10%) for identifying invasive carcinoma than those with LGD (0 of 28). The diagnostic yield of additional sectioning is significantly higher in the setting of high grade as compared to low grade dysplasia, suggesting that sampling at the discretion of the pathologist may be sufficient for the latter.	[Bosch, Dustin E.; Yeh, Matthew M.; Schmidt, Rodney A.; Swanson, Paul E.; Truong, Camtu D.] Univ Washington, Sch Med, Dept Pathol, 1959 NE Pacific St, Seattle, WA 98195 USA	Truong, CD (reprint author), 1959 NE Pacific St, Seattle, WA 98195 USA.	cdtruong@uw.edu					Aloia TA, 2015, HPB, V17, P681, DOI 10.1111/hpb.12444; Berger-Richardson D, 2016, SURGERY, V161; Espinoza JA, 2016, BBA-REV CANCER, V1865, P245, DOI 10.1016/j.bbcan.2016.03.004; Fong YM, 2006, ANN SURG, V243, P767, DOI 10.1097/01.sla.0000219737.81943.4e; Goldin RD, 2009, HISTOPATHOLOGY, V55, P218, DOI 10.1111/j.1365-2559.2008.03192.x; Hartman D, 2013, AM J CLIN PATHOL, V139, P830, DOI 10.1309/AJCP90LNQAKHZQBQ; Hayes BD, 2014, ANN DIAGN PATHOL, V18, P181, DOI 10.1016/j.anndiagpath.2014.03.004; Katabi N, 2010, ARCH PATHOL LAB MED, V134, P1621, DOI 10.1043/2009-0580-RAR.1; Marks EI, 2016, WORLD J GASTROENTERO, V22, P1335, DOI 10.3748/wjg.v22.i4.1335; Renshaw AA, 2012, AM J CLIN PATHOL, V138, P374, DOI 10.1309/AJCPB0ZTXXIF6MOF; Roa I, 2014, AM J CLIN PATHOL, V141, P675, DOI 10.1309/AJCPQT3ELN2BBCKA; Sicklick JK, 2016, CANCER METAST REV, V35, P263, DOI 10.1007/s10555-016-9602-8; Talreja Vikash, 2016, Surg Res Pract, V2016, P9319147, DOI 10.1155/2016/9319147; Ward ZJ, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0150735; Wrenn SM, 2016, SURG ENDOSC, V31	15	1	1	1	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1092-9134	1532-8198		ANN DIAGN PATHOL	Ann. Diagn. Pathol.	DEC	2018	37						7	11		10.1016/j.anndiagpath.2018.08.003			5	Pathology	Pathology	HF9NS	WOS:000454569300002	30216818				2019-10-28	
J	Wee, YTF; Alkaff, SMF; Lim, JCT; Loh, JJH; Hilmy, MH; Ong, C; Nei, WL; Jain, A; Lim, A; Takano, A; Azhar, R; Wan, WK; Newell, E; Yeong, J; Lim, TKH				Wee, Yu Ting Felicia; Alkaff, Syed Muhammad Fahmy; Lim, Jeffrey Chun Tatt; Loh, Josh Jie Hua; Hilmy, Maryam Hazly; Ong, Clara; Nei, Wen Long; Jain, Amit; Lim, Alvin; Takano, Angela; Azhar, Rafay; Wan, Wei Keat; Newell, Evan; Yeong, Joe; Lim, Tony Kiat Hon			An integrated automated multispectral imaging technique that simultaneously detects and quantitates viral RNA and immune cell protein markers in fixed sections from Epstein-Barr virus-related tumours	ANNALS OF DIAGNOSTIC PATHOLOGY			English	Article						Epstein-Barr virus; Vectra; EBER-ISH; immunofluorescence; FFPE; Multispectral; EBV-associated cancers; Fluorescence-immunohistochemistry; fIHC	LYMPHOEPITHELIOMA-LIKE CARCINOMA; IN-SITU HYBRIDIZATION; T-CELLS; NASOPHARYNGEAL CARCINOMA; B-CELLS; LYMPHOCYTES; LMP1; IMMUNOHISTOCHEMISTRY; EXPRESSION; DIAGNOSIS	Background/aim: Epstein-Barr virus (EBV) is an oncovirus that is commonly associated with the development of lymphomas and epithelial carcinomas. In the era of immunotherapy, histological evaluation of EBV-related cancers is currently a multi-sample, multi-technique process requiring separate time-consuming detection of EBV-encoded small RNAs by in situ hybridisation (ISH), and parallel labelling of sections for cancer-associated protein markers. Methods: Using EBV-associated tumours as proof-of-concept for feasibility, here we developed an approach that allows simultaneous detection of EBV RNAs and multiple protein markers such as PD-L1, EBV-LMP, CD8, CD4, CD20, CD30 and CD15on a single tissue section based on our recently reported automated staining protocol. Results: We successfully combined multiplex immunofluorescence (mIF) to detect 3 abovementioned protein markers involved in cancer, with ISH, and applied the protocol to f tissue samples from patients diagnosed with EBV-associated pulmonary lymphoepithelioma-like carcinoma (LELC), gastric carcinoma and Hodgkin's Lymphoma. Empowered by the Vectra 3 Automated Quantitative Pathology Imaging System, we demonstrate the utility and potential of this integrated approach to concurrently detect and quantitate viral RNA and protein biomarkers of immune and tumour cells. Conclusion: This study represents an important step forward in the research and diagnosis of EBV-associated cancers, and could be readily modified to include other proteins and RNA markers to apply to other malignancies. More importantly, the novel automated ISH-mIF protocol that we detailly described here could also be readily reproduced by most of the diagnostic and research lab to future projects that aim to look at both RNA and protein markers.	[Wee, Yu Ting Felicia; Alkaff, Syed Muhammad Fahmy; Lim, Jeffrey Chun Tatt; Loh, Josh Jie Hua; Hilmy, Maryam Hazly; Ong, Clara; Lim, Alvin; Takano, Angela; Azhar, Rafay; Wan, Wei Keat; Yeong, Joe; Lim, Tony Kiat Hon] Singapore Gen Hosp, Div Pathol, Dept Anat Pathol, 20 Coll Rd,Diagnost Tower, Singapore 169856, Singapore; [Wee, Yu Ting Felicia] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Anat, MD 10,4 Med Dr, Singapore 117594, Singapore; [Nei, Wen Long; Jain, Amit] Natl Canc Ctr Singapore, 11 Hosp Dr, Singapore 169610, Singapore; [Newell, Evan; Yeong, Joe] Agcy Sci Technol & Res, Singapore Immunol Network, 8A Biomed Grove,Immunos Bldg, Biopolis 138648, Singapore	Yeong, J (reprint author), Singapore Gen Hosp, Div Pathol, Dept Anat Pathol, 20 Coll Rd,Diagnost Tower, Singapore 169856, Singapore.; Lim, TKH (reprint author), 20 Coll Rd,Level 10,Diagnost Tower, Singapore 169856, Singapore.	lim.kiat.hon@singhealth.com.sg		Yeong, Joe/0000-0002-6674-7153	Centre Grant (CG) grant of Singapore General Hospital [NMRC/CG/M011/2017_SGH]	This research was funded by the Centre Grant (CG) grant of Singapore General Hospital (NMRC/CG/M011/2017_SGH).	Abel EJ, 2014, HUM PATHOL, V45, P1092, DOI 10.1016/j.humpath.2014.01.008; AMBINDER RF, 1994, HUM PATHOL, V25, P602, DOI 10.1016/0046-8177(94)90227-5; BROUSSET P, 1992, LAB INVEST, V67, P457; Chan ATC, 2002, ANN ONCOL, V13, P1007, DOI 10.1093/annonc/mdf179; Chang K L, 1992, Diagn Mol Pathol, V1, P246, DOI 10.1097/00019606-199203000-00037; Chang YL, 2015, LUNG CANCER, V88, P254, DOI 10.1016/j.lungcan.2015.03.017; Cho J, 2016, J GASTRIC CANCER, V16, P1, DOI 10.5230/jgc.2016.16.1.1; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; Daniel E, 2017, VIROL RES TREAT, V8; Dawson CW, 2012, SEMIN CANCER BIOL, V22, P144, DOI 10.1016/j.semcancer.2012.01.004; Esbona K, 2016, BREAST CANCER RES, V18, DOI 10.1186/s13058-016-0695-3; Fang WF, 2015, ONCOTARGET, V6, P33019, DOI 10.18632/oncotarget.5028; Feng ZP, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.93652; Feng ZP, 2016, J IMMUNOL, V196, P3943, DOI 10.4049/jimmunol.1502635; Fiore C, 2012, J CLIN PATHOL, V65, P496, DOI 10.1136/jclinpath-2012-200734; Garnelo M, 2015, GUT, V15; Garnelo M, 2017, GUT, V66, P342, DOI 10.1136/gutjnl-2015-310814; Gu LH, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0182692; Gulley ML, 2002, AM J CLIN PATHOL, V117, P259; Gulley ML, 2001, J MOL DIAGN, V3, P1, DOI 10.1016/S1525-1578(10)60642-3; GUv Zyl, 2012, VIROLOGY, piv; Hamanishi J, 2007, P NATL ACAD SCI USA, V104, P3360, DOI 10.1073/pnas.0611533104; Hashmi AA, 2017, WORLD J SURG ONCOL, V15, DOI 10.1186/s12957-017-1147-y; Iizasa H, 2012, VIRUSES-BASEL, V4, P3420, DOI 10.3390/v4123420; Iwai Y, 2017, J BIOMED SCI, V24, DOI 10.1186/s12929-017-0329-9; Jiang L, 2015, ONCOTARGETS THER, V8, P1451, DOI 10.2147/OTT.S84234; Kang BW, 2016, ANN ONCOL, V27, P494, DOI 10.1093/annonc/mdv610; Kasai K, 1999, PATHOL RES PRACT, V195, P773, DOI 10.1016/S0344-0338(99)80120-4; Kobayashi M, 2004, INTERNAL MED, V43, P323, DOI 10.2169/internalmedicine.43.323; KOUVIDOU C, 1995, J CLIN PATHOL-CL MOL, V48, pM17; Kurth J, 2000, IMMUNITY, V13, P485, DOI 10.1016/S1074-7613(00)00048-0; Landais E, 2005, INT J DEV BIOL, V49, P285, DOI 10.1387/ijdb.041947el; Leong TYM, 2007, ADV ANAT PATHOL, V14, P129, DOI 10.1097/PAP.0b013e31803250c7; Liang YS, 2015, ONCOL LETT, V9, P1767, DOI 10.3892/ol.2015.2975; Lim JCT, 2018, PATHOLOGY, V50, P333, DOI 10.1016/j.pathol.2017.11.087; Lopez ME, 2014, BIO PROTOC, V4; Lovisa S, 2015, NAT MED, V21, P998, DOI 10.1038/nm.3902; Mlecnik B, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aad6352; Nghiem PT, 2016, NEW ENGL J MED, V374, P2542, DOI 10.1056/NEJMoa1603702; Ohtani H, 2009, J PATHOL, V217, P21, DOI 10.1002/path.2448; Ok CY, 2015, EXP MOL MED, V47, DOI 10.1038/emm.2014.82; Ok CY, 2013, BLOOD, V122, P328, DOI 10.1182/blood-2013-03-489708; Park S, 2007, BLOOD, V110, P972, DOI 10.1182/blood-2007-01-067769; Piccaluga Pier Paolo, 2011, Adv Hematol, V2011, P920898, DOI 10.1155/2011/920898; Pileri SA, 2002, J CLIN PATHOL, V55, P162, DOI 10.1136/jcp.55.3.162; Shi SR, 2011, J HISTOCHEM CYTOCHEM, V59, P13, DOI 10.1369/jhc.2010.957191; Shi SR, 2001, J HISTOCHEM CYTOCHEM, V49, P931, DOI 10.1177/002215540104900801; Soni V, 2007, ADV EXP MED BIOL, V597, P173; Stack EC, 2014, METHODS, V70, P46, DOI 10.1016/j.ymeth.2014.08.016; Tsao SW, 2015, J PATHOL, V235, P323, DOI 10.1002/path.4448; Weiss Lawrence M, 2013, Methods Mol Biol, V999, P223, DOI 10.1007/978-1-62703-357-2_16; Yeong J, 2017, BREAST CANC RES TREA, V23; Yeong J, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01209; Yeong J, 2017, BREAST CANCER RES TR, V163, P21, DOI 10.1007/s10549-017-4161-4; Zhang MH, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-10925-7	55	1	1	1	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1092-9134	1532-8198		ANN DIAGN PATHOL	Ann. Diagn. Pathol.	DEC	2018	37						12	19		10.1016/j.anndiagpath.2018.09.002			8	Pathology	Pathology	HF9NS	WOS:000454569300003	30218928				2019-10-28	
J	Mok, Y; Agaimy, A; Wang, S; Kuick, CH; Chang, KTE; Petersson, F				Mok, Yingting; Agaimy, Abbas; Wang, Shi; Kuick, Chik Hong; Chang, Kenneth Tou-En; Petersson, Fredrik			High-grade myoepithelial carcinoma can show histologically undifferentiated/anaplastic features	ANNALS OF DIAGNOSTIC PATHOLOGY			English	Article						Anaplastic carcinoma; Myoepithelial carcinoma; Submandibular; Sinonasal; Salivary gland; Fine needle aspiration	SALIVARY-GLANDS; PAROTID-GLAND; SINONASAL CARCINOMA; TUMOR; HEAD	High grade malignant tumors with a poorly-/un-differentiated morphology pose significant diagnostic challenges. Increasingly, the use of adjunct immunohistochemical and molecular tests to characterize and delineate the histopathologic phenotype of these tumors has become necessary, particularly in head and neck tumors. Recently, several entities with a poorly-/un-differentiated light microscopic morphology have been defined based on specific immunohistochemical and genetic characteristics. We herein describe two cases of high-grade myoepithelial carcinoma, one occurring in the submandibular gland and the other occurring in the left nasal cavity, both showing undifferentiated histological and anaplastic cytomorphological features. This led to very broad differential diagnostic considerations and the diagnosis was only established after extensive immunohistochemical studies. Molecular testing for HPV was negative in both cases. Gene fusion analysis using a targeted sequencing assay (Archer (R) FusionPlex (R) system) did not identify fusions involving PLAG1, HMGA2, EWSR1 or ALK genes in either case. The submandibular tumor showed an aggressive clinical course, with diffuse pulmonary metastases at presentation, whilst the nasal cavity tumor showed only localized disease. Awareness of a subcategory of high-grade myoepithelial carcinomas with undifferentiated light microscopical features is of significant importance in antibody selection for immunohistochemical investigation of poorly-/undifferentiated malignant tumors in the head and neck region. This histological variant of myoepithelial carcinoma adds to the growing list of differential diagnoses in this diagnostically complex and multifaceted field.	[Mok, Yingting; Wang, Shi; Petersson, Fredrik] Natl Univ Hlth Syst, Dept Pathol, 5 Lower Kent Ridge Rd, Singapore 119074, Singapore; [Agaimy, Abbas] Friedrich Alexander Univ Erlangen Nuremberg, Inst Pathol, Erlangen, Germany; [Kuick, Chik Hong; Chang, Kenneth Tou-En] KK Womens & Childrens Hosp, Dept Pathol & Lab Med, Singapore, Singapore; [Chang, Kenneth Tou-En] Duke NUS Med Sch, Singapore, Singapore	Petersson, F (reprint author), Natl Univ Hlth Syst, Dept Pathol, 5 Lower Kent Ridge Rd, Singapore 119074, Singapore.	fredrikpetersson@live.se			VIVA-KKH Pediatric Brain and Solid Tumor Programme	This study was supported by the VIVA-KKH Pediatric Brain and Solid Tumor Programme.	Agaimy A, 2017, AM J SURG PATHOL, V41, P458, DOI 10.1097/PAS.0000000000000797; Agaimy A, 2016, AM J SURG PATHOL, V40, P181, DOI 10.1097/PAS.0000000000000527; Bishop JA, 2017, AM J SURG PATHOL, V41, P1690, DOI 10.1097/PAS.0000000000000944; Bishop JA, 2013, AM J SURG PATHOL, V37, P836, DOI 10.1097/PAS.0b013e31827b1cd6; Dalin MG, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01178-z; DONATH K, 1982, J CANCER RES CLIN, V103, P75, DOI 10.1007/BF00410308; El-Naggar A, 2017, WHO CLASSIFICATION H; Kane SV, 2010, ARCH OTOLARYNGOL, V136, P702, DOI 10.1001/archoto.2010.104; Kong M, 2015, AM J SURG PATHOL, V39, P931, DOI 10.1097/PAS.0000000000000452; KRAEMER BB, 1983, CANCER, V52, P2115, DOI 10.1002/1097-0142(19831201)52:11<2115::AID-CNCR2820521124>3.0.CO;2-Z; Mok Y, 2016, HEAD NECK-J SCI SPEC, V38, pE2483, DOI 10.1002/hed.24462; Ogawa I, 2003, PATHOL INT, V53, P704, DOI 10.1046/j.1440-1827.2003.01536.x; Pang B, 2011, APPL IMMUNOHISTO M M, V19, P70, DOI 10.1097/PAI.0b013e3181eec73c; Petersson F, 2011, HEAD NECK PATHOL, V5, P144, DOI 10.1007/s12105-010-0226-y; Santos KCP, 2017, ONCOL LETT, V13, P2679, DOI 10.3892/ol.2017.5783; Savera AT, 2000, AM J SURG PATHOL, V24, P761, DOI 10.1097/00000478-200006000-00001; Shin DM, 2001, CANCER EPIDEM BIOMAR, V10, P603; Subramaniam MM, 2012, HISTOPATHOLOGY, V61, P1232, DOI 10.1111/j.1365-2559.2012.04340.x; Subramaniam MM, 2011, HISTOPATHOLOGY, V59, P1269, DOI 10.1111/j.1365-2559.2011.03997.x; Toyosawa S, 1999, PATHOL INT, V49, P887, DOI 10.1046/j.1440-1827.1999.00952.x; Wang CX, 2015, J ORAL MAXIL SURG, V73, P1938, DOI 10.1016/j.joms.2015.03.054; WIRMAN JA, 1976, CANCER, V37, P1840, DOI 10.1002/1097-0142(197604)37:4<1840::AID-CNCR2820370431>3.0.CO;2-U; YAKU Y, 1983, VIRCHOWS ARCH A, V401, P89, DOI 10.1007/BF00644792	23	0	0	1	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1092-9134	1532-8198		ANN DIAGN PATHOL	Ann. Diagn. Pathol.	DEC	2018	37						20	24		10.1016/j.anndiagpath.2018.09.004			5	Pathology	Pathology	HF9NS	WOS:000454569300004	30236544				2019-10-28	
J	Kir, G; Girgin, RB; Soylemez, T; Melemez, MK; Topal, CS; Turan, T; Caskurlu, T; Yildirim, A				Kir, Gozde (Gozde); Girgin, Rabia Burcin (Burgin); Soylemez (Soylemez), Tuce (Tuce); Melemez, Mukaddes Kubra (Kubra); Topal, Cumhur Selcuk (Selcuk); Turan, Turgay; Caskurlu (Caskurlu), Turhan; Yildirim, Asif (Asif )			Assessment of transurethral resection of the bladder specimens with pT1 high-grade urothelial carcinoma for the predictor features of muscularis propria invasion on radical cystectomy specimens	ANNALS OF DIAGNOSTIC PATHOLOGY			English	Article							TUMOR NECROSIS; OUTCOMES; CANCER; DIAMETER; DEPTH		[Kir, Gozde (Gozde); Girgin, Rabia Burcin (Burgin); Soylemez (Soylemez), Tuce (Tuce)] Istanbul Medeniyet Univ, Goztepe Training & Res Hosp, Pathol Dept, Goztepe Egt & Aras Hastanesi Patol Lab, Dr Erkin Caddesi, TR-34720 Istanbul, Turkey; [Melemez, Mukaddes Kubra (Kubra)] Istanbul Medeniyet Univ, Sch Med, Goztepe Egt & Aras Hastanesi Patol Lab, Dr Erkin Caddesi, TR-34720 Istanbul, Turkey; [Topal, Cumhur Selcuk (Selcuk)] Umraniye Training & Res Hosp, Pathol Dept, Adem Yavuz Cad 1, TR-34764 Istanbul, Turkey; [Turan, Turgay; Caskurlu (Caskurlu), Turhan; Yildirim, Asif (Asif )] Istanbul Medeniyet Univ, Goztepe Training & Res Hosp, Urol Dept, Goztepe Egt & Aras Hastanesi Urol Klin, Dr Erkin Caddesi, TR-34720 Istanbul, Turkey	Kir, G (reprint author), Istanbul Medeniyet Univ, Goztepe Res & Training Hosp, Pathol Dept, TR-34720 Istanbul, Turkey.	gozkir@yahoo.com	Yildirim, Asif/N-5388-2019				Babjuk M, 2017, EUR UROL, V71, P447, DOI 10.1016/j.eururo.2016.05.041; Bertz S, 2011, HISTOPATHOLOGY, V59, P722, DOI 10.1111/j.1365-2559.2011.03989.x; Brimo F, 2013, HUM PATHOL, V44, P95, DOI 10.1016/j.humpath.2012.04.020; Cheng L, 1999, CANCER, V86, P1035, DOI 10.1002/(SICI)1097-0142(19990915)86:6<1035::AID-CNCR20>3.0.CO;2-D; Egner J.R., 2010, JAMA-J AM MED ASSOC, V304, P1726, DOI DOI 10.1001/JAMA.2010.1525; Fritsche HM, 2010, EUR UROL, V57, P300, DOI 10.1016/j.eururo.2009.09.024; Grignon DJ, 2016, WHO CLASSIFICATION T, P81; Guzzo JT, 2016, CAMPBELL WALSH UROLO, P2223; Hu ZH, 2014, ANN DIAGN PATHOL, V18, P49, DOI 10.1016/j.anndiagpath.2013.11.002; Leivo MZ, 2018, AM J SURG PATHOL, V42, pE1, DOI 10.1097/PAS.0000000000000964; Moschini M, 2017, UROL ONCOL-SEMIN ORI, V35, P335, DOI 10.1016/j.urolonc.2016.12.006; Ord JJ, 2007, J UROLOGY, V178, P677, DOI 10.1016/j.juro.2007.03.112; Seitz C, 2010, J UROLOGY, V184, P1895, DOI 10.1016/j.juro.2010.06.106; Soave A, 2015, UROLOGY, V86, P92, DOI 10.1016/j.urology.2015.03.036; Zhang XK, 2015, JPN J CLIN ONCOL, V45, P1069, DOI 10.1093/jjco/hyv127; Zigeuner R, 2010, EUR UROL, V57, P575, DOI 10.1016/j.eururo.2009.11.035	16	0	0	1	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1092-9134	1532-8198		ANN DIAGN PATHOL	Ann. Diagn. Pathol.	DEC	2018	37						25	29		10.1016/j.anndiagpath.2018.09.003			5	Pathology	Pathology	HF9NS	WOS:000454569300005	30236545				2019-10-28	
J	Lee, H; Fu, ZY; Koo, BH; Sheehan, CE; Young, GQ; Lin, JM; Patil, DT; Yang, ZH				Lee, Hwajeong; Fu, Zhiyan; Koo, Brandon H.; Sheehan, Christine E.; Young, Gloria Q.; Lin, Jingmei; Patil, Deepa T.; Yang, Zhaohai			The expression of TTF1, CDX2 and ISL1 in 74 poorly differentiated neuroendocrine carcinomas	ANNALS OF DIAGNOSTIC PATHOLOGY			English	Article						Neuroendocrine carcinoma; Lung; Gastroenteropancreatic; Immunohistochemistry; TTF1; CDX2	CELL; TUMORS; NEOPLASMS; MARKER; EVEROLIMUS; ENDOCRINE; DIAGNOSIS; ORIGIN; PANEL; PDX-1	Background: The expression profile of immunohistochemical markers of origin in poorly differentiated neuroendocrine carcinoma (PDNEC) is not well studied. Materials and methods: Seventy-four PDNECs from gastroenteropancreatic (GEP) organs and the lung, including 48 large cell NEC (LCNEC) and 26 small cell carcinomas (SmCC), were subject to immunohistochemical staining for CDX2, TTF1 and ISL1. The staining intensity (1 to 3) and percentage of positive tumor cells [0 (negative), 1 ( < 50%) and 2 (_50%)] were assessed. The multiplicative index (maximum 6) was calculated and the average total score (aTS) was determined for each primary site and histologic subtype. Results: In the 38 GEP and 36 lung PDNECs, CDX2, TTF1 and ISL1 staining was observed in 71% (aTS 2.8), 16% (aTS 0.4), 63% (aTS 1.9), and 22% (aTS 0.6), 72% (aTS 2.9) and 92% (aTS 3.8), respectively. GEP PDNECs showed a higher aTS for CDX2 and lower aTS for TTF1 and ISL1, compared to that of lung PDNECs (Student's t-test, p < 0.001). SmCC had a higher aTS for TTF1 and ISL1 (p < 0.001) and lower aTS for CDX2 (p < 0.002) than that of LCNEC. Conclusions: CDX2 and TTF1 demonstrate potential utility in suggesting the primary site of PDNEC. In addition, CDX2 may be useful in supporting the diagnosis of LCNEC in cases with overlapping or borderline morphology. Utility of ISL1 as an adjunctive diagnostic marker of SmCC remains to be studied.	[Lee, Hwajeong; Fu, Zhiyan; Sheehan, Christine E.] Albany Med Coll, Anat Pathol, Albany, NY 12208 USA; [Koo, Brandon H.] Albany Med Coll, Albany, NY 12208 USA; [Young, Gloria Q.] NYU, Pathol & Lab Med, New York, NY USA; [Lin, Jingmei] Indiana Univ, Pathol & Lab Med, Indianapolis, IN 46204 USA; [Patil, Deepa T.] Cleveland Clin, Anat Pathol, Cleveland, OH 44106 USA; [Yang, Zhaohai] Penn State Hershey Med Ctr, Pathol, Hershey, PA USA	Yang, ZH (reprint author), Penn State Hershey Med Ctr, Dept Pathol, MC H179,500 Univ Dr, Hershey, PA 17033 USA.	leeh5@amc.edu; fuz@amc.edu; koob@amc.edu; SheehaC@amc.edu; gloria.young@nyumc.org; jinglin@iupui.edu; patild@ccf.org; zyang2@pennstatehealth.psu.edu					Agaimy A, 2013, MODERN PATHOL, V26, P995, DOI 10.1038/modpathol.2013.40; Ainechi S, 2018, APPL IMMUNOHISTO M M, V26, P545, DOI 10.1097/PAI.0000000000000473; Bari MF, 2014, HISTOPATHOLOGY, V64, P547, DOI 10.1111/his.12278; Bellizzi AM, 2013, ADV ANAT PATHOL, V20, P285, DOI 10.1097/PAP.0b013e3182a2dc67; Bollard J, 2013, NEUROENDOCRINOLOGY, V97, P331, DOI 10.1159/000347063; Brambilla E, 2015, WHO CLASSIFICATION T, V4, P63; Chan ES, 2012, AM J SURG PATHOL, V36, P737, DOI 10.1097/PAS.0b013e31824aba59; Couderc C, 2011, AM J PATHOL, V178, P336, DOI 10.1016/j.ajpath.2010.11.023; Fasano M, 2015, J THORAC ONCOL, V10, P1133, DOI 10.1097/JTO.0000000000000589; Graham RP, 2013, AM J SURG PATHOL, V37, P399, DOI 10.1097/PAS.0b013e31826f042c; Hiroshima K, 2017, TRANSL LUNG CANCER R, V6, P530, DOI 10.21037/tlcr.2017.06.12; Iyoda A, 2011, EXP THER MED, V2, P1041, DOI 10.3892/etm.2011.343; Jaffee IM, 2006, ARCH PATHOL LAB MED, V130, P1522; Kloppel G, 2017, WHO CLASSIFICATION T, P211; Koo J, 2015, SEMIN DIAGN PATHOL, V32, P456, DOI 10.1053/j.semdp.2015.09.013; La Rosa S, 2012, AM J SURG PATHOL, V36, P601, DOI 10.1097/PAS.0b013e318242e21c; Liau JY, 2016, APPL IMMUNOHISTO M M, V24, P57, DOI 10.1097/PAI.0000000000000149; Lin XQ, 2007, APPL IMMUNOHISTO M M, V15, P407, DOI 10.1097/01.pai.0000210416.53493.0f; Milione M, 2018, ENDOCR-RELAT CANCER, V25, P583, DOI 10.1530/ERC-17-0557; Nassar H, 2005, AM J SURG PATHOL, V29, P588, DOI 10.1097/01.pas.0000157974.05397.4f; Nolting S, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0182852; Rindi G, 2010, WHO CLASSIFICATION T, V4, P13; Rossi G, 2005, J CLIN ONCOL, V23, P8774, DOI 10.1200/JCO.2005.02.8233; Saqi A, 2005, AM J CLIN PATHOL, V123, P394, DOI 10.1309/UKN6PVRKXHG422DA; Srivastava A, 2009, AM J SURG PATHOL, V33, P626, DOI 10.1097/PAS.0b013e31818d7d8b; Strosberg JR, 2010, PANCREAS, V39, P799, DOI 10.1097/MPA.0b013e3181ebb56f; Tacha D, 2013, APPL IMMUNOHISTO M M, V21, P59, DOI 10.1097/PAI.0b013e318257cc1c; Tsoukalas N, 2018, ANN TRANSL MED, V6, DOI 10.21037/atm.2018.04.03; Werling RW, 2003, AM J SURG PATHOL, V27, P303, DOI 10.1097/00000478-200303000-00003; Yang ZH, 2017, AM J SURG PATHOL, V41, P915, DOI 10.1097/PAS.0000000000000876; Yao JC, 2011, NEW ENGL J MED, V364, P514, DOI 10.1056/NEJMoa1009290; Yatabe Y, 2004, J PATHOL, V203, P645, DOI 10.1002/path.1566	32	0	0	2	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1092-9134	1532-8198		ANN DIAGN PATHOL	Ann. Diagn. Pathol.	DEC	2018	37						30	34		10.1016/j.anndiagpath.2018.09.005			5	Pathology	Pathology	HF9NS	WOS:000454569300006	30236546				2019-10-28	
J	AbdullGaffar, B; Keloth, T				AbdullGaffar, Badr; Keloth, Tasnim			Laryngeal sarcomas: A case series of 5 cases	ANNALS OF DIAGNOSTIC PATHOLOGY			English	Article						Larynx; Sarcoma; Mesenchymal; Malignancy	CARTILAGINOUS TUMORS; KAPOSIS-SARCOMA; CHONDROSARCOMA; OSTEOSARCOMA; ANGIOSARCOMA; EXPERIENCE	Primary sarcomas of the larynx are rare and miscellaneous. The most common is chondrosarcoma. Other sarcomas are very rare. Sarcomas can have heterogeneous morphologic features of spindle, small round, epithelioid, pleomorphic and giant cells. Laryngeal sarcomas may mimic carcinomas, lymphomas, small cell carcinoma, mesothelioma and melanoma. This imposes diagnostic challenges for unfamiliar pathologists particularly in small laryngeal biopsies. Our aim was to study the different types of sarcomas that can involve the larynx in our institution, to investigate their diagnostic challenges and potential pitfalls and to find helpful histologic clues to avoid misinterpretation and missed diagnosis. We performed a retrospective review study over 13 years. We retrieved 5 cases of laryngeal sarcomas. They included Kaposi sarcoma, low-grade chondrosarcoma, epithelioid angiosarcoma, polypoid leiomyosarcoma and small cell osteosarcoma. The age range was between 32 and 74 years with an average age of 52 years. The male to female ratio was 3:2. The Kaposi sarcoma and chondrosarcoma were correctly diagnosed. The angiosarcoma was initially missed as recurrent carcinoma. The leiomyosarcoma was initially inferred as polypoid sarcomatoid squamous cell carcinoma. The small cell osteosarcoma initiated the differential diagnosis of high-grade lymphoma, small cell carcinoma, undifferentiated carcinoma, Ewing sarcoma and rhabdomyosarcoma. An implementation of a panel of immunohistochemical markers guided by certain histomorphologic clues was helpful to make the correct diagnosis. Pathologists should be aware of the morphologic spectrum and different growth patterns of laryngeal sarcomas. Immunohistochemistry studies are essential. Correct diagnosis, classification and grading of laryngeal sarcomas are clinically important for the prognosis and appropriate management of patients.	[AbdullGaffar, Badr; Keloth, Tasnim] Rashid Hosp, Pathol Sect, Oud Metha Rd, Dubai 4545, U Arab Emirates	AbdullGaffar, B (reprint author), Rashid Hosp, Pathol Sect, Oud Metha Rd, Dubai 4545, U Arab Emirates.	badraah009@yahoo.com		AbdullGaffar, Badr/0000-0001-6350-1214			Berge JK, 1998, ARCH OTOLARYNGOL, V124, P207, DOI 10.1001/archotol.124.2.207; BRANDWEIN M, 1992, LARYNGOSCOPE, V102, P858, DOI 10.1288/00005537-199208000-00004; CADY B, 1968, ANN SURG, V167, P116, DOI 10.1097/00000658-196801000-00019; Casiraghi Odile, 2004, Ann Diagn Pathol, V8, P189, DOI 10.1053/j.anndiagpath.2004.04.001; CLERF LH, 1946, ARCH OTOLARYNGOL, V44, P517; Oliveira JFD, 2014, BRAZ J OTORHINOLAR, V80, P354, DOI 10.1016/j.bjorl.2014.05.004; FERLITO A, 1984, AM J OTOLARYNG, V5, P350, DOI 10.1016/S0196-0709(84)80005-8; FERLITO A, 1985, ANN OTO RHINOL LARYN, V94, P93; Fernandez-Acenero MJ, 2009, ACTA OTO-LARYNGOL, V129, P108, DOI 10.1080/00016480802008207; Figi FA, 1933, ARCHIV OTOLARYNGOL, V18, P21; Friedman AD, 2012, J LARYNGOL OTOL, V126, P706, DOI 10.1017/S0022215112000928; GORENSTEIN A, 1980, ARCH OTOLARYNGOL, V106, P8; HACIHANEFIOGLU U, 1983, ANN OTO RHINOL LARYN, V92, P81, DOI 10.1177/000348948309200120; HAMLYN PJ, 1986, J LARYNGOL OTOL, V100, P1163, DOI 10.1017/S0022215100100763; Hart J, 2011, ARCH PATHOL LAB MED, V135, P268, DOI 10.1043/1543-2165-135.2.268; Havens FZ, 1941, ARCHIV OTOLARYNGOL, V34, P1113; Hellquist H, 2018, VIRCHOWS ARCH, V472, P705, DOI 10.1007/s00428-018-2348-7; HUIZENGA C, 1970, CANCER, V26, P201, DOI 10.1002/1097-0142(197007)26:1<201::AID-CNCR2820260126>3.0.CO;2-S; HYAMS VJ, 1970, LARYNGOSCOPE, V80, P755; Karatayli-Ozgursoy S, 2016, AM J OTOLARYNG, V37, P279, DOI 10.1016/j.amjoto.2016.01.005; Kozelsky TF, 1997, J SURG ONCOL, V65, P269, DOI 10.1002/(SICI)1096-9098(199708)65:4<269::AID-JSO8>3.0.CO;2-3; KRATZ RC, 1961, ANN OTO RHINOL LARYN, V70, P239, DOI 10.1177/000348946107000119; Lewis JE, 1997, ANN OTO RHINOL LARYN, V106, P94, DOI 10.1177/000348949710600202; Liu Chia-Yu, 2006, J Chin Med Assoc, V69, P120; Luna-Ortiz K, 2017, CLIN OTOLARYNGOL, V42, P1389, DOI 10.1111/coa.12889; Madrigal Fernando Martinez, 2002, Ann Diagn Pathol, V6, P1, DOI 10.1053/adpa.2002.30604; Mochloulis G, 1996, J LARYNGOL OTOL, V110, P1034, DOI 10.1017/S0022215100135698; Mosalleum E, 2015, HEAD NECK PATHOL, V9, P158, DOI 10.1007/s12105-014-0550-8; Nakajima H, 1997, CANCER, V79, P2095, DOI 10.1002/(SICI)1097-0142(19970601)79:11<2095::AID-CNCR6>3.0.CO;2-O; NICOLAI P, 1990, ANN OTO RHINOL LARYN, V99, P515, DOI 10.1177/000348949009900704; Paczona R, 1999, ANN OTO RHINOL LARYN, V108, P677, DOI 10.1177/000348949910800711; Rinaldo A, 2000, ACTA OTO-LARYNGOL, V120, P680; Schiff NF, 1997, ANN OTO RHINOL LARYN, V106, P563, DOI 10.1177/000348949710600706; Stavrakas M, 2016, J LARYNGOL OTOL, V130, P850, DOI 10.1017/S0022215116008604; Thomas LD, 2002, AM INDIAN CULT RES J, V26, P153, DOI 10.1097/00000478-200202000-00002; Thompson LDR, 2002, AM J SURG PATHOL, V26, P836, DOI 10.1097/00000478-200207000-00002; TODA S, 1989, PATHOL RES PRACT, V185, P860, DOI 10.1016/S0344-0338(89)80287-0; Wadhwa A K, 2000, Ear Nose Throat J, V79, P42	38	0	0	1	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1092-9134	1532-8198		ANN DIAGN PATHOL	Ann. Diagn. Pathol.	DEC	2018	37						35	41		10.1016/j.anndiagpath.2018.09.007			7	Pathology	Pathology	HF9NS	WOS:000454569300007	30241033				2019-10-28	
J	Jung, MJ; Maldonado, J; Schwartz, MR; Sneige, N; Ayala, AG; Ro, JY				Jung, Minjung; Maldonado, Joyce; Schwartz, Mary R.; Sneige, Nour; Ayala, Alberto G.; Ro, Jae Y.			Clinical presentation of ductal carcinoma in situ of breast with intraluminal crystalloids: Radiologic-histologic correlation	ANNALS OF DIAGNOSTIC PATHOLOGY			English	Article						Intraluminal crystalloids; Ductal carcinoma in situ; Radiologic finding; Literature review	NEEDLE-ASPIRATION-CYTOLOGY; PROSTATIC ADENOCARCINOMA; MICROCALCIFICATIONS; LESIONS	Intraluminal crystalloids have rarely been described in the breast, particularly in cases with ductal carcinoma in situ (DCIS). We recently encountered a case of DCIS of the breast associated with numerous intraluminal crystalloids. The patient presented with a mass in the right breast, and microcalcifications were detected on screening and diagnostic mammograms; the patient underwent needle biopsies, lumpectomy, and skin-sparing mastectomy. Invasive ductal carcinoma associated with extensive DCIS was diagnosed. Multiple refractile, eosinophilic crystalloids, with variable morphologies including rectangular, triangular and needle-like with sharp borders, were observed within the lumina of DCIS, besides calcium phosphate microcalcifications. We report this case together with a literature review on crystalloid-containing lesions in breast and non-breast tissues. We also studied radiologic findings of these crystalloids using a specimen radiograph.	[Jung, Minjung; Maldonado, Joyce; Schwartz, Mary R.; Sneige, Nour; Ayala, Alberto G.; Ro, Jae Y.] Cornell Univ, Houston Methodist Hosp, Dept Pathol & Genom Med, Weill Med Coll, 6565 Fannin St, Houston, TX 77030 USA	Ro, JY (reprint author), Cornell Univ, Houston Methodist Hosp, Dept Pathol & Genom Med, Weill Med Coll, 6565 Fannin St, Houston, TX 77030 USA.	jaero@houstonmethodist.org					Baker R, 2010, BRIT J CANCER, V103, P1034, DOI 10.1038/sj.bjc.6605873; Bezic J, 2011, HEAD NECK PATHOL, V5, P419, DOI 10.1007/s12105-011-0273-z; Coyne JD, 2004, HISTOPATHOLOGY, V44, P401, DOI 10.1111/j.1365-2559.2004.01785.x; Henneberry JM, 1997, AM J SURG PATHOL, V21, P725, DOI 10.1097/00000478-199706000-00014; Henrot P, 2014, DIAGN INTERV IMAG, V95, P141, DOI 10.1016/j.diii.2013.12.011; Jain M, 2001, DIAGN CYTOPATHOL, V25, P162, DOI 10.1002/dc.2029; JENSEN P E, 1980, Prostate, V1, P25, DOI 10.1002/pros.2990010105; Lomme MM, 2005, BREAST J, V11, P510, DOI 10.1111/j.1075-122X.2005.00143.x; Mesa H, 2015, HUM PATHOL, V46, P600, DOI 10.1016/j.humpath.2015.01.004; MOLBERG KH, 1994, AM J CLIN PATHOL, V101, P266, DOI 10.1093/ajcp/101.3.266; Nasuti JF, 2000, DIAGN CYTOPATHOL, V22, P167, DOI 10.1002/(SICI)1097-0339(20000301)22:3<167::AID-DC7>3.0.CO;2-P; Quddus MR, 2014, BREAST J, V20, P84, DOI 10.1111/tbj.12210; RO JY, 1991, ARCH PATHOL LAB MED, V115, P145; Ro JY, 1997, ARCH PATHOL LAB MED, V121, P593; RO JY, 1986, CANCER, V57, P2397, DOI 10.1002/1097-0142(19860615)57:12<2397::AID-CNCR2820571226>3.0.CO;2-1; RO JY, 1988, SEMIN DIAGN PATHOL, V5, P273; RO JY, 1987, J LARYNGOL OTOL, V101, P1175, DOI 10.1017/S0022215100103457; Scimeca M, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-286; Scott R, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-00183-y; SHIPKEY FH, 1964, CANCER-AM CANCER SOC, V17, P821, DOI 10.1002/1097-0142(196407)17:7<821::AID-CNCR2820170702>3.0.CO;2-I; Varma M, 2002, ARCH PATHOL LAB MED, V126, P554	21	0	0	1	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1092-9134	1532-8198		ANN DIAGN PATHOL	Ann. Diagn. Pathol.	DEC	2018	37						42	46		10.1016/j.anndiagpath.2018.09.001			5	Pathology	Pathology	HF9NS	WOS:000454569300008	30241034				2019-10-28	
J	Kocabey, DU; Cakir, E; Dirilenoglu, F; Kucukzeybek, BB; Ekinci, N; Sari, AA				Kocabey, Duygu Unal; Cakir, Ebru; Dirilenoglu, Fikret; Kucukzeybek, Betul Bolat; Ekinci, Nese; Sari, Aysegul Akder			Analysis of clinical and pathological findings in inflammatory fibroid polyps of the gastrointestinal system: A series of 69 cases	ANNALS OF DIAGNOSTIC PATHOLOGY			English	Article							HELICOBACTER-PYLORI; PDGFRA MUTATIONS; DEVON FAMILY; TRACT; MULTIPLE; SPECTRUM; PATTERN; GROWTH; TUMORS		[Kocabey, Duygu Unal; Cakir, Ebru; Kucukzeybek, Betul Bolat; Ekinci, Nese; Sari, Aysegul Akder] Izmir Katip Celebi Univ, Ataturk Training & Res Hosp, Dept Pathol, Izmir, Turkey; [Dirilenoglu, Fikret] Near East Univ, Dept Pathol, Fac Med, Nicosia, Cyprus	Kocabey, DU (reprint author), Izmir Katip Celebi Univ, Ataturk Training & Res Hosp, Dept Pathol, Izmir, Turkey.	dyg.unl@gmail.com					Albuquerque A, 2014, VIRCHOWS ARCH, V465, P643, DOI 10.1007/s00428-014-1659-6; ALLIBONE RO, 1992, GUT, V33, P1004, DOI 10.1136/gut.33.7.1004; ANTHONY PP, 1984, GUT, V25, P854, DOI 10.1136/gut.25.8.854; Carmack SW, 2009, AM J GASTROENTEROL, V104, P1524, DOI 10.1038/ajg.2009.139; Daum O, 2010, VIRCHOWS ARCH, V456, P491, DOI 10.1007/s00428-010-0914-8; HELWIG EB, 1953, SURG GYNECOL OBSTET, V96, P355; Hirasaki S, 2003, INTERNAL MED, V42, P259; Hirasaki S, 2007, INTERNAL MED, V46, P855, DOI 10.2169/internalmedicine.46.6445; Huss S, 2012, HISTOPATHOLOGY, V61, P59, DOI 10.1111/j.1365-2559.2012.04203.x; Kim MK, 2000, APPL IMMUNOHISTO M M, V8, P147, DOI 10.1097/00022744-200006000-00009; Lasota J, 2009, MODERN PATHOL, V22, P1049, DOI 10.1038/modpathol.2009.62; Liu TC, 2013, AM J SURG PATHOL, V37, P586, DOI 10.1097/PAS.0b013e31827ae11e; Makhlouf HR, 2002, HUM PATHOL, V33, P307, DOI 10.1053/hupa.2002.32213; Mori M, 1992, Eur J Surg Oncol, V18, P632; Mucientes P, 2012, ANN DIAGN PATHOL, V16, P148, DOI 10.1016/j.anndiagpath.2011.01.001; Nishiyama Y, 2003, INTERNAL MED, V42, P263, DOI 10.2169/internalmedicine.42.263; NKANZA NK, 1980, BRIT J SURG, V67, P271, DOI 10.1002/bjs.1800670414; Ozolek JA, 2004, APPL IMMUNOHISTO M M, V12, P59; Schildhaus HU, 2008, J PATHOL, V216, P176, DOI 10.1002/path.2393; Schildhaus H-U, 2009, Pathologe, V30 Suppl 2, P117, DOI 10.1007/s00292-009-1196-2; Shalom A, 2000, EUR J SURG, V166, P54; Sobin LH, 2002, HUM PATHOL, V33, P1241, DOI 10.1053/hupa.2002.129934; STOLTE M, 1990, ENDOSCOPY, V22, P203, DOI 10.1055/s-2007-1012848; VANEK J, 1949, AM J PATHOL, V25, P397; Yamashita K, 2011, ENDOSCOPY, V43, pE171, DOI 10.1055/s-0030-1256289; Zamecnik M, 2002, HUM PATHOL, V33, P1241, DOI 10.1053/hupa.2002.129932	26	1	1	1	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1092-9134	1532-8198		ANN DIAGN PATHOL	Ann. Diagn. Pathol.	DEC	2018	37						47	50		10.1016/j.anndiagpath.2018.09.006			4	Pathology	Pathology	HF9NS	WOS:000454569300009	30245331				2019-10-28	
J	Shoyele, O; Vidhun, R; Dodge, J; Cheng, ZD; Margules, R; Nee, P; Sieber, S				Shoyele, Olubunmi; Vidhun, Ramapriya; Dodge, Jessica; Cheng, Zandra; Margules, Richard; Nee, Paul; Sieber, Steven			Cystic neutrophilic granulomatous mastitis: A clinicopathologic study of a distinct entity with supporting evidence of a role for Corynebacterium-targeted therapy	ANNALS OF DIAGNOSTIC PATHOLOGY			English	Article						Cystic neutrophilic granulomatous mastitis; Corynebacterium; Gram-positive bacilli; MALDI-TOF MS	ASSOCIATION; INFECTION; WOMEN	Cystic neutrophilic granulomatous mastitis (CNGM) is a distinct histopathologic entity characterized by neutrophilic and granulomatous inflammation surrounding clear cystic spaces. Rare gram-positive bacilli are sometimes identified within these cystic spaces. Studies in the literature have identified these gram-positive bacilli to be Corynebacterium species. We describe the clinicopathologic features of 7 cases of CNGM, including a case with evidence of Corynebacterium amycolatum. Patients were young to middle aged parous women ranging in age from 28 to 53 years (median age: 41 years). Gram-positive bacilli were identified in 4 cases, all within cystic spaces. Microbial culture from a 41-year old Hispanic woman grew Corynebacterium species on multiple occasions and Corynebacterium amycolatum was identified by matrix-assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF MS) on two separate occasions. Antibiotic susceptibility testing performed both times showed resistance to multiple antibiotics and susceptibility to vancomycin. Follow-up of all patients (range 3-12 months, median 6 months) showed a widely variable clinical course and varying response to a variety of treatment modalities. Five of the seven CNGM patients were parous, reproductive-aged Hispanic women who were born outside of the United States. Our findings further support the association of CNGM with corynebacteria and gram-positive bacilli. Furthermore, this study shows that Corynebacterium amycolatum, a nonlipophilic and multidrug-resistant corynebacterium can be associated with CNGM, hence the need for targeted antibiotic therapy. We propose identifying corynebacteria to the species level and performing antibiotic susceptibility testing in patients with CNGM because of the varied susceptibility testing profile that has been reported among different species of corynebacteria.	[Shoyele, Olubunmi; Vidhun, Ramapriya; Dodge, Jessica; Sieber, Steven] Western Connecticut Hlth Network, Dept Pathol & Lab Med, Danbury, CT USA; [Cheng, Zandra; Margules, Richard] Western Connecticut Hlth Network, Dept Surg, Danbury, CT USA; [Nee, Paul] Western Connecticut Hlth Network, Dept Infect Dis, Danbury, CT USA; [Shoyele, Olubunmi] Wayne State Univ, Dept Pathol & Lab Med, Detroit Med Ctr, Sch Med, Detroit, MI 48201 USA	Shoyele, O (reprint author), Wayne State Univ, Dept Pathol & Lab Med, Detroit Med Ctr, Sch Med, Detroit, MI 48201 USA.	bonidare@yahoo.com			Department of Pathology and Laboratory Medicine, Western Connecticut Health Network, Danbury Hospital, USA	We thank the Department of Pathology and Laboratory Medicine, Western Connecticut Health Network, Danbury Hospital, USA for funding support.	[Anonymous], 2016, CLSI GUID M45; Bouton ME, 2015, AM J SURG, V210, P258, DOI 10.1016/j.amjsurg.2014.08.044; COHEN C, 1977, S AFR MED J, V52, P14; Collins MD, 1988, FEMS MICROBIOL LETT, DOI [10.1111/j.1574-6968.1988.tb02755, DOI 10.1111/J.1574-6968.1988.TB02755]; D'Alfonso TM, 2015, AM J SURG PATHOL, V39, P1440, DOI 10.1097/PAS.0000000000000479; Dalal A, 2008, J MED MICROBIOL, V57, P1299, DOI 10.1099/jmm.0.2008/003343-0; Dobinson HC, 2015, J CLIN MICROBIOL, V53, P2895, DOI 10.1128/JCM.00760-15; FITZGIBBONS PL, 1985, HUM PATHOL, V16, P851, DOI 10.1016/S0046-8177(85)80259-8; Funke G, 1997, CLIN MICROBIOL REV, V10, P125, DOI 10.1128/CMR.10.1.125; Goldstein EJC, 2003, ANTIMICROB AGENTS CH, V47, P1968, DOI 10.1128/AAC.47.6.1968-1971.2003; Johnson MG, 2016, J CLIN MICROBIOL, V54, P1938, DOI 10.1128/JCM.03131-15; Johnstone KJ, 2017, PATHOLOGY, V49, P405, DOI 10.1016/j.pathol.2017.01.006; Kutsuna S, 2015, INTERNAL MED, V54, P1815, DOI 10.2169/internalmedicine.54.4254; Mathelin C, 2005, BREAST J, V11, P357, DOI 10.1111/j.1075-122X.2005.21562.x; Pandey TS, 2014, BREAST J, V20, P258, DOI 10.1111/tbj.12263; Patel RA, 2010, J GEN INTERN MED, V25, P270, DOI 10.1007/s11606-009-1207-2; Patel R, 2015, CLIN CHEM, V61, P100, DOI 10.1373/clinchem.2014.221770; Poojary I, 2017, INFECT DIS-NOR, V49, P528, DOI 10.1080/23744235.2017.1296184; Renshaw AA, 2011, AM J CLIN PATHOL, V136, P424, DOI 10.1309/AJCP1W9JBRYOQSNZ; Rosen PP., 2009, ROSENS BREAST PATHOL, P38; Stappaerts I, 1999, ACTA CLIN BELG, V54, P207, DOI 10.1080/17843286.1999.11754233; Taylor GB, 2003, PATHOLOGY, V35, P109, DOI [10.1080/0031302031000082197, 10.1080/00313020307574]; Troxell ML, 2016, AM J CLIN PATHOL, V145, P635, DOI [10.1093/AJCP/AQW046, 10.1093/ajcp/aqw046]; 2009, MMWR MORBID MORTAL W, V58, P1317	24	0	0	3	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1092-9134	1532-8198		ANN DIAGN PATHOL	Ann. Diagn. Pathol.	DEC	2018	37						51	56		10.1016/j.anndiagpath.2018.08.005			6	Pathology	Pathology	HF9NS	WOS:000454569300010	30248572				2019-10-28	
J	Schwartz, Z; Bowe, RB; Coleman, M; Magro, CM				Schwartz, Ziv; Bowe, Robert B.; Coleman, Morton; Magro, Cynthia M.			Pediatric oral Epstein-Barr virus associated self-remitting CD30+lymphoproliferative disorder: A distinct entity	ANNALS OF DIAGNOSTIC PATHOLOGY			English	Article						Lymphomatoid Papulosis; LyP; CD30; Epstein Barr virus; EBV; Oral lymphomatoid papulosis	CELL LYMPHOPROLIFERATIVE DISORDERS; POSITIVE MUCOCUTANEOUS ULCER; LYMPHOMATOID PAPULOSIS; MUCOSAL INVOLVEMENT	Epstein-Barr virus (EBV) has a well-known association with lymphoproliferative disorders of B and T cell origin. EBV-related B cell lymphoproliferative disorders include Hodgkin and Burkitt lymphomas, lymphomatoid granulomatosis, EBV positive diffuse large cell B cell lymphoma of the elderly, as well as B cell lymphomas associated with solid organ transplantation and methotrexate use. EBV-related T cell disorders are primarily represented by NK/T- cell lymphoma. In a subset of patients, EBV has been implicated in CD30 positive B cell lymphoproliferative disorders of the oral mucosa falling under the rubric of the mucocutaneous ulcer of the oral cavity. We previously reported on an index series of endogenous CD30 positive T cell lymphoproliferative disorder of the oral cavity resembling borderline type C lymphomatoid papulosis. The clinical manifestation of type C oral lymphomatoid papulosis is that of a recurrent self-remitting ulcer of the oral mucosa, which histologically resembles anaplastic large cell lymphoma. Such cases can be misdiagnosed as aggressive lymphoma leading to unnecessary treatment with aggressive chemotherapeutic regimens. Whereas none of the patients in our index series exhibited EBV positivity, here we discuss a very unique example of a 14-year-old girl diagnosed with EBV positive CD30 positive lymphoproliferative disorder strongly resembling the cases of intra-oral type C lymphomatoid papulosis. The patient was initially diagnosed by a senior hematopathology consultant as having EBV positive aggressive NK/T-cell lymphoma. The significance of raising physician awareness regarding pediatric oral EBV associated CD30 positive lymphoproliferative disease of the oral cavity lies in preventing inadvertent exposure to toxic chemotherapeutic agents intended for treatment of aggressive look-alikes, namely anaplastic large cell lymphoma. Additionally, we include a literature review of similar reports of pediatric intraoral EBV positive CD30 positive T cell lymphoproliferative disease.	[Schwartz, Ziv; Coleman, Morton; Magro, Cynthia M.] Weill Cornell Med, 1300 York Ave, New York, NY 10065 USA; [Schwartz, Ziv] SUNY Downstate Coll Med, 450 Clarkson Ave, Brooklyn, NY 11203 USA; [Bowe, Robert B.] NYU Langone Hosp Brooklyn, 110 55th St, Brooklyn, NY 11220 USA	Magro, CM (reprint author), Weill Cornell Med, 1300 York Ave, New York, NY 10065 USA.	Robert.Bowe@nyumc.org; cym2003@med.cornell.edu					Abdel-Naser MB, 2011, DERMATOLOGY, V222, P113, DOI 10.1159/000325460; Agarwal M, 2008, INT J SURG PATHOL, V16, P286, DOI 10.1177/1066896907313755; Allabert C, 2008, ANN DERMATOL VENER, V135, P273, DOI 10.1016/j.annder.2007.11.021; Benslama L, 2015, REV STOMATOL CHIR, V116, P111, DOI 10.1016/j.revsto.2015.01.007; Booken N, 2013, ACTA DERM-VENEREOL, V93, P250, DOI 10.2340/00015555-1488; Chimenti S, 2001, J AM ACAD DERMATOL, V44, P339, DOI 10.1067/mjd.2001.102669; de-Misa RF, 2010, CLIN EXP DERMATOL, V35, P165, DOI 10.1111/j.1365-2230.2009.03251.x; Dojcinov SD, 2011, BLOOD, V117, P4726, DOI 10.1182/blood-2010-12-323238; Dojcinov SD, 2010, AM J SURG PATHOL, V34, P405, DOI 10.1097/PAS.0b013e3181cf8622; Ficarra G, 1997, ORAL ONCOL, V33, P375; Gru AA, 2017, SEMIN DIAGN PATHOL, V34, P60, DOI 10.1053/j.semdp.2016.11.003; Hong M, 2015, J PATHOL TRANSL MED, V49, P525, DOI 10.4132/jptm.2015.07.13; Kato N, 1998, AM J DERMATOPATH, V20, P522, DOI 10.1097/00000372-199810000-00020; Magalhaes M, 2015, CLIN CASE REP, V3, P531, DOI 10.1002/ccr3.287; Oyama T, 2003, AM J SURG PATHOL, V27, P16, DOI 10.1097/00000478-200301000-00003; Oyama T, 2007, CLIN CANCER RES, V13, P5124, DOI 10.1158/1078-0432.CCR-06-2823; Pujol RM, 2005, DERMATOLOGY, V210, P53, DOI 10.1159/000081485; Roberts TK, 2016, EXP HEMATOL ONCOL, V5, DOI 10.1186/s40164-016-0042-5; Sadiku Shemsedin, 2012, J Med Case Rep, V6, P288, DOI 10.1186/1752-1947-6-288; Schwartz Z, 2017, ANN DIAGN PATHOL, V31, P50, DOI 10.1016/j.anndiagpath.2017.06.003; Sciubba J, 2000, ORAL SURG ORAL MED O, V90, P195, DOI 10.1067/moe.2000.107054; Serra-Guillen C, 2007, ACTAS DERMO-SIFILOGR, V98, P265, DOI 10.1016/S0001-7310(07)70060-1; Shimoyama Y, 2008, CANCER SCI, V99, P1085, DOI 10.1111/j.1349-7006.2008.00813.x	23	1	1	1	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1092-9134	1532-8198		ANN DIAGN PATHOL	Ann. Diagn. Pathol.	DEC	2018	37						57	61		10.1016/j.anndiagpath.2018.08.004			5	Pathology	Pathology	HF9NS	WOS:000454569300011	30292067				2019-10-28	
J	Tadei, MB; Mayorquim, MV; de Souza, CB; Cost, SD; Possebon, L; Souza, HR; Iyomasa-Pilon, MM; Geromel, MR; Girol, AP				Tadei, Maryam Buainain; Mayorquim, Matheus Vicente; de Souza, Camila Brambilla; Cost, Sara de Souza; Possebon, Lucas; Souza, Helena Ribeiro; Iyomasa-Pilon, Melina Mizusaki; Geromel, Mairto Roberis; Girol, Ana Paula			Expression of the Annexin A1 and its correlation with matrix metalloproteinases and the receptor for formylated peptide-2 in diffuse astrocytic tumors	ANNALS OF DIAGNOSTIC PATHOLOGY			English	Article						Astrocytomas; Glioblastomas; Annexin A1; Metalloproteinases; FPR	PROTEIN; GROWTH; CELLS; INFLAMMATION; PHENOTYPE; INVASION; ANXA1; FPR	Astrocytomas represent the majority of cerebral gliomas. Studies show that the anti-inflammatory protein Annexin-A1 (ANXA1) is associated with the tumor invasion process and that its actions can be mediated by the receptor for formylated peptides (FPR). Therefore, we evaluated the expression of ANXA1, the receptor FPR2 and matrix metalloproteinases 2 and 9 (MMP-2 and MMP-9) in brain astrocytomas. Detection of proteins was performed in sections of diffuse astrocytomas (grade II), anaplastic astrocytomas (grade III) and glioblastomas (GBM, grade IV) and quantifications were made by densitometry. Our analyses showed increased expression of ANXA1 in astrocytomas of all grades, but especially in GBM. The expression of FPR2 is similar to that found for ANXA1, being higher in GBM. Immunostaining for MMPs is also stronger as the degree of malignancy increases, especially with respect to MMP-9. The positive correlation between ANXA1/FPR2 and ANXA1/MMP-9 was observed in all tumors studied. The data indicate the possible action of ANXA1 and FPR2 on the development and progression of astrocytomas, related to increased expression of MMP-9. Thereby, ANXA1 and FPR2 are involved in the biology and malignancy of diffuse astrocytic tumors.	[Tadei, Maryam Buainain; Mayorquim, Matheus Vicente; de Souza, Camila Brambilla; Cost, Sara de Souza; Possebon, Lucas; Souza, Helena Ribeiro; Iyomasa-Pilon, Melina Mizusaki; Geromel, Mairto Roberis; Girol, Ana Paula] Univ Ctr Padre Albino UNIFIPA, Catanduva, SP, Brazil; [Possebon, Lucas; Girol, Ana Paula] Sao Paulo State Univ, UNESP, Inst Biosci Humanities & Exact Sci Ibilce, Dept Biol,Lab Immunomorphol, Sao Jose do Rio Preto Campus, Sao Paulo, Brazil	Girol, AP (reprint author), Univ Ctr Padre Albino UNIFIPA, Dept Phys & Biol Sci, Rua Estudantes 225, BR-15809144 Catanduva, SP, Brazil.	anapaula.girol@fipa.com.br	Possebon, Lucas P/G-1132-2015	Possebon, Lucas P/0000-0002-7065-526X; Costa, Sara Souza/0000-0002-9359-5482	Padre Albino University Center (UNIFIPA) institutional scientific resources	This work was supported by Padre Albino University Center (UNIFIPA) institutional scientific resources.	Bizzarro V, 2015, ONCOTARGET, V6, P25074, DOI 10.18632/oncotarget.4725; Boudhraa Z, 2014, ARCH DERMATOL RES, V306, P903, DOI 10.1007/s00403-014-1517-z; Boudhraa Z, 2016, CLIN SCI, V130, P205, DOI 10.1042/CS20150415; Chen XC, 2017, ONCOTARGET, V8, P65969, DOI 10.18632/oncotarget.19622; Cheng SX, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072376; Gastardelo TS, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0111317; Gobbetti T, 2016, BIOL CHEM, V397, P981, DOI 10.1515/hsz-2016-0200; Guo CM, 2013, FUTURE ONCOL, V9, P1773, DOI [10.2217/FON.13.114, 10.2217/fon.13.114]; Holdhoff M, 2018, J NATL COMPR CANC NE, V16, P642, DOI 10.6004/jnccn.2018.0045; Huang J, 2010, BRIT J CANCER, V102, P1052, DOI 10.1038/sj.bjc.6605591; Huang J, 2007, CANCER RES, V67, P5906, DOI 10.1158/0008-5472.CAN-07-0691; Kam AYF, 2007, J NEUROCHEM, V103, P1553, DOI 10.1111/j.1471-4159.2007.04876.x; Kam AYF, 2007, CELL SIGNAL, V19, P2106, DOI 10.1016/j.cellsig.2007.06.005; Kargiotis O, 2008, ONCOGENE, V27, P4830, DOI 10.1038/onc.2008.122; Lakka SS, 2005, BRAIN PATHOL, V15, P327; Liu MY, 2012, INT IMMUNOPHARMACOL, V14, P283, DOI 10.1016/j.intimp.2012.07.015; Louis DN, 2016, ACTA NEUROPATHOL, V131, P803, DOI 10.1007/s00401-016-1545-1; Mallawaaratchy DM, 2017, J NEURO-ONCOL, V131, P233, DOI 10.1007/s11060-016-2298-3; Mallawaaratchy DM, 2015, J NEUROPATH EXP NEUR, V74, P425, DOI 10.1097/NEN.0000000000000187; McArthur S, 2016, FLUIDS BARRIERS CNS, V13, DOI 10.1186/s12987-016-0043-0; McArthur S, 2010, J IMMUNOL, V185, P6317, DOI 10.4049/jimmunol.1001095; Migeotte I, 2006, CYTOKINE GROWTH F R, V17, P501, DOI 10.1016/j.cytogfr.2006.09.009; Muracciole X, 2002, INT J RADIAT ONCOL, V52, P592, DOI 10.1016/S0360-3016(01)02699-2; Nager Mireia, 2012, Chemother Res Pract, V2012, P192362, DOI 10.1155/2012/192362; Pagliara V, 2014, BBA-MOL CELL RES, V1843, P2631, DOI 10.1016/j.bbamcr.2014.07.008; Popescu AM, 2016, WSPOLCZESNA ONKOL, V20, P109, DOI 10.5114/wo.2015.56122; Ruano Y, 2008, CANCER-AM CANCER SOC, V112, P1575, DOI 10.1002/cncr.23338; Schittenhelm J, 2009, MODERN PATHOL, V22, P1600, DOI 10.1038/modpathol.2009.132; Smith HK, 2015, FASEB J, V29, P2161, DOI 10.1096/fj.14-263160; Souza HR, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0173417; Takaoka RTC, 2018, PATHOL RES PRACT, V214, P181, DOI 10.1016/j.prp.2017.12.003; Yang Y, 2011, AM J PATHOL, V179, P1504, DOI 10.1016/j.ajpath.2011.05.059; Zhou Y, 2005, JNCI-J NATL CANCER I, V97, P823, DOI 10.1093/jnci/dji142	33	2	2	1	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1092-9134	1532-8198		ANN DIAGN PATHOL	Ann. Diagn. Pathol.	DEC	2018	37						62	66		10.1016/j.anndiagpath.2018.08.002			5	Pathology	Pathology	HF9NS	WOS:000454569300012	30286327				2019-10-28	
J	Choi, SM; O'Malley, DP				Choi, Sarah M.; O'Malley, Dennis P.			Diagnostically relevant updates to the 2017 WHO classification of lymphoid neoplasms	ANNALS OF DIAGNOSTIC PATHOLOGY			English	Review						WHO Classification of Tumours of; Haematopoietic and Lymphoid Tissues; Lymphoid tumors; Lymphoma; Lymphoid neoplasms; In situ neoplasia	MANTLE CELL LYMPHOMA; CHRONIC LYMPHOCYTIC-LEUKEMIA; L265P SOMATIC MUTATION; FOLLICULAR LYMPHOMA; MONOCLONAL-ANTIBODIES; SOX11 EXPRESSION; BREAST IMPLANTS; DIAGNOSIS; DISEASE; CHILDREN	The recent 2017 WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues contains a number of updates under the category of lymphoid neoplasms. These changes include introduction of new entities, amended classification or terminology, and addition of newly discovered diagnostic and molecular features. In this review, we perform a focused, concise summary of selected lymphoid neoplasms and discuss changes in their classification. Rather than a comprehensive overview, we place specific emphasis on important and diagnostically relevant aspects of each entity that are novel or different from the previous WHO iteration and bring the practicing pathologist quickly up to speed with the updated classification.	[Choi, Sarah M.] Univ Michigan, Ann Arbor, MI 48105 USA; [O'Malley, Dennis P.] Neogen Labs Inc, 31 Columbia, Aliso Viejo, CA 92656 USA; [O'Malley, Dennis P.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA	O'Malley, DP (reprint author), Neogen Labs Inc, 31 Columbia, Aliso Viejo, CA 92656 USA.	dennis.omalley@neogenomics.com					Aladily TN, 2012, AM J SURG PATHOL, V36, P1000, DOI 10.1097/PAS.0b013e31825749b1; Carvajal-Cuenca A, 2012, HAEMATOL-HEMATOL J, V97, P270, DOI 10.3324/haematol.2011.052621; Castellar ERP, 2014, BLOOD, V124, P1473, DOI 10.1182/blood-2014-04-571091; Delabie J, 2011, BLOOD, V118, P148, DOI 10.1182/blood-2011-02-335216; Fazi C, 2011, BLOOD, V118, P6618, DOI 10.1182/blood-2011-05-357251; Gibson SE, 2011, HAEMATOL-HEMATOL J, V96, P1144, DOI 10.3324/haematol.2011.042333; Gonzalez-Farre B, 2017, MODERN PATHOL, V30, P745, DOI 10.1038/modpathol.2016.233; Hallek M, 2008, BLOOD, V111, P5446, DOI 10.1182/blood-2007-06-093906; Huang YL, 2009, AM J SURG PATHOL, V33, P682, DOI 10.1097/PAS.0b013e3181971591; Jegalian AG, 2011, BLOOD, V118, P2976, DOI 10.1182/blood-2011-05-355255; Katzenberger T, 2009, BLOOD, V113, P1053, DOI 10.1182/blood-2008-07-168682; Liu QY, 2013, AM J SURG PATHOL, V37, P333, DOI 10.1097/PAS.0b013e31826b9b57; Malamut G, 2013, DIGEST LIVER DIS, V45, P377, DOI 10.1016/j.dld.2012.12.001; Marti GE, 2005, BRIT J HAEMATOL, V130, P325, DOI 10.1111/j.1365-2141.2005.05550.x; Misdraji J, 2011, AM J SURG PATHOL, V35, P1255, DOI 10.1097/PAS.0b013e318224e661; Mozos A, 2009, HAEMATOL-HEMATOL J, V94, P1555, DOI 10.3324/haematol.2009.010264; Nakashima MO, 2014, APPL IMMUNOHISTO M M, V22, P720, DOI 10.1097/PAI.0000000000000067; Oksenhendler E, 2002, BLOOD, V99, P2331, DOI 10.1182/blood.V99.7.2331; Perry AM, 2013, BLOOD, V122, P3599, DOI 10.1182/blood-2013-07-512830; Pillai RK, 2013, HAEMATOLOGICA, V98, P1571, DOI 10.3324/haematol.2013.085506; Roden AC, 2008, MODERN PATHOL, V21, P455, DOI 10.1038/modpathol.3801024; Salaverria I, 2011, BLOOD, V118, P139, DOI 10.1182/blood-2011-01-330795; Siddiqi IN, 2016, MODERN PATHOL, V29, P570, DOI 10.1038/modpathol.2016.51; Soldini D, 2014, AM J SURG PATHOL, V38, P86, DOI 10.1097/PAS.0b013e3182a43996; Strati P, 2015, BLOOD, V126, P454, DOI 10.1182/blood-2015-02-585059; Swerdlow SH, 2017, WHO CLASSIFICATION T; Swerdlow SH, 2016, VIRCHOWS ARCH, V468, P259, DOI 10.1007/s00428-015-1858-9; Tiacci E, 2011, NEW ENGL J MED, V364, P2305, DOI 10.1056/NEJMoa1014209; Treon SP, 2012, NEW ENGL J MED, V367, P826, DOI 10.1056/NEJMoa1200710; Varettoni M, 2013, BLOOD, V121, P2522, DOI 10.1182/blood-2012-09-457101; Waterfall JJ, 2014, NAT GENET, V46, P8, DOI 10.1038/ng.2828; Xochelli A, 2014, BLOOD, V123, P1199, DOI 10.1182/blood-2013-07-515155	32	0	0	4	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1092-9134	1532-8198		ANN DIAGN PATHOL	Ann. Diagn. Pathol.	DEC	2018	37						67	74		10.1016/j.anndiagpath.2018.09.011			8	Pathology	Pathology	HF9NS	WOS:000454569300013	30308438				2019-10-28	
J	Montgomery, E; Arnold, CA; Lam-Himlin, D; Salimian, K; Waters, K				Montgomery, Elizabeth; Arnold, Christina A.; Lam-Himlin, Dora; Salimian, Kevan; Waters, Kevin			Some observations on Barrett esophagus and associated dysplasia	ANNALS OF DIAGNOSTIC PATHOLOGY			English	Review						Barrett esophagus; Dysplasia; Endoscopic mucosal resections; Duplicated muscularis mucosae	DUPLICATED MUSCULARIS MUCOSAE; COLUMNAR-LINED ESOPHAGUS; LYMPH-NODE METASTASIS; INTESTINAL METAPLASIA; CRYPT DYSPLASIA; GRADE DYSPLASIA; DIAGNOSIS; MANAGEMENT; RISK; DIFFERENTIATION	Biopsy samples from esophageal columnar metaplasia and dysplasia are commonly encountered in Western pathology practice and knowing a few pitfalls can save both pathologists and patients a great deal of anxiety. Herein we discuss criteria for Barrett esophagus, evaluation of dysplasia, and some pitfalls in reviewing endoscopic mucosal resections. Also included is a summary of suggested follow-up for patients with Barrett esophagus.	[Montgomery, Elizabeth; Salimian, Kevan] Johns Hopkins Univ, Dept Pathol, Baltimore, MD 21218 USA; [Arnold, Christina A.] Ohio State Univ, Dept Pathol, Columbus, OH 43210 USA; [Lam-Himlin, Dora] Mayo Clin, Dept Pathol, Scottsdale, AZ USA; [Waters, Kevin] Cedars Sinai Hlth Syst, Dept Pathol, Los Angeles, CA USA	Montgomery, E (reprint author), 410 North Broadway,Weinberg Bldg Room 2242, Baltimore, MD 21231 USA.	emontgom@jhmi.edu					Abraham SC, 2007, AM J SURG PATHOL, V31, P1719, DOI 10.1097/PAS.0b013e318093e3bf; Aida J, 2015, AM J SURG PATHOL, V39, P188, DOI 10.1097/PAS.0000000000000350; Amin MB, 2017, AJCC CANC STAGING MA; Bennett C, 2015, AM J GASTROENTEROL, V110, P662, DOI 10.1038/ajg.2015.55; Canto MI, 2015, ENDOSCOPY, V47, P582, DOI [10.1055/s-0034-1392200, 10.1055/s-0034-1391734]; Chandrasoma P, 2012, AM J SURG PATHOL, V36, P1, DOI 10.1097/PAS.0b013e31822a5a2c; Chu PG, 2003, AM J SURG PATHOL, V27, P952, DOI 10.1097/00000478-200307000-00010; Coco DP, 2011, AM J SURG PATHOL, V35, P45, DOI 10.1097/PAS.0b013e3181ffdd14; Curvers WL, 2010, AM J GASTROENTEROL, V105, P1523, DOI 10.1038/ajg.2010.171; Estrella JS, 2011, AM J SURG PATHOL, V35, P1045, DOI 10.1097/PAS.0b013e318219ccef; Fitzgerald RC, 2014, GUT, V63, P7, DOI 10.1136/gutjnl-2013-305372; Greene CL, 2016, J GASTROINTEST SURG, V20, P851, DOI 10.1007/s11605-015-3056-0; Hahn HP, 2009, AM J SURG PATHOL, V33, P1006, DOI 10.1097/PAS.0b013e31819f57e9; Kaneshiro DK, 2011, AM J SURG PATHOL, V35, P697, DOI 10.1097/PAS.0b013e3182159c4b; Lewis JT, 2008, AM J SURG PATHOL, V32, P566, DOI 10.1097/PAS.0b013e31815bf8c7; Lomo LC, 2006, AM J SURG PATHOL, V30, P423, DOI 10.1097/00000478-200604000-00001; Mahajan D, 2010, MODERN PATHOL, V23, P1, DOI 10.1038/modpathol.2009.147; Manner H, 2015, SURG ENDOSC, V29, P1888, DOI 10.1007/s00464-014-3881-3; Montgomery E, 2001, HUM PATHOL, V32, P368, DOI 10.1053/hupa.2001.23510; Ormsby AH, 1999, HUM PATHOL, V30, P288, DOI 10.1016/S0046-8177(99)90007-2; Ormsby AH, 2000, GASTROENTEROLOGY, V119, P683, DOI 10.1053/gast.2000.16482; Panarelli NC, 2016, AM J SURG PATHOL, V40, pe83, DOI 10.1097/PAS.0000000000000654; Patil DT, 2013, HUM PATHOL, V44, P1146, DOI 10.1016/j.humpath.2012.10.004; Pech O, 2014, GASTROENTEROLOGY, V146, P652, DOI 10.1053/j.gastro.2013.11.006; Phillips RW, 2003, AM J SURG PATHOL, V27, P1442, DOI 10.1097/00000478-200311000-00006; REID BJ, 1988, HUM PATHOL, V19, P166, DOI 10.1016/S0046-8177(88)80344-7; RIDDELL RH, 1983, HUM PATHOL, V14, P931, DOI 10.1016/S0046-8177(83)80175-0; Rucker-Schmidt RL, 2009, AM J SURG PATHOL, V33, P886, DOI 10.1097/PAS.0b013e318198a1d4; Salimian KJ, 2018, AM J SURG PATHOL, V42, P264, DOI 10.1097/PAS.0000000000000971; Shaheen NJ, 2016, AM J GASTROENTEROL, V111, P30, DOI 10.1038/ajg.2015.322; Shaheen NJ, 2009, NEW ENGL J MED, V360, P2277, DOI 10.1056/NEJMoa0808145; Sharma P, 2006, GASTROENTEROLOGY, V131, P1392, DOI 10.1053/j.gastro.2006.08.032; Smith J, 2016, AM J SURG PATHOL, V40, P537, DOI 10.1097/PAS.0000000000000601; Spechler SJ, 2011, GASTROENTEROLOGY, V140, P1084, DOI 10.1053/j.gastro.2011.01.030; Terheggen G, 2017, GUT, V66, P783, DOI 10.1136/gutjnl-2015-310126; van der Wel MJ, 2016, ADV EXP MED BIOL, V908, P137, DOI 10.1007/978-3-319-41388-4_8; Vieth Michael, 2016, Cesk Patol, V52, P154; Voltaggio Lysandra, 2017, Surg Pathol Clin, V10, P781, DOI 10.1016/j.path.2017.07.002; Waters KM, 2018, AM J SURG PATHOL, V42, P1723, DOI 10.1097/PAS.0000000000001162; Zhu WJ, 2009, AM J CLIN PATHOL, V132, P94, DOI 10.1309/AJCP78CKIOJWOVFN	40	0	0	2	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1092-9134	1532-8198		ANN DIAGN PATHOL	Ann. Diagn. Pathol.	DEC	2018	37						75	82		10.1016/j.anndiagpath.2018.09.013			8	Pathology	Pathology	HF9NS	WOS:000454569300014	30312881				2019-10-28	
J	Koch, LK; Yeh, MM				Koch, Lisa K.; Yeh, Matthew M.			Nonalcoholic fatty liver disease (NAFLD): Diagnosis, pitfalls, and staging	ANNALS OF DIAGNOSTIC PATHOLOGY			English	Review							HEPATOCELLULAR-CARCINOMA; CRYPTOGENIC CIRRHOSIS; HEPATITIS-C; HISTOPATHOLOGICAL FEATURES; HISTOLOGIC FEATURES; ADVANCED FIBROSIS; STEATOSIS GRADES; SCORING SYSTEM; VITAMIN-E; STEATOHEPATITIS	Nonalcoholic fatty liver disease (NAFLD) is increasingly prevalent and strongly associated with obesity, diabetes and the metabolic syndrome, not only in the Western societies, but also in most regions of the world in the 21st century. The spectrum of its histopathology ranges from steatosis to nonalcoholic steatohepatitis (NASH), with risk for progressive fibrosis that may lead to cirrhosis and hepatocellular carcinoma (HCC). Benign and malignant liver tumors have also been more frequently reported with the increasing prevalence of obesity and diabetes. This review addresses the pathology of NAFLD and NASH, and their diagnostic features, diagnostic pitfalls, grading and staging, and clinical correlation.	[Koch, Lisa K.; Yeh, Matthew M.] Univ Washington, Sch Med, Dept Pathol, 1959 NE Pacific St,NE140D,Box 356100, Seattle, WA 98195 USA; [Yeh, Matthew M.] Univ Washington, Sch Med, Dept Med, Seattle, WA 98195 USA	Yeh, MM (reprint author), Univ Washington, Sch Med, Dept Pathol, 1959 NE Pacific St,NE140D,Box 356100, Seattle, WA 98195 USA.	myeh@uw.edu					Adams LA, 2005, J HEPATOL, V42, P132, DOI 10.1016/j.jhep.2004.09.012; Adams LA, 2017, GUT, V66, P1138, DOI 10.1136/gutjnl-2017-313884; Ando S, 2015, VIRCHOWS ARCH, V467, P535, DOI 10.1007/s00428-015-1836-2; Angulo P, 2007, HEPATOLOGY, V45, P846, DOI 10.1002/hep.21496; Angulo P, 2015, GASTROENTEROLOGY, V149, P389, DOI 10.1053/j.gastro.2015.04.043; Ayata G, 2002, HUM PATHOL, V33, P1098, DOI 10.1053/hupa.2002.129419; Bedossa P, 2012, HEPATOLOGY, V56, P1751, DOI 10.1002/hep.25889; Belfort R, 2006, NEW ENGL J MED, V355, P2297, DOI 10.1056/NEJMoa060326; Bioulac-Sage P, 2007, HEPATOLOGY, V46, P740, DOI 10.1002/hep.21743; Bosch DE, 2017, HUM PATHOL, V69, P55, DOI 10.1016/j.humpath.2017.09.008; Brunt EM, 2011, HEPATOLOGY, V53, P810, DOI 10.1002/hep.24127; Brunt EM, 2009, HEPATOLOGY, V49, P809, DOI 10.1002/hep.22724; Brunt EM, 1999, AM J GASTROENTEROL, V94, P2467, DOI 10.1016/S0002-9270(99)00433-5; Brunt EM, 2003, MODERN PATHOL, V16, P49, DOI 10.1097/01.MP.0000042420.21.21088.C7; Carr RM, 2017, DIGEST DIS SCI, V62, P1354, DOI 10.1007/s10620-017-4495-0; Cho SJ, 2016, HUM PATHOL, V50, P135, DOI 10.1016/j.humpath.2015.12.002; Clouston AD, 2002, BEST PRACT RES CL GA, V16, P767, DOI 10.1053/bega.2002.0329; Dogan S, 2015, EUR J GASTROEN HEPAT, V27, P298, DOI 10.1097/MEG.0000000000000286; Ekstedt M, 2015, HEPATOLOGY, V61, P1547, DOI 10.1002/hep.27368; Gill RM, 2011, AM J SURG PATHOL, V35, P1400, DOI 10.1097/PAS.0b013e3182254283; Gonzalez RS, 2017, ARCH PATHOL LAB MED, V141, P98, DOI 10.5858/arpa.2015-0388-OA; Guy CD, 2012, HUM PATHOL, V43, P790, DOI 10.1016/j.humpath.2011.07.007; Hagstrom H, 2017, SCAND J GASTROENTERO, V52, P87, DOI 10.1080/00365521.2016.1230779; Haukeland JW, 2009, SCAND J GASTROENTERO, V44, P853, DOI 10.1080/00365520902845268; Hulkova H, 2012, HISTOPATHOLOGY, V60, P1107, DOI 10.1111/j.1365-2559.2011.04164.x; Imajo K, 2016, GASTROENTEROLOGY, V150, P626, DOI 10.1053/j.gastro.2015.11.048; Jain D, 2013, ARCH PATHOL LAB MED, V137, P961, DOI 10.5858/arpa.2012-0048-OA; Kamal S, 2018, BMJ OPEN GASTROENTER, V5, DOI 10.1136/bmjgast-2017-000150; Kleiner DE, 2005, HEPATOLOGY, V41, P1313, DOI 10.1002/hep.20701; Lackner C, 2008, J HEPATOL, V48, P821, DOI 10.1016/j.jhep.2008.01.026; Lapumnuaypol K, 2018, EUR J GASTROEN HEPAT, V30, P854, DOI 10.1097/MEG.0000000000001144; Lee JS, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0171922; LEFKOWITCH JH, 1986, J HEPATOL, V2, P313, DOI 10.1016/S0168-8278(86)80043-5; Liggi M, 2013, CLIN RES HEPATOL GAS, V37, P36, DOI 10.1016/j.clinre.2012.03.038; Lindor KD, 2004, HEPATOLOGY, V39, P770, DOI 10.1002/hep.20092; Liu TC, 2014, MODERN PATHOL, V27, P420, DOI 10.1038/modpathol.2013.148; LUDWIG J, 1980, MAYO CLIN PROC, V55, P434; Martins NM, 2008, J APPL TOXICOL, V28, P337, DOI 10.1002/jat.1284; Massart Julie, 2017, J Clin Transl Res, V3, P212, DOI 10.18053/jctres.03.2017S1.006; McPherson S, 2010, GUT, V59, P1265, DOI 10.1136/gut.2010.216077; Middleton MS, 2017, GASTROENTEROLOGY, V153, P753, DOI 10.1053/j.gastro.2017.06.005; Miller ER, 2005, ANN INTERN MED, V142, P37, DOI 10.7326/0003-4819-142-1-200501040-00110; Mori S, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0203084; Mueller S, 2009, WORLD J GASTROENTERO, V15, P3462, DOI 10.3748/wjg.15.3462; Muntoni S, 2018, PREVALENCE CHOLESTER; Murthy A, 2014, NATURE, V506, P456, DOI 10.1038/nature13044; Nelson A, 2009, J CLIN GASTROENTEROL, V43, P990, DOI 10.1097/MCG.0b013e31819c392e; Ogawa Y, 1998, LANCET, V351, P725, DOI 10.1016/S0140-6736(05)78493-2; Ong JP, 2001, LIVER, V21, P266, DOI 10.1034/j.1600-0676.2001.021004266.x; Palumbo CS, 2019, INFLAMM BOWEL DIS, V25, P124, DOI 10.1093/ibd/izy200; Paradis V, 2009, HEPATOLOGY, V49, P851, DOI [10.1002/hep.227.34, 10.1002/hep.22734]; Patton HM, 2006, J PEDIATR GASTR NUTR, V43, P413, DOI 10.1097/01.mpg.0000239995.58388.56; Peppercorn PD, 1998, BRIT J CANCER, V77, P2008, DOI 10.1038/bjc.1998.333; Perez-Gutierrez OZ, 2013, ANN HEPATOL, V12, P416, DOI 10.1016/S1665-2681(19)31004-X; Poonawala A, 2000, HEPATOLOGY, V32, P689, DOI 10.1053/jhep.2000.17894; Ratziu V, 2002, HEPATOLOGY, V35, P1485, DOI 10.1053/jhep.2002.33324; Ratziu V, 2008, GASTROENTEROLOGY, V135, P100, DOI 10.1053/j.gastro.2008.03.078; Reilly NR, 2015, J HEPATOL, V62, P1405, DOI 10.1016/j.jhep.2015.01.013; Sahoo S, 2003, SEMIN LIVER DIS, V23, P295; Salomao M, 2012, HUM PATHOL, V43, P737, DOI 10.1016/j.humpath.2011.07.005; Salomao M, 2010, AM J SURG PATHOL, V34, P1630, DOI 10.1097/PAS.0b013e3181f31caa; Sanyal AJ, 2003, AM J GASTROENTEROL, V98, P2064, DOI 10.1016/S0002-9270(03)00551-3; Sanyal AJ, 2010, NEW ENGL J MED, V362, P1675, DOI 10.1056/NEJMoa0907929; Sartini A, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-017-0124-2; Satapathy SK, 2015, ANN HEPATOL, V14, P789, DOI 10.5604/16652681.1171749; Schwinnner JB, 2005, HEPATOLOGY, V42, P641, DOI 10.1002/hep.20842; Simon TG, 2018, INFLAMM BOWEL DIS, V24, P2247, DOI 10.1093/ibd/izy128; Singhi AD, 2012, AM J SURG PATHOL, V36, P710, DOI 10.1097/PAS.0b013e3182495c73; Sourianarayanane Achuthan, 2013, J Crohns Colitis, V7, pe279, DOI 10.1016/j.crohns.2012.10.015; Sumida Y, 2012, BMC GASTROENTEROL, V12, DOI 10.1186/1471-230X-12-2; Suzuki A, 2012, CLIN GASTROENTEROL H, V10, P786, DOI 10.1016/j.cgh.2012.01.020; Takahashi T, 2018, HEART VESSELS, V33, P733, DOI 10.1007/s00380-017-1113-1; Tandra S, 2011, J HEPATOL, V55, P654, DOI 10.1016/j.jhep.2010.11.021; Tang A, 2015, RADIOLOGY, V274, P416, DOI 10.1148/radiol.14140754; Thuluvath PJ, 2018, J HEPATOL, V68, P519, DOI 10.1016/j.jhep.2017.11.018; Torbenson M, 2006, AM J SURG PATHOL, V30, P508, DOI 10.1097/00000478-200604000-00012; Vernon G, 2018, SYSTEMATIC REV EPIDE; Wisell J, 2006, AM J SURG PATHOL, V30, P1085; Xun YH, 2012, J DIGEST DIS, V13, P588, DOI 10.1111/j.1751-2980.2012.00631.x; Yeh MM, 2015, HUM PATHOL, V46, P1769, DOI 10.1016/j.humpath.2015.07.018; Yoshihisa A, 2018, ESC HEART FAIL, V5, P262, DOI 10.1002/ehf2.12222; Zhang Z, 2018, J INT MED RES; Zucman-Rossi J, 2006, HEPATOLOGY, V43, P515, DOI 10.1002/hep.21068	83	1	1	6	10	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1092-9134	1532-8198		ANN DIAGN PATHOL	Ann. Diagn. Pathol.	DEC	2018	37						83	90		10.1016/j.anndiagpath.2018.09.009			8	Pathology	Pathology	HF9NS	WOS:000454569300015	30312882				2019-10-28	
J	Brenn, T				Brenn, Thomas			Melanocytic lesions - Staying out of trouble	ANNALS OF DIAGNOSTIC PATHOLOGY			English	Review						Melanoma; Nevi; Melanocytic; Immunohistochemistry; Genetics; Diagnosis	ACRAL LENTIGINOUS MELANOMA; MALIGNANT-MELANOMA; DESMOPLASTIC MELANOMA; BLUE NEVUS; VULVA; MUTATIONS; DISTINCT; DIFFERENTIATION; DIAGNOSIS; PATTERNS	The diagnosis of melanocytic tumors is notoriously difficult and represents one of the most challenging areas in surgical pathology associated with significant risk for litigation. One reason is the wide morphologic spectrum of melanocytic tumors and the fact that many histological features are shared by both benign melanocytic nevi and melanoma. Awareness of the many morphologic variations and variants of nevi and melanoma, their clinical setting, immunohistochemical phenotype and genetic profile is necessary for the correct diagnosis. The article discusses the features of three variants of melanoma, desmoplastic, acral lentiginous and vulvar mucosal lentiginous melanoma, and their benign melanocytic mimics with emphasis on distinguishing features.	[Brenn, Thomas] Univ Calgary, Dept Pathol & Lab Med, Cumming Sch Med, 9-3535 Res Rd NW, Calgary, AB T2L 2K8, Canada; [Brenn, Thomas] Univ Calgary, Dept Med, Cumming Sch Med, 9-3535 Res Rd NW, Calgary, AB T2L 2K8, Canada; [Brenn, Thomas] Univ Calgary, Arnie Charbonneau Canc Inst, Cumming Sch Med, 9-3535 Res Rd NW, Calgary, AB T2L 2K8, Canada; [Brenn, Thomas] Univ Edinburgh, Dept Pathol, Western Gen Hosp, Crewe Rd, Edinburgh EH4 2XU, Midlothian, Scotland	Brenn, T (reprint author), Univ Calgary, Dept Pathol & Lab Med, Cumming Sch Med, Diagnost & Sci Ctr, 9-3535 Res Rd NW, Calgary, AB T2L 2K8, Canada.	thomas.brenn@ucalgary.ca					Blokhin E, 2013, J CUTAN PATHOL, V40, P796, DOI 10.1111/cup.12186; BOYD AS, 1994, J AM ACAD DERMATOL, V31, P740, DOI 10.1016/S0190-9622(94)70235-7; Busam KJ, 2004, AM J SURG PATHOL, V28, P1518, DOI 10.1097/01.pas.0000141391.91677.a4; Busam KJ, 2000, AM J SURG PATHOL, V24, P92, DOI 10.1097/00000478-200001000-00011; Chen LL, 2013, J AM ACAD DERMATOL, V68, P825, DOI 10.1016/j.jaad.2012.10.041; Clark WH, 1998, HUM PATHOL, V29, pS1, DOI 10.1016/S0046-8177(98)80028-2; Fernandez-Flores A, 2017, ANN DIAGN PATHOL, V26, P64, DOI 10.1016/j.anndiagpath.2016.08.005; Ferreira I, 2018, HISTOPATHOLOGY, V72, P679, DOI 10.1111/his.13418; Gerami P, 2011, J CUTAN PATHOL, V38, P329, DOI 10.1111/j.1600-0560.2010.01666.x; Gleason BC, 2008, AM J SURG PATHOL, V32, P51, DOI 10.1097/PAS.0b013e318068420c; Hawkins WG, 2005, ANN SURG ONCOL, V12, P207, DOI 10.1245/ASO.2005.03.022; Jung HJ, 2013, JAMA DERMATOL, V149, P1281, DOI 10.1001/jamadermatol.2013.5853; Kiuru M, 2012, J CUTAN PATHOL, V39, P940, DOI 10.1111/j.1600-0560.2012.01962.x; Kuchelmeister C, 2000, BRIT J DERMATOL, V143, P275, DOI 10.1046/j.1365-2133.2000.03651.x; LeBoit PE, 2000, AM J DERMATOPATH, V22, P556, DOI 10.1097/00000372-200012000-00012; McCalmont TH, 2011, J CUTAN PATHOL, V38, P943, DOI [10.1111/j.1600-0560.2011.01820_2.x, 10.1111/j.1600-0560.2011.01821.x]; Moon KR, 2018, J INVEST DERMATOL, V138, P933, DOI 10.1016/j.jid.2017.11.017; Moxley KM, 2011, GYNECOL ONCOL, V122, P612, DOI 10.1016/j.ygyno.2011.04.007; Murali R, 2010, CANCER-AM CANCER SOC, V116, P4130, DOI 10.1002/cncr.25148; Palicka GA, 2010, ARCH DERMATOL, V146, P1085, DOI 10.1001/archdermatol.2010.299; Raber G, 1996, CANCER, V78, P2353, DOI 10.1002/(SICI)1097-0142(19961201)78:11<2353::AID-CNCR13>3.0.CO;2-#; Ragnarsson-Olding BK, 1999, CANCER, V86, P1285, DOI 10.1002/(SICI)1097-0142(19991001)86:7<1285::AID-CNCR25>3.0.CO;2-P; Raspagliesi F, 2000, ANN SURG ONCOL, V7, P738, DOI 10.1007/s10434-000-0738-x; Saida T, 2011, AM J DERMATOPATH, V33, P468, DOI 10.1097/DAD.0b013e318201ac8f; Shain AH, 2015, NAT GENET, V47, P1194, DOI 10.1038/ng.3382; Sherrill AM, 2011, AM J DERMATOPATH, V33, P35, DOI 10.1097/DAD.0b013e3181e5dfa0; Sidiropoulos M, 2014, AM J DERMATOPATH, V36, P629, DOI 10.1097/DAD.0000000000000069; Signoretti S, 1999, AM J SURG PATHOL, V23, P283, DOI 10.1097/00000478-199903000-00006; Stang A, 2005, GYNECOL ONCOL, V96, P216, DOI 10.1016/j.ygyno.2004.09.052; Teramoto Y, 2018, BRIT J DERMATOL, V178, P443, DOI 10.1111/bjd.15803; Tseng D, 2014, J AM ACAD DERMATOL, V71, P229, DOI 10.1016/j.jaad.2014.03.033; Van Raamsdonk CD, 2009, NATURE, V457, P599, DOI 10.1038/nature07586; WEINSTOCK MA, 1994, AM J OBSTET GYNECOL, V171, P1225, DOI 10.1016/0002-9378(94)90137-6; Wiedemeyer K, 2018, AM J SURG PATHOL, V42, P821, DOI 10.1097/PAS.0000000000001051; Wiesner T, 2015, AM J SURG PATHOL, V39, P1357, DOI 10.1097/PAS.0000000000000451; Yeh I, 2012, AM J SURG PATHOL, V36, P1258, DOI 10.1097/PAS.0b013e31825b62ec; Yelamos O, 2016, J INVEST DERMATOL, V136, P1858, DOI 10.1016/j.jid.2016.05.094	37	0	0	1	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1092-9134	1532-8198		ANN DIAGN PATHOL	Ann. Diagn. Pathol.	DEC	2018	37						91	102		10.1016/j.anndiagpath.2018.09.010			12	Pathology	Pathology	HF9NS	WOS:000454569300016	30312883				2019-10-28	
J	Lindholm, K; Moran, CA				Lindholm, Kaleigh; Moran, Cesar A.			Primary mediastinal melanotic schwannian tumors: A clinicopathological and immunohistochemical study of 5 cases	ANNALS OF DIAGNOSTIC PATHOLOGY			English	Article						Melanotic schwannian tumor; Melanotic neurogenic tumor; Mediastinal schwannoma		Mediastinal neurogenic tumors are unusual and more so is the presence of melanotic neurogenic tumors. We present five cases of mediastinal melanotic neurogenic tumors. The patients are five men between the ages of 34 and 43 years (average: 38.5 years). All patients presented with non-specific symptoms that included back pain and cough. Diagnostic imaging revealed the presence of a posterior mediastinal mass without connection to the spinal canal, and surgical resection was accomplished in all of the patients. Histologically, the five tumors showed a spindle epithelioid cellular proliferation, nuclear atypia, mitotic activity, and melanin deposition. Histochemical stain for Fontana Masson clearly demonstrated the presence of melanin pigment in all the cases, while S-100 protein was only focally positive in tumor cells. Other immunohistochemical stains including SOX-10, MITF, HMB-45, and Melan A were negative. Clinical follow-up showed that two patients died 22 and 30 months after initial diagnosis; one remains alive, 6 months after initial diagnosis; two patients were lost to follow up. Melanotic neurogenic tumors represent a diagnostic challenge for pigmented thoracic tumors and careful analysis of the morphology and immunohistochemistry is required to lead to proper diagnosis.	[Lindholm, Kaleigh; Moran, Cesar A.] Univ Texas MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA	Lindholm, K (reprint author), Univ Texas MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA.	kelindholm@mdanderson.org					ABBOTT AE, 1990, ANN THORAC SURG, V49, P1006, DOI 10.1016/0003-4975(90)90891-9; Boland JM, 2015, HUM PATHOL, V46, P419, DOI 10.1016/j.humpath.2014.11.017; Klemm KM, 1999, MODERN PATHOL, V12, P946; KRAUSZ T, 1984, HISTOPATHOLOGY, V8, P881, DOI 10.1111/j.1365-2559.1984.tb02403.x; Lioulias A G, 2003, Eur J Cardiothorac Surg, V23, P105, DOI 10.1016/S1010-7940(02)00673-5; LOWMAN RM, 1980, CANCER-AM CANCER SOC, V46, P391, DOI 10.1002/1097-0142(19800715)46:2<391::AID-CNCR2820460230>3.0.CO;2-C; Moran CA, 1997, CANCER, V79, P398, DOI 10.1002/(SICI)1097-0142(19970115)79:2<398::AID-CNCR24>3.0.CO;2-V; PARIS F, 1979, THORAX, V34, P243, DOI 10.1136/thx.34.2.243; Prieto-Rodriguez M, 1998, DIAGN CYTOPATHOL, V19, P298, DOI 10.1002/(SICI)1097-0339(199810)19:4<298::AID-DC15>3.0.CO;2-I; Rothenburger M, 2001, THORAC CARDIOV SURG, V49, P306, DOI 10.1055/s-2001-17794; ROWLANDS D, 1987, J CLIN PATHOL, V40, P1449, DOI 10.1136/jcp.40.12.1449; Takeda SI, 2004, EUR J CARDIO-THORAC, V26, P807, DOI 10.1016/j.ejcts.2004.07.014; Torres-Mora J, 2014, AM J SURG PATHOL, V38, P94, DOI 10.1097/PAS.0b013e3182a0a150; Virgilio E, 2013, AM SURGEON, V79, pE22; WOODRUFF JM, 1981, AM J SURG PATHOL, V5, P733, DOI 10.1097/00000478-198112000-00001; Zhang HY, 2005, CHINESE MED J-PEKING, V118, P1451	16	0	0	1	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1092-9134	1532-8198		ANN DIAGN PATHOL	Ann. Diagn. Pathol.	DEC	2018	37						103	106		10.1016/j.anndiagpath.2018.10.001			4	Pathology	Pathology	HF9NS	WOS:000454569300017	30316045				2019-10-28	
J	Tang, XF; Yang, L; Duan, S; Guo, H; Guo, QN				Tang, Xue-Feng; Yang, Li; Duan, Song; Guo, Hong; Guo, Qiao-Nan			Intestinal T-cell and NK/T-cell lymphomas: A clinicopathological study of 27 Chinese patients	ANNALS OF DIAGNOSTIC PATHOLOGY			English	Article						Intestine; T-Cell lymphoma; NK/T-cell lymphoma; Monomorphic epitheliotropic intestinal T-cell lymphoma	CLASSIFICATION; FEATURES	Background: Intestinal T-cell and NK/T-cell lymphomas are rare and aggressive. The diagnosis is quite difficult, especial in biopsy specimens. This study investigates the clinicopathological features of intestinal T-cell and NK/T-cell lymphomas to aid their differential diagnosis. Methods: Clinical data of 27 cases were collected. Including extranodal NK/T-cell lymphoma, nasal type (ENKTCL-N), monomorphic epitheliotropic intestinal T-cell lymphoma (MEITL), peripheral T-cell lymphoma, not otherwise specified (PTCL, NOS), anaplastic large-cell lymphoma, ALK + (ALCL, ALK +) and angioimmunoblastic T-cell lymphoma (ALTL). The histologic features, immunohistochemical findings, T-cell receptor gene rearrangement results, and follow-up data were analyzed, with review of literature. Results: The age of the patients (N = 27) was 15-85 years (mean, 47.5 years), and male:female ratio, 3.5:1. Abdominal pain and B symptoms were the most common symptoms. Although 85.2% of the patients were in clinical stage I-II, 59.3% died within 1 year. MEITL showed certain distinctive clinic opathological features from ENKTCL-N. Compared to lesions at other sites, there were no differences in the morphological features, immunophenotype and TCR gene rearrangement of intestinal ENKTCL-N, PTCL, NOS, ALCL, ALK + and AITL. Conclusion: Intestinal T-cell and NK/T-cell lymphomas are a heterogeneous group of lymphomas. They could be classified to 5 histological subtypes in our study. ENKTCL-N and MEITL formed the majority of the tumor types. Each subtype has distinctive pathological features, but most of them have diamal prognosis.	[Tang, Xue-Feng; Guo, Qiao-Nan] Third Mil Med Univ, Dept Pathol, Xinqiao Hosp, Chongqing, Peoples R China; [Yang, Li; Guo, Hong] Third Mil Med Univ, Dept Gastroenterol, Xinqiao Hosp, Chongqing, Peoples R China; [Duan, Song] Chongqing Three Gorges Cent Hosp, Dept Pathol, Chongqing, Peoples R China	Guo, QN (reprint author), Third Mil Med Univ, Dept Pathol, Xinqiao Hosp, Chongqing, Peoples R China.	guoqn@tmmu.edu.cn			Xinqiao Hospital Clinical Foundation Project of China [2014YLC01]	The authors thank Ms. Ya-Li Wang and Bo Liu (Institute of Pathology and Xinqiao Hospital, Third Military Medical University) for her and his assistance in IHC, PCR and sequencing techniques. This work was supported by grants from the Xinqiao Hospital Clinical Foundation Project of China (2014YLC01).	Cazzola M, 2016, BLOOD, V127, P2361, DOI 10.1182/blood-2016-03-657379; Chan JKC, 2011, AM J SURG PATHOL, V35, P1557, DOI 10.1097/PAS.0b013e318222dfcd; Chen Y, 2017, HEMATOL ONCOL, V35; Fang JC, 2015, INT J SURG PATHOL, V23, P609, DOI 10.1177/1066896915595863; Karaarslan S, 2015, POL J PATHOL, V66, P161, DOI 10.5114/PJP.2015.53013; Kikuma K, 2014, HUM PATHOL, V45, P1276, DOI 10.1016/j.humpath.2013.10.038; Kim SJ, 2013, J HEMATOL ONCOL, V6, DOI 10.1186/1756-8722-6-86; MUSSHOFF K, 1977, STRAHLENTHER ONKOL, V153, P218; Roberti A, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12602; Sabattini E, 2008, WHO CLASSIFICATION T; Sun J, 2011, MODERN PATHOL, V24, P983, DOI 10.1038/modpathol.2011.45; Vainder Charles, 2016, JAAD Case Rep, V2, P390; Mahuad CV, 2016, RARE TUMORS, V8, P88, DOI 10.4081/rt.2016.6266; Yu JB, 2009, HUM PATHOL, V40, P807, DOI 10.1016/j.humpath.2008.08.020; Zheng SM, 2012, ARCH IRAN MED, V15, P36, DOI 012151/AIM.0011	15	0	1	1	5	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1092-9134	1532-8198		ANN DIAGN PATHOL	Ann. Diagn. Pathol.	DEC	2018	37						107	117		10.1016/j.anndiagpath.2018.10.004			11	Pathology	Pathology	HF9NS	WOS:000454569300018	30317149				2019-10-28	
J	Hornick, JL				Hornick, Jason L.			Subclassification of pleomorphic sarcomas: How and why should we care?	ANNALS OF DIAGNOSTIC PATHOLOGY			English	Review						Pleomorphic sarcoma; Myxofibrosarcoma; Dedifferentiated liposarcoma; Immunohistochemistry; MDM2	CLINICOPATHOLOGICAL ANALYSIS; DEDIFFERENTIATED LIPOSARCOMA; EXTRASKELETAL OSTEOSARCOMA; EPITHELIOID VARIANT; MYXOFIBROSARCOMA; GRADE; DIFFERENTIATION; EMPHASIS; RHABDOMYOSARCOMA; CLASSIFICATION	Pleomorphic sarcomas are a heterogeneous group of mesenchymal neoplasms with widely varied clinical behavior but overlapping histologic appearances. The following guidelines are helpful when approaching the diagnosis of a pleomorphic sarcoma. (1) Be aware of the relative incidence of the various sarcoma types: several pleomorphic sarcomas are relatively common (e.g., dedifferentiated liposarcoma and undifferentiated pleomorphic sarcoma), whereas others are exceptionally rare. (2) Pay attention to anatomic location: some pleomorphic sarcomas have a predilection for somatic soft tissues, especially the thigh (e.g., undifferentiated pleomorphic sarcoma, pleomorphic liposarcoma, pleomorphic rhabdomyosarcoma), whereas other pleomorphic sarcomas most often arise in the retroperitoneum (e.g., dedifferentiated liposarcoma). (3) Carefully sample the resection specimen, paying particular attention to areas with differences in gross appearances (e.g., fleshy, fibrous, mucoid, or gritty). (4) Search for histologic clues (i.e., myxoid stroma, lipoblasts, and osteoid matrix, in order to diagnose myxofibrosarcoma, pleomorphic liposarcoma, and extraskeletal osteosarcoma, respectively); these critical diagnostic features may be limited in extent. (5) Apply immunohistochemistry judiciously, after generating a differential diagnosis; always exclude metastatic sarcomatoid carcinoma and melanoma before diagnosing a pleomorphic sarcoma. This review will present an approach to the diagnosis of pleomorphic sarcomas, emphasizing differential diagnosis and the application of ancillary studies (immunohistochemistry and FISH), when relevant.	[Hornick, Jason L.] Harvard Med Sch, Dept Pathol, Brigham & Womens Hosp, Boston, MA USA	Hornick, JL (reprint author), Brigham & Womens Hosp, Dept Pathol, 75 Francis St, Boston, MA 02115 USA.	jhornick@bwh.harvard.edu					ANGERVALL L, 1977, ACTA PATH MICRO IM A, V85, P127; Berner K, 2015, ANTICANCER RES, V35, P2129; Binh MBN, 2005, AM J SURG PATHOL, V29, P1340, DOI 10.1097/01.pas.0000170343.09562.39; Boland JM, 2010, AM J SURG PATHOL, V34, P837, DOI 10.1097/PAS.0b013e3181dbf2f7; Boughzala-Bennadji R, 2018, INT J RADIAT ONCOL, V102, P399, DOI 10.1016/j.ijrobp.2018.05.055; CHUNG EB, 1987, CANCER, V60, P1132, DOI 10.1002/1097-0142(19870901)60:5<1132::AID-CNCR2820600536>3.0.CO;2-L; Conner JR, 2013, HISTOPATHOLOGY, V63, P36, DOI 10.1111/his.12138; Dantey K, 2017, HUM PATHOL, V66, P86, DOI 10.1016/j.humpath.2017.02.015; Dei Tos AP, 2014, HISTOPATHOLOGY, V64, P38, DOI 10.1111/his.12311; Deyrup AT, 2003, CANCER, V98, P805, DOI 10.1002/cncr.11617; Downes KA, 2001, MODERN PATHOL, V14, P179, DOI 10.1038/modpathol.3880280; EVANS HL, 1994, AM J SURG PATHOL, V18, P1150, DOI 10.1097/00000478-199411000-00009; Fletcher CDM, 2001, J CLIN ONCOL, V19, P3045, DOI 10.1200/JCO.2001.19.12.3045; Furlong MA, 2001, MODERN PATHOL, V14, P595, DOI 10.1038/modpathol.3880357; GAFFNEY EF, 1993, AM J SURG PATHOL, V17, P601, DOI 10.1097/00000478-199306000-00008; Gebhard S, 2002, AM J SURG PATHOL, V26, P601, DOI 10.1097/00000478-200205000-00006; Ghadimi MP, 2011, CANCER-AM CANCER SOC, V117, P5359, DOI 10.1002/cncr.26195; Goldstein-Jackson SY, 2005, J CANCER RES CLIN, V131, P520, DOI 10.1007/s00432-005-0687-7; Gronchi A, 2015, AM J SURG PATHOL, V39, P383, DOI 10.1097/PAS.0000000000000366; Henricks WH, 1997, AM J SURG PATHOL, V21, P271, DOI 10.1097/00000478-199703000-00002; Hong NJL, 2013, ANN SURG ONCOL, V20, P80, DOI 10.1245/s10434-012-2572-3; Hornick JL, 2004, AM J SURG PATHOL, V28, P1257, DOI 10.1097/01.pas.0000135524.73447.4a; Huang HY, 2004, HUM PATHOL, V35, P612, DOI 10.1016/j.humpath.2004.01.016; Jensen ML, 1998, AM J SURG PATHOL, V22, P588, DOI 10.1097/00000478-199805000-00010; Keung EZ, 2014, J AM COLL SURGEONS, V218, P206, DOI 10.1016/j.jamcollsurg.2013.10.009; Kikuta K, 2017, JPN J CLIN ONCOL, V47, P334, DOI 10.1093/jjco/hyw199; Le Guellec S, 2014, AM J SURG PATHOL, V38, P293, DOI 10.1097/PAS.0000000000000131; LEE JSY, 1995, CANCER, V76, P2253, DOI 10.1002/1097-0142(19951201)76:11<2253::AID-CNCR2820761112>3.0.CO;2-8; Makise N, 2018, AM J SURG PATHOL, V42, P656, DOI 10.1097/PAS.0000000000001014; Makise N, 2017, AM J SURG PATHOL, V41, P1523, DOI 10.1097/PAS.0000000000000910; Marino-Enriquez A, 2010, AM J SURG PATHOL, V34, P1122, DOI 10.1097/PAS.0b013e3181e5dc49; Massi D, 2004, EJSO-EUR J SURG ONC, V30, P1131, DOI 10.1016/j.ejso.2004.07.018; MCCORMICK D, 1994, AM J SURG PATHOL, V18, P1213, DOI 10.1097/00000478-199412000-00004; Mentzel T, 1996, AM J SURG PATHOL, V20, P391, DOI 10.1097/00000478-199604000-00001; MERCK C, 1983, ACTA PATH MICRO IM A, V91, P1; Miettinen M, 1999, MODERN PATHOL, V12, P722; Nascimento AF, 2007, AM J SURG PATHOL, V31, P99, DOI 10.1097/01.pas.0000213379.94547.e7; Nicolas MM, 2010, HUM PATHOL, V41, P663, DOI 10.1016/j.humpath.2009.10.005; Noujaim J, 2015, ANTICANCER RES, V35, P6213; Oda Y, 2001, AM J SURG PATHOL, V25, P1030, DOI 10.1097/00000478-200108000-00007; Schurch W, 1996, AM J SURG PATHOL, V20, P131, DOI 10.1097/00000478-199602000-00001; Scoccianti G, 2016, J SURG ONCOL, V114, P50, DOI 10.1002/jso.24250; Sioletic S, 2013, HISTOPATHOLOGY, V62, P287, DOI 10.1111/j.1365-2559.2012.04348.x; Sirvent N, 2007, AM J SURG PATHOL, V31, P1476, DOI 10.1097/PAS.0b013e3180581fff; SORDILLO PP, 1983, CANCER, V51, P727, DOI 10.1002/1097-0142(19830215)51:4<727::AID-CNCR2820510429>3.0.CO;2-I; Tan MCB, 2016, ANN SURG, V263, P593, DOI 10.1097/SLA.0000000000001149; Thway Khin, 2015, Sarcoma, P812089, DOI 10.1155/2015/812089; Tos APD, 2006, HISTOPATHOLOGY, V48, P51, DOI 10.1111/j.1365-2559.2005.02289.x; Tos APD, 2000, J PATHOL, V190, P531; Wang WL, 2012, CANCER-AM CANCER SOC, V118, P2900, DOI 10.1002/cncr.26590; Widemann BC, 2018, J CLIN ONCOL, V36, P160, DOI 10.1200/JCO.2017.75.3467; Willems SM, 2006, MODERN PATHOL, V19, P407, DOI 10.1038/modpathol.3800550	52	3	3	1	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1092-9134	1532-8198		ANN DIAGN PATHOL	Ann. Diagn. Pathol.	DEC	2018	37						118	124		10.1016/j.anndiagpath.2018.10.006			7	Pathology	Pathology	HF9NS	WOS:000454569300019	30340082				2019-10-28	
J	Nuzzo, AM; Camm, EJ; Sferruzzi-Perri, AN; Ashmore, TJ; Yung, HW; Cindrova-Davies, T; Spiroski, AM; Sutherland, MR; Logan, A; Austin-Williams, S; Burton, GJ; Rolfo, A; Todros, T; Murphy, MP; Giussani, DA				Nuzzo, Anna M.; Camm, Emily J.; Sferruzzi-Perri, Amanda N.; Ashmore, Thomas J.; Yung, Hong-wa; Cindrova-Davies, Tereza; Spiroski, Ana-Mishel; Sutherland, Megan R.; Logan, Angela; Austin-Williams, Shani; Burton, Graham J.; Rolfo, Alessandro; Todros, Tullia; Murphy, Michael P.; Giussani, Dino A.			Placental Adaptation to Early-Onset Hypoxic Pregnancy and Mitochondria-Targeted Antioxidant Therapy in a Rodent Model	AMERICAN JOURNAL OF PATHOLOGY			English	Article							ENDOPLASMIC-RETICULUM STRESS; ISCHEMIA-REPERFUSION INJURY; UNFOLDED PROTEIN RESPONSE; OXIDATIVE STRESS; FETAL-GROWTH; VITAMIN-C; CARDIOVASCULAR DYSFUNCTION; MATERNAL HYPOXIA; MEMBRANE THICKNESS; INDUCED APOPTOSIS	The placenta responds to adverse environmental conditions by adapting its capacity for substrate transfer to maintain fetal growth and development. Early-onset hypoxia effects on placental morphology and activation of the unfolded protein response (UPR) were determined using an established rat model in which fetal growth restriction is minimized. We further established whether maternal treatment with a mitochondria-targeted antioxidant (MitoQ) confers protection during hypoxic pregnancy. Wistar dams were exposed to normoxia (21% 02) or hypoxia (13% to 14% 02) from days 6 to 20 of pregnancy with and without MitoQ treatment (500 wnol/L in drinking water). On day 20, animals were euthanized and weighed, and the placentas from male fetuses were processed for stereology to assess morphology. UPR activation in additional cohorts of frozen placentas was determined with Western blot analysis. Neither hypoxic pregnancy nor MitoQ treatment affected fetal. growth. Hypoxia increased placental volume and the fetal capillary surface area and induced mitochondrial stress as well as the UPR, as evidenced by glucose-regulated protein 78 and activating transcription factor (ATF) 4 protein up-regulation. MitoQ treatment in hypoxic pregnancy increased placental maternal blood space surface area and volume and prevented the activation of mitochondrial stress and the ATF4 pathway. The data suggest that mitochondria-targeted antioxidants may be beneficial in complicated pregnancy via mechanisms protecting against placental stress and enhancing placental perfusion.	[Nuzzo, Anna M.; Rolfo, Alessandro; Todros, Tullia] Univ Turin, Dept Surg Sci, Turin, Italy; [Camm, Emily J.; Sferruzzi-Perri, Amanda N.; Ashmore, Thomas J.; Yung, Hong-wa; Cindrova-Davies, Tereza; Spiroski, Ana-Mishel; Sutherland, Megan R.; Austin-Williams, Shani; Burton, Graham J.; Giussani, Dino A.] Univ Cambridge, Dept Physiol Dev & Neurosci, Cambridge CB2 3EG, England; [Logan, Angela; Murphy, Michael P.] Univ Cambridge, MRC, Mitochondrial Biol Unit, Cambridge, England; [Camm, Emily J.; Sferruzzi-Perri, Amanda N.; Yung, Hong-wa; Cindrova-Davies, Tereza; Burton, Graham J.; Giussani, Dino A.] Ctr Trophoblast Res, Cambridge, England	Giussani, DA (reprint author), Univ Cambridge, Dept Physiol Dev & Neurosci, Cambridge CB2 3EG, England.	dag26@cam.ac.uk	; Murphy, Michael/C-2120-2009	Spiroski, Ana-Mishel/0000-0002-8584-8048; Austin-Williams, Shani/0000-0002-8255-583X; Sutherland, Megan/0000-0002-0841-1635; Nuzzo, Anna Maria/0000-0001-9115-2007; Giussani, Dino/0000-0002-1308-1204; Murphy, Michael/0000-0003-1115-9618	British Heart FoundationBritish Heart Foundation [PG/14/5/30547]; Medical Research CouncilMedical Research Council UK (MRC) [MC_U105663142]; Wellcome TrustWellcome Trust [110159/Z/15/Z]		Adlam VJ, 2005, FASEB J, V19, P1088, DOI 10.1096/fj.05-3718com; BADDELEY AJ, 1986, J MICROSC-OXFORD, V142, P259, DOI 10.1111/j.1365-2818.1986.tb04282.x; Balaban RS, 2005, CELL, V120, P483, DOI 10.1016/j.cell.2005.02.001; Blais JD, 2004, MOL CELL BIOL, V24, P7469, DOI 10.1128/MCB.24.17.7469-7482.2004; Brain KL, 2015, PHYSIOL REP, V3, DOI 10.14814/phy2.12614; Burton GJ, 2009, PLACENTA, V30, pS43, DOI 10.1016/j.placenta.2008.11.003; BURTON GJ, 1992, J DEV PHYSIOL, V17, P39; Burton GJ, 2004, J SOC GYNECOL INVEST, V11, P342, DOI 10.1016/j.jsgi.2004.03.003; Burton GJ, 2016, PHYSIOL REV, V96, P1509, DOI 10.1152/physrev.00029.2015; Burton GJ, 2011, PREGNANCY HYPERTENS, V1, P72, DOI 10.1016/j.preghy.2010.12.002; Camm EJ, 2011, FASEB J, V25, P420, DOI 10.1096/fj.10-158188; Camm EJ, 2010, AM J OBSTET GYNECOL, V203, DOI 10.1016/j.ajog.2010.06.046; Cartwright JE, 2007, ADV EXP MED BIOL, V618, P113; Chacko BK, 2010, BIOCHEM J, V432, P9, DOI 10.1042/BJ20100308; Chandel NS, 1998, P NATL ACAD SCI USA, V95, P11715, DOI 10.1073/pnas.95.20.11715; Chandran K, 2009, BIOPHYS J, V96, P1388, DOI 10.1016/j.bpj.2008.10.042; Cindrova-Davies T, 2013, AM J PATHOL, V182, P1448, DOI 10.1016/j.ajpath.2013.01.001; Clifton VL, 2010, PLACENTA, V31, pS33, DOI 10.1016/j.placenta.2009.11.010; Coan PM, 2004, BIOL REPROD, V70, P1806, DOI 10.1095/biolreprod.103.024166; Cooke JP, 2003, ATHEROSCLEROSIS SUPP, V4, P53, DOI 10.1016/S1567-5688(03)00034-5; COX JS, 1993, CELL, V73, P1197, DOI 10.1016/0092-8674(93)90648-A; Cuffe JSM, 2014, J PHYSIOL-LONDON, V592, P3127, DOI 10.1113/jphysiol.2014.272856; Cullinan SB, 2006, INT J BIOCHEM CELL B, V38, P317, DOI 10.1016/j.biocel.2005.09.018; Dare AJ, 2015, REDOX BIOL, V5, P163, DOI 10.1016/j.redox.2015.04.008; Dare AJ, 2015, J HEART LUNG TRANSPL, V34, P1471, DOI 10.1016/j.healun.2015.05.007; Dimasuay KG, 2016, FRONT PHYSIOL, V7, DOI [10.3339/fphys.2016.00012, 10.3389/fphys.2016.00012]; Du L, 2017, J HUM HYPERTENS, V31, P49, DOI 10.1038/jhh.2016.17; ESTES SD, 1995, EXP CELL RES, V220, P47, DOI 10.1006/excr.1995.1290; Fonseca BM, 2012, REPROD BIOL, V12, P97, DOI 10.1016/S1642-431X(12)60080-1; Fu JH, 2015, TAIWAN J OBSTET GYNE, V54, P19, DOI 10.1016/j.tjog.2014.11.002; Gane EJ, 2010, LIVER INT, V30, P1019, DOI 10.1111/j.1478-3231.2010.02250.x; Ghosh A, 2010, FREE RADICAL BIO MED, V49, P1674, DOI 10.1016/j.freeradbiomed.2010.08.028; Gioscia-Ryan RA, 2014, J PHYSIOL-LONDON, V592, P2549, DOI 10.1113/jphysiol.2013.268680; Giussani DA, 2013, J DEV ORIG HLTH DIS, V4, P328, DOI 10.1017/S204017441300010X; Giussani DA, 2016, J PHYSIOL-LONDON, V594, P1215, DOI 10.1113/JP271099; Giussani DA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031017; Graham D, 2009, HYPERTENSION, V54, P322, DOI 10.1161/HYPERTENSIONAHA.109.130351; GUNDERSEN HJG, 1981, J MICROSC-OXFORD, V121, P65, DOI 10.1111/j.1365-2818.1981.tb01199.x; Haase VH, 2013, BLOOD REV, V27, P41, DOI 10.1016/j.blre.2012.12.003; Harding HP, 2003, MOL CELL, V11, P619, DOI 10.1016/S1097-2765(03)00105-9; Hatano N, 2003, GENES CELLS, V8, P847, DOI 10.1046/j.1365-2443.2003.00680.x; HEACOCK CS, 1990, BRIT J CANCER, V62, P217, DOI 10.1038/bjc.1990.264; Higgins JS, 2016, J PHYSIOL-LONDON, V594, P1341, DOI 10.1113/JP271057; Ho-Chen JK, 2006, METH MOLEC MED, V122, P427; Itani N, 2017, J PHYSIOL-LONDON, V595, P1563, DOI 10.1113/JP273393; Itani N, 2016, J PINEAL RES, V60, P16, DOI 10.1111/jpi.12283; Jang EA, 2015, FRONT PHYSIOL, V6, DOI 10.3389/fphys.2015.00176; Jansson N, 2013, J CLIN ENDOCR METAB, V98, P105, DOI 10.1210/jc.2012-2667; Jauniaux E, 2006, HUM REPROD UPDATE, V12, P747, DOI 10.1093/humupd/dml016; Jauslin ML, 2003, FASEB J, V17, P1972, DOI 10.1096/fj.03-0240fje; Jefferson JA, 2004, HIGH ALT MED BIOL, V5, P61, DOI 10.1089/152702904322963690; JENSEN EB, 1979, J MICROSC-OXFORD, V115, P19, DOI 10.1111/j.1365-2818.1979.tb00149.x; Kane AD, 2013, CIRC J, V77, P2604, DOI 10.1253/circj.CJ-13-0311; Lowes DA, 2008, FREE RADICAL BIO MED, V45, P1559, DOI 10.1016/j.freeradbiomed.2008.09.003; Matheson H, 2016, J PHYSIOL-LONDON, V594, P1371, DOI 10.1113/JP271073; MAYHEW TM, 1984, J ANAT, V139, P691; Mayhew TM, 2003, PLACENTA, V24, P191, DOI 10.1053/plac.2002.0895; McManus MJ, 2011, J NEUROSCI, V31, P15703, DOI 10.1523/JNEUROSCI.0552-11.2011; Mizuuchi M, 2016, J PATHOL, V238, P550, DOI 10.1002/path.4678; Murphy MP, 2007, ANNU REV PHARMACOL, V47, P629, DOI 10.1146/annurev.pharmtox.47.120505.105110; Ozawa K, 1999, J BIOL CHEM, V274, P6397, DOI 10.1074/jbc.274.10.6397; Ozawa K, 2001, J CLIN INVEST, V108, P41, DOI 10.1172/JCI200111772; Phillips TJ, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-06300-1; Poston L, 2006, LANCET, V367, P1145, DOI 10.1016/S0140-6736(06)68433-X; Pung YF, 2012, ARTERIOSCL THROM VAS, V32, P325, DOI 10.1161/ATVBAHA.111.241802; Rahimi R, 2009, HYPERTENS PREGNANCY, V28, P417, DOI 10.3109/10641950802629667; Rehman Hasibur, 2016, Int J Physiol Pathophysiol Pharmacol, V8, P14; Richter HG, 2012, J PHYSIOL-LONDON, V590, P1377, DOI 10.1113/jphysiol.2011.226340; Richter HG, 2009, J PINEAL RES, V46, P357, DOI 10.1111/j.1600-079X.2009.00671.x; Rodriguez-Cuenca S, 2010, FREE RADICAL BIO MED, V48, P161, DOI 10.1016/j.freeradbiomed.2009.10.039; Ron D, 2007, NAT REV MOL CELL BIO, V8, P519, DOI 10.1038/nrm2199; Rosario GX, 2008, DEV BIOL, V314, P362, DOI 10.1016/j.ydbio.2007.12.007; Rueda-Clausen CF, 2014, REPROD SCI, V21, P492, DOI 10.1177/1933719113503401; Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089; Schroder M, 2005, ANNU REV BIOCHEM, V74, P739, DOI 10.1146/annurev.biochem.73.011303.074134; Schwartz JE, 1998, BIOL NEONATE, V73, P313, DOI 10.1159/000013990; Sferruzzi-Perri AN, 2016, FRONT PHYSIOL, V7, DOI 10.3389/fphys.2016.00033; Smith RAJ, 2003, P NATL ACAD SCI USA, V100, P5407, DOI 10.1073/pnas.0931245100; Smith RAJ, 2010, ANN NY ACAD SCI, V1201, P96, DOI 10.1111/j.1749-6632.2010.05627.x; Snow BJ, 2010, MOVEMENT DISORD, V25, P1670, DOI 10.1002/mds.23148; Supinski GS, 2009, AM J PHYSIOL-REG I, V297, pR1095, DOI 10.1152/ajpregu.90902.2008; Thakor AS, 2010, J PINEAL RES, V49, P399, DOI 10.1111/j.1600-079X.2010.00813.x; Vaughan OR, 2013, BIOL REPROD, V89, DOI 10.1095/biolreprod.113.109678; West BT, 2009, EVAL HEALTH PROF, V32, P207, DOI 10.1177/0163278709338554; Williams SJ, 2005, AM J PHYSIOL-REG I, V288, pR360, DOI 10.1152/ajpregu.00178.2004; Wouters BG, 2008, NAT REV CANCER, V8, P851, DOI 10.1038/nrc2501; Xu CY, 2005, J CLIN INVEST, V115, P2656, DOI 10.1172/JCI26373; Yung HW, 2014, PLACENTA, V35, P103, DOI 10.1016/j.placenta.2013.11.016; Yung HW, 2014, J PATHOL, V234, P262, DOI 10.1002/path.4394; Yung HW, 2012, FASEB J, V26, P1970, DOI 10.1096/fj.11-190082; Yung HW, 2008, AM J PATHOL, V173, P451, DOI 10.2353/ajpath.2008.071193; Zhou JJ, 2013, HYPERTENSION, V62, P599, DOI 10.1161/HYPERTENSIONAHA.113.01449	92	6	6	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	DEC	2018	188	12					2704	2716		10.1016/j.ajpath.2018.07.027			13	Pathology	Pathology	HF4EX	WOS:000454187100001	30248337	Other Gold, Green Published			2019-10-28	
J	Shi, HS; Ebrahim, AS; Berger, EA				Shi, Haoshen; Ebrahim, Abdul S.; Berger, Elizabeth A.			A Contrast in Pathogenic Responses between C57BL/6J and BALB/cJ Mice Using a Model of Retinal Injury	AMERICAN JOURNAL OF PATHOLOGY			English	Article							AERUGINOSA CORNEAL INFECTION; LIPID-PEROXIDATION; ISCHEMIA; REPERFUSION; OXYGEN; INFLAMMATION; RESISTANCE; STRAINS; PROTEIN; STRESS	Ischemia is associated with the pathogenesis of retinal disease, including diabetic retinopathy and glaucoma. As a result, the retinal ischemia/reperfusion injury model has been used to study neurovascular changes. Historically, murine models of retinal disease are established in C57BL/6J (B6) mice, which have been described as type 1 dominant responders. In bacterial keratitis models, B6 mice are susceptible, whereas BALB/cJ (BALB/c; type 2 dominant) mice exhibit a resistant phenotype. As such, we questioned whether the type 1/type 2 paradigm could be extrapolated to events associated with retinal pathogenesis. The current study compares the retinal response of B6 with BALB/c mice to investigate strain-specific differences. Retinas were collected at 2 and 10 days after ischemia/reperfusion injury to examine differences in neurovascular degeneration, leukostasis, oxidative stress, glial activation, and select inflammatory mediators. Although both strains showed signs of retinal injury, significantly more damage was observed in B6 mice. Retinal thickness was reduced and vascular damage was more severe in B6 mice. Exacerbated response to injury in B6 versus BALB/c retinas was further supported by increased leukostasis, inflammatory mediators, reactive oxygen species, and lipid peroxidation. In addition, more terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling positive cells and increased glial activation were detected in B6 mice. These data indicate that B6 and BALB/c retinas differentially respond to injury, which has broader implications regarding the development and study of retinal diseases.	[Shi, Haoshen; Ebrahim, Abdul S.; Berger, Elizabeth A.] Wayne State Univ, Sch Med, Dept Ophthalmol Visual & Anat Sci, 540 E Canfield Ave, Detroit, MI 48201 USA	Berger, EA (reprint author), Wayne State Univ, Sch Med, Dept Ophthalmol Visual & Anat Sci, 540 E Canfield Ave, Detroit, MI 48201 USA.	eberger@med.wayne.edu	Berger, Elizabeth/W-6893-2019		National Eye InstituteUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI) [P30 EY004068, R01 EY023226]		Abcouwer SF, 2010, INVEST OPHTH VIS SCI, V51, P5920, DOI 10.1167/iovs.10-5264; Abiko T, 2003, DIABETES, V52, P829, DOI 10.2337/diabetes.52.3.829; Atkinson M.A., 2012, COLD SPRING HARB PER, V2; Berger EA, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003457; BRESNICK GH, 1976, T AM ACAD OPHTHALMOL, V81, pO694; Carion T, 2015, INVEST OPHTH VIS SCI, V56; Carion TW, 2018, FASEB J, V32, P5026, DOI 10.1096/fj.201701502R; De Vooght V, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012581; Deeds MC, 2011, LAB ANIM-UK, V45, P131, DOI 10.1258/la.2010.010090; Evangelho K, 2019, INT OPHTHALMOL, V39, P259, DOI 10.1007/s10792-017-0795-9; Feenstra Derrick J, 2013, J Clin Exp Ophthalmol, V4, P298; FLAHERTY JT, 1991, AM J MED, V91, pS79, DOI 10.1016/0002-9343(91)90288-9; Gorham JD, 1996, P NATL ACAD SCI USA, V93, P12467, DOI 10.1073/pnas.93.22.12467; Hangai M, 1996, EXP EYE RES, V63, P501, DOI 10.1006/exer.1996.0140; Hartsock MJ, 2016, JOVE-J VIS EXP, DOI 10.3791/54065; Hazlett LD, 2004, PROG RETIN EYE RES, V23, P1, DOI 10.1016/j.preteyeres.2003.10.002; Hazlett LD, 2000, INVEST OPHTH VIS SCI, V41, P805; Huang X, 2003, INVEST OPHTH VIS SCI, V44, P3409, DOI 10.1167/iovs.03-0162; Ishihara K, 2009, J NEUROCHEM, V110, P1965, DOI 10.1111/j.1471-4159.2009.06294.x; Izzotti A, 2006, MUTAT RES-REV MUTAT, V612, P105, DOI 10.1016/j.mrrev.2005.11.001; Jehle T, 2008, INVEST OPHTH VIS SCI, V49, P1056, DOI 10.1167/iovs.07-1050; Jiang YQ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065756; Jovicic N, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0134089; Kalyanaraman B, 2012, FREE RADICAL BIO MED, V52, P1, DOI 10.1016/j.freeradbiomed.2011.09.030; KAZUI M, 1994, J VASC SURG, V19, P473, DOI 10.1016/S0741-5214(94)70074-5; Kern TS, 2007, EXP DIABETES RES, DOI 10.1155/2007/95103; Kim CB, 2016, EYE BRAIN, V8, P67, DOI 10.2147/EB.S94447; Kowluru RA, 2001, DIABETES, V50, P1938, DOI 10.2337/diabetes.50.8.1938; Kowluru RA, 2007, EXP DIABETES RES, DOI 10.1155/2007/43603; Lai AKW, 2013, J DIABETES RES, DOI 10.1155/2013/106594; Lewis GP, 2003, INT REV CYTOL, V230, P263, DOI 10.1016/S0074-7696(03)30005-1; Lucey DR, 1999, INFECT DIS CLIN N AM, V13, P1, DOI 10.1016/S0891-5520(05)70039-8; Miyahara S, 2003, STROKE, V34, P2043, DOI 10.1161/01.STR.0000083052.01361.3D; Muller A, 2002, IMMUNOBIOLOGY, V205, P35, DOI 10.1078/0171-2985-00109; Neufeld AH, 2002, EXP EYE RES, V75, P521, DOI 10.1006/exer.2002.2042; Ramirez AI, 2017, FRONT AGING NEUROSCI, V9, DOI 10.3389/fnagi.2017.00214; Sakai K, 2014, SUBCELL BIOCHEM, V77, P61, DOI 10.1007/978-94-007-7920-4_5; Schulte S, 2008, AM J PATHOL, V172, P1500, DOI 10.2353/ajpath.2008.070776; SYPEK JP, 1993, J EXP MED, V177, P1797, DOI 10.1084/jem.177.6.1797; Szliter EA, 2007, J IMMUNOL, V178, P1105, DOI 10.4049/jimmunol.178.2.1105; Tang J, 2011, PROG RETIN EYE RES, V30, P343, DOI 10.1016/j.preteyeres.2011.05.002; Tarr Joanna M, 2013, ISRN Ophthalmol, V2013, P343560, DOI 10.1155/2013/343560; Villarroel M, 2010, WORLD J DIABETES, V1, P57, DOI 10.4239/wjd.v1.i2.57; Vohra R, 2013, SURV OPHTHALMOL, V58, P311, DOI 10.1016/j.survophthal.2012.08.010; Walsh N, 2004, CURR EYE RES, V29, P441, DOI 10.1080/02713680490522416; Wang LL, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023194; Watanabe H, 2004, SHOCK, V22, P460, DOI 10.1097/01.shk.0000142249.08135.e9; Yau JWY, 2012, DIABETES CARE, V35, P556, DOI 10.2337/dc11-1909; Zheng L, 2004, DIABETES, V53, P2960, DOI 10.2337/diabetes.53.11.2960; Zheng L, 2007, INVEST OPHTH VIS SCI, V48, P361, DOI 10.1167/iovs.06-0510	50	2	2	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	DEC	2018	188	12					2717	2728		10.1016/j.ajpath.2018.08.010			12	Pathology	Pathology	HF4EX	WOS:000454187100002	30236476	Bronze			2019-10-28	
J	Oura, Y; Nakamura, M; Takigawa, T; Fukushima, Y; Wakabayashi, T; Tsujikawa, M; Nishida, K				Oura, Yoshihito; Nakamura, Machiko; Takigawa, Tohru; Fukushima, Yoko; Wakabayashi, Taku; Tsujikawa, Motokazu; Nishida, Kohji			High-Temperature Requirement A 1 Causes Photoreceptor Cell Death in Zebrafish Disease Models	AMERICAN JOURNAL OF PATHOLOGY			English	Article							RETINAL-PIGMENT EPITHELIUM; GENOME-WIDE ASSOCIATION; AGE-RELATED MACULOPATHY; MACULAR DEGENERATION; RETICULAR PSEUDODRUSEN; GEOGRAPHIC ATROPHY; SERINE-PROTEASE; BINDING-PROTEIN; HUMAN HTRA1; SUSCEPTIBILITY	Age-related macular degeneration (AMD) is an important cause of blindness. It is characterized by a retinal pigment epithelium (RPE) disorder that leads to death of photoreceptor cells (PRCs). AMD has a strong genetic association with high-temperature requirement A 1 (HTRA1). The relationship between HTRA1 and the AMD phenotype is unknown. In this study, we show that the expression of HTRA1 in PRCs, as well as in RPE, is increased by the disease-associated HTRA1 mutation and aging. Terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling assay and quantitative PCR of apoptosis-associated caspases confirmed that PRC-specific overexpression of HTRA1 induced PRC death. Transgenic zebrafish overexpressing human HTRA1 in rod PRCs showed morphologic changes of the RPE, including PRC death and lipofuscin accumulation, features similar to those of early AMD. htra1 expression was also increased in a retinitis pigmentosa zebrafish model compared with wild type. In both fish lines, PRC death was rescued by the suppression of htra1 by the inhibitor 6-boroV. AKT forkhead box 03 signaling downstream of HTRA1 was activated via a tumor growth factor beta signal, resulting in PRC death. These findings suggest that HTRA1 derived from PRCs is associated with early AMD via PRC death. HTRA1 is a potentially effective target for neuroprotective therapy of early AMD and other degenerative diseases of PRCs.	[Oura, Yoshihito; Takigawa, Tohru; Fukushima, Yoko; Wakabayashi, Taku; Tsujikawa, Motokazu; Nishida, Kohji] Osaka Univ, Med Sch, Dept Ophthalmol, Suita, Osaka, Japan; [Nakamura, Machiko] Daiichi Sankyo Co Ltd, Pain & Neurosci Labs, Tokyo, Japan	Tsujikawa, M (reprint author), Osaka Univ, Grad Sch Med, Dept Biomed Informat, Div Hlth Sci, 1-7 Yamadaoka, Suita, Osaka 5650871, Japan.	moto@sahs.med.osaka-u.ac.jp					Altay L, 2016, INVEST OPHTH VIS SCI, V57, P4315, DOI 10.1167/iovs.15-18855; Anand R, 2000, OPHTHALMOLOGY, V107, P2224; Baird PN, 2008, HUM MOL GENET, V17, P1299, DOI 10.1093/hmg/ddn018; Beaufort N, 2014, P NATL ACAD SCI USA, V111, P16496, DOI 10.1073/pnas.1418087111; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Castellano Esther, 2011, Genes Cancer, V2, P261, DOI 10.1177/1947601911408079; Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31; Chien J, 2006, J CLIN INVEST, V116, P1994, DOI 10.1172/JCI27698; Clausen T, 2002, MOL CELL, V10, P443, DOI 10.1016/S1097-2765(02)00658-5; Cunningham ET, 2011, OPHTHALMOLOGY, V118, P2447, DOI 10.1016/j.ophtha.2011.05.026; Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236; Delori F, 2007, ORIGIN FUNDUS AUTOFL, P17; Delori FC, 2000, INVEST OPHTH VIS SCI, V41, P496; Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807; Ding XY, 2009, PROG RETIN EYE RES, V28, P1, DOI 10.1016/j.preteyeres.2008.10.001; FEENEY L, 1978, INVEST OPHTH VIS SCI, V17, P583; Finger RP, 2016, OPHTHALMOLOGY, V123, P599, DOI 10.1016/j.ophtha.2015.10.029; Finger RP, 2014, OPHTHALMOLOGY, V121, P1246, DOI 10.1016/j.ophtha.2013.12.032; Fisher SA, 2005, HUM MOL GENET, V14, P2257, DOI 10.1093/hmg/ddi230; Flynn E, 2014, INVEST OPHTH VIS SCI, V55, P5643, DOI 10.1167/iovs.14-14136; Friedrich U, 2015, HUM MOL GENET, V24, P6361, DOI 10.1093/hmg/ddv346; Friedrich U, 2011, HUM MOL GENET, V20, P1387, DOI 10.1093/hmg/ddr020; Fritsche LG, 2008, NAT GENET, V40, P892, DOI 10.1038/ng.170; Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448; Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578; Gibson JM, 2014, EXPERT OPIN DRUG SAF, V13, P1259, DOI 10.1517/14740338.2014.939951; Gil JQ, 2017, EYE, V31, P364, DOI 10.1038/eye.2016.207; Goldstein M, 2005, EYE, V19, P1315, DOI 10.1038/sj.eye.6701765; Grassmann F, 2017, GENETICS, V205, P919, DOI 10.1534/genetics.116.195966; Grau S, 2006, J BIOL CHEM, V281, P6124, DOI 10.1074/jbc.M500361200; Hamaoka T, 2002, GENESIS, V34, P215, DOI 10.1002/gene.10155; Hara K, 2009, NEW ENGL J MED, V360, P1729, DOI 10.1056/NEJMoa0801560; Hou YZ, 2014, J IMMUNOL, V193, P130, DOI 10.4049/jimmunol.1302700; Huang W, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075735; Iejima Daisuke, 2015, J Stem Cells, V10, P193; Iejima D, 2015, J BIOL CHEM, V290, P2784, DOI 10.1074/jbc.M114.593384; Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437; Jones A, 2011, P NATL ACAD SCI USA, V108, P14578, DOI 10.1073/pnas.1102853108; Kanda A, 2010, MOL VIS, V16, P1317; KANZAKI T, 1990, CELL, V61, P1051, DOI 10.1016/0092-8674(90)90069-Q; Kevany BM, 2010, PHYSIOLOGY, V25, P8, DOI 10.1152/physiol.00038.2009; Khan JC, 2006, BRIT J OPHTHALMOL, V90, P75, DOI 10.1136/bjo.2005.073643; Kim GY, 2012, MOL CELL BIOL, V32, P4482, DOI 10.1128/MCB.00872-12; KIMMEL CB, 1995, DEV DYNAM, V203, P253, DOI 10.1002/aja.1002030302; Klein R, 2013, OPHTHALMOLOGY, V120, P1210, DOI 10.1016/j.ophtha.2012.11.041; Lana TP, 2018, OPHTHALMIC GENET, V39, P46, DOI 10.1080/13816810.2017.1354382; Latendresse JR, 2002, TOXICOL PATHOL, V30, P524, DOI 10.1080/01926230290105721; Maguire MG, 2016, OPHTHALMOLOGY, V123, P1751, DOI 10.1016/j.ophtha.2016.03.045; Malicki J, 2002, METHODS, V28, P427, DOI 10.1016/S1046-2023(02)00262-1; Manning BD, 2007, CELL, V129, P1261, DOI 10.1016/j.cell.2007.06.009; Marinkovic D, 2007, J CLIN INVEST, V117, P2133, DOI 10.1172/JCI31807; Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047; Miyamoto K, 2007, CELL STEM CELL, V1, P101, DOI 10.1016/j.stem.2007.02.001; Nagai N, 2014, J NUTR BIOCHEM, V25, P1218, DOI 10.1016/j.jnutbio.2014.05.015; Nakao T, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032472; Ng TK, 2011, INVEST OPHTH VIS SCI, V52, P3706, DOI 10.1167/iovs.10-6773; Nicholson KM, 2002, CELL SIGNAL, V14, P381, DOI 10.1016/S0898-6568(01)00271-6; Rifkin DB, 2005, J BIOL CHEM, V280, P7409, DOI 10.1074/jbc.R400029200; Ruamviboonsuk P, 2017, J HUM GENET, V62, P957, DOI 10.1038/jhg.2017.72; Shen JK, 2007, HISTOL HISTOPATHOL, V22, P1301, DOI 10.14670/HH-22.1301; Swaroop A, 2009, ANNU REV GENOM HUM G, V10, P19, DOI 10.1146/annurev.genom.9.081307.164350; Takahashi A, 2016, AM J OPHTHALMOL, V168, P260, DOI 10.1016/j.ajo.2016.06.006; Thornton J, 2005, EYE, V19, P935, DOI 10.1038/sj.eye.6701978; Truebestein L, 2011, NAT STRUCT MOL BIOL, V18, P386, DOI 10.1038/nsmb.2013; Vierkotten S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022959; Wu ZC, 2014, OPHTHALMOLOGY, V121, P1445, DOI 10.1016/j.ophtha.2014.01.025; Yang SS, 2016, DOC OPHTHALMOL, V132, P17, DOI 10.1007/s10633-016-9523-4; Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811; Zheng WL, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024019; Zhou Q, 2016, OPHTHALMOLOGY, V123, P1530, DOI 10.1016/j.ophtha.2016.02.043; 1995, OPHTHALMOLOGE, V102, P647	71	1	1	1	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	DEC	2018	188	12					2729	2744		10.1016/j.ajpath.2018.08.012			16	Pathology	Pathology	HF4EX	WOS:000454187100003	30273602				2019-10-28	
J	Baek, JH; Gomez, IG; Wada, Y; Roach, A; Mahad, D; Duffield, JS				Baek, Jea-Hyun; Gomez, Ivan G.; Wada, Yukihiro; Roach, Allie; Mahad, Don; Duffield, Jeremy S.			Deletion of the Mitochondrial Complex-IV Cofactor Heme A:Farnesyltransferase Causes Focal Segmental Glomerulosclerosis and Interferon Response	AMERICAN JOURNAL OF PATHOLOGY			English	Article							CYTOCHROME-C-OXIDASE; CYCLIC GMP-AMP; TUMOR-NECROSIS-FACTOR; KIDNEY INJURY; CELL-DEATH; DNA; COX10; DYSFUNCTION; DEFICIENCY; DISEASE	Mutations in mitochondrial. DNA as well as nuclear-encoded mitochondrial proteins have been reported to cause tubulointerstitial kidney diseases and focal segmental glomerulosclerosis (FSGS). Recently, genes and pathways affecting mitochondrial turnover and permeability have been implicated in adult onset FSGS. Furthermore, dysfunctioning mitochondria may be capable of engaging intracellular innate immune-sensing pathways. To determine the impact of mitochondrial dysfunction in FSGS and secondary innate immune responses, we generated Cre/loxP transgenic mice to generate a loss-of-function deletion mutation of the complex IV assembly cofactor heme A:farnesyltransferase (COX10) restricted to cells of the developing nephrons. These mice develop severe, early-onset FSGS with innate immune activation and die prematurely with kidney failure. Mutant kidneys showed loss of glomerular and tubular epithelial function, epithelial apoptosis, and, in addition, a marked interferon response. In vitro modeling of Cox10 deletion in primary kidney epithelium compromises oxygen consumption, ATP generation, and induces oxidative stress. In addition, loss of Cox10 triggers a selective interferon response, which may be caused by the leak of mitochondrial DNA into the cytosol activating the intracellular DNA sensor, stimulator of interferon genes. This new animal model provides a mechanism to study mitochondrial dysfunction in vivo and demonstrates a direct link between mitochondria;. dysfunction and intracellular innate immune response.	[Baek, Jea-Hyun; Gomez, Ivan G.; Roach, Allie; Duffield, Jeremy S.] Biogen Inc, Res & Dev, 14 Cambridge Ctr, Cambridge, MA 02142 USA; [Gomez, Ivan G.; Roach, Allie; Duffield, Jeremy S.] Univ Washington, Dept Med, Div Nephrol, Seattle, WA 98109 USA; [Gomez, Ivan G.; Roach, Allie; Duffield, Jeremy S.] Univ Washington, Dept Pathol, Div Nephrol, Seattle, WA 98109 USA; [Wada, Yukihiro] Showa Univ, Sch Med, Dept Med, Div Nephrol, Tokyo, Japan; [Mahad, Don] Univ Edinburgh, Anne Rowling Regenerat Neurol Clin, Ctr Clin Brain Sci, Edinburgh, Midlothian, Scotland; [Mahad, Don] Univ Edinburgh, Ctr Neuroregenerat, Edinburgh, Midlothian, Scotland; [Duffield, Jeremy S.] Massachusetts Gen Hosp, Dept Med, Div Nephrol, Boston, MA 02114 USA	Baek, JH (reprint author), Biogen Inc, 225 Binney St, Cambridge, MA 02142 USA.; Duffield, JS (reprint author), Univ Washington, Sch Med, 850 Republican St, Seattle, WA 98109 USA.	jeahyun.baek@biogen.com; jeremysd@u.washington.edu	Baek, Jea Hyun/J-2752-2019	Baek, Jea Hyun/0000-0003-4439-5545; Wada, Yukihiro/0000-0001-5996-8735; Roach, Allie/0000-0001-5791-0708	NTH [DK093493, DK094768]; Biogen Inc.Biogen	Supported by NTH grants DK093493 and DK094768 (J.S.D.) and Biogen Inc.	Abdul-Sater AA, 2010, J BIOL CHEM, V285, P41637, DOI 10.1074/jbc.M110.137885; Ablasser A, 2014, J IMMUNOL, V192, P5993, DOI 10.4049/jimmunol.1400737; Alcubilla-Prats P, 2017, MED CLIN-BARCELONA, V148, P357, DOI 10.1016/j.medcli.2017.01.029; Anders HJ, 2010, KIDNEY INT, V77, P848, DOI 10.1038/ki.2010.71; [Anonymous], 2011, GUIDE CARE USE LAB A; Antonicka H, 2003, HUM MOL GENET, V12, P2693, DOI 10.1093/hmg/ddg284; Arnoult D, 2011, EMBO REP, V12, P901, DOI 10.1038/embor.2011.157; Baek JH, 2017, AM J PATHOL, V187, P1245, DOI 10.1016/j.ajpath.2017.02.011; Baek JH, 2015, J CLIN INVEST, V125, P3198, DOI 10.1172/JCI81166; Baek JH, 2012, J IMMUNOL, V189, P1699, DOI 10.4049/jimmunol.1200729; Bai JL, 2017, P NATL ACAD SCI USA, V114, P12196, DOI 10.1073/pnas.1708744114; Barber GN, 2014, TRENDS IMMUNOL, V35, P88, DOI 10.1016/j.it.2013.10.010; BAUD L, 1995, MINER ELECTROL METAB, V21, P336; BERTANI T, 1989, AM J PATHOL, V134, P419; Bhargava P, 2017, NAT REV NEPHROL, V13, P629, DOI 10.1038/nrneph.2017.107; Brown EJ, 2010, NAT GENET, V42, P72, DOI 10.1038/ng.505; Cai X, 2014, MOL CELL, V54, P289, DOI 10.1016/j.molcel.2014.03.040; Chan YK, 2016, NAT REV MICROBIOL, V14, P360, DOI 10.1038/nrmicro.2016.45; Che RC, 2014, AM J PHYSIOL-RENAL, V306, pF367, DOI 10.1152/ajprenal.00571.2013; Coenen MJH, 2004, ANN NEUROL, V56, P560, DOI 10.1002/ana.20229; Crow MK, 2014, J IMMUNOL, V192, P5459, DOI 10.4049/jimmunol.1002795; Diaz F, 2005, HUM MOL GENET, V14, P2737, DOI 10.1093/hmg/ddi307; Diaz F, 2006, MOL CELL BIOL, V26, P4872, DOI 10.1128/MCB.01767-05; Diaz F, 2012, HUM MOL GENET, V21, P5066, DOI 10.1093/hmg/dds350; Diaz F, 2010, BBA-MOL BASIS DIS, V1802, P100, DOI 10.1016/j.bbadis.2009.07.013; Dib B, 2015, BBA-MOL CELL RES, V1853, P2897, DOI 10.1016/j.bbamcr.2015.08.012; Dinour D, 2004, CLIN NEPHROL, V62, P149; Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635; Fernandes-Alnemri T, 2009, NATURE, V458, P509, DOI 10.1038/nature07710; Finsterer J, 2004, EUR J NEUROL, V11, P163, DOI 10.1046/j.1351-5101.2003.00728.x; Freitas MCS, 2011, TRANSPLANTATION, V92, P131, DOI 10.1097/TP.0b013e318220586e; Fukui H, 2007, P NATL ACAD SCI USA, V104, P14163, DOI 10.1073/pnas.0705738104; Galluzzi L, 2016, IMMUNITY, V44, P221, DOI 10.1016/j.immuni.2016.01.020; Gao DX, 2013, SCIENCE, V341, P903, DOI 10.1126/science.1240933; Genovese G, 2010, SCIENCE, V329, P841, DOI 10.1126/science.1193032; GUTTERIDGE JMC, 1993, FREE RADICAL RES COM, V19, P141, DOI 10.3109/10715769309111598; Hagiwara M, 2006, KIDNEY INT, V69, P1146, DOI 10.1038/sj.ki.5000207; Hatakeyama H, 2017, AM J PATHOL, V187, P110, DOI 10.1016/j.ajpath.2016.09.003; Holmstrom KM, 2014, NAT REV MOL CELL BIO, V15, P411, DOI 10.1038/nrm3801; Honda K, 2005, NATURE, V434, P772, DOI 10.1038/nature03464; Hron JD, 2004, J IMMUNOL, V173, P2134, DOI 10.4049/jimmunol.173.3.2134; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Huang DW, 2009, NUCLEIC ACIDS RES, V37, P1, DOI 10.1093/nar/gkn923; Humphreys BD, 2008, CELL STEM CELL, V2, P284, DOI 10.1016/j.stem.2008.01.014; Humphreys BD, 2013, J CLIN INVEST, V123, P4023, DOI 10.1172/JCI45361; Ichimura T, 1998, J BIOL CHEM, V273, P4135, DOI 10.1074/jbc.273.7.4135; Jaitin DA, 2006, MOL CELL BIOL, V26, P1888, DOI 10.1128/MCB.26.5.1888-1897.2006; Kawakami T, 2015, J AM SOC NEPHROL, V26, P1040, DOI 10.1681/ASN.2013111202; Klootwijk ED, 2015, NEPHROL DIAL TRANSPL, V30, P1456, DOI 10.1093/ndt/gfu377; Kobayashi A, 2008, CELL STEM CELL, V3, P169, DOI 10.1016/j.stem.2008.05.020; Kottgen A, 2009, NAT GENET, V41, P712, DOI 10.1038/ng.377; Korkmaz E, 2016, J AM SOC NEPHROL, V27, P63, DOI 10.1681/ASN.2014121240; Kramer A, 2014, BIOINFORMATICS, V30, P523, DOI 10.1093/bioinformatics/btt703; Kriz W, 2013, AM J PHYSIOL-RENAL, V304, pF333, DOI 10.1152/ajprenal.00478.2012; Lazear HM, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003118; Lemos DR, 2018, J AM SOC NEPHROL, V29, P1690, DOI 10.1681/ASN.2017121283; Li B, 2010, FASEB J, V24, P4767, DOI 10.1096/fj.10-154757; Li B, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-323; Li XD, 2013, SCIENCE, V341, P1390, DOI 10.1126/science.1244040; Lim Kenneth, 2017, Clin Nephrol Case Stud, V5, P20, DOI 10.5414/CNCS109083; Lood C, 2016, NAT MED, V22, P146, DOI 10.1038/nm.4027; Lopez-Novoa JM, 2011, J TRANSL MED, V9, DOI 10.1186/1479-5876-9-13; Love Michael I, 2014, Genome Biol, V15, P550; Lowik MM, 2009, EUR J PEDIATR, V168, P1291, DOI 10.1007/s00431-009-1017-x; Ma LJ, 2017, J AM SOC NEPHROL, V28, P1093, DOI 10.1681/ASN.2016050567; Ma LJ, 2003, KIDNEY INT, V64, P350, DOI 10.1046/j.1523-1755.2003.00058.x; Nacionales DC, 2007, ARTHRITIS RHEUM, V56, P3770, DOI 10.1002/art.23023; Nakagawa N, 2016, JCI INSIGHT, V1, DOI 10.1172/jci.insight.87446; Neilson EG, 2006, NAT CLIN PRACT NEPHR, V2, P101, DOI 10.1038/ncpneph0093; Ng ACH, 2014, MOL CELL BIOL, V34, P1427, DOI 10.1128/MCB.01021-13; Niaudet P, 1997, KIDNEY INT, V51, P1000, DOI 10.1038/ki.1997.140; Niemir ZI, 1997, KIDNEY INT, V52, P393, DOI 10.1038/ki.1997.346; Park E, 2017, PEDIATR NEPHROL, V32, P1547, DOI 10.1007/s00467-017-3657-9; Park E, 2017, AM J KIDNEY DIS, V70, P139, DOI 10.1053/j.ajkd.2016.10.040; Ray PD, 2012, CELL SIGNAL, V24, P981, DOI 10.1016/j.cellsig.2012.01.008; Roberts TL, 2009, SCIENCE, V323, P1057, DOI 10.1126/science.1169841; Rongvaux A, 2014, CELL, V159, P1563, DOI 10.1016/j.cell.2014.11.037; Santiago-Raber ML, 2003, J EXP MED, V197, P777, DOI 10.1084/jem.20021996; Stokman G, 2017, J EXP MED, V214, P2405, DOI 10.1084/jem.20161031; Subramanian N, 2013, CELL, V153, P348, DOI 10.1016/j.cell.2013.02.054; Sun LJ, 2013, SCIENCE, V339, P786, DOI 10.1126/science.1232458; Sun QM, 2006, IMMUNITY, V24, P633, DOI 10.1016/j.immuni.2006.04.004; Tattoli I, 2008, EMBO REP, V9, P293, DOI 10.1038/sj.embor.7401161; Tsukihara T, 1996, SCIENCE, V272, P1136, DOI 10.1126/science.272.5265.1136; TZAGOLOFF A, 1993, BIOCHEM MOL BIOL INT, V31, P593; Valnot I, 2000, HUM MOL GENET, V9, P1245, DOI 10.1093/hmg/9.8.1245; Vanwalleghem G, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9078; Wang YP, 2017, ONCOTARGET, V8, P53602, DOI 10.18632/oncotarget.18657; West AP, 2017, TOXICOLOGY, V391, P54, DOI 10.1016/j.tox.2017.07.016; West AP, 2015, NATURE, V520, P553, DOI 10.1038/nature14156; White MJ, 2014, CELL, V159, P1549, DOI 10.1016/j.cell.2014.11.036; Wu JX, 2013, SCIENCE, V339, P826, DOI 10.1126/science.1229963	92	1	1	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	DEC	2018	188	12					2745	2762		10.1016/j.ajpath.2018.08.018			18	Pathology	Pathology	HF4EX	WOS:000454187100004	30268775				2019-10-28	
J	Zhang, YL; Thai, K; Kepecs, DM; Winer, D; Gilbert, RE				Zhang, Yanling; Thai, Kerni; Kepecs, David M.; Winer, Daniel; Gilbert, Richard E.			Reversing CXCL10 Deficiency Ameliorates Kidney Disease in Diabetic Mice	AMERICAN JOURNAL OF PATHOLOGY			English	Article							GROWTH-FACTOR-BETA; CHEMOKINE CXCL10; RENAL INJURY; MOUSE MODEL; INHIBITION; MECHANISMS; HYPERGLYCEMIA; NEPHROPATHY; PROGRESSION; FIBROSIS	The excessive accumulation of extracellular matrix material in the kidney is a histopathologic hallmark of diabetic kidney disease that correlates closely with declining function. Although considerable research has focused on the role of profibrotic factors, comparatively little attention has been paid to the possibility that a diminution in endogenous antifibrotic factors may also contribute. Among the latter, the ELR- CXC chemokines, CXCL9, CXCL10, and CXCL11, have been shown to provide a stop signal to prevent excessive fibrosis. Although the plasma concentrations of CXCL9 and CXCL11 were similar, those of CXCL10 were markedly lower in diabetic db/db mice compared with control db/m mice. In cell culture, CXCL10 inhibited kidney fibroblast collagen production in response to high glucose and the prosclerotic growth factor, transforming growth factor-beta. In vivo, recombinant murine CXCL10 reduced mesangial and peritubular matrix expansion, albuminuria, and glomerular hypertrophy in db/db mice. In bone marrow, a major source of circulating chemokines, the concentration of CXCL10 was lower in cells derived from diabetic mice than from their nondiabetic counterparts. Silencing of CXCR3, the cognate receptor for CXCL10, abrogated the antifibrotic effects of bone marrow derived secretions. In conclusion, experimental diabetes is a state of CXCL10 deficiency and that restoration of CXCL10 abundance prevented fibrosis and the development of diabetic kidney disease in mice.	[Zhang, Yanling; Thai, Kerni; Kepecs, David M.; Gilbert, Richard E.] St Michaels Hosp, Li Ka Shing Knowledge Inst, Keenan Res Ctr, Toronto, ON, Canada; [Winer, Daniel] TGHRI, Toronto, ON, Canada	Gilbert, RE (reprint author), St Michaels Hosp, 61 Queen St East, Toronto, ON M5C 2T2, Canada.	richard.gilbert@utoronto.ca			Kidney Foundation of Canada [KFOC160006]; Heart and Stroke Foundation of CanadaHeart & Stroke Foundation of Canada [000255]; Ontario Research Foundation (SCORR-ORF); Canada Research Chairs ProgramCanada Research Chairs	Supported by Kidney Foundation of Canada grant KFOC160006, Heart and Stroke Foundation of Canada grant 000255, the Ontario Research Foundation (SCORR-ORF), and the Canada Research Chairs Program (R.E.G.). R.E.G. is the Canada Research Chair in Diabetes Complications.	Advani A, 2007, P NATL ACAD SCI USA, V104, P14448, DOI 10.1073/pnas.0703577104; Alpers CE, 2011, CURR OPIN NEPHROL HY, V20, P278, DOI 10.1097/MNH.0b013e3283451901; Anders HJ, 2011, KIDNEY INT, V80, P915, DOI 10.1038/ki.2011.217; Antonelli A, 2014, AUTOIMMUN REV, V13, P272, DOI 10.1016/j.autrev.2013.10.010; BADER R, 1980, PATHOL RES PRACT, V167, P204, DOI 10.1016/S0344-0338(80)80051-3; Blobe GC, 2000, NEW ENGL J MED, V342, P1350, DOI 10.1056/NEJM200005043421807; Bone-Larson CL, 2001, J IMMUNOL, V167, P7077, DOI 10.4049/jimmunol.167.12.7077; Braga TT, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00602; Brosius FC, 2009, J AM SOC NEPHROL, V20, P2503, DOI 10.1681/ASN.2009070721; Casrouge A, 2011, J CLIN INVEST, V121, P308, DOI 10.1172/JCI40594; Chan CC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050577; Committee for the Update of the Guide for the Care and Use of Laboratory Animals:National Research Council:, 2011, GUIDE CARE USE LAB A; Decalf J, 2016, EMBO MOL MED, V8, P679, DOI 10.15252/emmm.201506145; Decleves AE, 2014, NAT REV NEPHROL, V10, P257, DOI 10.1038/nrneph.2014.31; Fadini GP, 2014, STEM CELL TRANSL MED, V3, P949, DOI 10.5966/sctm.2014-0052; Fine LG, 2008, KIDNEY INT, V74, P867, DOI 10.1038/ki.2008.350; Gilbert RE, 2015, DIABETOLOGIA, V58, P819, DOI 10.1007/s00125-014-3485-4; Jiang DH, 2010, J CLIN INVEST, V120, P2049, DOI 10.1172/JCI38644; Kosanam H, 2014, DIABETES, V63, P2432, DOI 10.2337/db12-1770; Ma LJ, 2009, FRONT BIOSCI-LANDMRK, V14, P2028, DOI 10.2741/3361; Masszi A, 2010, J CELL BIOL, V188, P383, DOI 10.1083/jcb.200906155; MAUER SM, 1984, J CLIN INVEST, V74, P1143, DOI 10.1172/JCI111523; McLennan SV, 2002, DIABETOLOGIA, V45, P268, DOI 10.1007/s00125-001-0730-4; Meissner EG, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0133236; Nakamura T, 2007, GASTROENTEROLOGY, V133, P91, DOI 10.1053/j.gastro.2007.03.110; Nakaya I, 2007, NEPHRON EXP NEPHROL, V107, pE12, DOI 10.1159/000106505; Njoku DB, 2009, J AUTOIMMUN, V32, P52, DOI 10.1016/j.jaut.2008.11.003; Pala L, 2005, DIABETOLOGIA, V48, P1168, DOI 10.1007/s00125-005-1749-8; Pelus LM, 2002, CRIT REV ONCOL HEMAT, V43, P257, DOI 10.1016/S1040-8428(01)00202-5; Proost P, 2001, BLOOD, V98, P3554, DOI 10.1182/blood.V98.13.3554; Rossi D, 2000, ANNU REV IMMUNOL, V18, P217, DOI 10.1146/annurev.immunol.18.1.217; Sakharova OV, 2001, CURR OPIN NEPHROL HY, V10, P727, DOI 10.1097/00041552-200111000-00001; Saxena A, 2014, CARDIOVASC RES, V103, P217, DOI 10.1093/cvr/cvu138; Tager AM, 2004, AM J RESP CELL MOL, V31, P395, DOI 10.1165/rcmb.2004-0175OC; Tampe D, 2014, NAT REV NEPHROL, V10, P226, DOI 10.1038/nrneph.2014.14; Tomankova T, 2015, AM J PHYSIOL-LUNG C, V308, pL603, DOI 10.1152/ajplung.00203.2014; van den Borne P, 2014, BIOMED RES INT, DOI 10.1155/2014/893106; Wu LL, 1997, KIDNEY INT, V51, P1553, DOI 10.1038/ki.1997.214; Wynn TA, 2007, J CLIN INVEST, V117, P524, DOI 10.1172/JCI31487; Yates CC, 2011, CELL MOL LIFE SCI, V68, P1871, DOI 10.1007/s00018-011-0663-0; Yuen DA, 2013, STEM CELLS, V31, P2408, DOI 10.1002/stem.1502; Yuen DA, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009543; Zhang YL, 2017, AM J PATHOL, V187, P80, DOI 10.1016/j.ajpath.2016.09.016; Zhang YL, 2012, DIABETES, V61, P2114, DOI 10.2337/db11-1365	44	0	0	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	DEC	2018	188	12					2763	2773		10.1016/j.ajpath.2018.08.017			11	Pathology	Pathology	HF4EX	WOS:000454187100005	30273603				2019-10-28	
J	Motawea, HKB; Chotani, MA; Ali, M; Ackerman, W; Zhao, GM; Ahmed, AAE; Buhimschi, CS; Buhimschi, IA				Motawea, Hanaa K. B.; Chotani, Maqsood A.; Ali, Mehboob; Ackerman, William; Zhao, Guomao; Ahmed, Amany A. E.; Buhimschi, Catalin S.; Buhimschi, Irina A.			Human Placenta Expresses alpha(2)-Adrenergic Receptors and May Be Implicated in Pathogenesis of Preeclampsia and Fetal Growth Restriction	AMERICAN JOURNAL OF PATHOLOGY			English	Article							CELL-SURFACE; ALPHA(2C)-ADRENOCEPTORS; LOCALIZATION; TROPHOBLAST; SUBTYPES; DIFFERENTIATION; TRANSLOCATION; TRAFFICKING; SYNCYTIUM; WOMEN	alpha(2)-Adrenergic receptors (alpha(2)ARs) are G-protein coupled receptors involved in catecholamine signaling by extracellular regulated protein kinase 1 and 2 (ERK1/2) pathways. We examined placental expression and function of alpha(2)AR subtypes in women with severe preeclampsia (sPE) with and without intrauterine growth restriction (IUGR). Placental biopsies were analyzed from 52 women with i) sPE (n = 8); ii) sPE + IUGR (n = 9); iii) idiopathic IUGR (n = 8); iv) idiopathic preterm birth (n = 16); and v) healthy term controls (n = 11). Expression of alpha(2)AR subtypes (alpha(2A), alpha(2B), alpha(2C)) and phospho-ERK1/2 (receptor activation marker) was investigated by immunohistochemistry and/or quantitative real-time RT-PCR. The effects of alpha(2C)AR knockdown on syncytialization (syncytin-1 and-2) and beta-human chorionic gonadotropin secretion were examined in BeWo cells stimulated with forskolin. The effects of alpha(2)AR agonist UK 14,304 and specific alpha(2C)AR antagonist were tested, using a trophoblast migration assay. All three alpha(2)ARs were expressed and functionally active in human placenta with site-specific localization. Highest alpha(2B)AR and alpha(2C)AR mRNA expression was identified in sPE + IUGR. alpha(2C)AR knockdown increased expression of syncytin-1 and -2 but decreased secretion of beta-human chorionic gonadotropin. UK 14,304 impaired trophoblast migration. The observed alpha(2)AR expression pattern suggests different function for each subtype. alpha(2)cAR modulates trophoblast syncytialization and migration and may carry pathogenic role in sPE + IUGR.	[Motawea, Hanaa K. B.; Ali, Mehboob; Ackerman, William; Zhao, Guomao; Buhimschi, Catalin S.; Buhimschi, Irina A.] Nationwide Childrens Hosp, Ctr Perinatal Res, Res Inst, 700 Childrens Dr, Columbus, OH 43215 USA; [Motawea, Hanaa K. B.; Ahmed, Amany A. E.] Helwan Univ, Fac Pharm, Cairo, Egypt; [Chotani, Maqsood A.] Univ Karachi, Int Ctr Chem & Biol Sci, Dr Panjwani Ctr Mol Med & Drug Res, Karachi, Pakistan; [Buhimschi, Catalin S.] Ohio State Univ, Coll Med, Dept Obstet & Gynecol, Columbus, OH 43210 USA; [Buhimschi, Catalin S.; Buhimschi, Irina A.] Nationwide Childrens Hosp, Dept Pediat, Columbus, OH 43215 USA	Buhimschi, IA (reprint author), Nationwide Childrens Hosp, Ctr Perinatal Res, Res Inst, 700 Childrens Dr, Columbus, OH 43215 USA.	irina.buhimschi@nationwidechildrens.org		Ackerman, William/0000-0001-7366-3903; Buhimschi, Irina/0000-0002-1701-1326; Ali, Mehboob/0000-0003-1657-7245	NIH/Eunice Kennedy Shriver National Institute of Child Health and Human Development (NIH/NICHD) [R01HD04732]; Center for Perinatal Research at The Research Institute at Nationwide Children's Hospital, Columbus, Ohio; Egyptian Cultural and Educational Bureau, Washington, DCEgyptian Cultural & Educational Bureau; Egyptian Cultural and Educational Sector, Cairo, EgyptEgyptian Cultural & Educational Bureau	Supported by NIH/Eunice Kennedy Shriver National Institute of Child Health and Human Development (NIH/NICHD) grant R01HD04732 (I.A.B.); the Center for Perinatal Research at The Research Institute at Nationwide Children's Hospital, Columbus, Ohio; and the graduate training Joint Supervision Program supported by The Egyptian Cultural and Educational Bureau, Washington, DC, and Egyptian Cultural and Educational Sector, Cairo, Egypt (H.K.B.M.).	Ali M, 2016, MOL CANCER THER, V15, P2220, DOI 10.1158/1535-7163.MCT-16-0092; American College of Obstetricians and Gynecologists, 2009, Obstet Gynecol, V113, P451, DOI 10.1097/AOG.0b013e31819930b0; [Anonymous], 2002, OBSTET GYNECOL, V99, P159; Bagamery K, 1999, ACTA OBSTET GYN SCAN, V78, P89, DOI 10.1034/j.1600-0412.1999.780203.x; Bailey SR, 2004, CIRC RES, V94, P1367, DOI 10.1161/01.RES.0000128407.45014.58; Brede M, 2004, BIOL CELL, V96, P343, DOI 10.1016/j.biolcel.2004.03.006; Castellucci M, 2000, HUM REPROD UPDATE, V6, P485, DOI 10.1093/humupd/6.5.485; CASTELLUCCI M, 1990, ANAT EMBRYOL, V181, P117; Chotani MA, 2004, AM J PHYSIOL-HEART C, V286, pH59, DOI 10.1152/ajpheart.00268.2003; Chotani MA, 2011, BBA-MOL CELL RES, V1813, P1495, DOI 10.1016/j.bbamcr.2011.05.006; Crassous PA, 2007, CURR TOP MED CHEM, V7, P187, DOI 10.2174/156802607779318190; Daunt DA, 1997, MOL PHARMACOL, V51, P711; Delidaki M, 2011, MOL CELL ENDOCRINOL, V332, P213, DOI 10.1016/j.mce.2010.10.013; FALKAY G, 1994, PLACENTA, V15, P661, DOI 10.1016/S0143-4004(05)80412-6; FALKAY G, 1994, J RECEPTOR RES, V14, P187, DOI 10.3109/10799899409066030; FLAVAHAN NA, 1985, AM J PHYSIOL, V249, pH950; Gilbach R, 2012, BRIT J PHARMACOL, V165, P90; Handwerger S, 2010, MOL CELL ENDOCRINOL, V323, P94, DOI 10.1016/j.mce.2009.12.015; Jeyaraj SC, 2001, MOL PHARMACOL, V60, P1195; Jeyaraj SC, 2012, AM J PHYSIOL-CELL PH, V303, pC499, DOI 10.1152/ajpcell.00461.2011; Knerr I, 2005, FEBS LETT, V579, P3991, DOI 10.1016/j.febslet.2005.06.029; Kohli U, 2015, PHYSIOL GENOMICS, V47, P400, DOI 10.1152/physiolgenomics.00124.2014; Kudo Y, 2003, BBA-MOL CELL RES, V1640, P25, DOI 10.1016/S0167-4889(03)00004-1; Lavon H, 2018, BRIT J ANAESTH, V120, P188, DOI 10.1016/j.bja.2017.11.004; Lee X, 2001, PLACENTA, V22, P808, DOI 10.1053/plac.2001.0722; Li HS, 2003, HYPERTENSION, V42, P895, DOI 10.1161/01.HYP.0000095613.41961.6E; Loregger T, 2003, PLACENTA, V24, pS104, DOI 10.1053/plac.2002.0929; Lyall F, 2013, HYPERTENSION, V62, P1046, DOI 10.1161/HYPERTENSIONAHA.113.01892; Manyonda IT, 1998, BRIT J OBSTET GYNAEC, V105, P641, DOI 10.1111/j.1471-0528.1998.tb10179.x; Moety GAFA, 2016, J MATERN-FETAL NEO M, V29, P413, DOI 10.3109/14767058.2014.1002763; Motawea HKB, 2013, AM J PHYSIOL-CELL PH, V305, pC829, DOI 10.1152/ajpcell.00221.2012; Muthig V, 2007, CIRC RES, V101, P682, DOI 10.1161/CIRCRESAHA.107.151563; Neumeister A, 2005, PHARMACOGENET GENOM, V15, P143, DOI 10.1097/01213011-200503000-00002; Newhouse SM, 2007, PLACENTA, V28, P999, DOI 10.1016/j.placenta.2007.04.008; Oliver EA, 2011, J CLIN ENDOCR METAB, V96, P689, DOI 10.1210/jc.2010-1418; Orendi K, 2010, REPRODUCTION, V140, P759, DOI 10.1530/REP-10-0221; Philipp M, 2002, NAT GENET, V31, P311, DOI 10.1038/ng919; Reijnders IF, 2018, ACTA OBSTET GYN SCAN, V97, P248, DOI 10.1111/aogs.13259; Roberts JM, 2013, OBSTET GYNECOL, V122, P1122, DOI 10.1097/01.AOG.0000437382.03963.88; Roland CS, 2016, CELL MOL LIFE SCI, V73, P365, DOI 10.1007/s00018-015-2069-x; Ruebner M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056145; Sarkar S, 2001, AM J PHYSIOL-REG I, V281, pR1966; Saunders C, 1999, PHARMACOL THERAPEUT, V84, P193, DOI 10.1016/S0163-7258(99)00032-7; Soygur B, 2016, REPRODUCTION, V152, pR167, DOI 10.1530/REP-16-0031; Tan CM, 2005, RECEPTORS, P241; UHLEN S, 1994, J PHARMACOL EXP THER, V271, P1558; WICE B, 1990, EXP CELL RES, V186, P306, DOI 10.1016/0014-4827(90)90310-7; Wright JD, 2013, OBSTET GYNECOL, V121, P1217, DOI [10.1097/AOG.0b013e31828ec686, 10.1097/01.AOG.0000429658.85846.f9]	48	0	0	1	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	DEC	2018	188	12					2774	2785		10.1016/j.ajpath.2018.08.011			12	Pathology	Pathology	HF4EX	WOS:000454187100006	30273604				2019-10-28	
J	Liu, J; Wu, MJ; He, JX; Xiao, CJ; Xue, YX; Fu, T; Lin, CP; Dong, D; Li, ZJ				Liu, Jun; Wu, Mingjuan; He, Jingxin; Xiao, Chengju; Xue, Yunxia; Fu, Ting; Lin, Cuipei; Dong, Dong; Li, Zhijie			Antibiotic-Induced Dysbiosis of Gut Microbiota L Impairs Corneal Nerve Regeneration by Affecting CCR2-Negative Macrophage Distribution	AMERICAN JOURNAL OF PATHOLOGY			English	Article							DELTA-T-CELLS; EPITHELIAL ABRASION; PERIPHERAL-NERVES; PROBIOTICS; BRAIN; HEMATOPOIESIS; DEGENERATION; INFLAMMATION; RECRUITMENT; RESIDENT	Although antibiotics are useful, they can also bring negative effects. We found that antibiotic-treated mice exhibit an alteration in the gene expression profile of corneal tissues and a decrease in corneal nerve density. During corneal wound healing, antibiotic treatment was found to impair corneal nerve regeneration, an effect that could be largely reversed by reconstitution of the gut microbiota via fecal transplant. Furthermore, CCR2(-) corneal macrophages were found to participate in the repair of damaged corneal nerves, and a decrease in CCR2(-) corneal macrophages in antibiotic-treated mice, which could be reversed by fecal transplant, was observed. Adoptive transfer of CCR2(-) corneal macrophages promoted corneal nerve regeneration in antibiotic-treated mice. The application of probiotics after administration of antibiotics also restored the proportion of CCR2(-) corneal macrophages and increased the regeneration of corneal nerve fibers after epithelial abrasion. These results suggest that dysbiosis of the gut microbiota induced by antibiotic treatment impairs corneal nerve regeneration by affecting CCR2(-) macrophage distribution in the cornea. This study also indicates the potential of probiotics as a therapeutic strategy for promoting the regeneration of damaged corneal nerve fibers when the gut microbiota is in dysbiosis.	[Liu, Jun] Jinan Univ, Minist Educ, Integrated Chinese & Western Med Postdoctoral Res, Guangzhou, Guangdong, Peoples R China; [Liu, Jun; Wu, Mingjuan; Xiao, Chengju; Li, Zhijie] Jinan Univ, Minist Educ, Key Lab Regenerat Med, Guangzhou, Guangdong, Peoples R China; [Liu, Jun; He, Jingxin; Xue, Yunxia; Fu, Ting; Lin, Cuipei; Dong, Dong; Li, Zhijie] Jinan Univ, Med Sch, Int Ocular Surface Res Ctr, Guangzhou 510632, Guangdong, Peoples R China; [Liu, Jun; He, Jingxin; Xue, Yunxia; Fu, Ting; Lin, Cuipei; Dong, Dong; Li, Zhijie] Jinan Univ, Med Sch, Inst Ophthalmol, Guangzhou 510632, Guangdong, Peoples R China; [Li, Zhijie] Henan Prov Peoples Hosp, Dept Ophthalmol, Zhengzhou, Henan, Peoples R China; [Li, Zhijie] Baylor Coll Med, Childrens Nutr Res Ctr, Dept Pediat, Sect Leukocyte Biol, Houston, TX 77030 USA	Li, ZJ (reprint author), Jinan Univ, Med Sch, Int Ocular Surface Res Ctr, Guangzhou 510632, Guangdong, Peoples R China.; Li, ZJ (reprint author), Jinan Univ, Med Sch, Inst Ophthalmol, Guangzhou 510632, Guangdong, Peoples R China.	tzhijieli@jnu.edu.cn			National Natural Science Foundation of ChinaNational Natural Science Foundation of China [81470603, 81770962, 81700808]; Ph.D. Start-up Fund of the Natural Science Foundation of Guangdong Province of China [2018A030310605]; China Postdoctoral Science FoundationChina Postdoctoral Science Foundation [2017M622913]; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [5R0IEY018239-08]	Supported by National Natural Science Foundation of China grants 81470603 (Z.L.), 81770962 (Z.L.), and 81700808 (Y.X.); Ph.D. Start-up Fund of the Natural Science Foundation of Guangdong Province of China grant 2018A030310605 (J.L.); China Postdoctoral Science Foundation grant 2017M622913 (J.L.); and NIH grant 5R0IEY018239-08 (C.W.S.).	Allen S. J., 2010, COCHRANE DB SYST REV, V2010; Anitha M, 2012, GASTROENTEROLOGY, V143, P1006, DOI 10.1053/j.gastro.2012.06.034; Appleyard CB, 2011, AM J PHYSIOL-GASTR L, V301, pG1004, DOI 10.1152/ajpgi.00167.2011; BAKER KS, 1993, INVEST OPHTH VIS SCI, V34, P137; Barrette B, 2008, J NEUROSCI, V28, P9363, DOI 10.1523/JNEUROSCI.1447-08.2008; Bassaganya-Riera J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031238; Bercik P, 2014, ADV EXP MED BIOL, V817, P279, DOI 10.1007/978-1-4939-0897-4_13; BEUCHE W, 1984, J NEUROCYTOL, V13, P767, DOI 10.1007/BF01148493; Byeseda SE, 2009, AM J PATHOL, V175, P571, DOI 10.2353/ajpath.2009.090112; Chen PW, 2015, ACTA NEUROPATHOL, V129, P97, DOI 10.1007/s00401-014-1369-9; Chucair-Elliott AJ, 2015, INVEST OPHTH VIS SCI, V56, P1097, DOI 10.1167/iovs.14-15596; Cryan JF, 2012, NAT REV NEUROSCI, V13, P701, DOI 10.1038/nrn3346; DEUTSCH G, 1975, BRIT J CANCER, V31, P75, DOI 10.1038/bjc.1975.9; Dorrestein PC, 2014, IMMUNITY, V40, P824, DOI 10.1016/j.immuni.2014.05.015; Erny D, 2015, NAT NEUROSCI, V18, P965, DOI 10.1038/nn.4030; GARCIAHIRSCHFELD J, 1994, EXP EYE RES, V59, P597, DOI 10.1006/exer.1994.1145; GRIFFIN JW, 1993, J NEUROPATH EXP NEUR, V52, P553, DOI 10.1097/00005072-199311000-00001; Hamamoto H, 2004, ANTIMICROB AGENTS CH, V48, P774, DOI 10.1128/AAC.48.3.774-779.2004; Horie H, 2004, J NEUROSCI, V24, P1873, DOI 10.1523/JNEUROSCI.4483-03.2004; Ishida Y, 1999, CHEMOTHERAPY, V45, P183, DOI 10.1159/000007181; Jandhyala SM, 2015, WORLD J GASTROENTERO, V21, P8787, DOI 10.3748/wjg.v21.i29.8787; Josefsdottir KS, 2017, BLOOD, V129, P729, DOI 10.1182/blood-2016-03-708594; Kamada N, 2013, NAT REV IMMUNOL, V13, P321, DOI 10.1038/nri3430; Khosravi A, 2014, CELL HOST MICROBE, V15, P374, DOI 10.1016/j.chom.2014.02.006; Kigerl KA, 2009, J NEUROSCI, V29, P13435, DOI 10.1523/JNEUROSCI.3257-09.2009; Li SX, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061799; Li Z, 2007, AM J PATHOL, V171, P838, DOI 10.2353/ajpath.2007.070008; Li ZJ, 2006, INVEST OPHTH VIS SCI, V47, P1947, DOI 10.1167/iovs.05-1193; Li ZJ, 2011, FASEB J, V25, P2659, DOI 10.1096/fj.11-184804; Li ZJ, 2011, AM J PATHOL, V178, P1106, DOI 10.1016/j.ajpath.2010.12.001; Liu J, 2017, MUCOSAL IMMUNOL, V10, P1145, DOI 10.1038/mi.2016.139; Liu Q, 2012, AM J PATHOL, V181, P452, DOI 10.1016/j.ajpath.2012.04.010; Marteau P, 2006, GUT, V55, P1692, DOI 10.1136/gut.2004.051458; Meijer BJ, 2011, J CLIN GASTROENTEROL, V45, pS139, DOI 10.1097/MCG.0b013e31822103f7; Moayyedi P, 2010, GUT, V59, P325, DOI 10.1136/gut.2008.167270; Mohle L, 2016, CELL REP, V15, P1945, DOI 10.1016/j.celrep.2016.04.074; Morgun A, 2015, GUT, V64, P1732, DOI 10.1136/gutjnl-2014-308820; Mostafa S, 2014, J CLIN PSYCHOPHARM, V34, P483, DOI 10.1097/JCP.0000000000000150; Mueller M, 2003, LAB INVEST, V83, P175, DOI 10.1097/01.LAB.0000056993.28149.BF; Muller LJ, 2003, EXP EYE RES, V76, P521, DOI 10.1016/S0014-4835(03)00050-2; Niemi JP, 2013, J NEUROSCI, V33, P16236, DOI 10.1523/JNEUROSCI.3319-12.2013; O'Hara AM, 2006, EMBO REP, V7, P688, DOI 10.1038/sj.embor.7400731; Parra A, 2010, NAT MED, V16, P1396, DOI 10.1038/nm.2264; PERRY VH, 1992, BIOESSAYS, V14, P401, DOI 10.1002/bies.950140610; Rao S, 2011, SCAND J INFECT DIS, V43, P386, DOI 10.3109/00365548.2010.544671; REID TW, 1993, J CELL BIOCHEM, V52, P476, DOI 10.1002/jcb.240520411; Round JL, 2009, NAT REV IMMUNOL, V9, P313, DOI 10.1038/nri2515; Sampson TR, 2015, CELL HOST MICROBE, V17, P565, DOI 10.1016/j.chom.2015.04.011; Sunderland S, 1979, Adv Neurol, V22, P271; VANDERWA.D, 1974, J HYG-CAMBRIDGE, V73, P197, DOI 10.1017/S0022172400024025; Wu HJ, 2010, IMMUNITY, V32, P815, DOI 10.1016/j.immuni.2010.06.001; Wu JJ, 2017, J NEUROINFLAMM, V14, DOI 10.1186/s12974-017-0828-3	52	0	0	0	6	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	DEC	2018	188	12					2786	2799		10.1016/j.ajpath.2018.08.009			14	Pathology	Pathology	HF4EX	WOS:000454187100007	30470496	Other Gold			2019-10-28	
J	Garcia-Monzon, C; Petrov, PD; Rey, E; Maranon, P; del Pozo-Maroto, E; Guzman, C; de Cia, JR; Casado-Collado, AJ; Vargas-Castrillon, J; Saez, A; Miguilena-Colina, ME; Lo Iacono, O; Castell, JV; Gonzalez-Rodriguez, A; Jover, R				Garcia-Monzon, Carmelo; Petrov, Petar D.; Rey, Esther; Maranon, Patricia; del Pozo-Maroto, Elvira; Guzman, Carla; Rodriguez de Cia, Javier; Casado-Collado, Alfonso J.; Vargas-Castrillon, Javier; Saez, Alicia; Miguilena-Colina, Maria E.; Lo Iacono, Oreste; Castell, Jose V.; Gonzalez-Rodriguez, Agueda; Jover, Ramiro			Angiopoietin-Like Protein 8 Is a Novel Vitamin D Receptor Target Gene Involved in Nonalcoholic Fatty Liver Pathogenesis	AMERICAN JOURNAL OF PATHOLOGY			English	Article							TRIGLYCERIDE-METABOLISM; ANGPTL8 BETATROPHIN; INSULIN-RESISTANCE; DISEASE; STEATOHEPATITIS; EXPRESSION; NAFLD; PREVALENCE; DIAGNOSIS; HISTOLOGY	Hepatic vitamin D receptor (VDR) expression is increased in patients with nonalcoholic fatty liver (NAFL) and is required for liver steatosis in an NAFL mouse model. However, how hepatocyte VDR is involved in setting up steatosis remains unclear. The authors transduced human hepatocyte-erived cells with an adenoviral vector encoding human VDR and found that angiopoietin-like protein 8 (ANGPTL8) expression was increased upon VDR activation by vitamin D or lithocholic acid. The mRNA levels of hepatic VDR and vitamin D related genes [cytochrome P450 (CYP) 2R1, CYP27A1, and CYP3A4] were higher in NAFL patients compared with normal liver subjects. Noteworthy, hepatic ANGPTL8 mRNA and protein levels were elevated in NAFL patients, and its mRNA correlated with VDR mRNA and with the steatosis grade. Moreover, increases in serum conjugated bile acids, including the VDR agonist glycine-lithocholic acid, were observed in NAFL patients. Additionally, free fatty acids and insulin were able to up-regulate both VDR and ANGPTL8 mRNA in human hepatocytes, whereas ANGPTL8 gene knockdown attenuated free fatty acids induced triglyceride accumulation in these cells. In conclusion, activated VDR up-regulates ANGPTL8 expression, contributing to triglyceride accumulation in human hepatocytes. Moreover, hepatic ANGPTL8 mRNA positively correlates with VDR mRNA content and the grade of steatosis in NAFL patients, suggesting that this novel pathway may play a key role in the pathogenesis of hepatosteatosis.	[Garcia-Monzon, Carmelo; Rey, Esther; Maranon, Patricia; del Pozo-Maroto, Elvira; Rodriguez de Cia, Javier; Casado-Collado, Alfonso J.; Vargas-Castrillon, Javier; Saez, Alicia; Miguilena-Colina, Maria E.; Gonzalez-Rodriguez, Agueda] Santa Cristina Univ Hosp, Inst Invest Sanitaria Princesa, Liver Res Unit, Madrid, Spain; [Garcia-Monzon, Carmelo; Petrov, Petar D.; Rey, Esther; Maranon, Patricia; del Pozo-Maroto, Elvira; Rodriguez de Cia, Javier; Vargas-Castrillon, Javier; Saez, Alicia; Castell, Jose V.; Gonzalez-Rodriguez, Agueda; Jover, Ramiro] CIBEREHD, Madrid, Spain; [Lo Iacono, Oreste] Hosp Tajo, Gastroenterol Unit, Madrid, Spain; [Petrov, Petar D.; Guzman, Carla; Castell, Jose V.; Jover, Ramiro] Inst Invest Sanitaria La Fe, Expt Hepatol Unit, Valencia, Spain; [Castell, Jose V.; Jover, Ramiro] Univ Valencia, Dept Bioquim & Biol Mol, Valencia, Spain	Garcia-Monzon, C (reprint author), Santa Cristina Univ Hosp, Inst Invest Sanitaria Princesa, Liver Res Unit, CIBEREHD, C Maestro Vives 2, Madrid 28009, Spain.	cgmonzon@salud.madrid.org	JOVER, RAMIRO/P-7602-2019	JOVER, RAMIRO/0000-0002-4914-5804; Casado Collado, Alfonso Jaime/0000-0002-6542-8513	Institute de Salud Carlos HI, Spain [PI13/01299, PI17/00535, CP14/00181, PI16/00823, PI13/01470, PI17/01089]; European FEDEREuropean Union (EU); Instituto de Salud Carlos III, SpainInstituto de Salud Carlos III	Supported by Institute de Salud Carlos HI, Spain, grants PI13/01299 and PI17/00535 (C.G.-M.), grants CP14/00181 and PI16/00823 (A.G.-R.), and grants PI13/01470 and PI17/01089 (R.J.), all cofunded with European FEDER contribution, and by a CIBEREHD contract funded by the Instituto de Salud Carlos III, Spain (P.D.P.).	Barchetta I, 2012, HEPATOLOGY, V56, P2180, DOI 10.1002/hep.25930; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Bozic M, 2016, J HEPATOL, V65, P748, DOI 10.1016/j.jhep.2016.05.031; Bril F, 2015, J HEPATOL, V62, P405, DOI 10.1016/j.jhep.2014.08.040; Brunt EM, 1999, AM J GASTROENTEROL, V94, P2467, DOI 10.1016/S0002-9270(99)00433-5; Chalasani N, 2012, GASTROENTEROLOGY, V142, P1592, DOI 10.1053/j.gastro.2012.04.001; EASL, 2016, DIABETOLOGIA, V59, P1121, DOI [10.1007/s00125-016-3902-y, 10.1016/j.jhep.2015.11.004]; Eliades M, 2013, ALIMENT PHARM THER, V38, P246, DOI 10.1111/apt.12377; Garcia-Canaveras JC, 2012, J LIPID RES, V53, P2231, DOI 10.1194/jlr.D028803; Garcia-Monzon C, 2015, LIVER INT, V35, P1983, DOI 10.1111/liv.12813; Grundy SM, 2002, CIRCULATION, V106, P3143, DOI 10.1161/circ.106.25.3143; Hazlehurst JM, 2013, EUR J ENDOCRINOL, V169, pR27, DOI 10.1530/EJE-13-0296; Kwok RM, 2013, HEPATOLOGY, V58, P1166, DOI 10.1002/hep.26390; Lee YH, 2016, SCI REP-UK, V6, DOI 10.1038/srep24013; Loomba R, 2016, AM J GASTROENTEROL, V111, P986, DOI 10.1038/ajg.2016.65; Masuoka HC, 2013, ANN NY ACAD SCI, V1281, P106, DOI 10.1111/nyas.12016; MATTHEWS DR, 1985, DIABETOLOGIA, V28, P412, DOI 10.1007/BF00280883; Mattijssen F, 2012, BBA-MOL CELL BIOL L, V1821, P782, DOI 10.1016/j.bbalip.2011.10.010; Mele C, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-03538-7; Nakano T, 2011, J HEPATOL, V55, P415, DOI 10.1016/j.jhep.2010.11.028; Nelson JE, 2016, AM J GASTROENTEROL, V111, P852, DOI 10.1038/ajg.2016.51; Patel YA, 2016, AM J GASTROENTEROL, V111, P1591, DOI 10.1038/ajg.2016.406; Rosen CJ, 2011, NEW ENGL J MED, V364, P248, DOI 10.1056/NEJMcp1009570; Salamone F, 2010, J HEPATOL, V53, P1146, DOI 10.1016/j.jhep.2010.06.013; Targher G, 2007, NUTR METAB CARDIOVAS, V17, P517, DOI 10.1016/j.numecd.2006.04.002; Than NN, 2015, ATHEROSCLEROSIS, V239, P192, DOI 10.1016/j.atherosclerosis.2015.01.001; von Loeffelholz C, 2017, HORM METAB RES, V49, P343, DOI 10.1055/s-0043-102950; Wang Y, 2013, P NATL ACAD SCI USA, V110, P16109, DOI 10.1073/pnas.1315292110; Younossi ZM, 2016, HEPATOLOGY, V64, P73, DOI 10.1002/hep.28431; Zhang R, 2016, OPEN BIOL, V6, DOI 10.1098/rsob.150272; Zhang R, 2013, BIOCHEM BIOPH RES CO, V432, P401, DOI 10.1016/j.bbrc.2013.01.129; Zhang Y, 2016, BBA-MOL CELL BIOL L, V1861, P130, DOI 10.1016/j.bbalip.2015.11.003	32	1	1	1	9	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	DEC	2018	188	12					2800	2810		10.1016/j.ajpath.2018.07.028			11	Pathology	Pathology	HF4EX	WOS:000454187100008	30248338	Bronze			2019-10-28	
J	Montrose, DC; Zhou, XK; McNally, EM; Sue, E; Wang, HH; Nishiguchi, R; Verma, A; Elemento, O; Simpson, KW; Yang, PY; Hla, T; Dannenberg, AJ				Montrose, David C.; Zhou, Xi K.; McNally, Erin M.; Sue, Erika; Wang, Hanhan; Nishiguchi, Ryohei; Verma, Akanksha; Elemento, Olivier; Simpson, Kenneth W.; Yang, Peiying; Hla, Timothy; Dannenberg, Andrew J.			Colonoscopic-Guided Pinch Biopsies in Mice as a Useful Model for Evaluating the Roles of Host and Luminal Factors in Colonic Inflammation	AMERICAN JOURNAL OF PATHOLOGY			English	Article							FORMYL PEPTIDE RECEPTOR; SPHINGOSINE 1-PHOSPHATE; CELL EXTRUSION; BOWEL-DISEASE; COLITIS; MUCOSAL; SPHINGOSINE-1-PHOSPHATE; BACTERIA; REQUIRES; ACTIVATION	Colonic inflammation, a hallmark of inflammatory bowel disease, can be influenced by host intrinsic and extrinsic factors. There continues to be a need for models of colonic inflammation that can both provide insights into disease pathogenesis and be used to investigate potential therapies. Herein, we tested the utility of colonoscopic-guided pinch biopsies in mice for studying colonic inflammation and its treatment. Gene expression profiling of colonic wound beds after injury showed marked changes, including increased expression of genes important for the inflammatory response. Interestingly, many of these gene expression changes mimicked those alterations found in inflammatory bowel disease patients. Biopsy-induced inflammation was associated with increases in neutrophils, macrophages, and natural killer cells. Injury also Led to elevated Levels of sphingosine-1-phosphate (SIP), a bioactive lipid that is an important mediator of inflammation mainly through its receptor, S1P(1). Genetic deletion of S1P(1) in the endothelium did not alter the inflammatory response but Led to increased colonic bleeding. Bacteria invaded into the wound beds, raising the possibility that microbes contributed to the observed changes in mucosal gene expression. In support of this, reducing bacterial abundance markedly attenuated the inflammatory response to wounding. Taken together, this study demonstrates the utility of the pinch biopsy model of colonic injury to elucidate the molecular underpinnings of colonic inflammation and its treatment.	[Montrose, David C.; McNally, Erin M.; Sue, Erika; Nishiguchi, Ryohei; Dannenberg, Andrew J.] Weill Cornell Med, Dept Med, 525 E 68th St,Room E-806, New York, NY 10065 USA; [Zhou, Xi K.; Wang, Hanhan] Weill Cornell Med, Dept Healthcare Policy & Res, New York, NY 10065 USA; [Verma, Akanksha; Elemento, Olivier] Weill Cornell Med, Dept Physiol & Biophys, New York, NY 10065 USA; [Simpson, Kenneth W.] Cornell Univ, Coll Vet Med, Dept Clin Sci, Ithaca, NY 14853 USA; [Yang, Peiying] Univ Texas MD Anderson Canc Ctr, Dept Palliat Rehabil & Integrat Med, Houston, TX 77030 USA; [Hla, Timothy] Boston Childrens Hosp, Vasc Biol Program, Boston, MA USA; [Hla, Timothy] Harvard Med Sch, Dept Surg, Boston, MA USA	Montrose, DC (reprint author), Weill Cornell Med, Dept Med, 525 E 68th St,Room E-806, New York, NY 10065 USA.; Dannenberg, AJ (reprint author), Weill Cornell Med, Dept Med, 525 E 68th St,Room E-803, New York, NY 10065 USA.	dam2040@med.cornell.edu; ajdannen@med.cornell.edu	Verma, Akanksha/W-1810-2019		New York Crohn's Foundation; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R35 HL135821]	Supported by The New York Crohn's Foundation (A.J.D.) and NIH grant R35 HL135821 (T.H.).	Abt MC, 2012, IMMUNITY, V37, P158, DOI 10.1016/j.immuni.2012.04.011; Alam A, 2014, MUCOSAL IMMUNOL, V7, P645, DOI 10.1038/mi.2013.84; Alam A, 2016, NAT MICROBIOL, V1, DOI [10.1038/NMICROBIOL.2015.21, 10.1038/nmicrobiol.2015.21]; Bassett SA, 2015, NUTRIENTS, V7, P1798, DOI 10.3390/nu7031798; Blaho VA, 2011, CHEM REV, V111, P6299, DOI 10.1021/cr200273u; Chen ML, 2016, INFLAMM BOWEL DIS, V22, P1157, DOI 10.1097/MIB.0000000000000714; Coleman OI, 2018, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01927; Danese S, 2011, NEW ENGL J MED, V365, P1713, DOI 10.1056/NEJMra1102942; Deguchi Y, 2006, ONCOL REP, V16, P699; Doulberis M, 2016, SCAND J GASTROENTERO, V51, P893, DOI 10.3109/00365521.2016.1162325; Eisenhoffer GT, 2012, NATURE, V484, P546, DOI 10.1038/nature10999; El Feghaly RE, 2015, CURR OPIN GASTROEN, V31, P24, DOI 10.1097/MOG.0000000000000131; Eun CS, 2014, INFECT IMMUN, V82, P2239, DOI 10.1128/IAI.01513-13; Galvani S, 2015, SCI SIGNAL, V8, DOI 10.1126/scisignal.aaa2581; Gu YP, 2011, J CELL BIOL, V193, P667, DOI 10.1083/jcb.201010075; Halfvarson J, 2017, NAT MICROBIOL, V2, DOI 10.1038/nmicrobiol.2017.4; Hamilton MJ, 2014, INFLAMM BOWEL DIS, V20, P2364, DOI 10.1097/MIB.0000000000000142; Holgersen K, 2015, J CROHNS COLITIS, V9, P492, DOI 10.1093/ecco-jcc/jjv050; Janeczko S, 2008, VET MICROBIOL, V128, P178, DOI 10.1016/j.vetmic.2007.10.014; Johansson MEV, 2014, GUT, V63, P281, DOI 10.1136/gutjnl-2012-303207; Kleessen B, 2002, SCAND J GASTROENTERO, V37, P1034, DOI 10.1080/003655202320378220; Klesney-Tait J, 2006, NAT IMMUNOL, V7, P1266, DOI 10.1038/ni1411; Kuhn KA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0114195; Law CW, 2014, GENOME BIOL, V15, DOI 10.1186/gb-2014-15-2-r29; Leoni G, 2013, J CLIN INVEST, V123, P443, DOI 10.1172/JCI65831; Manieri NA, 2015, J CLIN INVEST, V125, P3606, DOI 10.1172/JCI81423; McVerry BJ, 2005, CELL SIGNAL, V17, P131, DOI 10.1016/j.cellsig.2004.08.006; Miyoshi H, 2012, SCIENCE, V338, P108, DOI 10.1126/science.1223821; Montrose DC, 2015, PROSTAG OTH LIPID M, V116, P26, DOI 10.1016/j.prostaglandins.2014.10.002; Montrose DC, 2013, J LIPID RES, V54, P843, DOI 10.1194/jlr.M034108; Morrison PJ, 2013, MUCOSAL IMMUNOL, V6, P1143, DOI 10.1038/mi.2013.11; Neurath MF, 2010, GASTROENTEROLOGY, V139, P1837, DOI 10.1053/j.gastro.2010.10.007; Newman AM, 2015, NAT METHODS, V12, P453, DOI [10.1038/NMETH.3337, 10.1038/nmeth.3337]; Nishida A, 2018, CLIN J GASTROENTEROL, V11, P1, DOI 10.1007/s12328-017-0813-5; Pappu R, 2007, SCIENCE, V316, P295, DOI 10.1126/science.1139221; Pascal V, 2017, GUT, V66, P813, DOI 10.1136/gutjnl-2016-313235; Rivera J, 2008, NAT REV IMMUNOL, V8, P753, DOI 10.1038/nri2400; Sanada Y, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023933; Sanchez T, 2004, J CELL BIOCHEM, V92, P913, DOI 10.1002/jcb.20127; Sandborn WJ, 2016, NEW ENGL J MED, V374, P1754, DOI 10.1056/NEJMoa1513248; Scott FL, 2016, BRIT J PHARMACOL, V173, P1778, DOI 10.1111/bph.13476; Seno H, 2009, P NATL ACAD SCI USA, V106, P256, DOI 10.1073/pnas.0803343106; Shaner RL, 2009, J LIPID RES, V50, P1692, DOI 10.1194/jlr.D800051-JLR200; Shaw KA, 2016, GENOME MED, V8, DOI 10.1186/s13073-016-0331-y; Swidsinski A, 2007, GUT, V56, P343, DOI 10.1136/gut.2006.098160; Wang LC, 2009, MICROVASC RES, V77, P39, DOI 10.1016/j.mvr.2008.09.005; Wick EC, 2014, INFLAMM BOWEL DIS, V20, P821, DOI 10.1097/MIB.0000000000000019; Yen D, 2006, J CLIN INVEST, V116, P1310, DOI 10.1172/JCI21404	48	0	0	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	DEC	2018	188	12					2811	2825		10.1016/j.ajpath.2018.08.016			15	Pathology	Pathology	HF4EX	WOS:000454187100009	30273600				2019-10-28	
J	Strowitzki, MJ; Kirchberg, J; Tuffs, C; Schiedeck, M; Ritter, AS; Biller, M; Harnoss, JM; Lasitschka, F; Schmidt, T; Radhakrishnan, P; Ulrich, A; Schneider, M				Strowitzki, Moritz J.; Kirchberg, Johanna; Tuffs, Christopher; Schiedeck, Maximilian; Ritter, Alina S.; Biller, Marvin; Harnoss, Jonathan M.; Lasitschka, Felix; Schmidt, Thomas; Radhakrishnan, Praveen; Ulrich, Alexis; Schneider, Martin			Loss of Prolyl-Hydroxylase 1 Protects against 1 Biliary Fibrosis via Attenuated Activation of Hepatic Stellate Cells	AMERICAN JOURNAL OF PATHOLOGY			English	Article							NF-KAPPA-B; LIVER FIBROSIS; OXYGEN SENSOR; EXPERIMENTAL-MODELS; HYPOXIA; EXPRESSION; DEFICIENCY; MECHANISMS; RESOLUTION; APOPTOSIS	Liver fibrosis, eventually progressing to cirrhosis necessitating liver transplantation, poses a significant clinical problem. Oxygen shortage (hypoxia) and hypoxia-inducible transcription factors (HIFs) have been acknowledged as important drivers of Liver fibrosis. The significance of oxygen-sensing HIF prolyl-ydroxylase (PHD) enzymes in this context has, however, remained elusive. In this study, we demonstrate that loss of PHD1 (PHD1(-/-)) attenuates the development of liver fibrosis in mice subjected to chronic bile duct injury, induced by 3,5-diethoxycarbonyl-1,4-dihydrocollidine. This effect was accompanied with reduced recruitment of inflammatory leukocytes and attenuated occurrence of profibrotic myofibroblasts in PHD1(-/-) livers. Further analyses focused on the significance of PHD1 in the activation of hepatic stellate cells (HSCs), which represent the driving force in liver fibrosis. Primary HSCs isolated from PHD1(-/-) mice displayed significantly attenuated myofibroblast differentiation and profibrogenic properties compared with HSCs isolated from wild-type mice. Consistently, the expression of various profibrogenic and promitogenic factors was reduced in PHD1(-/-) HSCs, without alterations in HIF-1 alpha protein levels. Of importance, PHD1 protein was expressed in HSCs within human livers, and PHD1 transcript expression was significantly increased with disease severity in hepatic tissue from patients with liver fibrosis. Collectively, these findings indicate that PHD1 deficiency protects against liver fibrosis and that these effects are partly due to attenuated activation of HSCs. PHD1 may represent a therapeutic target to alleviate liver fibrosis.	[Strowitzki, Moritz J.; Kirchberg, Johanna; Tuffs, Christopher; Schiedeck, Maximilian; Ritter, Alina S.; Biller, Marvin; Harnoss, Jonathan M.; Schmidt, Thomas; Radhakrishnan, Praveen; Ulrich, Alexis; Schneider, Martin] Univ Hosp Heidelberg, Dept Gen Visceral & Transplantat Surg, Heidelberg, Germany; [Lasitschka, Felix] Univ Hosp Heidelberg, Inst Pathol, Heidelberg, Germany	Schneider, M (reprint author), Heidelberg Univ, Dept Gen Visceral & Transplantat Surg, Neuenheimer Feld 110, D-69120 Heidelberg, Germany.	m.schneider@uni-heidelberg.de	Schmidt, Thomas/Y-8431-2019	Schmidt, Thomas/0000-0002-7166-3675; Strowitzki, Moritz J./0000-0001-6967-9283	German Federal Ministry of Education and Research (BMBF)Federal Ministry of Education & Research (BMBF) [031L0084]; German Research Foundation (DFG)German Research Foundation (DFG) [SCHN 947/4-2, STR 1570/1-1]; Braun Foundation [BBST-D-18-00018]	Supported by the German Federal Ministry of Education and Research (BMBF) grant 031L0084 (M.S.), the German Research Foundation (DFG) grants SCHN 947/4-2 (M.S.) and STR 1570/1-1 (M.J.S.), and the Braun Foundation grant BBST-D-18-00018 (M.J.S.).	[Anonymous], 2011, GUIDE CARE USE LAB A; Aragones J, 2008, NAT GENET, V40, P170, DOI 10.1038/ng.2007.62; Bataller R, 2005, J CLIN INVEST, V115, P209, DOI 10.1172/JCI200524282; Bataller R, 2001, HEPATOLOGY, V33, P956, DOI 10.1053/jhep.2001.23500; Bozova S, 2007, APMIS, V115, P795, DOI 10.1111/j.1600-0463.2007.apm_610.x; Copple BL, 2010, HEPATOL RES, V40, P530, DOI 10.1111/j.1872-034X.2010.00635.x; DESMET VJ, 1994, HEPATOLOGY, V19, P1513, DOI 10.1016/0270-9139(94)90250-X; Fickert P, 2002, AM J PATHOL, V161, P2019, DOI 10.1016/S0002-9440(10)64480-X; Fickert P, 2007, AM J PATHOL, V171, P525, DOI 10.2353/ajpath.2007.061133; Fitzpatrick SF, 2016, BIOCHEM BIOPH RES CO, V474, P579, DOI 10.1016/j.bbrc.2016.04.085; Fong GH, 2008, CELL DEATH DIFFER, V15, P635, DOI 10.1038/cdd.2008.10; Friedman SL, 2008, PHYSIOL REV, V88, P125, DOI 10.1152/physrev.00013.2007; Geerts A, 2001, SEMIN LIVER DIS, V21, P311, DOI 10.1055/s-2001-17550; Guyot C, 2006, INT J BIOCHEM CELL B, V38, P135, DOI 10.1016/j.biocel.2005.08.021; Harnoss JM, 2017, ANN SURG, V265, P782, DOI 10.1097/SLA.0000000000001696; Harnoss JM, 2015, HYPOXIA, V3, P1, DOI 10.2147/HP.S60872; Hintermann E, 2010, J AUTOIMMUN, V35, P424, DOI 10.1016/j.jaut.2010.09.003; Iredale JP, 1998, J CLIN INVEST, V102, P538, DOI 10.1172/JCI1018; JI SC, 1982, P NATL ACAD SCI-BIOL, V79, P5415, DOI 10.1073/pnas.79.17.5415; Kaelin WG, 2008, MOL CELL, V30, P393, DOI 10.1016/j.molcel.2008.04.009; Kennel KB, 2018, J PHYSIOL-LONDON, V596, P3899, DOI 10.1113/JP275327; Lee UE, 2011, BEST PRACT RES CL GA, V25, P195, DOI 10.1016/j.bpg.2011.02.005; Liang YJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042490; Liedtke C, 2013, FIBROGENESIS TISSUE, V6, DOI 10.1186/1755-1536-6-19; Liu W, 2011, PROTEOMICS, V11, P3556, DOI 10.1002/pmic.201100157; Lua I, 2016, J HEPATOL, V64, P1137, DOI 10.1016/j.jhep.2016.01.010; Luedde T, 2011, NAT REV GASTRO HEPAT, V8, P108, DOI 10.1038/nrgastro.2010.213; Manresa MC, 2016, AM J PHYSIOL-GASTR L, V311, pG1076, DOI 10.1152/ajpgi.00229.2016; Mederacke I, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3823; Mollenhauer M, 2012, LANGENBECK ARCH SURG, V397, P1313, DOI 10.1007/s00423-012-0998-5; Moon JO, 2009, AM J PHYSIOL-GASTR L, V296, pG582, DOI 10.1152/ajpgi.90368.2008; Nagy ZB, 2016, PATHOL ONCOL RES, V22, P505, DOI 10.1007/s12253-015-0027-4; Novo E, 2009, INT J BIOCHEM CELL B, V41, P2089, DOI 10.1016/j.biocel.2009.03.010; O'Leary JG, 2008, GASTROENTEROLOGY, V134, P1764, DOI 10.1053/j.gastro.2008.02.028; Oakley F, 2005, AM J PATHOL, V166, P695, DOI 10.1016/S0002-9440(10)62291-2; Rippe RA, 1999, DNA CELL BIOL, V18, P751, DOI 10.1089/104454999314890; Schadde E, 2017, SURGERY, V161, P666, DOI 10.1016/j.surg.2016.05.018; Schneider M, 2010, GASTROENTEROLOGY, V138, P1143, DOI 10.1053/j.gastro.2009.09.057; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; Semenza GL, 2014, ANNU REV PATHOL-MECH, V9, P47, DOI 10.1146/annurev-pathol-012513-104720; Troeger JS, 2012, GASTROENTEROLOGY, V143, P1073, DOI 10.1053/j.gastro.2012.06.036; Vinas O, 2003, HEPATOLOGY, V38, P919, DOI 10.1053/jhep.2003.50392; Walkin L, 2013, FIBROGENESIS TISSUE, V6, DOI 10.1186/1755-1536-6-18; Wang JZ, 2017, SCI REP-UK, V7, DOI 10.1038/srep41038; Weber S, 2008, CLIN LIVER DIS, V12, P747, DOI 10.1016/j.cld.2008.07.012; Wilhelm A, 2016, GUT, V65, P1175, DOI 10.1136/gutjnl-2014-308325; Xu L, 2005, GUT, V54, P142, DOI 10.1136/gut.2004.042127	47	2	2	1	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	DEC	2018	188	12					2826	2838		10.1016/j.ajpath.2018.08.003			13	Pathology	Pathology	HF4EX	WOS:000454187100010	30248340	Bronze			2019-10-28	
J	Kosumi, K; Hamada, T; Koh, H; Borowsky, J; Bullman, S; Twombly, TS; Nevo, D; Masugi, Y; Liu, L; da Silva, A; Chen, Y; Du, CX; Gu, MC; Li, CX; Li, WW; Liu, HL; Shi, Y; Mima, K; Song, MY; Nosho, K; Nowak, JA; Nishihara, R; Baba, H; Zhang, XH; Wu, K; Wang, ML; Huttenhower, C; Garrett, WS; Meyerson, ML; Lennerz, JK; Giannakis, M; Chan, AT; Meyerhardt, JA; Fuchs, CS; Ogino, S				Kosumi, Keisuke; Hamada, Tsuyoshi; Koh, Hideo; Borowsky, Jennifer; Bullman, Susan; Twombly, Tyler S.; Nevo, Daniel; Masugi, Yohei; Liu, Li; da Silva, Annacarolina; Chen, Yang; Du, Chunxia; Gu, Mancang; Li, Chenxi; Li, Wanwan; Liu, Hongli; Shi, Yan; Mima, Kosuke; Song, Mingyang; Nosho, Katsuhiko; Nowak, Jonathan A.; Nishihara, Reiko; Baba, Hideo; Zhang, Xuehong; Wu, Kana; Wang, Molin; Huttenhower, Curtis; Garrett, Wendy S.; Meyerson, Matthew L.; Lennerz, Jochen K.; Giannakis, Marios; Chan, Andrew T.; Meyerhardt, Jeffrey A.; Fuchs, Charles S.; Ogino, Shuji			The Amount of Bifidobacterium Genus in Colorectal Carcinoma Tissue in Relation to Tumor Characteristics and Clinical Outcome	AMERICAN JOURNAL OF PATHOLOGY			English	Article							SIGNET-RING CELL; MOLECULAR-FEATURES; ASPIRIN USE; MICROSATELLITE INSTABILITY; FUSOBACTERIUM-NUCLEATUM; INVERSE PROBABILITY; LACTIC-ACID; CANCER; SURVIVAL; MICROBIOTA	Evidence indicates a complex link between microbiota, tumor characteristics, and host immunity in the tumor microenvironment. In experimental studies, bifidobacteria appear to modulate intestinal epithelial cell differentiation. Accumulating evidence suggests that bifidobacteria may enhance the antitumor immunity and efficacy of immunotherapy. We hypothesized that the amount of bifidobacteria in colorectal carcinoma tissue might be associated with tumor differentiation and higher immune response to colorectal cancer. Using a molecular pathologic epidemiology database of 1313 rectal and colon cancers, we measured the amount of Bifidobacterium DNA in carcinoma tissue by a quantitative PCR assay. The multivariable regression model was used to adjust for potential confounders, including microsatellite instability status, CpG island methylator phenotype, long-interspersed nucleotide element-1 methylation, and KRAS, BRAF, and PIK3CA mutations. Intratumor bifidobacteria were detected in 393 cases (30%). The amount of bifidobacteria was associated with the extent of signet ring cells (P = 0.002). Compared with Bifidobacterium-negative cases, multivariable odd ratios for the extent of signet ring cells were 1.29 (95% CI, 0.74-2.24) for Bifidobacterium-low cases and 1.87 (95% CI, 1.16-3.02) for Bifidobacterium-high cases (P-trend = 0.01). The association between intratumor bifidobacteria and signet ring cells suggests a possible role of bifidobacteria in determining distinct tumor characteristics or as an indicator of dysfunctional mucosal barrier in colorectal cancer.	[Kosumi, Keisuke; Hamada, Tsuyoshi; Koh, Hideo; Borowsky, Jennifer; Twombly, Tyler S.; Masugi, Yohei; Liu, Li; da Silva, Annacarolina; Chen, Yang; Du, Chunxia; Gu, Mancang; Li, Chenxi; Li, Wanwan; Liu, Hongli; Shi, Yan; Mima, Kosuke; Nishihara, Reiko; Ogino, Shuji] Dana Farber Canc Inst, Dept Oncol Pathol, Boston, MA 02115 USA; [Bullman, Susan; Garrett, Wendy S.; Meyerson, Matthew L.; Giannakis, Marios; Meyerhardt, Jeffrey A.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA; Harvard Med Sch, Boston, MA USA; [Kosumi, Keisuke; Mima, Kosuke; Baba, Hideo] Kumamoto Univ, Grad Sch Med Sci, Dept Gastroenterol Surg, Kumamoto, Japan; [Koh, Hideo] Osaka City Univ, Grad Sch Med, Dept Hematol, Osaka, Japan; [Borowsky, Jennifer; Lennerz, Jochen K.] Harvard Med Sch, Massachusetts Gen Hosp, Ctr Integrated Diagnost, Dept Pathol, Boston, MA USA; [Song, Mingyang; Chan, Andrew T.] Harvard Med Sch, Massachusetts Gen Hosp, Clin & Translat Epidemiol Unit, Boston, MA USA; [Borowsky, Jennifer] Queensland Inst Med Res Berghofer, Conjoint Gastroenterol Lab, Brisbane, Qld, Australia; [Borowsky, Jennifer] Univ Queensland, Sch Med, Brisbane, Qld, Australia; [Bullman, Susan; Huttenhower, Curtis; Garrett, Wendy S.; Meyerson, Matthew L.; Giannakis, Marios; Ogino, Shuji] Broad Inst MIT & Harvard, Cambridge, MA 02142 USA; [Nevo, Daniel; Nishihara, Reiko; Wu, Kana; Wang, Molin; Ogino, Shuji] Harvard TH Chan Sch Publ Hlth, Dept Epidemiol, Boston, MA USA; [Nevo, Daniel; Nishihara, Reiko; Wang, Molin; Huttenhower, Curtis] Harvard TH Chan Sch Publ Hlth, Dept Biostat, Boston, MA USA; [Liu, Li; Song, Mingyang; Nishihara, Reiko; Wu, Kana] Harvard TH Chan Sch Publ Hlth, Dept Nutr, Boston, MA USA; [Garrett, Wendy S.] Harvard TH Chan Sch Publ Hlth, Dept Immunol & Infect Dis, Boston, MA USA; [Song, Mingyang; Chan, Andrew T.] Massachusetts Gen Hosp, Div Gastroenterol, Boston, MA 02114 USA; [Nosho, Katsuhiko] Sapporo Med Univ, Sch Med, Dept Gastroenterol Rheumatol & Clin Immunol, Sapporo, Hokkaido, Japan; [Nowak, Jonathan A.; Nishihara, Reiko; Ogino, Shuji] Brigham & Womens Hosp, Program MPE Mol Pathol Epidemiol, Dept Pathol, 75 Francis St, Boston, MA 02115 USA; [Giannakis, Marios] Brigham & Womens Hosp, Dept Med, 75 Francis St, Boston, MA 02115 USA; [Wu, Kana; Wang, Molin; Chan, Andrew T.] Brigham & Womens Hosp, Dept Med, Channing Div Network Med, 75 Francis St, Boston, MA 02115 USA; [Fuchs, Charles S.] Yale Canc Ctr, New Haven, CT USA; [Fuchs, Charles S.] Yale Sch Med, Dept Med, New Haven, CT USA; [Fuchs, Charles S.] Smilow Canc Hosp, New Haven, CT USA	Ogino, S (reprint author), Brigham & Womens Hosp, Program MPE Mol Pathol Epidemiol, 450 Brookline Ave,Room SM1036, Boston, MA 02215 USA.	shuji_ogino@dfci.harvard.edu	Giannakis, Marios/Z-4908-2019; Masugi, Yohei/W-8215-2019	Masugi, Yohei/0000-0002-6952-4043; da Silva, Annacarolina/0000-0002-0067-0288; Borowsky, Jennifer/0000-0003-3957-1364; Ogino, Shuji/0000-0002-3909-2323	US NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [P01 CA87969, UM1 CA186107, P01 CA55075, UM1 CA167552, U01 CA167552, P50 CA127003, R01 CA118553, R01 CA169141, R01 CA137178, K24 DK098311, R35 CA197735, R01 CA151993, K07 CA190673, K07 CA188126]; Dana-Farber/Harvard Cancer Center Nodal Award; Stand Up to Cancer Colorectal Cancer Dream Team Translational Research grant; Project P Fund grant; Bennett Family Fund grant; Entertainment Industry Foundation through the National Colorectal Cancer Research Alliance grant; Mitsukoshi Health and Welfare Foundation; Australia Awards-Endeavour Scholarships and Fellowships ProgramAustralian GovernmentDepartment of Industry, Innovation and Science; China Scholarship CouncilChina Scholarship Council; Huazhong University of Science and Technology fellowship grant; Japan Society for the Promotion of Science Overseas Research Fellowship grant [JP2017-775]; Friends of the Dana-Farber Cancer Institute grant	Supported by US NIH grants P01 CA87969 (M.S.), UM1 CA186107, P01 CA55075, UM1 CA167552, U01 CA167552, P50 CA127003 (C.S.F.), R01 CA118553 (C.S.F.), R01 CA169141 (C.S.F.), R01 CA137178 (A.T.C.), K24 DK098311 (A.T.C.), R35 CA197735 (S.O.), R01 CA151993 (S.O.), K07 CA190673 (RN.), and K07 CA188126 (X.Z.), the Dana-Farber/Harvard Cancer Center Nodal Award (S.O.), Stand Up to Cancer Colorectal Cancer Dream Team Translational Research grant (C.S.F. and M.Gi.), the Project P Fund grant, The Friends of the Dana-Farber Cancer Institute grant, the Bennett Family Fund grant, the Entertainment Industry Foundation through the National Colorectal Cancer Research Alliance grant, Japan Society for the Promotion of Science Overseas Research Fellowship grant JP2017-775 (K.K.), the Mitsukoshi Health and Welfare Foundation (T.H.), the Australia Awards-Endeavour Scholarships and Fellowships Program (J.B.), and China Scholarship Council and a Huazhong University of Science and Technology fellowship grant (L.L.). A.T.C. is a Stuart and Suzanne Steele Massachusetts General Hospital Research Scholar.	Alvi MA, 2017, BRIT J CANCER, V117, P203, DOI 10.1038/bjc.2017.168; Becker SFS, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0085717; Benjamin DJ, 2018, NAT HUM BEHAV, V2, P6, DOI 10.1038/s41562-017-0189-z; Bijlsma MF, 2017, NAT REV GASTRO HEPAT, V14, P333, DOI 10.1038/nrgastro.2017.33; Bosman FT, 2010, WHO CLASSIFICATION T; Brand A, 2016, CELL METAB, V24, P657, DOI 10.1016/j.cmet.2016.08.011; Chan AT, 2007, NEW ENGL J MED, V356, P2131, DOI 10.1056/NEJMoa067208; Chan AT, 2009, JAMA-J AM MED ASSOC, V302, P649, DOI 10.1001/jama.2009.1112; Colegio OR, 2014, NATURE, V513, P559, DOI 10.1038/nature13490; Dart A, 2016, NAT REV CANCER, V16, P676, DOI 10.1038/nrc.2016.109; Dejea CM, 2018, SCIENCE, V359, P592, DOI 10.1126/science.aah3648; Domingo E, 2018, LANCET GASTROENTEROL, V3, P635, DOI 10.1016/S2468-1253(18)30117-1; Dzutsev A, 2017, ANNU REV IMMUNOL, V35, P199, DOI 10.1146/annurev-immunol-051116-052133; Fukuda S, 2011, NATURE, V469, P543, DOI 10.1038/nature09646; Furet JP, 2009, FEMS MICROBIOL ECOL, V68, P351, DOI 10.1111/j.1574-6941.2009.00671.x; Gagliani N, 2014, CELL, V157, P776, DOI 10.1016/j.cell.2014.03.006; Giannakis M, 2016, CELL REP, V15, P857, DOI 10.1016/j.celrep.2016.03.075; Gopalakrishnan V, 2018, SCIENCE, V359, P97, DOI 10.1126/science.aan4236; Hamada T, 2017, J CLIN ONCOL, V35, P1836, DOI 10.1200/JCO.2016.70.7547; Hamada T, 2017, J GASTROENTEROL, V52, P265, DOI 10.1007/s00535-016-1272-3; Honda K, 2016, NATURE, V535, P75, DOI 10.1038/nature18848; Hu Y, 2016, CARCINOGENESIS, V37, P366, DOI 10.1093/carcin/bgw019; Imamura Y, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-135; Inamura K, 2015, ANN SURG ONCOL, V22, P1226, DOI 10.1245/s10434-014-4159-7; Ioannidis JPA, 2014, PLOS MED, V11, DOI 10.1371/journal.pmed.1001747; Kikuchi T, 2017, BIOCHEM BIOPH RES CO, V493, P306, DOI 10.1016/j.bbrc.2017.09.026; Kong XQ, 2017, CANCER MANAG RES, V9, P573, DOI 10.2147/CMAR.S149582; Laforest-Lapointe I, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00788; Lehouritis P, 2016, J CONTROL RELEASE, V222, P9, DOI 10.1016/j.jconrel.2015.11.030; Li HP, 2017, NAT GENET, V49, P708, DOI 10.1038/ng.3818; Liang ZZ, 2018, CLIN COLORECTAL CANC, V17, pE39, DOI 10.1016/j.clcc.2017.06.010; Liao XY, 2012, NEW ENGL J MED, V367, P1596, DOI 10.1056/NEJMoa1207756; Liu L, 2018, EUR J EPIDEMIOL, V33, P381, DOI 10.1007/s10654-017-0346-8; Loree JM, 2018, JNCI-J NATL CANCER I, V110, P1409, DOI 10.1093/jnci/djy067; Loree JM, 2018, CLIN CANCER RES, V24, P1062, DOI 10.1158/1078-0432.CCR-17-2484; Masugi Y, 2017, GUT, V66, P1463, DOI 10.1136/gutjnl-2016-311421; Matson V, 2018, SCIENCE, V359, P104, DOI 10.1126/science.aao3290; Meyerhardt JA, 2005, NEW ENGL J MED, V352, P476, DOI 10.1056/NEJMra040958; Mima K, 2016, CLIN TRANSL GASTROEN, V7, DOI 10.1038/ctg.2016.53; Mima K, 2016, GUT, V65, P1973, DOI 10.1136/gutjnl-2015-310101; Mima K, 2015, JAMA ONCOL, V1, P653, DOI 10.1001/jamaoncol.2015.1377; Mlecnik B, 2016, IMMUNITY, V44, P698, DOI 10.1016/j.immuni.2016.02.025; Morikawa T, 2011, JAMA-J AM MED ASSOC, V305, P1685, DOI 10.1001/jama.2011.513; Naxerova K, 2017, SCIENCE, V357, P55, DOI 10.1126/science.aai8515; Nishihara R, 2013, NEW ENGL J MED, V369, P1095, DOI 10.1056/NEJMoa1301969; Nosho K, 2010, J PATHOL, V222, P350, DOI 10.1002/path.2774; O'Callaghan A, 2016, FRONT MICROBIOL, V7, DOI 10.3389/fmicb.2016.00925; Ogino S, 2006, MODERN PATHOL, V19, P59, DOI 10.1038/modpathol.3800482; Ogino S, 2018, LANCET, V391, P2084, DOI 10.1016/S0140-6736(18)30953-X; Ogino S, 2018, GUT, V67, P1168, DOI 10.1136/gutjnl-2017-315537; Ogino S, 2017, NPJ PRECIS ONCOL, V1, DOI 10.1038/s41698-017-0042-x; Ogino S, 2016, EPIDEMIOLOGY, V27, P602, DOI 10.1097/EDE.0000000000000471; Ogino S, 2011, NAT REV CLIN ONCOL, V8, P711, DOI 10.1038/nrclinonc.2011.122; Ogino S, 2009, CLIN CANCER RES, V15, P6412, DOI 10.1158/1078-0432.CCR-09-1438; Ogino S, 2009, GUT, V58, P90, DOI 10.1136/gut.2008.155473; Pages F, 2018, LANCET, V391, P2128, DOI 10.1016/S0140-6736(18)30789-X; Rajpoot M, 2018, SEMIN CANCER BIOL, V52, P1, DOI 10.1016/j.semcancer.2018.02.003; Razenberg Lieke G E M, 2015, Clin Colorectal Cancer, V14, pe13, DOI 10.1016/j.clcc.2015.05.011; Routy B, 2018, NAT REV CLIN ONCOL, V15, P382, DOI 10.1038/s41571-018-0006-2; Routy B, 2018, SCIENCE, V359, P91, DOI 10.1126/science.aan3706; Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73; Schneider G, 2017, NAT REV CANCER, V17, P239, DOI 10.1038/nrc.2017.5; Schug ZT, 2016, NAT REV CANCER, V16, P708, DOI 10.1038/nrc.2016.87; Schug ZT, 2015, CANCER CELL, V27, P57, DOI 10.1016/j.ccell.2014.12.002; Seaman SR, 2013, STAT METHODS MED RES, V22, P278, DOI 10.1177/0962280210395740; Sears CL, 2018, NAT MED, V24, P254, DOI 10.1038/nm.4511; Sender R, 2016, PLOS BIOL, V14, DOI 10.1371/journal.pbio.1002533; Sivan A, 2015, SCIENCE, V350, P1084, DOI 10.1126/science.aac4255; Snyder A, 2015, SCIENCE, V350, P1031, DOI 10.1126/science.aad7706; Sobhani I, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016393; Taniguchi S, 2016, METHODS MOL BIOL, V1409, P49, DOI 10.1007/978-1-4939-3515-4_5; Tjalsma H, 2012, NAT REV MICROBIOL, V10, P575, DOI 10.1038/nrmicro2819; Tsilimigras MCB, 2017, NAT MICROBIOL, V2, DOI 10.1038/nmicrobiol.2017.8; Ubeda C, 2017, CLIN TRANSL IMMUNOL, V6, DOI 10.1038/cti.2017.2; White KA, 2017, J CELL SCI, V130, P663, DOI 10.1242/jcs.195297; Wolnerhanssen BK, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-08487-9; Xie J, 2005, STAT MED, V24, P3089, DOI 10.1002/sim.2174; Yamauchi M, 2012, GUT, V61, P847, DOI 10.1136/gutjnl-2011-300865	78	6	6	0	6	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	DEC	2018	188	12					2839	2852		10.1016/j.ajpath.2018.08.015			14	Pathology	Pathology	HF4EX	WOS:000454187100011	30243655				2019-10-28	
J	Xue, YC; Ruller, CM; Fung, G; Mohamud, Y; Deng, HY; Liu, HT; Zhang, JC; Feuer, R; Luo, HL				Xue, Yuan Chao; Ruller, Chelsea M.; Fung, Gabriel; Mohamud, Yasir; Deng, Haoyu; Liu, Huitao; Zhang, Jingchun; Feuer, Ralph; Luo, Honglin			Enteroviral Infection Leads to Transactive Response DNA-Binding Protein 43 Pathology in Vivo	AMERICAN JOURNAL OF PATHOLOGY			English	Article							AMYOTROPHIC-LATERAL-SCLEROSIS; SPINAL-CORD; COXSACKIEVIRUS REPLICATION; SEQUENCES; ALS; PERSISTENCE; TDP-43; RNA; DISSEMINATION; AGGREGATION	Amyotrophic Lateral sclerosis (ALS) is a fatal neurodegenerative disease that primarily affects motor neurons in the cerebral cortex, brainstem, and spinal cord, leading to progressive paralysis and eventual death. Approximately 95% of all ALS cases are sporadic without known causes. Enteroviruses have been suspected to play a role in ALS because of their ability to target motor neurons and to cause muscle weakness and paralysis. In vitro enteroviral infection results in cytoplasmic aggregation and cleavage of transactive response DNA binding protein-43, a pathologic hallmark of ALS. However, whether enteroviral infection can induce ALS-like pathologies in vivo remains to be characterized. In this study, neonatal BALB/C mice were intracranially inoculated with either a recombinant coxsackievirus B3 expressing enhanced green fluorescent protein or mock-infected for 2, 5, 10, 30, and 90 days. Histologic and immunohistochemical analysis of brain tissues demonstrated sustained inflammation (microglia and astrogliosis) and lesions in multiple regions of the brain (hippocampus, cerebral cortex, striatum, olfactory bulb, and putamen) in parallel with virus detection as early as 2 days for up to 90 days after infection. Most notably, ALS-like pathologies, including cytoplasmic mislocalization of transactive response DNA binding protein-43, p62-, and ubiquitin-positive inclusions, were observed in the areas of infection. These data provide the first pathologic evidence to support a possible link between enteroviral infection and ALS.	[Xue, Yuan Chao; Fung, Gabriel; Mohamud, Yasir; Deng, Haoyu; Liu, Huitao; Zhang, Jingchun; Luo, Honglin] Univ British Columbia, Ctr Heart Lung Innovat, Vancouver, BC, Canada; [Xue, Yuan Chao; Fung, Gabriel; Mohamud, Yasir; Deng, Haoyu; Zhang, Jingchun; Luo, Honglin] Univ British Columbia, Dept Pathol & Lab Med, Vancouver, BC, Canada; [Liu, Huitao] Univ British Columbia, Dept Expt Med, Vancouver, BC, Canada; [Ruller, Chelsea M.; Feuer, Ralph] San Diego State Univ, Integrated Regenerat Res Inst, Dept Biol, San Diego, CA 92182 USA; [Deng, Haoyu] Shanghai Jiao Tong Univ, Sch Med, Renji Hosp, Dept Vasc Surg, Shanghai, Peoples R China	Feuer, R (reprint author), San Diego State Univ, Dept Biol, Cell & Mol Biol Joint Doctoral Program, IRRI, 5500 Campanile Dr, San Diego, CA 92182 USA.; Luo, HL (reprint author), St Pauls Hosp, Ctr Heart Lung Innovat, Room 166,1081 Burrard St, Vancouver, BC V6Z 1Y6, Canada.	rfeuer@sdsu.edu; honglin.luo@hli.ubc.ca			Canadian Institutes of Health Research grantCanadian Institutes of Health Research (CIHR) [PJT-159546]; Natural Sciences and Engineering Research CouncilNatural Sciences and Engineering Research Council of Canada [RGPIN-2016-03811]; ALS Canada-Brain Canada Doctoral Fellowship; UBC ECOSCOPE training program; University of British Columbia; ALS Canada	Supported by the Canadian Institutes of Health Research grant PJT-159546 (H.L.), ALS Canada (H.L.), and the Natural Sciences and Engineering Research Council grant RGPIN-2016-03811 (H.Lu.). Y.M. is also the recipient of ALS Canada-Brain Canada Doctoral Fellowship. Y.C.X. is also supported by UBC ECOSCOPE training program. Y.C.X., Y.M., and H.D. are the recipients of a four-year Ph.D. fellowship from the University of British Columbia.	Ahmed Z, 2007, J HISTOCHEM CYTOCHEM, V55, P687, DOI 10.1369/jhc.6A7156.2007; AI-Chalabi A, 2014, LANCET NEUROL, V13, P1108, DOI 10.1016/S1474-4422(14)70219-4; Al-Chalabi A, 2017, NAT REV NEUROL, V13, P96, DOI 10.1038/nrneurol.2016.182; Berger MM, 2000, NEUROLOGY, V54, P20, DOI 10.1212/WNL.54.1.20; Blokhuis AM, 2013, ACTA NEUROPATHOL, V125, P777, DOI 10.1007/s00401-013-1125-6; Brown RH, 2017, NEW ENGL J MED, V377, P162, DOI [10.1056/NEJMra1603471, 10.1056/NEJMc1710379]; Chia R, 2018, LANCET NEUROL, V17, P94, DOI 10.1016/S1474-4422(17)30401-5; Corona AK, 2018, CELL REP, V22, P3304, DOI 10.1016/j.celrep.2018.03.003; ENG LF, 1994, BRAIN PATHOL, V4, P229, DOI 10.1111/j.1750-3639.1994.tb00838.x; Feuer R, 2005, J NEUROSCI, V25, P2434, DOI 10.1523/JNEUROSCI.4517-04.2005; Feuer R, 2003, AM J PATHOL, V163, P1379, DOI 10.1016/S0002-9440(10)63496-7; Feuer R, 2002, J VIROL, V76, P4430, DOI 10.1128/JVI.76.9.4430-4440.2002; Feuer R, 2009, J VIROL, V83, P9356, DOI 10.1128/JVI.02382-07; Fung G, 2015, CELL DEATH DIFFER, V22, P2087, DOI 10.1038/cdd.2015.58; Giraud P, 2001, NEUROLOGY, V56, P1777, DOI 10.1212/WNL.56.12.1777; Gustin KE, 2003, VIRUS RES, V95, P35, DOI 10.1016/S0168-1702(03)00165-5; Han J, 2010, BMC INFECT DIS, V10, DOI 10.1186/1471-2334-10-178; Hardiman O, 2017, NAT REV DIS PRIMERS, V3, DOI [10.1038/nrdp.2017.85, 10.1038/nrdp.2017.71]; Huang HI, 2015, VIRUSES-BASEL, V7, P6051, DOI 10.3390/v7112920; Julien J, 1999, J NEUROL, V246, P472, DOI 10.1007/s004150050386; Kury P, 2018, TRENDS MOL MED, V24, P379, DOI 10.1016/j.molmed.2018.02.007; Li W, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aac8201; Liddelow SA, 2017, IMMUNITY, V46, P957, DOI 10.1016/j.immuni.2017.06.006; Ling SC, 2013, NEURON, V79, P416, DOI 10.1016/j.neuron.2013.07.033; Lodato S, 2015, ANNU REV CELL DEV BI, V31, P699, DOI 10.1146/annurev-cellbio-100814-125353; Mackenzie IRA, 2007, ANN NEUROL, V61, P427, DOI 10.1002/ana.21147; Martinez A, 2017, EXPERT OPIN INV DRUG, V26, P403, DOI 10.1080/13543784.2017.1302426; Mohamud Y, 2018, CELL REP, V22, P3292, DOI 10.1016/j.celrep.2018.02.090; Neumann M, 2006, SCIENCE, V314, P130, DOI 10.1126/science.1134108; Nix WA, 2004, NEUROLOGY, V62, P1372, DOI 10.1212/01.WNL.0000123258.86752.51; Paez-Gonzalez P, 2014, NAT NEUROSCI, V17, P934, DOI 10.1038/nn.3734; Philips T, 2011, LANCET NEUROL, V10, P253, DOI 10.1016/S1474-4422(11)70015-1; Rentzos M, 2010, EUR NEUROL, V63, P285, DOI 10.1159/000287582; Rhoades RE, 2011, VIROLOGY, V411, P288, DOI 10.1016/j.virol.2010.12.014; Ruifrok AC, 2001, ANAL QUANT CYTOL, V23, P291; Ruller CM, 2012, AM J PATHOL, V180, P1107, DOI 10.1016/j.ajpath.2011.11.016; Sin J, 2015, VIROLOGY, V484, P288, DOI 10.1016/j.virol.2015.06.006; SWANSON NR, 1995, NEUROMUSCULAR DISORD, V5, P457, DOI 10.1016/0960-8966(95)00002-5; Tsueng G, 2011, J VIROL, V85, P5718, DOI 10.1128/JVI.02261-10; van Es MA, 2017, LANCET, V390, P2084, DOI 10.1016/S0140-6736(17)31287-4; Vandenberghe N, 2010, AMYOTROPH LATERAL SC, V11, P277, DOI 10.3109/17482960903262083; Walker MP, 2001, ANN NEUROL, V49, P249; WOODALL CJ, 1994, BRIT MED J, V308, P1541, DOI 10.1136/bmj.308.6943.1541; Xue YC, 2018, FRONT MOL NEUROSCI, V11, DOI 10.3389/fnmol.2018.00063; Yang WC, 2012, AMYOTROPH LATERAL SC, V13, P178, DOI 10.3109/17482968.2011.622405	45	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	DEC	2018	188	12					2853	2862		10.1016/j.ajpath.2018.08.013			10	Pathology	Pathology	HF4EX	WOS:000454187100012	30273599				2019-10-28	
J	Shangguan, YF; Wen, YX; Tan, Y; Qin, J; Jiang, HQ; Magdalou, J; Chen, LB; Wang, H				Shangguan, Yangfan; Wen, Yinxian; Tan, Yang; Qin, Jun; Jiang, Hongqiang; Magdalou, Jacques; Chen, Liaobin; Wang, Hui			Intrauterine Programming of Glucocorticoid-Insulin-Like Growth Factor-1 Axis-Mediated Developmental Origin of Osteoporosis Susceptibility in Female Offspring Rats with Prenatal Caffeine Exposure	AMERICAN JOURNAL OF PATHOLOGY			English	Article							BONE MASS; FETAL; EPIDEMIOLOGY; METHYLATION; FRACTURES; SYSTEMS; LEVEL; MODEL; HIP	Epidemiologic investigations suggest that excessive intake of caffeine during pregnancy is one of the risk factors for osteoporosis in adult offspring. However, the phenomena and mechanisms have remained obscure. This study found that prenatal caffeine exposure (PCE) leads to persistent bone dysplasia in gestational day 20 and postnatal week 12 offspring rats and increases the susceptibility to osteoporosis in postnatal week 28 offspring rats. In the embryonic period, PCE increases the concentration of serum corticosterone and inhibits the expression of insulin-like growth factor-1 (IGF1) and osteogenic differentiation genes. After birth, the recovery of IGF1 expression in PCE offspring is unable to completely compensate osteogenic function, and chronic stress can lead to a further decrease in IGF1 expression. In vitro experiments found that corticosterone instead of caffeine restrains mineralized nodule formation and osteoblast differentiation by inhibiting IGF1 expression. The corticosterone inhibits H3K9 and H3K14 histone acetylation of IGF1 in osteoblasts through glucocorticoid receptor and CCAAT and enhancer binding protein alpha, respectively. In conclusion, glucocorticoid instead of caffeine inhibits bone IGF1 expression via glucocorticoid receptor and CCAAT and enhancer binding protein alpha and mediates the PCE-induced bone dysplasia and bone mass reduction in offspring fetal rats, which may contribute to osteoporosis susceptibility in adulthood.	[Shangguan, Yangfan; Wen, Yinxian; Tan, Yang; Qin, Jun; Chen, Liaobin] Wuhan Univ, Zhongnan Hosp, Dept Orthoped Surg, Wuhan, Hubei, Peoples R China; [Shangguan, Yangfan; Wen, Yinxian; Tan, Yang; Qin, Jun; Chen, Liaobin; Wang, Hui] Hubei Prov Key Lab Dev Originated Dis, Wuhan, Hubei, Peoples R China; [Jiang, Hongqiang; Wang, Hui] Wuhan Univ, Basic Med Sch, Dept Pharmacol, Wuhan, Hubei, Peoples R China; [Magdalou, Jacques] Univ Lorraine, Fac Med, CNRS, UMR 7561, Vandoeuvre Les Nancy, France	Chen, LB (reprint author), Wuhan Univ, Zhongnan Hosp, Dept Orthoped Surg, Wuhan, Hubei, Peoples R China.; Wang, H (reprint author), Wuhan Univ, Basic Med Sch, Dept Pharmacol, Wuhan, Hubei, Peoples R China.	lbchen@whu.edu.cn; wanghui19@whu.edu.cn			National Natural Science Foundation of ChinaNational Natural Science Foundation of China [81220108026, 81430089, 81673524, 81371940, 81673490]	Supported by National Natural Science Foundation of China grants 81220108026, 81430089, and 81673524 (H.W.) and 81371940 and 81673490 (L.C.).	Baird J, 2011, OSTEOPOROSIS INT, V22, P1323, DOI 10.1007/s00198-010-1344-9; Bird AD, 2015, MOL ENDOCRINOL, V29, P158, DOI 10.1210/me.2014-1362; Bouxsein ML, 2010, J BONE MINER RES, V25, P1468, DOI 10.1002/jbmr.141; CARE Study Group, 2008, BMJ, V337, pa2332, DOI 10.1136/bmj.a2332; Chang KP, 2004, J BONE MINER RES, V19, P532, DOI 10.1359/JBMR.040109; Cooper C, 2006, OSTEOPOROSIS INT, V17, P337, DOI 10.1007/s00198-005-2039-5; Crane JL, 2013, BONE RES, V1, DOI 10.4248/BR201302007; Crudo A, 2012, ENDOCRINOLOGY, V153, P3269, DOI 10.1210/en.2011-2160; Deng Y, 2013, TOXICOL APPL PHARM, V269, P25, DOI 10.1016/j.taap.2013.02.008; Dennison EM, 2010, J DEV ORIG HLTH DIS, V1, P142, DOI 10.1017/S2040174409990146; Dolinoy DC, 2008, ENVIRON MOL MUTAGEN, V49, P4, DOI 10.1002/em.20366; Dolinoy DC, 2006, ENVIRON HEALTH PERSP, V114, P567, DOI 10.1289/ehp.8700; Feng YZ, 2013, NEUROENDOCRINOL LETT, V34, P624; Fowden AL, 2006, PHYSIOLOGY, V21, P29, DOI 10.1152/physiol.00050.2005; Gartner H, 2003, J CELL PHYSIOL, V194, P80, DOI 10.1002/jcp.10189; Godfrey Keith M, 2016, Nestle Nutr Inst Workshop Ser, V85, P71, DOI 10.1159/000439488; Godfrey KM, 2011, SEMIN REPROD MED, V29, P257, DOI 10.1055/s-0031-1275518; Guilbert J J, 2003, Educ Health (Abingdon), V16, P230; He Z, 2016, TOXICOL RES-UK, V5, P388, DOI 10.1039/c5tx00265f; Heppe DHM, 2014, J BONE MINER RES, V29, P2584, DOI 10.1002/jbmr.2299; Hollins Martin Caroline, 2014, Evid Based Nurs, V17, P106, DOI 10.1136/eb-2013-101683; Huang HG, 2015, TOXICOL APPL PHARM, V288, P84, DOI 10.1016/j.taap.2015.07.005; Hyatt MA, 2007, ENDOCRINOLOGY, V148, P4754, DOI 10.1210/en.2007-0303; Inder WJ, 2010, CLIN ENDOCRINOL, V73, P126, DOI 10.1111/j.1365-2265.2009.03683.x; Iqbal MM, 2000, SOUTH MED J, V93, P2; Knight CA, 2004, FOOD CHEM TOXICOL, V42, P1923, DOI 10.1016/j.fct.2004.05.002; Laires PA, 2015, ACTA REUMATOL PORT, V40, P223; Lane NE, 2006, AM J OBSTET GYNECOL, V194, pS3, DOI 10.1016/j.ajog.2005.08.047; Liu XL, 2015, CLIN ORAL IMPLAN RES, V26, P392, DOI 10.1111/clr.12360; Liu YS, 2012, TOXICOL APPL PHARM, V262, P205, DOI 10.1016/j.taap.2012.05.002; Magner NL, 2013, STEM CELLS, V31, P2095, DOI 10.1002/stem.1478; Mathavan N, 2015, CALCIFIED TISSUE INT, V97, P134, DOI 10.1007/s00223-015-9991-7; Moisiadis VG, 2014, NAT REV ENDOCRINOL, V10, P403, DOI 10.1038/nrendo.2014.74; Moisiadis VG, 2014, NAT REV ENDOCRINOL, V10, P391, DOI 10.1038/nrendo.2014.73; Nerlov C, 2008, CURR OPIN CELL BIOL, V20, P180, DOI 10.1016/j.ceb.2008.02.002; Ni QB, 2015, SCI REP-UK, V5, DOI 10.1038/srep14711; Orriss IR, 2006, BONE, V39, P300, DOI 10.1016/j.bone.2006.02.063; Puri G, 2012, Int J Stem Cells, V5, P96; Reagan-Shaw S, 2008, FASEB J, V22, P659, DOI 10.1096/fj.07-9574LSF; Rosenberg A, 2008, SEMIN PERINATOL, V32, P219, DOI 10.1053/j.semperi.2007.11.003; Schlussel MM, 2010, OSTEOPOROSIS INT, V21, P1981, DOI 10.1007/s00198-010-1236-z; Schuiling KD, 2011, J MIDWIFERY WOM HEAL, V56, P615, DOI 10.1111/j.1542-2011.2011.00135.x; Sedaghat K, 2015, IRAN J BASIC MED SCI, V18, P212; Staiger J, 2009, CARCINOGENESIS, V30, P832, DOI 10.1093/carcin/bgn273; Tan Y, 2012, TOXICOL LETT, V214, P279, DOI 10.1016/j.toxlet.2012.09.007; Vidal B, 2012, ACTA REUMATOL PORT, V37, P294; Wang LL, 2014, TOXICOL LETT, V224, P311, DOI 10.1016/j.toxlet.2013.11.006; Weng XP, 2008, AM J OBSTET GYNECOL, V198, DOI 10.1016/j.ajog.2007.10.803; Wu YM, 2015, TOXICOL APPL PHARM, V289, P109, DOI 10.1016/j.taap.2015.09.007; Xu D, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044497; Zeng CX, 2010, HEPATOLOGY, V52, P1702, DOI 10.1002/hep.23875; Zhang G, 2006, BONE, V38, P818, DOI 10.1016/j.bone.2005.11.019; Zhang HT, 2007, MOL PHARMACOL, V71, P1319, DOI 10.1124/mol.106.032011; Zhang XR, 2016, BRIT J PHARMACOL, V173, P2250, DOI 10.1111/bph.13506; 那键, 2013, [吉林大学学报. 医学版, Journal of Jilin Univeristy. Medicine edition], V39, P170	55	1	1	2	10	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	DEC	2018	188	12					2863	2876		10.1016/j.ajpath.2018.08.008			14	Pathology	Pathology	HF4EX	WOS:000454187100013	30273601				2019-10-28	
J	Davis, J; Xu, F; Hatfield, J; Lee, H; Hoos, MD; Popescu, D; Crooks, E; Kim, R; Smith, SO; Robinson, JK; Benveniste, H; Van Nostrand, WE				Davis, Judianne; Xu, Feng; Hatfield, Joshua; Lee, Hedok; Hoos, Michael D.; Popescu, Dominique; Crooks, Elliot; Kim, Regina; Smith, Steven O.; Robinson, John K.; Benveniste, Helene; Van Nostrand, William E.			A Novel Transgenic Rat Model of Robust Cerebral Microvascular Amyloid with Prominent Vasculopathy	AMERICAN JOURNAL OF PATHOLOGY			English	Article							BLOOD-BRAIN-BARRIER; BETA-PROTEIN; MOUSE MODEL; ALZHEIMERS-DISEASE; EARLY-ONSET; ANGIOPATHY; PATHOLOGY; MICE; NEUROINFLAMMATION; HEMORRHAGE	Accumulation of fibrillar amyloid 13 protein in blood vessels of the brain, a condition known as cerebral amyloid angiopathy (CAA), is a common pathology of elderly individuals, a prominent comorbidity of Alzheimer disease, and a driver of vascular cognitive impairment and dementia. Although several transgenic mouse strains have been generated that develop varying levels of CAA, consistent models of associated cerebral microhemorrhage and vasculopathy observed clinically have been lacking. Reliable preclinical animal models of CAA and microhemorrhage are needed to investigate the molecular pathogenesis of this condition. Herein, we describe the generation and characterization of a novel transgenic rat (rTg-DI) that produces low levels of human familial CAA Dutch/Iowa E22Q/D23N mutant amyloid beta protein in brain and faithfully recapitulates many of the pathologic aspects of human small vessel CAA. rTg-DI rats exhibit early-onset and progressive accumulation of cerebral microvascular fibrillar amyloid accompanied by early-onset and sustained behavioral deficits. Comparable to CAA in humans, the cerebral microvascular amyloid in rTg-DI rats causes capillary structural alterations, promotes prominent perivascular neuroinflammation, and produces consistent, robust micro hemorrhages and small-vessel occlusions that are readily detected by magnetic resonance imaging. The rTg-DI rats provide a new model to investigate the pathogenesis of small-vessel CAA and micro hemorrhages, to develop effective biomarkers for this condition and to test therapeutic interventions.	[Davis, Judianne; Xu, Feng; Hatfield, Joshua; Kim, Regina; Robinson, John K.; Van Nostrand, William E.] Univ Rhode Isl, George & Anne Ryan Inst Neurosci, 130 Flagg Rd, Kingston, RI 02881 USA; [Robinson, John K.] Univ Rhode Isl, Dept Psychol, Kingston, RI 02881 USA; [Van Nostrand, William E.] Univ Rhode Isl, Dept Biomed & Pharmaceut Sci, Kingston, RI 02881 USA; [Lee, Hedok; Benveniste, Helene] Yale Univ, Dept Anesthesiol, New Haven, CT USA; [Hoos, Michael D.; Crooks, Elliot; Smith, Steven O.] SUNY Stony Brook, Dept Biochem & Cell Biol, Stony Brook, NY 11794 USA; [Popescu, Dominique] SUNY Stony Brook, Dept Psychol, Stony Brook, NY 11794 USA	Van Nostrand, WE (reprint author), Univ Rhode Isl, George & Anne Ryan Inst Neurosci, 130 Flagg Rd, Kingston, RI 02881 USA.	wvannostrand@uri.edu			NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS091969, AG053991, NS092696, AG027317]	Supported by NIH grants NS091969 (W.E.V.N., J.K.R., and H.B.), AG053991 (H.B. and W.E.V.N.), NS092696 (W.E.V.N. and S.O.S.), and AG027317 (W.E.V.N. and S.O.S.).	Alonzo NC, 1998, J NEUROPATH EXP NEUR, V57, P353, DOI 10.1097/00005072-199804000-00008; Arvanitakis Z, 2011, ANN NEUROL, V69, P320, DOI 10.1002/ana.22112; Attems J, 2004, ACTA NEUROPATHOL, V107, P83, DOI 10.1007/s00401-003-0796-9; Attems J, 2011, NEUROPATH APPL NEURO, V37, P75, DOI 10.1111/j.1365-2990.2010.01137.x; Auriel E, 2012, CURR ATHEROSCLER REP, V14, P343, DOI 10.1007/s11883-012-0254-z; Bailey KR, 2006, ILAR J, V47, P124, DOI 10.1093/ilar.47.2.124; Bailey TL, 2004, NEUROL RES, V26, P573, DOI 10.1179/016164104225016272; Banerjee G, 2017, J NEUROL NEUROSUR PS, V88, P982, DOI 10.1136/jnnp-2016-314697; Biffi A, 2011, J CLIN NEUROL, V7, P1, DOI 10.3988/jcn.2011.7.1.1; Boyle PA, 2015, NEUROLOGY, V85, P1930, DOI 10.1212/WNL.0000000000002175; Brown WR, 2010, J ALZHEIMERS DIS, V21, P725, DOI 10.3233/JAD-2010-100219; Brown WR, 2009, J NEUROL SCI, V283, P28, DOI 10.1016/j.jns.2009.02.328; Calhoun ME, 1999, P NATL ACAD SCI USA, V96, P14088, DOI 10.1073/pnas.96.24.14088; Davis J, 1996, P NATL ACAD SCI USA, V93, P2996, DOI 10.1073/pnas.93.7.2996; Davis J, 2004, J BIOL CHEM, V279, P20296, DOI 10.1074/jbc.M312946200; Deane R, 2003, NAT MED, V9, P907, DOI 10.1038/nm890; DeMattos RB, 2002, P NATL ACAD SCI USA, V99, P10843, DOI 10.1073/pnas.162228299; Eikelenboom P, 2008, NEURODEGENER DIS, V5, P190, DOI 10.1159/000113699; Ellenbroek B, 2016, DIS MODEL MECH, V9, P1079, DOI 10.1242/dmm.026120; Esiri M, 2015, BRAIN PATHOL, V25, P51, DOI 10.1111/bpa.12221; GAMES D, 1995, NATURE, V373, P523, DOI 10.1038/373523a0; Gomori G, 1936, AM J PATHOL, V12, P655; Grabowski TJ, 2001, ANN NEUROL, V49, P697, DOI 10.1002/ana.1009; Greenberg SA, 2004, STROKE, V35, P2616, DOI 10.1161/01.str.0000143224.36527.44; Greenberg SM, 2018, STROKE, V49, P491, DOI 10.1161/STROKEAHA.117.016990; Hecht M, 2018, ACTA NEUROPATHOL, V135, P681, DOI 10.1007/s00401-018-1834-y; Herzig MC, 2004, NAT NEUROSCI, V7, P954, DOI 10.1038/nn1302; Hsiao K, 1996, SCIENCE, V274, P99, DOI 10.1126/science.274.5284.99; Jakel L, 2017, CLIN SCI, V131, P2469, DOI 10.1042/CS20170033; Jellinger KA, 2002, J NEURAL TRANSM, V109, P813, DOI 10.1007/s007020200068; JohnsonWood K, 1997, P NATL ACAD SCI USA, V94, P1550, DOI 10.1073/pnas.94.4.1550; Launer LJ, 2008, NEUROBIOL AGING, V29, P1587, DOI 10.1016/j.neurobiolaging.2007.03.008; Lee JS, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125297; LEVY E, 1990, SCIENCE, V248, P1124, DOI 10.1126/science.2111584; Long JM, 1998, J NEUROSCI METH, V84, P101, DOI 10.1016/S0165-0270(98)00100-9; Miao J, 2005, AM J PATHOL, V167, P505, DOI 10.1016/S0002-9440(10)62993-8; Miao JT, 2005, J NEUROSCI, V25, P6271, DOI 10.1523/JNEUROSCI.1306-05.2005; MILLER DL, 1993, ARCH BIOCHEM BIOPHYS, V301, P41, DOI 10.1006/abbi.1993.1112; Moody DM, 1997, ANN NY ACAD SCI, V826, P103, DOI 10.1111/j.1749-6632.1997.tb48464.x; MULLAN M, 1992, NAT GENET, V1, P345, DOI 10.1038/ng0892-345; Oakley H, 2006, J NEUROSCI, V26, P10129, DOI 10.1523/JNEUROSCI.1202-06.2006; Oberstein SAJL, 2001, NEUROLOGY, V57, P1066, DOI 10.1212/WNL.57.6.1066; Paravastu AK, 2008, P NATL ACAD SCI USA, V105, P18349, DOI 10.1073/pnas.0806270105; Rensink AAM, 2003, BRAIN RES REV, V43, P207, DOI 10.1016/j.brainresrev.2003.08.001; Richard E, 2010, J NEUROPATH EXP NEUR, V69, P1158, DOI 10.1097/NEN.0b013e3181fab558; Rozemuller Annemieke J. M., 2005, Current Drug Targets - CNS and Neurological Disorders, V4, P223, DOI 10.2174/1568007054038229; RUNGBY J, 1993, HISTOCHEM J, V25, P446, DOI 10.1007/BF00157809; Sellal F, 2017, J ALZHEIMERS DIS, V56, P37, DOI 10.3233/JAD-160709; Thal DR, 2003, J NEUROPATH EXP NEUR, V62, P1287, DOI 10.1093/jnen/62.12.1287; Thal DR, 2002, J NEUROPATH EXP NEUR, V61, P282, DOI 10.1093/jnen/61.3.282; Tycko R, 2011, ANNU REV PHYS CHEM, V62, P279, DOI 10.1146/annurev-physchem-032210-103539; VAN BROECKHOVEN C, 1990, SCIENCE, V248, P1120, DOI 10.1126/science.1971458; Van Nostrand WE, 2001, J BIOL CHEM, V276, P32860, DOI 10.1074/jbc.M104135200; VANNOSTRAND WE, 1989, NATURE, V341, P546; Vinters HV, 1998, ACTA NEUROPATHOL, V95, P235, DOI 10.1007/s004010050793; Wallays G, 2011, ARTERIOSCL THROM VAS, V31, P2881, DOI 10.1161/ATVBAHA.111.237859; Winkler DT, 2001, J NEUROSCI, V21, P1619; Xu F, 2007, NEUROSCIENCE, V146, P98, DOI 10.1016/j.neuroscience.2007.01.043; Xu F, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13527; Xu WJ, 2014, J ALZHEIMERS DIS, V38, P621, DOI 10.3233/JAD-130758; Yang S, 2004, GENOME RES, V14, P517, DOI 10.1101/gr.1984404; ZLOKOVIC BV, 1993, J BIOL CHEM, V268, P8019	62	0	0	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	DEC	2018	188	12					2877	2889		10.1016/j.ajpath.2018.07.030			13	Pathology	Pathology	HF4EX	WOS:000454187100014	30446159				2019-10-28	
J	Huhtaniemi, R; Oksala, R; Knuuttila, M; Mehmood, A; Aho, E; Laajala, TD; Nicorici, D; Aittokallio, T; Laiho, A; Elo, L; Ohlsson, C; Kallio, P; Makela, S; Mustonen, MVJ; Sipila, P; Poutanen, M				Huhtaniemi, Riikka; Oksala, Riikka; Knuuttila, Matias; Mehmood, Arfa; Aho, Eija; Laajala, Teemu D.; Nicorici, Daniel; Aittokallio, Tero; Laiho, Asta; Elo, Laura; Ohlsson, Claes; Kallio, Pekka; Makela, Sari; Mustonen, Mika V. J.; Sipila, Petra; Poutanen, Matti			Adrenals Contribute to Growth of Castration-Resistant VCaP Prostate Cancer Xenografts	AMERICAN JOURNAL OF PATHOLOGY			English	Article							ANDROGEN RECEPTOR EXPRESSION; ABIRATERONE ACETATE; HORMONE AGONISTS; MECHANISMS; STEROIDOGENESIS; ENZALUTAMIDE; GENE; ANTIANDROGENS; BIOCONDUCTOR; TESTOSTERONE	The role of adrenal androgens as drivers for castration-resistant prostate cancer (CRPC) growth in humans is generally accepted; however, the value of preclinical mouse models of CRPC is debatable, because mouse adrenals do not produce steroids activating the androgen receptor. In this study, we confirmed the expression of enzymes essential for de novo synthesis of androgens in mouse adrenals, with high intratissue concentration of progesterone (P-4) and moderate levels of androgens, such as androstenedione, testosterone, and dihydrotestosterone, in the adrenal glands of both intact and orchectomized (ORX) mice. ORX alone had no effect on serum P-4 concentration, whereas orchectomized and adrenalectomized (ORX + ADX) resulted in a significant decrease in serum P-4 and in a further reduction in the Low levels of serum androgens (androstenedione, testosterone, and dihydrotestosterone), measured by mass spectrometry. In line with this, the serum prostate-specific antigen and growth of VCaP xenografts in mice after ORX + ADX were markedly reduced compared with ORX alone, and the growth difference was not abolished by a glucocorticoid treatment. Moreover, ORX + ADX altered the androgen-dependent gene expression in the tumors, similar to that recently shown for the enzalutamide treatment. These data indicate that in contrast to the current view, and similar to humans, mouse adrenals synthesize significant amounts of steroids that contribute to the androgen receptor dependent growth of CRPC.	[Huhtaniemi, Riikka; Knuuttila, Matias; Laajala, Teemu D.; Makela, Sari; Sipila, Petra; Poutanen, Matti] Univ Turku, Res Ctr Integrat Physiol & Pharmacol, Turku, Finland; [Huhtaniemi, Riikka; Knuuttila, Matias; Laajala, Teemu D.; Makela, Sari; Sipila, Petra; Poutanen, Matti] Univ Turku, Turku Ctr Dis Modeling, Turku, Finland; [Laajala, Teemu D.; Aittokallio, Tero] Univ Turku, Inst Biomed, Dept Math & Stat, Turku, Finland; [Makela, Sari] Univ Turku, Funct Foods Forum, Turku, Finland; [Huhtaniemi, Riikka; Oksala, Riikka; Aho, Eija; Nicorici, Daniel; Kallio, Pekka; Mustonen, Mika V. J.] Orion Corp, Orion Pharma, Espoo, Finland; [Mehmood, Arfa; Laiho, Asta; Elo, Laura] Univ Turku, Turku Ctr Biotechnol, Turku, Finland; Abo Akad Univ, Turku, Finland; [Laajala, Teemu D.; Aittokallio, Tero] Univ Helsinki, Inst Mol Med Finland, Helsinki, Finland; [Ohlsson, Claes; Poutanen, Matti] Univ Gothenburg, Sahlgrenska Acad, Inst Med, Gothenburg, Sweden	Poutanen, M (reprint author), Univ Turku, Inst Biomed, Kiinamyllynkatu 10, FIN-20520 Turku, Finland.	matti.poutanen@utu.fi	Aittokallio, Tero/B-6583-2009; Elo, Laura/A-9449-2015	Aittokallio, Tero/0000-0002-0886-9769; Elo, Laura/0000-0001-5648-4532; Ohlsson, Claes/0000-0002-9633-2805; Makela, Sari/0000-0002-8698-4076; Sipila, Petra/0000-0001-8187-7143	Academy of FinlandAcademy of Finland; Cancer Foundation of Finland; Drug Research Doctoral Programme; Finnish Cultural FoundationFinnish Cultural Foundation; Sigrid Juselius FoundationSigrid Juselius Foundation; Swedish government under the Agreement for Medical Education and Research; Swedish Research CouncilSwedish Research Council; University of Turku; Orion Pharma of the Orion Corporation	Supported by the Academy of Finland, the Cancer Foundation of Finland, the Drug Research Doctoral Programme, the Finnish Cultural Foundation, the Sigrid Juselius Foundation, the Swedish government under the Agreement for Medical Education and Research, the Swedish Research Council, the University of Turku, and Orion Pharma of the Orion Corporation.	ANDERSSON S, 1990, P NATL ACAD SCI USA, V87, P3640, DOI 10.1073/pnas.87.10.3640; Arora VK, 2013, CELL, V155, P1309, DOI 10.1016/j.cell.2013.11.012; Attard G, 2008, J CLIN ONCOL, V26, P4563, DOI 10.1200/JCO.2007.15.9749; Beer TM, 2014, NEW ENGL J MED, V371, P424, DOI 10.1056/NEJMoa1405095; Bohl CE, 2005, P NATL ACAD SCI USA, V102, P6201, DOI 10.1073/pnas.0500381102; Cai CM, 2011, CANCER RES, V71, P6503, DOI 10.1158/0008-5472.CAN-11-0532; Chen CD, 2004, NAT MED, V10, P33, DOI 10.1038/nm972; Committee for the Update of the Guide for the Care and Use of Laboratory Animals;, 2011, NAT RES COUNC GUID C; Crona DJ, 2015, CLIN PHARMACOL THER, V98, P582, DOI 10.1002/cpt.256; CULIG Z, 1993, MOL ENDOCRINOL, V7, P1541, DOI 10.1210/me.7.12.1541; Dillard PR, 2008, MOL CELL ENDOCRINOL, V295, P115, DOI 10.1016/j.mce.2008.08.013; Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635; Efstathiou E, 2015, EUR UROL, V67, P53, DOI 10.1016/j.eururo.2014.05.005; Evaul K, 2010, ENDOCRINOLOGY, V151, P3514, DOI 10.1210/en.2010-0138; Fenton MA, 1997, CLIN CANCER RES, V3, P1383; Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210; Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r80; HAMPL R, 1988, EXP CLIN ENDOCRINOL, V92, P211, DOI 10.1055/s-0029-1210803; Heinlein CA, 2004, ENDOCR REV, V25, P276, DOI 10.1210/er.2002-0032; HIRAMOTO Y, 1987, CANCER IMMUNOL IMMUN, V25, P157; Hofland J, 2010, CANCER RES, V70, P1256, DOI 10.1158/0008-5472.CAN-09-2092; Knudsen KE, 2010, TRENDS ENDOCRIN MET, V21, P315, DOI 10.1016/j.tem.2010.01.002; Knuuttila M, 2018, AM J PATHOL, V188, P216, DOI 10.1016/j.ajpath.2017.08.036; Knuuttila M, 2014, AM J PATHOL, V184, P2163, DOI 10.1016/j.ajpath.2014.04.010; Koivisto P, 1997, CANCER RES, V57, P314; Kolinsky M, 2016, JAMA ONCOL, V2, P437, DOI 10.1001/jamaoncol.2015.4918; Korenchuk S, 2001, IN VIVO, V15, P163; Kumagai J, 2013, PROSTATE, V73, P1636, DOI 10.1002/pros.22655; Laajala TD, 2016, SCI REP-UK, V6, DOI 10.1038/srep30723; Laajala TD, 2012, CLIN CANCER RES, V18, P4385, DOI 10.1158/1078-0432.CCR-11-3215; LABRIE F, 1991, MOL CELL ENDOCRINOL, V78, pC113, DOI 10.1016/0303-7207(91)90116-A; Lee DK, 2003, J CLIN ENDOCR METAB, V88, P4043, DOI 10.1210/jc.2003-030261; Liao Y, 2014, BIOINFORMATICS, V30, P923, DOI 10.1093/bioinformatics/btt656; Lindzey J, 1998, ENDOCRINOLOGY, V139, P4092, DOI 10.1210/en.139.10.4092; Locke JA, 2008, CANCER RES, V68, P6407, DOI 10.1158/0008-5472.CAN-07-5997; Locke JA, 2009, J STEROID BIOCHEM, V115, P126, DOI 10.1016/j.jsbmb.2009.03.011; Lovgren T, 1996, CLIN CHEM, V42, P1196; Nilsson ME, 2015, ENDOCRINOLOGY, V156, P2492, DOI 10.1210/en.2014-1890; Nishii M, 2012, J ANDROL, V33, P1233, DOI 10.2164/jandrol.112.016493; O'Donnell A, 2004, BRIT J CANCER, V90, P2317, DOI 10.1038/sj.bjc.6601879; PRETLOW TG, 1993, J NATL CANCER I, V85, P394, DOI 10.1093/jnci/85.5.394; Pretorius E, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0159867; R Development Core Team R, 2011, R LANG ENV STAT COMP, V1, DOI [10.1007/978-3-540-74686-7, DOI 10.1007/978-3-540-74686-7]; Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007; Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616; Rygaard J, 1982, BIOMED RES, P51; Scher HI, 2012, NEW ENGL J MED, V367, P1187, DOI 10.1056/NEJMoa1207506; Scher HI, 2010, LANCET, V375, P1437, DOI 10.1016/S0140-6736(10)60172-9; Sharifi N, 2010, J INVEST MED, V58, P938, DOI 10.231/JIM.0b013e3181ff6bb8; Sprenger CCT, 2014, HORM CANCER-US, V5, P207, DOI 10.1007/s12672-014-0177-y; Stanbrough M, 2006, CANCER RES, V66, P2815, DOI 10.1158/0008-5472.CAN-05-4000; Stuchbery R, 2017, NAT REV UROL, V14, P49, DOI 10.1038/nrurol.2016.221; Sun MX, 2016, JAMA ONCOL, V2, P500, DOI 10.1001/jamaoncol.2015.4917; Sun SH, 2010, J CLIN INVEST, V120, P2715, DOI 10.1172/JCI41824; Suomi T, 2017, PLOS COMPUT BIOL, V13, DOI 10.1371/journal.pcbi.1005562; SYMS AJ, 1985, J BIOL CHEM, V260, P455; TAPLIN ME, 1995, NEW ENGL J MED, V332, P1393, DOI 10.1056/NEJM199505253322101; Van Asseldonk B, 2016, UROLOGY, V93, P3, DOI 10.1016/j.urology.2016.04.002; van Weerden WM, 2000, PROSTATE, V43, P263; VANDERKWAST TH, 1991, INT J CANCER, V48, P189, DOI 10.1002/ijc.2910480206; VANWEERDEN WM, 1992, LIFE SCI, V50, P857, DOI 10.1016/0024-3205(92)90204-3; Yuan X, 2014, ONCOGENE, V33, P2815, DOI 10.1038/onc.2013.235; Zhao XY, 2000, NAT MED, V6, P703	63	1	1	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	DEC	2018	188	12					2890	2901		10.1016/j.ajpath.2018.07.029			12	Pathology	Pathology	HF4EX	WOS:000454187100015	30273606				2019-10-28	
J	Diaz, RJ; Luck, A; Bondoc, A; Golbourn, B; Picard, D; Remke, M; Loukides, J; Sabha, N; Smith, C; Cusimano, MD; Rutka, JT				Diaz, Roberto J.; Luck, Amanda; Bondoc, Andrew; Golbourn, Brian; Picard, Daniel; Remke, Marc; Loukides, James; Sabha, Nesrin; Smith, Christian; Cusimano, Michael D.; Rutka, James T.			Characterization of a Clival Chordoma Xenograft Model Reveals Tumor Genomic Instability	AMERICAN JOURNAL OF PATHOLOGY			English	Article							FHIT GENE; EXPRESSION PATTERN; SURVIVAL PATTERNS; CELL; BRACHYURY; ESTABLISHMENT; GENERATION	Patient-derived xenografts retain the genotype of the parent tumors more readily than tumor cells maintained in culture. The two previously reported clival chordoma xenografts were derived from recurrent tumors after radiation. To study the genetics of clival chordoma in the absence of prior radiation exposure we established a patient-derived xenograft at primary resection of a clival chordoma. Epicranial grafting of clival chordoma collected during surgery was performed. Tumor growth was established in a nonobese diabetic/severe combined immunodeficiency mouse and tumors have been passaged serially for seven generations. Physaliferous cell architecture was shown in the regenerated tumors, which stained positive for Brachyury, cytokeratin, and 5100 protein. The tumors showed bone invasion. Single-nucleotide polymorphism analysis of the tumor xenograft was compared with the parental tumor. Copy number gain of the T gene (brachywy) and heterozygous loss of cyclin dependent kinase inhibitor 2A (CDKN2A) was observed. Heterozygous loss of the tumor-suppressor fragile histidine triad (FHIT) gene also was observed, although protein expression was preserved. Accumulation of copy number losses and gains as well as increased growth rate was observed over three generations. The patient-derived xenograft reproduces the phenotype of clival chordoma. This model can be used in the future to study chordoma biology and to assess novel treatments.	[Diaz, Roberto J.] McGill Univ, Montreal Neurol Inst & Hosp, Dept Neurol & Neurosurg, Montreal, PQ, Canada; [Luck, Amanda; Bondoc, Andrew; Golbourn, Brian; Loukides, James; Sabha, Nesrin; Smith, Christian; Rutka, James T.] Hosp Sick Children, Div Neurosurg, Toronto, ON, Canada; [Golbourn, Brian; Rutka, James T.] Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON, Canada; [Cusimano, Michael D.; Rutka, James T.] Univ Toronto, Dept Surg, Div Neurosurg, Toronto, ON, Canada; [Picard, Daniel; Remke, Marc] German Canc Consortium DKTK, Dept Pediat Neurooncogen, Heidelberg, Germany; German Canc Res Ctr, Heidelberg, Germany; [Picard, Daniel; Remke, Marc] Univ Hosp Dusseldorf, Fac Med, Dept Pediat Oncol Hematol & Clin Immunol, Dusseldorf, Germany; [Remke, Marc] Heinrich Heine Univ Dusseldorf, Fac Med, Dept Neuropathol, Dusseldorf, Germany; [Cusimano, Michael D.] St Michaels Hosp, Div Neurosurg, Toronto, ON, Canada	Diaz, RJ (reprint author), Montreal Neurol Hosp & Inst, Dept Neurol & Neurosurg, 3801 Rue Univ,Room 109, Montreal, PQ H3A 2B4, Canada.	roberto.diaz@mcgill.ca	Cusimano, Michael/X-4059-2019	Remke, Marc/0000-0002-9404-9993	Brainchild; Megan's Walk; Laurie Berman and Wiley Family Funds for Brain Tumor Research; German Research Foundation/Deutsche ForschungsgemeinschaftGerman Research Foundation (DFG) [RE 2857/2-1]	Supported by Brainchild, Megan's Walk, the Laurie Berman and Wiley Family Funds for Brain Tumor Research (J.T.R.), and German Research Foundation/Deutsche Forschungsgemeinschaft grant RE 2857/2-1 (D.P. and M.R.).	Baffa R, 1998, CANCER RES, V58, P4708; Bissig-Choisat B, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8339; Bozzi F, 2014, NEURO-ONCOLOGY, V16, P72, DOI [10.1093/neuonc/not238, 10.1093/neuonc/not152]; Brkic G, 2003, ANTICANCER RES, V23, P2601; Chambers KJ, 2014, LARYNGOSCOPE, V124, P1097, DOI 10.1002/lary.24420; Chapman DL, 1996, DEV BIOL, V180, P534, DOI 10.1006/dbio.1996.0326; D'Agostini F, 2006, CANCER RES, V66, P3936, DOI 10.1158/0008-5472.CAN-05-3666; Davies JM, 2014, J NEUROSURG, V120, P331, DOI 10.3171/2013.10.JNS13598; DeComas AM, 2010, J BONE JOINT SURG AM, V92A, P1231, DOI 10.2106/JBJS.I.00594; Diaz RJ, 2014, J NEUROSURG, V120, P528, DOI 10.3171/2013.9.JNS13671; Diaz RJ, 2012, NEOPLASIA, V14, P788, DOI 10.1593/neo.12526; Diaz RJ, 2011, J NEURO-ONCOL, V104, P411, DOI 10.1007/s11060-011-0559-8; Hallor KH, 2008, BRIT J CANCER, V98, P434, DOI 10.1038/sj.bjc.6604130; Hendricks DT, 1997, CANCER RES, V57, P2112; HERRMANN BG, 1991, DEVELOPMENT, V113, P913; Hsu W, 2011, J NEUROSURG, V115, P760, DOI 10.3171/2011.5.JNS11185; Ishii H, 2003, MOL CANCER RES, V1, P940; Karikari IO, 2014, J NEUROSURG-SPINE, V21, P386, DOI 10.3171/2014.4.SPINE13262; Lee AJX, 2011, CANCER RES, V71, P1858, DOI 10.1158/0008-5472.CAN-10-3604; Liu XZ, 2012, J ORTHOP RES, V30, P1666, DOI 10.1002/jor.22113; McMaster ML, 2001, CANCER CAUSE CONTROL, V12, P1, DOI 10.1023/A:1008947301735; Otani R, 2018, J NEUROSURG, V128, P1428, DOI 10.3171/2016.12.JNS161444; Owen JH, 2018, J NEUROSURG, V128, P701, DOI 10.3171/2016.10.JNS16877; Presneau N, 2011, J PATHOL, V223, P327, DOI 10.1002/path.2816; Reig G, 2014, DEVELOPMENT, V141, P1999, DOI 10.1242/dev.101451; SALISBURY JR, 1993, J PATHOL, V171, P59, DOI 10.1002/path.1711710112; Shah SR, 2017, CELL REP, V21, P495, DOI 10.1016/j.celrep.2017.09.057; Shen J, 2011, J CLIN NEUROSCI, V18, P96, DOI 10.1016/j.jocn.2010.03.066; Siu IM, 2012, J NEUROSURG, V116, P801, DOI 10.3171/2011.12.JNS111123; Sozzi G, 1996, CELL, V85, P17, DOI 10.1016/S0092-8674(00)81078-8; Trucco MM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079950; Virgilio L, 1996, P NATL ACAD SCI USA, V93, P9770, DOI 10.1073/pnas.93.18.9770; WILKINSON DG, 1990, NATURE, V343, P657, DOI 10.1038/343657a0; Wu Z, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0119523; Yamaguchi T, 2004, HISTOPATHOLOGY, V44, P597, DOI 10.1111/j.1365-2559.2004.01877.x; Zanesi N, 2001, P NATL ACAD SCI USA, V98, P10250, DOI 10.1073/pnas.191345898	36	0	0	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	DEC	2018	188	12					2902	2911		10.1016/j.ajpath.2018.08.004			10	Pathology	Pathology	HF4EX	WOS:000454187100016	30248342	Bronze			2019-10-28	
J	Yu, S; Yang, M; Lim, KM; Cho, Y; Kim, H; Lee, K; Jeong, SH; Coffey, RJ; Goldenring, JR; Nam, KT				Yu, Sungsook; Yang, Mijeong; Lim, Kyung-Min; Cho, Yejin; Kim, Hyunji; Lee, Keunwook; Jeong, Sang-Ho; Coffey, Robert J.; Goldenring, James R.; Nam, Ki Taek			Expression of LRIG1, a Negative Regulator of EGFR, Is Dynamically Altered during Different Stages of Gastric Carcinogenesis	AMERICAN JOURNAL OF PATHOLOGY			English	Article							GROWTH-FACTOR RECEPTOR; STEM-CELL MARKER; OXYNTIC ATROPHY; CHIEF CELLS; METAPLASIA; CANCER; MICE; OVEREXPRESSION; CARCINOMA; STOMACH	Leucine-rich repeats and immunoglobulin-like domains (LRIG)-1 is a transmembrane protein that antagonizes epidermal growth factor receptor signaling in epithelial tissues. LRIG1 is down-regulated in various epithelial cancers, including bladder, breast, and colorectal cancer, suggesting that it functions as a tumor suppressor. However, its role in gastric carcinogenesis is not well understood. Here, we investigated the changes in LRIG1 expression during the stages of gastric cancer. We used a DMP-777 induced spasmolytic polypeptide-expressing metaptasia mouse model. and a tissue array of human gastric cancer lesions. The effects of LRIG1 knockdown were also assessed using the human gastric cancer cell line SNU638 in a xenograft model. LRIG1 expression varied over the course of gastric carcinogenesis, increasing in spasmolytic polypeptide-expressing metaptasia lesions but disappearing in intestinal metaplasia and cancer lesions, and the increase was concurrent with the up-regulation of epidermal growth factor receptor. In addition, LRIG1 knockdown promoted the tumorigenic potential in vitro, which was manifested as increased proliferation, invasiveness, and migration as well as increased tumor size in vivo in the xenograft model. Furthermore, LRIG1 expression was determined to be a positive prognostic biomarker for the survival of gastric cancer patients. Collectively, our findings indicate that LRIG1 expression is closely related wto gastric carcinogenesis and may play a vital role as a tumor suppressor through the modulation of epidermal growth factor receptor activity.	[Yu, Sungsook; Yang, Mijeong; Cho, Yejin; Kim, Hyunji; Nam, Ki Taek] Yonsei Univ, Coll Med, Brain Korea 21 PLUS Project Med Sci, Severance Biomed Sci Inst, Seoul, South Korea; [Lim, Kyung-Min] Ewha Womans Univ, Coll Pharm, Seoul, South Korea; [Lee, Keunwook] Hallym Univ, Dept Biomed Sci, Chunchon, South Korea; [Jeong, Sang-Ho] Gyeongsang Natl Univ, Changwon Hosp, Dept Surg, Chang Won, South Korea; [Coffey, Robert J.; Goldenring, James R.] Vanderbilt Univ, Sch Med, Epithelial Biol Ctr, Nashville, TN 37212 USA; [Coffey, Robert J.] Vanderbilt Univ, Sch Med, Dept Med, Nashville, TN 37212 USA; [Goldenring, James R.] Vanderbilt Univ, Sch Med, Sect Surg Sci, Nashville, TN 37212 USA	Nam, KT (reprint author), Yonsei Univ, Coll Med, Severance Biomed Sci Inst, 50-1 Yonsei Ro, Seoul 03722, South Korea.	kitaek@yuhs.ac		Goldenring, James/0000-0002-7833-2940	National Research Foundation (NRF) - (Korean government) Korea Mouse Phenotyping Project [NRF-2016M3A9D5A01952416, 2013M3A9D5072551]; Ministry of Science, ICT and Future Planning [NRF-2017R1A2B2009850, NRF-2017M3A9F3041234]; Yonsei University College of Medicine [6-2015-0163]; Yonsei University Brain Korea 21 PLUS Project for Medical Science; Ministry of Education, Science and Technology NRF Basic Science Research Program [NRF-2015R1C1A2A01053575]; US Department of Veterans Affairs Merit Review AwardUS Department of Veteran Affairs [I01BX000930]; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [RO1 DK071590]; Ministry of Science and ICT grant [2018R1A5A2025286]	Supported by National Research Foundation (NRF; funded by the Korean government) Korea Mouse Phenotyping Project grants NRF-2016M3A9D5A01952416 and 2013M3A9D5072551, The Ministry of Science, ICT and Future Planning grants NRF-2017R1A2B2009850 and NRF-2017M3A9F3041234, and Ministry of Science and ICT grant 2018R1A5A2025286; Yonsei University College of Medicine faculty research grant 6-2015-0163; the Yonsei University Brain Korea 21 PLUS Project for Medical Science (K.T.N.); and Ministry of Education, Science and Technology NRF Basic Science Research Program grant NRF-2015R1C1A2A01053575 (S.Y.). J.R.G. is supported by US Department of Veterans Affairs Merit Review Award grant I01BX000930 and NIH grant RO1 DK071590.	Barrett T, 2013, NUCLEIC ACIDS RES, V41, pD991, DOI 10.1093/nar/gks1193; Bray F, 2015, INT J CANCER, V137, P2060, DOI 10.1002/ijc.29670; Choi E, 2018, GUT, V67, P1595, DOI 10.1136/gutjnl-2017-313874; Choi E, 2016, GASTROENTEROLOGY, V150, P918, DOI 10.1053/j.gastro.2015.11.049; Correa P, 2007, GASTROENTEROLOGY, V133, P659, DOI 10.1053/j.gastro.2007.06.026; Creighton CJ, 2010, J MAMMARY GLAND BIOL, V15, P253, DOI 10.1007/s10911-010-9173-1; Fox JG, 2007, J CLIN INVEST, V117, P60, DOI 10.1172/JCI30111; Fox JG, 1996, GASTROENTEROLOGY, V110, P155, DOI 10.1053/gast.1996.v110.pm8536852; Goldenring JR, 2006, AM J PHYSIOL-GASTR L, V291, pG999, DOI 10.1152/ajpgi.00187.2006; Goldenring JR, 2018, J PATHOL, V245, P132, DOI 10.1002/path.5066; Goldenring JR, 2010, PROG MOL BIOL TRANSL, V96, P117, DOI [10.1016/S1877-1173(10)96005-5, 10.1016/B978-0-12-381280-3.00005-1]; Goldenring JR, 2010, GASTROENTEROLOGY, V138, P2207, DOI 10.1053/j.gastro.2010.04.023; Goldoni S, 2007, ONCOGENE, V26, P368, DOI 10.1038/sj.onc.1209803; Gunasinghe NPAD, 2012, CANCER METAST REV, V31, P469, DOI 10.1007/s10555-012-9377-5; Gur G, 2004, EMBO J, V23, P3270, DOI 10.1038/sj.emboj.7600342; Hedman H, 2007, EUR J CANCER, V43, P676, DOI 10.1016/j.ejca.2006.10.021; Hoffmann W, 2015, INT J MOL SCI, V16, P19153, DOI 10.3390/ijms160819153; Honda S, 1998, CANCER RES, V58, P4255; Jensen KB, 2006, P NATL ACAD SCI USA, V103, P11958, DOI 10.1073/pnas.0601886103; Jensen KB, 2009, CELL STEM CELL, V4, P427, DOI 10.1016/j.stem.2009.04.014; Jeon TY, 2010, BRIT J CANCER, V102, P710, DOI 10.1038/sj.bjc.6605537; Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104; Ko YS, 2015, BRIT J CANCER, V113, P1186, DOI 10.1038/bjc.2015.273; Kou CH, 2015, BIOCHEM BIOPH RES CO, V464, P519, DOI 10.1016/j.bbrc.2015.06.173; Laederich MB, 2004, J BIOL CHEM, V279, P47050, DOI 10.1074/jbc.M409703200; Lee HJ, 2010, GASTROENTEROLOGY, V139, P213, DOI 10.1053/j.gastro.2010.04.008; Lennerz JKM, 2010, AM J PATHOL, V177, P1514, DOI 10.2353/ajpath.2010.100328; Ljuslinder I, 2007, ACTA ONCOL, V46, P1118, DOI 10.1080/02841860701426823; Miller JK, 2008, CANCER RES, V68, P8286, DOI 10.1158/0008-5472.CAN-07-6316; Mills JC, 2017, CELL MOL GASTROENTER, V4, P85, DOI 10.1016/j.jcmgh.2017.03.006; Nam KT, 2010, GASTROENTEROLOGY, V139, P2028, DOI 10.1053/j.gastro.2010.09.005; Nam KT, 2009, GASTROENTEROLOGY, V136, P1288, DOI 10.1053/j.gastro.2008.12.037; Petersen CP, 2018, GUT, V67, P805, DOI 10.1136/gutjnl-2016-312779; Petersen CP, 2014, GASTROENTEROLOGY, V146, P1727, DOI 10.1053/j.gastro.2014.02.007; Pisanu ME, 2017, CANCER LETT, V406, P93, DOI 10.1016/j.canlet.2017.07.027; Powell AE, 2012, CELL, V149, P146, DOI 10.1016/j.cell.2012.02.042; Segatto O, 2011, J CELL SCI, V124, P1785, DOI 10.1242/jcs.083303; Shao LM, 2014, INT J CLIN EXP MED, V7, P5067; Szasz AM, 2016, ONCOTARGET, V7, P49322, DOI 10.18632/oncotarget.10337; Thomasson M, 2003, BRIT J CANCER, V89, P1285, DOI 10.1038/sj.bjc.6601208; Vries RGJ, 2010, MOL ONCOL, V4, P373, DOI 10.1016/j.molonc.2010.05.001; Wang Y, 2013, BRIT J CANCER, V108, P1765, DOI 10.1038/bjc.2013.138; Wang Y, 2015, AM J PATHOL, V185, P1123, DOI 10.1016/j.ajpath.2014.12.014; Watanabe T, 1998, GASTROENTEROLOGY, V115, P642, DOI 10.1016/S0016-5085(98)70143-X; Weis VG, 2013, GUT, V62, P1270, DOI 10.1136/gutjnl-2012-302401; Weis VG, 2009, GASTRIC CANCER, V12, P189, DOI 10.1007/s10120-009-0527-6; Wong VWY, 2012, NAT CELL BIOL, V14, P401, DOI 10.1038/ncb2464; Yoshizawa N, 2007, LAB INVEST, V87, P1265, DOI 10.1038/labinvest.3700682; Zhou L, 2018, CANCER SCI, V109, P1044, DOI 10.1111/cas.13538	49	1	1	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	DEC	2018	188	12					2912	2923		10.1016/j.ajpath.2018.08.006			12	Pathology	Pathology	HF4EX	WOS:000454187100017	30248341				2019-10-28	
J	Bus, P; Gerrits, T; Heemskerk, SAC; Zandbergen, M; Wolterbeek, R; Bruijn, JA; Baelde, HJ; Scharpfenecker, M				Bus, Pascal; Gerrits, Tessa; Heemskerk, Sharon A. C.; Zandbergen, Malu; Wolterbeek, Ron; Bruijn, Jan A.; Baelde, Hans J.; Scharpfenecker, Marion			Endoglin Mediates Vascular Endothelial Growth Factor-A-Induced Endothelial Cell Activation by Regulating Akt Signaling	AMERICAN JOURNAL OF PATHOLOGY			English	Article							INTERCELLULAR-ADHESION MOLECULE-1; GLOMERULAR MACROPHAGE INFILTRATION; SMOOTH MUSCLE ACTIN; RAT MESANGIAL CELLS; PROTEIN-KINASE-C; VEGF-A; E-SELECTIN; EXPRESSION; VCAM-1; INFLAMMATION	In diabetic nephropathy, differential expression of growth factors leads to vascular changes, including endothelial cell activation, monocyte infiltration, and inflammation. Endoglin plays an important role in endothelial function and is also associated with inflammation. In the kidney, vascular endoglin expression is increased in animal models of renal injury, where it contributes to disease severity, possibly by promoting endothelial cell activation and inflammation. Herein, we investigated whether endoglin expression is associated with diabetic nephropathy. In addition, we examined whether reducing endothelial endoglin expression in vitro affects endothelial cell activation and monocyte adhesion and, if so, which intracellular pathways are involved. Finally, we analyzed whether glomerular endoglin expression is correlated with endothelial cell activation in patients with diabetic nephropathy. Endoglin levels were significantly increased in mice with type 1 diabetes compared with control mice. Reducing endoglin expression in cultured endothelial cells significantly impaired the vascular endothelial growth factor-A induced up-regulation of activation markers and monocyte adhesion. This was mediated by increased phosphorylation of Akt, thereby inhibiting activating transcription factor 2 phosphorylation, which regulates vascular cell adhesion molecule-1 (VCAM1) gene transcription in these cells. Last, endoglin colocalized with VCAM-1 in the glomeruli of diabetic patients, glomerular VCAM-1 expression was significantly increased in these patients, and this increase in VCAM-1 expression was correlated with increased glomerular endoglin expression. Thus, targeting endoglin function may have therapeutic value in patients at risk for diabetic nephropathy.	[Bus, Pascal; Gerrits, Tessa; Heemskerk, Sharon A. C.; Zandbergen, Malu; Bruijn, Jan A.; Baelde, Hans J.; Scharpfenecker, Marion] Leiden Univ, Med Ctr, Dept Pathol, POB 9600,L1Q,Room P0-107, NL-2300 RC Leiden, Netherlands; [Wolterbeek, Ron] Leiden Univ, Med Ctr, Dept Med Stat & Bioinformat, Leiden, Netherlands	Bus, P (reprint author), Leiden Univ, Med Ctr, Dept Pathol, POB 9600,L1Q,Room P0-107, NL-2300 RC Leiden, Netherlands.	p.bus@lumc.nl		baelde, Hans/0000-0002-1214-500X	Department of Pathology at the Leiden University Medical Center	Supported by the Department of Pathology at the Leiden University Medical Center.	Arthur HM, 2000, DEV BIOL, V217, P42, DOI 10.1006/dbio.1999.9534; Atkins RC, 2010, AM J KIDNEY DIS, V55, P205, DOI 10.1053/j.ajkd.2009.12.001; Awad AS, 2015, KIDNEY INT, V88, P722, DOI 10.1038/ki.2015.162; Baelde HJ, 2007, KIDNEY INT, V71, P637, DOI 10.1038/sj.ki.5002101; Basta G, 2002, CIRCULATION, V105, P816, DOI 10.1161/hc0702.104183; Botella LM, 2002, BLOOD, V100, P4001, DOI 10.1182/blood.V100.12.4001; Brownlee M, 2005, DIABETES, V54, P1615, DOI 10.2337/diabetes.54.6.1615; Bus P, 2017, DIABETOLOGIA, V60, P1813, DOI 10.1007/s00125-017-4322-3; Chow FY, 2005, J AM SOC NEPHROL, V16, P1711, DOI 10.1681/ASN.2004070612; Clausen P, 2000, DIABETIC MED, V17, P644, DOI 10.1046/j.1464-5491.2000.00347.x; Deeds MC, 2011, LAB ANIM-UK, V45, P131, DOI 10.1258/la.2010.010090; Docherty NG, 2006, NEPHROL DIAL TRANSPL, V21, P2106, DOI 10.1093/ndt/gfl179; Essawy M, 1997, NEPHROL DIAL TRANSPL, V12, P43, DOI 10.1093/ndt/12.1.43; Faulkner J, 2015, J DIABETES METAB, V6, DOI 10.4172/2155-6156.1000555; Fearnley GW, 2014, MOL BIOL CELL, V25, P2509, DOI 10.1091/mbc.E14-05-0962; FONTIJN R, 1995, EXP CELL RES, V216, P199, DOI 10.1006/excr.1995.1025; Rubio-Guerra AF, 2009, KIDNEY BLOOD PRESS R, V32, P106, DOI 10.1159/000210554; Gerber HP, 1998, J BIOL CHEM, V273, P30336, DOI 10.1074/jbc.273.46.30336; Gonlusen Gulfiliz, 2001, International Urology and Nephrology, V33, P299, DOI 10.1023/A:1015226426000; Griffin GK, 2012, J IMMUNOL, V188, P6287, DOI 10.4049/jimmunol.1200385; Grotendorst GR, 1996, CELL GROWTH DIFFER, V7, P469; Gurley SB, 2006, AM J PHYSIOL-RENAL, V290, pF214, DOI 10.1152/ajprenal.00204.2005; Hattori M, 1999, KIDNEY INT, V56, pS47, DOI 10.1046/j.1523-1755.1999.07112.x; Hirata K, 1998, DIABETOLOGIA, V41, P185, DOI 10.1007/s001250050888; Ichimura K, 2006, J HISTOCHEM CYTOCHEM, V54, P1291, DOI 10.1369/jhc.6A7000.2006; Irigoyen JP, 1999, CELL MOL LIFE SCI, V56, P104, DOI 10.1007/PL00000615; Blanco FJ, 2012, FRONT PHYSIOL, V3, DOI 10.3389/fphys.2012.00054; Jin Y, 2017, NAT CELL BIOL, V19, P639, DOI 10.1038/ncb3534; JOHNSON RJ, 1991, J CLIN INVEST, V87, P847, DOI 10.1172/JCI115089; Jonker L, 2002, MECH DEVELOP, V110, P193, DOI 10.1016/S0925-4773(01)00562-7; Jude EB, 2002, EUR J INTERN MED, V13, P185, DOI DOI 10.1016/S0953-6205(02)00014-6; Kim AH, 2001, MOL CELL BIOL, V21, P893, DOI 10.1128/MCB.21.3.893-901.2001; Kim I, 2001, J BIOL CHEM, V276, P7614, DOI 10.1074/jbc.M009705200; Koga M, 1998, DIABETIC MED, V15, P661, DOI 10.1002/(SICI)1096-9136(199808)15:8<661::AID-DIA645>3.0.CO;2-G; Li DY, 1999, SCIENCE, V284, P1534, DOI 10.1126/science.284.5419.1534; Liao JK, 2013, J CLIN INVEST, V123, P540, DOI 10.1172/JCI66843; Lindenmeyer MT, 2007, J AM SOC NEPHROL, V18, P1765, DOI 10.1681/ASN.2006121304; Min JK, 2005, CIRC RES, V96, P300, DOI 10.1161/01.RES.0000155330.07887.EE; Okada S, 2003, DIABETES, V52, P2586, DOI 10.2337/diabetes.52.10.2586; Okouchi M, 2002, DIABETOLOGIA, V45, P556, DOI 10.1007/s00125-001-0773-6; Onozato ML, 2004, KIDNEY INT, V65, P951, DOI 10.1111/j.1523-1755.2004.00470.x; Oujo B, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0110365; Page AV, 2013, VIRULENCE, V4, P507, DOI 10.4161/viru.24530; Pan CC, 2014, J BIOL CHEM, V289, P25486, DOI 10.1074/jbc.M114.578609; Quagliaro L, 2005, ATHEROSCLEROSIS, V183, P259, DOI 10.1016/j.atherosclerosis.2005.03.015; Rodriguez-Barbero A, 2001, BIOCHEM BIOPH RES CO, V282, P142, DOI 10.1006/bbrc.2001.4526; Rossi E, 2013, BLOOD, V121, P403, DOI 10.1182/blood-2012-06-435347; Sassy-Prigent C, 2000, DIABETES, V49, P466, DOI 10.2337/diabetes.49.3.466; Sato W, 2008, LAB INVEST, V88, P949, DOI 10.1038/labinvest; Scharpfenecker M, 2009, RADIOTHER ONCOL, V92, P484, DOI 10.1016/j.radonc.2009.06.013; SERON D, 1991, NEPHROL DIAL TRANSPL, V6, P917, DOI 10.1093/ndt/6.12.917; Simons M, 2012, PHYSIOLOGY, V27, P213, DOI 10.1152/physiol.00016.2012; Torsney E, 2002, INFLAMM RES, V51, P464, DOI 10.1007/PL00012413; Vestweber D, 2015, NAT REV IMMUNOL, V15, P692, DOI 10.1038/nri3908	54	0	1	1	8	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	DEC	2018	188	12					2924	2935		10.1016/j.ajpath.2018.08.005			12	Pathology	Pathology	HF4EX	WOS:000454187100018	30248336	Bronze			2019-10-28	
J	Ning, B; Chen, YJ; Waqar, AB; Yan, HZ; Shiomi, M; Zhang, JF; Chen, YE; Wang, YL; Itabe, H; Liang, JY; Fan, JL				Ning, Bo; Chen, Yajie; Waqar, Ahmed Bilal; Yan, Haizhao; Shiomi, Masashi; Zhang, Jifeng; Chen, Y. Eugene; Wang, Yanli; Itabe, Hiroyuki; Liang, Jingyan; Fan, Jianglin			Hypertension Enhances Advanced Atherosclerosis and Induces Cardiac Death in Watanabe Heritable Hyperlipidemic Rabbits	AMERICAN JOURNAL OF PATHOLOGY			English	Article							ONE-KIDNEY; AORTIC ATHEROSCLEROSIS; INTRAPLAQUE HEMORRHAGE; CORONARY PLAQUES; PROGRESSION; LESIONS; NEOVASCULARIZATION; ACCELERATION; HEMOGLOBIN; CELLS	Hypertension is a major risk factor for the development of atherosclerosis. Cardiovascular risk has been reported to be significantly increased in hyperlipidemic patients with hypertension. However, it is not clear whether hypertension can directly destabilize plaques, thereby enhancing cardiovascular events. To examine whether hypertension enhances the development of atherosclerosis and increases plaque vulnerability, we generated hypertensive Watanabe heritable hyperlipidemic (WHHL) rabbits by surgical removal of one kidney and partial ligation of the other renal artery and compared the nature of aortic and coronary atherosclerosis in hypertensive WHHL rabbits with normotensive WHHL rabbits. All hypertensive WHHL rabbits died from 34 to 56 weeks after surgery, whereas no normotensive WHHL rabbits died. Pathologic examinations revealed that hypertensive WHHL rabbits showed different degrees of myocardial infarction caused by severe coronary stenosis along with myocardial hypertrophy. Furthermore, aortic lesions in hypertensive WHHL rabbits exhibited a higher frequency of intraplaque hemorrhage and vulnerable plaques than those in normotensive WHHL rabbits. These results indicate that hypertension induced by the surgical removal of one kidney and partial ligation of the other renal artery method in WHHL rabbits may not only enhance the development of atherosclerosis but also destabilize the plaques, increasing cardiac death.	[Ning, Bo; Wang, Yanli; Fan, Jianglin] Xian Med Univ, Coll Clin Med, Xian, Shaanxi, Peoples R China; [Ning, Bo; Wang, Yanli; Fan, Jianglin] Xian Med Univ, Dept Pathol, Xian, Shaanxi, Peoples R China; [Ning, Bo; Chen, Yajie; Waqar, Ahmed Bilal; Yan, Haizhao; Fan, Jianglin] Univ Yamanashi, Grad Sch Med Sci, Fac Med, Dept Mol Pathol, Yamanashi, Japan; [Shiomi, Masashi] Kobe Univ, Sch Med, Inst Expt Anim, Kobe, Hyogo, Japan; [Zhang, Jifeng; Chen, Y. Eugene] Univ Michigan, Med Ctr, Ctr Adv Models Translat Sci & Therapeut, Ann Arbor, MI USA; [Itabe, Hiroyuki] Showa Univ, Sch Pharm, Dept Mol Biol, Div Biol Chem, Tokyo, Japan; [Liang, Jingyan] Yangzhou Univ, Sch Med, Vasc Biol Res Ctr, Yangzhou, Jiangsu, Peoples R China	Fan, JL (reprint author), Univ Yamanashi, Dept Mol Pathol, 1110 Shimokato, Yamanashi 4093898, Japan.	jianglin@yamanashi.ac.jp	Waqar, Ahmed Bilal/P-2954-2015	Waqar, Ahmed Bilal/0000-0001-8255-3634	National Key Research and Development Program of China [2016YFE0126000]; National Natural Science Foundation of ChinaNational Natural Science Foundation of China [81570392, 81770457]; JSPS KAKENHIMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI) [15H04718]; JSPS-CAS under the Japan China Research Cooperative Program; Natural Science Foundation of Shaanxi ProvinceNatural Science Foundation of Shaanxi Province [2017JZ028]; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01HL117491, R01HL129778]	Supported in part by the National Key Research and Development Program of China grant 2016YFE0126000 (J.L. and J.F.), the National Natural Science Foundation of China grants 81570392 (J.L.) and 81770457 (J.F.), JSPS KAKENHI grant 15H04718 (J.F.), JSPS-CAS under the Japan China Research Cooperative Program (J.F.), the Natural Science Foundation of Shaanxi Province grant 2017JZ028 (J.F.), and NIH grants R01HL117491 and R01HL129778 (Y.E.C.).	Borges GR, 2008, AM J PHYSIOL-REG I, V295, pR1904, DOI 10.1152/ajpregu.00107.2008; CHOBANIAN AV, 1983, PROG CARDIOVASC DIS, V26, P177, DOI 10.1016/0033-0620(83)90005-1; Chobanian AV, 1996, ARCH INTERN MED, V156, P1952, DOI 10.1001/archinte.156.17.1952; CHOBANIAN AV, 1990, HYPERTENSION, V15, P327, DOI 10.1161/01.HYP.15.3.327; CHOBANIAN AV, 1991, ADV EXP MED BIOL, V308, P45; CHOBANIAN AV, 1989, HYPERTENSION, V14, P203, DOI 10.1161/01.HYP.14.2.203; Committee for the Update of the Guide for the Care and Use of Laboratory Animals; National Research Council, 2011, GUIDE CARE USE LAB A; Daugherty A, 2000, J CLIN INVEST, V105, P1605, DOI 10.1172/JCI7818; Fan JL, 2015, PHARMACOL THERAPEUT, V146, P104, DOI 10.1016/j.pharmthera.2014.09.009; Fleiner M, 2004, CIRCULATION, V110, P2843, DOI 10.1161/01.CIR.0000146787.16297.E8; HEPTINSTALL R. H., 1958, ANGIOLOGY, V9, P84; Julius S, 2004, LANCET, V363, P2022, DOI 10.1016/S0140-6736(04)16451-9; Koike T, 2005, CARDIOVASC RES, V65, P524, DOI 10.1016/j.cardiores.2004.10.022; KOLETSKY S, 1968, EXP MOL PATHOL, V9, P322, DOI 10.1016/0014-4800(68)90023-3; Kolodgie FD, 2003, NEW ENGL J MED, V349, P2316, DOI 10.1056/NEJMoa035655; Lau DH, 2010, BLOOD PRESSURE, V19, P119, DOI 10.3109/08037050903576767; Levy AP, 2006, CURR MOL MED, V6, P479, DOI 10.2174/156652406778018626; Li JJ, 2012, ARTERIOSCL THROM VAS, V32, P1158, DOI 10.1161/ATVBAHA.112.246108; Li S, 2016, ARTERIOSCL THROM VAS, V36, P810, DOI 10.1161/ATVBAHA.115.306871; Li S, 2014, J ATHEROSCLER THROMB, V21, P648, DOI 10.5551/jat.21600; Mazzolai L, 2004, HYPERTENSION, V44, P277, DOI 10.1161/01.HYP.0000140269.55873.7b; MCGILL HC, 1985, ARTERIOSCLEROSIS, V5, P481, DOI 10.1161/01.ATV.5.5.481; Moreno PR, 2004, J AM COLL CARDIOL, V44, P2293, DOI 10.1016/j.jacc.2004.07.060; Moreno PR, 2004, CIRCULATION, V110, P2032, DOI 10.1161/01.CIR.0000143233.87854.23; MOSES C, 1954, CIRC RES, V2, P243, DOI 10.1161/01.RES.2.3.243; Nagy E, 2010, ARTERIOSCL THROM VAS, V30, P1347, DOI 10.1161/ATVBAHA.110.206433; NICKERSON CJ, 1992, EXP MOL PATHOL, V56, P173, DOI 10.1016/0014-4800(92)90034-9; Nussberger J, 2008, HYPERTENSION, V51, P1306, DOI 10.1161/HYPERTENSIONAHA.108.110932; PICK R, 1974, CIRC RES, V35, P472, DOI 10.1161/01.RES.35.3.472; Pugh CW, 2003, NAT MED, V9, P677, DOI 10.1038/nm0603-677; Purushothaman M, 2012, ARTERIOSCL THROM VAS, V32, P2769, DOI 10.1161/ATVBAHA.112.252122; ROBERTSON WB, 1968, LAB INVEST, V18, P538; Shiomi M, 2003, ARTERIOSCL THROM VAS, V23, P1239, DOI 10.1161/01.ATV.0000075947.28567.50; Shiomi M, 2008, CURR OPIN LIPIDOL, V19, P631, DOI 10.1097/MOL.0b013e3283189c18; Silvestre JS, 2001, CIRC RES, V89, P259, DOI 10.1161/hh1501.094269; SOLBERG LA, 1983, ARTERIOSCLEROSIS, V3, P187, DOI 10.1161/01.ATV.3.3.187; STARY HC, 1995, CIRCULATION, V92, P1355, DOI 10.1161/01.CIR.92.5.1355; Sugiyama F, 1997, LAB INVEST, V76, P835; Takaya N, 2005, CIRCULATION, V111, P2768, DOI 10.1161/CIRCULATIONAHA.104.504167; Thomas L, 2003, J CARDIOVASC PHARM, V41, P203, DOI 10.1097/00005344-200302000-00008; Tziakas DN, 2010, INT J CARDIOL, V142, P2, DOI 10.1016/j.ijcard.2009.10.031; Wang C, 2017, ARTERIOSCL THROM VAS, V37, P1282, DOI [10.1161/ATVBAHA.117.309139, 10.1161/atvbaha.117.309139]; Waqar AB, 2010, ATHEROSCLEROSIS, V213, P148, DOI 10.1016/j.atherosclerosis.2010.07.051; WATANABE Y, 1980, ATHEROSCLEROSIS, V36, P261, DOI 10.1016/0021-9150(80)90234-8; Weiss D, 2001, CIRCULATION, V103, P448; Yamada S, 2008, AM J PATHOL, V172, P1419, DOI 10.2353/ajpath.2008.070604; YAMAMOTO T, 1986, SCIENCE, V232, P1230, DOI 10.1126/science.3010466	47	1	1	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	DEC	2018	188	12					2936	2947		10.1016/j.ajpath.2018.08.007			12	Pathology	Pathology	HF4EX	WOS:000454187100019	30248339	Bronze			2019-10-28	
J	Yuan, XX; Bhat, OM; Meng, N; Lohner, H; Li, PL				Yuan, Xinxu; Bhat, Owais M.; Meng, Nan; Lohner, Hannah; Li, Pin-Lan			Protective Role of Autophagy in Nlrp3 Inflammasome Activation and Medial Thickening of Mouse Coronary Arteries	AMERICAN JOURNAL OF PATHOLOGY			English	Article							HIGH-FAT DIET; NEOINTIMA FORMATION; OXIDATIVE STRESS; CD38; EXPRESSION; CELLS; MICE; CONTRIBUTES; DYSFUNCTION; MYOCYTES	We hypothesized that autophagy and associated lysosome function serve as a critical modulator during Nod-like receptor family pyrin domain containing 3 (Nlrp3) inflammasome activation on proatherogenic stimuli. We first demonstrated that 7-ketocholesterol stimulated Nlrp3 inflammasome formation and activation as shown by increased colocalization of inflammasome components [Nlrp3 versus apoptosis associated speck-like protein (Asc) or caspase-1] and enhanced cleavage of caspase-1 into active caspase-1 to generate IL-1 beta in coronary artery smooth muscle cells. Deletion of the CD38 gene (CD38-1) that regulates lysosome function and autophagic flux also led to Nlrp3 inflammasome formation and activation. In the presence of rapamycin, the effects of either 7-ketocholesterol treatment or CD38 gene deletion were abolished. The autophagy inhibitor spautin-1 and the lysosome function blocker bafilomycin A1 also enhanced Nlrp3 inflammasome formation and activation. In animal experiments, we found that increased colocalization of Nlrp3 versus Asc or caspase-1 enhanced IL-1 beta accumulation and caspase-1 activity in the coronary arterial wall of CD38(-/-) mice on the Western diet compared with CD38(+/+) mice. This increased colocalization was blocked by treatment with rapamycin but enhanced by chloroquine, a water-soluble blocker of autophagic flux. Morphologic examinations confirmed that the media of coronary arteries was significantly thicker in CD38(-/-) mice on the Western diet than CD38(+/+) mice. In conclusion, the deficiency of autophagic flux promotes Nlrp3 inflammasome formation and activation in coronary artery smooth muscle cells on proatherogenic stimulation, leading to medial thickening of the coronary arterial wall.	[Yuan, Xinxu; Bhat, Owais M.; Meng, Nan; Lohner, Hannah; Li, Pin-Lan] Virginia Commonwealth Univ, Sch Med, Dept Pharmacol & Toxicol, POB 980613, Richmond, VA 23298 USA	Li, PL (reprint author), Virginia Commonwealth Univ, Sch Med, Dept Pharmacol & Toxicol, POB 980613, Richmond, VA 23298 USA.	pin-lan.li@vcuhealth.org	YUAN, XINXU/Q-9544-2019		NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [HL122937, HL057244, HL075316]	Supported by NIH grants HL122937 (P.-L.L.), HL057244 (P.-L.L.), and HL075316 (P.-L.L.).	Abais JM, 2015, ANTIOXID REDOX SIGN, V22, P1111, DOI 10.1089/ars.2014.5994; Abraham NG, 2014, HYPERTENSION, V64, P1352, DOI 10.1161/HYPERTENSIONAHA.114.03884; Adhikari N, 2015, J CARDIOVASC TRANSL, V8, P158, DOI 10.1007/s12265-015-9616-6; Alvarez K, 2017, INT REV IMMUNOL, V36, P259, DOI 10.1080/08830185.2017.1365146; Artlett CM, 2015, ANTIOXID REDOX SIGN, V22, P1162, DOI 10.1089/ars.2014.6148; Bao JX, 2017, FRONT BIOSCI-LANDMRK, V22, P558, DOI 10.2741/4502; Boini KM, 2014, BBA-MOL CELL RES, V1843, P836, DOI 10.1016/j.bbamcr.2014.01.033; Bracey NA, 2015, ANTIOXID REDOX SIGN, V22, P1176, DOI 10.1089/ars.2014.6125; Chen Y, 2015, J CELL MOL MED, V19, P2715, DOI 10.1111/jcmm.12657; Cutler RG, 2004, P NATL ACAD SCI USA, V101, P2070, DOI 10.1073/pnas.0305799101; Denes A, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.86; Deshpande DA, 2017, PHARMACOL THERAPEUT, V172, P116, DOI 10.1016/j.pharmthera.2016.12.002; Dinarello CA, 2010, CURR OPIN ENDOCRINOL, V17, P314, DOI 10.1097/MED.0b013e32833bf6dc; Duewell P, 2010, NATURE, V464, P1357, DOI 10.1038/nature08938; Elliott EI, 2015, IMMUNOL REV, V265, P35, DOI 10.1111/imr.12286; Fearon WF, 2008, CIRCULATION, V117, P2577, DOI 10.1161/CIRCULATIONAHA.108.772491; Feng YC, 2014, CELL RES, V24, P24, DOI 10.1038/cr.2013.168; Franceschi C, 2014, J GERONTOL A-BIOL, V69, pS4, DOI 10.1093/gerona/glu057; Fu XD, 2014, FREE RADICAL BIO MED, V71, P1, DOI 10.1016/j.freeradbiomed.2014.03.010; Guedes AGP, 2015, CAN J PHYSIOL PHARM, V93, P145, DOI 10.1139/cjpp-2014-0410; Guo WJ, 2014, AUTOPHAGY, V10, P972, DOI 10.4161/auto.28374; Harris J, 2011, J BIOL CHEM, V286, P9587, DOI 10.1074/jbc.M110.202911; Jabir MS, 2015, AUTOPHAGY, V11, P166, DOI 10.4161/15548627.2014.981915; Lamkanfi M, 2008, MOL CELL PROTEOMICS, V7, P2350, DOI 10.1074/mcp.M800132-MCP200; Latz E, 2013, NAT REV IMMUNOL, V13, P397, DOI 10.1038/nri3452; Lavandero S, 2013, AUTOPHAGY, V9, P1455, DOI 10.4161/auto.25969; Li X, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087552; LIU J, 1988, CIRC RES, V62, P1001, DOI 10.1161/01.RES.62.5.1001; Lynch-Day MA, 2012, COLD SPRING HARB PER, V2, DOI DOI 10.1101/CSHPERSPECT.A009357]; Mariathasan S, 2004, NATURE, V430, P213, DOI 10.1038/nature02664; Martinez FO, 2009, ANNU REV IMMUNOL, V27, P451, DOI 10.1146/annurev.immunol.021908.132532; Martinon F, 2006, NATURE, V440, P237, DOI 10.1038/nature04516; Martins JD, 2015, DNA CELL BIOL, V34, P274, DOI 10.1089/dna.2014.2752; Mateeva V, 2014, EXP DERMATOL, V23, P2; Mizushima N, 2011, CELL, V147, P728, DOI 10.1016/j.cell.2011.10.026; National Research Council, 2011, GUIDE CARE USE LAB A; Neven B, 2004, BLOOD, V103, P2809, DOI 10.1182/blood-2003-07-2531; Nixon RA, 2013, NAT MED, V19, P983, DOI 10.1038/nm.3232; Rajamaki K, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011765; Rubinsztein DC, 2012, NAT REV DRUG DISCOV, V11, P709, DOI 10.1038/nrd3802; Salminen A, 2012, AGING-US, V4, P166, DOI 10.18632/aging.100444; Schneider M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126007; Schroder K, 2010, SCIENCE, V327, P296, DOI 10.1126/science.1184003; Shi X, 2015, J STROKE CEREBROVASC, V24, P2455, DOI 10.1016/j.jstrokecerebrovasdis.2015.03.024; Toldo S, 2015, ANTIOXID REDOX SIGN, V22, P1146, DOI 10.1089/ars.2014.5989; Varghese GP, 2016, J AM HEART ASSOC, V5, DOI 10.1161/JAHA.115.003031; Xia M, 2014, AM J PATHOL, V184, P1617, DOI 10.1016/j.ajpath.2014.01.032; Xia M, 2011, CARDIOVASC RES, V89, P401, DOI 10.1093/cvr/cvq286; Xiong J, 2013, J CELL MOL MED, V17, P1598, DOI 10.1111/jcmm.12173; Xu M, 2015, CELL PHYSIOL BIOCHEM, V37, P432, DOI 10.1159/000430366; Xu M, 2012, FREE RADICAL BIO MED, V52, P357, DOI 10.1016/j.freeradbiomed.2011.10.485; Yuan XX, 2018, REDOX BIOL, V16, P21, DOI 10.1016/j.redox.2018.02.007; Zhang C, 2010, ANTIOXID REDOX SIGN, V13, P975, DOI 10.1089/ars.2010.3091; Zhang RZ, 2015, ASIAN PAC J TROP MED, V8, P823, DOI 10.1016/j.apjtm.2015.09.011; Zhang Y, 2014, CARDIOVASC RES, V102, P68, DOI 10.1093/cvr/cvu011; Zhou RB, 2011, NATURE, V469, P221, DOI 10.1038/nature09663; Zhou RB, 2010, NAT IMMUNOL, V11, P136, DOI 10.1038/ni.1831	57	2	2	1	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	DEC	2018	188	12					2948	2959		10.1016/j.ajpath.2018.08.014			12	Pathology	Pathology	HF4EX	WOS:000454187100020	30273598				2019-10-28	
J	Zhao, DX; Zhang, ML; Yuan, HP; Meng, CY; Zhang, BY; Wu, H				Zhao, Dongxu; Zhang, Minglei; Yuan, Hongping; Meng, Chunyang; Zhang, Boyin; Wu, Han			Ginsenoside Rb1 protects against spinal cord ischemia-reperfusion injury in rats by downregulating the Bax/Bcl-2 ratio and caspase-3 and p-Ask-1 levels	EXPERIMENTAL AND MOLECULAR PATHOLOGY			English	Article						Ginsenoside Rb1; spinal cord ischemia-reperfusion injury (SCII); apoptosis; Bax/Bcl-2 ratio; caspase-3; p-Ask-1	NF-KAPPA-B; CORTICAL NEURON APOPTOSIS; CYTOCHROME-C; ACTIVATION; BAX; ASK1; RD; MITOCHONDRIA; PARAPLEGIA; EXPRESSION	The aim of this study was to confirm the effects of ginsenoside Rb1 on neural cell apoptosis in the spinal cord of rats with spinal cord ischemia-reperfusion injury (SCII) and to explore its potential mechanisms. A total of 100 healthy adult Sprague-Dawley (SD) rats were randomly divided into four groups: normal control (n = 10), shamoperated (n = 10), SCII model (n = 40), and ginsenoside Rb1-treated groups (n = 40). Basso, Beattie, Bresnahan (BBB) scale was used to examine rat hindlimb locomotor function. Nissl and Tunnel staining were used to observe neural cell injury and apoptosis, respectively, in the spinal cord of rats with SCII. Immunofluorescence staining was performed to detect the expression of Bax and Bcl-2. The levels of caspase-3 and phosphorylated Ask-1 (p-Ask-1) were detected by western blotting. Ginsenoside Rb1 prevented neural cell apoptosis in the spinal cord and improved hindlimb locomotor dysfunction of rats (P < .05). Moreover, SCII-induced upregulation of caspase-3 and p-Ask-1 levels and the Bax/Bcl-2 ratio were significantly decreased by ginsenoside Rb1 (P < .05). The protective effects of ginsenoside Rb1 on neural cells in the spinal cord of rats with SCII were mediated by the ginsenoside Rb1-induced downregulation of caspase-3 and p-Ask-1 levels and the Bax/Bcl-2 ratio.	[Zhao, Dongxu; Zhang, Minglei; Meng, Chunyang; Zhang, Boyin; Wu, Han] Jilin Univ, China Japan Union Hosp, Dept Orthoped, 126 Xiantai St, Changchun 130033, Jilin, Peoples R China; [Yuan, Hongping] Jilin Univ, Hosp 4, Dept Nephrol, 2643 Dongfeng Ave, Changchun 130033, Jilin, Peoples R China	Wu, H (reprint author), Jilin Univ, China Japan Union Hosp, Dept Orthoped, 126 Xiantai St, Changchun 130033, Jilin, Peoples R China.	hanwu2016vip@163.com			basic department of provincial science and technology, department of key laboratory of Jilin province for precision medicine of bone and joint degenerative diseases [20180622005JC]	This work was supported by the basic department of provincial science and technology, department of key laboratory of Jilin province for precision medicine of bone and joint degenerative diseases (No. 20180622005JC).	Ahmed T, 2016, BRAIN RES BULL, V125, P30, DOI 10.1016/j.brainresbull.2016.04.002; Barthold S.W., 2011, GUIDE CARE USE LAB A; Bell MT, 2015, BRAIN RES, V1618, P55, DOI 10.1016/j.brainres.2015.04.053; CRAWFORD ES, 1986, J VASC SURG, V3, P389, DOI 10.1067/mva.1986.avs0030389; Daniele S, 2015, CELL SIGNAL, V27, P1609, DOI 10.1016/j.cellsig.2015.04.006; Fang F, 2012, BBA-MOL BASIS DIS, V1822, P286, DOI 10.1016/j.bbadis.2011.10.004; Ferguson AR, 2004, J NEUROTRAUM, V21, P1601, DOI 10.1089/neu.2004.21.1601; Finucane DM, 1999, J BIOL CHEM, V274, P2225, DOI 10.1074/jbc.274.4.2225; Gao Xiaoqun, 2006, J Huazhong Univ Sci Technolog Med Sci, V26, P17; Gokce EC, 2016, J NEUROSURG-SPINE, V24, P949, DOI 10.3171/2015.10.SPINE15612; Gui L., 2007, ANESTHESIOLOGY, V107, pA1558; Harada C., 2008, INVEST OPHTH VIS SCI, V49, P2058; Harris CA, 2001, J BIOL CHEM, V276, P37754; Hayashi T, 1998, STROKE, V29, P1007, DOI 10.1161/01.STR.29.5.1007; Huang F, 2015, MOL MED REP, V11, P3565, DOI 10.3892/mmr.2015.3162; Kakinohana M, 2011, STROKE, V42, P2302, DOI 10.1161/STROKEAHA.110.600429; Lee IS, 2010, B KOREAN CHEM SOC, V31, P2110, DOI 10.5012/bkcs.2010.31.7.2110; Li GH, 2016, CAN J PHYSIOL PHARM, V94, P97, DOI 10.1139/cjpp-2014-0164; Li YB, 2010, CURR NEUROVASC RES, V7, P85, DOI 10.2174/156720210791184952; Li YY, 2013, TOXICOLOGY, V312, P132, DOI 10.1016/j.tox.2013.08.008; de Lavor MSL, 2015, INT J CLIN EXP PATHO, V8, P9941; Liu XY, 2015, ACTA PHARMACOL SIN, V36, P421, DOI 10.1038/aps.2014.156; Mao WF, 2014, INT J NEUROSCI, V124, P281, DOI 10.3109/00207454.2013.838236; Misao J, 1996, CIRCULATION, V94, P1506, DOI 10.1161/01.CIR.94.7.1506; Nakahara S, 1999, J NEUROPATH EXP NEUR, V58, P442, DOI 10.1097/00005072-199905000-00003; Nasiraei-Moghadam S, 2010, J MOL NEUROSCI, V41, P156, DOI 10.1007/s12031-009-9312-6; Scott G. I., 2010, BRIT J PHARMACOL, V134, P1159; Song Y.-J, 2012, J BACTERIOL VIROL, V42, P63; Tan SJ, 2013, BIOL PHARM BULL, V36, P1634, DOI 10.1248/bpb.b13-00522; Tobiume K, 2001, EMBO REP, V2, P222, DOI 10.1093/embo-reports/kve046; Von Aspern K, 2015, J CARDIOVASC SURG, V56, P745; Wang BG, 2014, NEURAL REGEN RES, V9, P1678, DOI 10.4103/1673-5374.141802; Wang HL, 2007, CELL BIOL INT, V31, P1027, DOI 10.1016/j.cellbi.2007.03.017; Wang TA, 2010, EUR J PHARMACOL, V636, P121, DOI 10.1016/j.ejphar.2010.03.035; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Ye RD, 2013, EXPERT REV NEUROTHER, V13, P603, DOI [10.1586/ERN.13.51, 10.1586/ern.13.51]; Zhang B, 2006, J CEREBR BLOOD F MET, V26, P708, DOI 10.1038/sj.jcbfm.9600225; Zhou TT, 2015, INT IMMUNOPHARMACOL, V29, P334, DOI 10.1016/j.intimp.2015.10.032	38	6	7	2	22	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4800	1096-0945		EXP MOL PATHOL	Exp. Mol. Pathol.	DEC	2018	105	3					229	235		10.1016/j.yexmp.2018.09.001			7	Pathology	Pathology	HE4MW	WOS:000453342000001	30121168				2019-10-28	
J	Ibrahim, R; Dayoub, R; Melter, M; Weiss, TS				Ibrahim, Ra; Dayoub, Rania; Melter, Michael; Weiss, Thomas S.			Bile acids down-regulate the expression of Augmenter of Liver Regeneration (ALR) via SHP/HNF4 alpha 1 and independent of Egr-1	EXPERIMENTAL AND MOLECULAR PATHOLOGY			English	Article						Augmenter of liver regeneration; Bile acids; Cholestasis; Early growth response protein-1; Small heterodimer partner	GROWTH-FACTOR RECEPTOR; RESPONSE ELEMENT; ACTIVATION; PHOSPHORYLATION; IDENTIFICATION; CHOLESTASIS; HEPATOCYTES; MECHANISMS; APOPTOSIS; DNA	Bile acids (BA) are signaling molecules that activate nuclear factors and g-protein coupled receptors signaling to maintain metabolic homeostasis. However, accumulation of toxic BA promotes liver injury by initiating inflammation, inducing apoptosis and causing oxidative stress leading to cirrhosis and liver failure. Augmenter of Liver Regeneration (ALR) is a hepatotrophic growth factor with anti-apoptotic and anti-oxidative properties that has been shown to improve mitochondrial and hepatic functions in rats after bile duct ligation. In the current study we aimed to analyze the regulation of the pro-survival protein, ALR, under conditions of cytotoxic concentrations of BA. Promoter studies of ALR (- 733/ + 527 bp) revealed potential binding sites for various transcription factors like Egr-1, HNF4 alpha and two bile acid response elements (BARE). Using a full-length and several truncated promoter constructs for ALR we analyzed promoter activity and showed that BA reduce ALR promoter activity whereas Egr-1 transfection induces it. EMSA and supershift analysis confirmed the specific binding of Egr-1 to its response element within ALR promoter and this binding was reduced upon simultaneous stimulation with BA. We also showed that ALR promoter activity and protein expression are induced by HNF4 alpha 1 and repressed by SHP. In conclusion, these results indicate that BA negatively regulate ALR expression by SHP activation.	[Ibrahim, Ra; Dayoub, Rania; Melter, Michael; Weiss, Thomas S.] Univ Regensburg, Childrens Univ Hosp KUNO, Franz Josef Strauss Allee 11, D-93053 Regensburg, Germany; [Weiss, Thomas S.] Univ Regensburg Hosp, Ctr Liver Cell Res, Regensburg, Germany; [Dayoub, Rania] Damascus Univ, Fac Pharm, Dept Biochem & Microbiol, Damascus, Syria	Weiss, TS (reprint author), Univ Regensburg, Childrens Univ Hosp KUNO, Franz Josef Strauss Allee 11, D-93053 Regensburg, Germany.	thomas.weiss@ukr.de	Weiss, Thomas S./G-3989-2012	Weiss, Thomas S./0000-0003-0336-0581; Dayoub, Rania/0000-0001-5848-5571	German Academic Exchange Service (DAAD)Deutscher Akademischer Austausch Dienst (DAAD) [57169181]	This work was financially supported by the German Academic Exchange Service (DAAD, ID 57169181) through financing the Ph.D. studies of Sara Ibrahim at Regensburg University.	Allen K, 2011, AM J PATHOL, V178, P175, DOI 10.1016/j.ajpath.2010.11.026; Allen K, 2010, TOXICOL APPL PHARM, V243, P63, DOI 10.1016/j.taap.2009.11.013; Becher D, 1999, YEAST, V15, P1171, DOI 10.1002/(SICI)1097-0061(19990915)15:12<1171::AID-YEA443>3.0.CO;2-T; Bochkis IM, 2008, NAT MED, V14, P828, DOI 10.1038/nm.1853; BROOKS AR, 1991, J BIOL CHEM, V266, P7848; Cao Y, 2009, FREE RADICAL BIO MED, V47, P1057, DOI 10.1016/j.freeradbiomed.2009.07.017; CHIANG JYL, 1994, J BIOL CHEM, V269, P17502; Chiang JYL, 2000, J BIOL CHEM, V275, P10918, DOI 10.1074/jbc.275.15.10918; Dayoub R, 2013, MOL MED, V19, P237, DOI 10.2119/molmed.2013.00027; Dayoub R, 2010, BIOCHEM BIOPH RES CO, V395, P465, DOI 10.1016/j.bbrc.2010.04.023; Dussmann P, 2011, BMC DEV BIOL, V11, DOI 10.1186/1471-213X-11-28; Faubion WA, 1999, J CLIN INVEST, V103, P137, DOI 10.1172/JCI4765; FRANCAVILLA A, 1994, HEPATOLOGY, V20, P747, DOI 10.1016/0270-9139(94)90113-9; Gandhi CR, 1999, HEPATOLOGY, V29, P1435, DOI 10.1002/hep.510290522; GREIM H, 1972, GASTROENTEROLOGY, V63, P846; Higuchi H, 2002, J PHARMACOL EXP THER, V303, P461, DOI 10.1124/jpet.102.040030; Ilowski M, 2010, BIOCHEM BIOPH RES CO, V394, P915, DOI 10.1016/j.bbrc.2010.03.074; Kim WR, 2000, AM J GASTROENTEROL, V95, P1130; Kuhlkamp T, 2005, BIOL CHEM, V386, P1065, DOI 10.1515/BC.2005.122; Lee YK, 2000, MOL CELL BIOL, V20, P187, DOI 10.1128/MCB.20.1.187-195.2000; Lefebvre P, 2009, PHYSIOL REV, V89, P147, DOI 10.1152/physrev.00010.2008; Li Y, 2000, J BIOL CHEM, V275, P37443, DOI 10.1074/jbc.M004373200; Liao YJ, 2004, J BIOL CHEM, V279, P43107, DOI 10.1074/jbc.M407969200; Martin J, 2004, NATURE, V432, P988, DOI 10.1038/nature03187; Masuda N, 1997, BBA-GENE STRUCT EXPR, V1350, P27, DOI 10.1016/S0167-4781(96)00196-0; Pawlowski R, 2006, MOL CELL BIOCHEM, V288, P159, DOI 10.1007/s11010-006-9133-7; Poupon R, 2000, J HEPATOL, V32, P129, DOI 10.1016/S0168-8278(00)80421-3; Qiao L, 2001, MOL BIOL CELL, V12, P2629, DOI 10.1091/mbc.12.9.2629; RUSSELL DW, 1992, BIOCHEMISTRY-US, V31, P4737, DOI 10.1021/bi00135a001; Sokol TJ, 2005, J PEDIATR GASTR NUTR, V41, P235, DOI 10.1097/01.MPG.0000170600.80640.88; Staels B, 2009, DIABETES CARE, V32, pS237, DOI 10.2337/dc09-S355; Stroup D, 1997, AM J PHYSIOL-GASTR L, V273, pG508; Tan KP, 2007, MOL PHARMACOL, V72, P1380, DOI 10.1124/mol.107.039370; Tang C, 2015, J SURG RES, V196, P90, DOI 10.1016/j.jss.2015.02.060; Tanigawa K, 2000, J GASTROENTEROL, V35, P112, DOI 10.1007/s005350050023; Thasler WE, 2005, HISTOPATHOLOGY, V47, P57, DOI 10.1111/j.1365-2559.2005.02172.x; Weiss TS, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0184282; Wu Y, 2007, ARCH BIOCHEM BIOPHYS, V464, P48, DOI 10.1016/j.abb.2007.03.025; Zhang YX, 2011, J BIOL CHEM, V286, P29635, DOI 10.1074/jbc.M111.253039; Zhao YL, 2003, FEBS LETT, V540, P58, DOI 10.1016/S0014-5793(03)00158-3	40	2	2	0	4	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4800	1096-0945		EXP MOL PATHOL	Exp. Mol. Pathol.	DEC	2018	105	3					236	242		10.1016/j.yexmp.2018.09.004			7	Pathology	Pathology	HE4MW	WOS:000453342000002	30243934				2019-10-28	
J	Dmello, C; Sawant, S; Chaudhari, PR; Dongre, H; Ahire, C; D'Souza, ZC; Charles, SE; Rane, P; Costea, DE; Chaukar, D; Kane, S; Vaidya, M				Dmello, Crismita; Sawant, Sharada; Chaudhari, Pratik Rajeev; Dongre, Harsh; Ahire, Chetan; D'Souza, Zinia Charlotte; Charles, Silvania Emlit; Rane, Pallavi; Costea, Daniela Elena; Chaukar, Davendra; Kane, Shubhada; Vaidya, Milind			Aberrant expression of vimentin predisposes oral premalignant lesion derived cells towards transformation	EXPERIMENTAL AND MOLECULAR PATHOLOGY			English	Article						Vimentin; Benzo[a]pyrene; in vitro carcinogenesis; EMT		Objective: We have previously reported the aberrant expression of vimentin in human oral premalignant lesions and a 4-Nitroquinoline 1-oxide (4NQO) model of rat lingual carcinogenesis. Hence, we wanted to understand whether the expression of vimentin in early stage contributes to the process of transformation. Study design: Vimentin was stably expressed in oral premalignant lesion derived cells (vimentin negative) and various transformation related phenotypic assays were performed. Since vimentin alone failed to transform the cells, an additional carcinogenic stimulus benzo[a]pyrene (BP) was used. Concomitantly, immunohistochemistry (IHC) was performed on oral leukoplakia and tumor tissues for studying the expression of vimentin and E-cadherin. Results: Exogenous expression of vimentin led to the appearance of EMT and sternness-related signatures. Further, upon BP treatment, vimentin expressing clones showed an increase in vitro and in vivo transformation efficiency. Importantly, high vimentin-low E-cadherin expression significantly correlated with the grade of dysplasia, as also with the lymph node metastasis in oral tumors. Conclusion: Our study suggests that the expression of vimentin in early stages may be beneficial, although not sufficient to achieve transformation. Further, high vimentin-low E-cadherin expression, if validated in more number of early oral lesions, may prove useful in the identification of high risk human premalignant lesions.	[Dmello, Crismita; Sawant, Sharada; Chaudhari, Pratik Rajeev; Dongre, Harsh; Ahire, Chetan; D'Souza, Zinia Charlotte; Charles, Silvania Emlit; Vaidya, Milind] TMC, ACTREC, Vaidya Lab, Kharghar 410210, Navi Mumbai, India; [Dmello, Crismita; Sawant, Sharada; Chaudhari, Pratik Rajeev; Vaidya, Milind] Homi Bhabha Natl Inst, Training Sch Complex, Bombay 400085, Maharashtra, India; [Rane, Pallavi] ACTREC, Epidemiol & Clin Trials Unit, Kharghar 410210, Navi Mumbai, India; [Costea, Daniela Elena] Univ Bergen, Inst Clin Med, Gade Lab Pathol, Bergen, Norway; [Costea, Daniela Elena] Haukeland Hosp, Dept Pathol, Bergen, Norway; [Chaukar, Davendra] TMH, Surg Oncol Head & Neck Unit, Bombay, Maharashtra, India; [Kane, Shubhada] TMH, Dept Pathol, Bombay, Maharashtra, India	Vaidya, M (reprint author), TMC, ACTREC, Vaidya Lab, Kharghar 410210, Navi Mumbai, India.	mvaidya@actrec.gov.in	Dongre, Harsh/O-2246-2019	Dongre, Harsh/0000-0003-4378-2869; Costea, Daniela-Elena/0000-0001-7673-0358	Department of Biotechnology, IndiaDepartment of Biotechnology (DBT) India [BT/PR4583/MED/30/740/2012]; ACTREC, TMC, India	We thank Prof. Robert Goldman (Feinberg School of Medicine, Northwestern University, USA) for his generous gift of the emerald vimentin retroviral construct. We are thankful to Mr. Shridhar Nadkar and Mr. Rajesh Kadam for helping us with the animal work. We are thankful to Mrs. Tejaswinin Modak (former online trainer and instructor for English Writing Skills, Centre for e-learning and Training) for performing comprehensive language check. This work was supported by the grant from Department of Biotechnology, India (Grant no. BT/PR4583/MED/30/740/2012). CD was supported by the fellowship from ACTREC, TMC, India.	Balmain A, 2000, CARCINOGENESIS, V21, P371, DOI 10.1093/carcin/21.3.371; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; CHANG SE, 1992, INT J CANCER, V52, P896, DOI 10.1002/ijc.2910520612; da Silva SD, 2011, ORAL ONCOL, V47, P783, DOI 10.1016/j.oraloncology.2011.07.004; Damiani LA, 2008, CANCER RES, V68, P9005, DOI 10.1158/0008-5472.CAN-08-1276; Iyer S, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0059613, 10.1371/journal.pone.0053532]; Kidd ME, 2014, AM J RESP CELL MOL, V50, P1, DOI 10.1165/rcmb.2013-0314TR; Lahat G, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010105; Langa F, 2000, J CELL SCI, V113, P3463; Lanier MH, 2015, MOL BIOL CELL, V26, P4577, DOI 10.1091/mbc.E15-08-0552; Morel AP, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002888; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Nair DR, 2012, J CANCER RES THER, V8, P57, DOI 10.4103/0973-1482.92217; Prasad L., 2014, J OROFAC SCI, V6, P77; Raul U, 2004, INT J CANCER, V111, P662, DOI 10.1002/ijc.20349; Satelli A, 2011, CELL MOL LIFE SCI, V68, P3033, DOI 10.1007/s00018-011-0735-1; Sawant SS, 2014, ORAL DIS, V20, P453, DOI 10.1111/odi.12151; Sawant Sharada S., 2014, CLIN COMMUNICATIONS, V1; SILVERMAN S, 1976, CANCER-AM CANCER SOC, V38, P1790, DOI 10.1002/1097-0142(197610)38:4<1790::AID-CNCR2820380456>3.0.CO;2-I; TATAKE RJ, 1990, J CANCER RES CLIN, V116, P179, DOI 10.1007/BF01612674; Tellez CS, 2011, CANCER RES, V71, P3087, DOI 10.1158/0008-5472.CAN-10-3035; Tzivion G, 2000, J BIOL CHEM, V275, P29772, DOI 10.1074/jbc.M001207200; Vuoriluoto K, 2011, ONCOGENE, V30, P1436, DOI 10.1038/onc.2010.509	23	0	0	1	3	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4800	1096-0945		EXP MOL PATHOL	Exp. Mol. Pathol.	DEC	2018	105	3					243	251		10.1016/j.yexmp.2018.08.010			9	Pathology	Pathology	HE4MW	WOS:000453342000003	30189187				2019-10-28	
J	Ma, J; Ding, Y				Ma, Ji; Ding, Yong			Geniposide suppresses growth, migration and invasion of MKN45 cells by down-regulation of lncRNA HULC	EXPERIMENTAL AND MOLECULAR PATHOLOGY			English	Article						Gastric cancer; Geniposide; HULC; PI3K/AKT; JNK	LONG NONCODING RNAS; PI3K/AKT SIGNALING PATHWAY; GASTRIC-CANCER CELLS; INDUCED APOPTOSIS; IN-VITRO; MATRIX METALLOPROTEINASES; PROMOTES APOPTOSIS; LIVER-CANCER; PROLIFERATION; METASTASIS	Gastric cancer (GC) is a serious disease with high incidence rate and high mortality. Geniposide (GEN) exhibits multiple biological properties including anti-tumor function. However, effect of GEN on GC is not well studied. Hence, the effects of GEN on GC were investigated in our study. HULC expression in GC tissue and GC cell lines (MKN45, SGC-7901, MKN28, AGS) was detected by qRT-PCR. Cell viability, colony formation, migration, invasion and cell apoptosis were examined by CCK-8 assay, survival fraction assay, modified two-chamber migration assay, Millicell Hanging Cell Culture and flow cytometry analysis, respectively. The expression of matrix metalloproteinase (MMP)-2/9 and vimentin was detected by qRT-PCR and western blot, respectively. The expression of PI3K/AKT and JNK was measured by western blot. The expression of HULC was up-regulated both in GC tissue and cell lines (P < .05, P < .01 or P < .001). GEN negatively regulated the expression of HULC in MKN45 cells (P < .05 or P < .01). GEN decreased cell viability (P < .05), colony formation (P < .01), migration (P < .05) and invasion (P < .05) while HULC overexpression led to the opposite results in GEN-treated cells. The expression of phosphatidylinositol 3' -kinase (PI3K)/ protein kinase B (AKT) and c-Jun N-terminal kinase (JNK) was down-regulated by GEN (all P < .05) while reversed by HULC overexpression. HULC was up-regulated in GC. GEN inhibited MNK45 cell viability, colony formation, migration and invasion while induced cell apoptosis by down-regulation of HULC in MKN45 cells. GEN inactivated PI3K/AKT and JNK signal pathways through down-regulation of HULC.	[Ma, Ji] Henan Univ, Huaihe Hosp, Dept Endoscopy, Kaifeng 475000, Henan, Peoples R China; [Ding, Yong] Henan Univ, Sch Basic Med Sci, Jinming Rd, Kaifeng 475004, Henan, Peoples R China	Ding, Y (reprint author), Henan Univ, Sch Basic Med Sci, Jinming Rd, Kaifeng 475004, Henan, Peoples R China.	yongding0144@sina.com					Batista PJ, 2013, CELL, V152, P1298, DOI 10.1016/j.cell.2013.02.012; Brown GT, 2015, J PATHOL, V237, P273, DOI 10.1002/path.4586; Chang CH, 2017, J FOOD SCI, V82, P3021, DOI 10.1111/1750-3841.13955; Chen WQ, 2016, CA-CANCER J CLIN, V66, P115, DOI 10.3322/caac.21338; Chen Y, 2002, WORLD J GASTROENTERO, V8, P1014, DOI 10.3748/wjg.v8.i6.1014; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; Ferro A, 2014, EUR J CANCER, V50, P1330, DOI 10.1016/j.ejca.2014.01.029; Franken NAP, 2006, NAT PROTOC, V1, P2315, DOI 10.1038/nprot.2006.339; Fu H, 2009, ACTA BIOCH BIOPH SIN, V41, P648, DOI 10.1093/abbs/gmp053; Habtemariam S., 2018, GENIPIN, P6; Japanese Gastric Cancer Association, 2011, Gastric Cancer, V14, P113, DOI 10.1007/s10120-011-0042-4; Jin CJ, 2016, ONCOTARGET, V7, P51763, DOI 10.18632/oncotarget.10107; Kang JJ, 1997, FOOD CHEM TOXICOL, V35, P957, DOI 10.1016/S0278-6915(97)87265-1; Kang MH, 2010, EXP CELL RES, V316, P24, DOI 10.1016/j.yexcr.2009.10.010; Li D, 2009, ANTI-CANCER DRUG, V20, P59, DOI 10.1097/CAD.0b013e3283160fd6; Li HY, 2015, ONCOTARGET, V6, P27847, DOI 10.18632/oncotarget.4443; Li L, 2015, NEURAL REGEN RES, V10, P1617, DOI 10.4103/1673-5374.167760; Li Z, 2015, GASTRIC CANCER, V18, P43, DOI 10.1007/s10120-014-0340-8; Liang WC, 2015, ONCOTARGET, V6, P22513, DOI 10.18632/oncotarget.4154; Lu YH, 2017, GENE, V607, P41, DOI 10.1016/j.gene.2017.01.004; Martini M, 2014, ANN MED, V46, P372, DOI 10.3109/07853890.2014.912836; Osaki M, 2004, APOPTOSIS, V9, P667, DOI 10.1023/B:APPT.0000045801.15585.dd; Peng CH, 2005, CURR CANCER DRUG TAR, V5, P299, DOI 10.2174/1568009054064633; Qian Y., 2018, LACTOBACILLUS CASEI, P23; Sha M, 2014, PHARMACOLOGY, V93, P39, DOI 10.1159/000357683; Song XJ, 2014, LIFE SCI, V119, P9, DOI 10.1016/j.lfs.2014.10.006; St-Pierre Yves, 2003, Current Drug Targets - Inflammation and Allergy, V2, P206, DOI 10.2174/1568010033484133; Subramaniam D, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030590; Sun J, 2014, INT J MOL SCI, V15, P20434, DOI 10.3390/ijms151120434; Wang Guang-Yu, 2014, Bull Cancer, V101, pE27, DOI 10.1684/bdc.2014.2023; Wang Y, 2018, J CELL BIOCHEM, V119, P669, DOI 10.1002/jcb.26230; Yang S., 2016, INT J CLIN EXPT MED; Zhang YS, 2017, ANTIVIR THER, V22, P599, DOI 10.3851/IMP3152; Zhao J, 2014, EXPERT OPIN THER TAR, V18, P1207, DOI 10.1517/14728222.2014.941285; Zhao Y, 2014, ONCOL REP, V31, P358, DOI 10.3892/or.2013.2850; Zhu Y, 2016, ONCOTARGET, V7, P14429, DOI 10.18632/oncotarget.7418	36	4	4	0	6	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4800	1096-0945		EXP MOL PATHOL	Exp. Mol. Pathol.	DEC	2018	105	3					252	259		10.1016/j.yexmp.2018.08.011			8	Pathology	Pathology	HE4MW	WOS:000453342000004	30176223				2019-10-28	
J	Bahnassy, AA; Salem, SE; El-Sayed, M; Khorshid, O; Abdellateif, MS; Youssef, AS; Mohanad, M; Hussein, M; Zekri, ARN; Ali, NM				Bahnassy, Abeer A.; Salem, Salem E.; El-Sayed, Mohammad; Khorshid, Ola; Abdellateif, Mona S.; Youssef, Amira S.; Mohanad, Marwa; Hussein, Marwa; Zekri, Abdel-Rahman N.; Ali, Nasr M.			MiRNAs as molecular biomarkers in stage II egyptian colorectal cancer patients	EXPERIMENTAL AND MOLECULAR PATHOLOGY			English	Article						miRNAs; CRC; Stage II; Biomarkers; Egyptian patients; miR-21	DOWN-REGULATION; EXPRESSION; MICRORNAS; METASTASIS; PROGNOSIS; INVASION; MIR-21; DIAGNOSIS; SURVIVAL; PATHWAY	Aim: To assess the role of aberrant miRNAs expressions in stage II CRC patients from Egypt. Methods: Tumor tissue samples were obtained from 124 CRC stage II patients compared to 100 healthy controls for assessing miRNAs expression using; 1) a cataloged 84-miRNAs PCR array panel, and 2) another five miRNAs (miR-21, miR-137, miR-145, miR-320 and miR-498) that have been reported in previous studies to have a role in CRC, by quantitative real time PCR (qPCR). The results were correlated to patients' characteristics, response to treatment and survival. Results: There were 17 out of 84 miRNAs differentially expressed in the CRC patients. Twenty six miRNAs were significantly differentially expressed in the female CRC patients, while 16 miRNAs were significantly differentially expressed in the male CRC patients. Only, five miRNAs (miR-21, Let-7a-5p, miR-100-5p, miR-200c-3p and miR-23b-3p) were significantly common deregulated in CRC patients regardless gender. miR-21 was over expressed in 48.4% of the patients and it was significantly downregulated in females and over expressed in males. In univariate analysis; performance status, over-expression of miR-21 and miR-498 and reduced miR-137, miR-145, and miR-320 associated significantly with reduced DFS and OS whereas in multivariate analysis; miR-498 and miR-320 were independent prognostic factors for DFS and miR-21 was independent prognostic factors for OS. Conclusion: miRNAs expression differs significantly between male and female stage II CRC patients, miR-21, Let-7a-5p, miR-100-5p, miR-200c-3p and miR-23b-3p could be used as common diagnostic biomarkers for CRC. On the other hand, a three miRNAs panel (miR-21, miR-498 and miR-320) can predict recurrence and survival in those patients.	[Bahnassy, Abeer A.] Cairo Univ, Tissue Culture & Cytogenet Unit, Pathol Dept, Natl Canc Inst, Cairo, Egypt; [Salem, Salem E.; El-Sayed, Mohammad; Khorshid, Ola; Hussein, Marwa; Ali, Nasr M.] Cairo Univ, Med Oncol Dept, Natl Canc Inst, Cairo, Egypt; [Abdellateif, Mona S.] Cairo Univ, Med Biochem & Mol Biol, Canc Biol Dept, Natl Canc Inst, Cairo, Egypt; [Youssef, Amira S.; Zekri, Abdel-Rahman N.] Cairo Univ, Natl Canc Inst, Virol & Immunol Unit, Canc Biol Dept, Cairo, Egypt; [Mohanad, Marwa] Misr Univ Sci & Technol, Biochem Dept, Coll Pharmaceut Sci & Drug Mfg, 6th October, Egypt	Bahnassy, AA (reprint author), Cairo Univ, Pathol Dept, NCI, 1 Fom Khalig St, Cairo, Egypt.	chaya2000@hotmail.Com		Allahloubi, Nasr/0000-0002-6776-3622; Zekri, Abdel-Rahman/0000-0003-3939-0416			Akao Y, 2006, ONCOL REP, V16, P845; Asangani IA, 2008, ONCOGENE, V27, P2128, DOI 10.1038/sj.onc.1210856; Bai RP, 2015, INT J CANCER, V137, P2310, DOI 10.1002/ijc.29607; Balaguer F, 2010, CANCER RES, V70, P6609, DOI 10.1158/0008-5472.CAN-10-0622; Bandres E, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-29; Bonfrate L, 2013, J GASTROINTEST LIVER, V22, P311; Chen T, 2017, SCI REP-UK, V7, DOI 10.1038/srep44543; Cristobal I, 2015, INFLAMM BOWEL DIS, V21, pE24, DOI 10.1097/MIB.0000000000000572; Cristobal I, 2014, INT J COLORECTAL DIS, V29, P885, DOI 10.1007/s00384-014-1872-4; Dong YJ, 2014, CANCER MANAG RES, V6, P405, DOI 10.2147/CMAR.S35164; Feng Y, 2014, BRIT J CANCER, V110, P2300, DOI 10.1038/bjc.2014.122; Gellad ZF, 2010, GASTROENTEROLOGY, V138, P2177, DOI 10.1053/j.gastro.2010.01.056; Giordano S, 2013, HEPATOLOGY, V57, P840, DOI 10.1002/hep.26095; Gopalan V, 2015, EXP CELL RES, V330, P423, DOI 10.1016/j.yexcr.2014.08.006; Humphries B, 2015, ONCOTARGET, V6, P6472, DOI 10.18632/oncotarget.3052; Hur K, 2017, GUT, V66, P654, DOI 10.1136/gutjnl-2014-308737; Hwang WL, 2014, NAT CELL BIOL, V16, P268, DOI 10.1038/ncb2910; Jinushi T, 2014, CANCER MED-US, V3, P1544, DOI 10.1002/cam4.309; Kang WK, 2015, BMC GASTROENTEROL, V15, DOI 10.1186/s12876-015-0227-0; La Rocca G, 2009, J CELL PHYSIOL, V220, P485, DOI 10.1002/jcp.21796; Labbaye C, 2008, NAT CELL BIOL, V10, P788, DOI 10.1038/ncb1741; Liang LL, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.352; Liu RN, 2015, BIOMED PHARMACOTHER, V72, P52, DOI 10.1016/j.biopha.2015.04.005; Masuda T, 2017, CANCERS, V9, DOI 10.3390/cancers9090124; Mohammadi A, 2016, BIOMED PHARMACOTHER, V84, P705, DOI 10.1016/j.biopha.2016.09.099; Nielsen BS, 2011, CLIN EXP METASTAS, V28, P27, DOI 10.1007/s10585-010-9355-7; Oue N, 2014, INT J CANCER, V134, P1926, DOI 10.1002/ijc.28522; Pan C, 2017, ONCOTARGET, V8, P68317, DOI 10.18632/oncotarget.19344; Rokavec M, 2014, J CLIN INVEST, V124, P1853, DOI 10.1172/JCI73531; Schee K, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-505; Schepeler T, 2008, CANCER RES, V68, P6416, DOI 10.1158/0008-5472.CAN-07-6110; Schetter AJ, 2008, JAMA-J AM MED ASSOC, V299, P425, DOI 10.1001/jama.299.4.425; Slaby O, 2007, ONCOLOGY-BASEL, V72, P397, DOI 10.1159/000113489; Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262; Vishnubalaji R, 2016, ONCOTARGET, V7, P35789, DOI 10.18632/oncotarget.8937; Volinia S, 2006, P NATL ACAD SCI USA, V103, P2257, DOI 10.1073/pnas.0510565103; Wan LY, 2015, BIOCHEM BIOPH RES CO, V457, P125, DOI 10.1016/j.bbrc.2014.11.039; Wang ZG, 2012, BIOCHEM BIOPH RES CO, V427, P444, DOI 10.1016/j.bbrc.2012.06.123; Xia XC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080426	39	0	0	0	2	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4800	1096-0945		EXP MOL PATHOL	Exp. Mol. Pathol.	DEC	2018	105	3					260	271		10.1016/j.yexmp.2018.09.002			12	Pathology	Pathology	HE4MW	WOS:000453342000005	30213464				2019-10-28	
J	Aurtenetxe, O; Zaldumbide, L; Erramuzpe, A; Lopez, R; Lopez, JI; Cortes, JM; Pulido, R; Nunes-Xavier, CE				Aurtenetxe, Olaia; Zaldumbide, Laura; Erramuzpe, Asier; Lopez, Ricardo; Lopez, Jose, I; Cortes, Jesus M.; Pulido, Rafael; Nunes-Xavier, Caroline E.			DUSP5 expression associates with poor prognosis in human neuroblastoma	EXPERIMENTAL AND MOLECULAR PATHOLOGY			English	Article						MAP kinase phosphatase; Neuroblastoma differentiation; Neuroblastoma proliferation; Metastatic neuroblastoma	MAP KINASE PHOSPHATASES; RETINOIC ACID; NEURONAL DIFFERENTIATION; UP-REGULATION; ALK; CELLS; INHIBITORS; ONCOGENE; THERAPY; TARGETS	Regulation of growth and differentiation of neuroblastoma (NB) cells is the rational of some maintenance therapies for high-risk NB. MAP kinase phosphatases (MKPs) are potential physiologic regulators of neuronal differentiation and survival, but their expression patterns in NB are scarcely known. Here, an expression analysis of the MKP family has been performed using human NB tumor samples and human NB cell lines (SH-SY5Y, SMS-KCNR, and IMR-32) undergoing retinoic acid (RA)-induced differentiation or subjected to stimuli that activate the MAPK ERK1/2 pathway. We have identified candidate MKPs that could modulate differentiation and growth of NB cells. pERK1/2 high expression correlated with high expression of the MKP DUSP5 in NB tumors, and was associated with poor prognosis. ERK1/2 activation on SH-SY5Y cells was accompanied by increased cell proliferation, and correlated with the expression levels of DUSP5. Accordingly, siRNA knock-down of DUSP5 augmented proliferation of SH-SY5Y cells. Our findings provide insights into the dynamic expression of MKPs in NB cells, disclose DUSP5 as a potential marker of NB poor prognosis, and suggest a role for DUSP5 in limiting ERK1/2-mediated NB proliferation.	[Aurtenetxe, Olaia; Lopez, Jose, I; Pulido, Rafael; Nunes-Xavier, Caroline E.] Biocruces Bizkaia Hlth Res Inst, Biomarkers Canc Unit, Baracaldo 48903, Bizkaia, Spain; [Zaldumbide, Laura; Lopez, Jose, I] Univ Basque Country, UPV EHU, Cruces Univ Hosp, Dept Pathol, Baracaldo 48903, Bizkaia, Spain; [Erramuzpe, Asier; Cortes, Jesus M.] Biocruces Bizkaia Hlth Res Inst, Quantitat Biomed Unit, Baracaldo 48903, Bizkaia, Spain; [Lopez, Ricardo] Cruces Univ Hosp, Pediat Oncol & Hematol, Baracaldo 48903, Bizkaia, Spain; [Cortes, Jesus M.; Pulido, Rafael] IKERBASQUE, Basque Fdn Sci, Bilbao 48011, Bizkaia, Spain; [Nunes-Xavier, Caroline E.] Oslo Univ Hosp, Radiumhosp, Inst Canc Res, Dept Tumor Biol, POB 4950, N-0424 Oslo, Norway; [Erramuzpe, Asier; Cortes, Jesus M.] Univ Basque Country, UPV EHU, Dept Cell Biol & Histol, Leioa 48940, Bizkaia, Spain	Nunes-Xavier, CE (reprint author), Oslo Univ Hosp, Radiumhosp, Inst Canc Res, Dept Tumor Biol, POB 4950, N-0424 Oslo, Norway.; Pulido, R (reprint author), Hosp Univ Cruces, Biocruces Bizkaia Hlth Res Inst, Plaza Cruces S-N, Baracaldo 48903, Spain.	rafael.pulidomurillo@osakidetza.eus; carnun@rr-research.no	Lopez, Jose Ignacio/L-3884-2019; Almaraz, Ricardo Lopez/X-2931-2019; Nunes-Xavier, Caroline E./R-5893-2018; Cortes, Jesus/D-9949-2012	Lopez, Jose Ignacio/0000-0003-0842-5348; Almaraz, Ricardo Lopez/0000-0001-5521-9892; Nunes-Xavier, Caroline E./0000-0002-1875-6645; Cortes, Jesus/0000-0002-9059-8194; Erramuzpe Aliaga, Asier/0000-0002-9402-2184	BIOEF (EITB maratoia) [BI013/CI/001/BC]; Basque Country, Spain [BI013/Cl/001/BC]; Ministerio de Education y Ciencia and Ministerio de Economia y Competitividad (Spain and Fondo Europeo de Desarrollo Regional) [SAF2013-48812-R, SAF2016-79847-R]; Research Council of NorwayResearch Council of Norway [239813]; Basque GovernmentBasque Government; Basque Country Biobank	This work was partially supported by grants: BI013/CI/001/BC from BIOEF (EITB maratoia), Basque Country, Spain; SAF2013-48812-R (to RP), and SAF2016-79847-R (to RP and JIL) from Ministerio de Education y Ciencia and Ministerio de Economia y Competitividad (Spain and Fondo Europeo de Desarrollo Regional); and 239813 from The Research Council of Norway (to CENX). AE was supported by a predoctoral grant from the Basque Government (Programa de Formation de Personal Investigador no doctor, Departamento de Education, Politica Lingiiistica y Cultura del Gobierno Vasco). We thank Basque Country Biobank for help and support, Rosa Noguera and Samuel Navarro (Department of Pathology, Medical School, Universidad de Valencia, Spain) for providing cell lines, and Arantza Perez Dobaran (Department of Physiology, Universidad del Pais Vasco, UPV/EHU, Leioa, Bizkaia, Spain) for expert technical assistance.	Alonso A, 2016, FEBS J, V283, P1404, DOI 10.1111/febs.13600; Bagatell R, 2016, CURR OPIN PEDIATR, V28, P19, DOI 10.1097/MOP.0000000000000296; Bassiri H, 2015, TRANSL PEDIATR, V4, P226, DOI 10.3978/j.issn.2224-4336.2015.04.06; Berlanga P, 2017, EXPERT OPIN EMERG DR, V22, P63, DOI 10.1080/14728214.2017.1294159; Brodeur GM, 2014, NAT REV CLIN ONCOL, V11, P704, DOI 10.1038/nrclinonc.2014.168; Buffet C, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0184861; Buffet C, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0145484; Chen K, 2016, ONCOTARGET, V7, P75968, DOI 10.18632/oncotarget.12513; Cheung BB, 2015, WORLD J CLIN ONCOL, V6, P212, DOI 10.5306/wjco.v6.i6.212; Clark O, 2013, CANCER LETT, V328, P44, DOI 10.1016/j.canlet.2012.09.014; Dickinson RJ, 2006, J CELL SCI, V119, P4607, DOI 10.1242/jcs.03266; Edsjo A, 2007, SEMIN CANCER BIOL, V17, P248, DOI 10.1016/j.semcancer.2006.04.005; Eleveld TF, 2015, NAT GENET, V47, P864, DOI 10.1038/ng.3333; Evageliou NF, 2016, CLIN CANCER RES, V22, P4391, DOI 10.1158/1078-0432.CCR-15-2539; Frank E., 2016, WEKA WORKBENCH ONLIN; Futami H, 2010, CANCER LETT, V297, P220, DOI 10.1016/j.canlet.2010.05.014; GAETANO C, 1992, CANCER RES, V52, P4402; Haagenson KK, 2010, CANCER BIOL THER, V9, P337, DOI 10.4161/cbt.9.5.11217; Hendriks WJAJ, 2013, BBA-MOL BASIS DIS, V1832, P1673, DOI 10.1016/j.bbadis.2013.05.022; Hendriks WJAJ, 2013, FEBS J, V280, P708, DOI 10.1111/febs.12000; Keyse SM, 2008, CANCER METAST REV, V27, P253, DOI 10.1007/s10555-008-9123-1; Kidger AM, 2016, SEMIN CELL DEV BIOL, V50, P125, DOI 10.1016/j.semcdb.2016.01.009; Kucharska A, 2009, CELL SIGNAL, V21, P1794, DOI 10.1016/j.cellsig.2009.07.015; Lambertz I, 2015, CLIN CANCER RES, V21, P3327, DOI 10.1158/1078-0432.CCR-14-2024; Low HB, 2016, IMMUNE NETW, V16, P85, DOI 10.4110/in.2016.16.2.85; Mandl M, 2005, MOL CELL BIOL, V25, P1830, DOI 10.1128/MCB.25.5.1830-1845.2005; Maris JM, 2007, LANCET, V369, P2106, DOI 10.1016/S0140-6736(07)60983-0; Marshall GM, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002135; Matthay KK, 2016, NAT REV DIS PRIMERS, V2, DOI 10.1038/nrdp.2016.78; Mohlin SA, 2011, SEMIN CANCER BIOL, V21, P276, DOI 10.1016/j.semcancer.2011.09.002; Nalluri S, 2015, CANCER BIOL THER, V16, P276, DOI 10.1080/15384047.2014.1002333; Navarro Samuel, 2012, Expert Opin Med Diagn, V6, P555, DOI 10.1517/17530059.2012.704018; Niles RM, 2004, MUTAT RES-FUND MOL M, V555, P81, DOI 10.1016/j.mrfmmm.2004.05.020; Nunes-Xavier C, 2011, ANTI-CANCER AGENT ME, V11, P109, DOI 10.2174/187152011794941190; Nunes-Xavier CE, 2016, METHODS MOL BIOL, V1447, P25, DOI 10.1007/978-1-4939-3746-2_2; Nunes-Xavier CE, 2010, J BIOL CHEM, V285, P26417, DOI 10.1074/jbc.M110.121830; Ogawa S, 2011, CANCER SCI, V102, P302, DOI 10.1111/j.1349-7006.2010.01825.x; Padovan-Merhar OM, 2016, PLOS GENET, V12, DOI 10.1371/journal.pgen.1006501; PAHLMAN S, 1984, CELL DIFFER DEV, V14, P135, DOI 10.1016/0045-6039(84)90038-1; Peinemann F, 2015, COCHRANE DB SYST REV, V1; Pinto NR, 2015, J CLIN ONCOL, V33, P3008, DOI 10.1200/JCO.2014.59.4648; Reynolds CP, 2003, CANCER LETT, V197, P185, DOI 10.1016/S0304-3835(03)00108-3; Rios P, 2014, ANTIOXID REDOX SIGN, V20, P2251, DOI 10.1089/ars.2013.5709; SIDELL N, 1983, EXP CELL RES, V148, P21, DOI 10.1016/0014-4827(83)90184-2; Tanaka T, 2016, J PEDIATR SURG, V51, P2074, DOI 10.1016/j.jpedsurg.2016.09.043; Umapathy G, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2005470; Westermark UK, 2011, SEMIN CANCER BIOL, V21, P256, DOI 10.1016/j.semcancer.2011.08.001	47	1	1	1	4	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4800	1096-0945		EXP MOL PATHOL	Exp. Mol. Pathol.	DEC	2018	105	3					272	278		10.1016/j.yexmp.2018.08.008			7	Pathology	Pathology	HE4MW	WOS:000453342000006	30171833				2019-10-28	
J	Chaouali, M; Fernandes, V; Ghazouani, E; Pereira, L; Kochkar, R				Chaouali, Marwa; Fernandes, Veronica; Ghazouani, Ezzedine; Pereira, Luisa; Kochkar, Radhia			Association of STAT4, TGF beta 1, SH2B3 and PTPN22 polymorphisms with autoimmune hepatitis	EXPERIMENTAL AND MOLECULAR PATHOLOGY			English	Article						Autoimmune hepatitis; Genetic susceptibility; SH2B3; TGF beta 1; STAT4; PTPN22	GENOME-WIDE ASSOCIATION; RHEUMATOID-ARTHRITIS; RISK; GENE; SUSCEPTIBILITY; IDENTIFICATION; VARIANT	The physiopathology of autoimmune hepatitis (AIH) is complex and still not fully elucidated. The genes localized outside the histocompatibility complex involved in regulation and signal transduction of the immune system SH2B3, TGF beta 1, STAT4 and PTPN22 could be associated to the susceptibility and hepatocyte lysis mechanism of this lethal autoimmune disorder. Patients and methods: We investigated four polymorphic sites in SH2B3 (rs3184504), TGF beta 1 (rs1800471), STAT4 (rs7574865) and PTPN22 (rs2476601) in 45 AIH patients and 150 healthy controls from Tunisia using real-time PCR. Results: Significant associations were found for SH2B3 T allele (OR = 1.861; p = 0.015, pc = 0.366) and PTPN22 A allele (OR = 7.070; p = 0.026; pc = 1.00) and AIH with opposite homozygous being protective against the disease (CC genotype with OR = 0.420, p = 0.025; GG genotype with OR = 0.136, p = 0.025, respectively). No statistically significant associations were found for the TGF beta 1 and STAT4 polymorphisms with AIH susceptibility. Conclusion: Our work enlarges information on non-HLA genes that are associated with AIH by focusing in a region of the world that was poorly molecularly characterized for this disease.	[Chaouali, Marwa; Ghazouani, Ezzedine; Kochkar, Radhia] Mil Hosp Tunis, Dept Immunol, Tunis 1008, Tunisia; [Chaouali, Marwa] El Manar Univ, Lab Mycol Pathol & Biomarkers, Tunis 1092, Tunisia; [Fernandes, Veronica; Pereira, Luisa] Univ Porto, i3S, P-4200135 Porto, Portugal; [Fernandes, Veronica; Pereira, Luisa] Univ Porto IPATIMUP, Inst Patol & Imunol Mol, P-4200135 Porto, Portugal; [Pereira, Luisa] Univ Porto, Fac Med, Porto, Portugal	Chaouali, M (reprint author), Mil Hosp Tunis, Dept Immunol, Tunis 1008, Tunisia.	marouachaouali@gmail.com	Pereira, Luisa/H-3050-2011	Pereira, Luisa/0000-0002-4271-1527; fernandes, veronica/0000-0002-3873-2034	FEDER - Fundo Europeu de Desenvolvimento Regional funds through the COMPETE 2020 - Operacional Programme for Competitiveness and Internationalisation (POCI), Portugal; Portuguese funds through FCT Fundacao para a Ciencia e a Tecnologia, Portugal/Ministerio da Ciencia, Tecnologia e Inovacao, Tecnologia e Inovacao [POCI-01-0145-FEDER-016609]; FCT - Fundacao para a Ciencia e a Tecnologia/Ministerio da Ciencia, Tecnologia e Inovacao [SFRH/BPD/114927/2016]	This work was financed by FEDER - Fundo Europeu de Desenvolvimento Regional funds through the COMPETE 2020 - Operacional Programme for Competitiveness and Internationalisation (POCI), Portugal 2020, and by Portuguese funds through FCT Fundacao para a Ciencia e a Tecnologia, Portugal/Ministerio da Ciencia, Tecnologia e Inovacao in the framework of the project "Biomedical anthropological study in Arabian Peninsula based on high throughput genomics" (POCI-01-0145-FEDER-016609). The Author V. Fernandes has a post-doc grant through FCT - Fundacao para a Ciencia e a Tecnologia/Ministerio da Ciencia, Tecnologia e Inovacao (SFRH/BPD/114927/2016).	Abelson AK, 2009, ANN RHEUM DIS, V68, P1746, DOI 10.1136/ard.2008.097642; Aizawa Y, 2017, CLIN EXP GASTROENTER, V10, P9, DOI 10.2147/CEG.S101440; Altshuler DM, 2012, NATURE, V491, P56, DOI 10.1038/nature11632; Barrett JC, 2009, NAT GENET, V41, P703, DOI 10.1038/ng.381; Ramirez OB, 2016, IMMUNOL LETT, V175, P40, DOI 10.1016/j.imlet.2016.05.003; Bottini N, 2004, NAT GENET, V36, P337, DOI 10.1038/ng1323; Chaouali M, 2017, EGYPT J MED HUM GENE, V18, P335, DOI DOI 10.1016/j.ejmhg.2017.02.003; Chaouali M, 2017, REV FRANC LAB, V491, P60; Czaja AJ, 1997, HEPATOLOGY, V25, P317; de Boer YS, 2014, GASTROENTEROLOGY, V147, P443, DOI 10.1053/j.gastro.2014.04.022; El-Sherbini SM, 2013, ACTA BIOCH BIOPH SIN, V45, P330, DOI 10.1093/abbs/gmt003; Excoffier L, 2010, MOL ECOL RESOUR, V10, P564, DOI 10.1111/j.1755-0998.2010.02847.x; Ikari K, 2006, RHEUMATOLOGY, V45, P1345, DOI 10.1093/rheumatology/kel169; Li Qian, 2013, Zhonghua Yi Xue Yi Chuan Xue Za Zhi, V30, P111, DOI 10.3760/cma.j.issn.1003-9406.2013.01.027; Li XF, 2017, ONCOTARGET, V8, P60933, DOI 10.18632/oncotarget.17458; Li YJ, 2000, J IMMUNOL, V164, P5199, DOI 10.4049/jimmunol.164.10.5199; Liberal R, 2015, J CLIN TRANSL HEPATO, V3, P42, DOI 10.14218/JCTH.2014.00032; Liberal R, 2011, BEST PRACT RES CL GA, V25, P653, DOI 10.1016/j.bpg.2011.09.009; Migita K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071382; Muratori L, 2013, J AUTOIMMUN, V46, P74, DOI 10.1016/j.jaut.2013.06.016; Orru V, 2009, HUM MOL GENET, V18, P569, DOI 10.1093/hmg/ddn363; Paladino N, 2010, CLIN IMMUNOL, V134, P305, DOI 10.1016/j.clim.2009.11.004; Remmers EF, 2007, NEW ENGL J MED, V357, P977, DOI 10.1056/NEJMoa073003; Strettell MDJ, 1997, GASTROENTEROLOGY, V112, P2028, DOI 10.1053/gast.1997.v112.pm9178696; Suthanthiran M, 2000, P NATL ACAD SCI USA, V97, P3479, DOI 10.1073/pnas.050420897; Tang J, 2012, HEPATOB PANCREAT DIS, V11, P125, DOI 10.1016/S1499-3872(12)60136-2; Tomer Y, 2015, J AUTOIMMUN, V60, P32, DOI 10.1016/j.jaut.2015.03.006; Umemura T, 2017, J HUM GENET, V62, P963, DOI 10.1038/jhg.2017.74; Umemura T, 2016, SCI REP-UK, V6, DOI 10.1038/srep29770; Umemura T, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100565; Wang QX, 2016, J AUTOIMMUN, V66, P98, DOI 10.1016/j.jaut.2015.10.006; Westra HJ, 2013, NAT GENET, V45, P1238, DOI 10.1038/ng.2756	32	1	1	0	2	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4800	1096-0945		EXP MOL PATHOL	Exp. Mol. Pathol.	DEC	2018	105	3					279	284		10.1016/j.yexmp.2018.10.001			6	Pathology	Pathology	HE4MW	WOS:000453342000007	30291855				2019-10-28	
J	Diao, X; Zhou, J; Wang, SY; Ma, X				Diao, Xin; Zhou, Jing; Wang, Shengyu; Ma, Xuan			Upregulation of miR-132 contributes to the pathophysiology of COPD via targeting SOCS5	EXPERIMENTAL AND MOLECULAR PATHOLOGY			English	Article						COPD; CD8(+) T cells; miR-132; SOCS5; THP-1; Cytokines	CIGARETTE-SMOKE EXTRACT; OBSTRUCTIVE PULMONARY-DISEASE; EXPRESSION; INFLAMMATION; PATHOGENESIS; MECHANISMS; MICRORNA; CELLS	The role of microRNAs has been recently identified in chronic obstructive pulmonary disease (COPD). This study aimed to examine the role of miR-132 in the pathophysiology of COPD and to explore the underlying molecular mechanisms of miR-132 in COPD. MiR-132 and suppressor of cytokine signaling 5 (SOCS5) mRNA expression were detected by qRT-PCR. The number of CD4(+) and CD8(+) T cells was analyzed by flow cytometry. SOCS5 and epidermal growth factor receptor (EGFR) protein levels were determined by western blot. Interleukin-1 beta (IL-1 beta) and tumor necrosis factor-alpha (TNF-alpha) concentrations were measured by ELISA. MiR-132 expression was upregulated in the serum from COPD patients and smokers compared with nonsmoker controls. The number of CD8(+)T cells was significantly increased in the serum from COPD patients and smokers. MiR-132 expression was negatively correlated with FEV1/FITC%, and positively correlated with CD8(+) T cells (%). MiR-132 overexpression repressed SOCS5 expression via directly targeting SOCS5 3'UTR in human monocyte-like cells (THP1), which was confirmed by luciferase reporter assay. MiR-132 overexpression increased EGFR protein levels and the concentrations of inflammatory cytokines (IL-beta and TNF-alpha) in THP-1 cells, and these effects were attenuated by enforced expression of SOCS5. Further, cigarette smoke extract (CSE) treatment up-regulated miR-132 expression, down-regulated SOCS5 expression, and increased inflammatory cytokines levels, which was attenuated by miR-132 knockdown in THP-1 cells. Consistent findings were also found in the human bronchial epithelial cells (BEAS-2B). Collectively, our data implicated that miR-132 may promote inflammation in THP-1 and BEAS-2B cells at least via targeting SOCS5 in COPD.	[Diao, Xin; Zhou, Jing; Wang, Shengyu; Ma, Xuan] Xian Med Univ, Affiliated Hosp 1, Dept Resp & Crit Care Med, Xian 710077, Shaanxi, Peoples R China	Diao, X (reprint author), Xian Med Univ, Affiliated Hosp 1, Dept Resp & Crit Care Med, Xian 710077, Shaanxi, Peoples R China.	doctordx@yeah.net			Social Science and Technology Development Project of Shaanxi Province	This study was supported by Social Science and Technology Development Project of Shaanxi Province (No.2016SF-066).	Akbas F, 2012, EXP LUNG RES, V38, P286, DOI 10.3109/01902148.2012.689088; Aryal S, 2013, TRANSL RES, V162, P208, DOI 10.1016/j.trsl.2013.04.003; Bagdonas E, 2015, INT J CHRONIC OBSTR, V10, P995, DOI 10.2147/COPD.S82518; Baginski TK, 2006, AM J RESP CELL MOL, V35, P165, DOI 10.1165/rcmb.2005-0259OC; Ballweg K, 2014, AM J PHYSIOL-LUNG C, V307, pL895, DOI 10.1152/ajplung.00180.2014; Chen L, 2014, EUR RESPIR J, V44, P634, DOI 10.1183/09031936.00171313; Ezzie ME, 2012, THORAX, V67, P122, DOI 10.1136/thoraxjnl-2011-200089; Hodge S, 2015, RESPIROLOGY, V20, P95, DOI 10.1111/resp.12415; Hua L, 2015, BIO-MED MATER ENG, V26, pS1903, DOI 10.3233/BME-151493; Ji YF, 2018, J CELL BIOCHEM, V119, P5528, DOI 10.1002/jcb.26720; Johannessen A, 2013, AM J RESP CRIT CARE, V188, P51, DOI 10.1164/rccm.201212-2276OC; Kario E, 2005, J BIOL CHEM, V280, P7038, DOI 10.1074/jbc.M408575200; Kedzierski L, 2017, ELIFE, V6, DOI 10.7554/eLife.20444; Kim HY, 2016, J GASTROEN HEPATOL, V31, P1727, DOI 10.1111/jgh.13321; Leuenberger C, 2016, J MOL MED, V94, P725, DOI 10.1007/s00109-016-1388-1; Li H, 2015, INHAL TOXICOL, V27, P822, DOI 10.3109/08958378.2015.1116644; Liu F, 2015, EXP LUNG RES, V41, P261, DOI 10.3109/01902148.2015.1004206; Mizuno S, 2012, CHEST, V142, P663, DOI 10.1378/chest.11-2746; Molina-Pinelo S, 2014, EUR RESPIR J, V43, P1740, DOI 10.1183/09031936.00091513; Negewo NA, 2015, RESPIROLOGY, V20, P1160, DOI 10.1111/resp.12642; Nicholson SE, 2005, P NATL ACAD SCI USA, V102, P2328, DOI 10.1073/pnas.0409675102; Park MH, 2016, SPRINGERPLUS, V5, DOI 10.1186/s40064-016-2363-6; Rom O, 2013, RESP PHYSIOL NEUROBI, V187, P5, DOI 10.1016/j.resp.2013.01.013; Rovina N, 2013, MEDIAT INFLAMM, DOI 10.1155/2013/413735; Schamberger AC, 2014, EXPERT OPIN DRUG DIS, V9, P609, DOI 10.1517/17460441.2014.913020; Shen W, 2017, INT J CHRONIC OBSTR, V12, P705, DOI 10.2147/COPD.S128031; Smith MC, 2014, INT J CHRONIC OBSTR, V9, P871, DOI 10.2147/COPD.S49621; Xie LH, 2014, MOL BIOSYST, V10, P1072, DOI 10.1039/c3mb70564a; Zhang LW, 2014, CARDIOVASC DRUG THER, V28, P303, DOI 10.1007/s10557-014-6533-x	29	2	2	1	2	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4800	1096-0945		EXP MOL PATHOL	Exp. Mol. Pathol.	DEC	2018	105	3					285	292		10.1016/j.yexmp.2018.10.002			8	Pathology	Pathology	HE4MW	WOS:000453342000008	30292646				2019-10-28	
J	Magdy, YM; El-Kharashi, OA; El-Waseef, DAA; Nabih, ES; Abd El Samad, AA				Magdy, Yosra M.; El-Kharashi, Omnyah A.; El-Waseef, Dalia A. A.; Nabih, Enas S.; Abd El Samad, Abeer A.			Insights into hepatic and renal FXR/DDAH-1/eNOS pathway and its role in the potential benefit of rosuvastatin and silymarin in hepatic nephropathy	EXPERIMENTAL AND MOLECULAR PATHOLOGY			English	Article						Cirrhosis; DDAH-1; FXR; Kidney; Rosuvastatin; Silymarin	FARNESOID-X RECEPTOR; INDUCED LIVER-CIRRHOSIS; BILE-ACID RECEPTORS; ASYMMETRIC DIMETHYLARGININE; OXIDATIVE STRESS; FATTY LIVER; TGF-BETA; FIBROSIS; KIDNEY; RAT	Objectives: The repression of renal Farnesoid X Receptor (FXR) had been shown to result from lack of bile acid production from cirrhotic liver. We hypothesized that silymarin and rosuvastatin (Rvs) could have a hepatorenal therapeutic effects in hepatic nephropathy through induction of FXR. Methods: Forty two male Wistar rats were used; naive (n = 12); six of them were sacrificed after 4 weeks and six continued till the end of the experiment. Thirty rats were treated as follows: Rvs, silymarin, thioacetamide (TAA), TAA + Rvs and TAA + silymarin. Liver and kidney function tests as well as the renal and hepatic expression of transforming growth factor beta 1 (TGF beta 1), FXR, dimethylarginine dimethylaminohydrolase-1 (DDAH-1) and eNOS were performed. Histological and immuno-histochemical studies of liver and kidney were also done. Results: TAA-inducted liver cirrhosis was associated with significant deterioration of liver and renal functions together with increasing expression of hepatic and renal TGF beta 1 and decreasing expression of hepatic and renal FXR, DDAH-1 and eNOS. Giving silymarin or Rvs induced hepatic and renal improvement which was evidenced biochemically and histologically. Significant positive correlation was detected between all the investigated biomarkers except for the correlation between FXR and TGF beta 1 which was negative. Conclusions: In conclusion, liver cirrhosis is associated with deterioration of renal functions. Silymarin and Rvs have a potential hepatorenal therapeutic benefit through simultaneous enhancement of FXR/DDAH-1/eNOS pathway in both organs.	[Magdy, Yosra M.; El-Kharashi, Omnyah A.] Ain Shams Univ, Fac Med, Dept Clin Pharmacol, Cairo, Egypt; [El-Waseef, Dalia A. A.; Abd El Samad, Abeer A.] Ain Shams Univ, Fac Med, Dept Histol & Cell Biol, Cairo, Egypt; [Nabih, Enas S.] Ain Shams Univ, Fac Med, Dept Med Biochem & Mol Biol, Cairo, Egypt	El-Kharashi, OA (reprint author), Ain Shams Univ, Fac Med, PO 38, Cairo, Egypt.	Omnyah_Aly@med.asu.edu.eg	Alaa El-Din Aly El-Waseef, Dalia/Y-4087-2018	Alaa El-Din Aly El-Waseef, Dalia/0000-0001-8199-2512			Abraldes JG, 2007, J HEPATOL, V46, P1040, DOI 10.1016/j.jhep.2007.01.020; Ali AH, 2015, ANN TRANSL MED, V3, DOI 10.3978/j.issn.2305-5839.2014.12.06; Alqasoumi SI, 2014, SAUDI PHARM J, V22, P258, DOI 10.1016/j.jsps.2013.12.001; Border WA, 1998, KIDNEY INT, V54, P1390, DOI 10.1046/j.1523-1755.1998.00127.x; Byun HW, 2014, HEPATOB PANCREAT DIS, V13, P65, DOI 10.1016/S1499-3872(14)60009-6; Campese VM, 2005, J AM SOC NEPHROL, V16, pS11, DOI 10.1681/ASN.2004110958; Carello KA, 2006, AM J PHYSIOL-HEART C, V290, pH209, DOI 10.1152/ajpheart.00208.2005; Chmielewski Michal, 2002, Przegl Lek, V59, P519; Cichoz-Lach H, 2014, WORLD J GASTROENTERO, V20, P8082, DOI 10.3748/wjg.v20.i25.8082; DELALASTRA CA, 1991, PHYTOTHER RES, V5, P191; Ding L, 2015, MOL MED REP, V11, P4431, DOI 10.3892/mmr.2015.3270; Dixit N, 2007, INDIAN J PHARMACOL, V39, P172, DOI 10.4103/0253-7613.36534; El-Din SHS, 2015, RES PHARM SCI, V10, P275; Feher J, 2012, CURR PHARM BIOTECHNO, V13, P210, DOI 10.2174/138920112798868818; Forrest EH, 1996, ALIMENT PHARM THERAP, V10, P219, DOI 10.1111/j.0953-0673.1996.00219.x; Galkina E, 2006, J AM SOC NEPHROL, V17, P368, DOI 10.1681/ASN.2005080859; Gu M, 2016, FRONT PHARMACOL, V7, DOI 10.3389/fphar.2016.00345; Hamed AM, 2017, BIOMED PHARMACOTHER, V85, P68, DOI 10.1016/j.biopha.2016.11.114; Herman-Edelstein M, 2018, CURR OPIN NEPHROL HY, V27, P56, DOI 10.1097/MNH.0000000000000374; Hu TH, 2006, J BIOL CHEM, V281, P39831, DOI 10.1074/jbc.M606779200; Hu ZJ, 2012, KIDNEY BLOOD PRESS R, V36, P85, DOI 10.1159/000341485; Kwalny-Krochin B, 2012, POL ARCH MED WEWN, V122, P270; Lagrutta LC, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0170608; Lan HY, 2012, SEMIN NEPHROL, V32, P236, DOI 10.1016/j.semnephrol.2012.04.002; Lan HY, 2003, CURR OPIN NEPHROL HY, V12, P25, DOI 10.1097/01.mnh.0000049812.98789.97; Lin SL, 2008, AM J PATHOL, V173, P1617, DOI 10.2353/ajpath.2008.080433; Link A, 2006, EUR HEART J, V27, P2945, DOI 10.1093/eurheartj/ehl277; Liu C, 2015, GENET MOL RES, V14, P10760, DOI 10.4238/2015.September.9.15; Lu TM, 2004, AM J CARDIOL, V94, P157, DOI 10.1016/j.amjcard.2004.03.052; Mahmoud NH, 2006, EGYPT SOC TOXICOL, V34, P43; Matsuzaki K, 2009, FRONT BIOSCI-LANDMRK, V14, P2923, DOI 10.2741/3423; Mihout F, 2011, J PATHOL, V223, P37, DOI 10.1002/path.2769; Mohamed DI, 2018, GENE, V651, P9, DOI 10.1016/j.gene.2018.02.001; Mookerjee RP, 2015, J HEPATOL, V62, P325, DOI 10.1016/j.jhep.2014.08.024; Moreno M, 2009, AM J PHYSIOL-GASTR L, V296, pG147, DOI 10.1152/ajpgi.00462.2007; Morishima C, 2010, GASTROENTEROLOGY, V138, P671, DOI 10.1053/j.gastro.2009.09.021; Muriel P, 2005, BASIC CLIN PHARMACOL, V96, P375, DOI 10.1111/j.1742-7843.2005.pto_06.x; Natarajan SK, 2006, HEPATOLOGY, V43, P1248, DOI 10.1002/hep.21179; Onozato ML, 2008, DIABETES, V57, P172, DOI 10.2337/db06-1772; Passauer J, 2005, KIDNEY INT, V67, P1665, DOI 10.1111/j.1523-1755.2005.00259.x; Pipili Chrysoula, 2014, World J Gastrointest Pharmacol Ther, V5, P156, DOI 10.4292/wjgpt.v5.i3.156; Reif S, 2004, J HEPATOL, V41, P235, DOI 10.1016/j.jhep.2004.04.010; Salama SM, 2012, EVID-BASED COMPL ALT, DOI 10.1155/2012/137083; Schuppan D, 2003, CELL DEATH DIFFER, V10, pS59, DOI 10.1038/sj.cdd.4401163; Shimizu T, 2014, ARTERIOSCL THROM VAS, V34, P2246, DOI 10.1161/ATVBAHA.114.303715; Shirin H, 2013, WORLD J GASTROENTERO, V19, P241, DOI 10.3748/wjg.v19.i2.241; Soto C, 2010, PHYTOMEDICINE, V17, P1090, DOI 10.1016/j.phymed.2010.04.011; Tousson E, 2014, AM J ZOOL RES, V2, P51; Trauner M, 2011, DIGEST DIS, V29, P98, DOI 10.1159/000324141; Uzbekov Rustem, 2013, BMC Res Notes, V6, P386, DOI 10.1186/1756-0500-6-386; Zhang W, 2013, BIOMOL THER, V21, P264, DOI 10.4062/biomolther.2013.020; Zhang X., 2014, PNAS, V111, P77	52	2	2	1	3	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4800	1096-0945		EXP MOL PATHOL	Exp. Mol. Pathol.	DEC	2018	105	3					293	310		10.1016/j.yexmp.2018.10.004			18	Pathology	Pathology	HE4MW	WOS:000453342000009	30308196				2019-10-28	
J	Qu, Y; Liang, XC; Liu, D; Jia, HM; Wang, WL				Qu, Yuan; Liang, Xingchi; Liu, Dan; Jia, Huimin; Wang, Weilin			MSX2 and BCL2 expressions in the development of anorectal malformations in ethylenethiourea-induced rat embryos	EXPERIMENTAL AND MOLECULAR PATHOLOGY			English	Article						Anorectal malformations; Development; MSX2; BCL2; Apoptosis	NEURAL CREST CELLS; APOPTOTIC ELIMINATION; NUMBERED RHOMBOMERES; MEDIATES APOPTOSIS; STEM-CELLS; GENE; BMP4; EVOLUTION; PATTERNS; HINDGUT	Background: This study aimed to determine Msh homeobox 2 (MSX2) and B cell lymphoma-2 (BCL2) expression patterns during anorectal development in anorectal malformations (ARM) and normal rat embryos, with the goals of determining the role of MSX2 and BCL2 in ARM pathogenesis. Methods: ARM was induced in rat embryos with ethylenethiourea administered to dams on gestational day 10 (GD10). Embryos were harvested by cesarean deliveries from GD14 to GD16. MSX2 and BCL2 expression was evaluated via immunohistochemical staining, immunofluorescence, western blotting and quantitative real-time polymerase chain reaction (qRT-PCR). Results: Immunohistochemical staining of ARM embryos revealed that MSX2 was mainly expressed in the epithelium of the hindgut and urorectal septum (URS) on GD14. On GD15 and GD16, MSX2-immunolabeled cells were noted in the epithelium of the rectum, fistula and URS. However, in normal embryos, faint immunopositivity for MSX2 was demonstrated in the epithelium of the rectum and URS from GD14 to GD16. As for BCL2, in normal embryos, BCL2-immunopositive cells were extensively expressed in the epithelium of the hindgut and URS on GD14 and GD15. In ARM embryos, weak immunopositivity for BCL2 was detected in the epithelium of hindgut and URS on GD14 and GD15. Immunofluorescence revealed that MSX2 and BCL2 colocalized in the hindgut. In ARM embryos, we observed more MSX2-positive than BCL2-positive cells on GD14; the normal embryos had the opposite pattern. Analyses by western blot and qRT-PCR showed that MSX2 protein and mRNA expression was significantly increased in ARM embryos compared with the normal embryos on GD15 and GD16 (p < 0.05). However, BCL2 protein and mRNA expression was significantly decreased in ARM embryos compared with the normal embryos on GD14 (p < 0.05). The MSX2/BCL2 ratio of protein and mRNA expression level in the ARM group was the highest on GD15. Conclusion: These results indicate that upregulation of MSX2 and downregulation of BCL2 during cloacal development into the rectum and urethra might be related to the ARM development, and MSX2 promoted apoptosis through reduction of BCL2 expression during the development of anorectal development in ARM.	[Qu, Yuan; Liang, Xingchi; Liu, Dan; Jia, Huimin; Wang, Weilin] China Med Univ, Shengjing Hosp, Dept Pediat Surg, 36 Sanhao St, Shenyang 110004, Liaoning, Peoples R China	Jia, HM (reprint author), China Med Univ, Shengjing Hosp, Dept Pediat Surg, 36 Sanhao St, Shenyang 110004, Liaoning, Peoples R China.	jiahm@sj-hospital.org			National Natural Science Foundation of ChinaNational Natural Science Foundation of China [81671503]	This work was supported by the National Natural Science Foundation of China (grant no. 81671503).	Ashkenazi A, 2017, NAT REV DRUG DISCOV, V16, P273, DOI 10.1038/nrd.2016.253; Bai YZ, 2004, J PEDIATR SURG, V39, P587, DOI 10.1016/j.jpedsurg.2003.12.002; Bai YZ, 2000, J PEDIATR SURG, V35, P462, DOI 10.1016/S0022-3468(00)90215-X; BELL JR, 1993, GENOMICS, V16, P123, DOI 10.1006/geno.1993.1149; Carter TC, 2013, ANN HUM GENET, V77, P31, DOI 10.1111/j.1469-1809.2012.00734.x; Cass DL, 1998, J PEDIATR SURG, V33, P1043, DOI 10.1016/S0022-3468(98)90528-0; Chandra D, 2002, J BIOL CHEM, V277, P50842, DOI 10.1074/jbc.M207622200; Chen QJ, 2009, J PEDIATR SURG, V44, P1884, DOI 10.1016/j.jpedsurg.2009.02.004; Chipuk JE, 2010, MOL CELL, V37, P299, DOI 10.1016/j.molcel.2010.01.025; Czabotar PE, 2014, NAT REV MOL CELL BIO, V15, P49, DOI 10.1038/nrm3722; DAVIDSON D, 1995, TRENDS GENET, V11, P405, DOI 10.1016/S0168-9525(00)89124-6; Gomes WA, 2001, DEV BIOL, V237, P212, DOI 10.1006/dbio.2001.0344; GRAHAM A, 1993, DEVELOPMENT, V119, P233; GRAHAM A, 1994, NATURE, V372, P684, DOI 10.1038/372684a0; Gremel G, 2011, BRIT J CANCER, V105, P565, DOI 10.1038/bjc.2011.249; Israsena N, 2002, J NEUROSCI RES, V69, P803, DOI 10.1002/jnr.10362; Kiyono M, 2003, MOL CELL BIOL, V23, P4627, DOI 10.1128/MCB.23.13.4627-4636.2003; Kluth D, 1997, Semin Pediatr Surg, V6, P180; Levitt MA, 2005, CURR OPIN PEDIATR, V17, P394, DOI 10.1097/01.mop.0000163665.36798.ac; Li Y, 2010, J CELL BIOCHEM, V111, P1346, DOI 10.1002/jcb.22861; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; MACKENZIE A, 1992, DEVELOPMENT, V115, P403; Mandhan P, 2006, PEDIATR SURG INT, V22, P31, DOI 10.1007/s00383-005-1575-6; Marazzi G, 1997, DEV BIOL, V186, P127, DOI 10.1006/dbio.1997.8576; Miyagawa S, 2014, CELL DEATH DIFFER, V21, P990, DOI 10.1038/cdd.2014.21; Moore SW, 2013, PEDIATR SURG INT, V29, P665, DOI 10.1007/s00383-013-3306-8; Ngan ESW, 2011, J CLIN INVEST, V121, P3467, DOI 10.1172/JCI43737; Nievelstein RAJ, 1998, TERATOLOGY, V57, P70, DOI 10.1002/(SICI)1096-9926(199802)57:2<70::AID-TERA5>3.0.CO;2-A; OPPENHEIM RW, 1991, ANNU REV NEUROSCI, V14, P453, DOI 10.1146/annurev.neuro.14.1.453; Pena A, 2000, AM J SURG, V180, P370, DOI 10.1016/S0002-9610(00)00491-8; Pyati UJ, 2006, DEVELOPMENT, V133, P2275, DOI 10.1242/dev.02388; Qadir AS, 2011, BIOCHEM BIOPH RES CO, V408, P399, DOI 10.1016/j.bbrc.2011.04.029; Qi BQ, 2002, J PEDIATR SURG, V37, P1305, DOI 10.1053/jpsu.2002.34996; Richter A, 2014, STEM CELLS, V32, P636, DOI 10.1002/stem.1592; Rintala RJ, 2008, SEMIN PEDIATR SURG, V17, P79, DOI 10.1053/j.sempedsurg.2008.02.003; Seifert AW, 2008, DEV BIOL, V318, P143, DOI 10.1016/j.ydbio.2008.03.017; Sergi C, 2000, AM J PATHOL, V156, P1589, DOI 10.1016/S0002-9440(10)65031-6; Shamas-Din A, 2011, BBA-MOL CELL RES, V1813, P508, DOI 10.1016/j.bbamcr.2010.11.024; Tai CC, 2009, J SURG RES, V156, P278, DOI 10.1016/j.jss.2009.03.087; Takahashi K, 1998, DEVELOPMENT, V125, P1627; Torihashi S, 2009, DIFFERENTIATION, V77, P277, DOI 10.1016/j.diff.2008.10.003; Tsuda T, 2011, EUR J PEDIATR SURG, V21, P238, DOI 10.1055/s-0031-1273691; van den Brink GR, 2007, PHYSIOL REV, V87, P1343, DOI 10.1152/physrev.00054.2006; VANDERPUTTE SCJ, 1986, J PEDIATR SURG, V21, P434, DOI 10.1016/S0022-3468(86)80515-2; Vieux-Rochas M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0051700; Wang C, 2015, PEDIATR SURG INT, V31, P795, DOI 10.1007/s00383-015-3685-0; Wong EHM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069142; Wu QQ, 2015, CELL RES, V25, P1314, DOI 10.1038/cr.2015.118; Yang ZH, 2017, NEUROCHEM RES, V42, P3160, DOI 10.1007/s11064-017-2354-1; Zacchetti G, 2007, DEVELOPMENT, V134, P3967, DOI 10.1242/dev.010991; Zhang Hai-lan, 2013, Journal of China Medical University, V42, P399; Zhang T, 2009, INT J COLORECTAL DIS, V24, P1039, DOI 10.1007/s00384-009-0705-3	52	1	1	0	3	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4800	1096-0945		EXP MOL PATHOL	Exp. Mol. Pathol.	DEC	2018	105	3					311	321		10.1016/j.yexmp.2018.09.005			11	Pathology	Pathology	HE4MW	WOS:000453342000010	30268882				2019-10-28	
J	Watanabe, K; Karuppagounder, V; Sreedhar, R; Kandasamy, G; Harima, M; Velayutham, R; Arumugam, S				Watanabe, Kenichi; Karuppagounder, Vengadeshprabhu; Sreedhar, Remya; Kandasamy, Geetha; Harima, Meilei; Velayutham, Ravichandiran; Arumugam, Somasundaram			Basidiomycetes-X, an edible mushroom, alleviates the development of atopic dermatitis in NC/Nga mouse model	EXPERIMENTAL AND MOLECULAR PATHOLOGY			English	Article						Basidiomycetes-X; Tumor necrosis factor; Cytokine; Atopic dermatitis; Inflammation; Interferon	SKIN INFLAMMATION; EXTRACT; PATHWAY; MICE	Basidiomycetes-X (BDM-X) is a novel edible mushroom recently identified as a new fungi species and is effective against oxidative stress and anti-inflammation associated with immune response. However the effect of BDM-X on atopic dermatitis (AD) has not been elucidated. In this study, we have investigated the effect of BDM-X on AD skin lesions in NC/Nga mouse model. AD-like lesion was induced by the application of house dust mite extract (DfE) to the dorsal skin of NC/Nga mouse. After AD induction, BDM-X was administered once daily for 2 weeks. We have analyzed the effects of BDM-X on dermatitis severity, histopathological changes and changes in inflammatory and proinflammatory proteins expressions in DfE induced AD mice skin. Treatment with BDM-X attenuated the development of AD-like clinical symptoms and effectively inhibited hyperkeratosis, parakeratosis, acanthosis and mast cells in AD mice skin. Furthermore, BDM-X treatment inhibited DIE induced tumor necrosis factor (TNF)alpha, high mobility group protein (HMG)B1, nuclear factor kappa (NF kappa)B and inflammatory cytokines. These results indicate that BDM-X inhibits AD through modulating nil and Th2 responses and diminishing the mast cells infiltration in the skin lesions in NC/Nga mice.	[Watanabe, Kenichi] Niigata Univ, Sch Med & Dent Sci, Dept Lab Med & Clin Epidemiol Prevent Noncommunic, Chuo Ku, 757 Ichibancho, Niigata 9518510, Japan; [Watanabe, Kenichi; Karuppagounder, Vengadeshprabhu; Sreedhar, Remya; Harima, Meilei; Arumugam, Somasundaram] Niigata Univ Pharm & Appl Life Sci, Fac Pharmaceut Sci, Dept Clin Pharmacol, Akiha Ku, 265-1 Higashijima, Niigata 9568603, Japan; [Karuppagounder, Vengadeshprabhu] Penn State Coll Med, Dept Orthoped & Rehabil, 500 Univ Dr, Hershey, PA 17033 USA; [Kandasamy, Geetha] King Khalid Univ, Coll Pharm, Dept Clin Pharm, Abha, Saudi Arabia; [Harima, Meilei] Niigata Univ Rehabil, Fac Allied Hlth Sci, 2-16 Kaminoyama, Niigata 9580053, Japan; [Velayutham, Ravichandiran; Arumugam, Somasundaram] Natl Inst Pharmaceut Educ & Res, 168 Manicktala Main Rd, Kolkata 700054, W Bengal, India	Arumugam, S (reprint author), Natl Inst Pharmaceut Educ & Res, Dept Pharmacol & Toxicol, 168 Manicktala Main Rd, Kolkata 700054, W Bengal, India.; Watanabe, K (reprint author), Dept Lab Med & Clin Epidemiol Prevent Noncommunic, Chuo Ku, 757 Ichibancho, Niigata 9518510, Japan.	wataken@med.niigata-u.ac.jp; somasundaram143@gmail.com			Ministry of Education, Culture, Sports, Science and Technology of JapanMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT); Promotion and Mutual Aid Corporation for Private Schools, JapanPromotion and Mutual Aid Corporation for Private Schools of Japan [23602012, 26460239]	This research was supported by Ministry of Education, Culture, Sports, Science and Technology of Japan, and by a grant from the Promotion and Mutual Aid Corporation for Private Schools, Japan (23602012 and 26460239) respectively.	Aim S., 2016, IN VITRO CELL DEV, V52, P287; Arumugam S, 2012, FREE RADICAL RES, V46, P154, DOI 10.3109/10715762.2011.647010; Choi EJ, 2016, MOLECULES, V21, DOI 10.3390/molecules21080993; Choi JH, 2013, FOOD CHEM TOXICOL, V53, P38, DOI 10.1016/j.fct.2012.11.025; Hanifin JM, 2001, EXP DERMATOL, V10, P11, DOI 10.1034/j.1600-0625.2001.100102.x; Ipaktchi K, 2006, SHOCK, V26, P201, DOI 10.1097/01.shk.0000225739.13796.f2; Jesenak M, 2016, J DERMATOL TREAT, V27, P351, DOI 10.3109/09546634.2015.1117565; Karki R, 2012, EVID-BASED COMPL ALT, DOI 10.1155/2012/153568; Karuppagounder V, 2015, CYTOKINE, V76, P206, DOI 10.1016/j.cyto.2015.05.016; Karuppagounder V, 2015, EXP DERMATOL, V24, P418, DOI 10.1111/exd.12685; Karuppagounder V, 2014, INT IMMUNOPHARMACOL, V23, P617, DOI 10.1016/j.intimp.2014.10.014; Kim SR, 2012, EVID-BASED COMPL ALT, DOI 10.1155/2012/545497; Kuo IH, 2013, J ALLERGY CLIN IMMUN, V131, P266, DOI 10.1016/j.jaci.2012.12.1563; Larsen L, 2011, J DERMATOL SCI, V64, P85, DOI 10.1016/j.jdermsci.2011.07.008; Matsuoka H, 2003, ALLERGY, V58, P139, DOI 10.1034/j.1398-9995.2003.23790.x; Mizuno M, 2013, J CLIN BIOCHEM NUTR, V52, P202, DOI 10.3164/jcbn.13-3; Ngatu NR, 2012, ALLERGOL INT, V61, P597, DOI 10.2332/allergolint.11-OA-0393; Park HS, 2015, BIOSCI BIOTECH BIOCH, V79, P147, DOI 10.1080/09168451.2014.963500; Saegusa J, 2009, AM J PATHOL, V174, P922, DOI 10.2353/ajpath.2009.080500; Suh W, 2017, BIOMOL THER, V25, P165, DOI 10.4062/biomolther.2016.063; Udompataikul M, 2012, J DRUGS DERMATOL, V11, P366; Watanabe K, 2015, J CLIN BIOCHEM NUTR, V56, P186, DOI 10.3164/jcbn.14-75; Watanabe T, 2008, BIOL PHARM BULL, V31, P111, DOI 10.1248/bpb.31.111	23	0	0	1	9	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4800	1096-0945		EXP MOL PATHOL	Exp. Mol. Pathol.	DEC	2018	105	3					322	327		10.1016/j.yexmp.2018.10.005			6	Pathology	Pathology	HE4MW	WOS:000453342000011	30312598				2019-10-28	
J	McNulty, SN; Schwetye, K; Goldstein, M; Carter, J; Schmidt, RE; Ansstas, G; Tsien, CI; Kim, AH; Dahiya, S				McNulty, Samantha N.; Schwetye, Katherine; Goldstein, Michael; Carter, Jamal; Schmidt, Robert E.; Ansstas, George; Tsien, Christina, I; Kim, Albert H.; Dahiya, Sonika			Analysis of point mutations and copy number variation in Grade II and III meningioma	EXPERIMENTAL AND MOLECULAR PATHOLOGY			English	Article						Meningioma; Next-generation sequencing; Clinical sequencing; Copy number variation	CENTRAL-NERVOUS-SYSTEM; ANAPLASTIC MENINGIOMAS; CLASSIFICATION; TUMORS; AKT1; HETEROZYGOSITY; CHROMOSOME-10; LANDSCAPE; DISCOVERY; BLOCKADE	Meningiomas are among the most common tumors of the adult central nervous system (CNS). They are classified by the World Health Organization into three pathologic grades with increasing severity: grade I are benign with favorable treatment outcomes and low recurrence rates while grade III display malignant behavior and poor progression-free survival. Previous studies have shown that inactivation of NF-2 is the most common genetic event in high-grade meningioma; however, there is dearth of molecular data to distinguish grade II (AM-II) from the even more aggressive grade III (AM-III). As part of a routine diagnostic workup, 19 AM-II and 5 AM-III were submitted for targeted sequencing on a panel of twenty-four genes relevant to CNS tumors. The data generated during the course of clinical care was collected and re-analyzed with the aim of identifying molecular features to distinguish AM-II and AM-HI. Our cases contained several well-characterized, potentially actionable mutations, but we did not find any novel, recurrent sequence variants. Copy number variations were common in both AM-II and AM-III; chr22q loss was the most prevalent followed in decreasing frequency by losses of chr1p, chrl4q, and chr10. In particular, chr10 loss was noted in 4 of 5 AM-III cases but none of the AM-II cases. This suggests that chr10 loss may serve as a diagnostic and perhaps a prognostic marker to differentiate AM-II from AM-III. If confirmed in larger studies, our finding could further aid the classification of meningioma.	[McNulty, Samantha N.; Schwetye, Katherine; Carter, Jamal; Schmidt, Robert E.; Dahiya, Sonika] Washington Univ, Sch Med, Dept Pathol & Immunol, Campus Box 8118,660 S Euclid Ave, St Louis, MO 63110 USA; [Goldstein, Michael; Tsien, Christina, I] Washington Univ, Sch Med, Dept Radiat Oncol, St Louis, MO 63110 USA; [Ansstas, George] Washington Univ, Sch Med, Dept Med, Div Oncol, St Louis, MO 63110 USA; [Kim, Albert H.] Washington Univ, Sch Med, Dept Neurol Surg, St Louis, MO 63110 USA	Dahiya, S (reprint author), Washington Univ, Sch Med, Dept Pathol & Immunol, Campus Box 8118,660 S Euclid Ave, St Louis, MO 63110 USA.	sdahiya@wustl.edu		Dahiya, Sonika/0000-0002-5585-0964	Division of Neuropathology, Department of Pathology and Immunology of Washington University in St. Louis, MO	This study was funded by the Division of Neuropathology, Department of Pathology and Immunology of Washington University in St. Louis, MO. The authors have no conflicts of interest to disclose.	Baia G, 2008, NEOPLASIA, V10, P604, DOI 10.1593/neo.08356; Bi WL, 2016, J NEUROSURG, V125, P525, DOI 10.3171/2015.6.JNS15591; Brastianos PK, 2013, NAT GENET, V45, P285, DOI 10.1038/ng.2526; Brennan CW, 2013, CELL, V155, P462, DOI 10.1016/j.cell.2013.09.034; Clark VE, 2013, SCIENCE, V339, P1077, DOI 10.1126/science.1233009; Cuevas IC, 2005, CANCER RES, V65, P5070, DOI 10.1158/0008-5472.CAN-05-0240; Fevre-Montange M, 2009, INT J ONCOL, V35, P1395, DOI 10.3892/ijo_00000457; Goutagny S, 2014, BRAIN PATHOL, V24, P184, DOI 10.1111/bpa.12110; Hagemann IS, 2015, CANCER-AM CANCER SOC, V121, P631, DOI 10.1002/cncr.29089; Harmanci AS, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14433; Koboldt DC, 2012, GENOME RES, V22, P568, DOI 10.1101/gr.129684.111; Kuilman T, 2015, GENOME BIOL, V16, DOI 10.1186/s13059-015-0617-1; Li H, 2011, BIOINFORMATICS, V27, P2987, DOI 10.1093/bioinformatics/btr509; Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324; LINDBLOM A, 1994, INT J CANCER, V56, P354, DOI 10.1002/ijc.2910560310; Louis DN, 2007, ACTA NEUROPATHOL, V114, P97, DOI 10.1007/s00401-007-0243-4; Louis DN, 2016, ACTA NEUROPATHOL, V131, P803, DOI 10.1007/s00401-016-1545-1; McNeill KA, 2016, NEUROL CLIN, V34, P981, DOI 10.1016/j.ncl.2016.06.014; Mihaila D, 2003, CLIN CANCER RES, V9, P4443; Ostrom QT, 2017, NEURO-ONCOLOGY, V19, pV1, DOI 10.1093/neuonc/nox158; REMPEL SA, 1993, CANCER RES, V53, P2386; Rizvi NA, 2015, SCIENCE, V348, P124, DOI 10.1126/science.aaa1348; Sahm F, 2017, LANCET ONCOL, V18, P682, DOI 10.1016/S1470-2045(17)30155-9; Sahm F, 2016, JNCI-J NATL CANCER I, V108, DOI 10.1093/jnci/djv377; Sahm F, 2013, ACTA NEUROPATHOL, V126, P757, DOI 10.1007/s00401-013-1187-5; Si W. L, 2017, NPJ GENOM MED, V2; Snyder A, 2014, NEW ENGL J MED, V371, P2189, DOI 10.1056/NEJMoa1406498; Strickland MR, 2017, J NEUROSURG, V127, P438, DOI 10.3171/2016.8.JNS161076; Talevich E, 2016, PLOS COMPUT BIOL, V12, DOI 10.1371/journal.pcbi.1004873; Weber RG, 1997, P NATL ACAD SCI USA, V94, P14719, DOI 10.1073/pnas.94.26.14719; Wen PY, 2010, J NEURO-ONCOL, V99, P365, DOI 10.1007/s11060-010-0349-8	31	0	0	0	2	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4800	1096-0945		EXP MOL PATHOL	Exp. Mol. Pathol.	DEC	2018	105	3					328	333		10.1016/j.yexmp.2018.10.007			6	Pathology	Pathology	HE4MW	WOS:000453342000012	30316860				2019-10-28	
J	Afroz, F; Kist, A; Hua, J; Zhou, YB; Sokoya, EM; Padbury, R; Nieuwenhuijs, V; Barritt, G				Afroz, Farhana; Kist, Alwyn; Hua, Jin; Zhou, Yabin; Sokoya, Elke M.; Padbury, Robert; Nieuwenhuijs, Vincent; Barritt, Greg			Rapamycin induces the expression of heme oxygenase-1 and peroxyredoxin-1 in normal hepatocytes but not in tumorigenic liver cells	EXPERIMENTAL AND MOLECULAR PATHOLOGY			English	Article						Liver; Ischemia reperfusion; Rapamycin; Heme oxygenase-1; Peroxiredoxin-1; Quantitative PCR	ISCHEMIA-REPERFUSION INJURY; HEPATOCELLULAR-CARCINOMA RECURRENCE; ENDOPLASMIC-RETICULUM STRESS; PROTEIN-KINASE-C; ISCHEMIA/REPERFUSION INJURY; MAMMALIAN TARGET; HEPATIC ISCHEMIA; OXIDATIVE STRESS; COBALT-PROTOPORPHYRIN; MOLECULAR-MECHANISMS	Rapamycin (sirolimus) is employed as an immunosuppressant following liver transplant, to inhibit the re-growth of cancer cells following liver resection for hepatocellular carcinoma (HCC), and for the treatment of advanced HCC. Rapamycin also induces the expression of antioxidant enzymes in the liver, suggesting that pretreatment with the drug could provide a potential strategy to reduce ischemia reperfusion injury following liver surgery. The aim of this study was to further investigate the actions of rapamycin in inducing expression of the antioxidant enzymes heme oxygenase-1 (HO-1) and peroxiredoxin-1 (Prx-1) in normal liver and in tumorigenic liver cells. A rat model of segmental hepatic ischemia and reperfusion, cultured freshly-isolated rat hepatocytes, and tumorigenic H4IIE rat liver cells in culture were employed. Expression of HO-1 and Prx-1 was measured using quantitative PCR and western blot. Rapamycin pre-treatment of normal liver in vivo or normal hepatocytes in vitro led to a substantial induction of mRNA encoding HO-1 and Prx-1. The dose-response curve for the action of rapamycin on mRNA expression was biphasic, showing an increase in expression at 0 - 0.1 mu M rapamycin but a decrease from maximum at concentrations greater than 0.1 mu M. By contrast, in H4IIE cells, rapamycin inhibited the expression of HO-1 and Prx-1 mRNA. Oltipraz, an established activator of transcription factor Nrf2, caused a large induction of HO-1 and Prx-1 mRNA. The dose response curve for the inhibition by rapamycin of HO-1 and Prx-4 mRNA expression, determined in the presence of oltipraz, was monophasic with half maximal inhibition at about 0.01 mu M. It is concluded that, at concentrations comparable to those used clinically, pre-treatment of the liver with rapamycin induces the expression of HO-1 and Prx-1. However, the actions of rapamycin on the expression of these two antioxidant enzymes in normal hepatocytes are complex and, in tumorigenic liver cells, differ from those in normal hepatocytes. Further studies are warranted to evaluate preconditioning the livers of patients subject to liver resection or liver transplant with rapamycin as a viable strategy to reduce IR injury following liver surgery.	[Afroz, Farhana; Kist, Alwyn; Hua, Jin; Zhou, Yabin; Barritt, Greg] Flinders Univ S Australia, Coll Med & Publ Hlth, Discipline Med Biochem, GPO Box 2100, Adelaide, SA 5001, Australia; [Sokoya, Elke M.] Flinders Univ S Australia, Coll Med & Publ Hlth, Discipline Human Physiol, Adelaide, SA, Australia; [Padbury, Robert] Flinders Univ S Australia, Flinders Med Ctr, HPB & Liver Transplant Unit, Adelaide, SA, Australia; [Padbury, Robert] Flinders Univ S Australia, Coll Med & Publ Hlth, Adelaide, SA, Australia; [Nieuwenhuijs, Vincent] Isala, Dept Surg, Zwolle, Netherlands	Barritt, G (reprint author), Flinders Univ S Australia, Coll Med & Publ Hlth, Discipline Med Biochem, GPO Box 2100, Adelaide, SA 5001, Australia.	Greg.Barritt@flinders.edu.au			Cancer Council S.A.s Beat Cancer ProjectCancer Council South Australia; Flinders Foundation; Flinders University of South Australia	This work was supported by the Cancer Council S.A.s Beat Cancer Project (on behalf of its donors and the State Government of South Australia through the Department of Health), the Flinders Foundation, and Flinders University of South Australia.	Aguilar-Melero P, 2013, J PROTEOMICS, V79, P161, DOI 10.1016/j.jprot.2012.12.005; Akhtar MZ, 2013, TRANSPL P, V45, P2083, DOI 10.1016/j.transproceed.2013.04.004; Amersi F, 1999, J CLIN INVEST, V104, P1631, DOI 10.1172/JCI7903; Aromataris EC, 2006, J PHYSIOL-LONDON, V573, P611, DOI 10.1113/jphysiol.2006.109819; Atef Y, 2017, N-S ARCH PHARMACOL, V390, P871, DOI 10.1007/s00210-017-1389-9; Bozaykut P, 2016, MECH AGEING DEV, V157, P17, DOI 10.1016/j.mad.2016.07.001; Cabre N, 2016, HEPATOL SURG NUTR, V5, P438, DOI 10.21037/hbsn.2016.09.11; Castro J, 2009, BIOCHEM J, V418, P553, DOI 10.1042/BJ20081052; Cheng ML, 2015, HEPATOB PANCREAT DIS, V14, P485, DOI 10.1016/S1499-3872(15)60425-8; Cheng YY, 2017, CURR PHARM DESIGN, V23, P3884, DOI 10.2174/1381612823666170413122439; Cho JY, 2017, JAMA SURG, V152, P386, DOI 10.1001/jamasurg.2016.5040; Cholongitas E, 2014, TRANSPL INT, V27, P1039, DOI 10.1111/tri.12372; Colella AD, 2012, ANAL BIOCHEM, V430, P108, DOI 10.1016/j.ab.2012.08.015; Cotterell AH, 2015, DIGEST DIS SCI, V60, P2579, DOI 10.1007/s10620-015-3729-2; Dasari BVM, 2017, BEST PRACT RES CL GA, V31, P211, DOI 10.1016/j.bpg.2017.03.002; Datta G, 2013, WORLD J GASTROENTERO, V19, P1683, DOI 10.3748/wjg.v19.i11.1683; Dibble CC, 2015, TRENDS CELL BIOL, V25, P545, DOI 10.1016/j.tcb.2015.06.002; Dutkowski P, 2015, GASTROENTEROLOGY, V148, P307, DOI 10.1053/j.gastro.2014.08.045; Elias-Miro M, 2013, FREE RADICAL RES, V47, P555, DOI 10.3109/10715762.2013.811721; EVANS MJ, 1977, CELL TISSUE KINET, V10, P233, DOI 10.1111/j.1365-2184.1977.tb00291.x; Font-Burgada J, 2016, CELL METAB, V23, P48, DOI 10.1016/j.cmet.2015.12.015; Ge M, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.236; Ghazal K, 2018, CLIN RES HEPATOL GAS, V42, P237, DOI 10.1016/j.clinre.2017.10.001; Gilda JE, 2013, ANAL BIOCHEM, V440, P186, DOI 10.1016/j.ab.2013.05.027; Gurtler A, 2013, ANAL BIOCHEM, V433, P105, DOI 10.1016/j.ab.2012.10.010; Han XY, 2018, BIOMATERIALS, V156, P134, DOI 10.1016/j.biomaterials.2017.11.039; HASSELGREN PO, 1982, ACTA PHYSIOL SCAND, V114, P143, DOI 10.1111/j.1748-1716.1982.tb06963.x; Ishii T, 2000, J BIOL CHEM, V275, P16023, DOI 10.1074/jbc.275.21.16023; Jones L, 2011, BBA-BIOMEMBRANES, V1808, P745, DOI 10.1016/j.bbamem.2010.12.013; Karin M, 2016, CARCINOGENESIS, V37, P541, DOI 10.1093/carcin/bgw060; Kato H, 2001, AM J TRANSPLANT, V1, P121, DOI 10.1034/j.1600-6143.2001.10205.x; Kim YJ, 2007, CANCER RES, V67, P546, DOI 10.1158/0008-5472.CAN-06-2401; Kist A, 2012, J SURG RES, V176, P468, DOI 10.1016/j.jss.2011.10.033; Klempner SJ, 2013, CANCER DISCOV, V3, P1345, DOI 10.1158/2159-8290.CD-13-0063; KUTTY RK, 1995, P NATL ACAD SCI USA, V92, P1177, DOI 10.1073/pnas.92.4.1177; Lai IR, 2008, TRANSPLANTATION, V85, P732, DOI 10.1097/TP.0b013e3181664e70; Lee SC, 2016, AM J TRANSPLANT, V16, P2042, DOI 10.1111/ajt.13729; Li J, 2018, MOL MED REP, V17, P4567, DOI 10.3892/mmr.2018.8384; Liu AD, 2016, ONCOTARGET, V7, P78372, DOI 10.18632/oncotarget.13281; Liu AD, 2014, CRIT CARE MED, V42, pE762, DOI 10.1097/CCM.0000000000000659; Liu B, 2015, INT J CLIN EXP MED, V8, P19867; Liu P, 2017, HEPATOLOGY, V66, P167, DOI 10.1002/hep.29183; Liu YX, 2010, DIGEST DIS SCI, V55, P2255, DOI 10.1007/s10620-009-1002-2; Mann CD, 2009, EUR J CANCER PREV, V18, P13, DOI 10.1097/CEJ.0b013e3282f0c090; Martinez-Cisuelo V, 2016, EXP GERONTOL, V83, P130, DOI 10.1016/j.exger.2016.08.002; MESSINA JL, 1992, J BIOL CHEM, V267, P9223; Nagai S, 2015, HEPATOLOGY, V61, P895, DOI 10.1002/hep.27358; Nakamura K, 2018, AM J TRANSPLANT, V18, P1110, DOI 10.1111/ajt.14586; Nakamura K, 2017, J HEPATOL, V67, P1232, DOI 10.1016/j.jhep.2017.08.010; Nguyen T, 2009, J BIOL CHEM, V284, P13291, DOI 10.1074/jbc.R900010200; Pagliassotti MJ, 2016, METABOLISM, V65, P1238, DOI 10.1016/j.metabol.2016.05.002; Paine A, 2010, BIOCHEM PHARMACOL, V80, P1895, DOI 10.1016/j.bcp.2010.07.014; Peters J, 2010, DIGEST SURG, V26, P455; Piton A, 2005, CARCINOGENESIS, V26, P343, DOI 10.1093/carcin/bgh316; PITOT H. C., 1964, NAT CANCER INST MONOGR, V13, P229; Prieto I, 2017, REDOX BIOL, V12, P1020, DOI 10.1016/j.redox.2017.04.036; Qi X, 2014, ONCOTARGET, V5, P11103, DOI 10.18632/oncotarget.2549; Quesnelle KM, 2015, ARCH TOXICOL, V89, P651, DOI 10.1007/s00204-014-1437-x; Ramos-Gomez M, 2001, P NATL ACAD SCI USA, V98, P3410, DOI 10.1073/pnas.051618798; Reiniers MJ, 2014, ANTIOXID REDOX SIGN, V21, P1119, DOI 10.1089/ars.2013.5486; REUBER MD, 1961, J NATL CANCER I, V26, P891; Antolin GS, 2011, TRANSPL P, V43, P714, DOI 10.1016/j.transproceed.2011.01.105; Sapisochin G, 2017, NAT REV GASTRO HEPAT, V14, P203, DOI 10.1038/nrgastro.2016.193; Simillis C, 2016, SURGERY, V159, P1157, DOI 10.1016/j.surg.2015.10.011; Soll C, 2011, J HEPATOL, V54, P182, DOI 10.1016/j.jhep.2010.07.049; Song IS, 2009, CARCINOGENESIS, V30, P1106, DOI 10.1093/carcin/bgp104; Su HW, 2006, LIVER TRANSPLANT, V12, P1634, DOI 10.1002/lt.20852; Sun QK, 2014, MED ONCOL, V31, DOI 10.1007/s12032-013-0786-2; Toso C, 2011, AM J TRANSPLANT, V11, P2031, DOI 10.1111/j.1600-6143.2011.03689.x; Toso C, 2010, HEPATOLOGY, V51, P1237, DOI 10.1002/hep.23437; Tullius SG, 2002, TRANSPLANTATION, V74, P591, DOI 10.1097/00007890-200209150-00001; van Riel WG, 2016, HEPATOBIL SURG NUTR, V5, P58, DOI 10.3978/j.issn.2304-3881.2015.07.05; VARGAS AM, 1994, DIABETES, V43, P792, DOI 10.2337/diabetes.43.6.792; Wang XH, 2005, WORLD J GASTROENTERO, V11, P690, DOI 10.3748/wjg.v11.i5.690; Weerachayaphorn J, 2009, HEPATOLOGY, V50, P1588, DOI 10.1002/hep.23151; Wilson CH, 2016, CELL DEATH DISCOV, V2, DOI 10.1038/cddiscovery.2016.9; Wilson CH, 2015, BIOCHEM J, V466, P379, DOI 10.1042/BJ20140881; Wilson CH, 2011, PROTEOMICS, V11, P4385, DOI 10.1002/pmic.201100053; Xu DW, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.386; Yao JY, 2016, BIOCHEM BIOPH RES CO, V473, P867, DOI 10.1016/j.bbrc.2016.03.141; Yates MS, 2007, ACTA PHARMACOL SIN, V28, P1331, DOI 10.1111/j.1745-7254.2007.00688.x; Yun N, 2010, ANTIOXID REDOX SIGN, V13, P1503, DOI 10.1089/ars.2009.2873; Zahradka P, 1998, BBA-BIOMEMBRANES, V1375, P131, DOI 10.1016/S0005-2736(98)00144-8; Zhai Y, 2013, NAT REV GASTRO HEPAT, V10, P79, DOI 10.1038/nrgastro.2012.225; Zhang B., 2016, MOLECULES, V21; Zhang XL, 2016, APOPTOSIS, V21, P721, DOI 10.1007/s10495-016-1234-5; Zhang ZH, 2019, J ENVIRON SCI HEAL A, V54, P127, DOI [10.1080/08941939.2018.1447053, 10.1080/10934529.2018.1530539]; Zhu J, 2015, TRANSPL P, V47, P1646, DOI 10.1016/j.transproceed.2015.05.013; Zhu JJ, 2015, TRANSPLANTATION, V99, P48, DOI 10.1097/TP.0000000000000476	89	1	1	3	8	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4800	1096-0945		EXP MOL PATHOL	Exp. Mol. Pathol.	DEC	2018	105	3					334	344		10.1016/j.yexmp.2018.09.006			11	Pathology	Pathology	HE4MW	WOS:000453342000013	30290159				2019-10-28	
J	Arbelaez, LFG; Pardo, AC; Swenson, ER; Alvarez, BV; Mosca, SM; Fantinelli, JC				Gonzalez Arbelaez, Luisa F.; Ciocci Pardo, Alejandro; Swenson, Erik R.; Alvarez, Bernardo, V; Mosca, Susana M.; Fantinelli, Juliana C.			Cardioprotection of benzolamide in a regional ischemia model: Role of eNOS/NO	EXPERIMENTAL AND MOLECULAR PATHOLOGY			English	Article						Benzolamide; Carbonic anhydrase inhibition; eNOS/NO; Coronary artery occlusion	NITRIC-OXIDE SYNTHASE; REPERFUSION INJURY; PEROXYNITRITE; MECHANISMS; BINDS; AKT	Background - Recent studies from our laboratory show the cardioprotective action of benzolamide (BZ, carbonic anhydrase inhibitor) against ischemia-reperfusion injury. However, the mechanisms involved have not been fully elucidated. Objective: To examine the participation of the endothelial nitric oxide synthase (eNOS)/nitric oxide (NO) in the effects of BZ in a model of regional ischemia. Methods: Isolated rat hearts perfused by Langendorff technique were submitted to 40 min of coronary artery occlusion followed by 60 min of reperfusion (IC). Other hearts received BZ during the first 10 min of reperfusion in absence or presence of L-NAME, NOS inhibitor. The infarct size (IS) and the post-ischemic recovery of myocardial function were measured. Oxidative/nitrosative damage were assessed by reduced glutathione (GSH) content, thiobarbituric acid reactive substances (TSARS) and 3-nitrotyrosine levels. The expression of phosphorylated forms of Akt, p38MAPK and eNOS, and the concentration of inducible nitric oxide synthase (iNOS) were also determined. Results: BZ significantly decreased IS (6.2 +/- 0.5% vs. 34 +/- 4%), improved post-ischemic contractility, preserved GSH levels and diminished TBARS and 3-nitrotyrosine. In IC hearts, P-Akt, P-p38MAPK and P-eNOS decreased and iNOS increased. After BZ addition the levels of P-kinases and P-eNOS increased and iNOS decreased. Except for P-Akt, P-p38MAPK and iNOS, the effects of BZ were abolished by L-NAME. Conclusions: Our data demonstrate that the treatment with BZ at the onset of reperfusion was effective to reduce cell death, contractile dysfunction and oxidative/nitrosative damage produced by coronary artery occlusion. These BZ-mediated beneficial actions appear mediated by eNOS/NO-dependent pathways.	[Gonzalez Arbelaez, Luisa F.; Ciocci Pardo, Alejandro; Alvarez, Bernardo, V; Mosca, Susana M.; Fantinelli, Juliana C.] Dr Horacio E Cingolani Univ Nacl La Plata, La Plata, Buenos Aires, Argentina; [Swenson, Erik R.] Univ Washington, VA Puget Sound Hlth Care Syst, Dept Med Pulm & Crit Care Med, Seattle, WA 98108 USA	Fantinelli, JC (reprint author), Univ Nacl La Plata, Ctr Invest Cardiovasc, RA-1900 La Plata, Buenos Aires, Argentina.	julianafantinelli@ciclaplata.org.ar			Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET) of ArgentinaConsejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET) [PIP0886]	This study was supported by the Grant PIP0886 from the Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET) of Argentina to Dra M Nolly and J C Fantinelli.	Bagheri F, 2016, LIFE SCI, V165, P43, DOI 10.1016/j.lfs.2016.09.013; Bernink F. J., 2017, INT J CARDIOL, P261; Braunersreuther V, 2012, CURR PHARM BIOTECHNO, V13, P97, DOI 10.2174/138920112798868782; Buege J A, 1978, Methods Enzymol, V52, P302; Dimmeler S, 1999, NATURE, V399, P601, DOI 10.1038/21224; Feissner R. F., 2002, FRONT BIOSCI, P1197; Gao F, 2002, CIRCULATION, V105, P1497, DOI 10.1161/01.CIR.0000012529.00367.0F; Heusch G, 2008, CIRCULATION, V118, P1915, DOI 10.1161/CIRCULATIONAHA.108.805242; Jugdutt Bodh I, 2002, Heart Fail Rev, V7, P391, DOI 10.1023/A:1020718619155; Katori T, 2006, FREE RADICAL BIO MED, V41, P1606, DOI 10.1016/j.freeradbiomed.2006.08.023; Li XJ, 2002, J BIOL CHEM, V277, P36085, DOI 10.1074/jbc.M111952200; Liu Y. H., 2005, AM J PHYSIOL-HEART C, P616; Mungrue IN, 2002, J CLIN INVEST, V109, P735, DOI 10.1172/JCI200213265; Peng T. I, 2012, NY ACAD SCI, P183; Perez N. G., 2017, J APPL PHYSIOL, DOI [10.1152/japplphysiol.00957, DOI 10.1152/JAPPLPHYSIOL.00957]; Schulz R, 2004, CARDIOVASC RES, V61, P402, DOI 10.1016/j.cardiores.2003.09.019; Sedlak J, 1986, ANAL BIOCHEM, P192; Song YX, 2013, LIFE SCI, V92, P1215, DOI 10.1016/j.lfs.2013.05.007; Sterling D, 2002, J BIOL CHEM, V277, P25239, DOI 10.1074/jbc.M202562200; Suzuki M, 2002, J CLIN INVEST, V109, P509, DOI 10.1172/JC1200214270; Vargas LA, 2016, CARDIOVASC PATHOL, V25, P468, DOI 10.1016/j.carpath.2016.08.003; Vaughan-Jones R. D., J CARDIOVASC ELECTRO, P134; Wang GW, 2005, AM J PHYSIOL-HEART C, V288, pH1290, DOI 10.1152/ajpheart.00796.2004; Yellon DM, 2007, NEW ENGL J MED, V357, P1121, DOI 10.1056/NEJMra071667; Zweier JL, 2006, CARDIOVASC RES, V70, P181, DOI 10.1016/j.cardiores.2006.02.025	25	0	0	0	3	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4800	1096-0945		EXP MOL PATHOL	Exp. Mol. Pathol.	DEC	2018	105	3					345	351		10.1016/j.yexmp.2018.10.003			7	Pathology	Pathology	HE4MW	WOS:000453342000014	30308197				2019-10-28	
J	Pires-Luis, A; Montezuma, D; Vieira, J; Ramalho-Carvalho, J; Santos, C; Teixeira, M; Jeronimo, C; Henrique, R				Pires-Luis, A.; Montezuma, D.; Vieira, J.; Ramalho-Carvalho, J.; Santos, C.; Teixeira, M.; Jeronimo, C.; Henrique, R.			Hybrid oncocytic/chromophobe renal cell tumor: An integrated genetic and epigenetic characterization of a case	EXPERIMENTAL AND MOLECULAR PATHOLOGY			English	Article						Kidney cancer; Hybrid oncocytic-chromophobe renal cell; tumor; HOCT; FISH; microRNA	ONCOCYTOMA; CARCINOMAS; DIAGNOSIS; KIDNEY	Introduction: Hybrid oncocytic/chromophobe tumor (HOCT) is a renal cell neoplasm displaying overlapping cellular and architectural features of both renal oncocytoma (RO) and chromophobe renal cell carcinoma (chRCC). It has been described in the context of oncocytosis, Bin-Hogg-Dube syndrome, and also sporadically. Thus far, HOCT immunohischemical profile and cytogenetic alterations have been reported, but not epigenetic alterations. Herein, we characterize a HOCT case, including microRNA expression, comparing it to sporadic RO and chRCC. Methods: An HOCT was entirely submitted. Representative paraffin blocks were selected for histochemical, immunohistochemical and FISH analyses. MicroRNAs were extracted from the two components separately and selected microRNA expression was performed. Results: This 4 cm HOCT, from a 69 year-old female, was composed mainly by oncocytic cells with an insular distribution (RO-like) and areas of larger clarified cells (chRCC-like). The two areas displayed different features: RO-like areas showed negative colloidal iron staining, multifocal CD15, negative CK7, focal multiple tetrasomies, and higher miR21 expression; chRCC-like areas showed colloidal iron diffuse staining with moderate intensity, focal CD15 and CK7, no numeric chromosomic alterations, and higher miR141 and miR200b expression. Conclusion: microRNA expression in the two HOCT components is similar to its sporadic tumors counterparts. Morphologic, immunohistochemical, cytogenetic and epigenetic data on this case suggest either two independent pathogenic pathways or an early pathogenic divergence for RO-like and chRCC-like components of HOCT.	[Pires-Luis, A.; Montezuma, D.; Henrique, R.] Portuguese Oncol Inst Porto, Dept Pathol, Rua Dr Antonio Bernardino de Almeida, P-4200072 Porto, Portugal; [Pires-Luis, A.; Ramalho-Carvalho, J.; Jeronimo, C.; Henrique, R.] Portuguese Oncol Inst Porto, Res Ctr, Canc Biol & Epigenet Grp, Porto, Portugal; [Pires-Luis, A.] Univ Porto, Inst Biomed Sci Abel Salazar ICBAS, Dept Microscopy, Porto, Portugal; [Vieira, J.; Santos, C.; Teixeira, M.] Portuguese Oncol Inst Porto, Dept Genet, Porto, Portugal; [Teixeira, M.; Jeronimo, C.; Henrique, R.] Univ Porto, Inst Biomed Sci Abel Salazar ICBAS, Dept Pathol & Mol Immunol, Porto, Portugal	Henrique, R (reprint author), Portuguese Oncol Inst Porto, Dept Pathol, Rua Dr Antonio Bernardino de Almeida, P-4200072 Porto, Portugal.	henrique@ipoporto.min-saude.pt			Research Center of Portuguese Oncology Institute of Porto [PI 74-CI-IPOP-19-2016]; FCT - Fundagao para a Ciencia e a Tecnologia fellowships [SFRH/SINTD/94217/2013, SFRH/BD/71293/2010]	This work was supported by a grant from Research Center of Portuguese Oncology Institute of Porto (PI 74-CI-IPOP-19-2016). ASP-L and JRC were supported by FCT - Fundagao para a Ciencia e a Tecnologia fellowships (SFRH/SINTD/94217/2013 and SFRH/BD/71293/2010, respectively).	Brunelli M, 2005, MODERN PATHOL, V18, P161, DOI 10.1038/modpathol.3800286; Delongchamps NB, 2009, BJU INT, V103, P1381, DOI 10.1111/j.1464-410X.2008.08263.x; Jones M. L., 2008, THEORY PRACTICE HIST, P175; Kryvenko ON, 2014, ARCH PATHOL LAB MED, V138, P1531, DOI 10.5858/arpa.2013-0653-RA; Liu L, 2007, ARCH PATHOL LAB MED, V131, P1290; Mai KT, 2005, PATHOL RES PRACT, V201, P385, DOI 10.1016/j.prp.2005.03.008; Moch H, 2016, WHO CLASSIFICATION T; Paulo P, 2017, J MOL DIAGN, V19, P502, DOI [10.1016/j.jmoldx.2017.0.5.001, 10.1016/j.jmoldx.2017.05.001]; Pavlovich CP, 2002, AM J SURG PATHOL, V26, P1542, DOI 10.1097/00000478-200212000-00002; Petersson F, 2010, VIRCHOWS ARCH, V456, P355, DOI 10.1007/s00428-010-0898-4; Pote N, 2013, VIRCHOWS ARCH, V462, P633, DOI 10.1007/s00428-013-1422-4; Silva-Santos RM, 2013, BRIT J CANCER, V109, P2646, DOI 10.1038/bjc.2013.552; Tickoo SK, 1999, AM J SURG PATHOL, V23, P1094, DOI 10.1097/00000478-199909000-00013; Vieira J, 2010, GENE CHROMOSOME CANC, V49, P935, DOI 10.1002/gcc.20805; Waldert M, 2010, EUR UROL, V57, P661, DOI 10.1016/j.eururo.2009.05.009	15	1	1	2	3	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4800	1096-0945		EXP MOL PATHOL	Exp. Mol. Pathol.	DEC	2018	105	3					352	356		10.1016/j.yexmp.2018.10.008			5	Pathology	Pathology	HE4MW	WOS:000453342000015	30343009				2019-10-28	
J	Wang, WG; Zhan, RS; Zhou, JH; Wang, JL; Chen, SJ				Wang, Weiguo; Zhan, Ruisen; Zhou, Jiahui; Wang, Jianlong; Chen, Shijie			MiR-10 targets NgR to modulate the proliferation of microglial cells and the secretion of inflammatory cytokines	EXPERIMENTAL AND MOLECULAR PATHOLOGY			English	Article						miR-10; NgR; Microglial cells (MCs); Proliferation; Inflammatory cytokine	SPINAL-CORD-INJURY; MACROPHAGES; PLASTICITY; EXPRESSION; RECOVERY	The present study is aimed to investigate the molecular mechanism of miR-10 targeting NgR to regulate the proliferation and inflammatory cytokine secretion in microglia cells (MCs). The expression levels of NgR, IL-1 beta, and TNF-alpha in rat MCs were detected by QPCR and Immunoblotting assays. The proliferation of MC was detected by MTT and Soft agar clone formation assays. The target gene of miR-10 was verified by dual luciferase reporter gene assay. Overexpressed miR-10 downregulated the expression of NgR, promoted MC proliferation and inhibited inflammatory cytokine secretion. On the other hand, the inhibition of miR-10 upregulated the expression of NgR, inhibited MC proliferation and promoted inflammatory cytokine secretion. It was found that miR-10 targeted to regulate NgR. Overexpression of NgR restored the regulation effects of miR-10 on MC proliferation and inflammatory cytokine secretion. In summary, miR-10 can promote MC proliferation and inhibit the inflammatory cytokine secretion via targeting the NgR gene to down-regulate its expression.	[Wang, Weiguo; Zhan, Ruisen; Zhou, Jiahui; Wang, Jianlong; Chen, Shijie] Cent S Univ, Xiangya Hosp 3, Dept orthoped, 138 Tongzipo Rd, Changsha 410013, Hunan, Peoples R China	Wang, JL; Chen, SJ (reprint author), Cent S Univ, Xiangya Hosp 3, Dept orthoped, 138 Tongzipo Rd, Changsha 410013, Hunan, Peoples R China.	tearsacz@csu.edu.cn; shijiechencsu@163.com			Natural Science Foundation of Hunan Province, ChinaNatural Science Foundation of Hunan Province [11JJ5079, 2015JJ6116]	This study was supported by the Natural Science Foundation of Hunan Province, China (Grant No. 11JJ5079 and 2015JJ6116).	Darsalia V, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103114; David S, 2015, NEUROSCIENCE, V307, P311, DOI 10.1016/j.neuroscience.2015.08.064; Miguel Marcia de, 2009, Rev. Bras. Anestesiol., V59, P350, DOI 10.1590/S0034-70942009000300011; Fang YQ, 2015, J BIOL CHEM, V290, P28901, DOI 10.1074/jbc.M115.678326; Guzik-Kornacka A. M., 2016, BLOCKING NOGO SIGNAL; Hutchison ER, 2013, GLIA, V61, P1018, DOI 10.1002/glia.22483; Jee MK, 2012, BRAIN, V135, P1237, DOI 10.1093/brain/aws047; Kong HM, 2015, J MOL NEUROSCI, V57, P28, DOI 10.1007/s12031-015-0574-x; Kopper TJ, 2018, J NEUROSCI RES, V96, P969, DOI 10.1002/jnr.24114; Lee BB, 2014, SPINAL CORD, V52, P110, DOI 10.1038/sc.2012.158; Liddelow SA, 2017, NATURE, V541, P481, DOI 10.1038/nature21029; Louw A. M., 2015, BIOL MED, V12, P643; Nieto-Diaz M, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00053; Pogue AI, 2010, NEUROSCI LETT, V476, P18, DOI 10.1016/j.neulet.2010.03.054; Ponomarev ED, 2011, NAT MED, V17, P64, DOI 10.1038/nm.2266; Schwab ME, 2014, CURR OPIN NEUROBIOL, V27, P53, DOI 10.1016/j.conb.2014.02.011; Svahn AJ, 2016, DEV NEUROBIOL, V76, P507, DOI 10.1002/dneu.22328; Szczepanik AM, 2001, J NEUROIMMUNOL, V113, P49, DOI 10.1016/S0165-5728(00)00404-5; Yan J, 2012, J NEUROCHEM, V120, P721, DOI 10.1111/j.1471-4159.2011.07619.x; Yu YM, 2011, EUR J NEUROSCI, V33, P1587, DOI 10.1111/j.1460-9568.2011.07643.x; Zawadzka M, 2005, GLIA, V49, P36, DOI 10.1002/glia.20092; Zhou HT, 2012, MOL MED REP, V5, P842, DOI 10.3892/mmr.2011.719; Zhou X, 2014, NEURAL REGEN RES, V9, P1787, DOI 10.4103/1673-5374.143423	23	2	2	1	7	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4800	1096-0945		EXP MOL PATHOL	Exp. Mol. Pathol.	DEC	2018	105	3					357	363		10.1016/j.yexmp.2018.10.006			7	Pathology	Pathology	HE4MW	WOS:000453342000016	30312597				2019-10-28	
J	Soh, RYZ; Lim, JP; Samy, RP; Chua, PJ; Bay, BH				Soh, Regina You Zhen; Lim, Jia Pei; Samy, Ramar Perumal; Chua, Pei Jou; Bay, Boon Huat			A-kinase anchor protein 12 (AKAP12) inhibits cell migration in breast cancer	EXPERIMENTAL AND MOLECULAR PATHOLOGY			English	Article						Breast cancer; A-kinase anchor protein 12 (AKAP12); Tumor suppressor; Cell migration	GENE-EXPRESSION; CLINICAL IMPORTANCE; TUMOR-SUPPRESSOR; C SUBSTRATE; SSECKS; SRC; TRANSFORMATION; AKAP12/GRAVIN; CARCINOMA; GRAVIN	A-kinase anchor protein 12 (AKAP12) also known as Gravin and SSeCKS, is a novel potent scaffold protein for many key signaling factors, such as protein kinase C (PKC), PKA, cyclins as well as F-actin. AKAP12 expression is known to be suppressed in several human malignancies including breast, prostate, gastric and colon cancers. In this study, we evaluated the role of AKAP12 in the migration of breast cancer cells, an important cellular process in cancer progression. AKAP12 gene expression was analyzed in human breast cancer tissues using the Gene expression-based Outcome for Breast cancer Online (GOBO) database and TissueScan array, followed by relapse free survival (RFS) analysis with the Kaplan-Meier Plotter. AKAP12 protein was then analyzed in normal MCF10A breast cell line and six different breast cancer cell lines (AU565, Hs578T, MCF7, MDA-MB-231, T47D and ZR751). After which, siRNA-mediated knockdown of AKAP12 was carried out in MCF10A, MDA-MB-231 and Hs578T cells, followed by phenotypic assays. AKAP12 was observed to be reduced in breast cancer tissues as analyzed by GOBO and TissueScan array. Kaplan Meier survival analysis revealed that patients with AKAP12 gene expression had a higher RFS survival. There was also decreased AKAP12 protein expression in breast cancer cell lines compared to MCF10A normal epithelial breast cell line. Knockdown of AKAP12 in both MCF10A cells and Hs578T cells induced cell migration but did not alter cell proliferation. Moreover, siAKAP12 in aggressive MDA-MB-231 breast cancer cells led to an increase in cell migration. Immunofluorescence analysis of AKAP12 depleted MCF10A cells also revealed formation of thick stress fibers which could affect cell migration. Hence, the findings in this study suggest that AKAP12 is a potential metastasis suppressor in breast cancer.	[Soh, Regina You Zhen; Lim, Jia Pei; Samy, Ramar Perumal; Chua, Pei Jou; Bay, Boon Huat] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Anat, 4 Med Dr,MD10, Singapore 117594, Singapore; [Lim, Jia Pei] Agcy Sci Technol & Res, Inst Mol & Cell Biol, Translat Biomed Prote Grp, 61 BioPolis Dr, Singapore 138673, Singapore	Chua, PJ; Bay, BH (reprint author), Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Anat, 4 Med Dr,MD10, Singapore 117594, Singapore.	antcpj@nus.edu.sg; boon_huat_bay@nuhs.edu.sg		Bay, Boon Huat/0000-0001-8553-5087	National Medical Research Council of SingaporeNational Medical Research Council, Singapore [NMRC/CIRG/1370/2013]; Ong Hin Tiang Cancer Research Scholarship	This study was supported by a research grant NMRC/CIRG/1370/2013 from the National Medical Research Council of Singapore. Jia Pei Lim is a recipient of the Ong Hin Tiang Cancer Research Scholarship. The authors would like to thank Umamaheswari Muniasamy for technical assistance.	Akakura S., 2012, J SIGNAL TRANSDUCT; Akakura S, 2008, CANCER RES, V68, P5096, DOI 10.1158/0008-5472.CAN-07-5619; Akakura S, 2010, CELL CYCLE, V9, P4656, DOI 10.4161/cc.9.23.13974; Bayraktar S, 2012, CANCER-AM CANCER SOC, V118, P1515, DOI 10.1002/cncr.26428; Choi MC, 2004, ONCOGENE, V23, P7095, DOI 10.1038/sj.onc.1207932; Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210; Gardel ML, 2010, ANNU REV CELL DEV BI, V26, P315, DOI 10.1146/annurev.cellbio.011209.122036; Gelman Irwin H, 2010, Genes Cancer, V1, P1147, DOI 10.1177/1947601910392984; GORDON T, 1992, J CLIN INVEST, V90, P992, DOI 10.1172/JCI115976; Gyorffy B, 2010, BREAST CANCER RES TR, V123, P725, DOI 10.1007/s10549-009-0674-9; Hayashi M, 2012, J SURG ONCOL, V105, P381, DOI 10.1002/jso.22135; Howe AK, 2011, CURR OPIN CELL BIOL, V23, P554, DOI 10.1016/j.ceb.2011.05.006; Lim JP, 2017, BMC CANCER, V17, DOI 10.1186/s12885-017-3187-7; Lin XY, 2000, MOL CELL BIOL, V20, P7259, DOI 10.1128/MCB.20.19.7259-7272.2000; Lin XY, 1997, CANCER RES, V57, P2304; LIN XY, 1995, MOL CELL BIOL, V15, P2754; Liu WW, 2010, CANCER BIOL THER, V9, P862, DOI 10.4161/cbt.9.11.11633; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Nauert JB, 1997, CURR BIOL, V7, P52, DOI 10.1016/S0960-9822(06)00027-3; Quinn DI, 2005, EUR J CANCER, V41, P858, DOI 10.1016/j.ejca.2004.12.035; Rangel R, 2017, CANCER RES, V77, P4089, DOI 10.1158/0008-5472.CAN-17-0785; Ringner M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017911; Su B, 2006, CANCER RES, V66, P5599, DOI 10.1158/0008-5472.CAN-05-4123; Su B, 2010, J BIOL CHEM, V285, P4578, DOI 10.1074/jbc.M109.073494; Welcsh PL, 2001, HUM MOL GENET, V10, P705, DOI 10.1093/hmg/10.7.705; Wong W, 2004, NAT REV MOL CELL BIO, V5, P959, DOI 10.1038/nrm1527; Xia W, 2001, CANCER RES, V61, P5644; Yildirim M, 2013, J BUON, V18, P635; Yildirim M, 2007, LEUKEMIA LYMPHOMA, V48, P1167, DOI 10.1080/10428190701377055; Yoon DK, 2007, CANCER LETT, V254, P111, DOI 10.1016/j.canlet.2007.02.017	30	0	0	1	3	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4800	1096-0945		EXP MOL PATHOL	Exp. Mol. Pathol.	DEC	2018	105	3					364	370		10.1016/j.yexmp.2018.10.010			7	Pathology	Pathology	HE4MW	WOS:000453342000017	30385176				2019-10-28	
J	Linck, L; Liebig, J; Voller, D; Eichner, N; Lehmann, G; Meister, G; Bosserhoff, A				Linck, Lisa; Liebig, Janika; Voeller, Daniel; Eichner, Norbert; Lehmann, Gerhard; Meister, Gunter; Bosserhoff, Anja			MicroRNA-sequencing data analyzing melanoma development and progression	EXPERIMENTAL AND MOLECULAR PATHOLOGY			English	Article						Melanoma; microRNA; RNA-Seq	ARGONAUTE PROTEINS; CELL-PROLIFERATION; EXPRESSION; INVASION; PATHWAY; MIRNAS	MicroRNAs (miRNAs) deregulated in melanoma are of growing importance in cancer research. We aimed to define the miRNAome of melanoma cell lines and primary melanocytes by RNA-Seq using identical cell lines as in a published miRNA expression study based on eDNA arrays. We identified 79 miRNAs, which are significantly deregulated during melanoma development. In addition, we could also determine 29 miRNAs being involved in melanoma progression. Interestingly, not all characterized miRNAs derived from cDNA array analyses of our and other groups could be found to be differentially expressed using RNA-Seq analyses, however, new miRNAs, formerly not associated with melanoma, were found to be strongly regulated.	[Linck, Lisa; Liebig, Janika; Voeller, Daniel; Bosserhoff, Anja] Friedrich Alexander Univ Erlangen Nurnberg, Emil Fischer Ctr, Inst Biochem, D-91054 Erlangen, Germany; [Eichner, Norbert; Lehmann, Gerhard; Meister, Gunter] Univ Regensburg, Lab RNA Biol, Biochem Ctr Regensburg BZR, D-93053 Regensburg, Germany	Bosserhoff, A (reprint author), Friedrich Alexander Univ Erlangen Nurnberg, Inst Biochem, Fahrstr 17, D-91054 Erlangen, Germany.	anja.bosserhoff@fau.de		Linck-Paulus, Lisa/0000-0001-8581-684X	Deutsche ForschungsgemeinschaftGerman Research Foundation (DFG) [BO1573, FOR2127]; Interdisciplinary Center for Clinical Research (IZKF) Erlangen [D24]	This work was supported by the Deutsche Forschungsgemeinschaft (BO1573 and the Research Consortium FOR2127), and the Interdisciplinary Center for Clinical Research (IZKF) Erlangen (D24). Work in the Meister lab was supported by a grant from the Deutsche Forschungsgemeinschaft (FOR2127).	Anaya J, 2016, PEERJ COMPUT SCI, DOI 10.7717/peerj-cs.67; Caramuta S, 2010, J INVEST DERMATOL, V130, P2062, DOI 10.1038/jid.2010.63; Chen JM, 2011, AM J PATHOL, V179, P2162, DOI 10.1016/j.ajpath.2011.07.010; Core Team R, 2016, R LANG ENV STAT COMP; Creighton CJ, 2009, BRIEF BIOINFORM, V10, P490, DOI 10.1093/bib/bbp019; Ding N, 2015, GENE, V572, P135, DOI 10.1016/j.gene.2015.07.013; Dueck A, 2012, NUCLEIC ACIDS RES, V40, P9850, DOI 10.1093/nar/gks705; Ender C, 2010, J CELL SCI, V123, P1819, DOI 10.1242/jcs.055210; Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840; Guo BY, 2016, ONCOL REP, V36, P2412, DOI 10.3892/or.2016.5020; Haflidadottir BS, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011574; Han H, 2015, BMC MED GENOMICS, V8, DOI 10.1186/s12920-015-0116-y; Ho CK, 2002, P NATL ACAD SCI USA, V99, P12709, DOI 10.1073/pnas.192184699; Jacob K, 1998, MELANOMA RES, V8, P211, DOI 10.1097/00008390-199806000-00003; JACOB K, 1995, INT J CANCER, V60, P668, DOI 10.1002/ijc.2910600517; Janga SC, 2011, ADV EXP MED BIOL, V722, P59, DOI 10.1007/978-1-4614-0332-6_4; Kappelmann M, 2013, ONCOGENE, V32, P2984, DOI 10.1038/onc.2012.307; Kawamata T, 2010, TRENDS BIOCHEM SCI, V35, P368, DOI 10.1016/j.tibs.2010.03.009; Kozubek J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072699; Leidner RS, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057841; Levati L, 2009, INT J ONCOL, V35, P393, DOI 10.3892/ijo_00000352; Liu SJ, 2012, J PATHOL, V226, P61, DOI 10.1002/path.2964; Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702; Meister G, 2004, NATURE, V431, P343, DOI 10.1038/nature02873; Meister G, 2013, NAT REV GENET, V14, P447, DOI 10.1038/nrg3462; Metzker ML, 2010, NAT REV, V11, P31, DOI [DOI 10.1038/NRG2626, 10.1038/nrg2626]; Mirnezami AHF, 2009, EJSO-EUR J SURG ONC, V35, P339, DOI 10.1016/j.ejso.2008.06.006; Mueller DW, 2009, J INVEST DERMATOL, V129, P1740, DOI 10.1038/jid.2008.452; Pall GS, 2008, NAT PROTOC, V3, P1077, DOI 10.1038/nprot.2008.67; Parkin DM, 2001, INT J CANCER, V94, P153, DOI 10.1002/ijc.1440; Philippidou D, 2010, CANCER RES, V70, P4163, DOI 10.1158/0008-5472.CAN-09-4512; Pinto R, 2015, EXPERT OPIN THER TAR, V19, P1027, DOI 10.1517/14728222.2015.1065818; Ren JW, 2015, INT J CLIN EXP PATHO, V8, P6356; Satzger I, 2010, INT J CANCER, V126, P2553, DOI 10.1002/ijc.24960; Stark MS, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009685; Streicher KL, 2012, ONCOGENE, V31, P1558, DOI 10.1038/onc.2011.345; Sun Y, 2017, ONCOTARGET, V8, P3509, DOI 10.18632/oncotarget.13862; Visone R, 2009, AM J PATHOL, V174, P1131, DOI 10.2353/ajpath.2009.080794; Voller D, 2013, BRIT J CANCER, V109, P3116, DOI 10.1038/bjc.2013.646; Voller D, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0161165; WELCH BL, 1947, BIOMETRIKA, V34, P28, DOI 10.1093/biomet/34.1-2.28; Zeng Y, 2003, P NATL ACAD SCI USA, V100, P9779, DOI 10.1073/pnas.1630797100; Zhang D, 2016, BIOMED PHARMACOTHER, V84, P166, DOI 10.1016/j.biopha.2016.09.022; Zhang KJ, 2018, GENE, V641, P272, DOI 10.1016/j.gene.2017.10.055	44	1	1	1	3	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4800	1096-0945		EXP MOL PATHOL	Exp. Mol. Pathol.	DEC	2018	105	3					371	379		10.1016/j.yexmp.2018.11.001			9	Pathology	Pathology	HE4MW	WOS:000453342000018	30414979				2019-10-28	
J	Ahmad, F; Nathani, R; Venkat, J; Bharda, A; Vanere, V; Bhatia, S; Das, BR				Ahmad, Firoz; Nathani, Richa; Venkat, Janani; Bharda, Anahita; Vanere, Veena; Bhatia, Simi; Das, Bibhu Ranjan			Molecular evaluation of BRAF gene mutation in thyroid tumors: Significant association with papillary tumors and extra thyroidal extension indicating its role as a biomarker of aggressive disease	EXPERIMENTAL AND MOLECULAR PATHOLOGY			English	Article						BRAF mutation; Thyroid tumors; Pyrosequencing; India	HIGH PREVALENCE; RAS MUTATIONS; CLINICOPATHOLOGICAL FEATURES; CARCINOMA; RET/PTC; CANCER; REARRANGEMENTS; RET	Background: Somatic mutation of the BRAF gene is one to be the most commonly known genetic change in thyroid tumors especially papillary thyroid cancers. The T1799A activating point mutation is detected in > 98% of the thyroid tumors, and result in substitution of amino acid valine at position 600 to glutamic acid. Method In this study, we evaluated BRAF mutation in 95 Indian thyroid tumors by pyrosequencing assay. Results: Overall, 36 cases (38%) showed presence of BRAF V600E mutation, while none of the cases showed V600 K mutation. BRAF mutation was found predominantly in female patients in comparison to males (38.4% vs. 36.4%, p = .86). Likewise, smaller sized tumors (<= 2.0 cm) showed increased frequency of BRAF mutation as compared to larger sized tumors which were greater than equal to 2 cm (46% vs. 34.4%, p = .64). Furthermore, the frequency of BRAF mutations was significantly higher in conventional PTC tumor type in comparison to nonconventional and other than PTC tumor type (56% vs. 35% vs. 4%, p = .0007). Notably, a significant correlation between presence of BRAF mutation and extra-thyroidal extension was noted. Nevertheless, presence of BRAF mutation was neither associated with capsular/vascular invasion, nor with tumor necrosis. Conclusions: Pyrosequencing assay was found to be highly sensitive and accurate method for detecting BRAF point mutations. The frequency and distribution pattern of BRAF mutations is similar to global reports. Furthermore, association of BRAF mutation with extra thyroidal extension indicates its aggressive nature and thus can provide insights into the progression of thyroid tumors from less aggressive to poorly differentiated subtype.	[Ahmad, Firoz; Nathani, Richa; Venkat, Janani; Bharda, Anahita; Das, Bibhu Ranjan] SRL Ltd, Res & Dev Div, Plot 1,Prime Sq Bldg,SV Rd, Bombay, Maharashtra, India; [Vanere, Veena; Bhatia, Simi] SRL Ltd, Histopathol Div, Plot 1,Prime Sq Bldg,SV Rd, Bombay, Maharashtra, India	Das, BR (reprint author), SRL Ltd, Clin Res Serv, Ctr Excellence Mol Pathol, Res & Dev, SV Rd, Bombay 400062, Maharashtra, India.	brdas@srl.in		Ahmad, Firoz/0000-0002-5841-077X			Amin MB, 2017, AJCC CANC STAGING MA; Cantwell-Dorris ER, 2011, MOL CANCER THER, V10, P385, DOI 10.1158/1535-7163.MCT-10-0799; Capella G, 1996, DIAGN MOL PATHOL, V5, P45, DOI 10.1097/00019606-199603000-00008; Carta C, 2006, CLIN ENDOCRINOL, V64, P105, DOI 10.1111/j.1365-2265.2005.02401.x; Chakraborty A, 2012, ENDOCR PATHOL, V23, P83, DOI 10.1007/s12022-011-9184-5; Cheng S, 2011, CLIN CANCER RES, V17, P2385, DOI 10.1158/1078-0432.CCR-10-2837; Cho U, 2014, J KOREAN MED SCI, V29, P1054, DOI 10.3346/jkms.2014.29.8.1054; Cohen J, 2003, J NATL CANCER I, V95, P625, DOI 10.1093/jnci/95.8.625; Dufort S, 2011, J EXP CLIN CANC RES, V30, DOI 10.1186/1756-9966-30-57; Fakhruddin N, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-04948-3; Frasca F, 2008, ENDOCR-RELAT CANCER, V15, P191, DOI 10.1677/ERC-07-0212; Frattini M, 2004, ONCOGENE, V23, P7436, DOI 10.1038/sj.onc.1207980; Garcia-Rostan G, 2003, J CLIN ONCOL, V21, P3226, DOI 10.1200/JCO.2003.10.130; Goutas N, 2008, ANTICANCER RES, V28, P305; Guerra A, 2014, INT J SURG, V12, pS91, DOI 10.1016/j.ijsu.2014.05.045; Heinzerling L, 2013, BRIT J CANCER, V108, P2164, DOI 10.1038/bjc.2013.143; Henke LE, 2015, CANCER MED-US, V4, P791, DOI 10.1002/cam4.417; Huang T., 2001, BIOMARKER RES, V1, P3; Ito Y, 2009, ENDOCR J, V56, P89, DOI 10.1507/endocrj.K08E-208; Jin LP, 2016, ONCOTARGET, V7, P18346, DOI 10.18632/oncotarget.7811; Kang SH, 2013, AM J CLIN PATHOL, V139, P759, DOI 10.1309/AJCPN3ULH6YWBHPH; Kebebew E, 2007, ANN SURG, V246, P466, DOI 10.1097/SLA.0013618148563d; Khan MS, 2014, MUTAGENESIS, V29, P131, DOI 10.1093/mutage/get066; Kimura ET, 2003, CANCER RES, V63, P1454; Lloyd, 2017, WHO CLASS TUM END OR; Lu HZ, 2017, ONCOL LETT, V13, P1595, DOI 10.3892/ol.2017.5661; Mathur A, 2011, CANCER-AM CANCER SOC, V117, P4390, DOI 10.1002/cncr.26072; Melck AL, 2010, ONCOLOGIST, V15, P1285, DOI 10.1634/theoncologist.2010-0156; Ming J, 2015, INT J CLIN EXP PATHO, V8, P15155; Namba H, 2003, J CLIN ENDOCR METAB, V88, P4393, DOI 10.1210/jc.2003-030305; Nikiforov YE, 2002, ENDOCR PATHOL, V13, P3, DOI 10.1385/EP:13:1:03; Nikiforova MN, 2003, J CLIN ENDOCR METAB, V88, P5399, DOI 10.1210/jc.2003-030838; Ogino S, 2005, J MOL DIAGN, V7, P413, DOI 10.1016/S1525-1578(10)60571-5; Pennelli G, 2011, THYROID, V21, P1393, DOI 10.1089/thy.2011.0120; Ricarte-Filho JC, 2009, CANCER RES, V69, P4885, DOI 10.1158/0008-5472.CAN-09-0727; Schlumberger MJ, 1998, NEW ENGL J MED, V338, P297, DOI 10.1056/NEJM199801293380506; Shi CL, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0167414; Soares P, 2003, ONCOGENE, V22, P4578, DOI 10.1038/sj.onc.1206706; Xing M, 2005, ENDOCR-RELAT CANCER, V12, P245, DOI 10.1677/erc.1.0978; Xu XL, 2003, CANCER RES, V63, P4561; Yarchoan M, 2015, J CLIN ONCOL, V33, P7, DOI 10.1200/JCO.2014.59.3657; Zou MJ, 2014, THYROID, V24, P1256, DOI 10.1089/thy.2013.0610	42	1	1	1	1	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4800	1096-0945		EXP MOL PATHOL	Exp. Mol. Pathol.	DEC	2018	105	3					380	386		10.1016/j.yexmp.2018.11.002			7	Pathology	Pathology	HE4MW	WOS:000453342000019	30414980				2019-10-28	
J	Yang, ZB; Chen, WW; Chen, HP; Cai, SX; Ling, JD; Qiu, LZ				Yang, Zhao-Bin; Chen, Wen-Wen; Chen, Hui-Ping; Cai, Shu-Xian; Ling, Jian-Dong; Qiu, Lu-Zhen			MiR-155 aggravated septic liver injury by oxidative stress-mediated ER stress and mitochondrial dysfunction via targeting Nrf-2	EXPERIMENTAL AND MOLECULAR PATHOLOGY			English	Article						Septic liver injury; MiR-155; Nrf-2; Oxidative stress; ER stress	REDUCES HMGB1 SECRETION; HEME OXYGENASE 1; RAW 264.7 CELLS; UNITED-STATES; SEVERE SEPSIS; LUNG INJURY; MICRORNA-155; INHIBITION; EPIDEMIOLOGY; MACROPHAGES	Objective: Liver is uniquely vulnerable during sepsis. MicroRNA-155 (miR-155) is confirmed to play crucial roles in septic liver injury. The present study aims to investigate the mechanisms of miR-155 in septic liver injury. Methods: The sepsis model was established by intraperitoneal injection of lipopolysaccharide (LPS) in mice. Mice were divided into four groups: Vehicle, miR-155 antagomir, LPS, LPS + miR-155 antagomir. The survival rate and body weight were monitored. Liver injury was assessed by H&E staining. The levels of serum ALT and inflammatory cytokines were determined by ELISA kits. Oxidative stress was detected by MDA and SOD detection kits. The miR-155, Nrf-2, and markers related to oxidative stress, endoplasmic reticulum (ER) stress, mitochondrial injury and apoptosis were detected by western blotting and qPCR. Apoptosis in liver tissues was detected by TUNELstaining. Results: MiR-155 antagomir alleviated liver injury as evidenced by enhancing survival rate and body weight, inhibiting inflammatory cell infiltration, liver cells necrosis and decreasing ALT level. The productions of TNF-alpha, IL-6 were suppressed, while anti-inflammatory cytokine IL-10 was promoted by miR-155 antagomir. Oxidative stress was inhibited by miR-155 antagomir via enhancing nuclear factor, erythroid 2-like 2 (Nrf-2) expression. ER stress and Cytochrome C (Cyto-C) release were restrained by miR-155 antagomir. Sepsis-induced apoptosis was repressed by miR-155 antagomir as manifested by the decreased levels of Bax, cleaved caspase-12, 9 and 3, and increased levels of Bcl-2 and uncleaved PARP. Conclusion: MiR-155 antagomir relieved septic liver injury through inhibiting oxidative stress-mediated ER stress, mitochondrial dysfunction and apoptosis via targeting Nrf-2, suggesting miR-155 as a therapeutic target for septic liver injury.	[Yang, Zhao-Bin; Chen, Hui-Ping; Cai, Shu-Xian; Qiu, Lu-Zhen] Zhangzhou Municipal Hosp Fujian Prov, Med Intens Care Unit, 59 Shengli West Rd, Zhangzhou 363000, Fujian, Peoples R China; [Chen, Wen-Wen] Zhangzhou Municipal Hosp Fujian Prov, Dept Neonatol, Zhangzhou 363000, Peoples R China; [Ling, Jian-Dong] Fujian Med Univ, Affiliated Hosp 1, Intens Care Unit, 20 Chazhong Rd, Fuzhou 350001, Fujian, Peoples R China	Qiu, LZ (reprint author), Zhangzhou Municipal Hosp Fujian Prov, Med Intens Care Unit, 59 Shengli West Rd, Zhangzhou 363000, Fujian, Peoples R China.; Ling, JD (reprint author), Fujian Med Univ, Affiliated Hosp 1, Intens Care Unit, 20 Chazhong Rd, Fuzhou 350001, Fujian, Peoples R China.	linjiandong386@163.com; qiuluzhen613@163.com			Youth Research Project of Fujian Provincial Health and Family Planning Commission [2017-2-63]	This study was supported by Youth Research Project of Fujian Provincial Health and Family Planning Commission (No. 2017-2-63).	Alivernini S, 2018, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01932; Angus DC, 2001, CRIT CARE MED, V29, P1303, DOI 10.1097/00003246-200107000-00002; Angus DC, 2013, NEW ENGL J MED, V369, P2063, DOI 10.1056/NEJMc1312359; Cao ST, 2018, J ANIM SCI, V96, P1795, DOI 10.1093/jas/sky104; Cao YW, 2015, J ETHNOPHARMACOL, V161, P92, DOI 10.1016/j.jep.2014.12.013; Chen CZ, 2017, TOXICOL LETT, V278, P38, DOI 10.1016/j.toxlet.2017.07.215; Chen WQ, 2016, ONCOTARGET, V7, P16593, DOI 10.18632/oncotarget.7565; Chen X, 2016, SCI REP-UK, V6, DOI 10.1038/srep20196; Chen YL, 2016, AM J TRANSL RES, V8, P5685; Della Giustina A, 2018, INFLAMMATION, V41, P315, DOI 10.1007/s10753-017-0689-z; Ferreiro E, 2012, Int J Cell Biol, V2012, P735206, DOI 10.1155/2012/735206; Fleischmann C, 2016, DTSCH ARZTEBL INT, V113, P159, DOI [10.3238/arztebl.2016.0159, 10.3238/arztebl.2016.0660b]; Fu JB, 2016, J TOXICOL SCI, V41, P745, DOI 10.2131/jts.41.745; Glembotski CC, 2014, J MOL CELL CARDIOL, V71, P11, DOI 10.1016/j.yjmcc.2013.09.018; Han Y, 2016, CLIN LAB, V62, P2355, DOI 10.7754/Clin.Lab.2016.160511; Huang P, 2017, METALLOMICS, V9, P1756, DOI 10.1039/c7mt00179g; Khamaneh AM, 2015, J PHYSIOL BIOCHEM, V71, P301, DOI 10.1007/s13105-015-0413-0; Kim SR, 2015, BIOCHEM PHARMACOL, V95, P279, DOI 10.1016/j.bcp.2015.04.007; Kim YM, 2015, INT IMMUNOPHARMACOL, V26, P112, DOI 10.1016/j.intimp.2015.03.014; Li AL, 2016, EXP THER MED, V12, P1531, DOI 10.3892/etm.2016.3476; Li J, 2017, ONCOTARGET, V8, P96027, DOI 10.18632/oncotarget.21630; Liu F, 2017, SHOCK, V48, P61, DOI 10.1097/SHK.0000000000000839; Lv X, 2015, MOL MED REP, V12, P6013, DOI 10.3892/mmr.2015.4188; Ma FY, 2017, PHARM BIOL, V55, P1263, DOI 10.1080/13880209.2017.1297838; Martin GS, 2003, NEW ENGL J MED, V348, P1546, DOI 10.1056/NEJMoa022139; Mo CF, 2014, ANTIOXID REDOX SIGN, V20, P574, DOI 10.1089/ars.2012.5116; Nishitoh H, 2012, J BIOCHEM, V151, P217, DOI 10.1093/jb/mvr143; Plackova P, 2016, FREE RADICAL BIO MED, V97, P223, DOI 10.1016/j.freeradbiomed.2016.06.004; Pulkkinen KH, 2011, FREE RADICAL BIO MED, V51, P2124, DOI 10.1016/j.freeradbiomed.2011.09.014; Qu YJ, 2018, CANCER SCI, V109, P618, DOI 10.1111/cas.13472; Safer AM, 2015, EXP THER MED, V9, P787, DOI 10.3892/etm.2014.2158; Tang Q, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.453; Wan C, 2016, TOXICOL APPL PHARM, V295, P85, DOI 10.1016/j.taap.2016.01.023; Wang H, 2016, MOL THER-NUCL ACIDS, V5, DOI 10.1038/mtna.2016.80; Wang YC, 2017, APOPTOSIS, V22, P1147, DOI 10.1007/s10495-017-1393-z; Wang ZH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080547; Wei YZ, 2017, MOL MED REP, V16, P7287, DOI 10.3892/mmr.2017.7584; Zenkov NK, 2013, BIOCHEMISTRY-MOSCOW+, V78, P19, DOI 10.1134/S0006297913010033; Zhang JY, 2015, EUR J IMMUNOL, V45, P829, DOI 10.1002/eji.201445066; Zhang R, 2017, ONCOL REP, V37, P2137, DOI 10.3892/or.2017.5486; Zhang Z, 2018, BIOSCIENCE REP, V38, DOI 10.1042/BSR20180620; Zhou Y, 2017, ONCOTARGET, V8, P47317, DOI 10.18632/oncotarget.17636	42	2	3	3	7	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4800	1096-0945		EXP MOL PATHOL	Exp. Mol. Pathol.	DEC	2018	105	3					387	394		10.1016/j.yexmp.2018.09.003			8	Pathology	Pathology	HE4MW	WOS:000453342000020	30218645				2019-10-28	
J	Senel, U; Coskun, OS; Tuysuz, EC; Sahin, M; Bayrak, OF; Cakmak, B; Tanriverdi, HI; Kuskucu, A				Senel, Ufuk; Coskun, Ozlem Silan; Tuysuz, Emre Can; Sahin, Mesut; Bayrak, Omer Faruk; Cakmak, Bulent; Tanriverdi, Halil Ibrahim; Kuskucu, Aysegul			Smooth muscle cell differentiation from rabbit amniotic cells	EXPERIMENTAL AND MOLECULAR PATHOLOGY			English	Article						Mesenchymal stem cell; Differentiation; Smooth muscle cell; Rabbit amnion cells; Tissue engineering	FLUID STEM-CELLS; TISSUE; REGENERATION; EXPRESSION; SCAFFOLDS; PROTEINS	Amniotic fluid (AF) is the liquid layer that provides mechanical support and allows movement of the fetus during embryogenesis. Mesenchymal stem cells (MSCs), which have differentiation capacity, are also found in AF-derived cells at a low ratio. Smooth muscle cells (SMCs) play an important role in organ function and are frequently used in tissue engineering. We examined the differentiation of AF-derived MSCs (AMSCs) into SMCs. AMSCs were sorted from cultured amniotic cells and differentiated into SMCs using differentiation agents, including platelet-derived growth factor BB (PDGF-BB) and tumor growth factor beta (TGF-beta). Characterization of differentiated SMCs was confirmed morphologically, molecularly (via quantitative polymerase chain reaction [qPCR] and immunocytochemistry [ICC]), and functionally (using a contractile assay and fluo-4 calcium signaling assay). Poly(lactide-co-glycolide) (PLGA) scaffolds were fabricated, and the attachment capacity of AMSCs was assessed via scanning electron microscopy. AMSCs were successfully differentiated into SMCs. Our results indicate that AMSCs change their morphology and exhibit increased expression of ACTA2 and MYH11, which was confirmed via qPCR and ICC. Furthermore, functional experiments revealed that differentiated SMCs had both contraction ability and increased Ca-2 concentration in the cytoplasm. Finally, PLGA scaffolds were prepared and AMSCs were successfully planted onto the scaffolds. The AMSCs fully differentiated into functional SMCs, and the PLGA polymer is a suitable scaffold material for AMSCs. With further clinical trials, AF-derived MSC-based SMC engineering may become a highly efficient treatment option.	[Senel, Ufuk; Tanriverdi, Halil Ibrahim] Gaziosmanpasa Univ, Fac Med, Dept Pediat Surg, TR-60100 Tokat, Turkey; [Coskun, Ozlem Silan; Tuysuz, Emre Can; Bayrak, Omer Faruk; Kuskucu, Aysegul] Yeditepe Univ, Med Sch, Dept Med Genet, TR-34755 Istanbul, Turkey; [Coskun, Ozlem Silan; Tuysuz, Emre Can] Yeditepe Univ, Inst Sci, Dept Biotechnol, TR-34755 Istanbul, Turkey; [Sahin, Mesut] Ataturk Univ, Dept Nanosci & Nanoengn, Inst Sci, TR-25240 Erzurum, Turkey; [Cakmak, Bulent] Gaziosmanpasa Univ, Fac Med, Dept Obstet & Gynecol, TR-60100 Tokat, Turkey	Kuskucu, A (reprint author), Yeditepe Univ Hastanesi, Genet Tani Merkezi, Koftuncu Sokak Acibadem Mahallesi Istek Vakfi 3, Istanbul, Turkey.	aysegul.kuskucu@yeditepe.edu.tr		Tanriverdi, Halil Ibrahim/0000-0002-2760-9954	Scientific and Technological Research Council of Turkey (TUBITAK)Turkiye Bilimsel ve Teknolojik Arastirma Kurumu (TUBITAK) [114S878]	This study was supported by the Scientific and Technological Research Council of Turkey (TUBITAK, project no.: 114S878).	Benavides OM, 2015, J BIOMED MATER RES A, V103, P2645, DOI 10.1002/jbm.a.35402; Cananzi M, 2009, REPROD BIOMED ONLINE, V18, P17, DOI 10.1016/S1472-6483(10)60111-3; Capetanaki Y, 1997, CELL STRUCT FUNCT, V22, P103, DOI 10.1247/csf.22.103; Christ GJ, 2015, FRONT PHARMACOL, V6, DOI 10.3389/fphar.2015.00053; COOPER JA, 1987, J CELL BIOL, V105, P1473, DOI 10.1083/jcb.105.4.1473; De Coppi P, 2007, NAT BIOTECHNOL, V25, P100, DOI 10.1038/nbt1274; de Lara Janz F, 2014, FUND CLIN PHARMACOL, V28, P211, DOI 10.1111/fcp.12006; Dogan A, 2014, MAT SCI ENG C-MATER, V44, P246, DOI 10.1016/j.msec.2014.08.035; Drukker M, 2002, P NATL ACAD SCI USA, V99, P9864, DOI 10.1073/pnas.142298299; Egan TM, 2004, J NEUROSCI, V24, P3413, DOI 10.1523/JNEUROSCI.5429-03.2004; El-Mounayri O, 2013, CARDIOVASC RES, V98, P125, DOI 10.1093/cvr/cvs357; Fauza D, 2004, BEST PRACT RES CL OB, V18, P877, DOI 10.1016/j.bpobgyn.2004.07.001; Ghionzoli M, 2013, FASEB J, V27, P4853, DOI 10.1096/fj.12-218578; Guan XA, 2011, J TISSUE ENG REGEN M, V5, P220, DOI 10.1002/term.308; Harris LJ, 2011, J SURG RES, V168, P306, DOI 10.1016/j.jss.2009.08.001; HATHAWAY DR, 1991, CIRCULATION, V83, P382, DOI 10.1161/01.CIR.83.2.382; Hill KL, 2010, EXP HEMATOL, V38, P246, DOI 10.1016/j.exphem.2010.01.001; Howard D, 2008, J ANAT, V213, P66, DOI 10.1111/j.1469-7580.2008.00878.x; Huang HR, 2006, BIOCHEM BIOPH RES CO, V351, P321, DOI 10.1016/j.bbrc.2006.09.171; in 'tAnker PS, 2003, BLOOD, V102, P1548, DOI 10.1182/blood-2003-04-1291; Kim BS, 2012, BMC MED, V10, DOI 10.1186/1741-7015-10-94; Klemmt PAB, 2011, EXPERT OPIN BIOL TH, V11, P1297, DOI 10.1517/14712598.2011.587800; Kunisaki SM, 2012, ORGANOGENESIS, V8, DOI 10.4161/org.22238; Liu MM, 2014, BIOCHEM ENG J, V82, P71, DOI 10.1016/j.bej.2013.11.001; Liu YX, 2013, DEV GROWTH DIFFER, V55, P591, DOI 10.1111/dgd.12052; Maraldi T, 2011, TISSUE ENG PT A, V17, P2833, DOI 10.1089/ten.tea.2011.0062; MIANO JM, 1994, CIRC RES, V75, P803, DOI 10.1161/01.RES.75.5.803; Mimeault M, 2006, STEM CELLS, V24, P2319, DOI 10.1634/stemcells.2006-0066; Modena Alberto Bacchi, 2004, Acta Biomed, V75 Suppl 1, P11; Parolini O, 2009, REGEN MED, V4, P275, DOI 10.2217/17460751.4.2.275; Ratz PH, 2005, AM J PHYSIOL-CELL PH, V288, pC769, DOI 10.1152/ajpcell.00529.2004; Rennie K., 2012, STEM CELLS INT, V2012; Rensen SSM, 2007, NETH HEART J, V15, P100, DOI 10.1007/BF03085963; Rosner M, 2012, AMINO ACIDS, V42, P1591, DOI 10.1007/s00726-011-0929-8; Roubelakis MG, 2007, STEM CELLS DEV, V16, P931, DOI 10.1089/scd.2007.0036; Roubelakis MG, 2012, STEM CELLS INT, DOI 10.1155/2012/107836; Salem SA, 2013, MALAYS J MED SCI, V20, P80; Saxena AK, 2010, PEDIATR SURG INT, V26, P557, DOI 10.1007/s00383-010-2591-8; Sessarego N, 2008, HAEMATOL-HEMATOL J, V93, P339, DOI 10.3324/haematol.11869; Shih CC, 2007, STEM CELLS DEV, V16, P893, DOI 10.1089/scd.2007.0070; Shoae-Hassani A, 2013, BJU INT, V112, P854, DOI 10.1111/bju.12195; Sinha S, 2014, CELL MOL LIFE SCI, V71, P2271, DOI 10.1007/s00018-013-1554-3; Slamecka J. Jr., 2013, Slovak Journal of Animal Science, V46, P11; Snetkov VA, 1998, PEDIATR RES, V43, P548, DOI 10.1203/00006450-199804000-00019; Song B, 2016, STEM CELLS INT, V2016; Sun HL, 2010, BIOMATERIALS, V31, P1133, DOI 10.1016/j.biomaterials.2009.10.030; Torricelli Francesca, 1993, Italian Journal of Anatomy and Embryology, V98, P119; Underwood Mark A, 2005, J Perinatol, V25, P341, DOI 10.1038/sj.jp.7211290; Vazao H, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017771; Xie CQ, 2007, ARTERIOSCL THROM VAS, V27, pE311, DOI 10.1161/ATVBAHA.107.154260; Xie CQ, 2011, ARTERIOSCL THROM VAS, V31, P1485, DOI 10.1161/ATVBAHA.110.221101; Zhang L, 2012, VASC PHARMACOL, V56, P280, DOI 10.1016/j.vph.2012.02.014	52	0	0	1	4	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4800	1096-0945		EXP MOL PATHOL	Exp. Mol. Pathol.	DEC	2018	105	3					395	403		10.1016/j.yexmp.2018.11.003			9	Pathology	Pathology	HE4MW	WOS:000453342000021	30414978				2019-10-28	
J	Scott, CM; Wong, EM; Joo, JE; Dugue, PA; Jung, CH; O'Callaghan, N; Dowty, J; Giles, GG; Hopper, JL; Southey, MC				Scott, Cameron M.; Wong, Ee Ming; Joo, JiHoon Eric; Dugue, Pierre-Antoine; Jung, Chol-Hee; O'Callaghan, Neil; Dowty, James; Giles, Graham G.; Hopper, John L.; Southey, Melissa C.			Genome-wide DNA methylation assessment of 'BRCA1-like' early-onset breast cancer: Data from the Australian Breast Cancer Family Registry	EXPERIMENTAL AND MOLECULAR PATHOLOGY			English	Article						Genome-Wide; Methylation; HM450K; BRCA1; Early-Onset Breast Cancer	EPITHELIAL-MESENCHYMAL TRANSITION; POPULATION-BASED ESTIMATE; GERMLINE MUTATIONS; YOUNG-WOMEN; PROMOTER; PROTEIN; GENE; RISK	Breast cancers arising in women carrying a germline mutation in BRCA1 are typically high-grade, early-onset and have distinct morphological features (BRCA1-like). However, the majority of early-onset breast cancers of this morphological type are not associated with germline BRCA1 mutations or constitutional BRCA1 promoter methylation. We aimed to assess DNA methylation across the genome for associations with the "BRCA1-like" morphology. Genome-wide methylation in blood-derived DNA was measured using the Infinium HumanMethylation450K BeadChip assay for women under the age of 40 years participating in the Australian Breast Cancer Family Study (ABCFS) diagnosed with: i)BRCA1-like breast cancer (n = 30); and ii) breast cancer without BRCA1-like morphological features (non BRCA1-like; n = 30), and age-matched unaffected women (controls; n = 30). Corresponding tumour-derived DNA from 43 of the affected women was also assessed. Methylation of blood-derived DNA was found to be elevated across 17 consecutive marks in the BRCA1 promoter region and decreased at several other genomic regions (including TWIST2 and CTBP1) for 7 women (23%) diagnosed with BRCA1-like breast cancer compared with women in the other groups. Corresponding tumour-derived DNA available from 5 of these 7 women had elevated methylation within the BRCA1 and SPHK2 promoter region and decreased methylation within the ADAP1, IGF2BP3 and SPATA13 promoter region when compared with the other breast tumours. These methylation marks could be biomarkers of risk for BRCA1-like breast cancer, and could be responsible in part for their distinctive morphological features and biology. As such, they may assist with prevention and targeted therapies for this cancer subtype.	[Scott, Cameron M.; Wong, Ee Ming; Joo, JiHoon Eric; O'Callaghan, Neil; Southey, Melissa C.] Univ Melbourne, Dept Clin Pathol, Genet Epidemiol Lab, Melbourne, Vic 3010, Australia; [Scott, Cameron M.] La Trobe Univ, Sch Canc Med, Olivia Newton John Canc Res Inst, Heidelberg, Vic 3084, Australia; [Wong, Ee Ming; Southey, Melissa C.] Monash Univ, Sch Clin Sci Monash Hlth, Precis Med, Clayton, Vic 3168, Australia; [Joo, JiHoon Eric] Univ Melbourne, Ctr Canc Res, Dept Clin Pathol, Colorectal Oncogen Grp, Melbourne, Vic, Australia; [Dugue, Pierre-Antoine; Dowty, James; Giles, Graham G.; Hopper, John L.] Univ Melbourne, Ctr Epidemiol & Biostat, Melbourne, Vic 3010, Australia; [Dugue, Pierre-Antoine; Giles, Graham G.; Southey, Melissa C.] Canc Council Victoria, Canc Epidemiol & Intelligence Div, Melbourne, Vic 3004, Australia; [Jung, Chol-Hee] Univ Melbourne, Melbourne Bioinformat, Parkville, Vic, Australia	Southey, MC (reprint author), Monash Univ, Sch Clin Sci Monash Hlth, Precis Med, Clayton, Vic 3168, Australia.	cameron.scott@onjcri.org.au; eeming.wong@monash.edu; ji.joo@unimelb.edu.au; Pierre-Antoine.Dugue@cancervic.org.au; jungch@unimelb.edu.au; neil.ocallaghan@unimelb.edu.au; jdowty@unimelb.edu.au; graham.giles@cancervic.org.au; j.hopper@unimelb.edu.au; msouthey@unimelb.edu.au		Dowty, James/0000-0003-2383-0886; Giles, Graham/0000-0003-4946-9099; Southey, Melissa/0000-0002-6313-9005; JUNG, Chol-Hee/0000-0002-2992-3162; DUGUE, PIERRE-ANTOINE/0000-0003-2736-3023; Wong, Ee Ming/0000-0002-7288-7865	National Health and Medical Research Council of AustraliaNational Health and Medical Research Council of Australia; New South Wales Cancer CouncilCancer Council New South Wales; Victorian Health Promotion Foundation (Australia); USA National Cancer InstituteUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [UM1 CA164920]; Genetic Epidemiology Laboratory Honours Scholarship; Department of Pathology; University of MelbourneUniversity of Melbourne	The Australia site of Breast Cancer Family Registry was supported by the National Health and Medical Research Council of Australia, the New South Wales Cancer Council, the Victorian Health Promotion Foundation (Australia) and grant UM1 CA164920 from the USA National Cancer Institute. The content of this manuscript does not necessarily reflect the views or policies of the National Cancer Institute or any of the collaborating centers in the Breast Cancer Family Registry (BCFR), nor does mention of trade names, commercial products, or organizations imply endorsement by the USA Government or the BCFR. JLH is a Senior Principle Research Fellow of the NHMRC and MCS is a Senior Research Fellow. CMS was a recipient of a Genetic Epidemiology Laboratory Honours Scholarship, Department of Pathology, The University of Melbourne.	Anders CK, 2010, CLIN CANCER RES, V16, P4702, DOI 10.1158/1078-0432.CCR-10-0939; Andrulis IL, 2002, HUM MUTAT, V20, P65, DOI 10.1002/humu.10097; Apicella C, 2007, CLIN GENET, V72, P87, DOI 10.1111/j.1399-0004.2007.00841.x; Armes JE, 1998, CANCER-AM CANCER SOC, V83, P2335, DOI 10.1002/(SICI)1097-0142(19981201)83:11<2335::AID-CNCR13>3.0.CO;2-N; Aryee MJ, 2014, BIOINFORMATICS, V30, P1363, DOI 10.1093/bioinformatics/btu049; Ball MP, 2009, NAT BIOTECHNOL, V27, P361, DOI 10.1038/nbt.1533; Bibikova M, 2011, GENOMICS, V98, P288, DOI 10.1016/j.ygeno.2011.07.007; Deng Y, 2012, MOL CARCINOGEN, V51, P500, DOI 10.1002/mc.20813; Dite GS, 2003, J NATL CANCER I, V95, P448, DOI 10.1093/jnci/95.6.448; Dobrovic A, 1997, CANCER RES, V57, P3347; Du P, 2008, BIOINFORMATICS, V24, P1547, DOI 10.1093/bioinformatics/btn224; Du P, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-587; Eisinger F, 1996, CANCER RES, V56, P471; Fang X, 2011, ONCOGENE, V30, P4707, DOI 10.1038/onc.2011.181; Goldgar DE, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2919; Hellman A, 2007, SCIENCE, V315, P1141, DOI 10.1126/science.1136352; Hopper JL, 1999, CANCER EPIDEM BIOMAR, V8, P741; Houseman EA, 2012, BMC BIOINFORMATICS, V13, DOI 10.1186/1471-2105-13-86; Igarashi N, 2003, J BIOL CHEM, V278, P46832, DOI 10.1074/jbc.M306577200; Iwamoto T, 2011, BREAST CANCER RES TR, V129, P69, DOI 10.1007/s10549-010-1188-1; Jaffe AE, 2014, GENOME BIOL, V15, DOI 10.1186/gb-2014-15-2-r31; Johannsson OT, 1997, EUR J CANCER, V33, P362, DOI 10.1016/S0959-8049(97)89007-7; John EM, 2004, BREAST CANCER RES, V6, pR375, DOI 10.1186/bcr801; Joo JE, 2013, BMC BIOTECHNOL, V13, DOI 10.1186/1472-6750-13-23; Kawasaki Y, 2007, ONCOGENE, V26, P7620, DOI 10.1038/sj.onc.1210574; Kohn KW, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099269; Lakhani SR, 1998, JNCI-J NATL CANCER I, V90, P1138, DOI 10.1093/jnci/90.15.1138; Le Calvez-Kelm F, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2810; Leong T, 2000, INT J RADIAT ONCOL, V48, P959, DOI 10.1016/S0360-3016(00)00728-8; Liu H, 2003, J BIOL CHEM, V278, P40330, DOI 10.1074/jbc.M304455200; Maksimovic J, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv526; Mouchawar J, 2010, CANCER RES, V70, P4795, DOI 10.1158/0008-5472.CAN-09-0851; Neuhausen S. L, 2009, BREAST CANC RES; Smith LD, 2007, EUR J CANCER, V43, P823, DOI 10.1016/j.ejca.2007.01.011; Smyth GK, 2004, STAT APPL GENET MOL, V3, P1, DOI DOI 10.2202/1544-6115.1027; Snell C, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr1858; Southey MC, 2011, BRIT J CANCER, V104, P903, DOI 10.1038/bjc.2011.41; Southey MC, 1999, BRIT J CANCER, V79, P34, DOI 10.1038/sj.bjc.6690008; Southey MC, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2796; Su P, 2014, INT J CLIN EXP PATHO, V7, P3008; Trinh BN, 2001, METHODS, V25, P456, DOI 10.1006/meth.2001.1268; Walter O, 2009, HUM PATHOL, V40, P1528, DOI 10.1016/j.humpath.2009.05.005; Wong Ee Ming, 2015, BMC Res Notes, V8, P543, DOI 10.1186/s13104-015-1487-z; Wong EM, 2011, CANCER PREV RES, V4, P23, DOI 10.1158/1940-6207.CAPR-10-0212; Yang J, 2004, CELL, V117, P927, DOI 10.1016/j.cell.2004.06.006	45	0	0	1	2	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4800	1096-0945		EXP MOL PATHOL	Exp. Mol. Pathol.	DEC	2018	105	3					404	410		10.1016/j.yexmp.2018.11.006			7	Pathology	Pathology	HE4MW	WOS:000453342000022	30423315				2019-10-28	
J	Sun, H; Li, QS; Jin, YJ; Qiao, HM				Sun, Hao; Li, Qingsong; Jin, Yingji; Qiao, Hongmei			Associations of tumor necrosis factor-alpha polymorphisms with the risk of asthma: a meta-analysis	EXPERIMENTAL AND MOLECULAR PATHOLOGY			English	Article						Tumor necrosis factor-alpha (TNF-alpha); Gene polymorphisms; Asthma; Meta-analysis	TNF-ALPHA; GENES	Objective: Recently, potential correlations between tumor necrosis factor-alpha (TNF-alpha) polymorphisms and asthma were investigated by some pilot studies, but the results of these studies were inconsistent. Therefore, we performed this meta-analysis to better evaluate the relationship between TNF-alpha polymorphisms and the risk of asthma. Methods: Eligible studies were searched in PubMed, Medline, Embase and CNKI. Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated to assess correlations between TNF-alpha polymorphisms and asthma. Results: A total of 50 studies were included for analyses. Significant associations with the risk of asthma were detected for TNF-alpha - 238 G/A, - 308 G/A and - 857C/T polymorphisms in overall analyses. Further subgroup analyses according to ethnicity of participants revealed that TNF-alpha - 238 G/A polymorphism was significantly correlated with the risk of asthma in Caucasians, TNF-alpha - 308 G/A polymorphism was significantly correlated with the risk of asthma in West Asians, TNF-alpha - 857C/T polymorphism was significantly correlated with the risk of asthma in Caucasians, TNF-alpha - 863C/A polymorphism was significantly correlated with the risk of asthma in East Asians, and TNF-alpha - 1031 T/C polymorphism was significantly correlated with the risk of asthma in Caucasians and East Asians. Conclusions: Our findings indicated that TNF-alpha - 238 G/A, - 308 G/A, - 857C/T, - 863C/A and - 1031 T/C polymorphisms may serve as potential biological markers for asthma in certain ethnicities.	[Sun, Hao; Jin, Yingji] Taizhou Peoples Hosp, Dept Paediat, Taizhou, Peoples R China; [Li, Qingsong] Taizhou Peoples Hosp, Dept Orthoped, Taizhou, Peoples R China; [Qiao, Hongmei] Jilin Univ, First Hosp, Dept Paediat, 71 Xinmin St, Changchun 130021, Jilin, Peoples R China	Qiao, HM (reprint author), Jilin Univ, First Hosp, Dept Paediat, 71 Xinmin St, Changchun 130021, Jilin, Peoples R China.	hongmeiqiao99869@163.com					Cavkaytar O, 2014, ALLERGOL IMMUNOPATH, V42, P162, DOI 10.1016/j.aller.2012.10.004; Chen XJ, 2011, J HUAZHONG U SCI-MED, V31, P137, DOI 10.1007/s11596-011-0165-1; Freeman GJ, 2010, IMMUNOL REV, V235, P172, DOI 10.1111/j.0105-2896.2010.00903.x; Jiffri EH, 2011, GENET TEST MOL BIOMA, V15, P293, DOI 10.1089/gtmb.2010.0157; Moher D, 2009, ANN INTERN MED, V151, P264, DOI 10.7326/0003-4819-151-4-200908180-00135; Pawankar R, 2012, CURR OPIN ALLERGY CL, V12, P39, DOI 10.1097/ACI.0b013e32834ec13b; Ricciardolo FLM, 2013, INT J IMMUNOPATH PH, V26, P75, DOI 10.1177/039463201302600107; Sharma S, 2006, AM J RESP CELL MOL, V35, P488, DOI 10.1165/rcmb.2006-0084OC; Shin HD, 2004, HUM MOL GENET, V13, P397, DOI 10.1093/hmg/ddh036; Stang A, 2010, EUR J EPIDEMIOL, V25, P603, DOI 10.1007/s10654-010-9491-z; Wills-Karp M, 2004, NAT REV GENET, V5, P376, DOI 10.1038/nrg1326; Xie X, 2017, SCAND J IMMUNOL, V86, P50, DOI 10.1111/sji.12560; Xie XC, 2017, LUNG, V195, P353, DOI 10.1007/s00408-017-0006-5; Yang GD, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099962; Zhang YM, 2012, CURR OPIN PULM MED, V18, P6, DOI 10.1097/MCP.0b013e32834dc532	15	13	13	0	1	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4800	1096-0945		EXP MOL PATHOL	Exp. Mol. Pathol.	DEC	2018	105	3					411	416		10.1016/j.yexmp.2018.08.012			6	Pathology	Pathology	HE4MW	WOS:000453342000023	30176222				2019-10-28	
J	Mubariz, F; Bryant, JL; Nimmagadda, VKC; Ray, J; Makar, TK				Mubariz, Fahad; Bryant, Joseph L.; Nimmagadda, Vamshi K. C.; Ray, Jayanta; Makar, Tapas K.			AQP4 and HIVAN (vol 105, pg 71, 2018)	EXPERIMENTAL AND MOLECULAR PATHOLOGY			English	Correction									[Mubariz, Fahad; Nimmagadda, Vamshi K. C.; Makar, Tapas K.] Univ Maryland, Dept Neurol, Baltimore, MD 21201 USA; [Makar, Tapas K.] VA Med Ctr, Baltimore, MD USA; [Bryant, Joseph L.] Univ Maryland, Inst Human Virol, Baltimore, MD 21201 USA; [Ray, Jayanta] Univ Maryland, Dept Chem & Biochem, Baltimore, MD 21201 USA	Makar, TK (reprint author), Univ Maryland, Dept Neurol, Baltimore, MD 21201 USA.	tmakar@som.umaryland.edu					Mubariz F, 2018, EXP MOL PATHOL, V105, P71, DOI 10.1016/j.yexmp.2018.05.004	1	0	0	0	0	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4800	1096-0945		EXP MOL PATHOL	Exp. Mol. Pathol.	DEC	2018	105	3					417	417		10.1016/j.yexmp.2018.08.007			1	Pathology	Pathology	HE4MW	WOS:000453342000024	30360924				2019-10-28	
J	Rocken, C				Roecken, C.			Opening Speech of the Congress President of the German Society for Pathology	PATHOLOGE			German	Editorial Material									[Roecken, C.] Christian Albrechts Univ Kiel, Univ Klinikum Schleswig Holstein, Inst Pathol, Arnold Heller Str 3-14, D-24105 Kiel, Germany	Rocken, C (reprint author), Christian Albrechts Univ Kiel, Univ Klinikum Schleswig Holstein, Inst Pathol, Arnold Heller Str 3-14, D-24105 Kiel, Germany.	christoph.roecken@uksh.de	Rocken, Christoph/A-9239-2010	Rocken, Christoph/0000-0002-6989-8002				0	0	0	0	0	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	0172-8113	1432-1963		PATHOLOGE	Pathologe	DEC	2018	39			2			175	176		10.1007/s00292-018-0513-z			2	Pathology	Pathology	HE6XV	WOS:000453565100001	30302560				2019-10-28	
J	Boor, P				Boor, P.			MIF in kidney diseases. A story of Dr. Jekyll and Mr. Hyde	PATHOLOGE			German	Article						Acute kidney injury; Chronic renal insufficiency; Glomerulonephritis; Macrophage migration-inhibitory factors; Cell proliferation	MIGRATION-INHIBITORY FACTOR; PARIETAL EPITHELIAL-CELLS; FIBROSIS; GLOMERULONEPHRITIS; INFLAMMATION	BackgroundMacrophage migration-inhibitory factor (MIF) is acytokine best known for its proinflammatory and disease-aggravating role in anumber of conditions, including atherosclerosis, autoimmune diseases, sepsis, and glomerulonephritides.ObjectivesIn our studies we aimed to define the role of MIF on local renal resident cells, in particular the renal epithelium.ResultsWe have shown that MIF exerts local effects on glomerular cells, in particular the parietal epithelial cells and mesangial cells, promoting their pathological proliferation and aggravating disease course of amurine model of immune-mediated glomerulonephritis. In contrast, in alarge set of animal and in vitro experiments, we have shown that in the setting of chronic kidney disease, MIF had an unexpected and potent antifibrotic and anti-inflammatory effect. This was mediated by enhanced regeneration and reduced cell-cycle arrest of tubular epithelial cells. Finally, in acombined approach using clinical studies, animal models, and in vitro experiments, we have shown that MIF is also renoprotective in the setting of acute kidney injury. In this setting, MIF-modulated programmed cell death of tubular cells and thereby reduced necroinflammation and kidney injury.ConclusionsTaken together, MIF has adual role in kidney diseases, promoting (auto)immune glomerular diseases and limiting tubular cell injury in the setting of acute and chronic kidney diseases. These data suggest potential safety issues of systemic MIF targeted therapies, but also open new therapeutic options by targeting MIF or its analogues to tubular cells.	[Boor, P.] Univ Klinikum RWTH Aachen, Inst Pathol, Pauwelsstr 30, D-52074 Aachen, Germany; [Boor, P.] Univ Klinikum RWTH Aachen, Med Klin Nephrol & Immunol 2, Aachen, Germany	Boor, P (reprint author), Univ Klinikum RWTH Aachen, Inst Pathol, Pauwelsstr 30, D-52074 Aachen, Germany.	pboor@ukaachen.de	Boor, Peter/C-7707-2011	Boor, Peter/0000-0001-9921-4284			Amdur RL, 2009, KIDNEY INT, V76, P1089, DOI 10.1038/ki.2009.332; Boor P, 2015, AM J TRANSPLANT, V15, P863, DOI 10.1111/ajt.13180; Boor P, 2014, NEPHROL DIAL TRANSPL, V29, pI45, DOI 10.1093/ndt/gft273; Boor P, 2010, NAT REV NEPHROL, V6, P643, DOI 10.1038/nrneph.2010.120; Couser WG, 2011, KIDNEY INT, V80, P1258, DOI 10.1038/ki.2011.368; Djudjaj S, 2019, MOL ASPECTS MED, V65, P16, DOI 10.1016/j.mam.2018.06.002; Djudjaj S, 2017, J AM SOC NEPHROL, V28, P3590, DOI 10.1681/ASN.2017020190; Djudjaj S, 2016, J AM SOC NEPHROL, V27, P1650, DOI 10.1681/ASN.2015020149; Hallan SI, 2006, J AM SOC NEPHROL, V17, P2275, DOI 10.1681/ASN.2005121273; Hoi Alberta Y., 2007, Inflammation & Allergy Drug Targets, V6, P183, DOI 10.2174/187152807781696455; Hoi AY, 2006, J IMMUNOL, V177, P5687, DOI 10.4049/jimmunol.177.8.5687; Jha V, 2013, LANCET, V382, P260, DOI 10.1016/S0140-6736(13)60687-X; Kuppe C, 2015, KIDNEY INT, V88, P990, DOI 10.1038/ki.2015.116; Lan HY, 1997, J EXP MED, V185, P1455, DOI 10.1084/jem.185.8.1455; Leng L, 2011, J IMMUNOL, V186, P527, DOI 10.4049/jimmunol.1001767; Leung JCK, 2004, NEPHROL DIAL TRANSPL, V19, P1976, DOI 10.1093/ndt/gfh323; Linkermann A, 2014, NAT REV IMMUNOL, V14, P759, DOI 10.1038/nri3743; Mehta RL, 2015, LANCET, V385, P2616, DOI 10.1016/S0140-6736(15)60126-X; Ochi A, 2017, AM J PHYSIOL-RENAL, V313, pF767, DOI 10.1152/ajprenal.00683.2016; Qi D, 2009, J CLIN INVEST, V119, P3807, DOI 10.1172/JCI39738; Smeets B, 2014, AM J PATHOL, V184, P3239, DOI 10.1016/j.ajpath.2014.08.007; Smeets B, 2012, SEMIN NEPHROL, V32, P357, DOI 10.1016/j.semnephrol.2012.06.007; Starlets D, 2006, BLOOD, V107, P4807, DOI 10.1182/blood-2005-11-4334; Stoppe C, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aan4886; Yang L, 2010, NAT MED, V16, P535, DOI 10.1038/nm.2144; Yang NS, 1998, MOL MED, V4, P413, DOI 10.1007/BF03401748	26	0	0	0	3	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	0172-8113	1432-1963		PATHOLOGE	Pathologe	DEC	2018	39			2			177	184		10.1007/s00292-018-0535-6			8	Pathology	Pathology	HE6XV	WOS:000453565100002	30406830				2019-10-28	
J	Weiler, S				Weiler, S.			YAP induces chromosomal instability in liver cancer patients	PATHOLOGE			German	Article						Hepatocellular carcinoma; Chromosomal instability; Transcription factors; Gene signature; Cell proliferation	YES-ASSOCIATED PROTEIN; FORKHEAD BOX M1; SIZE	BackgroundThe Hippo/YAP signaling pathway is acentral regulator of organ growth and cell proliferation. Activation of the transcriptional co-activator and oncogene YAP (yes-associated protein) supports the development of liver cancer.AimsThe aim of this work was to analyze the molecular mechanisms which are responsible for YAP-induced hepatocarcinogenesis.MethodsYAP was silenced using siRNAs in liver cancer cell lines and effects on target gene expression were analyzed via real-time polymerase chain reaction (PCR) and western immunoblotting. Immunoprecipitation and chromatin immunoprecipitation was used to study interacting proteins and binding to target gene promoter regions, respectively. Transgenic mice with liver-specific and inducible YAP expression were used for in vivo analysis. Gene expression data from hepatocellular carcinoma (HCC) patients were used to analyze YAP-dependent gene signatures and to correlate with clinical data. HCC tissue microarrays were analyzed using immunohistochemistry.ResultsTogether with the transcription factors TEAD4 and FOXM1, YAP induces the expression of genes which are responsible for the development of chromosomal instability (CIN). The overexpression of these CIN genes characterizes liver cancer patients with apoor prognosis. Mechanistically, YAP/TEAD4 and FOXM1 bind to the promoter regions of the CIN genes to directly regulate their expression. The treatment of YAP-transgenic mice with aspecific FOXM1 inhibitor reduces the YAP-dependent hepatomegaly, CIN gene expression and CIN. The analysis of human HCC tissue samples confirms the statistical correlation between YAP, FOXM1 and CIN.DiscussionThese results reveal anew oncogenic mechanism of the Hippo/YAP signaling pathway and identify YAP and FOXM1 as potential targets for targeted therapies.	[Weiler, S.] Heidelberg Univ, Pathol Inst, Neuenheimer Feld 224, D-69120 Heidelberg, Germany	Weiler, S (reprint author), Heidelberg Univ, Pathol Inst, Neuenheimer Feld 224, D-69120 Heidelberg, Germany.	sofia.weiler@med.uni-heidelberg.de					Bakhoum SF, 2012, J CLIN INVEST, V122, P1138, DOI 10.1172/JCI59954; Carter SL, 2006, NAT GENET, V38, P1043, DOI 10.1038/ng1861; Dong JX, 2007, CELL, V130, P1120, DOI 10.1016/j.cell.2007.07.019; Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210; Halasi M, 2013, MOL CANCER THER, V12, P245, DOI 10.1158/1535-7163.MCT-12-0712; Kwok JMM, 2008, MOL CANCER THER, V7, P2022, DOI 10.1158/1535-7163.MCT-08-0188; Lin C, 2017, LIVER INT, V29, P840; Patel SH, 2017, GASTROENTEROLOGY, V152, P533, DOI 10.1053/j.gastro.2016.10.047; Tschaharganeh DF, 2013, GASTROENTEROLOGY, V144, P1530, DOI 10.1053/j.gastro.2013.02.009; Weiler SME, 2017, GASTROENTEROLOGY, V152, P2037, DOI 10.1053/j.gastro.2017.02.018	10	0	0	0	1	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	0172-8113	1432-1963		PATHOLOGE	Pathologe	DEC	2018	39			2			185	188		10.1007/s00292-018-0494-y			4	Pathology	Pathology	HE6XV	WOS:000453565100003	30206654				2019-10-28	
J	Fromme, JE; Schildhaus, HU				Fromme, J. E.; Schildhaus, H. -U.			FGFR3 overexpression is a relevant alteration in colorectal cancer	PATHOLOGE			German	Article						Colorectal cancer; Metastases; FGFR; RNA in situ hybridization; Biomarkers	ADVANCED SOLID TUMORS; DOSE-ESCALATION; PHASE-I; SENSITIVITY; EXPRESSION; INHIBITOR; BGJ398	BackgroundFibroblast growth factor receptor (FGFR) signalling plays an important role in embryogenesis as well as in tumorigenesis. In current studies FGFR has proved to be apotential molecular target in avariety of solid tumours. In colorectal cancer (CRC) data on FGFR alterations is very sparse. However, there is ahuge need for targeted therapies in this tumour entity with an incidence of 140,000individuals (USA 2018) and a5-year relative survival rate of only 14% in metastatic disease.ObjectivesThis article shall provide an overview of the FGFRs and the most frequent FGF ligand alterations in primary and metastatic CRC.ResultsIn primary tumours and metastases various FGFR and FGF alterations can be observed. Primary tumours as well as metastases show FGFR alterations at the genomic (by fluorescence in situ hybridization) as well as on the ribonucleic acid (RNA) expression level (by RNA in situ hybridization). In both cohorts FGFR3 overexpression is the most frequent alteration and is associated with an unfavourable prognosis in metastases.ConclusionsFGFR3 overexpression defines asubgroup of metastatic colorectal cancers with an unfavourable prognosis. Since FGFR3 alterations can present apotential therapeutic target, patients with FGFR3 overexpression should be included into clinical studies with FGFR inhibitors.	[Fromme, J. E.; Schildhaus, H. -U.] Georg August Univ, Univ Med Gottingen, Inst Pathol, Robert Koch Str 40, D-37075 Gottingen, Germany	Fromme, JE (reprint author), Georg August Univ, Univ Med Gottingen, Inst Pathol, Robert Koch Str 40, D-37075 Gottingen, Germany.	Fromme.julia@googlemail.com					Chae YK, 2017, ONCOTARGET, V8, P16052, DOI 10.18632/oncotarget.14109; Courjal F, 1997, CANCER RES, V57, P4360; Fromme Julia Elisabeth, 2018, Oncotarget, V9, P32204, DOI 10.18632/oncotarget.25941; Goke F, 2015, CLIN CANCER RES, V21, P4356, DOI 10.1158/1078-0432.CCR-14-3357; Grose R, 2005, CYTOKINE GROWTH F R, V16, P179, DOI 10.1016/j.cytogfr.2005.01.003; Hong DS, 2015, CLIN CANCER RES, V21, P4801, DOI 10.1158/1078-0432.CCR-14-3063; Joerger M, 2017, J CLIN ONCOL, V35, DOI 10.1200/JCO.2017.35.6_suppl.386; Jung EJ, 2012, HUM PATHOL, V43, P1559, DOI 10.1016/j.humpath.2011.12.002; National Cancer Institute, 2018, CANC STAT FACTS COL; Nogova L, 2017, J CLIN ONCOL, V35, P157, DOI 10.1200/JCO.2016.67.2048; Parish A, 2015, CELL CYCLE, V14, P2121, DOI 10.1080/15384101.2015.1041691; Soria JC, 2014, ANN ONCOL, V25, P2244, DOI 10.1093/annonc/mdu390; Touat M, 2015, CLIN CANCER RES, V21, P2684, DOI 10.1158/1078-0432.CCR-14-2329; Turner N, 2010, NAT REV CANCER, V10, P116, DOI 10.1038/nrc2780; Weiss J, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3001451; Wynes MW, 2014, CLIN CANCER RES, V20, P3299, DOI 10.1158/1078-0432.CCR-13-3060	16	0	0	0	0	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	0172-8113	1432-1963		PATHOLOGE	Pathologe	DEC	2018	39			2			189	192		10.1007/s00292-018-0504-0			4	Pathology	Pathology	HE6XV	WOS:000453565100004	30267148				2019-10-28	
J	Schulz, H; Tator, M; Spillner, J; Dreher, M; Knuchel-Clarke, R; Kloten, V; Dahl, E				Schulz, H.; Tator, M.; Spillner, J.; Dreher, M.; Knuechel-Clarke, R.; Kloten, V.; Dahl, E.			Liquid biopsy in human non-small-cell lung cancer. Blood-based analysis of ctDNA methylation	PATHOLOGE			German	Article						Liquid biopsy; Non-small-cell lung carcinoma; DNA methylation; Genetic promoter regions; DNA sequence analysis	GROWTH-FACTOR RECEPTOR; ACQUIRED-RESISTANCE; DNA METHYLATION; PLASMA; MUTATIONS; HYPERMETHYLATION	BackgroundUse of liquid biopsy for minimal invasive follow-up diagnostics of non-small-cell lung carcinomas (NSCLCs).ObjectivesSystematic search for new putative blood-based hypermethylation biomarkers to discriminate NSCLC patients from patients without amalign disease.MethodsQuantitative analysis of gene promoter DNA methylation of potential biomarkers from cfDNA (plasma) with pyrosequencing.ResultscfDNA hypermethylation in plasma confirmed significant higher methylation frequencies of the candidate gene CFTR of the NSCLC patients compared to the combined control groups and to NSCLC patients after curative therapy of primary NSCLC (post-NSCLC). ROC-analysis of the best discriminatory CpGs of the CFTR promotor (CpG1-2-4) revealed asensitivity of 52% in NSCLC patients and aspecificity of 90% in the post-NSCLC group (AUC: 0.69; p<0.05).ConclusionsPromotor hypermethylation of the potential biomarker CFTR shows adiscriminatory potential for differentiation of NSCLC patients to patients without amalign disease and should further be investigated.	[Schulz, H.; Tator, M.; Knuechel-Clarke, R.; Kloten, V.; Dahl, E.] Uniklin RWTH Aachen, Inst Pathol, Arbeitsgrp Mol Onkol, Pauwelsstr 30, D-52074 Aachen, Germany; [Spillner, J.] Uniklin RWTH Aachen, Klin Thorax Herz & Gefasschirurg, Aachen, Germany; [Dreher, M.] Uniklin RWTH Aachen, Klin Pneumol & Internist Intens Med, Aachen, Germany; [Dahl, E.] Uniklin RWTH Aachen, RWTH Zent Biomat Bank RWTH cBMB, Inst Pathol, Aachen, Germany	Schulz, H (reprint author), Uniklin RWTH Aachen, Inst Pathol, Arbeitsgrp Mol Onkol, Pauwelsstr 30, D-52074 Aachen, Germany.	Hanna.schulz@rwth-aachen.de					Aberle DR, 2013, NEW ENGL J MED, V369, P920, DOI 10.1056/NEJMoa1208962; [Anonymous], 2018, S3 LEITL PRAV DIAGN; Bach PB, 2012, JAMA-J AM MED ASSOC, V307, P2418, DOI 10.1001/jama.2012.5521; Balak MN, 2006, CLIN CANCER RES, V12, P6494, DOI 10.1158/1078-0432.CCR-06-1570; Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X; Baylin SB, 2011, NAT REV CANCER, V11, P726, DOI 10.1038/nrc3130; Berlin K, 2004, BISULFITE CONVERSION; Day E, 2013, METHODS, V59, P101, DOI 10.1016/j.ymeth.2012.08.001; Delaney C, 2015, METHODS MOL BIOL, V1343, P249, DOI 10.1007/978-1-4939-2963-4_19; Diaz LA, 2012, NATURE, V486, P537, DOI 10.1038/nature11219; Diehl F, 2005, P NATL ACAD SCI USA, V102, P16368, DOI 10.1073/pnas.0507904102; Diehl F, 2008, NAT MED, V14, P985, DOI 10.1038/nm.1789; Esteller M, 2002, J PATHOL, V196, P1, DOI 10.1002/path.1024; Frangioni JV, 2008, J CLIN ONCOL, V26, P4012, DOI 10.1200/JCO.2007.14.3065; Goeckenjan G, 2011, Pneumologie, V65, P39, DOI 10.1055/s-0030-1256562; HOCHBERG Y, 1988, BIOMETRIKA, V75, P800, DOI 10.1093/biomet/75.4.800; Kaedbey R, 2015, CLIN LYMPHOMA MYELOM, V15, pe45, DOI DOI 10.1016/j.clml.2015.07.180; Kimura H, 2006, CLIN CANCER RES, V12, P3915, DOI 10.1158/1078-0432.CCR-05-2324; Kozower BD, 2010, ANN THORAC SURG, V90, P875, DOI 10.1016/j.athoracsur.2010.03.115; MANDEL P, 1948, C R Seances Soc Biol Fil, V142, P241; Nelder J. A., 2004, GEN LINEAR MODELS, V4; Norton SE, 2013, CLIN BIOCHEM, V46, P1561, DOI 10.1016/j.clinbiochem.2013.06.002; Oxnard GR, 2014, CLIN CANCER RES, V20, P1698, DOI 10.1158/1078-0432.CCR-13-2482; Patz EF, 2014, JAMA INTERN MED, V174, P269, DOI 10.1001/jamainternmed.2013.12738; Paweletz CP, 2016, CLIN CANCER RES, V22, P915, DOI 10.1158/1078-0432.CCR-15-1627-T; Son JW, 2011, RESPIROLOGY, V16, P1203, DOI 10.1111/j.1440-1843.2011.01994.x; STROUN M, 1989, ONCOLOGY, V46, P318; Stroun M, 2001, CLIN CHIM ACTA, V313, P139, DOI 10.1016/S0009-8981(01)00665-9; Wender R, 2013, CA-CANCER J CLIN, V63, P107, DOI 10.3322/caac.21172; Wiencke JK, 2014, EPIGENETICS-US, V9, P1360, DOI 10.4161/15592294.2014.967589; Yu HA, 2013, CLIN CANCER RES, V19, P2240, DOI 10.1158/1078-0432.CCR-12-2246	31	0	0	2	5	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	0172-8113	1432-1963		PATHOLOGE	Pathologe	DEC	2018	39			2			193	198		10.1007/s00292-018-0536-5			6	Pathology	Pathology	HE6XV	WOS:000453565100005	30377787				2019-10-28	
J	Aumann, K				Aumann, K.			Protein-dysregulation in human and murine myeloproliferative neoplasms	PATHOLOGE			German	Article						BCR-ABL fusion proteins; Immunohistochemistry; Carcinogenesis; Bone marrow; Myeloproliferative disorders	CHRONIC MYELOID-LEUKEMIA; TRANSCRIPTION FACTOR NF-E2; BCR-ABL; ESSENTIAL THROMBOCYTHEMIA; GAB2; CELLS; RECOMMENDATIONS; TRANSFORMATION; MANAGEMENT; DISEASE	In this work different types of dysregulation of signaling proteins in the context of myeloproliferative neoplasms are examined. In this heterogeneous disease group, uncontrolled cell proliferation plays acrucial role for the initiation of tumorigenesis, which Robert Weinberg described as ahallmark for the development of cancer. Protein dysregulation in form of overexpression of GAB2, aprotein involved in formation of the CML-pathognomonic BCR/ABL-translocation complex, results in an enhanced disease phenotype in aBcr/Abl-positive mouse model and disease acceleration is associated with achange of the subcellular localization of GAB2 in human blasts in CML-bone marrow biopsies. Furthermore, analyses of amouse model show that aprotein dysregulation caused by adistinct translocation (Tel-Syk) leads to the formation of aspecific and morphologically very characteristic phenotype in the bone marrow of diseased mice. Moreover, results were presented which show that in certain subgroups of Myeloproliferative Neoplasms the protein NFE2, which is initially known only as atranslocating factor, is apparently regulated by altering its subcellular localization. The difference in the subcellular localization of NFE2 in erythroid bone marrow cells is so clear between Essential Thrombocythemia and Primary Myelofibrosis that quantitative NFE2 immunohistochemistry can be used as an ancillary tool to diagnostically discriminate these two entities in an early stage.	[Aumann, K.] Albert Ludwigs Univ Freiburg, Inst Klin Pathol, Univ Klinikum Freiburg, Med Fak, Breisacher Str 115a, D-79106 Freiburg, Germany	Aumann, K (reprint author), Albert Ludwigs Univ Freiburg, Inst Klin Pathol, Univ Klinikum Freiburg, Med Fak, Breisacher Str 115a, D-79106 Freiburg, Germany.	konrad.aumann@uniklinik-freiburg.de					ANDREWS NC, 1993, NATURE, V362, P722, DOI 10.1038/362722a0; Aumann K, 2013, BLOOD, V122, P93, DOI 10.1182/blood-2012-11-463257; Aumann K, 2011, HUM PATHOL, V42, P719, DOI 10.1016/j.humpath.2010.09.012; Baccarani M, 2006, BLOOD, V108, P1809, DOI 10.1182/blood-2006-02-005686; Baccarani M, 2009, J CLIN ONCOL, V27, P6041, DOI 10.1200/JCO.2009.25.0779; Buchner M, 2009, CANCER RES, V69, P5424, DOI 10.1158/0008-5472.CAN-08-4252; Buhr T, 2012, HAEMATOL-HEMATOL J, V97, P360, DOI 10.3324/haematol.2011.047811; Deininger M, 2005, BLOOD, V105, P2640, DOI 10.1182/blood-2004-08-3097; Dierks C, 2010, CANCER RES, V70, P6193, DOI 10.1158/0008-5472.CAN-08-3719; Gu HH, 1997, J BIOL CHEM, V272, P16421, DOI 10.1074/jbc.272.26.16421; Gu HH, 1998, MOL CELL, V2, P729, DOI 10.1016/S1097-2765(00)80288-9; Halbach S, 2016, LEUKEMIA, V30, P1942, DOI 10.1038/leu.2016.92; Halbach S, 2016, GAB2 ITS ROLE TYROSI; IGARASHI K, 1994, NATURE, V367, P568, DOI 10.1038/367568a0; Kogan SC, 2002, BLOOD, V100, P238, DOI 10.1182/blood.V100.1.238; Kometani K, 2006, CANCER RES, V66, P9967, DOI 10.1158/0008-5472.CAN-06-1346; Koschmieder S, 2005, BLOOD, V105, P324, DOI 10.1182/blood-2003-12-4369; Kroft S, 2015, DIAGNOSTIC SURG PATH, P696; Kuno Y, 1999, BRIT J HAEMATOL, V106, P570, DOI 10.1046/j.1365-2141.1999.01607.x; Maroun CR, 1999, MOL CELL BIOL, V19, P1784; Nishida K, 2002, BLOOD, V99, P1866, DOI 10.1182/blood.V99.5.1866; Ren R, 2005, NAT REV CANCER, V5, P172, DOI 10.1038/nrc1567; Sattler M, 2002, CANCER CELL, V1, P479, DOI 10.1016/S1535-6108(02)00074-0; Scherr M, 2006, BLOOD, V107, P3279, DOI 10.1182/blood-2005-08-3087; Sprissler C, 2014, BLOOD CANCER J, V4, DOI 10.1038/bcj.2014.53; Sprissler C, 2013, ROLLE SYK HAMATOLOGI; Steegmann JL, 2016, LEUKEMIA, V30, P1648, DOI 10.1038/leu.2016.104; Swerdlow SH, 2017, WHO CLASSIFICATION T; Wilkins BS, 2008, BLOOD, V111, P60, DOI 10.1182/blood-2007-05-091850; Wohrle FU, 2013, LEUKEMIA, V27, P118, DOI 10.1038/leu.2012.222; Wohrle FU, 2009, CELL COMMUN SIGNAL, V7, DOI 10.1186/1478-811X-7-22; Wohrle FU, 2012, GAB2 SIGNALING CHRON	32	0	0	0	0	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	0172-8113	1432-1963		PATHOLOGE	Pathologe	DEC	2018	39			2			199	207		10.1007/s00292-018-0520-0			9	Pathology	Pathology	HE6XV	WOS:000453565100006	30350174				2019-10-28	
J	Berezowska, S				Berezowska, S.			Lung cancer under stress	PATHOLOGE			German	Article						Immunohistochemistry; Autophagy; LC3; p62; Non-small cell lung cancer	AUTOPHAGY; P62; P62/SQSTM1; EXPRESSION; LC3B	BackgroundAutophagy is acellular mechanism involved in maintaining cellular homeostasis and warranting cellular survival under stress, and may be therapeutically exploited. Autophagy assessment in vitro is well established, but analysis in formalin-fixed and paraffin-embedded (FFPE) tissue is still poorly standardized. Expression analysis of autophagy-associated markers in diagnostic FFPE tissue aids in translating in vitro findings to the clinic and may contribute to afuture quest for predictive markers.Material and methodsWe have established areliable visualization of autophagy-related proteins in FFPE tissue by immunohistochemistry, using lung cancer cell lines with functionally modified autophagy states and marker-depletion, respectively, and evaluated the prognostic impact of autophagy-related markers in lung cancer patients.ResultsDot-like staining was observed for LC3 and p62, representing the degrading autophagic vesicles. Stainings correlated significantly with quantitative protein expression assessed by western blot in cell lines and FFPE tumor tissue. In stageI/II non-small cell lung cancer cases and alarge cohort of pulmonary squamous cell carcinomas, dot-like LC3 and p62 staining lacked clear prognostic value, but p62 expression was an independent prognostic factor for shorter survival in both cohorts and using internal validation models.ConclusionsValid visualization of autophagy-related markers in FFPE tissue is feasible. We could not demonstrate aclear prognostic role of autophagy status as deducted from LC3-p62 co-expression. The autophagy independent role of p62 in lung cancer warrants further investigation, as well as crosstalk with other stress factors or the role of autophagy induction during or after treatment.	[Berezowska, S.] Univ Bern, Inst Pathol, Murtenstr 31, CH-3008 Bern, Switzerland	Berezowska, S (reprint author), Univ Bern, Inst Pathol, Murtenstr 31, CH-3008 Bern, Switzerland.	sabina.berezowska@pathology.unibe.ch		Berezowska, Sabina/0000-0001-5442-9791			Adams O, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0197610; Berezowska S, 2017, METHODS MOL BIOL, V1560, P189, DOI 10.1007/978-1-4939-6788-9_13; Chen N, 2009, BBA-MOL CELL RES, V1793, P1516, DOI 10.1016/j.bbamcr.2008.12.013; Chude CI, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18061279; Fan LH, 2018, APOPTOSIS, V23, P187, DOI 10.1007/s10495-018-1445-z; Inoue D, 2012, CANCER SCI, V103, P760, DOI 10.1111/j.1349-7006.2012.02216.x; Jiang PD, 2014, CELL RES, V24, P69, DOI 10.1038/cr.2013.161; Katsuragi Y, 2015, FEBS J, V282, P4672, DOI 10.1111/febs.13540; Klionsky DJ, 2016, AUTOPHAGY, V12, P1, DOI 10.1080/15548627.2015.1100356; Ladoire S, 2016, AUTOPHAGY, V12, P864, DOI 10.1080/15548627.2016.1154244; Langer R, 2018, CANCERS, DOI [10.1016/j.humpath.2017.11.019., DOI 10.1016/J.HUMPATH.2017.11.019.]; Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018; Liu JL, 2014, BRIT J CANCER, V111, P944, DOI 10.1038/bjc.2014.355; Mancias JD, 2016, J MOL BIOL, V428, P1659, DOI 10.1016/j.jmb.2016.02.027; Martinet W, 2017, CELLS, V6, DOI 10.3390/cells6030017; Martinet W, 2013, AUTOPHAGY, V9, P386, DOI 10.4161/auto.22968; Mathew R, 2007, NAT REV CANCER, V7, P961, DOI 10.1038/nrc2254; Mizushima N, 2018, NAT CELL BIOL, V20, P521, DOI 10.1038/s41556-018-0092-5; Mizushima N, 2010, FEBS LETT, V584, P1279, DOI 10.1016/j.febslet.2010.02.053; Moscat J, 2012, TRENDS BIOCHEM SCI, V37, P230, DOI 10.1016/j.tibs.2012.02.008; Nezis IP, 2012, ANTIOXID REDOX SIGN, V17, P786, DOI 10.1089/ars.2011.4394; Onorati AV, 2018, CANCER-AM CANCER SOC, V124, P3307, DOI 10.1002/cncr.31335; Ruan HH, 2018, ONCOTARGET, V9, P4258, DOI 10.18632/oncotarget.23101; Schlafli AM, 2015, EUR J HISTOCHEM, V59, P137, DOI 10.4081/ejh.2015.2481; Schlafli AM, 2016, ONCOTARGET, V7, P39544, DOI 10.18632/oncotarget.9647; Wang XF, 2015, INT J CLIN EXP PATHO, V8, P10644; White E, 2009, CLIN CANCER RES, V15, P5308, DOI 10.1158/1078-0432.CCR-07-5023	27	0	0	0	0	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	0172-8113	1432-1963		PATHOLOGE	Pathologe	DEC	2018	39			2			208	214		10.1007/s00292-018-0506-y			7	Pathology	Pathology	HE6XV	WOS:000453565100007	30280323	Green Published			2019-10-28	
J	Bremmer, F				Bremmer, F.			Identification of diagnostic tumour markers and therapeutic targets in testicular tumours	PATHOLOGE			German	Article						Testicular germ cell tumor; Cadherin; Beta-catenin; SOX9; Transmembrane proteins	GERM-CELL TUMORS; CARCINOMA-IN-SITU; CORD-STROMAL TUMORS; N-CADHERIN; BETA-CATENIN; NUCLEAR-LOCALIZATION; RISK-FACTORS; EXPRESSION; CANCER; TESTIS	Today, tumour classification has been expanded due to immunohistochemical and molecular-pathological analyses due to corresponding patterns/profiles of protein and gene expression. The latter analyses often include growth factors and their ligands, intracellular signalling pathways, DNA-binding proteins, and oncogenes and suppressor genes, thus functionally including primarily the regulation of growth including angiogenesis and apoptosis as well as the induction of metastases to adhesion and migration disorders. Based on observations that testicular tumours often show microcalcifications, possibly due to impaired calcium metabolism, we focused on calcium-dependent transmembrane proteins, particularly cadherins, in the search for new tumour markers and therapeutic targets. N-cadherin is expressed differently in the various subtypes of germ cell tumours and is useful in N-cadherin-positive germ cell tumours as anovel therapeutic targeting structure, particularly in cisplatin resistance, due to functional analysis. In the tumours of the sex cord stroma beta-catenin and the transcription factor SOX-9 give aclear classification of these tumours. Thus, morphological investigations prove to be pilot experiments to purposefully narrow the spectrum of functionally important proteins and thus to establish promising new differential diagnostic markers or target structures.	[Bremmer, F.] Univ Med Gottingen, Inst Pathol, Robert Koch Str 40, D-37075 Gottingen, Germany	Bremmer, F (reprint author), Univ Med Gottingen, Inst Pathol, Robert Koch Str 40, D-37075 Gottingen, Germany.	felix.bremmer@med.uni-goettingen.de					Albers P, 2003, J CLIN ONCOL, V21, P1505, DOI 10.1200/JCO.2003.07.169; Bokemeyer C, 2008, ANN ONCOL, V19, P448, DOI 10.1093/annonc/mdm526; Bremmer F, 2017, VIRCHOWS ARCH, V470, P421, DOI 10.1007/s00428-017-2090-6; Bremmer F, 2013, APMIS, V121, P976, DOI 10.1111/apm.12053; Bremmer F, 2015, ONCOTARGET, V6, P33426, DOI 10.18632/oncotarget.5288; Bremmer F, 2012, BMC CLIN PATHOL, V12, DOI 10.1186/1472-6890-12-19; Chaboissier MC, 2004, DEVELOPMENT, V131, P1891, DOI 10.1242/dev.01087; Chang H, 2008, DEVELOPMENT, V135, P1875, DOI 10.1242/dev.018572; Chung S, 2013, ONCOGENE, V32, P422, DOI 10.1038/onc.2012.65; Hay E, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008284; Hazan RB, 2004, ANN NY ACAD SCI, V1014, P155, DOI 10.1196/annals.1294.016; Heidenreich A, 1998, CANCER, V83, P1002, DOI 10.1002/(SICI)1097-0142(19980901)83:5<1002::AID-CNCR27>3.0.CO;2-A; Honecker F, 2009, J CLIN ONCOL, V27, P2129, DOI 10.1200/JCO.2008.18.8623; Jager T, 2010, ONCOL REP, V23, P1125, DOI 10.3892/or_00000741; Juliachs M, 2014, CLIN CANCER RES, V20, P658, DOI 10.1158/1078-0432.CCR-13-1131; Li BH, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0155910; Li G, 2001, CANCER RES, V61, P3819; Mayer F, 2003, CLIN CANCER RES, V9, P767; Nalla AK, 2011, EXP CELL RES, V317, P2512, DOI 10.1016/j.yexcr.2011.07.024; Oechsle K, 2011, EUR UROL, V60, P850, DOI 10.1016/j.eururo.2011.06.019; Oliva EYR, 2016, WHO CLASSIFICATION T; Perotti A, 2009, ANN ONCOL, V20, P741, DOI 10.1093/annonc/mdn695; Perrone F, 2014, AM J SURG PATHOL, V38, P66, DOI 10.1097/PAS.0b013e31829cdbc6; Persons DL, 1999, CLIN CANCER RES, V5, P1007; Rajpert-De Meyts E, 2006, HUM REPROD UPDATE, V12, P303, DOI 10.1093/humupd/dmk006; Sanders DSA, 1999, J CLIN PATHOL-MOL PA, V52, P151, DOI 10.1136/mp.52.3.151; Schrader M, 2009, ONCOLOGY-BASEL, V76, P77, DOI 10.1159/000187426; Schweyer S, 2004, BRIT J CANCER, V91, P589, DOI 10.1038/sj.bjc.6601919; SKAKKEBAEK NE, 1987, INT J ANDROL, V10, P19, DOI 10.1111/j.1365-2605.1987.tb00161.x; Ulbright TM, 2016, WHO CLASSIFICATION T; Ulbright TM, 2013, TUMORS TESTIS ADJACE; van Casteren NJ, 2009, INT J ANDROL, V32, P279, DOI 10.1111/j.1365-2605.2008.00937.x; van der Zwan YG, 2015, EUR UROL, V67, P692, DOI 10.1016/j.eururo.2014.07.011; Van Marck V, 2005, CANCER RES, V65, P8774, DOI 10.1158/0008-5472.CAN-04-4414; Velasco A, 2008, INT J CANCER, V122, P1774, DOI 10.1002/ijc.23291; Wermann H, 2010, J PATHOL, V221, P433, DOI 10.1002/path.2725; Xiao GQ, 2012, VIRCHOWS ARCH, V461, P713, DOI 10.1007/s00428-012-1332-x; Yarom N, 2013, CURR CLIN PHARMACOL, V8, P81; Zhang C, 2015, AM J SURG PATHOL, V39, P1390, DOI 10.1097/PAS.0000000000000455	39	0	0	1	2	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	0172-8113	1432-1963		PATHOLOGE	Pathologe	DEC	2018	39			2			215	220		10.1007/s00292-018-0493-z			6	Pathology	Pathology	HE6XV	WOS:000453565100008	30206653				2019-10-28	
J	Ormanns, S				Ormanns, S.			Personalized cancer medicine. Biomarkers formolecular therapy stratification in pancreatic carcinoma	PATHOLOGE			German	Article						Adenocarcinoma; Therapy targets; Pancreatic neoplasms; Precision medicine; Tumor biomarkers	NUCLEOSIDE TRANSPORTER 1; PHASE-III; NAB-PACLITAXEL; DUCTAL ADENOCARCINOMA; ADJUVANT GEMCITABINE; SPARC EXPRESSION; PLUS GEMCITABINE; CHEMOTHERAPY; MULTICENTER; MECHANISMS	Ductal adenocarcinoma of the pancreas has avery poor prognosis and arising incidence. Even after curative intent resection, which is possible in aminority of patients, most patients relapse, whereas the majority is diagnosed with inoperable or metastatic disease. That's why palliative systemic chemotherapy is the current therapeutic mainstay. Biomarker-based tumor characterization could identify potential therapy targets and enable apersonalized cancer medicine. Although potentially targetable alterations occur at very low frequencies, the possible impact on patient outcome can be significant. This article summarizes some of the contributions to these aspects and gives an outlook on their clinical meaning.	[Ormanns, S.] Ludwig Maximilians Univ Munchen, Pathol Inst, Med Fak, Thalkirchner Str 36, D-80337 Munich, Germany	Ormanns, S (reprint author), Ludwig Maximilians Univ Munchen, Pathol Inst, Med Fak, Thalkirchner Str 36, D-80337 Munich, Germany.	steffen.ormanns@med.uni-muenchen.de					Bailey P, 2016, NATURE, V531, P47, DOI 10.1038/nature16965; Barbari SR, 2017, DNA REPAIR, V56, P16, DOI 10.1016/j.dnarep.2017.06.003; Binenbaum Y, 2015, DRUG RESIST UPDATE, V23, P55, DOI 10.1016/j.drup.2015.10.002; Cavalcante LD, 2014, EUR J PHARMACOL, V741, P8, DOI [10.1010/j.ejphar.2014.07.041, 10.1016/j.ejphar.2014.07.041]; Damaraju VL, 2003, ONCOGENE, V22, P7524, DOI 10.1038/sj.onc.1206952; Dreyer SB, 2017, CLIN CANCER RES, V23, P1638, DOI 10.1158/1078-0432.CCR-16-2411; Elander NO, 2018, BRIT J CANCER, V118, P1084, DOI 10.1038/s41416-018-0005-1; Farrell JJ, 2009, GASTROENTEROLOGY, V136, P187, DOI 10.1053/j.gastro.2008.09.067; Golan T, 2014, BRIT J CANCER, V111, P1132, DOI 10.1038/bjc.2014.418; Greenhalf W, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/djt347; Guenther M, 2018, J CANCER RES CLIN, V144, P2161, DOI 10.1007/s00432-018-2746-x; Hellmann MD, 2018, NEW ENGL J MED, V378, P2093, DOI 10.1056/NEJMoa1801946; Hendifar A, 2017, ANN ONCOL, DOI [10.1093/annonc/mdx369.126, DOI 10.1093/ANNONC/MDX369.126]; Hidalgo M, 2015, CLIN CANCER RES, V21, P4811, DOI 10.1158/1078-0432.CCR-14-3222; Hilmi M, 2018, WORLD J GASTROENTERO, V24, P2137, DOI 10.3748/wjg.v24.i20.2137; Hingorani SR, 2015, ASCO M ABSTRACTS S15, V33, P4006, DOI DOI 10.1200/jco.2015.33.3_suppl.359; Hingorani SR, 2016, CLIN CANCER RES, V22, P2848, DOI 10.1158/1078-0432.CCR-15-2010; Hruban RH, 2007, MODERN PATHOL, V20, pS61, DOI 10.1038/modpathol.3800685; Humphris JL, 2017, GASTROENTEROLOGY, V152, P68, DOI 10.1053/j.gastro.2016.09.060; Jacobetz MA, 2013, GUT, V62, P112, DOI 10.1136/gutjnl-2012-302529; Johnson BA, 2017, CLIN CANCER RES, V23, P1656, DOI 10.1158/1078-0432.CCR-16-2318; Kaufman B, 2015, J CLIN ONCOL, V33, P244, DOI 10.1200/JCO.2014.56.2728; Kleeff J, 2007, INT J CANCER, V121, P699, DOI 10.1002/ijc.22871; Kleeff J, 2016, NAT REV DIS PRIMERS, V2, DOI 10.1038/nrdp.2016.22; Le DT, 2017, SCIENCE, V357, P409, DOI 10.1126/science.aan6733; Moore MJ, 2007, J CLIN ONCOL, V25, P1960, DOI 10.1200/JCO.2006.07.9525; Neoptolemos JP, 2018, NAT REV GASTRO HEPAT, V15, P332, DOI 10.1038/s41575-018-0005-x; Neoptolemos JP, 2017, LANCET, V389, P1011, DOI 10.1016/S0140-6736(16)32409-6; Oettle H, 2013, JAMA-J AM MED ASSOC, V310, P1473, DOI 10.1001/jama.2013.279201; Ormanns S, 2016, BRIT J CANCER, V115, P1520, DOI 10.1038/bjc.2016.355; Ormanns S, 2014, J CANCER RES CLIN, V140, P1625, DOI 10.1007/s00432-014-1774-4; Ormanns S, 2014, EUR J CANCER, V50, P1891, DOI 10.1016/j.ejca.2014.04.023; Ottaiano A, 2017, ACTA ONCOL, V56, P377, DOI 10.1080/0284186X.2017.1288922; Paniccia A, 2015, JAMA SURG, V150, P701, DOI 10.1001/jamasurg.2015.0668; Poplin E, 2013, J CLIN ONCOL, V31, P4453, DOI 10.1200/JCO.2013.51.0826; Provenzano PP, 2012, CANCER CELL, V21, P418, DOI 10.1016/j.ccr.2012.01.007; Rahib L, 2014, CANCER RES, V74, P2913, DOI 10.1158/0008-5472.CAN-14-0155; Shaw AT, 2013, NEW ENGL J MED, V368, P2385, DOI 10.1056/NEJMoa1214886; Siegel RL, 2018, CA-CANCER J CLIN, V68, P7, DOI 10.3322/caac.21442; Singhi AD, 2017, J NATL COMPR CANC NE, V15, P555, DOI 10.6004/jnccn.2017.0058; Sinn M, 2015, EUR J CANCER, V51, P1546, DOI 10.1016/j.ejca.2015.05.005; Svrcek M, 2015, HISTOPATHOLOGY, V66, P457, DOI 10.1111/his.12577; Von Hoff DD, 2011, J CLIN ONCOL, V29, P4548, DOI 10.1200/JCO.2011.36.5742; Waddell N, 2015, NATURE, V518, P495, DOI 10.1038/nature14169; Witkiewicz AK, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7744; Yi ZB, 2018, J CLIN ONCOL, V36, DOI 10.1200/JCO.2018.36.15_suppl.1039	46	0	0	0	2	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	0172-8113	1432-1963		PATHOLOGE	Pathologe	DEC	2018	39			2			221	224		10.1007/s00292-018-0539-2			4	Pathology	Pathology	HE6XV	WOS:000453565100009	30361776				2019-10-28	
J	Steinestel, K				Steinestel, K.			Regulator proteins of actin dynamics as possible targets of antineoplastic therapies	PATHOLOGE			German	Article						Cell migration; Invasion; Metastasis; Radioresistance; Synaptogenesis	NUCLEAR RIBONUCLEOPROTEIN K; CANCER-CELL MIGRATION; HNRNP-K; N-WASP; COMPLEX; INHIBITION	BackgroundThe ability of tumor cells to leave the primary tumor is prerequisite for metastatic spread. In previous studies, we identified regulator proteins of actin reorganization with essential functions in both synaptogenesis and tumor cell migration.ObjectiveThe aim of the studies summarized in this article is to identify signaling pathways associated with actin-related proteins that might represent potential molecular targets for antiinvasive and/or antineoplastic therapies.Materials and methodsWe used immunohistochemical analyses of protein expression as well as in vitro techniques (cell culture, fluorescence microscopy, RNAi-based knockdown of protein expression, protein biochemistry and in vivo animal experiment substitutes).ResultsWe show that phosphorylation of Abelson interactor1 (Abi1) is essential for the adhesion and invasion of colorectal carcinoma cells and might be targeted by the tyrosine kinase inhibitor STI571/Glivec (R). HnRNPK, aprotein interaction partner of Abi1, is upregulated in malignant melanoma in response to ionizing radiation; this upregulation is impaired upon application of the MEK inhibitor PD98059, enhancing radiosensivity of melanoma. Edelfosin, an alkyl-lipid blocker of the Abi1 interaction partner SK3, inhibits invasion of urothelial carcinoma cells.ConclusionThe studies summarized in this overview confirm acentral role for the investigated proteins in tumor cell invasion and resistance to antineoplastic therapies and identify possible molecular targets for novel therapeutic compounds.	[Steinestel, K.] Bundeswehrkrankenhaus Ulm, Inst Pathol & Mol Pathol, Oberer Eselsberg 40, D-89081 Ulm, Germany	Steinestel, K (reprint author), Bundeswehrkrankenhaus Ulm, Inst Pathol & Mol Pathol, Oberer Eselsberg 40, D-89081 Ulm, Germany.	konradsteinestel@bundeswehr.org					Bellone G, 2004, CANCER BIOL THER, V3, P385, DOI 10.4161/cbt.3.4.727; Blanchoin L, 2014, PHYSIOL REV, V94, P235, DOI 10.1152/physrev.00018.2013; Boeckers TM, 2006, CELL TISSUE RES, V326, P409, DOI 10.1007/s00441-006-0274-5; Campellone KG, 2010, NAT REV MOL CELL BIO, V11, P237, DOI 10.1038/nrm2867; Chantome A, 2013, CANCER RES, V73, P4852, DOI 10.1158/0008-5472.CAN-12-4572; Chen HJ, 2010, CANCER RES, V70, P9979, DOI 10.1158/0008-5472.CAN-10-2394; Davidson Andrew J., 2013, Communicative & Integrative Biology, V6, pe27033, DOI 10.4161/cib.27033; Eder S, 2015, ONCOTARGET, V6, P17178, DOI 10.18632/oncotarget.3935; Folci A, 2014, J NEUROSCI, V34, P9088, DOI 10.1523/JNEUROSCI.0303-14.2014; Girault A, 2011, CURR CANCER DRUG TAR, V11, P1111, DOI 10.2174/156800911798073069; Innocenti M, 2005, NAT CELL BIOL, V7, P969, DOI 10.1038/ncb1304; Le Clainche C, 2008, PHYSIOL REV, V88, P489, DOI 10.1152/physrev.00021.2007; LeClaire LL, 2008, J CELL BIOL, V182, P647, DOI 10.1083/jcb.200802145; Liebau S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018148; Moumen A, 2005, CELL, V123, P1065, DOI 10.1016/j.cell.2005.09.032; Nagerl UV, 2007, J NEUROSCI, V27, P8149, DOI 10.1523/JNEUROSCI.0511-07.2007; POLLARD TD, 1986, J CELL BIOL, V103, P2747, DOI 10.1083/jcb.103.6.2747; Proepper C, 2007, EMBO J, V26, P1397, DOI 10.1038/sj.emboj.7601569; Proepper C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027045; Ridley AJ, 2011, CELL, V145, P1012, DOI 10.1016/j.cell.2011.06.010; SLATON JW, 1994, J UROLOGY, V152, P1594, DOI 10.1016/S0022-5347(17)32485-0; Steinestel KE, 2010, CHARAKTERISIERUNG IN; Steinestel K, 2016, TUMOR BIOL, V37, P6275, DOI 10.1007/s13277-015-4509-5; Steinestel K, 2015, GASTROENT RES PRACT, DOI 10.1155/2015/930157; Steinestel K, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-145; Steinestel K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040671; Wang C, 2007, MOL CANCER RES, V5, P1031, DOI 10.1158/1541-7786.MCR-06-0391; Wen FS, 2010, ANN SURG ONCOL, V17, P2619, DOI 10.1245/s10434-010-1121-1; Yoo YD, 2006, J BIOL CHEM, V281, P15352, DOI 10.1074/jbc.M511825200; Zhang J, 2015, HUM PATHOL, V46, P1331, DOI 10.1016/j.humpath.2015.05.015	30	0	0	1	1	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	0172-8113	1432-1963		PATHOLOGE	Pathologe	DEC	2018	39			2			225	230		10.1007/s00292-018-0495-x			6	Pathology	Pathology	HE6XV	WOS:000453565100010	30229281				2019-10-28	
J	Enderle-Ammour, K; Wellner, U; Kocsmar, E; Kiss, A; Lotz, G; Csanadi, A; Bader, M; Schilling, O; Werner, M; Bronsert, P				Enderle-Ammour, K.; Wellner, U.; Kocsmar, E.; Kiss, A.; Lotz, G.; Csanadi, A.; Bader, M.; Schilling, O.; Werner, M.; Bronsert, P.			Three-dimensional reconstruction of solid tumors. Morphological evidence for tumor heterogeneity	PATHOLOGE			German	Article						Cadherins; Three-dimensional imaging; Epithelial-mesenchymal transition; Neoplasms; Zinc finger E-box-binding homeobox 1	CELL INVASION; CANCER; EMT; EXPRESSION; SNAIL	BackgroundIn histopathological routine diagnostics, three-dimensional tissue samples are analyzed histologically and/or immunohistochemically in two-dimensional sectional planes due to the high expenditure of time and the lack of digitization possibilities.AimHere, we demonstrate the application of three-dimensional reconstruction to solid tumors and analyze inter-/intratumoral heterogeneity with respect to epithelial-mesenchymal transition (EMT).MethodsTissue samples from pancreatic, lung, colorectal, and breast cancers as well as colorectal liver metastases were serially processed in 4m sections. For individual analyses, alternating stains (cytokeratin AE1/3, zinc finger E-box-binding homeobox1 (ZEB1), eCadherin) were performed. Subsequently, the tumor cells were analyzed for their morphology (epitheloid amoeboid, mesenchymal) and the expression of ZEB1 and eCadherin. For statistical analysis, all tumor cell aggregates were hierarchically annotated and analyzed.ResultsTumor buds are predominantly associated with the main tumor mass. Furthermore, ashutteling of eCadherin could be observed within tumor cell aggregates smaller than nine cells. ZEB1 is only increasingly expressed in tumor cell groups smaller than five cells.ConclusionsThe initial tumor budding and the subsequent decoupling of the tumor bud from the main tumor mass is most likely atwo-part process. However, the EMT is not statistically significantly increased within the tumor bud detached from the main tumor mass. It could be shown that the currently valid and known definition of atumor bud as acell cluster of less than or equal to five cells cannot be completely classified in the concept of EMT represented by eCadherin and ZEB1.	[Enderle-Ammour, K.; Csanadi, A.; Bader, M.; Werner, M.; Bronsert, P.] Univ Klinikum Freiburg, Inst Klin Pathol, Breisacher Str 115A, D-79106 Freiburg, Germany; [Schilling, O.] Univ Klinikum Freiburg, Inst Mol Med & Zellforsch, Freiburg, Germany; [Wellner, U.] Univ Klinikum Schleswig Holstein, Chirurg Klin, Campus Lubeck, Lubeck, Germany; [Werner, M.; Bronsert, P.] Univ Klinikum Freiburg, Biobank Tumorzentrum Freiburg, Freiburg, Germany; [Enderle-Ammour, K.; Csanadi, A.; Werner, M.; Bronsert, P.] Albert Ludwigs Univ Freiburg, Med Fak, Freiburg, Germany; [Kocsmar, E.; Kiss, A.; Lotz, G.] Semmelweis Univ, Inst Pathol 2, Budapest, Hungary	Bronsert, P (reprint author), Univ Klinikum Freiburg, Inst Klin Pathol, Breisacher Str 115A, D-79106 Freiburg, Germany.	peter.bronsert@uniklinik-freiburg.de					Aigner K, 2007, FEBS LETT, V581, P1617, DOI 10.1016/j.febslet.2007.03.026; Bronsert P, 2014, J PATHOL, V234, P410, DOI 10.1002/path.4416; Deutsche Krebsgesellschaft Deutsche Krebshil- fe, 2017, LEITL ONK S3 LEITL K; Enderle-Ammour K, 2017, TUMOR BIOL, V39, DOI 10.1177/1010428317705501; Grigore AD, 2016, J CLIN MED, V5, P51, DOI 10.3390/jcm5050051; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; IMAI T, 1960, OBSTET GYNECOL, V16, P296; Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104; Kohler I, 2015, J GASTROEN HEPATOL, V30, P78, DOI 10.1111/jgh.12752; Lugli A, 2017, MODERN PATHOL, V30, P1299, DOI 10.1038/modpathol.2017.46; Peinado H, 2007, NAT REV CANCER, V7, P415, DOI 10.1038/nrc2131; Prall F, 2007, HISTOPATHOLOGY, V50, P151, DOI 10.1111/j.1365-2559.2006.02551.x; Sanchez-Tillo E, 2010, ONCOGENE, V29, P3490, DOI 10.1038/onc.2010.102; Stemmer V, 2008, ONCOGENE, V27, P5075, DOI 10.1038/onc.2008.140; van Zijl F, 2011, MUTAT RES-REV MUTAT, V728, P23, DOI 10.1016/j.mrrev.2011.05.002; Wellner U, 2009, NAT CELL BIOL, V11, P1487, DOI 10.1038/ncb1998; Yamada N, 2017, HUM PATHOL, V60, P151, DOI 10.1016/j.humpath.2016.10.007	18	0	0	0	2	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	0172-8113	1432-1963		PATHOLOGE	Pathologe	DEC	2018	39			2			231	235		10.1007/s00292-018-0529-4			5	Pathology	Pathology	HE6XV	WOS:000453565100011	30361775				2019-10-28	
J	Erber, R; Hartmann, A; Beckmann, MW; Mackensen, A; Kremer, A; Reimann, H; Hubner, H; Hein, A; Lux, MP; Jud, S; Haberle, L; Gass, P; Volz, B; Schulz-Wendtland, R; Rubner, M; Fasching, PA				Erber, R.; Hartmann, A.; Beckmann, M. W.; Mackensen, A.; Kremer, A.; Reimann, H.; Huebner, H.; Hein, A.; Lux, M. P.; Jud, S.; Haeberle, L.; Gass, P.; Volz, B.; Schulz-Wendtland, R.; Ruebner, M.; Fasching, P. A.			TILGen study-immunological targets in patients with breast cancer. Influence of tumor-infiltrating lymphocytes	PATHOLOGE			German	Article						Immunotherapy; Breast neoplasms; Neoadjuvant therapy; Neoplasm antigens; Tumor-infiltrating lymphocytes	T-CELLS; CHEMOTHERAPY; HER2	BackgroundThe interaction of our immune system with breast cancer (BC) cells prompted the investigation of tumor-infiltrating lymphocytes (TILs) and targeted, tumor antigen-specific immunotherapy.ObjectivesCorrelation between TILs and pathological complete response (pCR) after neoadjuvant systemic therapy (NACT). Tumor-specific antigens (TSAs) in HER2+ and triple negative BC and establishment of TSA-specific therapies within the interdisciplinary TILGen study.MethodsIllustration of the TILGen study design. Assessment of TILs and correlation with pCR within this BC study.ResultspCR was achieved in 38.4% (56/146) and associated with estrogen receptor/progesterone receptor negative (ER-/PR-) and HER2+ tumors. Lymphocytic predominant BC (LPBC) was found in 16.4% (24/146), particularly in ER-/PR- (ER-: 27.3% vs. ER+: 9.9%, PR-: 22.3% vs. PR+: 8.2%), large, and poorly differentiated BC. TILs were significantly correlated with pCR in multivariate analysis. In LPBC, pCR was achieved in 66.7%, whereas it was 32.8% in non-LPBC.ConclusionsFirst results confirm the influence of the human immune system on the response to NACT in HER2+ and triple negative BC. TSA-specific immunotherapy might improve the outcome in BC patients but there is an urgent need for comprehensive studies to further investigate this issue.	[Erber, R.; Hartmann, A.] Friedrich Alexander Univ Erlangen Nurnberg FAU, Comprehens Canc Ctr Erlangen EMN, Univ Klinikum Erlangen, Pathol Inst, Krankenhausstr 8-10, D-91054 Erlangen, Germany; [Beckmann, M. W.; Huebner, H.; Hein, A.; Lux, M. P.; Jud, S.; Haeberle, L.; Gass, P.; Volz, B.; Ruebner, M.; Fasching, P. A.] Friedrich Alexander Univ Erlangen Nurnberg FAU, Comprehens Canc Ctr Erlangen EMN, Univ Klinikum Erlangen, Frauenklin, Erlangen, Germany; [Mackensen, A.; Kremer, A.; Reimann, H.] Friedrich Alexander Univ Erlangen Nurnberg FAU, Comprehens Canc Ctr Erlangen EMN, Univ Klinikum Erlangen, Hamatol & Internist Onkol,Med Klin 5, Erlangen, Germany; [Schulz-Wendtland, R.] Friedrich Alexander Univ Erlangen Nurnberg FAU, Comprehens Canc Ctr Erlangen EMN, Univ Klinikum Erlangen, Radiol Inst Gynakol Radiol, Erlangen, Germany	Erber, R (reprint author), Friedrich Alexander Univ Erlangen Nurnberg FAU, Comprehens Canc Ctr Erlangen EMN, Univ Klinikum Erlangen, Pathol Inst, Krankenhausstr 8-10, D-91054 Erlangen, Germany.	Ramona.Erber@uk-erlangen.de	Hein, Alexander/F-6999-2010; Jud, Sebastian Michael/G-2752-2010	Hein, Alexander/0000-0003-2601-3398; Jud, Sebastian Michael/0000-0002-8894-2785			Arbeitsgemeinschaft Gynakologische Onkologie e. V, 2018, LEITL KOMM MAMM VERS; Beckmann MW, 2011, ONKOLOGIE, V34, P362, DOI 10.1159/000329601; Denkert C, 2018, LANCET ONCOL, V19, P40, DOI 10.1016/S1470-2045(17)30904-X; Domschke C, 2016, BREAST CARE, V11, P102, DOI 10.1159/000446061; ELSTON CW, 1991, HISTOPATHOLOGY, V19, P403, DOI 10.1111/j.1365-2559.1991.tb00229.x; Fasching PA, 2015, GEBURTSH FRAUENHEILK, V75, P41, DOI 10.1055/s-0034-1396215; Finney HM, 1998, J IMMUNOL, V161, P2791; Fitzgerald Julie C, 2017, Crit Care Med, V45, pe124, DOI 10.1097/CCM.0000000000002053; Gass P, 2018, GEBURTSH FRAUENHEILK, V78, P707, DOI 10.1055/a-0642-9462; Ghiringhelli F, 2007, CANCER IMMUNOL IMMUN, V56, P641, DOI 10.1007/s00262-006-0225-8; Hein A, 2016, BREAST CANCER RES TR, V158, P59, DOI 10.1007/s10549-016-3850-8; Jiang XG, 2014, MOL CELL ENDOCRINOL, V382, P673, DOI 10.1016/j.mce.2013.06.003; Loi S, 2014, ANN ONCOL, V25, P1544, DOI 10.1093/annonc/mdu112; Lu YC, 2016, SEMIN IMMUNOL, V28, P22, DOI 10.1016/j.smim.2015.11.002; Lux MP, 2017, GEBURTSH FRAUENHEILK, V77, P1281, DOI 10.1055/s-0043-122885; Mao Y, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0115103; Salgado R, 2015, ANN ONCOL, V26, P259, DOI 10.1093/annonc/mdu450; Schneeweiss A, 2018, GEBURTSH FRAUENHEILK, V78, P246, DOI 10.1055/s-0044-101614; Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101; Swisher SK, 2016, ANN SURG ONCOL, V23, P2242, DOI 10.1245/s10434-016-5173-8; Taran FA, 2018, GEBURTSH FRAUENHEILK, V78, P237, DOI 10.1055/s-0044-101613; Topalian SL, 2015, CANCER CELL, V27, P450, DOI 10.1016/j.ccell.2015.03.001; Tresp V, 2016, P IEEE, V104, P2180, DOI 10.1109/JPROC.2016.2615052; von Minckwitz G, 2012, J CLIN ONCOL, V30, P1796, DOI 10.1200/JCO.2011.38.8595; Wahba HA, 2015, CANCER BIOL MED, V12, P106, DOI 10.7497/j.issn.2095-3941.2015.0030; Wurfel F, 2018, BREAST CARE, V13, P8, DOI 10.1159/000486949; Wunderle M, 2018, GEBURTSH FRAUENHEILK, V78, P481, DOI 10.1055/a-0603-4350; Zacharakis N, 2018, NAT MED, V24, P724, DOI 10.1038/s41591-018-0040-8	28	0	0	0	2	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	0172-8113	1432-1963		PATHOLOGE	Pathologe	DEC	2018	39			2			236	240		10.1007/s00292-018-0526-7			5	Pathology	Pathology	HE6XV	WOS:000453565100012	30406831				2019-10-28	
J	Feder, IS; Julich, M; Tannapfel, A; Tischoff, I				Feder, I. S.; Juelich, M.; Tannapfel, A.; Tischoff, I.			The German Mesothelioma Register. Current pathological diagnostics and services	PATHOLOGE			German	Article						Asbestos; Lung; Pleura; BAP1; p16-Deletion	IDIOPATHIC PULMONARY-FIBROSIS; PLEURAL MESOTHELIOMA; HELSINKI CRITERIA; ASBESTOS; CANCER; CLEARANCE; DEPOSITION	BackgroundIn Germany, asbestos-related diseases (asbestosis, lung cancer, mesothelioma) are recognised and compensated occupational diseases. The histologic diagnosis of mesothelioma is sometimes achallenge; additional immunohistochemical and molecular methods are needed.With lung dust analysis, the current asbestos fibre burden of the lung is measured (biomonitoring). Identification of gradeI asbestosis (minimal asbestosis) requires directed histological examinations with up to 400-fold magnification, additional iron staining and possibly in connection with alung dust analysis.ObjectivesDemonstration of current pathologic diagnostics in association with mesothelioma and lung dust analysis.Materials and methodsAnalysis of routine data from the German Mesothelioma Register.ResultsContrary to reactive mesothelial hyperplasia, malignant mesotheliomas have anuclear BAP1 loss-of-expression in up to 66% of cases. For differential diagnosis between reactive versus malignant, ap16-FISH test may be helpful. BAP1 loss-of-expression and p16-deletion are independent markers.Evaluation of the dataset of the German Mesothelioma Register of patients with repeated tissue sampling proves the detection of asbestos fibres at the same level even after 40years. The asbestos fibre burden in the human lung remains stable over this long period of time. In the electron microscopic analysis, white asbestos was predominantly found.ConclusionsThe well-known and industrially appreciated characteristics of asbestos fibres (in ancient ?sigma epsilon sigma sigma asbestos imperishable) as biopersistent have also been experimentally confirmed in human lungs.	[Feder, I. S.; Juelich, M.; Tannapfel, A.; Tischoff, I.] Ruhr Univ Bochum, Inst Pathol, Deutsch Mesotheliomregister, Georgius Agricola Stiftung Ruhr, Burkle de la Camp Pl 1, D-44789 Bochum, Germany	Feder, IS (reprint author), Ruhr Univ Bochum, Inst Pathol, Deutsch Mesotheliomregister, Georgius Agricola Stiftung Ruhr, Burkle de la Camp Pl 1, D-44789 Bochum, Germany.	inke.feder@rub.de					Attanoos RL, 2016, HISTOPATHOLOGY, V69, P492, DOI 10.1111/his.12951; Baur X, 2011, Pneumologie, V65, pe1, DOI 10.1055/s-0030-1255992; Bernstein D, 2013, CRIT REV TOXICOL, V43, P154, DOI 10.3109/10408444.2012.756454; Chiosea S, 2008, MODERN PATHOL, V21, P742, DOI 10.1038/modpathol.2008.45; CHURG A, 1988, EXP LUNG RES, V14, P567, DOI 10.3109/01902148809087829; CHURG A, 1994, ANN OCCUP HYG, V38, P625, DOI 10.1093/annhyg/38.4.625; Cigognetti M, 2015, MODERN PATHOL, V28, P1043, DOI 10.1038/modpathol.2015.65; Cooke WE, 1924, BMJ-BRIT MED J, V1924, P147, DOI 10.1136/bmj.2.3317.147; De Vuyst P, 1998, EUR RESPIR J, V11, P1416, DOI 10.1183/09031936.98.11061416; DGUV, 2011, FALK EMPF EMPF BEG A; EITNER F, 1984, ARB SOZIALMED PRAVEN, V19, P1; Farzin M, 2015, PATHOLOGY, V47, P302, DOI 10.1097/PAT.0000000000000250; Feder IS, 2017, EUR RESPIR J, V49, DOI 10.1183/13993003.02534-2016; Finkelstein MM, 1999, AM J IND MED, V35, P401, DOI 10.1002/(SICI)1097-0274(199904)35:4<401::AID-AJIM12>3.0.CO;2-4; Galateau-Salle F, 2015, WHO CLASSIFICATION T; Gibbs AR, 1996, THORAX, V51, P327, DOI 10.1136/thx.51.3.327; Gilham C, 2016, OCCUP ENVIRON MED, V73, P290, DOI 10.1136/oemed-2015-103074; Henderson DW, 1997, SCAND J WORK ENV HEA, V23, P311; Husain AN, 2018, ARCH PATHOL LAB MED, V142, P89, DOI 10.5858/arpa.2017-0124-RA; Konietzko N, 1992, ASBEST UND LUNGE; Ladou J, 2010, ENVIRON HEALTH PERSP, V118, P897, DOI 10.1289/ehp.1002285; MONSO E, 1991, BRIT J IND MED, V48, P327; Neumann V, 2013, DTSCH ARZTEBL INT, V110, P319, DOI 10.3238/arztebl.2013.0319; Roggli VL, 2010, ARCH PATHOL LAB MED, V134, P462, DOI 10.1043/1543-2165-134.3.462; Takeda M, 2014, J CLIN PATHOL, V67, P1038, DOI 10.1136/jclinpath-2014-202465; Tannapfel A, 2017, DTSCH MESOTHELIOMREG; Tischoff I, 2011, RECENT RESULTS CANC, V189, P57, DOI 10.1007/978-3-642-10862-4_5; Wolff H, 2015, SCAND J WORK ENV HEA, V41, P5, DOI 10.5271/sjweh.3462; Yusa T, 2015, AM J IND MED, V58, P444, DOI 10.1002/ajim.22430	29	0	0	1	1	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	0172-8113	1432-1963		PATHOLOGE	Pathologe	DEC	2018	39			2			241	246		10.1007/s00292-018-0509-8			6	Pathology	Pathology	HE6XV	WOS:000453565100013	30446780				2019-10-28	
J	Fend, F; Quintanilla-Martinez, L				Fend, F.; Quintanilla-Martinez, L.			Clonal evolution of early lymphoproliferations	PATHOLOGE			German	Article						Follicular lymphoma; Genetic testing; Clonal evolution; Monoclonal gammopathy of undetermined significance; Cell proliferation; In situ follicular neoplasia	MANTLE CELL LYMPHOMA; FOLLICULAR LYMPHOMA; IN-SITU; GLYCOSYLATION	The identification and molecular characterisation of premalignant precursor lesions of lymphomas, such as monoclonal gammopathy of unknown significance (MGUS) and the so-called in situ lymphoproliferations, has made significant progress in the recent years. The in situ follicular neoplasia (ISFN), the best-characterised entity, is by definition not identifiable by morphology and represents at(14;18)+ precursor lesion of follicular lymphoma with characteristic immunophenotype, low potential for progression, and already identifiable secondary genetic alterations. The use of high-throughput genetic techniques on microdissected tissues has generated novel insights into clonal evolution and biological progression of early lesions and documented that an isolated genetic analysis is insufficient to understand the complexity of proliferations.	[Fend, F.; Quintanilla-Martinez, L.] Eberhard Karls Univ Tubingen, Univ Klinikum Tubingen, Inst Pathol & Neuropathol, Liebermeisterstr 8, D-72076 Tubingen, Germany	Fend, F (reprint author), Eberhard Karls Univ Tubingen, Univ Klinikum Tubingen, Inst Pathol & Neuropathol, Liebermeisterstr 8, D-72076 Tubingen, Germany.	falko.fend@med.uni-tuebingen.de					Adam P, 2012, MODERN PATHOL, V25, P1629, DOI 10.1038/modpathol.2012.117; Bonzheim I, 2011, BLOOD, V118, P3442, DOI 10.1182/blood-2011-07-368944; Carvajal-Cuenca A, 2012, HAEMATOL-HEMATOL J, V97, P270, DOI 10.3324/haematol.2011.052621; Coelho V, 2010, P NATL ACAD SCI USA, V107, P18587, DOI 10.1073/pnas.1009388107; Cong PJ, 2002, BLOOD, V99, P3376, DOI 10.1182/blood.V99.9.3376; Henopp T, 2011, HISTOPATHOLOGY, V59, P139, DOI 10.1111/j.1365-2559.2011.03897.x; Jegalian AG, 2011, BLOOD, V118, P2976, DOI 10.1182/blood-2011-05-355255; Kosmidis P, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0178503; Mamessier E, 2014, HAEMATOLOGICA, V99, P481, DOI 10.3324/haematol.2013.094474; Montes-Moreno S, 2010, HISTOPATHOLOGY, V56, P658, DOI 10.1111/j.1365-2559.2010.03529.x; Roulland S, 2014, J CLIN ONCOL, V32, P1347, DOI 10.1200/JCO.2013.52.8190; Roulland S, 2011, ADV IMMUNOL, V111, P1, DOI 10.1016/B978-0-12-385991-4.00001-5; Schmidt J, 2014, LEUKEMIA, V28, P1103, DOI 10.1038/leu.2013.307; Sungalee S, 2014, J CLIN INVEST, V124, P5337, DOI 10.1172/JCI72415; Zhu DL, 2002, BLOOD, V99, P2562, DOI 10.1182/blood.V99.7.2562	15	0	0	1	2	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	0172-8113	1432-1963		PATHOLOGE	Pathologe	DEC	2018	39			2			247	249		10.1007/s00292-018-0525-8			3	Pathology	Pathology	HE6XV	WOS:000453565100014	30377786				2019-10-28	
J	Haroske, G; Zwonitzer, R; Hufnagl, P; Haroske, G; Burrig, KF; Fuzesi, L; Hofstadter, F; Morz, M; Schrader, J; Kayser, G; Perez-Bouza, A; Hufnagl, P; Kalinski, T; Zwonitzer, R				Haroske, G.; Zwoenitzer, R.; Hufnagl, P.; Haroske, G.; Buerrig, K. -F.; Fuezesi, L.; Hofstaedter, F.; Moerz, M.; Schrader, J.; Kayser, G.; Perez-Bouza, A.; Hufnagl, P.; Kalinski, T.; Zwoenitzer, R.		Kommission Digitale Pathologie	"Digital Pathology in Diagnostics - reporting on Digital Images" Guideline of the Professional Association of German Pathologists	PATHOLOGE			German	Article							LIGHT-MICROSCOPY; SLIDE; CONCORDANCE		[Haroske, G.; Kommission Digitale Pathologie] Bundesverband Deutsch Pathologen EV, Robert Koch Pl 9, D-10115 Berlin, Germany; [Zwoenitzer, R.] Imassense GmbH, Berlin, Germany; [Hufnagl, P.] Charite Univ Med Berlin, Inst Pathol, Berlin, Germany	Haroske, G (reprint author), Bundesverband Deutsch Pathologen EV, Robert Koch Pl 9, D-10115 Berlin, Germany.	haroske@icloud.com					Campbell WS, 2014, HUM PATHOL, V45, P1713, DOI 10.1016/j.humpath.2014.04.007; Cross S, 2018, BEST PRACTICE RECOMM; DICOM Working Group Twenty- Six ( Pathology), 2018, MIN TC 2018 5 15; Goacher E, 2017, ARCH PATHOL LAB MED, V141, P151, DOI 10.5858/arpa.2016-0025-RA; Haroske G, 2018, PATHOLOGE, V39, P216, DOI 10.1007/s00292-018-0433-y; Hufnagl P, 2018, PATHOLOGE, V39, P222, DOI 10.1007/s00292-018-0436-8; Hufnagl P, 2018, LEITFADEN DIGITALE P; Jukic DM, 2011, ARCH PATHOL LAB MED, V135, P372, DOI 10.1043/2009-0678-OA.1; Kayser G, 2012, PATHOLOGE S1, V33, P177; Mukhopadhyay S, 2018, AM J SURG PATHOL, V42, P39, DOI 10.1097/PAS.0000000000000948; Pantanowitz L, 2013, ARCH PATHOL LAB MED, V137, P1710, DOI 10.5858/arpa.2013-0093-CP	11	0	0	0	0	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	0172-8113	1432-1963		PATHOLOGE	Pathologe	DEC	2018	39			2			250	252		10.1007/s00292-018-0528-5			3	Pathology	Pathology	HE6XV	WOS:000453565100015	30397786				2019-10-28	
J	Hirsch, D; Gaiser, T				Hirsch, D.; Gaiser, T.			Crohn's disease-associated colorectal carcinogenesis. TP53 mutations and copy number gains of chromosome arm5p as (early) markers of tumor progression	PATHOLOGE			German	Article						Sequencing; Tumor evolution; Mutation; Chromosomal aberration; Inflammatory bowel disease	INFLAMMATORY-BOWEL-DISEASE; ULCERATIVE-COLITIS; CANCER; DISTINCT; REVEALS; ADENOCARCINOMA; DYSPLASIA; EVOLUTION; PATTERNS; RISK	BackgroundPatients with inflammatory bowel diseases, i.e., ulcerative colitis and Crohn's disease (CD), face an increased risk of developing colorectal cancer (CRC). Evidence, mainly from ulcerative colitis, suggests that TP53 mutations represent an initial step in the progression from inflamed colonic epithelium to CRC.ObjectivesIn this study, we aimed to analyze the genetic events that define CD-CRCs, in particular the dynamics of their development from histologically undetectable precursor lesions to invasive disease.Materials and methodsWe analyzed 73tissue samples from 28patients with CD-CRC, including precursor lesions by next generation sequencing (563 gene panel) and array-based comparative genomic hybridization. The results were compared with our own data and the Cancer Genome Atlas data on sporadic CRC.ResultsThe gain of 5p was significantly more prevalent in CD-CRCs than in sporadic CRCs, despite an overall similar chromosomal aberration pattern. CD-CRCs had adistinct mutation signature with TP53 being the most frequently mutated gene in CD-CRCs. TP53 mutations and copy number alterations were early events in CD progression and could sometimes already be detected in non-dysplastic colonic mucosa, indicating occult tumor evolution.ConclusionsMolecular profiling of CD-CRCs and precursor lesions revealed an inflammation-associated landscape of genome alterations: gains of 5p and TP53 mutations occurred early in tumor development. Detection of these aberrations in precursor lesions may help predict disease progression and distinguishes CD-associated from sporadic colorectal neoplasia.	[Hirsch, D.; Gaiser, T.] Heidelberg Univ, Med Fak Mannheim, Univ Med Mannheim, Inst Pathol, Theodor Kutzer Ufer 1-3, D-68167 Mannheim, Germany	Hirsch, D; Gaiser, T (reprint author), Heidelberg Univ, Med Fak Mannheim, Univ Med Mannheim, Inst Pathol, Theodor Kutzer Ufer 1-3, D-68167 Mannheim, Germany.	daniela.hirsch@umm.de; timo.gaiser@umm.de					Averboukh F, 2011, COLORECTAL DIS, V13, P1230, DOI 10.1111/j.1463-1318.2011.02639.x; BARDI G, 1995, CANCER GENET CYTOGEN, V82, P82, DOI 10.1016/0165-4608(95)00000-8; Beaugerie L, 2015, NEW ENGL J MED, V372, P1441, DOI 10.1056/NEJMra1403718; CHOI PM, 1994, GUT, V35, P950, DOI 10.1136/gut.35.7.950; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Gaiser T, 2013, INT J CANCER, V132, P1800, DOI 10.1002/ijc.27869; Galandiuk S, 2012, GASTROENTEROLOGY, V142, P855, DOI 10.1053/j.gastro.2011.12.004; Galata C, 2018, J CLIN GASTROENTEROL, V52, P635, DOI 10.1097/MCG.0000000000000817; Garnis C, 2005, ONCOGENE, V24, P4806, DOI 10.1038/sj.onc.1208643; GILLEN CD, 1994, GUT, V35, P1590, DOI 10.1136/gut.35.11.1590; Hirsch D, 2018, CLIN CANCER RES, V24, P4997, DOI 10.1158/1078-0432.CCR-18-0630; Hirsch D, 2012, GENE CHROMOSOME CANC, V51, P490, DOI 10.1002/gcc.21937; Huang KK, 2018, CANCER CELL, V33, P137, DOI 10.1016/j.ccell.2017.11.018; Lennerz JK, 2016, INT J COLORECTAL DIS, V31, P973, DOI 10.1007/s00384-016-2574-x; Ma JJ, 2016, TUMOR BIOL, V37, P9077, DOI 10.1007/s13277-015-4555-z; Noffsinger AE, 2001, HISTOPATHOLOGY, V39, P482, DOI 10.1046/j.1365-2559.2001.01274.x; Ott C, 2018, DIGESTION, V98, P143, DOI 10.1159/000487710; Ribeiro MB, 1996, ANN SURG, V223, P186, DOI 10.1097/00000658-199602000-00011; Richter H, 2003, AM J PATHOL, V163, P287, DOI 10.1016/S0002-9440(10)63652-8; Ried T, 1996, GENE CHROMOSOME CANC, V15, P234, DOI 10.1002/(SICI)1098-2264(199604)15:4<234::AID-GCC5>3.0.CO;2-2; Robles AI, 2016, GASTROENTEROLOGY, V150, P931, DOI 10.1053/j.gastro.2015.12.036; Sato A, 1999, PATHOL INT, V49, P858, DOI 10.1046/j.1440-1827.1999.00965.x; Scotto L, 2008, MOL CANCER, V7, DOI 10.1186/1476-4598-7-58; Shia J, 2017, MODERN PATHOL, V30, P599, DOI 10.1038/modpathol.2016.198; Tan YN, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0121944; Tsai JH, 2017, GASTROENTEROLOGY, V153, P1492, DOI 10.1053/j.gastro.2017.08.031; Ullman TA, 2011, GASTROENTEROLOGY, V140, P1807, DOI 10.1053/j.gastro.2011.01.057; van Dieren JM, 2006, DIAGN MOL PATHOL, V15, P216, DOI 10.1097/01.pdm.0000213470.92925.18; Yaeger R, 2016, GASTROENTEROLOGY, V151, P278, DOI 10.1053/j.gastro.2016.04.001; Zhao JK, 2013, J TRANSL MED, V11, DOI 10.1186/1479-5876-11-288	30	0	0	0	1	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	0172-8113	1432-1963		PATHOLOGE	Pathologe	DEC	2018	39			2			253	261		10.1007/s00292-018-0496-9			9	Pathology	Pathology	HE6XV	WOS:000453565100016	30229283				2019-10-28	
J	Langer, F; Stark, H; Braubach, P; Ackermann, M; Hussein, K; Teiken, K; Maegel, L; Kuehnel, M; Jonigk, D				Laenger, F.; Stark, H.; Braubach, P.; Ackermann, M.; Hussein, K.; Teiken, K.; Maegel, L.; Kuehnel, M.; Jonigk, D.			Injury patterns in interstitial lung diseases	PATHOLOGE			German	Article						Interstitial lung disease; Fibroelastosis; Lung transplantation; Gene expression; Lung parenchym	IDIOPATHIC PULMONARY-FIBROSIS; PLEUROPARENCHYMAL FIBROELASTOSIS; ORGANIZING PNEUMONIA; RISK-FACTORS; FEATURES; PATHOLOGY; UPDATE	Interstitial lung diseases (ILD) consist of acomplex group of hundreds of non-neoplastic pulmonary diseases with divergent clinical presentation, morphology and progression tendency. This great number of clinical entities contrasts with alimited number of injury patterns. By definition, an adequate classification requires asynopsis of the clinical, radiological and morphological findings. The ATS/ERS (American Thoracic Society/ European Respiratory Society) guidelines recommend an open lung biopsy if high-resolution computed tomography does not provide conclusive results. Due to the focal nature and overlapping features of injury patterns, microscopic categorization is not always possible. In order to broaden the diagnostic criteria by using molecular patterns the Lung Research Working Group of the Institute of Pathology of Hannover Medical School, Europe's leading transplant center, is working up fresh explanted human lungs in astandardized manner. These fresh specimens are used for translational research by means of functional, morphological and molecular techniques in order to identify disease-specific regulatory processes and to make them usable diagnostically and therapeutically.	[Laenger, F.; Stark, H.; Braubach, P.; Hussein, K.; Teiken, K.; Maegel, L.; Kuehnel, M.; Jonigk, D.] Med Hsch Hannover MHH, Inst Pathol, Carl Neuberg Str 1, D-30625 Hannover, Germany; [Laenger, F.; Stark, H.; Braubach, P.; Teiken, K.; Maegel, L.; Kuehnel, M.; Jonigk, D.] Deutsch Zentrum Lungenforsch DZL, Biomed Res Endstage & Obstruct Lung Dis Hannover, Hannover, Germany; [Ackermann, M.] Univ Klinikum Dusseldorf, Inst Pathol, Dusseldorf, Germany	Jonigk, D (reprint author), Med Hsch Hannover MHH, Inst Pathol, Carl Neuberg Str 1, D-30625 Hannover, Germany.	Jonigk.Danny@MH-Hannover.de					Ackermann M, 2017, AM J RESP CRIT CARE, V196, pE48, DOI 10.1164/rccm.201703-0591IM; Baumgartner KB, 2000, AM J EPIDEMIOL, V152, P307, DOI 10.1093/aje/152.4.307; CARRINGT.CB, 1969, NEW ENGL J MED, V280, P787, DOI 10.1056/NEJM196904102801501; Carrington CB, 1966, AM J MED, V6, P90214, DOI [10.1016/0002-9343, DOI 10.1016/0002-9343]; Cottin V, 2016, RESPIROLOGY, V21, P245, DOI 10.1111/resp.12588; Feinstein MB, 2015, J CLIN PATHOL, V68, P441, DOI 10.1136/jclinpath-2014-202626; Ferri C, 2016, AUTOIMMUN REV, V15, P61, DOI 10.1016/j.autrev.2015.09.003; Frankel SK, 2004, CHEST, V126, P2007, DOI 10.1378/chest.126.6.2007; Garcia-Sancho C, 2011, RESP MED, V105, P1902, DOI 10.1016/j.rmed.2011.08.022; Guiot J, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0171344; HOMOLKA J, 1987, CAN MED ASSOC J, V137, P1003; Hutchinson J, 2015, EUR RESPIR J, V46, P795, DOI 10.1183/09031936.00185114; Izykowski N, 2016, J TRANSL MED, V14, DOI 10.1186/s12967-016-0933-6; Jonigk D, 2017, J PATHOL CLIN RES, V3, P17, DOI 10.1002/cjp2.60; Jonigk D, 2015, AM J PATHOL, V185, P3178, DOI 10.1016/j.ajpath.2015.08.016; Jonigk D, 2011, METHODS MOL BIOL, V755, P67, DOI 10.1007/978-1-61779-163-5_5; Jonigk D, 2011, AM J PATHOL, V178, P599, DOI 10.1016/j.ajpath.2010.10.032; Kellner M, 2016, SCI REP-UK, V6, DOI 10.1038/srep35606; Kellner M, 2015, THORAX, V70, P1197, DOI 10.1136/thoraxjnl-2015-207131; Kokosi MA, 2016, RESPIROLOGY, V21, P600, DOI 10.1111/resp.12693; Konen E, 2003, AM J ROENTGENOL, V181, P1539, DOI 10.2214/ajr.181.6.1811539; Larsen BT, 2017, ARCH PATHOL LAB MED, V141, P901, DOI 10.5858/arpa.2016-0299-SA; Lederer DJ, 2018, NEW ENGL J MED, V378, P1811, DOI 10.1056/NEJMra1705751; Lettieri CJ, 2005, CHEST, V127, P1600, DOI 10.1378/chest.127.5.1600; Liebow A A, 1966, Trans Stud Coll Physicians Phila, V34, P47; LIEBOW AA, 1965, AM J MED, V39, P369, DOI 10.1016/0002-9343(65)90206-8; Miles LA, 2016, BLOOD, V127, P1079, DOI 10.1182/blood-2016-01-687673; Milstone AP, 2000, J HEART LUNG TRANSPL, V19, P744, DOI 10.1016/S1053-2498(00)00134-0; Parish JM, 2003, MAYO CLIN PROC, V78, P630, DOI 10.4065/78.5.630; Peca D, 2015, EUR J HUM GENET, V23, P1033, DOI 10.1038/ejhg.2015.45; Raghu G, 2015, AM J RESP CRIT CARE, V192, pE3, DOI 10.1164/rccm.201506-1063ST; Raghu G, 2015, AM J RESP CRIT CARE, V191, P252, DOI 10.1164/rccm.201411-2044ED; Raghu G, 2011, AM J RESP CRIT CARE, V183, P788, DOI 10.1164/rccm.2009-040GL; Rosenbaum JN, 2015, HUM PATHOL, V46, P137, DOI 10.1016/j.humpath.2014.10.007; Rossi G, 2015, CLIN REV ALLERG IMMU, V49, P36, DOI 10.1007/s12016-015-8479-6; Sato M, 2012, J HEART LUNG TRANSPL, V31, P354, DOI 10.1016/j.healun.2011.12.015; Sato M, 2011, J HEART LUNG TRANSPL, V30, P735, DOI 10.1016/j.healun.2011.01.712; Snetselaar R, 2015, CHEST, V148, P1011, DOI 10.1378/chest.14-3078; Spagnolo P, 2018, ARTHRITIS RHEUMATOL, V70, P1544, DOI 10.1002/art.40574; Takeuchi Y, 2015, HISTOPATHOLOGY, V66, P536, DOI 10.1111/his.12553; Tobin RW, 1998, AM J RESP CRIT CARE, V158, P1804, DOI 10.1164/ajrccm.158.6.9804105; Travis WD, 2013, AM J RESP CRIT CARE, V188, P733, DOI 10.1164/rccm.201308-1483ST; von der Thusen JH, 2011, MODERN PATHOL, V24, P1633, DOI 10.1038/modpathol.2011.114; Wang Y, 2009, AM J HUM GENET, V84, P52, DOI 10.1016/j.ajhg.2008.11.010; Yan Z, 2014, AUTOIMMUN REV, V13, P1020, DOI 10.1016/j.autrev.2014.08.028	45	2	2	0	1	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	0172-8113	1432-1963		PATHOLOGE	Pathologe	DEC	2018	39			2			262	271		10.1007/s00292-018-0503-1			10	Pathology	Pathology	HE6XV	WOS:000453565100017	30397788				2019-10-28	
J	Kreipe, H				Kreipe, H.			Ki67: biological intertumor variance versus variance of assay	PATHOLOGE			German	Article						Ki67; Proliferation marker; Cell cycle; Immunohistochemistry; Breast cancer	EARLY BREAST-CANCER; INTERNATIONAL EXPERT CONSENSUS; KI-67 LABELING INDEX; NEEDLE CORE BIOPSY; PRIMARY THERAPY; IMMUNOHISTOCHEMICAL ASSESSMENT; INTEROBSERVER REPRODUCIBILITY; PROGNOSTIC-SIGNIFICANCE; PREDICTIVE-VALUE; PROLIFERATION	Since its first description at the Institute of Pathology in Kiel more than 34years ago, the immunohistochemical proliferation marker Ki67 has been shown to be of prognostic significance in ahuge number of retrospective and even some prospective trials on malignant tumours of various tissue derivation. Lack of standardization in the evaluation provides potential sources of variance in assessment. Tumour area to be assessed, minimum number of cells to be analyzed, tedious counting cell by cell or semiquantitative eyeballing, choice of immunohistochemical techniques represent nonstandardized issues that potentially lead to considerable assay heterogeneity. In addition, interpretation is not homogeneous, in particular with regard to thresholds between high and low proliferative activity. Due to these numerous potential methodological limitations, for along time Ki67 was not generally accepted as aprognostic marker, in particular outside Germany and by nonpathologists. However, in recent years ashift has taken place. Despite the challenge that biological heterogeneity may be hidden by differences in assay performance, Ki67 now plays an important auxiliary role in grading of malignant neoplasms such as breast cancer, neuroendocrine tumours and malignant lymphomas. In this context it is applied in clinical diagnostics as well as in clinical trials for the purpose of stratification. Because of its widespread use, it is of utmost importance to raise awareness of the potential methodological limitations in order to use Ki67 in ameaningful way.	[Kreipe, H.] Hannover Med Sch, Inst Pathol, Carl Neuberg Str 1, D-30625 Hannover, Germany	Kreipe, H (reprint author), Hannover Med Sch, Inst Pathol, Carl Neuberg Str 1, D-30625 Hannover, Germany.	kreipe.hans@mh-hannover.de					BOEGE F, 1995, AM J PATHOL, V146, P1302; Cheang MCU, 2009, JNCI-J NATL CANCER I, V101, P736, DOI 10.1093/jnci/djp082; Christgen M, 2014, PATHOLOGE, V35, P54, DOI 10.1007/s00292-013-1843-5; Christgen M, 2015, HUM PATHOL, V46, P1341, DOI 10.1016/j.humpath.2015.05.016; de Azambuja E, 2007, BRIT J CANCER, V96, P1504, DOI 10.1038/sj.bjc.6603756; Denkert C, 2013, ANN ONCOL, V24, P2786, DOI 10.1093/annonc/mdt350; Dowsett M, 2011, J NATL CANCER I, V103, P1656, DOI 10.1093/jnci/djr393; FRIERSON HF, 1995, AM J CLIN PATHOL, V103, P195; GERDES J, 1984, J IMMUNOL, V133, P1710; Gluz O, 2016, J CLIN ONCOL, V34, P2341, DOI 10.1200/JCO.2015.63.5383; Goldhirsch A, 2013, ANN ONCOL, V24, P2206, DOI 10.1093/annonc/mdt303; Goldhirsch A, 2011, ANN ONCOL, V22, P1736, DOI 10.1093/annonc/mdr304; Goldhirsch A, 2009, ANN ONCOL, V20, P1319, DOI 10.1093/annonc/mdp322; HALL PA, 1993, ONCOGENE, V8, P203; Inwald EC, 2013, BREAST CANCER RES TR, V139, P539, DOI 10.1007/s10549-013-2560-8; Jones RL, 2009, BREAST CANCER RES TR, V116, P53, DOI 10.1007/s10549-008-0081-7; KREIPE H, 1993, AM J PATHOL, V142, P651; Kwok TC, 2010, HISTOPATHOLOGY, V57, P212, DOI 10.1111/j.1365-2559.2010.03620.x; Lehr HA, 1999, HUM PATHOL, V30, P1314, DOI 10.1016/S0046-8177(99)90062-X; LELLE RJ, 1987, CANCER, V59, P83, DOI 10.1002/1097-0142(19870101)59:1<83::AID-CNCR2820590119>3.0.CO;2-I; Mengel M, 2002, J PATHOL, V198, P292, DOI 10.1002/path.1218; O'Shea AM, 2011, HISTOPATHOLOGY, V59, P543, DOI 10.1111/j.1365-2559.2011.03916.x; Penault-Llorca F, 2009, J CLIN ONCOL, V27, P2809, DOI 10.1200/JCO.2008.18.2808; Raap M, 2017, VIRCHOWS ARCH, V471, P501, DOI 10.1007/s00428-017-2142-y; Scholzen T, 2000, J CELL PHYSIOL, V182, P311, DOI 10.1002/(SICI)1097-4652(200003)182:3<311::AID-JCP1>3.0.CO;2-9; SCHWAB U, 1982, NATURE, V299, P65, DOI 10.1038/299065a0; Sheri A, 2012, ANN ONCOL, V23, P219, DOI 10.1093/annonc/mds307; Stuart-Harris R, 2008, BREAST, V17, P323, DOI 10.1016/j.breast.2008.02.002; Varga Z, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037379; Viale G, 2008, JNCI-J NATL CANCER I, V100, P207, DOI 10.1093/jnci/djm289; Viale G, 2008, J CLIN ONCOL, V26, P5569, DOI 10.1200/JCO.2008.17.0829; von Wasielewski R, 2006, PATHOLOGE, V27, P337, DOI 10.1007/s00292-006-0855-9; Yerushalmi R, 2010, LANCET ONCOL, V11, P174, DOI 10.1016/S1470-2045(09)70262-1	33	1	1	0	1	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	0172-8113	1432-1963		PATHOLOGE	Pathologe	DEC	2018	39			2			272	277		10.1007/s00292-018-0502-2			6	Pathology	Pathology	HE6XV	WOS:000453565100018	30327857				2019-10-28	
J	Metze, D				Metze, D.			Systematic analysis of pathological changes in inflammatory dermatoses. New dermatopathological criteria and algorithms	PATHOLOGE			German	Article						Exanthema; drug-induced; Genodermatosis; Autoinflammatory syndrome; Autoimmune disease; Granulocytes	GENERALIZED PUSTULAR PSORIASIS; CLUE	Standardized analysis of histological findings in aroutinely stained section without knowledge of the clinical picture (blind fashion) allows an objective assessment of the pathological changes. In inflammatory dermatoses diagnostic algorithms and criteria have been proven. They follow defined main inflammatory patterns, the composition of the inflammatory infiltrate and additional criteria. Taking into account the stage of development and the possibility of collision phenomena, this approach will give ahistological diagnosis, or at least alimited number of differential diagnoses. However, the final diagnosis always results from the synopsis of the clinical picture and additional parameters. The modern development of algorithms and new histological criteria are outlined in autoimmune dermatoses, autoinflammatory syndromes, drug reactions and genodermatoses.	[Metze, D.] Univ Hautklin Munster, Von Esmarchstr 58, Munster, Germany	Metze, D (reprint author), Univ Hautklin Munster, Von Esmarchstr 58, Munster, Germany.	metzed@uni-muenster.de					Ackerman AB, 2005, HISTOLOGIC DIAGNOSIS; Bergman R, 2010, J AM ACAD DERMATOL, V62, P107, DOI 10.1016/j.jaad.2009.05.016; Berki DM, 2015, J INVEST DERMATOL, V135, P2964, DOI 10.1038/jid.2015.288; Boer-Auer A, 2013, HAUTARZT, V64, P195, DOI 10.1007/s00105-012-2530-9; Broekaert SMC, 2016, AM J DERMATOPATH, V38, P39, DOI 10.1097/DAD.0000000000000390; Chanal J, 2013, BRIT J DERMATOL, V169, P1041, DOI 10.1111/bjd.12488; Frosch M, 2005, EXP DERMATOL, V14, P259, DOI 10.1111/j.0906-6705.2005.00271.x; Goletz S, 2014, J AM ACAD DERMATOL, V71, P185, DOI 10.1016/j.jaad.2014.02.036; Huffmeier U, 2014, BRIT J DERMATOL, V170, P202, DOI 10.1111/bjd.12548; Kerl K, 2016, HISTOPATHOLOGIE HAUT, P185; Kieffer C, 2009, MEDICINE, V88, P23, DOI 10.1097/MD.0b013e3181943f5e; Lipsker D, 2008, DERMATOLOGY, V216, P283, DOI 10.1159/000113940; Metze D, 2007, HAUTARZT, V58, P735, DOI 10.1007/s00105-007-1381-2; Metze D, 1996, J CUTAN PATHOL, V23, P211, DOI 10.1111/j.1600-0560.1996.tb01469.x; Metze D, 2012, MCKEE SKIN PATHOLOGY, P46; Metze D, 2018, DERMATOLOGY, P924; Metze D, 2016, HISTOPATHOLOGIE HAUT, P404; Metze D, 2000, AM J DERMATOPATH, V22, P345; Metze D, 2015, B FALCOS DERMATOLOGI; Naik HB, 2013, DERMATOL CLIN, V31, P405, DOI 10.1016/j.det.2013.04.001; Naim M, 2011, AM J DERMATOPATH, V33, P695, DOI 10.1097/DAD.0b013e31820a285d; Oji V, 2016, ROOKS TXB DERMATOLOG; Oji V, 2010, AM J HUM GENET, V87, P274, DOI 10.1016/j.ajhg.2010.07.005; Rose C, 2007, AM J DERMATOPATH, V29, P119, DOI 10.1097/DAD.0b013e31803326e6; Schmidt E, 2016, HISTOPATHOLOGIE HAUT, P37; Setta-Kaffetzi N, 2013, J INVEST DERMATOL, V133, P1366, DOI 10.1038/jid.2012.490; Sidoroff A, 2001, J CUTAN PATHOL, V28, P113, DOI 10.1034/j.1600-0560.2001.028003113.x; Terra JB, 2013, BRIT J DERMATOL, V169, P100, DOI 10.1111/bjd.12308; Weyers Wolfgang, 2011, Dermatol Pract Concept, V1, P33, DOI 10.5826/dpc.0101a09	29	0	0	0	0	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	0172-8113	1432-1963		PATHOLOGE	Pathologe	DEC	2018	39			2			278	284		10.1007/s00292-018-0497-8			7	Pathology	Pathology	HE6XV	WOS:000453565100019	30302562				2019-10-28	
J	Moll, R				Moll, R.			Transcription factors in tumor diagnosis	PATHOLOGE			German	Article						Differentiation markers; Immunohistochemistry; Sensitivity and Specificity; Tumor markers; Transcription factors	UNKNOWN PRIMARY; CARCINOMA; MARKER	Transcription factors are aheterogeneous group of DNA-binding proteins that regulate the transcription of distinct genes. Due to their cell-type specificity and cell lineage restriction, numerous transcription factors have been established in recent years as excellent, sensitive, and specific immunohistochemical tumor markers. As compared to other cytoplasmic and membranous differentiation markers, the nuclear immunolocalization of transcription factors is often more stably preserved. Therefore, cell lineage-specific transcription factors can be detected even in poorly differentiated metastatic tumors. However, for their reliable diagnostic use, detailed knowledge is required on their expression profiles, which are often more complex than initially assumed.CDX2 is asensitive marker for colorectal adenocarcinomas but is also expressed in upper abdominal adenocarcinomas, mucinous carcinomas of lung and ovary, and midgut neuroendocrine tumors. Ahigher degree of specificity for colorectal origin is provided by SATB2. TTF-1 is avaluable marker particularly for pulmonary adenocarcinomas, but may also be focally expressed aberrantly in abdominal and gynecological adenocarcinomas. GATA3 is found in breast and urothelial carcinomas but also in squamous cell carcinomas. PAX8 is ahighly sensitive marker of all subtypes of gynecological adenocarcinomas, renal cell carcinomas, and thyroid carcinomas. Further transcription factors characterized by molecular biology have meanwhile become diagnostically relevant, the number of which is increasing.Principally, for the diagnostic use of transcription factors as immunohistochemical tumor markers, clinical and radiological data as well as conventional histopathology should always be carefully considered and if necessary they should be applied in the context of amarker panel.	[Moll, R.] Philipps Univ Marburg, Inst Pathol, Baldingerstr, D-35043 Marburg, Germany; [Moll, R.] Univ Klinikum Giessen & Marburg UKGM, Standort Marburg, Baldingerstr, D-35043 Marburg, Germany	Moll, R (reprint author), Philipps Univ Marburg, Inst Pathol, Baldingerstr, D-35043 Marburg, Germany.; Moll, R (reprint author), Univ Klinikum Giessen & Marburg UKGM, Standort Marburg, Baldingerstr, D-35043 Marburg, Germany.	mollr@med.uni-marburg.de					Barbareschi M, 2003, AM J SURG PATHOL, V27, P141, DOI 10.1097/00000478-200302000-00001; Conner JR, 2015, ADV ANAT PATHOL, V22, P149, DOI 10.1097/PAP.0000000000000069; Dabbs D. J., 2019, DIAGNOSTIC IMMUNOHIS; Dalerba P, 2016, NEW ENGL J MED, V374, P211, DOI 10.1056/NEJMoa1506597; Lin F, 2014, ARCH PATHOL LAB MED, V138, P1015, DOI 10.5858/arpa.2013-0452-OA; Miettinen M, 2014, AM J SURG PATHOL, V38, P13, DOI 10.1097/PAS.0b013e3182a0218f; Moll R, 2019, PATHOLOGE; Ordonez NG, 2012, APPL IMMUNOHISTO M M, V20, P429, DOI 10.1097/PAI.0b013e31825439bc; Stelow EB, 2018, SEMIN DIAGN PATHOL, V35, P143, DOI 10.1053/j.semdp.2017.11.012; Toriyama A, 2014, HISTOPATHOLOGY, V65, P465, DOI 10.1111/his.12405	10	0	0	0	2	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	0172-8113	1432-1963		PATHOLOGE	Pathologe	DEC	2018	39			2			285	290		10.1007/s00292-018-0518-7			6	Pathology	Pathology	HE6XV	WOS:000453565100020	30298190				2019-10-28	
J	Reis, H; Szarvas, T				Reis, H.; Szarvas, T.			Urachal cancer - current concepts of a rare cancer	PATHOLOGE			German	Article						Urachal carcinoma; Bladder; Diagnosis; Therapy; Molecular pathology	COMPREHENSIVE MOLECULAR CHARACTERIZATION; MICROSATELLITE INSTABILITY; PROMOTER MUTATIONS; CARCINOMA; ADENOCARCINOMA; CHEMOTHERAPY; KRAS; NEOPLASMS; SURVIVAL; FEATURES	Urachal cancer is arare but aggressive disease. In addition to the non-glandular tumors, non-cystic urachal adenocarcinomas are nowadays distinguished from the primary cystic variant. (Immunohistochemical) markers are only of minor differential diagnostic value and, therefore, the diagnosis is primarily established in amultidisciplinary approach. The non-cystic variant accounts for the majority of cases (83%), is more common in men (63%), shows amedian age at diagnosis of 51years and has a5-year survival rate of about 50%. In organ-confined disease, usually apartial cystectomy of the tumor in the bladder dome, including the median umbilical ligament and umbilicus, is performed. In advanced stages, systemic therapy is needed while 5-fuorouracil (5-FU) containing regimes have been shown to be more effective. Due to the rarity of the tumor, targeted therapy approaches based on abiological rationale are becoming increasingly relevant. As molecular data are still sparse, we compiled and analyzed the largest urachal cancer cohort to date. In 31% of the cases, MAPK-/PI3K signaling pathway alterations were detected (especially in K-/NRAS) with implications for anti-EGFR therapy approaches. Further potentially therapeutic alterations were detected in FGFR1, MET, PDGFRA, and erbB2/HER2. Additionally, PD-L1 tumor cell expression (clone: 22C3) was demonstrated in 16% of cases, therefore making anti-PD-1/PD-L1 immuno-oncological approaches worth considering despite the absence of mismatch repair deficiency (MMR-d) and/or high microsatellite instability (MSI-h). Finally, urachal adenocarcinomas seem to be adistinct entity on the molecular level with closer resemblance to colorectal adenocarcinomas than to urothelial carcinomas.	[Reis, H.] Univ Duisburg Essen, Westdeutsch Tumorzentrum Essen, Univ Med Essen, Inst Pathol, Hufelandstr 55, D-45147 Essen, Germany; [Szarvas, T.] Univ Duisburg Essen, Westdeutsch Tumorzentrum Essen, Univ Med Essen, Urol Klin, Essen, Germany; [Szarvas, T.] Semmelweis Univ, Urol Klin, Budapest, Hungary	Reis, H (reprint author), Univ Duisburg Essen, Westdeutsch Tumorzentrum Essen, Univ Med Essen, Inst Pathol, Hufelandstr 55, D-45147 Essen, Germany.	Henning.Reis@uk-essen.de		Reis, Henning/0000-0003-1373-5295			Aggen DH, 2017, J IMMUNOTHER CANCER, V5, DOI 10.1186/s40425-017-0299-1; Amin MB, 2014, AM J SURG PATHOL, V38, P1033, DOI 10.1097/PAS.0000000000000250; Ashley RA, 2006, CANCER, V107, P712, DOI 10.1002/cncr.22060; Bang YJ, 2010, LANCET, V376, P1302; Begg RC, 1930, J ANAT, V64, P170; Boland CR, 2010, GASTROENTEROLOGY, V138, P2073, DOI 10.1053/j.gastro.2009.12.064; Bruins HM, 2012, J UROLOGY, V188, P1102, DOI 10.1016/j.juro.2012.06.020; Cha S, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2209-1; Collazo-Lorduy A, 2016, EUR UROL, V70, P771, DOI 10.1016/j.eururo.2016.04.037; Cullen TS, 1916, EMBRYOLOGY ANATOMY D; Dhillon J, 2015, HUM PATHOL, V46, P1808, DOI 10.1016/j.humpath.2015.07.021; Gopalan A, 2009, AM J SURG PATHOL, V33, P659, DOI 10.1097/PAS.0b013e31819aa4ae; GRIGNON DJ, 1991, CANCER-AM CANCER SOC, V67, P2165, DOI 10.1002/1097-0142(19910415)67:8<2165::AID-CNCR2820670827>3.0.CO;2-M; Hang JF, 2017, PATHOLOGY, V49, P316, DOI 10.1016/j.pathol.2016.11.017; Herr HW, 2007, J UROLOGY, V178, P74, DOI 10.1016/j.juro.2007.03.022; Hue, 1863, UNION MED, V6, P418; Iyer G, 2017, J CLIN ONCOL, V35, DOI 10.1200/JCO.2017.35.15_suppl.4511; Jung HA, 2014, CHEMOTHERAPY, V60, P73, DOI 10.1159/000368071; Kardos J, 2017, JCO PRECIS ONCOL, P1; Kim IK, 2014, KOREAN J UROL, V55, P574, DOI 10.4111/kju.2014.55.9.574; Loh KP, 2016, CLIN GENITOURIN CANC, V14, pE449, DOI 10.1016/j.clgc.2016.03.013; Lopez-Beltran A, 2016, WHO CLASSIFICATION T, P113; Modos O, 2016, ONCOTARGET, V7, P39293, DOI 10.18632/oncotarget.9828; MOSTOFI FK, 1955, CANCER-AM CANCER SOC, V8, P741, DOI 10.1002/1097-0142(1955)8:4<741::AID-CNCR2820080417>3.0.CO;2-C; Muzny DM, 2012, NATURE, V487, P330, DOI 10.1038/nature11252; Niedworok C, 2016, J UROLOGY, V195, P1690, DOI 10.1016/j.juro.2015.11.067; Nyirady P, 2016, EUR UROL, V70, P776, DOI 10.1016/j.eururo.2016.07.004; Paner GP, 2016, ADV ANAT PATHOL, V23, P71, DOI 10.1097/PAP.0000000000000110; Paner GP, 2012, AM J SURG PATHOL, V36, P432, DOI 10.1097/PAS.0b013e31823fe49c; Pinthus JH, 2006, J UROLOGY, V175, P2042, DOI 10.1016/S0022-5347(06)00263-1; Reis H, 2018, INT J CANCER, V143, P1764, DOI 10.1002/ijc.31547; Reis H, 2018, DIS MARKERS, DOI 10.1155/2018/7308168; SCHUBERT GE, 1982, J UROLOGY, V127, P40, DOI 10.1016/S0022-5347(17)53595-8; SHELDON CA, 1984, J UROLOGY, V131, P1, DOI 10.1016/S0022-5347(17)50167-6; Siefker-Radtke AO, 2003, J UROLOGY, V169, P1295, DOI 10.1097/01.ju.0000054646.49381.01; Siefker-Radtke A, 2006, EXPERT REV ANTICANC, V6, P1715, DOI 10.1586/14737140.6.12.1715; Siefker-Radtke A, 2012, SEMIN ONCOL, V39, P619, DOI 10.1053/j.seminoncol.2012.08.011; Singh H, 2016, ONCOTARGET, V7, P29211, DOI 10.18632/oncotarget.8640; Sirintrapun SJ, 2014, HUM PATHOL, V45, P327, DOI 10.1016/j.humpath.2013.09.008; Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101; Szarvas T, 2016, UROL ONCOL-SEMIN ORI, V34, P388, DOI 10.1016/j.urolonc.2016.04.012; Therkildsen C, 2014, ACTA ONCOL, V53, P852, DOI 10.3109/0284186X.2014.895036; Thiem S, 2017, PATHOL INT, V67, P597, DOI 10.1111/pin.12594; Upadhyay V, 2003, EUR J PEDIATR SURG, V13, P372; Vinagre J, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3185; Weinstein JN, 2014, NATURE, V507, P315, DOI 10.1038/nature12965; WHEELER JD, 1954, CANCER-AM CANCER SOC, V7, P119, DOI 10.1002/1097-0142(195401)7:1<119::AID-CNCR2820070113>3.0.CO;2-8; Wright JL, 2006, CANCER, V107, P721, DOI 10.1002/cncr.22059; Wu S, 2014, EUR UROL, V65, P274, DOI 10.1016/j.eururo.2013.10.038; Yanagihara Y, 2013, CHEMOTHERAPY, V59, P402, DOI 10.1159/000362400	50	1	1	2	3	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	0172-8113	1432-1963		PATHOLOGE	Pathologe	DEC	2018	39			2			291	300		10.1007/s00292-018-0498-7			10	Pathology	Pathology	HE6XV	WOS:000453565100021	30470871				2019-10-28	
J	Rocken, C				Roecken, C.			Amyloid Registry Kiel. An interim balance	PATHOLOGE			German	Article						Amyloidosis; Immunohistochemistry; Molecular biology; Polarization microscopy; Carpal tunnel syndrome	LIGHT-CHAIN AMYLOIDOSIS	Amyloid is apathologic fibrillar aggregation of polypeptides in across--sheet conformation. Amyloidoses are caused by the deposition of amyloid and may occur as cerebal and extracerebral diseases. A total of 35 different amyloid proteins have been identified. The Amyloid Registry Kiel was founded in 2009at the Department of Pathology of the Christian-Albrechts-University Kiel. It currently houses more than 6700 cases of diverse anatomical origin with histologically confirmed amyloid and amyloidosis. This large series of cases provides unique insights into an otherwise rare disease. This includes the validation of novel dyes for the histological recognition and diagnosis of amyloid (luminescent conjugated polythiophenes), the in-depth analysis of amyloid associated with carpal tunnel syndrome, the distribution pattern of diverse amyloids in biopsies of the gastrointestinal tract and the prognostic significance of immunoglobulin light chain-derived AL amyloid load in cardiac biopsies. Finally, the application of MALDI (matrix-assisted laser desorption/ionization) mass spectrometry imaging provided valuable insights into the complexity of amyloid deposits, which consist of adiagnostic disease-specific and amyloid-specific protein/peptide mixture.	[Roecken, C.] Christian Albrechts Univ Kiel, Inst Pathol, Univ Klinikum Schleswig Holstein, Campus Kiel,Arnold Heller Str 3-14, D-24105 Kiel, Germany	Rocken, C (reprint author), Christian Albrechts Univ Kiel, Inst Pathol, Univ Klinikum Schleswig Holstein, Campus Kiel,Arnold Heller Str 3-14, D-24105 Kiel, Germany.	christoph.roecken@uksh.de	Rocken, Christoph/A-9239-2010	Rocken, Christoph/0000-0002-6989-8002			Eriksson M, 2009, AM J SURG PATHOL, V33, P58, DOI 10.1097/PAS.0b013e3181788566; Freudenthaler S, 2016, VIRCHOWS ARCH, V468, P569, DOI 10.1007/s00428-016-1916-y; Gioeva Z, 2013, AMYLOID, V20, P1, DOI 10.3109/13506129.2012.750604; Hahn K, 2017, AMYLOID, V24, P78, DOI 10.1080/13506129.2017.1316711; Hund E, 2018, TRANSTHYRETIN AMYLOI; Kristen AV, 2016, J AM COLL CARDIOL, V68, P13, DOI 10.1016/j.jacc.2016.04.035; Linke RP, 2000, VIRCHOWS ARCH, V436, P439, DOI 10.1007/s004280050471; Mahmood S, 2015, LANCET HAEMATOL, V2, pE241, DOI 10.1016/S2352-3026(15)00068-X; Merlini G, 2003, NEW ENGL J MED, V349, P583, DOI 10.1056/NEJMra023144; Nilsson KPR, 2010, AM J PATHOL, V176, P563, DOI 10.2353/ajpath.2010.080797; Nilsson KPR, 2009, FEBS LETT, V583, P2593, DOI 10.1016/j.febslet.2009.04.016; Nilsson KPR, 2005, BIOCHEMISTRY-US, V44, P3718, DOI 10.1021/bi047402u; Rocken C, 2009, PATHOLOGE, V30, P182, DOI 10.1007/s00292-009-1128-1; Rocken C, 2015, LANCET HAEMATOL, V2, pE225, DOI 10.1016/S2352-3026(15)00071-X; Sipe JD, 2016, AMYLOID, V23, P209, DOI 10.1080/13506129.2016.1257986; Sjolander D, 2016, AMYLOID, V23, P98, DOI 10.3109/13506129.2016.1158159; Winter M, 2017, PROTEOMICS, V17, DOI 10.1002/pmic.201700236; Winter M, 2015, J HISTOCHEM CYTOCHEM, V63, P772, DOI 10.1369/0022155415595264	18	0	0	0	3	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	0172-8113	1432-1963		PATHOLOGE	Pathologe	DEC	2018	39			2			301	305		10.1007/s00292-018-0515-x			5	Pathology	Pathology	HE6XV	WOS:000453565100022	30302563				2019-10-28	
J	Ripperger, T; Schlegelberger, B				Ripperger, T.; Schlegelberger, B.			Genetic predisposition to childhood cancer	PATHOLOGE			German	Article						DNA mismatch repair; Genetic predisposition to disease; Genetic counselling; Early detection of cancer; Li-Fraumeni syndrome	MISMATCH REPAIR-DEFICIENCY; SUSCEPTIBILITY; INDIVIDUALS; FAMILIES	Tackling the topic of genetic predisposition to childhood cancer requires close co-operation between pathologists, pediatric oncologists, and human geneticists. It is not just about the precise diagnosis and the most effective treatment of the cancer, but also to prevent further cancerous diseases for those affected and also their family members. On the basis of examples such as Li-Fraumeni syndrome, constitutional mismatch repair deficiency (CMMRD), medullo- and neuroblastoma, as well as hematological neoplasias, we will discuss the criteria for tumor predisposition genetic syndromes, the relationship between somatic and germline variants, and the immediate clinical consequences. In some cases, the diagnosis of agenetic tumor predisposition syndrome has immediate consequences for the treatment, e.g. to avoid radiotherapy for Li-Fraumeni syndrome, which would otherwise significantly increase the probability of secondary, independent tumors. Predictive diagnostics can be offered to identify the family members who carry the pathogenic variant. Because of their increased tumor risk, they should be integrated into cancer surveillance programs. Evidence-based data show that this significantly improves overall survival.	[Ripperger, T.; Schlegelberger, B.] Hannover Med Sch, Inst Humangenet, Carl Neuberg Str 1, D-30625 Hannover, Germany	Schlegelberger, B (reprint author), Hannover Med Sch, Inst Humangenet, Carl Neuberg Str 1, D-30625 Hannover, Germany.	Schlegelberger.Brigitte@mh-hannover.de					Agaimy A, 2018, SEMIN DIAGN PATHOL, V35, P193, DOI 10.1053/j.semdp.2018.01.002; Churchman ML, 2018, CANCER CELL, V33, P937, DOI 10.1016/j.ccell.2018.03.021; Grobner SN, 2018, NATURE, V555, P321, DOI 10.1038/nature25480; Jarvinen HJ, 2000, GASTROENTEROLOGY, V118, P829, DOI 10.1016/S0016-5085(00)70168-5; Jongmans MCJ, 2016, EUR J MED GENET, V59, P116, DOI 10.1016/j.ejmg.2016.01.008; Mosse YP, 2008, NATURE, V455, P930, DOI 10.1038/nature07261; Oldridge DA, 2015, NATURE, V528, P418, DOI 10.1038/nature15540; Ripperger T, 2009, LEUKEMIA, V23, P1364, DOI 10.1038/leu.2009.87; Ripperger T, 2018, HAEMATOLOGICA, V103, pE55, DOI 10.3324/haematol.2017.178723; Ripperger T, 2017, AM J MED GENET A, V173, P1017, DOI 10.1002/ajmg.a.38142; Ripperger T, 2016, EUR J HUM GENET, V24, DOI 10.1038/ejhg.2015.278; Ripperger T, 2011, HAEMATOL-HEMATOL J, V96, P1892, DOI 10.3324/haematol.2011.053710; Ripperger T, 2010, HAEMATOL-HEMATOL J, V95, P841, DOI 10.3324/haematol.2009.015503; Schlegelberger B, 2015, PEDIATR BLOOD CANCER, V62, P1481, DOI 10.1002/pbc.25486; Shah S, 2013, NAT GENET, V45, P1226, DOI 10.1038/ng.2754; Stanulla M, 2018, J CLIN ONCOL, V36, P1240, DOI 10.1200/JCO.2017.74.3617; Tolbert VP, 2017, CURR OPIN GENET DEV, V42, P81, DOI 10.1016/j.gde.2017.03.008; Vasen HFA, 2014, J MED GENET, V51, P283, DOI 10.1136/jmedgenet-2013-102238; Waszak SM, 2018, LANCET ONCOL, V19, P785, DOI 10.1016/S1470-2045(18)30242-0; Wlodarski MW, 2016, BLOOD, V127, P1387, DOI 10.1182/blood-2015-09-669937	20	0	0	0	4	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	0172-8113	1432-1963		PATHOLOGE	Pathologe	DEC	2018	39			2			306	310		10.1007/s00292-018-0542-7			5	Pathology	Pathology	HE6XV	WOS:000453565100023	30397787	Other Gold			2019-10-28	
J	Timme-Bronsert, S; Bronsert, P; Werner, M; Kulemann, B; Hoppner, J				Timme-Bronsert, S.; Bronsert, P.; Werner, M.; Kulemann, B.; Hoeppner, J.			Circulating tumor cells in pancreatic cancer. Results of morphological and molecular analyses and comparisons with the primary tumor	PATHOLOGE			German	Article						Pancreatic ductal carcinoma; Genetic testing; Mutation; Prognosis; Circulating neoplastic cells	PROGRESSION; STATISTICS	BackgroundPancreatic ductal adenocarcinoma (PDAC) is adisease with apoor prognosis. PDAC shows characteristic mutations within codon 12/13. Circulating tumor cells (CTC) detected in blood samples of patients with cancer are hypothesized as the means of systemic tumor spread. But less is known about morphological/molecular characteristics or the pathophysiological meaning of PDAC CTC.ObjectivesThe aim of the study was acytomorphological and genetic analysis of CTC from patients with PDAC followed by the correlation of the results with those of the corresponding tumor in the pancreas.Material and methodsBlood samples of 58patients with PDAC and 10 normal control donors were processed through a size-based CTC isolation. KRAS-mutation analyses were performed for CTC and the primary tumor and the results were compared. Furthermore, their potential as aprognostic marker was evaluated.ResultsIn patients with different UICC stages CTC were detected, but not in normal control patients. There was atrend for aworse median overall survival (OS) for patients with >3CTC/ml. Patients with aKRAS(G12V) mutation showed atrend for abetter median OS compared to those with other KRAS mutations (10months) or even without KRAS mutation. Fifty-eight percent of the patients presented concordant KRAS mutations in the primary tumor and corresponding CTC, while 42% were discordant. The median OS for both groups was similar.ConclusionsDetection and characterization of CTC (for example by KRAS mutation analysis) may be useful for prognosis. Furthermore, it expands our knowledge of tumor biology and may detect possible tumor heterogeneity regarding the mutation profile of some cancer types.	[Timme-Bronsert, S.; Bronsert, P.; Werner, M.] Univ Klinikum Freiburg, Inst Klin Pathol, Breisacher Str 115A, D-79106 Freiburg, Germany; [Kulemann, B.; Hoeppner, J.] Univ Klinikum Freiburg, Dept Allgemein & Viszeralchirurg, Freiburg, Germany; [Timme-Bronsert, S.; Bronsert, P.; Werner, M.; Kulemann, B.; Hoeppner, J.] Albert Ludwigs Univ Freiburg, Med Fak, Freiburg, Germany; [Bronsert, P.; Werner, M.] Univ Klinikum Freiburg, Biobank Tumorzentrum Freiburg, Freiburg, Germany	Timme-Bronsert, S (reprint author), Univ Klinikum Freiburg, Inst Klin Pathol, Breisacher Str 115A, D-79106 Freiburg, Germany.	sylvia.timme@uniklinik-freiburg.de					Ankeny JS, 2016, BRIT J CANCER, V114, P1367, DOI 10.1038/bjc.2016.121; Cauley CE, 2015, J AM COLL SURGEONS, V221, P699, DOI 10.1016/j.jamcollsurg.2015.05.014; Cohen SJ, 2009, ANN ONCOL, V20, P1223, DOI 10.1093/annonc/mdn786; Conroy T, 2011, NEW ENGL J MED, V364, P1817, DOI 10.1056/NEJMoa1011923; Cristofanilli M, 2004, NEW ENGL J MED, V351, P781, DOI 10.1056/NEJMoa040766; Jemal A, 2010, CA-CANCER J CLIN, V60, P277, DOI [10.3322/caac.20073, 10.1002/caac.20073]; Klein CA, 2009, NAT REV CANCER, V9, P302, DOI 10.1038/nrc2627; Kulemann B, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-04601-z; Kulemann B, 2016, TUMOR BIOL, V37, P7547, DOI 10.1007/s13277-015-4589-2; Kulemann B, 2015, PANCREAS, V44, P547, DOI 10.1097/MPA.0000000000000324; Muller V, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3243; Pailler E, 2013, J CLIN ONCOL, V31, P2273, DOI 10.1200/JCO.2012.44.5932; Panteleakou Z, 2009, MOL MED, V15, P101, DOI 10.2119/molmed.2008.00116; Rhim AD, 2012, CELL, V148, P349, DOI 10.1016/j.cell.2011.11.025; Siegel RL, 2015, CA-CANCER J CLIN, V65, P5, DOI 10.3322/caac.21254	15	0	0	0	2	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	0172-8113	1432-1963		PATHOLOGE	Pathologe	DEC	2018	39			2			311	314		10.1007/s00292-018-0550-7			4	Pathology	Pathology	HE6XV	WOS:000453565100024	30483865				2019-10-28	
J	Wickenhauser, C				Wickenhauser, C.			WHO classification of myeloid neoplasms	PATHOLOGE			German	Review						DNA sequence analysis; High-throughput nucleotide sequencing; Myelodysplastic-myeloproliferative diseases; Myeloid leukemia; World Health Organization	CSF3R MUTATIONS; LEUKEMIA; MANAGEMENT; REVISION; PROPOSAL	In 2014, two advisory committees (one each for myeloid and lymphoid neoplasms) of about 100 pathologists, hematologists, oncologists, and geneticists met in Chicago to revise the WHO diagnostic criteria. The goal was to define disease entities that should be modified, removed, or added based on new insights. In particular, to improve a biologically meaningful classification, a number of new molecular genetic markers were included, which had proved to be of diagnostic and/or prognostic relevance. The resulting differentiated diagnostic procedure is a challenge for the hematopathologist. Not only is it necessary to pool the information from a multimodal diagnostic process and to compare the results of morphology, immunophenotyping, and clinical information. It is also essential to integrate the techniques of fluorescence in situ hybridization and next generation sequencing into the diagnostic process. Hematopathological diagnostics have become more labor-intensive and cost-intensive as a result of this further differentiation.	[Wickenhauser, C.] Univ Klinikum Halle Saale, Inst Pathol, Magdeburger Str 14, D-06112 Halle, Saale, Germany	Wickenhauser, C (reprint author), Univ Klinikum Halle Saale, Inst Pathol, Magdeburger Str 14, D-06112 Halle, Saale, Germany.	claudia.wickenhauser@uk-halle.de					Arber DA, 2016, BLOOD, V127, P2391, DOI 10.1182/blood-2016-03-643544; Baccarani M, 2013, BLOOD, V122, P872, DOI 10.1182/blood-2013-05-501569; Barbui T, 2014, AM J HEMATOL, V89, P52, DOI 10.1002/ajh.23585; Deininger Michael W, 2015, Am Soc Clin Oncol Educ Book, pe381, DOI 10.14694/EdBook_AM.2015.35.e381; Gambacorti-Passerini CB, 2015, BLOOD, V125, P499, DOI 10.1182/blood-2014-06-579466; Gerstung M, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms6901; Gisslinger H, 2017, LEUKEMIA, V31, P774, DOI 10.1038/leu.2016.291; Haferlach C, 2009, BLOOD, V114, P3024, DOI 10.1182/blood-2009-01-197871; Haferlach T, 2014, LEUKEMIA, V28, P241, DOI 10.1038/leu.2013.336; HARRIS NL, 1994, BLOOD, V84, P1361; Harris NL, 2000, ANN ONCOL, V11, P3, DOI 10.1023/A:1008383406103; Hehlmann R, 2015, ANN HEMATOL, V94, pS103, DOI 10.1007/s00277-015-2331-1; Itzykson R, 2013, J CLIN ONCOL, V31, P2428, DOI 10.1200/JCO.2012.47.3314; Jaiswal S, 2014, NEW ENGL J MED, V371, P2488, DOI 10.1056/NEJMoa1408617; Malcovati L, 2015, BLOOD, V126, P233, DOI 10.1182/blood-2015-03-633537; Maxson JE, 2013, NEW ENGL J MED, V368, P1781, DOI 10.1056/NEJMoa1214514; Papaemmanuil E, 2013, BLOOD, V122, P3616, DOI 10.1182/blood-2013-08-518886; Patnaik MM, 2016, BLOOD CANCER J, V6, DOI 10.1038/bcj.2016.5; Piazza R, 2013, NAT GENET, V45, P18, DOI 10.1038/ng.2495; Schanz J, 2012, J CLIN ONCOL, V30, P820, DOI 10.1200/JCO.2011.35.6394; Schlenk RF, 2013, BLOOD, V122, P1576, DOI 10.1182/blood-2013-05-503847; Swerdlow SH, 2008, WHO CLASSIFICATION T; Tefferi A, 2014, LEUKEMIA, V28, P1407, DOI 10.1038/leu.2014.35; Thiele J, 2011, BLOOD, V117, P5710, DOI 10.1182/blood-2010-07-293761; Valent P, 2015, HEMATOL-AM SOC HEMAT, P98, DOI 10.1182/asheducation-2015.1.98	25	0	0	0	1	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	0172-8113	1432-1963		PATHOLOGE	Pathologe	DEC	2018	39			2			315	318		10.1007/s00292-018-0534-7			4	Pathology	Pathology	HE6XV	WOS:000453565100025	30374757				2019-10-28	
J	Bierhoff, E				Bierhoff, E.			Minutes of the Working Group on Dermatopathology 102nd Annual Congress of the German Society of Pathology, Berlin	PATHOLOGE			German	Editorial Material									[Bierhoff, E.] Heinz Werner Seifert Inst Dermatopathol, Trierer Str 70, D-53115 Bonn, Germany	Bierhoff, E (reprint author), Heinz Werner Seifert Inst Dermatopathol, Trierer Str 70, D-53115 Bonn, Germany.	erhard.bierhoff@t-online.de						0	0	0	0	0	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	0172-8113	1432-1963		PATHOLOGE	Pathologe	DEC	2018	39			2			319	321		10.1007/s00292-018-0488-9			3	Pathology	Pathology	HE6XV	WOS:000453565100026	30151784				2019-10-28	
J	Tannapfel, A				Tannapfel, A.			Meeting of the Gastroenteropathology Working Group on 24th May 2018 102nd Annual Conference of the German Society of Pathology in Berlin	PATHOLOGE			German	Editorial Material									[Tannapfel, A.] Ruhr Univ Bochum, Inst Pathol, Burkle de la Camp Pl 1, D-44789 Bochum, Germany	Tannapfel, A (reprint author), Ruhr Univ Bochum, Inst Pathol, Burkle de la Camp Pl 1, D-44789 Bochum, Germany.	Andrea.tannapfel@pathologie-bochum.de						0	0	0	0	0	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	0172-8113	1432-1963		PATHOLOGE	Pathologe	DEC	2018	39			2			322	323		10.1007/s00292-018-0484-0			2	Pathology	Pathology	HE6XV	WOS:000453565100027	30132133				2019-10-28	
J	Braunschweig, T; Schierle, K				Braunschweig, T.; Schierle, K.			Meeting of the Working Group on the History of Pathology 102nd Annual Congress of the German Society of Pathology	PATHOLOGE			German	Editorial Material									[Braunschweig, T.] Uniklin RWTH Aachen, Inst Pathol, Pauwelsstr 30, D-52074 Aachen, Germany; [Schierle, K.] Univ Klinikum Leipzig, Inst Pathol, Liebigstr 26, D-04103 Leipzig, Germany	Braunschweig, T (reprint author), Uniklin RWTH Aachen, Inst Pathol, Pauwelsstr 30, D-52074 Aachen, Germany.; Schierle, K (reprint author), Univ Klinikum Leipzig, Inst Pathol, Liebigstr 26, D-04103 Leipzig, Germany.	tbraunschweig@ukaachen.de; katrin.schierle@medizin.uni-leipzig.de						0	0	0	0	0	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	0172-8113	1432-1963		PATHOLOGE	Pathologe	DEC	2018	39			2			324	324		10.1007/s00292-018-0481-3			1	Pathology	Pathology	HE6XV	WOS:000453565100028	30120509	Bronze			2019-10-28	
J	Mayr, D				Mayr, D.			Minutes of the Working Group on Gynecopathology and Breast Pathology, 24th May 2018 102nd Annual Congress of the German Society of Pathology	PATHOLOGE			German	Editorial Material									[Mayr, D.] Ludwig Maximilians Univ Munchen, Med Fak, Pathol Inst, Thalkirchner Str 36, D-80337 Munich, Germany	Mayr, D (reprint author), Ludwig Maximilians Univ Munchen, Med Fak, Pathol Inst, Thalkirchner Str 36, D-80337 Munich, Germany.	doris.mayr@med.uni-muenchen.de						0	0	0	0	0	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	0172-8113	1432-1963		PATHOLOGE	Pathologe	DEC	2018	39			2			325	327		10.1007/s00292-018-0480-4			3	Pathology	Pathology	HE6XV	WOS:000453565100029	30203217				2019-10-28	
J	Fend, F				Fend, F.			Report by the Haematopathology Working Group of the German Society of Pathology Annual Meeting 2018	PATHOLOGE			German	Editorial Material									[Fend, F.] Eberhard Karls Univ Tubingen, Univ Klinikum Tubingen, Inst Pathol & Neuropathol, Liebermeisterstr 8, D-72076 Tubingen, Germany	Fend, F (reprint author), Eberhard Karls Univ Tubingen, Univ Klinikum Tubingen, Inst Pathol & Neuropathol, Liebermeisterstr 8, D-72076 Tubingen, Germany.	falko.fend@med.uni-tuebingen.de						0	0	0	0	1	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	0172-8113	1432-1963		PATHOLOGE	Pathologe	DEC	2018	39			2			328	328		10.1007/s00292-018-0537-4			1	Pathology	Pathology	HE6XV	WOS:000453565100030	30397785	Bronze			2019-10-28	
J	Baba, HA; Bohle, RM				Baba, H. A.; Bohle, R. M.			Report on the Meeting of the Working Group on Cardiac, Vascular, Renal, and Transplantation Pathology	PATHOLOGE			German	Editorial Material									[Baba, H. A.] Univ Klinikum Essen, Inst Pathol, Hufelandstr 55, D-45147 Essen, Germany; [Bohle, R. M.] Univ Klinikum Saarlandes, Inst Pathol, Kirrberger Str 100, D-66421 Homburg, Germany	Baba, HA (reprint author), Univ Klinikum Essen, Inst Pathol, Hufelandstr 55, D-45147 Essen, Germany.; Bohle, RM (reprint author), Univ Klinikum Saarlandes, Inst Pathol, Kirrberger Str 100, D-66421 Homburg, Germany.	Hideo.Baba@uk-essen.de; rainer.bohle@uniklinikum-saarland.de						0	0	0	0	0	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	0172-8113	1432-1963		PATHOLOGE	Pathologe	DEC	2018	39			2			329	329		10.1007/s00292-018-0491-1			1	Pathology	Pathology	HE6XV	WOS:000453565100031	30203216				2019-10-28	
J	Kayser, G; Haroske, G				Kayser, G.; Haroske, G.			Annual Report 2017/18 of the Working Group on Informatics, digital Pathology and Biobanks	PATHOLOGE			German	Editorial Material									[Kayser, G.] Univ Klinikum Freiburg, Dept Pathol, Inst Klin Pathol, Breisacher Str 115a, D-79106 Freiburg, Germany; [Haroske, G.] Klinikum Dresden Friedrichstadt, Inst Pathol Georg Schmorl, Friedrichstr 41, D-01067 Dresden, Germany	Kayser, G (reprint author), Univ Klinikum Freiburg, Dept Pathol, Inst Klin Pathol, Breisacher Str 115a, D-79106 Freiburg, Germany.; Haroske, G (reprint author), Klinikum Dresden Friedrichstadt, Inst Pathol Georg Schmorl, Friedrichstr 41, D-01067 Dresden, Germany.	gian.kayser@uniklinik-freiburg.de; haroske@icloud.com						0	0	0	0	0	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	0172-8113	1432-1963		PATHOLOGE	Pathologe	DEC	2018	39			2			330	330		10.1007/s00292-018-0514-y			1	Pathology	Pathology	HE6XV	WOS:000453565100032	30259104				2019-10-28	
J	Gurtl-Lackner, B				Gurtl-Lackner, B.			Report by the Working Group on Paediatric and Fetal Pathology of the German Society of Pathology Annual Meeting 2018	PATHOLOGE			German	Editorial Material									[Gurtl-Lackner, B.] Karolinska Univ Klinikum, Inst Pathol, Karolinska Vagen 20, S-17164 Stockholm, Sweden	Gurtl-Lackner, B (reprint author), Karolinska Univ Klinikum, Inst Pathol, Karolinska Vagen 20, S-17164 Stockholm, Sweden.	barbara.guertl-lackner@medunigraz.at						0	0	0	0	0	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	0172-8113	1432-1963		PATHOLOGE	Pathologe	DEC	2018	39			2			331	332		10.1007/s00292-018-0538-3			2	Pathology	Pathology	HE6XV	WOS:000453565100033	30374756				2019-10-28	
J	Scheil-Bertram, S; Wardelmann, E				Scheil-Bertram, S.; Wardelmann, E.			Minutes of the Meeting of the Working Group on Bone, Joint, and Soft Tissue Pathology DGP Congress on 24th May 2018, Berlin	PATHOLOGE			German	Editorial Material									[Scheil-Bertram, S.] HELIOS HSK Wiesbaden, Inst Pathol & Zytol, Ludwig Erhard Str 100, D-65199 Wiesbaden, Germany; [Wardelmann, E.] Univ Klinikum Munster, Gerhard Domagk Inst Pathol, Munster, Germany	Scheil-Bertram, S (reprint author), HELIOS HSK Wiesbaden, Inst Pathol & Zytol, Ludwig Erhard Str 100, D-65199 Wiesbaden, Germany.	scheil-bertram@pathologie-wiesbaden.de					Bhangu A. A., 2004, Sarcoma, V8, P1, DOI 10.1080/13577140410001679185; Casali PG, 2018, ANN ONCOL, V29, P51, DOI 10.1093/annonc/mdy096; Krenn V, 2014, PATHOL RES PRACT, V210, P779, DOI 10.1016/j.prp.2014.09.017; Krenn VT, 2017, PATHOL RES PRACT, V213, P541, DOI 10.1016/j.prp.2017.01.002; Meazza C, 2016, CANCER MED-US, V5, P1204, DOI 10.1002/cam4.669; Musa J, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.244; O'Donnell PW, 2014, CANCER-AM CANCER SOC, V120, P2866, DOI 10.1002/cncr.28793; Trovik Clement S., 2012, Sarcoma, P290698, DOI 10.1155/2012/290698; Venkataramani V, 2018, CLIN CANCER RES, V24, P460, DOI 10.1158/1078-0432.CCR-17-1778	9	0	0	0	0	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	0172-8113	1432-1963		PATHOLOGE	Pathologe	DEC	2018	39			2			333	337		10.1007/s00292-018-0499-6			5	Pathology	Pathology	HE6XV	WOS:000453565100034	30229284				2019-10-28	
J	Agaimy, A				Agaimy, A.			Report on the Session of the Head and Neck Pathology Working Group on 24th May 2018 at the 102nd Annual Meeting of the DGP in Berlin	PATHOLOGE			German	Editorial Material									[Agaimy, A.] Univ Klinikum Erlangen, Inst Pathol, Krankenhausstr 8-10, D-91054 Erlangen, Germany	Agaimy, A (reprint author), Univ Klinikum Erlangen, Inst Pathol, Krankenhausstr 8-10, D-91054 Erlangen, Germany.	abbas.agaimy@uk-erlangen.de						0	0	0	0	0	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	0172-8113	1432-1963		PATHOLOGE	Pathologe	DEC	2018	39			2			338	338		10.1007/s00292-018-0547-2			1	Pathology	Pathology	HE6XV	WOS:000453565100035	30377785				2019-10-28	
J	Haller, F; Lassmann, S; Siebolts, U				Haller, F.; Lassmann, S.; Siebolts, U.			Report of the Molecular Pathology Working Group	PATHOLOGE			German	Editorial Material									[Haller, F.] Univ Klinikum Erlangen, Inst Pathol, Erlangen, Germany; [Lassmann, S.] Univ Klinikum Freiburg, Inst Klin Pathol, Freiburg, Germany; [Siebolts, U.] Univ Klinikum Halle, Inst Pathol, Halle, Germany	Haller, F (reprint author), Univ Klinikum Erlangen, Inst Pathol, Erlangen, Germany.	florian.haller@uk-erlangen.de						0	0	0	0	0	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	0172-8113	1432-1963		PATHOLOGE	Pathologe	DEC	2018	39			2			339	340		10.1007/s00292-018-0511-1			2	Pathology	Pathology	HE6XV	WOS:000453565100036	30259103				2019-10-28	
J	Fisseler-Eckhoff, A				Fisseler-Eckhoff, A.			Report of the Working Group on Thoracic Pathology of the German Society of Pathology 2018	PATHOLOGE			German	Editorial Material							PULMONARY PATHOLOGY		[Fisseler-Eckhoff, A.] Helios HSKWiesbaden, Inst Pathol & Zytol, Ludwig Erhard Str 100, D-65199 Wiesbaden, Germany; [Fisseler-Eckhoff, A.] Gemeinschaftspraxis Pathol Wiesbaden, Wiesbaden, Germany	Fisseler-Eckhoff, A (reprint author), Helios HSKWiesbaden, Inst Pathol & Zytol, Ludwig Erhard Str 100, D-65199 Wiesbaden, Germany.	Annette.Fisseler-Eckhoff@helios-gesundheit.de					Bettendorf U, 2009, PATHOLOGE, V30, P20, DOI [10.1007/s00292-009-1179-3, 10.1007/s00292-008-1121-0, 10.1007/s00292-009-1195-3]; Fink L, 2015, PATHOLOGE, V36, P237, DOI 10.1007/s00292-015-0068-1; Fisseler-Eckhoff A, 2017, PATHOLOGE, V38, pS242, DOI 10.1007/s00292-017-0347-0; Junker K, 2014, PATHOLOGE, V35, P300, DOI 10.1007/s00292-014-1957-4; Junker K, 2013, PATHOLOGE, V34, P304, DOI 10.1007/s00292-013-1817-7; Schnabel PA, 2012, PATHOLOGE, V33, P351, DOI [10.1007/s00292-012-1644-2, 10.1007/s00292-011-1512-5]	6	0	0	0	0	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	0172-8113	1432-1963		PATHOLOGE	Pathologe	DEC	2018	39			2			341	343		10.1007/s00292-018-0489-8			3	Pathology	Pathology	HE6XV	WOS:000453565100037	30302561				2019-10-28	
J	Gaisa, NT; Kristiansen, G; Wild, PJ				Gaisa, N. T.; Kristiansen, G.; Wild, P. J.			Meeting Report of the Uropathology Working Group of the German Society of Pathology, 2018	PATHOLOGE			German	Editorial Material									[Gaisa, N. T.] Rhein Westfal TH Aachen, Inst Pathol, Pauwelsstr 30, D-52074 Aachen, Germany; [Kristiansen, G.] Univ Klinikum Bonn, Inst Pathol, Siegmund Freud Str 25, D-53127 Bonn, Germany; [Wild, P. J.] Klinikum Goethe Univ Frankfurt, Dr Senckenberg Inst Pathol, Theodor Stern Kai 7, D-60590 Frankfurt, Germany	Gaisa, NT (reprint author), Rhein Westfal TH Aachen, Inst Pathol, Pauwelsstr 30, D-52074 Aachen, Germany.; Kristiansen, G (reprint author), Univ Klinikum Bonn, Inst Pathol, Siegmund Freud Str 25, D-53127 Bonn, Germany.; Wild, PJ (reprint author), Klinikum Goethe Univ Frankfurt, Dr Senckenberg Inst Pathol, Theodor Stern Kai 7, D-60590 Frankfurt, Germany.	ngaisa@ukaachen.de; Glen.Kristiansen@ukb.uni-bonn.de; Peter.Wild@kgu.de						0	0	0	0	0	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	0172-8113	1432-1963		PATHOLOGE	Pathologe	DEC	2018	39			2			344	345		10.1007/s00292-018-0482-2			2	Pathology	Pathology	HE6XV	WOS:000453565100038	30120511				2019-10-28	
J	Schmidt, D				Schmidt, D.			Meeting of the Working Group on Cytopathology of the German Society of Pathology, 2018	PATHOLOGE			German	Editorial Material									[Schmidt, D.] Inst Pathol & Zytol, Gereonstr 14a, D-41747 Viersen, Germany	Schmidt, D (reprint author), Inst Pathol & Zytol, Gereonstr 14a, D-41747 Viersen, Germany.	dischmi57@gmail.com						0	0	0	0	0	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	0172-8113	1432-1963		PATHOLOGE	Pathologe	DEC	2018	39			2			346	347		10.1007/s00292-018-0483-1			2	Pathology	Pathology	HE6XV	WOS:000453565100039	30120510				2019-10-28	
J	Wittekind, C				Wittekind, C.			Gottfried Geiler 13.12.1927-28.04.2018, has works published, Pathologist	PATHOLOGE			German	Biographical-Item									[Wittekind, C.] Univ Klinikum Leipzig, Inst Pathol, Liebigstr 26, D-04103 Leipzig, Germany	Wittekind, C (reprint author), Univ Klinikum Leipzig, Inst Pathol, Liebigstr 26, D-04103 Leipzig, Germany.	Christian.Wittekind@medizin.uni-leipzig.de						0	0	0	0	0	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	0172-8113	1432-1963		PATHOLOGE	Pathologe	DEC	2018	39			2			348	349		10.1007/s00292-018-0492-0			2	Pathology	Pathology	HE6XV	WOS:000453565100040	30206652				2019-10-28	
J	Bultmann, B; Klingel, K				Bueltmann, B.; Klingel, K.			Reinhard Kandolf 10 September 1948-31 March 2017, has works published, Pathologist	PATHOLOGE			German	Biographical-Item									[Klingel, K.] Univ Klinikum Tubingen, Inst Pathol & Neuropathol, Liebermeisterstr 8, D-72076 Tubingen, Germany	Klingel, K (reprint author), Univ Klinikum Tubingen, Inst Pathol & Neuropathol, Liebermeisterstr 8, D-72076 Tubingen, Germany.; Bultmann, B (reprint author), Romerhofweg 9, D-72108 Rottenburg, Germany.	rb.bueltmann@t-online.de; karin.klingel@med.uni-tuebingen.de						0	0	0	0	3	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	0172-8113	1432-1963		PATHOLOGE	Pathologe	DEC	2018	39			2			350	351		10.1007/s00292-018-0512-0			2	Pathology	Pathology	HE6XV	WOS:000453565100041	30302564				2019-10-28	
J	Denk, H				Denk, H.			Gerhard Korb 9 February 1929-24 December 2017, has works published, Genealogist	PATHOLOGE			German	Biographical-Item									[Denk, H.] Med Univ Graz, Inst Pathol, Neue Stiftingtalstr 6, A-8010 Graz, Austria	Denk, H (reprint author), Med Univ Graz, Inst Pathol, Neue Stiftingtalstr 6, A-8010 Graz, Austria.	helmut.denk@medunigraz.at						0	0	0	0	0	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	0172-8113	1432-1963		PATHOLOGE	Pathologe	DEC	2018	39			2			352	352		10.1007/s00292-018-0556-1			1	Pathology	Pathology	HE6XV	WOS:000453565100042	30535875	Bronze			2019-10-28	
J	Storkel, S				Stoerkel, S.			Guenther Schubert August 17, 1930-October 23, 2017, has works published, Pathologist	PATHOLOGE			German	Biographical-Item									[Stoerkel, S.] BAG Pathol & Mol Pathol, Heusner Str 40, D-42283 Wuppertal, Germany	Storkel, S (reprint author), BAG Pathol & Mol Pathol, Heusner Str 40, D-42283 Wuppertal, Germany.	stephan.stoerkel@helios-gesundheit.de						0	0	0	0	0	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	0172-8113	1432-1963		PATHOLOGE	Pathologe	DEC	2018	39			2			353	354		10.1007/s00292-018-0490-2			2	Pathology	Pathology	HE6XV	WOS:000453565100043	30203218				2019-10-28	
J	Bierhoff, E				Bierhoff, E.			Juergen Vogel 6 May 1946-23 July 2017, has works published, Pathologist	PATHOLOGE			German	Biographical-Item									[Bierhoff, E.] Heinz Werner Seifert Inst Dermatopathol, Trierer Str 70, D-53115 Bonn, Germany	Bierhoff, E (reprint author), Heinz Werner Seifert Inst Dermatopathol, Trierer Str 70, D-53115 Bonn, Germany.	erhard.bierhoff@t-online.de						0	0	0	0	1	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	0172-8113	1432-1963		PATHOLOGE	Pathologe	DEC	2018	39			2			355	356		10.1007/s00292-018-0510-2			2	Pathology	Pathology	HE6XV	WOS:000453565100044	30229282				2019-10-28	
J	Kakudo, K; Bychkov, A; Bai, YH; Li, YQ; Liu, ZY; Jung, CK				Kakudo, Kennichi; Bychkov, Andrey; Bai, Yanhua; Li, Yaqiong; Liu, Zhiyan; Jung, Chan Kwon			The new 4th edition World Health Organization classification for thyroid tumors, Asian perspectives	PATHOLOGY INTERNATIONAL			English	Article						borderline tumor; follicular cell; pathology report; prognostic factors; risk stratification; thyroid carcinoma	DIFFUSE SCLEROSING VARIANT; LYMPH-NODE METASTASIS; COLUMNAR CELL VARIANT; KI-67 LABELING INDEX; ENCAPSULATED FOLLICULAR VARIANT; POORLY DIFFERENTIATED CARCINOMA; EXTENSIVE VASCULAR INVASION; PROMINENT HOBNAIL FEATURES; CRIBRIFORM-MORULAR VARIANT; HIGH-RISK GROUP	The new World Health Organization (WHO) classification of endocrine organs was published in 2017 and several amendments were made to the classification of thyroid tumors. The introduction of borderline category, including uncertain malignant potential (UMP) and noninvasive encapsulated follicular neoplasm with papillary-like nuclear features (NIFTP), significantly impacted pathology practice. The risk stratification of both papillary thyroid carcinoma (PTC) and follicular thyroid carcinoma (FTC) was emphasized as one of the most important elements in pathology reports to overcome the current problems of over diagnosis and over treatment of low-risk thyroid carcinomas. Follicular-patterned neoplasms (RAS-like tumors) were further classified into 6 prognostic groups [follicular adenoma, UMP and NIFTP, minimally invasive FTC, encapsulated angioinvasive FTC, widely invasive FTC and poorly differentiated carcinoma (PDC)]. In the PTC lineage (BRAF-like tumors), identification of aggressive variants and other prognostic factors were emphasized as they can only be judged by pathologists. PDC was defined with Turin consensus criteria more precisely, and PTC with solid/trabecular growth without high grade features was downgraded to solid/trabecular variant of PTC. Lastly, this review proposes a pathology reporting system from the perspective of Asian pathologists, which covers risk stratification recommended by the American Thyroid Association and new WHO classification of thyroid tumors. This review further introduces publications on Asian patient series treated by standard Asian thyroid practice. The authors consider these studies to provide a guide to current Asian thyroid practice, which cannot be supplemented by data elucidated from Western practice.	[Kakudo, Kennichi] Kindai Univ, Nara Hosp, Fac Med, Dept Pathol & Lab Med, 1248-1 Otoda Cho, Ikoma City 6300293, Japan; [Bychkov, Andrey] Kameda Med Ctr, Dept Pathol, Kawagoe, Chiba, Japan; [Bychkov, Andrey] Chulalongkorn Univ, Dept Pathol, Fac Med, Bangkok, Thailand; [Bai, Yanhua] Peking Univ Canc Hosp & Inst, Dept Pathol, Minist Educ, Key Lab Carcinogenesis & Translat Res, Beijing, Peoples R China; [Li, Yaqiong] Shandong Univ, Shandong Prov Hosp, Dept Pathol, Jinan, Shandong, Peoples R China; [Liu, Zhiyan] Shandong Univ, Cheeloo Coll Med, Sch Basic Med Sci, Dept Pathol, Jinan, Shandong, Peoples R China; [Jung, Chan Kwon] Catholic Univ Korea, Coll Med, Dept Hosp Pathol, Seoul, South Korea	Kakudo, K (reprint author), Kindai Univ, Nara Hosp, Fac Med, Dept Pathol & Lab Med, 1248-1 Otoda Cho, Ikoma City 6300293, Japan.	kakudo@thyroid.jp	Jung, Chan Kwon/C-7578-2014; Bychkov, Andrey/N-1884-2019; Liu, Zhiyan/C-5298-2016	Jung, Chan Kwon/0000-0001-6843-3708; Bychkov, Andrey/0000-0002-4203-5696; Liu, Zhiyan/0000-0001-9668-7756			Ackerman LV, 1974, SURGICAL PATHOLOGY, P327; Adeniran AJ, 2006, AM J SURG PATHOL, V30, P216, DOI 10.1097/01.pas.0000176432.73455.1b; Agrawal N, 2014, CELL, V159, P676, DOI 10.1016/j.cell.2014.09.050; Ahn HS, 2014, NEW ENGL J MED, V371, P1765, DOI 10.1056/NEJMp1409841; Akaishi J, 2015, WORLD J SURG, V39, P1728, DOI 10.1007/s00268-015-3021-9; Ali SZ, 2017, BETHESDA SYSTEM REPO; Alves VAF, 2018, CLINICS, V73, DOI 10.6061/clinics/2018/e576; Amacher AM, 2015, AM J SURG PATHOL, V39, P260, DOI 10.1097/PAS.0000000000000329; An JH, 2015, CLIN ENDOCRINOL, V82, P760, DOI 10.1111/cen.12579; Angell TE, 2017, CURR OPIN ENDOCRINOL, V24, P372, DOI 10.1097/MED.0000000000000354; Arganini M, 1988, SURGEY, V100, P1108; Asioli S, 2013, HUM PATHOL, V44, P320, DOI 10.1016/j.humpath.2012.06.003; Asioli S, 2010, AM J SURG PATHOL, V34, P44, DOI 10.1097/PAS.0b013e3181c46677; Bai Y, 2008, CANCER SCI, V99, P1908, DOI 10.1111/j.1349-7006.2008.00908.x; Bai YH, 2009, CANCER LETT, V281, P188, DOI 10.1016/j.canlet.2009.02.043; Bongiovanni M, 2017, CANCER CYTOPATHOL, V125, P389, DOI 10.1002/cncy.21860; Bongiovanni M, 2013, THYROID, V23, P1498, DOI 10.1089/thy.2013.0146; Brandler TC, 2018, AM J CLIN PATHOL, V150, P451, DOI [10.1093/AJCP/AQY075, 10.1093/ajcp/aqy075]; Bychkov A., 2018, PATHOLOGYONLINES JUN; Bychkov A, 2018, ENDOCR PATHOL, V29, P276, DOI 10.1007/s12022-018-9519-6; Bychkov A, 2017, THYROID, V27, P983, DOI 10.1089/thy.2017.0079; Bychkov A, 2017, MALAYS J PATHOL, V39, P95; Calebiro D, 2016, J CLIN INVEST, V126, P3383, DOI 10.1172/JCI84894; Cameselle-Teijeiro J, 1999, MODERN PATHOL, V12, P400; Can N, 2017, POL J PATHOL, V68, P197, DOI [10.5114/PJP.2017.71527, 10.5114/pjp.2017.71527]; Cao J, 2016, J CLIN PATHOL, V69, P872, DOI 10.1136/jclinpath-2015-203547; Chan JKC, 2002, AM J CLIN PATHOL, V117, P16; Chan JKC, 2017, WHO CLASSIFICATION T, P76; Chen JH, 2011, MODERN PATHOL, V24, P739, DOI 10.1038/modpathol.2011.2; CHEN KTK, 1977, AM J SURG PATHOL, V1, P123, DOI 10.1097/00000478-197706000-00003; Chereau N, 2018, J CLIN ENDOCR METAB, V101, P4603; Cho U, 2017, MODERN PATHOL, V30, P810, DOI 10.1038/modpathol.2017.9; Chow SM, 2003, EUR J SURG ONCOL, V29, P446, DOI 10.1016/S0748-7983(03)00005-2; Chung YJ, 2013, HISTOPATHOLOGY, V62, P578, DOI 10.1111/his.12025; Cipriani NA, 2015, THYROID, V25, P1209, DOI 10.1089/thy.2015.0297; Collini P, 2004, HISTOPATHOLOGY, V44, P35, DOI 10.1111/j.1365-2559.2004.01729.x; Cooper DS, 2009, THYROID, V19, P1167, DOI 10.1089/thy.2009.0110; Davies L, 2014, JAMA OTOLARYNGOL, V140, P317, DOI 10.1001/jamaoto.2014.1; de la Fouchardiere C, 2018, EUR J CANCER, V92, P40, DOI 10.1016/j.ejca.2017.12.027; De Lellis RA, 2004, TUMOURS ENDOCRINE OR; Dettmer MS, 2012, MODERN PATHOL, V25, p143A; Dettmer M, 2011, AM J SURG PATHOL, V35, P1866, DOI 10.1097/PAS.0b013e31822cf962; Dettmer MS, 2015, ENDOCR-RELAT CANCER, V22, P419, DOI 10.1530/ERC-15-0057; Dibelius G, 2014, THYROID, V24, P1319, DOI 10.1089/thy.2013.0586; Ebina A, 2014, SURGERY, V156, P1579, DOI 10.1016/j.surg.2014.08.060; Enriquez ML, 2012, AM J CLIN PATHOL, V137, P722, DOI 10.1309/AJCPXE3PUBWVZCGZ; Erickson LA, 2000, MODERN PATHOL, V13, P186, DOI 10.1038/modpathol.3880034; Erickson LA, 1998, MODERN PATHOL, V11, P169; Fagin JA, 2016, NEW ENGL J MED, V375, P1054, DOI 10.1056/NEJMra1501993; Feng JH, 2018, ENDOCRINE, V61, P499, DOI 10.1007/s12020-018-1644-y; Ferris RL, 2018, HEAD NECK-J SCI SPEC, V40, P1881, DOI 10.1002/hed.25141; Ganly I, 2018, CANCER CELL, V34, P256, DOI 10.1016/j.ccell.2018.07.002; Ganly I, 2015, HUM PATHOL, V46, P657, DOI 10.1016/j.humpath.2015.01.010; Ganly I, 2014, THYROID, V24, P662, DOI 10.1089/thy.2013.0503; Ganly I, 2013, J CLIN ENDOCR METAB, V98, pE962, DOI 10.1210/jc.2012-3539; Ghossein R, 2008, THYROID, V18, P1179, DOI 10.1089/thy.2008.0164; Ghossein R, 2014, THYROID, V24, P245, DOI 10.1089/thy.2012.0645; Ghossein RA, 2007, THYROID, V17, P655, DOI 10.1089/thy.2007.0061; Glomski K, 2017, ENDOCR PATHOL, V28, P177, DOI 10.1007/s12022-017-9483-6; Gnemmi V, 2014, HISTOPATHOLOGY, V64, P263, DOI 10.1111/his.12246; Gopa RK, 2018, CANCER CELL, V34, P242, DOI 10.1016/j.ccell.2018.06.013; GUNDRY SR, 1983, ARCH SURG-CHICAGO, V118, P529; Han JM, 2012, CLIN ENDOCRINOL, V77, P459, DOI 10.1111/j.1365-2265.2012.04396.x; HARACH HR, 1994, HISTOPATHOLOGY, V25, P549, DOI 10.1111/j.1365-2559.1994.tb01374.x; Haugen BR, 2017, THYROID, V27, P481, DOI 10.1089/thy.2016.0628; Haugen BR, 2016, THYROID, V26, P1, DOI 10.1089/thy.2015.0020; HAWK WA, 1976, CLEVELAND CLIN Q, V43, P207, DOI 10.3949/ccjm.43.4.207; Hay ID, 2008, SURGERY, V144, P980, DOI 10.1016/j.surg.2008.08.035; Hernandez-Prera JC, 2017, THYROID, V27, P1498, DOI 10.1089/thy.2017.0280; HERRERA MF, 1992, WORLD J SURG, V16, P669, DOI 10.1007/BF02067351; Hilzik D, 2006, CANCER, V106, P1286; Hirokawa M, 2002, AM J SURG PATHOL, V26, P1508, DOI 10.1097/00000478-200211000-00014; Hirokawa M, 2016, ENDOCR J, V63, P805, DOI 10.1507/endocrj.EJ16-0097; Hirokawa M, 2016, ENDOCR J, V63, P441, DOI 10.1507/endocrj.EJ15-0705; Hirokawa M, 2010, DIAGN CYTOPATHOL, V38, P890, DOI 10.1002/dc.21309; Hong JH, 2016, CLIN ENDOCRINOL, V85, P797, DOI 10.1111/cen.13115; Huang Wan-Ting, 2005, Kaohsiung Journal of Medical Sciences, V21, P241; Vuong HG, 2017, EUR J ENDOCRINOL, V177, P207, DOI 10.1530/EJE-17-0260; Vuong HG, 2017, EUR J ENDOCRINOL, V176, P433, DOI 10.1530/EJE-16-0863; Hwang TS, 2015, BIOMED RES INT, DOI 10.1155/2015/697068; Ieni A, 2016, REV ENDOCR METAB DIS, V17, P521, DOI 10.1007/s11154-016-9398-4; Ito M, 2014, ENDOCR J, V61, P1221, DOI 10.1507/endocrj.EJ14-0239; Ito Y, 2003, THYROID, V13, P381, DOI 10.1089/105072503321669875; Ito Y, 2003, SURG TODAY, V33, P277, DOI 10.1007/s005950300061; Ito Y, 2008, PATHOLOGY, V40, P617, DOI 10.1080/00313020802320630; Ito Y, 2008, WORLD J SURG, V32, P1535, DOI 10.1007/s00268-007-9406-7; Ito Y, 2007, WORLD J SURG, V31, P1417, DOI 10.1007/s00268-007-9095-2; Ito Y, 2007, NAT CLIN PRACT ENDOC, V3, P240, DOI 10.1038/ncpendmet0428; Ito Y, 2017, WORLD J SURG, V41, P742, DOI 10.1007/s00268-016-3784-7; Ito Y, 2016, ENDOCR J, V63, P913, DOI 10.1507/endocrj.EJ16-0277; Ito Y, 2013, ENDOCR J, V60, P637, DOI 10.1507/endocrj.EJ12-0419; Ito Y, 2010, WORLD J SURG, V34, P3015, DOI 10.1007/s00268-010-0746-3; Jeon MJ, 2017, EUR J ENDOCRINOL, V177, P25, DOI 10.1530/EJE-17-0160; Jeon MJ, 2016, THYROID, V26, P161, DOI 10.1089/thy.2015.0375; Jiang CH, 2018, CANCER MANAG RES, V10, P465, DOI 10.2147/CMAR.S157823; Jillard CL, 2016, THYROID, V26, P959, DOI 10.1089/thy.2016.0246; JOHNSON TL, 1988, AM J SURG PATHOL, V12, P22, DOI 10.1097/00000478-198801000-00003; Jung CK, 2018, HUM PATHOL, V81, P9, DOI 10.1016/j.humpath.2018.04.018; Jung CK, 2014, J CLIN ENDOCR METAB, V99, pE276, DOI 10.1210/jc.2013-2503; Jung CK, 2012, THYROID, V22, P791, DOI 10.1089/thy.2011.0123; Jung CK, 2017, J BASIC CLIN MED, V6, P26; Kakudo K, 2017, CYTOPATHOLOGY, V28, P455, DOI 10.1111/cyt.12491; Kakudo K, 2004, J CLIN PATHOL, V57, P1041, DOI 10.1136/jcp.2004.017889; Kakudo K, 2002, ENDOCR PATHOL, V13, P131, DOI 10.1385/EP:13:2:131; Kakudo K, 2017, J BASIC CLIN MED, V7, P10; Kakudo K, 2019, THYROID FNA CYTOLOGY; Kakudo K, 2017, J BASIC CLIN MED, V7, P21; Kakudo K, 2018, GLAND SURG, V7, pS8, DOI 10.21037/gs.2017.08.02; Kakudo K, 2017, PATHOL INT, V67, P179, DOI 10.1111/pin.12498; Kakudo K, 2015, ENDOCR J, V62, P1, DOI 10.1507/endocrj.EJ14-0293; Kakudo K, 2012, PATHOL INT, V62, P155, DOI 10.1111/j.1440-1827.2011.02773.x; Kakudo K, 2012, ENDOCR J, V59, P1; Kakudo K, 2009, PATHOL INT, V59, P359, DOI 10.1111/j.1440-1827.2009.02378.x; Karunamurthy A, 2016, ENDOCR-RELAT CANCER, V23, P295, DOI 10.1530/ERC-16-0043; KATOH R, 1995, HUM PATHOL, V26, P139, DOI 10.1016/0046-8177(95)90029-2; Kazaure HS, 2012, CANCER-AM CANCER SOC, V118, P3260, DOI 10.1002/cncr.26638; Kihara M, 2011, WORLD J SURG, V35, P558, DOI 10.1007/s00268-010-0907-4; Kim HJ, 2014, HEAD NECK-J SCI SPEC, V36, P1695, DOI 10.1002/hed.23511; Kim WG, 2014, KOREAN J INTERN MED, V29, P325, DOI 10.3904/kjim.2014.29.3.325; Kimura N, 2014, ENDOCR-RELAT CANCER, V21, P405, DOI 10.1530/ERC-13-0494; Kloppel G, WHO CLASSIFICATION T, P142; Knauf JA, 2011, ONCOGENE, V30, P3153, DOI 10.1038/onc.2011.44; Kumarasinghe P, 2019, STANDARDIZED REPORTI; Kwon H, 2017, J CLIN ENDOCR METAB, V102, P1917, DOI 10.1210/jc.2016-4026; Lam AKY, 2006, ANN SURG ONCOL, V13, P176, DOI 10.1245/ASO.2006.03.062; Lam AKY, 2017, AJSP-REV REP, V22, P209, DOI 10.1097/PCR.0000000000000183; Lam AKY, 2017, ENDOCR-RELAT CANCER, V24, pR109, DOI 10.1530/ERC-17-0014; Lam KY, 2000, ANN SURG, V231, P329, DOI 10.1097/00000658-200003000-00005; Lancia I, 2016, J CLIN INVEST, V126, P1052, DOI 10.1172/JCI85271; Lang BHH, 2017, ENDOCRINE, V55, P496, DOI 10.1007/s12020-016-1188-y; LANG W, 1980, VIRCHOWS ARCH A, V385, P125, DOI 10.1007/BF00427399; Lee DY, 2016, THYROID, V26, P404, DOI 10.1089/thy.2015.0316; Lee SE, 2017, THYROID, V27, P802, DOI 10.1089/thy.2016.0547; Lee YS, 2015, INT J CLIN EXP PATHO, V8, P7988; Lindsay S., 1960, CARCINOMA THYROID GL; Liu J, 2006, CANCER-AM CANCER SOC, V107, P1255, DOI 10.1002/cncr.22138; Liu ZY, 2011, J CLIN PATHOL, V64, P325, DOI 10.1136/jcp.2010.083956; Liu ZY, 2011, CANCER SCI, V102, P288, DOI 10.1111/j.1349-7006.2010.01769.x; Liu ZY, 2010, PATHOL INT, V60, P524, DOI 10.1111/j.1440-1827.2010.02551.x; Lloyd RV, 2018, HUM PATHOL, V74, P1, DOI 10.1016/j.humpath.2017.12.027; Lloyd RV, 2004, AM J SURG PATHOL, V28, P1336, DOI 10.1097/01.pas.0000135519.34847.f6; Lloyd RV, 2017, WHO CLASSIFICATION T; Lo CY, 2006, WORLD J SURG, V30, P759, DOI 10.1007/s00268-005-0363-8; Lubitz CC, 2014, THYROID, V24, P958, DOI 10.1089/thy.2013.0573; Mehrzad R, 2016, SURGERY, V159, P1396, DOI 10.1016/j.surg.2015.11.026; Mete O, 2011, MODERN PATHOL, V24, P1545, DOI 10.1038/modpathol.2011.119; Miyauchi A, 2018, THYROID, V28, P23, DOI 10.1089/thy.2017.0227; Miyauchi A, 2016, WORLD J SURG, V40, P516, DOI 10.1007/s00268-015-3392-y; Miyauchi A, 2013, EUR THYROID J, V2, P57, DOI 10.1159/000347148; Miyauchi A, 2013, ENDOCR J, V60, P415; Morandi L, 2017, ENDOCR-RELAT CANCER, V24, P107, DOI 10.1530/ERC-16-0546; Morris LGT, 2010, THYROID, V20, P153, DOI 10.1089/thy.2009.0352; Nabhan F, 2018, THYROID, V28, P729, DOI 10.1089/thy.2017.0635; Niemeier LA, 2012, CANCER, V118, P2068; Nikiforov YE, 2001, AM J SURG PATHOL, V25, P1478, DOI 10.1097/00000478-200112000-00002; Nikiforov YE, 2017, WHO CLASSIFICATION T, P78; Nikiforov YE, 2016, JAMA ONCOL, V2, P1023, DOI 10.1001/jamaoncol.2016.0386; Nishida T, 1999, AM J SURG PATHOL, V23, P205, DOI 10.1097/00000478-199902000-00010; Nishida T, 2000, AM J SURG PATHOL, V183, P80; Noguchi S, 2008, WORLD J SURG, V32, P747, DOI 10.1007/s00268-007-9453-0; O'Neill CJ, 2011, EJSO-EUR J SURG ONC, V37, P181, DOI 10.1016/j.ejso.2010.11.005; Oh HS, 2017, THYROID, V27, P1285, DOI 10.1089/thy.2017.0250; Ohori NP, 2017, CANCER CYTOPATHOL, V125, P692, DOI 10.1002/cncy.21892; Ohori NP, 2015, J BASIC CLIN MED, V4, P103; Pacini F, 2018, J ENDOCRINOL INVEST, V41, P849, DOI 10.1007/s40618-018-0884-2; Patel SG, 2017, SURGERY, V161, P168, DOI 10.1016/j.surg.2016.04.054; Paulson VA, 2017, THYROID, V27, P506, DOI 10.1089/thy.2016.0583; Perros P, 2014, CLIN ENDOCRINOL, V81, P1, DOI 10.1111/cen.12515; Piana S, 2010, AM J SURG PATHOL, V34, P868, DOI 10.1097/PAS.0b013e3181dbee07; Pisanu A, 2013, J ENDOCRINOL INVEST, V36, P78, DOI 10.3275/8241; Provenzale MA, 2016, EUR J ENDOCRINOL, V174, P813, DOI 10.1530/EJE-15-1223; Pulcrano M, 2007, THYROID, V17, P639, DOI 10.1089/thy.2007.0029; Renshaw AA, 2002, AM J CLIN PATHOL, V117, P19; Rivera M, 2010, MODERN PATHOL, V23, P1191, DOI 10.1038/modpathol.2010.112; Rivera M, 2010, HUM PATHOL, V41, P172, DOI 10.1016/j.humpath.2009.08.011; Rivera M, 2009, THYROID, V19, P119, DOI 10.1089/thy.2008.0303; Rohaizak Muhammad, 2003, Asian J Surg, V26, P183, DOI 10.1016/S1015-9584(09)60381-X; Rosai J, 2003, INT J SURG PATHOL, V11, P249, DOI 10.1177/106689690301100401; Rosai J, 2015, SERIES, P96; SAKAMOTO A, 1983, CANCER, V52, P1849, DOI 10.1002/1097-0142(19831115)52:10<1849::AID-CNCR2820521015>3.0.CO;2-X; Lino-Silva LS, 2012, HUM PATHOL, V43, P1596, DOI 10.1016/j.humpath.2011.10.027; Seethala RR, 2018, MODERN PATHOL, V31, P39, DOI 10.1038/modpathol.2017.130; Seethala RR, 2016, COLL AM PATHOLOGISTS; Shi XG, 2016, J CLIN ENDOCR METAB, V101, P263, DOI 10.1210/jc.2015-2917; SOARES J, 1989, PATHOL RES PRACT, V185, P200; Sobrinho-Simoes M, 2011, MODERN PATHOL, V24, pS10, DOI 10.1038/modpathol.2010.133; SOBRINHOSIMOES M, 1988, AM J CLIN PATHOL, V89, P264, DOI 10.1093/ajcp/89.2.264; Song E, 2018, EUR J ENDOCRINOL, V179, P135, DOI 10.1530/EJE-17-0991; Sugino K, 2013, ANN SURG ONCOL, V20, P2944, DOI 10.1245/s10434-013-2965-y; Sugino K, 2012, THYROID, V22, P798, DOI 10.1089/thy.2012.0051; Sugitani I, 2010, WORLD J SURG, V34, P1265, DOI 10.1007/s00268-009-0305-y; Sugitani I, 2010, WORLD J SURG, V34, P1222, DOI 10.1007/s00268-009-0359-x; Sujoy V, 2013, THYROID, V23, P714, DOI 10.1089/thy.2012.0455; Sywak M, 2004, J SURG ONCOL, V86, P44, DOI 10.1002/jso.20044; Takami H, 2013, TREATMENT THYROID CA, P1; Takami H, 2014, WORLD J SURG, V38, P2002, DOI 10.1007/s00268-014-2498-y; Tallini G, 1999, AM J SURG PATHOL, V23, P678, DOI 10.1097/00000478-199906000-00007; Tallini G, 2019, THYROID FNA CYTOLOGY; Tallini G, 2017, J CLIN ENDOCR METAB, V102, P15, DOI 10.1210/jc.2016-2976; Tang WH, 2003, PATHOL INT, V53, P204, DOI 10.1046/j.1320-5463.2003.01456.x; Teng LH, 2017, ONCOTARGET, V8, P22023, DOI 10.18632/oncotarget.15786; The Japan Thyroid Association, 2013, GUID CLIN PRACT MAN; The Japanese Society of Thyroid Surgery (JSTS), 2015, GEN RUL DESCR THYR C; Thomas GA, 1999, J CLIN ENDOCR METAB, V84, P4232, DOI 10.1210/jc.84.11.4232; THOMPSON NW, 1974, SURG GYNECOL OBSTET, V139, P555; Tomoda C, 2004, WORLD J SURG, V28, P886, DOI 10.1007/s00268-004-7475-4; Tronko MD, 1999, CANCER, V86, P149, DOI 10.1002/(SICI)1097-0142(19990701)86:1<149::AID-CNCR21>3.0.CO;2-A; Tuttle RM, 2017, JAMA OTOLARYNGOL, V143, P1015, DOI 10.1001/jamaoto.2017.1442; Uchino S, 2016, J CLIN ENDOCR METAB, V101, P4611, DOI 10.1210/jc.2016-2043; Valderrabano P, 2018, JAMA OTOLARYNGOL, V144, P788, DOI 10.1001/jamaoto.2018.1070; Volante M, 2007, AM J SURG PATHOL, V31, P1256, DOI 10.1097/PAS.0b013e3180309e6a; Wada N, 2003, ANN SURG, V237, P399, DOI 10.1097/00000658-200303000-00015; WARREN S, 1956, AM J CLIN PATHOL, V26, P64; Wenig BN, 1998, CANCER, V82, P740, DOI 10.1002/(SICI)1097-0142(19980215)82:4<740::AID-CNCR18>3.3.CO;2-T; Widder S, 2008, SURGERY, V144, P80, DOI 10.1016/j.surg.2007.11.014; Williams ED, 2008, THYROID, V18, P847, DOI 10.1089/thy.2008.0039; Williams ED, 2000, INT J SURG PATHOL, V8, P181, DOI 10.1177/106689690000800304; Williams ED, 2004, BRIT J CANCER, V90, P2219, DOI 10.1038/sj.bjc.6601860; Xing MZ, 2016, BMC MED, V14, DOI 10.1186/s12916-016-0559-9; Xu B, 2018, HISTOPATHOLOGY, V72, P32, DOI 10.1111/his.13335; Xu B, 2017, HUM PATHOL, V65, P133, DOI 10.1016/j.humpath.2017.05.013; Xu B, 2015, HUM PATHOL, V46, P1789, DOI 10.1016/j.humpath.2015.08.015; YAMASHINA M, 1992, AM J SURG PATHOL, V16, P392, DOI 10.1097/00000478-199204000-00008; Yoshida A, 2014, WORLD J SURG, V38, P2311, DOI 10.1007/s00268-014-2536-9; Yutan E, 2001, Curr Treat Options Oncol, V2, P331, DOI 10.1007/s11864-001-0026-4	225	3	3	1	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1320-5463	1440-1827		PATHOL INT	Pathol. Int.	DEC	2018	68	12					641	664		10.1111/pin.12737			24	Pathology	Pathology	HE9GF	WOS:000453756100001	30537125	Other Gold			2019-10-28	
J	Yoshino, T; Takata, K; Tanaka, T; Sato, Y; Tari, A; Okada, H				Yoshino, Tadashi; Takata, Katsuyoshi; Tanaka, Takehiro; Sato, Yasuharu; Tari, Akira; Okada, Hiroyuki			Recent progress in follicular lymphoma in Japan and characteristics of the duodenal type	PATHOLOGY INTERNATIONAL			English	Review						duodenal-type; follicular lymphoma; MALT lymphoma	B-CELL LYMPHOMA; EXPRESSION; IMMUNOGLOBULIN; FREQUENCY; DISTINCT; ORIGIN; TRANSLOCATION; ADHESION; ANTIGEN; WATCH	The incidence of lymphoma has rapidly increased over the last 40 years in Japan, following a trend that is very similar to that of breast cancer. In particular, the relative frequency of follicular lymphoma (FL) has reached that in Western countries. Given its indolence, a "watch-and-wait" approach is often applied to FL patients. We have shown that FL is often detected in the second portion of the duodenum and has a distinct follicular dendritic cell distribution and heavy chain variable usage similar to mucosa-associated lymphoid tissue (MALT) lymphoma. Although the t(14;18)(q32;q21) frequency is the same as in the nodal subtype of FL, there are also ongoing mutations, immunopositivity for cluster of differentiation 10 and B-cell lymphoma (BCL)6, and overexpression of BCL2. Gene expression profiling has shown that it is more similar to gastric MALT lymphoma than to nodal FL. Duodenal-type FL lacks the activation-induced cytidine deaminase (AID) expression observed in nodal ones, although this may be compensated for by BTB domain and CNC homolog 2. Based on these findings, duodenal-type FL has been included in the Revised 4th edition of the World Health Organization classification published in late 2017.	[Yoshino, Tadashi; Takata, Katsuyoshi; Tanaka, Takehiro] Okayama Univ, Dept Pathol, Grad Sch Med Dent & Pharmaceut Sci, Okayama, Japan; [Sato, Yasuharu] Okayama Univ, Grad Sch Hlth Sci, Dept Pathophysiol, Okayama, Japan; [Tari, Akira] Hiroshima Red Cross Hosp, Div Gastroenterol, Hiroshima, Japan; [Tari, Akira] Atom Bomb Survivor Hosp, Hiroshima, Japan; [Okada, Hiroyuki] Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Gastroenterol & Hepatol, Okayama, Japan	Yoshino, T (reprint author), Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Pathol, Kita Ku, 2-5-1 Shikata Cho, Okayama 7008558, Japan.	yoshino@md.okayama-u.ac.jp			Japan Society for the Promotion of Science KAKENHIMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI) [16390106, 19590348, 26293078]	The work presented here was supported in part by Japan Society for the Promotion of Science KAKENHI grants (nos. 16390106, 19590348, and 26293078). Tadashi Yoshino has been announced as the winner of the 2018 Japanese Society of Pathology Japan Pathology Award.	ANDREW DP, 1994, J IMMUNOL, V153, P3847; Bende RJ, 2003, AM J PATHOL, V162, P105, DOI 10.1016/S0002-9440(10)63802-3; BRISKIN MJ, 1993, NATURE, V363, P461, DOI 10.1038/363461a0; Cheah CY, 2016, ANN ONCOL, V27, P895, DOI 10.1093/annonc/mdw026; Cortelazzo S, 2016, J CLIN ONCOL, V34, P4015, DOI 10.1200/JCO.2016.67.2980; Cui W, 2011, PATHOL INT, V61, P737, DOI 10.1111/j.1440-1827.2011.02736.x; Esplugues E, 2011, NATURE, V475, P514, DOI 10.1038/nature10228; Ganapathi KA, 2014, HAEMATOLOGICA, V99, P1421, DOI 10.3324/haematol.2014.107938; Harris NL, 2008, FOLLICULAR LYMPHOMA, P220; Huet S, 2018, NAT REV CANCER, V18, P224, DOI 10.1038/nrc.2017.127; Igarashi K, 2014, IMMUNOL REV, V261, P116, DOI 10.1111/imr.12201; Jaffe ES, 2017, FOLLICULAR LYMPHOMA, P266; Lackraj T, 2018, BEST PRACT RES CL HA, V31, P2, DOI 10.1016/j.beha.2017.10.006; Levy D, 2017, BRAZ J MED BIOL RES, V50, DOI [10.1590/1414-431x20176172, 10.1590/1414-431X20176172]; Liu YX, 2001, MODERN PATHOL, V14, P798, DOI 10.1038/modpathol.3880393; Mannami T, 2001, MODERN PATHOL, V14, P641, DOI 10.1038/modpathol.3880366; Miyata-Takata T, 2015, SCI REP-UK, V5, DOI 10.1038/srep18434; Miyata-Takata T, 2014, PATHOL INT, V64, P527, DOI 10.1111/pin.12197; Nagakita K, 2016, PATHOL INT, V66, P444, DOI 10.1111/pin.12439; Nakamura S, 2006, PATHOL INT, V56, P576, DOI 10.1111/j.1440-1827.2006.02011.x; Ohnishi N, 2016, CANCER SCI, V107, P1687, DOI 10.1111/cas.13031; Sato Y, 2008, J CLIN PATHOL, V61, P377, DOI 10.1136/jcp.2007.049825; Sato Y, 2006, MODERN PATHOL, V19, P1578, DOI 10.1038/modpathol.3800692; Schmatz AI, 2011, J CLIN ONCOL, V29, P1445, DOI 10.1200/JCO.2010.32.9193; Schuler F, 2009, INT J CANCER, V124, P958, DOI 10.1002/ijc.23958; Takata K, 2018, PATHOL INT, V68, P1, DOI 10.1111/pin.12621; Takata K, 2014, CANCER SCI, V105, P608, DOI 10.1111/cas.12392; Takata K, 2013, MODERN PATHOL, V26, P22, DOI 10.1038/modpathol.2012.127; Takata K, 2011, CANCER SCI, V102, P1532, DOI 10.1111/j.1349-7006.2011.01980.x; Takata K, 2009, MODERN PATHOL, V22, P940, DOI 10.1038/modpathol.2009.51; Tamura M, 2011, PATHOL INT, V61, P742, DOI 10.1111/j.1440-1827.2011.02748.x; Taniguchi K, 2016, AM J SURG PATHOL, V40, P324, DOI 10.1097/PAS.0000000000000592; Tari A, 2018, J GASTROEN HEPATOL, V33, P1461, DOI 10.1111/jgh.14100; Tari A, 2016, SCAND J GASTROENTERO, V51, P321, DOI 10.3109/00365521.2015.1087589; Tierens A, 1998, BLOOD, V91, P2381, DOI 10.1182/blood.V91.7.2381.2381_2381_2386; Troussard X, 2017, AM J HEMATOL, V92, P1382, DOI 10.1002/ajh.24936; TSUJIMOTO Y, 1984, SCIENCE, V226, P1097, DOI 10.1126/science.6093263; Yasukawa M, 2001, BLOOD, V98, P486, DOI 10.1182/blood.V98.2.486; Yoshino T, 2000, AM J SURG PATHOL, V24, P688, DOI 10.1097/00000478-200005000-00007; YOSHINO T, 1994, BLOOD, V83, P1856; Yuda S, 2016, ANN HEMATOL, V95, P2017, DOI 10.1007/s00277-016-2800-1	41	0	0	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1320-5463	1440-1827		PATHOL INT	Pathol. Int.	DEC	2018	68	12					665	676		10.1111/pin.12733			12	Pathology	Pathology	HE9GF	WOS:000453756100002	30456840				2019-10-28	
J	Iemura, Y; Yamada, Y; Hirata, M; Kataoka, TR; Minamiguchi, S; Haga, H				Iemura, Yoshiki; Yamada, Yosuke; Hirata, Masahiro; Kataoka, Tatsuki R.; Minamiguchi, Sachiko; Haga, Hinonori			Histopathological characterization of the neuroglial tissue in ovarian teratoma associated with anti-N-methyl-D-aspartate (NMDA) receptor encephalitis	PATHOLOGY INTERNATIONAL			English	Article						anti-N-methyl-D-aspartate receptor encephalitis; histology; neurons; N-methyl-D-aspartate receptors; ovary; teratoma	HERPES-SIMPLEX ENCEPHALITIS; MANAGEMENT	Anti-N-methyl-D-aspartate (NMDA) receptor encephalitis is a rare but occasionally fatal limbic encephalitis that may be accompanied by ovarian teratoma. Since the neuroglial tissue within the teratoma may be involved in the pathogenesis of this encephalitis, we attempted morphological and immunohistochemical characterization of the neuroglial tissue in four cases of ovarian teratoma associated with anti-NMDA receptor encephalitis and 12 control cases, i.e., six consecutive cases of immature teratoma and six cases of mature teratoma with an abundant neuronal component, focusing mainly on NMDA receptor-expressing neurons. NMDA receptor-expressing neurons, being observed in all of the cases analyzed, were significantly densely aggregated (P = 0.030, Wilcoxon test) and relatively smaller in size in the encephalitis-associated cases than in the control cases, and the Ki-67 labeling index of neuroglial cells with these neurons was significantly higher in the encephalitis-associated cases (P = 0.004, Wilcoxon test). In the cases with encephalitis, aggregation of B-cells within or around the neuroglial tissue was also observed. Our present findings may be useful for more accurate diagnosis of anti-NMDA receptor encephalitis and contribute to a better understanding of the pathogenesis.	[Iemura, Yoshiki; Yamada, Yosuke; Hirata, Masahiro; Kataoka, Tatsuki R.; Minamiguchi, Sachiko; Haga, Hinonori] Kyoto Univ Hosp, Dept Diagnost Pathol, Kyoto 6068507, Japan	Yamada, Y (reprint author), Kyoto Univ Hosp, Dept Diagnost Pathol, Sakyo Ku, 54 Shogoin Kawahara Cho, Kyoto 6068507, Japan.	yyamada@kuhp.kyoto-u.ac.jp					Armangue T, 2015, NEUROLOGY, V85, P1736, DOI 10.1212/WNL.0000000000002125; Armangue T, 2014, ANN NEUROL, V75, P317, DOI 10.1002/ana.24083; Cinque P, 1996, J NEUROL NEUROSUR PS, V61, P339, DOI 10.1136/jnnp.61.4.339; Dabner M, 2012, INT J GYNECOL PATHOL, V31, P429, DOI 10.1097/PGP.0b013e31824a1de2; Dalmau J, 2007, ANN NEUROL, V61, P25, DOI 10.1002/ana.21050; Day GS, 2014, JAMA NEUROL, V71, P717, DOI 10.1001/jamaneurol.2014.488; Florance NR, 2009, ANN NEUROL, V66, P11, DOI 10.1002/ana.21756; Gable MS, 2012, CLIN INFECT DIS, V54, P899, DOI 10.1093/cid/cir1038; Iizuka T, 2008, NEUROLOGY, V70, P504, DOI 10.1212/01.wnl.0000278388.90370.c3; Leypoldt F, 2013, NEUROLOGY, V81, P1637, DOI 10.1212/WNL.0b013e3182a9f531; Linde A, 1997, CLIN DIAGN VIROL, V8, P83, DOI 10.1016/S0928-0197(97)00015-9; Martinez-Hernandez E, 2011, NEUROLOGY, V77, P589, DOI 10.1212/WNL.0b013e318228c136; Nosadini M, 2017, DEV MED CHILD NEUROL, V59, P796, DOI 10.1111/dmcn.13448; Tabata E, 2014, EUR NEUROL, V71, P42, DOI 10.1159/000353982; Tunkel AR, 2008, CLIN INFECT DIS, V47, P303, DOI 10.1086/589747; Vitaliani R, 2005, ANN NEUROL, V58, P594, DOI 10.1002/ana.20614	16	1	1	1	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1320-5463	1440-1827		PATHOL INT	Pathol. Int.	DEC	2018	68	12					677	684		10.1111/pin.12732			8	Pathology	Pathology	HE9GF	WOS:000453756100003	30427104				2019-10-28	
J	Takeya, H; Shiota, T; Yagi, T; Ohnishi, K; Baba, Y; Miyasato, Y; Kiyozumi, Y; Yoshida, N; Takeya, M; Baba, H; Komohara, Y				Takeya, Hiroto; Shiota, Takuya; Yagi, Taisuke; Ohnishi, Koji; Baba, Yoshifumi; Miyasato, Yuko; Kiyozumi, Yuki; Yoshida, Naoya; Takeya, Motohiro; Baba, Hideo; Komohara, Yoshihiro			High CD169 expression in lymph node macrophages predicts a favorable clinical course in patients with esophageal cancer	PATHOLOGY INTERNATIONAL			English	Article						CD169; CD8; esophageal cancer; lymph node; macrophage	TUMOR-INFILTRATING LYMPHOCYTES; PROGNOSTIC-SIGNIFICANCE; SINUS MACROPHAGES; CELL INFILTRATION; DIFFERENTIATION; HETEROGENEITY; INHIBITION; CARCINOMA	Recent findings indicate CD169-positive lymph node sinus macrophages (LySMs) in the regional lymph nodes (RLNs) play an important role in anti-cancer immunity. In the present study, we investigated the correlation between CD169 expression in RLNs and clinicopathologic factors. Higher CD169 expression in LySMs was significantly associated with longer cancer-specific survival (CSS). The density of tumor-infiltrating lymphocytes (TILs) in the cancer nest and CD169 expression on LySMs were positively associated in patients who underwent pretreatment. As CD169 expression is thought to reflect a high interferon signature in RLNs, we tried to identify immunity-related genes that are up-regulated by interferon in macrophages as well as CD169. Indoleamine 2,3-dioxygenase (IDO1) was found to be elevated by interferon, and expression of IDO1 was tested using immunohistochemistry. IDO1 expression on LySMs was positively correlated with CD169 expression; however, there was no significant correlation between IDO1 and clinicopathologic factors. These results suggest that high expression of CD169 in LySMs reflects a high potential for anti-cancer immune responses in esophageal cancer patients and that monitoring CD169 expression would be useful for evaluating the potential of anti-cancer immune reactions.	[Takeya, Hiroto; Shiota, Takuya; Ohnishi, Koji; Miyasato, Yuko; Takeya, Motohiro; Komohara, Yoshihiro] Kumamoto Univ, Grad Sch Med Sci, Dept Cell Pathol, 1-1-1 Honjo, Kumamoto 8608556, Japan; [Yagi, Taisuke; Baba, Yoshifumi; Kiyozumi, Yuki; Yoshida, Naoya; Baba, Hideo] Kumamoto Univ, Grad Sch Med Sci, Dept Gastroenterol Surg, 1-1-1 Honjo, Kumamoto 8608556, Japan; [Baba, Hideo; Komohara, Yoshihiro] Kumamoto Univ, Ctr Metab Regulat Hlth Aging, Honjo 1-1-1, Kumamoto, Kumamoto 8608556, Japan	Komohara, Y (reprint author), Kumamoto Univ, Grad Sch Med Sci, Dept Cell Pathol, Chuouku, Honjo 1-1-1, Kumamoto 8608556, Japan.	ycomo@kumamoto-u.ac.jp			Ministry of Education, Culture, Sports, Science and Technology of JapanMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT) [16H05162, 16K15248, 17H04060]	We thank Ms. Ikuko Yoshida, and Mr. Takenobu Nakagawa for their technical assistance. This work was supported by grants from the Ministry of Education, Culture, Sports, Science and Technology of Japan (No. 16H05162, 16K15248, 17H04060).	ALLRED DC, 1990, ARCH SURG-CHICAGO, V125, P107; Asano K, 2011, IMMUNITY, V34, P85, DOI 10.1016/j.immuni.2010.12.011; Beatty GL, 2017, CLIN CANCER RES, V23, P3269, DOI 10.1158/1078-0432.CCR-16-2272; Bernhard CA, 2015, P NATL ACAD SCI USA, V112, P5461, DOI 10.1073/pnas.1423356112; Brochez L, 2017, EUR J CANCER, V76, P167, DOI 10.1016/j.ejca.2017.01.011; Chen ZC, 2016, J PATHOL, V239, P450, DOI 10.1002/path.4742; Doi T, 2018, J CLIN ONCOL, V36, P61, DOI 10.1200/JCO.2017.74.9846; Durgeau A, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00014; Fujiwara Y, 2018, J CLIN EXP HEMATOP, V58, P17, DOI 10.3960/jslrt.17032; Galon J, 2014, J PATHOL, V232, P199, DOI 10.1002/path.4287; Gasteiger G, 2016, IMMUNOL REV, V271, P200, DOI 10.1111/imr.12399; Gregson EM, 2016, BRIT J CANCER, V115, P403, DOI 10.1038/bjc.2016.219; Jiang YB, 2017, ONCOTARGET, V8, P30175, DOI 10.18632/oncotarget.15621; Kitano Y, 2018, J PATHOL, V244, P346, DOI 10.1002/path.5021; Kiyozumi Y, 2019, ANN SURG, V269, P1101, DOI 10.1097/SLA.0000000000002754; Komohara Y, 2017, CANCER SCI, V108, P290, DOI 10.1111/cas.13137; Kudo T, 2017, LANCET ONCOL, V18, P631, DOI 10.1016/S1470-2045(17)30181-X; Lagergren J, 2017, LANCET, V390, P2383, DOI [10.1038/nrdp.2017.48, 10.1016/S0140-6736(17)31462-9]; Mellman I, 2011, NATURE, V480, P480, DOI 10.1038/nature10673; Naito M, 2008, PATHOL INT, V58, P143, DOI 10.1111/j.1440-1827.2007.02203.x; Naito Y, 1998, CANCER RES, V58, P3491; Ohnishi K, 2016, CANCER SCI, V107, P846, DOI 10.1111/cas.12929; Ohnishi K, 2013, CANCER SCI, V104, P1236, DOI 10.1111/cas.12212; Pages F, 2018, LANCET, V391, P2128, DOI 10.1016/S0140-6736(18)30789-X; Pennathur A, 2013, LANCET, V381, P400, DOI 10.1016/S0140-6736(12)60643-6; Perdiguero EG, 2016, NAT IMMUNOL, V17, P2, DOI 10.1038/ni.3341; Poschke I, 2016, J PATHOL, V240, P384, DOI 10.1002/path.4800; Prendergast GC, 2017, CANCER RES, V77, P6795, DOI 10.1158/0008-5472.CAN-17-2285; Pucci F, 2016, SCIENCE, V352, P242, DOI 10.1126/science.aaf1328; Saito Y, 2015, CANCER IMMUNOL RES, V3, P1356, DOI 10.1158/2326-6066.CIR-14-0180; Saunderson SC, 2014, BLOOD, V123, P208, DOI 10.1182/blood-2013-03-489732; Shigeoka M, 2013, CANCER SCI, V104, P1112, DOI 10.1111/cas.12188; Sudo T, 2017, ANN SURG ONCOL, V24, P3763, DOI 10.1245/s10434-017-5796-4; TAHARA H, 1990, VIRCHOWS ARCH A, V417, P311, DOI 10.1007/BF01605782; Takahashi K, 1996, PATHOL INT, V46, P473, DOI 10.1111/j.1440-1827.1996.tb03641.x; Takamatsu M, 2015, CANCER SCI, V106, P1008, DOI 10.1111/cas.12705; Takeya M, 2016, PATHOL INT, V66, P491, DOI 10.1111/pin.12440; Tsuchikawa T, 2011, CLIN EXP IMMUNOL, V164, P50, DOI 10.1111/j.1365-2249.2010.04311.x; Tsutsumi S, 2017, CANCER SCI, V108, P1119, DOI 10.1111/cas.13237; van Baren N, 2015, CANCER IMMUNOL RES, V3, P978, DOI 10.1158/2326-6066.CIR-15-0095; Yagi T, 2019, ANN SURG, V269, P471, DOI 10.1097/SLA.0000000000002616; Yokozaki H, 2018, PATHOL INT, V68, P334, DOI 10.1111/pin.12674; Zheng X, 2018, CELL PHYSIOL BIOCHEM, V45, P720, DOI 10.1159/000487164	43	1	1	2	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1320-5463	1440-1827		PATHOL INT	Pathol. Int.	DEC	2018	68	12					685	693		10.1111/pin.12736			9	Pathology	Pathology	HE9GF	WOS:000453756100004	30516869				2019-10-28	
J	Ishida, Y; Tsuda, M; Sawamura, Y; Fujii, K; Murai, H; Horiuchi, N; Orba, Y; Sawa, H; Hall, WW; Nagashima, K; Tanaka, S				Ishida, Yusuke; Tsuda, Masumi; Sawamura, Yutaka; Fujii, Kyoko; Murai, Hiroshi; Horiuchi, Naruyoshi; Orba, Yasuko; Sawa, Hirofumi; Hall, William W.; Nagashima, Kazuo; Tanaka, Shinya			"Integrated diagnosis" of pilocytic astrocytoma: Molecular diagnostic procedure for an unusual case	PATHOLOGY INTERNATIONAL			English	Article						BRAF V600E; Eprobe; KIAA-1549-fusion; pilocytic astrocytoma; pleomorphic xanthoastrocytoma	KIAA1549BRAF FUSION; MAPK PATHWAY; MUTATIONS; ACTIVATION; SYSTEM; GENE	A 24 year-old female presented with a mass lesion in the right temporal lobe. This case was difficult to diagnose using histological and immunological methods and therefore molecular analyses were applied to provide a definitive diagnosis. The tumor was well-demarcated, partially cystic, and irregularly-enhanced on gadolinium-enhanced T1-weighted magnetic resonance images. Pathologically, a large part of the tumor consisted of cells with fine cytoplasmic processes on a myxoid and mucinous background. Cells formed a microcystic structure around the mucinous tissue. Numerous eosinophilic granular bodies, but not Rosenthal fibers, were present. The solid and compact regions of the tumor were composed of fasciculation of dense fibrous glial tissues and occasional multinucleated giant cells. Tumor cells and their fragmented cytoplasmic processes were positively stained with GFAP, while eosinophilic granular bodies were both positive and negative. Xanthomatous changes were not detected and the reticulin fibers were restricted to vascular tissues. The MIB1 index was scored as approximately 10%. In molecular analyses of BRAF, the KIAA1549-BRAF (K16-B9) fusion gene was detected in all tumor regions, whereas BRAF V600E mutation was not detected by either conventional Sanger sequencing or the Eprobe-PCR method. Based on the results of the molecular analyses, this case was diagnosed as pilocytic astrocytoma.	[Ishida, Yusuke; Tsuda, Masumi; Fujii, Kyoko; Tanaka, Shinya] Hokkaido Univ, Dept Canc Pathol, Fac Med, Sapporo, Hokkaido, Japan; [Tsuda, Masumi; Tanaka, Shinya] Hokkaido Univ, Global Stn Soft Matter, Global Inst Collaborat Res & Educ, Sapporo, Hokkaido, Japan; [Sawamura, Yutaka] Sawamura Neurol & Neurosurg Clin, Sapporo, Hokkaido, Japan; [Murai, Hiroshi; Horiuchi, Naruyoshi] Sapporo Shuyukai Hosp, Dept Neurosurg, Sapporo, Hokkaido, Japan; [Orba, Yasuko; Sawa, Hirofumi] Hokkaido Univ, Res Ctr Zoonosis Control, Div Mol Pathobiol, Sapporo, Hokkaido, Japan; [Hall, William W.] Univ Coll Dublin, Natl Virus Reference Lab, Dublin, Ireland; [Nagashima, Kazuo] Sapporo Higashi Tokushukai Hosp, Dept Pathol, Sapporo, Hokkaido, Japan	Tsuda, M (reprint author), Hokkaido Univ, Fac Med, Dept Canc Pathol, Kita Ku, N15,W7, Sapporo, Hokkaido 0608638, Japan.	tsudam@med.hokudai.ac.jp	Sawa, Hirofumi/F-6954-2012		Ministry of Education, Culture, Sports, Science, and TechnologyMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT); Japanese Society for the Promotion of ScienceMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science; Ministry of Health, Labor, and Welfare of JapanMinistry of Health, Labour and Welfare, Japan; Global Station for Soft Matter, a project of Global Institution for Collaborative Research and Education at Hokkaido University	We thank Dr. Hiroshi Nishihara (Hokkaido University, the present address is Keio University) and K.K. DNAFORM (Yokohama, Japan) for providing the Eprobe-PCR system. This work was supported, in part, by Grants-in-Aid from the Ministry of Education, Culture, Sports, Science, and Technology; Japanese Society for the Promotion of Science; and Ministry of Health, Labor, and Welfare of Japan, and by Global Station for Soft Matter, a project of Global Institution for Collaborative Research and Education at Hokkaido University.	Antonelli M, 2015, PEDIATR BLOOD CANCER, V62, P724, DOI 10.1002/pbc.25272; Atsumi J, 2015, ONCOL REP, V33, P2719, DOI 10.3892/or.2015.3883; Badiali M, 2012, BRAIN PATHOL, V22, P841, DOI 10.1111/j.1750-3639.2012.00603.x; Becker AP, 2015, J NEUROPATH EXP NEUR, V74, P743, DOI 10.1097/NEN.0000000000000213; Colin C, 2013, NEUROPATH APPL NEURO, V39, P693, DOI 10.1111/nan.12013; Collins VP, 2015, ACTA NEUROPATHOL, V129, P775, DOI 10.1007/s00401-015-1410-7; Fontebasso AM, 2015, ONCOTARGET, V6, P31844, DOI 10.18632/oncotarget.5571; Forshew T, 2009, J PATHOL, V218, P172, DOI 10.1002/path.2558; Hanami T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070942; Hawkins C, 2011, CLIN CANCER RES, V17, P4790, DOI 10.1158/1078-0432.CCR-11-0034; Jones DTW, 2009, ONCOGENE, V28, P2119, DOI 10.1038/onc.2009.73; Lin A, 2012, J NEUROPATH EXP NEUR, V71, P66, DOI 10.1097/NEN.0b013e31823f2cb0; Pathak P, 2017, BRAIN PATHOL, V27, P580, DOI 10.1111/bpa.12444; Schindler G, 2011, ACTA NEUROPATHOL, V121, P397, DOI 10.1007/s00401-011-0802-6; Schubbert S, 2007, NAT REV CANCER, V7, P295, DOI 10.1038/nrc2109; Sievert AJ, 2009, BRAIN PATHOL, V19, P449, DOI 10.1111/j.1750-3639.2008.00225.x; Tatevossian RG, 2010, J CELL PHYSIOL, V222, P509, DOI 10.1002/jcp.21978; Theeler BJ, 2014, NEURO-ONCOLOGY, V16, P841, DOI 10.1093/neuonc/not246	18	0	0	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1320-5463	1440-1827		PATHOL INT	Pathol. Int.	DEC	2018	68	12					694	699		10.1111/pin.12734			6	Pathology	Pathology	HE9GF	WOS:000453756100005	30417961				2019-10-28	
J	Tsuji, H; Yasuoka, H; Nakamura, Y; Hirokawa, M; Hiroshima, T; Sakamaki, Y; Miyauchi, A; Tsujimoto, M				Tsuji, Hiromi; Yasuoka, Hironao; Nakamura, Yasushi; Hirokawa, Mitsuyoshi; Hiroshima, Takashi; Sakamaki, Yasushi; Miyauchi, Akira; Tsujimoto, Masahiko			Aggressive cribriform-morular variant of papillary thyroid carcinoma: Report of an unusual case with pulmonary metastasis displaying poorly differentiated features	PATHOLOGY INTERNATIONAL			English	Article						cribriform-morular variant of papillary thyroid carcinoma; immunohistochemistry; lung; metastasis; beta-catenin	EXPRESSION; MUTATIONS; CANCER	The cribriform-morular variant of papillary thyroid carcinoma (CMV-PTC) is a rare morphologic entity in which metastasis rarely occurs. Until now, only three cases of metastasis by CMV-PTC have been reported. We present a rare sporadic case of CMV-PTC with multiple lung metastases in a 28-year-old female, 3 years after total thyroidectomy. The lung tumor was not encapsulated but well-circumscribed and showed a mixture of cribriform, papillary, and solid patterns of growth with necrosis. The tall columnar carcinoma cells did not display the typical nuclear features of PTC. Carcinoma cells were positive for thyroid transcription factor 1, paired-box gene 8, estrogen receptor, progesterone receptor, and adenomatous polyposis coli, and showed positive nuclear and cytoplasmic staining for beta-catenin. Carcinoma cells were negative for thyroglobulin and CDX-2, and the Ki-67 labeling index was 22.1%. This immunoprofile suggests a pathological diagnosis of metastasis by a CMV-PTC displaying poorly differentiated features. To the best of our knowledge, our case is the first report of CMV-PTC with pulmonary metastasis that was confirmed by histological and immunohistochemical examinations. The present case suggests that CMV-PTC with a high Ki-67 labeling index may cause visceral metastasis.	[Tsuji, Hiromi; Yasuoka, Hironao; Tsujimoto, Masahiko] Osaka Police Hosp, Dept Diagnost Pathol, Osaka, Japan; [Nakamura, Yasushi] Osaka Cytopathol Lab, Dept Pathol, Osaka, Japan; [Hirokawa, Mitsuyoshi] Kuma Hosp, Dept Pathol, Kobe, Hyogo, Japan; [Hiroshima, Takashi; Sakamaki, Yasushi] Osaka Police Hosp, Dept Thorac Surg, Osaka, Japan; [Miyauchi, Akira] Kuma Hosp, Dept Surg, Kobe, Hyogo, Japan	Yasuoka, H (reprint author), Osaka Police Hosp, Dept Diagnost Pathol, Tennouji Ku, 10-31 Kitayama Cho, Osaka, Osaka, Japan.	hyasuoka@oph.gr.jp					Cabibi D, 2006, ANTICANCER RES, V26, P4357; Cameselle-Teijeiro J, 1999, MODERN PATHOL, V12, P400; Cameselle-Teijeiro J, 2001, AM J CLIN PATHOL, V115, P486; Cameselle-Teijeiro J, 2009, AM J CLIN PATHOL, V131, P134, DOI 10.1309/AJCP7ULS0VSISBEB; Fenton PA, 2001, THYROID, V11, P193, DOI 10.1089/105072501300042965; Garcia-Rostan G, 2001, AM J PATHOL, V158, P987, DOI 10.1016/S0002-9440(10)64045-X; HARACH HR, 1994, HISTOPATHOLOGY, V25, P549, DOI 10.1111/j.1365-2559.1994.tb01374.x; Heemstra KA, 2007, CLIN ENDOCRINOL, V66, P58, DOI 10.1111/j.1365-2265.2006.02685.x; Ito Y, 2011, ENDOCR J, V58, P685, DOI 10.1507/endocrj.EJ11-0022; Kovacs CMNV., 2012, DIAGNOSTIC PATHOLOGY, P104; Nakazawa T, 2013, INT J SURG PATHOL, V21, P379, DOI 10.1177/1066896912473355; Ng SB, 2003, PATHOLOGY, V35, P42, DOI 10.1080/003130202201476; Oh EJ, 2017, ENDOCR PATHOL, V28, P49, DOI 10.1007/s12022-016-9454-3; Pan DH, 2017, ONCOTARGETS THER, V10, P3261, DOI 10.2147/OTT.S135593; Rosai JASJ, 2017, WHO CLASSIFICATION T, P81; Spencer CA, 1998, J CLIN ENDOCR METAB, V83, P1121, DOI 10.1210/jc.83.4.1121; Tomoda C, 2004, WORLD J SURG, V28, P886, DOI 10.1007/s00268-004-7475-4; Xu B, 2003, J PATHOL, V199, P58, DOI 10.1002/path.1225; Yasuoka H, 2018, PATHOL INT, V68, P246, DOI 10.1111/pin.12649; Yasuoka H, 2017, BMC CLIN PATHOL, V17, DOI 10.1186/s12907-017-0048-x	20	1	1	1	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1320-5463	1440-1827		PATHOL INT	Pathol. Int.	DEC	2018	68	12					700	705		10.1111/pin.12728			6	Pathology	Pathology	HE9GF	WOS:000453756100006	30376202				2019-10-28	
J	Fukuda, M; Ishigaki, H; Ban, H; Sugimoto, M; Tanaka, E; Yonemaru, J; Kuroe, S; Namura, T; Matsubara, A; Moritani, S; Murakami, K; Andoh, A; Kushima, R				Fukuda, Masahide; Ishigaki, Hirohito; Ban, Hiromitsu; Sugimoto, Mitsushige; Tanaka, Eri; Yonemaru, Junpei; Kuroe, Shinobu; Namura, Tomo; Matsubara, Akiko; Moritani, Suzuko; Murakami, Kazunari; Andoh, Akira; Kushima, Ryoji			No transformation of a fundic gland polyp with dysplasia into invasive carcinoma after 14 years of follow-up in a proton pump inhibitor-treated patient: A case report	PATHOLOGY INTERNATIONAL			English	Article						dysplasia; endoscopic mucosal resection; fundic gland polyp; microcysts; proton pump inhibitor	VIENNA CLASSIFICATION; ADENOCARCINOMA; EXPRESSION; LESIONS	A fundic gland polyp (FGP) is a common gastric polyp. Intraepithelial neoplasia in FGPs, referred to as FGP with dysplasia, is often seen in patients with familial adenomatous polyposis (FAP). In sporadic FGPs, low-grade dysplasia (LGD) is rare, and high-grade dysplasia (HGD) or carcinoma arising from sporadic FGPs is extremely rare. Because of this rarity, the prognosis and appropriate management of these lesions have not been clarified. In the present case, a sporadic FGP with LGD did not develop into invasive carcinoma, but contained foci of HGD 14 years after diagnosis. The biopsy specimen of the polyp taken at the first esophagogastroduodenoscopy 15 years earlier was diagnosed as FGP without dysplasia. At the second histological examination, LGD was found. Because the polyp increased in size during proton pump inhibitor therapy for 14 years, endoscopic mucosal resection was performed. The pathological diagnosis of the resected specimen was FGP with HGD mixed in LGD, with no invasive carcinoma. Dysplasia in FGPs might have less malignant potential regardless of dysplasia or size.	[Fukuda, Masahide; Tanaka, Eri; Yonemaru, Junpei; Kuroe, Shinobu; Namura, Tomo; Matsubara, Akiko; Moritani, Suzuko; Kushima, Ryoji] Shiga Univ Med Sci Hosp, Div Diagnost Pathol, Otsu, Shiga, Japan; [Fukuda, Masahide; Murakami, Kazunari] Oita Univ, Dept Gastroenterol, Fac Med, Oita, Japan; [Ishigaki, Hirohito] Shiga Univ Med Sci, Dept Pathol, Div Pathol & Dis Regulat, Otsu, Shiga, Japan; [Ban, Hiromitsu; Sugimoto, Mitsushige; Andoh, Akira] Shiga Univ Med Sci Hosp, Div Gastrointestinal Endoscopy, Otsu, Shiga, Japan; [Andoh, Akira] Shiga Univ Med Sci Hosp, Dept Med, Otsu, Shiga, Japan	Kushima, R (reprint author), Shiga Univ Med Sci, Dept Clin Lab Med, Div Diagnost Pathol, Otsu, Shiga 5202192, Japan.	kushima@belle.shiga-med.ac.jp					Arnason T, 2014, HISTOPATHOLOGY, V65, P353, DOI 10.1111/his.12393; Cats A, 2000, HUM PATHOL, V31, P684, DOI 10.1053/hupa.2000.7637; Choi WT, 2018, HISTOPATHOLOGY, V72, P1007, DOI 10.1111/his.13460; Genta RM, 2009, CLIN GASTROENTEROL H, V7, P849, DOI 10.1016/j.cgh.2009.05.015; Jalving M, 2003, EUR J GASTROEN HEPAT, V15, P1229, DOI 10.1097/01.meg.0000085491.01212.d2; Jalving M, 2003, SCAND J GASTROENTERO, V38, P916, DOI 10.1080/00365520310005433; Japanese Gastric Canc Assoc, 2011, GASTRIC CANCER, V14, P101, DOI 10.1007/s10120-011-0041-5; Jung SH, 2010, GASTRIC CANCER, V13, P123, DOI 10.1007/s10120-010-0550-7; Kawase R, 2009, CLIN J GASTROENTEROL, V2, P279, DOI 10.1007/s12328-009-0096-6; Lauwers GY, 2010, WHO CLASSIFICATION T, P45; Ohmura K, 2000, HUM PATHOL, V31, P1031, DOI 10.1053/hupa.2000.16669; Schlemper RJ, 2000, GUT, V47, P251, DOI 10.1136/gut.47.2.251; Sekine S, 2002, VIRCHOWS ARCH, V440, P381, DOI 10.1007/s004280100527; TATSUTA M, 1980, CANCER, V45, P818, DOI 10.1002/1097-0142(19800215)45:4<818::AID-CNCR2820450435>3.0.CO;2-5; Togo K, 2016, WORLD J GASTROENTERO, V22, P9028, DOI 10.3748/wjg.v22.i40.9028; Tran-Duy A, 2016, CLIN GASTROENTEROL H, V14, P1706, DOI 10.1016/j.cgh.2016.05.018; Tsukashita S, 2001, INT J CANCER, V94, P166, DOI 10.1002/ijc.1460; WATANABE H, 1978, HUM PATHOL, V9, P269, DOI 10.1016/S0046-8177(78)80085-9	18	1	1	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1320-5463	1440-1827		PATHOL INT	Pathol. Int.	DEC	2018	68	12					706	711		10.1111/pin.12739			6	Pathology	Pathology	HE9GF	WOS:000453756100007	30511782				2019-10-28	
J	Milanetto, AC; Valbona, L; Alaggio, R; Munari, G; Pedrazzoli, S; Fassan, M; Pasquali, C				Milanetto, Anna Caterina; Valbona, Lico; Alaggio, Rita; Munari, Giada; Pedrazzoli, Sergio; Fassan, Matteo; Pasquali, Claudio			Adenosquamous carcinoma of the papilla of Vater: A phenotypic heterogeneity characterized by a common molecular landscape	PATHOLOGY INTERNATIONAL			English	Letter									[Milanetto, Anna Caterina; Valbona, Lico; Pasquali, Claudio] Univ Padua, Clin Chirurg 1, Dept Surg Oncol & Gastroenterol DiSCoG, Padua, Italy; [Alaggio, Rita; Munari, Giada; Fassan, Matteo] Univ Padua, Dept Med, Surg Pathol Unit, Padua, Italy; [Pedrazzoli, Sergio] Univ Padua, Clin Chirurg 4, Padua, Italy	Milanetto, AC (reprint author), Univ Padua, Clin Chirurg 1, Dept Surg Oncol & Gastroenterol DiSCoG, Padua, Italy.		Milanetto, Anna Caterina/AAC-5728-2019; alaggio, rita/AAC-2348-2019	Milanetto, Anna Caterina/0000-0002-3042-4360; alaggio, rita/0000-0003-3915-3816			Hoshimoto S, 2017, SCAND J GASTROENTERO, V52, P425, DOI 10.1080/00365521.2016.1273383; Hoshimoto S, 2015, WORLD J SURG ONCOL, V13, DOI 10.1186/s12957-015-0709-0; Qin BD, 2018, CANCER MANAG RES, V10, P439, DOI 10.2147/CMAR.S144850; Yachida S, 2016, CANCER CELL, V29, P229, DOI 10.1016/j.ccell.2015.12.012; Yang SJ, 2013, WORLD J SURG ONCOL, V11, DOI 10.1186/1477-7819-11-124	5	0	0	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1320-5463	1440-1827		PATHOL INT	Pathol. Int.	DEC	2018	68	12					715	716		10.1111/pin.12731			2	Pathology	Pathology	HE9GF	WOS:000453756100009	30417956				2019-10-28	
J	Kohashi, K; Oda, Y				Kohashi, K.; Oda, Y.			Oncogenic roles of SMARCB1/INI1 and its deficient tumors (vol 108, pg 547, 2017)	PATHOLOGY INTERNATIONAL			English	Correction																Kohashi K, 2017, CANCER SCI, V108, P547, DOI 10.1111/cas.13173	1	0	0	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1320-5463	1440-1827		PATHOL INT	Pathol. Int.	DEC	2018	68	12					717	717		10.1111/pin.12750			1	Pathology	Pathology	HE9GF	WOS:000453756100010					2019-10-28	
J	Kubota, T; Sasaki, Y; Shiozawa, E; Takimoto, M; Hishima, T; Chong, JM				Kubota, Tomomi; Sasaki, Yosuke; Shiozawa, Eisuke; Takimoto, Masafumi; Hishima, Tsunekazu; Chong, Ja-Mun			Age and CD20 Expression Are Significant Prognostic Factors in Human Herpes Virus-8-negative Effusion-based Lymphoma	AMERICAN JOURNAL OF SURGICAL PATHOLOGY			English	Article						HHV-8-negative effusion-based lymphoma; multivariate analysis; primary effusion lymphoma; prognosis	HEPATITIS-C VIRUS; OF-THE-LITERATURE; HUMAN-IMMUNODEFICIENCY-VIRUS; UNRELATED PRIMARY EFFUSION; HIV-SERONEGATIVE PATIENT; LIVER-CIRRHOSIS; PLEURAL EFFUSION; NEGATIVE PATIENT; DNA-SEQUENCES; RITUXIMAB	Human herpes virus-8 (HHV-8)-negative effusion-based lymphoma (HHV-8-negative EBL) can be distinguished from primary effusion lymphoma based on clinical and pathologic findings. Although the morphology between the 2 is similar and they both originate from body cavities with serous effusions and are characterized by lack of tumor masses, HHV-8-negative EBL generally occurs in older patients, and has favorable response to therapy and better prognosis than primary effusion lymphoma. However, no systematic studies have investigated prognostic factors in patients with HHV-8-negative EBL. In this report, clinical and pathologic characteristics of 67 cases of HHV-8-negative EBL, including 2 of our own cases, were analyzed. Univariate analyses revealed older age (70 y and above), Japanese ethnicity, pericardial effusion, CD20 expression, and chemotherapy with rituximab were significantly favorable prognostic factors. Peritoneal effusion was identified as an unfavorable prognostic factor. In the multivariate analysis, age and CD20 expression were independent prognostic factors (P = 0.013 and 0.003, respectively). A past history of induced fluid overload, hepatitis C viral infection, and peritoneal effusion were significantly correlated with patients aged below 70 years, while pericardial and pleural effusions were significantly correlated with patients aged 70 years and above. A comparison of cases with and without CD20 expression revealed that Japanese ethnicity and pericardial effusion were significantly correlated with CD20 expression, whereas a past history of induced fluid overload and peritoneal effusion were significantly correlated with the absence of CD20. We concluded that older age and CD20 expression are significant and favorable independent prognostic factors of HHV-8-negative EBL.	[Kubota, Tomomi; Chong, Ja-Mun] Tokyo Metropolitan Hlth & Med Treatment Corp, Toshima Hosp, Dept Pathol, Tokyo, Japan; [Sasaki, Yosuke; Shiozawa, Eisuke; Takimoto, Masafumi] Showa Univ, Dept Pathol, Tokyo, Japan; [Hishima, Tsunekazu] Komagome Hosp, Tokyo Metropolitan Canc & Infect Dis Ctr, Dept Pathol, Tokyo, Japan	Chong, JM (reprint author), Sakaecho 33-1, Tokyo 1730015, Japan.	shikofumi_tei@tokyo-hmt.jp			Tokyo Metropolitan Health and Medical Treatment Corporation Toshima Hospital	Supported by a clinical research Grant from Tokyo Metropolitan Health and Medical Treatment Corporation Toshima Hospital. The authors have disclosed that they have no significant relationships with, or financial interest in, any commercial companies pertaining to this article.	Adiguzel C, 2009, APMIS, V117, P222, DOI 10.1111/j.1600-0463.2008.00005.x; Alexanian S, 2013, AM J SURG PATHOL, V37, P241, DOI 10.1097/PAS.0b013e318267fabc; Ascoli V, 1997, HUM PATHOL, V28, P101, DOI 10.1016/S0046-8177(97)90287-2; Ashihara E, 2001, INT J HEMATOL, V74, P327, DOI 10.1007/BF02982069; Carbone A, 1996, BRIT J HAEMATOL, V94, P533, DOI 10.1046/j.1365-2141.1996.d01-1826.x; Castillo JJ, 2012, LEUKEMIA LYMPHOMA, V53, P2378, DOI 10.3109/10428194.2012.694075; Chiba H, 2003, ANN HEMATOL, V82, P773, DOI 10.1007/s00277-003-0734-x; Choi JW, 2015, J PATHOL TRANSL MED, V49, P409, DOI 10.4132/jptm.2015.06.03; Cooper AR, 2010, LEUKEMIA LYMPHOMA, V51, P2303, DOI 10.3109/10428194.2010.520775; Dai HY, 2014, LABMEDICINE, V45, P136, DOI 10.1309/LMICZ683ORLRJRJO; De Filippi R, 2009, BRIT J HAEMATOL, V147, P405, DOI 10.1111/j.1365-2141.2009.07846.x; Fan HB, 2014, J RES MED SCI, V19, P190; Fujiwara T, 2005, CANCER GENET CYTOGEN, V156, P49, DOI 10.1016/j.cancergencyto.2004.04.013; Hara T, 2001, J GASTROEN HEPATOL, V16, P948, DOI 10.1046/j.1440-1746.2001.2379d.x; Hermine O, 1996, NEW ENGL J MED, V334, P272; Hisamoto A, 2003, LEUKEMIA LYMPHOMA, V44, P2019, DOI 10.1080/1042819031000110955; Ichinohasama R, 1998, AM J SURG PATHOL, V22, P1528, DOI 10.1097/00000478-199812000-00010; Inoue Y, 2004, INT J HEMATOL, V79, P271, DOI 10.1532/IJH97.03107; Jenkins C, 2005, CLIN ONCOL-UK, V17, P636, DOI 10.1016/j.clon.2005.05.012; Kagoya Y, 2011, ANN HEMATOL, V90, P219, DOI 10.1007/s00277-010-0975-4; Kim HJ, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000008010; Kim KH, 2012, TUBERC RESPIR DIS, V73, P336, DOI 10.4046/trd.2012.73.6.336; Kobayashi Y, 2007, ACTA HAEMATOL-BASEL, V117, P132, DOI 10.1159/000097460; Koeda C, 2017, J GEN FAM MED, V18, P38, DOI 10.1002/jgf2.9; Kojima M, 2017, J CLIN EXP HEMATOP, V57, P69, DOI 10.3960/jslrt.17020; Lambe JS, 2009, HEMATOL ONCOL, V27, P203, DOI 10.1002/hon.892; Matsumoto Y, 2005, LEUKEMIA LYMPHOMA, V46, P415, DOI 10.1080/10428190400018364; Mohammad F, 2014, CASE REP ONCOL MED, DOI 10.1155/2014/436821; Nador RG, 1996, BLOOD, V88, P645, DOI 10.1182/blood.V88.2.645.bloodjournal882645; Nakamura H, 2015, PATHOL RES PRACT, V211, P1010, DOI 10.1016/j.prp.2015.08.002; Nakamura Y, 2003, INTERNAL MED, V42, P351, DOI 10.2169/internalmedicine.42.351; Nemr S, 2008, CHEST, V134, P196, DOI 10.1378/chest.07-2529; Niino D, 2008, Haematologica, V93, pe21, DOI 10.3324/haematol.12085; Nonami A, 2004, INTERNAL MED, V43, P236, DOI 10.2169/internalmedicine.43.236; Nussinson E, 2014, WORLD J GASTROENTERO, V20, P857, DOI 10.3748/wjg.v20.i3.857; Ohori NP, 2001, DIAGN CYTOPATHOL, V25, P50, DOI 10.1002/dc.2001; Ohshima K, 2002, LEUKEMIA LYMPHOMA, V43, P595, DOI 10.1080/10428190290012100; Oki Masayuki, 2016, Tokai J Exp Clin Med, V41, P123; Paner GP, 2003, LEUKEMIA LYMPHOMA, V44, P1811, DOI 10.1080/1042819031000104015; Rodriguez J, 2001, LEUKEMIA LYMPHOMA, V41, P185, DOI 10.3109/10428190109057969; Said J, 2017, WHO CLASSIFICATION T, P323; Saini N, 2013, CASE REP ONCOL MED, DOI 10.1155/2013/292301; Shimazaki M, 2003, EUR J HAEMATOL, V71, P62, DOI 10.1034/j.1600-0609.2003.00083.x; Shin J, 2017, CANCER RES TREAT, V49, P274, DOI 10.4143/crt.2016.076; Simonelli C, 2003, J CLIN ONCOL, V21, P3948, DOI 10.1200/JCO.2003.06.013; Takahashi T, 2010, AM J HEMATOL, V85, P85, DOI 10.1002/ajh.21568; Takao T, 2004, AM J HEMATOL, V77, P419, DOI 10.1002/ajh.20227; Terasaki Y, 2011, INT J HEMATOL, V94, P279, DOI 10.1007/s12185-011-0906-8; Terasaki Y, 2008, INTERNAL MED, V47, P2175, DOI 10.2169/internalmedicine.47.1565; Tsagarakis NJ, 2009, INT J HEMATOL, V90, P94, DOI 10.1007/s12185-009-0343-0; Wang T, 2011, J CLIN ONCOL, V29, pE747, DOI 10.1200/JCO.2011.35.7509; Wu WZ, 2014, ONCOL LETT, V7, P433, DOI 10.3892/ol.2013.1731; Wu W, 2013, AM J CLIN PATHOL, V140, P258, DOI 10.1309/AJCPHZ3CHO4HUWET; Xiao JN, 2013, CANCER CYTOPATHOL, V121, P661, DOI 10.1002/cncy.21311; Yamazaki K, 2013, J CLIN ONCOL, V31, pE435, DOI 10.1200/JCO.2012.46.8058; Youngster I, 2006, AGE AGEING, V35, P94, DOI 10.1093/ageing/afj009; Zhang EJ, 2016, SCI REP-UK, V6, DOI 10.1038/srep22730	57	0	0	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0147-5185	1532-0979		AM J SURG PATHOL	Am. J. Surg. Pathol.	DEC	2018	42	12					1607	1616		10.1097/PAS.0000000000001168			10	Pathology; Surgery	Pathology; Surgery	HA7BB	WOS:000450434700004	30273194				2019-10-28	
J	Steiner, DF; MacDonald, R; Liu, Y; Truszkowski, P; Hipp, JD; Gammage, C; Thng, F; Peng, L; Stumpe, MC				Steiner, David F.; MacDonald, Robert; Liu, Yun; Truszkowski, Peter; Hipp, Jason D.; Gammage, Christopher; Thng, Florence; Peng, Lily; Stumpe, Martin C.			Impact of Deep Learning Assistance on the Histopathologic Review of Lymph Nodes for Metastatic Breast Cancer	AMERICAN JOURNAL OF SURGICAL PATHOLOGY			English	Review						artificial intelligence; machine learning; digital pathology; breast cancer; computer aided detection	ISOLATED TUMOR-CELLS; DIGITAL PATHOLOGY; CARCINOMA; DIAGNOSIS	Advances in the quality of whole-slide images have set the stage for the clinical use of digital images in anatomic pathology. Along with advances in computer image analysis, this raises the possibility for computer-assisted diagnostics in pathology to improve histopathologic interpretation and clinical care. To evaluate the potential impact of digital assistance on interpretation of digitized slides, we conducted a multireader multicase study utilizing our deep learning algorithm for the detection of breast cancer metastasis in lymph nodes. Six pathologists reviewed 70 digitized slides from lymph node sections in 2 reader modes, unassisted and assisted, with a wash-out period between sessions. In the assisted mode, the deep learning algorithm was used to identify and outline regions with high likelihood of containing tumor. Algorithm-assisted pathologists demonstrated higher accuracy than either the algorithm or the pathologist alone. In particular, algorithm assistance significantly increased the sensitivity of detection for micrometastases (91% vs. 83%, P=0.02). In addition, average review time per image was significantly shorter with assistance than without assistance for both micrometastases (61 vs. 116s, P = 0.002) and negative images (111 vs. 137s, P = 0.018). Lastly, pathologists were asked to provide a numeric score regarding the difficulty of each image classification. On the basis of this score, pathologists considered the image review of micrometastases to be significantly easier when interpreted with assistance (P = 0.0005). Utilizing a proof of concept assistant tool, this study demonstrates the potential of a deep learning algorithm to improve pathologist accuracy and efficiency in a digital pathology workflow.	[Steiner, David F.; MacDonald, Robert; Liu, Yun; Truszkowski, Peter; Hipp, Jason D.; Gammage, Christopher; Peng, Lily; Stumpe, Martin C.] Google AI Healthcare, 1600 Amphitheatre Way, Mountain View, CA 94043 USA; [Thng, Florence] Verily Life Sci, Mountain View, CA USA	Steiner, DF (reprint author), Google AI Healthcare, 1600 Amphitheatre Way, Mountain View, CA 94043 USA.	davesteiner@google.com					Acs B, 2018, JAMA ONCOL, V4, P403, DOI 10.1001/jamaoncol.2017.5449; Apple SK, 2016, J PATHOL TRANSL MED, V50, P83, DOI 10.4132/jptm.2015.11.23; Badve SS, 2017, BREAST CANC STAGING; Bejnordi BE, 2017, JAMA-J AM MED ASSOC, V318, P2199, DOI 10.1001/jama.2017.14585; Biscotti CV, 2005, AM J CLIN PATHOL, V123, P281, DOI 10.1309/AGB1MJ9H5N43MEGX; Cabitza F, 2017, JAMA-J AM MED ASSOC, V318, P517, DOI 10.1001/jama.2017.7797; de Boer M, 2010, J NATL CANCER I, V102, P410, DOI 10.1093/jnci/djq008; de Boer M, 2009, NEW ENGL J MED, V361, P653, DOI 10.1056/NEJMoa0904832; Dendumrongsup T, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0116018; Fine Jeffrey L, 2014, J Pathol Inform, V5, P44, DOI 10.4103/2153-3539.145733; Gallas BD, 2012, ACAD RADIOL, V19, P463, DOI 10.1016/j.acra.2011.12.016; Gavrielides MA, 2011, ARCH PATHOL LAB MED, V135, P233, DOI 10.1043/1543-2165-135.2.233; Giuliano AE, 2011, JAMA-J AM MED ASSOC, V305, P569, DOI 10.1001/jama.2011.90; Krizhevsky A, 2017, COMMUN ACM, V60, P84, DOI 10.1145/3065386; LeCun Y, 2015, NATURE, V521, P436, DOI 10.1038/nature14539; Lester SC, 2009, ARCH PATHOL LAB MED, V133, P1515, DOI 10.1043/1543-2165-133.10.1515; Litjens G, 2017, CANC METASTASES LYMP; Litjens G, 2016, SCI REP-UK, V6, DOI 10.1038/srep26286; Liu Y., 2017, DETECTING CANC METAS; Mills AM, 2018, AM J SURG PATHOL, V42, P53, DOI 10.1097/PAS.0000000000000930; Mukhopadhyay S, 2018, AM J SURG PATHOL, V42, P39, DOI 10.1097/PAS.0000000000000948; Rabinovitch A, 2002, ACCREDIT QUAL ASSUR, V7, P473, DOI 10.1007/s00769-002-0537-0; Russakovsky O, 2015, INT J COMPUT VISION, V115, P211, DOI 10.1007/s11263-015-0816-y; Rutledge H, 2005, MODERN PATHOL, V18, P762, DOI 10.1038/modpathol.3800394; Taylor P, 2008, EUR J CANCER, V44, P798, DOI 10.1016/j.ejca.2008.02.016; Vestjens JH, 2012, BREAST CANCER RES TR, V131, P645, DOI 10.1007/s10549-011-1771-0; Weaver DL, 2011, NEW ENGL J MED, V364, P412, DOI 10.1056/NEJMoa1008108; Wilbur DC, 2009, AM J CLIN PATHOL, V132, P767, DOI 10.1309/AJCP8VE7AWBZCVQT; Wolff AC, 2013, J CLIN ONCOL, V31, P3997, DOI 10.1200/JCO.2013.50.9984	29	16	16	3	23	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0147-5185	1532-0979		AM J SURG PATHOL	Am. J. Surg. Pathol.	DEC	2018	42	12					1636	1646		10.1097/PAS.0000000000001151			11	Pathology; Surgery	Pathology; Surgery	HA7BB	WOS:000450434700007	30312179	Green Published			2019-10-28	
J	Kao, CS; Bangs, CD; Aldrete, G; Cherry, AM; Ulbright, TM				Kao, Chia-Sui; Bangs, Charles D.; Aldrete, Galina; Cherry, Athena M.; Ulbright, Thomas M.			A Clinicopathologic and Molecular Analysis of 34 Mediastinal Germ Cell Tumors Suggesting Different Modes of Teratoma Development	AMERICAN JOURNAL OF SURGICAL PATHOLOGY			English	Article						mediastinum; germ cell tumor; teratoma; yolk sac tumor; secondary somatic-type malignancy; isochromosome 12p; chromosome 12p copy number increase	MATURE CYSTIC TERATOMA; IN-SITU HYBRIDIZATION; CHROMOSOME-12 ABNORMALITIES; MALIGNANT TERATOMA; ISOCHROMOSOME 12P; GENETIC-ANALYSIS; CARCINOMA; CYTOGENETICS; SEMINOMA; EMPHASIS	Mediastinal teratomas are enigmatic; those in children and women are almost invariably benign but in men they may be benign or malignant. There are few data on the chromosome 12p status of mediastinal germ cell tumors (GCT), whereas increased 12p copy number is virtually uniform in malignant testicular GCTs. We therefore studied chromosome 12p copy number in 34 diverse mediastinal GCTs and correlated the results with morphology and follow-up to gain insight into possible pathogenesis. Four prepubertal (below 12y) children (3 females and 1 male), 7 postpubertal females (14 to 52 y) and 6 postpubertal males (12 to 40 y old) had pure, previously untreated teratomas; 15 were mature and 2 had low-grade immaturity. All lacked 12p copy number increase and cytologic atypia, and most (14/17) showed organoid morphology. On follow-up of 16, 1 died of postoperative complications and the remaining 15 were disease free (1 to 119 mo, mean: 39 mo). Eight postpubertal males (19 to 44 y old) had pure teratomas in postchemotherapy resections; 5/8 showed 12p copy number increase. All 8 had distinct cytologic atypia, with organoid morphology in 3. On follow-up, 6 were disease free after surgical resection (1.5 to 94 mo, mean 38 mo); 1 died of disease at 14.5 months, and 1 was alive with metastases at 176 months. Two postpubertal patients, 1 male (29 y) and 1 female (31 y), had teratoma with secondary somatic-type malignancies, with positive 12p copy number increase in the former but not the latter. The man's tumor occurred after chemotherapy and was a nonorganoid teratoma with primitive neuroectodermal tumor and malignant glioma; the woman's was a previously untreated organoid teratoma with an undifferentiated carcinoma component. The man died of disease (16 mo) and the woman was alive with metastases (27 mo). Seven patients had resections for mixed GCTs (4) or pure nonteratomatous tumors, all after chemotherapy; 5/7 had positive 12p copy number increase. The teratoma component of the 2 cases having one showed distinct cytologic atypia and lacked organoid morphology. On follow-up, 1 died of disease (5 mo), 2 were alive with disease (1, 1.5 mo), 3 were disease free (1 to 43 mo; mean: 18 mo), and 1 was alive with unknown status (31 mo). Our results support that mediastinal teratomas likely develop from 2 separate pathways. Those in children, women and some men arise as pure neoplasms from a nontransformed precursor cell and, therefore, lack 12p copy number increase, show no cytologic atypia, often have organoid morphology and are benign. Common 12p copy number increase, uniform atypia, infrequent organoid structures and malignant behavior support that pure teratomas after chemotherapy in postpubertal males derive from a malignantly transformed precursor cell. Interestingly, we identified organoid pancreatic differentiation only in the benign group and neuroglia more commonly in the malignant teratomas.	[Kao, Chia-Sui; Bangs, Charles D.; Aldrete, Galina; Cherry, Athena M.] Stanford Univ, Sch Med, Dept Pathol, Stanford, CA 94305 USA; [Ulbright, Thomas M.] Indiana Univ Sch Med, Dept Pathol & Lab Med, Indianapolis, IN 46202 USA	Ulbright, TM (reprint author), Indiana Univ, Hlth Pathol Lab, Room 4014,350 W 11th St, Indianapolis, IN 46202 USA.	tulbrigh@iupui.edu					ATKIN NB, 1993, GENE CHROMOSOME CANC, V6, P218, DOI 10.1002/gcc.2870060405; ATKIN NB, 1983, CANCER GENET CYTOGEN, V10, P199, DOI 10.1016/0165-4608(83)90125-5; Balzer BL, 2006, AM J SURG PATHOL, V30, P858, DOI 10.1097/01.pas.0000209831.24230.56; BOSL GJ, 1989, J NATL CANCER I, V81, P1874; Bosl GJ, 1990, JNCI-J NATL CANCER I, V82, P627; BROWN K, 1989, MED PEDIATR ONCOL, V17, P164, DOI 10.1002/mpo.2950170218; Bussey KJ, 1999, GENE CHROMOSOME CANC, V25, P134, DOI 10.1002/(SICI)1098-2264(199906)25:2<134::AID-GCC9>3.0.CO;2-Y; CASTEDO SMMJ, 1989, CANCER RES, V49, P672; Coskun U, 2002, MED PRIN PRACT, V11, P218, DOI 10.1159/000065812; Davis GL, 1996, INT J GYNECOL PATHOL, V15, P356, DOI 10.1097/00004347-199610000-00009; DELOZIERBLANCHET CD, 1987, INT J ANDROL, V10, P69, DOI 10.1111/j.1365-2605.1987.tb00167.x; GIBAS Z, 1986, CANCER GENET CYTOGEN, V19, P245, DOI 10.1016/0165-4608(86)90053-1; Gurda GT, 2014, MODERN PATHOL, V27, P562, DOI 10.1038/modpathol.2013.171; HIRAKAWA T, 1989, AM J SURG PATHOL, V13, P397, DOI 10.1097/00000478-198905000-00007; HOFFNER L, 1994, CANCER GENET CYTOGEN, V74, P54, DOI 10.1016/0165-4608(94)90029-9; Kashiwagi A, 1993, Nihon Hinyokika Gakkai Zasshi, V84, P1655; KNAPP RH, 1985, J THORAC CARDIOV SUR, V89, P82; Lim SC, 1998, PATHOL INT, V48, P834, DOI 10.1111/j.1440-1827.1998.tb03846.x; LINDER D, 1975, NEW ENGL J MED, V292, P63, DOI 10.1056/NEJM197501092920202; LINDER D, 1969, P NATL ACAD SCI USA, V63, P699, DOI 10.1073/pnas.63.3.699; Liu LP, 2016, HUM PATHOL, V56, P109, DOI 10.1016/j.humpath.2016.05.019; MANIVEL JC, 1989, CANCER, V64, P715, DOI 10.1002/1097-0142(19890801)64:3<715::AID-CNCR2820640325>3.0.CO;2-I; Marina N, 2006, J CLIN ONCOL, V24, P2544, DOI 10.1200/JCO.2005.04.1251; McKenney JK, 2007, ADV ANAT PATHOL, V14, P69, DOI 10.1097/PAP.0b013e31803240e6; Moran CA, 1997, CANCER-AM CANCER SOC, V80, P681, DOI 10.1002/(SICI)1097-0142(19970815)80:4<681::AID-CNCR6>3.0.CO;2-Q; Morishima Y, 1998, RESP MED, V92, P882, DOI 10.1016/S0954-6111(98)90395-X; Mostert M, 2000, LAB INVEST, V80, P1055, DOI 10.1038/labinvest.3780110; NORRIS HJ, 1976, CANCER, V37, P2359, DOI 10.1002/1097-0142(197605)37:5<2359::AID-CNCR2820370528>3.0.CO;2-Q; OOSTERHUIS JW, 1986, CANCER GENET CYTOGEN, V22, P149; Oosterhuis JW, 2005, NAT REV CANCER, V5, P210, DOI 10.1038/nrc1568; Perlman EJ, 2000, J PEDIAT HEMATOL ONC, V22, P100, DOI 10.1097/00043426-200003000-00003; Pienkowska-Grela B, 2002, CANCER GENET CYTOGEN, V134, P102, DOI 10.1016/S0165-4608(01)00619-7; Poulos C, 2006, MODERN PATHOL, V19, P766, DOI 10.1038/modpathol.3800596; Rivera C, 2011, J GYNECOL ONCOL, V22, P288, DOI 10.3802/jgo.2011.22.4.288; RODRIGUEZ E, 1992, CANCER RES, V52, P2285; Roelofs H, 2000, AM J PATHOL, V157, P1155, DOI 10.1016/S0002-9440(10)64631-7; Rosai J, 1995, INT J SURG PATHOL, V2, P73; SAMANIEGO F, 1990, GENE CHROMOSOME CANC, V1, P289, DOI 10.1002/gcc.2870010406; Sandberg AA, 1996, J UROLOGY, V155, P1531, DOI 10.1016/S0022-5347(01)66124-X; SCHLUMBERGER HG, 1946, ARCH PATHOL, V41, P398; Schneider DT, 2002, GENE CHROMOSOME CANC, V34, P115, DOI 10.1002/gcc.10053; Shimizu J, 2001, TUMORI, V87, P269; SMOLAREK TA, 1995, GENE CHROMOSOME CANC, V14, P252, DOI 10.1002/gcc.2870140403; Sung MT, 2008, AM J SURG PATHOL, V32, P146, DOI 10.1097/PAS.0b013e3181379edf; Takeda S, 2003, CANCER, V97, P367, DOI 10.1002/cncr.11068; Ulbright TM, 2004, ADV ANAT PATHOL, V11, P10, DOI 10.1097/00125480-200401000-00002; Vartanian RK, 2002, INT J GYNECOL PATHOL, V21, P418, DOI 10.1097/01.PGP.0000035813.01856.33; VOS A, 1990, CANCER GENET CYTOGEN, V46, P75, DOI 10.1016/0165-4608(90)90011-X; Zhang C, 2013, AM J SURG PATHOL, V37, P827, DOI 10.1097/PAS.0b013e31827dcc4c	49	0	0	2	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0147-5185	1532-0979		AM J SURG PATHOL	Am. J. Surg. Pathol.	DEC	2018	42	12					1662	1673		10.1097/PAS.0000000000001164			12	Pathology; Surgery	Pathology; Surgery	HA7BB	WOS:000450434700010	30256256				2019-10-28	
J	Bedran, NR; Carlos, R; de Andrade, BAB; Bueno, APS; Romanach, MJ; Milito, CB				Bedran, Natalia Rocha; Carlos, Roman; Benevenuto de Andrade, Bruno Augusto; Silva Bueno, Ana Paula; Romanach, Mario Jose; Milito, Cristiane Bedran			Clinicopathological and Immunohistochemical Study of Head and Neck Langerhans Cell Histiocytosis from Latin America	HEAD & NECK PATHOLOGY			English	Article						Langerhans cell histiocytosis; Immunohistochemistry; Head and neck; Oral cavity	EPSTEIN-BARR-VIRUS; EXPRESSION; DIAGNOSIS; MANIFESTATIONS; MIMICKING; CHILDHOOD; CHILDREN; BONE; AGE	Langerhans cell histiocytosis (LCH) is an inflammatory myeloid neoplastic proliferation with variable clinical behavior caused by the accumulation of CD1a(+)/CD207(+) histiocytes, associated with a variable number of eosinophils, lymphocytes, plasma cells and multinucleated giant cells, most commonly observed in male children. LCH is uncommon in the head and neck region, occurring as ulcerated and reddened plaques or nodules that cause destruction of adjacent soft tissues and bone. The exact etiology of LCH is still unknown and controversial, with possible etiologic role of viruses, including Epstein-Barr virus (EBV). The aim of this study was to describe the clinicopathologic and immunohistochemical features of patients with LCH of the head and neck region. Clinical data from 19 patients with LCH were obtained from the archives of the Federal University of Rio de Janeiro and the Clinical Head and Neck Center of Guatemala. All cases were submitted to morphological, immunohistochemical analysis with CD1a, CD207, CD3, CD20, CD68, S-100 and Ki-67 and in situ hybridization for EBV. Ten cases were female and 9 male, with mean age of 11.5 years. Fourteen cases were located in the oral cavity, three cases in lymph nodes, and two cases in the scalp. In regard to the oral lesions, 13 cases were intra-osseous with six cases in anterior mandible, five cases in posterior mandible, and two cases in posterior maxilla while one case was located exclusively in the gingiva. The inflammatory pattern showed variation in the number of plasma cells, eosinophils and lymphocytes, while tumor cells were positive for CD1a, S-100 and CD68 in all cases, and positive for CD207 in 18 cases. In situ hybridization for EBV were negative in all cases.	[Bedran, Natalia Rocha; Milito, Cristiane Bedran] Univ Fed Rio de Janeiro, Clementino Fraga Filho Univ Hosp, Sch Med, Dept Pathol, Rio De Janeiro, Brazil; [Carlos, Roman] Hosp Herrera Llerandi, Ctr Clin Cabeza & Cuello, Pathol Sect, Guatemala City, Guatemala; [Benevenuto de Andrade, Bruno Augusto; Romanach, Mario Jose] Fed Univ Rio De Janeiro FO UFRJ, Sch Dent, Dept Oral Diag & Pathol, Av Carlos Chagas Filho 373,Predio CCS Bloco K 2, BR-21941902 Rio De Janeiro, Brazil; [Silva Bueno, Ana Paula] Univ Fed Rio de Janeiro, Sch Med, Pediat Hematol Sect, Rio De Janeiro, Brazil	Romanach, MJ (reprint author), Fed Univ Rio De Janeiro FO UFRJ, Sch Dent, Dept Oral Diag & Pathol, Av Carlos Chagas Filho 373,Predio CCS Bloco K 2, BR-21941902 Rio De Janeiro, Brazil.	nataliabedran@hotmail.com; monchorcb@yahoo.com; augustodelima33@hotmail.com; apbueno65@gmail.com; marioromanach@ufrj.br; crismilito@gmail.com	de Andrade, Bruno Augusto Benevenuto/M-6274-2014; Romanach, Mario J/J-5175-2014; Romanach, Mario/Z-6068-2019	de Andrade, Bruno Augusto Benevenuto/0000-0002-3259-606X; Romanach, Mario J/0000-0002-7853-5916; Romanach, Mario/0000-0002-7853-5916			Ashraf MJ, 2012, IRAN RED CRESCENT ME, V14, P764, DOI 10.5812/ircmj.1302; Bank MI, 2003, APMIS, V111, P300, DOI 10.1034/j.1600-0463.2003.1110202.x; Baumgartner I, 1997, MED PEDIATR ONCOL, V28, P9, DOI 10.1002/(SICI)1096-911X(199701)28:1<9::AID-MPO3>3.0.CO;2-P; Berres ML, 2015, BRIT J HAEMATOL, V169, P3, DOI 10.1111/bjh.13247; Brousset PR, 2004, HUM PATHOL, V35, P1573, DOI 10.1016/j.humpath.2004.09.006; Buchmann L, 2006, OTOLARYNG HEAD NECK, V135, P312, DOI 10.1016/j.otohns.2006.03.019; Chen CJ, 2004, EUR J PEDIATR, V163, P536, DOI 10.1007/s00431-004-1493-y; DAGENAIS M, 1992, ORAL SURG ORAL MED O, V74, P230, DOI 10.1016/0030-4220(92)90388-7; DAVID R, 1989, AM J ROENTGENOL, V153, P1021, DOI 10.2214/ajr.153.5.1021; Ducassou S, 2013, PEDIATR BLOOD CANCER, V60, P1759, DOI 10.1002/pbc.24603; DUNCAN WK, 1988, ORAL SURG ORAL MED O, V65, P736, DOI 10.1016/0030-4220(88)90020-5; Eckardt A, 2003, ORAL ONCOL, V39, P687, DOI 10.1016/S1368-8375(03)00080-0; Emile JF, 2016, BLOOD, V127, P2672, DOI [10.1182/blood-2016-01-690636, 10.1182/blood-2016-01690636]; Facciolo Maria-Teresa, 2017, J Clin Exp Dent, V9, pe820, DOI 10.4317/jced.53774; Geissmann F, 1997, J PATHOL, V181, P301, DOI 10.1002/(SICI)1096-9896(199703)181:3<301::AID-PATH779>3.0.CO;2-2; Guimaraes LF, 2008, J DENT CHILD, V75, P64; HAGE C, 1993, HUM PATHOL, V24, P840, DOI 10.1016/0046-8177(93)90133-2; HASHIMOTO K, 1973, ARCH DERMATOL, V107, P263, DOI 10.1001/archderm.107.2.263; Haupt R, 2013, PEDIATR BLOOD CANCER, V60, P175, DOI 10.1002/pbc.24367; Hernandez-Juyol Miguel, 2003, Med Oral, V8, P19; Hicks J, 2005, ORAL SURG ORAL MED O, V100, pS42, DOI 10.1016/j.tripleo.2005.06.016; Jang KA, 2000, PEDIATR DERMATOL, V17, P364, DOI 10.1046/j.1525-1470.2000.017005364.x; Jeziorski E, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003262; KILPATRICK SE, 1995, CANCER, V76, P2471, DOI 10.1002/1097-0142(19951215)76:12<2471::AID-CNCR2820761211>3.0.CO;2-Z; Larralde M, 1999, INT J DERMATOL, V38, P693, DOI 10.1046/j.1365-4362.1999.00758.x; Lau SK, 2008, AM J SURG PATHOL, V32, P615, DOI 10.1097/PAS.0b013e31815b212b; Lewoczko KB, 2014, INT J PEDIATR OTORHI, V78, P1874, DOI 10.1016/j.ijporl.2014.08.015; LONGAKER MA, 1994, J AM ACAD DERMATOL, V31, P910, DOI 10.1016/S0190-9622(94)70258-6; Madrigal-Martinez-Pereda C, 2009, MED ORAL PATOL ORAL, V14, pE222; MCCLAIN K, 1994, AM J HEMATOL, V47, P16, DOI 10.1002/ajh.2830470104; Merglova V, 2014, J CRANIO MAXILL SURG, V42, P93, DOI 10.1016/j.jcms.2013.03.005; Minguez I, 2004, MED ORAL, V9, P149; Monsereenusorn C, 2015, HEMATOL ONCOL CLIN N, V29, P853, DOI 10.1016/j.hoc.2015.06.005; Murray M, 2011, J ORAL MAXIL SURG, V69, P2585, DOI 10.1016/j.joms.2011.01.008; Nicollas R, 2010, INT J PEDIATR OTORHI, V74, P669, DOI 10.1016/j.ijporl.2010.03.017; Pacino GA, 1999, MED ORAL, V4, P607; Panis V, 2016, QUINTESSENCE INT, V47, P731, DOI 10.3290/j.qi.a36568; Pileri SA, 2017, WHO CLASSIFICATION H, P130; PURTILO DT, 1980, LANCET, V1, P300; Querings K, 2006, ACTA DERM-VENEREOL, V86, P39, DOI 10.2340/00015555-0003; Sahm F, 2012, BLOOD, V120, pE28, DOI 10.1182/blood-2012-06-429597; Sakata N, 2008, PEDIATR BLOOD CANCER, V50, P924, DOI 10.1002/pbc.21249; Saliba I, 2008, INT J PEDIATR OTORHI, V72, P775, DOI 10.1016/j.ijporl.2008.02.001; Schenka AA, 2006, HUM PATHOL, V37, P1508, DOI 10.1016/j.humpath.2006.07.008; Shimakage M, 2004, HUM PATHOL, V35, P862, DOI 10.1016/j.humpath.2004.03.017; Stalemark H, 2008, PEDIATR BLOOD CANCER, V51, P76, DOI 10.1002/pbc.21504; Stein SL, 2001, ARCH PEDIAT ADOL MED, V155, P778, DOI 10.1001/archpedi.155.7.778; Swerdlow SH, 2017, WHO CLASSIFICATION T, P359; Varga E, 2015, J EUR ACAD DERMATOL, V29, P1205, DOI 10.1111/jdv.12792; Yashoda-Devi Bk, 2012, J Clin Exp Dent, V4, pe252, DOI 10.4317/jced.50728; Young LS, 2004, NAT REV CANCER, V4, P757, DOI 10.1038/nrc1452	51	2	3	0	1	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1936-055X	1936-0568		HEAD NECK PATHOL	Head Neck Pathol.	DEC	2018	12	4					431	439		10.1007/s12105-017-0867-1			9	Pathology	Pathology	HD9WP	WOS:000452915500001	29164473	Green Published			2019-10-28	
J	Lewis, JS; Shelton, J; Kuhs, KL; Smith, DK				Lewis, James S., Jr.; Shelton, Jeremy; Kuhs, Krystle Lang; Smith, Derek K.			p16 Immunohistochemistry in Oropharyngeal Squamous Cell Carcinoma Using the E6H4 Antibody Clone: A Technical Method Study for Optimal Dilution	HEAD & NECK PATHOLOGY			English	Article						Oropharyngeal; Squamous cell carcinoma; Immunohistochemistry; P16; Antibody; Human papillomavirus; E6H4	RISK HUMAN-PAPILLOMAVIRUS; NECK-CANCER; FAVORABLE PROGNOSIS; HEAD; HPV; IMPACT; EPIDEMIOLOGY; SURVIVAL	Routine testing for p16 immunohistochemistry (with selective HPV-specific test use) has been recommended for clinical practice in oropharyngeal squamous cell carcinoma (OPSCC). Data suggests that the E6H4 clone performs best for this purpose, yet no studies have evaluated the optimal antibody concentration for OPSCC testing. We evaluated three concentrations (undiluted, 1:5, and 1:10) of the primary antibody solution for E6H4 using tissue microarrays from a cohort of 199 OPSCC patients with a >70% staining cutoff for positivity. Concordance was evaluated using percent agreement and Cohen's kappa. The concentrations were evaluated for sensitivity and specificity using high risk HPV RNA in situ hybridization (RNA-ISH) and also correlated with Kaplan-Meier overall survival analysis. Inter-rater agreement was very high between p16 results at each concentration and also with RNA in situ hybridization (p < 0.0001 for all). Agreement between p16 undiluted and 1:5 dilution (agreement 98.2%; Kappa 0.943; p < 0.0001) was very high and between p16 undiluted and 1:10 dilution (agreement 79.2%; Kappa 0.512; p < 0.0001) much lower. Intensity of the staining did decrease with the 1:5 and 1:10 dilutions compared to undiluted, but not in a manner that obviously would change test interpretation or performance. Results suggest that the E6H4 antibody performs well at dilutions of up to 1:5 fold with a minor decrease in staining intensity, minimum loss of sensitivity, and no loss of specificity in OPSCC patients. This could result in reagent and cost savings.	[Lewis, James S., Jr.; Shelton, Jeremy] Vanderbilt Univ, Med Ctr, Dept Pathol Microbiol & Immunol, 3020D Vanderbilt Univ Hosp, Nashville, TN 37232 USA; [Lewis, James S., Jr.; Kuhs, Krystle Lang] Vanderbilt Univ, Med Ctr, Dept Otolaryngol, Nashville, TN 37232 USA; [Kuhs, Krystle Lang] Vanderbilt Univ, Sch Med, Div Epidemiol, Nashville, TN 37212 USA; [Smith, Derek K.] Vanderbilt Univ, Med Ctr, Dept Biostat, Nashville, TN USA; [Smith, Derek K.] Vanderbilt Univ, Med Ctr, Dept Oral & Maxillofacial Surg, Nashville, TN USA	Lewis, JS (reprint author), Vanderbilt Univ, Med Ctr, Dept Pathol Microbiol & Immunol, 3020D Vanderbilt Univ Hosp, Nashville, TN 37232 USA.; Lewis, JS (reprint author), Vanderbilt Univ, Med Ctr, Dept Otolaryngol, Nashville, TN 37232 USA.	James.lewis@vanderbilt.edu			NCI/NIH Cancer Center Support Grant [2P30 CA068485-14]; Vanderbilt Mouse Metabolic Phenotyping Center Grant [5U24DK059637-13]	We would like to thank Donna M. Posey for her wonderful assistance with clerical support and spreadsheet data management for the various aspects of this study. We also acknowledge the Translational Pathology Shared Resource (TPSR) supported by NCI/NIH Cancer Center Support Grant 2P30 CA068485-14 and the Vanderbilt Mouse Metabolic Phenotyping Center Grant 5U24DK059637-13.	Ang KK, 2010, NEW ENGL J MED, V363, P24, DOI 10.1056/NEJMoa0912217; Benson E, 2014, ORAL ONCOL, V50, P565, DOI 10.1016/j.oraloncology.2013.09.008; Gillison ML, 2015, HEMATOL ONCOL CLIN N, V29, P1045, DOI 10.1016/j.hoc.2015.08.003; Gillison ML, 2015, J CLIN ONCOL, V33, P3235, DOI 10.1200/JCO.2015.61.6995; Huang SH, 2015, HEAD NECK-J SCI SPEC, V37, P946, DOI 10.1002/hed.23690; Lewis JS, 2012, HEAD NECK PATHOL, V6, pS75, DOI 10.1007/s12105-012-0369-0; Lewis JS, 2012, HISTOPATHOLOGY, V60, P982, DOI 10.1111/j.1365-2559.2011.04169.x; Lewis JS, 2010, AM J SURG PATHOL, V34, P1088, DOI 10.1097/PAS.0b013e3181e84652; Lewis Jr JS, 2017, ARCH PATHOL LAB MED; Marur S, 2010, LANCET ONCOL, V11, P781, DOI 10.1016/S1470-2045(10)70017-6; O'Sullivan B, 2016, LANCET ONCOL, V17, P440, DOI 10.1016/S1470-2045(15)00560-4; OSullivan B, 2016, AJCC CANC STAGING MA; Rischin D, 2010, J CLIN ONCOL, V28, P4142, DOI 10.1200/JCO.2010.29.2904; Sedghizadeh PP, 2016, ORAL ONCOL, V54, P15, DOI 10.1016/j.oraloncology.2016.01.002; Shelton J, 2017, MODERN PATHOL, V30, P1194, DOI 10.1038/modpathol.2017.31; Ukpo OC, 2011, AM J SURG PATHOL, V35, P1343, DOI 10.1097/PAS.0b013e318220e59d; Westra WH, 2009, HEAD NECK PATHOL, V3, P78, DOI 10.1007/s12105-009-0100-y; Yom SS, 2015, INT J RADIAT ONCOL, V93, P986, DOI 10.1016/j.ijrobp.2015.09.002	18	1	1	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1936-055X	1936-0568		HEAD NECK PATHOL	Head Neck Pathol.	DEC	2018	12	4					440	447		10.1007/s12105-017-0871-5			8	Pathology	Pathology	HD9WP	WOS:000452915500002	29190003	Green Published			2019-10-28	
J	Mehrad, M; Dupont, WD; Plummer, WD; Lewis, JS				Mehrad, Mitra; Dupont, William D.; Plummer, W. Dale, Jr.; Lewis, James S., Jr.			Expression and Significance of Cytokeratin 7, a Squamocolumnar Junction Marker, in Head and Neck Squamous Cell Carcinoma	HEAD & NECK PATHOLOGY			English	Article						Oropharynx; Human papillomavirus; Cytokeratin 7; Squamous cell carcinoma; Head and neck; Tonsillar crypt epithelium	HUMAN-PAPILLOMAVIRUS; MESSENGER-RNA; ORAL-CAVITY; P16; SURVIVAL; TONSIL; TRENDS; CANCER; CRYPT; EGFR	The favorable features of high-risk human papillomavirus (HPV) in the head and neck are limited to those harboring transcriptionally-active HPV, which occur predominantly in the oropharynx (OP). Factors rendering the OP susceptible to HPV oncogenesis are largely unexplored. The role of cytokeratin 7 (CK7) in predisposition to HPV and cancer in the cervix has been evaluated. However, its significance in the H&N is unknown. CK7 immunohistochemistry was performed on a tissue microarray cohort of OP and non-oropharyngeal (NOP) squamous cell carcinomas (SCC) with known clinical follow-up and HPV E6/7 mRNA status. Expression was graded based on the distribution (1 <= 33%, 2 = 33-66%, 3 >= 66%) and intensity (1 = weak, 2 = strong) with combined score of >= 2 considered positive. Survival analysis was performed. Seventy-four NOP-SCCs and 204 OPSCCs were studied. HPV was positive in 2.7% of NOPSCCs and 70.9% of OPSCCs. CK7 was positive in 23.0% of OPSCCs and 14.8% of NOPSCCs (p = 0.2), and in 24.1% of HPV positive versus 17.2% of negative patients (p = 0.2). There was no correlation with age, race, gender, HPV status, histologic type, tumor subsite, treatment, stage, or co-morbidities, and CK7 expression was not significantly associated with overall or disease specific survival. In our series, CK7 is positive in similar to 25% of H&N SCCs, although usually only focally. While CK7 has been suspected to be overexpressed selectively in HPV-related OPSCCs due to their origination from tonsillar crypt epithelium, we did not find any significant difference by anatomic H&N subsite, nor by HPV status, for its expression and found no association with patient survival.	[Mehrad, Mitra; Lewis, James S., Jr.] Vanderbilt Univ, Sch Med, Med Ctr, Pathol,Microbiol & Immunol, C-3321A Med Ctr North, Nashville, TN 37232 USA; [Dupont, William D.; Plummer, W. Dale, Jr.] Vanderbilt Univ, Med Ctr, Biostat, Nashville, TN USA; [Lewis, James S., Jr.] Vanderbilt Univ, Med Ctr, Otolaryngol, Nashville, TN USA	Mehrad, M (reprint author), Vanderbilt Univ, Sch Med, Med Ctr, Pathol,Microbiol & Immunol, C-3321A Med Ctr North, Nashville, TN 37232 USA.	mitra.mehrad@vanderbilt.edu		Mehrad, Mitra/0000-0003-4180-8180			Adelstein David J, 2009, Head Neck, V31, P1393, DOI 10.1002/hed.21269; Bishop JA, 2015, SEMIN DIAGN PATHOL, V32, P344, DOI 10.1053/j.semdp.2015.02.013; Chaturvedi AK, 2013, J CLIN ONCOL, V31, P4550, DOI 10.1200/JCO.2013.50.3870; Chernock RD, 2009, HEAD NECK PATHOL, V3, P186, DOI 10.1007/s12105-009-0126-1; Chu PG, 2000, MODERN PATHOL, V13, P962, DOI 10.1038/modpathol.3880175; Combes JD, 2014, ORAL ONCOL, V50, P370, DOI 10.1016/j.oraloncology.2013.11.004; D'Souza G, 2007, NEW ENGL J MED, V356, P1944, DOI 10.1056/NEJMoa065497; Fakhry C, 2008, JNCI-J NATL CANCER I, V100, P261, DOI 10.1093/jnci/djn011; Fritsch H, 2010, INT J COLORECTAL DIS, V25, P1231, DOI 10.1007/s00384-010-0986-6; Herfs M, DISCRETE POPULATION, DOI [10.1073/pnas.1202684109, DOI 10.1073/PNAS.1202684109]; Hosoya A, 2010, ANAT REC, V293, P1864, DOI 10.1002/ar.21233; Isayeva T, 2015, MODERN PATHOL, V28, P631, DOI 10.1038/modpathol.2014.149; Kanduc D, 2002, J VIROL, V76, P7040, DOI 10.1128/JVI.76.14.7040-7048.2002; Kim SH, 2007, INT J CANCER, V120, P1418, DOI 10.1002/ijc.22464; Kumar B, 2008, J CLIN ONCOL, V26, P3128, DOI 10.1200/JCO.2007.12.7662; Lambaudie E, 2014, ANTICANCER RES, V34, P177; Lee H, 2017, DIAGN PATHOL, V12, DOI 10.1186/s13000-017-0609-4; Lewis JS, 2010, AM J SURG PATHOL, V34, P1088, DOI 10.1097/PAS.0b013e3181e84652; Meshman J, 2017, AM J OTOLARYNG, V38, P31, DOI 10.1016/j.amjoto.2016.09.007; Morbini P, 2015, HISTOL HISTOPATHOL, V30, P833, DOI 10.14670/HH-11-590; PERRY ME, 1994, J ANAT, V185, P111; Pytynia KB, 2014, ORAL ONCOL, V50, P380, DOI 10.1016/j.oraloncology.2013.12.019; Rautava J, 2012, HEAD NECK PATHOL, V6, pS3, DOI 10.1007/s12105-012-0367-2; Regauer S, 2000, HUM PATHOL, V31, P1096, DOI 10.1053/hupa.2000.6279; Shiboski CH, 2005, CANCER-AM CANCER SOC, V103, P1843, DOI 10.1002/cncr.20998; Ukpo OC, 2011, AM J SURG PATHOL, V35, P1343, DOI 10.1097/PAS.0b013e318220e59d; Wang X, 2011, CELL, V145, P1023, DOI 10.1016/j.cell.2011.05.026; Woods RSR, 2017, CANCER EPIDEM BIOMAR, V26, P702, DOI 10.1158/1055-9965.EPI-16-0619	28	1	1	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1936-055X	1936-0568		HEAD NECK PATHOL	Head Neck Pathol.	DEC	2018	12	4					448	454		10.1007/s12105-017-0874-2			7	Pathology	Pathology	HD9WP	WOS:000452915500003	29235037	Green Published			2019-10-28	
J	Mohindra, S; Sakr, H; Sturgis, C; Chute, DJ				Mohindra, Shalini; Sakr, Hany; Sturgis, Charles; Chute, Deborah J.			LEF-1 is a Sensitive Marker of Cribriform Morular Variant of Papillary Thyroid Carcinoma	HEAD & NECK PATHOLOGY			English	Article						Cribriform morular variant; Papillary thyroid carcinoma; LEF-1; Familial adenomatosis polyposis; CTNNB1/Wnt pathway	FAMILIAL ADENOMATOUS POLYPOSIS; BETA-CATENIN; NUCLEAR-LOCALIZATION; OVEREXPRESSION; MUTATION; FEATURES	Cribriform morular variant of PTC (CMV-PTC) frequently shows activation of the CTNNB1/Wnt pathway with nuclear accumulation of beta catenin. The utility of LEF-1, also in the CTNNB1/WNT pathway, in the diagnosis of CMV-PTC has not been previously studied. LEF-1 immunohistochemistry was performed on seven CMV-PTC, 52 benign cases and 101 malignant thyroid neoplasms. LEF-1 was scored by stain intensity (0 = no nuclear stain, 1 = weak nuclear stain, less than lymphocyte and 2 = strong nuclear stain, intense as lymphocyte) and percentage of positive cells at each intensity, for a maximum total score of 200. Sensitivity and specificity of LEF-1 stain for all cases and to differentiate between regular PTC and CMV-PTC was also calculated. Six of the seven CMV-PTCs showed >= 30% strong (2+) nuclear LEF-1 staining and a total score over 100. Beta catenin also showed strong and diffuse nuclear staining in these cases. One CMV-PTC was negative for both LEF-1 and beta catenin and did not have a history of FAP. All control PTC cases uniformly lacked LEF-1 staining at 2+ intensity. LEF-1 had a sensitivity of 86% and specificity of 98% for the diagnosis of CMV-PTC. LEF-1 is highly sensitive and specific marker for CMV-PTC, especially when used in the setting of a PTC neoplasm. The pattern of staining is important with >= 30% of cells showing strong 2+ nuclear staining having the highest combined sensitivity and specificity.	[Mohindra, Shalini; Sakr, Hany; Sturgis, Charles; Chute, Deborah J.] Cleveland Clin, Robert J Tomsich Pathol & Lab Med Inst, Dept Pathol, 9500 Euclid Ave,L25, Cleveland, OH 44195 USA	Chute, DJ (reprint author), Cleveland Clin, Robert J Tomsich Pathol & Lab Med Inst, Dept Pathol, 9500 Euclid Ave,L25, Cleveland, OH 44195 USA.	chuted@ccf.org					Bilodeau EA, 2015, HUM PATHOL, V46, P255, DOI 10.1016/j.humpath.2014.10.018; Boonyaarunnate T, 2013, ACTA CYTOL, V57, P127, DOI 10.1159/000345879; Cameselle-Teijeiro J, 1999, MODERN PATHOL, V12, P400; Garcia-Rostan G, 1999, CANCER RES, V59, P1811; HARACH HR, 1994, HISTOPATHOLOGY, V25, P549, DOI 10.1111/j.1365-2559.1994.tb01374.x; Hirokawa M, 2010, DIAGN CYTOPATHOL, V38, P890, DOI 10.1002/dc.21309; Jung CK, 2009, THYROID, V19, P905, DOI 10.1089/thy.2008.0332; Kaya S, 2016, AM J TRANSL RES, V8, P1228; Kermanshahi TR, 2014, APPL IMMUNOHISTO M M, V22, P728, DOI 10.1097/PAI.0000000000000109; Kononen J, 1998, NAT MED, V4, P844, DOI 10.1038/nm0798-844; Koo JS, 2011, ACTA CYTOL, V55, P13, DOI 10.1159/000320856; Kurihara K, 2000, JPN J CANCER RES, V91, P1100, DOI 10.1111/j.1349-7006.2000.tb00891.x; Levy RA, 2014, FAM CANCER, V13, P547, DOI 10.1007/s10689-014-9732-5; Pradhan D, 2015, PATHOL RES PRACT, V211, P712, DOI 10.1016/j.prp.2015.04.011; Singhi AD, 2014, MODERN PATHOL, V27, P1355, DOI 10.1038/modpathol.2014.40; Tandon B, 2011, MODERN PATHOL, V24, P1433, DOI 10.1038/modpathol.2011.103	16	2	2	0	3	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1936-055X	1936-0568		HEAD NECK PATHOL	Head Neck Pathol.	DEC	2018	12	4					455	462		10.1007/s12105-017-0873-3			8	Pathology	Pathology	HD9WP	WOS:000452915500004	29243023	Green Published			2019-10-28	
J	Agaimy, A; Semrau, S; Koch, M; Thompson, LDR				Agaimy, Abbas; Semrau, Sabine; Koch, Michael; Thompson, Lester D. R.			Sinonasal Leiomyosarcoma: Clinicopathological Analysis of Nine Cases with Emphasis on Common Association with Other Malignancies and Late Distant Metastasis	HEAD & NECK PATHOLOGY			English	Article						Leiomyosarcoma; Nasal cavity; Maxillary sinus; Sarcoma; Muscle, smooth; Immunohistochemistry; Retinoblastoma	HEREDITARY RETINOBLASTOMA SURVIVORS; NASAL CAVITY; IMMUNOHISTOCHEMICAL ANALYSIS; SARCOMA; TUMORS; LEIOMYOMA; TRACT; 2ND	Sinonasal tract (SNT) leiomyosarcoma (LMS) is exceedingly rare with < 100 cases reported. Their relationship to retinoblastoma and other malignancies, along with previous irradiation has not been clarified. Routine and consultation cases were reviewed for histologically and immunohistochemically proven SNT LMS. The tumors were tested with antibodies against a-smooth muscle actin, desmin, h-caldesmon, HMB45, S100 protein, Rb1, MDM2, CDK4 and EBV (EBER-ISH). Nine tumors affecting 5 males and 4 females aged 26 to 77 years (median: 48 years) were identified in the maxillary sinus (n = 4), nasal cavity (n = 3) and combined SNT (n = 2). Three patients had previous irradiation (2 for retinoblastoma, 1 for fibrous dysplasia) and 1 patient had chemotherapy and stem cell transplantation for Hodgkin lymphoma. One patient had prostatic adenocarcinoma (prior) and rectal adenocarcinoma (post) to the LMS. All patients with follow-up developed either local recurrences and/or metastases, principally to lung (time to metastasis: 16-156 months, mean 62 months). Histologically, 6 tumors were conventional high-grade LMS, two had glycogen-rich clear cell (PEComa-like) morphology and one was spindle cell low-grade. The latter showed grade 2 in the recurrence and grade 3 in the lung metastases. Two cases showed dedifferentiation to anaplastic pleomorphic (inflammatory MFH-like) phenotype. Immunohistochemistry revealed diffuse expression of at least 2 smooth muscle markers in 8 and only actin in one case/s. All other markers were negative. RB1 loss was observed in 6/8 cases tested. Sinonasal tract leiomyosarcomas are rare aggressive sarcomas that frequently develop in a background of previous cancer therapy (4/9), most frequently irradiation. Their varied morphology underlines the wide differential diagnostic considerations. Long-term survival may be achieved with aggressive multimodal therapy.	[Agaimy, Abbas] Univ Hosp, Inst Pathol, Krankenhausstr 8-10, D-91054 Erlangen, Germany; [Semrau, Sabine] Univ Hosp, Dept Radiat Oncol, Erlangen, Germany; [Koch, Michael] Univ Hosp, Dept Otorhinolaryngol Head & Neck Surg, Erlangen, Germany; [Thompson, Lester D. R.] Woodland Hills Med Ctr, Dept Pathol, 5601 De Soto Ave, Woodland Hills, CA 91367 USA	Agaimy, A (reprint author), Univ Hosp, Inst Pathol, Krankenhausstr 8-10, D-91054 Erlangen, Germany.	abbas.agaimy@uk-erlangen.de					Agaimy A, 2015, HEAD NECK PATHOL, V9, P463, DOI 10.1007/s12105-015-0636-y; Banerjee SS, 2001, INT J SURG PATHOL, V9, P309, DOI 10.1177/106689690100900410; Bishop JA, 2015, HEAD NECK PATHOL, V9, P507, DOI 10.1007/s12105-015-0624-2; Fletcher C, 2013, WHO CLASSIFICATION T; Flucke U, 2017, WHO CLASSIFICATION H, P35; Fritchie KJ, 2016, HISTOPATHOLOGY, V69, P930, DOI 10.1111/his.13045; FU YS, 1975, CANCER, V35, P1300, DOI 10.1002/1097-0142(197505)35:5<1300::AID-CNCR2820350508>3.0.CO;2-Z; Huang HY, 2003, ARCH PATHOL LAB MED, V127, P297; Hussein K, 2014, EUR J CANCER, V50, P2417, DOI 10.1016/j.ejca.2014.06.006; KURUVILLA A, 1990, ARCH OTOLARYNGOL, V116, P1278; Lewis JT, 2012, AM J SURG PATHOL, V36, P517, DOI 10.1097/PAS.0b013e3182426886; MacCarthy A, 2013, BRIT J CANCER, V108, P2455, DOI 10.1038/bjc.2013.228; Papoian V, 2014, AM J OTOLARYNG, V35, P254, DOI 10.1016/j.amjoto.2013.10.011; Rodjan F, 2013, EUR J CANCER, V49, P1939, DOI 10.1016/j.ejca.2013.01.010; Rooper LM, 2016, HUM PATHOL, V55, P44, DOI 10.1016/j.humpath.2016.04.009; Sandruck J, 2004, GYNECOL ONCOL, V92, P701, DOI 10.1016/j.ygyno.2003.10.043; Schutz A, 2013, J ORAL MAXIL SURG, V71, P1132, DOI 10.1016/j.joms.2012.12.011; Ulrich CT, 2005, LARYNGOSCOPE, V115, P2242, DOI 10.1097/01.mlg.0000183767.97518.09; Vincenzi A, 2002, J CLIN PATHOL, V55, P872, DOI 10.1136/jcp.55.11.872; Wong JR, 2014, J CLIN ONCOL, V32, P3284, DOI 10.1200/JCO.2013.54.7844	20	0	0	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1936-055X	1936-0568		HEAD NECK PATHOL	Head Neck Pathol.	DEC	2018	12	4					463	470		10.1007/s12105-017-0876-0			8	Pathology	Pathology	HD9WP	WOS:000452915500005	29270859	Green Published			2019-10-28	
J	Thompson, LDR; Lau, SK				Thompson, Lester D. R.; Lau, Sean K.			Sinonasal Tract Solitary Fibrous Tumor: A Clinicopathologic Study of Six Cases with a Comprehensive Review of the Literature	HEAD & NECK PATHOLOGY			English	Review						Solitary fibrous tumors; Nasal cavity; Paranasal sinuses; Immunohistochemistry; Differential diagnosis; STAT6 protein; Human	NASAL CAVITY; NAB2-STAT6 FUSION; NUCLEAR EXPRESSION; SYNOVIAL SARCOMA; HEMANGIOPERICYTOMA; STAT6; HEAD; DIAGNOSIS; SINUS; NECK	Solitary fibrous tumors (SFTs) are well recognized in the head and neck region, but rarely arise in the sinonasal tract (SNT). Six primary SNT SFTs were identified in the files of Southern California Permanente Medical Group between 2006 and 2017. The patients included five males and one female ranging in age from 33 to 72 years (mean 52 years), most of whom presented clinically with nasal obstruction. Three tumors involved the nasal cavity alone, one involved the paranasal sinuses, and two involved both the nasal cavity and paranasal sinuses. Histologically, the tumors were characterized by a variably cellular proliferation of cytologically bland spindle cells within a collagenous stroma with prominent interspersed branching vessels. Mitotic activity was low (range 0-2 per 10 high power fields) and there was no evidence of pleomorphism or tumor necrosis. Surface ulceration was noted. By immunohistochemistry, the lesional cells were positive for CD34, STAT6 and bcl-2. Clinical follow up information was available for all patients (range 32-102 months; mean 72 months). There were no recurrences or metastases and all were alive with no evidence of disease at last follow-up. SFTs rarely affect the SNT, but should be considered in the differential diagnosis of SNT mesenchymal lesions. Immunohistochemical expression of STAT6 can aid in diagnosis and separation of SFT from other spindle cell lesions occurring at this anatomic site. In combination with cases reported in the literature, primary SNT SFT behave in an indolent manner with conservative treatment.	[Thompson, Lester D. R.] Southern Calif Permanente Med Grp, Woodland Hills Med Ctr, Dept Pathol, 5601 De Soto Ave, Woodland Hills, CA 91365 USA; [Lau, Sean K.] Orange County Anaheim Med Ctr, Anaheim, CA USA	Thompson, LDR (reprint author), Southern Calif Permanente Med Grp, Woodland Hills Med Ctr, Dept Pathol, 5601 De Soto Ave, Woodland Hills, CA 91365 USA.	Lester.D.Thompson@kp.org					Abe T, 2005, AURIS NASUS LARYNX, V32, P285, DOI 10.1016/j.anl.2005.01.003; Agaimy A, 2015, HEAD NECK PATHOL, V9, P463, DOI 10.1007/s12105-015-0636-y; Agaimy A, 2014, HISTOPATHOLOGY, V65, P667, DOI 10.1111/his.12452; Agale SV, 2015, INT J RES MED SCI, V3, P2877; Alobid I, 2003, ACTA OTO-LARYNGOL, V123, P71, DOI 10.1080/003655402000028052; Azani AB, 2015, HEAD NECK PATHOL, V9, P323, DOI 10.1007/s12105-014-0593-x; Barthelmess S, 2014, AM J PATHOL, V184, P1209, DOI 10.1016/j.ajpath.2013.12.016; Bongiovanni M, 2002, J PATHOL, V198, P252, DOI 10.1002/path.1195; Bowe SN, 2012, LARYNGOSCOPE, V122, P1748, DOI 10.1002/lary.23350; Brunnemann RB, 1999, MODERN PATHOL, V12, P1034; Buob D, 2003, ARCH PATHOL LAB MED, V127, P1196; Cassarino David S, 2003, Ann Diagn Pathol, V7, P169, DOI 10.1016/S1092-9134(03)00016-9; Chan JKC, 1997, HISTOPATHOLOGY, V31, P568, DOI 10.1046/j.1365-2559.1997.2400897.x; Chauhan Suman S, 2004, Arch Pathol Lab Med, V128, pe1; Cheah AL, 2014, PATHOLOGY, V46, P389, DOI 10.1097/PAT.0000000000000122; Chmielecki J, 2013, NAT GENET, V45, P131, DOI 10.1038/ng.2522; Corina L, 2006, OTOLARYNG HEAD NECK, V134, P1063, DOI 10.1016/j.otohns.2005.03.048; Cox DP, 2010, ORAL SURG ORAL MED O, V110, P79, DOI 10.1016/j.tripleo.2010.01.023; Demicco EG, 2015, AM J CLIN PATHOL, V143, P672, DOI 10.1309/AJCPN25NJTOUNPNF; Demicco EG, 2012, MODERN PATHOL, V25, P1298, DOI 10.1038/modpathol.2012.83; DeVito N, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0140362; Dnyaneshwar A, 2013, OPEN ACCESS SCI REP, V2, P631; Doyle LA, 2014, MODERN PATHOL, V27, P390, DOI 10.1038/modpathol.2013.164; Eloy PH, 2006, EUR ARCH OTO-RHINO-L, V263, P833, DOI 10.1007/s00405-006-0073-3; Fletcher CDM, 2013, WHO CLASSIFICATION T, P80; Fujikura T, 2012, J NIPPON MED SCH, V79, P373, DOI 10.1272/jnms.79.373; Fukunaga M, 1997, MODERN PATHOL, V10, P443; Fukunaga M, 1995, PATHOL INT, V45, P952, DOI 10.1111/j.1440-1827.1995.tb03421.x; Furze AD, 2008, ARCH OTOLARYNGOL, V134, P334, DOI 10.1001/archotol.134.3.334; Ganly I, 2006, ARCH OTOLARYNGOL, V132, P517, DOI 10.1001/archotol.132.5.517; Ge W, 2016, ONCOL LETT, V12, P2475, DOI 10.3892/ol.2016.4967; Gengler C, 2006, HISTOPATHOLOGY, V48, P63, DOI 10.1111/j.1365-2559.2005.02290.x; Geramizadeh Bita, 2016, Iran J Pathol, V11, P195; Gold JS, 2002, CANCER, V94, P1057, DOI 10.1002/cncr.10328; Han YA, 2015, INT J CLIN EXP PATHO, V8, P13166; Hasegawa T, 1999, HUM PATHOL, V30, P1464, DOI 10.1016/S0046-8177(99)90169-7; Hicks DL, 2004, SKULL BASE-INTERD AP, V14, P203, DOI 10.1055/s-2004-860951; Huang HY, 2003, ARCH PATHOL LAB MED, V127, P297; Insabato L, 2009, INT J SURG PATHOL, V17, P250, DOI 10.1177/1066896909333779; Janjua A, 2011, SKULL BASE-INTERD AP, V21, P129, DOI 10.1055/s-0031-1275259; Jo VY, 2017, HEAD NECK PATHOL, V11, P119, DOI 10.1007/s12105-016-0737-2; Jurado-Ramos A, 2009, J LARYNGOL OTOL, V123, P457, DOI 10.1017/S0022215108002132; Kao YC, 2016, HISTOPATHOLOGY, V68, P492, DOI 10.1111/his.12772; Kessler A, 1999, OTOLARYNG HEAD NECK, V121, P826, DOI 10.1053/hn.1999.v121.a95230; Kim HJ, 2005, KOREAN J RADIOL, V6, P136, DOI 10.3348/kjr.2005.6.3.136; Kim TA, 1996, AM J NEURORADIOL, V17, P1767; Knott PD, 2003, LARYNGOSCOPE, V113, P783, DOI 10.1097/00005537-200305000-00004; Kodama S, 2009, AURIS NASUS LARYNX, V36, P100, DOI 10.1016/j.anl.2008.01.001; Koelsche C, 2014, HISTOPATHOLOGY, V65, P613, DOI 10.1111/his.12431; Kohmura T, 1999, EUR ARCH OTO-RHINO-L, V256, P233, DOI 10.1007/s004050050148; Konstantinidis I, 2003, AURIS NASUS LARYNX, V30, P303, DOI 10.1016/S0385-8146(03)00064-6; Kunzel J, 2016, EUR ARCH OTO-RHINO-L, V273, P1589, DOI 10.1007/s00405-015-3670-1; Lasota J, 2015, MODERN PATHOL, V28, P715, DOI 10.1038/modpathol.2014.161; Lewis JT, 2012, AM J SURG PATHOL, V36, P517, DOI 10.1097/PAS.0b013e3182426886; Mathew George Ani, 2015, Iran J Otorhinolaryngol, V27, P307; Mentzel T, 1997, VIRCHOWS ARCH, V430, P445, DOI 10.1007/s004280050054; Mohajeri A, 2013, GENE CHROMOSOME CANC, V52, P873, DOI 10.1002/gcc.22083; Morales-Cadena M, 2006, OTOLARYNG HEAD NECK, V135, P980, DOI 10.1016/j.otohns.2005.10.042; Morimitsu Y, 2000, APMIS, V108, P617, DOI 10.1034/j.1600-0463.2000.d01-105.x; Mosquera JM, 2009, AM J SURG PATHOL, V33, P1314, DOI 10.1097/PAS.0b013e3181a6cd33; Nai Gisele Alborghetti, 2009, Braz. j. otorhinolaryngol., V75, P769, DOI 10.1590/S1808-86942009000500029; NAMON A, 1992, AM J RHINOL, V6, P135, DOI 10.2500/105065892781874658; NIELSEN GP, 1995, AM J SURG PATHOL, V19, P748, DOI 10.1097/00000478-199507000-00002; Nielsen GP, 1997, MODERN PATHOL, V10, P1028; Papadakis I, 2013, HEAD NECK-J SCI SPEC, V35, pE77, DOI 10.1002/hed.21909; Pasquali S, 2016, EJSO-EUR J SURG ONC, V42, P1064, DOI 10.1016/j.ejso.2016.01.023; Pasquini E, 2003, J LARYNGOL OTOL, V117, P889, DOI 10.1258/002221503322542926; Poo WC, 2011, AM J CLIN PATHOL, V135, P839, DOI 10.1309/AJCP45SSNAOPXYXU; Rajan KV, 2006, INDIAN J OTOLARYNGOL, V58, P316, DOI 10.1007/BF03050859; Rizzo S, 2015, ACTA OTORHINOLARYNGO, V35, P455, DOI 10.14639/0392-100X-163813; Robinson DR, 2013, NAT GENET, V45, P180, DOI 10.1038/ng.2509; Rooper LM, 2016, HUM PATHOL, V55, P44, DOI 10.1016/j.humpath.2016.04.009; Roy S, 2015, J CANCER RES THER, V11, DOI 10.4103/0973-1482.138045; Sanchez-Romero C, 2018, HEAD NECK PATHOL, V12, P52, DOI 10.1007/s12105-017-0824-z; Smith LM, 2007, ENT-EAR NOSE THROAT, V86, P382, DOI 10.1177/014556130708600709; Stringfellow HF, 1996, J LARYNGOL OTOL, V110, P468, DOI 10.1017/S0022215100134000; Subramaniam MM, 2012, HISTOPATHOLOGY, V61, P1232, DOI 10.1111/j.1365-2559.2012.04340.x; Subramaniam MM, 2011, HISTOPATHOLOGY, V59, P1269, DOI 10.1111/j.1365-2559.2011.03997.x; Tai HC, 2015, MODERN PATHOL, V28, P1324, DOI 10.1038/modpathol.2015.90; Takasaki K, 2009, CASE REP MED, DOI 10.1155/2009/316042; Thompson LDR, 2003, AM J SURG PATHOL, V27, P737, DOI 10.1097/00000478-200306000-00004; Thway K, 2016, INT J SURG PATHOL, V24, P281, DOI 10.1177/1066896915627485; Thway K, 2014, ANN DIAGN PATHOL, V18, P369, DOI 10.1016/j.anndiagpath.2014.09.002; Turkoglu E, 2009, BMJ CASE REP; Vallat-Decouvelaere AV, 1998, AM J SURG PATHOL, V22, P1501, DOI 10.1097/00000478-199812000-00007; van Houdt WJ, 2013, ANN SURG ONCOL, V20, P4090, DOI 10.1245/s10434-013-3242-9; Varghese L, 2016, J CLIN CASE REP, V6, P824; Vermeulen S, 2012, B-ENT, V8, P219; Wilky BA, 2013, ANN SURG ONCOL, V20, P4080, DOI 10.1245/s10434-013-3241-x; WITKIN GB, 1991, AM J SURG PATHOL, V15, P842, DOI 10.1097/00000478-199109000-00004; Wushou A, 2015, ONCOTARGET, V6, P41875, DOI 10.18632/oncotarget.6174; Xue Y, 2014, JPN J CLIN ONCOL, V44, P926, DOI 10.1093/jjco/hyu100; Yang BT, 2013, AM J NEURORADIOL, V34, P1248, DOI 10.3174/ajnr.A3485; Yoshida A, 2014, AM J SURG PATHOL, V38, P552, DOI 10.1097/PAS.0000000000000137; Zeitler DM, 2007, SKULL BASE-INTERD AP, V17, P239, DOI 10.1055/s-2007-984489; Zielinska-Kazmierska Bogna, 2015, J Oral Biol Craniofac Res, V5, P112, DOI 10.1016/j.jobcr.2015.04.001; ZUKERBERG LR, 1991, AM J SURG PATHOL, V15, P126, DOI 10.1097/00000478-199102000-00004	97	1	1	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1936-055X	1936-0568		HEAD NECK PATHOL	Head Neck Pathol.	DEC	2018	12	4					471	480		10.1007/s12105-017-0878-y			10	Pathology	Pathology	HD9WP	WOS:000452915500006	29282671	Green Published			2019-10-28	
J	Broadwater, DR; Peker, D				Broadwater, Devin R.; Peker, Deniz			Systemic Non-Hodgkin T Cell Lymphomas Presenting in the Head and Neck Region: An Institutional Experience of a Rare Entity	HEAD & NECK PATHOLOGY			English	Article						Non-Hodgkin; T Cell; Lymphoma; Head and neck	PART 2	T cell lymphoma (TCL) is a group of rare and aggressive diseases. TCL primary to head and neck organs often present as extranodal NK/T cell lymphoma, nasal type. Systemic TCL with initial head and neck presentation is extremely rare. Here we report our institutional experience. Clinicopathologic data was collected from patients diagnosed with TCL and treated at the University of Alabama at Birmingham between 2002 and 2012. Eleven cases of systemic TCL initially presented at head and neck region were identified. The median age was 54 years and male: female ratio was 1.8. The most common sites involved were sinonasal tissue, tonsil, tongue and larynx. Most patients presented with a mass lesion without systemic symptoms. The presentation of TCL primary to the head and neck region is often non-specific. A misdiagnosis of undifferentiated tumor or chronic inflammation due to ambiguous morphology is not uncommon. TCL should be considered in differential diagnosis and a thorough evaluation is warranted for accurate diagnosis.	[Broadwater, Devin R.; Peker, Deniz] Univ Alabama Birmingham, Dept Pathol, 1802 6th Ave S,NP 3545, Birmingham, AL 35233 USA	Peker, D (reprint author), Univ Alabama Birmingham, Dept Pathol, 1802 6th Ave S,NP 3545, Birmingham, AL 35233 USA.	dpeker@uabmc.edu					Budhy TI, 2001, BRIT J ORAL MAX SURG, V39, P460, DOI 10.1054/bjom.2001.0718; Deng XW, 2016, ANN HEMATOL, V95, P1271, DOI 10.1007/s00277-016-2696-9; Devi Seema, 2015, Natl J Maxillofac Surg, V6, P99, DOI 10.4103/0975-5950.168217; Han AY, 2017, OTOLARYNG HEAD NECK, V156, P870, DOI 10.1177/0194599817695808; Kaushansky K, 2010, WILLIAMS HEMATOLOGY; Ma H, 2017, INT J CLIN ONCOL, V22, P18, DOI 10.1007/s10147-016-1045-2; Parkins GE, 2009, BRIT J ORAL MAX SURG, V47, P550, DOI 10.1016/j.bjoms.2008.11.003; Shankland KR, 2012, LANCET, V380, P848, DOI 10.1016/S0140-6736(12)60605-9; Swerdlow SH, 2008, WHO CLASSIFICATION T; Walter C, 2015, INT J MED SCI, V12, P141, DOI 10.7150/ijms.10483; Zucca E, 1999, ANN ONCOL, V10, P1023, DOI 10.1023/A:1008313229892; Zucca E, 1997, ANN ONCOL, V8, P727, DOI 10.1023/A:1008282818705	12	0	0	0	6	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1936-055X	1936-0568		HEAD NECK PATHOL	Head Neck Pathol.	DEC	2018	12	4					481	487		10.1007/s12105-017-0881-3			7	Pathology	Pathology	HD9WP	WOS:000452915500007	29302898	Green Published			2019-10-28	
J	Jalaly, JB; Sanati, S; Chernock, RD; Dibe, DG; El-Mofty, SK				Jalaly, Jalal B.; Sanati, Souzan; Chernock, Rebecca D.; Dibe, Dikson G.; El-Mofty, Samir K.			Salivary Duct Carcinoma and Invasive Ductal Carcinoma of the Breast: A Comparative Immunohistochemical Study	HEAD & NECK PATHOLOGY			English	Article						Salivary glands; Breast; Neoplasms; Immunohistochemistry; Estrogens; Progesterone	APOCRINE CARCINOMAS; PROGNOSTIC-FACTORS; ANDROGEN-RECEPTOR; PAROTID-GLAND; EXPRESSION; CANCER; METASTASIS; GENE	Salivary duct carcinoma (SDC) is a high-grade salivary gland malignancy with great morphological resemblance to invasive ductal carcinoma (IDC) of the breast. Rarely, female patients may have a past history of both SDC and IDC. When these patients present with distant metastasis, accurate identification of the primary tumor is particularly difficult. Additionally, rare metastasis of SDC to the breast and IDC to the salivary (parotid) gland can also present a diagnostic challenge. Our aim was to develop an immunohistochemical panel that reliably distinguishes SDC from IDC. We included all SDCs diagnosed from 1989 to 2016 (23 cases) and 29 treatment naive and histologically similar IDCs. All cases were stained with androgen receptor (AR), estrogen receptor-alpha (ER-alpha), progesterone receptor (PR), HER-2, CK5/6, p63, and beta-catenin. The great majority (> 90%) of both SDCs and IDCs reacted positively to AR. The main discrepancy in the immunohistochemical profiles was a distinctly different reactivity to ER-alpha, PR and HER-2. While 28 IDCs (96.6%) reacted positively to ER-alpha and/or PR, the majority expressing both (82.8%) with a moderate to strong staining intensity, only 2 SDCs expressed ER-alpha (8.7%) and 5 others expressed PR (21.7%) with only one case expressing both (P value < 0.05). On the other hand, 8 SDC (34.8%) were positive for HER-2 while none of the IDCs were positive (P value < 0.05). ER-alpha, PR, and HER-2 may be helpful to distinguish SDC from IDC. Positive reactivity to ER-alpha, PR or both and negative HER-2 favors a diagnosis of IDC while ER-alpha, PR negative, HER-2 positive tumors are more likely SDC.	[Jalaly, Jalal B.; Sanati, Souzan; Chernock, Rebecca D.; Dibe, Dikson G.; El-Mofty, Samir K.] Washington Univ, Sch Med, Dept Pathol & Immunol, 660 S Euclid Ave,Box 8118, St Louis, MO 63110 USA	El-Mofty, SK (reprint author), Washington Univ, Sch Med, Dept Pathol & Immunol, 660 S Euclid Ave,Box 8118, St Louis, MO 63110 USA.	Elmofty@wustl.edu	Jalaly, Jalal/I-7650-2019		Washington University Department of Pathology	Washington University Department of Pathology funded this study.	Ando K, 2011, BREAST CARE, V6, P471, DOI 10.1159/000335222; BLOOM HJG, 1957, BRIT J CANCER, V11, P359, DOI 10.1038/bjc.1957.43; Butler RT, 2014, HEAD NECK PATHOL, V8, P133, DOI 10.1007/s12105-013-0493-5; Chandrasekar Chetana, 2016, J Oral Maxillofac Pathol, V20, P505; Cochrane DR, 2014, BREAST CANCER RES, V16, DOI 10.1186/bcr3599; El-Naggar A, 2017, WHO CLASSIFICATION H; ELSTON CW, 1991, HISTOPATHOLOGY, V19, P403, DOI 10.1111/j.1365-2559.1991.tb00229.x; Fan CY, 2000, AM J SURG PATHOL, V24, P579, DOI 10.1097/00000478-200004000-00014; Gilbert MR, 2016, JAMA OTOLARYNGOL, V142, P489, DOI 10.1001/jamaoto.2015.3930; Guo SS, 2015, INT J CLIN EXP MED, V8, P21765; Harvey JM, 1999, J CLIN ONCOL, V17, P1474, DOI 10.1200/JCO.1999.17.5.1474; Jayaprakash V, 2014, HEAD NECK-J SCI SPEC, V36, P694, DOI 10.1002/hed.23350; Kleinsasser O, 1967, Arch Klin Exp Ohren Nasen Kehlkopfheilkd, V189, P302, DOI 10.1007/BF00455855; Miettinen M, 2014, AM J SURG PATHOL, V38, P13, DOI 10.1097/PAS.0b013e3182a0218f; Onitilo AA, 2009, CLIN MED RES, V7, P4, DOI 10.3121/cmr.2009.825; Piris A, 2014, HUM PATHOL, V45, P320, DOI 10.1016/j.humpath.2013.09.007; Salovaara E, 2013, EUR ARCH OTO-RHINO-L, V270, P281, DOI 10.1007/s00405-012-1997-4; Skalova A, 2003, HISTOPATHOLOGY, V42, P348, DOI 10.1046/j.1365-2559.2003.01600.x; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Vranic S, 2015, HUM PATHOL, V46, P1350, DOI 10.1016/j.humpath.2015.05.017; Wick MR, 1998, AM J CLIN PATHOL, V109, P75; Williams L, 2015, AM J SURG PATHOL, V39, P705, DOI 10.1097/PAS.0000000000000413; Williams MD, 2007, AM J SURG PATHOL, V31, P1645, DOI 10.1097/PAS.0b013e3180caa099; Zhu SB, 2015, ARCH PATHOL LAB MED, V139, P55, DOI 10.5858/arpa.2014-0167-RA	24	1	1	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1936-055X	1936-0568		HEAD NECK PATHOL	Head Neck Pathol.	DEC	2018	12	4					488	492		10.1007/s12105-017-0882-2			5	Pathology	Pathology	HD9WP	WOS:000452915500008	29302899	Green Published			2019-10-28	
J	Reddy, R; Davidova, L; Bhattacharyya, I; Cohen, DM; Islam, MN; Fitzpatrick, SG				Reddy, Rekha; Davidova, Liya; Bhattacharyya, Indraneel; Cohen, Donald M.; Islam, Mohammed N.; Fitzpatrick, Sarah G.			Dermatologic Lesions Submitted to an Oral and Maxillofacial Pathology Biopsy Service: An Analysis of 2487 Cases	HEAD & NECK PATHOLOGY			English	Article						Head and neck neoplasms; Dermatology; Pathology, Oral; Histology	DERMATOPATHOLOGY	Skin lesions are often submitted to oral and maxillofacial pathology practices. The purpose of this study is to evaluate the frequency, distribution, variability, and composition of dermatologic lesions within a large oral and maxillofacial pathology biopsy service. An IRB-approved retrospective search of skin lesions diagnosed at University of Florida oral and maxillofacial pathology biopsy service between 1994 and 2015 was performed. 2487 cases were included in the study. Gender was reported in 2466 cases, of which 59% were male and 41% female. Age was provided in 2367 cases and ranged from 2 weeks to 96 years with an average of 55 years. Location was indicated in 2473 cases. Lips were the most common (41.7%), followed by face (25.3%), neck (7.4%), nose (6.5%), periorbital (5.3%), ear (4.1%), and scalp (3.8%). Of the 2487 cases, five diagnoses (actinic keratosis/cheilitis, intradermal nevus, epidermal inclusion cyst, seborrheic keratosis, and basal cell carcinoma) constituted 84.4% of the cases. 69 of 2487 cases (2.8%) resulted in dermatopathologic consultation prior to final reporting. Skin lesions accounted for similar to 1.0% of all lesions submitted to an oral and maxillofacial pathology biopsy service. This study found a large variation in the dermatologic lesions submitted to an oral pathology biopsy service. Although most were routine in complexity, dermatopathology consultation was an important tool in the diagnosis of the more challenging cases. This study may help pathologists gain a better understanding of the frequency and variability of dermatologic lesions submitted to an oral and maxillofacial pathology biopsy service and promote more interdisciplinary consultation within the field. This study evaluated the incidence and scope of dermatologic lesions submitted to a large oral and maxillofacial pathology biopsy service over a long time period. A wide scope of lesions was found, and dermatopathology consultation was important to quality assurance.	[Reddy, Rekha; Davidova, Liya; Bhattacharyya, Indraneel; Cohen, Donald M.; Islam, Mohammed N.; Fitzpatrick, Sarah G.] Univ Florida, Coll Dent, Oral & Maxillofacial Pathol, 1395 Ctr Dr,Room D8-6, Gainesville, FL 32610 USA	Reddy, R (reprint author), Univ Florida, Coll Dent, Oral & Maxillofacial Pathol, 1395 Ctr Dr,Room D8-6, Gainesville, FL 32610 USA.	rreddy@dental.ufl.edu		/0000-0002-5506-7400			Fernandez CA, 2012, SOUTH MED J, V105, P524, DOI 10.1097/SMJ.0b013e318268cf63; Fuertes L, 2016, AM J DERMATOPATH, V38, P92, DOI 10.1097/DAD.0000000000000361; Goldenberg G, 2008, J CUTAN PATHOL, V35, P658, DOI 10.1111/j.1600-0560.2007.00869.x; Jones AV, 2006, J ORAL PATHOL MED, V35, P392, DOI 10.1111/j.1600-0714.2006.00451.x; Zevallos JC, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000003630	5	0	0	0	3	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1936-055X	1936-0568		HEAD NECK PATHOL	Head Neck Pathol.	DEC	2018	12	4					493	499		10.1007/s12105-018-0885-7			7	Pathology	Pathology	HD9WP	WOS:000452915500009	29340950	Green Published			2019-10-28	
J	Upadhyaya, JD; Fitzpatrick, SG; Islam, MN; Bhattacharyya, I; Cohen, DM				Upadhyaya, Jasbir D.; Fitzpatrick, Sarah G.; Islam, Mohammed N.; Bhattacharyya, Indraneel; Cohen, Donald M.			A Retrospective 20-Year Analysis of Proliferative Verrucous Leukoplakia and Its Progression to Malignancy and Association with High-risk Human Papillomavirus	HEAD & NECK PATHOLOGY			English	Article						Proliferative verrucous leukoplakia; Verrucous hyperplasia; Verrucous carcinoma; Squamous cell carcinoma; P16(INK4A); Human papillomavirus	SQUAMOUS-CELL CARCINOMA; P53 EXPRESSION; P16; HEAD; HYPERPLASIA; RECURRENCE; PROTEINS	Proliferative verrucous leukoplakia (PVL) is defined as an aggressive, relentless and recalcitrant form of leukoplakia that has a high propensity for malignant transformation. The aim of this study was to evaluate the malignant potential of PVL and determine its possible association with high-risk human papillomavirus (HPV). Twenty cases with a clinical and biopsy proven diagnosis of PVL were collected from the University of Florida Oral Medicine clinic database. Immunohistochemistry was performed to evaluate the expression of p16(INK4A) and p53 genes in the PVL lesions. The lesions were also tested for high-risk HPV by DNA in-situ hybridization. The average age of the patients at the time of first biopsy was 62.7 years. Most patients had multiple sites of involvement, gingiva being the most common location. The lesions progressed to malignancy in approximately 50% of patients. The expression of p16(INK4A) gene was considered negative, with at least a 50-65% immuno-reactivity observed in only three cases that progressed to malignancy. No expression of high-risk HPV was detected, whereas p53 staining was positive in less than 25% of the cells demonstrating gene expression. No definite association between PVL and high-risk HPV infection could be established. Due to the high transformation potential of PVL, early recognition with aggressive treatment, including multiple biopsies, and continued close clinical follow-up, remain the mainstay of favorable management of this condition.	[Upadhyaya, Jasbir D.; Fitzpatrick, Sarah G.; Islam, Mohammed N.; Bhattacharyya, Indraneel; Cohen, Donald M.] Univ Florida, Coll Dent, Dept Oral & Maxillofacial Diagnost Sci, 1395 Ctr Dr, Gainesville, FL 32610 USA	Upadhyaya, JD (reprint author), Univ Florida, Coll Dent, Dept Oral & Maxillofacial Diagnost Sci, 1395 Ctr Dr, Gainesville, FL 32610 USA.	jupadhyaya@dental.ufl.edu	Upadhyaya, Jasbir/L-4724-2019				Acin S, 2011, J PATHOL, V225, P479, DOI 10.1002/path.2971; Adegboyega PA, 2005, APPL IMMUNOHISTO M M, V13, P171, DOI 10.1097/01.pai.0000132190.39351.9b; Akrish S, 2015, OR SURG OR MED OR PA, V119, P318, DOI 10.1016/j.oooo.2014.10.023; Bagan JV, 2007, J ORAL MAXIL SURG, V65, P46, DOI 10.1016/j.joms.2005.12.066; Bagan JV, 2011, ORAL ONCOL, V47, P732, DOI 10.1016/j.oraloncology.2011.05.008; Bagan JV, 2004, ORAL ONCOL, V40, P440, DOI 10.1016/j.oraloncology.2003.10.008; Bagan JV, 2003, J ORAL PATHOL MED, V32, P379, DOI 10.1034/j.1600-0714.2003.00167.x; Batsakis JG, 1999, ORAL ONCOL, V35, P354, DOI 10.1016/S1368-8375(99)00007-X; Benson E, 2014, ORAL ONCOL, V50, P565, DOI 10.1016/j.oraloncology.2013.09.008; Campisi G, 2004, ORAL ONCOL, V40, P835, DOI 10.1016/j.oraloncology.2004.02.007; Carrard VC, 2013, MED ORAL PATOL ORAL, V18, pE411, DOI 10.4317/medoral.18912; Cerero-Lapiedra R, 2010, MED ORAL PATOL ORAL, V15, pE839, DOI 10.4317/medoral.15.e839; El-Naggar A, 2017, WHO CLASSIFICATION H; Eversole L R, 2000, J Calif Dent Assoc, V28, P922; Feller Liviu, 2006, J Int Acad Periodontol, V8, P67; Femiano F, 2001, INT J ORAL MAX SURG, V30, P318, DOI 10.1054/ijom.2001.0066; Fettig A, 2000, ORAL SURG ORAL MED O, V90, P723, DOI 10.1067/moe.2000.108950; Gopalakrishnan R, 1997, ORAL SURG ORAL MED O, V83, P471, DOI 10.1016/S1079-2104(97)90148-7; HANSEN LS, 1985, ORAL SURG ORAL MED O, V60, P285, DOI 10.1016/0030-4220(85)90313-5; Hay CM, 2016, J LOW GENIT TRACT DI, V20, P252, DOI 10.1097/LGT.0000000000000182; Lee JJ, 2000, CLIN CANCER RES, V6, P1702; Lewis JS, 2012, MODERN PATHOL, V25, P1212, DOI 10.1038/modpathol.2012.79; MUNGER K, 1989, EMBO J, V8, P4099, DOI 10.1002/j.1460-2075.1989.tb08594.x; MURRAH VA, 1994, ANN OTO RHINOL LARYN, V103, P660, DOI 10.1177/000348949410300816; PALEFSKY JM, 1995, J ORAL PATHOL MED, V24, P193, DOI 10.1111/j.1600-0714.1995.tb01165.x; Poveda-Roda R, 2010, MED ORAL PATOL ORAL, V15, pE3, DOI 10.4317/medoral.15.e3; Reuschenbach M, 2008, INT J CANCER, V123, P2626, DOI 10.1002/ijc.23837; Santos M, 2004, INT J GYNECOL PATHOL, V23, P206, DOI 10.1097/01.pgp.0000130108.03231.89; SCHEFFNER M, 1991, P NATL ACAD SCI USA, V88, P5523, DOI 10.1073/pnas.88.13.5523; SHEAR M, 1980, CANCER, V46, P1855, DOI 10.1002/1097-0142(19801015)46:8<1855::AID-CNCR2820460825>3.0.CO;2-#; Shin DM, 1996, J NATL CANCER I, V88, P519, DOI 10.1093/jnci/88.8.519; Silverman S, 1997, ORAL SURG ORAL MED O, V84, P154, DOI 10.1016/S1079-2104(97)90062-7; SLOOTWEG PJ, 1983, J MAXILLOFAC SURG, V11, P13, DOI 10.1016/S0301-0503(83)80006-X; Thennavan A, 2015, INDIAN J CANCER, V52, P498, DOI 10.4103/0019-509X.178424; Wang Sophia S, 2003, J Natl Cancer Inst Monogr, P35; Zakrzewska JM, 1996, ORAL SURG ORAL MED O, V82, P396	36	2	2	0	4	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1936-055X	1936-0568		HEAD NECK PATHOL	Head Neck Pathol.	DEC	2018	12	4					500	510		10.1007/s12105-018-0893-7			11	Pathology	Pathology	HD9WP	WOS:000452915500010	29427033	Green Published			2019-10-28	
J	Agaimy, A; Mueller, SK; Harrer, T; Bauer, S; Thompson, LDR				Agaimy, Abbas; Mueller, Sarina K.; Harrer, Thomas; Bauer, Sebastian; Thompson, Lester D. R.			Head and Neck Kaposi Sarcoma: Clinicopathological Analysis of 11 Cases	HEAD & NECK PATHOLOGY			English	Article						Kaposi sarcoma; Ear canal; Differential diagnosis; Oral cavity; Head and neck; HIV; HHV8; Immunohistochemistry		Kaposi sarcoma (KS) of the head and neck area is uncommon with limited published case series. Our routine and consultation files were reviewed for histologically and immunohistochemically proven KS affecting any cutaneous or mucosal head and neck site. Ten males and one female aged 42-78 years (median, 51 years; mean, 52 years) were retrieved. Eight patients were HIV-positive and three were HIV-negative. The affected sites were skin (n = 5), oral/oropharyngeal mucosa (n = 5), and lymph nodes (n = 3) in variable combination. The ear (pinna and external auditory canal) was affected in two cases; both were HIV-negative. Multifocal non-head and neck KS was reported in 50% of patients. At last follow-up (12-94 months; median, 46 months), most of patients were either KS-free (n = 8) or had ongoing remission under systemic maintenance therapy (n = 2). One patient was alive with KS (poor compliance). Histopathological evaluation showed classical features of KS. One case was predominantly sarcomatoid with prominent inflammation mimicking undifferentiated sarcoma. Immunohistochemistry showed consistent expression of CD31, CD34, ERG, D2-40 and HHV8 in all cases. This is one of the few series devoted to head and neck KS showing high prevalence of HIV-positivity, but also unusual presentations in HIV-negative patients with primary origin in the skin of the ear and the auditory canal. KS should be included in the differential diagnosis of difficult-to-classify spindle cell lesions at this uncommon location.	[Agaimy, Abbas] Univ Hosp, Inst Pathol, Krankenhausstr 8-10, D-91054 Erlangen, Germany; [Mueller, Sarina K.] Univ Hosp, Dept Otorhinolaryngol Head & Neck Surg, D-91054 Erlangen, Germany; [Harrer, Thomas] Univ Hosp, Dept Internal Med 3, D-91054 Erlangen, Germany; [Bauer, Sebastian] Univ Duisburg Essen, Sch Med, Western German Canc Ctr, Sarcoma Ctr, D-45122 Essen, Germany; [Thompson, Lester D. R.] Woodland Hills Med Ctr, Dept Pathol, 5601 De Soto Ave, Woodland Hills, CA 91367 USA	Agaimy, A (reprint author), Univ Hosp, Inst Pathol, Krankenhausstr 8-10, D-91054 Erlangen, Germany.	abbas.agaimy@uk-erlangen.de	Bauer, Sebastian/D-8120-2012; Thompson, Lester D. R./J-8404-2016	Bauer, Sebastian/0000-0001-5949-8120; Thompson, Lester D. R./0000-0003-3714-1432			BATSAKIS JG, 1995, ANN OTO RHINOL LARYN, V104, P668, DOI 10.1177/000348949510400815; Bunn B K, 2012, SADJ, V67, P590; Castle JT, 2000, CANCER-AM CANCER SOC, V88, P15, DOI 10.1002/(SICI)1097-0142(20000101)88:1<15::AID-CNCR4>3.0.CO;2-0; Choussy O, 2008, HEAD NECK-J SCI SPEC, V30, P411, DOI 10.1002/hed.20691; Cossu S, 1997, AM J DERMATOPATH, V19, P16, DOI 10.1097/00000372-199702000-00004; De Pasquale R, 1999, J AM ACAD DERMATOL, V40, P312, DOI 10.1016/S0190-9622(99)70473-1; Delbrouck C., 1998, Acta Oto-Rhino-Laryngologica Belgica, V52, P29; Gourin Christine G, 2004, Curr Opin Otolaryngol Head Neck Surg, V12, P122, DOI 10.1097/00020840-200404000-00012; Grayson W, 2008, DIAGN PATHOL, V3, DOI 10.1186/1746-1596-3-31; Kaposi M, 1872, ARCH DERMATOL SYPHIL, V4, P265, DOI DOI 10.1007/BF01830024; Kumarasamy N, 2008, INT J STD AIDS, V19, P786, DOI 10.1258/ijsa.2008.008016; Lanternier F, 2008, AIDS, V22, P1163, DOI 10.1097/QAD.0b013e3283031a8a; Mentzel T, 2013, WHO CLASSIFICATION T, V4, P151; Mouden K, 2016, CLIN SARCOMA RES, V6, DOI 10.1186/s13569-016-0044-4; Nelson BL, 2007, HEAD NECK PATHOL, V1, P1, DOI 10.1007/s12105-007-0017-2; Nervi SJ, 2006, ARCH OTOLARYNGOL, V132, P555, DOI 10.1001/archotol.132.5.555; Patrikidou A, 2009, HEAD NECK-J SCI SPEC, V31, P260, DOI 10.1002/hed.20945; Peng KA, 2014, OTOLARYNG HEAD NECK, V151, P627, DOI 10.1177/0194599814545747; Purgina B., 2011, PATHOL RES INT, V2011, DOI DOI 10.4061/2011/469150.EPUB; Rachadi H, 2016, DERMATOL ONLINE J, V22; Ramirez-Amador V, 2010, ORAL ONCOL, V46, P135, DOI 10.1016/j.oraloncology.2009.12.006; Stavrakas M, 2016, J LARYNGOL OTOL, V130, P850, DOI 10.1017/S0022215116008604; Szajerka T, 2007, AIDS REV, V9, P230; Thariat J, 2012, RARE TUMORS, V4, P156, DOI 10.4081/rt.2012.e49; Wong BLK, 2016, CRIT REV ONCOL HEMAT, V104, P156, DOI 10.1016/j.critrevonc.2016.06.005; Wyatt ME, 1998, J LARYNGOL OTOL, V112, P280, DOI 10.1017/S0022215100158359	26	0	0	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1936-055X	1936-0568		HEAD NECK PATHOL	Head Neck Pathol.	DEC	2018	12	4					511	516		10.1007/s12105-018-0902-x			6	Pathology	Pathology	HD9WP	WOS:000452915500011	29508130	Green Published			2019-10-28	
J	Siamantas, I; Kalogirou, EM; Tosios, KI; Fourmousis, I; Sklavounou, A				Siamantas, Ioannis; Kalogirou, Eleni-Marina; Tosios, Konstantinos I.; Fourmousis, Ioannis; Sklavounou, Alexandra			Spongiotic Gingival Hyperplasia Synchronously Involving Multiple Sites: Case Report and Review of the Literature	HEAD & NECK PATHOLOGY			English	Review						Spongiotic gingival hyperplasia; Multifocal; Generalized; Localized; Gingivitis		Localized juvenile spongiotic gingival hyperplasia (LJSGH) is a gingival lesion with unique clinicopathologic features that may involve synchronously multiple sites. We present a case with lesions clinically consistent with LJSGH in four jaw quadrants, confirmed by biopsy and review the English literature on multifocal LJSGH cases. A 19 year-old woman presented with circumscribed, erythematous overgrowths on the right and left maxillary and mandibular gingiva. With the provisional diagnosis of multifocal LJSGH, total excision of four maxillary lesions was performed. Clinical, microscopic and immunohistochemical examination with cytokeratin 19 confirmed the diagnosis of LJSGH in multiple sites. The excised lesions showed partial to complete recurrence after 4 months, while spontaneous regression of all but one lesion was observed after 15 months. Twenty cases with synchronous involvement of the gingiva of at least two teeth were previously reported. Their clinical features were comparable to that of solitary LJSGH. Only one case involved all four jaw quadrants. Spontaneous remission has not been documented before. The recognition of multiple lesions with clinicopathologic features diagnostic of LJSGH in the same adult patient argue against the designations "localized" and "juvenile". Recurrences are common, while remission might occur.	[Kalogirou, Eleni-Marina; Tosios, Konstantinos I.; Sklavounou, Alexandra] Univ Athens, Dept Oral Med & Pathol, Sch Dent, 2 Thivon St, Athens 11527, Greece; [Fourmousis, Ioannis] Univ Athens, Sch Dent, Dept Periodontol, 2 Thivon St, Athens, Greece	Tosios, KI (reprint author), Univ Athens, Dept Oral Med & Pathol, Sch Dent, 2 Thivon St, Athens 11527, Greece.	ktosios@dent.uoa.gr					Allon I, 2016, HISTOPATHOLOGY, V68, P549, DOI 10.1111/his.12774; Argyris PP, 2015, J ORAL PATHOL MED, V44, P37, DOI 10.1111/jop.12214; Chang JYF, 2008, ORAL SURG ORAL MED O, V106, P411, DOI 10.1016/j.tripleo.2008.04.024; Nogueira VKC, 2017, INT J PAEDIATR DENT, V27, P231, DOI 10.1111/ipd.12278; Damm Douglas D, 2009, Gen Dent, V57, P451; Darling MR, 2007, J PERIODONTOL, V78, P1235, DOI 10.1902/jop.2007.060502; Silva BSD, 2015, OR SURG OR MED OR PA, V119, P3, DOI 10.1016/j.oooo.2014.07.005; Decani S, 2013, Ann Stomatol (Roma), V4, P41; Fernandes DT, 2018, CLIN ADV PERIODONTIC, V8, P17, DOI 10.1902/cap.2017.170018; Flaitz Catherine M, 2010, Tex Dent J, V127, P1312; Kalogirou EM, 2017, J CLIN PEDIATR DENT, V41, P228, DOI 10.17796/1053-4628-41.3.228; MacNeill SR, 2011, CLIN ADV PERIODONTIC, V1, P199, DOI 10.1902/cap.2011.110003; Noonan Vikki, 2013, J Mass Dent Soc, V62, P45; Rossmann JA, 2011, OPEN PATHOL J, V5, P23, DOI DOI 10.2174/1874375701105010023; Solomon LW, 2013, PEDIATR DENT, V35, P360	15	4	4	1	1	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1936-055X	1936-0568		HEAD NECK PATHOL	Head Neck Pathol.	DEC	2018	12	4					517	521		10.1007/s12105-018-0903-9			5	Pathology	Pathology	HD9WP	WOS:000452915500012	29512024	Green Published			2019-10-28	
J	Cracolici, V; Krausz, T; Cipriani, NA				Cracolici, Vincent; Krausz, Thomas; Cipriani, Nicole A.			Ubiquitin Immunostaining in Thyroid Neoplasms Marks True Intranuclear Cytoplasmic Pseudoinclusions and May Help Differentiate Papillary Carcinoma from NIFTP	HEAD & NECK PATHOLOGY			English	Article						Thyroid; NIFTP; Papillary thyroid carcinoma; Pseudoinclusions; Ubiquitin	NUCLEAR FEATURES; PITFALL	Papillary thyroid carcinoma (PTC) is defined by an invasive growth pattern and classic nuclear features: enlarged, grooved, overlapping nuclei with chromatin clearing and intranuclear cytoplasmic pseudoinclusions (INCP). True INCPs are characteristic of PTC, but may infrequently be seen in noninvasive follicular thyroid neoplasms with papillary-like nuclear features (NIFTP). Nuclear abnormalities that mimic INCP ("pseudo-pseudoinclusions") are common in a variety of thyroid lesions. H&E and ubiquitin-stained whole tissue sections of classic PTC (n = 25) and NIFTP (n = 35) were evaluated. On H&E, true INCPs were present in all (100%) PTCs and absent in all NIFTPs (0%). Pseudo-pseudoinclusions were present in 13 (37%) NIFTPs. In 24 (96%) PTCs, ubiquitin was strongly expressed within INCPs. In NIFTPs, optically clear nuclei or pseudo-pseudoinclusions did not express ubiquitin (0/35). Occasionally, nuclear vacuoles in NIFTP demonstrated a marginated staining pattern, in which strong ubiquitin expression was seen at the periphery of the nucleus, but the central pale area was negative. In addition, 2 NIFTPs demonstrated intrafollicular psammomatoid calcifications which were strongly ubiquitin-positive. Psammoma bodies in PTC were ubiquitin-negative in the majority of cases. We report a previously undescribed finding: strong ubiquitin expression in true INCPs in PTC, absence of true INCPs in NIFTP, and absence of ubiquitin expression in pseudo-pseudoinclusions in NIFTP. This finding supports the difference between true INCPs (found only in PTC) and pseudo-pseudoinclusions (found in NIFTP). Using strict histologic criteria and ubiquitin immunostaining, the presence of true pseudoinclusions may exclude a diagnosis of NIFTP. Caution should be exercised when interpreting nuclear vacuoles or pseudo-pseudoinclusions.	[Cracolici, Vincent; Krausz, Thomas; Cipriani, Nicole A.] Univ Chicago, Dept Pathol, Med Ctr, 5841 S Maryland Ave, Chicago, IL 60637 USA	Cracolici, V (reprint author), Univ Chicago, Dept Pathol, Med Ctr, 5841 S Maryland Ave, Chicago, IL 60637 USA.	vincent.cracolici@uchospitals.edu					Afkhami M, 2016, THYROID, V26, P242, DOI 10.1089/thy.2015.0227; Al-Brahim N, 2006, ARCH PATHOL LAB MED, DOI [10.1043/1543-2165(2006)130[1057:PTCAO]2.0.CO;2, DOI 10.1043/1543-2165(2006)130[1057:PTCAO]2.0.CO;2]; Asioli S, 2009, HISTOPATHOLOGY, V54, P571, DOI 10.1111/j.1365-2559.2009.03259.x; Baloch Zubair W, 2006, Am J Clin Pathol, V125 Suppl, pS135; Bizzarro T, 2016, CANCER CYTOPATHOL, V124, P699, DOI 10.1002/cncy.21777; Bussolati G, 2008, ROM J MORPHOL EMBRYO, V49, P435; Fischer AH, 2001, HISTOL HISTOPATHOL, V16, P1, DOI 10.14670/HH-16.1; Fluge O, 2006, THYROID, DOI [10.1089/THY.2006.16.161, DOI 10.1089/THY.2006.16.161]; Glickman MH, 2002, PHYSIOL REV, V82, P373, DOI 10.1152/physrev.00027.2001; Goellner JR, 2000, CANCER CYTOPATHOL, V90, P41, DOI 10.1002/(SICI)1097-0142(20000225)90:1<41::AID-CNCR6>3.0.CO;2-1; Howitt BE, 2015, AM J CLIN PATHOL, V144, P850, DOI 10.1309/AJCPEIE12POICULI; Hung YP, 2018, HISTOPATHOLOGY, V72, P53, DOI 10.1111/his.13363; Ip YT, 2010, INT J SURG PATHOL, V18, P465, DOI 10.1177/1066896910385342; JOHANNESSEN JV, 1980, LAB INVEST, V43, P287; Johnson DN, 2018, ARCH PATHOL LAB MED, V142, P838, DOI 10.5858/arpa.2017-0118-OA; Kaneko C, 1996, ACTA CYTOL, V40, P417; Kim BK, 2013, ENDOCR J, V60, P155, DOI 10.1507/endocrj.EJ12-0294; Nikiforov YE, 2016, JAMA ONCOL, V2, P1023, DOI 10.1001/jamaoncol.2016.0386; Pandit AA, 2001, ACTA CYTOL, V45, P173, DOI 10.1159/000327273; Petrilli G, 2017, AM J SURG PATHOL, V41, P140, DOI 10.1097/PAS.0000000000000763; Pusztaszeri MP, 2013, ENDOCR PATHOL, V24, P246, DOI 10.1007/s12022-013-9242-2; Rosai J, 2006, HISTOPATHOLOGY, V49, P107, DOI 10.1111/j.1365-2559.2006.02451.x; ROSE DSC, 1995, J CLIN PATHOL, V48, P676, DOI 10.1136/jcp.48.7.676; Seethala RR, 2018, MODERN PATHOL, V31, P39, DOI 10.1038/modpathol.2017.130; Sipina LV, 2010, BIOCHEMISTRY-MOSCOW+, V75, P1148, DOI 10.1134/S0006297910090087; Tuccilli C, 2015, J BIOL REG HOMEOS AG, V29, P655; Wilkinson KD, 2005, P NATL ACAD SCI USA, V102, P15280, DOI 10.1073/pnas.0504842102	27	1	1	0	1	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1936-055X	1936-0568		HEAD NECK PATHOL	Head Neck Pathol.	DEC	2018	12	4					522	528		10.1007/s12105-018-0905-7			7	Pathology	Pathology	HD9WP	WOS:000452915500013	29512025	Green Published			2019-10-28	
J	Ko, EM; McHugh, JB				Ko, Eugene M.; McHugh, Jonathan B.			Primary Leiomyosarcoma of the Buccal Mucosa: Report of a Case and Review of the Literature	HEAD & NECK PATHOLOGY			English	Review						Leiomyosarcoma; Oral cavity; Head and neck	PRIMARY ORAL LEIOMYOSARCOMA; SOFT-TISSUE SARCOMAS; HEAD; NECK; METASTASES; TONGUE	This clinicopathologic study of primary oral leiomyosarcoma of the buccal mucosa involves a literature review of 15 cases with the addition of our report of a case. The demographic details, tumor size, treatment and outcome are documented for all the cases. In addition, this review examines the histologic features of leiomyosarcoma while noting that differentiation from other spindle cell tumors can be challenging, underscoring the necessity of an immunohistochemical work up for an accurate diagnosis. The unpredictability of the clinical behavior of these aggressive tumors requires, at the very least, wide local surgical excision and prolonged follow up.	[Ko, Eugene M.] Univ Michigan, Sch Dent, 1011 N Univ Ave, Ann Arbor, MI 48109 USA; [McHugh, Jonathan B.] Univ Michigan, Dept Pathol, Ann Arbor, MI 48109 USA	Ko, EM (reprint author), Univ Michigan, Sch Dent, 1011 N Univ Ave, Ann Arbor, MI 48109 USA.	eugeneko@umich.edu	ko, eugene/M-7656-2019	ko, eugene/0000-0003-0863-0640			Ahn JH, 2012, J ORAL MAXIL SURG, V70, P1745, DOI 10.1016/j.joms.2011.06.201; Chang AE, 2014, OTOLARYNG HEAD NECK, V151, P976, DOI 10.1177/0194599814551539; Chudasama P, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-017-02602-0; de Bree R, 2010, ORAL ONCOL, V46, P786, DOI 10.1016/j.oraloncology.2010.09.001; Dry SM, 2000, HISTOPATHOLOGY, V36, P210; Eppsteiner RW, 2011, ARCH OTOLARYNGOL, V137, P921, DOI 10.1001/archoto.2011.147; Ethunandan M, 2007, INT J ORAL MAX SURG, V36, P409, DOI 10.1016/j.ijom.2006.12.015; Fernandez-Flores A, 2013, AM J DERMATOPATH, V35, P763, DOI 10.1097/DAD.0b013e318287e0c6; IZUMI K, 1995, ORAL SURG ORAL MED O, V80, P310, DOI 10.1016/S1079-2104(05)80389-0; KRISHNAN V, 1991, J ORAL MAXIL SURG, V49, P652, DOI 10.1016/0278-2391(91)90350-U; Lo Muzio L, 2000, ORAL ONCOL, V36, P519, DOI 10.1016/S1368-8375(00)00044-0; Mesquita RA, 1998, J ORAL MAXIL SURG, V56, P504, DOI 10.1016/S0278-2391(98)90723-6; Montgomery E, 2002, HISTOPATHOLOGY, V40, P518, DOI 10.1046/j.1365-2559.2002.01412.x; Nagpal Deepak Kumar J, 2013, J Oral Maxillofac Pathol, V17, P149, DOI 10.4103/0973-029X.110732; Nikitakis NG, 2002, ORAL ONCOL, V38, P201, DOI 10.1016/S1368-8375(01)00047-1; ROBINSON EC, 1978, BRIT J ORAL SURG, V16, P100; SCHENBERG ME, 1993, J CRANIO MAXILL SURG, V21, P342, DOI 10.1016/S1010-5182(05)80495-0; Schutz A, 2013, J ORAL MAXIL SURG, V71, P1132, DOI 10.1016/j.joms.2012.12.011; Singh Rabindra P., 2008, Sarcoma, P1, DOI 10.1155/2008/654987; Solar AA, 2011, PERIODONTOL 2000, V57, P177, DOI 10.1111/j.1600-0757.2011.00388.x; Suarez-Alen F, 2015, GERODONTOLOGY, V32, P314, DOI 10.1111/ger.12126; Vilos GA, 2005, J ORAL MAXIL SURG, V63, P1461, DOI 10.1016/j.joms.2005.06.018; Yadav Renu, 2008, J Oral Sci, V50, P215, DOI 10.2334/josnusd.50.215; Yan B, 2010, ORAL DIS, V16, P198, DOI 10.1111/j.1601-0825.2009.01635.x; Zhang CZ, 2015, NATURE, V522, P179, DOI 10.1038/nature14493	25	0	0	0	2	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1936-055X	1936-0568		HEAD NECK PATHOL	Head Neck Pathol.	DEC	2018	12	4					529	533		10.1007/s12105-018-0907-5			5	Pathology	Pathology	HD9WP	WOS:000452915500014	29536346	Green Published			2019-10-28	
J	Bauer, JL; Toluie, S; Thompson, LDR				Bauer, Justin L.; Toluie, Sherwin; Thompson, Lester D. R.			Metastases to the Parathyroid Glands: A Comprehensive Literature Review of 127 Reported Cases	HEAD & NECK PATHOLOGY			English	Review						Parathyroid glands; Parathyroid neoplasms; Parathyroid hormone (PTH); Comorbidity; Calcium; Metastatic tumors; Secondary neoplasms; Breast neoplasms; Lung neoplasms; Melanoma	RENAL-CELL CARCINOMA; ENDOCRINE ORGAN METASTASES; TO-TUMOR METASTASIS; MALIGNANT-MELANOMA; PRIMARY HYPERPARATHYROIDISM; BREAST-CARCINOMA; PATIENT; HYPOCALCEMIA	Metastases to the head and neck organs are uncommon, potentially representing the initial presentation of an occult malignancy. Single case reports and small series report metastases to the parathyroid gland, but there is no large review of the literature on secondary tumors involving the parathyroid glands. A review of the English literature between 1950 and 2017 was performed of all metastases or secondary involvement of the parathyroid glands. One hundred and twenty-seven cases of metastatic tumors were reported, although potentially significantly unrepresented in autopsy series (parathyroid glands are not routinely examined) and due to reporting bias. Women were affected more commonly than men (5.8:1; 99 vs. 17, respectively), with a mean age at presentation of 58.5 years, when reported. The most common primary sites of malignancies that metastasized to the parathyroid glands were breast carcinomas (66.9%, n = 85), melanoma (11.8%, n = 15), and lung carcinoma (5.5%, n = 7), with carcinomas representing 86.6% of metastases. Metastases were nearly always identified as part of widely metastatic disease, with only five (3.2%) cases reported as isolated metastases. Tumor-to-tumor metastases comprised 5.5% of all metastases to the parathyroid glands (metastases to parathyroid adenoma). A significant clinical finding of metastases to the parathyroid glands was the development of deranged calcium homeostasis, well beyond the 9 (7.2%) cases with primary parathyroid gland disease present. Although concurrent conditions (renal disease; bone metastases) may partially affect calcium metabolism, the onset of calcium derangement seemed to coincide with parathyroid gland metastases and not systemic disease. In summary, metastases to the parathyroid glands are uncommon, potentially under-recognized in patients who have otherwise widely metastatic tumors. Women are affected more often than men, with breast carcinomas (66.9%) and melanoma (11.8%) the most common primary tumors. Calcium homeostasis is affected, probably as a result of parathyroid gland parenchymal destruction.	[Thompson, Lester D. R.] Woodland Hills Med Ctr, Dept Pathol, Southern Calif Permanente Med Grp, 5601 De Soto Ave, Woodland Hills, CA 91365 USA; [Bauer, Justin L.] Univ Calif San Diego, San Diego, CA 92103 USA; [Toluie, Sherwin] Univ Calif Los Angeles, Los Angeles, CA USA	Thompson, LDR (reprint author), Woodland Hills Med Ctr, Dept Pathol, Southern Calif Permanente Med Grp, 5601 De Soto Ave, Woodland Hills, CA 91365 USA.	jlb@dartmouth.edu; sherwintoluie@yahoo.com; Lester.D.Thompson@kp.org	Thompson, Lester D. R./J-8404-2016	Thompson, Lester D. R./0000-0003-3714-1432			BENISOVICH VI, 1991, CANCER, V68, P1106, DOI 10.1002/1097-0142(19910901)68:5<1106::AID-CNCR2820680534>3.0.CO;2-3; BORDEN H, 1976, CAN ANAESTH SOC J, V23, P616, DOI 10.1007/BF03006744; BUMPERS HL, 1993, ARCH SURG-CHICAGO, V128, P1344; Chrisoulidou A, 2012, WORLD J SURG ONCOL, V10, DOI 10.1186/1477-7819-10-121; CIFUENTES N, 1979, J SURG ONCOL, V11, P193, DOI 10.1002/jso.2930110303; DELAMONTE SM, 1983, CANCER RES, V43, P3427; DELAMONTE SM, 1984, AM J PATHOL, V114, P131; DRICKMAN A, 1961, ARCH SURG-CHICAGO, V82, P576, DOI 10.1001/archsurg.1961.01300100090009; Fulciniti F, 2011, DIAGN CYTOPATHOL, V39, P681, DOI 10.1002/dc.21528; GATTUSO P, 1988, SOUTHERN MED J, V81, P1467, DOI 10.1097/00007611-198811000-00039; GODDARD CJR, 1990, BRIT J HOSP MED, V43, P72; Heffess CS, 2002, CANCER, V95, P1869, DOI 10.1002/cncr.10901; HERMUS A, 1988, KLIN WOCHENSCHR, V66, P643, DOI 10.1007/BF01728807; HORWITZ CA, 1972, AM J MED, V52, P797, DOI 10.1016/0002-9343(72)90086-1; INOSHITA T, 1985, MIL MED, V150, P323; Ito Y, 2009, ENDOCR J, V56, P251, DOI 10.1507/endocrj.K08E-297; KING LR, 1964, ACTA ENDOCRINOL-COP, V47, P121, DOI 10.1530/acta.0.0470121; Lee HE, 2011, PATHOL INT, V61, P593, DOI 10.1111/j.1440-1827.2011.02707.x; Lee SH, 2013, J CLIN ENDOCR METAB, V98, P3127, DOI 10.1210/jc.2013-1227; MARGOLIS CI, 1969, NEW YORK STATE J MED, V69, P702; Mariette X, 1993, Eur J Med, V2, P242; Ofo E, 2014, INT J SURG CASE REP, V5, P378, DOI 10.1016/j.ijscr.2014.04.010; PATEL JK, 1978, AM J SURG, V135, P807, DOI 10.1016/0002-9610(78)90171-X; Pazaitou-Panayiotou Kalliopi, 2005, Hormones (Athens), V4, P213; SCHWARTZ IS, 1982, MT SINAI J MED, V49, P499; Shifrin AL, 2013, ENDOCR PRACT, V19, pE163, DOI 10.4158/EP13267.CR; Tang WH, 2002, ARCH PATHOL LAB MED, V126, P1511; Thompson LDR, 2000, CANCER, V89, P1076, DOI 10.1002/1097-0142(20000901)89:5<1076::AID-CNCR17>3.0.CO;2-M; Torregrossa L, 2016, ONCOL LETT, V12, P3224, DOI 10.3892/ol.2016.5071; Venkatraman L, 2007, J CLIN PATHOL, V60, P1058, DOI 10.1136/jcp.2005.035352; VIADANA E, 1973, CANCER RES, V33, P179; WATANABE T, 1983, JPN J CLIN ONCOL, V13, P441; WOOLNER LB, 1958, CANCER, V11, P975, DOI 10.1002/1097-0142(195809/10)11:5<975::AID-CNCR2820110518>3.0.CO;2-N	33	3	3	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1936-055X	1936-0568		HEAD NECK PATHOL	Head Neck Pathol.	DEC	2018	12	4					534	541		10.1007/s12105-017-0850-x			8	Pathology	Pathology	HD9WP	WOS:000452915500015	28875280	Green Published			2019-10-28	
J	Sakagiannis, G; Giotakis, E; Thompson, LDR				Sakagiannis, Georgios; Giotakis, Evangelos; Thompson, Lester D. R.			Localized Nasopharyngeal Amyloidosis: A Clinicopathologic Series of 7 Cases with a Literature Review	HEAD & NECK PATHOLOGY			English	Review						Nasopharyngeal amyloidosis; Amyloidosis; Palatine tonsils; Nasopharynx	DEPOSITS; TUMOR; HEAD; CT; NECK	Localized nasopharyngeal amyloidosis is an extremely rare entity with only 25 cases described in the English and German literature. We present a case series of seven patients with localized nasopharyngeal amyloidosis and combine the findings with a thorough review the literature.	[Sakagiannis, Georgios] Attikon Univ Hosp, Ear Nose Throat & Head & Neck Dept, Athens, Greece; [Sakagiannis, Georgios; Giotakis, Evangelos] Hippokrat Univ Hosp, Ear Nose Throat Head & Neck Dept, Athens, Greece; [Thompson, Lester D. R.] Woodland Hills Med Ctr, Dept Pathol, Los Angeles, CA USA	Sakagiannis, G (reprint author), Attikon Univ Hosp, Ear Nose Throat & Head & Neck Dept, Athens, Greece.; Sakagiannis, G (reprint author), Hippokrat Univ Hosp, Ear Nose Throat Head & Neck Dept, Athens, Greece.	gsakorl@gmail.com					Chen YS, 2010, J CHIN MED ASSOC, V73, P549, DOI 10.1016/S1726-4901(10)70119-2; Dominguez S, 1996, INT J PEDIATR OTORHI, V36, P61, DOI 10.1016/0165-5876(96)01330-4; Durbec M, 2012, EUR ANN OTORHINOLARY, V129, P160, DOI 10.1016/j.anorl.2011.10.010; GEANMARTON AD, 1991, RADIOLOGY, V181, P521, DOI 10.1148/radiology.181.2.1924798; GLENNER GG, 1980, NEW ENGL J MED, V302, P1283, DOI 10.1056/NEJM198006053022305; GLENNER GG, 1980, NEW ENGL J MED, V302, P1333, DOI 10.1056/NEJM198006123022403; Hazenberg BPC, 2013, RHEUM DIS CLIN N AM, V39, P323, DOI 10.1016/j.rdc.2013.02.012; HEGARTY JL, 1993, AM J NEURORADIOL, V14, P215; Johner C H, 1972, Trans Am Acad Ophthalmol Otolaryngol, V76, P1354; Karimi K, 2010, LARYNGOSCOPE, V120, pS197, DOI 10.1002/lary.21664; Kramer R, 1935, ARCHIV OTOLARYNGOL, V21, P324; Kumar B, 2016, HEAD NECK PATHOL, V10, P379, DOI 10.1007/s12105-016-0681-1; Lim JS, 1999, AM J RHINOL, V13, P209, DOI 10.2500/105065899781389768; Luo M, 2016, STRAHLENTHER ONKOL, V192, P944, DOI 10.1007/s00066-016-0996-6; Mirza AH, 2013, J SURG CASE REP, DOI 10.1093/jscr/rjs048; Motosugi U, 2007, EUR RADIOL, V17, P852, DOI 10.1007/s00330-006-0304-4; Munichor M, 2000, ACTA CYTOL, V44, P673, DOI 10.1159/000328546; Nandapalan V, 1998, HEAD NECK-J SCI SPEC, V20, P73; Nienhuis HLA, 2016, KIDNEY DIS-BASEL, V2, P10, DOI 10.1159/000444206; Panda N K, 1994, Ear Nose Throat J, V73, P335; Panda NK, 2007, AM J OTOLARYNG, V28, P208, DOI 10.1016/j.amjoto.2006.08.009; Patel A, 2002, AM J OTOLARYNG, V23, P308, DOI 10.1053/ajot.2002.124195; Pitkaranta A, 2000, OTOLARYNG HEAD NECK, V122, P309, DOI 10.1016/S0194-5998(00)70263-4; Legaza ES, 2013, ACTA OTORRINOLAR ESP, V64, P377, DOI 10.1016/j.otorri.2012.02.008; SCOTT PP, 1986, SEMIN ROENTGENOL, V21, P103, DOI 10.1016/0037-198X(86)90027-1; SIMPSON GT, 1984, ANN OTO RHINOL LARYN, V93, P374, DOI 10.1177/000348948409300418; Sipe JD, 2016, AMYLOID, V23, P209, DOI 10.1080/13506129.2016.1257986; Sipe JD, 2014, AMYLOID, V21, P221, DOI 10.3109/13506129.2014.964858; URBAN BA, 1993, RADIOGRAPHICS, V13, P1295, DOI 10.1148/radiographics.13.6.8290725; Wu AY, 2011, OPHTHAL PLAST RECONS, V27, pE132, DOI 10.1097/IOP.0b013e31820367ca; Yoshida A, 2008, J CLIN ONCOL, V26, P5817, DOI 10.1200/JCO.2008.18.6338; Zack Zonk MS, 1984, J LARYNGOL OTOL, V98, P519; Zhuang Yu-Long, 2005, J Chin Med Assoc, V68, P142	33	1	1	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1936-055X	1936-0568		HEAD NECK PATHOL	Head Neck Pathol.	DEC	2018	12	4					542	547		10.1007/s12105-017-0880-4			6	Pathology	Pathology	HD9WP	WOS:000452915500016	29282670	Green Published			2019-10-28	
J	Pantanowitz, L; Thompson, LDR; Rossi, ED				Pantanowitz, Liron; Thompson, Lester D. R.; Rossi, Esther Diana			Diagnostic Approach to Fine Needle Aspirations of Cystic Lesions of the Salivary Gland	HEAD & NECK PATHOLOGY			English	Review						Fine-needle; Cyst fluid; Cysts; Cytology; Salivary glands; Milan system	ANALOG SECRETORY CARCINOMA; ACINIC-CELL-CARCINOMA; TYROSINE-RICH CRYSTALLOIDS; PAROTID-GLAND; MUCOEPIDERMOID CARCINOMA; WARTHIN TUMOR; LYMPHOEPITHELIAL CYST; CYTOLOGICAL FEATURES; NONTYROSINE CRYSTALLOIDS; CYTOPATHOLOGIC FEATURES	Fine needle aspiration (FNA) has diagnostic and therapeutic value in the management of salivary gland cysts. Rendering an accurate diagnosis from an aspirated salivary gland cyst is challenging because of the broad differential diagnosis, possibility of sampling error, frequent hypocellularity of specimens, morphologic heterogeneity, and overlapping cytomorphology of many cystic entities. To date, there have been no comprehensive review articles providing a practical diagnostic approach to FNA of cystic lesions of salivary glands. This article reviews the cytopathology of salivary gland cysts employing 2017 World Health Organization terminology, addresses the accuracy of FNA, and presents The Milan System approach for reporting in cystic salivary gland cases. The utility of separating FNA specimens from salivary gland cysts, based upon the presence of mucin and admixed lymphocytes in cyst fluid is demonstrated. A reliable approach to interpreting FNA specimens from patients with cystic salivary gland lesions is essential to accurately determine which of these patients may require subsequent surgery.	[Pantanowitz, Liron] Univ Pittsburgh, Dept Pathol, Med Ctr, Pittsburgh, PA 15260 USA; [Thompson, Lester D. R.] Woodland Hills Med Ctr, Dept Pathol, Woodland Hills, CA USA; [Rossi, Esther Diana] Univ Cattolica Sacro Cuore, Agostino Gemelli Sch Med, Div Anat Pathol & Histol, Rome, Italy; [Pantanowitz, Liron] UPMC, Dept Pathol, Shadyside UPMC Canc Pavilion, Pittsburgh, PA 15232 USA	Pantanowitz, L (reprint author), Univ Pittsburgh, Dept Pathol, Med Ctr, Pittsburgh, PA 15260 USA.; Pantanowitz, L (reprint author), UPMC, Dept Pathol, Shadyside UPMC Canc Pavilion, Pittsburgh, PA 15232 USA.	pantanowitzl@upmc.edu		Rossi, Esther/0000-0003-3819-4229			Ahamed AS, 2014, J PHARM BIOALLIED SC, V6, P185, DOI 10.4103/0975-7406.137464; Al-Abbadi M., 2011, SALIVARY GLAND CYTOL, P215; Ali SZ, 2002, DIAGN CYTOPATHOL, V27, P244, DOI 10.1002/dc.10167; Allison DB, 2017, DIAGN CYTOPATHOL, V45, P800, DOI 10.1002/dc.23780; Arora VK, 2016, DIAGN CYTOPATHOL, V44, P770, DOI 10.1002/dc.23515; Bajaj J, 2014, ACTA CYTOL, V58, P501, DOI 10.1159/000368070; Bajwa MS, 2018, MILAN SYSTEM REPORTI, P157; Ballo MS, 1997, DIAGN CYTOPATHOL, V17, P230, DOI 10.1002/(SICI)1097-0339(199709)17:3<230::AID-DC12>3.0.CO;2-G; Baloch Z, 2018, MILAN SYSTEM REPORTI, P1; Basak K, 2014, MEDICINE, V93, DOI 10.1097/MD.0000000000000246; BERNIER JL, 1958, CANCER, V11, P1156, DOI 10.1002/1097-0142(195811/12)11:6<1156::AID-CNCR2820110611>3.0.CO;2-2; Bialek EJ, 2016, J ULTRASON, V16, P191, DOI 10.15557/JoU.2016.0020; Bishop JA, 2013, CANCER CYTOPATHOL, V121, P228, DOI 10.1002/cncy.21245; Budnick S, 2017, WHO CLASSIFICATION H, P191; Chen KTK, 2007, ACTA CYTOL, V51, P675; Chin S, 2014, J CYTOL, V31, P221, DOI 10.4103/0970-9371.151140; Monteiro BVD, 2016, ANN DIAGN PATHOL, V21, P44, DOI 10.1016/j.anndiagpath.2016.02.001; Edwards PC, 2005, ACTA CYTOL, V49, P489, DOI 10.1159/000326193; Ellis GL AP, 2008, TUMORS SALIVARY GLAN; Elsheikh TM, 2014, HEAD NECK CYTOHISTOL, P76; Faquin WC, SALIVARY GLAND CYTOP; Firat P, 2007, CYTOPATHOLOGY, V18, P184, DOI 10.1111/j.1365-2303.2006.00400.x; Gadodia Ankur, 2012, Ear Nose Throat J, V91, pE17; Gong X, 2012, OR SURG OR MED OR PA, V114, P382, DOI 10.1016/j.oooo.2012.04.014; Gonzalez MF, 2018, CYTOPATHOLOGY, V29, P100, DOI 10.1111/cyt.12465; GOULD AR, 1983, J ORAL PATHOL MED, V12, P478, DOI 10.1111/j.1600-0714.1983.tb00360.x; Granter SR, 1999, DIAGN CYTOPATHOL, V20, P44, DOI 10.1002/(SICI)1097-0339(199901)20:1<44::AID-DC10>3.0.CO;2-K; Griffith CC, 2013, CANCER CYTOPATHOL, V121, P234, DOI 10.1002/cncy.21249; Gupta N, 2009, DIAGN CYTOPATHOL, V37, P203, DOI 10.1002/dc.20991; Hang JF, 2017, DIAGN CYTOPATHOL, V45, P1132, DOI 10.1002/dc.23785; Hegde PN, 2013, J CLIN DIAGN RES, V7, P550, DOI 10.7860/JCDR/2013/4857.2822; Ho C, 2013, INT J SURG PATHOL, V21, P282, DOI 10.1177/1066896912462128; HORIE Y, 1994, PATHOL INT, V44, P535, DOI 10.1111/j.1440-1827.1994.tb02604.x; Iwai T, 2012, J CRANIOFAC SURG, V23, pE374, DOI 10.1097/SCS.0b013e318254359f; Jayaram Gita, 2002, Malays J Pathol, V24, P107; Joseph TP, 2015, J CYTOL, V32, P21, DOI 10.4103/0970-9371.155226; Kai K, 2017, ACTA CYTOL, V61, P469, DOI 10.1159/000477390; Kawahara A, 2010, DIAGN CYTOPATHOL, V38, P377, DOI 10.1002/dc.21232; Khalbuss WE, 2013, QUICK COMPENDIUM CYT; Khatib Y, 2016, INDIAN J PATHOL MICR, V59, P368, DOI 10.4103/0377-4929.188114; Kim MW, 2016, J ULTRAS MED, V35, P877, DOI 10.7863/ultra.15.06062; Koudounarakis E, 2016, HEAD NECK-J SCI SPEC, V38, pE2437, DOI 10.1002/hed.24401; Kumar Kr Ashok, 2013, J Oral Maxillofac Pathol, V17, P248, DOI 10.4103/0973-029X.119744; Kumar U, 2017, J CLIN DIAGN RES, V11, DOI 10.7860/JCDR/2017/21347.9772; Kuwabara H, 2015, DIAGN CYTOPATHOL, V43, P114, DOI 10.1002/dc.23119; Layfield L., 1997, CYTOPATHOLOGY HEAD N; Layfield LJ, 2002, DIAGN CYTOPATHOL, V26, P324, DOI 10.1002/dc.10108; Layfield LJ, 2002, DIAGN CYTOPATHOL, V27, P197, DOI 10.1002/dc.10168; Lemos LB, 1997, ACTA CYTOL, V41, P1709; Madrigal E, 2017, J AM SOC CYTOPATHOL, V6, pS82; MEDEIROS LJ, 1990, HUM PATHOL, V21, P974; Michelow P, 2012, DIAGN CYTOPATHOL, V40, P684, DOI 10.1002/dc.21597; Moatamed NA, 2009, DIAGN CYTOPATHOL, V37, P720, DOI 10.1002/dc.21088; Mosunjac MB, 2009, CYTOPATHOLOGY, V20, P96, DOI 10.1111/j.1365-2303.2007.00480.x; Nasuti JF, 2000, DIAGN CYTOPATHOL, V22, P167, DOI 10.1002/(SICI)1097-0339(20000301)22:3<167::AID-DC7>3.0.CO;2-P; Oza N, 2016, DIAGN CYTOPATHOL, V44, P519, DOI 10.1002/dc.23459; Pantanowitz L, 2006, DIAGN CYTOPATHOL, V34, P749, DOI 10.1002/dc.20539; Parwani AV, 2003, CANCER CYTOPATHOL, V99, P166, DOI 10.1002/cncr.11207; Patel DK, 2016, ACTA OTO-LARYNGOL, V136, P83, DOI 10.3109/00016489.2015.1081276; Pusztaszeri M, 2018, MILAN SYSTEM REPORTI, P43; RAUBENHEIMER EJ, 1990, ORAL SURG ORAL MED O, V70, P480, DOI 10.1016/0030-4220(90)90215-E; Righi PD, 1998, ANN PLAS SURG, V41, P89, DOI 10.1097/00000637-199807000-00017; Sagiv D, 2017, EUR ARCH OTO-RHINO-L, V274, P1993, DOI 10.1007/s00405-016-4436-0; Said-Al-Naief N, 2017, INT J SURG PATHOL, V25, P127, DOI 10.1177/1066896916670005; Samulski TD, 2014, CYTOJOURNAL, V11, DOI 10.4103/1742-6413.139726; Schneller J, 2001, ACTA CYTOL, V45, P605, DOI 10.1159/000327872; SEIFERT G, 1981, VIRCHOWS ARCH A, V390, P273, DOI 10.1007/BF00496559; Shet T, 2006, ACTA CYTOL, V50, P388, DOI 10.1159/000325978; Shilpi, 2017, DIAGN CYTOPATHOL, V45, P640, DOI 10.1002/dc.23701; Skalova A, WHO CLASSIFICATION H; Squilaci S, 2011, PATHOLOGICA, V103, P32; Srivastava S, 2016, DIAGN CYTOPATHOL, V44, P66, DOI 10.1002/dc.23384; Stewart CJR, 2000, DIAGN CYTOPATHOL, V22, P139; Stojanov IJ, 2017, HEAD NECK PATHOL, V11, P469, DOI 10.1007/s12105-017-0810-5; TAKEDA Y, 1991, J ORAL PATHOL MED, V20, P234, DOI 10.1111/j.1600-0714.1991.tb00425.x; Takita H, 2017, JPN J RADIOL, V35, P629, DOI 10.1007/s11604-017-0678-z; Upile T, 2012, HEAD NECK ONCOL, V4, DOI 10.1186/1758-3284-4-24; Viguer JM, 2010, CYTOPATHOLOGY, V21, P164, DOI 10.1111/j.1365-2303.2009.00667.x; Wade TV, 2011, PATHOLOG RES INT, V2011; Wang WY, 2015, BRIT J ORAL MAX SURG, V53, P655, DOI 10.1016/j.bjoms.2015.04.005; Wenig BM, 2016, ATLAS HEAD NECK PATH; Williamson JD, 2000, AM J CLIN PATHOL, V114, P564, DOI 10.1309/GUT1-F58A-V4WV-0D8P; Wu LY, 2009, HUM PATHOL, V40, P683, DOI 10.1016/j.humpath.2008.10.012; Yada N, 2012, OR SURG OR MED OR PA, V114, pE43, DOI 10.1016/j.oooo.2012.02.011	84	2	2	3	4	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1936-055X	1936-0568		HEAD NECK PATHOL	Head Neck Pathol.	DEC	2018	12	4					548	561		10.1007/s12105-018-0904-8			14	Pathology	Pathology	HD9WP	WOS:000452915500017	29524082	Green Published			2019-10-28	
J	Uraizee, I; Cipriani, NA; Ginat, DT				Uraizee, Imran; Cipriani, Nicole A.; Ginat, Daniel T.			Adenoid Cystic Carcinoma of the Oral Cavity: Radiology-Pathology Correlation	HEAD & NECK PATHOLOGY			English	Article						Adenoid cystic carcinoma; Pathology; Radiology	HEAD; PET/CT	Adenoid cystic carcinoma in the oral cavity is an uncommon salivary gland malignancy that has a propensity for perineural spread. A high-grade variant is evidenced by an abundance of pleomorphic cells, loss of the classic biphasic epithelial-myoepithelial growth pattern, and comedonecrosis, as well as elevated Ki-67. CT and MRI can both be useful for demonstrating the extent of invasion in oral cavity-associated adenoid cystic carcinoma, which can attain the inferior alveolar nerve for perineural spread by direct invasion through the mandible. Reflecting the aggressive nature of this high-grade malignancy, (18)FDG-PET can demonstrate hypermetabolism and can be useful for staging. These features are exemplified in this sine qua non radiology-pathology correlation article.	[Uraizee, Imran; Cipriani, Nicole A.] Univ Chicago, Dept Pathol, 5841 S Maryland Ave, Chicago, IL 60637 USA; [Ginat, Daniel T.] Univ Chicago, Dept Radiol, 5841 S Maryland Ave, Chicago, IL 60637 USA	Ginat, DT (reprint author), Univ Chicago, Dept Radiol, 5841 S Maryland Ave, Chicago, IL 60637 USA.	dtg1@uchicago.edu			University of Chicago Office of Faculty Affairs through the Faculty Initiatives Fund for our Head and Neck Radiology-Pathology Trainee Conference	We are grateful for support received from the University of Chicago Office of Faculty Affairs through the Faculty Initiatives Fund for our Head and Neck Radiology-Pathology Trainee Conference, during which this case was presented.	AZUMI N, 1987, CANCER, V60, P1589, DOI 10.1002/1097-0142(19871001)60:7<1589::AID-CNCR2820600729>3.0.CO;2-U; Bertagna F, 2015, REV ESP MED NUCL IMA, V34, P295, DOI 10.1016/j.remn.2015.04.003; Brayer KJ, 2015, CANC DISCOV; Dillon PM, 2016, HEAD NECK-J SCI SPEC, V38, P620, DOI 10.1002/hed.23925; Hellquist H, 2016, ADV THER, V33, P357, DOI 10.1007/s12325-016-0298-5; Jaso J, 2011, ARCH PATHOL LAB MED, V135, P511, DOI 10.1043/2009-0527-RS.1; Li N, 2012, CANCER-AM CANCER SOC, V118, P3945, DOI 10.1002/cncr.26740; Mitani Y, 2015, CLIN CANC RES; Moskaluk CA, 2013, HEAD NECK PATHOL, V7, P17, DOI 10.1007/s12105-013-0426-3; Norberg-Spaak L, 2000, HEAD NECK-J SCI SPEC, V22, P489, DOI 10.1002/1097-0347(200008)22:5<489::AID-HED8>3.0.CO;2-X; Penner CR, 2002, MODERN PATHOL, V15, P687, DOI 10.1097/01.MP.0000018973.17736.F8; Persson M, 2009, P NATL ACAD SCI USA, V106, P18740, DOI 10.1073/pnas.0909114106; Purohit BS, 2014, INSIGHTS IMAGING, V5, P585, DOI 10.1007/s13244-014-0349-x; Roh JL, 2007, J NUCL MED, V48, P240; Rooper L, 2015, HEAD NECK PATHOL, V9, P79, DOI 10.1007/s12105-014-0554-4; SPIRO RH, 1974, AM J SURG, V128, P512, DOI 10.1016/0002-9610(74)90265-7; Vila L, 2009, MODERN PATHOL, V22, P1296, DOI 10.1038/modpathol.2009.95; Wysocki PT, 2016, ONCOTARGET, V7, P66239, DOI 10.18632/oncotarget.11288; Yousem DM, 2000, RADIOLOGY, V216, P19, DOI 10.1148/radiology.216.1.r00jl4519	19	1	1	0	1	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1936-055X	1936-0568		HEAD NECK PATHOL	Head Neck Pathol.	DEC	2018	12	4					562	566		10.1007/s12105-017-0849-3			5	Pathology	Pathology	HD9WP	WOS:000452915500018	28879643	Green Published			2019-10-28	
J	Sultan, AS; Schwartz, MK; Caccamese, JF; Papadimitriou, JC; Basile, J; Foss, RD; Younis, RH				Sultan, Ahmed S.; Schwartz, Michael K.; Caccamese, John F., Jr.; Papadimitriou, John C.; Basile, John; Foss, Robert D.; Younis, Rania H.			Juvenile Trabecular Ossifying Fibroma	HEAD & NECK PATHOLOGY			English	Article						Benign fibro-osseous lesions; Ossifying fibroma; Juvenile trabecular ossifying fibroma; Mandible; Oral cavity	LESIONS; JAW	Benign fibro-osseous lesions within the maxillofacial region represent a heterogeneous group of benign entities with overlapping histologic features. Ossifying fibroma, the rarest of these entities, represents a true neoplasm. Juvenile ossifying fibroma (JOF) is considered an aggressive rapidly growing sub-type. It tends to occur in the first or second decades of life. Based on histological and clinical features it can further be classified into two variants, namely juvenile trabecular ossifying fibroma (JTOF) and juvenile psammomatoid ossifying fibroma (JPOF). JTOF features a proliferation of cellular fibroblastic tissue admixed with woven bone trabeculae with varying histologic presentations. Correlation with clinical and radiographic features is essential to differentiate it from other fibro-osseous lesions. A case of JTOF of the mandible is exemplified in this Sine Qua Non Radiology-Pathology article.	[Sultan, Ahmed S.; Basile, John; Younis, Rania H.] Univ Maryland, Sch Dent, Dept Oncol & Diagnost Sci, Baltimore, MD 21201 USA; [Schwartz, Michael K.] Maryland Ctr Oral Surg & Dent Implants, 600 N Wolfe St, Baltimore, MD 21287 USA; [Caccamese, John F., Jr.] Univ Maryland, Sch Dent, Dept Oral & Maxillofacial Surg, Baltimore, MD 21201 USA; [Papadimitriou, John C.] Univ Maryland, Sch Med, Dept Pathol, Baltimore, MD 21201 USA; [Basile, John; Younis, Rania H.] Univ Maryland, Greenebaum Canc Ctr, Baltimore, MD 21201 USA; [Foss, Robert D.] Johns Hopkins Oral Pathol Lab, Dermatopathol & Oral Pathol Div, 600 N Wolfe St,Blalock 907, Baltimore, MD 21287 USA	Sultan, AS (reprint author), Univ Maryland, Sch Dent, Dept Oncol & Diagnost Sci, Baltimore, MD 21201 USA.	asultan@umaryland.edu		Younis, Rania/0000-0001-5781-5460; Sultan, Ahmed S./0000-0001-5286-4562			Chi AC, 2016, ORAL MAXILLOFACIAL P; El-Mofty S, 2002, ORAL SURG ORAL MED O, V93, P296, DOI 10.1067/moe.2002.121545; El- Mofty SK, 2017, WHO CLASSIFICATION H, P251; Foss RD, 2007, HEAD NECK PATHOL, V1, P33, DOI 10.1007/s12105-007-0001-x; Han J, 2016, INT J ORAL MAX SURG, V45, P368, DOI 10.1016/j.ijom.2015.12.004; Slootweg PJ, 2012, VIRCHOWS ARCH, V461, P699, DOI 10.1007/s00428-012-1329-5; SLOOTWEG PJ, 1994, J ORAL PATHOL MED, V23, P385, DOI 10.1111/j.1600-0714.1994.tb00081.x; SLOOTWEG PJ, 1990, J CRANIO MAXILL SURG, V18, P210, DOI 10.1016/S1010-5182(05)80413-5; Slootweg PJ, 1996, SEMIN DIAGN PATHOL, V13, P104; White SC, 2013, ORAL RADIOLOGY PRINC, P394; Woo S- B, 2017, ORAL PATHOLOGY COMPR	11	1	1	1	2	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1936-055X	1936-0568		HEAD NECK PATHOL	Head Neck Pathol.	DEC	2018	12	4					567	571		10.1007/s12105-017-0862-6			5	Pathology	Pathology	HD9WP	WOS:000452915500019	29027609	Green Published			2019-10-28	
J	Anzai, T; Saito, T; Tsuyama, S; Toh, M; Ikeda, K; Ito, S				Anzai, Takashi; Saito, Tsuyoshi; Tsuyama, Sho; Toh, Miri; Ikeda, Katsuhisa; Ito, Shin			A Case of Glomangiopericytoma at the Nasal Septum	HEAD & NECK PATHOLOGY			English	Article						Glomangiopericytoma; Endoscopic sinus surgery; Nasal septum; Hemangiopericytoma; beta-Catenin	SINONASAL-TYPE HEMANGIOPERICYTOMA	Glomangiopericytoma (GPC) is a rare sinonasal perivascular tumor that accounts for <0.5-1% of all sinonasal tumors. GPC is categorized as a low-grade neoplasm with borderline malignancy and a tendency of local recurrence. GPC is a rare mesenchymal neoplasm characterized by the perivascular proliferation of tumor cells, and it requires being distinguished from solitary fibrous tumors. Here, we report a case of GPC in a 68-year-old male patient who presented at the emergency room of our hospital with a complaint of sudden epistaxis. A small, reddish, protruding tumor was observed on the right nasal septum. A biopsy revealed a possible perivascular tumor such as a GPC or solitary fibrous tumor. Thus, we performed complete resection with endoscopic surgery. The size of the resected tumor was 12x5 mm, and it showed a uniform proliferation of oval-to-short spindle-shaped cells with slightly branching vascular structures. The tumor cells showed minimal cytologic atypia and there were an average of 3 mitoses in 10 high power fields. Necrosis was not observed. The tumor cells showed strong and diffuse nuclear immunostaining with beta catenin and were negative with STAT6, CD34 and bcl-2. The MIB-1 labeling index was approximately 5%. Genetic testing revealed CTNNB1 mutation (p.S33C). Thus, a diagnosis of low grade GPC was made on the biopsy and the patient could be successfully treated with endoscopic resection.	[Anzai, Takashi; Toh, Miri; Ikeda, Katsuhisa; Ito, Shin] Juntendo Univ, Sch Med, Dept Otorhinolaryngol Head & Neck Surg, Bunkyo Ku, 2-1-1 Hongo, Tokyo 1138421, Japan; [Saito, Tsuyoshi; Tsuyama, Sho] Juntendo Univ, Sch Med, Dept Human Pathol, Bunkyo Ku, 2-1-1 Hongo, Tokyo 1138421, Japan	Ito, S (reprint author), Juntendo Univ, Sch Med, Dept Otorhinolaryngol Head & Neck Surg, Bunkyo Ku, 2-1-1 Hongo, Tokyo 1138421, Japan.	shin709@juntendo.ac.jp					Akaike K, 2015, INT J CLIN EXP PATHO, V8, P3299; Catalano PJ, 1996, HEAD NECK-J SCI SPEC, V18, P42, DOI 10.1002/(SICI)1097-0347(199601/02)18:1<42::AID-HED6>3.0.CO;2-Z; Kowalski PJ, 2001, HEAD NECK-J SCI SPEC, V23, P492, DOI 10.1002/hed.1065; Lasota J, 2015, MODERN PATHOL, V28, P715, DOI 10.1038/modpathol.2014.161; Thompson LDR, 2003, AM J SURG PATHOL, V27, P737, DOI 10.1097/00000478-200306000-00004	5	1	1	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1936-055X	1936-0568		HEAD NECK PATHOL	Head Neck Pathol.	DEC	2018	12	4					572	575		10.1007/s12105-017-0870-6			4	Pathology	Pathology	HD9WP	WOS:000452915500020	29168109	Other Gold, Green Published			2019-10-28	
J	Rawal, YB; Anderson, KM				Rawal, Yeshwant B.; Anderson, Kenneth M.			Adenosquamous Carcinoma of the Tongue	HEAD & NECK PATHOLOGY			English	Article						Oral; Tongue; Carcinoma; Squamous; Adenocarcinoma	HEAD; NECK; MOUTH	A 51-year-old white female presented with a painful ulcer of the left ventrolateral tongue. An incisional biopsy confirmed a diagnosis of adenosquamous carcinoma. The adenosquamous carcinoma is an uncommon malignant tumor with histopathological features of a squamous carcinoma and an adenocarcinoma. A definitive diagnosis requires histopathological examination of a deep biopsy involving the submucosal tissue. This malignant tumor shows aggressive behavior with early invasive growth and a poor prognosis. The histopathological findings and differential diagnosis of a case of adenosquamous carcinoma of the tongue are discussed.	[Rawal, Yeshwant B.] Univ Washington, Sch Dent, Dept Oral & Maxillofacial Surg, B 204 Magnuson Hlth Sci Ctr, 1959 NE Pacific St,Box 357133, Seattle, WA 98195 USA; [Anderson, Kenneth M.] Univ Tennessee, Ctr Hlth Sci, Coll Dent, Diagnost Sci & Oral Med, Memphis, TN 38163 USA	Rawal, YB (reprint author), Univ Washington, Sch Dent, Dept Oral & Maxillofacial Surg, B 204 Magnuson Hlth Sci Ctr, 1959 NE Pacific St,Box 357133, Seattle, WA 98195 USA.	ybrawal@uw.edu; kander20@uthsc.edu					Abdelsayed RA, 1998, ORAL SURG ORAL MED O, V85, P173, DOI 10.1016/S1079-2104(98)90422-X; Alos L, 2004, HISTOPATHOLOGY, V44, P570, DOI 10.1111/j.1365-2559.2004.01881.x; Barnes L., 2005, PATHOLOGY GENETICS H; Carlson DL, 2009, ARCH PATHOL LAB MED, V133, P692, DOI 10.1043/1543-2165-133.5.692; ELLIS GL, 1991, SURG PATHOLOGY SALIV, P455; FUJINO K, 1995, AM J OTOLARYNG, V16, P115, DOI 10.1016/0196-0709(95)90042-X; GERUGHTY RM, 1968, CANCER, V22, P1140, DOI 10.1002/1097-0142(196811)22:6<1140::AID-CNCR2820220610>3.0.CO;2-1; Izumi K, 1998, ORAL SURG ORAL MED O, V85, P178, DOI 10.1016/S1079-2104(98)90423-1; Kass JI, 2015, LARYNGOSCOPE, V125, pE371, DOI 10.1002/lary.25519; Keelawat S, 2002, AM J OTOLARYNG, V23, P160, DOI 10.1053/ajot.2002.123462; Lee RJ, 2017, OR SURG OR MED OR PA, V124, P114, DOI 10.1016/j.oooo.2017.03.004; Masand RP, 2011, HEAD NECK PATHOL, V5, P108, DOI 10.1007/s12105-011-0245-3; Schick U, 2013, OR SURG OR MED OR PA, V116, P313, DOI 10.1016/j.oooo.2013.05.003; Scully C, 1999, INT J ORAL MAX SURG, V28, P125; Sheahan P, 2005, ORL-J OTO-RHIN-LARYN, V67, P10, DOI 10.1159/000083008; Sheahan P, 2003, EUR ARCH OTO-RHINO-L, V260, P509, DOI 10.1007/s00405-003-0616-9; SIAR CH, 1987, ORAL SURG ORAL MED O, V63, P216, DOI 10.1016/0030-4220(87)90315-X	17	0	0	0	2	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1936-055X	1936-0568		HEAD NECK PATHOL	Head Neck Pathol.	DEC	2018	12	4					576	579		10.1007/s12105-017-0877-z			4	Pathology	Pathology	HD9WP	WOS:000452915500021	29243024	Green Published			2019-10-28	
J	Sanchez-Romero, C; Carlos, R; Soares, CD; de Almeida, OP				Sanchez-Romero, Celeste; Carlos, Roman; Soares, Ciro Dantas; de Almeida, Oslei Paes			Unusual Multinucleated Giant Cell Reaction in a Tongue Squamous Cell Carcinoma: Histopathological and Immunohistochemical Features	HEAD & NECK PATHOLOGY			English	Article						Oral squamous cell carcinoma; Multinucleated giant cells; Immunohistochemistry; Phagocytosis	TUMOR-ASSOCIATED MACROPHAGES; EXPRESSION; RANK; STROMA	Multinucleated giant cell (MGC) reaction in oral squamous cell carcinoma (OSCC) usually represents a stromal foreign body reaction to keratin from neoplastic epithelial cells. We describe and illustrate by double immunohistochemistry a case of a tongue squamous cell carcinoma (SCC) in a 70-year-old female patient, with a copious MGC reaction not associated to keratin, showing a histopathological pattern not described before. The MGCs were directly associated with neoplastic cells, which are phagocytosed by the MGCs. Immunohistochemistry for CD68, AE1/AE3, CD163, CD11c, RANK, RANK-L, OPG were performed, as well as double staining for CD68 and AE1/AE3 to better illustrate the relationship between MGCs and neoplastic cells. The clinical and biological significance of this pattern of MGC reaction in OSCC needs to be better elucidated.	[Sanchez-Romero, Celeste; Soares, Ciro Dantas; de Almeida, Oslei Paes] Univ Campinas UNICAMP, Piracicaba Dent Sch, Dept Oral Diag, Oral Pathol Sect, Ave Limeira 901,POB 52, BR-1314903 Sao Paulo, Brazil; [Carlos, Roman] Hosp Herrera Llerandi, Ctr Clin Cabeza & Cuello, Guatemala City, Guatemala	Sanchez-Romero, C (reprint author), Univ Campinas UNICAMP, Piracicaba Dent Sch, Dept Oral Diag, Oral Pathol Sect, Ave Limeira 901,POB 52, BR-1314903 Sao Paulo, Brazil.	csr_90@hotmail.com	Soares, Ciro/D-4401-2015	Soares, Ciro/0000-0002-6861-6640; Sanchez-Romero, Celeste/0000-0001-5365-2692			Brandwein-Gensler A, 2005, AM J SURG PATHOL, V29, P167; Branstetter D, 2015, J BONE ONCOL, V4, P59, DOI 10.1016/j.jbo.2015.06.002; Brooks E, 2009, HEAD NECK PATHOL, V3, P95, DOI 10.1007/s12105-009-0110-9; BURKHARDT A, 1975, Journal of Maxillofacial Surgery, V3, P217, DOI 10.1016/S0301-0503(75)80048-8; Chuang FH, 2009, J ORAL PATHOL MED, V38, P753, DOI 10.1111/j.1600-0714.2009.00793.x; Santos HBD, 2017, J ORAL PATHOL MED, V46, P773, DOI 10.1111/jop.12565; de Visser KE, 2006, CONTRIB MICROBIOL, V13, P118, DOI 10.1159/000092969; De Wever O, 2003, J PATHOL, V200, P429, DOI 10.1002/path.1398; Emanuel PO, 2007, J CUTAN PATHOL, V34, P930, DOI 10.1111/j.1600-0560.2007.00748.x; Essa AAM, 2014, J ORAL PATHOL MED, V43, P778, DOI 10.1111/jop.12197; Essa AAM, 2016, PATHOLOGY, V48, P219, DOI 10.1016/j.pathol.2016.02.006; Falleni M, 2017, MELANOMA RES, V27, P200, DOI 10.1097/CMR.0000000000000352; Helming L, 2007, IMMUNOBIOLOGY, V212, P785, DOI 10.1016/j.imbio.2007.09.012; Hu JM, 2017, ONCOTARGET, V8, P21526, DOI 10.18632/oncotarget.15630; Khan UA, 2014, J CELL BIOCHEM, V115, P1290, DOI 10.1002/jcb.24781; Laoui D, 2011, INT J DEV BIOL, V55, P861, DOI 10.1387/ijdb.113371dl; Ma JL, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-112; Petruzzi MNMR, 2017, DIAGN PATHOL, V12, DOI 10.1186/s13000-017-0623-6; Patil Shankargouda, 2013, J Int Oral Health, V5, P147; Reid MD, 2017, CANCER CYTOPATHOL, V125, P563, DOI 10.1002/cncy.21859; Sica A, 2008, SEMIN CANCER BIOL, V18, P349, DOI 10.1016/j.semcancer.2008.03.004; Taylor RM, 2012, LAB INVEST, V92, P600, DOI 10.1038/labinvest.2012.5; Weber M, 2016, ORAL ONCOL, V52, P75, DOI 10.1016/j.oraloncology.2015.11.001; Won KY, 2011, PATHOLOGY, V43, P318, DOI 10.1097/PAT.0b013e3283463536; Zhang XY, 2013, ORAL ONCOL, V49, P119, DOI 10.1016/j.oraloncology.2012.08.004	25	0	0	1	2	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1936-055X	1936-0568		HEAD NECK PATHOL	Head Neck Pathol.	DEC	2018	12	4					580	586		10.1007/s12105-018-0892-8			7	Pathology	Pathology	HD9WP	WOS:000452915500022	29427031	Green Published			2019-10-28	
J	Wasserman, JK; Papp, S; Hope, AJ; Perez-Ordonez, B				Wasserman, Jason K.; Papp, Sylvia; Hope, Andrew J.; Perez-Ordonez, Bayardo			Epstein-Barr Virus-Positive Large Cell Neuroendocrine Carcinoma of the Nasopharynx: Report of a Case with Complete Clinical and Radiological Response After Combined Chemoradiotherapy	HEAD & NECK PATHOLOGY			English	Article						Epstein-Barr virus; Large cell neuroendocrine carcinoma; Nasopharynx; Radiation therapy	ADJUVANT CHEMOTHERAPY; TUMORS	Neuroendocrine carcinomas of the head and neck are rare and are classified as well differentiated, moderately differentiated, and poorly differentiated carcinomas with the latter category being subdivided into small cell and large cell neuroendocrine carcinoma (LCNEC). While most carcinomas in the nasopharynx are associated with Epstein-Barr virus (EBV), there has been only one previous report demonstrating a link between EBV and LCNEC of the nasopharynx. In this report we describe a second case of EBV-positive LCNEC arising in the nasopharynx with bilateral cervical metastases. The patient was treated with a combination of radiation and chemotherapy which resulted in a complete clinical and radiological response. The patient is still disease free 3 years after presentation. The results of this case suggest that EBV-positive LCNEC is sensitive to chemoradiotherapy and as a result may have better prognosis than EBV-negative LCNEC arising in the nasopharynx or other sites.	[Wasserman, Jason K.; Papp, Sylvia; Hope, Andrew J.; Perez-Ordonez, Bayardo] Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON, Canada; [Wasserman, Jason K.; Papp, Sylvia; Hope, Andrew J.; Perez-Ordonez, Bayardo] Toronto Gen Hosp, Univ Hlth Network, Lab Med Program, Dept Pathol, 200 Elizabeth St, Toronto, ON M5G 2C4, Canada	Perez-Ordonez, B (reprint author), Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON, Canada.; Perez-Ordonez, B (reprint author), Toronto Gen Hosp, Univ Hlth Network, Lab Med Program, Dept Pathol, 200 Elizabeth St, Toronto, ON M5G 2C4, Canada.	bayardo.perez-ordonez@uhn.ca					Bates T, 2014, HEAD NECK PATHOL, V8, P127, DOI 10.1007/s12105-013-0471-y; Chua MLK, 2016, LANCET, V387, P1012, DOI 10.1016/S0140-6736(15)00055-0; Dumars C, 2015, J PEDIAT HEMATOL ONC, V37, P474, DOI 10.1097/MPH.0000000000000334; Dworakowska D, 2009, ENDOCR-RELAT CANCER, V16, P45, DOI 10.1677/ERC-08-0142; El-Naggar A, 2017, WHO CLASSIFICATION H; Elloumi F, 2014, CANCER RADIOTHER, V18, P208, DOI 10.1016/j.canrad.2014.03.003; Gao W, 2017, ONCOTARGET, V8, P20297, DOI 10.18632/oncotarget.15526; Iyoda A, 2006, ANN THORAC SURG, V82, P1802, DOI 10.1016/j.athoracsur.2006.05.109; Iyoda A, 2014, GEN THORAC CARDIOVAS, V62, P351, DOI 10.1007/s11748-014-0379-9; Kao HL, 2012, AM J SURG PATHOL, V36, P185, DOI 10.1097/PAS.0b013e318236d822; Kraft S, 2012, AM J SURG PATHOL, V36, P321, DOI 10.1097/PAS.0b013e31823f2f17; Laan TPVD, 2014, HEAD NECK-J SCI SPEC, V37, P707; Lee AWM, 2015, J CLIN ONCOL, V33, P3356, DOI 10.1200/JCO.2015.60.9347; Petersson F, 2015, SEMIN DIAGN PATHOL, V32, P54, DOI 10.1053/j.semdp.2015.02.021; Sarkaria IS, 2011, ANN THORAC SURG, V92, P1180, DOI 10.1016/j.athoracsur.2011.05.027; Sturgis CD, 2015, CASE REP PATHOL, V2015, P1; Travis WD, 2014, THORAC SURG CLIN, V24, P257, DOI 10.1016/j.thorsurg.2014.04.001	17	3	3	0	1	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1936-055X	1936-0568		HEAD NECK PATHOL	Head Neck Pathol.	DEC	2018	12	4					587	591		10.1007/s12105-017-0883-1			5	Pathology	Pathology	HD9WP	WOS:000452915500023	29302900	Green Published			2019-10-28	
J	Perks, AC; Farthing, PM; Murphy, R; Hegarty, AM				Perks, Alexandra C.; Farthing, Paula M.; Murphy, Ruth; Hegarty, Anne M.			A Case of Concomitant Pemphigus Foliaceus and Oral Pemphigus Vulgaris	HEAD & NECK PATHOLOGY			English	Article						Pemphigus; Desmogleins; Epitopes; Autoimmune disease	CLINICAL-FEATURES; TRANSITION; AUTOANTIBODIES; VARIANTS; PROFILES; LESSONS	Pemphigus is a chronic autoimmune condition that can affect multiple areas of the body. The two main subtypes of pemphigus are pemphigus vulgaris (PV) and pemphigus foliaceus (PF) which can rarely occur concurrently or even transition from one to the other. The process of transition may be explained by qualitative changes in desmoglein autoantibody profile. We present a rare case of concomitant PF and oral PV and explore the literature on transitions between pemphigus subtypes and whether this case could represent a transition from PF to PV. Furthermore, the realities of multidisciplinary patient management are discussed.	[Perks, Alexandra C.; Hegarty, Anne M.] Charles Clifford Dent Hosp, Oral Med Unit, 76 Wellesley Rd, Sheffield S10 2SZ, S Yorkshire, England; [Perks, Alexandra C.; Farthing, Paula M.] Univ Sheffield, Unit Oral & Maxillofacial Pathol, Sch Clin Dent, 19 Claremont Crescent, Sheffield S10 2TA, S Yorkshire, England; [Murphy, Ruth] Royal Hallamshire Hosp, Dept Dermatol, Glossop Rd, Sheffield S10 2JF, S Yorkshire, England	Perks, AC (reprint author), Charles Clifford Dent Hosp, Oral Med Unit, 76 Wellesley Rd, Sheffield S10 2SZ, S Yorkshire, England.; Perks, AC (reprint author), Univ Sheffield, Unit Oral & Maxillofacial Pathol, Sch Clin Dent, 19 Claremont Crescent, Sheffield S10 2TA, S Yorkshire, England.	alexperks1@gmail.com; p.farthing@sheffield.ac.uk; ruth.murphy@sth.nhs.uk; anne.hegarty@sth.nhs.uk					Amagai M, 1999, BRIT J DERMATOL, V140, P351; Amagai M, 2009, VET DERMATOL, V20, P308, DOI 10.1111/j.1365-3164.2009.00831.x; [Anonymous], 2011, EPITOPE SPREADING; Cawson RA, 2008, CAWSONS ESSENTIALS O; Chakravarty K, 2008, RHEUMATOLOGY, V47, P924, DOI 10.1093/rheumatology/kel216a; Chan LS, 1998, J INVEST DERMATOL, V110, P103, DOI 10.1046/j.1523-1747.1998.00107.x; Chang SN, 1997, BRIT J DERMATOL, V137, P303; Durmaz K, 2017, DERMATOL CASE REP, V2, P2; Feliciani C, 2005, INT J DERMATOL, V44, P139, DOI 10.1111/j.1365-4632.2005.02071.x; Hacker MK, 2002, CLIN IMMUNOL, V105, P64, DOI 10.1006/clim.2002.5259; Harman KE, 2002, BRIT J DERMATOL, V146, P684, DOI 10.1046/j.1365-2133.2002.04608.x; Herrero-Gonzalez JE, 2016, INT J DERMATOL, V55, P634, DOI 10.1111/ijd.12990; Ishii K, 2000, J AM ACAD DERMATOL, V42, P859, DOI 10.1016/S0190-9622(00)90253-6; Ito T, 2016, J EUR ACAD DERMATOL, V30, P455, DOI 10.1111/jdv.12832; Izumi T, 1998, BRIT J DERMATOL, V139, P688; James KA, 2011, DERMATOL CLIN, V29, P405, DOI 10.1016/j.det.2011.03.012; KAWANA S, 1994, ARCH DERMATOL, V130, P1534, DOI 10.1001/archderm.130.12.1534; Koga H, 2012, BRIT J DERMATOL, V166, P976, DOI 10.1111/j.1365-2133.2012.10827.x; Komai A, 2001, BRIT J DERMATOL, V144, P1177, DOI 10.1046/j.1365-2133.2001.04227.x; Mahmood T, 2012, N AM J MED SCI, V4, P429, DOI 10.4103/1947-2714.100998; Mahoney MG, 1999, J CLIN INVEST, V103, P461, DOI 10.1172/JCI5252; Mandel VD, 2016, J DERMATOL, V43, P940, DOI 10.1111/1346-8138.13314; Martel P, 2002, BRIT J DERMATOL, V147, P1263, DOI 10.1046/j.1365-2133.2002.04981.x; Muramatsu K, 2016, J DERMATOL, V43, P1350, DOI 10.1111/1346-8138.13493; NEUMANNJENSEN B, 1980, BRIT J DERMATOL, V102, P585, DOI 10.1111/j.1365-2133.1980.tb07660.x; Ogata K, 2001, BRIT J DERMATOL, V144, P421, DOI 10.1046/j.1365-2133.2001.04043.x; Park SG, 2006, YONSEI MED J, V47, P278, DOI 10.3349/ymj.2006.47.2.278; Paulie S., 2016, ENZYME LINKED IMMUNO, P1, DOI DOI 10.1002/9780470015902.A0002625.PUB3; Pigozzi B, 2008, J EUR ACAD DERMATOL, V22, P242, DOI 10.1111/j.1468-3083.2007.02298.x; Regezi J, 2017, ORAL PATHOLOGY CLIN; Ronco P, 2009, PEDIATR NEPHROL, V24, P3, DOI 10.1007/s00467-008-1009-5; Salato VK, 2005, CLIN IMMUNOL, V116, P54, DOI 10.1016/j.clim.2005.03.005; Sami N, 2001, CLIN EXP IMMUNOL, V125, P492, DOI 10.1046/j.1365-2249.2001.01637.x; Scully C, 2013, ORAL MAXILLOFACIAL M; Toth GG, 2002, INT J DERMATOL, V41, P525, DOI 10.1046/j.1365-4362.2002.15452.x; Tsuji Y, 2002, ARCH DERMATOL, V138, P95, DOI 10.1001/archderm.138.1.95; Vanderlugt CL, 2002, NAT REV IMMUNOL, V2, P85, DOI 10.1038/nri724	37	0	0	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1936-055X	1936-0568		HEAD NECK PATHOL	Head Neck Pathol.	DEC	2018	12	4					592	597		10.1007/s12105-017-0884-0			6	Pathology	Pathology	HD9WP	WOS:000452915500024	29340948	Other Gold, Green Accepted, Green Published			2019-10-28	
J	Sanchez-Romero, C; Carlos, R; de Almeida, OP; Romanach, MJ				Sanchez-Romero, Celeste; Carlos, Roman; de Almeida, Oslei Paes; Romanach, Mario Jose			Microcystic Calcifying Epithelial Odontogenic Tumor	HEAD & NECK PATHOLOGY			English	Article						Calcifying epithelial odontogenic tumor; Microcystic; Mandible; Immunohistochemistry	CYSTIC VARIANT	Microcystic variant of calcifying epithelial odontogenic tumor is rare. We herein describe an additional well-documented case of microcystic CEOT. The affected patient is a Guatemalan 42-year-old female with an expansile well-defined mixed radiolucent-radiopaque lesion located in the right posterior mandible. The lesion was associated to an unerupted third molar. Histopathologic examination revealed nests and cords of moderately pleomorphic, eosinophilic polyhedral epithelial cells surrounded by a fibromyxoid stroma. The neoplastic cells showed microcystic pattern made of pseudo-glandular spaces with variable diameter. Occasional amyloid deposits and calcified acellular material were observed. Tumor cells were positive for AE1/AE3, CK14, CK19, p63, CD138, and beta-catenin. Conservative surgical resection was performed with an uneventful immediate post-surgical follow-up. After 1 year follow-up there is no evidence of recurrence. Pathologists should be aware of this unusual microcystic presentation of CEOT, which may pose a diagnostic challenge and potential diagnostic dilemma.	[Sanchez-Romero, Celeste; de Almeida, Oslei Paes] Univ Estadual Campinas, Piracicaba Dent Sch, Dept Oral Diag, Oral Pathol, Piracicaba, Brazil; [Carlos, Roman] Hosp Herrera Llerandi, Ctr Clin Cabeza & Cuello, Div Pathol, Guatemala City, Guatemala; [Romanach, Mario Jose] Univ Fed Rio de Janeiro, Sch Dent, Dept Oral Diag & Pathol, Oral Pathol, Ave Carlos Chagas Filho 373,Predio CCS Bloco K, BR-21941902 Rio De Janeiro, Brazil	Romanach, MJ (reprint author), Univ Fed Rio de Janeiro, Sch Dent, Dept Oral Diag & Pathol, Oral Pathol, Ave Carlos Chagas Filho 373,Predio CCS Bloco K, BR-21941902 Rio De Janeiro, Brazil.	marioromanach@ufrj.br	Romanach, Mario/Z-6068-2019; Romanach, Mario J/J-5175-2014	Romanach, Mario/0000-0002-7853-5916; Romanach, Mario J/0000-0002-7853-5916; Sanchez-Romero, Celeste/0000-0001-5365-2692			Afrogheh A, 2014, HEAD NECK PATHOL, V8, P214, DOI 10.1007/s12105-013-0490-8; Azevedo RS, 2013, OR SURG OR MED OR PA, V116, P759, DOI 10.1016/j.oooo.2013.08.023; Barreras CMU, 2014, HEAD NECK PATHOL, V8, P229, DOI 10.1007/s12105-013-0494-4; Channappa NK, 2012, J INVESTIG CLIN DENT, V3, P152, DOI 10.1111/j.2041-1626.2011.00092.x; Chrcanovic BR, 2017, J CRANIO MAXILL SURG, V45, P1117, DOI 10.1016/j.jcms.2017.05.007; Dantas RCM, 2015, J CRANIOFAC SURG, V26, P1722, DOI 10.1097/SCS.0000000000001777; FRANKLIN CD, 1976, ORAL SURG ORAL MED O, V42, P753, DOI 10.1016/0030-4220(76)90098-0; Friedrich RE, 2011, IN VIVO, V25, P259; Goode Robert K, 2004, Oral Maxillofac Surg Clin North Am, V16, P323, DOI 10.1016/j.coms.2004.03.002; Gopalakrishnan R, 2006, ORAL SURG ORAL MED O, V102, P773, DOI 10.1016/j.tripleo.2005.09.029; Gratzinger D, 2008, J ORAL PATHOL MED, V37, P177, DOI 10.1111/j.1600-0714.2007.00613.x; Hunter KD, 2014, HEAD NECK PATHOL, V8, P392, DOI 10.1007/s12105-014-0582-0; Philipsen HP, 2000, ORAL ONCOL, V36, P17, DOI 10.1016/S1368-8375(99)00061-5; Sedghizadeh PP, 2007, ORAL SURG ORAL MED O, V104, pE30, DOI 10.1016/j.tripleo.2006.06.050; Turatti Eveline, 2015, J Clin Exp Dent, V7, pe163, DOI 10.4317/jced.51995; Wright JM, 2017, WHO CLASSIFICATION H, P220	16	2	2	1	2	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1936-055X	1936-0568		HEAD NECK PATHOL	Head Neck Pathol.	DEC	2018	12	4					598	603		10.1007/s12105-017-0868-0			6	Pathology	Pathology	HD9WP	WOS:000452915500025	29164474	Green Published			2019-10-28	
J	Paredes, SEY; Segato, RAB; Moreira, LD; Moreira, A; Serrano, KVD; Rodrigues, CT; Almeida, LY; Leon, JE				Yacarini Paredes, Silvia Elena; Bezerra Segato, Raquel Assed; Moreira, Leila Daher; Moreira, Alcides; Diaz Serrano, Kranya Victoria; Rodrigues, Clarissa Teles; Almeida, Luciana Yamamoto; Leon, Jorge Esquiche			Dentoalveolar Abscesses Not Associated with Caries or Trauma: A Diagnostic Hallmark of Hypophosphatemic Rickets Initially Misdiagnosed as Hypochondroplasia	HEAD & NECK PATHOLOGY			English	Article						Dentoalveolar abscesses; Oral manifestations; Hypophosphatemic rickets; Pediatric patient; Oral histopathology; mu-CT		Hypophosphatemic rickets is a rare genetic disorder involving the regulation of fibroblast growth factor 23 (FGF23), a phosphaturic agent, clinically showing bowing of the legs, short stature and dentoalveolar abscesses. A 7-year-old boy, with previous hypochondroplasia diagnosis, was referred to our pediatric dentistry clinic presenting short stature, bone deformities and sinus tracts at deciduous teeth apex levels not related with trauma, restorations or dental caries. After deciduous teeth extraction, due to root resorption and mobility, light microscopy exhibited typical hypophosphatemic dentin, and micro-computed tomography revealed tubular clefts and porosities throughout the teeth. Laboratory tests confirmed the HR diagnosis, after which the treatment was initiated.	[Yacarini Paredes, Silvia Elena; Bezerra Segato, Raquel Assed; Diaz Serrano, Kranya Victoria] Univ Sao Paulo, Sch Dent Ribeirao Preto, Dept Pediat Dent, Sao Paulo, SP, Brazil; [Moreira, Leila Daher; Moreira, Alcides] Univ Grande Dourados UNIGRAN MS, Diagnost Bucal Ctr, Dourados, Brazil; [Rodrigues, Clarissa Teles] Univ Sao Paulo, Sch Dent Bauru, Dept Dent Endodont & Dent Mat, Sao Paulo, SP, Brazil; [Almeida, Luciana Yamamoto] Univ Sao Paulo, Ribeirao Preto Med Sch FMRP, Dept Clin Med, Div Hematol, Sao Paulo, SP, Brazil; [Leon, Jorge Esquiche] Univ Sao Paulo, Sch Dent Ribeirao Preto, Dept Stomatol Publ Oral Hlth & Forens Dent, Oral Pathol, Sao Paulo, SP, Brazil	Leon, JE (reprint author), Univ Sao Paulo, Sch Dent Ribeirao Preto, Dept Stomatol Publ Oral Hlth & Forens Dent, Oral Pathol, Sao Paulo, SP, Brazil.	jleon@forp.usp.br	Almeida, Luciana Y/C-3045-2016; Diaz-Serrano, Kranya Victoria/H-3400-2015; Leon, Jorge Esquiche/D-7511-2013; Bezerra da Silva, Raquel/M-8655-2016	Almeida, Luciana Y/0000-0001-5403-4052; Diaz-Serrano, Kranya Victoria/0000-0001-9497-0005; Leon, Jorge Esquiche/0000-0002-9668-5870; Bezerra da Silva, Raquel/0000-0002-0230-1347	 [FAPESP 2016/11419-0];  [2011/52090-8]	This study was supported by the following Grants: FAPESP 2016/11419-0 and 2011/52090-8 (Jorge Esquiche Leon).	Albright F, 1937, AM J DIS CHILD, V54, P529; Chen J, 2018, GENE, V641, P355, DOI 10.1016/j.gene.2017.10.062; Cheon Chong Kun, 2014, Ann Pediatr Endocrinol Metab, V19, P36, DOI 10.6065/apem.2014.19.1.36; Cremonesi I, 2014, SCANNING, V36, P456, DOI 10.1002/sca.21141; Douyere D, 2009, ORAL SURG ORAL MED O, V107, P525, DOI 10.1016/j.tripleo.2008.12.003; Foster BL, 2014, J DENT RES, V93, P7, DOI 10.1177/0022034514529150; GALLO LG, 1979, J DENT CHILD, V46, P55; Goldsweig BK, 2015, CURR OSTEOPOROS REP, V13, P88, DOI 10.1007/s11914-015-0259-y; Pavone Vito, 2015, Eur J Orthop Surg Traumatol, V25, P221, DOI 10.1007/s00590-014-1496-y; Penido MGMG, 2014, PEDIATR NEPHROL, V29, P361, DOI 10.1007/s00467-013-2466-z; Pereira CM, 2004, J ENDODONT, V30, P241, DOI 10.1097/00004770-200404000-00015; Pettifor JM, 2012, CALCIFIED TISSUE INT, V91, P297, DOI 10.1007/s00223-012-9651-0; Razali NN, 2015, J PEDIATR ENDOCR MET, V28, P1009, DOI 10.1515/jpem-2014-0366; Ribeiro TR, 2015, DENTOMAXILLOFAC RAD, V44, DOI 10.1259/dmfr.20140347; Sabandal MMI, 2015, CLIN ORAL INVEST, V19, P759, DOI 10.1007/s00784-015-1425-4; White KE, 2014, CURR OSTEOPOROS REP, V12, P252, DOI 10.1007/s11914-014-0223-2; Yamazaki H, 1985, JPN J PEDIAT DENT, V23, P204	17	0	0	1	2	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1936-055X	1936-0568		HEAD NECK PATHOL	Head Neck Pathol.	DEC	2018	12	4					604	609		10.1007/s12105-017-0872-4			6	Pathology	Pathology	HD9WP	WOS:000452915500026	29190002	Green Published			2019-10-28	
J	dos Santos, JL; Altemani, AMDM; Trivellato, AE; Sverzut, CE; Almeida, LY; Teixeira, LR; Ribeiro-Silva, A; Leon, JE				dos Santos, Jessica Luana; de Almeida Milani Altemani, Albina Messias; Trivellato, Alexandre Elias; Sverzut, Cassio Edvard; Almeida, Luciana Yamamoto; Teixeira, Lucas Ribeiro; Ribeiro-Silva, Alfredo; Leon, Jorge Esquiche			Intraoral Pigmented Low-Grade Adenocarcinoma, Not Otherwise Specified: Case Report and Immunohistochemical Study	HEAD & NECK PATHOLOGY			English	Article						Adenocarcinoma, not otherwise specified; Salivary gland neoplasms; Pigmentation; Melanin; Oral cavity; Immunohistochemistry	SALIVARY-GLAND TUMORS; MUCOEPIDERMOID CARCINOMA; MELANIN PIGMENTATION; PLEOMORPHIC ADENOMA; LIPOFUSCIN; CELLS; NEOPLASMS; MARKER	Salivary adenocarcinoma, not otherwise specified (AdCaNOS) is a rare malignant tumor with potential diagnostic challenge, which mainly affects the parotid glands; however, the minor salivary glands can also be involved by AdCaNOS. This paper reports a case of a 45-year-old Afro-descendant woman complaining of a slow-growing mass with 6 months of evolution in the left superior vestibular fornix. Microscopic examination revealed an infiltrative epithelial neoplasm composed of predominantly solid growth pattern, arranged in a lobular configuration, admixed with glandular or ductal structures. Perineural invasion was evident. The tumor cells were polygonal or oval showing focally mild nuclear pleomorphism, and eosinophilic or clear cytoplasm. Notably, some areas exhibited intracytoplasmic pigment granules mainly in non-luminal cells, as well as sebaceous-like cells, discrete hyaline material deposition and foci of infiltration of residual salivary gland parenchyma. Tumor cells were negative for PAS, mucicarmine and Alcian blue stains. By immunohistochemistry, the tumor cells were diffuse and strongly positive for pan-cytokeratin (CK) AE1/AE3, 34betaE12 CK, vimentin, p63 and S100. CK7 and EMA strongly highlighted the ductal structures. Solid areas also showed diffuse and moderate expression of CD56. Podoplanin (D2-40), GFAP and Calponin, followed by DOG-1, were focally positive; whereas CK20, a-SMA, h-Caldesmon, CD57, ERBB2/HER2 and p53 were negative. Ki-67 was <2%. Consecutive serial tissue sections using CD57 confirmed the perineural invasion. Positivity for HMB-45 and MART-1/Melan-A, as well as Fontana-Masson stain (and potassium permanganate bleaching-sensitive), identified the pigment granules as melanin. To the best of our knowledge, this is the first case of intraoral low-grade AdCaNOS with intracytoplasmic melanin granules.	[dos Santos, Jessica Luana; Almeida, Luciana Yamamoto; Teixeira, Lucas Ribeiro; Ribeiro-Silva, Alfredo] Univ Sao Paulo, Ribeirao Preto Med Sch FMRP, Dept Pathol & Forens Med, Oral Pathol, Ave Cafe S-N, BR-14040904 Sao Paulo, Brazil; [de Almeida Milani Altemani, Albina Messias] Univ Estadual Campinas, Fac Med Sci, Dept Pathol, Div Pathol, Rua Tessalia Vieira de Camargo 126, BR-13083887 Sao Paulo, Brazil; [Trivellato, Alexandre Elias; Sverzut, Cassio Edvard] Univ Sao Paulo, Ribeirao Preto Dent Sch FORP, Dept Oral & Maxillofacial Surg & Periodontol, Oral & Maxillofacial Surg, Ave Cafe S-N, BR-14040904 Sao Paulo, Brazil; [Leon, Jorge Esquiche] Univ Sao Paulo, Ribeirao Preto Dent Sch FORP, Dept Stomatol Publ Oral Hlth & Forens Dent, Oral Pathol, Ave Cafe S-N, BR-14040904 Sao Paulo, Brazil	Leon, JE (reprint author), Univ Sao Paulo, Ribeirao Preto Dent Sch FORP, Dept Stomatol Publ Oral Hlth & Forens Dent, Oral Pathol, Ave Cafe S-N, BR-14040904 Sao Paulo, Brazil.	jleon@forp.usp.br	Almeida, Luciana Y/C-3045-2016; Trivellato, Alexandre/I-2827-2014; Leon, Jorge Esquiche/D-7511-2013	Almeida, Luciana Y/0000-0001-5403-4052; Santos, Jessica/0000-0002-4721-2292; Trivellato, Alexandre/0000-0002-7856-2228; Leon, Jorge Esquiche/0000-0002-9668-5870	State of Sao Paulo Research FoundationFundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [2011/52090-8, 2016/11419-0]	Jorge Esquiche Leon has received research Grants from State of Sao Paulo Research Foundation (2011/52090-8 and 2016/11419-0).	Abu El-Naaj I, 2011, J ORAL MAXIL SURG, V69, P1967, DOI 10.1016/j.joms.2010.10.010; AUFDEMORTE TB, 1985, J ORAL MAXIL SURG, V43, P876, DOI 10.1016/0278-2391(85)90226-5; BATSAKIS JG, 1990, ANN OTO RHINOL LARYN, V99, P835, DOI 10.1177/000348949009901015; BATSAKIS JG, 1992, ANN OTO RHINOL LARYN, V101, P102, DOI 10.1177/000348949210100123; BUCHNER A, 1978, ORAL SURG ORAL MED O, V46, P79, DOI 10.1016/0030-4220(78)90441-3; BUCHNER A, 1977, J ORAL PATHOL MED, V6, P106, DOI 10.1111/j.1600-0714.1977.tb01637.x; Chatura K R, 2015, J Oral Maxillofac Pathol, V19, P77, DOI 10.4103/0973-029X.157206; Chenevert J, 2012, MODERN PATHOL, V25, P919, DOI 10.1038/modpathol.2012.57; d'Ischia M, 2013, PIGM CELL MELANOMA R, V26, P616, DOI 10.1111/pcmr.12121; Deng RZ, 2012, OR SURG OR MED OR PA, V113, P655, DOI 10.1016/j.oooo.2011.11.019; Desai SS, 2006, VIRCHOWS ARCH, V448, P521, DOI 10.1007/s00428-005-0125-x; El-Naggar A, 2017, WHO CLASSIFICATION H; Fonseca FP, 2012, OR SURG OR MED OR PA, V114, P230, DOI 10.1016/j.oooo.2012.04.008; Gao M, 2017, INT J ORAL MAX SURG, V46, P343, DOI 10.1016/j.ijom.2016.09.021; Ghazali N, 2016, OR SURG OR MED OR PA, V122, P292, DOI [10.1016/j.0000.2016.03.020, 10.1016/j.oooo.2016.03.020]; Huh KH, 2003, ORAL SURG ORAL MED O, V95, P752, DOI 10.1067/moe.2003.246; Li J, 2004, ARCH PATHOL LAB MED, V128, P1385; Liyanage RLPR, 2014, OR SURG OR MED OR PA, V117, pE449, DOI 10.1016/j.oooo.2013.08.031; Marucci G, 2005, INT J SURG PATHOL, V13, P295, DOI 10.1177/106689690501300313; Matsumoto Y, 2001, ORAL SURG ORAL MED O, V92, P299, DOI 10.1067/moe.2001.116820; Nikitakis NG, 2004, MODERN PATHOL, V17, P407, DOI 10.1038/modpathol.3800064; Oide T, 2017, HUM PATHOL, V67, P181, DOI 10.1016/j.humpath.2017.03.010; Paker I, 2012, DIAGN CYTOPATHOL, V40, P48, DOI 10.1002/dc.21584; Patra SK, 2012, LARYNGOSCOPE, V122, P1579, DOI 10.1002/lary.23310; Pires FR, 2007, ORAL ONCOL, V43, P463, DOI 10.1016/j.oraloncology.2006.04.008; Seethala RR, 2009, HEAD NECK PATHOL, V3, P69, DOI 10.1007/s12105-009-0102-9; Sekine J, 2005, VIRCHOWS ARCH, V446, P460, DOI 10.1007/s00428-005-1213-7; Shin SJ, 2000, HISTOPATHOLOGY, V37, P456, DOI 10.1046/j.1365-2559.2000.01013.x; SPIRO RH, 1982, AM J SURG, V144, P423, DOI 10.1016/0002-9610(82)90416-0; Stenner M, 2009, EUR ARCH OTO-RHINO-L, V266, P333, DOI 10.1007/s00405-008-0882-7; Takeda Y, 1996, PATHOL INT, V46, P467, DOI 10.1111/j.1440-1827.1996.tb03639.x; Takeda Y, 2000, PATHOL INT, V50, P15, DOI 10.1046/j.1440-1827.2000.00998.x; Takeda Y, 2004, VIRCHOWS ARCH, V445, P199, DOI 10.1007/s00428-004-1050-0; Takeda Yasunori, 2006, J Oral Sci, V48, P253, DOI 10.2334/josnusd.48.253; Thoeny Harriet C, 2007, Cancer Imaging, V7, P52, DOI 10.1102/1470-7330.2007.0008; Yih WY, 2005, J ORAL MAXIL SURG, V63, P805, DOI 10.1016/j.joms.2005.02.021	36	0	0	0	1	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1936-055X	1936-0568		HEAD NECK PATHOL	Head Neck Pathol.	DEC	2018	12	4					610	618		10.1007/s12105-017-0875-1			9	Pathology	Pathology	HD9WP	WOS:000452915500027	29274041	Green Published			2019-10-28	
J	Laliberte, C; Leong, IT; Holmes, H; Monteiro, EA; O'Sullivan, B; Dickson, BC				Laliberte, Catherine; Leong, Iona T.; Holmes, Howard; Monteiro, Eric A.; O'Sullivan, Brian; Dickson, Brendan C.			Sclerosing Epithelioid Fibrosarcoma of the Jaw: Late Recurrence from a Low Grade Fibromyxoid Sarcoma	HEAD & NECK PATHOLOGY			English	Article						EWSR1-CREB3L1; Sclerosing epithelioid fibrosarcoma; Low-grade fibromyxoid sarcoma; Jaw; Mandible; Sarcoma; Case report	BONE; SERIES; MARKER; MUC4	Sclerosing epithelioid fibrosarcoma (SEF) is an uncommon variant of fibrosarcoma that is characterized by a distinct morphology. It most frequently presents in the deep soft tissues of the lower extremities, often in intimate association with fascia and periosteum, although reports of the head and neck involvement have been reported. A minority of cases show morphological, immunohistochemical and molecular overlap with low grade fibromyxoid sarcoma (LG-FMS). Herein, we describe a case of a bland spindle cell neoplasm presenting in the jaw that was initially incompletely excised. Over the course of 20 years the tumor subsequently recurred with a SEF morphology. Molecular testing performed on both specimens subsequently confirmed the presence of an EWSR1-CREB3L1 gene fusion. This report highlights the diagnostic difficulty with LG-FMS, particularly in unusual anatomic locations; reiterates the potential for the uncommon EWSR1-CREB3L1 fusion product in LG-FMS; and, reaffirms the potential for progression and/or overlap between LG-FMS to SEF over time.	[Laliberte, Catherine; Leong, Iona T.; Holmes, Howard; Dickson, Brendan C.] Mt Sinai Hosp, Dept Pathol & Lab Med, 600 Univ Ave,Suite 6-500-12-5, Toronto, ON M5G 1X5, Canada; [Laliberte, Catherine; Leong, Iona T.; Holmes, Howard] Univ Toronto, Fac Dent, Toronto, ON, Canada; [Monteiro, Eric A.] Mt Sinai Hosp, Dept Otolaryngol, Toronto, ON, Canada; [Monteiro, Eric A.] Univ Toronto, Dept Otolaryngol Head & Neck Surg, Toronto, ON, Canada; [O'Sullivan, Brian] Princess Margaret Hosp, Dept Radiat Oncol, Toronto, ON, Canada; [O'Sullivan, Brian] Univ Toronto, Dept Radiat Oncol, Toronto, ON, Canada; [Dickson, Brendan C.] Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON, Canada	Dickson, BC (reprint author), Mt Sinai Hosp, Dept Pathol & Lab Med, 600 Univ Ave,Suite 6-500-12-5, Toronto, ON M5G 1X5, Canada.; Dickson, BC (reprint author), Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON, Canada.	Brendan.Dickson@sinaihealthsystem.ca		O'Sullivan, Brian/0000-0001-8887-843X			Antonescu CR, 2001, AM J SURG PATHOL, V25, P699, DOI 10.1097/00000478-200106000-00001; Arbajian E, 2014, AM J SURG PATHOL, V38, P801, DOI 10.1097/PAS.0000000000000158; Chow LTC, 2004, J CLIN PATHOL, V57, P90, DOI 10.1136/jcp.57.1.90; Cowan ML, 2016, HEAD NECK PATHOL, V10, P161, DOI 10.1007/s12105-015-0647-8; Doyle LA, 2012, AM J SURG PATHOL, V36, P1444, DOI 10.1097/PAS.0b013e3182562bf8; Doyle LA, 2011, AM J SURG PATHOL, V35, P733, DOI 10.1097/PAS.0b013e318210c268; Evans HL, 2011, AM J SURG PATHOL, V35, P1450, DOI 10.1097/PAS.0b013e31822b3687; EVANS HL, 1993, AM J SURG PATHOL, V17, P595, DOI 10.1097/00000478-199306000-00007; Folk GS, 2007, HEAD NECK PATHOL, V1, P13, DOI 10.1007/s12105-007-0002-9; Folpe AL, 2000, AM J SURG PATHOL, V24, P1353, DOI 10.1097/00000478-200010000-00004; Grunewald Thomas G. P., 2010, Sarcoma, P431627, DOI 10.1155/2010/431627; Guillou L, 2007, AM J SURG PATHOL, V31, P1387, DOI 10.1097/PAS.0b013e3180321959; Lau PPL, 2013, AM J SURG PATHOL, V37, P734, DOI 10.1097/PAS.0b013e31827560f8; MEISKINDBLOM JM, 1995, AM J SURG PATHOL, V19, P979, DOI 10.1097/00000478-199509000-00001; Mertens F, 2005, LAB INVEST, V85, P408, DOI 10.1038/labinvest.3700230; Prieto-Granada C, 2015, GENE CHROMOSOME CANC, V54, P28, DOI 10.1002/gcc.22215; Puls F, 2016, HISTOPATHOLOGY, V68, P760, DOI 10.1111/his.12791; Rekhi B, 2011, ANN DIAGN PATHOL, V15, P303, DOI 10.1016/j.anndiagpath.2011.02.005; Wang GF, 2010, ULTRASTRUCT PATHOL, V34, P99, DOI 10.3109/01913121003605576; Wojcik JB, 2014, AM J SURG PATHOL, V38, P1538, DOI 10.1097/PAS.0000000000000265	20	0	0	0	2	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1936-055X	1936-0568		HEAD NECK PATHOL	Head Neck Pathol.	DEC	2018	12	4					619	622		10.1007/s12105-017-0879-x			4	Pathology	Pathology	HD9WP	WOS:000452915500028	29274042	Green Published			2019-10-28	
J	Shah, AA; Lamarre, ED; Bishop, JA				Shah, Akeesha A.; Lamarre, Eric D.; Bishop, Justin A.			Human Papillomavirus-Related Multiphenotypic Sinonasal Carcinoma: A Case Report Documenting the Potential for Very Late Tumor Recurrence	HEAD & NECK PATHOLOGY			English	Article						Human papillomavirus; Multiphenotypic sinonasal carcinoma; Adenoid cystic carcinoma; Sinonasal carcinoma; Carcinoma with adenoid cystic-like features	CYSTIC-LIKE FEATURES; HEAD; HPV	Human papillomavirus (HPV)-related multiphenotypic sinonasal carcinoma is a peculiar sinonasal tract tumor that demonstrates features of both a surface-derived and salivary gland carcinoma. Implicit in its name, this tumor has a consistent association with high-risk HPV, particularly type 33. It was first described in 2013 under the designation of HPV-related carcinoma with adenoid cystic carcinoma-like features. However, since its initial description additional cases have emerged which demonstrate a wide morphologic spectrum and relatively indolent clinical behavior. Herein we report our experience with a case of HPV-related multiphenotypic sinonasal carcinoma that was initially classified as adenoid cystic carcinoma in the 1980s. The patient recurred after a 30-year disease free interval. RNA in situ hybridization confirmed the presence of high-risk HPV in both her recurrence and her initial tumor in the 1980s, which allowed for reclassification as HPV-related multiphenotypic sinonasal carcinoma. Our case adds to the literature of this relatively newly described entity and supports the indolent clinical behavior of this neoplasm but also demonstrates a potential for very late local recurrence.	[Shah, Akeesha A.] Cleveland Clin Fdn, Dept Pathol, Robert J Tomsich Pathol & Lab Med Inst, 9500 Euclid Ave,L25, Cleveland, OH 44195 USA; [Lamarre, Eric D.] Cleveland Clin Fdn, Head & Neck Inst, 9500 Euclid Ave, Cleveland, OH 44195 USA; [Bishop, Justin A.] Univ Texas Southwestern Med Ctr Dallas, Dept Pathol, 5323 Harry Hines Blvd CS3-620, Dallas, TX 75390 USA	Shah, AA (reprint author), Cleveland Clin Fdn, Dept Pathol, Robert J Tomsich Pathol & Lab Med Inst, 9500 Euclid Ave,L25, Cleveland, OH 44195 USA.	shaha8@ccf.org; lamarre@ccf.org; justin.bishop@utsouthwestern.edu					Andreasen S, 2017, HISTOPATHOLOGY, V70, P880, DOI 10.1111/his.13162; Bishop JA, 2017, AM J SURG PATHOL, V41, P1690, DOI 10.1097/PAS.0000000000000944; Bishop JA, 2013, AM J SURG PATHOL, V37, P836, DOI 10.1097/PAS.0b013e31827b1cd6; Bishop JA, 2013, AM J SURG PATHOL, V37, P185, DOI 10.1097/PAS.0b013e3182698673; Bishop JA, 2012, AM J SURG PATHOL, V36, P1874, DOI 10.1097/PAS.0b013e318265fb2b; El-Naggar A, 2017, WHO CLASSIFICATION H; Hwang SJ, 2015, AURIS NASUS LARYNX, V42, P53, DOI 10.1016/j.anl.2014.07.005; Seethala RR, 2007, AM J SURG PATHOL, V31, P1683, DOI 10.1097/PAS.0b013e3180dc928c	8	5	5	2	4	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1936-055X	1936-0568		HEAD NECK PATHOL	Head Neck Pathol.	DEC	2018	12	4					623	628		10.1007/s12105-018-0895-5			6	Pathology	Pathology	HD9WP	WOS:000452915500029	29445997	Green Published			2019-10-28	
J	Raubenheimer, E; Noffke, C				Raubenheimer, Erich; Noffke, Claudia			Regarding the Use of the Term "Cementum" in Pathologic Proliferations	HEAD & NECK PATHOLOGY			English	Letter							DYSPLASIA		[Raubenheimer, Erich] Ampath Histopathol Lab, Pretoria, South Africa	Raubenheimer, E (reprint author), Ampath Histopathol Lab, Pretoria, South Africa.	raubenheimere@ampath.co.za					AGAZZI C, 1953, Arch Ital Otol Rinol Laringol, V64, P1; Hwang EH, 2001, DENTOMAXILLOFAC RAD, V30, P230, DOI 10.1038/sj.dmfr.4600608; Ma C, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000004417; Odell EW, 2017, WHO CLASSIFICATION H, P203; Philipsen HP, 2005, WHO CLASSIFICATION H, P319; Rajendran R., 2012, SHAFERS TXB ORAL PAT, P588; Raubenheimer EJ, 2016, HEAD NECK PATHOL, V10, P437, DOI 10.1007/s12105-016-0720-y; Reichart PA, 2004, ORAL ONCOL EXTRA, V40, P8; Riminucci M, 2001, J BONE MINER RES, V16, P1710, DOI 10.1359/jbmr.2001.16.9.1710; Su L, 1997, ORAL SURG ORAL MED O, V84, P301, DOI 10.1016/S1079-2104(97)90348-6	10	1	1	0	1	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1936-055X	1936-0568		HEAD NECK PATHOL	Head Neck Pathol.	DEC	2018	12	4					629	630		10.1007/s12105-018-0888-4			2	Pathology	Pathology	HD9WP	WOS:000452915500030	29445998	Green Published			2019-10-28	
J	El-Mofty, S				El-Mofty, Samir			Regarding the Use of the Term "Cementum" in Fibro-Osseous Lesions of the Craniofacial Skeleton	HEAD & NECK PATHOLOGY			English	Letter									[El-Mofty, Samir] Washington Univ, St Louis, MO 63130 USA	El-Mofty, S (reprint author), Washington Univ, St Louis, MO 63130 USA.	elmofty@wustl.edu					El-Mofty S.K., 2017, WHO CLASSIFICATION H, P253; El-Mofty SK, 2014, HEAD NECK PATHOL, V8, P432, DOI 10.1007/s12105-014-0590-0; El- Mofty SK, 2017, WHO CLASSIFICATION H, P251; Eversole R, 2008, HEAD NECK PATHOL, V2, P177, DOI 10.1007/s12105-008-0057-2; Otaify GA, 2018, BONE, V107, P161, DOI 10.1016/j.bone.2017.11.012	5	0	0	0	1	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1936-055X	1936-0568		HEAD NECK PATHOL	Head Neck Pathol.	DEC	2018	12	4					631	632		10.1007/s12105-018-0889-3			2	Pathology	Pathology	HD9WP	WOS:000452915500031	29450846	Green Published			2019-10-28	
J	Jung, J; Kang, E; Chae, SM; Kim, H; Park, SY; Yun, BL; Kim, SM; Jang, MJ; Kim, SW; Kim, EK				Jung, Jaehag; Kang, Eunyoung; Chae, Su Min; Kim, Hyojin; Park, So Yeon; Yun, Bo La; Kim, Sun Mi; Jang, Mijung; Kim, Sung-Won; Kim, Eun-Kyu			Development of a Management Algorithm for the Diagnosis of Cellular Fibroepithelial Lesions From Core Needle Biopsies	INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY			English	Article						cellular fibroepithelial lesions; core needle biopsy; fibroadenoma; phyllodes tumor; management	PHYLLODES TUMOR; HISTOLOGICAL FEATURES; SONOGRAPHIC FEATURES; SURGICAL EXCISION; BREAST; FIBROADENOMA; DISTINCTION	Purpose. Surgical excision is recommended for complete evaluation of cellular fibroepithelial lesions identified from core needle biopsy. The purpose of this study was to determine factors associated with phyllodes tumor among cellular fibroepithelial lesions from core biopsies and develop a scoring system to predict the risk of phyllodes tumor. Methods. We retrospectively reviewed clinical data of 169 breast lesions that were diagnosed as cellular fibroepithelial lesions from core needle biopsy at the Seoul National University Bundang Hospital between March 2005 and January 2013. The clinical, histopathologic, and radiologic characteristics were compared between phyllodes tumors and fibroadenomas during the final diagnosis after surgical excision. Results. Of the 169 lesions, 17 were observed and 152 were surgically removed. After excision, final pathology revealed 60 (39.5%) fibroadenomas and 92 (60.5%) phyllodes tumors. Multivariate analysis demonstrated that age (>= 40 years), stromal overgrowth, and stromal cellularity were independent factors associated with phyllodes tumors. A scoring system was developed based on a multivariate logistic regression model, and the area under the receiver operating characteristic curve was 0.828 (95% confidence interval = 0.763-0.893). Conclusion. The scoring system will help clinicians make appropriate treatment for patients with cellular fibroepithelial lesions on core needle biopsy.	[Jung, Jaehag] Eulji Univ, Dept Surg, Coll Med, Daejeon, South Korea; [Kang, Eunyoung; Chae, Su Min; Kim, Eun-Kyu] Seoul Natl Univ, Bundang Hosp, Seoul Natl Univ Coll Med, Dept Surg, 82 Gumi Ro 173 Beon Gil, Seongnam Si 463707, Gyeonggi Do, South Korea; [Kim, Hyojin; Park, So Yeon] Seoul Natl Univ, Bundang Hosp, Seoul Natl Univ Coll Med, Dept Pathol, Seongnam, South Korea; [Yun, Bo La; Kim, Sun Mi; Jang, Mijung] Seoul Natl Univ, Bundang Hosp, Seoul Natl Univ Coll Med, Dept Radiol, Seongnam, South Korea; [Kim, Sung-Won] Daerim St Marys Hosp, Dept Surg, Seoul, South Korea	Kang, E (reprint author), Seoul Natl Univ, Bundang Hosp, Seoul Natl Univ Coll Med, Dept Surg, 82 Gumi Ro 173 Beon Gil, Seongnam Si 463707, Gyeonggi Do, South Korea.	key5002@gmail.com					Adamietz BR, 2011, ULTRASCHALL MED, V32, P67, DOI 10.1055/s-0031-1282024; Barrio AV, 2007, ANN SURG ONCOL, V14, P2961, DOI 10.1245/s10434-007-9439-z; Bode MK, 2007, ACTA RADIOL, V48, P708, DOI 10.1080/02841850701367911; Chao TC, 2002, ULTRASOUND OBST GYN, V20, P64, DOI 10.1046/j.1469-0705.2002.00736.x; Choi J, 2012, PATHOL INT, V62, P120, DOI 10.1111/j.1440-1827.2011.02761.x; Dillon MF, 2006, SURGERY, V140, P779, DOI 10.1016/j.surg.2006.03.022; Jacklin RK, 2006, J CLIN PATHOL, V59, P454, DOI 10.1136/jcp.2005.025866; Jacobs TW, 2005, AM J CLIN PATHOL, V124, P342, DOI 10.1309/5N2C4N5XCV8XW8JL; Jara-Lazaro AR, 2010, HISTOPATHOLOGY, V57, P220, DOI 10.1111/j.1365-2559.2010.03607.x; Khosravi-Shahi P, 2011, SURG ONCOL, V20, pE143, DOI 10.1016/j.suronc.2011.04.007; Lee AHS, 2007, HISTOPATHOLOGY, V51, P336, DOI 10.1111/j.1365-2559.2007.02786.x; Maity PP, 2013, MICRON, V48, P34, DOI 10.1016/j.micron.2013.02.004; Morgan JM, 2010, HISTOPATHOLOGY, V56, P489, DOI 10.1111/j.1365-2559.2010.03514.x; Reinfuss M, 1996, CANCER-AM CANCER SOC, V77, P910, DOI 10.1002/(SICI)1097-0142(19960301)77:5<910::AID-CNCR16>3.0.CO;2-6; Resetkova E, 2010, BREAST J, V16, P573, DOI 10.1111/j.1524-4741.2010.01013.x; Ross DS, 2017, BREAST J, V23, P182, DOI 10.1111/tbj.12706; Schisterman EF, 2005, EPIDEMIOLOGY, V16, P73, DOI 10.1097/01.ede.0000147512.81966.ba; Tan BY, 2016, HISTOPATHOLOGY, V68, P5, DOI 10.1111/his.12876; Tsang AKH, 2011, HISTOPATHOLOGY, V59, P600, DOI 10.1111/j.1365-2559.2011.03939.x; Van Osdol AD, 2014, JAMA SURG, V149, P1081, DOI 10.1001/jamasurg.2014.73; Yasir S, 2014, AM J CLIN PATHOL, V142, P362, DOI 10.1309/AJCPZUZ96RESGPUP; Yilmaz E, 2002, ACTA RADIOL, V43, P34, DOI 10.1080/028418502127347619; 정혜경, 2011, [Journal of The Korean Radiological Society, 대한영상의학회지], V64, P603	23	0	0	0	0	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1066-8969	1940-2465		INT J SURG PATHOL	Int. J. Surg. Pathol.	DEC	2018	26	8					684	692		10.1177/1066896918775525			9	Pathology; Surgery	Pathology; Surgery	HA5TJ	WOS:000450340700001	29774785				2019-10-28	
J	Michaels, PD; Robinson, H; Nardi, V; Iafrate, AJ; Le, L; Lennerz, JK				Michaels, Phillip D.; Robinson, Hayley; Nardi, Valentina; Iafrate, A. John; Le, Long; Lennerz, Jochen K.			MET Amplification in Esophageal Squamous Carcinoma	INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY			English	Editorial Material							ADENOCARCINOMA		[Michaels, Phillip D.; Robinson, Hayley; Nardi, Valentina; Iafrate, A. John; Le, Long; Lennerz, Jochen K.] Massachusetts Gen Hosp, Boston, MA 02114 USA; [Michaels, Phillip D.] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA	Lennerz, JK (reprint author), Massachusetts Gen Hosp, Dept Pathol, Ctr Integrated Diagnost, 55 Fruit St, Boston, MA 02114 USA.	JLennerz@partners.org		Michaels, Phillip/0000-0003-3827-953X			Ali SM, 2015, ONCOLOGIST, V20, P499, DOI 10.1634/theoncologist.2014-0378; Kwak EL, 2016, NEW ENGL J MED, V375, P1983, DOI 10.1056/NEJMcpc1610714; Lennerz JK, 2011, J CLIN ONCOL, V29, P4803, DOI 10.1200/JCO.2011.35.4928; Tuynman JB, 2008, BRIT J CANCER, V98, P1102, DOI 10.1038/sj.bjc.6604251	4	0	0	0	0	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1066-8969	1940-2465		INT J SURG PATHOL	Int. J. Surg. Pathol.	DEC	2018	26	8					731	732		10.1177/1066896918764301			2	Pathology; Surgery	Pathology; Surgery	HA5TJ	WOS:000450340700009	29552946				2019-10-28	
J	Rindi, G; Klimstra, DS; Abedi-Ardekani, B; Asa, SL; Bosman, FT; Brambilla, E; Busam, KJ; de Krijger, RR; Dietel, M; El-Naggar, AK; Fernandez-Cuesta, L; Kloppel, G; McCluggage, WG; Moch, H; Ohgaki, H; Rakha, EA; Reed, NS; Rous, BA; Sasano, H; Scarpa, A; Scoazec, JY; Travis, WD; Tallini, G; Trouillas, J; van Krieken, JH; Cree, IA				Rindi, Guido; Klimstra, David S.; Abedi-Ardekani, Behnoush; Asa, Sylvia L.; Bosman, Frederik T.; Brambilla, Elisabeth; Busam, Klaus J.; de Krijger, Ronald R.; Dietel, Manfred; El-Naggar, Adel K.; Fernandez-Cuesta, Lynnette; Kloeppel, Guenter; McCluggage, W. Glenn; Moch, Holger; Ohgaki, Hiroko; Rakha, Emad A.; Reed, Nicholas S.; Rous, Brian A.; Sasano, Hironobu; Scarpa, Aldo; Scoazec, Jean-Yves; Travis, William D.; Tallini, Giovanni; Trouillas, Jacqueline; van Krieken, J. Han; Cree, Ian A.			A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal	MODERN PATHOLOGY			English	Article							MEDULLARY-THYROID CARCINOMA; SMALL-CELL CARCINOMA; AGGRESSIVE PITUITARY-TUMORS; KI-67 PROLIFERATIVE INDEX; HIGH-GRADE; SMALL-INTESTINE; PROGNOSTIC-SIGNIFICANCE; GENOMIC LANDSCAPE; EUROPEAN-SOCIETY; PROSTATE-CANCER	The classification of neuroendocrine neoplasms (NENs) differs between organ systems and currently causes considerable confusion. A uniform classification framework for NENs at any anatomical location may reduce inconsistencies and contradictions among the various systems currently in use. The classification suggested here is intended to allow pathologists and clinicians to manage their patients with NENs consistently, while acknowledging organ-specific differences in classification criteria, tumor biology, and prognostic factors. The classification suggested is based on a consensus conference held at the International Agency for Research on Cancer (IARC) in November 2017 and subsequent discussion with additional experts. The key feature of the new classification is a distinction between differentiated neuroendocrine tumors (NETs), also designated carcinoid tumors in some systems, and poorly differentiated NECs, as they both share common expression of neuroendocrine markers. This dichotomous morphological subdivision into NETs and NECs is supported by genetic evidence at specific anatomic sites as well as clinical, epidemiologic, histologic, and prognostic differences. In many organ systems, NETs are graded as G1, G2, or G3 based on mitotic count and/or Ki-67 labeling index, and/or the presence of necrosis; NECs are considered high grade by definition. We believe this conceptual approach can form the basis for the next generation of NEN classifications and will allow more consistent taxonomy to understand how neoplasms from different organ systems inter-relate clinically and genetically.	[Rindi, Guido] Univ Cattolica, Fdn Policlin Univ A Gemelli, Ist Anat Patol, Rome, Italy; [Klimstra, David S.; Busam, Klaus J.; Travis, William D.] Mem Sloan Kettering Canc Ctr, Dept Pathol, 1275 York Ave, New York, NY 10021 USA; [Abedi-Ardekani, Behnoush; Fernandez-Cuesta, Lynnette; Ohgaki, Hiroko; Cree, Ian A.] WHO, IARC, Lyon, France; [Asa, Sylvia L.] Univ Toronto, Univ Hlth Network, Toronto, ON, Canada; [Bosman, Frederik T.] Univ Lausanne, Med Ctr, Lausanne, Switzerland; [Brambilla, Elisabeth] Univ UGA, CHUGA, Grenoble, France; [de Krijger, Ronald R.] Univ Med Ctr Utrecht, Dept Pathol, Utrecht, Netherlands; [de Krijger, Ronald R.] Princess Maxima Ctr Pediat Oncol, Utrecht, Netherlands; [Dietel, Manfred] Charite, Berlin, Germany; [El-Naggar, Adel K.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA; [Kloeppel, Guenter] Tech Univ Munich, Dept Pathol, Munich, Germany; [McCluggage, W. Glenn] Belfast Hlth & Social Care Trust, Dept Pathol, Belfast, Antrim, North Ireland; [Moch, Holger] Univ Hosp Zurich, Zurich, Switzerland; [Rakha, Emad A.] Univ Nottingham, Nottingham, England; [Reed, Nicholas S.] Beatson West Scotland Canc Ctr, Glasgow, Lanark, Scotland; [Rous, Brian A.] Natl Canc Registrat & Anal Serv, Fulbourn, England; [Sasano, Hironobu] Tohoku Univ, Dept Pathol, Sch Med, Sendai, Miyagi, Japan; [Scarpa, Aldo] Univ & Hosp Trust Verona, ARC Net Res Ctr, Sect Pathol, Verona, Italy; [Scarpa, Aldo] Univ & Hosp Trust Verona, Dept Diagnost & Publ Hlth, Verona, Italy; [Scoazec, Jean-Yves] Gustave Roussy Canc Campus, Dept Pathol, Villejuif, France; [Tallini, Giovanni] Univ Bologna, Univ Med Ctr, Bologna, Italy; [Trouillas, Jacqueline] Fac Med Lyon Est, Lyon, France; [van Krieken, J. Han] Radboud Univ Nijmegen, Med Ctr, Nijmegen, Netherlands	Cree, IA (reprint author), WHO, IARC, Lyon, France.	creei@iarc.fr	Fernandez-Cuesta, Lynnette/Z-1875-2019; Rakha, Emad/Q-5554-2019	Fernandez-Cuesta, Lynnette/0000-0002-0724-6703; Kloppel, Gunter/0000-0002-6688-086X; Rous, Brian/0000-0002-7619-461X; van Krieken, Joannes/0000-0002-8105-0450; Asa, Sylvia/0000-0001-8418-5054; Rakha, Emad/0000-0002-5009-5525	World Health Organization (WHO) Classification of Tumors Group and International Agency for Research on Cancer	This work was funded by the World Health Organization (WHO) Classification of Tumors Group and International Agency for Research on Cancer.	ALBORESSAAVEDRA J, 1985, SEMIN DIAGN PATHOL, V2, P137; Ali AS, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0187667; Asa SL, 2017, ENDOCR-RELAT CANCER, V24, pC5, DOI 10.1530/ERC-17-0004; Asa SL, 2018, HISTOPATHOLOGY, V72, P133, DOI 10.1111/his.13295; Asa SL, 2018, PATHOLOGY, V50, P111, DOI 10.1016/j.pathol.2017.09.003; Aslan DL, 2005, AM J CLIN PATHOL, V123, P874, DOI 10.1309/QYV05GEGKUL2RTT; Aung PP, 2013, HUM PATHOL, V44, P873, DOI 10.1016/j.humpath.2012.08.013; Banck MS, 2013, J CLIN INVEST, V123, P2502, DOI 10.1172/JCI67963; Basturk O, 2015, AM J SURG PATHOL, V39, P683, DOI 10.1097/PAS.0000000000000408; Basturk O, 2014, AM J SURG PATHOL, V38, P437, DOI 10.1097/PAS.0000000000000169; Becker JC, 2017, NAT REV DIS PRIMERS, V3, DOI 10.1038/nrdp.2017.77; Bell D, 2017, VIRCHOWS ARCH, V471, P667, DOI 10.1007/s00428-017-2155-6; Beltran H, 2011, CANCER DISCOV, V1, P487, DOI 10.1158/2159-8290.CD-11-0130; BONDESON L, 1993, AM J SURG PATHOL, V17, P820, DOI 10.1097/00000478-199308000-00007; Bosman FT, 2010, WHO CLASSIF TUMOURS, V3, P417; Caplin ME, 2015, ANN ONCOL, V26, P1604, DOI 10.1093/annonc/mdv041; Carlson D, 2010, ARCH PATHOL LAB MED, V134, P1639, DOI 10.1043/2009-0578-CCR.1; Cheuk W, 2001, ARCH PATHOL LAB MED, V125, P228; Cree IA, 1996, LANCET, V347, P273, DOI 10.1016/S0140-6736(96)90455-9; Debelenko LV, 1997, HUM MOL GENET, V6, P2285, DOI 10.1093/hmg/6.13.2285; Elisei R, 2008, J CLIN ENDOCR METAB, V93, P682, DOI 10.1210/jc.2007-1714; Epstein JI, 2014, AM J SURG PATHOL, V38, P756, DOI 10.1097/PAS.0000000000000208; Erickson LA, 1999, AM J SURG PATHOL, V23, P288, DOI 10.1097/00000478-199903000-00007; Fernandez-Cuesta L, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4518; Francis JM, 2013, NAT GENET, V45, P1483, DOI 10.1038/ng.2821; Frank-Raue K, 2013, THYROID, V23, P294, DOI 10.1089/thy.2012.0236; Genome P, 2013, SCI TRANSL MED, V5; George J, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03099-x; George J, 2015, NATURE, V524, P47, DOI 10.1038/nature14664; Goto K, 2017, AM J DERMATOPATH, V39, P250, DOI 10.1097/DAD.0000000000000657; Haack H, 2009, AM J SURG PATHOL, V33, P984, DOI 10.1097/PAS.0b013e318198d666; Hadoux J, 2016, LANCET DIABETES ENDO, V4, P64, DOI 10.1016/S2213-8587(15)00337-X; Howitt BE, 2017, CURR ONCOL REP, V19, DOI 10.1007/s11912-017-0617-2; Inzani F, 2017, REV ENDOCR METAB DIS, V18, P381, DOI 10.1007/s11154-017-9428-x; Jedrych J, 2014, J CUTAN PATHOL, V41, P113, DOI 10.1111/cup.12263; Jesinghaus M, 2017, MODERN PATHOL, V30, P610, DOI 10.1038/modpathol.2016.220; Jiao YC, 2011, SCIENCE, V331, P1199, DOI 10.1126/science.1200609; Karpathakis A, 2016, CLIN CANCER RES, V22, P250, DOI 10.1158/1078-0432.CCR-15-0373; Kasaian K, 2013, J PATHOL, V230, P249, DOI 10.1002/path.4203; Kimura N, 2014, ENDOCR-RELAT CANCER, V21, P405, DOI 10.1530/ERC-13-0494; Klimstra DS, 2010, AM J SURG PATHOL, V34, P300, DOI 10.1097/PAS.0b013e3181ce1447; Kloppel G, 2017, VISC MED, V33, P324, DOI 10.1159/000481390; Kloppel G, 2016, PATHOLOGY HEAD NECK, P515; Knopf A, 2017, HEAD NECK-J SCI SPEC, V39, P92, DOI 10.1002/hed.24540; Konukiewitz B, 2017, MODERN PATHOL, V30, P587, DOI 10.1038/modpathol.2016.217; Krishnan B, 1997, J UROLOGY, V157, P2059, DOI 10.1016/S0022-5347(01)64674-3; Kruijff S, 2014, ANN SURG ONCOL, V21, P426, DOI 10.1245/s10434-013-3288-8; Kulke MH, 2010, PANCREAS, V39, P735, DOI 10.1097/MPA.0b013e3181ebb168; Kurman RJ, 2014, WHO CLASSIFICATION T; Lakhani S. R., 2012, IARC WHO CLASSIFICAT, V4, P240; Lano IM, 2018, J CUTAN PATHOL, V45, P54, DOI 10.1111/cup.13051; Lee SM, 2015, ARCH PATHOL LAB MED, V139, P1062, DOI 10.5858/arpa.2013-0703-RS; Lenders N, 2018, MALIGNANT TRANSFORMA; Lloyd RV, 2017, WHO CLASSIFICATION T; McCormack A, 2018, EUR J ENDOCRINOL, V178, P265, DOI 10.1530/EJE-17-0933; MENDELSOHN G, 1984, CANCER, V54, P657, DOI 10.1002/1097-0142(1984)54:4<657::AID-CNCR2820540412>3.0.CO;2-V; Mete O, 2018, MOD PATHOL; Mete O, 2017, ENDOCR PATHOL, V28, P228, DOI 10.1007/s12022-017-9498-z; Mete O, 2016, MODERN PATHOL, V29, P131, DOI 10.1038/modpathol.2015.151; Mian C, 2011, EUR J ENDOCRINOL, V164, P971, DOI 10.1530/EJE-11-0079; Miremadi A, 2002, HISTOPATHOLOGY, V40, P215, DOI 10.1046/j.1365-2559.2002.01336.x; Moch H, 2016, WHO CLASSIFICATION T; Moura MM, 2015, ENDOCR-RELAT CANCER, V22, pR235, DOI 10.1530/ERC-15-0070; Nicholson SA, 2002, AM J SURG PATHOL, V26, P1184, DOI 10.1097/01.PAS.0000022995.91977.CD; Nieser M, 2017, NEUROENDOCRINOLOGY, V104, P302, DOI 10.1159/000446917; Paik JY, 2011, HUM PATHOL, V42, P1385, DOI 10.1016/j.humpath.2010.12.013; Pandya C, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.92061; Papotti M, 2000, SEMIN DIAGN PATHOL, V17, P109; Patibandla JR, 2018, GYNECOL ONCOL; PEARSE AGE, 1977, MED BIOL, V55, P115; Peifer M, 2012, NAT GENET, V44, P1104, DOI 10.1038/ng.2396; Pelosi G, 2005, AM J SURG PATHOL, V29, P179, DOI 10.1097/01.pas.0000149690.75462.29; Pelosi G, 2014, J THORAC ONCOL, V9, P273, DOI 10.1097/JTO.0000000000000092; Quinn AM, 2017, AM J SURG PATHOL, V41, P263, DOI 10.1097/PAS.0000000000000767; Raverot G, 2018, EUR J ENDOCRINOL, V178, pG1, DOI 10.1530/EJE-17-0796; Raverot G, 2017, J CLIN ENDOCR METAB, V102, P3368, DOI 10.1210/jc.2017-00773; Rekhtman N, 2016, CLIN CANCER RES, V22, P3618, DOI 10.1158/1078-0432.CCR-15-2946; Rindi G, 2014, ENDOCR-RELAT CANCER, V21, P1, DOI 10.1530/ERC-13-0246; Rossi G, 2005, J CLIN ONCOL, V23, P8774, DOI 10.1200/JCO.2005.02.8233; Rudin CM, 2012, NAT GENET, V44, P1111, DOI 10.1038/ng.2405; SADLER DW, 1989, LANCET, V1, P785; Sahan EK, 2015, TURK J GASTROENTEROL, V26, P104, DOI 10.5152/tjg.2015.1965; Sarkaria IS, 2011, ANN THORAC SURG, V92, P1180, DOI 10.1016/j.athoracsur.2011.05.027; Scarpa A, 2017, NATURE, V543, P65, DOI 10.1038/nature21063; SCHANTZ A, 1973, CANCER-AM CANCER SOC, V31, P600, DOI 10.1002/1097-0142(197303)31:3<600::AID-CNCR2820310316>3.0.CO;2-0; Shia J, 2002, AM J SURG PATHOL, V26, P863, DOI 10.1097/00000478-200207000-00004; Siegel RL, 2018, CA-CANCER J CLIN, V68, P7, DOI 10.3322/caac.21442; Simbolo M, 2017, J PATHOL, V241, P488, DOI 10.1002/path.4853; Singhi AD, 2018, HISTOPATHOLOGY, V72, P168, DOI 10.1111/his.13408; Sorbye H, 2013, ANN ONCOL, V24, P152, DOI 10.1093/annonc/mds276; Strosberg JR, 2010, PANCREAS, V39, P799, DOI 10.1097/MPA.0b013e3181ebb56f; Swarts DRA, 2017, HISTOPATHOLOGY, V70, P412, DOI 10.1111/his.13096; Tamas EF, 2006, AM J SURG PATHOL, V30, P980, DOI 10.1097/00000478-200608000-00008; Tang LH, 2016, CLIN CANCER RES, V22, P1011, DOI 10.1158/1078-0432.CCR-15-0548; Tanizaki Y, 2007, ENDOCR PATHOL, V18, P217, DOI 10.1007/s12022-007-9006-y; Tavassoli FA, 2003, PATHOLOGY GENETICS T; Thompson LDR, 2002, AM J SURG PATHOL, V26, P551, DOI 10.1097/00000478-200205000-00002; Tisell LE, 2003, BRIT J CANCER, V89, P2093, DOI 10.1038/sj.bjc.6601453; Travis W, 1999, HISTOLOGICAL TYPING; Travis WD, 1998, AM J SURG PATHOL, V22, P934, DOI 10.1097/00000478-199808000-00003; Travis WD, 2015, WHO CLASSIFICATION T; Travis WE, 2004, PATHOLOGY GENETICS T; Travis WD, 2014, THORAC SURG CLIN, V24, P257, DOI 10.1016/j.thorsurg.2014.04.001; Trouillas J, 2018, EUR J ENDOCRINOL; van Velthuysen MLF, 2014, NEUROENDOCRINOLOGY, V100, P221, DOI 10.1159/000369275; Verrienti A, 2016, ENDOCR-RELAT CANCER, V23, P665, DOI 10.1530/ERC-16-0132; Vijayvergia N, 2016, BRIT J CANCER, V115, P564, DOI 10.1038/bjc.2016.229; Walts AE, 2012, MODERN PATHOL, V25, P1258, DOI 10.1038/modpathol.2012.81; Wang J, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-147; WENIG BM, 1988, CANCER, V62, P2658, DOI 10.1002/1097-0142(19881215)62:12<2658::AID-CNCR2820621235>3.0.CO;2-M; Wincewicz A, 2017, ROM J MORPHOL EMBRYO, V58, P655; Woischke C, 2017, MODERN PATHOL, V30, P95, DOI 10.1038/modpathol.2016.150; WOODRUFF JM, 1991, ORL J OTO-RHINO-LARY, V53, P194, DOI 10.1159/000276219	113	37	37	2	7	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0893-3952	1530-0285		MODERN PATHOL	Mod. Pathol.	DEC	2018	31	12					1770	1786		10.1038/s41379-018-0110-y			17	Pathology	Pathology	HC2HR	WOS:000451623400001	30140036	Green Accepted, Green Published, Other Gold			2019-10-28	
J	Palsgrove, DN; Brosnan-Cashman, JA; Giannini, C; Raghunathan, A; Jentoft, M; Bettegowda, C; Gokden, M; Lin, D; Yuan, M; Lin, MT; Heaphy, CM; Rodriguez, FJ				Palsgrove, Doreen N.; Brosnan-Cashman, Jacqueline A.; Giannini, Caterina; Raghunathan, Aditya; Jentoft, Mark; Bettegowda, Chetan; Gokden, Murat; Lin, Doris; Yuan, Ming; Lin, Ming-Tseh; Heaphy, Christopher M.; Rodriguez, Fausto J.			Subependymal giant cell astrocytoma-like astrocytoma: a neoplasm with a distinct phenotype and frequent neurofibromatosis type-1-association	MODERN PATHOLOGY			English	Article							HISTONE CHAPERONE; TELOMERES; ATRX; RECQL4; INACTIVATION; INSTABILITY; PREVALENCE; MECHANISM; SARCOMAS; DIFFUSE	Neurofibromatosis type-1 is a familial genetic syndrome associated with a predisposition to develop peripheral and central nervous system neoplasms. We have previously reported on a subset of gliomas developing in these patients with morphologic features resembling subependymal giant cell astrocytoma, but the molecular features of these tumors remain undefined. A total of 14 tumors were studied and all available slides were reviewed. Immunohistochemical stains and telomere-specific FISH were performed on all cases. In addition, next-generation sequencing was performed on 11 cases using a platform targeting 644 cancer-related genes. The average age at diagnosis was 28 years (range: 4-60, 9F/5M). All tumors involved the supratentorial compartment. Tumors were predominantly low grade (n = 12), with two high-grade tumors, and displayed consistent expression of glial markers. Next-generation sequencing demonstrated inactivating NF1 mutations in 10 (of 11) cases. Concurrent TSC2 and RPTOR mutations were present in two cases (1 sporadic and 1 neurofibromatosis type-1-associated). Interestingly, alternative lengthening of telomeres was present in 4 (of 14) (29%) cases. However, an ATRX mutation associated with aberrant nuclear ATRX expression was identified in only one (of four) cases with alternative lenghtening of telomeres. Gene variants in the DNA helicase RECQL4 (n = 2) and components of the Fanconi anemia complementation group (FANCD2, FANCF, FANCG) (n = 1) were identified in two alternative lenghtening of telomere-positive/ATRX-intact cases. Other variants involved genes related to NOTCH signaling, DNA maintenance/repair pathways, and epigenetic modulators. There were no mutations identified in DAXX, PTEN, PIK3C genes, TP53, H3F3A, HIST1H3B, or in canonical hotspots of IDH1, IDH2, or BRAF. A subset of subependymal giant cell astrocytoma-like astrocytomas are alternative lenghtening of telomere-positive and occur in the absence of ATRX alterations, thereby suggesting mutations in other DNA repair/maintenance genes may also facilitate alternative lenghtening of telomeres. These findings suggest that subependymal giant cell astrocytoma-like astrocytoma represents a biologically distinct group that merits further investigation.	[Palsgrove, Doreen N.; Brosnan-Cashman, Jacqueline A.; Yuan, Ming; Lin, Ming-Tseh; Heaphy, Christopher M.; Rodriguez, Fausto J.] Sidney Kimmel Comprehens Canc Ctr, Dept Pathol, Baltimore, MD 21231 USA; [Palsgrove, Doreen N.; Bettegowda, Chetan; Lin, Ming-Tseh; Heaphy, Christopher M.; Rodriguez, Fausto J.] Johns Hopkins Univ, Sch Med, Baltimore, MD 21205 USA; [Giannini, Caterina; Raghunathan, Aditya] Mayo Clin, Dept Lab Med & Pathol, Rochester, MN USA; [Jentoft, Mark] Mayo Clin, Jacksonville, FL 32224 USA; [Bettegowda, Chetan] Sidney Kimmel Comprehens Canc Ctr, Dept Neurosurg, Baltimore, MD USA; [Gokden, Murat] Univ Arkansas Med Sci, Dept Pathol, Little Rock, AR 72205 USA; [Lin, Doris] Sidney Kimmel Comprehens Canc Ctr, Dept Radiol, Baltimore, MD USA	Rodriguez, FJ (reprint author), Sidney Kimmel Comprehens Canc Ctr, Dept Pathol, Baltimore, MD 21231 USA.; Rodriguez, FJ (reprint author), Johns Hopkins Univ, Sch Med, Baltimore, MD 21205 USA.	frodrig4@jhmi.edu		Raghunathan, Aditya/0000-0001-6198-7441; Brosnan-Cashman, Jacqueline/0000-0001-9579-2853	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [P30 CA006973, 5T32CA193145-02]; Lauren's First and Goal; Stick it to Brain Tumors Annual Women's Ice Hockey Tournament; A Kids' Brain Tumor Cure Foundation/Pediatric low-grade astrocytoma foundation; Pilocytic/Pilomyxoid Fund	This work was supported in part by NIH grant 5T32CA193145-02 (DNP), the Pilocytic/Pilomyxoid Fund, including Lauren's First and Goal, and the Stick it to Brain Tumors Annual Women's Ice Hockey Tournament (FJR); the A Kids' Brain Tumor Cure Foundation/Pediatric low-grade astrocytoma foundation (FJR), NIH grant P30 CA006973 to the Sidney Kimmel Comprehensive Cancer Center (PI: W Nelson).	Banerjee S, 2011, P NATL ACAD SCI USA, V108, P15996, DOI 10.1073/pnas.1019012108; Bollo RJ, 2009, J NEUROS-PEDIATR, V4, P85, DOI 10.3171/2009.3.PEDS08225; Brat DJ, 2015, NEW ENGL J MED, V372, P2481, DOI 10.1056/NEJMoa1402121; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chan JA, 2004, J NEUROPATH EXP NEUR, V63, P1236, DOI 10.1093/jnen/63.12.1236; Croteau DL, 2014, ANNU REV BIOCHEM, V83, P519, DOI 10.1146/annurev-biochem-060713-035428; Croteau DL, 2012, TRENDS GENET, V28, P624, DOI 10.1016/j.tig.2012.08.003; Danussi C, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03476-6; Ferrarelli LK, 2013, DNA REPAIR, V12, P518, DOI 10.1016/j.dnarep.2013.04.005; Franz DN, 2013, LANCET, V381, P125, DOI 10.1016/S0140-6736(12)61134-9; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Garcia-Exposito L, 2016, CELL REP, V17, P1858, DOI 10.1016/j.celrep.2016.10.048; Goodwin LR, 2018, MOL CELL NEUROSCI, V87, P55, DOI 10.1016/j.mcn.2017.10.008; Gutmann DH, 2013, GENOME RES, V23, P431, DOI 10.1101/gr.142604.112; Heaphy CM, 2011, AM J PATHOL, V179, P1608, DOI 10.1016/j.ajpath.2011.06.018; Heaphy CM, 2011, SCIENCE, V333, P425, DOI 10.1126/science.1207313; Henson JD, 2005, CLIN CANCER RES, V11, P217; Jentoft M, 2011, INT J CLIN EXP PATHO, V4, P43; Jones DTW, 2013, NAT GENET, V45, P927, DOI 10.1038/ng.2682; Lewis PW, 2010, P NATL ACAD SCI USA, V107, P14075, DOI 10.1073/pnas.1008850107; Lopes MB, 2016, WHO CLASSIFICATION T, P90; Lopes MBS, 1996, ACTA NEUROPATHOL, V91, P368, DOI 10.1007/s004010050438; Louis DN, 2016, WHO CLASSIFICATION T; Mo DL, 2018, CANCER LETT, V413, P1, DOI 10.1016/j.canlet.2017.10.021; Mukherjee J, 2018, CANCER RES, V78, P2966, DOI 10.1158/0008-5472.CAN-17-2269; Nguyen DN, 2013, BRAIN PATHOL, V23, P237, DOI 10.1111/j.1750-3639.2012.00630.x; O'Sullivan RJ, 2014, NAT STRUCT MOL BIOL, V21, P167, DOI 10.1038/nsmb.2754; Reinhardt A, 2018, ACTA NEUROPATHOL; Ritchie K, 2008, J CELL BIOL, V180, P315, DOI 10.1083/jcb.200706083; Rodriguez EF, 2011, ACTA NEUROPATHOL, V121, P407, DOI 10.1007/s00401-010-0784-9; Rodriguez FJ, 2008, J NEUROPATH EXP NEUR, V67, P240, DOI 10.1097/NEN.0b013e318165eb75; Rodriguez FJ, 2016, ACTA NEUROPATHOL, V132, P761, DOI 10.1007/s00401-016-1619-0; Rodriguez FJ, 2010, AM J SURG PATHOL, V34, P147, DOI 10.1097/PAS.0b013e3181c75238; Rodriguez FJ, 2018, MOD PATHOL S2, pS665; Root H, 2016, HUM MOL GENET, V25, P3255, DOI 10.1093/hmg/ddw175; Salloum R, 2017, ACTA NEUROPATHOL COM, V5, DOI 10.1186/s40478-017-0479-8; Sidorova JM, 2018, DNA HELICASE DEFICIE, DOI [10.1002/9780470015902.a0006065.pub3, DOI 10.1002/9780470015902.A0006065.PUB3]; Sturm D, 2012, CANCER CELL, V22, P425, DOI 10.1016/j.ccr.2012.08.024; Ulaner GA, 2004, GENE CHROMOSOME CANC, V41, P155, DOI 10.1002/gcc.20074; Vizcaino MA, 2014, CLIN NEUROPATHOL, V33, P380, DOI 10.5414/NP300766; Woo LL, 2006, EXP CELL RES, V312, P3443, DOI 10.1016/j.yexcr.2006.07.023; Zhang JH, 2013, NAT GENET, V45, P602, DOI 10.1038/ng.2611	42	1	1	1	2	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0893-3952	1530-0285		MODERN PATHOL	Mod. Pathol.	DEC	2018	31	12					1787	1800		10.1038/s41379-018-0103-x			14	Pathology	Pathology	HC2HR	WOS:000451623400002	29973652	Green Accepted			2019-10-28	
J	Suster, D; Pihan, G; Mackinnon, AC; Suster, S				Suster, David; Pihan, German; Mackinnon, Alexander C.; Suster, Saul			Expression of PD-L1/PD-1 in lymphoepithelioma-like carcinoma of the thymus	MODERN PATHOLOGY			English	Article							DEATH LIGAND 1; PROGNOSTIC VALUE; PD-1	Poorly differentiated non-keratinizing squamous cell carcinoma of the thymus, also known as lymphoepithelioma-like carcinoma, is a rare primary malignant neoplasm of thymic origin. The mainstay of treatment for these tumors is surgical and they tend to respond poorly to chemotherapy. The checkpoint programmed cell death ligand-1 protein (PD-L1) bound to its receptor (PD-1) has been demonstrated to be an important therapeutic target for many different tumors. Expression of PD-L1/PD-1 in lymphoepithelioma-like carcinoma of the thymus may indicate that these tumors are potential targets for inhibitor therapy. Twenty-one cases of lymphoepithelioma-like carcinoma of the thymus were collected and reviewed. Tissue microarrays were created using triplicate 2 mm cores for each case. PD-L1/PD-1 staining pattern (neoplastic cells versus tumor infiltrating lymphocytes) was documented for each case. Out of 21 cases, 15 (71.4%) showed various degrees of membranous PD-L1 staining. Of the positive cases, 48% showed high expression of PD-L1 (>50% of tumor cells) and 24% showed low expression (<50%). PD-1 staining showed focal positivity in 12/20 (60%) cases among tumor infiltrating lymphocytes. PD-L1/PD-1 inhibitor therapy has been applied successfully in other solid malignant tumors with high expression of PD-L1/PD-1. The high level of PD-L1 expression in our cases indicates that PD-L1 may play a role in the pathogenesis of these tumors and that PD-L1/PD-1 blockade may be a viable therapeutic option for patients with lymphoepithelioma-like carcinoma of the thymus who have failed other first-line therapies.	[Suster, David; Pihan, German] Beth Israel Deaconess Med Ctr, Dept Pathol, 330 Brookline Ave, Boston, MA 02215 USA; [Suster, David; Pihan, German] Harvard Med Sch, Boston, MA USA; [Mackinnon, Alexander C.; Suster, Saul] Med Coll Wisconsin, Milwaukee, WI 53226 USA	Suster, S (reprint author), Med Coll Wisconsin, Milwaukee, WI 53226 USA.	ssuster@mcw.edu					Asao T, 2016, LUNG CANCER, V93, P77, DOI 10.1016/j.lungcan.2016.01.004; Bernard-Tessier A, 2018, B CANCER, V105, P140, DOI 10.1016/j.bulcan.2017.10.030; Chalabreysse L, 2004, HISTOPATHOLOGY, V44, P367, DOI 10.1111/j.1365-2559.2004.01796.x; de Montpreville VT, 2013, VIRCHOWS ARCH, V462, P307, DOI 10.1007/s00428-013-1371-y; du Vignaux CM, 2017, CURR TREAT OPTION ON, V18, DOI 10.1007/s11864-017-0495-8; Katsuya Y, 2016, LUNG CANCER, V99, P4, DOI 10.1016/j.lungcan.2016.05.007; Katsuya Y, 2015, LUNG CANCER, V88, P154, DOI 10.1016/j.lungcan.2015.03.003; Leisibach P, 2016, J THORAC DIS, V8, P2580, DOI 10.21037/jtd.2016.08.82; Mahoney KM, 2015, CLIN THER, V37, P764, DOI 10.1016/j.clinthera.2015.02.018; Marchevsky AM, 2017, HUM PATHOL, V60, P16, DOI 10.1016/j.humpath.2016.09.023; MASAOKA A, 1981, CANCER, V48, P2485, DOI 10.1002/1097-0142(19811201)48:11<2485::AID-CNCR2820481123>3.0.CO;2-R; Padda SK, 2015, J THORAC ONCOL, V10, P500, DOI 10.1097/JTO.0000000000000429; Reck M, 2016, NEW ENGL J MED, V375, P1823, DOI 10.1056/NEJMoa1606774; Sunshine J, 2015, CURR OPIN PHARMACOL, V23, P32, DOI 10.1016/j.coph.2015.05.011; Suster D, 2017, MODERN PATHOL, V30, p496A; SUSTER S, 1991, CANCER-AM CANCER SOC, V67, P1025, DOI 10.1002/1097-0142(19910215)67:4<1025::AID-CNCR2820670427>3.0.CO;2-F; Tiseo M, 2017, LUNG CANCER, V104, P24, DOI 10.1016/j.lungcan.2016.12.005; Weissferdt A, 2017, MODERN PATHOL, V30, P826, DOI 10.1038/modpathol.2017.6; Weissferdt A, 2012, AM J CLIN PATHOL, V138, P103, DOI 10.1309/AJCP88FZTWANLRCB; Yokoyama S, 2016, CLIN CANCER RES, V22, P4727, DOI 10.1158/1078-0432.CCR-16-0434; Yokoyama S, 2016, ANN THORAC SURG, V101, P1361, DOI 10.1016/j.athoracsur.2015.10.044; Zuazo M, 2017, ANN TRANSL MED, V5, DOI 10.21037/atm.2017.06.11	22	0	0	0	1	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0893-3952	1530-0285		MODERN PATHOL	Mod. Pathol.	DEC	2018	31	12					1801	1806		10.1038/s41379-018-0097-4			6	Pathology	Pathology	HC2HR	WOS:000451623400003	29973653				2019-10-28	
J	Miligy, IM; Gorringe, KL; Toss, MS; Al-Kawaz, AA; Simpson, P; Diez-Rodriguez, M; Nolan, CC; Ellis, IO; Green, AR; Rakha, EA				Miligy, Islam M.; Gorringe, Kylie L.; Toss, Michael S.; Al-Kawaz, Abdulbaqi A.; Simpson, Peter; Diez-Rodriguez, Maria; Nolan, Christopher C.; Ellis, Ian O.; Green, Andrew R.; Rakha, Emad A.			Thioredoxin-interacting protein is an independent risk stratifier for breast ductal carcinoma in situ	MODERN PATHOLOGY			English	Article							TXNIP; EXPRESSION; CANCER; DCIS; PROLIFERATION; SUPPRESSION; APOPTOSIS; STRESS; SYSTEM; GROWTH	Current clinicopathological parameters are useful predictors of breast ductal carcinoma in situ behavior, but they are insufficient to define high-risk patients for disease progression precisely. Thioredoxin-interacting protein (TXNIP) is a key player of oxidative stress. This study aims to evaluate the role of TXNIP as a predictor of ductal carcinoma in situ progression. Tissue microarrays from 776 pure ductal carcinoma in situ and 239 mixed ductal carcinoma in situ and invasive tumors were constructed. All patients were treated at a single institution with a long-term follow-up and TXNIP expression was assessed using immunohistochemistry. TXNIP expression was investigated in terms of associations with clinicopathological and molecular features and patient outcome. Loss/reduced cytoplasmic expression of TXNIP was associated with features of aggressiveness including high nuclear grade (p = 1.6 x 10(-5)), presence of comedo necrosis (p = 0.001), and estrogen receptor negative (ER-)/HER2-ductal carcinoma in situ (p = 4.6 x 10(-5)). Univariate analysis showed an inverse association between TXNIP expression and outcome in terms of shorter local recurrence-free survival (p = 0.009). Multivariable analyses showed that independent predictors of ductal carcinoma in situ recurrence were low TXNIP expression (p = 0.005, HR = 0.51, and 95% CI: 0.32-0.81), larger ductal carcinoma in situ size, and high nuclear grade. TXNIP functions as a tumor suppressor gene with loss of its expression associated with ductal carcinoma in situ recurrence. TXNIP can be used as a potentially useful marker in prognostic stratification of ductal carcinoma in situ for management decisions.	[Miligy, Islam M.; Toss, Michael S.; Al-Kawaz, Abdulbaqi A.; Diez-Rodriguez, Maria; Nolan, Christopher C.; Ellis, Ian O.; Green, Andrew R.; Rakha, Emad A.] Univ Nottingham, Nottingham City Hosp, Sch Med, Acad Pathol,Div Canc & Stem Cells, Nottingham, England; [Miligy, Islam M.; Rakha, Emad A.] Menoufia Univ, Dept Histopathol, Fac Med, Shibin Al Kawm, Egypt; [Gorringe, Kylie L.] Peter MacCallum Canc Ctr, Canc Genom Program, Melbourne, Vic, Australia; [Gorringe, Kylie L.] Univ Melbourne, Sir Peter MacCallum Dept Oncol, Parkville, Vic, Australia; [Toss, Michael S.] Assiut Univ, South Egypt Canc Inst, Dept Histopathol, Assiut, Egypt; [Simpson, Peter] Univ Queensland, Clin Res Ctr, Fac Med, Brisbane, Qld, Australia	Rakha, EA (reprint author), Univ Nottingham, Nottingham City Hosp, Sch Med, Acad Pathol,Div Canc & Stem Cells, Nottingham, England.; Rakha, EA (reprint author), Menoufia Univ, Dept Histopathol, Fac Med, Shibin Al Kawm, Egypt.	emad.rakha@nottingham.ac.uk	Simpson, Peter/F-1225-2010; Rakha, Emad/Q-5554-2019	Simpson, Peter/0000-0002-4816-8289; Ellis, Ian/0000-0001-5292-8474; Gorringe, Kylie/0000-0001-5681-2022; Rakha, Emad/0000-0002-5009-5525; Green, Andrew/0000-0002-0488-5913	Egyptian Ministry of Higher Education and Scientific Research; Victorian Cancer Agency; UICC Yamagiwa-Yoshida Memorial International Cancer Study Grant	This research was supported and funded by the Egyptian Ministry of Higher Education and Scientific Research. We thank the Nottingham Health Science Biobank and Breast Cancer Now Tissue Bank for the provision of tissue samples. KLG supported by the Victorian Cancer Agency and a UICC Yamagiwa-Yoshida Memorial International Cancer Study Grant.	Allegra CJ, 2010, J NATL CANCER I, V102, P161, DOI 10.1093/jnci/djp485; Bartova M, 2014, BRATISL MED J, V115, P445, DOI 10.4149/BLL_2014_088; Butler LM, 2002, P NATL ACAD SCI USA, V99, P11700, DOI 10.1073/pnas.182372299; Camp RL, 2004, CLIN CANCER RES, V10, P7252, DOI 10.1158/1078-0432.CCR-04-0713; Carraro DM, 2014, BIOSCIENCE REP, V34, P18, DOI 10.1042/BSR20130077; Curtis C, 2012, NATURE, V486, P346, DOI 10.1038/nature10983; Cutuli B, 2014, RADIOTHER ONCOL, V112, P1, DOI 10.1016/j.radonc.2014.06.011; Doebar SC, 2016, BREAST CANCER RES TR, V158, P179, DOI 10.1007/s10549-016-3862-4; Dolled-Filhart M, 2006, CANCER RES, V66, P5487, DOI 10.1158/0008-5472.CAN-06-0100; Dunn LL, 2010, ARTERIOSCL THROM VAS, V30, P2089, DOI 10.1161/ATVBAHA.110.209643; Elgort Marc G, 2010, Genes Cancer, V1, P893, DOI 10.1177/1947601910389604; Fleischer T, 2014, GENOME BIOL, V15, DOI [10.1186/PREACCEPT-2333349012841587, 10.1186/s13059-014-0435-x]; Gauthier ML, 2007, CANCER CELL, V12, P479, DOI 10.1016/j.ccr.2007.10.017; Goldberg SF, 2003, CANCER RES, V63, P432; Gong Y, 2009, AM J CLIN PATHOL, V132, P228, DOI 10.1309/AJCP4M2VUZCLDALN; Gorringe KL, 2015, MODERN PATHOL, V28, P1174, DOI 10.1038/modpathol.2015.75; Hammond MEH, 2010, J ONCOL PRACT, V6, P195, DOI 10.1200/JOP.777003; Jin HO, 2011, ONCOGENE, V30, P3792, DOI 10.1038/onc.2011.102; Kim JY, 2016, J BREAST CANCER, V19, P185, DOI 10.4048/jbc.2016.19.2.185; Kim SY, 2007, CELL MOL IMMUNOL, V4, P345; Li J, 2017, ONCOL REP, V37, P3369, DOI 10.3892/or.2017.5577; Lu J, 2012, ANTIOXID REDOX SIGN, V17, P1738, DOI 10.1089/ars.2012.4650; McCarty K S Jr, 1984, Semin Diagn Pathol, V1, P297; Morrison JA, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-62; Nie WW, 2015, ONCOTARGET, V6, P3003, DOI 10.18632/oncotarget.3096; Nishizawa K, 2011, CARCINOGENESIS, V32, P1459, DOI 10.1093/carcin/bgr137; Perez AA, 2015, J HISTOCHEM CYTOCHEM, V63, P408, DOI 10.1369/0022155415576540; Rakha EA, 2015, J CLIN PATHOL, V68, P93, DOI 10.1136/jclinpath-2014-202571; Raldow AC, 2016, J CLIN ONCOL, V34, P3963, DOI 10.1200/JCO.2016.67.8532; Schnitt SJ, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2228; Schroder K, 2010, SCIENCE, V327, P296, DOI 10.1126/science.1184003; Sheth SS, 2006, ONCOGENE, V25, P3528, DOI 10.1038/sj.onc.1209394; Solin LJ, 2013, JNCI-J NATL CANCER I, V105, P701, DOI 10.1093/jnci/djt067; Tome ME, 2005, BLOOD, V106, P3594, DOI 10.1182/blood-2005-02-0487; Vincent-Salomon A, 2008, CLIN CANCER RES, V14, P1956, DOI 10.1158/1078-0432.CCR-07-1465; Welsh SJ, 2002, CANCER RES, V62, P5089; Woolston CM, 2012, MODERN PATHOL, V25, P1106, DOI 10.1038/modpathol.2012.60; Yoshihara E, 2014, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00514; Zhou JB, 2013, MITOCHONDRION, V13, P163, DOI [10.1016/j.mito2012.06.004, 10.1016/j.mito.2012.06.004]; Zhou JBA, 2011, INT J BIOCHEM CELL B, V43, P1668, DOI 10.1016/j.biocel.2011.09.005; Zhou WJ, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-653	41	5	5	0	2	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0893-3952	1530-0285		MODERN PATHOL	Mod. Pathol.	DEC	2018	31	12					1807	1815		10.1038/s41379-018-0086-7			9	Pathology	Pathology	HC2HR	WOS:000451623400004	29955142	Green Accepted			2019-10-28	
J	de Boer, M; Verschuur-Maes, AHJ; Buerger, H; Moelans, CB; Steenkamer, M; Savola, S; van Diest, PJ				de Boer, Mirthe; Verschuur-Maes, Anoek H. J.; Buerger, Horst; Moelans, Cathy B.; Steenkamer, Maryvonne; Savola, Suvi; van Diest, Paul J.			Role of columnar cell lesions in breast carcinogenesis: analysis of chromosome 16 copy number changes by multiplex ligation-dependent probe amplification	MODERN PATHOLOGY			English	Article							CARCINOMA IN-SITU; COMPARATIVE GENOMIC HYBRIDIZATION; FLAT EPITHELIAL ATYPIA; TUMOR-SUPPRESSOR GENES; LOBULAR CARCINOMA; DUCTAL HYPERPLASIA; CANCER PROGRESSION; ALLELIC LOSS; 16Q LOSS; EXPRESSION	Columnar cell lesions have been proposed as precursor lesions of low-grade breast cancer. The molecular characteristic of low-grade breast neoplasia is whole-arm loss of chromosome 16q. Copy number changes of 6 genes on 16p and 20 genes on 16q were analysed by multiplex ligation-dependent probe amplification in 165 lesions of 103 patients. Twenty-three columnar cell lesions and 19 atypical ducal hyperplasia lesions arising in columnar cell lesions were included, as well as cases of usual ductal hyperplasia, blunt duct adenosis, ductal carcinoma in situ, lobular neoplasia and invasive carcinoma. Usual ductal hyperplasia and blunt duct adenosis lacked whole-arm losses of 16q. In contrast, columnar cell lesions without atypia, columnar cell lesions with atypia, atypical ductal hyperplasia, low-grade ductal carcinoma in situ and low-grade invasive carcinomas increasingly harboured whole-arm losses of 16q (17%, 27%, 47% and 57%, respectively). However, no recurrent losses in specific genes could be identified. In several patients, columnar cell lesions and atypical ductal hyperplasia harboured similar losses as related ductal carcinoma in situ or invasive carcinomas within the same breast. There were indications for 16q breakpoints near the centromere. Whole-arm gains on 16p were relatively scarce and there was no relation between whole-arm gains of 16p and progression of lesions of the low-grade breast neoplasia family. In conclusion, columnar cell lesions (with and without atypia) often harbour whole-arm losses of 16q, which underlines their role as precursors in low-grade breast carcinogenesis, in contrast with usual ductal hyperplasia and blunt duct adenosis. However, no recurrent losses in specific genes could be identified, pointing to minor events in multiple tumour suppressor genes rather than major events in a single 16q gene contributing to low-grade breast carcinogenesis.	[de Boer, Mirthe; Moelans, Cathy B.; van Diest, Paul J.] Univ Med Ctr Utrecht, Dept Pathol, Heidelberglaan 100, NL-3584 CX Utrecht, Netherlands; [Verschuur-Maes, Anoek H. J.] Gelre Hosp, Apeldoorn, Netherlands; [Buerger, Horst] Inst Pathol, Paderborn, Germany; [Steenkamer, Maryvonne; Savola, Suvi] MRC Holland, Amsterdam, Netherlands	van Diest, PJ (reprint author), Univ Med Ctr Utrecht, Dept Pathol, Heidelberglaan 100, NL-3584 CX Utrecht, Netherlands.	p.j.vandiest@umcutrecht.nl		Savola, Suvi/0000-0002-6221-8617; Moelans, Cathy/0000-0001-9992-8703			Abdel-Fatah TMA, 2008, AM J SURG PATHOL, V32, P513, DOI 10.1097/PAS.0b013e318161d1a5; Aulmann S, 2009, AM J SURG PATHOL, V33, P1646, DOI 10.1097/PAS.0b013e3181adfdcf; Brogi E., 2014, ROSENS BREAST PATHOL, P183; Buerger H, 1999, J PATHOL, V189, P521, DOI 10.1002/(SICI)1096-9896(199912)189:4<521::AID-PATH472>3.0.CO;2-B; Buerger H, 1999, J PATHOL, V187, P396, DOI 10.1002/(SICI)1096-9896(199903)187:4<396::AID-PATH286>3.0.CO;2-L; Burger H, 2013, HISTOL HISTOPATHOL, V28, P311, DOI 10.14670/HH-28.311; Cleton-Jansen AM, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-105; Collins L, 2012, WHO CLASSIFICATION T, P84; Ellis IO, 2012, WHO CLASSIFICATION T, V4, P34; Ellsworth RE, 2010, ANN SURG ONCOL, V17, P1688, DOI 10.1245/s10434-010-0910-x; Etzell JE, 2001, HUM PATHOL, V32, P292, DOI 10.1053/hupa.2001.22759; Farabegoli F, 2004, MODERN PATHOL, V17, P449, DOI 10.1038/modpathol.3800059; Fraser JL, 1998, AM J SURG PATHOL, V22, P1521, DOI 10.1097/00000478-199812000-00009; Gao YX, 2009, J MOL MED, V87, P145, DOI 10.1007/s00109-008-0408-1; Go EML, 2012, HUM PATHOL, V43, P1924, DOI 10.1016/j.humpath.2012.02.001; Gomes DS, 2014, DIAGN PATHOL, V9, DOI 10.1186/1746-1596-9-121; Green AR, 2009, BREAST CANCER RES TR, V113, P59, DOI 10.1007/s10549-008-9905-8; Hanby AM, 2012, WHO CLASSIFICATION T, P86; Hungermann D, 2011, J PATHOL, V224, P517, DOI 10.1002/path.2938; Hwang ES, 2004, CANCER, V100, P2562, DOI 10.1002/cncr.20273; Kunju LP, 2007, HUM PATHOL, V38, P35, DOI 10.1016/j.humpath.2006.08.008; Lacle MM, 2013, MODERN PATHOL, V26, P1461, DOI 10.1038/modpathol.2013.94; Lacroix-Triki M, 2010, J PATHOL, V222, P282, DOI 10.1002/path.2763; LAKHANI SR, 1995, J CLIN PATHOL, V48, P611, DOI 10.1136/jcp.48.7.611; Lakhani SR, 2012, WHO CLASSIFICATION T, P78; Lakhani SR, 2012, WHO CLASSIFICATION T, P40; Larson PS, 2006, J PATHOL, V209, P307, DOI 10.1002/path.1973; Lerwill MF, 2008, ARCH PATHOL LAB MED, V132, P615, DOI 10.1043/1543-2165(2008)132[615:FEAOTB]2.0.CO;2; Loo LWM, 2008, GENE CHROMOSOME CANC, V47, P1049, DOI 10.1002/gcc.20610; Lu YJ, 1998, CANCER RES, V58, P4721; Mastracci TL, 2006, GENE CHROMOSOME CANC, V45, P1007, DOI 10.1002/gcc.20368; Moelans CB, 2009, CELL ONCOL, V31, P1, DOI 10.3233/CLO-2009-0461; Moinfar F, 2000, CANCER-AM CANCER SOC, V88, P2072, DOI 10.1002/(SICI)1097-0142(20000501)88:9<2072::AID-CNCR13>3.3.CO;2-8; Myhre S, 2013, MOL ONCOL, V7, P704, DOI 10.1016/j.molonc.2013.02.018; Nordgard SH, 2008, GENE CHROMOSOME CANC, V47, P680, DOI 10.1002/gcc.20569; Nowee ME, 2007, J PATHOL, V213, P46, DOI 10.1002/path.2217; Rakha E., 2012, DIAGN HISTOPATHOL, V18, P124; Rakha EA, 2006, GENE CHROMOSOME CANC, V45, P527, DOI 10.1002/gcc.20318; Rakha EA, 2004, BRIT J CANCER, V91, P1591, DOI 10.1038/sj.bjc.6602144; Riener MO, 2008, HUM PATHOL, V39, P1621, DOI 10.1016/j.humpath.2008.02.021; Roylance R, 2006, ONCOGENE, V25, P6544, DOI 10.1038/sj.onc.1209659; Roylance R, 2002, J PATHOL, V196, P32, DOI 10.1002/path.1006; Schnitt S. J., 2012, WHO CLASSIFICATION T, P90; Schnitt SJ, 2003, BREAST CANCER RES, V5, P263, DOI 10.1186/bcr625; Schnitt SJ, 2003, ADV ANAT PATHOL, V10, P113, DOI 10.1097/00125480-200305000-00001; Schouten JP, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/gnf056; Shaaban AM, 2002, AM J SURG PATHOL, V26, P421, DOI 10.1097/00000478-200204000-00003; Simpson JF, 2012, WHO CLASSIFICATION T, P88; Simpson PT, 2005, AM J SURG PATHOL, V29, P734, DOI 10.1097/01.pas.0000157295.93914.3b; Stacher E, 2011, HISTOPATHOLOGY, V59, P549, DOI 10.1111/j.1365-2559.2011.03918.x; Stange DE, 2006, CLIN CANCER RES, V12, P345, DOI 10.1158/1078-0432.CCR-05-1633; Tan PH, 2005, J CLIN PATHOL, V58, P705, DOI 10.1136/jcp.2004.025239; Turashvili G, 2008, VIRCHOWS ARCH, V452, P589, DOI 10.1007/s00428-008-0609-6; van Diest PJ, 2002, BRIT MED J, V325, P648, DOI 10.1136/bmj.325.7365.648; van Wezel T, 2005, BREAST CANCER RES, V7, pR998, DOI 10.1186/bcr1337; Vos CBJ, 1999, BRIT J CANCER, V81, P1410, DOI 10.1038/sj.bjc.6693372; Waldman FM, 2001, HUM PATHOL, V32, P222, DOI 10.1053/hupa.2001.21564	57	0	0	1	1	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0893-3952	1530-0285		MODERN PATHOL	Mod. Pathol.	DEC	2018	31	12					1816	1833		10.1038/s41379-018-0099-2			18	Pathology	Pathology	HC2HR	WOS:000451623400005	29976944				2019-10-28	
J	Lin, YB; Seger, N; Chen, Y; Hesla, AC; Wejde, J; Ghaderi, M; Tsagkozis, P; Larsson, O; Haglund, F				Lin, Yingbo; Seger, Nelly; Chen, Yi; Hesla, Asle C.; Wejde, Johan; Ghaderi, Mehran; Tsagkozis, Panagiotis; Larsson, Olle; Haglund, Felix			hTERT promoter mutations in chondrosarcomas associate with progression and disease-related mortality	MODERN PATHOLOGY			English	Article							TERT PROMOTER; OLLIER DISEASE; ENCHONDROMA; RELIABILITY; TUMORS; CELLS; IDH1	Chondrosarcomas are malignant skeletal tumors with chondroid differentiation. Prognosis is largely dependent on histological grading, which suffer from significant interobserver variability. Telomerase activity and abundant telomerase reverse transcriptase (hTERT) expression has previously been associated with chondrosarcoma grade and metastasis. We therefore analyzed the hTERT promoter in clinicopathologically well-characterized chondrosarcomas (grade 1-3) from 87 patients. Using Sanger sequencing we identified an activating -124 C > T mutation in 23 cases (26%). Promoter mutations were significantly associated with increased histological grade (8% of grade 1, 32% of grade 2 and 46% of grade 3, P = 0.002), suggesting a role in tumor progression. In four chondrosarcomas where the histopathological grade was heterogenous, the hTERT mutation was only identified in the higher-grade areas. Additionally, hTERT promoter mutations were significantly associated with worse metastasis-free survival (P = 0.018), chondrosarcoma-specific survival (P = 0.022) and older patient age (P = 0.003). These data suggest that hTERT promoter mutations are common in high grade conventional chondrosarcomas. Granted that additional studies can confirm these findings; hTERT promoter analysis could potentially serve as an adjuvant prognostic marker in routine chondrosarcoma grading. This study reinforces the rationale of telomerase targeted therapy in a subset of chondrosarcomas.	[Lin, Yingbo; Seger, Nelly; Chen, Yi; Wejde, Johan; Ghaderi, Mehran; Larsson, Olle; Haglund, Felix] Karolinska Inst, Dept Oncol Pathol, Canc Ctr Karolinska, Stockholm, Sweden; [Hesla, Asle C.; Tsagkozis, Panagiotis] Karolinska Inst, Dept Mol Med & Surg, Stockholm, Sweden; [Hesla, Asle C.; Tsagkozis, Panagiotis] Karolinska Univ Hosp Solna, Dept Orthoped Surg, Stockholm, Sweden; [Wejde, Johan; Ghaderi, Mehran; Larsson, Olle; Haglund, Felix] Karolinska Univ Hosp Solna, Dept Clin Pathol & Cytol, Stockholm, Sweden	Haglund, F (reprint author), Karolinska Inst, Dept Oncol Pathol, Canc Ctr Karolinska, Stockholm, Sweden.; Haglund, F (reprint author), Karolinska Univ Hosp Solna, Dept Clin Pathol & Cytol, Stockholm, Sweden.	Felix.Haglund@ki.se			Cancer Society in Stockholm; Swedish Cancer SocietySwedish Cancer Society; Swedish Children Cancer Foundation; Stockholm County CouncilStockholm County Council; Karolinska InstitutetKarolinska Institutet	This study was supported by the Cancer Society in Stockholm, the Swedish Cancer Society and the Swedish Children Cancer Foundation, the Stockholm County Council and Karolinska Institutet.	Amary MF, 2011, NAT GENET, V43, P1262, DOI 10.1038/ng.994; Amary MF, 2011, J PATHOL, V224, P334, DOI 10.1002/path.2913; Bell RJA, 2015, SCIENCE, V348, P1036, DOI 10.1126/science.aab0015; Bjornsson J, 1998, CANCER, V83, P2105; Bovee JVMG, 1999, AM J HUM GENET, V65, P689, DOI 10.1086/302532; Eefting D, 2009, AM J SURG PATHOL, V33, P50, DOI 10.1097/PAS.0b013e31817eec2b; Fletcher CDM, 2013, WHO CLASSIFICATION T, P80; Haglund F, 2013, ENDOCR-RELAT CANCER, V22, pL9; Horn S, 2013, SCIENCE, V339, P959, DOI 10.1126/science.1230062; Italiano A, 2013, ANN ONCOL, V24, P2916, DOI 10.1093/annonc/mdt374; Jones KB, 2007, J BONE JOINT SURG AM, V89A, P2113, DOI 10.2106/JBJS.F.01530; Killela PJ, 2013, P NATL ACAD SCI USA, V110, P6021, DOI 10.1073/pnas.1303607110; Martin JA, 2004, CLIN ORTHOP RELAT R, P117, DOI 10.1097/01.blo.0000141647.22689.de; Martin JA, 2002, CELL GROWTH DIFFER, V13, P397; Murphey MD, 1998, RADIOGRAPHICS, V18, P1213, DOI 10.1148/radiographics.18.5.9747616; Oshiro Y, 1998, CANCER, V83, P2324, DOI 10.1002/(SICI)1097-0142(19981201)83:11<2324::AID-CNCR12>3.0.CO;2-U; Pansuriya TC, 2011, NAT GENET, V43, P1256, DOI 10.1038/ng.1004; Parsch D, 2008, CANCER INVEST, V26, P590, DOI 10.1080/07357900802072905; Saito T, 2016, MOL CLIN ONCOL, V4, P61, DOI 10.3892/mco.2015.674; Scheel C, 2001, ONCOGENE, V20, P3835, DOI 10.1038/sj.onc.1204493; Tallini G, 2002, J PATHOL, V196, P194, DOI 10.1002/path.1023; Tarpey PS, 2013, NAT GENET, V45, P923, DOI 10.1038/ng.2668; Vinagre J, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3185	23	2	2	1	2	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0893-3952	1530-0285		MODERN PATHOL	Mod. Pathol.	DEC	2018	31	12					1834	1841		10.1038/s41379-018-0098-3			8	Pathology	Pathology	HC2HR	WOS:000451623400006	30065261				2019-10-28	
J	van Zummeren, M; Kremer, WW; Leeman, A; Bleeker, MCG; Jenkins, D; van de Sandt, M; Doorbar, J; Heideman, DAM; Steenbergen, RDM; Snijders, PJF; Kenter, GG; Quint, WGV; Berkhof, J; Meijer, CJLM				van Zummeren, Marjolein; Kremer, Wieke W.; Leeman, Annemiek; Bleeker, Maaike C. G.; Jenkins, David; van de Sandt, Miekel; Doorbar, John; Heideman, Danielle A. M.; Steenbergen, Renske D. M.; Snijders, Peter J. F.; Kenter, Gemma G.; Quint, Wim G. V.; Berkhof, Johannes; Meijer, Chris J. L. M.			HPV E4 expression and DNA hypermethylation of CADM1, MAL, and miR124-2 genes in cervical cancer and precursor lesions	MODERN PATHOLOGY			English	Article							HIGH-RISK HPV; INTRAEPITHELIAL NEOPLASIA; PROMOTER METHYLATION; SCRAPES; WOMEN; TERMINOLOGY; BIOLOGY; MARKERS; PROTEIN	In this study, we evaluate the expression of human papillomavirus E4 protein (marker for the onset of a productive infection) and hypermethylation of host-cell CADM1, MAL, and miR124-2 genes (marker for an advanced, transforming infection) in cervical intraepithelial neoplasia (CIN) and cancer. A total of 115 cervical lesions were categorized by 3 pathologists into no dysplasia, CIN1, CIN2, CIN3, or cancer by classical histomorphological grading criteria, and by an immunoscore (cumulative value: 0-6) grading system based on Ki-67 (score: 0-3) and p16(ink4a) (score: 0-3) expression. Lesions were immunostained for E4 protein and analyzed for hypermethylation of CADM1, MAL, or miR124-2 genes. Expression of E4 and hypermethylation levels were related to CIN grade based on both classical and immunoscore grading. Hypermethylation increased with severity of the lesion as defined by both classical histomorphological grading and immunoscore criteria, and was always present in carcinomas (22/22). Extensive E4 expression decreased with increasing CIN grade and immunoscore, being most frequent in classically graded CIN1 or in lesions with cumulative immunoscore 1-3 and absent in carcinomas. High-grade lesions (CIN2/3 or immunoscore: 4-6) showed less E4 expression, which was inversely related to an increasing hypermethylation. Extensive E4 expression, as observed in a small proportion of high-grade lesions (6/49 and 8/43, respectively), was mostly associated with a negative methylation marker status (5/6 and 7/8, respectively). Our results illustrate the gradual transition of productive CIN (reflected by extensive E4 expression), to advanced transforming CIN (reflected by extensive hypermethylation) and cancer. Expression patterns of E4 and hypermethylation status of host-cell genes, may be used to identify cervical lesions at risk for cervical cancer, providing a better guidance for clinicians on treatment decisions.	[van Zummeren, Marjolein; Kremer, Wieke W.; Bleeker, Maaike C. G.; Heideman, Danielle A. M.; Steenbergen, Renske D. M.; Snijders, Peter J. F.; Meijer, Chris J. L. M.] Vrije Univ Amsterdam Med Ctr, Canc Ctr Amsterdam, Dept Pathol, Amsterdam, Netherlands; [Leeman, Annemiek; Jenkins, David; van de Sandt, Miekel; Quint, Wim G. V.] DDL Diagnost Lab, Rijswijk, Netherlands; [Doorbar, John] Univ Cambridge, Dept Pathol, Cambridge, England; [Kenter, Gemma G.] Ctr Gynecol Oncol Amsterdam, Dept Gynecol, Amsterdam, Netherlands; [Berkhof, Johannes] Vrije Univ Amsterdam Med Ctr, Dept Epidemiol & Biostat, Amsterdam, Netherlands	Meijer, CJLM (reprint author), Vrije Univ Amsterdam Med Ctr, Canc Ctr Amsterdam, Dept Pathol, Amsterdam, Netherlands.	cjlm.meijer@vumc.nl		Steenbergen, Renske/0000-0002-2327-9839	Sanofi Pasteur/MSD	1) D.A.M.H., P.J.F.S., R.D.M.S., and C.J.L.M. M. are minority shareholders of self-screen B.V., a spin-off company of VUmc; (2) self-screen B.V. holds patents related to the work (i.e., hrHPV test and methylation markers for cervical screening); (3) D.A. M.H. has been on the speaker's bureau of Qiagen and serves occasionally on the scientific advisory boards of Pfizer and Bristol-Meyers Squibb; (4) P.J.F.S. has been on the speakers bureau of Roche diagnostics, Gen-Probe, Abbott, Qiagen and Seegene and has been a consultant for Crucell B.V.; (5) J.B. received consultancy fees from Roche, GlaxoSmithKline, and Merck and received travel support from DDL. All fees were collected by his employer; (6) C.J.L.M. M. served occasionally on the scientific advisory board (expert meeting) of Qiagen and SPMSD/Merck, and has by occasion been consultant for Qiagen; he has been co-investigator on a Sanofi Pasteur/MSD sponsored HPV vaccination trial in men of which his institute received research funding; (7) C.J.L.M. M. has small number of shares of Qiagen, is minority shareholder of Self-Screen bv of which he is part-time director since sept 2017. He was minority shareholder of Diassay B.V. until April 2016; (8) M.V.Z., W.W.K., A.L., M.C.G.B., D.J., J.D., and G.G.K. declare that they have no conflict of interest.	Baak JPA, 2006, J CLIN PATHOL, V59, P1017, DOI 10.1136/jcp.2005.027839; Bierkens M, 2013, INT J CANCER, V133, P1293, DOI 10.1002/ijc.28138; Burgers WA, 2007, ONCOGENE, V26, P1650, DOI 10.1038/sj.onc.1209950; Castle PE, 2009, OBSTET GYNECOL, V113, P18, DOI 10.1097/AOG.0b013e31818f5008; Darragh TM, 2012, J LOW GENIT TRACT DI, V16, P205, DOI 10.1097/LGT.0b013e31825c31dd; De Strooper LMA, 2014, CANCER PREV RES, V7, P1251, DOI 10.1158/1940-6207.CAPR-14-0237; De Strooper LMA, 2014, J CLIN PATHOL, V67, P1067, DOI 10.1136/jclinpath-2014-202616; Doorbar J, 2015, REV MED VIROL, V25, P2, DOI 10.1002/rmv.1822; Doorbar J, 2013, VIROLOGY, V445, P80, DOI 10.1016/j.virol.2013.07.008; Doorbar J, 2012, VACCINE, V30, pF55, DOI 10.1016/j.vaccine.2012.06.083; Federation of Biomedical Scientific Societies, 2011, HUM TISS MED RES COD; Griffin H, 2015, MODERN PATHOL, V28, P977, DOI 10.1038/modpathol.2015.52; Griffin H, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049974; Heatley MK, 2002, HISTOPATHOLOGY, V40, P377, DOI 10.1046/j.1365-2559.2002.01365.x; Herrington CS, 2015, CYTOPATHOLOGY, V26, P346, DOI 10.1111/cyt.12307; Kyrgiou M, 2014, BMJ-BRIT MED J, V349, DOI 10.1136/bmj.g6192; Luttmer R, 2016, EXPERT REV MOL DIAGN, V16, P961, DOI 10.1080/14737159.2016.1217157; OSTOR AG, 1993, INT J GYNECOL PATHOL, V12, P186; Overmeer RM, 2008, J PATHOL, V215, P388, DOI 10.1002/path.2367; Overmeer RM, 2011, INT J CANCER, V129, P2218, DOI 10.1002/ijc.25890; Overmeer RM, 2009, J PATHOL, V219, P327, DOI 10.1002/path.2598; Schiffman M, 2016, NAT REV DIS PRIMERS, V2, DOI 10.1038/nrdp.2016.86; Sie D, 2014, CELL ONCOL, V37, P353, DOI 10.1007/s13402-014-0196-2; Snellenberg S, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-551; Steenbergen RDM, 2014, NAT REV CANCER, V14, P395, DOI 10.1038/nrc3728; van Baars R, 2016, INT J CANCER, V138, P463, DOI 10.1002/ijc.29706; van Baars R, 2015, AM J SURG PATHOL, V39, P1518, DOI 10.1097/PAS.0000000000000498; van den Brule AJC, 2002, J CLIN MICROBIOL, V40, P779, DOI 10.1128/JCM.40.3.779-787.2002; van der Marel J, 2014, GYNECOL ONCOL, V135, P201, DOI 10.1016/j.ygyno.2014.08.040; van Zummeren M, J CLIN PATHOL; Van Zummeren M, 2017, AIDS, V31, P1945, DOI 10.1097/QAD.0000000000001583; Verlaat W, 2017, CLIN CANCER RES, V23, P3813, DOI 10.1158/1078-0432.CCR-16-2641; Wentzensen N, 2009, GYNECOL ONCOL, V112, P293, DOI 10.1016/j.ygyno.2008.10.012; Wentzensen N, 2015, J CLIN ONCOL, V33, P83, DOI 10.1200/JCO.2014.55.9948; Wilting SM, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-167; Wright TC, 2011, BLAUSTEIN'S PATHOLOGY OF THE FEMALE GENITAL TRACT, SIXTH EDITION, P193, DOI 10.1007/978-1-4419-0489-8_5	36	3	3	1	2	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0893-3952	1530-0285		MODERN PATHOL	Mod. Pathol.	DEC	2018	31	12					1842	1850		10.1038/s41379-018-0101-z			9	Pathology	Pathology	HC2HR	WOS:000451623400007	30135508				2019-10-28	
J	Auguste, A; Genestie, C; De Bruyn, M; Adam, J; Le Formal, A; Drusch, F; Pautier, P; Crosbie, EJ; MacKay, H; Kitchener, HC; Powell, M; Pollock, PM; Mileshkin, L; Edmondson, RJ; Nout, R; Nijman, HW; Creutzberg, CL; Bosse, T; Leary, A				Auguste, Aurelie; Genestie, Catherine; De Bruyn, Marco; Adam, Julien; Le Formal, Audrey; Drusch, Francoise; Pautier, Patricia; Crosbie, Emma J.; MacKay, Helen; Kitchener, Henry C.; Powell, Melanie; Pollock, Pamela M.; Mileshkin, Linda; Edmondson, Richard J.; Nout, Remi; Nijman, Hans W.; Creutzberg, Carien L.; Bosse, Tjalling; Leary, Alexandra			Refinement of high-risk endometrial cancer classification using DNA damage response biomarkers: a TransPORTEC initiative	MODERN PATHOLOGY			English	Article							REPAIR DEFECTS; RADIOTHERAPY; SENSITIVITY; GAMMA-H2AX; DEFICIENCY; BRCA1; 53BP1	The TransPORTEC consortium previouslclassified high-risk endometrial cancer including poor-risk histologies such as clear cells, into four molecular subtypes "POLE mutated," "microsatellite unstable," "TP53 mutated," and "no specific molecular profile." We evaluated whether DNA damage response biomarkers could further refine this high-risk tumors classification, in particular the heterogeneous "no specific molecular profile" and "TP53 mutated" subsets recently qualified as poor prognosis in high-risk endometrial cancer. DNA damage response biomarkers including proteins involved in DNA damage (delta-H2AX), homologous recombination (RAD51), regulators of error-prone Non Homologous End-Joining (DNA-pk, FANCD2), and PARP-1 were evaluated in 116 high-risk tumors by immunohistochemistry. CD8 and PD-1 expression by immunochemistry and mutation analyses were performed previously. Survival outcome were calculated using Kaplan-Meier and Log-rank test. None of the DNA damage response biomarkers alone were prognostic. However markers were informative within molecular subsets. Among the "no specific molecular profile" subset, delta-H2AX+ was significantly predictive of poor disease free survival (Hazard Ratio = 2.56; p = 0.026), and among "TP53 mutated," a DNA-pk+/FANCD2-profile (favouring error-prone Non Homologous End-Joining) predicted worst disease free survival (Hazard Ratio = 4.95; p = 0.009) resulting in five distinct prognostic subgroups from best to worst prognosis: group1 "POLE mutated/Microsatellite unstable" > group2 "no specific molecular profile with no DNA damage" > group3 "TP53 mutated/Non Homologous End-Joining negative" > group4 "no specific molecular profile with high DNA damage" > group5 "TP53 mutated/Non Homologous End-Joining positive"; p = 0.0002). Actionable targets were also different among subsets. Group3 had significantly higher infiltration of PD-1+ immune cells (p = 0.003), segregating with group1. Group2 had frequent PI3K pathway mutations and ER positivity. While group5, with the worst prognosis, had high DNA damage and PARP-1 expression providing a rationale for PARP inhibition. Our findings have refined the TransPORTEC prognostic classification of high-risk endometrial cancer into five distinct subgroups by integrating DNA damage response biomarkers and identified molecular subtype-specific therapeutic strategies.	[Auguste, Aurelie; Genestie, Catherine; Le Formal, Audrey; Leary, Alexandra] Gustave Roussy, INSERM, Gynecol Unit, U981, Villejuif, France; [Genestie, Catherine; Adam, Julien] Gustave Roussy, Dept Med Oncol, Dept Pathol, Villejuif, France; [De Bruyn, Marco] Univ Groningen, Univ Med Ctr Groningen, Dept Obstet & Gynecol, Groningen, Netherlands; [Drusch, Francoise] Gustave Roussy, Histocyto Pathol Platform, Villejuif, France; [Pautier, Patricia; Leary, Alexandra] Gustave Roussy, Dept Med Oncol, Villejuif, France; [Crosbie, Emma J.; Kitchener, Henry C.] Univ Manchester, St Marys Hosp, Inst Canc Sci, Manchester, Lancs, England; [MacKay, Helen] Univ Toronto, Univ Hlth Network, Princess Margaret Hosp, Dept Obstet & Gynecol,Div Gynecol Oncol, Toronto, ON, Canada; [Powell, Melanie] Arts Hlth NHS Trust, Dept Clin Oncol, London, England; [Pollock, Pamela M.] Queensland Univ Technol, Inst Hlth & Biomed Innovat, Brisbane, Qld, Australia; [Mileshkin, Linda; Edmondson, Richard J.] Peter Mac Callum Canc Ctr, Div Canc Med, East Melbourne, Australia; [Edmondson, Richard J.] Univ Manchester, Inst Canc Sci, St Marys Hosp, Manchester, Lancs, England; [Nout, Remi; Creutzberg, Carien L.] Eiden Univ, Dept Clin Oncol, Med Ctr, Leiden, Netherlands; [Nijman, Hans W.] Univ Groningen, Univ Med Ctr Groningen, Dept Gynecol, Groningen, Netherlands; [Bosse, Tjalling] Leiden Univ, Dept Pathol, Med Ctr, Leiden, Netherlands	Auguste, A; Leary, A (reprint author), Gustave Roussy, INSERM, Gynecol Unit, U981, Villejuif, France.; Leary, A (reprint author), Gustave Roussy, Dept Med Oncol, Villejuif, France.	aurelie.auguste@gustaverousy.fr; alexandra.leary@gustaveroussy.fr		Auguste, Aurelie/0000-0001-5115-0218; leary, alexandra/0000-0002-2043-2244; Crosbie, Emma/0000-0003-0284-8630	Department of HealthDiabetes UK [NIHR-CS-012-009]		AALDERS J, 1980, OBSTET GYNECOL, V56, P419; Adamo A, 2010, MOL CELL, V39, P25, DOI 10.1016/j.molcel.2010.06.026; Blake P, 2009, LANCET, V373, P137, DOI 10.1016/S0140-6736(08)61767-5; Bouwman P, 2010, NAT STRUCT MOL BIOL, V17, P688, DOI 10.1038/nsmb.1831; de Boer SM, 2018, LANCET ONCOL, V19, P295, DOI 10.1016/S1470-2045(18)30079-2; Eggink FA, 2017, ONCOIMMUNOLOGY, V6, DOI 10.1080/2162402X.2016.1264565; Gachechiladze M, 2017, INT J CANCER, V141, P1286, DOI 10.1002/ijc.30764; Gachechiladze M, 2017, LUNG CANCER, V105, P31, DOI 10.1016/j.lungcan.2017.01.009; Getz G, 2013, NATURE, V497, P67, DOI 10.1038/nature12113; Graeser M, 2010, CLIN CANCER RES, V16, P6159, DOI 10.1158/1078-0432.CCR-10-1027; Kuo LJ, 2008, IN VIVO, V22, P305; Lieber MR, 2010, ANNU REV BIOCHEM, V79, P181, DOI 10.1146/annurev.biochem.052308.093131; Lord CJ, 2015, ANNU REV MED, V66, P455, DOI 10.1146/annurev-med-050913-022545; McCormick A, 2017, CLIN CANCER RES, V23, P2050, DOI 10.1158/1078-0432.CCR-16-0564; McMeekin DS, 2016, J CLIN ONCOL, V34, P3062, DOI 10.1200/JCO.2016.67.8722; Morice P, 2016, LANCET, V387, P1094, DOI 10.1016/S0140-6736(15)00130-0; Mukhopadhyay A, 2010, CLIN CANCER RES, V16, P2344, DOI 10.1158/1078-0432.CCR-09-2758; Olaussen KA, 2013, LUNG CANCER, V80, P216, DOI 10.1016/j.lungcan.2013.01.014; Pace P, 2010, SCIENCE, V329, P219, DOI 10.1126/science.1192277; Rojo F, 2012, ANN ONCOL, V23, P1156, DOI 10.1093/annonc/mdr361; Schultheis AM, 2016, INT J GYNECOL PATHOL, V35, P289, DOI 10.1097/PGP.0000000000000243; Shen JF, 2015, CANCER DISCOV, V5, P752, DOI 10.1158/2159-8290.CD-14-0849; Siddiqui MS, 2015, MUTAT RES-REV MUTAT, V766, P1, DOI 10.1016/j.mrrev.2015.07.001; Stelloo E, 2015, MODERN PATHOL, V28, P836, DOI 10.1038/modpathol.2015.43; Talhouk A, 2016, Gynecol Oncol Res Pract, V3, P14, DOI 10.1186/s40661-016-0035-4; Yang ZM, 2017, ACTA PHARMACOL SIN, V38, P1038, DOI 10.1038/aps.2017.8	26	2	2	0	1	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0893-3952	1530-0285		MODERN PATHOL	Mod. Pathol.	DEC	2018	31	12					1851	1861		10.1038/s41379-018-0055-1			11	Pathology	Pathology	HC2HR	WOS:000451623400008	29955143				2019-10-28	
J	Schoolmeester, JK; Michal, M; Steiner, P; Michal, M; Folpe, AL; Sukov, WR				Schoolmeester, J. Kenneth; Michal, Michael; Steiner, Petr; Michal, Michal; Folpe, Andrew L.; Sukov, William R.			Lipoblastoma-like tumor of the vulva: a clinicopathologic, immunohistochemical, fluorescence in situ hybridization and genomic copy number profiling study of seven cases	MODERN PATHOLOGY			English	Article							SPINDLE-CELL; LIPOMAS; LIP	Lipoblastoma-like tumor of the vulva was first described as a benign mesenchymal neoplasm of adipocytic differentiation having features of lipoblastoma, myxoid liposarcoma, and spindle cell lipoma. Prior studies of lipoblastoma-like tumor have evaluated PLAG1, HMGA2, and RB1 immunohistochemistry and DDIT3 rearrangement status, with results supporting its distinction from lipoblastoma and myxoid liposarcoma. However, absent RB1 expression was reported in a majority of tested cases, suggesting that lipoblastoma-like tumor may have underlying 13q alterations and be related to RB1-deleted soft tissue tumors. To further understand the molecular genetics of lipoblastoma-like tumor, we examined 7 cases by RB1 immunohistochemistry, DDIT3 and PLAG1 break apart FISH probes, RB1 enumeration FISH probe, and genomic copy number analysis by microarray. Patient age ranged from 21 to 56 years (median 35 years). Clinical follow up was available for 5 patients (71%) ranging 3-264 months (median 74 months). Microscopically, lipoblastoma-like tumor formed large lobules separated by thin and/or thick bands of fibrous tissue and had a prominent network of thin-walled vessels. Each tumor was predominantly composed of spindle cells and lipoblasts with variable quantities of mature adipocytes. RB1 immunohistochemistry exhibited a heterogeneous or "mosaic" pattern of weak and negative nuclear expression in all seven cases. DDIT3 and PLAG1 FISH were negative in each case. No evidence of RB1 regional gain or loss was identified by FISH. Genomic copy number analysis by chromosomal microarray showed a normal diploid profile in six tumors (86%). One tumor had copy number abnormalities consisting of an 11.9 megabase deletion from 1p13.3 to 1p11.2 and monosomy 14. Although lipoblastoma-like tumor has features of lipoblastoma, myxoid liposarcoma, and spindle cell lipoma, it is genetically different from these tumors. Furthermore, lipoblastoma-like tumor does not appear to have structural abnormalities of 13q resulting in deletion of RB1.	[Schoolmeester, J. Kenneth; Folpe, Andrew L.; Sukov, William R.] Mayo Clin, Dept Lab Med & Pathol, Rochester, MN 55905 USA; [Michal, Michael; Steiner, Petr; Michal, Michal] Charles Univ Prague, Fac Med Pilsen, Dept Pathol, Plzen, Czech Republic; [Michal, Michael] Charles Univ Prague, Fac Med Pilsen, Biomed Ctr, Plzen, Czech Republic	Schoolmeester, JK (reprint author), Mayo Clin, Dept Lab Med & Pathol, Rochester, MN 55905 USA.	Schoolmeester.j@mayo.edu	Michal, Michael/I-3497-2017	Michal, Michael/0000-0003-4403-7027			Agaimy A, 2017, HUM PATHOL, V60, P192, DOI 10.1016/j.humpath.2016.10.016; Atallah D, 2007, J REPROD MED, V52, P223; Bartuma H, 2008, CANCER GENET CYTOGEN, V183, P60, DOI 10.1016/j.cancergencyto.2008.01.017; Brandal P, 2006, J PATHOL, V208, P388, DOI 10.1002/path.1879; Chen BJ, 2012, AM J SURG PATHOL, V36, P1119, DOI 10.1097/PAS.0b013e31825d532d; Coffin CM, 2009, AM J SURG PATHOL, V33, P1705, DOI 10.1097/PAS.0b013e3181b76462; Creytens D., 2018, INT J GYNECOL PATHOL; DalCin P, 1997, HISTOPATHOLOGY, V31, P222, DOI 10.1046/j.1365-2559.1997.2450851.x; Din NU, 2016, AM J CLIN PATHOL, V146, P487, DOI [10.1093/ajcp/aqw137, 10.1093/AJCP/AQW137]; ENZINGER FM, 1975, CANCER, V36, P1852, DOI 10.1002/1097-0142(197511)36:5<1852::AID-CNCR2820360542>3.0.CO;2-U; Fletcher C, 2013, WHO CLASSIFICATION T; Jahanseir K, 2017, INT J GYNECOL PATHOL; Jeong TJ, 2010, ACTA DERM-VENEREOL, V90, P537, DOI 10.2340/00015555-0904; Lae ME, 2002, HISTOPATHOLOGY, V40, P505, DOI 10.1046/j.1365-2559.2002.01409.x; Mentzel T, 2007, AM J DERMATOPATH, V29, P443, DOI 10.1097/DAD.0b013e318145413c; Michal M, 2017, HUM PATHOL, V65, P140, DOI 10.1016/j.humpath.2017.05.006; Mirkovic J, 2015, AM J SURG PATHOL, V39, P1290, DOI 10.1097/PAS.0000000000000448; Sukov WR, 2012, AM J SURG PATHOL, V36, P663, DOI 10.1097/PAS.0b013e31824dd972; ten Heuvel SE, 2007, ANN SURG ONCOL, V14, P222, DOI 10.1245/s10434-006-9043-7; Val-Bernal JF, 2016, ACTAS DERMO-SIFILOGR, V107, P88, DOI 10.1016/j.ad.2015.05.013	20	3	3	2	4	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0893-3952	1530-0285		MODERN PATHOL	Mod. Pathol.	DEC	2018	31	12					1862	1868		10.1038/s41379-018-0102-y			7	Pathology	Pathology	HC2HR	WOS:000451623400009	29976943				2019-10-28	
J	Sjodahl, G; Eriksson, P; Lovgren, K; Marzouka, NAD; Bernardo, C; Nordentoft, I; Dyrskjot, L; Liedberg, F; Hoglund, M				Sjodahl, Gottfrid; Eriksson, Pontus; Lovgren, Kristina; Marzouka, Nour-Al-Dain; Bernardo, Carina; Nordentoft, Iver; Dyrskjot, Lars; Liedberg, Fredrik; Hoglund, Mattias			Discordant molecular subtype classification in the basal-squamous subtype of bladder tumors and matched lymph-node metastases	MODERN PATHOLOGY			English	Article							CISPLATIN-BASED CHEMOTHERAPY; UROTHELIAL CARCINOMA; NEOADJUVANT CISPLATIN; CLONAL EVOLUTION; CANCER; EXPRESSION; OVEREXPRESSION; IDENTIFICATION; AMPLIFICATION; CYSTECTOMY	Molecular subtypes of muscle-invasive bladder tumors have emerged as a promising research tool with potential to stratify patients for neoadjuvant treatment. Prior to radical cystectomy, the utility of molecular classification and biomarkers depend on concordance between tissue from transurethrally resected specimens and disseminated disease. We assess the concordance of molecular subtypes and a large number of potential biomarkers in 67 pairs of muscle-invasive bladder tumors and synchronous lymph-node metastases. Tissue cores were stained for 29 immunohistochemistry markers and immunohistochemistry-based molecular subtype classification was performed. Molecular subtype was determined by mRNA profiling for 57 bladder tumors and 28 matched lymph-node metastases. Full section immunohistochemistry was performed to assess intra-tumor subtype heterogeneity in discordant cases, and exome sequencing was performed for 20 sample pairs. Discordant subtype classification between the bladder tumor and lymph-node metastasis was generally rare (12/67, 18%), but most (7/12, 58%) involved the Basal/Squamous-like subtype. Discordant Basal/Squamous-like tumors showed either Urothelial-like or Genomically Unstable, luminal-like phenotype in the lymph-node metastasis. Full section immunohistochemistry revealed intra-tumor subtype heterogeneity for six discordant cases including four involving the Basal/Squamous-like subtype. Subtype concordance for non-Basal/Squamous-like tumors was 91%. RNA-based classification agreed with immunohistochemistry classification but quantitative assessment is necessary to avoid false detection of subtype shifts. Most high confidence cancer mutations were shared between samples (n = 93, 78%), and bladder tumor private mutations (n = 20, 17%) were more frequent than those private to the lymph-node metastasis (n = 7, 6%). We conclude that bladder tumors and lymph-node metastases have overall similar molecular subtype, biomarker expression, and cancer mutations. The main exception was tumors of the Basal/Squamous-like subtype where most cases showed discordant classification, some with evidence of intra-tumor heterogeneity. The data are of relevance for neoadjuvant treatment stratification and raises questions on the dynamics of molecular subtypes during bladder cancer progression.	[Sjodahl, Gottfrid; Liedberg, Fredrik] Lund Univ, Div Urol Res, Dept Translat Med, Lund, Sweden; [Sjodahl, Gottfrid; Liedberg, Fredrik] Skane Univ Hosp, Dept Urol, Malmo, Sweden; [Eriksson, Pontus; Lovgren, Kristina; Marzouka, Nour-Al-Dain; Bernardo, Carina; Hoglund, Mattias] Lund Univ, Div Oncol & Pathol, Dept Clin Sci, Lund, Sweden; [Nordentoft, Iver; Dyrskjot, Lars] Aarhus Univ Hosp, Dept Mol Med MOMA, Dept Clin Med, Aarhus, Denmark; [Nordentoft, Iver; Dyrskjot, Lars] Aarhus Univ, Aarhus, Denmark	Sjodahl, G (reprint author), Lund Univ, Div Urol Res, Dept Translat Med, Lund, Sweden.; Sjodahl, G (reprint author), Skane Univ Hosp, Dept Urol, Malmo, Sweden.	gottfrid.sjodahl@med.lu.se	Bernardo, Carina/R-3637-2019; Marzouka, Nour al dain/Y-5334-2019	Bernardo, Carina/0000-0002-1667-6510; Marzouka, Nour al dain/0000-0002-9029-3702; Nordentoft, Iver Kristiansen/0000-0003-4856-4086; Sjodahl, Gottfrid/0000-0002-7869-0473; Dyrskjot, Lars/0000-0001-7061-9851	Swedish Cancer SocietySwedish Cancer Society [2016/314, 2017/278]; Lund Medical Faculty (ALF) [2014/354]; Skane University Hospital Research Funds; Sten K Johnson Foundation; Krapperup Foundation; Skane County Council's research and development Foundation [REGSKANE-622351]; Gosta Jonsson Research Foundation; Biocare	Microarray data were generated by the SCIBLU genomics facility in Lund, Sweden. This research was supported by grants from the Swedish Cancer Society (2016/314 and 2017/278), Lund Medical Faculty (ALF) (2014/354), Skane University Hospital Research Funds, Sten K Johnson Foundation, The Krapperup Foundation, Skane County Council's research and development Foundation REGSKANE-622351, Gosta Jonsson Research Foundation, and Biocare. The authors wish to thank Jaegil Kim for performing TCGA subtype classification.	Adzhubei IA, 2010, NAT METHODS, V7, P248, DOI 10.1038/nmeth0410-248; BADALAMENT RA, 1990, J UROLOGY, V143, P912, DOI 10.1016/S0022-5347(17)40134-0; Balar AV, 2017, LANCET, V389, P67, DOI 10.1016/S0140-6736(16)32455-2; Baras AS, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0131245; Bellmunt J, 2017, NEW ENGL J MED, V376, P1015, DOI 10.1056/NEJMoa1613683; Byrne RA, 2001, J UROLOGY, V165, P1473, DOI 10.1016/S0022-5347(05)66330-6; Cano F, 2012, EMBO J, V31, P3596, DOI 10.1038/emboj.2012.218; Carlsson J, 2015, RADIOL ONCOL, V49, P50, DOI 10.2478/raon-2014-0015; Cheung KJ, 2013, CELL, V155, P1639, DOI 10.1016/j.cell.2013.11.029; Choi W, 2014, CANCER CELL, V25, P152, DOI 10.1016/j.ccr.2014.01.009; Dadhania V, 2016, EBIOMEDICINE, V12, P105, DOI 10.1016/j.ebiom.2016.08.036; Damrauer JS, 2014, P NATL ACAD SCI USA, V111, P3110, DOI 10.1073/pnas.1318376111; DeFrances MC, 2012, EUR J IMMUNOL, V42, P2754, DOI 10.1002/eji.201141653; Faltas BM, 2016, NAT GENET, V48, P1490, DOI 10.1038/ng.3692; Fleischmann A, 2011, EUR UROL, V60, P350, DOI 10.1016/j.eururo.2011.05.035; Font A, 2011, ANN ONCOL, V22, P139, DOI 10.1093/annonc/mdq333; Forbes SA, 2017, NUCLEIC ACIDS RES, V45, pD777, DOI 10.1093/nar/gkw1121; Griffiths G, 2011, J CLIN ONCOL, V29, P2171, DOI 10.1200/JCO.2010.32.3139; Groenendijk FH, 2016, EUR UROL, V69, P384, DOI 10.1016/j.eururo.2015.01.014; Grossman HB, 2003, NEW ENGL J MED, V349, P859, DOI 10.1056/NEJMoa022148; Hansel DE, 2008, AM J CLIN PATHOL, V130, P274, DOI 10.1309/41VLTFX3YPP1HF6F; Jimenez RE, 2001, CLIN CANCER RES, V7, P2440; Jones TD, 2005, CANCER-AM CANCER SOC, V104, P1901, DOI 10.1002/cncr.21466; Lee JY, 2016, SCI REP-UK, V6, DOI 10.1038/srep28623; Lek M, 2016, NATURE, V536, P285, DOI 10.1038/nature19057; Liu D, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-02320-7; Madersbacher S, 2003, J CLIN ONCOL, V21, P690, DOI 10.1200/JCO.2003.05.101; Nordentoft I, 2014, CELL REP, V7, P1649, DOI 10.1016/j.celrep.2014.04.038; Plimack ER, 2015, EUR UROL, V68, P959, DOI 10.1016/j.eururo.2015.07.009; Pouessel D, 2016, ANN ONCOL, V27, P1311, DOI 10.1093/annonc/mdw170; Priedigkeit N, 2017, JAMA ONCOL, V3, P666, DOI 10.1001/jamaoncol.2016.5630; Robertson AG, 2017, CELL, V171, P540, DOI 10.1016/j.cell.2017.09.007; Rosenberg JE, 2016, LANCET, V387, P1909, DOI 10.1016/S0140-6736(16)00561-4; Seiler R, 2017, EUR UROL, V72, P142, DOI [10.1016/j.eururo.2017.03.021, 10.1016/j.eururo.2017.03.030]; Seiler R, 2014, MODERN PATHOL, V27, P87, DOI 10.1038/modpathol.2013.125; Sflomos G, 2016, CANCER CELL, V29, P407, DOI 10.1016/j.ccell.2016.02.002; Sjodahl G, 2017, J PATHOL, V242, P113, DOI 10.1002/path.4886; Sjodahl G, 2012, CLIN CANCER RES, V18, P3377, DOI 10.1158/1078-0432.CCR-12-0077-T; Stephen TL, 2014, IMMUNITY, V41, P427, DOI 10.1016/j.immuni.2014.08.012; Teo HL, 2010, NAT CELL BIOL, V12, P758, DOI 10.1038/ncb2080; Thomsen MBH, 2016, MOL ONCOL, V10, P1450, DOI 10.1016/j.molonc.2016.08.003; Turo R, 2015, J UROLOGY, V193, P325, DOI 10.1016/j.juro.2014.06.026; Van Allen EM, 2014, CANCER DISCOV, V4, P1140, DOI 10.1158/2159-8290.CD-14-0623; Yoshihara K, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3612	44	6	6	0	3	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0893-3952	1530-0285		MODERN PATHOL	Mod. Pathol.	DEC	2018	31	12					1869	1881		10.1038/s41379-018-0096-5			13	Pathology	Pathology	HC2HR	WOS:000451623400010	29967424				2019-10-28	
J	Papke, DJ; Nowak, JA; Yurgelun, MB; Frieden, A; Srivastava, A; Lindeman, NI; Sholl, LM; MacConaill, LE; Dong, F				Papke, David J., Jr.; Nowak, Jonathan A.; Yurgelun, Matthew B.; Frieden, Alexander; Srivastava, Amitabh; Lindeman, Neal I.; Sholl, Lynette M.; MacConaill, Laura E.; Dong, Fei			Validation of a targeted next-generation sequencing approach to detect mismatch repair deficiency in colorectal adenocarcinoma	MODERN PATHOLOGY			English	Article							MICROSATELLITE INSTABILITY DETECTION; LYNCH-SYNDROME; CANCER PATIENTS; MUTATION; PERFORMANCE; GUIDELINES	Mismatch repair protein deficiency is a hallmark of cancers associated with Lynch syndrome and is a biomarker for response to immunotherapy. With the increasing adoption of cancer next-generation sequencing, there has been a movement to develop screening approaches that take advantage of the unique mutational signatures of mismatch repair-deficient tumors. Here, we develop a sequencing-based metric that distinguishes mismatch repair-deficient from mismatch repair-proficient colorectal adenocarcinomas with comparison to immunohistochemical staining. We find that a single criterion of three or more single base pair insertion or deletion mutations per megabase sequenced, occurring in mononucleotide repeat regions of four or more nucleotides, is sufficient to detect mismatch repair deficiency with 96% sensitivity and 100% specificity in a training set of 241 cancers and 96% sensitivity and 99% specificity in a validation set of 436 additional cancers. Using data from the same cohort, we also find that sequencing information from only three genes-ARID1A, KMT2D, and SOX9-is sufficient to detect mismatch repair-deficient colorectal adenocarcinomas with 76% sensitivity and 98% specificity in the validation set. These findings support the notion that targeted next-generation sequencing already being performed for clinical or research purposes can also be used to accurately detect mismatch repair deficiency in colorectal adenocarcinomas.	[Papke, David J., Jr.; Nowak, Jonathan A.; Frieden, Alexander; Srivastava, Amitabh; Lindeman, Neal I.; Sholl, Lynette M.; Dong, Fei] Harvard Med Sch, Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA; [Yurgelun, Matthew B.] Harvard Med Sch, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA USA; [MacConaill, Laura E.] Harvard Med Sch, Dana Farber Canc Inst, Ctr Canc Genome Discovery, Boston, MA USA	Dong, F (reprint author), Harvard Med Sch, Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA.	fdong1@bwh.harvard.edu					Boland CR, 1998, CANCER RES, V58, P5248; Colas C, 2012, ADV CANCER RES, V113, P121, DOI 10.1016/B978-0-12-394280-7.00004-X; Cortes-Ciriano I, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15180; De Roock W, 2010, LANCET ONCOL, V11, P753, DOI 10.1016/S1470-2045(10)70130-3; DePristo MA, 2011, NAT GENET, V43, P491, DOI 10.1038/ng.806; Gan C, 2015, GENES-BASEL, V6, P46, DOI 10.3390/genes6010046; Garcia EP, 2017, ARCH PATHOL LAB MED, V141, P751, DOI 10.5858/arpa.2016-0527-OA; Giardiello FM, 2014, AM J GASTROENTEROL, V109, P1159, DOI 10.1038/ajg.2014.186; Green RC, 2009, J NATL CANCER I, V101, P331, DOI 10.1093/jnci/djn499; Hampel H, 2005, NEW ENGL J MED, V352, P1851, DOI 10.1056/NEJMoa043146; Hanse RJ, 2016, NAT MED, V22, P1342, DOI 10.1038/nm.4191; Huang MN, 2015, SCI REP-UK, V5, DOI 10.1038/srep13321; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; Kautto EA, 2017, ONCOTARGET, V8, P7452, DOI 10.18632/oncotarget.13918; Kopetz S, 2015, J CLIN ONCOL, V33, P4032, DOI 10.1200/JCO.2015.63.2497; Liao XY, 2012, NEW ENGL J MED, V367, P1596, DOI 10.1056/NEJMoa1207756; Lievre A, 2006, CANCER RES, V66, P3992, DOI 10.1158/0008-5472.CAN-06-0191; MacConaill LE, 2014, J MOL DIAGN, V16, P660, DOI 10.1016/j.jmoldx.2014.06.004; Maruvka YE, 2017, NAT BIOTECHNOL, V35, P951, DOI 10.1038/nbt.3966; Muzny DM, 2012, NATURE, V487, P330, DOI 10.1038/nature11252; Niu BF, 2014, BIOINFORMATICS, V30, P1015, DOI 10.1093/bioinformatics/btt755; Nowak JA, 2017, J MOL DIAGN, V19, P84, DOI 10.1016/j.jmoldx.2016.07.010; Overman MJ, 2017, LANCET ONCOL, V18, P1182, DOI 10.1016/S1470-2045(17)30422-9; Prasad V, 2018, JAMA ONCOL, V4, P157, DOI 10.1001/jamaoncol.2017.4182; Richman SD, 2009, J CLIN ONCOL, V27, P5931, DOI 10.1200/JCO.2009.22.4295; Salipante SJ, 2014, CLIN CHEM, V60, P1192, DOI 10.1373/clinchem.2014.223677; Sartore-Bianchi A, 2016, LANCET ONCOL, V17, P738, DOI 10.1016/S1470-2045(16)00150-9; Shia J, 2008, J MOL DIAGN, V10, P293, DOI 10.2353/jmoldx.2008.080031; Stadler ZK, 2016, J CLIN ONCOL, V34, P2141, DOI 10.1200/JCO.2015.65.1067; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; Tran B, 2011, CANCER-AM CANCER SOC, V117, P4623, DOI 10.1002/cncr.26086; Trano G, 2010, BRIT J CANCER, V102, P482, DOI 10.1038/sj.bjc.6605509; van Riel E, 2010, HERED CANCER CLIN PR, V8, DOI 10.1186/1897-4287-8-7	33	3	3	0	1	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0893-3952	1530-0285		MODERN PATHOL	Mod. Pathol.	DEC	2018	31	12					1882	1890		10.1038/s41379-018-0091-x			9	Pathology	Pathology	HC2HR	WOS:000451623400011	29955144				2019-10-28	
J	Pearlman, R; Markow, M; Knight, D; Chen, W; Arnold, CA; Pritchard, CC; Hampel, H; Frankel, WL				Pearlman, Rachel; Markow, Michael; Knight, Deborah; Chen, Wei; Arnold, Christina A.; Pritchard, Colin C.; Hampel, Heather; Frankel, Wendy L.			Two-stain immunohistochemical screening for Lynch syndrome in colorectal cancer may fail to detect mismatch repair deficiency	MODERN PATHOLOGY			English	Article							MICROSATELLITE INSTABILITY; SOMATIC MUTATIONS; ANTIBODY PANEL; MSH6; GERMLINE; TUMORS; CARCINOMAS; EXPRESSION; GUIDELINES; MANAGEMENT	Universal screening for Lynch syndrome in colorectal cancer is recommended, and immunohistochemistry for the mismatch repair proteins is commonly used. To reduce cost, some screen using only MSH6 and PMS2, with reflex to the partner stain if either are absent (two-stain method). An expression pattern revealing absent MSH2 and intact MSH6 is not expected, but could result in failed Lynch syndrome detection. We analyzed tumors with absent MSH2 but any degree of MSH6 expression to determine if the two-stain method could miss MSH2 mutations. One-thousand seven-hundred thirty colorectal cancer patients from the Ohio Colorectal Cancer Prevention Initiative underwent tumor screening using microsatellite instability and immunohistochemistry. The two-stain method was used for 1235 cases; staining for all four proteins was completed for 495 cases. The proportion of positive cells and staining intensity were reviewed for MSH6, as well as MSH2 when available. Patients with mismatch repair deficiency underwent next-generation sequencing of germline DNA for mismatch repair genes. If negative, tumor next-generation sequencing was performed to assess for somatic mutations. Overall, thirty-three (1.9%, 33/1730) MSH2-absent cases were identified. Of those, fourteen had no MSH6 expression but eight (0.5%, 8/1730) had ambiguous and eleven (0.6%, 11/1730) had convincing MSH6 expression that could have been interpreted as intact. Germline next-generation sequencing identified MSH2 mutations in 11/14 cases with absence of both stains, 7/8 cases with ambiguous MSH6 expression, and 9/11 cases with convincing MSH6 expression. All remaining cases, except one, had double somatic mutations. The two-stain method fails to detect some patients with Lynch syndrome: (1) significant staining weaker than the control may be incorrectly interpreted as intact MSH6, or (2) Weak or focal/patchy MSH6 can be retained with the absence of MSH2. Accordingly, we recommend the four-stain method be used for optimal Lynch syndrome screening detection.	[Pearlman, Rachel; Hampel, Heather] Ohio State Univ, Dept Internal Med, Ctr Comprehens Canc, Wexner Med Ctr, Columbus, OH 43210 USA; [Markow, Michael; Knight, Deborah; Chen, Wei; Arnold, Christina A.; Frankel, Wendy L.] Ohio State Univ, Dept Pathol, Wexner Med Ctr, Columbus, OH 43210 USA; [Pritchard, Colin C.] Univ Washington, Dept Lab Med, Seattle, WA 98195 USA	Frankel, WL (reprint author), Ohio State Univ, Dept Pathol, Wexner Med Ctr, Columbus, OH 43210 USA.	Wendy.Frankel@osumc.edu			Pelotonia, an annual cycling event in Columbus, Ohio; National Cancer InstituteUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [P30CA16058]; Solove Research Institute	The Ohio Colorectal Cancer Prevention Initiative is supported by a grant from Pelotonia, an annual cycling event in Columbus, Ohio, that supports cancer research at The Ohio State University Comprehensive Cancer Center-James Cancer Hospital and Solove Research Institute. This study was also supported in part by the National Cancer Institute (grant P30CA16058). We thank Shawn Scully for his help with the figures.	Bacher JW, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132727; Bacher JW, 2004, DIS MARKERS, V20, P237, DOI 10.1155/2004/136734; Bao F, 2010, AM J SURG PATHOL, V34, P1798, DOI 10.1097/PAS.0b013e3181f906cc; Buckingham L, 2007, MOL DIAGNOSTICS FUND; Desai DC, 2000, J MED GENET, V37, P646, DOI 10.1136/jmg.37.9.646; Geurts-Giele WRR, 2014, J PATHOL, V234, P548, DOI 10.1002/path.4419; Giardiello FM, 2014, AM J GASTROENTEROL, V109, P1159, DOI 10.1038/ajg.2014.186; Graham RP, 2015, AM J SURG PATHOL, V39, P1370, DOI 10.1097/PAS.0000000000000459; Hall G, 2010, PATHOLOGY, V42, P409, DOI 10.3109/00313025.2010.493871; Hampel H, 2005, NEW ENGL J MED, V352, P1851, DOI 10.1056/NEJMoa043146; Hampel H, 2008, J CLIN ONCOL, V26, P5783, DOI 10.1200/JCO.2008.17.5950; Haraldsdottir S, 2014, GASTROENTEROLOGY, V147, P1308, DOI 10.1053/j.gastro.2014.08.041; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; Kantelinen J, 2012, HUM MUTAT, V33, P1294, DOI 10.1002/humu.22119; Le DT, 2015, NEW ENGL J MED, V372, P2509, DOI 10.1056/NEJMoa1500596; LYNCH HT, 1988, GASTROENTEROL CLIN N, V17, P679; Mensenkamp AR, 2014, GASTROENTEROLOGY, V146, P643, DOI 10.1053/j.gastro.2013.12.002; Mojtahed A, 2011, MODERN PATHOL, V24, P1004, DOI 10.1038/modpathol.2011.55; Muller W, 2001, Fam Cancer, V1, P87, DOI 10.1023/A:1013840907881; Nord AS, 2011, BMC GENOMICS, V12, DOI 10.1186/1471-2164-12-184; O'Regan T, 2013, NEW ZEAL MED J, V126, P70; Palomaki GE, 2009, GENET MED, V11, P42, DOI 10.1097/GIM.0b013e31818fa2db; Pastrello C, 2006, EUR J HUM GENET, V14, P63, DOI 10.1038/sj.ejhg.5201517; Pearlman R, 2017, JAMA ONCOL, V3, P464, DOI 10.1001/jamaoncol.2016.5194; Pritchard CC, 2012, J MOL DIAGN, V14, P357, DOI 10.1016/j.jmoldx.2012.03.002; Radu OM, 2011, HUM PATHOL, V42, P1247, DOI 10.1016/j.humpath.2010.11.016; Shia J, 2013, MODERN PATHOL, V26, P131, DOI 10.1038/modpathol.2012.138; Sourrouille I, 2013, FAM CANCER, V12, P27, DOI 10.1007/s10689-012-9568-9; van der Klift H, 2005, GENE CHROMOSOME CANC, V44, P123, DOI 10.1002/gcc.20219; Vasen HFA, 2013, GUT, V62, P812, DOI 10.1136/gutjnl-2012-304356; Vilkin A, 2014, HUM PATHOL, V45, P2029, DOI 10.1016/j.humpath.2014.07.005; Walsh MD, 2012, MODERN PATHOL, V25, P722, DOI 10.1038/modpathol.2011.209; Yurgelun MB, 2012, CANCER PREV RES, V5, P574, DOI 10.1158/1940-6207.CAPR-11-0519	33	6	6	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0893-3952	1530-0285		MODERN PATHOL	Mod. Pathol.	DEC	2018	31	12					1891	1900		10.1038/s41379-018-0058-y			10	Pathology	Pathology	HC2HR	WOS:000451623400012	29967423				2019-10-28	
J	Shyu, S; Heath, JE; Burke, AP				Shyu, Susan; Heath, Jonathon E.; Burke, Allen P.			Neuroendocrine cell proliferations in lungs explanted for fibrotic interstitial lung disease and emphysema	PATHOLOGY			English	Article						Neuroendocrine cell hyperplasia; NECH; fibrotic lung disease; sarcoidosis; lung transplantation	PULMONARY ENDOCRINE-CELLS; OBLITERATIVE BRONCHIOLITIS; CARCINOID-TUMORS; HYPERPLASIA; DIAGNOSIS; SPECTRUM; INFANCY	Using recently proposed pathological criteria, we determined the incidence of neuroendocrine cell proliferation in a series of explants with lung disease. Cases were defined as NECH (>= 3 bronchioles with >= 5 endocrine cells), borderline diffuse neuroendocrine cell hyperplasia (DPNECH) (1-3 tumourlets with or without NECH), and DPNECH (>= 3 tumourlets with NECH). Endocrine cells were identified by immunohistochemical staining for synaptophysin. There were 65 explants with interstitial lung disease (57 with non-sarcoid fibrotic lung disease, 8 with sarcoidosis), and 21 with centrilobular emphysema. Over one-third of all explant cases demonstrated histological criteria for NECH. There were three cases of DPNECH in the non-sarcoid fibrotic lung disease group (5%) and 20 cases of NECH (35%). The emphysema group had one case of DPNECH (5%), two cases of borderline DPNECH (10%), and seven cases with NECH (33%). The sarcoidosis group had two cases of DPNECH (25%) and three cases of NECH (38%). NECH is common in interstitial lung disease and emphysema. These results suggest that fibrotic lung disease is a predisposing factor for neuroendocrine cell proliferation, in addition to the known risk of epithelial neoplasms.	[Shyu, Susan; Heath, Jonathon E.; Burke, Allen P.] Univ Maryland Med Syst, Dept Pathol, 22 S Greene St,NWB43, Baltimore, MD 21201 USA; [Shyu, Susan; Heath, Jonathon E.; Burke, Allen P.] Univ Maryland, Sch Med, Dept Pathol, Baltimore, MD 21201 USA	Shyu, S (reprint author), Univ Maryland Med Syst, Dept Pathol, 22 S Greene St,NWB43, Baltimore, MD 21201 USA.	susanshyu@gmail.com					AGUAYO SM, 1992, NEW ENGL J MED, V327, P1285, DOI 10.1056/NEJM199210293271806; AGUAYO SM, 1990, J CLIN INVEST, V86, P838, DOI 10.1172/JCI114782; Aubry MC, 2007, CHEST, V131, P1635, DOI 10.1378/chest.06-2788; Aubry MC, 2002, MAYO CLIN PROC, V77, P763, DOI 10.4065/77.8.763; Baniak NM, 2016, PATHOL RES PRACT, V212, P125, DOI 10.1016/j.prp.2015.12.006; Caimmi S, 2016, ITAL J PEDIATR, V42, DOI 10.1186/s13052-016-0295-y; Cazzato S, 2013, EARLY HUM DEV, V89, pS39, DOI 10.1016/j.earlhumdev.2013.07.021; Chassagnon G, 2015, CLIN RADIOL, V70, P317, DOI 10.1016/j.crad.2014.10.012; Chatterjee Kshitij, 2016, Pneumonol Alergol Pol, V84, P174, DOI 10.5603/PiAP.2016.0020; Cutz E, 2007, PEDIATR DEVEL PATHOL, V10, P419, DOI 10.2350/07-04-0267.1; Dahiya M, 2000, ARCH PATHOL LAB MED, V124, P171; Das S, 2011, CURR OPIN PEDIATR, V23, P325, DOI 10.1097/MOP.0b013e3283464a37; Davies SJ, 2007, THORAX, V62, P248, DOI 10.1136/thx.2006.063065; Gorshtein A, 2012, CANCER-AM CANCER SOC, V118, P612, DOI 10.1002/cncr.26200; Gosney JR, 2011, HISTOPATHOLOGY, V59, P751, DOI 10.1111/j.1365-2559.2011.03992.x; GOSNEY JR, 1989, J PATHOL, V157, P127, DOI 10.1002/path.1711570207; Gosney JR, 1997, EUR RESPIR J, V10, P388, DOI 10.1183/09031936.97.10020388; GOSNEY JR, 1988, THORAX, V43, P878, DOI 10.1136/thx.43.11.878; GUBBELMANS HLL, 1991, EUR RESPIR J, V4, P824; Hendifar AE, 2017, J THORAC ONCOL, V12, P425, DOI 10.1016/j.jtho.2016.11.2222; Levy NT, 1997, MAYO CLIN PROC, V72, P112, DOI 10.4065/72.2.112; Lyall MS, 2005, J PATHOL, V207, P13; Marchevsky AM, 2015, SEMIN DIAGN PATHOL, V32, P438, DOI 10.1053/j.semdp.2015.08.002; Marchevsky AM, 2015, HUM PATHOL, V46, P176, DOI 10.1016/j.humpath.2014.10.019; MILLER MA, 1978, AM J MED, V65, P373, DOI 10.1016/0002-9343(78)90835-5; MILLER RR, 1995, AM J SURG PATHOL, V19, P653, DOI 10.1097/00000478-199506000-00005; Pietrangeli V, 2015, LUNG, V193, P1051, DOI 10.1007/s00408-015-9817-4; Reyes LJ, 2007, RESP MED, V101, P1840, DOI 10.1016/j.rmed.2005.10.024; SHEERIN N, 1995, THORAX, V50, P207, DOI 10.1136/thx.50.2.207; Travis WD, 2015, WHO CLASSIFICATION T, P78; Weichselbaum M, 2005, RESP RES, V6, DOI 10.1186/1465-9921-6-115; WILSON NJE, 1993, THORAX, V48, P1252, DOI 10.1136/thx.48.12.1252; Yancheva SG, 2015, HISTOPATHOLOGY, V67, P501, DOI 10.1111/his.12672; Young LR, 2011, CHEST, V139, P1060, DOI 10.1378/chest.10-1304; Zhou HJ, 2014, J BRONCHOL INTERN PU, V21, P342, DOI 10.1097/LBR.0000000000000098	35	0	0	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0031-3025	1465-3931		PATHOLOGY	Pathology	DEC	2018	50	7					699	702		10.1016/j.pathol.2018.08.003			4	Pathology	Pathology	HC4PM	WOS:000451785700001	30360902				2019-10-28	
J	Leichsenring, J; Stogbauer, F; Volckmar, AL; Buchhalter, I; Oliveira, C; Kirchner, M; Frohling, S; Hassel, J; Enk, A; Schirmacher, P; Endris, V; Penzel, R; Stenzinger, A				Leichsenring, Jonas; Stoegbauer, Fabian; Volckmar, Anna-Lena; Buchhalter, Ivo; Oliveira, Cristiano; Kirchner, Martina; Froehling, Stefan; Hassel, Jessica; Enk, Alexander; Schirmacher, Peter; Endris, Volker; Penzel, Roland; Stenzinger, Albrecht			Genetic profiling of melanoma in routine diagnostics: assay performance and molecular characteristics in a consecutive series of 274 cases	PATHOLOGY			English	Article						Melanoma; molecular diagnostics; BRAF; NRAS; triple wild type	OPEN-LABEL; BRAF; MUTATIONS; LANDSCAPE; NRAS; NF1; SENSITIVITY; RESISTANCE; CHILDHOOD; BLOCKADE	A deeper understanding of melanoma biology has opened up new avenues for mechanistically informed therapies. However, data on the prevalence of druggable genetic lesions in melanoma are still conflicting and realworld performance data on high-throughput genetic profiling of melanoma cases using formalin fixed, paraffin embedded (FFPE) tissue with variable tumour cellularity and quality are lacking. We retrospectively analysed targeted next-generation sequencing data of 274 consecutive melanoma samples obtained for routine di-agnostics between December 2013 and July 2017. Actionable mutations were detected in 197 cases (71.9%), of which activating BRAF (mostly p.V600E/K) and RAS (mostly p.Q61R/K) mutations occurred in 40.5% (n = 111) and 30.3% (n = 83) of cases, respectively. We identified driver mutations of the Triple-WT subgroup in 10.6% of cases (n = 29; 10 with activating KIT mutations). Median turnaround time was 5 working days with no dropouts. Tumour cellularity ranged from 5% to 95% and successful sequencing was possible at DNA concentrations as low as 0.03 ng/mu L (median 10.58 ng/mu L; range 0.03-209.05 ng/mu L). Fast, quality-controlled high-throughput genetic profiling of FFPE melanoma samples is feasible and provides a landscape of genetic aberrations in melanoma that is currently relevant in clinical practice and approximates TCGA subtypes.	[Leichsenring, Jonas; Stoegbauer, Fabian; Volckmar, Anna-Lena; Oliveira, Cristiano; Kirchner, Martina; Schirmacher, Peter; Endris, Volker; Penzel, Roland; Stenzinger, Albrecht] Univ Hosp Heidelberg, Inst Pathol, Neuenheimer Feld 224, D-69120 Heidelberg, Germany; [Buchhalter, Ivo] DKFZ, Omics IT & Data Management Core Facil, Heidelberg, Germany; [Froehling, Stefan; Schirmacher, Peter; Stenzinger, Albrecht] German Canc Consortium DKTK, Partner Site, Heidelberg, Germany; [Froehling, Stefan; Schirmacher, Peter; Stenzinger, Albrecht] German Canc Res Ctr, Heidelberg, Germany; [Froehling, Stefan] Natl Ctr Tumor Dis NCT, Dept Translat Oncol, Heidelberg, Germany; [Froehling, Stefan] Heidelberg Univ Hosp, Sect Personalized Oncol, Heidelberg, Germany; [Hassel, Jessica; Enk, Alexander] Ruprecht Karl Univ Heidelberg, Dept Dermatol, Univ Hosp, Heidelberg, Germany	Stenzinger, A (reprint author), Univ Hosp Heidelberg, Inst Pathol, Neuenheimer Feld 224, D-69120 Heidelberg, Germany.	albrecht.stenzinger@med.uni-heidelberg.de		Buchhalter, Ivo/0000-0003-0764-5832	German Cancer Consortium (DKTK)	This study was funded by the German Cancer Consortium (DKTK, to PS and AS). The authors state that there are no conflicts of interest to disclose.	Akbani R, 2015, CELL, V161, P1681, DOI 10.1016/j.cell.2015.05.044; Ascierto PA, 2013, LANCET ONCOL, V14, P249, DOI 10.1016/S1470-2045(13)70024-X; Carvajal RD, 2011, JAMA-J AM MED ASSOC, V305, P2327, DOI 10.1001/jama.2011.746; Cirenajwis H, 2017, MOL ONCOL, V11, P438, DOI 10.1002/1878-0261.12050; Corless C., 2014, OTHER KIT MUTATIONS; Deutsche Krebsgesellschaft Deutsche Krebshilfe AWMF, 2016, LEITL PROGR ONK DIAG; Dhomen N, 2009, HEMATOL ONCOL CLIN N, V23, P529, DOI 10.1016/j.hoc.2009.04.001; Dummer R, 2017, LANCET ONCOL, V18, P435, DOI 10.1016/S1470-2045(17)30180-8; Endris V, 2013, J MOL DIAGN, V15, P765, DOI 10.1016/j.jmoldx.2013.06.002; Erdei E, 2010, EXPERT REV ANTICANC, V10, P1811, DOI 10.1586/ERA.10.170; Ferlay J, 2010, INT J CANCER, V127, P2893, DOI 10.1002/ijc.25516; Forbes SA, 2015, NUCLEIC ACIDS RES, V43, pD805, DOI 10.1093/nar/gku1075; Gibney GT, 2013, CANCER DISCOV, V3, P260, DOI 10.1158/2159-8290.CD-13-0017; Girotti MR, 2013, CANCER DISCOV, V3, P158, DOI 10.1158/2159-8290.CD-12-0386; Girotti MR, 2015, CANCER CELL, V27, P85, DOI 10.1016/j.ccell.2014.11.006; Goldinger Simone M, 2013, EJC Suppl, V11, P92, DOI 10.1016/j.ejcsup.2013.07.011; Gray-Schopfer V, 2007, NATURE, V445, P851, DOI 10.1038/nature05661; Guo J, 2017, ANN ONCOL, V28, P1380, DOI 10.1093/annonc/mdx079; Guo J, 2011, J CLIN ONCOL, V29, P2904, DOI 10.1200/JCO.2010.33.9275; Hayward NK, 2017, NATURE, V545, P175, DOI 10.1038/nature22071; Hodis E, 2012, CELL, V150, P251, DOI 10.1016/j.cell.2012.06.024; Janakiraman M, 2010, CANCER RES, V70, P5901, DOI 10.1158/0008-5472.CAN-10-0192; Krauthammer M, 2015, NAT GENET, V47, P996, DOI 10.1038/ng.3361; Kwong LN, 2012, NAT MED, V18, P1503, DOI 10.1038/nm.2941; Larribere L, 2016, PIGM CELL MELANOMA R, V29, P417, DOI 10.1111/pcmr.12488; Lu C, 2015, J INVEST DERMATOL, V135, P816, DOI 10.1038/jid.2014.425; McGranahan N, 2016, SCIENCE, V351, P1463, DOI 10.1126/science.aaf1490; National Comprehensive Cancer Network (NCCN), 2017, MEL; Nazarian R, 2010, NATURE, V468, P973, DOI 10.1038/nature09626; Oliveira C, 2016, CNVPANELIZER RELIABL; Parkin DM, 2001, INT J CANCER, V94, P153, DOI 10.1002/ijc.1440; Puzanov I, 2015, INVEST NEW DRUG, V33, P159, DOI 10.1007/s10637-014-0167-5; Raaijmakers MIG, 2016, ONCOTARGET, V7, P77163, DOI 10.18632/oncotarget.12848; Rizvi NA, 2015, SCIENCE, V348, P124, DOI 10.1126/science.aaa1348; Rosenberg JE, 2016, LANCET, V387, P1909, DOI 10.1016/S0140-6736(16)00561-4; Shain AH, 2015, NEW ENGL J MED, V373, P1926, DOI 10.1056/NEJMoa1502583; Van Allen EM, 2015, SCIENCE, V350, P207, DOI 10.1126/science.aad0095; Wong JR, 2013, PEDIATRICS, V131, P846, DOI 10.1542/peds.2012-2520	38	3	3	1	2	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0031-3025	1465-3931		PATHOLOGY	Pathology	DEC	2018	50	7					703	710		10.1016/j.pathol.2018.08.004			8	Pathology	Pathology	HC4PM	WOS:000451785700002	30348504				2019-10-28	
J	Luzar, B; Martin, B; Fisher, C; Calonje, E				Luzar, Bostjan; Martin, Blanca; Fisher, Cyril; Calonje, Eduardo			Cutaneous malignant glomus tumours: applicability of currently established malignancy criteria for tumours occurring in the skin	PATHOLOGY			English	Article						Glomus tumour; skin; cutaneous (superficial); malignancy criteria; prognosis	GLOMANGIOSARCOMA	Glomus tumours (GTs) have traditionally been classified into benign GTs, GTs with uncertain malignant potential and malignant GTs, based on a combination of criteria such as size of the tumour, degree of nuclear atypia and the level of mitotic activity. Several of the proposed grading criteria are difficult, or even impossible to apply for GTs occurring in the skin. The aim of the study was to analyse the applicability of the currently established GT malignancy criteria for tumours occurring in the skin and to establish their prognostic significance. A total of 25 benign cutaneous GTs, 11 new cutaneous malignant GTs and 36 cutaneous malignant GTs previously published in the literature were studied. We analysed the following clinicopathological features and correlated them with disease outcome: age, sex, site, size, depth of invasion, degree of nuclear atypia, mitotic activity, growth pattern, vascular invasion, spindle-cell morphology and tumoural necrosis. Of all the clinicopathological parameters analysed, only tumoural necrosis was found by univariate analysis (p = 0.001) to be associated with adverse biological behaviour, and none by multivariate analysis. Multivariate statistical analysis failed to detect any clini-copathological features predictive of the disease outcome (e.g., local recurrence, development of metastatic spread and/or death of disease) in cutaneous malignant GTs. Furthermore, the currently established malignancy criteria for cutaneous GTs can be difficult to apply, mainly due to their smaller size. Likewise, counting mitotic activity per 50 high power fields can often not be accomplished in GTs occurring at superficial locations. Complete excision of these tumours coupled with long-term follow-up is the mainstay of treatment for cutaneous malignant GTs. The results of our study also suggest that cutaneous malignant GTs follow a more indolent clinical course than their deep soft tissue counterparts.	[Luzar, Bostjan] Univ Ljubljana, Inst Pathol, Fac Med, Korytkova 2, Ljubljana 1000, Slovenia; [Martin, Blanca; Calonje, Eduardo] St Thomas Hosp, St Johns Inst Dermatol, Dept Dermatopathol, London, England; [Fisher, Cyril] Royal Marsden NHS Fdn Trust, Dept Histopathol, London, England; [Fisher, Cyril] Royal Marsden NHS Fdn Trust, Sarcoma Unit, London, England	Luzar, B (reprint author), Univ Ljubljana, Inst Pathol, Fac Med, Korytkova 2, Ljubljana 1000, Slovenia.	bostjan.luzar@mf.uni-lj.si					AIBA M, 1988, CANCER, V61, P1467, DOI 10.1002/1097-0142(19880401)61:7<1467::AID-CNCR2820610733>3.0.CO;2-3; Binesh F, 2013, BMJ CASE REP; Chou TM, 2016, ANN PLAS SURG, V76, pS35, DOI 10.1097/SAP.0000000000000684; Cibull TL, 2008, J CUTAN PATHOL, V35, P765, DOI 10.1111/j.1600-0560.2007.00898.x; Damavandy AA, 2016, AM J DERMATOPATH, V38, P384, DOI 10.1097/DAD.0000000000000481; Dashti NK, 2017, AM J SURG PATHOL, V41, P1532, DOI 10.1097/PAS.0000000000000913; De Chiara Annarosaria, 2003, Sarcoma, V7, P87, DOI 10.1080/1357714031000081207; Enzinger FM, 1983, SOFT TISSUE TUMORS; Folpe AL, 2001, AM J SURG PATHOL, V25, P1, DOI 10.1097/00000478-200101000-00001; Folpe AL, 2013, WHO CLASSIFICATION T, P116; Gombos Z, 2008, ARCH PATHOL LAB MED, V132, P1448, DOI 10.1043/1543-2165(2008)132[1448:GT]2.0.CO;2; GOULD EW, 1990, CANCER, V65, P310, DOI 10.1002/1097-0142(19900115)65:2<310::AID-CNCR2820650221>3.0.CO;2-Q; Hegyi L, 1998, J CLIN PATHOL, V51, P872, DOI 10.1136/jcp.51.11.872; Kayal JD, 2001, DERMATOL SURG, V27, P837, DOI 10.1046/j.1524-4725.2001.01036.x; Khoury T, 2005, AM J DERMATOPATH, V27, P428, DOI 10.1097/01.dad.0000148281.96494.d4; Lancerotto L, 2012, INT J SURG PATHOL, V20, P420, DOI 10.1177/1066896911432454; LopezRios F, 1997, J CUTAN PATHOL, V24, P571, DOI 10.1111/j.1600-0560.1997.tb01462.x; Masson P, 1924, LYON CHIR, V21, P257; Miettinen M, 2002, AM J SURG PATHOL, V26, P301, DOI 10.1097/00000478-200203000-00003; Park JH, 2003, J DERMATOL, V30, P827, DOI 10.1111/j.1346-8138.2003.tb00486.x; Perez de la Fuente T, 2005, Chir Main, V24, P199, DOI 10.1016/j.main.2005.06.006; Terada T, 2014, POL J PATHOL, V65, P241, DOI 10.5114/PJP.2014.45789; TSUNEYOSHI M, 1982, CANCER, V50, P1601, DOI 10.1002/1097-0142(19821015)50:8<1601::AID-CNCR2820500823>3.0.CO;2-5; Watanabe K, 1995, Fukushima J Med Sci, V41, P71; Watanabe K, 1998, BRIT J DERMATOL, V139, P1097; Zhu YZ, 2013, J CARDIOTHORAC SURG, V8, DOI 10.1186/1749-8090-8-146	26	0	0	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0031-3025	1465-3931		PATHOLOGY	Pathology	DEC	2018	50	7					711	717		10.1016/j.pathol.2018.08.005			7	Pathology	Pathology	HC4PM	WOS:000451785700003	30314644				2019-10-28	
J	Wang, RC; Sakata, S; Chen, BJ; Chang, ST; Hsieh, PP; Yang, CS; Baba, S; Takeuchi, K; Chuang, SS				Wang, Ren Ching; Sakata, Seiji; Chen, Bo-Jung; Chang, Sheng-Tsung; Hsieh, Pin-Pen; Yang, Chi-Shun; Baba, Satoko; Takeuchi, Kengo; Chuang, Shih-Sung			Mycosis fungoides in Taiwan shows a relatively high frequency of large cell transformation and CD56 expression	PATHOLOGY			English	Article						CD56; DUSP22/MUM1; MUM1; mycosis fungoides; Taiwan; transformation	CUTANEOUS LYMPHOMA; ORGANIZATION; PROTEIN	Mycosis fungoides ( MF) is an indolent cutaneous T-cell lymphoma and may transform into large cell lymphoma in the disease course. The incidence of MF in Taiwan is lower as compared to that in the West. In this study we aimed to characterise the clinicopathological, immunohistochemical, and genetic features of transformed MF (t-MF) in Taiwan. We retrospectively collected MF cases from April 2004 to April 2015 from four medical centres in Taiwan, reviewed the clinical history and histopathology, and performed immunohistochemistry, in situ hybridisation for EBV (EBER), and fluorescence in situ hybridisation (FISH) for DUSP22/MUM1 gene translocation. Fifty-one specimens from 32 patients with MF were identified with a male to female ratio of 1.5:1 and a median age of 50.5 (range 16-82). Tumours from 11 patients (34%) underwent large cell transformation, with the median age at 61 (range 26-82). The tumour cells of t-MF expressed CD30 and MUM1 in 82% and 100% cases, respectively. CD56 was expressed in two (10%) of 21 MF cases and two (18%) of 11 t-MF cases, respectively; and all four CD56-positive cases were of a helper T-cell phenotype. All CD56 expressing MF and t-MF tumours tested for EBER were negative. FISH study showed rearranged DUSP22/IRF4 in one (9%) of 11 t-MF cases, but not in any of the 19 non-transformed MF specimens. Four patients with t-MF died of disease and six were alive with disease in a median follow-up time of 25 months (mean 44.7 months). Large cell transformation and aberrant CD56 expression were more frequent in patients with MF in Taiwan compared to those in the West. Larger case series and/or national studies are needed to clarify the significance and impact of large cell transformation on the prognosis of patients with MF.	[Wang, Ren Ching; Yang, Chi-Shun] Taichung Vet Gen Hosp, Dept Pathol & Lab Med, Taichung, Taiwan; [Sakata, Seiji; Baba, Satoko; Takeuchi, Kengo] Japanese Fdn Canc Res, Inst Canc, Pathol Project Mol Targets, Tokyo, Japan; [Chen, Bo-Jung] Taipei Med Univ, Shuang Ho Hosp, Dept Pathol, New Taipei, Taiwan; [Chang, Sheng-Tsung; Chuang, Shih-Sung] Chi Mei Med Ctr, Dept Pathol, 901 Chung Hwa Rd, Tainan 71004, Taiwan; [Chang, Sheng-Tsung] Natl Tainan Inst Nursing, Dept Nursing, Tainan, Taiwan; [Hsieh, Pin-Pen] Kaohsiung Vet Gen Hosp, Dept Pathol & Lab Med, Kaohsiung, Taiwan; [Hsieh, Pin-Pen] Natl Def Med Ctr, Taipei, Taiwan; [Baba, Satoko; Takeuchi, Kengo] Japanese Fdn Canc Res, Inst Canc, Div Pathol, Tokyo, Japan; [Takeuchi, Kengo] Japanese Fdn Canc Res, Canc Inst Hosp, Dept Pathol, Tokyo, Japan; [Chuang, Shih-Sung] Taipei Med Univ, Sch Med, Dept Pathol, Taipei, Taiwan; [Chuang, Shih-Sung] Natl Taiwan Univ, Taipei, Taiwan	Chuang, SS (reprint author), Chi Mei Med Ctr, Dept Pathol, 901 Chung Hwa Rd, Tainan 71004, Taiwan.	cmh5301@mail.chimei.org.tw	Takeuchi, Kengo/C-3614-2008	Takeuchi, Kengo/0000-0002-1599-5800	Ministry of Science and Technology, Taipei, Taiwan [MOST 103-2314-B-384 -003]	This work was supported by the research grant MOST 103-2314-B-384 -003 (to S-SC) from Ministry of Science and Technology, Taipei, Taiwan. The authors state that there are no conflicts of interest to disclose.	Arulogun SO, 2008, BLOOD, V112, P3082, DOI 10.1182/blood-2008-05-154609; Cerroni L, 2014, SKIN LYMPHOMA ILLUST, P344; Chuang SS, 2017, J FORMOS MED ASSOC, V116, P620, DOI 10.1016/j.jfma.2016.11.006; Falini B, 2000, BLOOD, V95, P2084, DOI 10.1182/blood.V95.6.2084; Feldman AL, 2009, LEUKEMIA, V23, P574, DOI 10.1038/leu.2008.320; Gualco G, 2010, APPL IMMUNOHISTO M M, V18, P301, DOI 10.1097/PAI.0b013e3181cf1126; Hamada T, 2014, J DERMATOL, V41, P3, DOI 10.1111/1346-8138.12299; Horst BA, 2009, AM J DERMATOPATH, V31, P74, DOI 10.1097/DAD.0b013e31818ffbe8; Jawed SI, 2014, J AM ACAD DERMATOL, V70, DOI 10.1016/j.jaad.2013.08.033; Kim Meeran, 2014, Korean J Pathol, V48, P390, DOI 10.4132/KoreanJPathol.2014.48.5.390; Kiran T, 2013, LEUKEMIA RES, V37, P396, DOI 10.1016/j.leukres.2012.12.001; Klekotka PA, 2006, ARCH DERMATOL, V142, P1370, DOI 10.1001/archderm.142.10.1370; Liao JB, 2010, ARCH PATHOL LAB MED, V134, P996, DOI 10.1043/2009-0132-OA.1; Nikolaou VA, 2009, BRIT J DERMATOL, V161, P826, DOI 10.1111/j.1365-2133.2009.09301.x; Ohshima A, 2003, BRIT J DERMATOL, V149, P891, DOI 10.1046/j.1365-2133.2003.05533.x; Park JH, 2012, J AM ACAD DERMATOL, V67, P1200, DOI 10.1016/j.jaad.2012.02.033; Pham-Ledard A, 2010, J INVEST DERMATOL, V130, P816, DOI 10.1038/jid.2009.314; Pimpinelli N, 2005, J AM ACAD DERMATOL, V53, P1053, DOI 10.1016/j.jaad.2005.08.057; Ralfkiaer E, 2008, WHO CLASSIFICATION T, P196; SALHANY KE, 1988, AM J PATHOL, V132, P265; Santucci M, 2003, CANCER, V97, P610, DOI 10.1002/cncr.11107; Sawada Y, 2010, ACTA DERM-VENEREOL, V90, P525, DOI 10.2340/00015555-0831; Shiomi T, 2013, J CUTAN PATHOL, V40, P317, DOI 10.1111/cup.12067; Song SX, 2013, AM J CLIN PATHOL, V139, P466, DOI 10.1309/AJCPOBDP2OQAJ5BR; Takeuchi Kengo, 2013, Haematologica, V98, pe32, DOI 10.3324/haematol.2012.076851; Vergier B, 2000, BLOOD, V95, P2212; Wain EM, 2005, J AM ACAD DERMATOL, V53, P158, DOI 10.1016/j.jaad.2005.01.133; Wasco MJ, 2008, HUM PATHOL, V39, P557, DOI 10.1016/j.humpath.2007.08.013	28	0	0	0	2	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0031-3025	1465-3931		PATHOLOGY	Pathology	DEC	2018	50	7					718	724		10.1016/j.pathol.2018.08.008			7	Pathology	Pathology	HC4PM	WOS:000451785700004	30348505				2019-10-28	
J	Xue, T; Wang, WG; Zhou, XY; Li, XQ				Xue, Tian; Wang, Wei-Ge; Zhou, Xiao-Yan; Li, Xiao-Qiu			EBV-positive diffuse large B-cell lymphoma features PD-L1 protein but not mRNA overexpression	PATHOLOGY			English	Article						PD-L1; MYC; EBV-positive diffuse large B-cell lymphoma	DEATH LIGAND 1; HODGKIN LYMPHOMA; EXPRESSION; MYC; SURVIVAL; SUBSET; UPDATE; POOR	Programmed cell death ligand 1 (PD-L1) is upregulated in various types of haematological malignancies and is associated with immunosuppression. This study aimed to investigate the expression pattern of PD-L1 in Epstein-Barr virus (EBV)-positive diffuse large B-cell lymphoma (DLBCL). We retrospectively analysed clinicopathological characteristics in 30 cases of EBV-positive DLBCL and immunohistochemically evaluated the level of membrane bound PD-L1 protein. Twenty-eight cases expressed PD-L1 protein, 15 of which showed an intense positive staining. In addition, we investigated the relationships between PD-L1 protein and PD-L1 mRNA and MYC, respectively. The expression level of PD-L1 protein was not fully parallel with PD-L1 mRNA, and no significant correlation was observed between PD-L1 protein and MYC. Notably, PD-L1 mRNA was at a low dosage, which indicated that there might be other mechanisms inducing the overexpression of membrane bound PD-L1 protein apart from genetic alterations. Furthermore, the low expression level of MYC may not interfere with the PD-L1 protein expression in EBV-positive DLBCL. In conclusion, overexpression of PD-L1 protein can be observed in EBVpositive DLBCL, and the level was non-parallel with both PD-L1 mRNA and MYC. Moreover, we emphasise that immunohistochemistry is a clinically reasonable method for screening formalin fixed, paraffin embedded (FFPE) tumour samples in this entity.	[Xue, Tian; Wang, Wei-Ge; Zhou, Xiao-Yan; Li, Xiao-Qiu] Fudan Univ, Shanghai Canc Ctr, Dept Pathol, 270 Dongan Rd, Shanghai 200032, Peoples R China; [Xue, Tian; Wang, Wei-Ge; Zhou, Xiao-Yan; Li, Xiao-Qiu] Fudan Univ, Dept Oncol, Shanghai Med Coll, Shanghai, Peoples R China	Li, XQ (reprint author), Fudan Univ, Shanghai Canc Ctr, Dept Pathol, 270 Dongan Rd, Shanghai 200032, Peoples R China.	leexiaoqiu@hotmail.com					Andorsky DJ, 2011, CLIN CANCER RES, V17, P4232, DOI 10.1158/1078-0432.CCR-10-2660; Ansell SM, 2015, NEW ENGL J MED, V372, P311, DOI 10.1056/NEJMoa1411087; Atsaves V, 2017, LEUKEMIA, V31, P1633, DOI 10.1038/leu.2017.103; Beltran BE, 2011, CL LYMPH MYELOM LEUK, V11, P512, DOI 10.1016/j.clml.2011.07.003; Bi XW, 2016, J HEMATOL ONCOL, V9, DOI 10.1186/s13045-016-0341-7; Bollard CM, 2014, J CLIN ONCOL, V32, P798, DOI 10.1200/JCO.2013.51.5304; Casey SC, 2016, SCIENCE, V352, P227, DOI 10.1126/science.aac9935; Castillo JJ, 2016, AM J HEMATOL, V91, P529, DOI 10.1002/ajh.24370; Chen BJ, 2013, CLIN CANCER RES, V19, P3462, DOI 10.1158/1078-0432.CCR-13-0855; Dirmeier U, 2005, ONCOGENE, V24, P1711, DOI 10.1038/sj.onc.1208367; Durand-Panteix S, 2012, J IMMUNOL, V189, P181, DOI 10.4049/jimmunol.1102277; Georgiou K, 2016, BLOOD, V127, P3026, DOI 10.1182/blood-2015-12-686550; Green MR, 2010, BLOOD, V116, P3268, DOI 10.1182/blood-2010-05-282780; Hans CP, 2004, BLOOD, V103, P275, DOI 10.1182/blood-2003-05-1545; Hawkes EA, 2015, LANCET ONCOL, V16, pE234, DOI 10.1016/S1470-2045(15)70103-8; Jelinek T, 2017, IMMUNOLOGY, V152, P357, DOI 10.1111/imm.12788; Kiyasu J, 2015, BLOOD, V126, P2193, DOI 10.1182/blood-2015-02-629600; Kloo B, 2011, P NATL ACAD SCI USA, V108, P272, DOI 10.1073/pnas.1008969108; Kwon D, 2016, HISTOPATHOLOGY, V68, P1079, DOI 10.1111/his.12882; Lu TX, 2015, SCI REP-UK, V5, DOI 10.1038/srep12168; Nicolae A, 2015, BLOOD, V126, P863, DOI 10.1182/blood-2015-02-630632; Ok CY, 2013, BLOOD, V122, P328, DOI 10.1182/blood-2013-03-489708; Perrine SR, 2007, BLOOD, V109, P2571, DOI 10.1182/blood-2006-01-024703; Roemer MGM, 2016, J CLIN ONCOL, V34, P2690, DOI 10.1200/JCO.2016.66.4482; Stine ZE, 2015, CANCER DISCOV, V5, P1024, DOI 10.1158/2159-8290.CD-15-0507; Swerdlow SH, 2017, WHO CLASSIFICATION T; Wilson WH, 2015, NAT MED, V21, P922, DOI 10.1038/nm.3884; Xerri L, 2008, HUM PATHOL, V39, P1050, DOI 10.1016/j.humpath.2007.11.012	28	0	0	0	1	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0031-3025	1465-3931		PATHOLOGY	Pathology	DEC	2018	50	7					725	729		10.1016/j.pathol.2018.08.011			5	Pathology	Pathology	HC4PM	WOS:000451785700005	30389217				2019-10-28	
J	Hany, H; Shalaby, A; Al Kashef, W; Kandil, W; Shahin, RA; El-Alfy, H; Besheer, T; Farag, R; Mohamed, M				Hany, Heba; Shalaby, Asem; Al Kashef, Wagdi; Kandil, Wageha; Shahin, Rehab-Allah; El-Alfy, Hatem; Besheer, Tarek; Farag, Raghda; Mohamed, Mie			Evaluation of the role of Notch1 expression in hepatic carcinogenesis with clinico-pathological correlation	PATHOLOGY			English	Article						Notch1; hepatocellular carcinoma; carcinogenesis	HUMAN HEPATOCELLULAR-CARCINOMA; CELL-CYCLE ARREST; POOR-PROGNOSIS; CANCER; GROWTH; ACTIVATION; CONTRIBUTES; RECEPTORS; APOPTOSIS; PATHWAY	The role of Notch pathway in hepatocarcinogenesis is unclear with conflicting results reported from different researchers. This study aimed to investigate the exact role of Notch1 in hepatocarcinogenesis and its influence on survival and to determine the possibility of it being a target therapy. Differential immunohistochemical expression of Notch1 in 100 cases of hepatocellular carcinoma (HCC) and adjacent non-neoplastic liver tissue was performed. The results showed that expression of Notch1 was significantly higher in the non-neoplastic hepatic tissues than in HCC tissues (p < 0.001), but there was no significant difference in Notch1 expression between cirrhotic and non-cirrhotic liver tissue (p = 0.197). Notch1 expression was higher in low grade than in high grade HCC (p = 0.036). Notch1 expression showed reverse correlation with mitotic count (p = 0.008), and necrosis (p = 0.005). The disease free survival was shorter in patients displaying low levels of Notch1 expression (p = 0.045). The overall survival showed no significant difference between high and low levels of Notch1 expression; however, it was somewhat longer in patients with high Notch1 expression (p = 0.220). In conclusion, the tumour suppressor role of Notch1 was supported and the use of Notch1 agonists may have a role in improving the prognosis of HCC.	[Hany, Heba; Shalaby, Asem; Al Kashef, Wagdi; Kandil, Wageha; Shahin, Rehab-Allah; Mohamed, Mie] Mansoura Univ, Dept Pathol, Coll Med, Mansoura, Egypt; [Shalaby, Asem] Sultan Qaboos Univ, Dept Pathol, Coll Med & Hlth Sci, Muscat, Oman; [El-Alfy, Hatem; Besheer, Tarek; Farag, Raghda] Mansoura Univ, Mansoura Univ Hosp, Dept Trop Dis, Mansoura, Egypt	Shalaby, A (reprint author), Sultan Qaboos Univ, Coll Med, Dept Pathol, Muscat, Oman.	asemali444@yahoo.com	Shalaby, Asem/Y-8321-2019; Shalaby, Asem A E/A-1158-2019	Shalaby, Asem/0000-0001-8032-2306; Shalaby, Asem A E/0000-0002-7400-3373	Project Funding Unit in Mansoura University under the Competitive Funding Programme (CFP)	This work represents a part of the outcome of a research project supported by The Project Funding Unit in Mansoura University under the Competitive Funding Programme (CFP) and titled 'A Tissue Based Progression Model for Hepatic Carcinogenesis with its Clinical Implication'. The authors state that there are no conflicts of interest to disclose.	Abou-Alfa GK, 2017, AM JOINT COMMITTEE C, P289; Ahn S, 2013, HEPATOB PANCREAT DIS, V12, P286, DOI 10.1016/S1499-3872(13)60046-6; Alavian SM, 2016, HEPAT MON, V16, DOI 10.5812/hepatmon.35106; Ayaz F, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00345; Bolos V, 2009, CLIN TRANSL ONCOL, V11, P11, DOI 10.1007/s12094-009-0305-2; Chikara S, 2013, TRANSL LUNG CANCER R, V2, P449, DOI 10.3978/j.issn.2218-6751.2013.10.15; Chu D, 2010, ANN SURG ONCOL, V17, P1337, DOI 10.1245/s10434-009-0893-7; D'Souza B, 2010, CURR TOP DEV BIOL, V92, P73, DOI 10.1016/S0070-2153(10)92003-6; Espinoza I, 2013, ONCOTARGETS THER, V6, P1249, DOI 10.2147/OTT.S36162; Gao J, 2012, INT J ONCOL, V41, P1773, DOI 10.3892/ijo.2012.1606; Geisler F, 2015, HEPATOLOGY, V61, P382, DOI 10.1002/hep.27268; Ghouri YA, 2017, J CARCINOG, V16, P9; Gil-Garcia B, 2016, BIOL CELL, V108, P29, DOI 10.1111/boc.201500029; Giovannini C, 2006, ANTICANCER RES, V26, P2123; Giovannini C, 2016, ONCOTARGET, V7, P39609, DOI 10.18632/oncotarget.9203; Giovannini C, 2009, J HEPATOL, V50, P969, DOI 10.1016/j.jhep.2008.12.032; Gramantieri L, 2004, J HEPATOL, V40, P103, DOI 10.1016/S0168-8278(04)90340-6; Gramantieri L, 2007, LIVER INT, V27, P997, DOI 10.1111/j.1478-3231.2007.01544.x; Ha SY, 2016, CANCER RES TREAT, V48, P180, DOI 10.4143/crt.2014.321; Hanlon L, 2010, CANCER RES, V70, P4280, DOI 10.1158/0008-5472.CAN-09-4645; Huntzicker EG, 2015, HEPATOLOGY, V61, P942, DOI 10.1002/hep.27566; Hussein WM, 2016, INFECT AGENTS CANCER, V11, DOI 10.1186/s13027-016-0083-8; LARSSON C, 1994, GENOMICS, V24, P253, DOI 10.1006/geno.1994.1613; Lehman EM, 2009, INT J CANCER, V124, P690, DOI 10.1002/ijc.23937; Leong KG, 2006, BLOOD, V107, P2223, DOI 10.1182/blood-2005-08-3329; Liu J, 2015, ONCOL REP, V34, P3174, DOI 10.3892/or.2015.4300; Liu M, 2012, MOL CELL, V45, P171, DOI 10.1016/j.molcel.2011.11.018; Lobry C, 2014, BLOOD, V123, P2451, DOI 10.1182/blood-2013-08-355818; Lobry C, 2011, J EXP MED, V208, P1931, DOI 10.1084/jem.20111855; Lu J, 2016, ONCOL LETT, V12, P3, DOI 10.3892/ol.2016.4609; Ma S, 2013, EXP CELL RES, V319, P126, DOI 10.1016/j.yexcr.2012.09.007; Meurette O, 2009, CANCER RES, V69, P5015, DOI 10.1158/0008-5472.CAN-08-3478; Ning L, 2009, AM J TRANSL RES, V1, P358; Pascua S, 2016, WORLD J HEPATOL, V8, P421, DOI 10.4254/wjh.v8.i9.421; Poon RTP, 2000, ANN SURG, V231, P544, DOI 10.1097/00000658-200004000-00014; Qi RZ, 2003, CANCER RES, V63, P8323; Ranganathan P, 2011, NAT REV CANCER, V11, P338, DOI 10.1038/nrc3035; Schlageter M, 2014, WORLD J GASTROENTERO, V20, P15955, DOI 10.3748/wjg.v20.i43.15955; Sokolowski KM, 2015, HEPATOMA RES, V1, P11; South AP, 2012, SEMIN CELL DEV BIOL, V23, P458, DOI 10.1016/j.semcdb.2012.01.017; Sriuranpong V, 2001, CANCER RES, V61, P3200; Strazzabosco M, 2012, GASTROENTEROLOGY, V143, P1430, DOI 10.1053/j.gastro.2012.10.025; Sun LC, 2015, ANTI-CANCER AGENT ME, V15, P809, DOI 10.2174/1871520615666150202102809; Talora C, 2005, EXP CELL RES, V305, P343, DOI 10.1016/j.yexcr.2005.01.015; Viatour P, 2011, J EXP MED, V208, P1963, DOI 10.1084/jem.20110198; Villanueva A, 2012, GASTROENTEROLOGY, V143, P1660, DOI 10.1053/j.gastro.2012.09.002; Wang CM, 2009, J BIOL CHEM, V284, P16183, DOI 10.1074/jbc.M109.002105; Wang F, 2013, BIOTECHNOL LETT, V35, P29, DOI 10.1007/s10529-012-1048-7; Wang F, 2012, ONCOL REP, V27, P1170, DOI 10.3892/or.2012.1620; Wang F, 2010, CANCER LETT, V298, P64, DOI 10.1016/j.canlet.2010.06.003; Wang M, 2009, NEOPLASMA, V56, P533, DOI 10.4149/neo_2009_06_533; Xu P, 2009, PATHOL ONCOL RES, V15, P703, DOI 10.1007/s12253-009-9173-x; Zhou L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057382; Zhou L, 2013, TUMOR BIOL, V34, P543, DOI 10.1007/s13277-012-0580-3	54	0	0	0	3	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0031-3025	1465-3931		PATHOLOGY	Pathology	DEC	2018	50	7					730	736		10.1016/j.pathol.2018.08.007			7	Pathology	Pathology	HC4PM	WOS:000451785700006	30389219				2019-10-28	
J	Lee, SJ; Chung, KY; Kwon, JE; Yoon, SO; Kim, SK				Lee, Seok Joo; Chung, Kee Yang; Kwon, Ji Eun; Yoon, Sun Och; Kim, Sang Kyum			Expression of EpCAM in adenoid cystic carcinoma	PATHOLOGY			English	Article						Adenoid cystic carcinoma; EpCAM; Ber-EP4; biomarker; non-salivary gland	CELL ADHESION MOLECULE; KIT GENE-MUTATIONS; EP-CAM; SALIVARY-GLAND; C-KIT; BREAST-CANCER; MONOCLONAL-ANTIBODY; PROTEIN EXPRESSION; MYB EXPRESSION; PHASE-II	The mutational landscape of adenoid cystic carcinoma (ACC) is currently being revealed, but further studies are needed to identify biomarkers as therapeutic targets or prognostic factors of ACC. In this study, we investigated the expression of epithelial cell adhesion molecule (EpCAM) in ACCs. We retrospectively collected 83 cases of surgically resected ACCs. Using tissue microarray, we conducted immunohistochemical staining using the anti-EpCAM antibody. EpCAM expression was analysed by intensity score and the total immunostaining score. The positivity was 97.6% (81/83 cases), regardless of the intensity score. A higher histological grade (p = 0.006) and specific tumour location (non-salivary gland origin, p = 0.02) showed a correlation with higher EpCAM intensity. Higher EpCAM expression by total immunostaining score was associated with histological grade (p = 0.004), distant metastasis (p = 0.004) and poorer prognosis (overall survival p = 0.015 and progressionfree survival p = 0.033). We suggest EpCAM as a candidate prognostic marker and a putative therapeutic target in ACC. Also, ACCs arising from salivary gland and non-salivary gland sites, respectively, might display different pathophysiologies in which EpCAM could play a role.	[Lee, Seok Joo; Yoon, Sun Och; Kim, Sang Kyum] Yonsei Univ, Coll Med, Dept Pathol, Seoul, South Korea; [Chung, Kee Yang] Yonsei Univ, Dept Dermatol, Coll Med, Seoul, South Korea; [Kwon, Ji Eun] Ajou Univ, Dept Pathol, Sch Med, Suwon, South Korea	Kim, SK (reprint author), Yonsei Univ, Med Ctr, Dept Pathol, 134 Sinchon Dong, Seoul, South Korea.	nicekyumi@yuhs.ac		Kim, Sang Kyum/0000-0003-0768-9923; Yoon, Sun Och/0000-0002-5115-1402; Chung, Kee Yang/0000-0003-3257-0297	Basic Science Research Program through the National Research Foundation of Korea (NRF) - Ministry of Education [2016R1D1A1B03931581]	This research was supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education (grant number: 2016R1D1A1B03931581). The authors state that there are no conflicts of interest to disclose.	Andreadis D, 2006, ORAL ONCOL, V42, P57, DOI 10.1016/j.oraloncology.2005.06.014; Baeuerle PA, 2007, BRIT J CANCER, V96, P417, DOI 10.1038/sj.bjc.6603494; Balzar M, 1999, J MOL MED, V77, P699, DOI 10.1007/s001099900038; Brill LB, 2011, MODERN PATHOL, V24, P1169, DOI 10.1038/modpathol.2011.86; Fong D, 2008, J CLIN PATHOL, V61, P31, DOI 10.1136/jcp.2006.037333; Freier K, 2005, ORAL ONCOL, V41, P934, DOI 10.1016/j.oraloncology.2005.05.005; Gastl G, 2000, LANCET, V356, P1981, DOI 10.1016/S0140-6736(00)03312-2; Ghosal N, 2011, BRIT J ORAL MAX SURG, V49, P510, DOI 10.1016/j.bjoms.2010.09.013; Gold KA, 2014, CLIN CANCER RES, V20, P1946, DOI 10.1158/1078-0432.CCR-13-1959; Goossens-Beumer IJ, 2014, BRIT J CANCER, V110, P2935, DOI 10.1038/bjc.2014.226; Ho AS, 2013, NAT GENET, V45, P791, DOI 10.1038/ng.2643; Hotte SJ, 2005, J CLIN ONCOL, V23, P585, DOI 10.1200/JCO.2005.06.125; JIMENEZ FJ, 1995, MODERN PATHOL, V8, P854; Kimura H, 2007, INT J ONCOL, V30, P171; Kroepil Feride, 2013, BMC Res Notes, V6, P253, DOI 10.1186/1756-0500-6-253; Kurtz JE, 2010, EXPERT OPIN BIOL TH, V10, P951, DOI 10.1517/14712598.2010.482098; Liao MY, 2015, ONCOTARGET, V6, P24947, DOI 10.18632/oncotarget.4453; Lin YC, 2012, INT J ORAL MAX SURG, V41, P354, DOI 10.1016/j.ijom.2011.12.022; Mitani Y, 2010, CLIN CANCER RES, V16, P4722, DOI 10.1158/1078-0432.CCR-10-0463; Moskaluk CA, 2010, MODERN PATHOL, V23, P905, DOI 10.1038/modpathol.2010.61; NASCIMENTO AG, 1986, CANCER, V57, P312, DOI 10.1002/1097-0142(19860115)57:2<312::AID-CNCR2820570220>3.0.CO;2-A; Ogura E, 1998, ANTICANCER RES, V18, P3669; Osta WA, 2004, CANCER RES, V64, P5818, DOI 10.1158/0008-5472.CAN-04-0754; PERZIN KH, 1978, CANCER, V42, P265, DOI 10.1002/1097-0142(197807)42:1<265::AID-CNCR2820420141>3.0.CO;2-Z; Phattarataratip E, 2016, ANN DIAGN PATHOL, V24, P62, DOI 10.1016/j.anndiagpath.2016.05.007; Ruf P, 2007, BRIT J CANCER, V97, P315, DOI 10.1038/sj.bjc.6603881; Schmidt M, 2010, ANN ONCOL, V21, P275, DOI 10.1093/annonc/mdp314; Schnell U, 2013, BBA-BIOMEMBRANES, V1828, P1989, DOI 10.1016/j.bbamem.2013.04.018; Sen S, 2016, HISTOPATHOLOGY, V68, P897, DOI 10.1111/his.12870; Songun I, 2005, BRIT J CANCER, V92, P1767, DOI 10.1038/sj.bjc.6602519; SPIRO RH, 1974, AM J SURG, V128, P512, DOI 10.1016/0002-9610(74)90265-7; Spizzo G, 2003, BRIT J CANCER, V88, P574, DOI 10.1038/sj.bjc.6600741; Spizzo G, 2006, GYNECOL ONCOL, V103, P483, DOI 10.1016/j.ygyno.2006.03.035; Stoecklein NH, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-165; Swanson PE, 1998, J CUTAN PATHOL, V25, P153, DOI 10.1111/j.1600-0560.1998.tb01708.x; SZANTO PA, 1984, CANCER, V54, P1062, DOI 10.1002/1097-0142(19840915)54:6<1062::AID-CNCR2820540622>3.0.CO;2-E; TELLECHEA O, 1993, AM J DERMATOPATH, V15, P452, DOI 10.1097/00000372-199310000-00007; Terada T, 2013, INT J CLIN EXP PATHO, V6, P932; Varga M, 2004, CLIN CANCER RES, V10, P3131, DOI 10.1158/1078-0432.CCR-03-0528; Vila L, 2009, MODERN PATHOL, V22, P1296, DOI 10.1038/modpathol.2009.95; Warneke VS, 2013, BRIT J CANCER, V109, P2217, DOI 10.1038/bjc.2013.536; Went P, 2006, BRIT J CANCER, V94, P128, DOI 10.1038/sj.bjc.6602924; Went P, 2005, AM J SURG PATHOL, V29, P83, DOI 10.1097/01.pas.0000.146028.70868.7a; Went PT, 2004, HUM PATHOL, V35, P122, DOI 10.1016/S0046-8177(03)00502-1; West RB, 2011, AM J SURG PATHOL, V35, P92, DOI 10.1097/PAS.0b013e3182002777; Xia YC, 2014, ONCOL LETT, V8, P1670, DOI 10.3892/ol.2014.2400; Xie X, 2005, WORLD J GASTROENTERO, V11, P344, DOI 10.3748/wjg.v11.i3.344; Zeidler R, 1999, J IMMUNOL, V163, P1246; Zhu SB, 2015, ARCH PATHOL LAB MED, V139, P55, DOI 10.5858/arpa.2014-0167-RA	49	0	0	0	1	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0031-3025	1465-3931		PATHOLOGY	Pathology	DEC	2018	50	7					737	741		10.1016/j.pathol.2018.08.013			5	Pathology	Pathology	HC4PM	WOS:000451785700007	30389218	Other Gold			2019-10-28	
J	Co, M; Cheng, VCC; Wei, JN; Wong, SCY; Chan, SMS; Shek, T; Kwong, A				Co, Michael; Cheng, Vincent C. C.; Wei, Jiannan; Wong, Sally C. Y.; Chan, Sally M. S.; Shek, Tony; Kwong, Ava			Idiopathic granulomatous mastitis: a 10-year study from a multicentre clinical database	PATHOLOGY			English	Article						Mastitis; granuloma; Corynebacterium	CORYNEBACTERIUM-KROPPENSTEDTII; MANAGEMENT; DISEASE	Idiopathic granulomatous mastitis (IGM) is an uncommon, chronic inflammatory breast disease with elusive aetiology, simulating malignancy clinically and radiologically. Here we present our 10-year review on a region-wide multi-centre IGM database. A retrospective study was performed on a prospectively maintained database from three University affiliated hospitals in Hong Kong and Shenzhen, China. All patients with biopsy proven IGM were included while patients with positive culture of Mycobacterium tuberculosis were excluded. Disease recurrence rate and its prognosticators were evaluated. A total of 102 patients were included between January 2007 and December 2017. Median age was 33 years (range 20-54). Most patients presented with painful inflammatory mass (n = 57); median size at presentation was 37 mm (6-92 mm). Sixty-three patients had bacterial culture performed on the pus sample: eight patients had Corynebacterium kroppenstedtii while four had Corynebacterium species not otherwise specified. Seventy-seven (75.5%) patients received conservative treatment with oral cortico-steroid (+/- antibiotics) and drainage only, while 25 (24.5%) patients received breast lump excision after initial medical treatment. Twelve (11.8%) patients developed recurrence after a median follow-up interval of 14 months (4-51 months). Univariate analysis revealed that abscess on presentation, history of smoking, and presence of C. kroppenstedtii were significant prognosticators for recurrence. Subsequent multivariate analysis with logistic regression revealed cigarette smoking and isolation of C. kroppenstedtii as independent risk factors for disease recurrence (p < 0.05). In conclusion, IGM is uncommon with a recurrence rate of 12%, especially in patients with history of smoking and isolation of C. kroppenstedtii.	[Co, Michael; Kwong, Ava] Queen Mary Hosp, Dept Surg, Hong Kong, Hong Kong, Peoples R China; [Co, Michael; Chan, Sally M. S.; Kwong, Ava] Univ Hong Kong, Dept Surg, Hong Kong, Hong Kong, Peoples R China; [Cheng, Vincent C. C.; Wong, Sally C. Y.] Queen Mary Hosp, Dept Microbiol, Hong Kong, Hong Kong, Peoples R China; [Wei, Jiannan] Univ Hong Kong, Dept Surg, Shenzhen Hosp, Shenzhen, Peoples R China; [Shek, Tony] Queen Mary Hosp, Dept Pathol, Hong Kong, Hong Kong, Peoples R China	Kwong, A (reprint author), Univ Hong Kong, Queen Mary Hosp, Dept Surg, K1401, Hong Kong, Hong Kong, Peoples R China.	avakwong@hku.hk	Kwong, Ava/D-8005-2013	Kwong, Ava/0000-0002-6968-9489; CO, MICHAEL/0000-0002-1705-051X			Akbulut S, 2011, ARCH GYNECOL OBSTET, V284, P1189, DOI 10.1007/s00404-010-1825-2; Akcan A, 2006, WORLD J SURG, V30, P1403, DOI 10.1007/s00268-005-0476-0; Altintoprak F, 2015, WORLD J SURG, V39, P2718, DOI 10.1007/s00268-015-3147-9; Asoglu O, 2005, BREAST J, V11, P108, DOI 10.1111/j.1075-122X.2005.21576.x; Bani-Hani Kamal E, 2004, Breast J, V10, P318, DOI 10.1111/j.1075-122X.2004.21336.x; Baslaim MM, 2007, WORLD J SURG, V31, P1677, DOI 10.1007/s00268-007-9116-1; Bouton ME, 2015, AM J SURG, V210, P258, DOI 10.1016/j.amjsurg.2014.08.044; Collins MD, 1998, INT J SYST BACTERIOL, V48, P1449, DOI 10.1099/00207713-48-4-1449; DAVIES JD, 1983, J CLIN PATHOL, V36, P363, DOI 10.1136/jcp.36.3.363-a; DEHERTOGH DA, 1980, NEW ENGL J MED, V303, P799, DOI 10.1056/NEJM198010023031406; Dixon JM, 1996, BRIT J SURG, V83, P820, DOI 10.1002/bjs.1800830630; Fazzio RT, 2016, INSIGHTS IMAGING, V7, P531, DOI 10.1007/s13244-016-0499-0; GOING JJ, 1987, J CLIN PATHOL, V40, P535, DOI 10.1136/jcp.40.5.535; Gunduz Y, 2014, BREAST J, V20, P586, DOI 10.1111/tbj.12335; Hladik M, 2011, J PLAST RECONSTR AES, V64, P1604, DOI 10.1016/j.bjps.2011.07.011; KESSLER E, 1972, AM J CLIN PATHOL, V58, P642; Lai ECH, 2005, BREAST J, V11, P454, DOI 10.1111/j.1075-122X.2005.00127.x; Pandey TS, 2014, BREAST J, V20, P258, DOI 10.1111/tbj.12263; Riegel P, 2004, INT J MED MICROBIOL, V294, P413, DOI 10.1016/j.ijmm.2004.07.013; ROWE PH, 1984, BRIT J CLIN PRACT, V38, P32; SALAM IMA, 1995, BRIT J SURG, V82, P214; Schmajuk G, 2009, J RHEUMATOL, V36, P1559, DOI 10.3899/jrheum.090091; Sheybani F, 2015, OBSTET GYNECOL, V125, P801, DOI 10.1097/AOG.0000000000000734; Skandarajah A, 2015, ANZ J SURG, V85, P979, DOI 10.1111/ans.12929; Taghizadeh R, 2007, BREAST J, V13, P509, DOI 10.1111/j.1524-4741.2007.00474.x; Tauch A, 2008, J BIOTECHNOL, V136, P22, DOI 10.1016/j.jbiotec.2008.03.004; Tse GMK, 2004, PATHOLOGY, V36, P254, DOI 10.1080/00313020410001692602; Wilson JP, 2007, AM SURGEON, V73, P798; Wong SCY, 2018, J CLIN PATHOL, V71, P781, DOI 10.1136/jclinpath-2017-204834	29	4	4	2	3	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0031-3025	1465-3931		PATHOLOGY	Pathology	DEC	2018	50	7					742	747		10.1016/j.pathol.2018.08.010			6	Pathology	Pathology	HC4PM	WOS:000451785700008	30389215				2019-10-28	
J	Henderson, A; Tan, E; McCarthy, KL; Paterson, DL				Henderson, A.; Tan, E.; McCarthy, K. L.; Paterson, D. L.			Activity of ceftolozane/tazobactam against a collection of Pseudomonas aeruginosa isolates from bloodstream infections in Australia	PATHOLOGY			English	Article						Ceftolozane/tazobactam; Pseudomonas aeruginosa; antimicrobial susceptibility testing	INITIAL ANTIMICROBIAL THERAPY; RESISTANCE; ENTEROBACTERIACEAE; TAZOBACTAM; MECHANISMS; SUSCEPTIBILITY; ETEST	Pseudomonas aeruginosa is a common pathogen causing nosocomial infection. In particular, bloodstream infection (BSI) is associated with a high rate of morbidity and mortality. Ceftolozane/tazobactam is a new beta-lactam/beta-lactamase antimicrobial with activity against P. aeruginosa as well as multidrug resistant (MDR) Gram negative Enterobacteriaceae. Ceftolozane/tazobactam has frequently been used in salvage therapy for MDR P. aeruginosa infections. The aim of this study was to determine the activity of ceftolozane/tazobactam against P. aeruginosa isolates from BSIs collected from three clinical microbiology laboratories in Queensland, Australia, with a high proportion of isolates demonstrating beta-lactam resistance. Antimicrobial susceptibility testing was performed by broth microdilution using custom made sensititre plates sourced from ThermoFisher Scientific. In addition to ceftolozane/tazobactam, we also tested piperacillin/tazobactam, ceftazidime, cefepime, meropenem, doripenem, imipenem, aztreonam, ciprofloxacin, levofloxacin, gentamicin, amikacin, tobramycin and colistin. Overall, ceftolozane/tazobactam was the most active agent tested [(MIC50/90 = 1/2 mu g/mL, 96% susceptible (S)]. Against 44 isolates with resistance to at least one other beta-lactam agent, 40 were susceptible to ceftolozane/tazobactam. Three ceftolozane/tazobactam resistant isolates were susceptible to colistin, with one of those isolates also susceptible to levofloxacin but not to any other antimicrobials tested. One ceftolozane/tazobactam resistant isolate was susceptible only to meropenem and doripenem but was non-susceptible to imipenem. An association was found between fluoroquinolone resistance and aminoglycoside resistance but not with beta-lactam resistance. In summary, ceftolozane/tazobactam was active against most strains tested, including those resistant to other beta-lactams. Laboratories should consider testing P. aeruginosa against ceftolozane/tazobactam in suspected MDR or extensively drug resistant (XDR) infections.	[Henderson, A.; Tan, E.; McCarthy, K. L.; Paterson, D. L.] Univ Queensland, UQ Ctr Clin Res, Brisbane, Qld, Australia; [Henderson, A.] Princess Alexandra Hosp, Infect Management Serv, Bldg 17,199 Ipswich Rd, Brisbane, Qld 4002, Australia	Henderson, A (reprint author), Princess Alexandra Hosp, Infect Management Serv, Bldg 17,199 Ipswich Rd, Brisbane, Qld 4002, Australia.	andrew@hendonet.com		Paterson, David/0000-0003-2079-4437; Henderson, Andrew/0000-0002-2149-0745	MSD; Study, Education, and Research Committee (SERC) of Pathology Queensland	Funding for purchasing of the Sensititre Plates from ThermoScientific was provided by MSD. Funding for consumables was provided for through a grant awarded by the Study, Education, and Research Committee (SERC) of Pathology Queensland. The authors state that there are no conflicts of interest to disclose.	Bonomo RA, 2006, CLIN INFECT DIS, V43, pS49, DOI 10.1086/504477; Cabot G, 2011, ANTIMICROB AGENTS CH, V55, P1906, DOI 10.1128/AAC.01645-10; Dantas RCC, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0176774; Cheong HS, 2008, EUR J CLIN MICROBIOL, V27, P1219, DOI 10.1007/s10096-008-0568-5; Clinical and Laboratory Standards Institute, 2018, M100 CLSI; El Zowalaty ME, 2016, POL J MICROBIOL, V65, P23, DOI 10.5604/17331331.1197272; EUCAST, BREAKP TABL INT MICS; Farrell DJ, 2013, ANTIMICROB AGENTS CH, V57, P6305, DOI 10.1128/AAC.01802-13; Flynt LK, 2017, J CLIN MICROBIOL, V55, P334, DOI 10.1128/JCM.01920-16; Fraile-Ribot PA, 2017, J ANTIMICROB CHEMOTH; Haidar G, 2017, CLIN INFECT DIS, V65, P110, DOI 10.1093/cid/cix182; Harbarth S, 2003, AM J MED, V115, P529, DOI 10.1016/S0002-9343(03)00505-9; Hocquet D, 2007, ANTIMICROB AGENTS CH, V51, P3531, DOI 10.1128/AAC.00503-07; Humphries RM, 2018, J CLIN MICROBIOL, V56, DOI 10.1128/JCM.01633-17; Caston JJ, 2017, ANTIMICROB AGENTS CH, V61, DOI 10.1128/AAC.02136-16; Karlowsky JA, 2017, BRAZ J INFECT DIS, V21, P343, DOI 10.1016/j.bjid.2017.03.006; MacVane SH, 2017, ANTIMICROB AGENTS CH, V61, DOI [10.1128/AAC.01183-17, 10.1128/AAC.01183]; Merchant S, 2018, J GLOB ANTIMICROB RE, V14, P33, DOI 10.1016/j.jgar.2018.02.005; Merck Sharpe & Dohme, 2016, ZYB CEFT TAZ PACK IN; Moya B, 2012, ANTIMICROB AGENTS CH, V56, P4771, DOI 10.1128/AAC.00680-12; Moya B, 2010, ANTIMICROB AGENTS CH, V54, P1213, DOI 10.1128/AAC.01104-09; Munita JM, 2017, CLIN INFECT DIS, V65, P158, DOI 10.1093/cid/cix014; Patel UC, 2016, INFECT DIS THER, V5, P73, DOI 10.1007/s40121-016-0104-3; Pfaller MA, 2017, J GLOB ANTIMICROB RE, V10, P186, DOI 10.1016/j.jgar.2017.05.025; Sader HS, 2014, J ANTIMICROB CHEMOTH, V69, P2713, DOI 10.1093/jac/dku184; Shortridge D, 2018, MICROB DRUG RESIST, V24, P563, DOI 10.1089/mdr.2017.0266; Simar S, 2017, OCHSNER J, V17, P239; Smith KP, 2017, J CLIN MICROBIOL, V55, P470, DOI 10.1128/JCM.02128-16; Zhanel GG, 2014, DRUGS, V74, P31, DOI 10.1007/s40265-013-0168-2	29	0	0	1	8	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0031-3025	1465-3931		PATHOLOGY	Pathology	DEC	2018	50	7					748	752		10.1016/j.pathol.2018.08.009			5	Pathology	Pathology	HC4PM	WOS:000451785700009	30392710				2019-10-28	
J	Morales, MPF; Hopprich, R; Wise, R; Shephard, L; Weldhagen, GF				Morales, Manuel Pastor Forero; Hopprich, Ryan; Wise, Rolf; Shephard, Lisa; Weldhagen, Gerhard F.			Cost-effective implementation of a custom MALDI-TOF library for the identification of South Australian Nocardia isolates	PATHOLOGY			English	Article						MALDI-TOF; Nocardia; laboratory implementation	DESORPTION IONIZATION-TIME; FLIGHT MASS-SPECTROMETRY; RAPID IDENTIFICATION; MS; MICROORGANISMS; MYCOBACTERIUM	Mass spectrometry plays a significant role in the routine identification of micro-organisms and provides the ability to incorporate newly found pathogens into the database in a cost-effective fashion. This work aims to highlight the role of mass spectrometry through improved identification of Nocardia species in a diagnostic clinical microbiology laboratory. Prior to this study we constructed a custom inhouse matrix-assisted laser desorption ionisation-time of flight (MALDI-TOF) library for Nocardia isolates consisting of isolates identified to the species level. Subsequently over a period of 5 years, we isolated a further 153 Nocardia clinical isolates, of which 91.5% (140/153) were identified correctly with the custom MALDI-TOF library and 8.5% (13/153) needed further molecular sequencing for final identification. We estimate our cost savings to be approximately 9,800 AUD overall with this implementation over the study period. Continued expansion and maintenance of this custom library will eventually result in little or no 16S ribosomal DNA sequencing needed for specific identification of Nocardia isolates.	[Morales, Manuel Pastor Forero; Hopprich, Ryan; Wise, Rolf; Shephard, Lisa; Weldhagen, Gerhard F.] SA Pathol, Dept Microbiol & Infect Dis, 1 Frome Rd, Adelaide, SA 5000, Australia	Morales, MPF (reprint author), SA Pathol, Dept Microbiol & Infect Dis, 1 Frome Rd, Adelaide, SA 5000, Australia.	Manuel.Morales@sa.gov.au			SA Pathology	This study was internally funded by SA Pathology. The authors state that there are no conflicts of interest to disclose.	Agterof MJ, 2007, NETH J MED, V65, P199; Almeida LA, 2013, INFECT GENET EVOL, V13, P67, DOI 10.1016/j.meegid.2012.08.011; Ambrosioni J, 2010, INFECTION, V38, P89, DOI 10.1007/s15010-009-9193-9; Blosser SJ, 2016, J CLIN MICROBIOL, V54, P1251, DOI 10.1128/JCM.02942-15; Brown-Elliott BA, 2006, CLIN MICROBIOL REV, V19, P259, DOI 10.1128/CMR.19.2.259-282.2006; Buckwalter SP, 2016, J CLIN MICROBIOL, V54, P376, DOI 10.1128/JCM.02128-15; Cloud JL, 2004, J CLIN MICROBIOL, V42, P578, DOI 10.1128/JCM.42.2.578-584.2004; Cloud JL, 2011, US CLIN LAB CASES MY; Conville PS, 2006, J CLIN MICROBIOL, V44, P2760, DOI 10.1128/JCM.00155-06; Conville PS, 2018, J CLIN MICROBIOL, V56, DOI 10.1128/JCM.01419-17; El-Bouri K, 2012, BRIT J BIOMED SCI, V69, P47; Fryer AA, 2013, J CLIN PATHOL, V66, P62, DOI 10.1136/jclinpath-2011-200524; Girard V, 2017, DIAGN MICR INFEC DIS, V87, P7, DOI 10.1016/j.diagmicrobio.2016.09.024; GOODFELLOW M, 1971, J GEN MICROBIOL, V69, P33, DOI 10.1099/00221287-69-1-33; Institute CaLS, 2008, INT CRIT ID BACT FUN; Jenkins SG, 2012, MAYO CLIN PROC, V87, P290, DOI 10.1016/j.mayocp.2012.01.007; Jorgensen J. H, 2015, MANUAL CLIN MICROBIO; Kong FR, 2010, J CLIN MICROBIOL, V48, P3928, DOI 10.1128/JCM.01113-10; Lartigue MF, 2013, INFECT GENET EVOL, V13, P230, DOI 10.1016/j.meegid.2012.10.012; Markin RS, 2000, CLIN CHEM, V46, P764; McTaggart LR, 2010, J CLIN MICROBIOL, V48, P4525, DOI 10.1128/JCM.00883-10; Saleeb PG, 2011, J CLIN MICROBIOL, V49, P1790, DOI 10.1128/JCM.02135-10; Totty H, 2016, J CLIN MICROBIOL, V54, P2626, DOI 10.1128/JCM.01096-16; Verroken A, 2010, J CLIN MICROBIOL, V48, P4015, DOI 10.1128/JCM.01234-10; WALLACE RJ, 1988, ANTIMICROB AGENTS CH, V32, P1776, DOI 10.1128/AAC.32.12.1776; Wattal C, 2017, EUR J CLIN MICROBIOL, V36, P807, DOI 10.1007/s10096-016-2864-9; Wauters G, 2005, J CLIN MICROBIOL, V43, P2624, DOI 10.1128/JCM.43.6.2624-2628.2005; Wieser A, 2012, APPL MICROBIOL BIOT, V93, P965, DOI 10.1007/s00253-011-3783-4; Wilson JW, 2012, MAYO CLIN PROC, V87, P403, DOI 10.1016/j.mayocp.2011.11.016; Xiao M, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0147487; Yarbrough ML, 2017, DIAGN MICR INFEC DIS, V89, P92, DOI 10.1016/j.diagmicrobio.2017.06.019	31	0	0	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0031-3025	1465-3931		PATHOLOGY	Pathology	DEC	2018	50	7					753	757		10.1016/j.pathol.2018.08.006			5	Pathology	Pathology	HC4PM	WOS:000451785700010	30482608				2019-10-28	
J	Madigan, VM; Sinickas, VG; Giltrap, D; Kyriakou, P; Ryan, K; Chan, HT; Clifford, V				Madigan, Victoria M.; Sinickas, Vincent G.; Giltrap, Dawn; Kyriakou, Peter; Ryan, Katherine; Chan, Hiu-Tat; Clifford, Vanessa			Health service impact of testing for respiratory pathogens using cartridge-based multiplex array versus molecular batch testing	PATHOLOGY			English	Article						Respiratory viruses; molecular virology; rapid diagnostics	RAPID DIAGNOSIS; TURNAROUND TIME; FILMARRAY RP; VIRAL PANEL; VIRUSES; MANAGEMENT; ASSAY; RVP	There is increasing demand for access to rapid microbiological testing, with a view to improving clinical outcomes. The possibility of rapid testing has been facilitated by development of cartridge-based random access molecular technologies that are now widely available. Whether the expense of cartridge-based assays is justified in terms of clinical or laboratory cost savings is controversial. This prospective study evaluated the impact of the Biofire FilmArray Respiratory Panel ('FilmArray'), a cartridge-based random access molecular test, compared with standard batched molecular testing using an 'in-house' respiratory polymerase chain reaction (PCR) on laboratory and health service outcomes for adult patients at a tertiary-level adult hospital in Melbourne, Australia. Laboratory result turnaround time was significantly reduced with the FilmArray (median 4.4 h) compared to a standard validated in-house respiratory PCR assay (median 21.6 h, p < 0.0001) and there was a significant increase in diagnostic yield with the Filmarray (71/124, 57.3%) compared to in-house PCR (79/200; 39.5%; p = 0.002). Despite improved result turnaround time and increased diagnostic yield from testing, there was no corresponding reduction in hospital length of stay or use of isolation beds. Although cartridge-based molecular testing reduced turnaround time to result for respiratory pathogen testing, it did not impact on health service outcomes such as hospital length of stay. Further work is warranted to determine whether cartridge-based tests at the point of care can improve clinical and health service impacts.	[Madigan, Victoria M.; Sinickas, Vincent G.; Giltrap, Dawn; Kyriakou, Peter; Ryan, Katherine; Chan, Hiu-Tat; Clifford, Vanessa] Royal Melbourne Hosp, Dept Microbiol, Melbourne, Vic, Australia; [Clifford, Vanessa] Univ Melbourne, Melbourne, Vic, Australia; [Clifford, Vanessa] Murdoch Childrens Res Inst, Parkville, Vic, Australia	Sinickas, VG (reprint author), Royal Melbourne Hosp, Dept Microbiol, Grattan St, Parkville, Vic 3050, Australia.	Victoria.Madigan@mh.org.au		Clifford, Vanessa/0000-0001-9758-867X	Victor Hurley Research grant in aid through the Royal Melbourne Hospital, Parkville, Australia	This study was supported by a Victor Hurley Research grant in aid through the Royal Melbourne Hospital, Parkville, Australia. The authors state that there are no conflicts of interest to disclose.	Babady NE, 2013, EXPERT REV MOL DIAGN, V13, P779, DOI 10.1586/14737159.2013.848794; Babady NE, 2012, J CLIN MICROBIOL, V50, P2282, DOI 10.1128/JCM.06186-11; Binnicker MJ, 2015, J CLIN MICROBIOL, V53, P3723, DOI 10.1128/JCM.02103-15; Bonner AB, 2003, PEDIATRICS, V112, P363, DOI 10.1542/peds.112.2.363; Brendish NJ, 2017, LANCET RESP MED, V5, P401, DOI [10.1016/S2213-2600(17)30120-0, 10.1016/s2213-2600(17)30120-0]; Falsey AR, 2007, ARCH INTERN MED, V167, P354, DOI 10.1001/archinte.167.4.ioi60207; Green DA, 2016, J CLIN MICROBIOL, V54, P2950, DOI 10.1128/JCM.01579-16; Mayer LM, 2017, PNEUMONIA, V9, DOI 10.1186/s41479-017-0028-z; McCulloh RJ, 2014, J PEDIAT INF DIS SOC, V3, P146, DOI 10.1093/jpids/pit073; Mills JM, 2011, J HOSP INFECT, V77, P248, DOI 10.1016/j.jhin.2010.11.019; Pettit NN, 2015, J MED MICROBIOL, V64, P312, DOI 10.1099/jmm.0.000007; Popowitch EB, 2013, J CLIN MICROBIOL, V51, P1528, DOI 10.1128/JCM.03368-12; Rand KH, 2015, DIAGN MICR INFEC DIS, V82, P154, DOI 10.1016/j.diagmicrobio.2015.01.007; Rappo U, 2016, J CLIN MICROBIOL, V54, P2096, DOI 10.1128/JCM.00549-16; Rogers BB, 2015, ARCH PATHOL LAB MED, V139, P636, DOI 10.5858/arpa.2014-0257-OA; Subramony A, 2016, J PEDIATR-US, V173, P196, DOI 10.1016/j.jpeds.2016.02.050; Xu M, 2013, AM J CLIN PATHOL, V139, P118, DOI 10.1309/AJCPH7X3NLYZPHBW	17	0	0	1	1	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0031-3025	1465-3931		PATHOLOGY	Pathology	DEC	2018	50	7					758	763		10.1016/j.pathol.2018.08.012			6	Pathology	Pathology	HC4PM	WOS:000451785700011	30389216				2019-10-28	
J	Crowe, A; Brenton, L; Kingston, M; Jardine, D; Waters, MJ				Crowe, Amy; Brenton, Lisa; Kingston, Mikayla; Jardine, Darren; Waters, Mary Jo			Comparison of the carbapenem inactivation method (CIM) and modified carbapenem inactivation method (mCIM) for the detection of carbapenemase-producing organisms	PATHOLOGY			English	Letter							PERFORMANCE; TESTS		[Crowe, Amy; Brenton, Lisa; Kingston, Mikayla; Jardine, Darren; Waters, Mary Jo] St Vincents Pathol, Dept Microbiol, Melbourne, Vic, Australia	Crowe, A (reprint author), St Vincents Pathol, Dept Microbiol, Melbourne, Vic, Australia.	amy.crowe@svha.org.au					Aguirre-Quinonero A, 2017, DIAGN MICR INFEC DIS, V88, P214, DOI 10.1016/j.diagmicrobio.2017.03.009; Aktas E, 2017, MICROB DRUG RESIST, V23, P457, DOI 10.1089/mdr.2016.0092; Chang LWK, 2015, INTERN MED J, V45, P1037, DOI 10.1111/imj.12863; CLSI-Clinical and Laboratory Standards Institute, 2017, PERF STAND ANT SUSC; Gauthier L, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0170769; Madkour LA, 2017, J GLOB ANTIMICROB RE, V9, P10, DOI 10.1016/j.jgar.2016.12.015; Miller SA, 2017, J CLIN MICROBIOL, V55, P1827, DOI 10.1128/JCM.00157-17; Nordmann P, 2012, EMERG INFECT DIS, V18, P1503, DOI 10.3201/eid1809.120355; Pierce VM, 2017, J CLIN MICROBIOL, V55, P2321, DOI 10.1128/JCM.00193-17; Tijet N, 2016, J ANTIMICROB CHEMOTH, V71, P274, DOI 10.1093/jac/dkv283; van der Zwaluw K, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0123690; Viau R, 2016, CLIN MICROBIOL REV, V29, P1, DOI 10.1128/CMR.00108-14; Yildiz SS, 2017, ACTA MICROBIOL IMM H, V64, P9, DOI 10.1556/030.64.2017.009	13	1	1	1	4	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0031-3025	1465-3931		PATHOLOGY	Pathology	DEC	2018	50	7					764	766		10.1016/j.pathol.2018.05.009			3	Pathology	Pathology	HC4PM	WOS:000451785700012	30262183				2019-10-28	
J	Armstrong, B; Wehrhahn, MC				Armstrong, Benjamin; Wehrhahn, Michael C.			Low additional yield from prolonged culture of urine and differential detection of Actinotignum schaalii in a private laboratory setting	PATHOLOGY			English	Letter							FORMERLY ACTINOBACULUM-SCHAALII		[Armstrong, Benjamin; Wehrhahn, Michael C.] Douglass Hanly Moir Pathol, Dept Microbiol, Macquarie Pk, NSW, Australia	Armstrong, B (reprint author), Douglass Hanly Moir Pathol, Dept Microbiol, Macquarie Pk, NSW, Australia.	benharmstrong@gmail.com	Wehrhahn, Michael/M-5928-2019				Bank S, 2010, EMERG INFECT DIS, V16, P76, DOI 10.3201/eid1601.090761; Lawson PA, 1997, INT J SYST BACTERIOL, V47, P899, DOI 10.1099/00207713-47-3-899; Lotte R, 2016, CLIN MICROBIOL INFEC, V22, P28, DOI 10.1016/j.cmi.2015.10.038; Stevens RP, 2016, PATHOLOGY, V48, P367, DOI 10.1016/j.pathol.2016.03.006	4	0	0	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0031-3025	1465-3931		PATHOLOGY	Pathology	DEC	2018	50	7					766	767		10.1016/j.pathol.2018.08.002			3	Pathology	Pathology	HC4PM	WOS:000451785700013	30318165				2019-10-28	
J	Choy, KW; Wijeratne, N; Doery, J; Lam, M				Choy, Kay Weng; Wijeratne, Nilika; Doery, James; Lam, Matthew			An undetectable serum prealbumin measurement led to a diagnosis of monoclonal gammopathy: two cases of spurious results in the setting of paraproteinaemia	PATHOLOGY			English	Letter							INTERFERENCE		[Choy, Kay Weng; Wijeratne, Nilika; Doery, James; Lam, Matthew] Monash Hlth, Monash Pathol, Clayton, Vic, Australia; [Wijeratne, Nilika] Dorevitch Pathol, Heidelberg, Vic, Australia; [Wijeratne, Nilika] Monash Univ, Dept Med, Fac Med Nursing & Hlth Sci, Clayton, Vic, Australia	Choy, KW (reprint author), Monash Hlth, Monash Pathol, Clayton, Vic, Australia.	kayweng.choy@gmail.com		Wijeratne, Nilika/0000-0003-4214-5868			Dimeski G, 2015, BIOCHEM MEDICA, V25, P117, DOI 10.11613/BM.2015.014; King RI, 2010, PATHOLOGY, V42, P397, DOI 10.3109/00313025.2010.493868; Langman LJ, 1998, CLIN BIOCHEM, V31, P517, DOI 10.1016/S0009-9120(98)00064-2; Mockli GC, 1998, CLIN CHEM, V44, P190; Sia RSP, 1921, CHINA MED J, V35, P527; Smogorzewska A, 2004, CLIN CHEM, V50, P1691, DOI 10.1373/clinchem.2004.037499; Wong SL, 2017, J APPL LAB MED, V1, P745	7	0	0	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0031-3025	1465-3931		PATHOLOGY	Pathology	DEC	2018	50	7					767	769		10.1016/j.pathol.2018.04.007			4	Pathology	Pathology	HC4PM	WOS:000451785700014	30249449				2019-10-28	
J	Choy, KW				Choy, Kay Weng			A new hypoglycaemia pack has revolutionised hypoglycaemia investigations in infants and children	PATHOLOGY			English	Letter									[Choy, Kay Weng] Monash Hlth, Clayton, Vic, Australia	Choy, KW (reprint author), Monash Hlth, Clayton, Vic, Australia.	kayweng.choy@gmail.com					[Anonymous], 2011, GUIDELINES INVESTIGA; Lang TF, 2008, ANN CLIN BIOCHEM, V45, P486, DOI 10.1258/acb.2008.008037; Lang TF, 2011, ANN CLIN BIOCHEM, V48, P200, DOI 10.1258/acb.2011.011012; Shetty AK, 1999, PEDIATR EMERG CARE, V15, P399, DOI 10.1097/00006565-199912000-00006	4	0	0	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0031-3025	1465-3931		PATHOLOGY	Pathology	DEC	2018	50	7					769	773		10.1016/j.pathol.2018.06.004			6	Pathology	Pathology	HC4PM	WOS:000451785700015	30314648				2019-10-28	
J	Blennerhassett, R; McCaughan, G; Tegg, E				Blennerhassett, Richard; McCaughan, Georgia; Tegg, Elizabeth			An unexpected diagnosis: leukaemic presentation of blastic plasmacytoid dendritic cell neoplasm with massive splenomegaly	PATHOLOGY			English	Letter							SERIES		[Blennerhassett, Richard; McCaughan, Georgia; Tegg, Elizabeth] Westmead Hosp, Dept Haematol, Westmead, NSW, Australia; [Blennerhassett, Richard; McCaughan, Georgia; Tegg, Elizabeth] Univ Sydney, Sydney Med Sch, Sydney, NSW, Australia	Blennerhassett, R (reprint author), Westmead Hosp, Dept Haematol, Westmead, NSW, Australia.; Blennerhassett, R (reprint author), Univ Sydney, Sydney Med Sch, Sydney, NSW, Australia.	rblenner@gmail.com					BRODY JP, 1995, CANCER, V75, P2474, DOI 10.1002/1097-0142(19950515)75:10<2474::AID-CNCR2820751013>3.0.CO;2-Y; Feuillard J, 2002, BLOOD, V99, P1556, DOI 10.1182/blood.V99.5.1556; Julia F, 2014, AM J SURG PATHOL, V38, P673, DOI 10.1097/PAS.0000000000000156; Pagano L, 2013, HAEMATOLOGICA, V98, P239, DOI 10.3324/haematol.2012.072645; Rauh MJ, 2012, LEUKEMIA RES, V36, P81, DOI 10.1016/j.leukres.2011.07.033; Swerdlow SH, 2017, WHO CLASSIFICATION T, V2, P174; Tsagarakis NJ, 2010, LEUKEMIA RES, V34, P438, DOI 10.1016/j.leukres.2009.09.006	7	0	0	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0031-3025	1465-3931		PATHOLOGY	Pathology	DEC	2018	50	7					773	775		10.1016/j.pathol.2018.05.007			4	Pathology	Pathology	HC4PM	WOS:000451785700016	30274817				2019-10-28	
J	Forsyth, C; Melville, K; Tiley, C				Forsyth, Cecily; Melville, Kathleen; Tiley, Campbell			The delayed diagnosis of myeloproliferative neoplasms is common and results in a high incidence of potentially preventable thrombotic complications	PATHOLOGY			English	Letter									[Forsyth, Cecily] Wyong Hosp, Hamlyn Terrace, NSW, Australia; [Melville, Kathleen; Tiley, Campbell] Gosford Hosp, Gosford, NSW, Australia; [Melville, Kathleen] Calvary Mater Newcastle, Waratah, NSW, Australia	Forsyth, C (reprint author), Wyong Hosp, Hamlyn Terrace, NSW, Australia.	cecily.forsyth@healthemail.com.au		Tiley, Campbell/0000-0002-4314-0877			Barbui T, 2013, BLOOD, V122, P2176, DOI 10.1182/blood-2013-03-460154; Elliott MA, 2005, BRIT J HAEMATOL, V128, P275, DOI 10.1111/j.1365-2141.2004.05277.x; Elliott MA, 2010, HAEMATOL-HEMATOL J, V95, P1788, DOI 10.3324/haematol.2010.025064; Mesa RA, 2017, J NATL COMPR CANC NE, V15, P1193, DOI 10.6004/jnccn.2017.0157	4	1	1	0	1	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0031-3025	1465-3931		PATHOLOGY	Pathology	DEC	2018	50	7					775	776		10.1016/j.pathol.2018.05.010			2	Pathology	Pathology	HC4PM	WOS:000451785700017	30262184				2019-10-28	
J	Tomlinson, R; Yaxley, J				Tomlinson, Ross; Yaxley, Julian			Thrombotic thrombocytopenic purpura associated with Hodgkin lymphoma and non-Hodgkin lymphoma	PATHOLOGY			English	Letter									[Tomlinson, Ross; Yaxley, Julian] Sunshine Coast Univ Hosp, Birtinya, Qld, Australia; [Tomlinson, Ross] QML Pathol, Murrarie, Qld, Australia	Tomlinson, R (reprint author), Sunshine Coast Univ Hosp, Birtinya, Qld, Australia.; Tomlinson, R (reprint author), QML Pathol, Murrarie, Qld, Australia.	rossmtomlinson@gmail.com					CAREY RW, 1989, CANCER, V63, P1393, DOI 10.1002/1097-0142(19890401)63:7<1393::AID-CNCR2820630726>3.0.CO;2-X; Chao JH, 2013, BLOOD, V122, DOI 10.1182/blood.V122.21.5050.5050; CRAIN SM, 1980, AM J MED SCI, V280, P35, DOI 10.1097/00000441-198007000-00006; DUMOULINLAGRANGE M, 1983, NOUV REV FR HEMATOL, V25, P275; Francis KK, 2007, ONCOLOGIST, V12, P11, DOI 10.1634/theoncologist.12-1-11; GENEREAU T, 1994, ANN MED INTERNE, V145, P365; Hurtado-Cordovi J, 2011, CASE REP HEMATOL, DOI 10.1155/2011/385408; Saitoh T, 2008, CLIN LYMPHOMA MYELOM, V8, P62, DOI 10.3816/CLM.2008.n.007	8	0	0	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0031-3025	1465-3931		PATHOLOGY	Pathology	DEC	2018	50	7					776	777		10.1016/j.pathol.2018.05.011			2	Pathology	Pathology	HC4PM	WOS:000451785700018	30314645				2019-10-28	
J	Squires, L; Matsika, A; Turner, J; Fitness, J; Lourie, R				Squires, Lisa; Matsika, Admire; Turner, Jessica; Fitness, Jodie; Lourie, Rohan			ALK-rearranged inflammatory myofibroblastic tumour of placental membranes	PATHOLOGY			English	Letter							SITE		[Squires, Lisa; Matsika, Admire; Fitness, Jodie; Lourie, Rohan] Mater Hlth Serv, Mater Pathol, South Brisbane, Qld, Australia; [Squires, Lisa] Royal Brisbane & Womens Hosp, Pathol Queensland, Herston, Qld, Australia; [Squires, Lisa; Matsika, Admire] Univ Queensland, Dept Mol & Cellular Pathol, Fac Med, Brisbane, Qld, Australia; [Turner, Jessica] Mater Hlth Serv, Obstet & Gynaecol Dept, South Brisbane, Qld, Australia	Squires, L (reprint author), Mater Hlth Serv, Mater Pathol, South Brisbane, Qld, Australia.; Squires, L (reprint author), Royal Brisbane & Womens Hosp, Pathol Queensland, Herston, Qld, Australia.; Squires, L (reprint author), Univ Queensland, Dept Mol & Cellular Pathol, Fac Med, Brisbane, Qld, Australia.	lisa.squires@health.qld.gov.au	; Turner, Jessica/X-7920-2018	Matsika, Admire/0000-0002-4418-7394; Turner, Jessica/0000-0003-1224-7046; Lourie, Rohan/0000-0002-0093-911X			Banet N, 2015, INT J GYNECOL PATHOL, V34, P419, DOI 10.1097/PGP.0000000000000175; Bennett JA, 2017, MODERN PATHOL, V30, P1489, DOI 10.1038/modpathol.2017.69; Can NTT, 2013, INT J GYNECOL PATHOL, V32, P516, DOI 10.1097/PGP.0b013e3182763178; Ladwig NR, 2018, AM J SURG PATHOL, V42, P807, DOI 10.1097/PAS.0000000000001044; Schoolmeester JK, 2017, INT J GYNECOL PATHOL, V36, P228, DOI 10.1097/PGP.0000000000000323	5	0	0	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0031-3025	1465-3931		PATHOLOGY	Pathology	DEC	2018	50	7					777	779		10.1016/j.pathol.2018.05.008			4	Pathology	Pathology	HC4PM	WOS:000451785700019	30262185				2019-10-28	
J	Chuah, KL; Pang, B; Lim, D; Lee, CK; Chau, CYP				Chuah, Khoon Leong; Pang, Brendan; Lim, Diana; Lee, Chi Kuen; Chau, Cora Yuk-Ping			Combined hepatocellular carcinoma and high grade neuroendocrine carcinoma with EWSR1 gene rearrangement	PATHOLOGY			English	Letter							SOFT-TISSUE TUMORS; LIVER		[Chuah, Khoon Leong; Chau, Cora Yuk-Ping] Tan Tock Seng Hosp, Dept Pathol, Singapore, Singapore; [Pang, Brendan; Lim, Diana; Lee, Chi Kuen] Natl Univ Hlth Syst, Dept Pathol, Singapore, Singapore	Chuah, KL (reprint author), Tan Tock Seng Hosp, Dept Pathol, Singapore, Singapore.	gzzckl@singnet.com.sg					Baker E, 2016, AM SURGEON, V82, P1121; BARSKY SH, 1984, HUM PATHOL, V15, P892, DOI 10.1016/S0046-8177(84)80152-5; Fisher C, 2014, HISTOPATHOLOGY, V64, P134, DOI 10.1111/his.12269; Garcia MT, 2006, VIRCHOWS ARCH, V449, P376, DOI 10.1007/s00428-006-0251-0; Guo Y, 2011, AM J SURG PATHOL, V35, P799, DOI 10.1097/PAS.0b013e318219c036; Nishino H, 2016, CLIN J GASTROENTEROL, V9, P272, DOI 10.1007/s12328-016-0669-0; Rekhtman N, 2010, ARCH PATHOL LAB MED, V134, P1628, DOI 10.1043/2009-0583-RAR.1; Scarpa A, 2017, NATURE, V543, P65, DOI 10.1038/nature21063; Vargas AC, 2016, HISTOPATHOLOGY, V69, P1000, DOI 10.1111/his.13031; Zhao ZM, 2018, BMC CLIN PATHOL, V18, DOI 10.1186/s12907-018-0070-7	10	0	0	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0031-3025	1465-3931		PATHOLOGY	Pathology	DEC	2018	50	7					779	782		10.1016/j.pathol.2018.07.005			5	Pathology	Pathology	HC4PM	WOS:000451785700020	30314647				2019-10-28	
J	Wilsher, MJ				Wilsher, Mark J.			Unexpected histological appearance of breast implant associated fibrous pseudocapsules	PATHOLOGY			English	Letter							RECONSTRUCTION; RISK		[Wilsher, Mark J.] Unilabs IHS, London, England	Wilsher, MJ (reprint author), Unilabs IHS, London, England.	markwilsher@gmail.com					BARR RJ, 1984, J AM ACAD DERMATOL, V10, P652, DOI 10.1016/S0190-9622(84)80273-X; Bohac M, 2018, EUR J HISTOCHEM, V62, P1, DOI 10.4081/ejh.2018.2873; Brinton LA, 2004, AM J EPIDEMIOL, V160, P619, DOI 10.1093/aje/kwh272; Bui JM, 2015, AESTHET PLAST SURG, V39, P306, DOI 10.1007/s00266-014-0439-7; Carruthers CA, 2015, TISSUE ENG PT A, V21, P35, DOI [10.1089/ten.tea.2014.0095, 10.1089/ten.TEA.2014.0095]; Cavallo JA, 2015, ANN PLAS SURG, V75, P74, DOI 10.1097/SAP.0000000000000538; COOPER NE, 1991, HISTOPATHOLOGY, V19, P193, DOI 10.1111/j.1365-2559.1991.tb00016.x; Coyne JD, 2005, J CLIN PATHOL, V58, P1290, DOI 10.1136/jcp.2004.023259; de Boer M, 2018, JAMA ONCOL, V4, P335, DOI 10.1001/jamaoncol.2017.4510; Heidemann LN, 2018, PRS-GLOB OPEN, V6, DOI 10.1097/GOX.0000000000001625; Iqbal FM, 2015, BMJ CASE REP, V2015; Lucke S, 2015, BIOMED RES INT, DOI 10.1155/2015/938059; Myckatyn TM, 2015, PLAST RECONSTR SURG, V135, p43E, DOI 10.1097/PRS.0000000000000807; Onesti MG, 2017, J PLAST RECONSTR AES, V70, P1527, DOI 10.1016/j.bjps.2017.06.023; Yu D, 2016, ANN PLAS SURG, V76, P485, DOI 10.1097/SAP.0000000000000368	15	0	0	2	3	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0031-3025	1465-3931		PATHOLOGY	Pathology	DEC	2018	50	7					782	785		10.1016/j.pathol.2018.05.012			5	Pathology	Pathology	HC4PM	WOS:000451785700021	30314643				2019-10-28	
J	Donkin, R; Dettrick, A; Wyche, P; Grigg, S				Donkin, Rebecca; Dettrick, Andrew; Wyche, Penelope; Grigg, Sarah			Atypical finding of meningothelial-like inclusions in cervical lymph nodes	PATHOLOGY			English	Letter							WHORLS; LIPOSARCOMA; NODULES; PATTERN		[Donkin, Rebecca] Univ Sunshine Coast, Sippy Downs, Qld, Australia; [Dettrick, Andrew; Wyche, Penelope; Grigg, Sarah] Sunshine Coast Univ Hosp, Birtinya, Qld, Australia	Dettrick, A (reprint author), Sunshine Coast Univ Hosp, Birtinya, Qld, Australia.	andrew.dettrick@health.qld.gov.au	Donkin, Rebecca/H-7523-2019	Donkin, Rebecca/0000-0003-1869-4461			Dermawan JK, 2018, HISTOPATHOLOGY, V72, P1067, DOI 10.1111/his.13458; Fanburg-Smith JC, 1998, HISTOPATHOLOGY, V33, P414, DOI 10.1046/j.1365-2559.1998.00536.x; GAFFEY MJ, 1988, AM J SURG PATHOL, V12, P167, DOI 10.1097/00000478-198803000-00001; Ionescu DN, 2003, LAB INVEST, V83, p308A; Kfoury H, 2012, KOREAN J PATHOL, V46, P87, DOI 10.4132/KoreanJPathol.2012.46.1.87; Kim SH, 2003, YONSEI MED J, V44, P392, DOI 10.3349/ymj.2003.44.3.392; Matsumoto T, 2005, HISTOPATHOLOGY, V46, P594, DOI 10.1111/j.1365-2559.2005.02022.x; Niho S, 1999, HUM PATHOL, V30, P425, DOI 10.1016/S0046-8177(99)90118-1; Santi R, 2010, PATHOL INT, V60, P62, DOI 10.1111/j.1440-1827.2009.02478.x; TORIKATA C, 1990, VIRCHOWS ARCH A, V417, P113, DOI 10.1007/BF02190528; Wang J, 2008, J CUTAN PATHOL, V35, P65, DOI 10.1111/j.1600-0560.2007.00963.x; Zamecnik M, 2007, PATHOL INT, V57, P632, DOI 10.1111/j.1440-1827.2007.02151.x	12	0	0	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0031-3025	1465-3931		PATHOLOGY	Pathology	DEC	2018	50	7					785	787		10.1016/j.pathol.2018.06.003			4	Pathology	Pathology	HC4PM	WOS:000451785700022	30352703				2019-10-28	
J	Sharma, M; Miyamoto, H				Sharma, Meenal; Miyamoto, Hiroshi			Prostatic adenocarcinoma with aberrant diffuse expression of high molecular weight cytokeratin	PATHOLOGY			English	Letter							P63		[Sharma, Meenal; Miyamoto, Hiroshi] Univ Rochester, Med Ctr, Dept Pathol & Lab Med, Rochester, NY 14642 USA; [Miyamoto, Hiroshi] Univ Rochester, Med Ctr, Dept Oncol, Rochester, NY 14642 USA; [Miyamoto, Hiroshi] Univ Rochester, Med Ctr, Dept Urol, Rochester, NY 14642 USA	Miyamoto, H (reprint author), Univ Rochester, Med Ctr, Dept Pathol & Lab Med, Rochester, NY 14642 USA.; Miyamoto, H (reprint author), Univ Rochester, Med Ctr, Dept Oncol, Rochester, NY 14642 USA.; Miyamoto, H (reprint author), Univ Rochester, Med Ctr, Dept Urol, Rochester, NY 14642 USA.	hiroshi_miyamoto@urmc.rochester.edu		Miyamoto, Hiroshi/0000-0001-7610-7769			Ali TZ, 2008, AM J SURG PATHOL, V32, P1890, DOI 10.1097/PAS.0b013e31817ce994; Epstein JI, 2014, AM J SURG PATHOL, V38, pE6, DOI 10.1097/PAS.0000000000000238; Googe PB, 1997, AM J CLIN PATHOL, V107, P219, DOI 10.1093/ajcp/107.2.219; Oliai BR, 2002, AM J SURG PATHOL, V26, P1151, DOI 10.1097/01.PAS.0000024540.83286.D7; Osunkoya AO, 2008, AM J SURG PATHOL, V32, P461, DOI 10.1097/PAS.0b013e318157020e; Tani HL, 2015, MODERN PATHOL, V28, P446, DOI 10.1038/modpathol.2014.115; Yang XMJ, 1999, AM J SURG PATHOL, V23, P147, DOI 10.1097/00000478-199902000-00002	7	0	0	1	1	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0031-3025	1465-3931		PATHOLOGY	Pathology	DEC	2018	50	7					787	789		10.1016/j.pathol.2018.07.006			4	Pathology	Pathology	HC4PM	WOS:000451785700023	30342704				2019-10-28	
J	Jang, KY; Park, HS; Noh, SJ; Lee, H; Lee, MR				Jang, Kyu Yun; Park, Ho Sung; Noh, Sang Jae; Lee, Ho; Lee, Min Ro			Adenocarcinoma ex-goblet cell carcinoid of the ascending colon concurrent with conventional adenocarcinoma	PATHOLOGY			English	Letter							PATHOLOGICAL CLASSIFICATION; CLINICAL BEHAVIOR; TUMORS; APPENDIX; SPECTRUM		[Jang, Kyu Yun; Park, Ho Sung] Chonbuk Natl Univ, Dept Pathol, Med Sch, Jeonju, South Korea; [Jang, Kyu Yun; Park, Ho Sung; Lee, Min Ro] Chonbuk Natl Univ, Chonbuk Natl Univ Hosp, Res Inst Clin Med, Biomed Res Inst, Jeonju, South Korea; [Jang, Kyu Yun; Park, Ho Sung] Chonbuk Natl Univ, Res Inst Endocrine Sci, Jeonju, South Korea; [Noh, Sang Jae; Lee, Ho] Chonbuk Natl Univ, Med Sch, Dept Forens Med, Jeonju, South Korea; [Lee, Min Ro] Chonbuk Natl Univ, Med Sch, Dept Surg, Jeonju, South Korea	Park, HS (reprint author), Chonbuk Natl Univ, Dept Pathol, Med Sch, Jeonju, South Korea.; Park, HS (reprint author), Chonbuk Natl Univ, Chonbuk Natl Univ Hosp, Res Inst Clin Med, Biomed Res Inst, Jeonju, South Korea.; Park, HS (reprint author), Chonbuk Natl Univ, Res Inst Endocrine Sci, Jeonju, South Korea.	hspark@jbnu.ac.kr	NOH, SANG JAE/R-4395-2019	NOH, SANG JAE/0000-0002-7005-056X	Chonbuk National University; Medical Research Center Program through the National Research Foundation (NRF) - the Korean government (MSIP) [NRF-2017R1A5A2015061]	This work was supported by the research funds of Chonbuk National University in 2012, and by grants from the Medical Research Center Program (NRF-2017R1A5A2015061) through the National Research Foundation (NRF), which is funded by the Korean government (MSIP).	Albores-Saavedra J, 2009, AM J SURG PATHOL, V33, P1259, DOI 10.1097/PAS.0b013e3181a1b59e; BURKE AP, 1990, AM J CLIN PATHOL, V94, P27, DOI 10.1093/ajcp/94.1.27; GODDARD MJ, 1992, HISTOPATHOLOGY, V20, P345, DOI 10.1111/j.1365-2559.1992.tb00992.x; Gui XY, 2011, J SURG ONCOL, V103, P790, DOI 10.1002/jso.21863; McCusker ME, 2002, CANCER, V94, P3307, DOI 10.1002/cncr.10589; McGory ML, 2005, DIS COLON RECTUM, V48, P2264, DOI 10.1007/s10-005-0196-4; Reid MD, 2016, MODERN PATHOL, V29, P1243, DOI 10.1038/modpathol.2016.105; Taggart MW, 2015, ARCH PATHOL LAB MED, V139, P782, DOI 10.5858/arpa.2013-0047-OA; Tang LH, 2008, AM J SURG PATHOL, V32, P1429, DOI 10.1097/PAS.0b013e31817f1816; Toumpanakis C, 2007, DIS COLON RECTUM, V50, P315, DOI 10.1007/s10350-006-0762-4	10	0	0	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0031-3025	1465-3931		PATHOLOGY	Pathology	DEC	2018	50	7					789	792		10.1016/j.pathol.2018.06.005			5	Pathology	Pathology	HC4PM	WOS:000451785700024	30314646				2019-10-28	
J	Ravindran, P; Wiltshire, S; Das, K; Wilson, RB				Ravindran, P.; Wiltshire, S.; Das, K.; Wilson, R. B.			Vitamin C deficiency in an Australian cohort of metropolitan surgical patients (vol 50, pg 654, 2018)	PATHOLOGY			English	Correction																Ravindran P, 2018, PATHOLOGY, V50, P654, DOI 10.1016/j.pathol.2018.07.004	1	0	0	1	2	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0031-3025	1465-3931		PATHOLOGY	Pathology	DEC	2018	50	7					793	793		10.1016/j.pathol.2018.10.001			1	Pathology	Pathology	HC4PM	WOS:000451785700025					2019-10-28	
J	Matias-Guiu, X; Davidson, B; Lax, SF				Matias-Guiu, Xavier; Davidson, Ben; Lax, Sigurd F.			Can the classification of low-grade endometrial stromal tumors still be improved?	VIRCHOWS ARCHIV			English	Editorial Material							LIMITED INFILTRATION		[Matias-Guiu, Xavier] Hosp Arnau Vilanova, Dept Pathol, Lleida, Spain; [Matias-Guiu, Xavier] Univ Lleida, Hosp Univ Bellvitge, IRBLLEIDA, IDIBELL,CIBERONC, Lleida, Spain; [Davidson, Ben] Oslo Univ Hosp, Norwegian Radium Hosp, Dept Pathol, N-0310 Oslo, Norway; [Davidson, Ben] Univ Oslo, Inst Clin Med, Fac Med, N-0316 Oslo, Norway; [Lax, Sigurd F.] Hosp Graz Sued West, Dept Pathol, Goestingerstr 22, Graz, Austria; [Lax, Sigurd F.] Med Univ Graz, Auenbruggerpl 1, AT-8036 Graz, Austria	Matias-Guiu, X (reprint author), Hosp Arnau Vilanova, Dept Pathol, Lleida, Spain.; Matias-Guiu, X (reprint author), Univ Lleida, Hosp Univ Bellvitge, IRBLLEIDA, IDIBELL,CIBERONC, Lleida, Spain.	fjmatiasguiu.lleida.ics@gencat.cat	matias-guiu, xavier/C-3039-2009	matias-guiu, xavier/0000-0002-7201-6605			Dionigi A, 2002, AM J SURG PATHOL, V26, P567, DOI 10.1097/00000478-200205000-00003; Ferreira J, 2018, VIRCHOWS ARCH, V473, P665, DOI 10.1007/s00428-018-2470-6; Kim Kyu-Rae, 2005, Ann Diagn Pathol, V9, P57, DOI 10.1053/j.anndiagpath.2004.10.009; Nucci MR, 2016, MODERN PATHOL, V29, pS92, DOI 10.1038/modpathol.2015.140; Su TF, 2014, INT J SURG PATHOL, V22, P559, DOI 10.1177/1066896913506934	5	1	1	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0945-6317	1432-2307		VIRCHOWS ARCH	Virchows Arch.	DEC	2018	473	6					663	664		10.1007/s00428-018-2474-2			2	Pathology	Pathology	HC0IC	WOS:000451480700001	30367239	Bronze			2019-10-28	
J	Ferreira, J; Felix, A; Lennerz, JK; Oliva, E				Ferreira, Joana; Felix, Ana; Lennerz, Jochen K.; Oliva, Esther			Recent advances in the histological and molecular classification of endometrial stromal neoplasms	VIRCHOWS ARCHIV			English	Review						Endometrial stromal sarcoma; Uterus; Molecular; Sarcoma; Translocations	SMOOTH-MUSCLE TUMORS; OSSIFYING FIBROMYXOID TUMORS; INTERNAL TANDEM DUPLICATION; JAZF1-JJAZ1 GENE FUSION; CLEAR-CELL-SARCOMA; POLYMERASE CHAIN-REACTION; SEX CORD DIFFERENTIATION; IN-SITU HYBRIDIZATION; HIGH-GRADE; MESENCHYMAL TUMORS	This review addresses known features and recent developments in the histological, immunohistochemical, and molecular characterization of endometrial stromal neoplasms. We discuss the spectrum of these tumors, from the benign endometrial stromal nodule to low-grade endometrial stromal sarcoma to uterine undifferentiated sarcomas with a special emphasis on the expanding group of high-grade stromal sarcomas, recently added to the 2014 WHO classification, not only discussing the well-established YWHAE-FAM22 tumors but also two new groups, presenting with BCOR alterations including those with BCOR tandem internal duplications or NTRK fusions. It is likely that this high-grade category of endometrial stromal tumors will expand as increasing molecular data is available.	[Ferreira, Joana; Felix, Ana] Inst Portugues Oncol Francisco Gentil, Serv Anat Patol, Rua Prof Lima Basto, P-1099023 Lisbon, Portugal; [Ferreira, Joana; Felix, Ana] Univ Nova Lisboa CEDOC, Fac Ciencias Med, Lisbon, Portugal; [Lennerz, Jochen K.; Oliva, Esther] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA	Ferreira, J (reprint author), Inst Portugues Oncol Francisco Gentil, Serv Anat Patol, Rua Prof Lima Basto, P-1099023 Lisbon, Portugal.; Ferreira, J (reprint author), Univ Nova Lisboa CEDOC, Fac Ciencias Med, Lisbon, Portugal.	joanaferreira@gmail.com		Felix, Ana/0000-0002-2653-2262			Adegboyega PA, 2008, HUM PATHOL, V39, P1459, DOI 10.1016/j.humpath.2008.02.008; Aisagbonhi O, 2017, INT J GYNECOL PATHOL; Allen AJ, 2017, GYNECOL ONCOL REP, V20, P51, DOI 10.1016/j.gore.2017.03.002; Amant F, 2006, GYNECOL ONCOL, V103, P1137, DOI 10.1016/j.ygyno.2006.07.013; Amant F, 2011, ANTICANCER RES, V31, P2367; Antonescu CR, 2014, GENE CHROMOSOME CANC, V53, P183, DOI 10.1002/gcc.22132; Arias-Stella AJ, 2018, MOD PATHOL; Attygalle AD, 2017, INT J GYNECOL PATHOL, V36, P165, DOI 10.1097/PGP.0000000000000286; Baker PM, 2005, AM J SURG PATHOL, V29, P1394, DOI 10.1097/01.pas.0000172295.05527.28; Baker RJ, 1999, HUM PATHOL, V30, P671, DOI 10.1016/S0046-8177(99)90093-X; Busca A, 2018, INT J GYNECOL PATHOL, V37, P372, DOI 10.1097/PGP.0000000000000424; Caudell JJ, 2005, APPL IMMUNOHISTO M M, V13, P167, DOI 10.1097/01.pai.0000129057.38941.a1; CHANG KL, 1990, AM J SURG PATHOL, V14, P415, DOI 10.1097/00000478-199005000-00002; Chew I, 2010, ADV ANAT PATHOL, V17, P113, DOI 10.1097/PAP.0b013e3181cfb7c2; Chiang S, 2018, AM J SURG PATHOL, V42, P791, DOI 10.1097/PAS.0000000000001055; Chiang S, 2017, MODERN PATHOL, V30, P1251, DOI 10.1038/modpathol.2017.42; Chiang S, 2013, HISTOPATHOLOGY, V62, P124, DOI 10.1111/his.12048; Chiang S, 2011, AM J SURG PATHOL, V35, P1364, DOI 10.1097/PAS.0b013e3182262743; Chu PG, 2000, AM J CLIN PATHOL, V113, P374; Chu PG, 2001, MODERN PATHOL, V14, P465, DOI 10.1038/modpathol.3880335; CLEMENT PB, 1976, AM J CLIN PATHOL, V66, P512; CLEMENT PB, 1992, INT J GYNECOL PATHOL, V11, P163; Cossu-Rocca P, 2012, INT J GYNECOL PATHOL, V31, P570, DOI 10.1097/PGP.0b013e31824fe289; Croce S, 2013, MODERN PATHOL, V26, P1390, DOI 10.1038/modpathol.2013.69; D'Angelo E, 2013, AM J SURG PATHOL, V37, P514, DOI 10.1097/PAS.0b013e318272c612; DALCIN P, 1992, CANCER GENET CYTOGEN, V63, P43, DOI 10.1016/0165-4608(92)90062-D; Dewaele B, 2014, INT J CANCER, V134, P1112, DOI 10.1002/ijc.28440; Dionigi A, 2002, AM J SURG PATHOL, V26, P567, DOI 10.1097/00000478-200205000-00003; Endo M, 2013, HUM PATHOL, V44, P2603, DOI 10.1016/j.humpath.2013.04.003; ENZINGER FM, 1989, AM J SURG PATHOL, V13, P817, DOI 10.1097/00000478-198910000-00001; EVANS HL, 1982, CANCER-AM CANCER SOC, V50, P2170, DOI 10.1002/1097-0142(19821115)50:10<2170::AID-CNCR2820501033>3.0.CO;2-K; Fadare Oluwole, 2005, Ann Diagn Pathol, V9, P160, DOI 10.1016/j.anndiagpath.2005.03.002; FEKETE PS, 1984, INT J GYNECOL PATHOL, V3, P198, DOI 10.1097/00004347-198402000-00008; Flicker K, 2015, EXP MOL PATHOL, V98, P367, DOI 10.1016/j.yexmp.2015.03.009; FRANQUEMONT DW, 1991, AM J SURG PATHOL, V15, P861, DOI 10.1097/00000478-199109000-00006; Fukunaga M, 1997, PATHOL INT, V47, P412, DOI 10.1111/j.1440-1827.1997.tb04516.x; Garg G, 2010, GYNECOL ONCOL, V118, P8, DOI 10.1016/j.ygyno.2010.04.008; Gearhart MD, 2006, MOL CELL BIOL, V26, P6880, DOI 10.1128/MCB.00630-06; Gebre-Medhin S, 2012, AM J PATHOL, V181, P1069, DOI 10.1016/j.ajpath.2012.05.030; Ghetu AF, 2008, MOL CELL, V29, P384, DOI 10.1016/j.molcel.2007.12.026; Gil-Benso R, 1999, VIRCHOWS ARCH, V434, P307, DOI 10.1007/s004280050346; Graham RP, 2013, AM J SURG PATHOL, V37, P1751, DOI 10.1097/PAS.0b013e31829644b4; Gremel G, 2015, INT J CANCER, V136, P1608, DOI 10.1002/ijc.29141; Halbwedl I, 2005, GYNECOL ONCOL, V97, P582, DOI 10.1016/j.ygyno.2005.01.002; Hardell E, 2017, AM J SURG PATHOL, V41, P1231, DOI 10.1097/PAS.0000000000000894; Hemming ML, 2017, GYNECOL ONCOL, V145, P531, DOI 10.1016/j.ygyno.2017.03.021; Hoang LN, 2017, AM J SURG PATHOL, V41, P12, DOI 10.1097/PAS.0000000000000721; Horng HC, 2016, TAIWAN J OBSTET GYNE, V55, P472, DOI 10.1016/j.tjog.2016.04.034; Hrzenjak A, 2005, J MOL DIAGN, V7, P388, DOI 10.1016/S1525-1578(10)60568-5; Hrzenjak A, 2016, ORPHANET J RARE DIS, V11, DOI 10.1186/s13023-016-0400-8; Huang HY, 2004, AM J SURG PATHOL, V28, P224, DOI 10.1097/00000478-200402000-00010; Huynh KD, 2000, GENE DEV, V14, P1810; Irving JA, 2006, MODERN PATHOL, V19, P17, DOI 10.1038/modpathol.3800475; Isphording A, 2013, HUM PATHOL, V44, P837, DOI 10.1016/j.humpath.2012.08.007; Junco SE, 2013, STRUCTURE, V21, P665, DOI 10.1016/j.str.2013.02.013; Jung CK, 2008, MODERN PATHOL, V21, P756, DOI 10.1038/modpathol.2008.53; Kao YC, 2017, GENE CHROMOSOME CANC, V56, P42, DOI 10.1002/gcc.22400; Kao YC, 2016, AM J SURG PATHOL, V40, P1670, DOI 10.1097/PAS.0000000000000697; Kao YC, 2016, AM J SURG PATHOL, V40, P1009, DOI 10.1097/PAS.0000000000000629; KEMPSON RL, 1988, SEMIN DIAGN PATHOL, V5, P172; Khalifa MA, 1996, INT J GYNECOL PATHOL, V15, P171, DOI 10.1097/00004347-199604000-00013; Kibar Y, 2008, EUR J GYNAECOL ONCOL, V29, P397; Kim HS, 2015, INT J CLIN EXP PATHO, V8, P3316; Kim Yu-Hoon, 1996, Journal of Korean Medical Science, V11, P88; Klein WM, 2003, INT J GYNECOL PATHOL, V22, P181, DOI 10.1097/01.PGP.0000040026.16722.78; Koontz JI, 2001, P NATL ACAD SCI USA, V98, P6348, DOI 10.1073/pnas.101132598; Kurihara S, 2008, AM J SURG PATHOL, V32, P1228, DOI 10.1097/PAS.0b013e31816a3b42; Kurihara S, 2010, MODERN PATHOL, V23, P225, DOI 10.1038/modpathol.2009.162; Kurman RJ, 2014, WHO CLASSIFICATION F; Lee CH, 2015, HISTOPATHOLOGY, V67, P1, DOI 10.1111/his.12594; Lee CH, 2014, MODERN PATHOL, V27, P751, DOI 10.1038/modpathol.2013.199; Lee CH, 2012, AM J SURG PATHOL, V36, P1562, DOI 10.1097/PAS.0b013e31825fa931; Lee CH, 2012, AM J SURG PATHOL, V36, P641, DOI 10.1097/PAS.0b013e31824a7b1a; Lee CH, 2012, P NATL ACAD SCI USA, V109, P929, DOI 10.1073/pnas.1115528109; Lee CH, 2010, ADV ANAT PATHOL, V17, P222, DOI 10.1097/PAP.0b013e3181d973c2; Levine PH, 2001, INT J GYNECOL PATHOL, V20, P395, DOI 10.1097/00004347-200110000-00014; Lewis N, 2018, MODERN PATHOL, V31, P674, DOI 10.1038/modpathol.2017.162; Li H, 2008, SCIENCE, V321, P1357, DOI 10.1126/science.1156725; LIFSCHITZMERCER B, 1987, CANCER, V59, P1494, DOI 10.1002/1097-0142(19870415)59:8<1494::AID-CNCR2820590817>3.0.CO;2-V; LILLEMOE TJ, 1991, ARCH PATHOL LAB MED, V115, P215; LLORETA J, 1992, INT J GYNECOL PATHOL, V11, P293, DOI 10.1097/00004347-199210000-00008; Malpica A, 2006, MOD PATHOL; Marino-Enriquez A, 2018, AM J SURG PATHOL, V42, P335, DOI 10.1097/PAS.0000000000000993; McCluggage WG, 2008, INT J GYNECOL PATHOL, V27, P555, DOI 10.1097/PGP.0b013e31817a82f9; McCluggage WG, 2009, HISTOPATHOLOGY, V54, P365, DOI 10.1111/j.1365-2559.2009.03230.x; McCluggage WG, 2001, HISTOPATHOLOGY, V39, P273, DOI 10.1046/j.1365-2559.2001.01215.x; McCluggage WG, 1996, HISTOPATHOLOGY, V29, P369, DOI 10.1111/j.1365-2559.1996.tb01421.x; McCluggage WG, 2001, J CLIN PATHOL, V54, P481, DOI 10.1136/jcp.54.6.481; Micci F, 2006, CANCER RES, V66, P107, DOI 10.1158/0008-5472.CAN-05-2485; Micci F, 2003, CANCER GENET CYTOGEN, V144, P119, DOI 10.1016/S0165-4608(03)00025-6; Micci F, 2017, GENE CHROMOSOME CANC, V56, P841, DOI 10.1002/gcc.22485; Micci F, 2016, GENE CHROMOSOME CANC, V55, P834, DOI 10.1002/gcc.22380; Micci F, 2014, CANCER LETT, V347, P75, DOI 10.1016/j.canlet.2014.01.030; Nakayama M, 2006, INT J GYNECOL PATHOL, V25, P70, DOI 10.1097/01.pgp.0000183047.45459.36; Ng D, 2004, NAT GENET, V36, P411, DOI 10.1038/ng1321; NORRIS HJ, 1966, CANCER, V19, P755, DOI 10.1002/1097-0142(196606)19:6<755::AID-CNCR2820190604>3.0.CO;2-U; Nucci MR, 2007, AM J SURG PATHOL, V31, P65, DOI 10.1097/01.pas.0000213327.86992.d1; Nucci MR, 2001, AM J SURG PATHOL, V25, P455, DOI 10.1097/00000478-200104000-00004; O'Meara E, 2012, J PATHOL, V227, P72, DOI 10.1002/path.3985; Ohta Y, 2010, INT J GYNECOL PATHOL, V29, P374, DOI 10.1097/PGP.0b013e3181cef14b; Oliva E, 1999, INT J GYNECOL PATHOL, V18, P310, DOI 10.1097/00004347-199910000-00004; Oliva E, 1998, AM J SURG PATHOL, V22, P997, DOI 10.1097/00000478-199808000-00010; Oliva E, 2002, INT J GYNECOL PATHOL, V21, P48, DOI 10.1097/00004347-200201000-00009; Oliva E, 2002, AM J SURG PATHOL, V26, P403, DOI 10.1097/00000478-200204000-00001; Oliva E, 2007, AM J SURG PATHOL, V31, P1277, DOI 10.1097/PAS.0b013e318031f012; Panagopoulos I, 2012, PLOS ONE, V7, P3; Panagopoulos I, 2013, GENE CHROMOSOME CANC, V52, P610, DOI 10.1002/gcc.22057; Parra-Herran C, 2016, AM J SURG PATHOL, V40, P285, DOI 10.1097/PAS.0000000000000593; Prat J, 2015, INT J GYNECOL OBSTET, V131, pS105, DOI 10.1016/j.ijgo.2015.06.006; Rahimi S, 2018, APPL IMMUNOHISTOCHEM; Reich O, 2007, CURR OPIN ONCOL, V19, P347, DOI 10.1097/CCO.0b013e3281a7ef3a; Richmond AM, 2017, GYNECOL ONCOL REP, V19, P34, DOI 10.1016/j.gore.2016.12.002; Rothmund R, 2014, ARCH GYNECOL OBSTET, V290, P1195, DOI 10.1007/s00404-014-3320-7; Roy M, 2017, INT J GYNECOL PATHOL, V36, P420, DOI 10.1097/PGP.0000000000000353; Ryu H, 2015, ONCOL LETT, V10, P3310, DOI 10.3892/ol.2015.3674; Santiago T, 2017, MODERN PATHOL, V30, P884, DOI 10.1038/modpathol.2017.12; Schilder JM, 1999, OBSTET GYNECOL, V93, P805, DOI 10.1016/S0029-7844(98)00332-9; Schoolmeester JK, 2015, INT J GYNECOL PATHOL, V34, P576, DOI 10.1097/PGP.0000000000000187; Schoolmeester JK, 2013, AM J SURG PATHOL, V37, P938, DOI 10.1097/PAS.0b013e318282da9d; Sciallis AP, 2014, AM J SURG PATHOL, V38, P1161, DOI 10.1097/PAS.0000000000000256; Seagle BLL, 2017, GYNECOL ONCOL, V146, P254, DOI 10.1016/j.ygyno.2017.05.036; Shah VI, 2015, AM J SURG PATHOL, V39, P722, DOI 10.1097/PAS.0000000000000427; SREEKANTAIAH C, 1991, CANCER GENET CYTOGEN, V55, P163, DOI 10.1016/0165-4608(91)90073-4; Stewart CJR, 2014, HISTOPATHOLOGY, V65, P473, DOI 10.1111/his.12406; Sturm D, 2016, CELL, V164, P1060, DOI 10.1016/j.cell.2016.01.015; Su TF, 2014, INT J SURG PATHOL, V22, P559, DOI 10.1177/1066896913506934; Sumathi VP, 2004, INT J GYNECOL PATHOL, V23, P241, DOI 10.1097/01.pgp.0000130051.04396.13; Suzuki S, 2014, PATHOL RES PRACT, V210, P130, DOI 10.1016/j.prp.2013.09.009; Tanimoto A, 1996, PATHOL INT, V46, P231, DOI 10.1111/j.1440-1827.1996.tb03604.x; TAVASSOLI FA, 1981, HISTOPATHOLOGY, V5, P1, DOI 10.1111/j.1365-2559.1981.tb01761.x; Tavassoli FA, 2003, PATHOLOGY GENETICS T; Ueno-Yokohata H, 2015, NAT GENET, V47, P861, DOI 10.1038/ng.3338; Vilos GA, 2001, J AM ASSOC GYN LAP, V8, P805; Yamamoto Y, 2010, BLOOD, V116, P4274, DOI 10.1182/blood-2010-01-264432; Yilmaz A, 2002, AM J SURG PATHOL, V26, P1142, DOI 10.1097/01.PAS.0000022569.53433.DF	135	3	3	4	7	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0945-6317	1432-2307		VIRCHOWS ARCH	Virchows Arch.	DEC	2018	473	6					665	678		10.1007/s00428-018-2470-6			14	Pathology	Pathology	HC0IC	WOS:000451480700002	30324234				2019-10-28	
J	Asirvatham, JR; Jorns, JM; Zhao, LL; Jeffries, DO; Wu, AJ				Asirvatham, Jaya Ruth; Jorns, Julie M.; Zhao, Lili; Jeffries, Deborah O.; Wu, Angela J.			Outcomes of benign intraductal papillomas diagnosed on core biopsy: a review of 104 cases with subsequent excision from a single institution	VIRCHOWS ARCHIV			English	Review						Papilloma; Atypical; Upgrade; Core biopsy	BREAST PAPILLARY LESIONS; NEEDLE-BIOPSY; MANAGEMENT; ATYPIA; CARCINOMA; FEATURES; UPGRADE; RISK; B3	A diagnosis of papilloma with atypia on core biopsy (CB) requires excision, as the risk of associated malignancy is high (average 36.9%). The management of benign intraductal papillomas (IP) diagnosed on CB is controversial due to varying upgradation rates (0-29%, average 7%) reported on excision. Our aim was tostudy the clinical, radiological, and pathological features associated with benign IP upgradation at our institution. An electronic data base search (keyword papilloma), from Jan. 2000-Aug. 2015 identified 258 CBs. After exclusions, 104 CBs of benign IPs with subsequent excisions from 101 females were reviewed. The clinical, radiological, and pathological features between IPs that had upgrades (defined as malignancy or atypical ductal hyperplasia) and non-upgraded IPs were compared using descriptive statistics. Studies of benign IP on CB with at least 50 follow-up excisions published between 2008 and 2016 were analyzed. Residual IP was present in 83.6% (87/104) of reviewed excisions. There were six upgrades (5.6%) (4 to malignancy (3.8%) and 2 to atypical ductal hyperplasia).Upgrades were associated with mass on imaging with a trend to significance (p=.05). Two cases with malignant upgrade had a history of contralateral cancer. An analysis of 25 published studies showed an average malignant upgrade of 5.7% (182/3164). The majority of benign IP are not upgraded on excision; thus, not all need to be excised. Those that may warrant excision are those with prior history of carcinoma, those with a mass on imaging, and/or suboptimal or imaging-discordant CB sampling.	[Asirvatham, Jaya Ruth; Jorns, Julie M.; Wu, Angela J.] Univ Michigan, Dept Pathol & Lab Med, Ann Arbor, MI 48109 USA; [Asirvatham, Jaya Ruth] Univ Florida, Dept Pathol Immunol & Lab Med, Gainesville, FL 32610 USA; [Jorns, Julie M.] Med Coll Wisconsin, Dept Pathol, Milwaukee, WI 53226 USA; [Zhao, Lili] Univ Michigan, Dept Biostat, Ann Arbor, MI 48109 USA; [Jeffries, Deborah O.] Univ Michigan, Dept Radiol, Ann Arbor, MI 48109 USA	Asirvatham, JR (reprint author), Univ Michigan, Dept Pathol & Lab Med, Ann Arbor, MI 48109 USA.; Asirvatham, JR (reprint author), Univ Florida, Dept Pathol Immunol & Lab Med, Gainesville, FL 32610 USA.	ruthasirvatham@ufl.edu					Chang JM, 2011, AM J ROENTGENOL, V196, P723, DOI 10.2214/AJR.10.4615; Chang JM, 2010, EUR RADIOL, V20, P1093, DOI 10.1007/s00330-009-1649-2; Cheng TY, 2009, ANN SURG ONCOL, V16, P3375, DOI 10.1245/s10434-009-0637-8; Cyr AE, 2011, ANN SURG ONCOL, V18, P946, DOI 10.1245/s10434-010-1403-7; El-Sayed ME, 2008, HISTOPATHOLOGY, V53, P650, DOI 10.1111/j.1365-2559.2008.03158.x; Fu CY, 2012, EJSO-EUR J SURG ONC, V38, P1029, DOI 10.1016/j.ejso.2012.08.019; Glenn ME, 2015, ANN SURG ONCOL, V22, P1133, DOI 10.1245/s10434-014-4128-1; Holley SO, 2012, RADIOLOGY, V265, P379, DOI 10.1148/radiol.12111926; Jaffer S, 2013, BREAST J, V19, P130, DOI 10.1111/tbj.12073; Jaffer S, 2009, CANCER, V115, P2837, DOI 10.1002/cncr.24321; Jatake K, 2012, AM J SURG PATHOL, V36, P544, DOI [10.1097/PAS.0b013e318243fa00, DOI 10.1097/PAS.0B013E318243FA00]; Jung SY, 2010, WORLD J SURG, V34, P261, DOI 10.1007/s00268-009-0313-y; Kil WH, 2008, BREAST, V17, P258, DOI 10.1016/j.breast.2007.10.008; Kim MJ, 2011, CLIN RADIOL, V66, P530, DOI 10.1016/j.crad.2011.01.008; Lewis JT, 2006, AM J SURG PATHOL, V30, P665, DOI 10.1097/00000478-200606000-00001; Li X, 2012, AM J CLIN PATHOL, V138, P789, DOI 10.1309/AJCPTDQCHIWH4OHM; Pareja F, 2016, CANCER-AM CANCER SOC, V122, P2819, DOI 10.1002/cncr.30118; Rageth CJ, 2016, BREAST CANCER RES TR, V159, P203, DOI 10.1007/s10549-016-3935-4; Rizzo M, 2008, ANN SURG ONCOL, V15, P1040, DOI 10.1245/s10434-007-9780-2; Rizzo M, 2012, J AM COLL SURGEONS, V214, P280, DOI 10.1016/j.jamcollsurg.2011.12.005; Rozentsvayg E, 2011, RADIOL RES PRACT, DOI 10.1155/2011/679864; Shin HJ, 2008, AM J ROENTGENOL, V190, P630, DOI 10.2214/AJR.07.2664; Shouhed D, 2012, AM SURGEON, V78, P1161; Skandarajah AR, 2008, ANN SURG ONCOL, V15, P2272, DOI 10.1245/s10434-008-9962-6; Swapp RE, 2013, ANN SURG ONCOL, V20, P1900, DOI 10.1245/s10434-012-2846-9; Tatarian T, 2016, ANN SURG ONCOL, V23, P2501, DOI 10.1245/s10434-016-5182-7; Weisman PS, 2014, HUM PATHOL, V45, P583, DOI 10.1016/j.humpath.2013.10.027; Wen X, 2013, ANN SURG ONCOL, V20, P94, DOI 10.1245/s10434-012-2590-1; Wiratkapun C, 2013, DIAGN INTERV RADIOL, V19, P371, DOI 10.5152/dir.2013.017; Wyss P, 2014, BREAST J, V20, P394, DOI 10.1111/tbj.12283; Youk JH, 2012, ANN SURG ONCOL, V19, P922, DOI 10.1245/s10434-011-2033-4; Youk JH, 2011, RADIOLOGY, V258, P81, DOI 10.1148/radiol.10100728	32	1	1	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0945-6317	1432-2307		VIRCHOWS ARCH	Virchows Arch.	DEC	2018	473	6					679	686		10.1007/s00428-018-2449-3			8	Pathology	Pathology	HC0IC	WOS:000451480700003	30191301				2019-10-28	
J	del Arco, CD; Munoz, LE; Roldan, EM; Nieto, MAC; Medina, LO; de las Heras, SGG; Acenero, MJF				Diaz del Arco, Cristina; Estrada Munoz, Lourdes; Molina Roldan, Elena; Ceron Nieto, Ma Angeles; Ortega Medina, Luis; Gomez de las Heras, Soledad Garcia; Fernandez Acenero, Ma Jesus			Immunohistochemical classification of gastric cancer based on new molecular biomarkers: a potential predictor of survival	VIRCHOWS ARCHIV			English	Article						Molecular; Gastric; Classification; Immunohistochemistry; Prognosis	EXPRESSION; SUBTYPES; MUTATIONS; CARCINOMA; DIFFUSE; PATTERNS; ADENOCARCINOMA; AMPLIFICATION; METHYLATION; PROGRESSION	Several classification systems have been described for stratifying patients with gastric carcinoma (GC). However, their prognostic value is low, and there is an urgent need for identification of molecular markers and development of new classifications. Retrospective study of 206 cases of GC diagnosed and surgically resected in our hospital between 2000 and 2017. Clinicopathological features of all cases were assessed and tissue microarrays were constructed for immunohistochemical (IHC) study. Patients were stratified based on IHC results. Mean patient age was 71years and most patients were male (54.6%). Most tumors were located in the gastric antrum and body, and they were mostly fungoid or ulcerative lesions. GC were mainly intestinal-type tumors and 60.3% were diagnosed at pT3. 56.2% of patients showed recurrences and 29.4% died due to GC. According to our IHC classification, 23.5% of tumors showed microsatellite instability, 6% were E-cadherin negative, 53.5% were stable-p53 not overexpressed, and 17% were stable with p53 overexpression. IHC classification was significantly correlated with patient gender, gross morphology, Lauren classification, tumor necrosis, perineural infiltration, type of leading edge, and patient outcome. Multivariate analysis showed that IHC subtype was significantly and independently associated with overall survival, together with clinical symptoms, signet cell phenotype, tumor grade and vessel invasion. The application of IHC classifications based on molecular biomarkers in clinical practice can aid in the stratification of GC patients. More studies are needed to evaluate the reproducibility and clinical significance of these classifications.	[Diaz del Arco, Cristina; Molina Roldan, Elena; Ceron Nieto, Ma Angeles; Ortega Medina, Luis; Fernandez Acenero, Ma Jesus] Hosp Clin San Carlos, Dept Surg Pathol, Madrid 28040, Spain; [Diaz del Arco, Cristina; Ortega Medina, Luis; Fernandez Acenero, Ma Jesus] Univ Complutense Madrid, Madrid, Spain; [Estrada Munoz, Lourdes] Hosp Rey Juan Carlos, Dept Surg Pathol, Madrid, Spain; [Estrada Munoz, Lourdes; Gomez de las Heras, Soledad Garcia] Rey Juan Carlos Univ, Madrid, Spain	del Arco, CD (reprint author), Hosp Clin San Carlos, Dept Surg Pathol, Madrid 28040, Spain.; del Arco, CD (reprint author), Univ Complutense Madrid, Madrid, Spain.	crisdelarco@gmail.com		Estrada, Lourdes/0000-0002-9082-8578; Fernandez-Acenerp/0000-0002-2439-3553			Badary Dalia M, 2017, Pathophysiology, V24, P99, DOI 10.1016/j.pathophys.2017.02.006; Bass AJ, 2014, NATURE, V513, P202, DOI 10.1038/nature13480; Becker JC, 2006, WORLD J GASTROENTERO, V12, P3297, DOI 10.3748/wjg.v12.i21.3297; Bellini MF, 2012, J BIOMED BIOTECHNOL, DOI 10.1155/2012/891961; Birkman EM, 2018, VIRCHOWS ARCH, V472, P369, DOI 10.1007/s00428-017-2240-x; Bosman FT, 2010, WHO CLASSIFICATION T; Cai J, 2015, BRIT J CANCER, V113, P1720, DOI 10.1038/bjc.2015.367; Chen DS, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-017-0132-2; Chen KX, 2015, P NATL ACAD SCI USA, V112, P1107, DOI 10.1073/pnas.1422640112; Chen Z, 2018, BIOCH BIOPHYS RES CO; Chia NY, 2016, ANN ONCOL, V27, P763, DOI 10.1093/annonc/mdw040; Chia NY, 2015, GUT, V64, P707, DOI 10.1136/gutjnl-2013-306596; Chiurillo Miguel Angel, 2015, World J Exp Med, V5, P84, DOI 10.5493/wjem.v5.i2.84; Cole AJ, 2016, SCI REP-UK, V6, DOI 10.1038/srep26191; Cristescu R, 2015, NAT MED, V21, P449, DOI 10.1038/nm.3850; Deng NT, 2012, GUT, V61, P673, DOI 10.1136/gutjnl-2011-301839; Ferlay J, 2013, EUR J CANCER, V49, P1374, DOI 10.1016/j.ejca.2012.12.027; Gonzalez RS, 2016, HUM PATHOL, V56, P16, DOI 10.1016/j.humpath.2016.06.003; GOSEKI N, 1992, GUT, V33, P606, DOI 10.1136/gut.33.5.606; Graziano F, 2003, ANN ONCOL, V14, P1705, DOI 10.1093/annonc/mdg486; Gu LH, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0182692; Guner G, 2018, APPL IMMUNOHISTO M M, V26, pE107, DOI 10.1097/PAI.0000000000000618; Kakiuchi M, 2014, NAT GENET, V46, P583, DOI 10.1038/ng.2984; Kim DH, 2013, ARCH PATHOL LAB MED, V137, P1047, DOI 10.5858/arpa.2012-0193-OA; Kuan SF, 2017, HUM PATHOL, V63, P33, DOI 10.1016/j.humpath.2017.02.003; Lastraioli E, 2012, INT J SURG ONCOL, DOI 10.1155/2012/868645; LAUREN P, 1965, ACTA PATHOL MIC SC, V64, P31, DOI 10.1111/apm.1965.64.1.31; Lei ZD, 2013, GASTROENTEROLOGY, V145, P554, DOI 10.1053/j.gastro.2013.05.010; Li GQ, 2017, CELL PHYSIOL BIOCHEM, V44, P1242, DOI 10.1159/000485454; Lin XD, 2015, COMPUT STRUCT BIOTEC, V13, P448, DOI 10.1016/j.csbj.2015.08.001; Ma P, 2017, AM J TRANSL RES, V9, P3027; Majewski IJ, 2013, J PATHOL, V229, P621, DOI 10.1002/path.4152; MING SC, 1977, CANCER, V39, P2475, DOI 10.1002/1097-0142(197706)39:6<2475::AID-CNCR2820390626>3.0.CO;2-L; Murnyak B, 2016, ONCOTARGET, V7, P64910, DOI 10.18632/oncotarget.11912; Noguchi A, 2014, CANCER MED-US, V3, P1553, DOI 10.1002/cam4.310; Ooi A, 2017, HUM PATHOL, V61, P58, DOI 10.1016/j.humpath.2016.10.025; Park CK, 2016, ONCOTARGET, V7, P72099, DOI 10.18632/oncotarget.12291; Qu YP, 2013, CLIN CHIM ACTA, V424, P53, DOI 10.1016/j.cca.2013.05.002; Shah MA, 2011, CLIN CANCER RES, V17, P2693, DOI 10.1158/1078-0432.CCR-10-2203; Smyth EC, 2016, ANN ONCOL, V27, pv38, DOI 10.1093/annonc/mdw350; Stahl P, 2015, BMC GASTROENTEROL, V15, DOI 10.1186/s12876-015-0231-4; Tahara T, 2015, EPIGENOMICS-UK, V7, P475, DOI 10.2217/epi.15.4; Takeshima H, 2015, CANCER LETT, V357, P328, DOI 10.1016/j.canlet.2014.11.038; Tan IB, 2011, GASTROENTEROLOGY, V141, P476, DOI 10.1053/j.gastro.2011.04.042; Taylor D, 1999, HUM PATHOL, V30, P1221, DOI 10.1016/S0046-8177(99)90041-2; Wang K, 2014, NAT GENET, V46, P573, DOI 10.1038/ng.2983; Wang K, 2011, NAT GENET, V43, P1219, DOI 10.1038/ng.982; Willems L, 2012, CURR ONCOL REP, V14, P129, DOI 10.1007/s11912-012-0227-y; Wu YH, 2013, GUT, V62, P1100, DOI 10.1136/gutjnl-2011-301373; Xing XF, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2017.1356144; Xu WT, 2014, ASIAN PAC J CANCER P, V15, P17, DOI 10.7314/APJCP.2014.15.1.17; Yang TS, 2017, CANCER BIOL THER, V18, P806, DOI 10.1080/15384047.2017.1373219; Yao Y, 2004, LAB INVEST, V84, P915, DOI 10.1038/labinvest.3700117; Yemelyanova A, 2011, MODERN PATHOL, V24, P1248, DOI 10.1038/modpathol.2011.85; Zang ZJ, 2012, NAT GENET, V44, P570, DOI 10.1038/ng.2246; Zhang YZ, 2011, WORLD J GASTROENTERO, V17, P1710, DOI 10.3748/wjg.v17.i13.1710; Zhou YY, 2018, J CELL BIOCHEM, V119, P3608, DOI 10.1002/jcb.26563	57	3	3	2	7	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0945-6317	1432-2307		VIRCHOWS ARCH	Virchows Arch.	DEC	2018	473	6					687	695		10.1007/s00428-018-2443-9			9	Pathology	Pathology	HC0IC	WOS:000451480700004	30140949				2019-10-28	
J	Urbanowicz, M; Grabsch, HI; Fiteni, F; Liu, Y; Caballero, C; Flejou, JF				Urbanowicz, Maria; Grabsch, Heike I.; Fiteni, Frederic; Liu, Yan; Caballero, Carmela; Flejou, Jean-Francois			An international survey-based study on colorectal cancer pathology reportingguidelines versus local practice	VIRCHOWS ARCHIV			English	Article						Colorectal cancer; Guidelines; Pathology reporting; International survey	RECTAL-CANCER; PROGNOSTIC-SIGNIFICANCE; HISTOPATHOLOGY REPORTS; LYNCH-SYNDROME; COLON-CANCER; QUALITY; AUDIT; GUIDELINES; RESECTION; RECOMMENDATIONS	Different guidelines for colorectal cancer (CRC) pathology reporting have been published. We aimed to identify differences between publicly available CRC reporting guidelines and to survey pathologists from different countries to establish the degree of guideline implementation in local routine practice. We compared all core and non-core items of CRC reporting guidelines to identify discrepancies. We then created a survey, which was sent out to 782 pathologists practicing in 30 different countries. It included questions on the demographics of the reporting pathologist as well as resection specimen handling and microscopic evaluation, grading, staging, and additional techniques, such as immunohistochemistry or molecular pathology. First, core and non-core items of five national CRC reporting guidelines were compared and 12 items were found to differ. Different items are considered core or non-core by different guidelines and more than one TNM staging edition was applied across guidelines. The survey was completed by 143 pathologists from 30 countries. We identified differences between local practice and guidelines with potential clinical impact, e.g., tumor budding was never reported by 28.7% of responders, although it has prognostic value for survival in stage II CRC. This is the first international study comparing CRC pathology reporting guidelines with real-world local practices. There are differences in CRC pathology reporting guidelines and in guideline implementation into local practice, both with potential impact on patient care. Harmonization of datasets, use of templates, and audits of local pathology practice are needed to ensure best possible quality of CRC pathology reporting.	[Urbanowicz, Maria; Liu, Yan; Caballero, Carmela] EORTC, Ave Emmanuel Mounier 83-11, B-1200 Brussels, Belgium; [Urbanowicz, Maria; Flejou, Jean-Francois] European Soc Pathol, Rue Bara 6, B-1070 Brussels, Belgium; [Grabsch, Heike I.] Maastricht Univ, GROW Sch Oncol & Dev Biol, Dept Pathol, Med Ctr, P Debyelaan 25, NL-6229 HX Maastricht, Netherlands; [Grabsch, Heike I.] Univ Leeds, Sch Med, Pathol, Leeds, W Yorkshire, England; [Fiteni, Frederic] Univ Hosp Nimes, Dept Med Oncol, Pl Prof Robert Debre, F-30029 Nimes, France; [Fiteni, Frederic] Inst Canc Montpellier, Biometry Unit, 208 Ave Apothicaires, F-34298 Montpellier, France; [Fiteni, Frederic] Univ Montpellier, 163 Rue Auguste Broussonnet, F-34090 Montpellier, France; [Flejou, Jean-Francois] Sorbonne Univ, Hop St Antoine, AP HP, Serv Anat Pathol,Fac Med, 184 Rue Faubourg St Antoine, F-75012 Paris, France	Flejou, JF (reprint author), European Soc Pathol, Rue Bara 6, B-1070 Brussels, Belgium.; Flejou, JF (reprint author), Sorbonne Univ, Hop St Antoine, AP HP, Serv Anat Pathol,Fac Med, 184 Rue Faubourg St Antoine, F-75012 Paris, France.	jean-francois.flejou@aphp.fr		FLEJOU, Jean-Francois/0000-0002-4971-2434	ESP; EORTC Cancer Research Fund	No funding was destined for this publication. Maria Urbanowicz's work as Fellow at EORTC Headquarters was supported by a grant from the ESP and the EORTC Cancer Research Fund.	Amin M, 2017, AM JOINT COMMITTEE C; [Anonymous], 2009, GUID AUTH STRUCT CAN; [Anonymous], 2016, INT COLLABORATION CA; [Anonymous], 2017, LIBRO BLANCO ANATOMI; [Anonymous], 2016, COLORECTAL CANC STRU; [Anonymous], 2017, MOL TESTING STRATEGI; Appleton MAC, 1998, J CLIN PATHOL, V51, P30, DOI 10.1136/jcp.51.1.30; Balmana J, 2013, ANN ONCOL, V24, P73, DOI 10.1093/annonc/mdt209; Betge J, 2012, CANCER-AM CANCER SOC, V118, P628, DOI 10.1002/cncr.26310; Birbeck KF, 2002, ANN SURG, V235, P449, DOI 10.1097/00000658-200204000-00001; Bori R, 2009, PATHOL ONCOL RES, V15, P527, DOI 10.1007/s12253-009-9149-x; Brierley JD, 2016, INT UNION CANC UICC; Bull AD, 1997, J CLIN PATHOL, V50, P138, DOI 10.1136/jcp.50.2.138; Chan NG, 2008, CAN J SURG, V51, P284; Chang GJ, 2007, J NATL CANCER I, V99, P433, DOI 10.1093/jnci/djk092; Chapuis PH, 2007, ANZ J SURG, V77, P963, DOI 10.1111/j.1445-2197.2007.04291.x; Cross SS, 1998, J CLIN PATHOL, V51, P481, DOI 10.1136/jcp.51.6.481; Edge SB, 2010, AJCC CANC STAGING HD; Eon Y, 2006, GASTROEN CLIN BIOL, V30, P235, DOI 10.1016/S0399-8320(06)73159-1; Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210; Gavioli M, 2005, DIS COLON RECTUM, V48, P1851, DOI 10.1007/s10350-005-0133-6; Haugland HK, 2011, HUM PATHOL, V42, P36, DOI 10.1016/j.humpath.2010.06.009; Idowu MO, 2010, ARCH PATHOL LAB MED, V134, P969, DOI 10.1043/2009-0412-CP.1; Keating John, 2003, N Z Med J, V116, pU514; Labianca R, 2013, ANN ONCOL, V24, P64, DOI 10.1093/annonc/mdt354; Lanza G, 2011, DIGEST LIVER DIS, V43, pS344, DOI 10.1016/S1590-8658(11)60590-2; Liebig C, 2009, J CLIN ONCOL, V27, P5131, DOI 10.1200/JCO.2009.22.4949; Lim SB, 2010, DIS COLON RECTUM, V53, P377, DOI 10.1007/DCR.0b013e3181cf8ae5; Loughrey MB, 2017, G049 DATASET HISTOPA; Lugli A, 2017, MODERN PATHOL, V30, P1299, DOI 10.1038/modpathol.2017.46; Messenger DE, 2011, ARCH PATHOL LAB MED, V135, P1471, DOI 10.5858/arpa.2010-0558-OA; Nagtegaal ID, 2011, J CLIN ONCOL, V29, P2487, DOI 10.1200/JCO.2011.34.6429; Nakhleh RE, 2011, ARCH PATHOL LAB MED, V135, P1394, DOI 10.5858/arpa.2011-0192-RA; Nambiar A, 2010, INDIAN J CANCER, V47, P156, DOI 10.4103/0019-509X.63010; Nederland VKG, 2015, RICHTL ERF DARMK 2 0; Obaseki D, 2015, NIGER J GASTROENTERO, V7, P19; Olszyna-Serementa M, 2009, POL J PATHOL, V60, P130; Palmer K, 2008, BRIT MED J, V337, DOI 10.1136/bmj.a1832; Ryan R, 2005, HISTOPATHOLOGY, V47, P141, DOI 10.1111/j.1365-2559.2005.02176.x; Sluijter CE, 2016, VIRCHOWS ARCH, V468, P639, DOI 10.1007/s00428-016-1935-8; Sobin LH, 1997, CANCER, V80, P1803, DOI 10.1002/(SICI)1097-0142(19971101)80:9<1803::AID-CNCR16>3.0.CO;2-9; Srigley J, 2013, J ONCOL PRACT, V9, pE255, DOI 10.1200/JOP.2012.000818; Srigley JR, 2009, J SURG ONCOL, V99, P517, DOI 10.1002/jso.21282; Tang LH, 2016, PROTOCOL EXAMINATION; Umar A, 2004, J NATL CANCER I, V96, P261, DOI 10.1093/jnci/djh034; Van Cutsem E, 2016, ANN ONCOL, V27, P1386, DOI 10.1093/annonc/mdw235; Vasen HFA, 1999, GASTROENTEROLOGY, V116, P1453, DOI 10.1016/S0016-5085(99)70510-X; Washington MK, 2009, ARCH PATHOL LAB MED, V133, P1539, DOI 10.1043/1543-2165-133.10.1539; Winn RD, 2008, ANZ J SURG, V78, P796, DOI 10.1111/j.1445-2197.2008.04653.x; Woods YL, 2014, J CLIN PATHOL, V67, P499, DOI 10.1136/jclinpath-2013-202060	50	0	0	0	2	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0945-6317	1432-2307		VIRCHOWS ARCH	Virchows Arch.	DEC	2018	473	6					697	708		10.1007/s00428-018-2457-3			12	Pathology	Pathology	HC0IC	WOS:000451480700005	30255341	Green Published			2019-10-28	
J	Simbolo, M; Vicentini, C; Mafficini, A; Fassan, M; Pedron, S; Corbo, V; Mastracci, L; Rusev, B; Pedrazzani, C; Landoni, L; Grillo, F; Cingarlini, S; Rindi, G; Luchini, C; Scarpa, A; Lawlor, RT				Simbolo, Michele; Vicentini, Caterina; Mafficini, Andrea; Fassan, Matteo; Pedron, Serena; Corbo, Vincenzo; Mastracci, Luca; Rusev, Borislav; Pedrazzani, Corrado; Landoni, Luca; Grillo, Federica; Cingarlini, Sara; Rindi, Guido; Luchini, Claudio; Scarpa, Aldo; Lawlor, Rita T.			Mutational and copy number asset of primary sporadic neuroendocrine tumors of the small intestine	VIRCHOWS ARCHIV			English	Article						Neuroendocrine tumors; Small intestine; SRC; Prognostic markers		Small intestine neuroendocrine tumors (SI-NETs) represent the most common histotype among small intestine neoplasms, and metastatic disease is usually present at diagnosis. A retrospective series of 52 sporadic primary surgically resected SI-NETs, which were metastatic at diagnosis, was analyzed by high-coverage target sequencing (HCTS) for the mutational status of 57 genes and copy number status of 40 genes selected from recently published genome sequencing data. Seven genes were found to be recurrently mutated: CDKN1B (9.6%), APC and CDKN2C (each 7.7%), BRAF, KRAS, PIK3CA, and TP53 (each 3.8%). Copy number analysis showed frequent allelic loss of 4 genes located on chromosome 18 (BCL2, CDH19, DCC, and SMAD4) in 23/52 (44.2%) and losses on chromosomes 11 (38%) and 16 (15%). Other recurrent copy number variations were gains for genes located on chromosomes 4 (31%), 5 (27%), 14 (36%), and 20 (20%). Univariate survival analysis showed that SRC gene copy number gains were associated with a poorer prognosis (p=0.047). Recurrent copy number variations are important events in SI-NET and SRC may represent a novel prognostic biomarker for this tumor type.	[Simbolo, Michele; Vicentini, Caterina; Mafficini, Andrea; Fassan, Matteo; Corbo, Vincenzo; Rusev, Borislav; Scarpa, Aldo; Lawlor, Rita T.] Univ & Hosp Trust Verona, ARC Net Res Ctr, Policlin GB Rossi, Piazzale LA Scuro 10,Piastra Odontoiatr 2 Floor, Verona, Italy; [Simbolo, Michele; Vicentini, Caterina; Pedron, Serena; Corbo, Vincenzo; Rusev, Borislav; Luchini, Claudio; Scarpa, Aldo; Lawlor, Rita T.] Univ & Hosp Trust Verona, Sect Pathol, Dept Diagnost & Publ Hlth, Verona, Italy; [Fassan, Matteo] Univ Padua, Dept Med DIMED, Surg Pathol & Cytopathol Unit, Padua, Italy; [Mastracci, Luca; Grillo, Federica] Univ Genoa, Dept Surg & Diagnost Sci DISC, Genoa, Italy; [Mastracci, Luca; Grillo, Federica] IRCCS S Martino IST Univ Hosp, Genoa, Italy; [Pedrazzani, Corrado] Univ & Hosp Trust Verona, Dept Surg Gen & Hepatobiliary Surg, Verona, Italy; [Landoni, Luca] Univ & Hosp Trust Verona, Dept Surg & Oncol, Unit Surg B, Pancreas Inst, Verona, Italy; [Cingarlini, Sara] Univ & Hosp Trust Verona, Sect Med Oncol, Dept Med, Verona, Italy; [Rindi, Guido] Univ Cattolica, IRCCS Fdn Policlin A Gemelli, Intitute Pathol, Rome, Italy	Scarpa, A (reprint author), Univ & Hosp Trust Verona, ARC Net Res Ctr, Policlin GB Rossi, Piazzale LA Scuro 10,Piastra Odontoiatr 2 Floor, Verona, Italy.; Scarpa, A (reprint author), Univ & Hosp Trust Verona, Sect Pathol, Dept Diagnost & Publ Hlth, Verona, Italy.	aldo.scarpa@univr.it	Simbolo, Michele/AAB-1851-2019; Luchini, Claudio/O-2187-2019; Luchini, Claudio/Q-4922-2016	Simbolo, Michele/0000-0002-0866-4499; Luchini, Claudio/0000-0003-4901-4908; Luchini, Claudio/0000-0003-4901-4908; Landoni, Luca/0000-0002-2474-3496	Associazione Italiana Ricerca Cancro (AIRC)Associazione Italiana per la Ricerca sul Cancro (AIRC) [12182]; Italian Cancer Genome Project [FIRB RBAP10AHJB]	This work was supported by Associazione Italiana Ricerca Cancro (AIRC grant n. 12182, to AS); Italian Cancer Genome Project (FIRB RBAP10AHJB to AS). The funding agencies had no role in the collection, analysis, and interpretation of data and in the writing of the manuscript.	Andersson E, 2009, ENDOCR-RELAT CANCER, V16, P953, DOI 10.1677/ERC-09-0052; Banck MS, 2013, J CLIN INVEST, V123, P2502, DOI 10.1172/JCI67963; Bosman F.T., 2010, PATHOLOGY GENETICS T; Bottarelli L, 2013, HUM PATHOL, V44, P2736, DOI 10.1016/j.humpath.2013.06.019; Caplin ME, 1998, LANCET, V352, P799, DOI 10.1016/S0140-6736(98)02286-7; Cingolani Pablo, 2012, Frontiers in Genetics, V3, P35, DOI 10.3389/fgene.2012.00035; Cunningham JL, 2011, GENE CHROMOSOME CANC, V50, P82, DOI 10.1002/gcc.20834; Edge SB, 2010, ANN SURG ONCOL, V17, P1471, DOI 10.1245/s10434-010-0985-4; Francis JM, 2013, NAT GENET, V45, P1483, DOI 10.1038/ng.2821; Hashemi J, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-505; Jann H, 2011, CANCER-AM CANCER SOC, V117, P3332, DOI 10.1002/cncr.25855; Karpathakis A, 2016, CLIN CANCER RES, V22, P250, DOI 10.1158/1078-0432.CCR-15-0373; Kim DH, 2008, GENE CHROMOSOME CANC, V47, P84, DOI 10.1002/gcc.20510; Kulke MH, 2008, GENE CHROMOSOME CANC, V47, P591, DOI 10.1002/gcc.20561; Kytola S, 2001, AM J PATHOL, V158, P1803, DOI 10.1016/S0002-9440(10)64136-3; McLaren W, 2010, BIOINFORMATICS, V26, P2069, DOI 10.1093/bioinformatics/btq330; Modlin IM, 2003, CANCER-AM CANCER SOC, V97, P934, DOI 10.1002/cncr.11105; Modlin IM, 2008, LANCET ONCOL, V9, P61, DOI 10.1016/S1470-2045(07)70410-2; Nieser M, 2017, NEUROENDOCRINOLOGY, V104, P302, DOI 10.1159/000446917; Pan SY, 2011, WORLD J GASTRO ONCOL, V3, P33, DOI 10.4251/wjgo.v3.i3.33; Park C, 2016, ONCOTARGET, V7, P4024, DOI 10.18632/oncotarget.6602; Pizzi S, 2008, ENDOCR-RELAT CANCER, V15, P1013, DOI 10.1677/ERC-07-0230; Rindi G, 2001, Expert Rev Mol Diagn, V1, P323, DOI 10.1586/14737159.1.3.323; Simbolo M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062692; Thorvaldsdottir H, 2013, BRIEF BIOINFORM, V14, P178, DOI 10.1093/bib/bbs017; Verdugo AD, 2015, HORM METAB RES, V47, P452, DOI 10.1055/s-0034-1389992; Zamo A, 2012, J MOL DIAGN, V14, P30, DOI 10.1016/j.jmoldx.2011.07.007	27	4	4	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0945-6317	1432-2307		VIRCHOWS ARCH	Virchows Arch.	DEC	2018	473	6					709	717		10.1007/s00428-018-2450-x			9	Pathology	Pathology	HC0IC	WOS:000451480700006	30219970	Other Gold, Green Published			2019-10-28	
J	Zavalishina, L; Tsimafeyeu, I; Povilaitite, P; Raskin, G; Andreeva, Y; Petrov, A; Kharitonova, E; Rumyantsev, A; Pugach, I; Frank, G; Tjulandin, S				Zavalishina, Larisa; Tsimafeyeu, Ilya; Povilaitite, Patrisia; Raskin, Grigory; Andreeva, Yulia; Petrov, Alexey; Kharitonova, Ekaterina; Rumyantsev, Alexey; Pugach, Inna; Frank, Georgy; Tjulandin, Sergei			RUSSCO-RSP comparative study of immunohistochemistry diagnostic assays for PD-L1 expression in urothelial bladder cancer	VIRCHOWS ARCHIV			English	Article						PD-L1 expression; Concordance analysis; Immunohistochemistry diagnostic assays	METHOTREXATE; VINBLASTINE; MULTICENTER; DOXORUBICIN; CARCINOMA; CISPLATIN; GEMCITABINE; THERAPY	In this collaborative study by the Russian Society of Clinical Oncology and the Russian Society of Pathology, we assessed the concordance among three validated, commercially available PD-L1 immunohistochemistry assays for patients with urothelial cancer. Tumors from 100 urothelial cancer patients were stained with the antibody clones 22C3 (Agilent), SP142 (Ventana Medical Systems), and SP263 (Ventana Medical Systems), which are used in clinical trials of second-line therapy with checkpoint inhibitors. Four trained pathologists independently evaluated the percentages of tumor cells (TC) and tumor-infiltrating immune cells (IC) that were stained at any intensity by each of the antibodies. The test-specific cutoffs for the proportions of stained cells in a positive sample were pre-specified as TC + IC 10% or TC 10% for 22C3, IC 5% for SP142, and TC 25% or IC 25% for SP263. Three hundred immunohistochemistry slides were scored. The percentages of PD-L1 staining in the three assays without using any cutoff were higher in the IC than in the TC (55% versus 24% for 22C3, 45% versus 8% for SP142, and 72% versus 27% for SP263, respectively). The Pearson correlation coefficients for anti-PD-L1 staining in the IC were 0.5, 0.69, and 0.85 with 22C3/SP142, 22C3/SP263, and SP142/SP263, respectively. The Pearson correlation coefficients for PD-L1 staining in the TC were 0.93, 0.99, and 0.91 for the same pairs. Among the patients who were negative for PD-L1 staining by one test, 91-100% were also negative by the other tests. Among the patients who were positive by one test, 43-100% were also positive by the other tests. Our data indicate that repeated testing can be avoided as a patient with urothelial cancer who is classified as negative for PD-L1 expression by one of the three single tests using the corresponding cutoff rule is highly likely (91-100%) to be classified as negative by either of the other tests.	[Zavalishina, Larisa; Andreeva, Yulia; Frank, Georgy] Russian Med Acad Continuous Profess Educ, Dept Pathol, Moscow, Russia; [Zavalishina, Larisa; Povilaitite, Patrisia; Raskin, Grigory; Andreeva, Yulia; Petrov, Alexey; Frank, Georgy] Russian Soc Pathol, Moscow, Russia; [Tsimafeyeu, Ilya; Kharitonova, Ekaterina; Rumyantsev, Alexey; Pugach, Inna; Tjulandin, Sergei] Russian Soc Clin Oncol, Trubnaya Ul 25 K 1, Moscow 127051, Russia; [Povilaitite, Patrisia; Petrov, Alexey] Rostov Reg Bur Pathol, Rostov Na Donu, Russia; [Raskin, Grigory] AM Granov Russian Sci Ctr Radiol & Surg Technol, St Petersburg, Russia; [Rumyantsev, Alexey; Tjulandin, Sergei] NN Blokhin Russian Canc Res Ctr, Moscow, Russia	Tsimafeyeu, I (reprint author), Russian Soc Clin Oncol, Trubnaya Ul 25 K 1, Moscow 127051, Russia.	director@russco.org	Frank, Georgy/P-1111-2019		RocheRoche Holding	The presented study was supported by a research grant from the Roche.	Bellmunt J, 2017, NEW ENGL J MED, V376, P1015, DOI 10.1056/NEJMoa1613683; Bellmunt J, 2014, ANN ONCOL, V25, P40, DOI 10.1093/annonc/mdu223; Bellmunt J, 2017, CANCER TREAT REV, V54, P58, DOI 10.1016/j.ctrv.2017.01.007; Ferlay J, IARC CANC BASE, V11; Hirsch FR, 2017, J THORAC ONCOL, V12, P208, DOI 10.1016/j.jtho.2016.11.2228; Hoffman-Censits JH, 2016, J CLIN ONCOL, V34, DOI 10.1200/jco.2016.34.2_suppl.355; Kaprin A, 2012, MALIGNANT TUMORS RUS, P250; LOEHRER PJ, 1992, J CLIN ONCOL, V10, P1066, DOI 10.1200/JCO.1992.10.7.1066; Powles T, 2018, LANCET, V391, P748, DOI 10.1016/S0140-6736(17)33297-X; Powles T, 2017, JAMA ONCOL, V3, DOI 10.1001/jamaoncol.2017.2411; Ratcliffe MJ, 2017, CLIN CANCER RES, V23, P3585, DOI 10.1158/1078-0432.CCR-16-2375; Schwamborn K, 2017, ANN ONCOL, V28; Sharma P, 2017, LANCET ONCOL, V18, P312, DOI 10.1016/S1470-2045(17)30065-7; Tretiakova M, 2018, MODERN PATHOL, V31, P623, DOI 10.1038/modpathol.2017.188; von der Maase H, 2000, J CLIN ONCOL, V18, P3068, DOI 10.1200/JCO.2000.18.17.3068; von der Maase H, 2005, J CLIN ONCOL, V23, P4602, DOI 10.1200/JCO.2005.07.757	16	4	4	4	4	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0945-6317	1432-2307		VIRCHOWS ARCH	Virchows Arch.	DEC	2018	473	6					719	724		10.1007/s00428-018-2453-7			6	Pathology	Pathology	HC0IC	WOS:000451480700007	30209552				2019-10-28	
J	He, HY; Trpkov, K; Martinek, P; Isikci, OT; Maggi-Galuzzi, C; Alaghehbandan, R; Gill, AJ; Tretiakova, M; Lopez, JI; Williamson, SR; Montiel, DP; Sperga, M; Comperat, E; Brimo, F; Yilmaz, A; Pivovarcikova, K; Michalova, K; Slouka, D; Prochazkova, K; Hora, M; Bonert, M; Michal, M; Hes, O				He, Huiying; Trpkov, Kiril; Martinek, Petr; Isikci, Ozlem Tanas; Maggi-Galuzzi, Cristina; Alaghehbandan, Reza; Gill, Anthony J.; Tretiakova, Maria; Lopez, Jose Ignacio; Williamson, Sean R.; Montiel, Delia Perez; Sperga, Maris; Comperat, Eva; Brimo, Fadi; Yilmaz, Ali; Pivovarcikova, Kristyna; Michalova, Kveta; Slouka, David; Prochazkova, Kristyna; Hora, Milan; Bonert, Michael; Michal, Michal; Hes, Ondrej			"High-grade oncocytic renal tumor": morphologic, immunohistochemical, and molecular genetic study of 14 cases	VIRCHOWS ARCHIV			English	Article						Kidney; Oncocytic; Chromophobe renal cell carcinoma; High grade; Oncocytoma; Hybrid; Immunohistochemistry; Molecular biology	CELL CARCINOMA; FEATURES; T(6/11)(P21,Q12); NEOPLASMS; SPECTRUM	The spectrum of the renal oncocytic tumors has been expanded in recent years to include several novel and emerging entities. We describe a cohort of novel, hitherto unrecognized and morphologically distinct high-grade oncocytic tumors (HOT), currently diagnosed as unclassified in the WHO classification. We identified 14 HOT by searching multiple institutional archives. Morphologic, immunohistochemical (IHC), molecular genetic, and molecular karyotyping studies were performed to investigate these tumors. The patients included 3 men and 11 women, with age range from 25 to 73years (median 50, mean 49years). Tumor size ranged from 1.5 to 7.0cm in the greatest dimension (median 3, mean 3.4cm). The tumors were all pT1 stage. Microscopically, they showed nested to solid growth, and focal tubulocystic architecture. The neoplastic cells were uniform with voluminous oncocytic cytoplasm. Prominent intracytoplasmic vacuoles were frequently seen, but no irregular (raisinoid) nuclei or perinuclear halos were present. All tumors demonstrated prominent nucleoli (WHO/ISUP grade 3 equivalent). Nine of 14 cases were positive for CD117 and cytokeratin (CK) 7 was either negative or only focally positive in of 6/14 cases. All tumors were positive for AE1-AE3, CK18, PAX 8, antimitochondrial antigen, and SDHB. Cathepsin K was positive in 13/14 cases and CD10 was positive in 12/13 cases. All cases were negative for TFE3, HMB45, Melan-A. No TFEB and TFE3 genes rearrangement was found in analyzable cases. By array CGH, complete chromosomal losses or gains were not found in any of the cases, and 3/9 cases showed absence of any abnormalities. Chromosomal losses were detected on chromosome 19 (4/9), 3 with losses of the short arm (p) and 1 with losses of both arms (p and q). Loss of chromosome 1 was found in 3/9 cases; gain of 5q was found in 1/9 cases. On molecular karyotyping, 3/3 evaluated cases showed loss of heterozygosity (LOH) on 16p11.2-11.1 and 2/3 cases showed LOH at 7q31.31. Copy number (CN) losses were found at 7q11.21 (3/3), Xp11.21 (3/3), Xp11.22-11.21 (3/3), and Xq24-25 (2/3). CN gains were found at 13q34 (2/3). Ten patients with available follow up information were alive and without disease progression, after a mean follow-up of 28months (1 to 112months). HOT is a tumor with unique morphology and its IHC profile appears mostly consistent. HOT should be considered as an emerging renal entity because it does not meet the diagnostic criteria for other recognized eosinophilic renal tumors, such as oncocytoma, chromophobe renal cell carcinoma (RCC), TFE3 and TFEB RCC, SDH-deficient RCC, and eosinophilic solid and cystic RCC.	[He, Huiying] Peking Univ, Hlth Sci Ctr, Dept Pathol, Beijing, Peoples R China; [Trpkov, Kiril; Yilmaz, Ali] Calgary Lab Serv, Dept Pathol & Lab Med, Calgary, AB, Canada; [Trpkov, Kiril; Yilmaz, Ali] Univ Calgary, Calgary, AB, Canada; [Martinek, Petr; Pivovarcikova, Kristyna; Michalova, Kveta; Michal, Michal; Hes, Ondrej] Med Fac, Dept Pathol, Alej Svobody 80, Plzen 30460, Czech Republic; [Martinek, Petr; Pivovarcikova, Kristyna; Michalova, Kveta; Michal, Michal; Hes, Ondrej] Charles Univ Hosp Plzen, Alej Svobody 80, Plzen 30460, Czech Republic; [Isikci, Ozlem Tanas] Ankara Educ & Res Hosp, Dept Pathol, Ankara, Turkey; [Maggi-Galuzzi, Cristina] Cleveland Clin, Robert J Tomsich Pathol & Lab Med Inst, Cleveland, OH 44106 USA; [Alaghehbandan, Reza] Univ British Columbia, Royal Columbian Hosp, Fac Med, Dept Pathol, Vancouver, BC, Canada; [Gill, Anthony J.] Royal North Shore Hosp, Kolling Inst Med Res, Canc Diag & Pathol Grp, St Leonards, NSW 2065, Australia; [Gill, Anthony J.] Univ Sydney, Sydney, NSW 2006, Australia; [Gill, Anthony J.] Royal North Shore Hosp, NSW Hlth Pathol Dept Anat Pathol, St Leonards, NSW 2065, Australia; [Tretiakova, Maria] Harborview Med Ctr, Dept Anat Pathol, Seattle, WA USA; [Lopez, Jose Ignacio] Univ Basque Country UPV EHU, Cruces Univ Hosp, BioCruces Inst, Baracaldo, Bizkaia, Spain; [Williamson, Sean R.] Henry Ford Hosp, Dept Pathol, 2799 W Grand Blvd, Detroit, MI 48202 USA; [Montiel, Delia Perez] Inst Nacl Cancerol, Dept Pathol, Mexico City, DF, Mexico; [Sperga, Maris] Riga Stradins Univ, Dept Pathol, Riga, Latvia; [Comperat, Eva] Sorbonne Univ, Hop Tenon, HUEP, Serv Anat & Cytol Pathol, Paris, France; [Brimo, Fadi] McGill Univ, Dept Pathol, Montreal, PQ, Canada; [Slouka, David] Charles Univ Prague, Fac Med, Biomed Ctr, Prague, Czech Republic; [Slouka, David; Prochazkova, Kristyna; Hora, Milan] Charles Univ Hosp Plzen, Prague, Czech Republic; [Prochazkova, Kristyna; Hora, Milan] Charles Univ Prague, Fac Med, Dept Urol, Prague, Czech Republic; [Bonert, Michael] McMaster Univ, Fac Hlth Sci, Dept Pathol & Mol Med, Hamilton, ON, Canada	Hes, O (reprint author), Med Fac, Dept Pathol, Alej Svobody 80, Plzen 30460, Czech Republic.; Hes, O (reprint author), Charles Univ Hosp Plzen, Alej Svobody 80, Plzen 30460, Czech Republic.	hes@medima.cz	Prochazkova, Kristyna/M-2059-2017; Lopez, Jose Ignacio/L-3884-2019	Prochazkova, Kristyna/0000-0002-4306-7075; Lopez, Jose Ignacio/0000-0003-0842-5348; Hora, Milan/0000-0002-5061-3687	Charles University Research Fund [Q39]; project Institutional Research Fund of University Hospital Plzen [FN 00669806]	The study was supported by the Charles University Research Fund (project number Q39) and by the project Institutional Research Fund of University Hospital Plzen (FN 00669806).	Amin MB, 1997, AM J SURG PATHOL, V21, P1, DOI 10.1097/00000478-199701000-00001; Argani P, 2005, AM J SURG PATHOL, V29, P230, DOI 10.1097/01.pas.0000146007.54092.37; Argani P, 2006, AM J CLIN PATHOL, V126, P332, DOI 10.1309/EAEJTJGD5J4JB4F; Argani P, 2012, AM J SURG PATHOL, V36, P1516, DOI 10.1097/PAS.0b013e3182613d8f; Delongchamps NB, 2009, BJU INT, V103, P1381, DOI 10.1111/j.1464-410X.2008.08263.x; Eble JN, 2018, PATHOLOGY, V50, P24, DOI 10.1016/j.pathol.2017.09.005; Gill AJ, 2011, AM J SURG PATHOL, V35, P1578, DOI 10.1097/PAS.0b013e318227e7f4; Gill AJ, 2011, NEW ENGL J MED, V364, P885, DOI 10.1056/NEJMc1012357; Guo J, 2014, AM J SURG PATHOL, V38, P1457, DOI 10.1097/PAS.0000000000000248; Hes O, 2005, VIRCHOWS ARCH, V446, P383, DOI 10.1007/s00428-004-1187-x; Hes Ondrej, 2006, Ann Diagn Pathol, V10, P133, DOI 10.1016/j.anndiagpath.2005.12.002; Hes O, 2013, HISTOL HISTOPATHOL, V28, P1257, DOI 10.14670/HH-28.1257; Lefevre M, 2005, AM J SURG PATHOL, V29, P1576; Li YJ, 2018, HISTOPATHOLOGY, V72, P588, DOI 10.1111/his.13395; Mai KT, 2005, PATHOL RES PRACT, V201, P385, DOI 10.1016/j.prp.2005.03.008; Martigioni G, 2005, MODERN PATHOL, V18, p155A; Martignoni G, 2012, MODERN PATHOL, V25, P100, DOI 10.1038/modpathol.2011.136; McKenney JK, 2018, HISTOPATHOLOGY, V72, P1066, DOI 10.1111/his.13457; Moch H, 2016, WHO CLASSIFICATION T, P356; Ohe C, 2014, HUM PATHOL, V1, P31, DOI DOI 10.1016/J.EHPC.2014.08.003; Foix MP, 2016, VIRCHOWS ARCH, V469, P669, DOI 10.1007/s00428-016-2022-x; Pavlovich CP, 2002, AM J SURG PATHOL, V26, P1542, DOI 10.1097/00000478-200212000-00002; Peckova K, 2015, ANN DIAGN PATHOL, V19, P261, DOI 10.1016/j.anndiagpath.2015.05.001; Peckova K, 2014, ANN DIAGN PATHOL, V18, P351, DOI 10.1016/j.anndiagpath.2014.10.002; Perrino CM, 2018, HISTOPATHOLOGY, V72, P305, DOI 10.1111/his.13362; Petersson F, 2010, VIRCHOWS ARCH, V456, P355, DOI 10.1007/s00428-010-0898-4; Pitra T, 2019, ANN DIAGN PATHOL, V40, P189, DOI 10.1016/j.anndiagpath.2017.11.004; Sperga M, 2013, VIRCHOWS ARCH, V463, P563, DOI 10.1007/s00428-013-1457-6; Srigley JR, 2013, AM J SURG PATHOL, V37, P1469, DOI 10.1097/PAS.0b013e318299f2d1; Steiner P, 2018, VIRCHOWS ARCH, V473, P471, DOI 10.1007/s00428-018-2349-6; Trpkov K, 2017, AM J SURG PATHOL, V41, P1299, DOI 10.1097/PAS.0000000000000838; Trpkov K, 2016, AM J SURG PATHOL, V40, P60, DOI 10.1097/PAS.0000000000000508; Trpkov K, 2010, HISTOPATHOLOGY, V57, P893, DOI 10.1111/j.1365-2559.2010.03726.x; Williamson SR, 2017, HUM PATHOL, V63, P149, DOI 10.1016/j.humpath.2017.03.004	34	3	3	1	4	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0945-6317	1432-2307		VIRCHOWS ARCH	Virchows Arch.	DEC	2018	473	6					725	738		10.1007/s00428-018-2456-4			14	Pathology	Pathology	HC0IC	WOS:000451480700008	30232607				2019-10-28	
J	Dasgupta, S; Ewing-Graham, PC; van Kemenade, FJ; van Doorn, HC; Hegt, VN; Koljenovic, S				Dasgupta, Shatavisha; Ewing-Graham, Patricia C.; van Kemenade, Folkert J.; van Doorn, Helena C.; Hegt, Vincent Noordhoek; Koljenovic, Senada			Differentiated vulvar intraepithelial neoplasia (dVIN): the most helpful histological features and the utility of cytokeratins 13 and 17	VIRCHOWS ARCHIV			English	Article						Differentiated vulvar intraepithelial neoplasia; Cytokeratin 13; Cytokeratin 17; Vulva; Histology; Immunohistochemistry	SQUAMOUS-CELL CARCINOMA; IMMUNOHISTOCHEMICAL STAINING PATTERNS; ORAL EPITHELIAL DYSPLASIA; LICHEN-SCLEROSUS; GENE-EXPRESSION; P53; DIAGNOSIS; LESIONS; CLASSIFICATION; KERATIN-17	Differentiated vulvar intraepithelial neoplasia (dVIN) is the precursor lesion of HPV-negative vulvar squamous cell carcinoma (VSCC). The histopathological diagnosis of dVIN can be challenging, as it often resembles vulvar non-neoplastic epithelial disorders (NNED), especially lichen sclerosus (LS). We aimed to establish the most specific and reproducible histological features of dVIN and assessed cytokeratin 13 (CK13) and cytokeratin 17 (CK17) immunohistochemistry as a diagnostic aid. Consecutive cases of dVIN (n=180) and LS (n=105) from the period 2010 to 2013 were reviewed using a checklist of histological features. Each feature was recorded as present' or absent' and statistical comparison (dVIN vs LS) was made. Interobserver agreement between two pairs of pathologists was assessed for a subset of cases of dVIN (n=31) and LS and other NNED (n=23). Immunohistochemistry with CK13, CK17, MIB1 and p53 was performed on dVIN, LS, and other NNED cases. Macronucleoli, features of disturbed maturation and angulated nuclei were significantly more common in dVIN than LS (p<0.001). We found substantial agreement' for the diagnosis of dVIN (=0.71). Macronucleoli and deep keratinisation had the highest agreement. In dVIN, the mean percentage of cells staining with CK13 was 15 and with CK17, this was 74. For LS, the mean percentage of cells staining with CK13 was 31, and with CK17, this was 41. By plotting receiver operating characteristic curves (ROC), an area under the curve (AUC) of 0.52 was obtained for CK13, and an AUC of 0.87 was obtained for CK17. The most helpful histological features for diagnosing dVIN were macronucleoli, features of disturbed maturation, and angulated nuclei. Increased CK17 expression may have promise for supporting dVIN diagnosis.	[Dasgupta, Shatavisha; Ewing-Graham, Patricia C.; van Kemenade, Folkert J.; Hegt, Vincent Noordhoek; Koljenovic, Senada] Univ Med Ctr Rotterdam, Erasmus MC, Dept Pathol, Rotterdam, Netherlands; [van Doorn, Helena C.] Univ Med Ctr Rotterdam, Erasmus MC, Dept Gynaecol Oncol, Rotterdam, Netherlands	Ewing-Graham, PC (reprint author), Univ Med Ctr Rotterdam, Erasmus MC, Dept Pathol, Rotterdam, Netherlands.	s.dasgupta@erasmusmc.nl; p.ewing@erasmusmc.nl; f.vankemenade@erasmusmc.nl; h.vandoorn@erasmusmc.nl; hegt123@gmail.com; s.koljenovic@erasmusmc.nl	Dasgupta, Shatavisha/V-9920-2018	Dasgupta, Shatavisha/0000-0003-1804-5015; Ewing-Graham, Patricia C/0000-0002-1779-1115			[Anonymous], 2014, CLASS TUM FEM REPR O; ANSINK A, 1995, CANCER, V76, P638, DOI 10.1002/1097-0142(19950815)76:4<638::AID-CNCR2820760415>3.0.CO;2-M; Bloor BK, 2001, ORAL ONCOL, V37, P251, DOI 10.1016/S1368-8375(00)00094-4; Carrilho C, 2004, HUM PATHOL, V35, P546, DOI 10.1016/j.humpath.2004.01.021; Eva LJ, 2009, INT J GYNECOL CANCER, V19, P741, DOI 10.1111/IGC.0b013e3181a12fa2; Gambichler T, 2011, REGUL PEPTIDES, V167, P209, DOI 10.1016/j.regpep.2011.02.003; Hantschmann P, 2005, ANTICANCER RES, V25, P1739; Hoang LN, 2016, PATHOLOGY, V48, P291, DOI 10.1016/j.pathol.2016.02.015; Ida-Yonemochi H, 2012, MODERN PATHOL, V25, P784, DOI 10.1038/modpathol.2011.218; Khanom R, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0161163; Kitamura R, 2012, J CANCER RES CLIN, V138, P1299, DOI 10.1007/s00432-012-1202-6; Liegl B, 2006, HISTOPATHOLOGY, V48, P268, DOI 10.1111/j.1365-2559.2005.02321.x; Medeiros F, 2005, ADV ANAT PATHOL, V12, P20, DOI 10.1097/01.pqp.0000151268.72556.f3; Mikami T, 2011, ORAL ONCOL, V47, P497, DOI 10.1016/j.oraloncology.2011.03.015; Nazarian RM, 2014, AM J SURG PATHOL, V38, P78, DOI 10.1097/PAS.0000000000000111; Nobusawa A, 2014, PATHOL INT, V64, P20, DOI 10.1111/pin.12125; Noguchi S, 2011, ASIAN J ORAL MAXILLO, V23, P53, DOI DOI 10.1016/j.ajoms.2010.12.005; Ohkura S, 2005, ORAL ONCOL, V41, P607, DOI 10.1016/j.oraloncology.2005.01.011; Podoll MB, 2017, INT J GYNECOL PATHOL, V36, P273, DOI 10.1097/PGP.0000000000000317; Reutter JC, 2016, J LOW GENIT TRACT DI, V20, P261, DOI 10.1097/LGT.0000000000000211; Rolfe KJ, 2001, INT J GYNECOL CANCER, V11, P113; Santos M, 2004, INT J GYNECOL PATHOL, V23, P206, DOI 10.1097/01.pgp.0000130108.03231.89; Schaaij-Visser TBM, 2010, ORAL ONCOL, V46, P123, DOI 10.1016/j.oraloncology.2009.11.012; Scurry J, 2006, INT J GYNECOL PATHOL, V25, P176, DOI 10.1097/01.pgp.0000189238.19027.df; Singh N, 2015, AM J SURG PATHOL, V39, P52, DOI 10.1097/PAS.0000000000000291; TAKAHASHI H, 1995, HISTOPATHOLOGY, V26, P45, DOI 10.1111/j.1365-2559.1995.tb00619.x; van de Nieuwenhof HP, 2008, CRIT REV ONCOL HEMAT, V68, P131, DOI 10.1016/j.critrevonc.2008.02.012; van de Nieuwenhof HP, 2011, MODERN PATHOL, V24, P297, DOI 10.1038/modpathol.2010.192; van de Nieuwenhof HP, 2009, EUR J CANCER, V45, P851, DOI 10.1016/j.ejca.2008.11.037; van den Einden LCG, 2013, MODERN PATHOL, V26, P874, DOI 10.1038/modpathol.2012.235; Wasserman JK, 2016, HISTOPATHOLOGY, V68, P834, DOI 10.1111/his.12874; Yagyuu T, 2015, J ORAL PATHOL MED, V44, P523, DOI 10.1111/jop.12262; Yamashina M, 2014, ACTA CYTOL, V58, P67, DOI 10.1159/000355865; Yang B, 2000, AM J SURG PATHOL, V24, P429, DOI 10.1097/00000478-200003000-00013	34	1	1	0	1	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0945-6317	1432-2307		VIRCHOWS ARCH	Virchows Arch.	DEC	2018	473	6					739	747		10.1007/s00428-018-2436-8			9	Pathology	Pathology	HC0IC	WOS:000451480700009	30187167	Green Published			2019-10-28	
J	Lo Bello, G; Akarca, AU; Ambrosio, MR; Agostinelli, C; Molina-Kirsch, H; Ramsay, A; Rodriguez-Justo, M; Pugh, M; Zhao, SC; DeLisser, M; Sabattini, E; Dojcinov, S; Pileri, SA; Natkunam, Y; Leoncini, L; Marafioti, T				Lo Bello, Giuseppe; Akarca, Ayse U.; Ambrosio, Maria Raffaella; Agostinelli, Claudio; Molina-Kirsch, Hernan; Ramsay, Alan; Rodriguez-Justo, Manuel; Pugh, Matt; Zhao, Shuchun; DeLisser, Monique; Sabattini, Elena; Dojcinov, Stefan; Pileri, Stefano A.; Natkunam, Yasodha; Leoncini, Lorenzo; Marafioti, Teresa			Granulysin, a novel marker for extranodal NK/T cell lymphoma, nasal type	VIRCHOWS ARCHIV			English	Article						T cell lymphoma; Immunohistochemistry; Granulysin; NK-T cells; Phenotype	T-CELL; EXPRESSION; LYMPHOCYTES	Granulysin is a cytolytic protein expressed in cytotoxic T and natural killer (NK) cells. Abnormal serum levels of granulysin in lymphomas with NK and cytotoxic phenotype have been shown to correlate with tumour progression. In this study, we investigated the expression pattern of granulysin in routine sections of normal and reactive lymphoid tissues as well as in a large series of lymphomas. In normal tissues, granulysin labelled a small population of cells that double immunostaining revealed to belong to the pool of cytotoxic T/NK cells. Among lymphoid neoplasms, the highest expression of granulysin (71%) was found in extranodal NK/T cell lymphomas of nasal type (ENKTL). To note is that 29% of ENKTLs, which were negative for one or more of classical cytotoxic markers strongly expressed granulysin. Furthermore, expression of granulysin was observed in rare cases of T cell lymphomas with a cytotoxic phenotype (i.e. ALK-negative anaplastic large cell lymphoma (26%), enteropathy-associated T cell lymphoma (12%) and peripheral T cell lymphoma, NOS (4%)). None of the investigated non-Hodgkin B cell lymphomas, Hodgkin lymphoma and plasma cell myeloma were granulysin positive. The results suggest granulysin as a novel marker for a subset of cytotoxic NK cell derived malignancies and its usefulness is highlighted in those ENKTLs that lack expression of other cytotoxic markers but retain granulysin expression.	[Lo Bello, Giuseppe; Ambrosio, Maria Raffaella; Leoncini, Lorenzo] Univ Siena, Sect Pathol, Dept Med Biotechnol, I-53100 Siena, Italy; [Akarca, Ayse U.; Marafioti, Teresa] UCL, Univ Coll Hosp, Dept Histopathol, Rockefeller Bldg,UCL Site,21 Univ St, London WC1E 6JJ, England; [Agostinelli, Claudio; Sabattini, Elena] Univ Bologna, S Orsola Malpighi Hosp, Dept Expt Diagnost & Specialty Med, Haematopathol Unit, I-40138 Bologna, Italy; [Molina-Kirsch, Hernan] San Juan Gen Hosp, Dept Pathol, Guatemala City 10303, Guatemala; [Ramsay, Alan; Rodriguez-Justo, Manuel] Univ Coll London Hosp, Dept Cellular Pathol, London WC1E 6JJ, England; [Pugh, Matt; Dojcinov, Stefan] Univ Hosp Wales, Dept Pathol, Cardiff CF14 4XW, S Glam, Wales; [Zhao, Shuchun; DeLisser, Monique; Natkunam, Yasodha] Stanford Univ, Sch Med, Dept Pathol, Stanford, CA 94305 USA; [Pileri, Stefano A.] Univ Bologna, Univ Sch Med, I-40138 Bologna, Italy; [Pileri, Stefano A.] European Inst Oncol, Unit Haematopathol, Milan, Italy	Marafioti, T (reprint author), UCL, Univ Coll Hosp, Dept Histopathol, Rockefeller Bldg,UCL Site,21 Univ St, London WC1E 6JJ, England.	t.marafioti@ucl.ac.uk	LEONCINI, Lorenzo/U-4413-2019; Ambrosio, Maria Raffaella/S-2228-2019; Marafioti, Teresa/AAA-4652-2019; Ambrosio, Maria Raffaella/K-8953-2016	LEONCINI, Lorenzo/0000-0002-7457-300X; Ambrosio, Maria Raffaella/0000-0002-1172-6902; Agostinelli, Claudio/0000-0002-4945-1422; Teresa, Marafioti/0000-0003-1223-6275			Ambrosio MR, 2014, HUM PATHOL, V45, P648, DOI 10.1016/j.humpath.2013.09.015; Chan JKC, 2017, WHO CLASSIFICATION T, P368; Cheuk W, 2010, HEMATOPATHOLOGY, P473; Corradini P, 2014, ANN ONCOL, V25, P2339, DOI 10.1093/annonc/mdu152; Gualco G, 2011, AM J SURG PATHOL, V35, P1195, DOI 10.1097/PAS.0b013e31821ec4b5; Hsu FD, 2002, MODERN PATHOL, V15, P1374, DOI 10.1097/01.MP.0000039571.02827.CE; Kim SJ, 2013, J HEMATOL ONCOL, V6, DOI 10.1186/1756-8722-6-86; Kim TH, 2016, YONSEI MED J, V57, P846, DOI 10.3349/ymj.2016.57.4.846; Kishi A, 2002, CANCER IMMUNOL IMMUN, V50, P604, DOI 10.1007/s002620100228; Kitamura N, 2009, LEUKEMIA RES, V33, P908, DOI 10.1016/j.leukres.2009.01.032; Ko YH, 2010, HEMATOPATHOLOGY, P493; Krensky AM, 2009, TISSUE ANTIGENS, V73, P193, DOI 10.1111/j.1399-0039.2008.01218.x; Marafioti T, 2003, BLOOD, V102, P2868, DOI 10.1182/blood-2003-03-0692; Marafioti T, 2008, BLOOD, V111, P3778, DOI 10.1182/blood-2007-10-117531; Obata-Onai A, 2002, INT IMMUNOL, V14, P1085, DOI 10.1093/intimm/dxf086; OKADA S., 2012, INT SCHOLARLY RES NE, V6, P1, DOI [10.5402/2012/876203, DOI 10.5402/2012/876203]; Pena SV, 1997, J IMMUNOL, V158, P2680; Pont F, 2012, EUR J IMMUNOL, V42, P228, DOI 10.1002/eji.201141870; Rocca BJ, 2015, BIOMED RES INT, DOI 10.1155/2015/985950; Sekiguchi N, 2012, INT J HEMATOL, V96, P461, DOI 10.1007/s12185-012-1159-x; Shareef Mohamed Moustafa, 2015, Asian Pac J Cancer Prev, V16, P5359; Stenger S, 1998, SCIENCE, V282, P121, DOI 10.1126/science.282.5386.121; Takata K, 2015, AM J SURG PATHOL, V39, P1, DOI 10.1097/PAS.0000000000000312	23	1	1	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0945-6317	1432-2307		VIRCHOWS ARCH	Virchows Arch.	DEC	2018	473	6					749	757		10.1007/s00428-018-2434-x			9	Pathology	Pathology	HC0IC	WOS:000451480700010	30151671	Other Gold, Green Published			2019-10-28	
J	Kiil, K; Bein, J; Schuhmacher, B; Thurner, L; Schneider, M; Hansmann, ML; Hartmann, S				Kiil, Kati; Bein, Julia; Schuhmacher, Bianca; Thurner, Lorenz; Schneider, Markus; Hansmann, Martin-Leo; Hartmann, Sylvia			A high number of IgG4-positive plasma cells rules out nodular lymphocyte predominant Hodgkin lymphoma	VIRCHOWS ARCHIV			English	Article						Progressively transformed germinal centers; Nodular lymphocyte predominant Hodgkin lymphoma; IgG4-related disease; IgG4-associated lymphadenopathy	TRANSFORMED GERMINAL-CENTERS; PROGRESSIVE TRANSFORMATION; IGG4-RELATED DISEASE; MOLECULAR ANALYSIS; H-CELLS; ASSOCIATION	Nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) is a subtype of Hodgkin lymphoma that frequently shows a nodal growth pattern with abundant reactive B cells in the microenvironment. Early NLPHL cases can be particularly difficult to differentiate from progressively transformed germinal centers (PTGC). Since PTGC have been described to be IgG4 associated in a relatively high proportion of cases, the aim of the present study was to determine if IgG4 immunostaining can be helpful in the differential diagnosis between NLPHL and PTGC. We furthermore aimed to learn if LP cells can express IgG4. For this purpose, 58 cases of PTGC and 56 cases of NLPHL were assessed using IgG4 immunostaining. We could confirm that a significant number of PTGC cases showed high numbers of IgG4-positive plasma cells (22/58, 38%), whereas hot spot areas of IgG4-positive plasma cells were not found in any of the NLPHL cases. In lymph node areas with the differential diagnosis of NLPHL and PTGC, IgG4 immunostaining can therefore provide a helpful diagnostic tool to rule out NLPHL when a high number of IgG4-positive plasma cells are encountered. We also assessed 13 cases with a combination of NLPHL and PTGC in the same lymph node. Five of these cases presented hot spot areas of IgG4-positive plasma cells in the PTGC regions, while no significant numbers of IgG4-positive plasma cells were observed in the NLPHL part of the lymph node. LP cells were never IgG4 positive. Furthermore, immunoglobulin heavy chain rearrangements of single IgG4-positive plasma cells were analyzed, revealing a polyclonal plasma cell population. In summary, our data suggest that IgG4 immunostaining can provide additional information in the diagnostic workup of cases with the differential diagnosis of NLPHL and PTGC. IgG4's inefficiency in clearing antigens may explain why lymph nodes with PTGC are usually strongly enlarged and develop a high number of hyperplastic germinal centers. Polyclonal immunoglobulin heavy chain rearrangements in IgG4-positive plasma cells further support the hypothesis that PTGC represent a misled immune reaction.	[Kiil, Kati; Bein, Julia; Schuhmacher, Bianca; Schneider, Markus; Hansmann, Martin-Leo; Hartmann, Sylvia] Goethe Univ Hosp Frankfurt, Senckenberg Inst Pathol, Theodor Stern Kai 7, D-60590 Frankfurt, Germany; [Thurner, Lorenz] Saarland Univ, Sch Med, Jose Carreras Ctr Immuno & Gene Therapy & Interna, Homburg, Saar, Germany; [Hansmann, Martin-Leo; Hartmann, Sylvia] Goethe Univ, Reference & Consultant Ctr Lymph Node & Lymphoma, Frankfurt, Germany; [Hansmann, Martin-Leo] Frankfurt Inst Adv Studies, Frankfurt, Germany	Hartmann, S (reprint author), Goethe Univ Hosp Frankfurt, Senckenberg Inst Pathol, Theodor Stern Kai 7, D-60590 Frankfurt, Germany.; Hartmann, S (reprint author), Goethe Univ, Reference & Consultant Ctr Lymph Node & Lymphoma, Frankfurt, Germany.	s.hartmann@em.uni-frankfurt.de			Deutsche ForschungsgemeinschaftGerman Research Foundation (DFG) [HA6145/1-2, HA6145/3-1]	Deutsche Forschungsgemeinschaft grant numbers HA6145/1-2 and HA6145/3-1	Aalberse RC, 2002, IMMUNOLOGY, V105, P9, DOI 10.1046/j.0019-2805.2001.01341.x; Anagnostopoulos I, 2000, BLOOD, V96, P1889; BINDON CI, 1988, J EXP MED, V168, P127, DOI 10.1084/jem.168.1.127; Braeuninger A, 1997, P NATL ACAD SCI USA, V94, P9337, DOI 10.1073/pnas.94.17.9337; Brauninger A, 1999, BLOOD, V93, P2679, DOI 10.1182/blood.V93.8.2679.408k05_2679_2687; Brauninger A, 2001, BLOOD, V97, P714, DOI 10.1182/blood.V97.3.714; Carbonnelle-Puscian A, 2009, LEUKEMIA, V23, P952, DOI 10.1038/leu.2008.380; De Souza A, 2018, APPL IMMUNOHISTO M M, V26, P462, DOI 10.1097/PAI.0000000000000462; Della-Torre E, 2015, CLIN EXP IMMUNOL, V181, P191, DOI 10.1111/cei.12641; Deshpande V, 2012, MODERN PATHOL, V25, P1181, DOI 10.1038/modpathol.2012.72; Go H, 2012, HISTOPATHOLOGY, V60, P296, DOI 10.1111/j.1365-2559.2011.04089.x; HANSMANN ML, 1990, AM J CLIN PATHOL, V93, P219, DOI 10.1093/ajcp/93.2.219; HANSMANN ML, 1986, CANCER GENET CYTOGEN, V21, P319, DOI 10.1016/0165-4608(86)90212-8; Hartmann S, 2015, HUM PATHOL, V46, P1655, DOI 10.1016/j.humpath.2015.07.006; Kolfschoten MV, 2007, SCIENCE, V317, P1554, DOI 10.1126/science.1144603; KUPPERS R, 1993, EMBO J, V12, P4955, DOI 10.1002/j.1460-2075.1993.tb06189.x; Kuppers Ralf, 2013, Methods Mol Biol, V971, P49, DOI 10.1007/978-1-62703-269-8_3; OSBORNE BM, 1992, MODERN PATHOL, V5, P135; Prakash S, 2006, AM J SURG PATHOL, V30, P585, DOI 10.1097/01.pas.0000194741.87798.45; Sato Y, 2012, MODERN PATHOL, V25, P956, DOI 10.1038/modpathol.2012.54; SCHMID C, 1991, AM J PATHOL, V139, P1281; Swerdlow SH, 2017, WHO CLASSIFICATION T; Tsuboi H, 2012, ARTHRITIS RES THER, V14, DOI 10.1186/ar3924	23	1	1	0	5	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0945-6317	1432-2307		VIRCHOWS ARCH	Virchows Arch.	DEC	2018	473	6					759	764		10.1007/s00428-018-2460-8			6	Pathology	Pathology	HC0IC	WOS:000451480700011	30259184				2019-10-28	
J	Fernandez-Pol, S; van de Rijn, M; Natkunam, Y; Charville, GW				Fernandez-Pol, Sebastian; van de Rijn, Matt; Natkunam, Yasodha; Charville, Gregory W.			Immunohistochemistry for PAX7 is a useful confirmatory marker for Ewing sarcoma in decalcified bone marrow core biopsy specimens	VIRCHOWS ARCHIV			English	Article							TRANSCRIPTION FACTOR; EXPRESSION; TUMORS; CELLS	PAX7 has been recently demonstrated to be a highly sensitive marker for Ewing sarcoma, and thus far has only been shown to label a relatively small set of other mesenchymal neoplasms. Because the processing of bone marrow core biopsies can often hinder the performance of immunohistochemical stains, we set out to determine if our laboratory's PAX7 staining protocol effectively detects Ewing sarcoma in Bouin's fixed, decalcified bone marrow core biopsies. We stained ten core biopsies involved by Ewing sarcoma, nine non-involved core biopsies, and 13 core biopsies involved by histologic mimics of Ewing sarcoma. Only the ten biopsies involved by Ewing sarcoma and four biopsies with rhabdomyosarcoma showed strong nuclear PAX7 staining. None of the other tumors demonstrated PAX7 expression. This study demonstrates that the PAX7 staining protocol used in our laboratory is a useful marker for Ewing sarcoma and other PAX7-positive tumors in decalcified bone marrow core biopsies.	[Fernandez-Pol, Sebastian; van de Rijn, Matt; Natkunam, Yasodha; Charville, Gregory W.] Stanford Univ, Sch Med, Stanford, CA 94305 USA	Fernandez-Pol, S (reprint author), Stanford Univ, Sch Med, Stanford, CA 94305 USA.	sfernand@stanford.edu					Balamuth NJ, 2010, LANCET ONCOL, V11, P184, DOI 10.1016/S1470-2045(09)70286-4; Bock O, 2006, EUR J HAEMATOL, V77, P463, DOI 10.1111/j.0902-4441.2006.t01-1-EJH2826.x; BODGER MP, 1983, BLOOD, V61, P1006; BODGER MP, 1981, J IMMUNOL, V127, P2269; Charville GW, 2017, MODERN PATHOL, V30, P1312, DOI 10.1038/modpathol.2017.49; Charville GW, 2016, AM J SURG PATHOL, V40, P1305, DOI 10.1097/PAS.0000000000000717; DWORZAK MN, 1994, BLOOD, V83, P415, DOI 10.1182/blood.V83.2.415.bloodjournal832415; Miettinen M, 2011, AM J SURG PATHOL, V35, P432, DOI 10.1097/PAS.0b013e318206b67b; Toki S, 2018, HISTOPATHOLOGY, V73, P645, DOI 10.1111/his.13689	9	1	1	0	1	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0945-6317	1432-2307		VIRCHOWS ARCH	Virchows Arch.	DEC	2018	473	6					765	769		10.1007/s00428-018-2410-5			5	Pathology	Pathology	HC0IC	WOS:000451480700012	30014288				2019-10-28	
J	Cognat, E; Tible, M; Methnani, I; Chabriat, H; Adle-Biassette, H; Hugon, J; Paquet, C				Cognat, Emmanuel; Tible, Marion; Methnani, Ilyes; Chabriat, Hugues; Adle-Biassette, Homa; Hugon, Jacques; Paquet, Claire			Increased PKR level in human CADASIL brains	VIRCHOWS ARCHIV			English	Article						CADASIL; Small vessel disease; SVD; PKR; Autophagy	AUTOPHAGY; APOPTOSIS; DISEASE; KINASE	Cerebral autosomal dominant arteriolopathy with subcortical infarcts and leucoencephalopathy (CADASIL) is the most common form of hereditary small vessel disease (SVD) of the brain. Neuronal apoptosis has been demonstrated in the cortex of patients. Whether it is associated with an activation of the pro-apoptotic protein PKR pathway is unknown. Similarly, activation of autophagy in CADASIL has never been explored. Immunostaining of four CADASIL brains previously analyzed for cortical neuronal apoptosis and five control brains for PKR (phosphoPKR) and autophagy (ATG5, LC3II) activation markers. Significant nuclear pPKR staining was observed in CADASIL neurons comparatively to controls (p=0.001). No difference was observed between patients and controls with autophagy markers. We demonstrated the activation of PKR pathway in CADASIL. This was not associated with a detectable modulation of autophagy. These results open a new field to explore in order to better understand the mechanisms underlying cortical neurons apoptosis.	[Cognat, Emmanuel; Tible, Marion; Methnani, Ilyes; Hugon, Jacques; Paquet, Claire] INSERM, U942, Paris, France; [Cognat, Emmanuel; Hugon, Jacques; Paquet, Claire] Univ Paris Diderot, Sorbonne Paris Cite, UMRS, INSERM,U942, Paris, France; [Cognat, Emmanuel; Chabriat, Hugues; Adle-Biassette, Homa; Hugon, Jacques; Paquet, Claire] Lariboisiere Fernand Widal Hosp, APHP, Cognit Neurol Ctr, 200 Rue Faubourg St Denis, F-75475 Paris, France; [Chabriat, Hugues] Lariboisiere Fernand Widal Hosp, APHP, Dept Neurol, Paris, France; [Adle-Biassette, Homa] Lariboisiere Fernand Widal Hosp, APHP, Dept Pathol, Paris, France; [Adle-Biassette, Homa] INSERM, U1141, Paris, France	Paquet, C (reprint author), INSERM, U942, Paris, France.; Paquet, C (reprint author), Univ Paris Diderot, Sorbonne Paris Cite, UMRS, INSERM,U942, Paris, France.; Paquet, C (reprint author), Lariboisiere Fernand Widal Hosp, APHP, Cognit Neurol Ctr, 200 Rue Faubourg St Denis, F-75475 Paris, France.	claire.paquet@inserm.fr	COGNAT, Emmanuel/C-8571-2017	COGNAT, Emmanuel/0000-0002-3521-5832			Bose A, 2011, BRAIN PATHOL, V21, P189, DOI 10.1111/j.1750-3639.2010.00437.x; Chabriat H, 2009, LANCET NEUROL, V8, P643, DOI 10.1016/S1474-4422(09)70127-9; De Guio F, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0106311; Gray F, 2007, J NEUROPATH EXP NEUR, V66, P597, DOI 10.1097/nen.0b013e318093e574; Hugon J, 2017, ALZHEIMERS RES THER, V9, DOI 10.1186/s13195-017-0308-0; Joutel A, 2000, J CLIN INVEST, V105, P597, DOI 10.1172/JCI8047; Joutel A, 1997, LANCET, V350, P1511, DOI 10.1016/S0140-6736(97)08083-5; Jouvent E, 2008, BRAIN, V131, P2201, DOI 10.1093/brain/awn129; Menzies FM, 2010, BRAIN, V133, P93, DOI 10.1093/brain/awp292; Mouton-Liger F, 2014, J NEUROL, V261, P144, DOI 10.1007/s00415-013-7160-3; Ohsumi Y, 2014, CELL RES, V24, P9, DOI 10.1038/cr.2013.169; Paquet C, 2018, BRAIN PATHOL, V28, P603, DOI 10.1111/bpa.12567; Paquet C, 2010, ACTA NEUROPATHOL, V120, P813, DOI 10.1007/s00401-010-0758-y; Paquet C, 2009, J NEUROPATH EXP NEUR, V68, P190, DOI 10.1097/NEN.0b013e318196cd7c; Pickford F, 2008, J CLIN INVEST, V118, P2190, DOI 10.1172/JCI33585; Shen SS, 2012, MOL CELL, V48, P667, DOI 10.1016/j.molcel.2012.09.013; Steele JW, 2013, MOL PSYCHIATR, V18, P889, DOI 10.1038/mp.2012.106; Viswanathan A, 2006, STROKE, V37, P2690, DOI 10.1161/01.STR.0000245091.28429.6a; Zare-shahabadi A, 2015, REV NEUROSCIENCE, V26, P385, DOI 10.1515/revneuro-2014-0076	19	0	0	0	2	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0945-6317	1432-2307		VIRCHOWS ARCH	Virchows Arch.	DEC	2018	473	6					771	774		10.1007/s00428-018-2425-y			4	Pathology	Pathology	HC0IC	WOS:000451480700013	30073405				2019-10-28	
J	da Cunha, IW; da Costa, WH; Morini, MA; Bezerra, SM; Carraro, DM; Torrezan, GT; Formiga, MNC; Guimaraes, GC; Zequi, SC; Soares, FA				da Cunha, Isabela Werneck; da Costa, Walter Henriques; Morini, Mariana A.; Bezerra, Stephania Martins; Carraro, Dirce Maria; Torrezan, Giovana Tardin; Cruz Formiga, Maria Nirvana; Guimaraes, Gustavo Cardoso; Zequi, Stenio Cassio; Soares, Fernando Augusto			Expanding morphological and clinical aspects of hereditary leiomyomatosis and renal cell carcinoma (HLRCC): a case report in a patient with unusual morphology and clinical presentation	VIRCHOWS ARCHIV			English	Article						Fumarate hydratase; Uterine leiomyomas; Renal neoplasms	FUMARATE-HYDRATASE MUTATION; UTERINE LEIOMYOMAS; KIDNEY; CANCER; GERMLINE; SPECTRUM; FAMILIES; TUMORS; FH	Renal cell carcinoma (RCC) accounts for 2-3% of all malignant disease in adults. Hereditary RCC represents 5 to 8% of kidney tumors. Hereditary leiomyomatosis and renal cell carcinoma (HLRCC) represents an autosomal dominant syndrome that results from a germline mutation in fumarate hydratase gene (FH). HLRCC patients typically present with skin or uterine leiomyomas and renal neoplasms. HLRCC was recently recognized as a distinct renal tumor subtype by the WHO 2016 classification. Many morphological patterns such as papillary, solid, tubular, and cystic had been described as part of morphological aspects of HLRCC. In this study, we describe a case of a patient that had a history of persistence of ductus arteriosus (PDA) and cryptorchidism. In addition, the renal tumor showed a very unusual hystiocytoid morphological aspect. We confirmed the presence of a FH germline mutation both in the patient and his mother.	[da Cunha, Isabela Werneck; Morini, Mariana A.; Bezerra, Stephania Martins; Carraro, Dirce Maria; Torrezan, Giovana Tardin; Soares, Fernando Augusto] AC Camargo Canc Ctr, Dept Pathol, Rua Prof Antonio Prudente 211, BR-01509900 Sao Paulo, Brazil; [da Cunha, Isabela Werneck; Carraro, Dirce Maria; Torrezan, Giovana Tardin; Soares, Fernando Augusto] Natl Inst Sci & Technol Oncogen & Therapeut Innov, Sao Paulo, Brazil; [da Cunha, Isabela Werneck; Morini, Mariana A.; Soares, Fernando Augusto] Rede DOR Sao Luiz, Dept Pathol, Sao Paulo, Brazil; [da Costa, Walter Henriques; Guimaraes, Gustavo Cardoso; Zequi, Stenio Cassio] AC Camargo Canc Ctr, Dept Urol, Sao Paulo, Brazil; [Cruz Formiga, Maria Nirvana] AC Camargo Canc Ctr, Dept Oncogenet, Sao Paulo, Brazil	da Cunha, IW (reprint author), AC Camargo Canc Ctr, Dept Pathol, Rua Prof Antonio Prudente 211, BR-01509900 Sao Paulo, Brazil.; da Cunha, IW (reprint author), Natl Inst Sci & Technol Oncogen & Therapeut Innov, Sao Paulo, Brazil.; da Cunha, IW (reprint author), Rede DOR Sao Luiz, Dept Pathol, Sao Paulo, Brazil.	isabela.werneck@rededor.com.br	torrezan, giovana/P-9639-2019; GUIMARAES, GUSTAVO CARDOSO/H-3595-2012; Bezerra, Stephania M/X-9260-2018	torrezan, giovana/0000-0002-8659-5329; 	Department of Pathology of AC Camargo Cancer Center	This work was funded by the Department of Pathology of AC Camargo Cancer Center. The authors declare that they have no conflict of interest. This work was approved by the local ethics committee, number EC47/17.	Bardella C, 2011, J PATHOL, V225, P4, DOI 10.1002/path.2932; King SC, 2014, J UROLOGY, V191, P1665, DOI 10.1016/j.juro.2013.12.046; Launonen V, 2001, P NATL ACAD SCI USA, V98, P3387, DOI 10.1073/pnas.051633798; Linehan WM, 2010, ANNU REV MED, V61, P329, DOI 10.1146/annurev.med.042808.171650; Merino MJ, 2007, AM J SURG PATHOL, V31, P1578, DOI 10.1097/PAS.0b013e31804375b8; Moch H, 2016, EUR UROL, V70, P93, DOI 10.1016/j.eururo.2016.02.029; REED WB, 1973, ACTA DERM-VENEREOL, V53, P409; Sanz-Ortega J, 2013, AM J SURG PATHOL, V37, P74, DOI 10.1097/PAS.0b013e31825ec16f; Shuch B, 2014, J CLIN ONCOL, V32, P431, DOI 10.1200/JCO.2013.50.8192; Smith SC, 2016, AM J SURG PATHOL, V40, P1457, DOI 10.1097/PAS.0000000000000719; Tolvanen J, 2012, HUM REPROD, V27, P1865, DOI 10.1093/humrep/des105; Tomlinson IPM, 2002, NAT GENET, V30, P406, DOI 10.1038/ng849; Toro JR, 2003, AM J HUM GENET, V73, P95, DOI 10.1086/376435; Trpkov K, 2016, AM J SURG PATHOL, V40, P865, DOI 10.1097/PAS.0000000000000617; Wei MH, 2006, J MED GENET, V43, P18, DOI 10.1136/jmg.2005.033506	15	0	0	0	1	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0945-6317	1432-2307		VIRCHOWS ARCH	Virchows Arch.	DEC	2018	473	6					775	779		10.1007/s00428-018-2420-3			5	Pathology	Pathology	HC0IC	WOS:000451480700014	30171332				2019-10-28	
J	Tiniakos, D; Jurk, D				Tiniakos, Dina; Jurk, Diana			A novel Sudan Black B-based analogue revives lipofuscin as a biomarker for in vivo senescence	VIRCHOWS ARCHIV			English	Editorial Material							CELLS		[Tiniakos, Dina] Newcastle Univ, Fac Med Sci, Inst Cellular Med, Newcastle Upon Tyne, Tyne & Wear, England; [Tiniakos, Dina] Univ Athens, Sch Med, Aretaie Hosp, Dept Pathol, Athens, Greece; [Jurk, Diana] Inst Cell & Mol Biosci ICaMB, Campus Ageing & Vital, Newcastle Upon Tyne, Tyne & Wear, England; [Jurk, Diana] NUIA, Campus Ageing & Vital, Newcastle Upon Tyne, Tyne & Wear, England	Tiniakos, D (reprint author), Newcastle Univ, Fac Med Sci, Inst Cellular Med, Newcastle Upon Tyne, Tyne & Wear, England.; Tiniakos, D (reprint author), Univ Athens, Sch Med, Aretaie Hosp, Dept Pathol, Athens, Greece.	dina.tiniakos@newcastle.ac.uk		Jurk, Diana/0000-0003-4486-0857	Engineering and Physical Sciences Research Council (EPSRC)/Medical Research Council (MRC); AMS (The Academy of Medical Sciences) [REF: SBF003\1179]	DT is Training Strand Lead for the Newcastle Molecular Pathology Node funded by the Engineering and Physical Sciences Research Council (EPSRC)/Medical Research Council (MRC). DJ acknowledges funding from the AMS (The Academy of Medical Sciences, REF: SBF003\1179).	Evangelou K, 2017, AGING CELL, V16, P192, DOI 10.1111/acel.12545; Gorgoulis VG, 2010, CURR OPIN CELL BIOL, V22, P816, DOI 10.1016/j.ceb.2010.07.013; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; Jurk D, 2012, AGING CELL, V11, P996, DOI 10.1111/j.1474-9726.2012.00870.x; Milanovic M, 2018, NATURE, V553, P96, DOI 10.1038/nature25167; Munoz-Espin D, 2014, NAT REV MOL CELL BIO, V15, P482, DOI 10.1038/nrm3823; Myrianthopoulos V, 2019, PHARMACOL THERAPEUT, V193, P31, DOI 10.1016/j.pharmthera.2018.08.006; Ogrodnik M, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15691; Rodier F, 2011, J CELL BIOL, V192, P547, DOI 10.1083/jcb.201009094; Zhu Y, 2015, AGING CELL, V14, P644, DOI 10.1111/acel.12344	10	0	0	2	3	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0945-6317	1432-2307		VIRCHOWS ARCH	Virchows Arch.	DEC	2018	473	6					781	783		10.1007/s00428-018-2452-8			3	Pathology	Pathology	HC0IC	WOS:000451480700015	30225657				2019-10-28	
J	Wang, LS; Zhang, YP; Chen, YB; Skala, SL; Al-Ahmadie, HA; Wang, XM; Cao, XH; Veeneman, BA; Chen, J; Cieslik, M; Qiao, YY; Su, FY; Vats, P; Siddiqui, J; Xiao, H; Sadimin, ET; Epstein, JI; Zhou, M; Sangoi, AR; Trpkov, K; Osunkoya, AO; Giannico, GA; McKenney, JK; Argani, P; Tickoo, SK; Reuter, VE; Chinnaiyan, AM; Dhanasekaran, SM; Mehra, R				Wang, Lisha; Zhang, Yuping; Chen, Ying-Bei; Skala, Stephanie L.; Al-Ahmadie, Hikmat A.; Wang, Xiaoming; Cao, Xuhong; Veeneman, Brendan A.; Chen, Jin; Cieslik, Marcin; Qiao, Yuanyuan; Su, Fengyun; Vats, Pankaj; Siddiqui, Javed; Xiao, Hong; Sadimin, Evita T.; Epstein, Jonathan I.; Zhou, Ming; Sangoi, Ankur R.; Trpkov, Kiril; Osunkoya, Adeboye O.; Giannico, Giovanna A.; McKenney, Jesse K.; Argani, Pedram; Tickoo, Satish K.; Reuter, Victor E.; Chinnaiyan, Arul M.; Dhanasekaran, Saravana M.; Mehra, Rohit			VSTM2A Overexpression Is a Sensitive and Specific Biomarker for Mucinous Tubular and Spindle Cell Carcinoma (MTSCC) of the Kidney	AMERICAN JOURNAL OF SURGICAL PATHOLOGY			English	Article						mucinous tubular and spindle cell carcinoma; biomarker; transcriptome; RNA in situ hybridization; VSTM2A; IRX5	RENAL EPITHELIAL NEOPLASMS; CLASSIFICATION; EVOLUTION; FEATURES; CANCER; GENES	Our recent study revealed recurrent chromosomal losses and somatic mutations of genes in the Hippo pathway in mucinous tubular and spindle cell carcinoma (MTSCC). Here, we performed an integrative analysis of 907 renal cell carcinoma (RCC) samples (combined from The Cancer Genome Atlas and in-house studies) and the Knepper data set of microdissected rat nephrons. We identified VSTM2A and IRX5 as novel cancer-specific and lineage-specific biomarkers in MTSCC. We then assessed their expression by RNA in situ hybridization (ISH) in 113 tumors, including 33 MTSCC, 40 type 1 papillary RCC, 8 type 2 papillary RCC, 2 unclassified RCC, 15 clear cell RCC, and 15 chromophobe RCC. Sensitivity and specificity were calculated as the area under the receiver operating characteristics curve (AUC). All MTSCC tumors demonstrated moderate to high expression of VSTM2A (mean ISH score=255). VSTM2A gene expression assessed by RNA sequencing strongly correlated with VSTM2A ISH score (r(2)=0.81, P=0.00016). The majority of non-MTSCC tumors demonstrated negative or low expression of VSTM2A. IRX5, nominated as a lineage-specific biomarker, showed moderate to high expression in MTSCC tumors (mean ISH score=140). IRX5 gene expression assessed by RNA sequencing strongly correlated with IRX5 ISH score (r(2)=0.69, P=0.00291). VSTM2A (AUC: 99.2%) demonstrated better diagnostic efficacy than IRX5 (AUC: 87.5%), and may thus serve as a potential diagnostic marker to distinguish tumors with overlapping histology. Furthermore, our results suggest MTSCC displays an overlapping phenotypic expression pattern with the loop of Henle region of normal nephrons.	[Wang, Lisha; Zhang, Yuping; Wang, Xiaoming; Cao, Xuhong; Veeneman, Brendan A.; Chen, Jin; Cieslik, Marcin; Qiao, Yuanyuan; Su, Fengyun; Vats, Pankaj; Siddiqui, Javed; Chinnaiyan, Arul M.; Dhanasekaran, Saravana M.; Mehra, Rohit] Univ Michigan, Michigan Ctr Translat Pathol, Ann Arbor, MI 48109 USA; [Wang, Lisha; Zhang, Yuping; Skala, Stephanie L.; Wang, Xiaoming; Cao, Xuhong; Veeneman, Brendan A.; Chen, Jin; Cieslik, Marcin; Qiao, Yuanyuan; Su, Fengyun; Vats, Pankaj; Siddiqui, Javed; Xiao, Hong; Chinnaiyan, Arul M.; Dhanasekaran, Saravana M.; Mehra, Rohit] Univ Michigan, Dept Pathol, Ann Arbor, MI 48109 USA; [Chinnaiyan, Arul M.] Univ Michigan, Dept Urol, Ann Arbor, MI 48109 USA; [Chinnaiyan, Arul M.; Mehra, Rohit] Univ Michigan, Rogel Canc Ctr, Ann Arbor, MI 48109 USA; [Chinnaiyan, Arul M.] Howard Hughes Med Inst, Ann Arbor, MI USA; [Chen, Ying-Bei; Al-Ahmadie, Hikmat A.; Tickoo, Satish K.; Reuter, Victor E.] Mem Sloan Kettering Canc Ctr, Dept Pathol, 1275 York Ave, New York, NY 10021 USA; [Sadimin, Evita T.] Rutgers Canc Inst New Jersey, Dept Pathol, New Brunswick, NJ USA; [Epstein, Jonathan I.; Argani, Pedram] Johns Hopkins Med Inst, Dept Pathol, Baltimore, MD 21205 USA; [Epstein, Jonathan I.; Argani, Pedram] Johns Hopkins Med Inst, Dept Oncol, Baltimore, MD 21205 USA; [Zhou, Ming] Univ Texas Southwestern Med Ctr Dallas, Dept Pathol, Dallas, TX 75390 USA; [Sangoi, Ankur R.] EI Camino Hosp, Dept Pathol, Mountain View, CA USA; [Trpkov, Kiril] Univ Calgary, Dept Pathol & Lab Med, Calgary, AB, Canada; [Osunkoya, Adeboye O.] Emory Univ, Sch Med, Dept Pathol, Atlanta, GA 30322 USA; [Osunkoya, Adeboye O.] Emory Univ, Sch Med, Dept Urol, Atlanta, GA 30322 USA; [Giannico, Giovanna A.] Vanderbilt Univ, Sch Med, Dept Pathol, 221 Kirkland Hall, Nashville, TN 37235 USA; [Giannico, Giovanna A.] Vanderbilt Univ, Sch Med, Dept Microbiol & Immunol, 221 Kirkland Hall, Nashville, TN 37235 USA; [McKenney, Jesse K.] Cleveland Clin, Robert J Tomsich Pathol & Lab Med Inst, Anat Pathol, Cleveland, OH 44106 USA	Mehra, R (reprint author), Michigan Ctr Translat Pathol, Dept Pathol, 1500 E Med Ctr Dr, Ann Arbor, MI 48109 USA.	mrohit@med.umich.edu		Dhanasekaran, saravana mohan/0000-0002-0489-2224			Alexiev BA, 2014, PATHOL RES PRACT, V210, P454, DOI 10.1016/j.prp.2014.03.002; Argani P, 2008, AM J SURG PATHOL, V32, P1353, DOI 10.1097/PAS.0b013e31816a1c34; Chen FJ, 2016, CELL REP, V14, P2476, DOI 10.1016/j.celrep.2016.02.024; Chen HX, 2003, J MAMMARY GLAND BIOL, V8, P159, DOI 10.1023/A:1025996707117; Cheng CW, 2005, DEV BIOL, V287, P48, DOI 10.1016/j.ydbio.2005.08.029; Cheng L, 2009, HUM PATHOL, V40, P10, DOI 10.1016/j.humpath.2008.09.009; Cossu-Rocca P, 2006, MODERN PATHOL, V19, P488, DOI 10.1038/modpathol.3800565; Creighton CJ, 2013, NATURE, V499, P43, DOI 10.1038/nature12222; Davis CF, 2014, CANCER CELL, V26, P319, DOI 10.1016/j.ccr.2014.07.014; Dhillon J, 2009, AM J SURG PATHOL, V33, P44, DOI 10.1097/PAS.0b013e3181829ed5; Dobin A, 2015, CURR PROTOC BIOINFOR, V51; Eble JN, 2003, PATHOLOGY, V35, P499, DOI 10.1080/00313020310001619929; Fine SW, 2006, AM J SURG PATHOL, V30, P1554, DOI 10.1097/01.pas.0000213271.15221.e3; GomezSkarmeta JL, 1996, CELL, V85, P95, DOI 10.1016/S0092-8674(00)81085-5; Kenney PA, 2015, BJU INT, V116, P85, DOI 10.1111/bju.12992; Kouba EJ, 2016, MODERN PATHOL, V29, P1347, DOI 10.1038/modpathol.2016.133; Law CW, 2014, GENOME BIOL, V15, DOI 10.1186/gb-2014-15-2-r29; Lee JW, 2015, J AM SOC NEPHROL, V26, P2669, DOI 10.1681/ASN.2014111067; Liao Y, 2013, NUCLEIC ACIDS RES, V41, DOI 10.1093/nar/gkt214; Lindgren D, 2017, CELL REP, V20, P1476, DOI 10.1016/j.celrep.2017.07.043; Linehan WM, 2016, NEW ENGL J MED, V374, P135, DOI 10.1056/NEJMoa1505917; MacLennan GT, 1997, UROLOGY, V50, P679, DOI 10.1016/S0090-4295(97)00335-X; Mehra R, 2016, CANCER DISCOV, V6, P1258, DOI 10.1158/2159-8290.CD-16-0267; Mehra R, 2016, EUR UROL, V70, P549, DOI 10.1016/j.eururo.2015.12.003; Myrthue A, 2008, CLIN CANCER RES, V14, P3562, DOI 10.1158/1078-0432.CCR-07-4649; Paner GP, 2006, AM J SURG PATHOL, V30, P13, DOI 10.1097/01.pas.0000180443.94645.50; Parwani AV, 2001, HUM PATHOL, V32, P506, DOI 10.1053/hupa.2001.24320; Posadas EM, 2017, NAT REV NEPHROL, V13, P496, DOI 10.1038/nrneph.2017.82; Reggiani L, 2007, GENE DEV, V21, P2358, DOI 10.1101/gad.450707; Ren Q, 2018, AM J SURG PATHOL, V42, P767, DOI 10.1097/PAS.0000000000001038; Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007; Robinson MD, 2010, GENOME BIOL, V11, DOI 10.1186/gb-2010-11-3-r25; Sadimin ET, 2017, HISTOPATHOLOGY, V71, P719, DOI 10.1111/his.13298; Secco B, 2017, CELL REP, V18, P93, DOI 10.1016/j.celrep.2016.12.015; Shen SS, 2007, ANN DIAGN PATHOL, V11, P13, DOI 10.1016/j.anndiagpath.2006.09.005; Shuch B, 2015, EUR UROL, V67, P85, DOI 10.1016/j.eururo.2014.04.029; Skala SL, 2018, MODERN PATHOL, V31, P179, DOI 10.1038/modpathol.2017.99; Udager AM, 2016, ARCH PATHOL LAB MED, V140, P1026, DOI 10.5858/arpa.2016-0218-RA; Udager AM, 2014, AM J SURG PATHOL, V38, P567, DOI 10.1097/PAS.0000000000000127; Udager AM, 2014, CANCER J, V20, P29, DOI 10.1097/PPO.0000000000000017; Ursani NA, 2011, HUM PATHOL, V42, P444, DOI 10.1016/j.humpath.2010.07.018; Wang F, 2012, J MOL DIAGN, V14, P22, DOI 10.1016/j.jmoldx.2011.08.002; Wang LS, 2017, CLIN CANCER RES, V23, P5622, DOI 10.1158/1078-0432.CCR-17-0299; Wang LS, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-39; Wang MT, 2015, CELL, V163, P1237, DOI 10.1016/j.cell.2015.10.041; Zhang YJ, 2018, NAT GENET, V50, P814, DOI 10.1038/s41588-018-0120-1	46	2	2	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0147-5185	1532-0979		AM J SURG PATHOL	Am. J. Surg. Pathol.	DEC	2018	42	12					1571	1584		10.1097/PAS.0000000000001150			14	Pathology; Surgery	Pathology; Surgery	HA7BB	WOS:000450434700001	30285995				2019-10-28	
J	Herlitz, L; Hes, O; Michal, M; Tretiakova, M; Reyes-Mugica, M; Nguyen, JK; Troxell, ML; Przybycin, CG; Magi-Galluzzi, C; McKenney, JK				Herlitz, Leal; Hes, Ondrej; Michal, Michal; Tretiakova, Maria; Reyes-Mugica, Miguel; Nguyen, Jane K.; Troxell, Megan L.; Przybycin, Christopher G.; Magi-Galluzzi, Cristina; McKenney, Jesse K.			"Atrophic Kidney"-like Lesion Clinicopathologic Series of 8 Cases Supporting a Benign Entity Distinct From Thyroid-like Follicular Carcinoma	AMERICAN JOURNAL OF SURGICAL PATHOLOGY			English	Article						atrophic kidney-like tumor; atrophy; thyroid-like follicular carcinoma; glomerulocystic	RENAL-CELL CARCINOMA; FOLLICULAR CARCINOMA; TUMORS; FEATURES; TRISOMY-7; NEOPLASM; TISSUE; WT1; ABNORMALITIES; MORPHOLOGY	Renal mass lesions with a follicular architecture resembling atrophic kidney have been described, but their distinction from thyroid-like follicular carcinoma of the kidney remains controversial. We collected 8 cases of this purported atrophic kidney-like lesion to fully describe their clinical and histologic spectrum, their possible etiology, and to discuss their distinction from other renal neoplasms. Eight total cases were identified with patient ages ranging from 9 to 48 years (mean: 29y; median: 28.5y). Four patients were female and 4 were male. The tumors were unifocal and size ranged from 1.6 to 4.9 cm (mean: 3.4 cm; median: 3.4 cm). All 8 tumors had a remarkably similar histology. Each was enveloped by a smooth muscle rich capsule and had an overall low power follicular architecture. The luminal spaces of the follicles (or cysts) contained eosinophilic secretions and the lining epithelium was often flattened and atrophic, but some had more rounded cells with a distinctive hobnail arrangement. Many cysts contained discohesive round cells floating within the eosinophilic material, and some contained small intraluminal tufts with features of markedly atrophic glomeruli. Periodic acid-Schiff stains highlighted basement membrane material extending into these glomerular-like tufts, and some contained small distinct capillaries surrounded by endothelial cells, interspersed mesangial-like cells, and rare surrounding podocyte-like cells, providing additional evidence for glomerulocystic structures. Scattered calcifications were present within cysts (or within cyst walls) in varying numbers and were characterized by 2 types: psammoma body-like or more amorphous deposits. The tissue between cystic glomeruli contained predominantly small atrophic tubular structures, but collagenized stroma and smaller collapsed glomeruli were also present. The 2 tumors from the oldest 2 patients (48 and 39y) had a more striking degree of stromal hyalinization. Immunohistochemically, the cyst lining cells had a predominant WT-positive/PAX-8 negative/CK7-negative phenotype, while tubules were typically WT-1 negative/PAX-8 positive/CK7-positive. Upon comparison to a control group of 10 kidneys containing incidental non-mass-forming glomerulocystic change, the morphologic features and immunophenotype were identical. To date, no patient has had any recurrence or aggressive clinical behavior based on follow status in 7 of 8 cases (follow-up range: 9 to 168 mo; median: 24 mo; mean: 40 mo). In summary, we describe the clinicopathologic features of 8 unique, benign atrophic kidney-like lesions that may simply represent a non-neoplastic form of organizing tubular atrophy and glomerulocystic change, and emphasize their distinction from thyroid-like follicular carcinoma of the kidney.	[Herlitz, Leal; Nguyen, Jane K.; Przybycin, Christopher G.; Magi-Galluzzi, Cristina; McKenney, Jesse K.] Cleveland Clin, Robert J Tomsich Inst Pathol & Lab Med, Anat Pathol, Cleveland, OH USA; [Hes, Ondrej; Michal, Michal] Charles Univ Prague, Fac Med Plzen, Dept Pathol, Plzen, Czech Republic; [Tretiakova, Maria] Univ Washington, Dept Pathol, Med Ctr, Seattle, WA 98195 USA; [Reyes-Mugica, Miguel] Childrens Hosp Pittsburgh UPMC, Dept Pathol, Pittsburgh, PA USA; [Reyes-Mugica, Miguel] Childrens Hosp Pittsburgh UPMC, Dept Pediat Pathol, Pittsburgh, PA USA; [Troxell, Megan L.] Stanford Univ, Med Ctr, Dept Pathol, Stanford, CA 94305 USA	McKenney, JK (reprint author), Cleveland Clin, 9500 Euclid Ave,L25, Cleveland, OH 44195 USA.	mckennj@ccf.org					Alaghehbandan R, 2017, INT J SURG PATHOL, V25, P379, DOI 10.1177/1066896917696748; Amin MB, 2009, AM J SURG PATHOL, V33, P393, DOI 10.1097/PAS.0b013e31818cb8f5; Amin MB, 2004, MODERN PATHOL, V17, P136; Bariety J, 2006, KIDNEY INT, V69, P194, DOI 10.1038/sj.ki.5000069; Berens S, 2014, PATHOLOGE, V35, P83, DOI 10.1007/s00292-013-1772-3; Bissler JJ, 2010, PEDIATR NEPHROL, V25, P2049, DOI 10.1007/s00467-009-1416-2; Broberg K, 2001, GENE CHROMOSOME CANC, V30, P310, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1096>3.0.CO;2-C; CASALONE R, 1992, HUM GENET, V90, P71; Chen GL, 2007, BLOOD, V110, P1410, DOI 10.1182/blood-2006-09-018655; DALCIN P, 1992, P NATL ACAD SCI USA, V89, P9744, DOI 10.1073/pnas.89.20.9744; Eble JN, 2018, PATHOLOGY, V50, P24, DOI 10.1016/j.pathol.2017.09.005; ELFVING P, 1995, CYTOGENET CELL GENET, V69, P90, DOI 10.1159/000133945; Fadare O, 2010, ANN DIAGN PATHOL, V14, P284, DOI 10.1016/j.anndiagpath.2009.09.008; Gill AJ, 2011, AM J SURG PATHOL, V35, P1578, DOI 10.1097/PAS.0b013e318227e7f4; Hepinstall RH, 1992, PATHOLOGY KIDNEY, P1029; Hes O, 2005, VIRCHOWS ARCH, V446, P383, DOI 10.1007/s00428-004-1187-x; Hes O, 2014, ANN DIAGN PATHOL, V18, P82, DOI 10.1016/j.anndiagpath.2013.12.003; Kann M, 2015, DEVELOPMENT, V142, P1254, DOI 10.1242/dev.119735; Kojima F, 2015, ONCOL LETT, V9, P2368, DOI 10.3892/ol.2015.3060; KREIDBERG JA, 1993, CELL, V74, P679, DOI 10.1016/0092-8674(93)90515-R; Linehan WM, 2016, NEW ENGL J MED, V374, P135, DOI 10.1056/NEJMoa1505917; Maini MK, 1999, IMMUNOL TODAY, V20, P262, DOI 10.1016/S0167-5699(99)01472-3; Padilha M, 2013, HISTOPATHOLOGY, V62, P941, DOI 10.1111/his.12106; MARCUSSEN N, 1991, LAB INVEST, V65, P558; Michal M, 1998, Ann Diagn Pathol, V2, P149, DOI 10.1016/S1092-9134(98)80001-4; Moch H, 2016, WHO CLASSIFICATION T, P16; Muscara MJ, 2017, INT J SURG PATHOL, V25, P73, DOI 10.1177/1066896916662153; NADASDY T, 1994, HUM PATHOL, V25, P22, DOI 10.1016/0046-8177(94)90166-X; Ohe C, 2010, HISTOPATHOLOGY, V57, P494, DOI 10.1111/j.1365-2559.2010.03631.x; Oshiro Y, 2014, PATHOL INT, V64, P478, DOI 10.1111/pin.12193; Rao Q, 2012, AM J SURG PATHOL, V36, P1327, DOI 10.1097/PAS.0b013e31825aafb5; Rito M, 2017, PATHOL RES PRACT, V213, P286, DOI 10.1016/j.prp.2016.11.011; RYAN G, 1995, DEVELOPMENT, V121, P867; SANDERS PW, 1990, J CLIN INVEST, V85, P570, DOI 10.1172/JCI114474; SELYE H, 1946, J UROLOGY, V56, P399, DOI 10.1016/S0022-5347(17)69823-9; vandenBerg E, 1995, CANCER GENET CYTOGEN, V85, P152, DOI 10.1016/0165-4608(95)00035-6; Yang YX, 1999, AM J PATHOL, V154, P181, DOI 10.1016/S0002-9440(10)65264-9	37	1	1	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0147-5185	1532-0979		AM J SURG PATHOL	Am. J. Surg. Pathol.	DEC	2018	42	12					1585	1595		10.1097/PAS.0000000000001157			11	Pathology; Surgery	Pathology; Surgery	HA7BB	WOS:000450434700002	30285996				2019-10-28	
J	Pors, J; Cheng, A; Leo, JM; Kinloch, MA; Gilks, B; Hoang, L				Pors, Jennifer; Cheng, Angela; Leo, Joyce M.; Kinloch, Mary A.; Gilks, Blake; Hoang, Lynn			A Comparison of GATA3, TTF1, CD10, and Calretinin in Identifying Mesonephric and Mesonephric-like Carcinomas of the Gynecologic Tract	AMERICAN JOURNAL OF SURGICAL PATHOLOGY			English	Article						mesonephric carcinoma; mesonephric-like carcinoma; mesonephric carcinosarcoma; diagnosis; histology; immunohistochemistry; GATA3; TTF1; CD10; calretinin	FEMALE GENITAL-TRACT; RECURRENT KRAS MUTATIONS; UTERINE CERVIX; ENDOMETRIAL CANCER; USEFUL MARKER; ADENOCARCINOMA; EXPRESSION; CORPUS; TUMORS; IMMUNOREACTIVITY	Mesonephric carcinomas of the gynecologic tract are neoplasms that are often under-recognized due to their varied morphologic appearances. Recently, GATA3 and TTF1 have been reported to be useful immunohistochemical markers for distinguishing mesonephric carcinomas from its morphologic mimics. Herein, we compared the performance of GATA3 and TTF1 to the traditional markers used for mesonephric carcinomas, CD10 and calretinin. We studied 694 cases: 8 mesonephric carcinomas (7 cervical [includes 3 mesonephric carcinosarcomas], 1 vaginal), 5 mesonephric-like carcinomas (4 uterine corpus, 1 ovarian), 585 endometrial adenocarcinomas, and 96 cervical adenocarcinomas. Mesonephric-like carcinomas were defined as tumors exhibiting the classic morphologic features of mesonephric carcinoma, but occurring outside of the cervix and without convincing mesonephric remnants. GATA3 had the highest sensitivity and specificity (91% and 94%) compared with TTF1 (45% and 99%), CD10 (73% and 83%), and calretinin (36% and 89%). GATA3, however, also stained a substantial number of uterine carcinosarcomas (23/113, 20%). TTF1 was positive in 5/5 (100%) mesonephric-like carcinomas and only 1/8 (13%) mesonephric carcinomas. In 4/6 (67%) TTF1 positive cases, GATA3 exhibited an inverse staining pattern with TTF1. In summary, GATA3 was the best overall marker for mesonephric and mesonephric-like carcinomas, but cannot be used to distinguish mesonephric carcinosarcomas from Mullerian carcinosarcomas. The inverse staining pattern between GATA3 and TTF1, suggests that TTF1 may be useful when GATA3 is negative in small biopsies where mesonephric or mesonephric-like carcinoma is suspected. The greater TTF1 positivity in mesonephric-like carcinomas suggests they may be biologically different from prototypical mesonephric carcinomas.	[Pors, Jennifer; Gilks, Blake; Hoang, Lynn] Vancouver Gen Hosp, Dept Pathol & Lab Med, Vancouver, BC, Canada; [Pors, Jennifer; Gilks, Blake; Hoang, Lynn] Univ British Columbia, Vancouver, BC, Canada; [Cheng, Angela; Gilks, Blake; Hoang, Lynn] Genet Pathol Evaluat Ctr, Vancouver, BC, Canada; [Leo, Joyce M.] Royal Jubilee Hosp, Dept Pathol, Victoria, BC, Canada; [Kinloch, Mary A.] Saskatoon City Hosp, Dept Pathol, Saskatoon, SK, Canada	Hoang, L (reprint author), Univ British Columbia, Vancouver Gen Hosp, Dept Pathol & Lab Med, 1215-910 West 10th Ave, Vancouver, BC V5Z 1M9, Canada.	lien.hoang@vch.ca		Pors, Jennifer/0000-0002-8675-916X; Kinloch, Mary/0000-0002-0092-0312			Anagnostopoulos A, 2012, BMJ CASE REP, V2012, P1; Ando H, 2017, DIAGN PATHOL, V12, DOI 10.1186/s13000-017-0655-y; Bague S, 2004, AM J SURG PATHOL, V28, P601, DOI 10.1097/00000478-200405000-00006; Cavalcanti MS, 2017, INT J GYNECOL PATHOL, V36, P76, DOI 10.1097/PGP.0000000000000306; Chapel DB, 2018, INT J GYNECOL PATHOL, V37, P448, DOI 10.1097/PGP.0000000000000444; CLEMENT PB, 1995, AM J SURG PATHOL, V19, P1158, DOI 10.1097/00000478-199510000-00006; Ervine A, 2014, HISTOPATHOLOGY, V64, P840, DOI 10.1111/his.12332; FERRY JA, 1990, AM J SURG PATHOL, V14, P1100, DOI 10.1097/00000478-199012000-00002; Getz G, 2013, NATURE, V497, P67, DOI 10.1038/nature12113; Hoang LN, 2014, INT J GYNECOL PATHOL, V33, P483, DOI 10.1097/PGP.0b013e31829ff239; Houghton O, 2010, HISTOPATHOLOGY, V57, P342, DOI 10.1111/j.1365-2559.2010.03632.x; Howitt BE, 2018, PATHOLOGY, V50, P141, DOI 10.1016/j.pathol.2017.11.084; Howitt BE, 2015, AM J SURG PATHOL, V39, P1411, DOI 10.1097/PAS.0000000000000471; Kenny SL, 2012, AM J SURG PATHOL, V36, P799, DOI 10.1097/PAS.0b013e31824a72c6; Kim SS, 2016, INT J SURG PATHOL, V24, P153, DOI 10.1177/1066896915611489; Le Gallo M, 2014, CLIN CHEM, V60, P98, DOI 10.1373/clinchem.2013.205740; Marquette A, 2006, INT J GYNECOL CANCER, V16, P1450, DOI 10.1111/j.1525-1438.2006.00489.x; McCluggage WG, 2003, HISTOPATHOLOGY, V43, P144, DOI 10.1046/j.1365-2559.2003.01684.x; McFarland M, 2016, HISTOPATHOLOGY, V68, P1013, DOI 10.1111/his.12895; Miettinen M, 2014, AM J SURG PATHOL, V38, P13, DOI 10.1097/PAS.0b013e3182a0218f; Mirkovic J, 2018, AM J SURG PATHOL, V42, P227, DOI 10.1097/PAS.0000000000000958; Mirkovic J, 2015, MODERN PATHOL, V28, P1504, DOI 10.1038/modpathol.2015.103; Mirkovic J, 2015, HISTOPATHOLOGY, V67, P636, DOI 10.1111/his.12681; Na K, 2019, AM J SURG PATHOL, V43, P12, DOI 10.1097/PAS.0000000000000991; Ordi J, 2003, AM J SURG PATHOL, V27, P178, DOI 10.1097/00000478-200302000-00005; Ordi J, 2001, AM J SURG PATHOL, V25, P1540, DOI 10.1097/00000478-200112000-00011; Ordonez NG, 2012, APPL IMMUNOHISTO M M, V20, P429, DOI 10.1097/PAI.0b013e31825439bc; Pirog EC, 2000, AM J PATHOL, V157, P1055, DOI 10.1016/S0002-9440(10)64619-6; Roma AA, 2015, INT J GYNECOL PATHOL, V34, P480, DOI 10.1097/PGP.0000000000000167; Roma AA, 2014, INT J GYNECOL PATHOL, V33, P624, DOI 10.1097/PGP.0000000000000088; Siami K, 2007, AM J SURG PATHOL, V31, P1759, DOI 10.1097/PAS.0b013e3181131e21; Silver SA, 2001, AM J SURG PATHOL, V25, P379, DOI 10.1097/00000478-200103000-00013; Stolnicu S, 2018, AM J SURG PATHOL, V42, P214, DOI 10.1097/PAS.0000000000000986; Talhouk A, 2015, BRIT J CANCER, V113, P299, DOI 10.1038/bjc.2015.190; Talhouk A, 2017, CANCER-AM CANCER SOC, V123, P802, DOI 10.1002/cncr.30496; Vang R, 2011, BLAUSTEIN'S PATHOLOGY OF THE FEMALE GENITAL TRACT, SIXTH EDITION, P529, DOI 10.1007/978-1-4419-0489-8_11; Wani Y, 2008, INT J GYNECOL PATHOL, V27, P346, DOI [10.1097/PGP.0b013e318166067f, 10.1097/PGP.0b013618166067f]	37	3	3	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0147-5185	1532-0979		AM J SURG PATHOL	Am. J. Surg. Pathol.	DEC	2018	42	12					1596	1606		10.1097/PAS.0000000000001142			11	Pathology; Surgery	Pathology; Surgery	HA7BB	WOS:000450434700003	30148742				2019-10-28	
J	Dhall, D; Kim, SA; Mc Phaul, C; Kransdorf, EP; Kobashigawa, JA; Sundaram, V; Mirocha, J; Guindi, M				Dhall, Deepti; Kim, Stacey A.; Mc Phaul, Christopher; Kransdorf, Evan P.; Kobashigawa, Jon A.; Sundaram, Vinay; Mirocha, James; Guindi, Maha			Heterogeneity of Fibrosis in Liver Biopsies of Patients With Heart Failure Undergoing Heart Transplant Evaluation	AMERICAN JOURNAL OF SURGICAL PATHOLOGY			English	Article						congestive hepatopathy; congestive liver disease; fibrosis; liver biopsy; nodular regenerative hyperplasia; heart failure; heart transplant	HEPATIC-FIBROSIS; OUTCOME PREDICTION; CARDIAC CIRRHOSIS; DYSFUNCTION; STIFFNESS; FEATURES; DISEASE	Liver biopsies are commonly performed in heart transplant candidates to confirm congestive hepatopathy (CH) and to assess the degree of fibrosis. Heterogeneity of fibrosis is frequent in CH, making it difficult to stage fibrosis. In this study, we evaluated the prevalence of heterogeneity of fibrosis and nodular regenerative hyperplasia (NRH) in liver biopsies with CH secondary to heart failure. Fifty liver biopsies with CH secondary to heart failure were reviewed. The fibrosis was scored on trichrome stain as follows: stage 0 for no fibrosis, stage 1 for zone 3 fibrosis, stage 2 for zone 3 and portal fibrosis, stage 3 for bridging fibrosis, and stage 4 for cirrhosis. Both stage 3 and stage 4 fibrosis were classified as advanced fibrosis. A predominant pattern of fibrosis and a secondary pattern of fibrosis, defined as a different stage of fibrosis seen in at least 10% of the biopsy material, if present, were recorded. A biopsy was considered to show heterogenous fibrosis if there was at least a 2 stage difference between the predominant and secondary patterns. Thirteen biopsies (26%) showed heterogenous fibrosis. Sixteen biopsies (32%) showed some evidence of advanced fibrosis: 5 had uniform advanced fibrosis, 4 had predominant pattern of advanced fibrosis, and advanced fibrosis was focal in 7 biopsies from 6 patients. NRH-type changes were seen in 9 of 50 biopsies (18%). In conclusion, our study showed heterogenous fibrosis in the liver biopsy of a quarter of patients with CH due to heart failure, highlighting the limitations of fibrosis assessment in the biopsies, and suggests that correlation with the complete clinical information is essential for management decisions.	[Dhall, Deepti; Kim, Stacey A.; Mc Phaul, Christopher; Guindi, Maha] Cedars Sinai Med Ctr, Dept Pathol & Lab Med, Los Angeles, CA 90048 USA; [Mirocha, James] Cedars Sinai Med Ctr, Biostat Core, Los Angeles, CA 90048 USA; [Kransdorf, Evan P.; Kobashigawa, Jon A.] Cedars Sinai Med Ctr, Smidt Heart Inst, Los Angeles, CA 90048 USA; [Sundaram, Vinay] Cedars Sinai Med Ctr, Div Gastroenterol, Los Angeles, CA 90048 USA; [Sundaram, Vinay] Cedars Sinai Med Ctr, Comprehens Transplant Ctr, Los Angeles, CA 90048 USA	Dhall, D (reprint author), Cedars Sinai Med Ctr, Dept Pathol, 8700 Beverly Blvd, Los Angeles, CA 90048 USA.	deepti.dhall@cshs.org		Kobashigawa, Jon/0000-0001-9308-3172			Atluri P, 2014, ANN THORAC SURG, V98, P858, DOI 10.1016/j.athoracsur.2014.04.100; Bedossa P, 2003, HEPATOLOGY, V38, P1449, DOI 10.1016/j.hep.2003.09.022; Boland EW, 1938, ARCH INTERN MED, V62, P723, DOI 10.1001/archinte.1938.00180160002001; Cannon RM, 2012, TRANSPL INT, V25, P1223, DOI 10.1111/j.1432-2277.2012.01551.x; Chokshi A, 2012, J HEART LUNG TRANSPL, V31, P591, DOI 10.1016/j.healun.2012.02.008; Crespo-Leiro MG, 2008, AM J TRANSPLANT, V8, P1336, DOI 10.1111/j.1600-6143.2008.02227.x; Dai DF, 2014, MODERN PATHOL, V27, P1552, DOI 10.1038/modpathol.2014.79; Ditchl W, 2005, TRANSPL INT, V18, P697; Farr M, 2015, J HEART LUNG TRANSPL, V34, P873, DOI 10.1016/j.healun.2014.12.009; Gelow JM, 2010, CIRC-HEART FAIL, V3, P59, DOI 10.1161/CIRCHEARTFAILURE.109.872556; Hsu RB, 2008, EUR J CARDIO-THORAC, V34, P307, DOI 10.1016/j.ejcts.2008.05.003; Jharap B, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0120299; Krings G, 2014, AM J SURG PATHOL, V38, P205, DOI 10.1097/PAS.0000000000000099; Lebray P, 2008, HEPATOLOGY, V48, P2089, DOI 10.1002/hep.22594; LEFKOWITCH JH, 1986, J HEPATOL, V2, P313, DOI 10.1016/S0168-8278(86)80043-5; Louie CY, 2015, MODERN PATHOL, V28, P932, DOI 10.1038/modpathol.2015.40; Mehra MR, 2016, J HEART LUNG TRANSPL, V35, P1, DOI 10.1016/j.healun.2015.10.023; Myers RP, 2003, HEPATOLOGY, V37, P393, DOI 10.1053/jhep.2003.50062; Park Y, 2013, EUR J GASTROEN HEPAT, V25, P385, DOI 10.1097/MEG.0b013e32835b9bc9; Samsky MD, 2013, J AM COLL CARDIOL, V61, P2397, DOI 10.1016/j.jacc.2013.03.042; WANLESS IR, 1995, HEPATOLOGY, V21, P1232, DOI 10.1002/hep.1840210504	21	1	1	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0147-5185	1532-0979		AM J SURG PATHOL	Am. J. Surg. Pathol.	DEC	2018	42	12					1617	1624		10.1097/PAS.0000000000001163			8	Pathology; Surgery	Pathology; Surgery	HA7BB	WOS:000450434700005	30273196				2019-10-28	
J	Bove, KE; Thrasher, AD; Anders, R; Chung, CT; Cummings, OW; Finegold, MJ; Finn, L; Ranganathan, S; Kim, GE; Lovell, M; Magid, MS; Melin-Aldana, H; Russo, P; Shehata, B; Wang, L; White, F; Chen, Z; Spino, C; Magee, JC				Bove, Kevin E.; Thrasher, Andrew D.; Anders, Robert; Chung, Catherine T.; Cummings, Oscar W.; Finegold, Milton J.; Finn, Laura; Ranganathan, Sarangarajan; Kim, Grace E.; Lovell, Mark; Magid, Margret S.; Melin-Aldana, Hector; Russo, Pierre; Shehata, Bahig; Wang, Larry; White, Francis; Chen, Zhen; Spino, Catherine; Magee, John C.			Inflammation, Active Fibroplasia, and End-stage Fibrosis in 172 Biliary Atresia Remnants Correlate Poorly With Age at Kasai Portoenterostomy, Visceral Heterotaxy, and Outcome	AMERICAN JOURNAL OF SURGICAL PATHOLOGY			English	Article						biliary atresia; extrahepatic bile ducts; histogenesis; hilar plate; Kasai portoenterostomy; age; heterotaxy; outcome	PORTA-HEPATIS; ETIOLOGY; DIAGNOSIS; SURVIVAL; LIVER	Published histologic studies of the hilar plate or entire biliary remnant at the time of Kasai portoenterostomy (KHPE) have not provided deep insight into the pathogenesis of biliary atresia, relation to age at surgery, prognosis or the basis for successful drainage. We report detailed histologic findings in 172 centrally reviewed biliary remnants with an average of 6 sections per subject. Active lesions were classified as either necroinflammatory (rare/clustered in a few subjects) or active concentric fibroplasia with or without inflammation (common). Inactive lesions showed bland replacement by collagen and fibrous cords with little or no inflammation. Heterogeneity was common within a given remnant; however, relatively homogenous histologic patterns, defined as 3 or more inactive or active levels in the hepatic ducts levels, characterized most remnants. Homogeneity did not correlate with age at KHPE, presence/absence of congenital anomalies at laparotomy indicative of heterotaxy and outcome. Remnants from youngest subjects were more likely than older subjects to be homogenously inactive suggesting significantly earlier onset in the youngest subset. Conversely remnants from the oldest subjects were often homogenously active suggesting later onset or slower progression. More data are needed in remnants from subjects <30 days old at KHPE and in those with visceral anomalies. Prevalence of partially preserved epithelium in active fibroplastic biliary atresia lesions at all ages suggests that epithelial regression or injury may not be a primary event or that reepithelialization is already underway at the time of KHPE. We hypothesize that outcome after KHPE results from competition between active fibroplasia and reepithelialization of retained, collapsed but not obliterated lumens. The driver of active fibroplasia is unknown.	[Bove, Kevin E.; Thrasher, Andrew D.] Cincinnati Childrens Hosp Med Ctr, Div Pathol, Cincinnati, OH 45229 USA; [Bove, Kevin E.; Thrasher, Andrew D.] Cincinnati Childrens Hosp Med Ctr, Lab Med, Cincinnati, OH 45229 USA; [Anders, Robert] Johns Hopkins Sch Med, Dept Pathol, Baltimore, MD USA; [Chung, Catherine T.] Hosp Sick Children, Div Pathol, Toronto, ON, Canada; [Cummings, Oscar W.] Indiana Univ Sch Med, Dept Pathol, Indianapolis, IN 46202 USA; [Finegold, Milton J.] Texas Childrens Hosp, Dept Pathol, Houston, TX 77030 USA; [Finn, Laura] Seattle Childrens Hosp, Dept Labs, Seattle, WA USA; [Ranganathan, Sarangarajan] Childrens Hosp Pittsburgh UPMC, Dept Pathol, Pittsburgh, PA 15213 USA; [Russo, Pierre] Childrens Hosp Philadelphia, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA; [Kim, Grace E.] Univ Calif San Francisco, Dept Anat Pathol, San Francisco, CA 94143 USA; [Lovell, Mark] Childrens Hosp Colorado, Dept Pathol, Aurora, CO USA; [Magid, Margret S.] Mt Sinai Med Ctr, Kravis Childrens Hosp, Dept Pathol, New York, NY 10029 USA; [Melin-Aldana, Hector] Ann & Robert H Lurie Childrens Hosp, Dept Pathol, Chicago, IL USA; [Shehata, Bahig] Childrens Healthcare Atlanta, Dept Pathol, Atlanta, GA USA; [Wang, Larry] Childrens Hosp Los Angeles, Dept Pathol, Los Angeles, CA USA; [White, Francis] Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO USA; [Chen, Zhen] Quest Diagnost, Hlth Informat, Madison, NJ USA; [Spino, Catherine] Univ Michigan, Sch Publ Hlth, Ann Arbor, MI 48109 USA; [Magee, John C.] Univ Michigan, Dept Surg, Ann Arbor, MI 48109 USA	Bove, KE (reprint author), Cincinnati Childrens Hosp, Cincinnati, OH 45229 USA.	boveke@ucmail.uc.edu			National Institute of Diabetes, Digestive and Kidney DiseasesUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [DK 62445, DK 62497, DK 62470, DK62481, DK 62456, DK 84536, DK 84575, DK 62500, DK 62503, DK 62466, DK 62453, DK 62452, DK 84538, DK 62436]	Supported by U01 grants from the National Institute of Diabetes, Digestive and Kidney Diseases (DK 62445 [Mount Sinai School of Medicine], DK 62497 [Cincinnati Children's Hospital Medical Center], DK 62470 [Children's Healthcare of Atlanta], DK62481 [The Children's Hospital of Philadelphia], DK 62456 [The University of Michigan], DK 84536 [Riley Hospital for Children], DK 84575 [Seattle Children's Hospital], DK 62500 [UCSF Children's Hospital], DK 62503 [Johns Hopkins School of Medicine], DK 62466 [Children's Hospital of Pittsburgh of UPMC], DK 62453 [Children's Hospital Colorado], DK 62452 [Washington University School of Medicine], DK 84538 [Children's Hospital Los Angeles], DK 62436 [Ann & Robert H Lurie Children's Hospital of Chicago]). The authors have disclosed that they have no significant relationships with, or financial interest in, any commercial companies pertaining to this article.	Arva NC, 2015, PATHOL RES PRACT, V211, P252, DOI 10.1016/j.prp.2014.12.003; Bove KE, 2018, PEDIATR DEVEL PATHOL, V21, P29, DOI 10.1177/1093526617707851; Yam-Puc JC, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00188; Chen G, 2012, J PEDIATR SURG, V47, P2184, DOI 10.1016/j.jpedsurg.2012.09.002; Davenport M, 2004, J PEDIATR SURG, V39, P575, DOI 10.1016/j.jpedsurg.2003.12.014; Davenport M, 2008, ANN SURG, V247, P694, DOI 10.1097/SLA.0b013e3181638627; De Jong IEM, 2017, BIOCHIM BIOPHYS ACTA, V17, P30272; Feldman AG, 2012, SEMIN PEDIATR SURG, V21, P192, DOI 10.1053/j.sempedsurg.2012.05.003; GAUTIER M, 1981, ARCH PATHOL LAB MED, V105, P397; GAUTIER M, 1976, J PEDIATR-US, V89, P704, DOI 10.1016/S0022-3476(76)80787-1; GAUTIER M, 1979, ARCH FR PEDIATR, V36, pR3; Harpavat S, 2016, NEW ENGL J MED, V375, P605, DOI 10.1056/NEJMc1601230; Harpavat S, 2016, J PEDIATR GASTR NUTR, V62, P799, DOI 10.1097/MPG.0000000000001097; Humphrey TM, 2007, RADIOLOGY, V244, P845, DOI 10.1148/radiol.2443061051; Kolb M, 2017, THORAX, V72, P340, DOI 10.1136/thoraxjnl-2016-208710; Lobeck IN, 2017, AM J SURG PATHOL, V41, P354, DOI 10.1097/PAS.0000000000000805; Mack CL, 2012, SEMIN LIVER DIS, V32, P307, DOI 10.1055/s-0032-1329899; Magalhaes S M, 2001, Rev Soc Bras Med Trop, V34, P365; Mirkin LD, 1997, PEDIATR PATHOL LAB M, V17, P587, DOI 10.1080/107710497174552; Nakamura H, 2017, J LAPAROENDOSC ADV S, V27, P744, DOI 10.1089/lap.2016.0202; Petersen C, 2013, ORPHANET J RARE DIS, V8, DOI 10.1186/1750-1172-8-128; Russo P, 2016, AM J SURG PATHOL, V40, P1601, DOI 10.1097/PAS.0000000000000755; Schwarz KB, 2013, HEPATOLOGY, V58, P1724, DOI 10.1002/hep.26512; Serinet MO, 2009, PEDIATRICS, V123, P1280, DOI 10.1542/peds.2008-1949; Shen O, 2017, EARLY HUM DEV, V111, P16, DOI 10.1016/j.earlhumdev.2017.05.005; Song Z, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000007267; Stahlschmidt J, 2008, J PEDIATR SURG, V43, P1328, DOI 10.1016/j.jpedsurg.2007.09.017; Superina R, 2011, ANN SURG, V254, P577, DOI 10.1097/SLA.0b013e3182300950; TAN CEL, 1994, J PEDIATR SURG, V29, P1459, DOI 10.1016/0022-3468(94)90144-9; Tanaka H, 2015, J PEDIATR SURG, V50, P507, DOI 10.1016/j.jpedsurg.2014.08.002; Volpert D, 2001, J PEDIATR GASTR NUTR, V32, P265, DOI 10.1097/00005176-200103000-00006; Wong KKY, 2010, J PEDIATR GASTR NUTR, V51, P631, DOI 10.1097/MPG.0b013e3181e8e194; Zheng S, 2008, EUR J PEDIATR SURG, V18, P98, DOI 10.1055/s-2008-1038360	33	0	0	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0147-5185	1532-0979		AM J SURG PATHOL	Am. J. Surg. Pathol.	DEC	2018	42	12					1625	1635		10.1097/PAS.0000000000001146			11	Pathology; Surgery	Pathology; Surgery	HA7BB	WOS:000450434700006	30247160	Green Accepted			2019-10-28	
J	Walters, M; Pittelkow, MR; Hasserjian, RP; Harris, NL; Macon, WR; Kurtin, PJ; Rech, KLG				Walters, Matthew; Pittelkow, Mark R.; Hasserjian, Robert P.; Harris, Nancy Lee; Macon, William R.; Kurtin, Paul J.; Rech, Karen L. G.			Follicular Dendritic Cell Sarcoma With Indolent T-Lymphoblastic Proliferation Is Associated With Paraneoplastic Autoimmune Multiorgan Syndrome	AMERICAN JOURNAL OF SURGICAL PATHOLOGY			English	Article						follicular dendritic cell sarcoma; paraneoplastic autoimmune multiorgan syndrome; paraneoplastic pemphigus; indolent T-lymphoblastic proliferation; TdT; autoimmunity	VASCULAR CASTLEMANS-DISEASE; OF-THE-LITERATURE; PEMPHIGUS; LYMPHOMA; TUMORS; CLASSIFICATION; EXPRESSION; NEOPLASMS; CLUSTERIN	Nonclonal expansions of immature T cells outside of the thymus, termed indolent T-lymphoblastic proliferation (iT-LBP), have been identified in rare lymphoproliferative disorders. We report that iT-LBP is a frequent finding in cases of follicular dendritic cell sarcoma (FDCS), and shows an association with paraneoplastic autoimmune multiorgan syndrome (PAMS). We studied 31 cases of FDCS by paraffin immunohistochemistry using antibodies to CD21, CD23, CD35, clusterin, CXCL13, podoplanin, CD3, CD4, CD8, CD20, CD1a, and TdT. Chart review was performed to characterize the clinical behavior including evidence of autoimmune disease. FDCS occurred in a wide variety of nodal and extranodal sites. Fourteen of 31 (45%) cases contained immature TdT-positive T cells; in 5 cases these cells were numerous and present throughout the tumor. Four of these 5 patients with numerous immature T cells developed autoimmune disease, clinically categorized as PAMS and/or myasthenia gravis. PAMS persisted after tumor resection, causing severe morbidity and mortality. These findings suggest that the neoplastic follicular dendritic cells can recruit or foster the proliferation of immature T cells and that these cells may play a role in mediating PAMS. Recognition of iT-LBP in FDCS is important to avoid misdiagnosis as thymoma or T-lymphoblastic lymphoma, and may predict serious autoimmune complications in some patients.	[Walters, Matthew] Aurora Bay Care Med Ctr, Green Bay, WI USA; [Pittelkow, Mark R.] Mayo Clin, Dept Dermatol, Scottsdale, AZ USA; [Hasserjian, Robert P.; Harris, Nancy Lee] Harvard Med Sch, Massachusetts Gen Hosp, Dept Pathol, Boston, MA USA; [Macon, William R.; Kurtin, Paul J.; Rech, Karen L. G.] Mayo Clin, Dept Lab Med & Pathol, Rochester, MN USA	Rech, KLG (reprint author), Mayo Clin, Dept Lab Med & Pathol, Div Hematopathol, 200 First St SW, Rochester, MN 55905 USA.	rech.karen@mayo.edu					Billet SE, 2006, AUTOIMMUNITY, V39, P617, DOI 10.1080/08916930600972099; Bowen GM, 2000, ARCH DERMATOL, V136, P652, DOI 10.1001/archderm.136.5.652; Ceresoli Giovanni Luca, 2003, Haematologica, V88, pECR04; Chan ACL, 2001, HISTOPATHOLOGY, V38, P510, DOI 10.1046/j.1365-2559.2001.01134.x; CHAN JKC, 1994, AM J SURG PATHOL, V18, P517, DOI 10.1097/00000478-199405000-00013; Chan JKC, 1997, CANCER, V79, P294; Chan LS, 2000, ARCH DERMATOL, V136, P663, DOI 10.1001/archderm.136.5.663; Chow Simon C Y, 2015, Asian Cardiovasc Thorac Ann, V23, P732, DOI 10.1177/0218492314561501; Didona D, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00779; Duan GJ, 2010, AM J CLIN PATHOL, V133, P49, DOI 10.1309/AJCP7U8YISBUAVNW; Ferede A, 2018, BMJ CASE REP, V2018; Gill Harinder, 2010, Br J Haematol, V149, P464, DOI 10.1111/j.1365-2141.2010.08075.x; Grogg KL, 2005, MODERN PATHOL, V18, P260, DOI 10.1038/modpathol.3800294; Grogg KL, 2004, AM J SURG PATHOL, V28, P988, DOI 10.1097/01.pas.0000112536.76973.7f; Hartert M, 2010, AM J SURG PATHOL, V34, P742, DOI 10.1097/PAS.0b013e3181d7a2ee; Hsu C, 2011, J CLIN ONCOL, V29, pE369, DOI 10.1200/JCO.2010.32.7932; Jabbour MN, 2014, APPL IMMUNOHISTO M M, V22, P705, DOI 10.1097/PAI.0b013e318224a5ce; Jonkman MF, 2018, BRIT J DERMATOL, V178, pE146, DOI 10.1111/bjd.16146; Kim WY, 2010, HUM PATHOL, V41, P129, DOI 10.1016/j.humpath.2009.05.014; Laginestra MA, 2017, MOL CANCER RES, V15, P541, DOI 10.1158/1541-7786.MCR-16-0301; Lee IJ, 1999, J AM ACAD DERMATOL, V40, P294, DOI 10.1016/S0190-9622(99)70468-8; Lee SE, 2008, ACTA DERM-VENEREOL, V88, P410, DOI 10.2340/00015555-0446; Marzano AV, 2005, BRIT J DERMATOL, V153, P214, DOI 10.1111/j.1365-2133.2005.06695.x; Meijs M, 2008, INT J DERMATOL, V47, P632, DOI 10.1111/j.1365-4632.2008.03444.x; Nguyen VT, 2001, ARCH DERMATOL, V137, P193; Ohgami RS, 2013, ADV ANAT PATHOL, V20, P137, DOI 10.1097/PAP.0b013e31828d17ec; Ohgami RS, 2012, AM J SURG PATHOL, V36, P1619, DOI 10.1097/PAS.0b013e318264e223; Okahashi K, 2017, BRIT J DERMATOL, V176, P1406, DOI 10.1111/bjd.15389; Pileri SA, 2002, HISTOPATHOLOGY, V41, P1, DOI 10.1046/j.1365-2559.2002.01418.x; Sage PT, 2018, J IMMUNOL, V200, P2592, DOI 10.4049/jimmunol.1701231; Sander B, 2007, HUM PATHOL, V38, P668, DOI 10.1016/j.humpath.2006.08.030; Saygin C, 2013, CRIT REV ONCOL HEMAT, V88, P253, DOI 10.1016/j.critrevonc.2013.05.006; Soriano A, 2007, AM J HEMATOL, V82, P725, DOI 10.1002/ajh.20852; Su Z, 2015, INT J CLIN EXP PATHO, V8, P11983; Sugiura K, 2013, JAMA DERMATOL, V149, P111, DOI 10.1001/2013.jamadermatol.512; Wang J, 2005, BRIT J DERMATOL, V153, P558, DOI 10.1111/j.1365-2133.2005.06599.x; Yamada H, 2012, BRIT J DERMATOL, V166, P230, DOI 10.1111/j.1365-2133.2011.10520.x; Zhu XJ, 2007, J DERMATOL, V34, P503, DOI 10.1111/j.1346-8138.2007.00322.x	38	3	3	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0147-5185	1532-0979		AM J SURG PATHOL	Am. J. Surg. Pathol.	DEC	2018	42	12					1647	1652		10.1097/PAS.0000000000001158			6	Pathology; Surgery	Pathology; Surgery	HA7BB	WOS:000450434700008	30222603				2019-10-28	
J	Agaram, NP; Zhang, L; Cotzia, P; Antonescu, CR				Agaram, Narasimhan P.; Zhang, Lei; Cotzia, Paolo; Antonescu, Cristina R.			Expanding the Spectrum of Genetic Alterations in Pseudomyogenic Hemangioendothelioma With Recurrent Novel ACTB-FOSB Gene Fusions	AMERICAN JOURNAL OF SURGICAL PATHOLOGY			English	Article						ACTB; SERPINE1; FOSB; pseudomyogenic hemangioendothelioma	SARCOMA-LIKE HEMANGIOENDOTHELIOMA; EPITHELIOID SARCOMA; BONE; HEMANGIOMA; REARRANGEMENTS; HYBRIDIZATION; PERICYTOMA; NEOPLASM; T(7/12); SUBSET	Pseudomyogenic hemangioendothelioma (PHE) is an uncommon, rarely metastasizing vascular neoplasm with predilection to affect young adults. The tumors often present as multiple nodules involving various tissue planes, including superficial and deep soft tissues as well as bone. Recurrent SERPINE1-FOSB gene fusions have been reported as the hallmark genetic abnormality in PHE, however, in our experience, a number of cases with typical histology lack this genetic abnormality. In this study, we identify a novel ACTB-FOSB gene fusion, which is as prevalent as the initial translocation reported. We selected 15 consecutive cases of PHE with typical morphologic features which had material for molecular testing. The cohort included 10 males and 5 females, ranging in age from 17 to 58 years (median age: 33 y; mean age: 35.3 y). Eight (53%) cases were located in the lower extremities (foot, calf, tibia, thigh), 5 (33%) were located in the trunk, abdomen or pelvis (abdominal wall-2, shoulder, back, ischium) and 2 (13%) were located in the upper extremity (humerus and hand). Ten (67%) cases had multifocal presentation and 5 (33%) presented as solitary lesions. Three (20%) cases were located only in the superficial dermis and subcutaneous tissues, 4 (27%) involved the superficial and deep soft tissue and 8 (53%) cases involved only the deep soft tissue and bone. Using fluorescence in situ hybridization and ARCHER fusionplex analysis we identified a novel ACTB-FOSB gene fusion in 7 cases, while the remaining 8 had the previously described SERPINE1-FOSB fusion. The clinicopathologic features and behavior of PHE associated with the ACTB-FOSB gene fusion were similar to those harboring the SERPINE1-FOSB; except that tumors with the ACTB variant were more often associated with solitary presentation. In conclusion, our results expand the spectrum of genetic alterations in PHE with a novel gene fusion identified in half of the cases. We speculate that some of the novel targeted therapies that have shown promise in SERPINE1-FOSB-positive PHE might also be beneficial in this molecular subset.	[Agaram, Narasimhan P.; Zhang, Lei; Cotzia, Paolo; Antonescu, Cristina R.] Mem Sloan Kettering Canc Ctr, Dept Pathol, 1275 York Ave, New York, NY 10065 USA	Agaram, NP (reprint author), Mem Sloan Kettering Canc Ctr, Dept Pathol, 1275 York Ave, New York, NY 10065 USA.	agaramn@mskcc.org			Cycle for Survival; Kristin Ann Carr Foundation;  [P50 CA 140146-01];  [P30-CA008748]	Supported in part by: P50 CA 140146-01 (C.R.A.), P30-CA008748 (C.R.A.), Cycle for Survival (C.R.A.), Kristin Ann Carr Foundation (C.R.A.). The authors have disclosed that they have no significant relationships with, or financial interest in, any commercial companies pertaining to this article.	Amary MF, 2013, SKELETAL RADIOL, V42, P947, DOI 10.1007/s00256-013-1577-8; Antonescu C, 2014, MODERN PATHOL, V27, pS30, DOI 10.1038/modpathol.2013.176; Antonescu CR, 2018, AM J SURG PATHOL, V42, P553, DOI 10.1097/PAS.0000000000001010; Antonescu CR, 2014, GENE CHROMOSOME CANC, V53, P951, DOI 10.1002/gcc.22206; Billings SD, 2003, AM J SURG PATHOL, V27, P48, DOI 10.1097/00000478-200301000-00006; Bridge JA, 2012, HUM PATHOL, V43, P1524, DOI 10.1016/j.humpath.2012.01.019; Catar R, 2013, KIDNEY INT, V84, P1119, DOI 10.1038/ki.2013.217; Cheng DT, 2015, J MOL DIAGN, V17, P251, DOI 10.1016/j.jmoldx.2014.12.006; Dahlen A, 2004, BIOCHEM BIOPH RES CO, V325, P1318, DOI 10.1016/j.bbrc.2004.10.172; Durchdewald M, 2009, HISTOL HISTOPATHOL, V24, P14451, DOI 10.14670/HH-24.1451; Errani C, 2012, CLIN ORTHOP RELAT R, V470, P1498, DOI 10.1007/s11999-011-2070-0; Errani C, 2012, CANCER GENET-NY, V205, P12, DOI 10.1016/j.cancergen.2011.10.008; Errani C, 2011, GENE CHROMOSOME CANC, V50, P644, DOI 10.1002/gcc.20886; Fletcher C, 2013, WHO CLASSIFICATION T; Gabor KM, 2018, PEDIATR BLOOD CANCER, V65, DOI 10.1002/pbc.26781; Hornick JL, 2011, AM J SURG PATHOL, V35, P190, DOI 10.1097/PAS.0b013e3181ff0901; Huang SC, 2015, AM J SURG PATHOL, V39, P1313, DOI 10.1097/PAS.0000000000000469; Hung YP, 2017, AM J SURG PATHOL, V41, P596, DOI 10.1097/PAS.0000000000000795; Ide YH, 2015, PATHOL RES PRACT, V211, P415, DOI 10.1016/j.prp.2015.02.003; Inyang A, 2016, AM J SURG PATHOL, V40, P587, DOI 10.1097/PAS.0000000000000613; Joseph J, 2015, CLIN SARCOMA RES, V5, DOI 10.1186/s13569-015-0037-8; Le Loarer F, 2014, GENE CHROMOSOME CANC, V53, P475, DOI 10.1002/gcc.22159; Marconcini L, 1999, P NATL ACAD SCI USA, V96, P9671, DOI 10.1073/pnas.96.17.9671; Milde-Langosch K, 2005, EUR J CANCER, V41, P2449, DOI 10.1016/j.ejca.2005.08.008; Ozeki M, 2017, J PEDIAT HEMATOL ONC, V39, pE328, DOI 10.1097/MPH.0000000000000778; Pradhan D, 2018, HUM PATHOL, V71, P126, DOI 10.1016/j.humpath.2017.10.023; Rawal YB, 2017, HEAD NECK PATHOL, V11, P525, DOI 10.1007/s12105-016-0770-1; Rekhi B, 2016, INDIAN J PATHOL MICR, V59, P382, DOI 10.4103/0377-4929.188144; Requena L, 2013, JAMA DERMATOL, V149, P459, DOI 10.1001/jamadermatol.2013.3190; Righi A, 2015, SKELETAL RADIOL, V44, P727, DOI 10.1007/s00256-014-2024-1; Sabatakos G, 2000, NAT MED, V6, P985, DOI 10.1038/79683; Sheng WQ, 2012, HISTOPATHOLOGY, V61, P1219, DOI 10.1111/j.1365-2559.2012.04347.x; Sheng WQ, 2013, AM J DERMATOPATH, V35, P597, DOI 10.1097/DAD.0b013e31827c8051; Sugita S, 2016, DIAGN PATHOL, V11, DOI 10.1186/s13000-016-0530-2; Trombetta D, 2011, CANCER GENET-NY, V204, P211, DOI 10.1016/j.cancergen.2011.01.002; van IJzendoorn DGP, 2018, CLIN CANCER RES, V24, P2678, DOI 10.1158/1078-0432.CCR-17-3512; van IJzendoorn DGP, 2015, GENE CHROMOSOME CANC, V54, P565, DOI 10.1002/gcc.22269; Walther C, 2014, J PATHOL, V232, P534, DOI 10.1002/path.4322; Yin YM, 2009, BIOMED PHARMACOTHER, V63, P429, DOI 10.1016/j.biopha.2009.04.045	39	3	3	2	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0147-5185	1532-0979		AM J SURG PATHOL	Am. J. Surg. Pathol.	DEC	2018	42	12					1653	1661		10.1097/PAS.0000000000001147			9	Pathology; Surgery	Pathology; Surgery	HA7BB	WOS:000450434700009	30256258				2019-10-28	
J	Fujikura, K; Akita, M; Ajiki, T; Fukumoto, T; Itoh, T; Zen, Y				Fujikura, Kohei; Akita, Masayuki; Ajiki, Tetsuo; Fukumoto, Takumi; Itoh, Tomoo; Zen, Yoh			Recurrent Mutations in APC and CTNNB1 and Activated Wnt/beta-catenin Signaling in Intraductal Papillary Neoplasms of the Bile Duct A Whole Exome Sequencing Study	AMERICAN JOURNAL OF SURGICAL PATHOLOGY			English	Article						intraductal papillary neoplasm; cholangiocarcinoma; bile duct; exome sequencing; Wnt/beta-catenin	FAMILIAL ADENOMATOUS POLYPOSIS; INFLAMMATORY-BOWEL-DISEASE; BETA-CATENIN; RETROSPECTIVE COHORT; COLORECTAL CANCERS; PANCREATIC-CANCER; CARCINOMA; ADENOCARCINOMA; INVOLVEMENT; MECHANISMS	This study aimed to elucidate the genetic landscape of biliary papillary neoplasms. Of 28 cases examined, 7 underwent whole exome sequencing, while the remaining 21 were used for validation studies with targeted sequencing. In the whole exome sequencing study, 4/7 cases had mutations in either APC or CTNNB1, both of which belong to the Wnt/beta-catenin pathway. Somatic mutations were also identified in genes involved in RAS signaling (KRAS, BRAF), a cell cycle regulator (CDC27), histone methyltransferase (KMT2C, KMT2D), and DNA mismatch repair (MSH3, MSH6, PMS1). Combined with discovery and validation cohorts, mutations in APC or CTNNB1 were observed in 6/28 subjects (21%) and were mutually exclusive. When the cases were classified into intraductal papillary neoplasms of the bile duct (IPNBs, n=14) and papillary cholangiocarcinomas (n=14) based on the recently proposed classification criteria, mutations in APC and CTNNB1 appeared to be entirely restricted to IPNBs with 6/14 cases (43%) harboring mutations in either gene. These genetic alterations were detected across the 3 nonintestinal histologic types. In immunohistochemistry, the aberrant cytoplasmic and/or nuclear expression of beta-catenin was found in not only 5/6 IPNBs with APC or CTNNB1 mutations, but also 6/8 cases with wild-type APC and CTNNB1 (total 79%). In addition, APC and CTNNB1 alterations were exceptional in nonpapillary cholangiocarcinomas (n=29) with a single case harboring CTNNB1 mutation (3%). This study demonstrated recurrent mutations in APC and CTNNB1 in nonintestinal-type IPNBs, suggesting that activation of the Wnt/beta-catenin signaling pathway is relevant to the development and progression of IPNBs.	[Fujikura, Kohei; Akita, Masayuki; Itoh, Tomoo; Zen, Yoh] Kobe Univ, Grad Sch Med, Dept Diagnost Pathol, Kobe, Hyogo 6500017, Japan; [Akita, Masayuki; Ajiki, Tetsuo; Fukumoto, Takumi] Kobe Univ, Grad Sch Med, Dept Hepatobiliary Pancreat Surg, Kobe, Hyogo, Japan	Zen, Y (reprint author), Kobe Univ, Grad Sch Med, Dept Diagnost Pathol, Kobe, Hyogo 6500017, Japan.	yohzen@med.kobe-u.ac.jp			Ministry of Education, Culture, Sports, Science and Technology in JapanMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)	Supported a Grant-in-Aid for Scientific Research of the Ministry of Education, Culture, Sports, Science and Technology in Japan. The authors have disclosed that they have no significant relationships with, or financial interest in, any commercial companies pertaining to this article.	Ahn SM, 2014, HEPATOLOGY, V60, P1972, DOI 10.1002/hep.27198; Alexandrov LB, 2013, NATURE, V500, P415, DOI 10.1038/nature12477; Aust DE, 2001, MODERN PATHOL, V14, P29, DOI 10.1038/modpathol.3880253; Bailey P, 2016, NATURE, V531, P47, DOI 10.1038/nature16965; Barford D, 2011, PHILOS T R SOC B, V366, P3605, DOI 10.1098/rstb.2011.0069; Biankin AV, 2012, NATURE, V491, P399, DOI 10.1038/nature11547; Brannon AR, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0454-7; Caillie F, 2012, ANN SURG ONCOL, V19, P2924, DOI 10.1245/s10434-012-2221-x; Chan-on W, 2013, NAT GENET, V45, P1474, DOI 10.1038/ng.2806; Chen MF, 1998, ANN SURG, V227, P63, DOI 10.1097/00000658-199801000-00010; Chen TC, 2001, HEPATOLOGY, V34, P651, DOI 10.1053/jhep.2001.28199; Dulak AM, 2013, NAT GENET, V45, P478, DOI 10.1038/ng.2591; Fujikura K, 2016, HISTOPATHOLOGY, V69, P950, DOI 10.1111/his.13037; Futami H, 1997, J GASTROENTEROL, V32, P558, DOI 10.1007/BF02934100; Galiatsatos P, 2006, AM J GASTROENTEROL, V101, P385, DOI 10.1111/j.1572-0241.2006.00375.x; Garrean S, 2008, AM SURGEON, V74, P79; Giannakis M, 2016, CELL REP, V15, P857, DOI 10.1016/j.celrep.2016.03.075; Helleday T, 2014, NAT REV GENET, V15, P585, DOI 10.1038/nrg3729; Ilyas M, 2005, J PATHOL, V205, P130, DOI 10.1002/path.1692; JARVINEN HJ, 1983, DIS COLON RECTUM, V26, P525, DOI 10.1007/BF02563746; Jhunjhunwala S, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0436-9; Jiao YC, 2013, NAT GENET, V45, P1470, DOI 10.1038/ng.2813; Kovacs G, 2017, HISTOPATHOLOGY, V70, P273, DOI 10.1111/his.13059; Laleman W, 2013, SURG ENDOSC, V27, P3865, DOI 10.1007/s00464-013-2996-2; Lee SS, 2004, CANCER-AM CANCER SOC, V100, P783, DOI 10.1002/cncr.20031; Li ML, 2014, NAT GENET, V46, P872, DOI 10.1038/ng.3030; Lin SH, 2018, GUT, V67, P1299, DOI 10.1136/gutjnl-2016-313573; Lindberg J, 2013, EUR UROL, V63, P702, DOI 10.1016/j.eururo.2012.11.053; Litchfield K, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms6973; Matsumoto T, 2015, AM J CLIN PATHOL, V144, P452, DOI 10.1309/AJCPZ5T2POOFMQVN; Matthaei H, 2012, HPB, V14, P677, DOI 10.1111/j.1477-2574.2012.00504.x; Monda G, 2012, MOL CELL, V45, P680, DOI 10.1016/j.molcel.2012.01.013; Moon BS, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/djt373; Muzny DM, 2012, NATURE, V487, P330, DOI 10.1038/nature11252; Nakamura H, 2015, NAT GENET, V47, P1003, DOI 10.1038/ng.3375; Nakanuma Y, 2009, WHO CLASSIFICATION T, P217; O'Connor PM, 2010, INFLAMM BOWEL DIS, V16, P1411, DOI 10.1002/ibd.21217; Ong CK, 2012, NAT GENET, V44, P690, DOI 10.1038/ng.2273; Rao Q, 2013, MODERN PATHOL, V26, P725, DOI 10.1038/modpathol.2012.229; Robles AI, 2016, GASTROENTEROLOGY, V150, P931, DOI 10.1053/j.gastro.2015.12.036; Rocha FG, 2012, HEPATOLOGY, V56, P1352, DOI 10.1002/hep.25786; Rowan AJ, 2000, P NATL ACAD SCI USA, V97, P3352, DOI 10.1073/pnas.97.7.3352; Sasaki M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081706; Schlitter AM, 2014, MODERN PATHOL, V27, P73, DOI 10.1038/modpathol.2013.112; Schulze K, 2015, NAT GENET, V47, P505, DOI 10.1038/ng.3252; Seshagiri S, 2012, NATURE, V488, P660, DOI 10.1038/nature11282; Shibahara H, 2004, AM J SURG PATHOL, V28, P327, DOI 10.1097/00000478-200403000-00005; Skipworth JRA, 2011, HPB, V13, P342, DOI 10.1111/j.1477-2574.2011.00292.x; Springer S, 2015, GASTROENTEROLOGY, V149, P1501, DOI 10.1053/j.gastro.2015.07.041; Tsai JH, 2017, HISTOPATHOLOGY, V70, P756, DOI 10.1111/his.13125; Tsai JH, 2013, AM J SURG PATHOL, V37, P1862, DOI 10.1097/PAS.0b013e3182986bb5; van Heumen BWH, 2012, SURGERY, V151, P681, DOI 10.1016/j.surg.2011.12.008; Wang K, 2014, NAT GENET, V46, P573, DOI 10.1038/ng.2983; Wong SCC, 2004, CLIN CANCER RES, V10, P1401, DOI 10.1158/1078-0432.CCR-0157-03; Wood LD, 2014, AM J SURG PATHOL, V38, P389, DOI 10.1097/PAS.0000000000000146; Yan ML, 2015, WORLD J GASTROENTERO, V21, P3150, DOI 10.3748/wjg.v21.i10.3150; Yao Z, 2015, CANCER CELL, V28, P370, DOI 10.1016/j.ccell.2015.08.001; Zen Y, 2006, J HEPATOL, V44, P350, DOI 10.1016/j.jhep.2005.09.025; Zen Y, 2006, MODERN PATHOL, V19, P1243, DOI 10.1038/modpathol.3800643; Zen Y, 2014, HISTOPATHOLOGY, V65, P164, DOI 10.1111/his.12378	60	7	7	1	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0147-5185	1532-0979		AM J SURG PATHOL	Am. J. Surg. Pathol.	DEC	2018	42	12					1674	1685		10.1097/PAS.0000000000001155			12	Pathology; Surgery	Pathology; Surgery	HA7BB	WOS:000450434700011	30212390				2019-10-28	
J	Johncilla, M; Chen, ZM; Sweeney, J; Yantiss, RK				Johncilla, Melanie; Chen, Zhengming; Sweeney, Jacob; Yantiss, Rhonda K.			Tumor Grade Is Prognostically Relevant Among Mismatch Repair Deficient Colorectal Carcinomas	AMERICAN JOURNAL OF SURGICAL PATHOLOGY			English	Article						colorectal carcinoma; microsatellite instability; mismatch repair deficiency	MICROSATELLITE-INSTABILITY STATUS; COLON-CANCER; MUCINOUS ADENOCARCINOMA; NUCLEAR MORPHOMETRY; SURVIVAL	Intestinal-type colorectal adenocarcinomas are graded based on extent of glandular differentiation, although mucinous, signet-ring cell, and solid cancers are, by convention, classified as high grade. Mismatch repair-deficient tumors frequently show high-grade histologic features, yet the World Health Organization classifies them as low grade to reflect their favorable prognosis compared with mismatch repair-proficient cancers. Although some mismatch repair-deficient colorectal cancers behave aggressively, few authors have identified features that predict their behavior. We performed this study to determine which histologic features, if any, predicted outcome among mismatch repair-deficient colorectal carcinomas. We identified 116 mismatch repair-deficient colorectal carcinomas, including 77 localized (stage I to II) and 39 advanced (stage III to IV) tumors, and evaluated them for extent of gland formation, extracellular mucin, signet-ring cell differentiation, solid growth, nuclear grade, tumor-infiltrating lymphocytes and tumor budding. Relationships between these features, pathologic stage, and disease-free survival were assessed. We found that high-grade mismatch repair-deficient tumors were more often of advanced stage than low-grade tumors (46% vs. 23%, P=0.01). Disease-free survival was inversely associated with the presence of a dominant high-grade component and tumor budding (P=0.01 and 0.04, respectively). Predominantly solid tumors, in particular, were significantly associated with decreased disease-free survival compared with low-grade tumors (P=0.001). Nuclear grade and tumor-infiltrating lymphocytes were not associated with pathologic stage or outcome. We conclude that low-grade mismatch repair-deficient carcinomas present at an earlier stage and pursue a more favorable course than those mostly composed of high-grade elements. These findings suggest that mismatch repair status should not supplant histologic grade in the assessment of colorectal carcinomas.	[Johncilla, Melanie; Sweeney, Jacob; Yantiss, Rhonda K.] Weill Cornell Med, Dept Pathol & Lab Med, 525 East 68th St,Starr 1031E, New York, NY 10065 USA; [Chen, Zhengming] Weill Cornell Med, Div Biostat & Epidemiol, New York, NY 10065 USA	Johncilla, M (reprint author), Weill Cornell Med, Dept Pathol & Lab Med, 525 East 68th St,Starr 1031E, New York, NY 10065 USA.	mej9041@med.cornell.edu			Translational Research Program, Department of Pathology and Laboratory Medicine, Weill Cornell Medicine	Supported by Translational Research Program, Department of Pathology and Laboratory Medicine, Weill Cornell Medicine. The authors have disclosed that they have no significant relationships with, or financial interest in, any commercial companies pertaining to this article.	AMBROS RA, 1990, ANAL QUANT CYTOL, V12, P172; Amin MB, 2017, AJCC CANC STAGING MA; Andrici J, 2016, MODERN PATHOL, V29, P266, DOI 10.1038/modpathol.2015.159; Boland CR, 2010, GASTROENTEROLOGY, V138, P2073, DOI 10.1053/j.gastro.2009.12.064; Bosman FT, 2010, WHO CLASSIFICATION T; Buhmeida A, 2005, ANTICANCER RES, V25, P3083; Dukes C, 1937, Proc R Soc Med, V30, P371; Fernandez-Lopez F, 1999, DIS COLON RECTUM, V42, P386, DOI 10.1007/BF02236359; Gomez-Alvarez MA, 2017, GASTROENTEROL REV, V12, P208, DOI 10.5114/pg.2016.64740; GREEN JB, 1993, DIS COLON RECTUM, V36, P49, DOI 10.1007/BF02050301; Gryfe R, 2000, NEW ENGL J MED, V342, P69, DOI 10.1056/NEJM200001133420201; Kanemitsu Y, 2003, DIS COLON RECTUM, V46, P160, DOI 10.1097/01.DCR.0000044721.76711.6D; Kawakami H, 2015, CURR TREAT OPTION ON, V16, DOI 10.1007/s11864-015-0348-2; Landau MA, 2018, AM J SURG PATHOL, V42, P351, DOI 10.1097/PAS.0000000000001004; Leopoldo S, 2008, ANN SURG ONCOL, V15, P1429, DOI 10.1245/s10434-007-9757-1; Lugli A, 2012, BRIT J CANCER, V106, P1713, DOI 10.1038/bjc.2012.127; Ribic CM, 2003, NEW ENGL J MED, V349, P247, DOI 10.1056/NEJMoa022289; Rosty C, 2014, HUM PATHOL, V45, P2077, DOI 10.1016/j.humpath.2014.06.020; Rozek LS, 2016, JNCI-J NATL CANCER I, V108, P8; Rustgi AK, 2007, GENE DEV, V21, P2525, DOI 10.1101/gad.1593107; Ryan E, 2018, AM J SURG PATHOL, V42, P60, DOI 10.1097/PAS.0000000000000931; Shia J, 2017, MODERN PATHOL, V30, P599, DOI 10.1038/modpathol.2016.198; Shia JR, 2015, SEMIN DIAGN PATHOL, V32, P352, DOI 10.1053/j.semdp.2015.02.018; Tung SY, 1996, AM J GASTROENTEROL, V91, P2195; Verhulst J, 2012, J CLIN PATHOL, V65, P381, DOI 10.1136/jclinpath-2011-200340; Wright CL, 2003, AM J SURG PATHOL, V27, P1393, DOI 10.1097/00000478-200311000-00001; Zhang XC, 2013, WORLD J GASTRO ONCOL, V5, P12, DOI 10.4251/wjgo.v5.i2.12	27	1	1	1	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0147-5185	1532-0979		AM J SURG PATHOL	Am. J. Surg. Pathol.	DEC	2018	42	12					1686	1692		10.1097/PAS.0000000000001145			7	Pathology; Surgery	Pathology; Surgery	HA7BB	WOS:000450434700012	30179899				2019-10-28	
J	Paulk, A; Giannico, G; Epstein, JI				Paulk, Adina; Giannico, Giovanna; Epstein, Jonathan I.			PIN-like (Ductal) Adenocarcinoma of the Prostate	AMERICAN JOURNAL OF SURGICAL PATHOLOGY			English	Article						ductal adenocarcinoma; prostate adenocarcinoma; radical prostatectomy	CANCER; EXPRESSION; OUTCOMES	Prostatic intraepithelial neoplasia like (PIN-like ductal) carcinoma are rare tumors characterized by crowded, often cystically dilated glands architecturally resembling high-grade prostatic intraepithelial neoplasia, lined by malignant pseudostratified columnar epithelium. The largest prior series studied 9 radical prostatectomies (RPs) and suggested a behavior similar to Gleason score 6. We sought to investigate this rare tumor within a larger series. PIN-like carcinoma cases were identified from in-house and consultation files from 2008 to 2017. A total of 190 total cases were identified (in-house cases n=8, 4.2%, consult cases n=182, 95.8%); the diagnosis of PIN-like carcinoma was made on needle biopsy (n=181), transurethral resection (n=5) and RP (n=4). The average age was 70 years. The average number of cores with involvement by PIN-like carcinoma was 2 (1 to 12). The average maximum percentage by a PIN-like carcinoma component of any core was 43.5% (5% to 90%). In 58/181 (32.0%) biopsy cases, due to selective parts having been submitted for consultation, it was unknown whether there was an association with acinar carcinoma. A total of 72 cases showed exclusively PIN-like carcinoma. Highest grade groups (GGs) on biopsies with known acinar or papillary/cribriform ductal carcinomas were GG1 (n=23, 45.1%), GG2 (n=14, 27.5%), GG3 (n=9, 17.6%), GG4 (n=4, 7.8%), and GG5 (n=1, 2.0%). Of 44 cases where the patient would be considered eligible for active surveillance, 18 (41.0%) underwent RP. RP slides were available in 16 cases; 3 (18.8%) cases diagnosed on biopsy did not show PIN-like carcinoma on review of RP slides. PIN-like carcinoma was present without an associated acinar tumor in 3 (23.1%) RPs; 2 showing tumors with large, cystic dilated glands extending into periprostatic tissue. In 7/13 cases (53.8%), the acinar component was the dominant tumor and the PIN-like carcinoma component was small (<1 cm). The overall grade at RP was GG1 (5/13, 38.5%) and GG2 (8/13, 61.5%). In all cases with an acinar component, the acinar tumor was anatomically distinct from the PIN-like carcinoma tumor. The GGs of the separate acinar tumors were GG1 (6/10) and GG2 (4/10) with percent pattern 4 <= 5% in all 4 cases. No cases were associated with metastases to lymph nodes or seminal vesicle invasion. Extraprostatic extension was present in 6/13 (46.1%) cases, from the acinar component in 1 (7.7%) case and the PIN-like carcinoma component in 5 (83.3%) cases. In all 5 cases, there was a peculiar morphology of thin papillary projections into cystic dilated PIN-like carcinoma glands. Immunohistochemical expression of ERG was positive in 1/11 (9.1%) case. 1/11 (9.1%) case showed heterogeneous loss of PTEN. Overall, PIN-like carcinoma tumors are limited in size, not advanced in stage, not associated with high-grade cancer on RP, and show low rates of Gleason pattern 4 and TMPS-ERG rearrangement. Our study supports grading classic PIN-like carcinoma as Gleason pattern 3; at the current time we recommend grading thin papillary projections of PIN-like carcinoma as pattern 4. Longer term studies will be needed to determine the clinical significance of thin papillary projections in PIN-like carcinoma.	[Paulk, Adina; Epstein, Jonathan I.] Johns Hopkins Med Inst, Dept Pathol, Baltimore, MD 21205 USA; [Epstein, Jonathan I.] Johns Hopkins Med Inst, Dept Urol, Baltimore, MD 21205 USA; [Epstein, Jonathan I.] Johns Hopkins Med Inst, Dept Oncol, Baltimore, MD 21205 USA; [Giannico, Giovanna] Vanderbilt Univ, Med Ctr, Dept Pathol, Nashville, TN 37232 USA	Epstein, JI (reprint author), Johns Hopkins Univ Hosp, Dept Pathol, 401 N Broadway,Room 2242, Baltimore, MD 21231 USA.	jepstein@jhmi.edu					Amin A, 2011, AM J SURG PATHOL, V35, P615, DOI 10.1097/PAS.0b013e31820eb25b; Bock BJ, 1999, AM J SURG PATHOL, V23, P781, DOI 10.1097/00000478-199907000-00005; Brinker DA, 1999, AM J SURG PATHOL, V23, P1471, DOI 10.1097/00000478-199912000-00004; Hameed O, 2006, MODERN PATHOL, V19, P899, DOI 10.1038/modpathol.3800601; Humphrey PA, 2016, EUR UROL, V70, P106, DOI 10.1016/j.eururo.2016.02.028; Kojima F, 2017, ANN DIAGN PATHOL, V27, P7, DOI 10.1016/j.anndiagpath.2016.12.002; Lee TK, 2010, PATHOLOGY, V42, P319, DOI 10.3109/00313021003767314; Lotan TL, 2016, MODERN PATHOL, V29, P904, DOI 10.1038/modpathol.2016.88; Meeks JJ, 2012, BJU INT, V109, P831, DOI 10.1111/j.1464-410X.2011.10520.x; Morais CL, 2015, PROSTATE, V75, P1610, DOI 10.1002/pros.23042; Pettersson A, 2012, CANCER EPIDEM BIOMAR, V21, P1497, DOI 10.1158/1055-9965.EPI-12-0042; Seipel AH, 2014, HISTOPATHOLOGY, V65, P216, DOI 10.1111/his.12382; Tavora F, 2008, AM J SURG PATHOL, V32, P1060, DOI 10.1097/PAS.0b013e318160edaf	13	1	1	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0147-5185	1532-0979		AM J SURG PATHOL	Am. J. Surg. Pathol.	DEC	2018	42	12					1693	1700		10.1097/PAS.0000000000001139			8	Pathology; Surgery	Pathology; Surgery	HA7BB	WOS:000450434700013	30138215				2019-10-28	
J	Casteillo, F; Guy, JB; Dal-Col, P; Karpathiou, G; Pommier, B; Bayle-Bleuez, S; Fournel, P; Vassal, F; Forest, F				Casteillo, Francois; Guy, Jean-Baptiste; Dal-Col, Pierre; Karpathiou, Georgia; Pommier, Benjamin; Bayle-Bleuez, Sophie; Fournel, Pierre; Vassal, Francois; Forest, Fabien			Pathologic Subtypes of Lung Adenocarcinoma Brain Metastasis Is a Strong Predictor of Survival After Resection	AMERICAN JOURNAL OF SURGICAL PATHOLOGY			English	Article						brain metastasis; lung adenocarcinoma; histopathologic subtype; prognosis	RESPIRATORY SOCIETY CLASSIFICATION; INTERNATIONAL-ASSOCIATION; HISTOLOGIC SUBTYPE; PATIENT SURVIVAL; MUTATION STATUS; GROWTH-PATTERN; KRAS; RECURRENCE; PROGNOSIS; SYSTEM	Primary lung adenocarcinoma is classified according to predominant histopathologic architecture into lepidic, papillary, acinar, solid, and micropapillary subtypes. These subtypes are related to overall survival in primary lung adenocarcinoma. The main goal of our work was to evaluate the prognostic impact of this classification on surgical resection of brain adenocarcinoma metastases in 97 patients with surgically resected brain metastases of lung adenocarcinoma from 2008 to 2017. Histopathologic subtype is associated with overall survival (P=0.0085): 30.1 +/- 5.6 months for papillary-predominant pattern, 26.5 +/- 6.3 months for acinar-predominant pattern, 13.8 +/- 1.4 months for solid pattern, 11.6 +/- 10.1 for micropapillary pattern. A low grade group comprising acinar and papillary-predominant pattern tumors showed a longer overall survival (28.5 +/- 4.1 mo) when compared with high-grade-predominant pattern (solid and micropapillary patterns) (13.7 +/- 1.4 mo), P=0.0011. On multivariate analysis, age below 55 years at the time of resection (hazard ratio, 3.56; 95% confidence interval, 1.12-11.31) and groups of architectural patterns (hazard ratio, 4.25; 95% confidence interval, 1.83-9.9) were related to overall survival (P=0.031 and 0.00078, respectively). Predominant architectural pattern evaluated on the surgical specimen of brain metastasis is a major prognostic factor of overall survival in metastatic lung adenocarcinoma.	[Casteillo, Francois; Dal-Col, Pierre; Karpathiou, Georgia; Forest, Fabien] Univ Hosp St Etienne, North Hosp, Dept Pathol, St Etienne, France; [Pommier, Benjamin; Vassal, Francois] Univ Hosp St Etienne, North Hosp, Dept Neurosurg, St Etienne, France; [Bayle-Bleuez, Sophie] Univ Hosp St Etienne, North Hosp, Dept Pneumol, St Etienne, France; [Guy, Jean-Baptiste] Dept Radiotherapy, St Priest En Jarez, France; [Fournel, Pierre] Dept Oncol, St Priest En Jarez, France	Forest, F (reprint author), CHU St Etienne, Hop Nord, Serv Anat & Cytol Pathol, Ave Albert Raimond, F-42055 St Etienne 2, France.	fabien.forest@chu-st-etienne.fr	Forest, Fabien/O-7054-2019	Forest, Fabien/0000-0001-7582-3923			Boland JM, 2017, LUNG CANCER, V109, P14, DOI 10.1016/j.lungcan.2017.04.013; Clay TD, 2014, J THORAC ONCOL, V9, P654, DOI 10.1097/JTO.0000000000000150; Dai CY, 2017, AM J SURG PATHOL, V41, P1212, DOI 10.1097/PAS.0000000000000901; Forest F, 2017, EXP MOL PATHOL, V103, P306, DOI 10.1016/j.yexmp.2017.11.013; Galateau-Salle F, 2016, J THORAC ONCOL, V11, P142, DOI 10.1016/j.jtho.2015.11.005; Hung JJ, 2014, J CLIN ONCOL, V32, P2357, DOI 10.1200/JCO.2013.50.1049; Jain A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0123587; Kadota K, 2014, AM J SURG PATHOL, V38, P1118, DOI 10.1097/PAS.0000000000000246; Kadota K, 2012, MODERN PATHOL, V25, P1117, DOI 10.1038/modpathol.2012.58; Leeman JE, 2017, INT J RADIAT ONCOL, V97, P138, DOI 10.1016/j.ijrobp.2016.09.037; Mansuet-Lupo A, 2014, CHEST, V146, P633, DOI 10.1378/chest.13-2499; R Core Team, 2017, R LANG ENV STAT COMP; Rekhtman N, 2013, MODERN PATHOL, V26, P1307, DOI 10.1038/modpathol.2013.74; Russell PA, 2013, J THORAC ONCOL, V8, P461, DOI 10.1097/JTO.0b013e3182828fb8; Russell PA, 2011, J THORAC ONCOL, V6, P1496, DOI 10.1097/JTO.0b013e318221f701; Sperduto PW, 2017, JAMA ONCOL, V3, P827, DOI 10.1001/jamaoncol.2016.3834; Travis WD, 2011, J THORAC ONCOL, V6, P244, DOI 10.1097/JTO.0b013e318206a221; Tsao MS, 2015, J CLIN ONCOL, V33, P3439, DOI 10.1200/JCO.2014.58.8335; Warth A, 2012, J CLIN ONCOL, V30, P1438, DOI 10.1200/JCO.2011.37.2185; Yoshizawa A, 2013, J THORAC ONCOL, V8, P52, DOI 10.1097/JTO.0b013e3182769aa8	20	0	0	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0147-5185	1532-0979		AM J SURG PATHOL	Am. J. Surg. Pathol.	DEC	2018	42	12					1701	1707		10.1097/PAS.0000000000001161			7	Pathology; Surgery	Pathology; Surgery	HA7BB	WOS:000450434700014	30222604				2019-10-28	
J	Carter, JM; Wu, YH; Blessing, MM; Folpe, AL; Thorland, EC; Spinner, RJ; Jentoft, ME; Wang, C; Baheti, S; Niu, Z; Mauermann, ML; Klein, CJ				Carter, Jodi M.; Wu, Yanhong; Blessing, Melissa M.; Folpe, Andrew L.; Thorland, Erik C.; Spinner, Robert J.; Jentoft, Mark E.; Wang, Chen; Baheti, Saurabh; Niu, Zhiyv; Mauermann, Michelle L.; Klein, Christopher J.			Recurrent Genomic Alterations in Soft Tissue Perineuriomas	AMERICAN JOURNAL OF SURGICAL PATHOLOGY			English	Article						perineurioma; soft tissue; peripheral nerve sheath tumor	NERVE SHEATH TUMORS; OF-THE-LITERATURE; NEUROFIBROMATOSIS TYPE-1; NF2 GENE; INTRANEURAL PERINEURIOMA; CHROMOSOME-22 DELETIONS; TRAF7 MUTATIONS; MENINGIOMAS; PATIENT; SCHWANNOMAS	Perineuriomas are rare nerve sheath tumors, divided into intraneural and extraneural (soft tissue) types. Intraneural perineuriomas frequently contain TRAF7 mutations, and rarely, chr22q12 deletions. While chr22q losses can occur in soft tissue perineuriomas, comprehensive high-resolution molecular profiling has not been reported in these tumors and TRAF7 status is unknown. We used whole-exome sequencing and OncoScan single nucleotide polymorphism (SNP) array to evaluate 14 soft tissue perineuriomas. Thirteen cases showed 2 or more chromosomal abnormalities, composed primarily of large deletions. Recurrent chr22q deletions, containing the NF2 locus (n=6) and the previously unreported finding of chr17q deletions, with the NF1 locus (n=4) were frequent events and were mutually exclusive in all but1 case. In addition, 5 cases had varying chr2 deletions; and 4 cases had chr6 deletions. A chr10 deletion (previously reported in the sclerosing variant of soft tissue perineurioma) was observed in one case and another case had chr7 chromothripsis as the sole chromosomal abnormality. No TRAF7 mutations or alterations were identified in any case and no other evaluated gene (MAF < 0.0001) had recurrent, deleterious mutations in > 2 cases. The molecular genetic profiles showed no association with patient sex, age, tumoral histology or anatomic site. OncoScan SNP array analysis was performed on 10 cases and showed high concordance with the whole exome data, validating the large-scale deletions, duplications, and chr7 chromothripsis findings. In soft tissue perineuriomas, recurrent 22q12 deletions (with NF2) and 17q11 deletions (with NF1) appear to be mutually exclusive events, and alterations in NF1 or NF2 likely contribute to perineurioma pathogenesis, similar to other nerve sheath tumors. Moreover, the lack of TRAF7 mutations in soft tissue perineuriomas indicates divergent pathogenetic mechanisms from those of intraneural perineuriomas.	[Carter, Jodi M.; Wu, Yanhong; Blessing, Melissa M.; Folpe, Andrew L.; Thorland, Erik C.; Jentoft, Mark E.; Niu, Zhiyv] Mayo Clin, Dept Lab Med & Pathol, Rochester, MN 55905 USA; [Mauermann, Michelle L.; Klein, Christopher J.] Mayo Clin, Dept Neurol, 200 First St SW, Rochester, MN 55905 USA; [Spinner, Robert J.] Mayo Clin, Dept Neurosurg, Rochester, MN 55905 USA; [Wang, Chen; Baheti, Saurabh] Mayo Clin, Dept Hlth Sci Res, Rochester, MN 55905 USA; [Niu, Zhiyv; Klein, Christopher J.] Mayo Clin, Dept Clin Genom, Rochester, MN 55905 USA	Klein, CJ (reprint author), Mayo Clin, Dept Neurol, 200 First St SW, Rochester, MN 55905 USA.	klein.christopher@mayo.edu	Wang, Chen/B-3244-2011	Wang, Chen/0000-0003-2638-3081; Blessing, Melissa M./0000-0002-4014-4426	Department of Laboratory Medicine and Pathology of Mayo Clinic	Supported by the Department of Laboratory Medicine and Pathology of Mayo Clinic. The authors have disclosed that they have no significant relationships with, or financial interest in, any commercial companies pertaining to this article.	Agaimy A, 2014, ANN DIAGN PATHOL, V18, P95, DOI 10.1016/j.anndiagpath.2013.12.005; Ausmus GG, 2007, J CUTAN PATHOL, V34, P726, DOI 10.1111/j.1600-0560.2006.00702.x; BIJLSMA EK, 1992, GENE CHROMOSOME CANC, V5, P201, DOI 10.1002/gcc.2870050305; Bottillo I, 2009, J PATHOL, V217, P693, DOI 10.1002/path.2494; Brock JE, 2005, AM J SURG PATHOL, V29, P1164, DOI 10.1097/01.pas.0000158397.65190.9f; Clark VE, 2013, SCIENCE, V339, P1077, DOI 10.1126/science.1233009; Duff DJ, 2014, CANCER GENET-NY, V207, P263, DOI 10.1016/j.cancergen.2014.05.012; EMORY TS, 1995, AM J CLIN PATHOL, V103, P696; Giannini C, 1997, AM J SURG PATHOL, V21, P164, DOI 10.1097/00000478-199702000-00005; Goode B, 2018, MODERN PATHOL, V31, P660, DOI 10.1038/modpathol.2017.153; Hornick JL, 2005, AM J SURG PATHOL, V29, P845, DOI 10.1097/01.pas.0000155166.86409.d2; Klein CJ, 2017, ANN NEUROL, V81, P316, DOI 10.1002/ana.24854; Lasota J, 2001, AM J PATHOL, V158, P1223, DOI 10.1016/S0002-9440(10)64072-2; Macarenco RS, 2007, ARCH PATHOL LAB MED, V131, P625; MARTIN GA, 1990, CELL, V63, P843, DOI 10.1016/0092-8674(90)90150-D; MEREL P, 1995, GENE CHROMOSOME CANC, V13, P211, DOI 10.1002/gcc.2870130311; Mertens F, 2000, J PATHOL, V190, P31, DOI 10.1002/(SICI)1096-9896(200001)190:1<31::AID-PATH505>3.0.CO;2-#; Mott RT, 2005, CLIN NEUROPATHOL, V24, P69; Nishio J, 2014, SKELETAL RADIOL, V43, P1017, DOI 10.1007/s00256-014-1839-0; Paxton Christian N, 2015, J Assoc Genet Technol, V41, P61; Pitchford CW, 2006, AM J SURG PATHOL, V30, P1624, DOI 10.1097/01.pas.0000213340.70852.d4; Reuss DE, 2013, ACTA NEUROPATHOL, V125, P351, DOI 10.1007/s00401-013-1093-x; RUTTLEDGE MH, 1994, GENE CHROMOSOME CANC, V10, P122, DOI 10.1002/gcc.2870100207; RUTTLEDGE MH, 1994, NAT GENET, V6, P180, DOI 10.1038/ng0294-180; Santos-Briz A, 2013, AM J DERMATOPATH, V35, pE45, DOI 10.1097/DAD.0b013e31827747d6; Sato K, 2008, PATHOL INT, V58, P718, DOI 10.1111/j.1440-1827.2008.02299.x; Schaefer IM, 2013, INT J CLIN EXP PATHO, V6, P3003; Sciot R, 1999, AM J SURG PATHOL, V23, P849, DOI 10.1097/00000478-199907000-00015; Scoles DR, 1998, NAT GENET, V18, P354, DOI 10.1038/ng0498-354; TROFATTER JA, 1993, CELL, V72, P791, DOI 10.1016/0092-8674(93)90406-G; Upadhyaya M, 2008, HUM MUTAT, V29, P74, DOI 10.1002/humu.20793; Wang C, 2014, BIOINFORMATICS, V30, P2678, DOI 10.1093/bioinformatics/btu363; Wang W, 2016, NEUROLOGY, V86, P1762, DOI 10.1212/WNL.0000000000002659; WOLFF RK, 1992, AM J HUM GENET, V51, P478; Yap YS, 2014, ONCOTARGET, V5, P5873, DOI 10.18632/oncotarget.2194; Zotti T, 2012, J CELL PHYSIOL, V227, P1280, DOI 10.1002/jcp.24011	36	0	0	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0147-5185	1532-0979		AM J SURG PATHOL	Am. J. Surg. Pathol.	DEC	2018	42	12					1708	1714		10.1097/PAS.0000000000001169			7	Pathology; Surgery	Pathology; Surgery	HA7BB	WOS:000450434700015	30303818				2019-10-28	
J	Ma, CQ; Lowenthal, BM; Pai, RK				Ma, Changqing; Lowenthal, Brett M.; Pai, Reetesh K.			SATB2 Is Superior to CDX2 in Distinguishing Signet Ring Cell Carcinoma of the Upper Gastrointestinal Tract and Lower Gastrointestinal Tract	AMERICAN JOURNAL OF SURGICAL PATHOLOGY			English	Article						immunohistochemistry; breast carcinoma; metastasis; stomach; esophagogastric junction; distal esophagus; appendix; colorectum	APPENDICEAL MUCINOUS NEOPLASMS; IMMUNOHISTOCHEMICAL CHARACTERIZATION; COLORECTAL CARCINOMAS; TUMORS; ADENOCARCINOMA; SURVIVAL; ORIGIN; DISTINCTION; ESOPHAGUS; HISTOLOGY	Signet ring cell carcinomas of the gastrointestinal (GI) tract are clinically aggressive neoplasms with frequent intra-abdominal metastases at initial presentation. Currently available immunohistochemistry (IHC) markers cannot distinguish signet ring cell carcinomas of the lower GI tract and upper GI tract, suggesting the need for more specific diagnostic markers. SATB2 is a novel, sensitive marker for colorectal carcinoma. We hypothesized that SATB2 IHC can reliably identify primary and metastatic signet ring cell carcinomas of lower GI tract origin. SATB2 and CDX2 IHC was performed on 159 primary (n=93) and metastatic (n=66) signet ring cell carcinomas of GI tract origin and 13 metastatic breast carcinomas with signet ring cell features. Positive SATB2 expression (SATB2(+)) was identified in 82% (27/33) of appendiceal, 88% (43/49) of colorectal, 13% (7/54) of gastric, and 35% (8/23) of esophageal/esophagogastric junction signet ring cell carcinomas. Primary and metastatic signet ring cell carcinomas of lower GI tract origin were more frequently SATB2(+) than those from upper GI tract (70/82, 85% vs. 15/77, 19%, P<0.01). Compared with CDX2, SATB2(+) and dual-positive staining for SATB2 and CDX2 both had higher specificities for signet ring cell carcinomas from the lower GI tract (81% vs. 49% and 86% vs. 49%, respectively, P<0.01 for both). Two (15%) metastatic breast carcinoma were SATB2(+), but all 13 demonstrated negative CDX2 staining. In summary, our results show SATB2 is a relatively specific immunohistochemistry marker for both metastatic and primary signet ring cell carcinomas of lower GI tract origin.	[Ma, Changqing; Lowenthal, Brett M.; Pai, Reetesh K.] Univ Pittsburgh, Med Ctr, Dept Pathol, Pittsburgh, PA 15213 USA; [Lowenthal, Brett M.] Kaiser Permanente, Southern Calif Permanente Med Grp, San Diego, CA USA	Ma, CQ (reprint author), Univ Pittsburgh, Presbyterian Hosp, Dept Pathol, 200 Lothrop St,Room A-610, Pittsburgh, PA 15213 USA.	mac2@upmc.edu					[Anonymous], 2018, MEDCALC STAT SOFTWAR; Chirieac LR, 2005, CLIN CANCER RES, V11, P2229, DOI 10.1158/1078-0432.CCR-04-1840; Chu PG, 2004, AM J CLIN PATHOL, V121, P884, DOI 10.1309/A09ERYMFR64NERDW; Davison JM, 2014, MODERN PATHOL, V27, P1521, DOI 10.1038/modpathol.2014.37; Dennis JL, 2005, CLIN CANCER RES, V11, P3766, DOI 10.1158/1078-0432.CCR-04-2236; Dragomir A, 2014, AM J CLIN PATHOL, V141, P630, DOI 10.1309/AJCPWW2URZ9JKQJU; Farris AB, 2011, AM J SURG PATHOL, V35, P647, DOI 10.1097/PAS.0b013e31820f18a2; Hui Y, 2018, HUM PATHOL, V77, P11, DOI 10.1016/j.humpath.2018.01.002; Kang HJ, 2005, DIS COLON RECTUM, V48, P1161, DOI 10.1007/s10350-004-0932-1; Kim CJ, 2016, J CLIN PATHOL, V69, P1046, DOI 10.1136/jclinpath-2015-203588; Lauwers GY, 2010, WHO CLASSIFICATION T, P45; Li ZB, 2018, AM J CLIN PATHOL, V149, P241, DOI [10.1093/AJCP/AQX160, 10.1093/ajcp/aqx160]; Li ZB, 2017, AM J CLIN PATHOL, V147, P484, DOI [10.1093/ajcp/aqx023, 10.1093/AJCP/AQX023]; Lin F, 2014, ARCH PATHOL LAB MED, V138, P1015, DOI 10.5858/arpa.2013-0452-OA; Ma C, 2018, AM J SURG PATHOL; Magnusson K, 2011, AM J SURG PATHOL, V35, P937, DOI 10.1097/PAS.0b013e31821c3dae; Moh M, 2016, AM J SURG PATHOL, V40, P419, DOI 10.1097/PAS.0000000000000553; Pande R, 2008, DIS COLON RECTUM, V51, P50, DOI 10.1007/s10350-007-9073-7; PARAF F, 1995, AM J SURG PATHOL, V19, P183, DOI 10.1097/00000478-199502000-00007; Montiel DP, 2015, ANN DIAGN PATHOL, V19, P249, DOI 10.1016/j.anndiagpath.2015.05.004; Piessen G, 2009, ANN SURG, V250, P878, DOI 10.1097/SLA.0b013e3181b21c7b; Riihimaki M, 2016, ONCOTARGET, V7, P52307, DOI 10.18632/oncotarget.10740; Shetty S, 2013, AM SURGEON, V79, P1171; Strickland S, 2016, HISTOPATHOLOGY, V68, P977, DOI 10.1111/his.12899; Yang C, 2018, GASTROENTEROL RES, V11, P221, DOI 10.14740/gr1015w; Yang C, 2018, AM J SURG PATHOL, V42, P160, DOI 10.1097/PAS.0000000000000951	26	1	1	2	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0147-5185	1532-0979		AM J SURG PATHOL	Am. J. Surg. Pathol.	DEC	2018	42	12					1715	1722		10.1097/PAS.0000000000001159			8	Pathology; Surgery	Pathology; Surgery	HA7BB	WOS:000450434700016	30212392				2019-10-28	
J	Waters, KM; Salimian, KJ; Voltaggio, L; Montgomery, EA				Waters, Kevin M.; Salimian, Kevan J.; Voltaggio, Lysandra; Montgomery, Elizabeth A.			Refined Criteria for Separating Low-grade Dysplasia and Nondysplastic Barrett Esophagus Reduce Equivocal Diagnoses and Improve Prediction of Patient Outcome A 10-Year Review	AMERICAN JOURNAL OF SURGICAL PATHOLOGY			English	Review						Barrett esophagus; intestinal metaplasia; dysplasia; esophageal adenocarcinoma; goblet cells	RISK; ADENOCARCINOMA; PROGRESSION; CANCER; CLASSIFICATION; MANAGEMENT	The indefinite for dysplasia (IFD) category in Barrett esophagus (BE) is used for biopsies that are neither unequivocally dysplastic nor negative for dysplasia (NFD). In 2012, we refined our criteria so that BE with maintained cell polarity and surface gastric-type mucin vacuoles is considered NFD even with mild to moderate nuclear enlargement. A total of 1549 cases from 1130 patients with BE biopsies were identified from 2007 to 2016. Follow-up on patients with IFD biopsies was obtained to learn if the new thresholds better defined risk of progression. The earlier cases (2007-2011) were less likely than later cases (2012-2016) to be NFD (84.0% vs. 90.4%) and more likely to be IFD (8.4% vs. 4.3%). The proportions of low-grade dysplasia (3.9% vs. 2.5%, high-grade dysplasia (1.4% vs. 1.3%), and intramucosal carcinoma (2.3% vs. 1.6%) were similar between the earlier and later cases, respectively. Later IFD cases were more frequently dysplastic (3/21, 14.3%) on the next biopsy than earlier cases (1/48, 2.1%). The rate of dysplasia on the next biopsy for NFD cases was not higher in the later cases (6/222, 2.7%) than the earlier cases (16/360, 4.4%). Improved diagnostic criteria reduced the proportion of IFD cases by nearly 50% from 2007 to 2016. This change coincided with a higher proportion of IFD cases having dysplasia on the next biopsy. NFD patients had no increase in dysplasia on the next biopsy providing evidence that dysplastic cases are not missed by the refined criteria.	[Waters, Kevin M.] Cedars Sinai Med Ctr, Dept Pathol & Lab Med, Los Angeles, CA 90048 USA; [Salimian, Kevan J.; Voltaggio, Lysandra; Montgomery, Elizabeth A.] Johns Hopkins Univ Hosp, Dept Pathol, Baltimore, MD 21287 USA	Waters, KM (reprint author), Pacific Theatres Bldg,116 N,Robertson Blvd, Los Angeles, CA 90048 USA.	kevin.waters@cshs.org					Bergman JJGHM, 2012, GASTROENTEROLOGY, V142, pE18, DOI 10.1053/j.gastro.2012.02.053; Brown IS, 2010, MODERN PATHOL, V23, P834, DOI 10.1038/modpathol.2010.59; Curvers WL, 2010, AM J GASTROENTEROL, V105, P1523, DOI 10.1038/ajg.2010.171; Duits LC, 2015, GUT, V64, P700, DOI 10.1136/gutjnl-2014-307278; Hur C, CANCER, V119, P1149; Hvid-Jensen F, 2011, NEW ENGL J MED, V365, P1375, DOI 10.1056/NEJMoa1103042; Kaye PV, 2009, HISTOPATHOLOGY, V54, P699, DOI 10.1111/j.1365-2559.2009.03288.x; Kerkhof M, 2007, HISTOPATHOLOGY, V50, P920, DOI 10.1111/j.1365-2559.2007.02706.x; Kestens C, 2015, ENDOSCOPY, V47, P409, DOI 10.1055/s-0034-1391091; Kroep S, 2015, GASTROENTEROLOGY, V149, P577, DOI 10.1053/j.gastro.2015.04.045; Lim CH, 2007, ENDOSCOPY, V39, P581, DOI 10.1055/s-2007-966592; Lomo LC, 2006, AM J SURG PATHOL, V30, P423, DOI 10.1097/00000478-200604000-00001; Mahajan D, 2010, MODERN PATHOL, V23, P1, DOI 10.1038/modpathol.2009.147; Patil DT, 2013, HUM PATHOL, V44, P1146, DOI 10.1016/j.humpath.2012.10.004; Pohl H, 2005, J NATL CANCER I, V97, P142, DOI 10.1093/jnci/dji024; RIDDELL RH, 1983, HUM PATHOL, V14, P931, DOI 10.1016/S0046-8177(83)80175-0; Rucker-Schmidt RL, 2009, AM J SURG PATHOL, V33, P886, DOI 10.1097/PAS.0b013e318198a1d4; Shaheen NJ, 2016, AM J GASTROENTEROL, V111, P30, DOI 10.1038/ajg.2015.322; Sharma P, 2003, GUT, V52, P24, DOI 10.1136/gut.52.1.24; Siegel RL, 2018, CA-CANCER J CLIN, V68, P7, DOI 10.3322/caac.21442; ten Kate FJC, 2018, AM J SURG PATHOL, V42, P918, DOI 10.1097/PAS.0000000000001066; Thota PN, 2017, GASTROENTEROLOGY, V152, P987, DOI 10.1053/j.gastro.2016.12.005; Vieth Michael, 2016, Cesk Patol, V52, P154; Wani S, 2016, GASTROENTEROLOGY, V151, P822, DOI 10.1053/j.gastro.2016.09.040; Wani S, 2011, GASTROENTEROLOGY, V141, P1179, DOI 10.1053/j.gastro.2011.06.055; Yousef F, 2008, AM J EPIDEMIOL, V168, P237, DOI 10.1093/aje/kwn121	26	1	1	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0147-5185	1532-0979		AM J SURG PATHOL	Am. J. Surg. Pathol.	DEC	2018	42	12					1723	1729		10.1097/PAS.0000000000001162			7	Pathology; Surgery	Pathology; Surgery	HA7BB	WOS:000450434700017	30234520				2019-10-28	
J	Trippel, M; Slotta-Huspenina, J; Becker, K; Rau, T; Paepke, S; Maurer-Marti, F; Langer, R				Trippel, Mafalda; Slotta-Huspenina, Julia; Becker, Karen; Rau, Tilman; Paepke, Stefan; Maurer-Marti, Franziska; Langer, Rupert			Macroscopic Evaluation of the Trimmed Frozen Block Is a Helpful Tool for Intraoperative Assessment of Resection Margins of Breast Cancer Specimens	INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY			English	Article						breast; carcinoma; frozen section; margins	CONSERVING SURGERY; SECTION ANALYSIS; LUMPECTOMY MARGINS; LOCAL RECURRENCE; WOMEN; ACCURACY; EXCISION; EFFICACY; THERAPY; IMPACT	Introduction. The evaluation of the trimming surfaces (TS) of tissue blocks from frozen sections may serve as a supplementary examination tool for the intraoperative determination of resection margins of breast cancer specimens. This study aimed at the investigation of the feasibility and reliability of this technique, which has been described only very rarely in literature. Methods. Two observers assessed digital images from TS obtained from 57 resection margins. Findings were correlated with the diagnosis of the frozen section (FS) alone and the final diagnosis on formalin-fixed paraffin-embedded (FFPE) material. Results. The determination of the resection margin on TS was estimated as feasible for all cases. Interobserver congruence rate for TS was 96% (kappa = 0.81), which was lower compared with FFPE (100%, kappa = 1.0) but superior to FS (89%, kappa = 0.67). Intraobserver congruence of the 2 reviewers was 96.5% and 93.0% between TS and FFPE, and 91.1% and 92.5% between FS and FFPE, respectively. The combination of both intraoperative consultation techniques showed similar congruence but a slight improvement for the sensitivity (0.75 to 0.875) for the diagnosis of tumor at the resection margin in FFPE for Reviewer 1 but was unchanged for Reviewer 2. Conclusion. The additional evaluation of TS can be a helpful additional tool for intraoperative margin assessment of breast cancer specimens, in particular, when processing artifacts of FS are encountered.	[Trippel, Mafalda; Rau, Tilman; Langer, Rupert] Univ Bern, Bern, Switzerland; [Slotta-Huspenina, Julia; Becker, Karen; Paepke, Stefan] Tech Univ Munich, Munich, Germany; [Maurer-Marti, Franziska] Frauenklin Burgerspital Solothurn, Solothurn, Switzerland	Langer, R (reprint author), Univ Bern, Inst Pathol, Murtenstr 31, CH-3008 Bern, Switzerland.	Rupert.langer@pathology.unibe.ch					Boughey JC, 2016, J ONCOL PRACT, V12, pE413, DOI 10.1200/JOP.2015.005652; Boughey JC, 2014, SURGERY, V156, P190, DOI 10.1016/j.surg.2014.03.025; Brierley JD, 2017, TNM CLASSIFICATION M; Camp ER, 2005, J AM COLL SURGEONS, V201, P855, DOI 10.1016/j.jamcollsurg.2005.06.274; Cendan JC, 2005, J AM COLL SURGEONS, V201, P194, DOI 10.1016/j.jamcollsurg.2005.03.014; DeSantis CE, 2014, CA-CANCER J CLIN, V64, P252, DOI 10.3322/caac.21235; Ghazal-Aswad S, 1999, ANN ONCOL, V10, P329, DOI 10.1023/A:1008355506863; Houssami N, 2010, EUR J CANCER, V46, P3219, DOI 10.1016/j.ejca.2010.07.043; Hunt KK, 2014, J CLIN ONCOL, V32, P1401, DOI 10.1200/JCO.2013.54.8388; Jeevan R, 2012, BMJ-BRIT MED J, V345, DOI 10.1136/bmj.e4505; Jorns JM, 2017, EJSO-EUR J SURG ONC, V43, P1273, DOI 10.1016/j.ejso.2017.01.237; Kim MJ, 2016, BREAST CANCER-BASIC, V10, P205, DOI 10.4137/BCBCR.S40868; Landercasper J, 2014, ANN SURG ONCOL, V21, P3185, DOI 10.1245/s10434-014-3905-1; Laucirica R, 2005, ARCH PATHOL LAB MED, V129, P1565; Laws A, 2016, ANN SURG ONCOL, V23, P3290, DOI 10.1245/s10434-016-5401-2; McCahill LE, 2009, ARCH SURG-CHICAGO, V144, P455, DOI 10.1001/archsurg.2009.56; Mohsin SK, 2012, FROZEN SECTION LIB B; Muttalib M, 2005, BREAST, V14, P42, DOI 10.1016/j.breast.2004.10.002; Osako T, 2015, INT J CLIN ONCOL, V20, P1093, DOI 10.1007/s10147-015-0827-2; Schnitt SJ, 2012, AM J CLIN PATHOL, V138, P635, DOI 10.1309/AJCPPQ1JGV0GJIAB; St John ER, 2017, ANN SURG, V265, P300, DOI 10.1097/SLA.0000000000001897; Taxy JB, 2009, ARCH PATHOL LAB MED, V133, P1135, DOI 10.1043/1543-2165-133.7.1135; Viera AJ, 2005, FAM MED, V37, P360; Weber WP, 2008, WORLD J SURG, V32, P2599, DOI 10.1007/s00268-008-9757-8	24	0	0	2	2	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1066-8969	1940-2465		INT J SURG PATHOL	Int. J. Surg. Pathol.	DEC	2018	26	8					693	700		10.1177/1066896918780346			8	Pathology; Surgery	Pathology; Surgery	HA5TJ	WOS:000450340700002	29953301				2019-10-28	
J	Lam-ubol, A; Kitrueangphatchara, K; Putthanuparp, T; Arayakhun, R; Kwanthong, R; Choonhawarakorn, K				Lam-ubol, Aroonwan; Kitrueangphatchara, Kitwat; Putthanuparp, Thanapha; Arayakhun, Rinrada; Kwanthong, Raiwada; Choonhawarakorn, Kitiwadee			Nonformalin Fixative Agents: A Comparative Study of Fixative Efficacy and Histomorphology	INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY			English	Article						formalin; ethanol; jaggery; local anesthesia; fixation	INHALATION EXPOSURE; FORMALDEHYDE; MORPHOLOGY; ARTIFACTS; TRANSIT	Objectives. Formalin is a gold standard fixative agent. However, formalin possesses health hazards and is not always available in rural areas. The objective of this study was to compare tissue fixative efficacy of nonformalin fixative agents with formalin. Methods. Oral tissues obtained during impacted tooth removal were collected. The tissue fragments were sectioned and fixed in 4 different fixatives; 30% jaggery, 70% ethanol, 2% mepivacaine with 1:100 000 epinephrine, or formalin for 24 and 72 hours. All specimens were then immersed in formalin for another 24 hours and processed according to standard protocol. Hematoxylin and eosin-stained sections were evaluated by a pathologist. The cellular structure, cellular outline, and quality of staining were graded from 1 to 3 and average fixative efficacy scores were compared using 1-way analysis of variance. Fixative artifacts were described. Results. Fixative efficacy scores of 70% ethanol and 30% jaggery at 24 and 72 hours were not statistically different from those of formalin. Conversely, 2% mepivacaine demonstrated significantly lower fixative efficacy scores than other agents. Although efficacy of each fixative was not statistically different between 24 and 72 hours, efficacy of 70% ethanol was markedly reduced at 72 hours when compared with others. Acantholysis of epithelial cells was the most notable artifact at 72 hours when fixed with nonformalin fixative agents. Conclusion. Both 70% ethanol and 30% jaggery provided acceptable fixative efficacy at 24 hours. However, only 30% jaggery maintained fixative efficacy at 72 hours. Nevertheless, negative effects on the epithelial cells were unavoidable and should be interpreted with caution.	[Lam-ubol, Aroonwan; Kitrueangphatchara, Kitwat; Putthanuparp, Thanapha; Arayakhun, Rinrada; Kwanthong, Raiwada; Choonhawarakorn, Kitiwadee] Srinakharinwirot Univ, Bangkok, Thailand	Lam-ubol, A (reprint author), Srinakharinwirot Univ, Fac Dent, Dept Oral Surg & Oral Med, 114 Sukhumvit 23, Bangkok 10110, Thailand.	aroonwan@gmail.com		Lam-ubol, Aroonwan/0000-0001-6673-8831	Faculty of Dentistry, Srinakharinwirot University, Bangkok, Thailand	The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was supported by the Faculty of Dentistry, Srinakharinwirot University, Bangkok, Thailand.	BATTIFORA H, 1986, J HISTOCHEM CYTOCHEM, V34, P1095, DOI 10.1177/34.8.2426335; Chatterjee Shailja, 2014, J Oral Maxillofac Pathol, V18, pS111, DOI 10.4103/0973-029X.141346; Cox ML, 2006, EXP MOL PATHOL, V80, P183, DOI 10.1016/j.yexmp.2005.10.002; FOX CH, 1985, J HISTOCHEM CYTOCHEM, V33, P845, DOI 10.1177/33.8.3894502; Howat WJ, 2014, METHODS, V70, P12, DOI 10.1016/j.ymeth.2014.01.022; Iqbal Munawar, 2017, Information Processing in Agriculture, V4, P83, DOI 10.1016/j.inpa.2016.11.002; KERNS WD, 1983, CANCER RES, V43, P4382; Matsuda Y, 2011, J HISTOCHEM CYTOCHEM, V59, P68, DOI 10.1369/jhc.2010.957217; Nayaka MAH, 2009, FOOD CHEM, V115, P113, DOI 10.1016/j.foodchem.2008.11.067; Patil S, 2015, SCI CAIRO, V2015; Patil Shankargouda, 2015, J Nat Sci Biol Med, V6, P67, DOI 10.4103/0976-9668.149089; Patil Shankargouda, 2013, J Int Oral Health, V5, P31; Pelz K, 2008, J MED MICROBIOL, V57, P88, DOI 10.1099/jmm.0.47339-0; Rajanikanth M, 2015, J CLIN DIAGN RES, V9, pZM01, DOI 10.7860/JCDR/2015/11083.5615; Rastogi V, 2013, J CLIN DIAGN RES, V7, P2408, DOI 10.7860/JCDR/2013/6170.3541; Sengupta S, 2014, J MAXILLOFAC ORAL SU, V13, P148, DOI 10.1007/s12663-013-0473-z; Singhal Pallav, 2017, J Oral Maxillofac Pathol, V21, P70, DOI 10.4103/0973-029X.203771; Singhal P, 2016, J CLIN DIAGN RES, V10, pZC28, DOI 10.7860/JCDR/2016/19007.8236; Sinha Nidhi, 2017, J Oral Maxillofac Pathol, V21, P458, DOI 10.4103/jomfp.JOMFP_236_15; Sreeramulu D, 2013, OXID MED CELL LONGEV, DOI 10.1155/2013/369479; Swenberg J, 1980, Dev Toxicol Environ Sci, V8, P283; SWENBERG JA, 1980, CANCER RES, V40, P3398; Thavarajah Rooban, 2012, J Oral Maxillofac Pathol, V16, P400, DOI 10.4103/0973-029X.102496; Troiano NW, 2009, J HISTOTECHNOL, V32, P27; World Health Organization International Agency for Research on Cancer, 2006, IARC MON EV CARC RIS, V88; Yeung ECT, 2015, PLANT MICROTECHNIQUE	26	0	0	0	4	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1066-8969	1940-2465		INT J SURG PATHOL	Int. J. Surg. Pathol.	DEC	2018	26	8					701	706		10.1177/1066896918779450			6	Pathology; Surgery	Pathology; Surgery	HA5TJ	WOS:000450340700003	29873279				2019-10-28	
J	Lino-Silva, LS; Salcedo-Hernandez, RA; Segales-Rojas, P; Zepeda-Najar, C				Lino-Silva, Leonardo S.; Salcedo-Hernandez, Rosa A.; Segales-Rojas, Patricia; Zepeda-Najar, Cesar			Comparison of 3 Ways of Dissecting the Pancreatoduodenectomy Specimen and Their Impact in the Lymph Node Count and the Lymph Node Metastatic Ratio	INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY			English	Article						pancreas cancer; survival; lymph nodes; lymph node ratio; pancreatoduodenectomy	PANCREATIC HEAD CANCER; PROGNOSTIC-SIGNIFICANCE; DUCTAL ADENOCARCINOMA; INVOLVEMENT; RESECTION; SURVIVAL; NUMBER; LYMPHADENECTOMY; CARCINOMA; INVASION	Background. Lymph node metastasis (LNM) is a strong prognostic factor in the cancer of the pancreatobiliary tree, but it is influenced by the number of lymph nodes (LNs). The lymph node ratio (LNR) is considered a more reliable factor than the number of LNM. The aim was to examine the LN retrieval and the LNR of 3 pathologic work-up strategies. Methods. Pancreaticoduodenectomies (n = 165) were analyzed comparing 3 pathological dissection techniques, classified as "control," "Verbeke method," and "Adsay method" groups. Results. The mean of the dissected LNs and the number of cases with >20 LNs were superior in the Adsay method group, compared with the other groups (P < .001). The LNR was different between the Adsay and Verbeke groups (0.144 vs 0.069, P = .032). The median of the 3 positive LNs was associated with decreased survival compared with an absence of LNM (3-year specific survival of 48% vs 22%, P = .011). In the multivariate analysis, LNM (hazard ratio = 6.148, 95% confidence interval = 2.02-8.1, P = .042) and the evaluation of >15 LNs (hazard ratio = 12.52, 95% confidence interval = 5.51-21.01, P = .001) were independent predictors of survival. Conclusion. The Adsay technique for LN retrieval was associated with a better LN count, more cases with LNM, and an LNR >0.1.	[Lino-Silva, Leonardo S.; Salcedo-Hernandez, Rosa A.; Segales-Rojas, Patricia] Inst Nacl Cancerol, Mexico City, DF, Mexico; [Zepeda-Najar, Cesar] Hosp Angeles Tijuana, Tijuana, Baja California, Mexico	Lino-Silva, LS (reprint author), Inst Nacl Cancerol Mexico, Gastrointestinal Pathol Div, Ave San Fernando 22,Secc 16, Mexico City 14080, DF, Mexico.	saul.lino.sil@gmail.com		LINO-SILVA, LEONARDO SAUL/0000-0002-7394-5123; Zepeda-Najar, Cesar/0000-0002-4913-7695			Adsay NV, 2009, MODERN PATHOL, V22, P107, DOI 10.1038/modpathol.2008.167; Basturk O, 2015, ANN SURG ONCOL, V22, pS1187, DOI 10.1245/s10434-015-4861-0; Berger AC, 2004, AM SURGEON, V70, P235; Buc E, 2014, EJSO-EUR J SURG ONC, V40, P1578, DOI 10.1016/j.ejso.2014.04.012; Cameron JL, 2006, ANN SURG, V244, P10, DOI 10.1097/01.sla.0000217673.04165.ea; Gluth A, 2015, LANGENBECK ARCH SURG, V400, P757, DOI 10.1007/s00423-015-1318-7; House MG, 2007, J GASTROINTEST SURG, V11, P1549, DOI 10.1007/s11605-007-0243-7; Huebner M, 2012, J GASTROINTEST SURG, V16, P920, DOI 10.1007/s11605-012-1853-2; John BJ, 2013, HPB, V15, P674, DOI 10.1111/hpb.12019; Kakar S, 2017, AJCC CANC STAGING MA, P337; Malleo G, 2015, J AM COLL SURGEONS, V221, P367, DOI 10.1016/j.jamcollsurg.2015.02.019; Massucco P, 2009, ANN SURG ONCOL, V16, P3323, DOI 10.1245/s10434-009-0672-5; Murakami Y, 2010, J AM COLL SURGEONS, V211, P196, DOI 10.1016/j.jamcollsurg.2010.03.037; Nagakawa T, 1996, CANCER, V77, P640, DOI 10.1002/(SICI)1097-0142(19960215)77:4<640::AID-CNCR9>3.0.CO;2-K; Pai RK, 2011, AM J SURG PATHOL, V35, P228, DOI 10.1097/PAS.0b013e318206c37a; Pawlik TM, 2007, SURGERY, V141, P610, DOI 10.1016/j.surg.2006.12.013; Petrelli F, 2011, EJSO-EUR J SURG ONC, V37, P836, DOI 10.1016/j.ejso.2011.07.008; Sahin TT, 2011, PANCREAS, V40, P1029, DOI 10.1097/MPA.0b013e3182207893; Sierzega M, 2006, PANCREAS, V33, P240, DOI 10.1097/01.mpa.0000235306.96486.2a; Strobel O, 2015, ANN SURG, V261, P961, DOI 10.1097/SLA.0000000000000814; Tarantino I, 2017, BRIT J SURG, V104, P608, DOI 10.1002/bjs.10472; Verbeke CS, 2008, HISTOPATHOLOGY, V52, P787, DOI 10.1111/j.1365-2559.2007.02935.x; Westra WH, 1996, SURG PATHOLOGY DISSE, P88; Yamada S, 2016, LANGENBECK ARCH SURG, V401, P1143, DOI 10.1007/s00423-016-1412-5; Zacharias T, 2007, J GASTROINTEST SURG, V11, P350, DOI 10.1007/s11605-007-0113-3	25	0	1	1	2	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1066-8969	1940-2465		INT J SURG PATHOL	Int. J. Surg. Pathol.	DEC	2018	26	8					707	713		10.1177/1066896918780343			7	Pathology; Surgery	Pathology; Surgery	HA5TJ	WOS:000450340700004	29873282				2019-10-28	
J	Apellaniz, D; Pereira-Prado, V; Sicco, E; Vigil-Bastitta, G; Gonzalez-Gonzalez, R; Mosqueda-Taylor, A; Molina-Frechero, N; Hernandez, M; Sanchez-Romero, C; Bologna-Molina, R				Apellaniz, Delmira; Pereira-Prado, Vanesa; Sicco, Estefania; Vigil-Bastitta, Gabriela; Gonzalez-Gonzalez, Rogelio; Mosqueda-Taylor, Adalberto; Molina-Frechero, Nelly; Hernandez, Marcela; Sanchez-Romero, Celeste; Bologna-Molina, Ronell			Comparative Study of the Minichromosome Maintenance Proteins Complex (MCM 4/5/6) in Ameloblastoma and Unicystic Ameloblastoma	INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY			English	Article						MCM4; MCM5; MCM6; proliferation; ameloblastoma; unicystic ameloblastoma	PROLIFERATION MARKERS; EXPRESSION; KI-67; REPLICATION; CANCER; ADENOCARCINOMA; SURVIVAL; TUMORS; PCNA; KI67	Introduction. Solid/conventional ameloblastoma (AM) and unicystic ameloblastoma (UAM) are the most frequent benign epithelial odontogenic tumors located in the maxillary region, and their treatment usually consists of extensive surgical resection. Therefore, it is relevant to study molecular markers to better understand the biological behavior of these tumors. The aim of this study was to describe and compare the expression of proteins related to cellular proliferation: Ki-67 and MCM4-6 complex. Materials and Methods. An immunohistochemistry technique was performed, with antibodies against Ki-67, MCM4, MCM5, and MCM6, in 10 AM and 10 UAM tumors. The results were quantified using label index and analyzed statistically. Results. AM and UAM had greater expression of MCM6, followed by MCM5, MCM4, and Ki-67 (P < .05). Immunoexpression of Ki-67 and MCM5 was exclusively nuclear, whereas the expression of MCM4 and MCM6 was nuclear and cytoplasmic. Conclusion. The results suggest that MCM5 is a trustable cell proliferation marker with higher sensitivity compared with Ki-67 and may be useful to predict the biological behavior of AM and UAM. Despite this, further studies are necessary, including a correlation with clinical parameters to confirm these findings.	[Apellaniz, Delmira; Pereira-Prado, Vanesa; Sicco, Estefania; Vigil-Bastitta, Gabriela; Bologna-Molina, Ronell] Univ Republica, Montevideo, Uruguay; [Gonzalez-Gonzalez, Rogelio] Univ Juarez Estado Durango, Durango, CO, Mexico; [Mosqueda-Taylor, Adalberto; Molina-Frechero, Nelly] Univ Autonoma Metropolitana Xochimilco, Mexico City, DF, Mexico; [Hernandez, Marcela] Univ Chile, Santiago, Chile; [Sanchez-Romero, Celeste] Univ Estadual Campinas, Piracicaba, Brazil	Bologna-Molina, R (reprint author), Univ Republica, Fac Odontol, Mol Pathol Area, Las Heras 1925, Montevideo 14600, Uruguay.	ronellbologna@odon.edu.uy	Bologna-Molina, Ronell/I-6038-2018; Hernandez, Marcela/I-3266-2013; Gonzalez-Gonzalez, Rogelio/O-6947-2017	Bologna-Molina, Ronell/0000-0001-9755-4779; Hernandez, Marcela/0000-0001-8289-7314; Sicco, Estefania/0000-0003-1137-6866; Sanchez-Romero, Celeste/0000-0001-5365-2692; Gonzalez-Gonzalez, Rogelio/0000-0003-4457-704X	I+D projects CSIC (Comision Sectorial de Investigacion Cientifica), University of the Republic, Uruguay	The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This research received a grant from I+D projects CSIC (Comision Sectorial de Investigacion Cientifica), University of the Republic, Uruguay.	Ahlem B, 2015, EUR ANN OTORHINOLARY, V132, P275, DOI 10.1016/j.anorl.2015.08.016; Alver RC, 2014, DNA REPAIR, V19, P182, DOI 10.1016/j.dnarep.2014.03.012; Arias EE, 2007, GENE DEV, V21, P497, DOI 10.1101/gad.1508907; Black CC, 2010, ORAL SURG ORAL MED O, V110, P585, DOI 10.1016/j.tripleo.2010.02.040; Blow JJ, 2005, NAT REV MOL CELL BIO, V6, P476, DOI 10.1038/nrm1663; Bologna-Molina R, 2008, ORAL ONCOL, V44, P805, DOI 10.1016/j.oraloncology.2007.10.007; Bologna-Molina R, 2013, MED ORAL PATOL ORAL, V18, pE174, DOI 10.4317/medoral.18573; Bologna-Molina R, 2011, HISTOPATHOLOGY, V59, P801, DOI 10.1111/j.1365-2559.2011.03954.x; Braun KA, 2007, MOL BIOL CELL, V18, P1447, DOI 10.1091/mbc.E06-09-0792; Carreon-Burciaga RG, 2015, DIS MARKERS, DOI 10.1155/2015/683087; Choy B, 2016, HUM PATHOL, V57, P126, DOI 10.1016/j.humpath.2016.07.013; Das M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069607; Gakiopoulou H, 2007, BRIT J CANCER, V97, P1124, DOI 10.1038/sj.bjc.6603992; Giaginis C, 2011, DIGEST DIS SCI, V56, P777, DOI 10.1007/s10620-010-1348-5; Gonzalez-Gonzalez R, 2015, DIS MARKERS, V2015; Gonzalez-Gonzalez R, 2014, MED ORAL PATOL ORAL, V19, pE8, DOI 10.4317/medoral.19071; Heidebrecht HJ, 2001, LAB INVEST, V81, P1163, DOI 10.1038/labinvest.3780328; Heikinheimo K., 2017, WHO CLASSIFICATION H, P215; Huang XP, 2005, J CANCER RES CLIN, V131, P677, DOI 10.1007/s00432-005-0011-6; Iakovou M, 2015, J ORAL PATHOL MED, V44, P543, DOI 10.1111/jop.12263; Ishimi Y, 2003, EUR J BIOCHEM, V270, P1089, DOI 10.1046/j.1432-1033.2003.03440.x; Korkolopoulou P, 2005, HUM PATHOL, V36, P899, DOI 10.1016/j.humpath.2005.06.008; Ladstein RG, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-140; Meer S, 2003, ORAL SURG ORAL MED O, V95, P213, DOI 10.1067/moe.2003.62; Nakao Y, 2013, INT J ONCOL, V43, P1377, DOI 10.3892/ijo.2013.2081; Nguyen VQ, 2000, CURR BIOL, V10, P195, DOI 10.1016/S0960-9822(00)00337-7; Otero D, 2013, ORAL DIS, V19, P360, DOI 10.1111/odi.12010; Sandra F, 2001, ORAL ONCOL, V37, P193, DOI 10.1016/S1368-8375(00)00079-8; Scholzen T, 2000, J CELL PHYSIOL, V182, P311, DOI 10.1002/(SICI)1097-4652(200003)182:3<311::AID-JCP1>3.0.CO;2-9; Schrader C, 2005, BRIT J CANCER, V93, P939, DOI 10.1038/sj.bjc.6602795; Sekerci AE, 2015, MED ORAL PATOL ORAL, V20, pE34, DOI 10.4317/medoral.19157; Simon NE, 2014, BIOMED RES INT, DOI 10.1155/2014/549719; Soluk Tekkesin M, 2012, TURK J PATHOL, V28, P49, DOI 10.5146/tjpath.2012.01097; Stoeber K, 2001, J CELL SCI, V114, P2027; Yu SY, 2014, J ORAL PATHOL MED, V43, P344, DOI 10.1111/jop.12134	35	0	0	0	0	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1066-8969	1940-2465		INT J SURG PATHOL	Int. J. Surg. Pathol.	DEC	2018	26	8					714	720		10.1177/1066896918778341			7	Pathology; Surgery	Pathology; Surgery	HA5TJ	WOS:000450340700005	29845895				2019-10-28	
J	Parakh, R; Cheng, L; Tretiakova, M				Parakh, Rugvedita; Cheng, Lin; Tretiakova, Maria			PAX8-Positive B-Cell Lymphoma in Adrenal Gland Masquerading as Metastatic Renal Cell Carcinoma	INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY			English	Article						adrenal; lymphoma; PAX8; renal cell carcinoma; neoplasm	PAX8; TUMORS	Extranodal lymphomas involve adrenal glands as a mass lesion in 3% to 5% of cases as identified by imaging studies. Definitive diagnosis of the neoplasm is provided by morphological and immunophenotypical evaluation on limited tissue obtained by fine needle aspiration or core biopsy. We report a diagnostically challenging case that presented as masses involving adrenal gland and lung in the setting of a concurrent primary renal cell carcinoma. PAX8, a frequently used marker for renal cell carcinoma, was immunoreactive in the neoplastic cells of the adrenal mass, and thus highly suggestive for metastatic renal cell carcinoma. The neoplasm was eventually proven to represent PAX8-positive diffuse large B-cell lymphoma after extended immunohistochemical workup. This case of unusual presentation of synchronous renal cell carcinoma and adrenal lymphoma with overlapping PAX8 immunoreactivity serves as a potential diagnostic pitfall with significant clinical implications.	[Parakh, Rugvedita; Tretiakova, Maria] Univ Washington, Med Ctr, Seattle, WA 98195 USA; [Cheng, Lin] Rush Univ, Chicago, IL 60612 USA	Parakh, R (reprint author), Univ Washington, Med Ctr, Pathol & Lab Med, 1959 NE Pacific St, Seattle, WA 98195 USA.	rugpara@uw.edu					Lack EE, 2007, TUMORS ADRENAL GLAND, P215; Lam KY, 2002, CLIN ENDOCRINOL, V56, P95, DOI 10.1046/j.0300-0664.2001.01435.x; Laury AR, 2011, AM J SURG PATHOL, V35, P816, DOI 10.1097/PAS.0b013e318216c112; Moretti L, 2012, MODERN PATHOL, V25, P231, DOI 10.1038/modpathol.2011.162; Morgan EA, 2013, HISTOPATHOLOGY, V62, P406, DOI 10.1111/his.12020; PALING MR, 1983, AM J ROENTGENOL, V141, P303, DOI 10.2214/ajr.141.2.303; Pileri SA, 2002, HISTOPATHOLOGY, V41, P482, DOI 10.1046/j.1365-2559.2002.01538.x; Sangoi AR, 2011, AM J SURG PATHOL, V35, P678, DOI 10.1097/PAS.0b013e3182152629; Sasaki T, P US CAN AC PATH ANN; STRAUS DJ, 1983, CANCER, V51, P101, DOI 10.1002/1097-0142(19830101)51:1<101::AID-CNCR2820510121>3.0.CO;2-W	10	1	1	0	0	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1066-8969	1940-2465		INT J SURG PATHOL	Int. J. Surg. Pathol.	DEC	2018	26	8					721	724		10.1177/1066896918770022			4	Pathology; Surgery	Pathology; Surgery	HA5TJ	WOS:000450340700006	29665739				2019-10-28	
J	Charifa, A; Zhang, XC				Charifa, Ahmad; Zhang, Xuchen			Morphologic and Immunohistochemical Characteristics of Anorectal Melanoma	INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY			English	Article						anorectal melanoma; immunohistochemistry; pathology; Sox10	MALIGNANT-MELANOMA; DIAGNOSIS; MARKER; SOX10; KIT	Anorectal melanoma is a rare aggressive disease. Due to its rarity and considerable histologic and immunohistochemical variabilities, misdiagnosis as lymphoma, carcinoma, sarcoma, and/or gastrointestinal stromal tumor is not uncommon, particularly in amelanotic cases. We reviewed histologic features and immunohistochemical stains of 19 anorectal melanoma cases. Histopathologic features were evaluated including junctional activity, melanin pigment, and morphologic features. Immunohistochemical stains were performed using Sox10, S100 protein, HMB-45, melan-A, CD56, and cytokeratins. Epithelioid histopathologic morphology was observed in 63.2% of the cases followed by 47.4% of the cases with spindle-cell, 26.3% with lymphoma-like, and 26.3% with pleomorphic morphologies. Junctional melanocytic activity was seen in almost half of the cases. Melanin pigment was absent (amelanotic) in nearly 40% of the cases. Immunohistochemically, diffuse positive expression of Sox10, S100 protein, melan-A, and HMB-45 was seen in 100%, 40%, 53.3%, and 38.5% of the cases, respectively. Cytokeratins were negative and CD56 was positive in 2 cases. These findings indicate that anorectal melanomas often show one or combined histolopathologic features without presence of melanin pigment and absence of junctional melanocytic activity. Anorectal melanoma should be kept in mind in the differential diagnosis of malignant neoplasms of anorectal region with epithelioid, spindle-cell, lymphoma-like, and pleomorphic morphologies. Sox10 immunohistochemistry stain can be used as a first-line screening tool to avoid extensive or unnecessary workups and/or potential misdiagnosis.	[Charifa, Ahmad; Zhang, Xuchen] Yale Univ, Sch Med, Dept Pathol, 310 Cedar St,POB 208023, New Haven, CT 06520 USA	Zhang, XC (reprint author), Yale Univ, Sch Med, Dept Pathol, 310 Cedar St,POB 208023, New Haven, CT 06520 USA.	xuchen.zhang@yale.edu					Banerjee SS, 2000, HISTOPATHOLOGY, V36, P387; Chute DJ, 2006, AM J CLIN PATHOL, V126, P93, DOI 10.1309/DVWLTV8FFKC3L80H; Compton LA, 2015, DERMATOPATHOLOGY, V2, P15, DOI 10.1159/000377698; COOPER PH, 1982, DIS COLON RECTUM, V25, P693, DOI 10.1007/BF02629543; Hodi FS, 2013, J CLIN ONCOL, V31, P3182, DOI 10.1200/JCO.2012.47.7836; Kim RH, 2017, J CUTAN PATHOL, V44, P221, DOI 10.1111/cup.12867; Kottschade LA, 2014, AM J CLIN ONCOL-CANC, V37, P635, DOI 10.1097/COC.0b013e3182868e82; Miettinen M, 2015, AM J SURG PATHOL, V39, P826, DOI 10.1097/PAS.0000000000000398; Ohsie SJ, 2008, J CUTAN PATHOL, V35, P433, DOI 10.1111/j.1600-0560.2007.00891.x; Ordonez NG, 2013, ADV ANAT PATHOL, V20, P275, DOI 10.1097/PAP.0b013e318297a9d0; Santi R, 2015, J CLIN PATHOL, V68, P130, DOI 10.1136/jclinpath-2014-202572; Singer Marc, 2006, Clin Colon Rectal Surg, V19, P78, DOI 10.1055/s-2006-942348; Tariq MU, 2014, ANN DIAGN PATHOL, V18, P275, DOI 10.1016/j.anndiagpath.2014.08.002; Weinstein David, 2014, J Clin Aesthet Dermatol, V7, P13; Willis BC, 2015, APPL IMMUNOHISTO M M, V23, P109, DOI 10.1097/PAI.0000000000000097; Yang HM, 2017, MODERN PATHOL, V30, P286, DOI 10.1038/modpathol.2016.179	16	1	1	0	2	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1066-8969	1940-2465		INT J SURG PATHOL	Int. J. Surg. Pathol.	DEC	2018	26	8					725	729		10.1177/1066896918773177			5	Pathology; Surgery	Pathology; Surgery	HA5TJ	WOS:000450340700007	29759015				2019-10-28	
J	Van Bockstal, M				Van Bockstal, Mieke			A Rare Mammary Serendipity: Mucinous Metaplasia of the Breast	INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY			English	Editorial Material									[Van Bockstal, Mieke] Ghent Univ Hosp, Ghent, Belgium	Van Bockstal, M (reprint author), Ghent Univ Hosp, Dept Pathol, De Pintelaan 185, B-9000 Ghent, Belgium.	mieke.vanbockstal@ugent.be		Van Bockstal, Mieke R./0000-0003-4498-928X			Durham J R, 2000, Am J Clin Pathol, V113, pS3; Quddus MR, 2016, INT J SURG PATHOL, V24, P47, DOI 10.1177/1066896915604025; Tan PH, 2008, J CLIN PATHOL, V61, P11, DOI 10.1136/jcp.2006.046227; Tan PH, 2017, ATLAS DIFFERENTIAL D, P163; Tan PH, 2017, ATLAS DIFFERENTIAL D, P191; Yaqub O, 2018, RES POLICY, V47, P169, DOI 10.1016/j.respol.2017.10.007	6	0	0	0	1	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1066-8969	1940-2465		INT J SURG PATHOL	Int. J. Surg. Pathol.	DEC	2018	26	8					730	730		10.1177/1066896918761809			1	Pathology; Surgery	Pathology; Surgery	HA5TJ	WOS:000450340700008	29532695				2019-10-28	
J	Kumar, R; Sundaram, A; Saha, PK; Dey, P				Kumar, Rajesh; Sundaram, Archana; Saha, Pradip Kumar; Dey, Pranab			An Unusual Case of Extensive Osseous Metaplasia in Fibroma of Ovary	INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY			English	Editorial Material							ADENOCARCINOMA; THECOMAS		[Kumar, Rajesh; Sundaram, Archana; Saha, Pradip Kumar; Dey, Pranab] Postgrad Inst Med Educ & Res, Chandigarh, India	Dey, P (reprint author), Postgrad Inst Med Educ & Res, Dept Cytol & Gynaecol Pathol, 123B Type 5,Sect 24A, Chandigarh 160012, India.	deypranabi@hotmail.com					BOSSCHER J, 1990, GYNECOL ONCOL, V39, P228, DOI 10.1016/0090-8258(90)90439-R; Morizane M., 2003, Archives of Gynecology and Obstetrics, V267, P167, DOI 10.1007/s00404-001-0282-3; Mukonoweshuro P, 2005, GYNECOL ONCOL, V99, P222, DOI 10.1016/j.ygyno.2005.05.040; Pervatikar SK, 2009, INDIAN J PATHOL MICR, V52, P222, DOI 10.4103/0377-4929.48925; YOUNG RH, 1988, INT J GYNECOL PATHOL, V7, P343, DOI 10.1097/00004347-198812000-00005; ZHANG J, 1982, INT J GYNECOL PATHOL, V1, P270, DOI 10.1097/00004347-198203000-00004	6	0	0	0	0	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1066-8969	1940-2465		INT J SURG PATHOL	Int. J. Surg. Pathol.	DEC	2018	26	8					733	734		10.1177/1066896918766239			2	Pathology; Surgery	Pathology; Surgery	HA5TJ	WOS:000450340700010	29575966				2019-10-28	
J	Suarez-Zamora, DA; Rodriguez-Urrego, PA; Solano-Marino, J; Sierra-Arango, F; Palau-Lazaro, MA				Suarez-Zamora, David A.; Rodriguez-Urrego, Paula A.; Solano-Marino, Jaime; Sierra-Arango, Fernando; Palau-Lazaro, Mauricio A.			Esophageal Pyogenic Granuloma: A Case Report and Review of the Literature	INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY			English	Review						esophagus; gastrointestinal tract; lobular capillary hemangioma; pyogenic granuloma; vascular proliferations	BARRETTS-ESOPHAGUS	Pyogenic granuloma (PG) is a capillary hemangioma mainly found in the skin and oral mucosa, but rarely described in the esophagus. We report the case of a 66-year-old man who consulted for retrosternal pain. Endoscopic studies showed a 28-mm polypoid mass located at the distal esophageal mucosa. The patient underwent endoscopic resection, and the histopathological examination showed a neoplastic proliferation of small blood vessels growing in a lobular architecture, with edematous stroma and prominent inflammatory infiltrate. Special stains for fungus showed pseudohyphae compatible with Candida spp. Findings were consistent with those of an esophageal PG associated with Candida infection. This case is a reminder that PG can be found in the esophagus, can be associated with other entities such as Candida infection, and is one of the differential diagnoses of neoplastic vascular proliferations that may mimic malignancy. In addition, we reviewed previously reported cases of esophageal PG.	[Suarez-Zamora, David A.; Rodriguez-Urrego, Paula A.; Palau-Lazaro, Mauricio A.] Fdn Santa Fe Bogota, Dept Pathol & Labs, Carrera 7 117-15,Second Floor, Bogota, Colombia; [Solano-Marino, Jaime; Sierra-Arango, Fernando] Fdn Santa Fe Bogota, Div Gastroenterol, Bogota, Colombia; [Solano-Marino, Jaime; Sierra-Arango, Fernando; Palau-Lazaro, Mauricio A.] Univ Andes, Sch Med, Bogota, Colombia	Palau-Lazaro, MA (reprint author), Fdn Santa Fe Bogota, Dept Pathol & Labs, Carrera 7 117-15,Second Floor, Bogota, Colombia.	mapalau@hotmail.com	Suarez-Zamora, David A./V-1952-2019	Suarez-Zamora, David A./0000-0003-1159-0512; Sierra-Arango, Fernando/0000-0001-6372-7862			Cho WY, 2004, GASTROINTEST ENDOSC, V59, P539, DOI 10.1016/S0016-5107(03)02594-X; CRAIG RM, 1995, GASTROENTEROLOGY, V108, P1894, DOI 10.1016/0016-5085(95)90155-8; Val-Bernal JF, 2012, PATHOL RES PRACT, V208, P687, DOI 10.1016/j.prp.2012.08.010; Hoekstra ER, 2007, GASTROINTEST ENDOSC, V65, P1086, DOI 10.1016/j.gie.2006.10.033; Iwamuro M, 2015, INTERNAL MED, V54, P1737, DOI 10.2169/internalmedicine.54.4265; Meeks MW, 2016, CASE REP GASTROINTES, DOI 10.1155/2016/4398401; Misawa S, 2015, BMC GASTROENTEROL, V15, DOI 10.1186/s12876-015-0355-6; Okada N, 2003, ENDOSCOPY, V35, P375, DOI 10.1055/s-2003-38159; OKUMURA T, 1983, ACTA PATHOL JAPON, V33, P1303; Saito Y, 2013, DIS ESOPHAGUS, V26, P343, DOI 10.1111/j.1442-2050.2012.01351.x; Seoung HG, 2013, CLIN ENDOSC, V46, P81, DOI 10.5946/ce.2013.46.1.81; Tajika M, 2006, GASTROINTEST ENDOSC, V64, P269, DOI 10.1016/j.gie.2006.01.040; Val-Bernal JF, 2016, PATHOL RES PRACT, V212, P68, DOI 10.1016/j.prp.2015.11.001; van Eeden S, 2004, VIRCHOWS ARCH, V444, P590, DOI 10.1007/s00428-004-1013-5; Yu JH, 2016, GASTROENTEROLOGY, V150, pE1, DOI 10.1053/j.gastro.2015.08.013; Zhao JR, 2017, CLIN GASTROENTEROL H, V15, pE177, DOI 10.1016/j.cgh.2017.03.028	16	0	0	0	0	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1066-8969	1940-2465		INT J SURG PATHOL	Int. J. Surg. Pathol.	DEC	2018	26	8					735	738		10.1177/1066896918773476			4	Pathology; Surgery	Pathology; Surgery	HA5TJ	WOS:000450340700011	29737225				2019-10-28	
J	Mitra, S; Geethanjali, G; Rathi, S; Behera, A; Das, A				Mitra, Suvradeep; Geethanjali, Gude; Rathi, Sahaj; Behera, Arunanshu; Das, Ashim			Subcentimetric Incidental Intrahepatic Cholangiocarcinoma in an Explant Liver: Diagnostic Difficulty of a Rare Entity	INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY			English	Article						incidental cholangiocarcinoma; intrahepatic cholangiocarcinoma; explant liver; autoimmune hepatitis; chronic cholangiopathy	BILE-DUCT ADENOMA; TRANSPLANTATION; PATHOGENESIS; EXPERIENCE; OUTCOMES	Incidental intrahepatic cholangiocarcinoma (iCCA) is a rare neoplastic lesion in the explant liver specimens with an approximate incidence of 0.7%. The detection of iCCA is associated with poor prognosis in the posttransplant setting. The occurrence of a subcentimetric iCCA is very rare and poses a major diagnostic challenge to the pathologist. This article presents a rare case of subcentimetric iCCA in a young male in the background of advanced stage chronic liver disease resulting from autoimmune hepatitis possibly with chronic cholangiopathy along with the histomorphological differentials.	[Mitra, Suvradeep; Geethanjali, Gude; Rathi, Sahaj; Behera, Arunanshu; Das, Ashim] Postgrad Inst Med Educ & Res PGIMER, Chandigarh, India	Das, A (reprint author), Postgrad Inst Med Educ & Res PGIMER, Dept Histopathol, 5th Floor,Res Block A, Chandigarh 160012, India.	ashim126@gmail.com	Rathi, Sahaj/P-9277-2016	Rathi, Sahaj/0000-0001-6529-9080			Aishima S, 2014, PATHOL INT, V64, P551, DOI 10.1111/pin.12209; Ali JM, 2011, TRANSPLANTATION, V91, P1392, DOI 10.1097/TP.0b013e31821aba57; Ghali P, 2005, LIVER TRANSPLANT, V11, P1412, DOI 10.1002/lt.20512; Hughes NR, 2010, AM J SURG PATHOL, V34, P1312, DOI 10.1097/PAS.0b013e3181ead722; Moy AP, 2016, HISTOPATHOLOGY, V69, P423, DOI 10.1111/his.12942; Patkowski W, 2014, TRANSPL P, V46, P2774, DOI 10.1016/j.transproceed.2014.09.057; Serra V, 2016, TRANSPL P, V48, P366, DOI 10.1016/j.transproceed.2015.12.044	7	0	0	0	0	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1066-8969	1940-2465		INT J SURG PATHOL	Int. J. Surg. Pathol.	DEC	2018	26	8					739	744		10.1177/1066896918774843			6	Pathology; Surgery	Pathology; Surgery	HA5TJ	WOS:000450340700012	29742944				2019-10-28	
J	Kim, Y; Jung, MJ; Shin, SJ				Kim, Yeseul; Jung, Min Jung; Shin, Su-Jin			Heterotopic Gastric Mucosa in the Common Bile Duct With Cholangiocarcinoma	INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY			English	Article						gastric heterotopia; cholangiocarcinoma; common bile duct	GALLBLADDER	Gastric heterotopia within the biliary system is extremely rare. Moreover, the combination of gastric heterotopia in the bile duct with cholangiocarcinoma has not been reported. We describe a case of heterotopic gastric mucosa in the common bile duct with cholangiocarcinoma. An 80-year-old male was admitted with abdominal pain. Abdominal computed tomography revealed wall thickening from the hilar duct to the distal common bile duct. Biopsy from the distal bile duct showed only benign gastric foveolar-type epithelium and fundic glands. Although the diagnosis of the biopsy was benign, malignancy was strongly suspected from the radiologic findings, and excision of the bile ducts was performed. Microscopically, the resected specimen showed poorly formed malignant glands and gastric heterotopia also identified in the common bile duct. Three months later, the patient's state worsened due to recurrence, and he died. To our knowledge, this is the first report of gastric heterotopia in the bile duct accompanying cholangiocarcinoma.	[Kim, Yeseul; Shin, Su-Jin] Hanyang Univ, Coll Med, Dept Pathol, 222 Wangsimni Ro, Seoul 04763, South Korea; [Jung, Min Jung] Soonchunhyang Univ, Coll Med, Bucheon Hosp, Dept Pathol, Bucheon, South Korea	Shin, SJ (reprint author), Hanyang Univ, Coll Med, Dept Pathol, 222 Wangsimni Ro, Seoul 04763, South Korea.	charm@hanyang.ac.kr	Shin, Su-Jin/K-3248-2017	Shin, Su-Jin/0000-0001-9114-8438			BLUNDELL CR, 1982, AM J GASTROENTEROL, V77, P111; CURTIS LE, 1969, ARCH PATHOL, V88, P677; Elemen L, 2009, SURG TODAY, V39, P444, DOI 10.1007/s00595-008-3866-8; EVANS MM, 1990, SURGERY, V108, P96; Fukuda S, 2013, SURG TODAY, V43, P91, DOI 10.1007/s00595-012-0221-x; Fukuda Y, 2001, HEPATO-GASTROENTEROL, V48, P1337; GORLIN RJ, 1964, J PEDIATR-US, V64, P604, DOI 10.1016/S0022-3476(64)80356-5; KALMAN PG, 1981, SURGERY, V89, P384; Madrid C, 2003, PEDIATR RADIOL, V33, P129, DOI 10.1007/s00247-002-0718-3; MARTINEZURRUTIA MJ, 1990, J PEDIATR SURG, V25, P356, DOI 10.1016/0022-3468(90)90088-Q; Sciume C, 2005, Ann Ital Chir, V76, P93; WELLING RE, 1970, ARCH SURG-CHICAGO, V101, P626; Wollschlaeger B, 1995, J Am Board Fam Pract, V8, P134	13	0	0	0	1	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1066-8969	1940-2465		INT J SURG PATHOL	Int. J. Surg. Pathol.	DEC	2018	26	8					745	748		10.1177/1066896918775531			4	Pathology; Surgery	Pathology; Surgery	HA5TJ	WOS:000450340700013	29742955				2019-10-28	
J	Nayak, A; Bleiweiss, IJ; Dumoff, K; Bhuiya, TA				Nayak, Anupma; Bleiweiss, Ira J.; Dumoff, Kimberly; Bhuiya, Tawfiqul A.			Mucinous Cystadenocarcinoma of the Breast: Report of 2 Cases Including One With Long-Term Local Recurrence	INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY			English	Article						breast; mucinous; cystadenocarcinoma; rare; recurrence	OF-THE-LITERATURE; INFILTRATING DUCTAL CARCINOMA; EXPRESSION; TUMOR	Primary mucinous cystadenocarcinoma (MCA) of breast is an exceedingly rare tumor with histologic resemblance to MCA arising in ovary, pancreas, and gastrointestinal tract. In this article, we present 2 additional cases of MCA of breast, one highlighting the diagnostic challenges of a rare entity that may potentially lead to unnecessary chemotherapy and the second case presenting with recurrence after 8 years of primary surgical excision defying the indolent behavior reported in the literature. To our knowledge, this is the first reported instance of such behavior.	[Nayak, Anupma; Bleiweiss, Ira J.; Dumoff, Kimberly] Univ Penn, Philadelphia, PA 19104 USA; [Nayak, Anupma; Bleiweiss, Ira J.; Dumoff, Kimberly] Hosp Univ Penn, 3400 Spruce St, Philadelphia, PA 19104 USA; [Bhuiya, Tawfiqul A.] Northwell Hlth, Lake Success, NY USA	Nayak, A (reprint author), Hosp Univ Penn, 3400 Spruce St, Philadelphia, PA 19104 USA.	anupma.nayak@uphs.upenn.edu					Chen WY, 2004, PATHOL INT, V54, P781, DOI 10.1111/j.1440-1827.2004.01755.x; Coyne JD, 2006, HISTOPATHOLOGY, V49, P659, DOI 10.1111/j.1365-2559.2006.02471.x; Deng YT, 2012, PATHOL INT, V62, P429, DOI 10.1111/j.1440-1827.2012.02810.x; Domoto H, 2000, HISTOPATHOLOGY, V36, P567, DOI 10.1046/j.1365-2559.2000.00918-3.x; Gulwani H, 2010, INDIAN J PATHOL MICR, V53, P200, DOI 10.4103/0377-4929.59242; Honma N, 2003, ARCH PATHOL LAB MED, V127, P1031; Kim SE, 2012, KOREAN J PATHOL, V46, P611, DOI 10.4132/KoreanJPathol.2012.46.6.611; Koenig C, 1998, AM J SURG PATHOL, V22, P698, DOI 10.1097/00000478-199806000-00006; Koufopoulos N, 2017, RARE TUMORS, V9, P98, DOI 10.4081/rt.2017.7016; Kucukzeybek BB, 2014, POL J PATHOL, V65, P70, DOI 10.5114/PJP.2014.42673; Lee SH, 2008, PATHOL INT, V58, P601, DOI 10.1111/j.1440-1827.2008.02278.x; Li XY, 2012, BREAST J, V18, P282, DOI 10.1111/j.1524-4741.2012.01238.x; Lin DL, 2013, BREAST CARE, V8, P445, DOI 10.1159/000357657; Petersson F, 2010, HUM PATHOL, V41, P910, DOI 10.1016/j.humpath.2009.10.020; Rakici S, 2009, CASE REP ONCOL, V2, P210, DOI 10.1159/000253866; ROSEN PP, 1984, AM J SURG PATHOL, V8, P31, DOI 10.1097/00000478-198401000-00003; Sentani K, 2012, DIAGN CYTOPATHOL, V40, P624, DOI 10.1002/dc.21638; Seong M, 2016, J BREAST CANCER, V19, P330, DOI 10.4048/jbc.2016.19.3.330; Witherspoon LE, 2015, AM SURGEON, V81, pE106	19	0	2	0	3	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1066-8969	1940-2465		INT J SURG PATHOL	Int. J. Surg. Pathol.	DEC	2018	26	8					749	757		10.1177/1066896918775810			9	Pathology; Surgery	Pathology; Surgery	HA5TJ	WOS:000450340700014	29745281				2019-10-28	
J	Arboleda, PA; Sanchez-Romero, C; de Almeida, OP; Flores Alvarado, SA; Martinez Pedraza, R				Arboleda, Paola Aristizabal; Sanchez-Romero, Celeste; de Almeida, Oslei Paes; Flores Alvarado, Sergio A.; Martinez Pedraza, Ricardo			Calcifying Odontogenic Cyst Associated With Dentigerous Cyst in a 15-Year-Old Girl	INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY			English	Article						calcifying odontogenic cyst; dentigerous cyst; ghost cells; immunohistochemistry; odontogenic cyst	GHOST CELLS; TUMOR; LESIONS; RANGE	Calcifying odontogenic cyst (COC) is a rare odontogenic cyst with ameloblastic epithelial lining containing clusters of ghost cells. COCs have been described in association with several odontogenic tumors, more commonly odontomas and rarely with dentigerous cyst (DC). In this article, we describe a case of COC associated with DC in a 15-year-old girl, who presented with a swelling on the right middle third of the face, producing facial asymmetry. Panoramic radiography showed a well-circumscribed, corticated, and unilocular radiolucency at the level of the right maxillary sinus, involving 2 unerupted premolars. The lesion was enucleated and histologically revealed a COC associated with DC, which presented mucous metaplasia. Immunohistochemical reactions were performed to better illustrate this rare synchronous occurrence of COC and DC, showing positivity for CK5, CK14, CK19, and p63 in both lesions. CK18 was negative in COC, and Bcl-2 was negative in DC. Periodic acid Schiff highlighted the mucous cells in the DC lining.	[Arboleda, Paola Aristizabal; Sanchez-Romero, Celeste; de Almeida, Oslei Paes] Univ Estadual Campinas, Piracicaba Dent Sch, Piracicaba, SP, Brazil; [Flores Alvarado, Sergio A.] Inst Mexicano Seguro Social, Saltillo, Coahuila, Mexico; [Martinez Pedraza, Ricardo] Univ Autonoma Nuevo Leon, Monterrey, Nuevo Leon, Mexico	Sanchez-Romero, C (reprint author), Univ Campinas UNICAMP, Piracicaba Dent Sch, Dept Oral Diag, Av Limeira 901,POB 52, BR-13414903 Piracicaba, SP, Brazil.	csr_90@hotmail.com		Sanchez-Romero, Celeste/0000-0001-5365-2692			Barnes L, 2005, WHO CLASSIFICATION T; Basile JR, 2010, ORAL SURG ORAL MED O, V109, pE40, DOI 10.1016/j.tripleo.2009.12.026; Bernardes VD, 2008, HEAD NECK PATHOL, V2, P324, DOI 10.1007/s12105-008-0072-3; Chindasombatjaroen J, 2012, OR SURG OR MED OR PA, V113, P414, DOI 10.1016/j.oooo.2011.09.009; El-Naggar A, 2017, WHO CLASSIFICATION H; Fregnani ER, 2003, J ORAL PATHOL MED, V32, P163, DOI 10.1034/j.1600-0714.2003.00070.x; Gamoh S, 2017, ONCOL LETT, V14, P5785, DOI 10.3892/ol.2017.6993; GORLIN R J, 1962, Oral Surg Oral Med Oral Pathol, V15, P1235, DOI 10.1016/0030-4220(62)90159-7; HIRSHBERG A, 1994, J ORAL MAXIL SURG, V52, P555, DOI 10.1016/0278-2391(94)90087-6; HONG SP, 1991, ORAL SURG ORAL MED O, V72, P56, DOI 10.1016/0030-4220(91)90190-N; Iida S, 2006, ORAL SURG ORAL MED O, V101, P356, DOI 10.1016/j.tripleo.2005.08.037; Johnson NR, 2014, J INVESTIG CLIN DENT, V5, P9, DOI 10.1111/jicd.12044; Jones AV, 2006, J ORAL PATHOL MED, V35, P500, DOI 10.1111/j.1600-0714.2006.00455.x; Kaminagakura E, 2013, ANN DIAGN PATHOL, V17, P514, DOI 10.1016/j.anndiagpath.2013.07.002; Ledesma-Montes C, 2008, J ORAL PATHOL MED, V37, P302, DOI 10.1111/j.1600-0714.2007.00623.x; Lee J, 2014, J CRANIOFAC SURG, V25, pE259, DOI 10.1097/SCS.0000000000000563; Lucchese A, 2011, ULTRASTRUCT PATHOL, V35, P146, DOI 10.3109/01913123.2010.548111; Mabongo M, 2014, SADJ, V69, P412; Mortazavi H, 2016, IMAGNG SCI DENT, V46, P147, DOI 10.5624/isd.2016.46.3.147; Patil S, 2017, J CLIN DIAGN RES, V11, pZC47, DOI 10.7860/JCDR/2017/28895.10064; PRAETORIUS F, 1981, ACTA ODONTOL SCAND, V39, P227, DOI 10.3109/00016358109162284; Radheshyam C, 2015, CLIN COSMET INVESTIG, V7, P91, DOI 10.2147/CCIDE.S87864; Regezi JA, 2002, MODERN PATHOL, V15, P331, DOI 10.1038/modpathol.3880527; Rumayor A, 2015, J ORAL PATHOL MED, V44, P284, DOI 10.1111/jop.12234; Soares ECS, 2011, J CRANIOFAC SURG, V22, P554, DOI 10.1097/SCS.0b013e3182074616; Takeda Yasunori, 2005, J Oral Sci, V47, P77, DOI 10.2334/josnusd.47.77; Toida M, 1998, J ORAL PATHOL MED, V27, P49; Wright JM, 2017, HEAD NECK PATHOL, V11, P68, DOI 10.1007/s12105-017-0794-1; Yoon JH, 2004, ORAL SURG ORAL MED O, V98, P80, DOI 10.1016/j.tripleo.2004.01.003; Zhang LL, 2010, INT J ORAL MAX SURG, V39, P878, DOI 10.1016/j.ijom.2010.04.048	30	0	0	0	4	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1066-8969	1940-2465		INT J SURG PATHOL	Int. J. Surg. Pathol.	DEC	2018	26	8					758	765		10.1177/1066896918777639			8	Pathology; Surgery	Pathology; Surgery	HA5TJ	WOS:000450340700015	29890883				2019-10-28	
J	Kiefer, RM; Wojcik, J; Cooper, K; Weber, KL; Sebro, R				Kiefer, Ryan M.; Wojcik, John; Cooper, Kumarasen; Weber, Kristy L.; Sebro, Ronnie			Clear Cell Chondrosarcoma With Chondroblastoma-Like Features: A Case for Team Diagnosis	INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY			English	Article						clear cell chondrosarcoma; chondroblastoma; radiograph; magnetic resonance imaging	DEDIFFERENTIATED CHONDROSARCOMA; BONE	Clear cell chondrosarcoma (CCCS) is a rare variant of conventional chondrosarcoma with low-grade malignant features that may be confused radiographically and histologically with chondroblastoma. We report a case of a 50-year-old female who presented with 6 months of left hip pain. Initial radiographs demonstrated an osteolytic lesion with adjacent area of sclerosis in the proximal left femur. Magnetic resonance imaging demonstrated a marrow-infiltrative lesion with periosteal reaction and thickened enhancing periosteum. Biopsy of the sclerotic area demonstrated chondroblastoma-like findings, whereas biopsy of the lytic area showed features suggestive of CCCS. The patient eventually underwent en bloc resection and reconstruction with a proximal femoral megaprosthesis. The final diagnosis was CCCS. We present this unusual case with review of the radiographic and histologic features of CCCS with attention to its ability to mimic chondroblastomas. This case highlights the importance of sampling radiographically heterogeneous areas within a bone lesion to facilitate accurate diagnosis and appropriate management.	[Kiefer, Ryan M.; Wojcik, John; Cooper, Kumarasen; Weber, Kristy L.; Sebro, Ronnie] Univ Penn, Philadelphia, PA 19104 USA	Sebro, R (reprint author), Univ Penn, Dept Radiol, 3400 Spruce St, Philadelphia, PA 19104 USA.	Ronnie.sebro@uphs.upenn.edu		Kiefer, Ryan/0000-0001-7499-4245			Alexander J, 2014, HEAD NECK PATHOL, V8, P307, DOI 10.1007/s12105-014-0542-8; Amary MF, 2016, HISTOPATHOLOGY, V69, P121, DOI 10.1111/his.12945; Angelini Andrea, 2017, Eur J Orthop Surg Traumatol, V27, P843, DOI 10.1007/s00590-017-1996-7; Ayoub K S, 1999, Sarcoma, V3, P115, DOI 10.1080/13577149977749; Behjati S, 2013, NAT GENET, V45, P1479, DOI 10.1038/ng.2814; BJORNSSON J, 1984, AM J SURG PATHOL, V8, P223, DOI 10.1097/00000478-198403000-00009; BROWER AC, 1990, AM J ROENTGENOL, V154, P309, DOI 10.2214/ajr.154.2.2105021; Cannon CP, 2002, SKELETAL RADIOL, V31, P369, DOI 10.1007/s00256-002-0519-7; Collins MS, 2003, SKELETAL RADIOL, V32, P687, DOI 10.1007/s00256-003-0668-3; Donati D, 2008, ARCH ORTHOP TRAUM SU, V128, P137, DOI 10.1007/s00402-007-0353-4; Erickson JK, 2001, RADIOLOGY, V221, P463, DOI 10.1148/radiol.2212010262; Jiang XS, 2014, DIAGN CYTOPATHOL, V42, P784, DOI 10.1002/dc.23043; Kaim AH, 2002, SKELETAL RADIOL, V31, P88, DOI 10.1007/s00256-001-0450-3; Kurdi M, 2017, INT J SURG PATHOL, V25, P181, DOI 10.1177/1066896916666317; Kuroda N, 2009, MED MOL MORPHOL, V42, P185, DOI 10.1007/s00795-007-0359-6; Laitinen M, 2014, CASE REP ORTHOP, V2014; Manfrini M, 2014, CLIN SARCOMA RES, V4, DOI 10.1186/2045-3329-4-12; Meijer D, 2012, GENE CHROMOSOME CANC, V51, P899, DOI 10.1002/gcc.21974; Memis A, 2002, EUR RADIOL, V12, P427, DOI 10.1007/s003300101033; Nishio J, 2005, CANCER GENET CYTOGEN, V162, P74, DOI 10.1016/j.cancergencyto.2005.03.003; Ro JY, 2011, SARCOMA, V2011; Soder S, 2006, PATHOLOGY, V38, P35, DOI 10.1080/00313020500455803; UNNI KK, 1976, J BONE JOINT SURG AM, V58, P676, DOI 10.2106/00004623-197658050-00018; van Oosterwijk JG, 2013, AM J PATHOL, V182, P1347, DOI 10.1016/j.ajpath.2012.12.036	24	0	0	0	0	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1066-8969	1940-2465		INT J SURG PATHOL	Int. J. Surg. Pathol.	DEC	2018	26	8					766	771		10.1177/1066896918776092			6	Pathology; Surgery	Pathology; Surgery	HA5TJ	WOS:000450340700016	29774790				2019-10-28	
J	Suarez-Zamora, DA; Rodriguez-Urrego, PA; Soto-Montoya, C; Rivero-Rapalino, O; Palau-Lazaro, MA				Suarez-Zamora, David A.; Rodriguez-Urrego, Paula A.; Soto-Montoya, Camilo; Rivero-Rapalino, Oscar; Palau-Lazaro, Mauricio A.			Malignant Solitary Fibrous Tumor of the Humerus: A Case Report of an Extremely Rare Primary Bone Tumor	INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY			English	Article						bone; hemangiopericytoma; malignant; soft tissue; solitary fibrous tumor	EXPRESSION	Solitary fibrous tumor (SFT) is a spindle-shaped cell neoplasm originally described in the pleura, but subsequently found in many anatomic sites. Only few cases of primary SFTs in the bone have been previously described in the literature. We present the case of an 86-year-old man with a 1-week history of pain in his left arm. Imaging studies demonstrated a well-defined osteolytic lesion in the proximal humerus measuring 6.1 cm in diameter. Sections showed a round to spindle-shaped cell neoplasm with prominent mitotic activity (28 mitoses per 10 high-power fields) and areas of necrosis, focally surrounding staghorn-shaped vessels. The tumor cells were positive for CD34, CD99, Bcl-2, and STAT6 and negative for smooth muscle actin, epithelial membrane antigen, and cytokeratin AE1/AE3. These findings were consistent with a malignant SFT involving the left humerus. Although extremely rare, SFT should be considered in the differential diagnosis of primary bone tumors. This is the first case report of a primary SFT in a long bone with malignant histological features.	[Suarez-Zamora, David A.; Rodriguez-Urrego, Paula A.; Palau-Lazaro, Mauricio A.] Fdn Santa Fe Bogota, Dept Pathol & Labs, Carrera 7 117-15,Second Floor, Bogota 110111, Colombia; [Soto-Montoya, Camilo] Fdn Santa Fe Bogota, Dept Orthopaed Surg, Bogota, Colombia; [Rivero-Rapalino, Oscar] Fdn Santa Fe Bogota, Dept Diagnost Imaging, Bogota, Colombia; [Soto-Montoya, Camilo; Rivero-Rapalino, Oscar; Palau-Lazaro, Mauricio A.] Univ Andes, Sch Med, Bogota, Colombia	Palau-Lazaro, MA (reprint author), Fdn Santa Fe Bogota, Dept Pathol & Labs, Carrera 7 117-15,Second Floor, Bogota 110111, Colombia.	mauricio.palau@fsfb.org.co	Suarez-Zamora, David A./V-1952-2019	Suarez-Zamora, David A./0000-0003-1159-0512			Colia V, 2016, CLIN SARCOMA RES, V6, DOI 10.1186/s13569-016-0055-1; Dei Tos AP, 2014, MODERN PATHOL, V27, p15A; Doyle LA, 2014, MODERN PATHOL, V27, P390, DOI 10.1038/modpathol.2013.164; Kayani B, 2018, AM J CLIN ONCOL-CANC, V41, P687, DOI 10.1097/COC.0000000000000348; Keraliya AR, 2016, RADIOL CLIN N AM, V54, P565, DOI 10.1016/j.rcl.2015.12.006; Klemperer P, 1931, ARCH PATHOL, V11, P387; Oike N, 2017, WORLD J SURG ONCOL, V15, DOI 10.1186/s12957-017-1161-0; Sbaraglia Marta, 2017, Surg Pathol Clin, V10, P705, DOI 10.1016/j.path.2017.04.013; Seningen Justin L, 2012, Surg Pathol Clin, V5, P231, DOI 10.1016/j.path.2011.10.003; Thway K, 2016, INT J SURG PATHOL, V24, P281, DOI 10.1177/1066896915627485; Vallat-Decouvelaere AV, 1998, AM J SURG PATHOL, V22, P1501, DOI 10.1097/00000478-199812000-00007; Verbeke SLJ, 2010, AM J SURG PATHOL, V34, P777, DOI 10.1097/PAS.0b013e3181dbedf1; Vivero M, 2014, HISTOPATHOLOGY, V65, P71, DOI 10.1111/his.12377; Vogels RJC, 2014, DIAGN PATHOL, V9, DOI 10.1186/s13000-014-0224-6; Yoshida A, 2014, AM J SURG PATHOL, V38, P552, DOI 10.1097/PAS.0000000000000137	15	0	0	0	2	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1066-8969	1940-2465		INT J SURG PATHOL	Int. J. Surg. Pathol.	DEC	2018	26	8					772	776		10.1177/1066896918780348			5	Pathology; Surgery	Pathology; Surgery	HA5TJ	WOS:000450340700017	29961401				2019-10-28	
J	Liang, Y; Lu, WG; Zhang, XF; Lu, BJ				Liang, Yun; Lu, Weiguo; Zhang, Xiaofei; Lu, Bingjian			Tumor-infiltrating CD8+and FOXP3+lymphocytes before and after neoadjuvant chemotherapy in cervical cancer	DIAGNOSTIC PATHOLOGY			English	Article						Squamous cell carcinoma; Cervix; Tumor infiltrating lymphocytes; Neoadjuvant chemotherapy	PATHOLOGICAL-RESPONSE; LYMPHOCYTES; CELLS	Neoadjuvant chemotherapy (NACT) has been recently accepted as an effective alternative in patients with locally advanced cervical cancer. However, little is known about the effects of NACT on the immunological microenvironment in cervical cancers. In this study, we analyzed the alterations of tumor infiltrating lymphocytes (TILs) before and after NACT and analyzed their prognostic significance in advanced cervical cancer patients treated with platinum-based NACT. We recruited 137 patients with stage Ib2 and IIa2 cervical cancer retrospectively. Pretreatment biopsy and surgical specimens after NACT were immunostained with CD8 and Foxp3. The densities of intratumoral and peritumoral immunopositive TILs were analyzed separately. Foxp3+ T cells density significantly decreased in both intratumoral (median 28.49 vs. 19.97; Z = - 8.635, p < 0.001) and peritumoral (median 113.53 vs. 82.48; Z = - 3.741, p < 0.001) areas after NACT, whereas CD8+ T cell counts remained stable in both intratumoral (median 121.32 vs. 109.59; Z = - 0.817,p = 0.414) and peritumoral (median 402.56 vs. 390.84; Z = - 1.138,p = 0.255) areas. Patients with pathological complete response (pCR) had significantly lower number of Foxp3+ T cell density after NACT than non-pCR cases in both intratumoral (median16.12 vs. 22.00; Z = - 2.009, p = 0.045) and peritumoral areas(median 63.31 vs. 98.48; Z = - 2.469, p = 0.014). Multivariate analyses demonstrated that high ratio of intratumoral CD8/peritumoral Foxp3 in residual tumors was independent prognostic factor for both progression-free survival (HR = 0.297; 95% CI, 0.109-0.810, p = 0.018) and overall survival (HR = 0.078; 95% CI, 0.010-0.598, p = 0.014). NACT in cervical cancers can induce anti-cancer immunity by altering TILs subsets. An elevated intratumoral CD8/peritumoral Foxp3 ratio after NACT may confer a favorable clinical outcome.	[Liang, Yun; Lu, Bingjian] Zhejiang Univ, Sch Med, Womens Hosp, Dept Surg Pathol, Hangzhou 310006, Zhejiang, Peoples R China; [Lu, Weiguo; Lu, Bingjian] Zhejiang Univ, Ctr Uterine Canc Diag & Therapy Zhejiang Prov, Sch Med, Womens Hosp, Hangzhou 310006, Zhejiang, Peoples R China; [Lu, Weiguo; Zhang, Xiaofei] Zhejiang Univ, Sch Med, Womens Hosp, Dept Gynecol Oncol, Hangzhou 310006, Zhejiang, Peoples R China	Lu, BJ (reprint author), Zhejiang Univ, Sch Med, Womens Hosp, Dept Surg Pathol, Hangzhou 310006, Zhejiang, Peoples R China.; Lu, BJ (reprint author), Zhejiang Univ, Ctr Uterine Canc Diag & Therapy Zhejiang Prov, Sch Med, Womens Hosp, Hangzhou 310006, Zhejiang, Peoples R China.	lbj@zju.edu.cn			National Key R&D Program of China [2016YFC1302900]	This project was supported by National Key R&D Program of China 2016YFC1302900.	Bethwaite PB, 1996, PATHOLOGY, V28, P321, DOI 10.1080/00313029600169274; Buda A, 2015, INT J GYNECOL CANCER, V25, P1468, DOI 10.1097/IGC.0000000000000515; Emens LA, 2008, FRONT BIOSCI-LANDMRK, V13, P249, DOI 10.2741/2675; Gobert M, 2009, CANCER RES, V69, P2000, DOI 10.1158/0008-5472.CAN-08-2360; Gooden MJM, 2011, BRIT J CANCER, V105, P93, DOI 10.1038/bjc.2011.189; Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI 10.3322/caac.20115; Ladoire S, 2011, BREAST CANCER RES TR, V125, P65, DOI 10.1007/s10549-010-0831-1; Lee KB, 2008, INT J GYNECOL CANCER, V18, P1027, DOI 10.1111/j.1525-1438.2007.01136.x; Liang Y, 2016, VIRCHOWS ARCH, V468, P329, DOI 10.1007/s00428-015-1888-3; Miyashita M, 2015, BREAST CANCER RES, V17, DOI 10.1186/s13058-015-0632-x; Noble F, 2016, CANCER IMMUNOL IMMUN, V65, P651, DOI 10.1007/s00262-016-1826-5; Organization WH, 1979, WHO OFFS PUBL, V48; Piersma SJ, 2007, CANCER RES, V67, P354, DOI 10.1158/0008-5472.CAN-06-3388; Pircher A, 2014, LUNG CANCER, V85, P81, DOI 10.1016/j.lungcan.2014.04.001; Polcher M, 2010, CANCER IMMUNOL IMMUN, V59, P909, DOI 10.1007/s00262-010-0817-1; Sheu BC, 2007, J OBSTET GYNAECOL RE, V33, P103, DOI 10.1111/j.1447-0756.2007.00492.x; Shi QF, 2013, RADIAT RES, V179, P584, DOI 10.1667/RR3155.1; Wen Hong-wu, 2013, Zhonghua Fu Chan Ke Za Zhi, V48, P920; Zeng C, 2013, CANCER IMMUNOL IMMUN, V62, P481, DOI 10.1007/s00262-012-1348-8; Zitvogel L, 2008, NAT REV IMMUNOL, V8, P59, DOI 10.1038/nri2216	20	2	2	0	2	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND		1746-1596		DIAGN PATHOL	Diagn. Pathol.	NOV 24	2018	13								93	10.1186/s13000-018-0770-4			8	Pathology	Pathology	HD0ZU	WOS:000452239100002	30474571	DOAJ Gold, Green Published			2019-10-28	
J	Sakr, HI; Buckley, K; Baiocchi, R; Zhao, WJ; Hemminger, JA				Sakr, Hany I.; Buckley, Kaila; Baiocchi, Robert; Zhao, Weiqiang John; Hemminger, Jessica A.			Erdheim Chester disease in a patient with Burkitt lymphoma: a case report and review of literature	DIAGNOSTIC PATHOLOGY			English	Review						Erdheim Chester disease; ECD; BRAF; Burkitt lymphoma; Histiocytosis; Lymphoproliferative disorders	LANGERHANS CELL HISTIOCYTOSIS; CARDIAC INVOLVEMENT; PULMONARY INVOLVEMENT; BRAF; VEMURAFENIB; MANIFESTATIONS; DIAGNOSIS; SYSTEM; RARE	Erdheim Chester disease (ECD) is a rare, non-Langerhans cell histiocytosis characterized by widespread tissue infiltration by CD68-positive, CD1a-negative foamy histiocytes. ECD can be difficult to identify, and diagnosis relies on the presence of histiocytes with certain histologic and immunophenotypic features in an appropriate clinical and radiologic setting. Clinical signs and symptoms are variable depending on which organ systems are involved. Most patients have at least skeletal involvement with bone pain as well as fatigue. Other common manifestations include diabetes insipidus, cardiac, periaortic, or retro-orbital infiltration/fibrosis, kidney impairment, xanthelasmas, among others. Herein, we describe a case of BRAF-mutation positive ECD in a patient with Burkitt lymphoma, and we review recent literature. Underlying BRAF and other MAPK pathway mutations are identified in approximately 50% of cases of ECD, which aids in diagnosis as well as enables novel targeted treatments. ECD patients have an increased risk of myeloid neoplasms; however, unlike other histiocytoses, an association with lymphoproliferative disorders has not been recognized.	[Sakr, Hany I.; Buckley, Kaila; Zhao, Weiqiang John; Hemminger, Jessica A.] Ohio State Univ, Dept Pathol, Wexner Med Ctr, 410 W 10th Ave,308, Columbus, OH 43210 USA; [Baiocchi, Robert] Ohio State Univ, Dept Internal Med Hematol, Wexner Med Ctr, Columbus, OH 43210 USA	Buckley, K (reprint author), Ohio State Univ, Dept Pathol, Wexner Med Ctr, 410 W 10th Ave,308, Columbus, OH 43210 USA.	kailab979@aol.com					Arnaud L, 2011, BLOOD, V117, P2778, DOI 10.1182/blood-2010-06-294108; Arnaud L, 2010, ARTHRITIS RHEUM-US, V62, P3504, DOI 10.1002/art.27672; Disease EC, 2015, EUR J INTERN MED, V26, P223, DOI 10.1016/j.ejim.2015.03.004; Cavalli G, 2013, ANN RHEUM DIS, V72, P1691, DOI 10.1136/annrheumdis-2012-202542; Chester W, 1930, VIRCHOWS ARCH A, V279, P561, DOI 10.1007/BF01942684; Chung JH, 2005, RESPIROLOGY, V10, P389, DOI 10.1111/j.1440-1843.2005.00671.x; Diamond EL, 2014, BLOOD, V124, P483, DOI 10.1182/blood-2014-03-561381; Emile JF, 2016, BLOOD, V127, P2672, DOI [10.1182/blood-2016-01-690636, 10.1182/blood-2016-01690636]; Estrada-Veras JI, 2017, BLOOD ADV, V1, P357, DOI 10.1182/bloodadvances.2016001784; Feldman AL, 2008, BLOOD, V111, P5433, DOI 10.1182/blood-2007-11-124792; Gianfreda D, 2016, BLOOD, V128, P2468, DOI 10.1182/blood-2016-07-724815; Guo SP, 2015, HUM PATHOL, V46, P159, DOI 10.1016/j.humpath.2014.10.005; Haroche J, 2007, J CLIN ENDOCR METAB, V92, P2007, DOI 10.1210/jc.2006-2018; Haroche J, 2013, RHEUM DIS CLIN N AM, V39, P299, DOI 10.1016/j.rdc.2013.02.011; Haroche J, 2013, BLOOD, V121, P1495, DOI 10.1182/blood-2012-07-446286; Haroche J, 2009, CIRCULATION, V119, pE597, DOI 10.1161/CIRCULATIONAHA.108.825075; Haroun F, 2017, ANTICANCER RES, V37, P2777, DOI 10.21873/anticanres.11629; Hervier B, 2014, BLOOD, V124, P1119, DOI 10.1182/blood-2013-12-543793; Hyman DM, 2015, NEW ENGL J MED, V373, P726, DOI 10.1056/NEJMoa1502309; Ivan D, 2003, ARCH PATHOL LAB MED, V127, P337; Johnson WT, 2016, J CUTAN PATHOL, V43, P270, DOI 10.1111/cup.12636; Kumandas S, 2007, BRAIN DEV-JPN, V29, P227, DOI 10.1016/j.braindev.2006.08.013; Mazor RD, 2014, BMC MED, V12, DOI 10.1186/s12916-014-0221-3; Merli E, 2012, EUR HEART J-CARD IMG, V13, P198, DOI 10.1093/ejechocard/jer236; Nordmann TM, 2017, BLOOD, V129, P879, DOI 10.1182/blood-2016-09-740217; Oweity T, 2002, J NEUROSURG, V96, P344, DOI 10.3171/jns.2002.96.2.0344; Pan A, 2011, BMC GASTROENTEROL, V11, DOI 10.1186/1471-230X-11-77; Papo M, 2017, BLOOD, V130, P1007, DOI 10.1182/blood-2017-01-761718; Pavlidakey PG, 2011, CASE REP HEMATOL, DOI 10.1155/2011/941637; Roverano S, 2016, CLIN RHEUMATOL, V35, P1625, DOI 10.1007/s10067-016-3269-y; Sedrak P, 2011, AM J NEURORADIOL, V32, P2126, DOI 10.3174/ajnr.A2707; Shao HP, 2011, MODERN PATHOL, V24, P1421, DOI 10.1038/modpathol.2011.102; Sheu SY, 2004, J CLIN PATHOL, V57, P1225, DOI 10.1136/jcp.2004.018481; Tran TA, 2009, J PEDIAT HEMATOL ONC, V31, P782, DOI 10.1097/MPH.0b013e3181b76827; Vallonthaiel AG, 2016, WORLD J RADIOL, V8, P757, DOI 10.4329/wjr.v8.i8.757; Varadi Z, 2017, ONCOTARGETS THER, V10, P521, DOI 10.2147/OTT.S121615; Volpicelli ER, 2011, J CUTAN PATHOL, V38, P280, DOI 10.1111/j.1600-0560.2010.01650.x; Wimpissinger TF, 2005, UROLOGY, V65, pE29, DOI 10.1016/j.urology.2004.10.051	38	0	0	0	0	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1746-1596			DIAGN PATHOL	Diagn. Pathol.	NOV 24	2018	13								94	10.1186/s13000-018-0772-2			6	Pathology	Pathology	HD0ZU	WOS:000452239100001	30474563	DOAJ Gold, Green Published			2019-10-28	
J	Devins, K; Schuster, SJ; Caponetti, GC; Bogusz, AM				Devins, Kyle; Schuster, Stephen J.; Caponetti, Gabriel C.; Bogusz, Agata M.			Rare case of low-grade extranodal NK/T-cell lymphoma, nasal type, arising in the setting of chronic rhinosinusitis and harboring a novel N-terminal KIT mutation	DIAGNOSTIC PATHOLOGY			English	Article						NK/T-cell lymphoma; Epstein-Barr virus; Indolent; Low-grade; KIT mutation	BARR-VIRUS INFECTION; C-KIT; IMMUNOPHENOTYPE; PROGNOSIS	BackgroundExtranodal NK/T-cell lymphoma, nasal type (ENKTCL-NT), is a rare aggressive subtype of non-Hodgkin lymphoma characterized by angioinvasion, angiodestruction, necrosis and strong association with Epstein-Barr virus (EBV). ENKTCL-NT occurs worldwide and is more prevalent in Asian and the Native American populations of Mexico, Central and South America. It represents approximately 10% of all peripheral T-cell lymphomas worldwide. The aim of this report is to present a rare case of ENKTCL-NT with an unusually indolent clinical course and low-grade histopathologic features.Case presentationA 71-year-old Asian woman with a long-standing history of seasonal rhinosinusitis presented with persistent nasal congestion, cough, and fever unresponsive to antihistamines and antibiotics. Histopathological evaluation of a polypoid nasal mass revealed an atypical infiltrate with predominantly small lymphoid cells that were CD2+, surface CD3-, cytoplasmic CD3+, CD5(dim)+, CD7(dim)+, cytotoxic markers (granzyme B and perforin)+, EBER+ and CD56-. The Ki-67 proliferative index was very low (<1%). T-cell receptor gamma gene rearrangement studies were positive for a monoclonal rearrangement, and sequencing studies identified a novel KIT mutation (p. K167M, c. 500 A>T). A diagnosis of low-grade ENKTCL-NT was rendered.ConclusionsOur case of ENKTCL-NT is unusual due to (1) an indolent clinical course (2) low-grade histopathologic features including a low proliferative index (3) lack of CD56 expression and (4) a novel KIT mutation. This case raises awareness of the existence of a subset of cases of ENKTCL-NT that can potentially be misdiagnosed as a reactive process, particularly in patients with recurrent chronic rhinosinusitis.	[Devins, Kyle; Caponetti, Gabriel C.; Bogusz, Agata M.] Hosp Univ Penn, Dept Pathol & Lab Med, Div Hematopathol, 7-018 Gates Pavil,3400 Spruce St, Philadelphia, PA 19104 USA; [Schuster, Stephen J.; Bogusz, Agata M.] Univ Penn, Lymphoma Program, Abramson Canc Ctr, Philadelphia, PA 19104 USA	Bogusz, AM (reprint author), Hosp Univ Penn, Dept Pathol & Lab Med, Div Hematopathol, 7-018 Gates Pavil,3400 Spruce St, Philadelphia, PA 19104 USA.; Bogusz, AM (reprint author), Univ Penn, Lymphoma Program, Abramson Canc Ctr, Philadelphia, PA 19104 USA.	Kyle.Devins@uphs.upenn.edu; Agata.Bogusz@upsh.upenn.edu					ARBER DA, 1993, AM J SURG PATHOL, V17, P392, DOI 10.1097/00000478-199304000-00010; Ashman LK, 2013, EXPERT OPIN INV DRUG, V22, P103, DOI 10.1517/13543784.2013.740010; CHAN JKC, 1994, AM J SURG PATHOL, V18, P938, DOI 10.1097/00000478-199409000-00009; Chan JKC, 1997, BLOOD, V89, P4501, DOI 10.1182/blood.V89.12.4501; Hasserjian RP, 2007, AM J CLIN PATHOL, V127, P860, DOI 10.1309/2F39NX1AL3L54WU8; Haverkos BM, 2016, CURR HEMATOL MALIG R, V11, P514, DOI 10.1007/s11899-016-0355-9; Hongyo T, 2000, CANCER RES, V60, P2345; Huang YL, 2013, BEST PRACT RES CL HA, V26, P57, DOI 10.1016/j.beha.2013.04.006; Huang YL, 2010, BLOOD, V115, P1226, DOI 10.1182/blood-2009-05-221275; Isobe Y, 2009, J CLIN PATHOL, V62, P647, DOI 10.1136/jcp.2008.062976; Jiang QP, 2012, DIAGN PATHOL, V7, DOI 10.1186/1746-1596-7-133; Kim SJ, 2007, ANN ONCOL, V18, P1382, DOI 10.1093/annonc/mdm183; Kwong YL, 2005, LEUKEMIA, V19, P2186, DOI 10.1038/sj.leu.2403955; Kwong YL, 1997, BRIT J HAEMATOL, V97, P821, DOI 10.1046/j.1365-2141.1997.1462962.x; Lennartsson J, 2005, STEM CELLS, V23, P16, DOI 10.1634/stemcells.2004-0117; Patel JP, 2012, NEW ENGL J MED, V366, P1079, DOI 10.1056/NEJMoa1112304; Quintanilla-Martinez L, 1999, HUM PATHOL, V30, P849, DOI 10.1016/S0046-8177(99)90147-8; Seishima M, 2010, ACTA DERM-VENEREOL, V90, P102, DOI 10.2340/00015555-0778; Sloan CE, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0153016; Suzuki R, 2018, CURR HEMATOL MALIG R, V13, P7, DOI 10.1007/s11899-018-0430-5; Suzuki R, 2014, SEMIN HEMATOL, V51, P42, DOI 10.1053/j.seminhematol.2013.11.007; Swerdlow SH, 2016, WHO CLASSIFICATION T; Tabanelli VVR, 2014, CASE REP CLIN MED, V3, P596, DOI [10.4236/crcm.2014.311129, DOI 10.4236/CRCM.2014.311129]; Tse E, 2013, BLOOD, V121, P4997, DOI 10.1182/blood-2013-01-453233; Yamaguchi M, 2018, BLOOD, V131, P2528, DOI 10.1182/blood-2017-12-791418; Zhang Q, 2016, J POWER SOURCES, V336, P1, DOI 10.1016/j.jpowsour.2016.10.028; Zuriel D, 2012, AM J DERMATOPATH, V34, P194, DOI 10.1097/DAD.0b013e318230ee41	27	1	1	0	0	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1746-1596			DIAGN PATHOL	Diagn. Pathol.	NOV 23	2018	13								92	10.1186/s13000-018-0765-1			7	Pathology	Pathology	HB4ZC	WOS:000451065400001	30470245	DOAJ Gold, Green Published			2019-10-28	
J	Reschly-Krasowski, JM; Krasowski, MD				Reschly-Krasowski, Justine M.; Krasowski, Matthew D.			A Difficult Challenge for the Clinical Laboratory: Accessing and Interpreting Manufacturer Cross-Reactivity Data for Immunoassays Used in Urine Drug Testing	ACADEMIC PATHOLOGY			English	Article						amphetamines; benzodiazepines; designer drugs; false positives; immunoassay; opiates	MASS-SPECTROMETRY; EMERGING DRUGS; BATH SALTS; ABUSE; OXYCODONE; EPIDEMIC; OPIATES; UTILITY; MISUSE	Urine drug testing by immunoassay is widely used to detect nonmedical drug use and to monitor patients prescribed controlled substances. A key attribute of urine drug testing immunoassays is cross-reactivity, namely the response of various compounds compared to the target of the assay. In this report, we analyzed the variability in how manufacturer cross-reactivity data are summarized in package inserts for commercially available amphetamines, benzodiazepines, and opiates immunoassays, 3 broad drug classes commonly included in routine drug testing panels. Specifically, we determined the number of compounds tested for cross-reactivity, manner in which cross-reactivity is measured, concentration units used, how often compounds known to be cross-reactive with marketed urine drug testing immunoassays prior to 2010 were tested, availability of the package insert online, and how often cross-reactivity on "designer drugs" was found in the package inserts. There was wide variability in the number of compounds tested (both positive and negative), with the highest number of tested compounds generally found in point-of-care urine drug testing applications. Most package inserts used ng/mL as the concentration units and expressed cross-reactivity in terms of equivalent concentrations to the assay calibrator. Approximately 50% of package inserts were directly available online. Cross-reactivity data were sparse with respect to "off-target" drugs known to be cross-reactive prior to 2010 (an example being quinolone antibiotics and opiates immunoassays) and designer drugs. The present study indicates lack of consistency in cross-reactivity information in package inserts, complicating the interpretation of urine drug testing results. We use 3 example clinical cases to illustrate practical challenges accessing and interpreting cross-reactivity data.	[Reschly-Krasowski, Justine M.] City High Sch, Iowa City, IA USA; [Krasowski, Matthew D.] Univ Iowa Hosp & Clin, Dept Pathol, 200 Hawkins Dr,C671 GH, Iowa City, IA 52242 USA	Krasowski, MD (reprint author), Univ Iowa Hosp & Clin, Dept Pathol, 200 Hawkins Dr,C671 GH, Iowa City, IA 52242 USA.	matthew-krasowski@uiowa.edu					Akerele E, 2017, PSYCHIAT CLIN N AM, V40, P501, DOI 10.1016/j.psc.2017.05.006; Baden LR, 2001, JAMA-J AM MED ASSOC, V286, P3115, DOI 10.1001/jama.286.24.3115; Bergstrand MP, 2017, DRUG TEST ANAL, V9, P640, DOI 10.1002/dta.2003; Brady KT, 2016, AM J PSYCHIAT, V173, P18, DOI 10.1176/appi.ajp.2015.15020262; Clinical and Laboratory Standards Institute, 2017, TOX DRUG TEST MED LA; Cone EJ, 2008, J ANAL TOXICOL, V32, P530, DOI 10.1093/jat/32.8.530; Cone EJ, 2013, J ANAL TOXICOL, V37, P255, DOI 10.1093/jat/bkt031; Cottencin O, 2014, CURR PHARM DESIGN, V20, P4106, DOI 10.2174/13816128113199990622; Duenas-Garcia OF, 2011, OBSTET GYNECOL, V118, P360, DOI 10.1097/AOG.0b013e3182263f1b; Garg U, 2016, METHODS MOL BIOL, V1383, P1, DOI 10.1007/978-1-4939-3252-8_1; German CL, 2014, LIFE SCI, V97, P2, DOI 10.1016/j.lfs.2013.07.023; GILBERT RB, 1995, J ANAL TOXICOL, V19, P84, DOI 10.1093/jat/19.2.84; Gingras M, 2010, J ANAL TOXICOL, V34, P78, DOI 10.1093/jat/34.2.78; Graddy R, 2018, MED CLIN N AM, V102, P697, DOI 10.1016/j.mcna.2018.02.010; Gunderson EW, 2013, J ADDICT MED, V7, P153, DOI 10.1097/ADM.0b013e31829084b7; Hall C, 2013, CJEM, V15, P1; Kane SP., 2017, CLINCALC DRUGSTATS D; Kolodny A, 2015, ANNU REV PUBL HEALTH, V36, P559, DOI 10.1146/annurev-publhealth-031914-122957; Krasowski MD, 2014, BMC CLIN PATHOL, V14, DOI 10.1186/1472-6890-14-33; Krasowski MD, 2014, J CHEMINFORMATICS, V6, DOI 10.1186/1758-2946-6-22; Krasowski MD, 2009, BMC EMERG MED, V9, DOI 10.1186/1471-227X-9-5; Krasowski MD, 2009, THER DRUG MONIT, V31, P337, DOI 10.1097/FTD.0b013e31819c1b83; Krasowski MD, 2009, CLIN CHEM, V55, P1203, DOI 10.1373/clinchem.2008.118638; Lias CH, 2016, SAMHSA DTAB M; Lipari RN, 2013, TRENDS SUBSTANCE USE, P1; Liu L, 2018, AM J CLIN PATHOL, V149, P105, DOI [10.1093/AJCP/AQX138, 10.1093/ajcp/aqx138]; Magnani B, 2012, CLIN LAB MED, V32, P379, DOI 10.1016/j.cll.2012.07.001; Mahajan G, 2017, ANESTH ANALG, V125, P2094, DOI 10.1213/ANE.0000000000002565; Marin MJ, 2018, CLIN FOREN TOXICOL N, V2018, P1; McMillin GA, 2015, AM J CLIN PATHOL, V143, P234, DOI 10.1309/AJCPMJKBC6VJA1SP; McMillin Gwendolyn A, 2013, J Pain Palliat Care Pharmacother, V27, P322, DOI 10.3109/15360288.2013.847889; Melanson SEF, 2012, CLIN LAB MED, V32, P429, DOI 10.1016/j.cll.2012.06.004; Melanson SEF, 2010, ARCH PATHOL LAB MED, V134, P735, DOI 10.1043/1543-2165-134.5.735; Milone MC, 2012, J MED TOXICOL, V8, P408, DOI 10.1007/s13181-012-0274-7; Moeller KE, 2008, MAYO CLIN PROC, V83, P66, DOI 10.4065/83.1.66; Moosmann B, 2015, WORLD PSYCHIATRY, V14, P248, DOI 10.1002/wps.20236; Musselman ME, 2014, PHARMACOTHERAPY, V34, P745, DOI 10.1002/phar.1424; Nelson ME, 2014, EMERG MED CLIN N AM, V32, P1, DOI 10.1016/j.emc.2013.09.001; Pergolizzi JV, 2018, POSTGRAD MED, V130, P1, DOI 10.1080/00325481.2018.1407618; Petrie M, 2013, CLIN TOXICOL, V51, P83, DOI 10.3109/15563650.2013.768344; Saitman A, 2014, J ANAL TOXICOL, V38, P387, DOI 10.1093/jat/bku075; Tenore PL, 2010, J ADDICT DIS, V29, P436, DOI 10.1080/10550887.2010.509277; Ward MB, 2014, AM J CLIN PATHOL, V142, P586, DOI 10.1309/AJCPZ0DS4QLYNCQG; Weaver Michael F., 2015, Yale Journal of Biology and Medicine, V88, P247; Weiss RL, 2012, AM J CLIN PATHOL, V138, P20, DOI 10.1309/AJCP6OAULC3CMFEJ; Wu AHB, 2013, CLIN CHIM ACTA, V420, P4, DOI 10.1016/j.cca.2012.10.026; Yee LM, 2011, OBSTET GYNECOL, V117, P503, DOI 10.1097/AOG.0b013e318206c07c; Zhang YV, 2016, CLIN LAB MED, V36, P635, DOI 10.1016/j.cll.2016.07.001	48	2	2	0	0	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	2374-2895			ACAD PATHOL	Acad. Pathol.	NOV 21	2018	5								2374289518811797	10.1177/2374289518811797			10	Pathology	Pathology	HB8CW	WOS:000451313500001	30480089	DOAJ Gold, Green Published			2019-10-28	
J	Ma, J; Li, JH; Qian, MR; Han, WL; Tian, MM; Li, ZS; Wang, Z; He, SX; Wu, KC				Ma, Jing; Li, Jianhui; Qian, Meirui; Han, Weili; Tian, Miaomiao; Li, Zengshan; Wang, Zhe; He, Shuixiang; Wu, Kaichun			PD-L1 expression and the prognostic significance in gastric cancer: a retrospective comparison of three PD-L1 antibody clones (SP142, 28-8 and E1L3N)	DIAGNOSTIC PATHOLOGY			English	Article						Programmed cell death ligand 1; Immunohistochemistry; H-score; Multiplexed immunofluorescence	LIGAND 1 EXPRESSION; EPSTEIN-BARR-VIRUS; BREAST-CANCER; INFILTRATION; B7-H1; CELLS	Background: Immunohistochemistry (IHC) for programmed cell death ligand 1 (PD-L1) displays staining diversity. We compared IHC staining of PD-L1 in gastric cancer (GC) by using three commercially available antibody clones, and analyzed the correlation with the prognosis. Methods: IHC using PD-L1 antibodies (clones SP142, 28-8 and E1L3N) in 315 formalin-fixed paraffin-embedded samples was qualitatively compared at the 1, 5 and 10% cut-off by two pathologists on total, tumor and immune/stromal cells. We used computer - assisted scoring to quantitatively analyze and compare the "H-score" of PD-L1 expression in 66 samples on total cells. The antibody clone SP142 was selected to investigate the infiltration of PD-L1(+)CD8(+) T cells using automated quantitative immunofluorescence analyses (n = 50) and the prognostic significance. The prognoses were assessed by log-rank test. Results: PD-L1 clones SP142 and 28-8 displayed great concordance by qualitative (k = 0.816, 0.810 for total cells and tumor cells at the 5% cut-off) and quantitative analyses (R-2 = 0.7991, 0.8187 for positive percentage and "H-score"). PD-L1 clone SP142 showed the highest positivity in immune/stromal cells staining (18.41%) compared to 28-8 (7.62%), while clone E1L3N showed poor staining in both tumor and immune/stromal cells. Clone SP142, but not 28-8 and E1L3N, predicted a worse prognosis at the 5% cut-off (p = 0.0243). Both the clone SP142 and 28-8 had high inter-pathologist correlation for tumor staining (R-2 = 0.9805 and R-2 = 0.9853), but a moderate correlation for stromal/immune cell staining (R-2 = 0.5653 and R-2 = 0.5745). Furthermore, a higher density of PD-L1(+)CD8(+) T cells was correlated with a shorter survival time (R-2 = 0.0909, p = 0.0352). Conclusions: PD-L1 antibody clone SP142 was superior in cell staining, particularly in immune/stromal cell and prognosis. These findings are important for selection of PD-L1 antibody clones in the future diagnostic test.	[Ma, Jing; He, Shuixiang] Xi An Jiao Tong Univ, Affiliated Hosp, Dept Gastroenterol, Xian 710032, Shaanxi, Peoples R China; [Ma, Jing; Qian, Meirui; Han, Weili; Tian, Miaomiao; Wu, Kaichun] Fourth Mil Med Univ, Xijing Hosp, State Key Lab Canc Biol, Xian, Shaanxi, Peoples R China; [Ma, Jing; Qian, Meirui; Han, Weili; Tian, Miaomiao; Wu, Kaichun] Fourth Mil Med Univ, Xijing Hosp, Inst Digest Dis, Xian, Shaanxi, Peoples R China; [Li, Jianhui] Fourth Mil Med Univ, Tangdu Hosp, Dept Infect Dis, Xian, Shaanxi, Peoples R China; [Li, Zengshan; Wang, Zhe] Fourth Mil Med Univ, Pathol Dept, Xian, Shaanxi, Peoples R China	He, SX (reprint author), Xi An Jiao Tong Univ, Affiliated Hosp, Dept Gastroenterol, Xian 710032, Shaanxi, Peoples R China.; Wu, KC (reprint author), Fourth Mil Med Univ, Xijing Hosp, State Key Lab Canc Biol, Xian, Shaanxi, Peoples R China.; Wu, KC (reprint author), Fourth Mil Med Univ, Xijing Hosp, Inst Digest Dis, Xian, Shaanxi, Peoples R China.	dyyyjxk@mail.xjtu.edu.cn; kaicwu@fmmu.edu.cn			National Natural Science Foundation of ChinaNational Natural Science Foundation of China [81421003, 81627807]	This work was supported by grants from the National Natural Science Foundation of China (Nos. 81421003 and 81627807).	Adams TA, 2018, MODERN PATHOL, V31, P288, DOI 10.1038/modpathol.2017.126; Aghajani M, 2018, THYROID, V28, P349, DOI 10.1089/thy.2017.0441; Brown JR, 2014, CLIN CANCER RES, V20, P5995, DOI 10.1158/1078-0432.CCR-14-1622; Buttner R, 2017, J CLIN ONCOL, V35, P3867, DOI 10.1200/JCO.2017.74.7642; Eto S, 2016, GASTRIC CANCER, V19, P466, DOI 10.1007/s10120-015-0519-7; Gaule P, 2016, JAMA ONCOL; Gaule P, 2017, JAMA ONCOL, V3, P256, DOI 10.1001/jamaoncol.2016.3015; Geng YT, 2015, INT J CLIN ONCOL, V20, P273, DOI 10.1007/s10147-014-0701-7; Herbst RS, 2014, NATURE, V515, P563, DOI 10.1038/nature14011; Hou JY, 2014, EXP MOL PATHOL, V96, P284, DOI 10.1016/j.yexmp.2014.03.005; Jiang D, 2014, MED ONCOL, V31, DOI 10.1007/s12032-014-0268-1; Kim JW, 2016, GASTRIC CANCER, V19, P42, DOI 10.1007/s10120-014-0440-5; Kim ST, 2018, NAT MED, V24, P1449, DOI 10.1038/s41591-018-0101-z; Ma CQ, 2016, AM J SURG PATHOL, V40, P1496, DOI 10.1097/PAS.0000000000000698; Mahoney KM, 2015, CANCER IMMUNOL RES, V3, P1308, DOI 10.1158/2326-6066.CIR-15-0116; Muro K, 2016, LANCET ONCOL, V17, P717, DOI 10.1016/S1470-2045(16)00175-3; Qing Y, 2015, DRUG DES DEV THER, V9, P901, DOI 10.2147/DDDT.S75152; Rimm DL, 2017, JAMA ONCOL, V3, P1051, DOI 10.1001/jamaoncol.2017.0013; Seo AN, 2017, BRIT J CANCER, V117, P1753, DOI 10.1038/bjc.2017.369; Sun WY, 2016, J TRANSL MED, V14, DOI 10.1186/s12967-016-0925-6; Sunshine JC, 2017, CLIN CANCER RES, V23, P4938, DOI 10.1158/1078-0432.CCR-16-1821; Thompson ED, 2017, GUT, V66, P794, DOI 10.1136/gutjnl-2015-310839; Zhang L, 2015, INT J CLIN EXP PATHO, V8, P11084; Zheng BX, 2018, J HEMATOL ONCOL, V11, DOI 10.1186/s13045-018-0560-1	24	3	3	1	2	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1746-1596			DIAGN PATHOL	Diagn. Pathol.	NOV 21	2018	13								91	10.1186/s13000-018-0766-0			10	Pathology	Pathology	HB3AG	WOS:000450918000001	30463584	DOAJ Gold, Green Published			2019-10-28	
J	Mizdrak, M; Vukojevic, K; Filipovic, N; Capkun, V; Benzon, B; Durdov, MG				Mizdrak, Maja; Vukojevic, Katarina; Filipovic, Natalija; Capkun, Vesna; Benzon, Benjamin; Durdov, Merica Glavina			Expression of DENDRIN in several glomerular diseases and correlation to pathological parameters and renal failure - preliminary study	DIAGNOSTIC PATHOLOGY			English	Article						Dendrin; IgA glomerulonephritis; Podocythopathies; Renal function; Immunohistochemistry	PROTEIN; PODOCYTES	BackgroundIn glomerular injury dendrin translocates from the slit diaphragm to the podocyte nucleus, inducing apoptosis. We analyzed dendrin expression in IgA glomerulonephritis and Henoch Schonlein purpura (IgAN/HSP) versus in podocytopathies minimal change disease (MCD) and focal segmental glomerulosclerosis (FSGS), and compared it to pathohistological findings and renal function at the time of biopsy and the last follow-up.MethodsTwenty males and 13 females with median of age 35years (min-max: 3-76) who underwent percutaneous renal biopsy and had diagnosis of glomerular disease (GD) were included in this retrospective study. Fifteen patients had IgAN/HSP and eighteen podocytopathy. Control group consisted of ten patients who underwent nephrectomy due to renal cancer. Dendrin expression pattern (membranous, dual, nuclear or negative), number of dendrin positive nuclei and proportion of dendrin negative glomeruli were analyzed.ResultsIn GD and the control group significant differences in number of dendrin positive nuclei and proportion of dendrin negative glomeruli were found (P=0.004 and P=0.003, respectively). Number of dendrin positive nuclei was higher in podocytopathies than in IgAN/HSP, 3.90 versus 1.67 (P=0.028). Proportion of dendrin negative glomeruli correlated to higher rates of interstitial fibrosis (P=0.038), tubular atrophy (P=0.011) and globally sclerotic glomeruli (P=0.008). Dual and nuclear dendrin expression pattern were connected with lower rate of interstitial fibrosis and tubular atrophy than negative dendrin expression pattern (P=0.024 and P=0.017, respectively). Proportion of dendrin negative glomeruli correlated with lower creatinine clearance (CC) at the time of biopsy and the last follow-up (P=0.010 and P<0.001, respectively). Dendrin expression pattern correlated to CC at the last follow-up (P=0.009), being lower in patients with negative than nuclear or dual dendrin expression (P=0.034 and P=0.004, respectively).ConclusionIn this pilot study the number of dendrin positive nuclei was higher in podocytopathies than in inflammatory GD. Negative dendrin expression pattern correlated to chronic tubulointerstitial changes and lower CC, which needs to be confirmed in a larger series.	[Mizdrak, Maja] Univ Hosp Ctr Split, Dept Nephrol & Hemodialysis, Soltanska 1, Split 21000, Croatia; [Vukojevic, Katarina; Filipovic, Natalija] Univ Split, Sch Med, Dept Anat Histol & Embryol, Split, Croatia; [Capkun, Vesna] Univ Hosp Ctr Split, Dept Nucl Med, Split, Croatia; [Benzon, Benjamin; Durdov, Merica Glavina] Univ Hosp Ctr Split, Dept Pathol Forens Med & Cytol, Split, Croatia; [Benzon, Benjamin; Durdov, Merica Glavina] Univ Split, Sch Med, Split, Croatia	Mizdrak, M (reprint author), Univ Hosp Ctr Split, Dept Nephrol & Hemodialysis, Soltanska 1, Split 21000, Croatia.	mizdrakmaja@gmail.com	Filipovic, Natalija/D-4964-2017	Filipovic, Natalija/0000-0002-8943-4109			Alpers CE, 2015, ROBBINS COTRAN PATHO, P917; Asanuma K, 2011, AM J NEPHROL, V53749, P33; Asanuma K, 2007, P NATL ACAD SCI USA, V104, P10134, DOI 10.1073/pnas.0700917104; Becherucci F, 2015, AM J PATHOL, V185, P2072, DOI 10.1016/j.ajpath.2015.05.005; Campbell KN, 2013, J BIOL CHEM, V288, P17057, DOI 10.1074/jbc.C113.457390; Duner F, 2008, NEPHROL DIAL TRANSPL, V23, P2504, DOI 10.1093/ndt/gfn100; Huang ZS, 2016, BMC NEPHROL, V17, DOI 10.1186/s12882-016-0287-6; Kodama F, 2013, NEPHROL DIAL TRANSPL, V28, P1762, DOI 10.1093/ndt/gfs500; Menon MC, 2013, CONTRIB NEPHROL, V181, P41, DOI 10.1159/000348461; NeunerJehle M, 1996, J NEUROSCI RES, V46, P138, DOI 10.1002/(SICI)1097-4547(19961015)46:2<138::AID-JNR2>3.0.CO;2-I; Shirata N, 2017, J AM SOC NEPHROL, V28, P2655, DOI 10.1681/ASN.2016121356; Takano K, 2007, TOHOKU J EXP MED, V212, P81, DOI 10.1620/tjem.212.81; Wiggins RC, 2007, KIDNEY INT; Xiao ZJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0083133	14	0	0	0	1	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1746-1596			DIAGN PATHOL	Diagn. Pathol.	NOV 20	2018	13								90	10.1186/s13000-018-0767-z			9	Pathology	Pathology	HB1WY	WOS:000450820300003	30458823	DOAJ Gold, Green Published			2019-10-28	
J	Baydar, DE				Baydar, Dilek Ertoy			Massive Localized Lymphedema in an Unreported Location (Retroperitoneum)	DIAGNOSTIC PATHOLOGY			English	Article						Massive localized lymphedema; Lymphedema; Retroperitoneum; Surgery	MORBIDLY OBESE; LIPOSARCOMA	BackgroundMassive localized lymphedema (MLL) is a non-neoplastic benign soft tissue lesion that may be confused with sarcomas or other neoplastic proliferations both clinically and morphologically. Most occur in morbidly obese adults on the lower extremities. The objective of this article is to document a case of MLL in the retroperitoneal cavity which is a previously unreported site for this lesion, and to highlight its unusual clinical features.Case presentationThe patient was a non-obese male who had undergone major abdominal surgery due to bladder extrophy 17years ago. Abdominal ultrasonography detected a large incidental mass in the right renal sinus during his investigation for nephrolithiasis. The lesion extending from renal pelvis down to pelvis was resected and its histopathological findings were compatible with massive localized lymphedema.ConclusionsRetroperitoneum has to be added to the list of locations that MLL can be found. Liposarcoma will be a challenging differential diagnosis when the lesion is encountered in an unusual site.	[Baydar, Dilek Ertoy] Koc Univ, Sch Med, Dept Pathol, TR-34010 Istanbul, Turkey	Baydar, DE (reprint author), Koc Univ, Sch Med, Dept Pathol, TR-34010 Istanbul, Turkey.	dertoy@kuh.ku.edu.tr					Berenji M, 2010, EJSO-EUR J SURG ONC, V36, P104, DOI 10.1016/j.ejso.2009.03.005; Brewer MB, 2012, ANN PLAS SURG, V68, P101, DOI 10.1097/SAP.0b013e318211910e; Chopra K, 2015, ANN PLAS SURG, V74, P126, DOI 10.1097/SAP.0b013e31828bb332; Evans RJ, 2011, CAN J PLAST SURG, V19, pE30; Farshid G, 1998, AM J SURG PATHOL, V22, P1277, DOI 10.1097/00000478-199810000-00013; Fife C, 2014, OSTOMY WOUND MANAG, V60, P30; Kurt H, 2016, MODERN PATHOL, V29, P75, DOI 10.1038/modpathol.2015.135; Manduch M, 2009, J CLIN PATHOL, V62, P808, DOI 10.1136/jcp.2009.066555; Plaza JA, 2014, J AM ACAD DERMATOL, V71, P320, DOI 10.1016/j.jaad.2014.01.907; Tanas MR, 2009, MODERN PATHOL, V22, P1196, DOI 10.1038/modpathol.2009.84; Wu D, 2000, HUM PATHOL, V31, P1162, DOI 10.1053/hupa.2000.17987	11	0	0	0	0	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1746-1596			DIAGN PATHOL	Diagn. Pathol.	NOV 20	2018	13								89	10.1186/s13000-018-0769-x			4	Pathology	Pathology	HB1WY	WOS:000450820300001	30458829	DOAJ Gold, Green Published			2019-10-28	
J	Murakami, T; Akazawa, Y; Yatagai, N; Hiromoto, T; Sasahara, N; Saito, T; Sakamoto, N; Nagahara, A; Yao, T				Murakami, Takashi; Akazawa, Yoichi; Yatagai, Noboru; Hiromoto, Takafumi; Sasahara, Noriko; Saito, Tsuyoshi; Sakamoto, Naoto; Nagahara, Akihito; Yao, Takashi			Molecular characterization of sessile serrated adenoma/polyps with dysplasia/carcinoma based on immunohistochemistry, next-generation sequencing, and microsatellite instability testing: a case series study	DIAGNOSTIC PATHOLOGY			English	Article						Sessile serrated adenoma; polyp; Colorectal carcinoma; MLH1; FBXW7; TP53; Microsatellite instability	EARLY NEOPLASTIC PROGRESSION; BRAF MUTATION STATUS; F-BOX PROTEIN; COLORECTAL-CANCER; TUMOR-SUPPRESSOR; UBIQUITIN LIGASE; SOMATIC MUTATIONS; PROXIMAL COLON; POOR SURVIVAL; BETA-CATENIN	BackgroundColorectal sessile serrated adenoma/polyps (SSA/Ps) are considered early precursor lesions in the serrated neoplasia pathway. Recent studies have shown associations of SSA/Ps with lost MLH1 expression, a CpG island methylator phenotype, and BRAF mutations. However, the molecular biological features of SSA/Ps with early neoplastic progression have not yet been fully elucidated, owing to the rarity of cases of SSA/P with advanced histology such as cytologic dysplasia or invasive carcinoma. In this study, we aimed to elucidate the molecular biological features of SSA/Ps with dysplasia/carcinoma, representing relatively early stages of the serrated neoplasia pathway.MethodsWe performed immunostaining for -catenin, MLH1, and mucins (e.g., MUC2, MUC5AC, MUC6, and CD10); targeted next-generation sequencing; and microsatellite instability (MSI) testing in 8 SSA/P lesions comprised of 4 SSA/Ps with high-grade dysplasia and 4 SSA/Ps with submucosal carcinoma.ResultsLost MLH1 expression was found in 5 cases. All lesions studied were positive for nuclear -catenin expression. Regarding phenotypic mucin expression, all lesions were positive for MUC2, but negative for CD10. MUC5AC and MUC6 positivity was observed in 7 cases. Genetically, the most frequently mutated gene was BRAF (7 cases), and other mutations were detected in FBXW7 (3 cases); TP53 (2 cases), and KIT, PTEN, SMAD4, and SMARCB1 (1 case each). Furthermore, 4 of 8 lesions were MSI-high and the remaining 4 lesions were microsatellite-stable (MSS). Interestingly, all 4 MSI-high lesions displayed MLH1 loss, 3 of which harbored a FBXW7 mutation, but not a TP53 mutation. However, 2 MSS lesions harbored a TP53 mutation, although none harbored a FBXW7 mutation.ConclusionsSSA/Ps with dysplasia/carcinoma frequently harbored BRAF mutations. Activation of the WNT/-catenin signaling pathway may facilitate the development of dysplasia in SSA/Ps and progression to carcinoma. Furthermore, our results suggested that these lesions might be associated with both MSI-high and MSS colorectal cancer, which might be distinguished by distinct molecular biological features such as lost MLH1 expression, FBXW7 mutations, and TP53 mutations.	[Murakami, Takashi; Akazawa, Yoichi; Yatagai, Noboru; Hiromoto, Takafumi; Sakamoto, Naoto; Nagahara, Akihito] Juntendo Univ, Sch Med, Dept Gastroenterol, Bunkyo Ku, 2-1-1 Hongo, Tokyo 1138421, Japan; [Murakami, Takashi; Akazawa, Yoichi; Yatagai, Noboru; Hiromoto, Takafumi; Sasahara, Noriko; Saito, Tsuyoshi; Yao, Takashi] Juntendo Univ, Sch Med, Dept Human Pathol, Tokyo, Japan	Murakami, T (reprint author), Juntendo Univ, Sch Med, Dept Gastroenterol, Bunkyo Ku, 2-1-1 Hongo, Tokyo 1138421, Japan.; Murakami, T (reprint author), Juntendo Univ, Sch Med, Dept Human Pathol, Tokyo, Japan.	t-murakm@juntendo.ac.jp			Japan Society for the Promotion of ScienceMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science [18 K15796]	The work was supported in part by a Grant-in-Aid from the Japan Society for the Promotion of Science (#18 K15796 to T. Murakami).	Akhoondi S, 2007, CANCER RES, V67, P9006, DOI 10.1158/0008-5472.CAN-07-1320; Ban S, 2014, PATHOL INT, V64, P123, DOI 10.1111/pin.12147; Bengoechea-Alonso MT, 2010, ONCOGENE, V29, P5322, DOI 10.1038/onc.2010.278; Bettington M, 2017, GUT, V66, P97, DOI 10.1136/gutjnl-2015-310456; Cao J, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000002496; Chang CC, 2015, INT J BIOL MARKER, V30, pE88, DOI 10.5301/jbm.5000125; Cottu PH, 1996, ONCOGENE, V13, P2727; Day FL, 2013, CLIN CANCER RES, V19, P3285, DOI 10.1158/1078-0432.CCR-12-3614; de la Chapelle A, 2010, J CLIN ONCOL, V28, P3380, DOI 10.1200/JCO.2009.27.0652; Dhir M, 2011, INT J CANCER, V129, P1889, DOI 10.1002/ijc.25847; Diaz Z, 2013, MODERN PATHOL, V26, P1413, DOI 10.1038/modpathol.2013.81; Fryer CJ, 2004, MOL CELL, V16, P509, DOI 10.1016/j.molcel.2004.10.014; Fujita K, 2011, AM J SURG PATHOL, V35, P295, DOI 10.1097/PAS.0b013e318205df36; Inuzuka H, 2011, NATURE, V471, P104, DOI 10.1038/nature09732; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; Jass JR, 2006, HISTOPATHOLOGY, V49, P121, DOI 10.1111/j.1365-2559.2006.02466.x; Kambara T, 2004, GUT, V53, P1137, DOI 10.1136/gut.2003.037671; Khaidakov M, 2016, AM J CLIN PATHOL, V146, P530, DOI [10.1093/ajcp/aqw142, 10.1093/AJCP/AQW142]; KIM HG, 1994, AM J PATHOL, V145, P148; Kim KM, 2011, AM J SURG PATHOL, V35, P1274, DOI 10.1097/PAS.0b013e318224cd2e; Kim YH, 2008, INT J CANCER, V123, P2587, DOI 10.1002/ijc.23840; Koepp DM, 2001, SCIENCE, V294, P173, DOI 10.1126/science.1065203; Kwon YW, 2012, MOL CANCER RES, V10, P834, DOI 10.1158/1541-7786.MCR-12-0025; Leggett B, 2010, GASTROENTEROLOGY, V138, P2088, DOI 10.1053/j.gastro.2009.12.066; Malapelle U, 2016, J CLIN PATHOL, V69, P767, DOI 10.1136/jclinpath-2015-203403; Mao JH, 2004, NATURE, V432, P775, DOI 10.1038/nature03155; Mao JH, 2008, SCIENCE, V321, P1499, DOI 10.1126/science.1162981; Meldrum Cliff, 2011, Clin Biochem Rev, V32, P177; Miyoshi Yasuo, 1992, Human Molecular Genetics, V1, P229; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Murakami T, 2015, MODERN PATHOL, V28, P146, DOI 10.1038/modpathol.2014.41; Muzny DM, 2012, NATURE, V487, P330, DOI 10.1038/nature11252; Nateri AS, 2004, SCIENCE, V303, P1374, DOI 10.1126/science.1092880; O'Brien MJ, 2006, AM J SURG PATHOL, V30, P1491, DOI 10.1097/01.pas.0000213313.36306.85; O'Brien MJ, 2015, HISTOPATHOLOGY, V66, P49, DOI 10.1111/his.12564; Pai RK, 2012, AM J SURG PATHOL, V36, P744, DOI 10.1097/PAS.0b013e31824430d7; Patil DT, 2012, MODERN PATHOL, V25, P1423, DOI 10.1038/modpathol.2012.98; POWELL SM, 1992, NATURE, V359, P235, DOI 10.1038/359235a0; Rivlin Noa, 2011, Genes Cancer, V2, P466, DOI 10.1177/1947601911408889; Samowitz WS, 2005, CANCER RES, V65, P6063, DOI 10.1158/0008-5472.CAN-05-0404; Snover DC, 2010, WHO CLASSIFICATION T, V160, P165; Spring KJ, 2006, GASTROENTEROLOGY, V131, P1400, DOI 10.1053/j.gastro.2006.08.038; Spruck CH, 2002, CANCER RES, V62, P4535; Tetzlaff MT, 2004, P NATL ACAD SCI USA, V101, P3338, DOI 10.1073/pnas.0307875101; Torlakovic E, 2003, AM J SURG PATHOL, V27, P65, DOI 10.1097/00000478-200301000-00008; Tsunematsu R, 2004, J BIOL CHEM, V279, P9417, DOI 10.1074/jbc.M312337200; Walsh MD, 2013, MODERN PATHOL, V26, P1642, DOI 10.1038/modpathol.2013.101; Wang R, 2013, CELL RES, V23, P803, DOI 10.1038/cr.2013.42; Wei WY, 2005, CANCER CELL, V8, P25, DOI 10.1016/j.ccr.2005.06.005; Welcker M, 2004, P NATL ACAD SCI USA, V101, P9085, DOI 10.1073/pnas.0402770101; Wertz IE, 2011, NATURE, V471, P110, DOI 10.1038/nature09779; Yachida S, 2009, AM J SURG PATHOL, V33, P1823, DOI 10.1097/PAS.0b013e3181b6da19; Yada M, 2004, EMBO J, V23, P2116, DOI 10.1038/sj.emboj.7600217	53	2	2	0	3	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1746-1596			DIAGN PATHOL	Diagn. Pathol.	NOV 20	2018	13								88	10.1186/s13000-018-0771-3			10	Pathology	Pathology	HB1WY	WOS:000450820300002	30458818	DOAJ Gold, Green Published			2019-10-28	
J	Allen, TC				Allen, Timothy Craig			The Legal Aspects of Diversity in Academic Pathology	ACADEMIC PATHOLOGY			English	Article						diversity; inclusion; African American; mentoring; unconscious bias		Diversity and inclusion in academic pathology center on building a diverse, inclusive pathology faculty. Understanding the basics of federal law, and the US Supreme Court cases that interpret those laws, allows one to consider good practices in diversity hire recruitment and retention that protects the pathology chair, the pathology department, and the institution. Consideration of inclusion and unconscious bias are helpful in building and sustaining robust, valuable academic pathology faculty diversity.	[Allen, Timothy Craig] Univ Mississippi, Med Ctr, Dept Pathol, 2500 North State St, Jackson, MS 39216 USA	Allen, TC (reprint author), Univ Mississippi, Med Ctr, Dept Pathol, 2500 North State St, Jackson, MS 39216 USA.	tcallen@umc.edu					[Anonymous], 2016, IMPL FISH 2 US SUPR; [Anonymous], 2010, NAV COMPL LANDSC FOS; [Anonymous], RECR RET MIN LAW FAC; [Anonymous], SEARCH EXC DIV; Deo ME, 2014, BERKELEY J GENDER L, V29, P383; Green E. L., 2018, NY TIMES; Grewal D, 2013, ACAD MED HDB GUIDE A, P405; Grewal D, 2013, ACAD MED HDB GUIDE A, P407; Hurley Lawrence, 2016, REUTERS; Mangurian C, HARVARD BUSINESS REV; Miller FA, 2002, INCLUSION BREAKTHROU, P4; Oldmeadow JA, 2018, BRIT J SOC PSYCHOL, V57, P834, DOI 10.1111/bjso.12262; Springer A, 2006, DIVERSIFY FACULTY	13	0	0	0	0	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	2374-2895			ACAD PATHOL	Acad. Pathol.	NOV 14	2018	5								2374289518811142	10.1177/2374289518811142			7	Pathology	Pathology	HB1XV	WOS:000450824500001	30456296	DOAJ Gold, Green Published			2019-10-28	
J	Conran, RM; Elzie, CA; Knollmann-Ritschel, BE; Domen, RE; Powell, SZE				Conran, Richard M.; Elzie, Carrie A.; Knollmann-Ritschel, Barbara E.; Domen, Ronald E.; Powell, Suzanne Zein-Eldin			Due Process in Medical Education: Legal Considerations	ACADEMIC PATHOLOGY			English	Article						due process; student remediation; student dismissal; case law; professionalism		Throughout the medical education continuum, some students encounter difficulty in meeting academic or professional standards that leads to remediation or dismissal. Termination of a student without due process may lead to litigation by deprivation of a student's property or liberty interest. This article outlines the concept of procedural and substantive due process as applied to litigated student dismissal cases in undergraduate and graduate medical education. Determination of the amount of due process owed is based on whether the dismissal is academic or nonacademic. The decision to dismiss a student where the entire student record has been reviewed, due process provided, and the institution complied with its own policies is usually upheld by the courts in litigation.	[Conran, Richard M.; Elzie, Carrie A.] Eastern Virginia Med Sch, Dept Pathol, 700 West Olney, Norfolk, VA 23501 USA; [Knollmann-Ritschel, Barbara E.] Uniformed Serv Univ Hlth Sci, Dept Pathol, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA; [Domen, Ronald E.] Penn State Hershey Med Ctr, Dept Pathol, Hershey, PA USA; [Powell, Suzanne Zein-Eldin] Houston Methodist Hosp, Dept Pathol, Houston, TX USA	Conran, RM (reprint author), Eastern Virginia Med Sch, Dept Pathol, 700 West Olney, Norfolk, VA 23501 USA.	conranrm@evms.edu					Accreditation Council on Graduate Medical Education, ACGME I REQ 4 C 9 PR; ACGME Common Program Requirements, 2017, SECT 6 BACKGR INT; Epstein RM, 2002, JAMA-J AM MED ASSOC, V287, P226, DOI 10.1001/jama.287.2.226; Liaison Committee on Medical Education, 2018, 35 LCME; Liaison Committee on Medical Education, 2018, 99 LCME; Papadakis MA, 2005, NEW ENGL J MED, V353, P2673, DOI 10.1056/NEJMsa052596; Stewart James B, 1999, BLIND EYE TERRIFYING	7	0	0	0	0	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	2374-2895			ACAD PATHOL	Acad. Pathol.	NOV 14	2018	5								2374289518807460	10.1177/2374289518807460			21	Pathology	Pathology	HB1XY	WOS:000450825000001	30456295	DOAJ Gold, Green Published			2019-10-28	
J	Sanfilippo, F; Burns, KH; Borowitz, MJ; Jackson, JB; Hruban, RH				Sanfilippo, Fred; Burns, Kathleen H.; Borowitz, Michael J.; Jackson, J. Brooks; Hruban, Ralph H.			The Johns Hopkins Department of Pathology Novel Organizational Model: A 25-Year-Old Ongoing Experiment	ACADEMIC PATHOLOGY			English	Article						Department of Pathology; organizational structure; performance; culture; outcomes; strategic priorities	ACADEMIC HEALTH CENTERS; NORMATIVE BELIEFS; MEDICAL-SCHOOLS; CULTURE; PERFORMANCE; EXPECTATIONS	In 1993, the present Department of Pathology at Johns Hopkins was established with the leadership of a new chair (ie, referred to as department director at Hopkins) and upon the integration of 3 separate and independent departments at the Johns Hopkins School of Medicine (Pathology) and the Johns Hopkins Hospital (Pathology, Laboratory Medicine). This new department was organized into 17 divisions, each of which was expected to develop and maintain significant clinical, educational, and research programs of excellence. To facilitate performance and alignment across missions and parent organizations, a novel professional and administrative structure was created. Professionally, vice-chairs (ie, deputy directors) for research, teaching, and patient care were appointed to oversee and coordinate these activities across all units of the department. Likewise, to focus and enhance expertise, individual administrators were appointed for academic, clinical, and business affairs. A departmental executive committee was created consisting of the vice-chairs and administrators, which was presided over by the chair. Simultaneously, substantial effort was put into measuring and improving the organizational culture using evidence-based methods. Significant improvements were documented by the year 2000 in departmental performance in research, education, clinical service, culture, and finances. Under 2 successive leaders, the department has maintained its eminence across missions and financial performance. This 25-year experience supports the tenet that innovative and strategic organizational structures and functional alignments can provide sustainable competitive advantages in performance.	[Sanfilippo, Fred] Emory Univ, Dept Pathol & Lab Med, Atlanta, GA 30322 USA; [Burns, Kathleen H.; Borowitz, Michael J.; Hruban, Ralph H.] Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21205 USA; [Jackson, J. Brooks] Univ Iowa, Dept Pathol, Sch Med, Iowa City, IA 52242 USA	Sanfilippo, F (reprint author), 730GCR,1518 Clifton Rd, Atlanta, GA 30322 USA.	fred.sanfilippo@emory.edu					Barney J. B., 2006, GAINING SUSTAINING C; Burns KH, 2018, ACAD PATHOL, V5, DOI 10.1177/2374289518777463; COOKE RA, 1993, PSYCHOL REP, V72, P1299, DOI 10.2466/pr0.1993.72.3c.1299; COOKE RA, 1988, GROUP ORGAN STUD, V13, P245, DOI 10.1177/105960118801300302; Groysberg B, 2012, TALK INC TRUSTED LEA; Guileyardo Joseph M, 2015, Proc (Bayl Univ Med Cent), V28, P120; Hooper JE, 2018, ACAD PATHOL, V5, DOI 10.1177/2374289517744753; Keroack MA, 2011, AM J SURG, V202, P119, DOI 10.1016/j.amjsurg.2011.05.001; MCHUGH PR, 1994, ACAD MED, V69, P877, DOI 10.1097/00001888-199411000-00003; Roskoski R, 2017, RANKING TABLES NIH F; ROUSSEAU DM, 1990, GROUP ORGAN STUD, V15, P448, DOI 10.1177/105960119001500408; Sackmann S. A., 2011, HDB ORG CULTURE CLIM, P188, DOI DOI 10.4135/9781483307961.N12; Sanfilippo F, 2010, STUD HEALTH TECHNOL, V153, P383, DOI 10.3233/978-1-60750-533-4-383; Sanfilippo F, 2008, ACAD MED, V83, P845, DOI 10.1097/ACM.0b013e318181d2e7; ZIMMERMAN JE, 1993, CRIT CARE MED, V21, P1443, DOI 10.1097/00003246-199310000-00010	15	0	0	0	0	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	2374-2895			ACAD PATHOL	Acad. Pathol.	NOV 14	2018	5									10.1177/2374289518807460			14	Pathology	Pathology	HB1XZ	WOS:000450825300001		DOAJ Gold, Green Published			2019-10-28	
J	Chang, B; Meng, J; Zhu, HM; Du, X; Sun, LL; Wang, L; Li, SG; Yang, G				Chang, Bin; Meng, Jiao; Zhu, Huimin; Du, Xiang; Sun, Lili; Wang, Lei; Li, Shugang; Yang, Gong			Overexpression of the recently identified oncogene REDD1 correlates with tumor progression and is an independent unfavorable prognostic factor for ovarian carcinoma	DIAGNOSTIC PATHOLOGY			English	Article						REDD1; Ovarian cancer; Prognosis; Invasion; Migration	ACTIVATION; HYPOXIA; STRESS; MTOR; INHIBITION; EXPRESSION; APOPTOSIS; AUTOPHAGY; PATHWAY; GROWTH	BackgroundRegulated in development and DNA damage response (REDD1), a gene responding to hypoxia or multiple DNA damage events, was recently implicated in cancer development and progression. Previously, in vivo and in vitro experiments indicated that REDD1 functions as an oncogene in ovarian cancer cells. However, the role of REDD1 in cancer cell migration and invasion and in clinical significance of prognostic values is not examined in detail.MethodsWe detected the REDD1 protein expression by immunohistochemistry in 18 normal ovarian surface epithelium or fallopian tube epithelium specimens, 24 ovarian borderline tumors, and 229 ovarian cancers. Fisher's exact test, logistic regression analysis, the Kaplan-Meier method, and the log-rank test were used to evaluate the association of REDD1 with clinical factors, overall survival and disease-free survival. The prognostic predictive value of REDD1 for ovarian cancer patients was evaluated using multivariate Cox proportional hazard regression models. REDD1 expression in HEY, HEY A8, SKOV3, SKOV3 ip1, OVCA429, OVCA433 and A2780 human ovarian epithelial cancer cell lines was detected by western blotting. The role of REDD1 in cell invasion and migration was assessed by transwell migration and invasion assays using SKOV3, A2780, HEY, HEYA8, and SKOV3-REDD1 with parental A2780-REDD1 HEY-REDD1i and HEY A8-REDD1i.ResultsHigh expression of REDD1 was observed in 35.4% of primary ovarian carcinoma samples. Overexpression of cytoplasmic REDD1 in ovarian cancer was significantly associated with serous carcinoma (P<0.001), late-stage disease (P<0.001), ascites (P<0.001), and partial or non-response to chemotherapy (P<0.001). High cytoplasmic expression of REDD1 was correlated with poorer overall survival (P<0.001) and disease-free survival (P<0.001). The multivariate Cox proportional hazards regression analysis indicated that patients with high cytoplasmic REDD1 expression had a high risk of death (P<0.001) and high risk of an event (i.e., recurrence, progression, or death) (P<0.001). REDD1 was first reported as an independent prognostic factor in ovarian cancer patients. In addition, REDD1 overexpression enhanced ovarian cancer cell migration and invasion.ConclusionREDD1 is an independent unfavorable prognostic factor in ovarian carcinoma and may promote ovarian cancer metastasis.	[Chang, Bin; Du, Xiang; Wang, Lei] Fudan Univ, Shanghai Canc Ctr, Dept Pathol, Shanghai 20032, Peoples R China; [Meng, Jiao; Yang, Gong] Fudan Univ, Shanghai Canc Ctr, Canc Inst, Shanghai 20032, Peoples R China; [Chang, Bin; Meng, Jiao; Du, Xiang; Wang, Lei; Yang, Gong] Fudan Univ, Shanghai Med Coll, Dept Oncol, Shanghai 20032, Peoples R China; [Zhu, Huimin; Sun, Lili] Shihezi Univ, Dept Pathol, Shihezi 832003, Xinjiang, Peoples R China; [Li, Shugang] Shihezi Univ, Sch Med, Dept Prevent Med, Shihezi 832003, Xinjiang, Peoples R China; [Yang, Gong] Fudan Univ, Peoples Hosp Shanghai 5, Cent Lab, Shanghai 200240, Peoples R China	Yang, G (reprint author), Fudan Univ, Shanghai Canc Ctr, Canc Inst, Shanghai 20032, Peoples R China.; Yang, G (reprint author), Fudan Univ, Shanghai Med Coll, Dept Oncol, Shanghai 20032, Peoples R China.	binchang7551@163.com; yanggong@fudan.edu.cn			National Natural Science Foundation of ChinaNational Natural Science Foundation of China [81160316, 81260104]	This study was supported by the National Natural Science Foundation of China (No. 81160316 and 81260104).	Brugarolas J, 2004, GENE DEV, V18, P2893, DOI 10.1101/gad.1256804; Cao Man-ming, 2005, Di Yi Jun Yi Da Xue Xue Bao, V25, P1478; Chang B, 2009, MODERN PATHOL, V22, P817, DOI 10.1038/modpathol.2009.35; Chang B, 2009, CELL CYCLE, V8, P780, DOI 10.4161/cc.8.5.7887; Cheng Y, 2013, AUTOPHAGY, V9, P208, DOI 10.4161/auto.22801; Corradetti MN, 2005, J BIOL CHEM, V280, P9769, DOI 10.1074/jbc.C400557200; DeYoung MP, 2008, GENE DEV, V22, P239, DOI 10.1101/gad.1617608; Ellisen LW, 2005, CELL CYCLE, V4, P1500, DOI 10.4161/cc.4.11.2139; Ellisen LW, 2002, MOL CELL, V10, P995, DOI 10.1016/S1097-2765(02)00706-2; Horak P, 2010, P NATL ACAD SCI USA, V107, P4675, DOI 10.1073/pnas.0907705107; Jia W, 2014, INT J CLIN EXP PATHO, V7, P5940; Jin HO, 2013, CANCER LETT, V336, P319, DOI 10.1016/j.canlet.2013.03.021; Kimball SR, 2008, J BIOL CHEM, V283, P3465, DOI 10.1074/jbc.M706643200; Kolesnichenko M, 2012, CELL CYCLE, V11, P2391, DOI 10.4161/cc.20683; Kucejova B, 2011, MOL CANCER RES, V9, P1255, DOI 10.1158/1541-7786.MCR-11-0302; Lecomte S, 2017, CELL COMMUN SIGNAL, V15, DOI 10.1186/s12964-017-0182-1; Michel G, 2014, J CELL SCI, V127, P773, DOI 10.1242/jcs.136432; Seidmam JD, 2014, WHO CLASSIFICATION T, P15; Shoshani T, 2002, MOL CELL BIOL, V22, P2283, DOI 10.1128/MCB.22.7.2283-2293.2002; Sofer A, 2005, MOL CELL BIOL, V25, P5834, DOI 10.1128/MCB.25.14.5834-5845.2005; Zeng QH, 2018, CLIN CANCER RES, V24, P445, DOI 10.1158/1078-0432.CCR-17-0419	21	0	0	0	1	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1746-1596			DIAGN PATHOL	Diagn. Pathol.	NOV 14	2018	13								87	10.1186/s13000-018-0754-4			12	Pathology	Pathology	HA7VN	WOS:000450493200001	30428884	DOAJ Gold, Green Published			2019-10-28	
J	Wang, CS; Yun, T; Wang, ZC; Meng, NL; Fan, NJ; Lv, XX; Li, FL				Wang, Changsong; Yun, Tian; Wang, Zhicheng; Meng, Nianlong; Fan, Naijun; Lv, Xuexia; Li, Fulin			Pathological characteristics and genetic features of melanin-producing medullary thyroid carcinoma	DIAGNOSTIC PATHOLOGY			English	Article						Medullary thyroid carcinoma; Melanin; Immunohistochemistry; Diagnosis; Genetic feature	GLAND	ObjectiveTo study the clinicopathological characteristics and genetic features of melanin-producing medullary thyroid carcinoma (MP-MTC).MethodsThe immunophenotype of MP-MTC was studied using the immunohistochemical method, and its genetic features were assayed using an amplification refractory mutation system or PCR method.ResultsA 71-year-old man presented with a slowly growing 5-cm mass on the left side of the neck for approximately two months. The cut surface of the neoplasm was brown and black. Melanin was found in the cytoplasm of tumor cells or the extracellular matrix. The tumor cells were positive for AE1/AE3, S-100 protein, melan A, HMB-45, synaptophysin, calcitonin, chromogranin A, melanoma, and thyroid transcription factor-1 (TTF-1) and negative for thyroglobulin. No typical genetic features were observed in this case. The patient showed no symptoms and recurrence at 12months after the operation.ConclusionsThe tumor cells of MP-MTC were positive for melanin biomarkers, TTF-1 and exhibited no genetic features. Histopathology and immunohistochemistry of the tumor cells will aid accurate diagnosis.	[Wang, Changsong; Yun, Tian; Meng, Nianlong; Fan, Naijun; Lv, Xuexia; Li, Fulin] 150th Hosp PLA, Dept Pathol, Luoyang 471000, Henan, Peoples R China; [Wang, Zhicheng] 153th Hosp PLA, Dept Pathol, Zhengzhou 450042, Henan, Peoples R China	Wang, CS (reprint author), 150th Hosp PLA, Dept Pathol, Luoyang 471000, Henan, Peoples R China.	wangtmmu150@163.com		Wang, Changsong/0000-0001-5686-7912			BEERMAN H, 1990, HISTOPATHOLOGY, V16, P227, DOI 10.1111/j.1365-2559.1990.tb01108.x; BenRomdhane K, 1995, HISTOPATHOLOGY, V27, P569; Chigurupati MV, 2016, INDIAN J NUCL MED, V31, P45, DOI 10.4103/0972-3919.172361; de Lima MA, 2001, DIAGN CYTOPATHOL, V24, P206, DOI 10.1002/1097-0339(200103)24:3<206::AID-DC1042>3.0.CO;2-H; ENG HL, 1989, ARCH PATHOL LAB MED, V113, P377; Guiping Q, 2010, CHIN GER J CLIN ONCO, V9, P677, DOI [10.1007/s10330-010-0683-5, DOI 10.1007/S10330-010-0683-5]; Hirokawa M, 2016, INT J SURG CASE REP, V20, P118, DOI 10.1016/j.ijscr.2016.01.029; Ikeda T, 1998, ARCH PATHOL LAB MED, V122, P555; KIMURA N, 1989, ACTA CYTOL, V33, P61; MARCUS JN, 1982, CANCER, V49, P2518, DOI 10.1002/1097-0142(19820615)49:12<2518::AID-CNCR2820491219>3.0.CO;2-N; Matias-Guiu X, 2004, PATHOLOGY GENETICS T, V8, P86; POSEN JA, 1984, S AFR MED J, V65, P57; Singh K, 2008, DIAGN PATHOL, V3, DOI 10.1186/1746-1596-3-2; Singh Z N, 1999, Indian J Pathol Microbiol, V42, P159; Yanjun D, 2017, CLIN MED INSIGHTS PA, V10, P1	15	0	0	0	0	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1746-1596			DIAGN PATHOL	Diagn. Pathol.	NOV 13	2018	13								86	10.1186/s13000-018-0764-2			6	Pathology	Pathology	HA3UW	WOS:000450182700001	30424779	DOAJ Gold, Green Published			2019-10-28	
J	Dhanani, M; Nassar, A; Charles, MS; Dinh, T				Dhanani, Maya; Nassar, Aziza; Charles, Melissa S.; Tri Dinh			Cytology of the fallopian tube: A screening model for high-grade serous carcinoma	CYTOJOURNAL			English	Article						Cytology; fallopian tube; ovarian cancer; screening	INTRAEPITHELIAL CARCINOMA; OVARIAN-CANCER; MORTALITY	Ovarian cancer is a heterogeneous disease having the highest gynecologic fatality in the United States with a 5-year survival rate of 46.5%. Poor overall prognosis is mostly attributed to inadequate screening tools, and the majority of diagnoses occur at late stages of the disease. Due to genetic and biological underpinnings, ovarian high-grade serous carcinomas (HGSC) have etiologic evidence in the distal fallopian tube. Fallopian tube screening modalities are aggressively investigated, but few describe cytological characteristics of benign tubal specimens to help in the comparative detection of HGSC precursor cells. Here, we describe fimbrial cytomorphological and nuclear features of tubal specimens (n = 75) from patients clinically indicated for salpingectomy, bilateral or unilateral salpingo-oophorectomy, and hysterectomies for any diagnosis other than ovarian or peritoneal cancer. Fallopian tube histology was used as the diagnostic reference. A total of 75 samples had benign diagnoses. The benign cytological characteristics of fimbrial tubal specimens included ciliated cells in clustered arrangements with mild nuclear membrane irregularity, mild anisonucleosis, round and/or oval nuclei, hyperchromatic chromatin, and mild nuclear membrane irregularity. In contrast, none of the cytology samples had spindle-shaped nuclei, significantly marked anisonucleosis (n = 1), nor had hypochromasia as a characteristic feature. These cytological characteristics could be a potential area of distinction from HGSC precursor cells. Our study establishes cytomorphological characteristics of nonmalignant tubal cells which help underscore the importance of distinguishing malignant HGSC precursors through fimbrial brush sampling in minimally invasive approach.	[Dhanani, Maya; Tri Dinh] Mayo Clin, Dept Med & Surg Gynecol, Jacksonville, FL 32224 USA; [Nassar, Aziza] Mayo Clin, Dept Pathol & Lab Med, Jacksonville, FL 32224 USA; [Charles, Melissa S.] Loma Linda Univ, Sch Med, Dept Mol Biol, Loma Linda, CA 92350 USA	Dinh, T (reprint author), Mayo Clin, Dept Med & Surg Gynecol, Jacksonville, FL 32224 USA.	maya.dhanani@gmail.com; nassar.aziza@mayo.edu; mcharles@llu.edu; dinh.tri@mayo.edu					Baldwin LA, 2012, OBSTET GYNECOL, V120, P612, DOI 10.1097/AOG.0b013e318264f794; Berek JS, 2015, INT J GYNECOL OBSTET, V131, pS111, DOI 10.1016/j.ijgo.2015.06.007; Buys SS, 2011, JAMA-J AM MED ASSOC, V305, P2295, DOI 10.1001/jama.2011.766; Carlson JW, 2008, J CLIN ONCOL, V26, P4160, DOI 10.1200/JCO.2008.16.4814; Chen H, 2017, JOVE-J VIS EXP, DOI 10.3791/55887; Jacobs IJ, 2016, LANCET, V387, P945, DOI 10.1016/S0140-6736(15)01224-6; Karst AM, 2011, P NATL ACAD SCI USA, V108, P7547, DOI 10.1073/pnas.1017300108; Kindelberger DW, 2007, AM J SURG PATHOL, V31, P161, DOI 10.1097/01.pas.0000213335.40358.47; Kobayashi H, 2008, INT J GYNECOL CANCER, V18, P414, DOI 10.1111/j.1525-1438.2007.01035.x; Lee Y, 2007, J PATHOL, V211, P26, DOI 10.1002/path.2091; Meserve EEK, 2017, GYNECOL ONCOL, V146, P69, DOI 10.1016/j.ygyno.2017.04.015; Noone AM, SEER CANC STAT REV 1; Otsuka I, 2013, BRIT J CANCER, V109, P603, DOI 10.1038/bjc.2013.402; Rodriguez EF, 2013, ACTA CYTOL, V57, P611, DOI 10.1159/000353825; Seidman JD, 2011, BLAUSTEIN'S PATHOLOGY OF THE FEMALE GENITAL TRACT, SIXTH EDITION, P679, DOI 10.1007/978-1-4419-0489-8_14; Vang R, 2016, INT J GYNECOL PATHOL, V35, P48, DOI 10.1097/PGP.0000000000000207; Vang R, 2009, ADV ANAT PATHOL, V16, P267, DOI 10.1097/PAP.0b013e3181b4fffa; Vincent GK, 2010, P251138 US DEP COMM; Weir HK, 2015, CANCER-AM CANCER SOC, V121, P1827, DOI 10.1002/cncr.29258; Yoshida H, 2016, EUR J GYNAECOL ONCOL, V37, P404, DOI 10.12892/ejgo3023.2016	20	0	0	0	0	WOLTERS KLUWER MEDKNOW PUBLICATIONS	MUMBAI	WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA	0974-5963	1742-6413		CYTOJOURNAL	CytoJournal	NOV 12	2018	15								28	10.4103/cytojournal.cytojournal._58_17			8	Pathology	Pathology	HI1AO	WOS:000456176300002	30534183	DOAJ Gold			2019-10-28	
J	Tsuji, S; Tsuji, K; Otsuka, H; Murakami, T				Tsuji, Shunichiro; Tsuji, Kiyoshi; Otsuka, Hirokuni; Murakami, Takashi			Increased mast cells in endocervical smears of women with dysmenorrhea	CYTOJOURNAL			English	Article						Dysmenorrhea; endocervical smear; mast cells	ENDOMETRIOSIS; ASSOCIATION; MEDIATORS; PAIN	Background: Mast cells are observed in peritoneal endometriosis which causes dysmenorrhea. However, there is no report about the relationship between endocervical mast cells and dysmenorrhea. The aim of this study is to evaluate the relationship using endocervical smears. Materials and Methods: Between January 2016 and June 2016, patients filled out a questionnaire regarding dysmenorrhea and were classified into the dysmenorrhea or the control group (without dysmenorrhea). Patients underwent endocervical brushing and endocervical smears were obtained. The smears were stained with methylene blue to detect mast cells. The number of mast cells per slide was counted by microscopy and recorded. Results: Eighty-nine patients were enrolled in this study (dysmenorrhea group, 34; control group, 55). The median number of mast cells present in the endocervical one slides was 35 (interquartile range, 17-58) and 2 (interquartile range, 0-6) in the dysmenorrhea and control groups, respectively. There was a significant difference in the number of mast cells between the two groups (P < 0.0001). Conclusion: More mast cells were observed in the endocervical smears of women with dysmenorrhea than in those of women without dysmenorrhea.	[Tsuji, Shunichiro; Murakami, Takashi] Shiga Univ Med Sci, Dept Obstet, Otsu, Shiga, Japan; [Tsuji, Shunichiro; Murakami, Takashi] Shiga Univ Med Sci, Dept Gynecol, Otsu, Shiga, Japan; [Tsuji, Kiyoshi] Tsuji Ladies Clin, Osaka, Japan; [Otsuka, Hirokuni] Otsuka Ent Clin, Kawasaki, Kanagawa, Japan	Tsuji, S (reprint author), Shiga Univ Med Sci, Dept Obstet, Otsu, Shiga, Japan.; Tsuji, S (reprint author), Shiga Univ Med Sci, Dept Gynecol, Otsu, Shiga, Japan.	tsuji002@belle.shiga-med.ac.jp; t.hayumi@dream.ocn.ne.jp; otsuka46hiro@s03.itscom.net; tm@belle.shiga-med.ac.jp					Barbara G, 2004, GASTROENTEROLOGY, V126, P693, DOI 10.1053/j.gastro.2003.11.055; Canis M, 1997, FERTIL STERIL, V67, P817; Fujiwara H, 2004, AM J REPROD IMMUNOL, V51, P341, DOI 10.1111/j.1600-0897.2004.00166.x; Giudice LC, 2004, LANCET, V364, P1789, DOI 10.1016/S0140-6736(04)17403-5; Graziottin A, 2014, GYNECOL ENDOCRINOL, V30, P472, DOI 10.3109/09513590.2014.911280; Heron A, 2013, J NEUROIMMUNOL, V264, P1, DOI 10.1016/j.jneuroim.2013.09.018; Howard FM, 2009, J MINIM INVAS GYN, V16, P540, DOI 10.1016/j.jmig.2009.06.017; Ju H, 2014, EPIDEMIOL REV, V36, P104, DOI 10.1093/epirev/mxt009; KOBAYASHI TK, 1983, ACTA CYTOL, V27, P133; Lefebvre G, 2005, J OBSTET GYNAECOL CA, V27, P1117; Matsuzaki S, 1998, AM J REPROD IMMUNOL, V40, P291; Menzies FM, 2011, HUM REPROD UPDATE, V17, P383, DOI 10.1093/humupd/dmq053; Mori A, 1997, HUM REPROD, V12, P368, DOI 10.1093/humrep/12.2.368; NICHOLS TR, 1987, ANN ALLERGY, V59, P360; RUDOLPH MI, 1993, BRIT J OBSTET GYNAEC, V100, P1125, DOI 10.1111/j.1471-0528.1993.tb15178.x; SCHWARTZ LB, 1987, J IMMUNOL, V138, P2611	16	0	0	0	1	WOLTERS KLUWER MEDKNOW PUBLICATIONS	MUMBAI	WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA	0974-5963	1742-6413		CYTOJOURNAL	CytoJournal	NOV 12	2018	15								27	10.4103/cytojournal.cytojournal._54_17cramping			4	Pathology	Pathology	HI1AO	WOS:000456176300001	30534182	DOAJ Gold			2019-10-28	
J	Tariq, H; Gilbert, A; Sharkey, FE				Tariq, Hamza; Gilbert, Andrea; Sharkey, Francis E.			Intrathecal Methotrexate-Induced Necrotizing Myelopathy: A Case Report and Review of Histologic Features	CLINICAL MEDICINE INSIGHTS- PATHOLOGY			English	Review						Methotrexate; intrathecal; myelopathy; vacuolar degeneration	WHITE-MATTER; CHEMOTHERAPY	Central nervous system (CNS) relapse of acute lymphoblastic leukemia (ALL) is associated with a poor prognosis. However, prophylactic measures, including intrathecal (IT) methotrexate, reduce the incidence of CNS relapse in these patients considerably. Unfortunately, IT methotrexate can cause several neurologic complications, including transverse myelopathy; ie, the development of isolated spinal cord dysfunction over hours or days following the IT infusion of methotrexate, but in the absence of a compressive lesion. Transverse myelopathy following IT methotrexate is a well-established clinical phenomenon, but the histologic features have been described only very rarely. We report the autopsy findings from a 31-year-old man with a history of T-cell ALL who received prophylactic IT methotrexate in anticipation of a bone marrow transplant. Microscopic examination showed transverse necrosis of the thoracic cord, with massive infiltration by macrophages and lymphocytes, and perivascular lymphocytic infiltrates. There was cavitary necrosis of cervical and lumbar spinal cord involving the entire gray matter and focal white matter, as well as extensive subpial vacuolar degeneration of the dorsal and lateral columns.	[Tariq, Hamza; Gilbert, Andrea; Sharkey, Francis E.] UT Hlth San Antonio, Dept Pathol & Lab Med, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA	Tariq, H (reprint author), UT Hlth San Antonio, Dept Pathol & Lab Med, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.	TariqH@uthscsa.edu					Ackermann R, 2010, J NEURO-ONCOL, V97, P425, DOI 10.1007/s11060-009-0028-9; BARBER JR, 1984, J BIOL CHEM, V259, P7115; BLASBERG RG, 1975, J PHARMACOL EXP THER, V195, P73; CLARK AW, 1982, CANCER, V50, P42, DOI 10.1002/1097-0142(19820701)50:1<42::AID-CNCR2820500109>3.0.CO;2-M; Del Principe MI, 2014, MEDITERR J HEMATOL I, V6, DOI 10.4084/MJHID.2014.075; Ellison D, 2012, REFERENCE TEXT CNS P; Gokbuget N, 1998, J NEURO-ONCOL, V38, P167, DOI 10.1023/A:1005963732481; GRISOLD W, 1980, ACTA NEUROPATHOL, V49, P231, DOI 10.1007/BF00707111; Honda D, 2012, NEUROL MED TOKYO, V77, P35; Linnebank M, 2005, NEUROLOGY, V64, P912, DOI 10.1212/01.WNL.0000152840.26156.74; Pan Y, 2016, ONCOL LETT, V11, P4066, DOI 10.3892/ol.2016.4519; SHIBUTANI M, 1989, ACTA NEUROPATHOL, V78, P291, DOI 10.1007/BF00687759; SUZUKI K, 1984, ACTA NEUROPATHOL, V65, P145, DOI 10.1007/BF00690468; Teh H S, 2007, Singapore Med J, V48, pe46; Tomonaga M, 1978, ADV NEUROL SCI TOKYO, V22, P1204; Vezmar S, 2009, PEDIATR BLOOD CANCER, V52, P26, DOI 10.1002/pbc.21827; VONDERWEID NX, 1991, MED PEDIATR ONCOL, V19, P192, DOI 10.1002/mpo.2950190309; YIM YS, 1991, CANCER, V67, P2058, DOI 10.1002/1097-0142(19910415)67:8<2058::AID-CNCR2820670808>3.0.CO;2-G	18	0	0	0	0	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	1179-5557	2632-010X		CLIN MED INSIGHTS-PA	Clin. Med. Insights-Pathol.	NOV 4	2018	11								UNSP 1179555718809071	10.1177/1179555718809071			5	Pathology	Pathology	HG1OW	WOS:000454728600001	30450009	DOAJ Gold, Green Published			2019-10-28	
J	Zhang, ZY; Zhu, JG; Huang, YS; Li, WB; Cheng, HQ				Zhang, Zhenyu; Zhu, Jinfeng; Huang, Yansong; Li, Weibing; Cheng, Hongqiu			MYO18B promotes hepatocellular carcinoma progression by activating PI3K/AKT/mTOR signaling pathway	DIAGNOSTIC PATHOLOGY			English	Article						Hepatocellular carcinoma; MYO18B; PI3K; AKT; mTOR signaling pathway; Prognosis	TUMOR-SUPPRESSOR GENE; HUMAN LUNG-CANCER; MOLECULAR TARGETS; OVARIAN-CANCER; EXPRESSION; MTOR; THERAPY; MY018B; HETEROZYGOSITY; DIAGNOSIS	BackgroundMYO18B has been identified as a novel tumor suppressor gene in several cancers. However, its specific roles in the progression of hepatocellular carcinoma (HCC) has not been well defined.MethodsWe firstly identified the expression and prognostic values of MYO18B in HCC using TCGA cohort and our clinical data. Then, MYO18B knockdown by RNA inference was implemented to investigate the effects of MYO18B on HCC cells. Quantitative RT-PCR and Western blot were used to determine gene and protein expression levels. CCK-8 and colony formation assays were performed to examine cell proliferation capacity. Wound healing and transwell assays were used to evaluate the migration and invasion of HepG2 cells.ResultsMYO18B was overexpressed and correlated with poor prognosis in HCC. MYO18B expression was an independent risk factor for overall survival. Knockdown of MYO18B significantly inhibited the proliferation, migration and invasion of HepG2 cells. Meanwhile, MYO18B knockdown could effectively suppress the phosphorylation of PI3K, AKT, mTOR and P70S6K, suggesting that MYO18B might promote HCC progression by targeting PI3K/AKT/mTOR signaling pathway.ConclusionsMYO18B promoted tumor growth and migration via the activation of PI3K/AKT/mTOR signaling pathway. MYO18B might be a promising target for clinical intervention of HCC.	[Zhang, Zhenyu] Shenzhen Pingshan Dist Peoples Hosp, Dept Tradit Chinese Med, Shenzhen, Peoples R China; [Zhu, Jinfeng] Nantong Hosp Tradit Chinese Med, Dept Tradit Chinese Med, Nantong, Peoples R China; [Huang, Yansong; Li, Weibing; Cheng, Hongqiu] Shantou Univ, Coll Med, Dept Infect Dis, Affiliated Hosp 2, 69 Dongxia North Rd, Shantou 515041, Peoples R China	Cheng, HQ (reprint author), Shantou Univ, Coll Med, Dept Infect Dis, Affiliated Hosp 2, 69 Dongxia North Rd, Shantou 515041, Peoples R China.	179598450@qq.com; 982115479@qq.com			Joint Scientific Special foundation of Guangdong Provincial Department of Science and Technology-Academy of Traditional Chinese Medicine [2013A032500017]	This work is supported by the Joint Scientific Special foundation of Guangdong Provincial Department of Science and Technology-Academy of Traditional Chinese Medicine (NO: 2013A032500017).	Ajdarkosh H, 2015, DIAGN PATHOL, V10, DOI 10.1186/s13000-015-0371-4; Altomare DA, 2004, ONCOGENE, V23, P5853, DOI 10.1038/sj.onc.1207721; Bosetti C, 2014, BEST PRACT RES CL GA, V28, P753, DOI 10.1016/j.bpg.2014.08.007; Chaiteerakij R, 2015, CLIN GASTROENTEROL H, V13, P237, DOI 10.1016/j.cgh.2013.10.038; Edakuni N, 2006, ONCOL RES, V16, P235; Eiden AM, 2016, CLIN CANCER RES, V22, P277, DOI 10.1158/1078-0432.CCR-14-3239; El-Serag HB, 2008, GASTROENTEROLOGY, V134, P1752, DOI 10.1053/j.gastro.2008.02.090; Ersahin T, 2015, MOL BIOSYST, V11, P1946, DOI 10.1039/c5mb00101c; Faes S, 2015, INT J MOL SCI, V16, P21138, DOI 10.3390/ijms160921138; Forner A, 2018, LANCET, V391, P1301, DOI 10.1016/S0140-6736(18)30010-2; Franke TF, 2003, ONCOGENE, V22, P8983, DOI 10.1038/sj.onc.1207115; Guan XY, 2000, GENE CHROMOSOME CANC, V29, P110; Guertin DA, 2007, CANCER CELL, V12, P9, DOI 10.1016/j.ccr.2007.05.008; Inoue T, 2006, BIOCHEM BIOPH RES CO, V342, P829, DOI 10.1016/j.bbrc.2006.02.025; Kulik LM, 2015, CLIN LIVER DIS, V19, P23, DOI 10.1016/j.cld.2014.09.002; Li W, 2008, ONCOL REP, V20, P713, DOI 10.3892/or_00000064; Ma LF, 2015, DISCOV MED, V19, P7; Mabuchi S, 2009, CLIN CANCER RES, V15, P5404, DOI 10.1158/1078-0432.CCR-09-0365; Marrero JA, 2018, HEPATOLOGY, V68, P723, DOI 10.1002/hep.29913; Marrero JA, 2009, GASTROENTEROLOGY, V137, P110, DOI 10.1053/j.gastro.2009.04.005; Morgensztern D, 2005, ANTI-CANCER DRUG, V16, P797, DOI 10.1097/01.cad.0000173476.67239.3b; Nakano T, 2005, GENE CHROMOSOME CANC, V43, P162, DOI 10.1002/gcc.20180; Nishida N, 2011, CURR GENOMICS, V12, P130, DOI 10.2174/138920211795564359; Nishioka M, 2002, P NATL ACAD SCI USA, V99, P12269, DOI 10.1073/pnas.192445899; Niu ZS, 2016, WORLD J GASTROENTERO, V22, P9069, DOI 10.3748/wjg.v22.i41.9069; Papadimitrakopoulou V, 2006, J THORAC ONCOL, V1, P749, DOI 10.1016/S1556-0864(15)30399-3; Park SJ, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000005811; Pinter M, 2016, ESMO OPEN, V1, DOI 10.1136/esmoopen-2016-000042; Polivka J, 2014, PHARMACOL THERAPEUT, V142, P164, DOI 10.1016/j.pharmthera.2013.12.004; Porta C, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00064; Reichl P, 2016, ONCOL REP, V36, P613, DOI 10.3892/or.2016.4842; Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616; Salamon M, 2003, J MOL BIOL, V326, P137, DOI 10.1016/S0022-2836(02)01335-9; Singal AG, 2012, CANCER EPIDEM BIOMAR, V21, P793, DOI 10.1158/1055-9965.EPI-11-1005; TAKAHASHI K, 1993, HEPATOLOGY, V17, P794, DOI 10.1016/0270-9139(93)90154-F; Tani M, 2004, GENE CHROMOSOME CANC, V40, P146, DOI 10.1002/gcc.20027; Yanaihara N, 2004, INT J CANCER, V112, P150, DOI 10.1002/ijc.20339; Yap TA, 2008, CURR OPIN PHARMACOL, V8, P393, DOI 10.1016/j.coph.2008.08.004; Yokota J, 2004, CANCER SCI, V95, P197, DOI 10.1111/j.1349-7006.2004.tb02203.x; Zhou L, 2006, WORLD J GASTROENTERO, V12, P1175, DOI 10.3748/wjg.v12.i8.1175; Zhou Q, 2011, FUTURE ONCOL, V7, P1149, DOI [10.2217/fon.11.95, 10.2217/FON.11.95]; Zhu GN, 2004, WORLD J GASTROENTERO, V10, P1975	42	0	0	1	2	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1746-1596			DIAGN PATHOL	Diagn. Pathol.	NOV 3	2018	13								85	10.1186/s13000-018-0763-3			9	Pathology	Pathology	GZ3IJ	WOS:000449280000001	30390677	DOAJ Gold, Green Published			2019-10-28	
J	Gaillot-Durand, L; Brioude, F; Beneteau, C; Le Breton, F; Massardier, J; Michon, L; Devouassoux-Shisheboran, M; Allias, F				Gaillot-Durand, Lucie; Brioude, Frederic; Beneteau, Claire; Le Breton, Frederique; Massardier, Jerome; Michon, Lucas; Devouassoux-Shisheboran, Mojgan; Allias, Fabienne			Placental Pathology in Beckwith-Wiedemann Syndrome According to Genotype/Epigenotype Subgroups	FETAL AND PEDIATRIC PATHOLOGY			English	Article						Beckwith-Wiedemann syndrome; placenta; placental mesenchymal dysplasia; chorangioma; cytomegaly; 11p15 region	MESENCHYMAL DYSPLASIA; PHENOTYPE; P57; DIAGNOSIS; HYDROPS; RISK; CHORIOANGIOMA; ASSOCIATION; EXPRESSION; SPECTRUM	Objectives: To evaluate the frequency of placental pathological lesions in Beckwith-Wiedemann syndrome (BWS), an overgrowth disorder that exhibits etiologic molecular heterogeneity and variable phenotypic expression. Materials and methods: The study included 60 BWS patients with a proven molecular diagnosis and a placental pathological examination. Placentomegaly, placental mesenchymal dysplasia (PMD), chorangioma/chorangiomatosis, and extravillous trophoblastic (EVT) cytomegaly were evaluated and their frequencies in the different molecular subgroups were compared. Immunohistochemistry and fluorescent in situ hybridization (FISH) were performed on EVT cytomegaly. Results: Placentomegaly was found in 70.9% of cases, PMD in 21.7%, chorangioma/chorangiomatosis in 23.3%, and EVT cytomegaly in 21.7%; there was no significant intergroup difference. EVT cytomegaly showed loss of p57 expression, increased Ki67 proliferating index, and polyploidy on FISH analysis. Conclusions: There was no genotype/epigenotype-phenotype correlation concerning placental lesions in BWS. Diffuse EVT cytomegaly with polyploidy may represent a placental finding suggestive of BWS.	[Gaillot-Durand, Lucie; Le Breton, Frederique; Devouassoux-Shisheboran, Mojgan; Allias, Fabienne] Hosp Civils Lyon, Ctr Hosp Lyon Sud, Dept Pathol, 165 Chemin Grand Revoyet, F-69495 Lyon, France; [Gaillot-Durand, Lucie; Beneteau, Claire; Le Breton, Frederique; Massardier, Jerome; Allias, Fabienne] Soc Francaise Foetopathol SOFFOET, Rennes, France; [Brioude, Frederic] Sorbonne Univ, Hop Univ Paris Est, AP HP,Hop Armand Trousseau,Ctr Rech St Antoine, Dept Explorat Fonctionnelles Endocriniennes,Inser, Paris, France; [Beneteau, Claire] CHU Nantes, Dept Med Genet, Nantes, France; [Massardier, Jerome] Hosp Civils Lyon, Hop Femme Mere Enfants, Dept Gynecol & Obstet, Bron, France; [Michon, Lucas] Registre Malformat Rhone Alpes REMERA, Lyon, France	Allias, F (reprint author), Hosp Civils Lyon, Ctr Hosp Lyon Sud, Dept Pathol, 165 Chemin Grand Revoyet, F-69495 Lyon, France.	fabienne.allias@chu-lyon.fr					Allias F, 2009, FETAL PEDIATR PATHOL, V28, P9, DOI 10.1080/15513810802545350; Aoki A, 2011, J OBSTET GYNAECOL RE, V37, P1872, DOI 10.1111/j.1447-0756.2011.01654.x; Arizawa Masayoshi, 2002, Congenital Anomalies, V42, P309, DOI 10.1111/j.1741-4520.2002.tb00897.x; Armes JE, 2012, PATHOLOGY, V44, P519, DOI 10.1097/PAT.0b013e3283559c94; Baergen RN, 2011, MANUAL PATHOLOGY HUM, P372; Banet N, 2014, MODERN PATHOL, V27, P238, DOI 10.1038/modpathol.2013.143; Brioude F, 2013, HORM RES PAEDIAT, V80, P457, DOI 10.1159/000355544; Brioude F, 2018, NAT REV ENDOCRINOL, V14, P229, DOI 10.1038/nrendo.2017.166; Brioude F, 2015, HUM MUTAT, V36, P894, DOI 10.1002/humu.22824; Calvi BR, 2013, P NATL ACAD SCI USA, V110, P9621, DOI 10.1073/pnas.1306908110; Chan YF, 2003, AUST NZ J OBSTET GYN, V43, P475, DOI 10.1046/j.0004-8666.2003.00130.x; Cohen MM, 2005, PEDIATR DEVEL PATHOL, V8, P287, DOI 10.1007/s10024-005-1154-9; Cooper WN, 2005, EUR J HUM GENET, V13, P1025, DOI 10.1038/sj.ejhg.5201463; DRUT R, 1992, PEDIATR PATHOL, V12, P197, DOI 10.3109/15513819209023296; Drut RM, 1996, AM J MED GENET, V62, P145, DOI 10.1002/(SICI)1096-8628(19960315)62:2<145::AID-AJMG6>3.0.CO;2-V; ELLIOTT M, 1994, CLIN GENET, V46, P168; Engel JR, 2000, J MED GENET, V37, P921, DOI 10.1136/jmg.37.12.921; Gavanier D, 2017, J REPROD MED, V62, P366; Han DKM, 1996, J CLIN INVEST, V97, P1276, DOI 10.1172/JCI118543; Heerema-McKenney A, 2015, DIAGNOSTIC PATHOLOGY, VII, P2; Hiden U, 2009, J ANAT, V215, P60, DOI 10.1111/j.1469-7580.2008.01035.x; Hoffner L, 2008, HUM PATHOL, V39, P63, DOI 10.1016/j.humpath.2007.05.010; Ibrahim A, 2014, CLIN EPIGENETICS, V6, DOI 10.1186/1868-7083-6-11; Jauniaux E, 1997, PLACENTA, V18, P701, DOI 10.1016/S0143-4004(97)90012-6; Kavanagh E, 2011, BBA-REV CANCER, V1816, P50, DOI 10.1016/j.bbcan.2011.03.002; LAGE JM, 1991, HUM PATHOL, V22, P591, DOI 10.1016/0046-8177(91)90237-J; Lewis GH, 2013, INT J GYNECOL PATHOL, V32, P199, DOI 10.1097/PGP.0b013e3182630d8c; Linn RL, 2015, PEDIATR DEVEL PATHOL, V18, P146, DOI 10.2350/14-12-1583-CR.1; Maas SM, 2016, AM J MED GENET A, V170, P2248, DOI 10.1002/ajmg.a.37801; MCCOWAN LME, 1994, OBSTET GYNECOL, V83, P813; Monk D, 2015, AM J OBSTET GYNECOL, V213, pS152, DOI 10.1016/j.ajog.2015.06.032; MOSCOSO G, 1991, PATHOL RES PRACT, V187, P324; Mussa A, 2016, CLIN GENET, V90, P21, DOI 10.1111/cge.12759; Nessman C, 2001, ATLAS PATHOLOGIE PLA, P11; Ogino S, 2000, HUM PATHOL, V31, P945, DOI 10.1053/hupa.2000.9036; Ohyama M, 2000, PATHOL INT, V50, P759, DOI 10.1046/j.1440-1827.2000.01100.x; Paradinas FJ, 2001, HISTOPATHOLOGY, V39, P447, DOI 10.1046/j.1365-2559.2001.01256.x; Parveen Z, 2007, ARCH PATHOL LAB MED, V131, P131; Redline RW, 2015, AM J OBSTET GYNECOL, V213, pS21, DOI 10.1016/j.ajog.2015.05.056; Shuman C, 1993, GENEREVIEWS; TAKAYAMA M, 1986, GYNECOL OBSTET INVES, V22, P165, DOI 10.1159/000298909; Weksberg R, 2010, EUR J HUM GENET, V18, P8, DOI 10.1038/ejhg.2009.106	42	0	0	0	1	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1551-3815	1551-3823		FETAL PEDIATR PATHOL	Fetal Pediatr. Pathol.	NOV 2	2018	37	6					387	399		10.1080/15513815.2018.1504842			13	Pathology; Pediatrics	Pathology; Pediatrics	HP4QE	WOS:000461660100001	30633605				2019-10-28	
J	Pei, YY; Li, W; Du, L; Wei, FX				Pei, Yuanyuan; Li, Wei; Du, Li; Wei, Fengxiang			Novel Mutation of SYNGAP1 Associated with Autosomal Dominant Mental Retardation 5 in a Chinese Patient	FETAL AND PEDIATRIC PATHOLOGY			English	Article						SYNGAP1; autosomal dominant mental retardation 5 (MRD5); exome sequencing	INTELLECTUAL DISABILITY; KINASE; SPECTRUM; AUTISM	Introduction: Autosomal dominant de novo mutations in SYNGAP1 are a cause of intellectual disability (ID) and autism spectrum disorder (ASD), including autosomal dominant mental retardation 5 (MRD5). Case report: By performing exome sequencing, we discovered a novel heterozygous variant in SYNGAP1 (c.509 + 1G > A) in a 4-year-old ethnic Chinese boy with ID and ASD but without seizures or malformation. Conclusion: The c.509 + 1G > A mutation in the SYNGAP1 gene was present in a patient with MRD5.	[Pei, Yuanyuan; Li, Wei; Wei, Fengxiang] Shenzhen Longgang Maternal & Child Hlth Hosp, Genet Lab, Shenzhen 518172, Guangdong, Peoples R China; [Du, Li] Guangdong Women & Children Hosp, Med Genet Ctr, Guangzhou, Guangdong, Peoples R China	Wei, FX (reprint author), Shenzhen Longgang Maternal & Child Hlth Hosp, Genet Lab, Shenzhen 518172, Guangdong, Peoples R China.	haowei727499@163.com			Shenzhen Science and Technology Projects [JCYJ20170307144612471, JCYJ20150403094227974]; Medical Scientific Research Foundation of Guangdong Province [2016118111251132]	This work was supported by Shenzhen Science and Technology Projects, Grant Number: JCYJ20170307144612471 and JCYJ20150403094227974; Medical Scientific Research Foundation of Guangdong Province, Grant Number: 2016118111251132.	Berryer MH, 2013, HUM MUTAT, V34, P385, DOI 10.1002/humu.22248; Chen HJ, 1998, NEURON, V20, P895, DOI 10.1016/S0896-6273(00)80471-7; Clement JP, 2012, CELL, V151, P709, DOI 10.1016/j.cell.2012.08.045; Hamdan FF, 2009, NEW ENGL J MED, V360, P599, DOI 10.1056/NEJMoa0805392; Kim JH, 1998, NEURON, V20, P683, DOI 10.1016/S0896-6273(00)81008-9; Kim MJ, 2005, NEURON, V46, P745, DOI 10.1016/j.neuron.2005.04.031; Krepischi ACV, 2010, AM J MED GENET A, V152A, P2376, DOI 10.1002/ajmg.a.33554; Mignot C, 2016, J MED GENET, V53, P511, DOI 10.1136/jmedgenet-2015-103451; Pinto D, 2010, NATURE, V466, P368, DOI 10.1038/nature09146; Rumbaugh G, 2006, P NATL ACAD SCI USA, V103, P4344, DOI 10.1073/pnas.0600084103; WANG DS, 1994, BIOCHEM BIOPH RES CO, V203, P29, DOI 10.1006/bbrc.1994.2144; YAO L, 1994, P NATL ACAD SCI USA, V91, P9175, DOI 10.1073/pnas.91.19.9175	12	0	0	1	2	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1551-3815	1551-3823		FETAL PEDIATR PATHOL	Fetal Pediatr. Pathol.	NOV 2	2018	37	6					400	403		10.1080/15513815.2018.1497113			4	Pathology; Pediatrics	Pathology; Pediatrics	HP4QE	WOS:000461660100002	30572772				2019-10-28	
J	Li, X; Cheng, Q; Li, N; Chang, GY; Ding, Y; Li, J; Shen, YP; Wang, J; Wang, XM				Li, Xin; Cheng, Qing; Li, Niu; Chang, Guoying; Ding, Yu; Li, Juan; Shen, Yiping; Wang, Jian; Wang, Xiumin			SOPH Syndrome with Growth Hormone Deficiency, Normal Bone Age, and Novel Compound Heterozygous Mutations in NBAS	FETAL AND PEDIATRIC PATHOLOGY			English	Article						NBAS gene; SOPH syndrome; growth hormone deficiency	ACUTE LIVER-FAILURE; SHORT STATURE; ONSET; GENE	Background: Short stature with optic atrophy and Pelger-Huet anomaly (SOPH; MIM 614800) syndrome is a genetic disease caused by mutation in the neuroblastoma amplified sequence (NBAS) gene. Case report: We present a 11-year-old Chinese boy with SOPH syndrome, growth hormone deficiency with a normal bone age. Gene sequencing in the patient revealed a novel compound heterozygous mutation of c.5752A > C (Thr1918Pro) and c.500_501delTT (Phe167Cysfs*7) in the NBAS gene. Conclusions: To our best knowledge, these novel mutations in the NBAS gene have not been reported. Normal bone age with growth hormone deficiency in this patient is different from the patients with SOPH syndrome that have been previously reported. These findings enrich the mutant spectrum of the NBAS gene and add our understanding of SOPH syndrome.	[Li, Xin; Cheng, Qing; Chang, Guoying; Ding, Yu; Li, Juan; Wang, Xiumin] Shanghai Jiao Tong Univ, Shanghai Childrens Med Ctr, Dept Endocrinol, Sch Med, Shanghai, Peoples R China; [Li, Niu; Wang, Jian] Shanghai Jiao Tong Univ, Sch Med, Shanghai Childrens Med Ctr, Dept Med Genet, Shanghai, Peoples R China; [Shen, Yiping] Boston Childrens Hosp, Dept Lab Med, Boston, MA USA	Wang, XM (reprint author), Shanghai Jiao Tong Univ, Shanghai Childrens Med Ctr, Dept Endocrinol, Sch Med, Shanghai, Peoples R China.	wangxiumin@scmc.com.cn			Jin Lei Pediatric Endocrinology Growth Research Fund for Young Physicians [PEGRF 201708005]	This research was supported by Jin Lei Pediatric Endocrinology Growth Research Fund for Young Physicians (NO. PEGRF 201708005).	Aoki T, 2009, MOL BIOL CELL, V20, P2639, DOI 10.1091/mbc.E08-11-1104; Capo-Chichi JM, 2015, EUR J MED GENET, V58, P637, DOI 10.1016/j.ejmg.2015.11.005; Cardenas V, 2017, J PEDIATR-US, V186, P179, DOI 10.1016/j.jpeds.2017.03.040; Durand P, 2001, J PEDIATR-US, V139, P871, DOI 10.1067/mpd.2001.119989; Greulich WW, 1959, RADIOGRAPHIC ATLAS S; Haack TB, 2015, AM J HUM GENET, V97, P163, DOI 10.1016/j.ajhg.2015.05.009; He T Y, 2017, Zhonghua Er Ke Za Zhi, V55, P942, DOI 10.3760/cma.j.issn.0578-1310.2017.12.015; Kortum F, 2017, PEDIATRICS, V139, DOI 10.1542/peds.2016-0550; Longman D, 2013, NUCLEIC ACIDS RES, V41, P8319, DOI 10.1093/nar/gkt585; Maksimova N, 2010, J MED GENET, V47, P538, DOI 10.1136/jmg.2009.074815; Narkewicz MR, 2009, J PEDIATR-US, V155, P801, DOI 10.1016/j.jpeds.2009.06.005; Nicholas LM, 1997, PSYCHOSOM MED, V59, P372, DOI 10.1097/00006842-199707000-00006; Sandberg DE, 2005, HORM RES, V63, P275, DOI 10.1159/000086593; Segarra NG, 2015, AM J MED GENET A, V167, P2902, DOI 10.1002/ajmg.a.37338; Staufner C, 2016, J INHERIT METAB DIS, V39, P3, DOI 10.1007/s10545-015-9896-7; Visser-van Balen Hanneke, 2005, BMC Pediatr, V5, P15, DOI 10.1186/1471-2431-5-15	16	1	1	0	0	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1551-3815	1551-3823		FETAL PEDIATR PATHOL	Fetal Pediatr. Pathol.	NOV 2	2018	37	6					404	410		10.1080/15513815.2018.1509406			7	Pathology; Pediatrics	Pathology; Pediatrics	HP4QE	WOS:000461660100003	30592236				2019-10-28	
J	Beaufrere, A; Bonniere, M; Tantau, J; Roth, P; Schaefer, E; Brioude, F; Netchine, I; Bessieres, B; Gelot, A; Vekemans, M; Razavi, F; Heron, D; Attie-Bitach, T				Beaufrere, Aurelie; Bonniere, Maryse; Tantau, Julia; Roth, Philippe; Schaefer, Elodie; Brioude, Frederic; Netchine, Irene; Bessieres, Bettina; Gelot, Antoinette; Vekemans, Michel; Razavi, Ferechte; Heron, Delphine; Attie-Bitach, Tania			Corpus Callosum Abnormalities and Short Femurs in Beckwith-Wiedemann Syndrome: A Report of Two Fetal Cases	FETAL AND PEDIATRIC PATHOLOGY			English	Article						Beckwith-Wiedemann syndrome; omphalocele; corpus callosum abnormalities; short femurs	MALFORMATION; ASSOCIATION	Introduction: Beckwith-Wiedemann syndrome (BWS) is the most common overgrowth syndrome. Clinical features are highly variable, including occasional posterior fossa malformations but no femoral shortening. Case report: We report two fetuses with BWS associated with short femurs and corpus callosum hypoplasia. Case 2 was growth restricted. BWS was confirmed by molecular studies showing a loss of methylation at ICR2 at 11p15 chromosomic region in case 1 and a gain of methylation at ICR1 and a loss of methylation at ICR2 locus in case 2. Conclusion: Although the phenotype and the genotype of BWS is now well-known, the presence of corpus callosum abnormalities and short femurs expand the phenotypic spectrum of the disorder.	[Beaufrere, Aurelie; Bonniere, Maryse; Bessieres, Bettina; Vekemans, Michel; Razavi, Ferechte; Attie-Bitach, Tania] Hop Necker Enfants Malad, AP HP, Serv Histol Embryol Cytogenet, Unite Embryofoetopathol, Paris, France; [Tantau, Julia; Schaefer, Elodie; Heron, Delphine] Hop Trousseau, AP HP, Dept Genet Med, Paris, France; [Roth, Philippe] Hop Necker Enfants Malad, AP HP, Serv Gynecol Obstet, Paris, France; [Brioude, Frederic; Netchine, Irene] Hop Trousseau, AP HP, Serv Explorat Fonctionnelles Endocriniennes, Paris, France; [Gelot, Antoinette] Hop Trousseau, AP HP, Serv Anat & Cytol Pathol, Paris, France; [Attie-Bitach, Tania] Univ Paris 05, Inst Imagine, INSERM U1163, Paris, France	Beaufrere, A (reprint author), Hop Univ Necker Enfants Malad, Unite Embryofoetopathol, Serv Histol Embryol Cyfogenet, Paris, France.	aurelie.beaufrere@sfr.fr					Aoki A, 2011, J OBSTET GYNAECOL RE, V37, P1872, DOI 10.1111/j.1447-0756.2011.01654.x; Armes JE, 2012, PATHOLOGY, V44, P519, DOI 10.1097/PAT.0b013e3283559c94; Bui C, 2009, PRENATAL DIAG, V29, P906, DOI 10.1002/pd.2312; Choufani S, 2010, AM J MED GENET C, V154C, P343, DOI 10.1002/ajmg.c.30267; Gardiner K, 2012, AM J MED GENET A, V158A, P1388, DOI 10.1002/ajmg.a.35358; Kaiser-Rogers KA, 2006, J MED GENET, V43, P187, DOI 10.1136/jmg.2005.033571; Kent L, 2008, AM J MED GENET B, V147B, P1295, DOI 10.1002/ajmg.b.30729; Murphy R, 2012, BMC MED GENET, V13, DOI 10.1186/1471-2350-13-99; Mussa A, 2016, CLIN GENET, V89, P403, DOI 10.1111/cge.12635; Mussa A, 2016, EUR J MED GENET, V59, P52, DOI 10.1016/j.ejmg.2015.11.008; Pawoo N, 2014, ARCH PATHOL LAB MED, V138, P1247, DOI 10.5858/arpa.2013-0399-RS; Pelluard F, 2010, ANN PATHOL, V30, P301, DOI 10.1016/j.annpat.2010.05.007; Shuman C, 1993, GENEREVIEWS; Soejima H, 2013, J HUM GENET, V58, P402, DOI 10.1038/jhg.2013.51; Tenorio J, 2016, AM J MED GENET A, V170, P2740, DOI 10.1002/ajmg.a.37852; Tubbs RS, 2005, J NEUROSURG, V103, P172, DOI 10.3171/ped.2005.103.2.0172; Worth LL, 1999, MED PEDIATR ONCOL, V33, P591, DOI 10.1002/(SICI)1096-911X(199912)33:6<591::AID-MPO15>3.0.CO;2-T; Yamada K, 1999, PEDIATR NEUROSURG, V31, P163, DOI 10.1159/000028854	18	0	0	0	0	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1551-3815	1551-3823		FETAL PEDIATR PATHOL	Fetal Pediatr. Pathol.	NOV 2	2018	37	6					411	417		10.1080/15513815.2018.1520942			7	Pathology; Pediatrics	Pathology; Pediatrics	HP4QE	WOS:000461660100004	30595068				2019-10-28	
J	Fadiloglu, E; Ozten, G; Unal, C; Talim, B; Topaloglu, H; Beksac, MS				Fadiloglu, Erdem; Ozten, Gonca; Unal, Canan; Talim, Beril; Topaloglu, Haluk; Beksac, Mehmet Sinan			Prenatal Diagnosis of Merosin-Deficient Muscular Dystrophy	FETAL AND PEDIATRIC PATHOLOGY			English	Article						Merosin deficient muscular dystrophy; prenatal diagnosis; chorion villus sampling; immunohistochemistry	LAMININ ALPHA-2 CHAIN; LAMA2 MUTATIONS; IDENTIFICATION; EXPRESSION; PHENOTYPE	Goal: We evaluated the potential for prenatal diagnosis of merosin-negative muscular dystrophies by immunohistochemistry. Materials and Methods: This is a retrospective study of 12 pregnancies with merosin-negative muscular dystrophy in a prior child. Chorionic villus sampling (CVS) was performed between 11th to 13th gestational weeks. Merosin immunohistochemical studies were performed on trophoblastic cells. Results: Two of 12 were "merosin-negative," both were from the same family. Fetal ultrasonographies were evaluated as normal in these pregnancies. Eight of the 10 merosin-positive cases delivered healthy babies. Two were lost to follow-up. Conclusion: Prenatal diagnosis of merosin-negative muscular dystrophies can be accomplished by immunohistochemical analysis.	[Fadiloglu, Erdem; Ozten, Gonca; Unal, Canan; Beksac, Mehmet Sinan] Dept Obstet & Gynecol, Div Perinatol, Ankara, Turkey; [Talim, Beril] Dept Pediat, Div Pediat Pathol, Ankara, Turkey; [Topaloglu, Haluk] Hacettepe Univ, Dept Pediat, Div Pediat Neurol, Med Fac, Ankara, Turkey	Fadiloglu, E (reprint author), Hacettepe Univ, Dept Obstet & Gynecol, Div Perinatal Med, Tip Fak, TR-06100 Ankara, Turkey.	erdemfadiloglu@hacettepe.edu.tr					Allamand V, 2002, EUR J HUM GENET, V10, P91, DOI 10.1038/sj/ejhg/5200743; Chan SHS, 2014, NEUROMUSCULAR DISORD, V24, P677, DOI 10.1016/j.nmd.2014.05.008; Geranmayeh F, 2010, NEUROMUSCULAR DISORD, V20, P241, DOI 10.1016/j.nmd.2010.02.001; Guicheney P, 1997, NEUROMUSCULAR DISORD, V7, P180, DOI 10.1016/S0960-8966(97)00460-4; He Y, 2001, NEUROLOGY, V57, P1319, DOI 10.1212/WNL.57.7.1319; Kim Hyo Jeong, 2014, Korean J Pediatr, V57, P149, DOI 10.3345/kjp.2014.57.3.149; Leite CC, 2005, PEDIATR RADIOL, V35, P572, DOI 10.1007/s00247-004-1398-y; Mostacciuolo ML, 1996, HUM GENET, V97, P277, DOI 10.1007/BF02185752; Naom I, 1997, NEUROMUSCULAR DISORD, V7, P176, DOI 10.1016/S0960-8966(97)00448-3; Naom I, 1997, HUM GENET, V99, P535, DOI 10.1007/s004390050402; Nass D, 1999, EARLY HUM DEV, V55, P19, DOI 10.1016/S0378-3782(98)00108-X; Nissinen M, 1996, AM J HUM GENET, V58, P1177; Oliveira J, 2018, HUM MUTAT, V39, P1314, DOI 10.1002/humu.23599; Sewry CA, 1997, NEUROMUSCULAR DISORD, V7, P169, DOI 10.1016/S0960-8966(97)00425-2; Sewry CA, 1997, NEUROPEDIATRICS, V28, P217, DOI 10.1055/s-2007-973703; Turner C, 2015, J CLIN NEUROSCI, V22, P1983, DOI 10.1016/j.jocn.2015.04.016; Vainzof M, 2005, NEUROMUSCULAR DISORD, V15, P588, DOI 10.1016/j.nmd.2005.04.009; VOIT T, 1994, NEUROPEDIATRICS, V25, P332, DOI 10.1055/s-2008-1073050; Xiong H, 2015, CLIN GENET, V87, P233, DOI 10.1111/cge.12366; Zhang X, 1996, J BIOL CHEM, V271, P27664, DOI 10.1074/jbc.271.44.27664; Zhou J, 2018, FRONT GENET, V9, DOI 10.3389/fgene.2018.00043	21	0	0	0	0	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1551-3815	1551-3823		FETAL PEDIATR PATHOL	Fetal Pediatr. Pathol.	NOV 2	2018	37	6					418	423		10.1080/15513815.2018.1520944			6	Pathology; Pediatrics	Pathology; Pediatrics	HP4QE	WOS:000461660100005	30358464				2019-10-28	
J	Aldana, CAF; Poppiti, RJ				Aldana, Christopher Antonio Febres; Poppiti, Robert J.			Cholangitis Lenta Causing Bile Cast Nephropathy: A Unique Model of Hepatorenal Failure in Sepsis	FETAL AND PEDIATRIC PATHOLOGY			English	Article						Bile cast nephropathy; cholangitis lenta; cholestasis; hepatorenal syndrome; sepsis	ACUTE KIDNEY INJURY; CHOLEMIC NEPHROPATHY	Introduction: Inadequate perfusion and abnormal cellular metabolism are among the mechanisms of organ dysfunction in sepsis. Concomitant hepatorenal failure during the late phase of sepsis is poorly understood. Case report: The autopsy of a child who developed sepsis-induced hepatorenal failure revealed bile cast nephropathy, hepatic centrilobular necrosis and cholangitis lenta, a type of sepsis-induced cholestasis, with no biliary obstruction, fibrosis or cirrhosis. The liver and renal function declined at the same rate as procalcitonin increased. Discussion: Failure of resolution and persistent inflammation in sepsis can result in ductular injury and stagnation of bile with subsequent cholemia. The kidney failure was associated with the formation of intratubular bile casts. Conclusion: This case illustrates how severe cholestasis in combination with bile cast nephropathy may be potential and unrecognized contributors to hepatorenal failure in sepsis. Whether bile toxicity causes renal failure in the context of cholangitis lenta should be further studied.	[Aldana, Christopher Antonio Febres; Poppiti, Robert J.] Mt Sinai Med Ctr, Arkadi M Rywlin MD, Dept Pathol & Lab Med, 4300 Alton Rd, Miami Beach, FL 33140 USA; [Poppiti, Robert J.] Florida Int Univ, Herbert Wertheim Coll Med, Miami, FL 33199 USA	Aldana, CAF (reprint author), Mt Sinai Med Ctr, Arkadi M Rywlin MD, Dept Pathol & Lab Med, 4300 Alton Rd, Miami Beach, FL 33140 USA.	chrisfeb.2009@gmail.com		/0000-0002-4754-1344			Aniort J, 2017, AM J KIDNEY DIS, V69, P143, DOI 10.1053/j.ajkd.2016.08.023; Barakauskiene A, 2011, MED LITH, V47, P31; Better OS, 1999, AM J NEPHROL, V19, P343, DOI 10.1159/000013473; Boon AC, 2015, SCI REP-UK, V5, DOI 10.1038/srep15482; Hotchkiss RS, 2016, NAT REV DIS PRIMERS, V2, DOI 10.1038/nrdp.2016.45; Koskinas J, 2008, WORLD J GASTROENTERO, V14, P1389, DOI 10.3748/wjg.14.1389; Krones E, 2018, BBA-MOL BASIS DIS, V1864, P1356, DOI 10.1016/j.bbadis.2017.08.028; Krones E, 2017, J HEPATOL, V67, P110, DOI 10.1016/j.jhep.2017.02.019; Lin CC, 2007, J PEDIATR GASTR NUTR, V45, P228, DOI 10.1097/MPG.0b013e318074c5d0; Naini BV, 2012, HUM PATHOL, V43, P826, DOI 10.1016/j.humpath.2011.07.008; Nayak SL, 2017, J CLIN TRANSL HEPATO, V5, P92, DOI 10.14218/JCTH.2016.00063; Otto GP, 2011, CRIT CARE, V15, DOI 10.1186/cc10332; Rafat C, 2013, AM J KIDNEY DIS, V61, P782, DOI 10.1053/j.ajkd.2012.11.046; Rameshkumar R, 2017, CLIN EXP NEPHROL, V21, P1075, DOI 10.1007/s10157-016-1343-z; Rao RK, 2013, TISSUE BARRIERS, V1, DOI 10.4161/tisb.25718; Sato K, 2018, BBA-MOL BASIS DIS, V1864, P1262, DOI 10.1016/j.bbadis.2017.06.017; Torous VF, 2017, AM J SURG PATHOL, V41, P1607, DOI 10.1097/PAS.0000000000000959; Uslu A, 2010, EUR J GASTROEN HEPAT, V22, P1458, DOI 10.1097/MEG.0b013e32833f71f6; van Slambrouck CM, 2013, KIDNEY INT, V84, P192, DOI 10.1038/ki.2013.78	19	0	0	0	0	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1551-3815	1551-3823		FETAL PEDIATR PATHOL	Fetal Pediatr. Pathol.	NOV 2	2018	37	6					424	432		10.1080/15513815.2018.1520945			9	Pathology; Pediatrics	Pathology; Pediatrics	HP4QE	WOS:000461660100006	30351239				2019-10-28	
J	Tonni, G; Grisolia, G; Zampriolo, P; Prefumo, F; Fichera, A; Bonasoni, P; Lefebvre, M; Khung-Savatovsky, S; Guimiot, F; Rosenblatt, J; Araujo, E				Tonni, Gabriele; Grisolia, Gianpaolo; Zampriolo, Paolo; Prefumo, Federico; Fichera, Anna; Bonasoni, Paola; Lefebvre, Mathilde; Khung-Savatovsky, Suonavy; Guimiot, Fabien; Rosenblatt, Jonathan; Araujo Junior, Edward			TRAP Sequence in Monochorionic/Monoamniotic (MC/MA) Discordant Twins: Two Cases Treated with Fetoscopic Laser Surgery	FETAL AND PEDIATRIC PATHOLOGY			English	Article						TRAP sequence; monochorioni; monoamiotic twins; fetoscopic laser photocoagulation; fetal pathology; Cristal and Realistic Vue	REVERSED ARTERIAL PERFUSION; UMBILICAL-CORD OCCLUSION; INTERSTITIAL LASER; ACARDIAC TWIN; RADIOFREQUENCY; TRANSECTION; COAGULATION; ABLATION; INTERVENTION; ENTANGLEMENT	Introduction: Ablation of the acardiac twin umbilical cord in the TRAP protects the normal donor twin. Materials and methods: Two case descriptions, one of interstitial laser photocoagulation and one of laser umbilical cord occlusion (L-UCO) of the acardiac twin in monochorionic monoamniotic pregnancies are reported. Results: L-UCO in two pregnancies with TRAP syndrome in the second trimester resulted in intrauterine fetal death in both cases after 1 month. Case 1 had no detectable cause of fetal death. Case 2 had rupture of the amniotic sac causing anhydramnios and acute chorioamnionitis. A groove on the umbilical cord of the normal twin indicated a cord stricture due to cord entanglement. Conclusion: Our experience confirms that the best timing and optimal treatment of MC/MA twins complicated by TRAP sequence still remains a controversial clinical issue. Cord entanglement may continue be a potential clinical risk factor for adverse perinatal outcome even after ablation therapy.	[Tonni, Gabriele] Prenatal Diagnost Serv, Dept Obstet & Gynecol, Reggio Emilia, Italy; [Grisolia, Gianpaolo; Zampriolo, Paolo] Carlo Poma Hosp, Dept Obstet & Gynecol, Azienda Socio Sanitaria Terr Mantova, Mantua, Italy; [Prefumo, Federico] Dept Obstet & Gynecol, Brescia, Italy; [Fichera, Anna] Univ Brescia, Sez Materno Infantile Obstet & Gynecol, Brescia, Italy; [Bonasoni, Paola] Arcispedale S Maria Nuova, Reggio Emilia, Italy; [Lefebvre, Mathilde; Khung-Savatovsky, Suonavy; Guimiot, Fabien] Hop Univ Robert Debre, Unite Foetopathol, Paris, France; [Rosenblatt, Jonathan] Hop Univ Robert Debre, Obstet & Gynecol, Paris, France; [Araujo Junior, Edward] Univ Fed Sao Paulo, Paulista Sch Med, Obstet, Sao Paulo, Brazil	Tonni, G (reprint author), IRCCS AUSL Reggio Emilia, Obstet & Gynecol, Reggio Emilia, Italy.	Tonni.Gabriele@ausl.re.it	Prefumo, Federico/F-3837-2015	Prefumo, Federico/0000-0001-7793-714X			Benirschke K, 2009, PLACENTA, V30, P923, DOI 10.1016/j.placenta.2009.08.009; Benirscke K, 2006, PATHOLOGY HUMAN PLAC, P947; Berg C, 2014, ULTRASOUND OBST GYN, V44, P241, DOI 10.1002/uog.13349; Berg C, 2014, ULTRASOUND OBST GYN, V43, P60, DOI 10.1002/uog.12578; Bermudez C, 2003, J Matern Fetal Neonatal Med, V14, P277; Cabassa P, 2013, EUR J OBSTET GYN R B, V166, P127, DOI 10.1016/j.ejogrb.2012.10.009; Dias T, 2010, ULTRASOUND OBST GYN, V35, P201, DOI 10.1002/uog.7501; Gilbert-Barness E, 2007, POTTERS PATHOLOGY FE, V2; Guven MA, 2016, CLIN EXP OBSTET GYN, V43, P460, DOI 10.12891/ceog2139.2016; Hecher K, 2006, ULTRASOUND OBST GYN, V28, P688, DOI 10.1002/uog.3816; Jolly M, 2001, BRIT J OBSTET GYNAEC, V108, P1098, DOI 10.1016/S0306-5456(01)00250-9; Kashireddy P, 2015, LABMEDICINE, V46, P248, DOI 10.1309/LM4B4DU7UIMKLNAI; King JR, 2017, FETAL DIAGN THER, V42, P9, DOI 10.1159/000448948; Lewi L, 2010, AM J OBSTET GYNECOL, V203, DOI 10.1016/j.ajog.2010.04.018; Lopoo JB, 2000, FETAL DIAGN THER, V15, P177, DOI 10.1159/000021001; Middeldorp JM, 2008, FETAL DIAGN THER, V23, P121, DOI 10.1159/000111591; MOORE TR, 1990, AM J OBSTET GYNECOL, V163, P907, DOI 10.1016/0002-9378(90)91094-S; O'Donoghue K, 2008, PRENATAL DIAG, V28, P535, DOI 10.1002/pd.2025; Pagani G, 2013, ULTRASOUND OBST GYN, V42, P6, DOI 10.1002/uog.12495; Pepe Franco, 2015, J Prenat Med, V9, P29, DOI 10.11138/jpm/2015.9.3.029; Porreco RP, 2004, AM J OBSTET GYNECOL, V190, P572, DOI 10.1016/j.ajog.2003.07.001; Prefumo F, 2014, ULTRASOUND OBST GYN, V43, DOI 10.1002/uog.13229; Quintero R, 2002, DISCORDANT ANOMALOUS; Roethlisberger M, 2017, ULTRASOUND OBST GYN, V50, P40, DOI 10.1002/uog.16013; Rossi AC, 2013, ULTRASOUND OBST GYN, V41, P131, DOI 10.1002/uog.12345; Scheier M, 2012, FETAL DIAGN THER, V31, P35, DOI 10.1159/000334156; SEPULVEDA W, 1995, OBSTET GYNECOL, V86, P680, DOI 10.1016/0029-7844(95)00171-M; Soothill P, 2002, BJOG-INT J OBSTET GY, V109, P352, DOI 10.1016/S1470-0328(02)01043-1; Takano M, 2015, J OBSTET GYNAECOL RE, V41, P1326, DOI 10.1111/jog.12720; Tsao K, 2002, AM J OBSTET GYNECOL, V187, P635, DOI 10.1067/mob.2002.125242; Valsky DV, 2011, ULTRASOUND OBST GYN, V37, P684, DOI 10.1002/uog.8924; Wegrzyn P, 2012, GINEKOL POL, V83, P865; Weisz B, 2004, ULTRASOUND OBST GYN, V23, P451, DOI 10.1002/uog.1040; Yee KT, 2015, KEELINGS FETAL NEONA, P335	34	0	0	0	0	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1551-3815	1551-3823		FETAL PEDIATR PATHOL	Fetal Pediatr. Pathol.	NOV 2	2018	37	6					433	447		10.1080/15513815.2018.1526240			15	Pathology; Pediatrics	Pathology; Pediatrics	HP4QE	WOS:000461660100007	30636554				2019-10-28	
J	Chheda, P; Dama, T; Goradia, D; Pande, S; Vinarkar, S				Chheda, Pratiksha; Dama, Tavisha; Goradia, Dollar; Pande, Shailesh; Vinarkar, Sushant			A novel CFTR gene variant - p.Tyr517*associated with cystic fibrosis: a case report	FETAL AND PEDIATRIC PATHOLOGY			English	Article						Cystic fibrosis; CFTR; compound heterozygous		Introduction: Cystic fibrosis (CF) is a genetic disease usually diagnosed by clinical findings and abnormal sweat chloride testing. Case Report: We report a case of an 18-month-old Indian female with clinical findings suggestive of CF referred for genetic confirmation. The CFTR gene was sequenced for 23 mutations as per American College of Medical Genetics (ACMG) guidelines for CF and showed presence of a known common heterozygous delF508 (c.1521_1523delCTT, p.Phe508 del) variant. In addition to delF508 variant, exon 10 of CFTR gene also showed a novel variant c.1551C > G, p.Tyr517*, which was classified as "likely pathogenic" based on recent ACMG variant classification guidelines. The presence of compound heterozygous pathogenic variants along with classical clinical findings, confirmed the diagnosis of CF in this patient. Conclusion: The novel pathogenic variants (missense/nonsense/deletion/duplication) in CFTR gene are often identified and are associated with CF, thus highlighting the need of comprehensive complete CFTR gene analysis.	[Chheda, Pratiksha; Dama, Tavisha; Goradia, Dollar; Vinarkar, Sushant] Metropolis Healthcare Ltd, Dept Mol Pathol, Mumbai, Maharashtra, India; [Pande, Shailesh] Metropolis Healthcare Ltd, Dept Genet, Mumbai, Maharashtra, India	Chheda, P (reprint author), Metropolis Healthcare Ltd, Dept Mol Pathol, Mumbai, Maharashtra, India.	pratiksha.chheda@metropolisindia.com					Ashavaid Tester F, 2012, J Assoc Physicians India, V60, P39; Chami H, 2017, ANN THORAC MED, V12, P290, DOI 10.4103/atm.ATM_76_17; Elliott Aaron M, 2012, J Biomol Tech, V23, P24, DOI 10.7171/jbt.12-2301-003; Groman JD, 2002, NEW ENGL J MED, V347, P401, DOI 10.1056/NEJMoa011899; Kabra SK, 2007, PEDIATR PULM, V42, P1087, DOI 10.1002/ppul.20677; Lucarelli M, 2006, ANAL BIOCHEM, V353, P226, DOI 10.1016/j.ab.2006.03.022; Richards S, 2015, GENET MED, V17, P405, DOI 10.1038/gim.2015.30	7	0	0	0	0	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1551-3815	1551-3823		FETAL PEDIATR PATHOL	Fetal Pediatr. Pathol.	NOV 2	2018	37	6					448	451		10.1080/15513815.2018.1532473			4	Pathology; Pediatrics	Pathology; Pediatrics	HP4QE	WOS:000461660100008	30588852				2019-10-28	
J	Wang, H; Luo, CQ; Liu, Y; Li, SL; Jiang, NP; Zhang, GL; Xie, JS; Zhong, M				Wang, Hui; Luo, Caiqun; Liu, Yang; Li, Shengli; Jiang, Niping; Zhang, Guanglin; Xie, Jiansheng; Zhong, Mei			UPD16 itself is not a cause of intrauterine growth restriction	FETAL AND PEDIATRIC PATHOLOGY			English	Article						uniparental disomy; membranous placenta; intrauterine growth restriction; clinical whole-exome sequencing; chromosome microarray analysis	MATERNAL UNIPARENTAL DISOMY; TELOMERIC END; CHROMOSOME-16; ISODISOMY; FETAL; TRISOMY-16; DISEASE	Background: The clinical relevance of uniparental disomy (UPD16) for chromosome 16 is currently unclear. Methods and result: We performed chromosome microarray analysis on two fetus and their placentas, fluorescence in situ hybridization (FISH) to exclude the hidden chr16 trisomy mosaicism in the fetuses, and clinical whole-exome sequencing to assess for homozygosity mutations of autosomal-recessive diseases. Results: Microarray analysis of two fetuses had UPD16. The membranous placenta of the case 1 had confined placental mosaicism (CPM) for trisomy 16. Clinical whole-exome sequencing on chromosome 16 revealed three potentially pathogenic single nucleotide polymorphisms (SNPs). Gap-polymerase chain reaction (PCR) and MLPA for a-thal deletions demonstrated that case 2 was homozygous for the -SEA deletion. Conclusions: The poor outcome in these fetuses may be attributed to other factors, the membranous placenta and the -SEA deletion, respectively. Fetal UPD16 itself might be not correlated with intrauterine growth restriction (IUGR) and thus is not the basic cause of IUGR.	[Wang, Hui; Zhong, Mei] Southern Med Univ, Nanfang Hosp, Dept Obstet & Gynecol, 1838 North Guangzhou Rd, Guangzhou 510000, Guangdong, Peoples R China; [Wang, Hui; Luo, Caiqun; Liu, Yang; Jiang, Niping; Xie, Jiansheng] Shenzhen Matern & Child Healthcare Hosp, Prenatal Diag Ctr, 3012 Fuqiang Rd, Henzhen, Guangdong, Peoples R China; [Li, Shengli] Shenzhen Matern & Child Healthcare Hosp, Ultrasound Dept, Shenzhen, Guangdong, Peoples R China; [Zhang, Guanglin] Int Biolsland, AmCare Genom Lab, Guangzhou, Guangdong, Peoples R China	Zhong, M (reprint author), Southern Med Univ, Nanfang Hosp, Dept Obstet & Gynecol, 1838 North Guangzhou Rd, Guangzhou 510000, Guangdong, Peoples R China.; Xie, JS (reprint author), Shenzhen Matern & Child Healthcare Hosp, Prenatal Diag Ctr, 3012 Fuqiang Rd, Henzhen, Guangdong, Peoples R China.	jsxieszmch@aliyun.com; zhongmei@smu.edu.cn			Provincial Science and Technology Plan Project of Guangdong Province (the Sino-U.S. Joint Development Defects Transformation Medical Center Construction) [2015B050501006]; Shunde District Science and Technology Plan Project (South Wisdom Valley Innovative Research Team Program) [2015CXTD06]; Shenzhen Science and Technology Innovation Committee (Relationship between Placental Tissue Copy Variation and Intrauterine Growth Restriction) [JCYJ20170413092818116]	This study was supported by Provincial Science and Technology Plan Project of Guangdong Province (the Sino-U.S. Joint Development Defects Transformation Medical Center Construction; 2015B050501006 to ZhongMei); by Shunde District Science and Technology Plan Project (South Wisdom Valley Innovative Research Team Program, 2015CXTD06 to ZhongNa); by Shenzhen Science and Technology Innovation Committee (Relationship between Placental Tissue Copy Variation and Intrauterine Growth Restriction; JCYJ20170413092818116 to Xie Jiansheng).	Astner A, 1998, PRENATAL DIAG, V18, P1308, DOI 10.1002/(SICI)1097-0223(199812)18:12<1308::AID-PD443>3.0.CO;2-H; Au PKC, 2016, HEMOGLOBIN, V40, P66, DOI 10.3109/03630269.2015.1096283; Catarzi S, 2012, MOL GENET METAB, V105, P438, DOI 10.1016/j.ymgme.2011.11.196; Donovan FX, 2016, HUM MUTAT, V37, P465, DOI 10.1002/humu.22962; ENGEL E, 1980, AM J MED GENET, V6, P137, DOI 10.1002/ajmg.1320060207; Kalousek DK, 1996, J MED GENET, V33, P529, DOI 10.1136/jmg.33.7.529; Kotzot D, 2000, CLIN GENET, V58, P177, DOI 10.1034/j.1399-0004.2000.580304.x; Malvagia S, 2007, ANN HUM GENET, V71, P705, DOI 10.1111/j.1469-1809.2007.00373.x; NGO KY, 1993, AM J HUM GENET, V53, P1207; Schneider AS, 1996, AM J MED GENET, V66, P204, DOI 10.1002/(SICI)1096-8628(19961211)66:2<204::AID-AJMG16>3.0.CO;2-X; Soehn AS, 2016, NEUROLOGY, V87, P186, DOI 10.1212/WNL.0000000000002843; Van Opstal D, 1998, PRENATAL DIAG, V18, P35; VAUGHAN J, 1994, PRENATAL DIAG, V14, P751, DOI 10.1002/pd.1970140817; Wattanasirichaigoon D, 2008, CLIN GENET, V74, P284, DOI 10.1111/j.1399-0004.2008.01046.x; WILLIAMS J, 1992, PRENATAL DIAG, V12, P163, DOI 10.1002/pd.1970120304; Wolstenholme J, 1996, PRENATAL DIAG, V16, P511, DOI 10.1002/(SICI)1097-0223(199606)16:6<511::AID-PD904>3.0.CO;2-8; Xie YJ, 2017, EUR J OBSTET GYN R B, V211, P1, DOI 10.1016/j.ejogrb.2016.12.019; Yamazawa K, 2010, AM J MED GENET C, V154C, P329, DOI 10.1002/ajmg.c.30270; Yong PJ, 2009, J OBSTET GYNAECOL CA, V31, P605, DOI 10.1016/S1701-2163(16)34239-6	19	0	0	0	3	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1551-3815	1551-3823		FETAL PEDIATR PATHOL	Fetal Pediatr. Pathol.	NOV 2	2018	37	6					452	464		10.1080/15513815.2018.1538275			13	Pathology; Pediatrics	Pathology; Pediatrics	HP4QE	WOS:000461660100009	30468402				2019-10-28	
J	Sutherland, M; Craver, R				Sutherland, Monique; Craver, Randall			Multifocal Rounded Intraplacental Hematomas, Placental Abruption and Intrauterine Fetal Demise	FETAL AND PEDIATRIC PATHOLOGY			English	Article						Rounded intraparenchymal hematoma; fetal demise; abruption		Background: Rounded intraplacental hematomas (RIH) have a distinct rounded hemorrhagic appearance located within the placental parenchyma. Hemorrhagic villous infarctions (infarcts that when sectioned have hemorrhagic centers) are probably older RIH. RIH have been associated with acute abruptions. Case report: We describe multiple RIHs and hemorrhagic villous infarctions in various stages of development that arose between 20 and 27 weeks gestation, demonstrated by ultrasound, that developed an acute abruption and fetal death. Conclusions: The findings of RIHs, hemorrhagic infarcts, and lesions in between support the evolution of hemorrhagic villous infarctions from RIHs. These lesions can arise in the second trimester, and can be detected by ultrasound. These multiple lesions in various stages of evolution suggest an ongoing rather than a discrete insult.	[Sutherland, Monique] Louisiana State Univ, Dept Obstet & Gynecol, Hlth Sci Ctr, New Orleans, LA USA; [Craver, Randall] Childrens Hosp New Orleans, 200 Henry Clay Ave, New Orleans, LA 70118 USA; [Craver, Randall] LSUHSC, Dept Pathol, New Orleans, LA USA	Craver, R (reprint author), Childrens Hosp New Orleans, 200 Henry Clay Ave, New Orleans, LA 70118 USA.	randall.craver@lcmchealth.org					Claireaux A E, 1977, J Clin Pathol Suppl (R Coll Pathol), V11, P142; Fitzgerald B, 2011, J CLIN PATHOL, V64, P729, DOI 10.1136/jcp.2010.087916; Kraus FT, 2004, PLACENTAL PATHOLOGY, P127; Neville G, 2017, SOC PED PATH MARCH 4	4	0	0	0	0	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1551-3815	1551-3823		FETAL PEDIATR PATHOL	Fetal Pediatr. Pathol.	NOV 2	2018	37	6					465	469		10.1080/15513815.2018.1520373			5	Pathology; Pediatrics	Pathology; Pediatrics	HP4QE	WOS:000461660100010	30592229				2019-10-28	
J	Panoutsopoulou, K; Avgeris, M; Scorilas, A				Panoutsopoulou, Konstantina; Avgeris, Margaritis; Scorilas, Andreas			miRNA and long non-coding RNA: molecular function and clinical value in breast and ovarian cancers	EXPERT REVIEW OF MOLECULAR DIAGNOSTICS			English	Review						microRNA; lncRNA; non coding RNA; ovarian cancer; breast cancer	NF-KAPPA-B; EPITHELIAL-MESENCHYMAL TRANSITION; REGULATES CELL-PROLIFERATION; ENDOTHELIAL GROWTH-FACTOR; SIGNALING PATHWAY; DOWN-REGULATION; E-CADHERIN; POSTTRANSCRIPTIONAL REGULATION; DECREASED EXPRESSION; DRUG-RESISTANCE	Introduction: The elucidation of tumor molecular hallmarks and the identification of novel molecular markers are of first translational priority in breast and ovarian cancer research, aiming to support personalized disease treatment and monitoring decisions. Recent high-throughput studies have revealed that 80% of the genome is transcribed into RNAs without protein-coding potential, namely non-coding RNAs (ncRNAs), challenging the concept of 'junk DNA'. Undoubtedly, microRNAs (miRNAs) and long non-coding RNAs (lncRNAs) represent the best-studied family classes, emerging as the most powerful gene-expression regulators at epigenetic, transcriptional and post-transcriptional levels. Areas covered: Cancer research has highlighted the active implication of ncRNAs, most notably of miRNAs and lncRNAs, in almost every aspect of the cancer cells' biology as well as their deregulated expression in both breast and ovarian tumors. In the present manuscript we discuss the existing knowledge regarding the involvement of miRNAs and lncRNAs in the molecular background of breast and ovarian malignancies, to highlight their clinical utility in improving disease management. Expert commentary: miRNAs and lncRNAs represent central mediators of cancer cells' phenotype, and promising molecular markers and therapeutic targets to support precision medicine in breast and ovarian cancers.	[Panoutsopoulou, Konstantina; Avgeris, Margaritis; Scorilas, Andreas] Univ Athens, Dept Biochem & Mol Biol, Fac Biol, Athens 15701, Greece	Scorilas, A (reprint author), Univ Athens, Dept Biochem & Mol Biol, Fac Biol, Athens 15701, Greece.	ascorilas@biol.uoa.gr		Scorilas, Andreas/0000-0003-2427-4949; Panoutsopoulou, Konstantina/0000-0003-2773-4883	Stavros Niarchos Foundation grant [70/3/14318]	The research presented was carried out within the framework of a Stavros Niarchos Foundation grant to the National and Kapodistrian University of Athens [grant number 70/3/14318].	Adams BD, 2017, J CLIN INVEST, V127, P761, DOI 10.1172/JCI84424; Aggarwal BB, 2009, CLIN CANCER RES, V15, P425, DOI 10.1158/1078-0432.CCR-08-0149; Ameres SL, 2013, NAT REV MOL CELL BIO, V14, P475, DOI 10.1038/nrm3611; Anastasiadou E, 2018, NAT REV CANCER, V18, P5, DOI 10.1038/nrc.2017.99; Badgwell D, 2007, DIS MARKERS, V23, P397, DOI 10.1155/2007/309382; Bai L, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0173912; Bartel DP, 2018, CELL, V173, P20, DOI 10.1016/j.cell.2018.03.006; Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Berger AC, 2018, CANCER CELL, V33, P690, DOI 10.1016/j.ccell.2018.03.014; Bergers G, 2003, NAT REV CANCER, V3, P401, DOI 10.1038/nrc1093; Boyd NF, 2005, LANCET ONCOL, V6, P798, DOI 10.1016/S1470-2045(05)70390-9; BRANNAN CI, 1990, MOL CELL BIOL, V10, P28, DOI 10.1128/MCB.10.1.28; BROCKDORFF N, 1992, CELL, V71, P515, DOI 10.1016/0092-8674(92)90519-I; BROWN CJ, 1992, CELL, V71, P527, DOI 10.1016/0092-8674(92)90520-M; Burk U, 2008, EMBO REP, V9, P582, DOI 10.1038/embor.2008.74; Cabili MN, 2011, GENE DEV, V25, P1915, DOI 10.1101/gad.17446611; Carninci P, 2005, SCIENCE, V309, P1559, DOI 10.1126/science.1112014; Carpini JD, 2010, ANGIOGENESIS, V13, P43, DOI 10.1007/s10456-010-9163-3; Carthew RW, 2009, CELL, V136, P642, DOI 10.1016/j.cell.2009.01.035; Catalanotto C, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17101712; Chan JK, 2014, GYNECOL ONCOL, V133, P568, DOI 10.1016/j.ygyno.2014.03.564; Chen J, 2011, GYNECOL ONCOL, V121, P200, DOI 10.1016/j.ygyno.2010.12.339; Chen JW, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080266; Chen P, 2017, ONCOTARGETS THER, V10, P1423, DOI 10.2147/OTT.S118366; Chen R, 2008, ONCOGENE, V27, P4712, DOI 10.1038/onc.2008.112; Chen ZJ, 2016, EUR REV MED PHARMACO, V20, P3373; Choi MJ, 2015, ONCOGENE, V34, P3402, DOI 10.1038/onc.2014.270; Deng L, 2018, ONCOTARGET, V8; Derrien T, 2012, GENOME RES, V22, P1775, DOI 10.1101/gr.132159.111; Diamantopoulos MA, 2018, ANN TRANSL MED, V6, DOI 10.21037/atm.2018.06.10; Dinami R, 2017, ONCOTARGET, V8, P95674, DOI 10.18632/oncotarget.21680; Ding N, 2017, ONCOTARGETS THER, V10, P4905, DOI 10.2147/OTT.S142446; Djebali S, 2012, NATURE, V489, P101, DOI 10.1038/nature11233; Dong PX, 2016, J EXP CLIN CANC RES, V35, DOI 10.1186/s13046-016-0415-y; Duffy MJ, 2000, INT J BIOL MARKER, V15, P330; Dunham I, 2012, NATURE, V489, P57, DOI 10.1038/nature11247; Easton DF, 2015, NEW ENGL J MED, V372, P2243, DOI 10.1056/NEJMsr1501341; Engreitz JM, 2016, NAT REV MOL CELL BIO, V17, P756, DOI 10.1038/nrm.2016.126; Fang Y, 2017, ONCOTARGET, V8, P46090, DOI 10.18632/oncotarget.17552; Feng TB, 2016, ONCOTARGET, V7, P16205, DOI 10.18632/oncotarget.7578; Filipowicz W, 2008, NAT REV GENET, V9, P102, DOI 10.1038/nrg2290; Galtsidis S, 2017, CANCER LETT, V388, P96, DOI 10.1016/j.canlet.2016.11.036; Gao JY, 2015, ONCOL REP, V34, P3212, DOI 10.3892/or.2015.4318; Gao YC, 2015, TUMOR BIOL, V36, P4843, DOI 10.1007/s13277-015-3138-3; Gao Y, 2015, HUM MOL GENET, V24, P841, DOI 10.1093/hmg/ddu502; Gong C, 2011, J BIOL CHEM, V286, P19127, DOI 10.1074/jbc.M110.216887; Gong L, 2016, BIOMED PHARMACOTHER, V83, P58, DOI 10.1016/j.biopha.2016.05.049; Gregory PA, 2008, NAT CELL BIOL, V10, P593, DOI 10.1038/ncb1722; Gupta RA, 2010, NATURE, V464, P1071, DOI 10.1038/nature08975; Guttman M, 2009, NATURE, V458, P223, DOI 10.1038/nature07672; Ha M, 2014, NAT REV MOL CELL BIO, V15, P509, DOI 10.1038/nrm3838; Hagrass Hoda A, 2015, Genes Cancer, V6, P281; Halvorsen AR, 2017, DIS MARKERS, DOI 10.1155/2017/3098542; Han SH, 2017, J BREAST CANCER, V20, P35, DOI 10.4048/jbc.2017.20.1.35; Hannafon BN, 2016, BREAST CANCER RES, V18, DOI 10.1186/s13058-016-0753-x; He J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056647; He T, 2014, J PATHOL, V232, P499, DOI 10.1002/path.4324; Hironaka-Mitsuhashi A, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0187638; Hong FZ, 2013, J INT MED RES, V41, P64, DOI 10.1177/0300060513475759; Hu XW, 2014, CANCER CELL, V26, P344, DOI 10.1016/j.ccr.2014.07.009; Hua F, 2018, ONCOL RES, V26, P241, DOI 10.3727/096504017X14953948675412; Huang YS, 2016, ONCOTARGET, V7, P43256, DOI 10.18632/oncotarget.9673; Iliopoulos D, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2005053; Jayson GC, 2014, LANCET, V384, P1376, DOI 10.1016/S0140-6736(13)62146-7; Jiang SA, 2010, CANCER RES, V70, P3119, DOI 10.1158/0008-5472.CAN-09-4250; Jiang YZ, 2016, CANCER RES, V76, P2105, DOI 10.1158/0008-5472.CAN-15-3284; Jin MF, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103965; Jin Y, 2017, EUR REV MED PHARMACO, V21, P3176; Jung EJ, 2012, CANCER-AM CANCER SOC, V118, P2603, DOI 10.1002/cncr.26565; Kapranov P, 2007, SCIENCE, V316, P1484, DOI 10.1126/science.1138341; Katayama S, 2005, SCIENCE, V309, P1564, DOI 10.1126/science.1112009; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Kopp F, 2018, CELL, V172, P393, DOI 10.1016/j.cell.2018.01.011; Lagos-Quintana M, 2001, SCIENCE, V294, P853, DOI 10.1126/science.1064921; Lau NC, 2001, SCIENCE, V294, P858, DOI 10.1126/science.1065062; Le Thomas A, 2014, GENOME BIOL, V15, DOI 10.1186/gb4154; Lee RC, 2001, SCIENCE, V294, P862, DOI 10.1126/science.1065329; LEE RC, 1993, CELL, V75, P843, DOI 10.1016/0092-8674(93)90529-Y; Li BL, 2017, CHEM-BIOL INTERACT, V277, P33, DOI 10.1016/j.cbi.2017.08.014; Li J, 2017, INT J ONCOL, V50, P1087, DOI 10.3892/ijo.2017.3898; Li J, 2016, ONCOL REP, V36, P3241, DOI 10.3892/or.2016.5200; Li JN, 2017, SCI REP-UK, V7, DOI 10.1038/srep41330; Li PQ, 2016, CELL PHYSIOL BIOCHEM, V38, P1915, DOI 10.1159/000445553; Li QL, 2016, CANCER LETT, V383, P28, DOI 10.1016/j.canlet.2016.09.019; Liang H, 2018, ANGIOGENESIS; Liu BD, 2015, CANCER CELL, V27, P370, DOI 10.1016/j.ccell.2015.02.004; Liu G, 2014, J PATHOL, V233, P308, DOI 10.1002/path.4348; Liu HY, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0765-5; Liu J, 2017, ONCOL LETT, V14, P5711, DOI 10.3892/ol.2017.6953; Liu YC, 2018, CANCER SCI, V109, P2188, DOI 10.1111/cas.13647; Liu Y, 2017, GENE, V633, P42, DOI 10.1016/j.gene.2017.08.027; Lu Y, 2017, CANCER GENE THER, V24, P386, DOI 10.1038/cgt.2017.30; Luengo-Gil G, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0194638; Lv MM, 2016, ONCOTARGET, V7, P13047, DOI 10.18632/oncotarget.7509; Lv Y, 2016, INT J CLIN EXP PATHO, V9, P11222; Ma LN, 2013, RNA BIOL, V10, P925, DOI 10.4161/rna.24604; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Marchini S, 2011, LANCET ONCOL, V12, P273, DOI 10.1016/S1470-2045(11)70012-2; Martens-Uzunova ES, 2013, CANCER LETT, V340, P201, DOI 10.1016/j.canlet.2012.11.058; Mattick JS, 2011, FEBS LETT, V585, P1600, DOI 10.1016/j.febslet.2011.05.001; Mattick JS, 2006, HUM MOL GENET, V15, pR17, DOI 10.1093/hmg/ddl046; Matulonis UA, 2016, NAT REV DIS PRIMERS, V2, DOI 10.1038/nrdp.2016.61; Meng XD, 2016, ONCOTARGET, V7, P16923, DOI 10.18632/oncotarget.7850; Morris KV, 2014, NAT REV GENET, V15, P423, DOI 10.1038/nrg3722; Mourtada-Maarabouni M, 2009, ONCOGENE, V28, P195, DOI 10.1038/onc.2008.373; Mutlu M, 2016, SCI REP-UK, V6, DOI 10.1038/srep32541; Ozes AR, 2016, ONCOGENE, V35, P5350, DOI 10.1038/onc.2016.75; Pan Y, 2016, SCI REP-UK, V6, DOI 10.1038/srep25798; Papachristopoulou G, 2018, CLIN BREAST CANCER, V18, P305, DOI 10.1016/j.clbc.2017.11.007; Pasquinelli AE, 2000, NATURE, V408, P86, DOI 10.1038/35040556; Patel N, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0190245; Pickard MR, 2014, BREAST CANCER RES TR, V145, P359, DOI 10.1007/s10549-014-2974-y; Qiu JJ, 2016, ONCOTARGET, V7, P32478, DOI 10.18632/oncotarget.8744; Quinn JJ, 2016, NAT REV GENET, V17, P47, DOI 10.1038/nrg.2015.10; Reinhart BJ, 2000, NATURE, V403, P901, DOI 10.1038/35002607; Ren X, 2018, PATHOL ONCOL RES; Rinn JL, 2012, ANNU REV BIOCHEM, V81, P145, DOI 10.1146/annurev-biochem-051410-092902; Rodriguez-Gonzalez FG, 2011, BREAST CANCER RES TR, V127, P43, DOI 10.1007/s10549-010-0940-x; Romano G, 2017, CARCINOGENESIS, V38, P485, DOI 10.1093/carcin/bgx026; Roth C, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2766; Rothe F, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020980; Schmitt AM, 2016, CANCER CELL, V29, P452, DOI 10.1016/j.ccell.2016.03.010; Schwarzenbach H, 2012, BREAST CANCER RES TR, V134, P933, DOI 10.1007/s10549-012-1988-6; Shen Y, 2015, ONCOTARGET, V6, P8579, DOI 10.18632/oncotarget.3287; Shi HJ, 2018, AM J TRANSL RES, V10, P866; Shima H, 2018, BREAST CANC RES TREA; Siegel RL, 2018, CA-CANCER J CLIN, V68, P7, DOI 10.3322/caac.21442; Song R., 2018, CANC BIOMARK; Song TF, 2018, ONCOTARGET, V9, P4411, DOI 10.18632/oncotarget.23230; Stange DE, 2006, CLIN CANCER RES, V12, P345, DOI 10.1158/1078-0432.CCR-05-1633; Su XP, 2014, ONCOTARGET, V5, P9864, DOI 10.18632/oncotarget.2454; Tao FF, 2018, J GENET GENOMICS, V45, P137, DOI 10.1016/j.jgg.2018.03.001; Torre LA, 2018, CA-CANCER J CLIN, V68, P284, DOI 10.3322/caac.21456; Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262; Tryndyak VP, 2010, INT J CANCER, V126, P2575, DOI 10.1002/ijc.24972; Uehara M, 2008, INT J CLIN ONCOL, V13, P447, DOI 10.1007/s10147-008-0773-3; Ulitsky I, 2013, CELL, V154, P26, DOI 10.1016/j.cell.2013.06.020; Vaschetto LM, 2018, RNA BIOL, V15, P826, DOI 10.1080/15476286.2018.1451722; Vecchione A, 2013, P NATL ACAD SCI USA, V110, P9845, DOI 10.1073/pnas.1305472110; Wang HB, 2004, NATURE, V431, P873, DOI 10.1038/nature02985; Wang W, 2014, ONCOL REP, V32, P2127, DOI 10.3892/or.2014.3439; Wang YY, 2018, AM J CANCER RES, V8, P170; Weinberg MS, 2016, NUCLEIC ACIDS RES, V44, P6505, DOI 10.1093/nar/gkw139; Wentzensen N, 2016, J CLIN ONCOL, V34, P2888, DOI 10.1200/JCO.2016.66.8178; WIGHTMAN B, 1993, CELL, V75, P855, DOI 10.1016/0092-8674(93)90530-4; Wilson RC, 2013, ANNU REV BIOPHYS, V42, P217, DOI 10.1146/annurev-biophys-083012-130404; Wright Mathew W., 2011, Human Genomics, V5, P90; Wu H, 2017, TRENDS GENET, V33, P540, DOI 10.1016/j.tig.2017.05.004; Wu RL, 2016, J CANC SCI THER, V7, P258; Wurz K, 2010, GENE CHROMOSOME CANC, V49, P577, DOI 10.1002/gcc.20768; Xia CS, 2018, BIOCHIMIE, V147, P98, DOI 10.1016/j.biochi.2018.01.003; Xiang M, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2004497; Xing F, 2018, CANCER RES, V78, P4316, DOI 10.1158/0008-5472.CAN-18-1102; Xiu YL, 2017, ONCOTARGET, V8, P31727, DOI 10.18632/oncotarget.15955; Xu D, 2011, J CELL BIOL, V193, P409, DOI 10.1083/jcb.201010100; Xu SH, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11406; Yan X, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-220; Yang D, 2013, CANCER CELL, V23, P186, DOI 10.1016/j.ccr.2012.12.020; Yang H, 2008, CANCER RES, V68, P425, DOI 10.1158/0008-5472.CAN-07-2488; YANG K, 2017, SCI REP UK, V7; Yang N, 2008, CANCER RES, V68, P10307, DOI 10.1158/0008-5472.CAN-08-1954; Yang Y, 2016, ONCOTARGET, P6833; Ye ZX, 2015, INT J GYNECOL CANCER, V25, P1574, DOI 10.1097/IGC.0000000000000546; Yin G, 2010, ONCOGENE, V29, P3545, DOI 10.1038/onc.2010.111; Yin RT, 2018, INT J BIOCHEM CELL B, V97, P43, DOI 10.1016/j.biocel.2018.02.005; Yu JSL, 2016, DEVELOPMENT, V143, P3050, DOI 10.1242/dev.137075; Yu XF, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-29; Zaleski Martin, 2018, Oncotarget, V9, P22523, DOI 10.18632/oncotarget.25077; Zhang CY, 2017, TUMOR BIOL, V39, DOI 10.1177/1010428317701311; Zhang T, 2018, INT J BIOL SCI, V14, P622, DOI 10.7150/ijbs.24223; Zhang W, 2017, BIOMED PHARMACOTHER, V91, P312, DOI 10.1016/j.biopha.2017.04.085; Zhang Z, 2013, CELL DEATH DIFFER, V20, P1558, DOI 10.1038/cdd.2013.110; Zhao G, 2016, J CANC SCI THER, V7, P34; Zheng JZ, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-20680-y; Zhong L, 2017, ONCOTARGET, V8, P67861, DOI 10.18632/oncotarget.18919; Zhong SL, 2013, GENE, V531, P8, DOI 10.1016/j.gene.2013.08.062; Zhou YQ, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0155250; Zhu HY, 2018, BIOCHEM BIOPH RES CO, V496, P1308, DOI 10.1016/j.bbrc.2018.02.006; Zhu Weizhu, 2009, BMC Res Notes, V2, P89, DOI 10.1186/1756-0500-2-89; Zou J, 2017, AM J TRANSL RES, V9, P1357	181	5	5	2	11	TAYLOR & FRANCIS AS	OSLO	KARL JOHANS GATE 5, NO-0154 OSLO, NORWAY	1473-7159	1744-8352		EXPERT REV MOL DIAGN	Expert Rev. Mol. Diagn.	NOV 2	2018	18	11					963	979		10.1080/14737159.2018.1538794			17	Pathology	Pathology	GZ0TX	WOS:000449079100006	30338716				2019-10-28	
J	Van Der Pol, B				Van Der Pol, Barbara			We have the technology, but should we build the test?	EXPERT REVIEW OF MOLECULAR DIAGNOSTICS			English	Editorial Material						Molecular diagnostics; clinical utility; health outcomes; sexually transmitted infections; microbiome	MYCOPLASMA-GENITALIUM INFECTION; VAGINITIS; DIAGNOSIS; HOMINIS; WOMEN		[Van Der Pol, Barbara] Univ Alabama Birmingham, Sch Med, Birmingham, AL USA	Van Der Pol, B (reprint author), 703 19th St South,ZRB 238, Birmingham, AL 35111 USA.	bvanderpol@uabmc.edu		Van Der Pol, Barbara/0000-0003-3064-8564	Abbott Molecular; Luminex; Atlas Genetics; BD Diagnostics; Cepheid; Hologic; Rheonix; Roche Molecular; SpeeDx	The author received support from Abbott Molecular, Atlas Genetics; BD Diagnostics; Cepheid; Hologic; Luminex; Rheonix; Roche Molecular; SpeeDx. The author has no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript.	Arya OP, 2001, SEX TRANSM INFECT, V77, P58, DOI 10.1136/sti.77.1.58; Balkus JE, 2018, SEX TRANSM DIS, V45, P514, DOI 10.1097/OLQ.0000000000000799; Bing M, 2012, ANNU REV IMMUNOL, V66, P371; Brosh-Nissimov T, 2018, SEX HEALTH, V15, P298, DOI 10.1071/SH17190; Choe HS, 2013, INT J INFECT DIS, V17, pE1134, DOI 10.1016/j.ijid.2013.07.011; Gaydos CA, 2017, OBSTET GYNECOL, V130, P181, DOI 10.1097/AOG.0000000000002090; Horner P, 2018, J EUR ACAD DERMATOL, P1; Ison CA, 2018, INT J STD AIDS, V29, P680, DOI 10.1177/0956462417753527; PHEIFER TA, 1978, NEW ENGL J MED, V298, P1429, DOI 10.1056/NEJM197806292982601; Ravel J, 2011, P NATL ACAD SCI USA, V108, P4680, DOI 10.1073/pnas.1002611107; Rodrigues MM, 2011, J OBSTET GYNAECOL, V31, P237, DOI 10.3109/01443615.2010.548880; Schwebke JR, 2018, J CLIN MICROBIOL, V56; Tabrizi SN, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0156740; Unemo M, 2018, CLIN MICROBIOL INFEC, V24, P533, DOI 10.1016/j.cmi.2017.09.006; Xiao L, 2018, DIAGN MICR INFEC DIS, V91, P123, DOI 10.1016/j.diagmicrobio.2018.02.002	15	0	0	0	0	TAYLOR & FRANCIS AS	OSLO	KARL JOHANS GATE 5, NO-0154 OSLO, NORWAY	1473-7159	1744-8352		EXPERT REV MOL DIAGN	Expert Rev. Mol. Diagn.	NOV 2	2018	18	11					917	919		10.1080/14737159.2018.1535905			3	Pathology	Pathology	GZ0TX	WOS:000449079100001	30307788				2019-10-28	
J	Singh, VK; Simas, M; Pollard, H				Singh, Vijay K.; Simas, Madison; Pollard, Harvey			Biomarkers for acute radiation syndrome: challenges for developing radiation countermeasures following animal rule	EXPERT REVIEW OF MOLECULAR DIAGNOSTICS			English	Editorial Material						Acute radiation syndrome; animal rule; Biomarkers; countermeasures; radiation exposure	REGULATORY APPROVAL STATUS; INJURY-SPECIFIC MEDICINALS; IONIZING-RADIATION; EFFICACY		[Singh, Vijay K.; Simas, Madison] Uniformed Serv Univ Hlth Sci, F Edward Hebert Sch Med, Dept Pharmacol & Mol Therapeut, Div Radioprotectants, Bethesda, MD 20814 USA; [Singh, Vijay K.; Simas, Madison] Uniformed Serv Univ Hlth Sci, Armed Forces Radiobiol Res Inst, Bethesda, MD 20814 USA; [Pollard, Harvey] Uniformed Serv Univ Hlth Sci, Dept Anat Physiol & Genet, F Edward Hebert Sch Med, Bethesda, MD 20814 USA	Singh, VK (reprint author), F Edward Hebert Sch Med, Amer Med Sch, Armed Forces Radiobiol Res Inst, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA.	vijay.singh@usuhs.edu		Singh, Vijay/0000-0002-6631-3849			Basile LA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030434; Cheema AK, 2017, INT J MOL SCI, V19; Fendler W, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aal2408; Fragkos KC, 2018, UNITED EUR GASTROENT, V6, P181, DOI 10.1177/2050640617737632; Jones JW, 2017, PHARM RES-DORDR, V34, P2698, DOI 10.1007/s11095-017-2200-9; Kang AD, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058355; Kraus VB, 2018, NAT REV RHEUMATOL, V14, P354, DOI 10.1038/s41584-018-0005-9; Krivokrysenko VI, 2012, J PHARMACOL EXP THER, V343, P497, DOI 10.1124/jpet.112.196071; Pannkuk EL, 2018, HEALTH PHYS, V115, P3, DOI 10.1097/HP.0000000000000776; Pannkuk EL, 2017, INT J RADIAT BIOL, V93, P1151, DOI 10.1080/09553002.2016.1269218; Singh VK, 2017, EXPERT REV MOL DIAGN, V17, P871, DOI 10.1080/14737159.2017.1366316; Singh VK, 2017, INT J RADIAT BIOL, V93, P885, DOI 10.1080/09553002.2017.1332440; Singh VK, 2017, INT J RADIAT BIOL, V93, P870, DOI 10.1080/09553002.2017.1338782; U S Food and Drug Administration, 2014, GUID IND FDA STAFF Q; US Food and Drug Administration, 2015, GUID IND PROD DEV AN; US Food and Drug Administration, 2018, MOR BIOM QUAL	16	1	1	0	1	TAYLOR & FRANCIS AS	OSLO	KARL JOHANS GATE 5, NO-0154 OSLO, NORWAY	1473-7159	1744-8352		EXPERT REV MOL DIAGN	Expert Rev. Mol. Diagn.	NOV 2	2018	18	11					921	924		10.1080/14737159.2018.1533404			4	Pathology	Pathology	GZ0TX	WOS:000449079100002	30289289	Bronze			2019-10-28	
J	Regner, A; Meirelles, LD; Ikuta, N; Cecchini, A; Simon, D				Regner, Andrea; Meirelles, Lindolfo da Silva; Ikuta, Nilo; Cecchini, Andre; Simon, Daniel			Prognostic utility of circulating nucleic acids in acute brain injuries	EXPERT REVIEW OF MOLECULAR DIAGNOSTICS			English	Review						Acute brain injury; stroke; traumatic brain injury; nucleic acids; cell-free DNA; microRNA; prognosis	CELL-FREE DNA; PLASMA DNA; ISCHEMIC-STROKE; SERIAL PLASMA; EXTRACELLULAR VESICLES; MITOCHONDRIAL-DNA; ENDOTHELIAL-CELLS; PREDICTIVE MARKER; UNITED-STATES; FETAL DNA	Introduction: Acute brain injuries represent major causes of morbidity and mortality worldwide. Nevertheless, therapeutic options are centered mainly on supportive care, and accurate prognosis prediction following traumatic brain injury (TBI) or stroke remains a challenge in clinical settings. Areas covered: Circulating DNA and RNA have shown potential as predictive molecules in acute brain injuries. In particular, plasma cell-free DNA (cfDNA) levels have been correlated to severity, mortality, and outcome after TBI and stroke. The real-time quantitative polymerase chain reaction (qPCR) is the most widely used technique for determination of cfDNA in brain injuries; however, to consider the use of cfDNA in emergency settings, a quicker and easier methodology for detection should be established. A recent study proposed detection of cfDNA applying a rapid fluorescent test that showed compatible results with qPCR. Expert commentary: As a promising perspective, detection of cfDNA levels using simple, rapid, and cheap methodology has potential to translate to clinic as a point-of-care marker, supporting the clinical decision-making in emergency care settings. Conversely, miRNA profiles may be used as signatures to determine the type and severity of injuries. Additionally, in the future, some miRNAs may constitute innovative neurorestorative therapies without the common hurdles associated with cell therapy.	[Regner, Andrea; Meirelles, Lindolfo da Silva; Cecchini, Andre; Simon, Daniel] Univ Luterana Brasil, Sch Med, Canoas, RS, Brazil; [Regner, Andrea; Meirelles, Lindolfo da Silva; Ikuta, Nilo; Cecchini, Andre; Simon, Daniel] Univ Luterana Brasil, Grad Program Cellular & Mol Biol Appl Hlth PPGBio, Canoas, RS, Brazil; [Cecchini, Andre] Cristo Redentor Hosp, Neurosurg Serv, Porto Alegre, RS, Brazil	Regner, A (reprint author), Univ Luterana Brasil, PPG Biol Celular & Mol Aplicada Saude, Av Farroupilha 8001,Predio 22,5 Andar, BR-92425900 Canoas, RS, Brazil.	regner@uol.com.br			Fundacao de Amparo a Pesquisa do Estado do Rio Grande do SulFoundation for Research Support of the State of Rio Grande do Sul (FAPERGS); Conselho Nacional de Desenvolvimento Cientifico e TecnologicoNational Council for Scientific and Technological Development (CNPq) [03/2017 - PPSUS]	Research in the authors' laboratories has been funded by Fundacao de Amparo a Pesquisa do Estado do Rio Grande do Sul and Conselho Nacional de Desenvolvimento Cientifico e Tecnologico - Grant: FAPERGS/MS/CNPq/SESRS n. 03/2017 - PPSUS.	Aertker BM, 2016, EXP NEUROL, V275, P411, DOI 10.1016/j.expneurol.2015.01.008; Algattas H, 2014, INT J MOL SCI, V15, P309, DOI 10.3390/ijms15010309; Amantea D, 2017, CURR OPIN PHARMACOL, V35, P111, DOI 10.1016/j.coph.2017.07.014; Andriessen TMJC, 2011, J NEUROTRAUM, V28, P2019, DOI 10.1089/neu.2011.2034; Llompart-Pou JA, 2016, INJURY, V47, pS61, DOI 10.1016/S0020-1383(16)30608-8; Arnalich F, 2011, CRIT CARE, V15, DOI 10.1186/cc10365; Balusu S, 2016, EMBO MOL MED, V8, P1162, DOI 10.15252/emmm.201606271; Bhalala OG, 2013, NAT REV NEUROL, V9, P328, DOI 10.1038/nrneurol.2013.67; Bhomia M, 2016, SCI REP-UK, V6, DOI 10.1038/srep28148; Bronkhorst AJ, 2015, CLIN CHIM ACTA, V450, P243, DOI 10.1016/j.cca.2015.08.028; Burda JE, 2016, EXP NEUROL, V275, P305, DOI 10.1016/j.expneurol.2015.03.020; Bustamante A, 2016, J CIRC BIOMARK, V5; Cai W, 2017, TRANSL STROKE RES, V8, P107, DOI 10.1007/s12975-016-0504-4; da Fonseca ACC, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00362; Chieregato A, 2010, ACTA ANAESTH SCAND, V54, P696, DOI 10.1111/j.1399-6576.2010.02234.x; Chou SHY, 2014, NEUROCRIT CARE, V21, P187, DOI 10.1007/s12028-014-0039-z; CHUSED TM, 1972, CLIN EXP IMMUNOL, V12, P465; Coronado Victor G., 2011, Morbidity and Mortality Weekly Report, V60, P1; Dewdney B, 2018, J STROKE CEREBROVASC, V27, P522, DOI 10.1016/j.jstrokecerebrovasdis.2017.09.058; Di Pietro V, 2018, FRONT NEUROL, V9, DOI 10.3389/fneur.2018.00429; Di Pietro V, 2017, J NEUROTRAUM, V34, P1948, DOI 10.1089/neu.2016.4857; Dilek A, 2013, J CRIT CARE, V28, DOI 10.1016/j.jcrc.2013.03.005; Ding K, 2015, J SURG RES, V194, P239, DOI 10.1016/j.jss.2014.09.026; El-Menyar A, 2017, WORLD NEUROSURG, V107, P6, DOI [10.1016/J.WNEU.2017.07.070, 10.1016/j.wneu.2017.07.070]; Feigin VL, 2017, CIRC RES, V120, P439, DOI 10.1161/CIRCRESAHA.116.308413; Fleischhacker M, 2007, BBA-REV CANCER, V1775, P181, DOI 10.1016/j.bbcan.2006.10.001; Gandolfi M, 2017, NEURAL PLAST, DOI 10.1155/2017/1389475; Glebova KV, 2018, CRIT REV CL LAB SCI, V55, P55, DOI 10.1080/10408363.2017.1420032; Gogenur M, 2017, CRIT CARE, V21, DOI 10.1186/s13054-016-1578-9; Goldshtein H, 2009, ANN CLIN BIOCHEM, V46, P488, DOI 10.1258/acb.2009.009002; Grande PO, 2017, FRONT NEUROL, V8, DOI 10.3389/fneur.2017.00315; Harish G, 2015, J NEUROCHEM, V134, P156, DOI 10.1111/jnc.13082; Heiss WD, 2012, ANN NY ACAD SCI, V1268, P26, DOI 10.1111/j.1749-6632.2012.06668.x; Hernandez-Ontiveros DG, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00030; Hoff J, 2016, CURR ATHEROSCLER REP, V18, DOI 10.1007/s11883-016-0566-5; Hu XM, 2017, CIRC RES, V120, P449, DOI 10.1161/CIRCRESAHA.116.308427; Hunter MP, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003694; Kim AS, 2013, STROKE, V44, pS123, DOI 10.1161/STROKEAHA.111.000067; Krishnamurthy K., 2016, TRANSLATIONAL RES TR; Kumar A, 2017, J NEUROINFLAMM, V14, DOI 10.1186/s12974-017-0819-4; Lam NYL, 2006, RESUSCITATION, V68, P71, DOI 10.1016/j.resuscitation.2005.05.021; Lawrence T, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2016-012197; Lee I, 2014, BBA-MOL BASIS DIS, V1842, P1579, DOI [10.1016/j.bbadis.201405.031, 10.1016/j.bbadis.2014.05.031]; LEON SA, 1977, CANCER RES, V37, P646; Lewen A, 2000, J NEUROTRAUM, V17, P871, DOI 10.1089/neu.2000.17.871; Li GW, 2018, PROG NEUROBIOL, V163, P59, DOI 10.1016/j.pneurobio.2017.08.002; Lo YMD, 2000, CLIN CHEM, V46, P319; Lo YMD, 1999, AM J HUM GENET, V64, P218, DOI 10.1086/302205; Lo YMD, 1997, LANCET, V350, P485, DOI 10.1016/S0140-6736(97)02174-0; Loane DJ, 2016, EXP NEUROL, V275, P316, DOI 10.1016/j.expneurol.2015.08.018; Logsdon AF, 2015, COMPR PHYSIOL, V5, P1147, DOI 10.1002/cphy.c140057; Lorente L, 2017, BRAIN SCI, V7, DOI 10.3390/brainsci7110142; Louveau A, 2015, NATURE, V523, P337, DOI 10.1038/nature14432; Lozano D, 2015, NEUROPSYCH DIS TREAT, V11, P97, DOI 10.2147/NDT.S65815; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Macher H, 2012, CLIN CHIM ACTA, V414, P12, DOI 10.1016/j.cca.2012.08.001; Maciel EN, 2001, J NEUROCHEM, V79, P1237, DOI 10.1046/j.1471-4159.2001.00670.x; Majdan M, 2017, PLOS MED, V14, DOI 10.1371/journal.pmed.1002331; MANDEL P, 1948, C R Seances Soc Biol Fil, V142, P241; Manley GT, 2013, JAMA-J AM MED ASSOC, V310, P473, DOI 10.1001/jama.2013.169158; Marmarou Anthony, 2007, Neurosurg Focus, V22, pE1; Martinez B, 2017, NEURAL REGEN RES, V12, P1749, DOI 10.4103/1673-5374.219025; MAXWELL WL, 1988, J PATHOL, V155, P327, DOI 10.1002/path.1711550408; McCabe C, 2018, NEUROPHARMACOLOGY, V134, P169, DOI 10.1016/j.neuropharm.2017.09.022; McGinn MJ, 2016, NEUROSURG CLIN N AM, V27, P397, DOI 10.1016/j.nec.2016.06.002; Mckee Ann C, 2015, Handb Clin Neurol, V127, P45, DOI 10.1016/B978-0-444-52892-6.00004-0; Mitra B, 2017, J CLIN NEUROSCI, V38, P37, DOI 10.1016/j.jocn.2016.12.009; Mozaffarian D, 2015, CIRCULATION, V131, pE29, DOI 10.1161/CIR.0000000000000152; Nagy Z, 2017, BRAIN RES BULL, V134, P30, DOI 10.1016/j.brainresbull.2017.06.011; Nguyen R, 2016, CAN J NEUROL SCI, V43, P774, DOI 10.1017/cjn.2016.290; Njock MS, 2015, BLOOD, V125, P3202, DOI 10.1182/blood-2014-11-611046; O'Connell GC, 2017, BRAIN INJURY, V31, P1369, DOI 10.1080/02699052.2017.1312018; Peeters W, 2015, ACTA NEUROCHIR, V157, P1683, DOI 10.1007/s00701-015-2512-7; Rainer TH, 2003, CLIN CHEM, V49, P562, DOI 10.1373/49.4.562; Rainer TH, 2007, CLIN CHIM ACTA, V376, P190, DOI 10.1016/j.cca.2006.08.025; Raposo G, 2013, J CELL BIOL, V200, P373, DOI 10.1083/jcb.201211138; Redell JB, 2010, J NEUROTRAUM, V27, P2147, DOI 10.1089/neu.2010.1481; Regner A, 2018, TRAUMATIC BRAIN INJU, P49; Roberts DJ, 2013, J NEUROTRAUM, V30, P1727, DOI 10.1089/neu.2012.2842; Rodrigues Filho Edison Moraes, 2014, Rev. bras. ter. intensiva, V26, P305, DOI 10.5935/0103-507X.20140043; Rodrigues EM, 2014, J NEUROTRAUM, V31, P1639, DOI 10.1089/neu.2013.3178; Sacco RL, 2013, STROKE, V44, P2064, DOI 10.1161/STR.0b013e318296aeca; Savitsky B, 2016, BRAIN INJURY, V30, P1194, DOI 10.1080/02699052.2016.1187290; Shaked G, 2014, SCAND J TRAUMA RESUS, V22, DOI 10.1186/1757-7241-22-21; Shivaji T, 2014, BMC NEUROL, V14, DOI 10.1186/1471-2377-14-2; Stoffel M, 1997, ACT NEUR S, V70, P91; Sun LQ, 2018, BEHAV BRAIN RES, V340, P126, DOI 10.1016/j.bbr.2016.09.020; Taylor CA, 2017, MMWR SURVEILL SUMM, V66, P1, DOI 10.15585/mmwr.ss6609a1; TEASDALE G, 1974, LANCET, V2, P81; Thelin EP, 2017, ACTA NEUROCHIR, V159, P209, DOI 10.1007/s00701-016-3046-3; Thurairajah K, 2018, EUR J TRAUMA EMERG S, V44, P325, DOI 10.1007/s00068-018-0954-3; Tsai NW, 2011, CLIN CHIM ACTA, V412, P476, DOI 10.1016/j.cca.2010.11.036; Vajpeyee Atulabh, 2018, Neurointervention, V13, P13, DOI 10.5469/neuroint.2018.13.1.13; Vajtr D, 2009, PHYSIOL RES, V58, P263; Vats K, 2018, ANN NY ACAD SCI, V1431, P14, DOI 10.1111/nyas.13852; Verite JJ, 2018, J NEUROINFLAMM, V15, P8; Vidale S, 2017, J CLIN NEUROL, V13, P1, DOI 10.3988/jcn.2017.13.1.1; Wagner J, 2012, BIOCHEM MEDICA, V22, P24; Wang HC, 2012, EUR J NEUROL, V19, P1532, DOI 10.1111/j.1468-1331.2012.03761.x; Wang HC, 2014, J NEUROTRAUM, V31, P1039, DOI 10.1089/neu.2013.3070; Wang HC, 2013, J NEUROSURG, V118, P13, DOI 10.3171/2012.8.JNS112093; Wang KK, 2018, EXPERT REV MOL DIAGN, V18, P165, DOI 10.1080/14737159.2018.1428089; Wang P, 2018, PROG NEUROBIOL, V163, P98, DOI 10.1016/j.pneurobio.2018.01.001; West AP, 2017, NAT REV IMMUNOL, V17, P363, DOI 10.1038/nri.2017.21; Wu HM, 2013, J NEUROTRAUM, V30, P352, DOI 10.1089/neu.2012.2610; Xu HZ, 2017, NEURAL PLAST, DOI 10.1155/2017/5405104; Xu XM, 2017, J NEUROSCI, V37, P10498, DOI 10.1523/JNEUROSCI.1139-17.2017; Yang T, 2016, J NEUROCHEM, V137, P122, DOI 10.1111/jnc.13534; Yokobori S, 2013, CNS NEUROSCI THER, V19, P556, DOI 10.1111/cns.12127; Yurgel VC, 2007, J NEUROTRAUM, V24, P1172, DOI 10.1089/neu.2006.0160; Zeng LL, 2016, CNS NEUROSCI THER, V22, P961, DOI 10.1111/cns.12589; Zhang XP, 2005, CRIT CARE, V9, P66, DOI 10.1186/cc2950; Zhao ZQ, 2004, EXP NEUROL, V190, P356, DOI 10.1016/j.expneurol.2004.06.015	113	0	0	4	8	TAYLOR & FRANCIS AS	OSLO	KARL JOHANS GATE 5, NO-0154 OSLO, NORWAY	1473-7159	1744-8352		EXPERT REV MOL DIAGN	Expert Rev. Mol. Diagn.	NOV 2	2018	18	11					925	938		10.1080/14737159.2018.1535904			14	Pathology	Pathology	GZ0TX	WOS:000449079100003	30307786				2019-10-28	
J	Qureshi, AP; Stachler, MD; Haque, O; Odze, RD				Qureshi, Alia P.; Stachler, Matthew D.; Haque, Omar; Odze, Robert D.			Biomarkers for Barrett's esophagus - a contemporary review	EXPERT REVIEW OF MOLECULAR DIAGNOSTICS			English	Review						Barrett's esophagus; biomarkers; dysplasia/carcinoma sequence; esophageal adenocarcinoma; gene expression; high grade dysplasia	PROGRESSION PREDICTION; NEOPLASTIC PROGRESSION; CLONAL EXPANSION; INCREASED RISK; ADENOCARCINOMA; P53; OVEREXPRESSION; HETEROZYGOSITY; METAPLASIA; ANEUPLOIDY	Introduction: Esophageal adenocarcinoma (EAC) has a poor 5-year survival rate (10%-18%), and incidence has increased dramatically in the past three decades. Barrett's esophagus (BE) is the precursor lesion to EAC and is the replacement of the normally squamous lined esophagus with columnar cells that develop an intestinal phenotype characterized by the presence of goblet cells. Given the known precursor state, EAC is amenable to screening and surveillance strategies (analogous to colon cancer). However, unlike from colon cancer screening, BE poses challenges that make effective screening difficult. Robust and concerted effort is under way to find biomarkers of BE. Areas covered: This review summarizes current known biomarkers for BE. These include dysplasia, genomic markers, and gene expression alterations that occur early in the dysplasia/carcinoma sequence. Expert commentary: Despite the tremendous breadth of work in studying molecular advances, the ideal biomarker for BE has not yet been discerned. This review comments on innovations in the field of BE research that combine state-of-the-art molecular advances with simple technologies.	[Qureshi, Alia P.; Haque, Omar] Harvard Med Sch, Beth Israel Deaconess Med Ctr, Dept Surg, 330 Brookline Ave, Boston, MA 02215 USA; [Stachler, Matthew D.; Odze, Robert D.] Harvard Med Sch, Brigham & Womens Hosp, Dept Pathol, Boston, MA 02215 USA	Qureshi, AP (reprint author), Harvard Med Sch, Beth Israel Deaconess Med Ctr, Dept Surg, 330 Brookline Ave, Boston, MA 02215 USA.	aquresh2@bidmc.harvard.edu					Agrawal N, 2012, CANCER DISCOV, V2, P899, DOI 10.1158/2159-8290.CD-12-0189; Bani-Hani K, 2000, J NATL CANCER I, V92, P1316, DOI 10.1093/jnci/92.16.1316; Davelaar AL, 2015, GENE CHROMOSOME CANC, V54, P82, DOI 10.1002/gcc.22220; Eads C, 2000, ROLE CPG ISLAND HYPE; Ell C, 2007, GASTROINTEST ENDOSC, V65, P3, DOI 10.1016/j.gie.2006.04.033; Fang M, 2004, AM J GASTROENTEROL, V99, P1887, DOI 10.1111/j.1572-0241.2004.30886.x; Fang Y, 2013, ANN NY ACAD SCI, V1300, P187, DOI 10.1111/nyas.12249; Fitzgerald RC, 2015, UNITED EUR GASTROENT, V3, P226, DOI 10.1177/2050640615576677; Galipeau PC, 1999, J NATL CANCER I, V91, P2087, DOI 10.1093/jnci/91.24.2087; Jin Z, 2007, ONCOGENE, V26, P6332, DOI 10.1038/sj.onc.1210461; Jin Z, 2009, CANCER RES, V69, P4112, DOI 10.1158/0008-5472.CAN-09-0028; Kadri S, 2011, BIOMARK MED, V5, P397, DOI [10.2217/BMM.11.40, 10.2217/bmm.11.40]; Kahn A, 2015, J CLIN ONCOL, V33, DOI 10.1200/jco.2015.33.3_suppl.20; Kastelein F, 2013, GUT, V62, P1676, DOI 10.1136/gutjnl-2012-303594; Khara Harshit S, 2014, J Gastrointest Cancer, V45, P137, DOI 10.1007/s12029-013-9570-y; Kuzmanov U, 2016, P NATL ACAD SCI USA, V113, P12592, DOI 10.1073/pnas.1606444113; Kuzmanov U, 2013, GENOME MED, V5, DOI 10.1186/gm441; Lao-Sirieix P, 2009, GUT, V58, P1451, DOI 10.1136/gut.2009.180281; Levine DS, 2000, AM J GASTROENTEROL, V95, P1152; Li XD, 2018, GASTROENTEROLOGY, V155, P771, DOI 10.1053/j.gastro.2018.05.050; Li X, 2015, CANCER PREV RES, V8, P845, DOI 10.1158/1940-6207.CAPR-15-0130; Li XH, 2008, CANCER PREV RES, V1, P413, DOI 10.1158/1940-6207.CAPR-08-0121; Maley CC, 2004, CANCER RES, V64, P7629, DOI 10.1158/0008-5472.CAN-04-1738; Moinova H, 2017, GASTROENTEROLOGY, V152, pS662, DOI 10.1016/S0016-5085(17)32332-6; Moinova H, 2017, GASTROENTEROLOGY, V152, pS105, DOI 10.1016/S0016-5085(17)30693-5; Moinova HR, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aao5848; Mokrowiecka A, 2012, ADV MED SCI-POLAND, V57, P71, DOI 10.2478/v10039-012-0003-0; NAEF AP, 1975, J THORAC CARDIOV SUR, V70, P826; Naini BV, 2015, BEST PRACT RES CL GA, V29, P77, DOI 10.1016/j.bpg.2014.11.004; RABINOVITCH PS, 1989, LAB INVEST, V60, P65; Reid BJ, 2015, GASTROENTEROLOGY, V149, P1142, DOI 10.1053/j.gastro.2015.07.010; Risques RA, 2007, CANCER EPIDEM BIOMAR, V16, P2649, DOI 10.1158/1055-9965.EPI-07-0624; Ross-Innes CS, 2015, NAT GENET, V47, P1038, DOI 10.1038/ng.3357; Shah AK, 2016, DATA BRIEF, V7, P1058, DOI 10.1016/j.dib.2016.03.081; Sikkema M, 2009, GASTROENTEROLOGY, V136, pA747; Singh A, 2014, ESOPHAGEAL DIS EVALU, P177; Souza RF, 2010, TECH GASTROINTEST EN, V12, P116, DOI 10.1016/j.tgie.2010.02.006; Stachler MD, 2018, GASTROENTEROLOGY, V155, P156, DOI 10.1053/j.gastro.2018.03.047; Stachler MD, 2015, NAT GENET, V47, P1047, DOI 10.1038/ng.3343; Thrift AP, 2013, AM J GASTROENTEROL, V108, P915, DOI 10.1038/ajg.2013.72; Varghese S, 2015, GASTROENTEROLOGY, V149, P1511, DOI 10.1053/j.gastro.2015.07.053; Wani S, 2016, GASTROENTEROLOGY, V151, P822, DOI 10.1053/j.gastro.2016.09.040; Yantiss RK, 2010, ARCH PATHOL LAB MED, V134, P1589, DOI 10.1043/2009-0547-RAR1.1; Younes M, 2017, HISTOPATHOLOGY, V71, P27, DOI 10.1111/his.13193; Zhang YW, 2013, WORLD J GASTROENTERO, V19, P5598, DOI 10.3748/wjg.v19.i34.5598	45	2	2	3	7	TAYLOR & FRANCIS AS	OSLO	KARL JOHANS GATE 5, NO-0154 OSLO, NORWAY	1473-7159	1744-8352		EXPERT REV MOL DIAGN	Expert Rev. Mol. Diagn.	NOV 2	2018	18	11					939	946		10.1080/14737159.2018.1538793			8	Pathology	Pathology	GZ0TX	WOS:000449079100004	30345836				2019-10-28	
J	Hattinger, CM; Patrizio, MP; Tavanti, E; Luppi, S; Magagnoli, F; Picci, P; Serra, M				Hattinger, Claudia Maria; Patrizio, Maria Pia; Tavanti, Elisa; Luppi, Silvia; Magagnoli, Federica; Picci, Piero; Serra, Massimo			Genetic testing for high-grade osteosarcoma: a guide for future tailored treatments?	EXPERT REVIEW OF MOLECULAR DIAGNOSTICS			English	Review						Genetic biomarkers; osteosarcoma; prognosis; tailored treatments; toxicity	LONG NONCODING RNAS; GENOME-WIDE ASSOCIATION; INDUCED HEARING-LOSS; TUMOR-SUPPRESSOR; POOR-PROGNOSIS; PROMOTER HYPERMETHYLATION; EPIGENETIC ALTERATIONS; ABERRANT METHYLATION; EXPRESSION PROFILE; CELL METASTASIS	Introduction: Genetic characterization of osteosarcoma has evolved during the last decade, thanks to the integrated application of conventional and new candidate-driven and genome-wide technologies. Areas covered: This review provides an overview of the state of art in genetic testing applied to osteosarcoma, with particular regard to novel candidate genetic biomarkers that can be analyzed in tumor tissue and blood samples, which might be used to predict toxicity and prognosis, detect disease relapse, and improve patients' selection criteria for tailoring treatment. Expert commentary: Genetic testing based on modern technologies is expected to indicate new osteosarcoma-related prognostic markers and driver genes, which may highlight novel therapeutic targets and patients stratification biomarkers. The definition of tailored or targeted treatment approaches may improve outcome of patients with localized tumors and, even more, of those with metastatic disease, for whom progress in cure probability is highly warranted.	[Hattinger, Claudia Maria; Patrizio, Maria Pia; Tavanti, Elisa; Luppi, Silvia; Magagnoli, Federica; Picci, Piero; Serra, Massimo] IRCCS Ist Ortoped Rizzoli, Lab Expt Oncol, Bologna, Italy	Serra, M (reprint author), IRCCS Ist Ortoped Rizzoli, Pharmacogen & Pharmacogenet Res Unit, Lab Expt Oncol, Via Barbiano 1-10, I-40136 Bologna, Italy.	massimo.serra@ior.it	Patrizio, Maria Pia/N-5340-2018; Hattinger, Claudia/Q-1212-2016; Serra, Massimo/J-4878-2016	Patrizio, Maria Pia/0000-0003-3291-7748; Hattinger, Claudia/0000-0002-9316-5095; Serra, Massimo/0000-0003-0742-1177; Magagnoli, Federica/0000-0002-7158-335X	Italian Association for Cancer Research (Associazione Italiana per la Ricerca sul Cancro, A.I.R.C.)Associazione Italiana per la Ricerca sul Cancro (AIRC); Istituto Ortopedico Rizzoli	The authors are supported by grants from the Italian Association for Cancer Research (Associazione Italiana per la Ricerca sul Cancro, A.I.R.C.; grants to Massimo Serra) and Istituto Ortopedico Rizzoli (5 x mille contributions to the Rizzoli Institute).	Anninga JK, 2011, EUR J CANCER, V47, P2431, DOI 10.1016/j.ejca.2011.05.030; Bachman KE, 1999, CANCER RES, V59, P798; Ballinger ML, 2016, LANCET ONCOL, V17, P1261, DOI 10.1016/S1470-2045(16)30147-4; Baroy T, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0163859; Bayani J, 2003, GENE CHROMOSOME CANC, V36, P7, DOI 10.1002/gcc.10132; Benassi MS, 2001, CANCER, V92, P3062, DOI 10.1002/1097-0142(20011215)92:12<3062::AID-CNCR10161>3.0.CO;2-X; Benassi MS, 1999, INT J CANCER, V84, P489, DOI 10.1002/(SICI)1097-0215(19991022)84:5<489::AID-IJC7>3.0.CO;2-D; Bolha L, 2017, DIS MARKERS, DOI 10.1155/2017/7243968; Chakravarty Debyani, 2017, JCO Precis Oncol, V2017, DOI 10.1200/PO.17.00011; Cheetham SW, 2013, BRIT J CANCER, V108, P2419, DOI 10.1038/bjc.2013.233; Chen F, 2015, BMC MED, V13, DOI 10.1186/s12916-015-0278-7; Chen FY, 2016, TUMOR BIOL, V37, P13403, DOI 10.1007/s13277-016-5256-y; Chen JS, 2016, ONCOL REP, V35, P3285, DOI 10.3892/or.2016.4719; Chen RL, 2017, ONCOTARGET, V8, P20462, DOI 10.18632/oncotarget.14726; Chen WY, 2004, CANCER CELL, V6, P387, DOI 10.1016/j.ccr.2004.08.030; Chen X, 2014, CELL REP, V7, P104, DOI 10.1016/j.celrep.2014.03.003; Cong ML, 2016, TUMOR BIOL, V37, P9441, DOI 10.1007/s13277-015-4414-y; Cote GM, 2013, CURR TREAT OPTION ON, V14, P454, DOI 10.1007/s11864-013-0239-3; Dong D, 2016, TUMOR BIOL, V37, P6447, DOI 10.1007/s13277-015-4527-3; Dong YQ, 2015, TUMOR BIOL, V36, P1477, DOI 10.1007/s13277-014-2631-4; Easwaran H, 2012, GENOME RES, V22, P837, DOI 10.1101/gr.131169.111; Egas-Bejar Daniela, 2014, Oncoscience, V1, P167; Ferrari S, 2015, EXPERT OPIN PHARMACO, V16, P2727, DOI 10.1517/14656566.2015.1102226; Garzon R, 2010, NAT REV DRUG DISCOV, V9, P775, DOI 10.1038/nrd3179; Geng S, 2016, J CELL MOL MED, V20, P1611, DOI 10.1111/jcmm.12852; Geng S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0091566; Gianferante DM, 2017, NAT REV ENDOCRINOL, V13, P480, DOI 10.1038/nrendo.2017.16; Grobner SN, 2018, NATURE, V555, P321, DOI 10.1038/nature25480; Han WF, 2017, BIOCHEM BIOPH RES CO, V491, P91, DOI 10.1016/j.bbrc.2017.07.049; Harada K, 2002, ONCOGENE, V21, P4345, DOI 10.1038/sj.onc.1205446; Harrison DJ, 2018, EXPERT REV ANTICANC, V18, P39, DOI 10.1080/14737140.2018.1413939; Hattinger CM, 2017, EXPERT OPIN DRUG MET, V13, P245, DOI 10.1080/17425255.2017.1246532; Hattinger CM, 2015, EXPERT OPIN EMERG DR, V20, P495, DOI 10.1517/14728214.2015.1051965; Hattinger CM, 2015, EXPERT OPIN DRUG MET, V11, P1449, DOI 10.1517/17425255.2015.1060220; Hou P, 2006, CANCER-AM CANCER SOC, V106, P1602, DOI 10.1002/cncr.21762; Inbal B, 1997, NATURE, V390, P180; Ji F, 2013, BONE, V56, P220, DOI 10.1016/j.bone.2013.05.020; Jones KB, 2012, CANCER RES, V72, P1865, DOI 10.1158/0008-5472.CAN-11-2663; Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029; Jones PA, 2016, NAT REV GENET, V17, P630, DOI 10.1038/nrg.2016.93; Kager L, 2003, J CLIN ONCOL, V21, P2011, DOI 10.1200/JCO.2003.08.132; Kandoth C, 2013, NATURE, V502, P333, DOI 10.1038/nature12634; Kansara M, 2014, NAT REV CANCER, V14, P722, DOI 10.1038/nrc3838; Karlsson EK, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-12-r132; Kobayashi Eisuke, 2012, Sarcoma, P359739, DOI 10.1155/2012/359739; Koster R, 2018, INT J CANCER, V142, P1594, DOI 10.1002/ijc.31195; Kovac M, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9940; Kresse SH, 2009, GENE CHROMOSOME CANC, V48, P679, DOI 10.1002/gcc.20675; Kumar RMR, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17060877; Lambrecht L, 2017, PHARMACOGENOMICS, V18, P787, DOI 10.2217/pgs-2017-0013; Lee H, 2008, BIOINFORMATICS, V24, P889, DOI 10.1093/bioinformatics/btn034; Leroy B, 2017, CANCER RES, V77, P1250, DOI 10.1158/0008-5472.CAN-16-2179; Li BH, 2014, MOL BIOL REP, V41, P3303, DOI 10.1007/s11033-014-3193-7; Li F, 2015, INT J CLIN EXP PATHO, V8, P11414; Li JP, 2013, BIOCHEM BIOPH RES CO, V433, P200, DOI 10.1016/j.bbrc.2013.02.083; Li W, 2016, J BONE ONCOL, V5, P80, DOI 10.1016/j.jbo.2016.05.003; Li ZH, 2017, CELL PHYSIOL BIOCHEM, V42, P1407, DOI 10.1159/000479205; Lim S, 2003, ONCOL REP, V10, P897; Liu CB, 2016, AM J TRANSL RES, V8, P4095; Liu XY, 2017, ONCOTARGET, V8, P62769, DOI 10.18632/oncotarget.19370; Lorenz S, 2016, ONCOTARGET, V7, P5273, DOI 10.18632/oncotarget.6567; Ma B, 2016, TUMOR BIOL, V37, P4445, DOI 10.1007/s13277-015-4301-6; Ma CB, 2016, ONCOL REP, V35, P3257, DOI 10.3892/or.2016.4718; Maire G, 2011, CANCER GENET-NY, V204, P138, DOI 10.1016/j.cancergen.2010.12.012; Marino-Enriquez Adrian, 2016, Surg Pathol Clin, V9, P457, DOI 10.1016/j.path.2016.04.009; Mirabello L, 2015, CANCER DISCOV, V5, P920, DOI 10.1158/2159-8290.CD-15-0125; Mirabello L, 2015, JNCI-J NATL CANCER I, V107, DOI 10.1093/jnci/djv101; Morrow James J., 2015, Critical Reviews in Oncogenesis, V20, P173, DOI 10.1615/CritRevOncog.2015013713; Namlos HM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048086; Ni Z, 2016, GENET MOL RES, V15, DOI 10.4238/gmr.15027807; Oh JH, 2006, CLIN ORTHOP RELAT R, P216, DOI 10.1097/01.blo.0000188063.56091.69; Palmini G, 2017, MOLECULES, V22, DOI 10.3390/molecules22030417; Park JA, 2017, J PEDIAT HEMATOL ONC, V39, pE270, DOI [10.1097/MPH.0000000000000802, 10.1097/mph.0000000000000802]; Park JA, 2016, BLOOD RES, V51, P50, DOI 10.5045/br.2016.51.1.50; Patino-Garcia A, 2003, J PEDIAT HEMATOL ONC, V25, P362, DOI 10.1097/00043426-200305000-00003; PEGG AE, 1990, CANCER RES, V50, P6119; Pei H, 2015, MOL CELL BIOCHEM, V400, P245, DOI 10.1007/s11010-014-2281-2; Perry JA, 2014, P NATL ACAD SCI USA, V111, pE5564, DOI 10.1073/pnas.1419260111; Piperno-Neumann S, 2016, LANCET ONCOL, V17, P1070, DOI 10.1016/S1470-2045(16)30096-1; Poos K, 2013, PLOS COMPUT BIOL, V9, DOI 10.1371/journal.pcbi.1003210; Pussegoda K, 2013, CLIN PHARMACOL THER, V94, P243, DOI 10.1038/clpt.2013.80; Raimondi L, 2017, ONCOTARGET, V8, P100831, DOI 10.18632/oncotarget.19852; Rathi A, 2003, CLIN CANCER RES, V9, P3674; Ribi S, 2015, ONCOTARGET, V6, P7727, DOI 10.18632/oncotarget.3115; Rinn JL, 2012, ANNU REV BIOCHEM, V81, P145, DOI 10.1146/annurev-biochem-051410-092902; Rosas SLB, 2001, CANCER RES, V61, P939; Ross CJD, 2009, NAT GENET, V41, P1345, DOI 10.1038/ng.478; Sadikovic B, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-202; SAKAI T, 1991, AM J HUM GENET, V48, P880; Sandberg AA, 2003, CANCER GENET CYTOGEN, V145, P1, DOI 10.1016/S0165-4608(03)00105-5; Savage SA, 2013, NAT GENET, V45, P799, DOI 10.1038/ng.2645; Serra M, 2017, PHARMACOGENOMICS J, V17, P11, DOI 10.1038/tpj.2016.45; Serra M, 2017, EXPERT OPIN DRUG MET, V13, P123, DOI 10.1080/17425255.2017.1260300; Shen L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109138; Smida J, 2017, INT J CANCER, V141, P816, DOI 10.1002/ijc.30778; Smida J, 2010, CLIN CANCER RES, V16, P4256, DOI 10.1158/1078-0432.CCR-10-0284; Song K, 2016, TUMOR BIOL, V37, P6493, DOI 10.1007/s13277-015-4530-8; Sun JB, 2016, MOL BIOL REP, V43, P427, DOI 10.1007/s11033-016-3975-1; Sun XH, 2015, INT J CLIN EXP PATHO, V8, P2994; Sun XH, 2015, TUMOR BIOL, V36, P2127, DOI 10.1007/s13277-014-2822-z; Talluri S, 2012, CELL CYCLE, V11, P3189, DOI 10.4161/cc.21263; Tian ZZ, 2015, INT J CLIN EXP PATHO, V8, P15138; Tsuchiya T, 2000, CANCER GENET CYTOGEN, V120, P91, DOI 10.1016/S0165-4608(99)00255-1; Varshney Jyotika, 2015, Front Mol Biosci, V2, P31, DOI 10.3389/fmolb.2015.00031; Vos HI, 2016, PHARMACOGENET GENOM, V26, P243, DOI 10.1097/FPC.0000000000000212; Wang B, 2015, MOL CELLS, V38, P432, DOI 10.14348/molcells.2015.2327; Wang K, 2016, TUMOR BIOL, V37, P1105, DOI 10.1007/s13277-015-3904-2; Wang W, 2015, ONCOTARGET, V6, P10297, DOI 10.18632/oncotarget.3305; Wang YD, 2016, TUMOR BIOL, V37, P15211, DOI 10.1007/s13277-016-5417-z; Wang ZG, 2017, ONCOTARGET, V8, P31465, DOI 10.18632/oncotarget.16356; Wang ZL, 2016, EXP THER MED, V11, P1293, DOI 10.3892/etm.2016.3085; Worst BC, 2016, EUR J CANCER, V65, P91, DOI 10.1016/j.ejca.2016.06.009; Wu SF, 2016, GENE, V584, P83, DOI 10.1016/j.gene.2016.03.021; Xia WK, 2016, ONCOTARGETS THER, V9, P4645, DOI 10.2147/OTT.S103376; Xie Lu, 2018, Oncotarget, V9, P11465, DOI 10.18632/oncotarget.23222; Xu SH, 2014, WORLD J SURG ONCOL, V12, DOI 10.1186/1477-7819-12-195; Yang ZZ, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.272; Zhang C, 2016, ONCOL REP, V35, P3275, DOI 10.3892/or.2016.4700; Zhang HG, 2017, WORLD J SURG ONCOL, V15, DOI 10.1186/s12957-017-1142-3; Zhang JH, 2015, NEW ENGL J MED, V373, P2336, DOI 10.1056/NEJMoa1508054; Zhang SL, 2016, BIOCHEM BIOPH RES CO, V472, P557, DOI 10.1016/j.bbrc.2016.03.040; Zhao HX, 2016, AM J TRANSL RES, V8, P3503; Zhou CS, 2016, CELL ONCOL, V39, P463, DOI 10.1007/s13402-016-0288-2; Zhou ZH, 2016, CLIN SCI, V130, P921, DOI 10.1042/CS20150509; Zhu JF, 2012, AM J PATHOL, V180, P2440, DOI 10.1016/j.ajpath.2012.02.023	125	1	1	2	4	TAYLOR & FRANCIS AS	OSLO	KARL JOHANS GATE 5, NO-0154 OSLO, NORWAY	1473-7159	1744-8352		EXPERT REV MOL DIAGN	Expert Rev. Mol. Diagn.	NOV 2	2018	18	11					947	961		10.1080/14737159.2018.1535903			15	Pathology	Pathology	GZ0TX	WOS:000449079100005	30324828				2019-10-28	
J	Tsiakanikas, P; Giaginis, C; Kontos, CK; Scorilas, A				Tsiakanikas, Panagiotis; Giaginis, Constantinos; Kontos, Christos K.; Scorilas, Andreas			Clinical utility of microRNAs in renal cell carcinoma: current evidence and future perspectives	EXPERT REVIEW OF MOLECULAR DIAGNOSTICS			English	Review						Diagnosis; prognosis; molecular classification; biomarkers; tumor markers; miRNA	PROGNOSTIC MARKER; POTENTIAL BIOMARKER; DOWN-REGULATION; EXPRESSION; CANCER; PROLIFERATION; MIRNAS; METASTASIS; IDENTIFICATION; RESISTANCE	Introduction: MicroRNAs (miRNAs) are small, non-coding RNA molecules that epigenetically regulate gene expression. Recently, it has been shown that miRNAs are heavily involved in renal carcinogenesis by controlling the expression of proteins related to renal cell carcinoma (RCC) and, thus, the activity of key signaling pathways involved in pivotal cell processes. Areas covered: This review focuses on the role of miRNAs as emerging biomarkers in RCC. We summarize the oncogenic and/or tumor-suppressive functions of miRNAs as well as the strong clinical information that these RNA molecules provide. Expert commentary: miRNAs that could be either exploited as standalone biomarkers or integrated into molecular signatures with high clinical interest should be considered as ideal for diagnostic purposes and accurate molecular classification of renal tumors. Furthermore, miRNAs could serve as prognostic biomarkers, predicting disease-free and overall survival of RCC patients and, thus, reducing over- and/or under-treatment of patients. miRNA may also be used as predictors of patients' response to targeted therapy with tyrosine kinase inhibitors, contributing to the decision-making process for the selection of the appropriate treatment plan.	[Tsiakanikas, Panagiotis; Kontos, Christos K.; Scorilas, Andreas] Univ Athens, Dept Biochem & Mol Biol, Athens, Greece; [Giaginis, Constantinos] Univ Aegean, Sch Environm, Dept Food Sci & Nustrit, Lemnos, Greece	Giaginis, C (reprint author), Univ Aegean, Sch Environm, Dept Food Sci & Nutr, Lemnos 81400, Greece.	cgiaginis@aegean.gr	; Kontos, Christos/C-2757-2012	Scorilas, Andreas/0000-0003-2427-4949; Giaginis, Constantinos/0000-0003-2878-4831; Kontos, Christos/0000-0002-9935-8461	Stavros Niarchos Foundation	The research presented herein was carried out within the framework of a Stavros Niarchos Foundation grant to the National and Kapodistrian University of Athens.	Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002; Calin GA, 2006, NAT REV CANCER, V6, P857, DOI 10.1038/nrc1997; Chang I, 2015, ONCOTARGET, V6, P7774, DOI 10.18632/oncotarget.3484; Chang TC, 2007, MOL CELL, V26, P745, DOI 10.1016/j.molcel.2007.05.010; Chen FJ, 2016, CELL REP, V14, P2476, DOI 10.1016/j.celrep.2016.02.024; Chen XY, 2014, CLIN CANCER RES, V20, P2617, DOI 10.1158/1078-0432.CCR-13-3224; Chiyomaru T, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043812; Chow TFF, 2010, J UROLOGY, V183, P743, DOI 10.1016/j.juro.2009.09.086; Christinat Y, 2015, ONCOTARGET, V6, P10521, DOI 10.18632/oncotarget.3294; Crispen PL, 2011, EUR UROL, V59, P18, DOI 10.1016/j.eururo.2010.08.042; Dal Bo M, 2015, ONCOTARGET, V6, P19381; DeCastro GJ, 2008, UROL CLIN N AM, V35, P581, DOI 10.1016/j.ucl.2008.07.005; Dey N, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037366; Dias F, 2013, PHARMACOGENOMICS, V14, P1793, DOI 10.2217/pgs.13.184; Dimova DK, 2005, ONCOGENE, V24, P2810, DOI 10.1038/sj.onc.1208612; Duns G, 2013, GENE CHROMOSOME CANC, V52, P165, DOI 10.1002/gcc.22016; Dutta KK, 2007, CANCER SCI, V98, P1845, DOI 10.1111/j.1349-7006.2007.00619.x; Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840; Faragalla H, 2012, J MOL DIAGN, V14, P385, DOI 10.1016/j.jmoldx.2012.02.003; Favaro E, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010345; Fridman E, 2010, J MOL DIAGN, V12, P687, DOI 10.2353/jmoldx.2010.090187; Friedman RC, 2009, GENOME RES, V19, P92, DOI 10.1101/gr.082701.108; Fritz HKM, 2014, EUR J CANCER, V50, P1758, DOI 10.1016/j.ejca.2014.03.281; Fu Q, 2014, CANCER SCI, V105, P1427, DOI 10.1111/cas.12507; Gamez-Pozo A, 2012, NEOPLASIA, V14, P1144, DOI 10.1593/neo.12734; Gao Y, 2016, ONCOTARGET, V7, P20324, DOI 10.18632/oncotarget.7951; Garofalo M, 2009, CANCER CELL, V16, P498, DOI 10.1016/j.ccr.2009.10.014; Gossage L, 2015, NAT REV CANCER, V15, P55, DOI 10.1038/nrc3844; Goto K, 2013, MOL CLIN ONCOL, V1, P235, DOI 10.3892/mco.2012.46; Guertin DA, 2007, CANCER CELL, V12, P9, DOI 10.1016/j.ccr.2007.05.008; Hauser S, 2012, CANCER EPIDEMIOL, V36, P391, DOI 10.1016/j.canep.2012.04.001; Huang Y, 2009, EJSO-EUR J SURG ONC, V35, P1119, DOI 10.1016/j.ejso.2009.04.010; Humphries B, 2015, ONCOTARGET, V6, P6472, DOI 10.18632/oncotarget.3052; Iwamoto H, 2014, INT J ONCOL, V44, P53, DOI 10.3892/ijo.2013.2169; Jonasch E, 2014, BMJ-BRIT MED J, V349, DOI 10.1136/bmj.g4797; Juan D, 2010, UROLOGY, V75, P835, DOI 10.1016/j.urology.2009.10.033; Khella HWZ, 2013, CARCINOGENESIS, V34, P2231, DOI 10.1093/carcin/bgt184; Khella HWZ, 2017, J CLIN PATHOL, V70, P854, DOI 10.1136/jclinpath-2017-204341; Khella HWZ, 2015, MOL THER, V23, P1748, DOI 10.1038/mt.2015.129; Khella HWZ, 2015, AM J PATHOL, V185, P693, DOI 10.1016/j.ajpath.2014.11.017; Khella HWZ, 2012, TUMOR BIOL, V33, P131, DOI 10.1007/s13277-011-0255-5; Kosaka N, 2010, CANCER SCI, V101, P2087, DOI 10.1111/j.1349-7006.2010.01650.x; Krichevsky AM, 2009, J CELL MOL MED, V13, px, DOI 10.1111/j.1582-4934.2008.00556.x; Li XC, 2014, CELL PHYSIOL BIOCHEM, V33, P1631, DOI 10.1159/000362946; Liu HQ, 2010, BMC SYST BIOL, V4, DOI 10.1186/1752-0509-4-51; Ljungberg B, 2015, EUR UROL, V67, P913, DOI 10.1016/j.eururo.2015.01.005; Long QZ, 2015, TUMOR BIOL, V36, P7017, DOI 10.1007/s13277-015-3369-3; Lou N, 2017, UROL ONCOL, V35; Lukamowicz-Rajska M, 2016, ONCOTARGET, V7, P78433, DOI 10.18632/oncotarget.12618; Machackova T, 2016, TUMOR BIOL, V37, P14653, DOI 10.1007/s13277-016-5310-9; McCormick RI, 2013, BRIT J CANCER, V108, P1133, DOI 10.1038/bjc.2013.56; Merhautova J, 2015, BIOMED RES INT, DOI 10.1155/2015/941980; Moch H, 2013, SEMIN CANCER BIOL, V23, P3, DOI 10.1016/j.semcancer.2012.06.006; Mytsyk Y, 2018, INT UROL NEPHROL, V50, P851, DOI 10.1007/s11255-018-1841-x; Nakada C, 2008, J PATHOL, V216, P418, DOI 10.1002/path.2437; Nakada C, 2011, J PATHOL, V224, P280, DOI 10.1002/path.2860; Nakata W, 2015, ONCOTARGET, V6, P21645, DOI 10.18632/oncotarget.4064; Neal CS, 2010, BMC MED, V8, DOI 10.1186/1741-7015-8-64; Nofech-Mozes R, 2016, CANCER MED-US, V5, P656, DOI 10.1002/cam4.631; Nogueira I, 2018, PHARMACOGENOMICS, V19, P249, DOI 10.2217/pgs-2017-0160; Nolte E, 2017, ONCOTARGET, V8, P11676, DOI 10.18632/oncotarget.14644; Papadopoulos EI, 2016, BIOL CHEM, V397, P529, DOI 10.1515/hsz-2015-0284; Pecot CV, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3427; Petillo D, 2009, INT J ONCOL, V35, P109, DOI 10.3892/ijo_00000318; Pichiorri F, 2010, CANCER CELL, V18, P367, DOI 10.1016/j.ccr.2010.09.005; Prior C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0086263; Redova M, 2013, TUMOR BIOL, V34, P481, DOI 10.1007/s13277-012-0573-2; Redova M, 2012, J TRANSL MED, V10, DOI 10.1186/1479-5876-10-55; Ricketts CJ, 2014, NAT GENET, V46, P214, DOI 10.1038/ng.2904; Samaan S, 2015, J MOL DIAGN, V17, P136, DOI 10.1016/j.jmoldx.2014.10.005; Shinmei S, 2013, INT J UROL, V20, P468, DOI 10.1111/j.1442-2042.2012.03182.x; Silva-Santos RM, 2013, BRIT J CANCER, V109, P2646, DOI 10.1038/bjc.2013.552; Slaby O, 2012, GENE CHROMOSOME CANC, V51, P707, DOI 10.1002/gcc.21957; Tang K, 2015, SCI REP-UK, V5, DOI 10.1038/srep10272; Teixeira AL, 2014, TUMOR BIOL, V35, P4057, DOI 10.1007/s13277-013-1531-3; Timmers C, 2007, MOL CELL BIOL, V27, P65, DOI 10.1128/MCB.02147-06; Vergho D, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-25; Verine J, 2010, EUR UROL, V58, P701, DOI 10.1016/j.eururo.2010.08.031; Volinia S, 2006, P NATL ACAD SCI USA, V103, P2257, DOI 10.1073/pnas.0510565103; von Brandenstein M, 2012, AM J PATHOL, V180, P1787, DOI 10.1016/j.ajpath.2012.01.014; Voss MH, 2011, HEMATOL ONCOL CLIN N, V25, P835, DOI 10.1016/j.hoc.2011.04.008; Wach S, 2013, BRIT J CANCER, V109, P714, DOI 10.1038/bjc.2013.313; Wang C, 2015, SCI REP-UK, V5, DOI 10.1038/srep07610; Wang GH, 2013, INT UROL NEPHROL, V45, P373, DOI 10.1007/s11255-012-0374-y; Wang XG, 2015, MOL CANCER RES, V13, P1567, DOI 10.1158/1541-7786.MCR-15-0128; Welford SM, 2010, MOL CELL BIOL, V30, P4595, DOI 10.1128/MCB.01618-09; White NMA, 2011, J UROLOGY, V186, P1077, DOI 10.1016/j.juro.2011.04.110; Wotschofsky Z, 2013, CLIN CHIM ACTA, V416, P5, DOI 10.1016/j.cca.2012.11.010; Wotschofsky Z, 2012, INT J BIOL SCI, V8, P1363, DOI 10.7150/ijbs.5106; Wu XW, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035661; Wulfken LM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025787; Xiang C, 2016, J HUAZHONG U SCI-MED, V36, P186, DOI 10.1007/s11596-016-1564-0; Yamamura S, 2012, CARCINOGENESIS, V33, P294, DOI 10.1093/carcin/bgr286; Yang J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087606; Youssef YM, 2011, EUR UROL, V59, P721, DOI 10.1016/j.eururo.2011.01.004; Zhang BH, 2007, DEV BIOL, V302, P1, DOI 10.1016/j.ydbio.2006.08.028; Zhang CZ, 2012, J TRANSL MED, V10, DOI 10.1186/1479-5876-10-119; Zhang T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080544; Zhao JJ, 2014, INT J CLIN EXP PATHO, V7, P3318; Zhao J, 2013, BIOCHEM BIOPH RES CO, V438, P439, DOI 10.1016/j.bbrc.2013.07.095	100	3	3	2	4	TAYLOR & FRANCIS AS	OSLO	KARL JOHANS GATE 5, NO-0154 OSLO, NORWAY	1473-7159	1744-8352		EXPERT REV MOL DIAGN	Expert Rev. Mol. Diagn.	NOV 2	2018	18	11					981	991		10.1080/14737159.2018.1539668			11	Pathology	Pathology	GZ0TX	WOS:000449079100007	30345829				2019-10-28	
J	Ioffe, OB				Ioffe, Olga B.			Rare but important diagnostic entities: potpourri of case reports with teachable moments	AJSP-REVIEWS AND REPORTS			English	Editorial Material									[Ioffe, Olga B.] Univ Maryland, Sch Med, Dept Pathol, Baltimore, MD 21201 USA	Ioffe, OB (reprint author), 22 S Greene St, Baltimore, MD 21201 USA.	oioffe@umaryland.edu						0	0	0	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1082-9784	1533-4015		AJSP-REV REP	AJSP-Rev. Rep.	NOV-DEC	2018	23	6					247	248		10.1097/PCR.0000000000000288			2	Pathology	Pathology	HK0XW	WOS:000457629000001					2019-10-28	
J	Balis, UGJ; Williams, CL; Cheng, J; Parwani, A; McClintock, DS				Balis, Ulysses G. J.; Williams, Christopher L.; Cheng, Jerome; Parwani, Anil; McClintock, David S.			Whole-Slide Imaging: Thinking Twice Before Hitting the Delete Key	AJSP-REVIEWS AND REPORTS			English	Letter									[Balis, Ulysses G. J.; Cheng, Jerome; McClintock, David S.] Univ Michigan, 2800 Plymouth Rd,NCRC Bldg 35,Room 30-1593, Ann Arbor, MI 48109 USA; [Williams, Christopher L.] Univ Oklahoma, Oklahoma City, OK USA; [Parwani, Anil] Ohio State Univ, Columbus, OH 43210 USA	Balis, UGJ (reprint author), Univ Michigan, 2800 Plymouth Rd,NCRC Bldg 35,Room 30-1593, Ann Arbor, MI 48109 USA.	ulysses@med.umich.edu					[Anonymous], 2017, ANATOMIC PATHOLOGY C; Beck AH, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002564	2	0	0	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1082-9784	1533-4015		AJSP-REV REP	AJSP-Rev. Rep.	NOV-DEC	2018	23	6					249	250		10.1097/PCR.0000000000000283			2	Pathology	Pathology	HK0XW	WOS:000457629000002					2019-10-28	
J	Karrs, JX; Gohlke, AL; Poklepovic, A; Oliveira, AM; Richard, H; Pavlick, DC; Smith, SC				Karrs, Jeremiah Xavier; Gohlke, Amanda Lynn; Poklepovic, Andrew; Oliveira, Andre M.; Richard, Hope; Pavlick, Dean C.; Smith, Steven Christopher			Follicular Dendritic Cell Sarcoma With NF2 Mutation	AJSP-REVIEWS AND REPORTS			English	Article						follicular dendritic cell sarcoma; next-generation sequencing; NF2; soft tissue sarcoma	TUMOR; NF2/MERLIN	Follicular dendritic cell sarcoma (FDCS) is recognized as a diagnostically challenging neoplasm requiring rigorous exclusion of more common entities and high index of suspicion for diagnosis. Here, we report an aggressive case of FDCS arising in the mediastinum, which due to sampling limitations and the inherent difficulty of diagnosis required extensive workup with multiple samples prior to definitive classification. The patient was a 35-year-old woman who presented with progressive dyspnea and mediastinal mass on imaging studies. The initial sampling of the lesion had histologic features raising consideration of FDCS, but was too limited to allow definitive diagnosis, while progressing rapidly enough to require administration of chemotherapy even prior to classification. Repeat samples obtained via fine-needle aspiration and bronchoscopy enabled the diagnosis of FDCS, and high-throughput sequencing revealed apparently pathogenic NF2 mutations previously not reported in this disease. Unfortunately, the patient died of widely metastatic disease, which we comprehensively documented at autopsy. Together, these observations provide previously unreported insights into the end stage of this disease and experience relevant to its prospective recognition and workup.	[Karrs, Jeremiah Xavier; Gohlke, Amanda Lynn; Richard, Hope; Smith, Steven Christopher] VCU Sch Med, Dept Pathol, POB 980662, Richmond, VA 23298 USA; [Karrs, Jeremiah Xavier] VCU Sch Med, Dept Mol Diagnost, Richmond, VA 23298 USA; [Poklepovic, Andrew] VCU Sch Med, Div Hematol & Oncol, Richmond, VA 23298 USA; [Oliveira, Andre M.] Mayo Clin, Dept Pathol, Rochester, MN USA; [Pavlick, Dean C.] Fdn Med Inc, Canc Genom Res, Cambridge, MA USA; [Smith, Steven Christopher] VCU Sch Med, Dept Surg, POB 980662, Richmond, VA 23298 USA	Smith, SC (reprint author), VCU Sch Med, Dept Pathol, POB 980662, Richmond, VA 23298 USA.; Smith, SC (reprint author), VCU Sch Med, Dept Surg, POB 980662, Richmond, VA 23298 USA.	steven.c.smith@vcuhealth.org					Aguzzi A, 2010, EUR J IMMUNOL, V40, P2134, DOI 10.1002/eji.201040765; Baser ME, 2004, NEUROFIBROMATOSIS; Beltrami S, 2013, ANTICANCER RES, V33, P1; Chan JKC, 1997, CANCER, V79, P294; Curto M, 2008, BRIT J CANCER, V98, P256, DOI 10.1038/sj.bjc.6604002; Curto M, 2007, J CELL BIOL, V177, P893, DOI 10.1083/jcb.200703010; Frampton GM, 2013, NAT BIOTECHNOL, V31, P1023, DOI 10.1038/nbt.2696; Go H, 2014, HISTOPATHOLOGY, V65, P261, DOI 10.1111/his.12416; Griffin GK, 2016, MODERN PATHOL, V29, P67, DOI 10.1038/modpathol.2015.130; Grogg KL, 2004, AM J SURG PATHOL, V28, P988, DOI 10.1097/01.pas.0000112536.76973.7f; He J, 2016, BLOOD, V127, P3004, DOI 10.1182/blood-2015-08-664649; Hu JB, 2016, J CARDIOTHORAC SURG, V11, DOI 10.1186/s13019-016-0464-5; Ma Y, 2015, ONCOTARGETS THER, V8, P1823, DOI 10.2147/OTT.S86502; McClatchey AI, 1998, GENE DEV, V12, P1121, DOI 10.1101/gad.12.8.1121; MONDA L, 1986, AM J PATHOL, V122, P562; Neirop K, 2002, SEMIN IMMUNOL, V14, P251; Petrilli AM, 2016, ONCOGENE, V35, P537, DOI 10.1038/onc.2015.125; Schroeder RD, 2014, ONCOTARGET, V5, P67, DOI 10.18632/oncotarget.1557; Sun JX, 2018, PLOS COMPUT BIOL, V14, DOI 10.1371/journal.pcbi.1005965; Viola P, 2016, HISTOPATHOLOGY, V69, P752, DOI 10.1111/his.12998; Wu A, 2016, ARCH PATHOL LAB MED, V140, P186, DOI 10.5858/arpa.2014-0374-RS; Yakushijin Y, 2007, INT J CLIN ONCOL, V12, P56, DOI 10.1007/s10147-006-0626-x	22	1	1	1	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1082-9784	1533-4015		AJSP-REV REP	AJSP-Rev. Rep.	NOV-DEC	2018	23	6					251	254		10.1097/PCR.0000000000000277			4	Pathology	Pathology	HK0XW	WOS:000457629000003					2019-10-28	
J	Katsushima, H; Nakajima, S; Takagawa, M; Fukuhara, N; Ichikawa, S; Itakura, Y; Harigae, H; Ichinohasama, R				Katsushima, Hiroki; Nakajima, Shinji; Takagawa, Masanori; Fukuhara, Noriko; Ichikawa, Satoshi; Itakura, Yuko; Harigae, Hideo; Ichinohasama, Ryo			A Composite Lymphoma Consisting of a Mantle Cell Lymphoma and a Peripheral T-Cell Lymphoma: A Rare Case With Literature Review	AJSP-REVIEWS AND REPORTS			English	Review						composite lymphoma; flow cytometry; mantle cell lymphoma; peripheral T-cell lymphoma	CLASSICAL HODGKIN LYMPHOMA; MARGINAL ZONE LYMPHOMA; B-CELL; IN-SITU; LYMPHOCYTIC LYMPHOMA; FOLLICULAR LYMPHOMA; LEUKEMIA	A composite lymphoma (CL) is defined as 2 or more morphologically and immunophenotypically distinct lymphomas or lymphoid neoplasms that occur in the same organ or tissue. Many types of CL have been described in the literature, including 52 cases of CL with a component of mantle cell lymphoma (MCL) and only 2 cases of CL consisting of MCL and T-cell lymphoma. We hereby present a case of CL consisting of MCL and peripheral T-cell lymphoma, not otherwise specified. Morphologic features and flow cytometry analysis were both instrumental in the diagnosis of CL. In addition, we reviewed 52 reported cases of CL with MCL as a component. We found that the proliferation patterns of MCL have a relationship with the other component of the CL. We also found that many patients with CL had a history of lymphoproliferative disorders including lymphomas; this was observed in 9 of 52 cases, including 5 cases of MCL and 2 cases of another component of CL. This rate (approximately 17%) is relatively high and should not be ignored.	[Katsushima, Hiroki; Ichinohasama, Ryo] Tohoku Univ Hosp, Div Hematopathol, Sendai, Miyagi, Japan; [Nakajima, Shinji; Takagawa, Masanori] Japanese Red Cross Ishinomaki Hosp, Dept Internal Med, Ishinomaki, Miyagi, Japan; [Fukuhara, Noriko; Ichikawa, Satoshi; Harigae, Hideo] Tohoku Univ, Dept Hematol & Rheumatol, Grad Sch Med, Sendai, Miyagi, Japan; [Itakura, Yuko] Japanese Red Cross Ishinomaki Hosp, Dept Pathol, Ishinomaki, Miyagi, Japan	Katsushima, H (reprint author), Tohoku Univ Hosp, Div Hematopathol, Aoba Ku, 1-1 Seiryo Machi, Sendai, Miyagi 9808574, Japan.	katsushima@med.tohoku.ac.jp			Japan Society for the Promotion of Science (JSPS KAKENHI)Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI) [24590677/15 K08609]	This work was supported in part by Grants-in-Aid for Scientific Research from the Japan Society for the Promotion of Science (JSPS KAKENHI no. 24590677/15 K08609).	Addada J, 2010, ACTA HAEMATOL-BASEL, V123, P194, DOI 10.1159/000297525; Andhavarapu S, 2014, EUR J HAEMATOL, V93, P537, DOI 10.1111/ejh.12344; Aqel N, 2008, HISTOPATHOLOGY, V52, P256, DOI 10.1111/j.1365-2559.2007.02906.x; Cachia AR, 1997, HUM PATHOL, V28, P1291, DOI 10.1016/S0046-8177(97)90203-3; Caleo A, 2003, AM J SURG PATHOL, V27, P1577, DOI 10.1097/00000478-200312000-00012; Cooper CL, 2007, HISTOPATHOLOGY, V51, P856, DOI 10.1111/j.1365-2559.2007.02859.x; Demurtas A, 2011, AM J CLIN PATHOL, V135, P541, DOI 10.1309/AJCPQKE25ADCFZWN; Felten CL, 2004, LEUKEMIA LYMPHOMA, V45, P2143, DOI 10.1080/10428190410001711479; Fend F, 1999, AM J PATHOL, V154, P1857, DOI 10.1016/S0002-9440(10)65443-0; Giua R, 2015, J AM GERIATR SOC, V63, P824, DOI 10.1111/jgs.13355; Hayes SJ, 2006, HISTOPATHOLOGY, V48, P621, DOI 10.1111/j.1365-2559.2005.02296.x; Ho AK, 2011, INT J SURG PATHOL, V19, P643, DOI 10.1177/1066896911405656; Hoeller S, 2013, HUM PATHOL, V44, P110, DOI 10.1016/j.humpath.2012.04.022; Huwait H, 2010, AM J DERMATOPATH, V32, P65, DOI 10.1097/DAD.0b013e3181af7dee; ILgenfritz RB, 2009, HUM PATHOL, V40, P259, DOI 10.1016/j.humpath.2008.05.017; Ioachim HL, 2009, LYMPH NODE PATHOLOGY, P452; Katsushima H, 2017, LEUKEMIA LYMPHOMA, V58, P80, DOI 10.1080/10428194.2016.1183254; Korac P, 2013, APPL IMMUNOHISTO M M, V21, P572, DOI 10.1097/PAI.0b013e3182582bd8; Kourelis TV, 2011, ACTA HAEMATOL-BASEL, V126, P40, DOI 10.1159/000324193; La Fortune K, 2013, CASE REP HEMATOL, DOI 10.1155/2013/386147; Leduc C, 2015, AM J DERMATOPATH, V37, P232, DOI 10.1097/DAD.0000000000000233; Lefebvre C, 2007, HUM PATHOL, V38, P660, DOI 10.1016/j.humpath.2006.08.023; Lima M, 2003, CYTOM PART B-CLIN CY, V51B, P41, DOI 10.1002/cyto.b.10005; Liu YX, 2014, AM J CLIN PATHOL, V141, P737, DOI 10.1309/AJCPAWDDYO5OQYCD; Looi A, 2005, OPHTHALMOLOGY, V112, P114, DOI 10.1016/j.ophtha.2004.07.025; Matsuoka Akihito, 2013, Rinsho Ketsueki, V54, P2056; Mokhtar Nadia M, 2007, J Egypt Natl Canc Inst, V19, P171; Papathomas TG, 2012, HUM PATHOL, V43, P467, DOI 10.1016/j.humpath.2011.08.024; Perdigao J, 2010, J HEMATOP, V3, P91; Rodig SJ, 2006, CANCER GENET CYTOGEN, V171, P44, DOI 10.1016/j.cancergencyto.2006.06.018; Roullet MR, 2010, AM J CLIN PATHOL, V133, P584, DOI 10.1309/AJCP5RT4MRSDGKSX; Schneider S, 2014, INT J CANCER, V134, P832, DOI 10.1002/ijc.28422; Senhara Tsuyoshi, 2009, Rinsho Ketsueki, V50, P517; Sloan C, 2015, AM J CLIN PATHOL, V143, P274, DOI 10.1309/AJCP06VIKFMTRCXD; Swerdlow SH, 2008, WHO CLASSIFICATION T; Taverna J, 2014, CASE REP HEMATOL, DOI 10.1155/2014/145129; Tinguely M, 2003, AM J SURG PATHOL, V27, P1483, DOI 10.1097/00000478-200311000-00014; Tsang P, 1999, HUM PATHOL, V30, P988, DOI 10.1016/S0046-8177(99)90256-3; Visco C, 2011, AM J SURG PATHOL, V35, P177, DOI 10.1097/PAS.0b013e3182049a9c; Wang ED, 2014, HUM PATHOL, V45, P768, DOI 10.1016/j.humpath.2013.11.008; Wang HY, 2008, HUM PATHOL, V39, P781, DOI 10.1016/j.humpath.2007.08.023; Wang S, 2013, HUM PATHOL, V44, P2658, DOI 10.1016/j.humpath.2013.07.007; Warnke RA, 1994, TUMORS LYMPH NODES S, P329; Zamo A, 2006, VIRCHOWS ARCH, V448, P639, DOI 10.1007/s00428-006-0158-9	44	0	0	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1082-9784	1533-4015		AJSP-REV REP	AJSP-Rev. Rep.	NOV-DEC	2018	23	6					255	261		10.1097/PCR.0000000000000286			7	Pathology	Pathology	HK0XW	WOS:000457629000004					2019-10-28	
J	Alwatari, Y; Preciado, C; Tondon, R; Shiraff, A				Alwatari, Yahya; Preciado, Christopher; Tondon, Rashmi; Shiraff, Adam			Brown Bowel Syndrome Presenting as a Small Bowel Obstruction	AJSP-REVIEWS AND REPORTS			English	Article							COMPLICATION	Brown bowel syndrome (BBS) is a rare condition characterized by lipofuscin deposition in the muscularis propria of the bowel. It is associated with vitamin E deficiency and malabsorptive syndromes. We report a case of BBS in a patient with previously undiagnosed primary intestinal lymphangiectasia. The patient had a longstanding history of malnutrition as well as bilateral lower extremity lymphedema and chylous ascites. He presented to our hospital with small bowel obstruction (SBO). Initial magnetic resonance enterography revealed a dilated duodenum, which when biopsied revealed only lymphangiectasia and lymphedema. He was managed conservatively and discharged following resolution of the obstruction. The patient presented again 1 month later with SBO that failed to resolve with conservative treatment. Subsequent exploratory laparotomy discovered a portion of pale, edematous, aperistaltic jejunum. The specimen was resected, and pathologic examination revealed brown granular pigment deposition within the muscularis propria, which was highlighted by periodic acid-Schiff and lipofuscin stains, diagnostic of BBS. Nutritional workup revealed multiple deficiencies. The patient's clinical findings and history were suggestive of primary intestinal lymphangiectasia with resulting nutritional deficiencies leading to BBS. Outpatient follow-up after recovery revealed an elevated 24-hour fecal alpha 1 antitrypsin, which supports this diagnosis. The patient has since improved following adherence to a low-fat diet. The combined clinical, radiographic, and pathologic findings in this case allowed for the resolution of this complex diagnostic dilemma. Although rare, BBS remains an important consideration in the differential diagnosis of a patient with SBO and history of chylous ascites and should be viewed as a symptom of underlying treatable nutritional deficiency.	[Alwatari, Yahya; Shiraff, Adam] Univ Penn, Dept Surg, Philadelphia, PA 19104 USA; [Preciado, Christopher; Tondon, Rashmi] Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA	Alwatari, Y (reprint author), 3400 Spruce St, Philadelphia, PA 19104 USA.	Yahya.Alwaiari@uphs.upenn.edu					Albrecht H, 2014, DIGESTION, V89, P105, DOI 10.1159/000357228; Anand Akash, 2005, J La State Med Soc, V157, P338; Anderson HD, 1939, P SOC EXP BIOL MED, V42, P750; Bialas M, 2013, POL J PATHOL, V64, P228, DOI 10.5114/PJP.2013.38329; FOSTER CS, 1979, HISTOPATHOLOGY, V3, P1, DOI 10.1111/j.1365-2559.1979.tb02977.x; HURLEY JP, 1991, J ROY SOC MED, V84, P437; PAPPENHEIMER AM, 1946, AM J PATHOL, V22, P395; Raithel M, 2015, WORLD J GASTROENTERO, V21, P10461, DOI 10.3748/wjg.v21.i36.10461; RODRIGUEZ IN, 1993, REV ESP ENFERM DIG, V83, P281; Surampalli V, 2017, J CLIN DIAGN RES, V11, pOD17, DOI 10.7860/JCDR/2017/29055.10522; TOFFLER AH, 1963, ANN INTERN MED, V58, P872, DOI 10.7326/0003-4819-58-5-872; Wagner E., 1861, ARCH HEILKUNDE, V2, P455; WALDRON D, 1994, IRISH J MED SCI, V163, P404, DOI 10.1007/BF02975037; WARD HC, 1992, J PEDIATR SURG, V27, P1593, DOI 10.1016/0022-3468(92)90521-8	14	0	0	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1082-9784	1533-4015		AJSP-REV REP	AJSP-Rev. Rep.	NOV-DEC	2018	23	6					262	265		10.1097/PCR.0000000000000276			4	Pathology	Pathology	HK0XW	WOS:000457629000005					2019-10-28	
J	Shafique, K; Lee, LH; Samad, A; Wang, L; Klimstra, DS				Shafique, Khurram; Lee, Lik Hang; Samad, Arbaz; Wang, Lu; Klimstra, David S.			Pancreatic-Type Mixed Acinar Neuroendocrine Carcinoma Arising in the Common Bile Duct: A Case Report	AJSP-REVIEWS AND REPORTS			English	Article						common bile duct cancer; mixed acinar neuroendocrine carcinoma; pancreatic cancer; pancreatic heterotopia	ALPHA-FETOPROTEIN PRODUCTION; CELL-CARCINOMA; ENDOCRINE CARCINOMA; STEM/PROGENITOR CELLS; BILIARY TREE; LIVER; STOMACH; NEOPLASMS; DIFFERENTIATION; METAPLASIA	Mixed acinar neuroendocrine carcinoma (MAcNEC) of pancreatic type arising in an extrapancreatic location is extremely rare. We present a case of a 70-year-old woman with constipation, abdominal discomfort, and jaundice. Imaging studies revealed a 1.8-cm solid mass in the common bile duct causing dilatation of intrahepatic and extrahepatic bile ducts, which was resected. Microscopically, the tumor was limited to the wall of the bile duct, without involvement of the pancreas, and was composed of solid sheets and nests of relatively monomorphic cells with minimal to moderate amounts of cytoplasm, granular chromatin, focally prominent nucleoli, and up to 160 mitoses per 10 high-power fields. Immunohistochemistry showed equal to or greater than 30% positivity for synaptophysin, chromogranin, chymotrypsin, and trypsin. A diagnosis of MAcNEC was rendered. Immunohistochemistry plays a pivotal role in the identification of these tumors and discrimination from other related entities, neuroendocrine neoplasms in particular. Because pancreatic heterotopia has been described in the common bile duct, we postulate that this case of MAcNEC in the common bile duct, the first to be reported in the literature, may have arisen via malignant transformation of pancreatic heterotopia.	[Shafique, Khurram] Hosp Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA; [Lee, Lik Hang] Univ British Columbia, Dept Pathol & Lab Med, St Pauls Hosp, Vancouver, BC, Canada; [Samad, Arbaz] Atlantic Hlth Syst, Dept Pathol, Morristown, NJ USA; [Wang, Lu; Klimstra, David S.] St Jude Childrens Res Hosp, Dept Pathol, 332 N Lauderdale St, Memphis, TN 38105 USA; [Klimstra, David S.] Mem Sloan Kettering Canc Ctr, Dept Pathol, 1275 York Ave, New York, NY 10021 USA	Shafique, K (reprint author), Hosp Univ Penn, Dept Pathol & Lab Med, 6 Founders,Room FO6-055,3400 Spruce St, Philadelphia, PA 19104 USA.	Khurram.Shafique@uphs.upenn.edu					Agaimy A, 2011, MODERN PATHOL, V24, P1620, DOI 10.1038/modpathol.2011.127; Ambrosini-Spaltro A, 2009, HUM PATHOL, V40, P746, DOI 10.1016/j.humpath.2008.10.006; Basturk O, 2015, AM J SURG PATHOL, V39, P683, DOI 10.1097/PAS.0000000000000408; Bosman FT, 2010, WHO CLASSIFICATION T; Carpino G, 2012, J ANAT, V220, P186, DOI 10.1111/j.1469-7580.2011.01462.x; Chiaravalli AM, 2009, VIRCHOWS ARCH, V455, P527, DOI 10.1007/s00428-009-0852-5; Chmielecki J, 2014, CANCER DISCOV, V4, P1398, DOI 10.1158/2159-8290.CD-14-0617; Cingolani N, 2000, HUM PATHOL, V31, P938, DOI 10.1053/hupa.2000.9075; Deutsch G, 2001, DEVELOPMENT, V128, P871; DOGLIONI C, 1993, AM J SURG PATHOL, V17, P1134, DOI 10.1097/00000478-199311000-00006; Fukunaga M, 2002, HUM PATHOL, V33, P569, DOI 10.1053/hupa.2002.126345; Hervieu V, 2008, VIRCHOWS ARCH, V452, P337, DOI 10.1007/s00428-007-0556-7; Ho C, 2016, MOD PATHOL S2, V29; Hochwald SN, 2002, J CLIN ONCOL, V20, P2633, DOI 10.1200/JCO.2002.10.030; Holen KD, 2002, J CLIN ONCOL, V20, P4673, DOI 10.1200/JCO.2002.02.005; Hosoda W, 2013, PATHOL INT, V63, P176, DOI 10.1111/pin.12045; Jain D, 2005, AM J SURG PATHOL, V29, P1524, DOI 10.1097/01.pas.0000169498.89035.f9; Jakobsen M, 2016, HISTOL HISTOPATHOL, V31, P1381, DOI 10.14670/HH-11-767; Jiao YC, 2014, J PATHOL, V232, P428, DOI 10.1002/path.4310; Kawakami H, 2007, J GASTROENTEROL, V42, P694, DOI 10.1007/s00535-007-2070-8; KLIMSTRA DS, 1994, AM J SURG PATHOL, V18, P765, DOI 10.1097/00000478-199408000-00002; KLIMSTRA DS, 1992, AM J SURG PATHOL, V16, P815, DOI 10.1097/00000478-199209000-00001; Kuo FY, 2009, AM J SURG PATHOL, V33, P66, DOI 10.1097/PAS.0b013e31818c8482; Kusafuka K, 2009, MED MOL MORPHOL, V42, P167, DOI 10.1007/s00795-009-0446-y; La Rosa S, 2012, AM J SURG PATHOL, V36, P1782, DOI 10.1097/PAS.0b013e318263209d; Makhlouf HR, 1999, ARCH PATHOL LAB MED, V123, P707; Mizuno Y, 2007, SURG TODAY, V37, P704, DOI 10.1007/s00595-006-3384-5; Moncur JT, 2002, HUM PATHOL, V33, P449, DOI 10.1053/hupa.2002.124040; Ohike N, 2004, VIRCHOWS ARCH, V445, P231, DOI 10.1007/s00428-004-1037-x; Reid LM, 2016, HEPATOLOGY, V64, P4, DOI 10.1002/hep.28606; Sigel CS, 2013, CANCER CYTOPATHOL, V121, P459, DOI 10.1002/cncy.21279; Soubra A, 2011, RARE TUMORS, V3, DOI 10.4081/rt.2011.e15; SUDA K, 1984, ARCH PATHOL LAB MED, V108, P835; Sullivan PS, 2013, ACTA CYTOL, V57, P296, DOI 10.1159/000343683; Sumiyoshi T, 2014, INTERNAL MED, V53, P2679, DOI 10.2169/internalmedicine.53.3007; Sun YY, 2004, HUM PATHOL, V35, P263, DOI 10.1016/j.humpath.2003.09.020; Wildgruber M, 2013, ROFO-FORTSCHR RONTG, V185, P572, DOI 10.1055/s-0032-1330711; Yantiss RK, 2002, AM J SURG PATHOL, V26, P893, DOI 10.1097/00000478-200207000-00007; Zundler S, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2184-6	39	0	0	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1082-9784	1533-4015		AJSP-REV REP	AJSP-Rev. Rep.	NOV-DEC	2018	23	6					266	270		10.1097/PCR.0000000000000278			5	Pathology	Pathology	HK0XW	WOS:000457629000006					2019-10-28	
J	Medlicott, SAC; Eidus, L; Trpkov, K				Medlicott, Shaun A. C.; Eidus, Leslie; Trpkov, Kiril			Isolated Pulse Granuloma in a Mesenteric Lymph Node: Unusual Nodal Manifestation Associated With Crohn Disease Complicated by Ileal Adenocarcinoma	AJSP-REVIEWS AND REPORTS			English	Article						Crohn disease; ileal adenocarcinoma; lymph node; mesentery; pulse granuloma	INFLAMMATORY-BOWEL-DISEASE; CLINICAL-SIGNIFICANCE	Pulse granuloma is an unusual inflammatory reaction to legumes. Pulse granulomas of the gastrointestinal tract are typically accompanied by significant mural damage due to ulceration, fistula, or perforation. We describe a solitary pulse granuloma in a mesenteric lymph node of a 74-year-old male patient with Crohn disease, who presented with an ileal adenocarcinoma, but without demonstrable fistula or perforation. To our knowledge, this is only the second reported example of Crohn disease associated with a pulse granuloma in a mesenteric node and also only the second example of a nodal location for any documented pulse granuloma. We postulate that mesenteric lymph node pulse granuloma may represent a unique and unusual type of morphology associated with Crohn disease.	[Medlicott, Shaun A. C.; Eidus, Leslie; Trpkov, Kiril] Rockyview Gen Hosp, Dept Pathol & Lab Med, Calgary Lab Serv, 7007 14 St, Calgary, AB T2V 1P9, Canada; [Medlicott, Shaun A. C.; Eidus, Leslie; Trpkov, Kiril] Univ Calgary, 7007 14 St, Calgary, AB T2V 1P9, Canada	Trpkov, K (reprint author), Rockyview Gen Hosp, Dept Pathol & Lab Med, Calgary Lab Serv, 7007 14 St, Calgary, AB T2V 1P9, Canada.; Trpkov, K (reprint author), Univ Calgary, 7007 14 St, Calgary, AB T2V 1P9, Canada.	kiril.trpkov@cls.ab.ca					ADKINS K F, 1972, New Zealand Dental Journal, V68, P209; El-Labban NG, 1981, ORAL SURG ORAL MED O, V10, P147; HARRISON JD, 1986, J ORAL PATHOL MED, V15, P322, DOI 10.1111/j.1600-0714.1986.tb00633.x; Jess T, 2007, INFLAMM BOWEL DIS, V13, P481, DOI 10.1002/ibd.20036; Karamurzin YS, 2009, HISTOPATHOLOGY, V54, P268, DOI 10.1111/j.1365-2559.2008.03208.x; KNOBLICH R, 1969, AM REV RESPIR DIS, V99, P380; KOVI J, 1981, AM J CLIN PATHOL, V76, P385; Lewars P H, 1971, Br J Oral Surg, V8, P264; Li Y, 2015, INFLAMM BOWEL DIS, V21, P2613, DOI 10.1097/MIB.0000000000000541; Molnar T, 2005, WORLD J GASTROENTERO, V11, P3118, DOI 10.3748/wjg.v11.i20.3118; Nambudripad R, 2008, INT J SURG PATHOL, V16, P96, DOI 10.1177/1066896907307233; Nowacki NB, 2015, AM J SURG PATHOL, V39, P84, DOI 10.1097/PAS.0000000000000308; PRICE AB, 1975, HUM PATHOL, V6, P7, DOI 10.1016/S0046-8177(75)80107-9; Ramzan NN, 2002, INFLAMM BOWEL DIS, V8, P168, DOI 10.1097/00054725-200205000-00002; Rhee DD, 2006, ARCH PATHOL LAB MED, V130, P1839; Shepherd NA, 2002, HISTOPATHOLOGY, V41, P166, DOI 10.1046/j.1365-2559.2002.01441.x; Sura R, 2011, ALIMENT PHARM THER, V33, P930, DOI 10.1111/j.1365-2036.2011.04605.x; TALACKO AA, 1988, INT J ORAL MAX SURG, V17, P343, DOI 10.1016/S0901-5027(88)80059-6; Tschen JA, 2008, J CUTAN PATHOL, V35, P343, DOI 10.1111/j.1600-0560.2007.00812.x; Turner K, 2014, INFLAMM BOWEL DIS, V20, P2271, DOI 10.1097/MIB.0000000000000196; Zhai Jing, 2004, Ann Diagn Pathol, V8, P375, DOI 10.1053/j.anndiagpath.2004.08.010	21	0	0	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1082-9784	1533-4015		AJSP-REV REP	AJSP-Rev. Rep.	NOV-DEC	2018	23	6					271	273		10.1097/PCR.0000000000000273			3	Pathology	Pathology	HK0XW	WOS:000457629000007					2019-10-28	
J	Baratelli, F; Wei, C; Elatre, W; Xiao, GQ; Ward, P; Pettersson, J; Campan, M; Larsen, BT; Ashley, P; Wang, L; Cohen, R; Koss, M				Baratelli, Felicita; Wei, Christina; Elatre, Wafaa; Xiao, Guang-Qian; Ward, Pamela; Pettersson, Jonas; Campan, Mihaela; Larsen, Brandon T.; Ashley, Prosper; Wang, Linan; Cohen, Robbin; Koss, Michael			Expanding the Spectrum of Ciliated Muconodular Papillary Tumor of the Lung: A Case Showing Nonpapillary and Purely Glandular Morphology	AJSP-REVIEWS AND REPORTS			English	Article						ciliated adenocarcinoma; ciliated muconodular papillary tumor	MUTATIONS; ADENOCARCINOMA; DISEASE; CANCER	We report an unusual case of a subpleural bronchiolar/glandular proliferation in a 76-year-old Hispanic woman with microscopic features reminiscent of those of the so-called ciliated muconodular papillary tumor (CMPT). The lesion presented radiologically as a solitary subpleural nodule measuring 2.7 x 1.2 cm with low standard uptake value (SUV) of 1.4. Microscopically, it was circumscribed but unencaspulated and consisted of mucous-filled spaces lined by cytologically bland cuboidal to low columnar cells, including goblet cells and ciliated epithelium, with underlying nodular collections of basaloid cells. The lining cells stained diffusely for CK7 but only focally for TTF-1 and CEA, whereas the basal cells expressed CK5/6. Ki-67 showed a proliferative index of less than 1%. Target gene mutation analysis with a 50-cancer-related-gene panel using next-generation sequencing showed the bronchiolar proliferation to harbor an EGFR in frame exon 20 insertion mutation with 30% allele frequency, which supports a neoplastic diagnosis. Accordingly, given the mutually exclusive nature of driver mutations, a BRAF V600E mutation was absent by both immunohistochemical and next-generation sequencing analysis. Microscopic evidence of metastatic spread was not seen in 8 regional lymph nodes examined. Given the histomorphology and immunohistochemical findings, the mutational profile and the reported heterogeneous microscopic patterns of CMPTs, including glandular component, we suggest the tumor herein described be a glandular variant of CMPT. We therefore suggest that the term ciliated muconodular tumor may be more appropriate for this group of lesions.	[Baratelli, Felicita; Wei, Christina; Elatre, Wafaa; Xiao, Guang-Qian; Ward, Pamela; Pettersson, Jonas; Campan, Mihaela; Larsen, Brandon T.; Ashley, Prosper; Wang, Linan; Cohen, Robbin; Koss, Michael] LAC USC, Los Angeles, CA USA	Baratelli, F (reprint author), Cedars Sinai Med Ctr, Dept Pathol, 8700 Beverly Blvd, Los Angeles, CA 90048 USA.	felicita.baratelli@cshs.org					Arcila ME, 2013, MOL CANCER THER, V12, P220, DOI 10.1158/1535-7163.MCT-12-0620; Cano-Jimenez E, 2009, ARCH BRONCONEUMOL, V45, P57, DOI 10.1016/j.arbres.2007.11.001; Chu HH, 2017, HUM PATHOL CASE REPO, V7, P8; Chuang HW, 2014, PATHOL INT, V64, P352, DOI 10.1111/pin.12179; COLBY TL, 1991, ATLAS PULMONARY SURG; de Carvalho MEP, 2002, PATHOL RES PRACT, V198, P577, DOI 10.1078/0344-0338-00305; Fukuoka J, 2005, AM J SURG PATHOL, V29, P948, DOI 10.1097/01.pas.0000168177.71405.ac; Harada T, 2008, RESP MED CME, V1, P176; Ishikawa Y., 2002, PATHOL CLIN MED, V20, P964; Jin Y, 2017, PATHOL INT, V67, P171, DOI 10.1111/pin.12512; Kamata T, 2016, J THORAC ONCOL, V11, P261, DOI 10.1016/j.jtho.2015.10.021; Kon T, 2016, PATHOL INT, V66, P633, DOI 10.1111/pin.12460; LAMBERT MW, 1955, J PATHOL BACTERIOL, V70, P311, DOI 10.1002/path.1700700206; Lau KW, 2016, HUM PATHOL, V49, P22, DOI 10.1016/j.humpath.2015.09.038; Liu LP, 2016, AM J SURG PATHOL, V40, P1631, DOI 10.1097/PAS.0000000000000707; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; NAKAMURA S, 1992, ACTA PATHOL JAPON, V42, P745; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; Park WY, 2012, MODERN PATHOL, V25, P1265, DOI 10.1038/modpathol.2012.76; Sato S, 2010, INTERACT CARDIOV TH, V11, P685, DOI 10.1510/icvts.2009.229989; Spencer H, 1968, PATHOLOGY LUNG, V2, P31; Sugase T, 2016, SURG CASE REP, V2, DOI 10.1186/s40792-016-0266-y; Travis D, 2017, WHO CLASSIFICATION T, V7	23	0	0	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1082-9784	1533-4015		AJSP-REV REP	AJSP-Rev. Rep.	NOV-DEC	2018	23	6					274	278		10.1097/PCR.0000000000000285			5	Pathology	Pathology	HK0XW	WOS:000457629000008					2019-10-28	
J	Mehrad, M; Bittar, HET; Yousem, SA				Mehrad, Mitra; Bittar, Humberto E. Trejo; Yousem, Samuel A.			Human Polyomavirus 7 and WU Polyomavirus-Associated Lymphocytic Bronchitis/Bronchiolitis in Native and Allograft Lung Biopsies From Immunocompromised Patients: Report of 3 Cases and Review of Literature	AJSP-REVIEWS AND REPORTS			English	Review						human polyomavirus; immunosuppression; lung transplantation; PyV7; WUPyV	MERKEL CELL POLYOMAVIRUS; KI; IDENTIFICATION; PREVALENCE; CHILDREN; BK	Human polyomavirus (PyV) family comprised 13 DNA viruses, which cause subclinical infection in more than 90% of the general population. However, significant disease including cancer is mainly observed in immunosuppressed patients. Few studies have investigated the detection of PyV in the respiratory tract. In this report, 3 transbronchial biopsies showed viral inclusions on histologic examination and were evaluated for anti-SV40 large T antigen (SV40 T Ag) by immunohistochemistry (IHC), in situ hybridization, and viral genome sequencing by polymerase chain reaction. Patients 1 and 2 were immunosuppressed lung transplant recipients. Patient 1 presented with diffuse pruritic rash and respiratory failure, and patient 2 with PyV viremia. Patient 3 had chronic lymphocytic leukemia/small lymphocytic lymphoma and presented with cough and shortness of breath. Histologic examination of all 3 lung biopsies were similar and revealed predominantly bronchial epithelial cells with enlarged nuclei, smudgy chromatin quality, and lymphocytic bronchitis/bronchiolitis with a patchy alveolar septal mononuclear infiltrate. SV40 large T antigen IHC was positive in all cases, whereas in situ hybridization for BK and JC virus was negative. Polymerase chain reaction sequencing identified PyV7 in case 1 and WUPyV in cases 2 and 3. We describe for the first time that PyV7 and WUPyV may be associated with lymphocytic bronchitis/bronchiolitis in the lungs of immunosuppressed individuals. It is important to be cognizant of the cross-reactivity of SV40 T Ag IHC with other types of PyV and equally essential to distinguish PyV bronchitis from other viral pathogens.	[Mehrad, Mitra; Bittar, Humberto E. Trejo; Yousem, Samuel A.] Univ Pittsburgh, Presbyterian Hosp, Dept Pathol, Med Ctr, Pittsburgh, PA 15213 USA; [Mehrad, Mitra] Vanderbilt Univ, Med Ctr, Dept Pathol Microbiol & Immunol, Third Floor,MCN C-3311B, Nashville, TN 37232 USA	Mehrad, M (reprint author), Vanderbilt Univ, Med Ctr, Dept Pathol Microbiol & Immunol, Third Floor,MCN C-3311B, Nashville, TN 37232 USA.	mitra.mehrad@vanderbilt.edu					Allander T, 2007, J VIROL, V81, P4130, DOI 10.1128/JVI.00028-07; Bialasiewicz S, 2008, J CLIN VIROL, V41, P63, DOI 10.1016/j.jcv.2007.11.001; Bialasiewicz S, 2016, AM J TRANSPLANT, V22; Bialasiewicz S, 2010, J VIROL, V84, P6229, DOI 10.1128/JVI.02658-09; Cimino PJ, 2013, EXP MOL PATHOL, V94, P40, DOI 10.1016/j.yexmp.2012.09.019; Dinwiddie DL, 2016, GENOME ANNOUNC, V4; Duncavage EJ, 2011, J CUTAN PATHOL, V38, P790, DOI 10.1111/j.1600-0560.2011.01765.x; Feng HC, 2008, SCIENCE, V319, P1096, DOI 10.1126/science.1152586; GARDNER SD, 1971, LANCET, V1, P1253; Gaynor AM, 2007, PLOS PATHOG, V3, P595, DOI 10.1371/journal.ppat.0030064; HARLOW E, 1981, J VIROL, V39, P861; Ho JH, 2015, J INFECT DIS, V211, P1560, DOI 10.1093/infdis/jiu524; Imajoh M, 2013, J DERMATOL, V40, P657, DOI 10.1111/1346-8138.12180; Neske F, 2010, BMC INFECT DIS, V10, DOI 10.1186/1471-2334-10-215; Nicol JTJ, 2013, CLIN VACCINE IMMUNOL, V20, P363, DOI 10.1128/CVI.00438-12; PADGETT BL, 1971, LANCET, V1, P1257; Rahiala J, 2016, PEDIATR TRANSPLANT, V20, P424, DOI 10.1111/petr.12659; Rockett RJ, 2015, EMERG INFECT DIS, V21, P365, DOI 10.3201/eid2102.141429; Rockett RJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062764; Schowalter RM, 2010, CELL HOST MICROBE, V7, P509, DOI 10.1016/j.chom.2010.05.006; Schrama D, 2012, J INVEST DERMATOL, V132, P239, DOI 10.1038/jid.2011.261; Scola N, 2012, BRIT J DERMATOL, V167, P1315, DOI 10.1111/j.1365-2133.2012.11141.x; Sharp CP, 2009, J INFECT DIS, V199, P398, DOI 10.1086/596062; Siebrasse EA, 2015, EMERG INFECT DIS, V21, P103, DOI 10.3201/eid2101.140855; Siebrasse EA, 2012, EMERG INFECT DIS, V18, P1676, DOI 10.3201/eid1810.120359; Toptan T, 2016, JCI INSIGHT, V1, DOI 10.1172/jci.insight.85562	26	0	0	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1082-9784	1533-4015		AJSP-REV REP	AJSP-Rev. Rep.	NOV-DEC	2018	23	6					279	283		10.1097/PCR.0000000000000270			5	Pathology	Pathology	HK0XW	WOS:000457629000009					2019-10-28	
J	Hibbert, JM; Janssen, K; Simper, NB				Hibbert, Joseph Milo; Janssen, Karmon; Simper, Novae B.			Renal Cell Carcinoma With (Angio) Leiomyomatous Stroma in a Patient With TSC2 Mutation: A Case Report	AJSP-REVIEWS AND REPORTS			English	Article						clear cell papillary; renal cell carcinoma with (angio) leiomyomatous stroma; TCEB1 mutation; tuberous sclerosis; RAT	ANGIOMYOADENOMATOUS TUMOR	We present the case of a 34-year-old woman with a TSC2 gene mutation diagnosed with 4 distinct renal cell carcinomas with (angio)leiomyomatous stroma and 2 concomitant angiomyolipomas of the left kidney. Histologically, the nodules, located in the renal cortex, were mostly encapsulated with an abundant smooth muscle stromal component, which delved into the central epithelial component of the tumor forming septations. The epithelial component was made up of elongated tubules, papillae, and acinar structures with clear to eosinophilic cytoplasm and apical snouts. Focal acinar structures were filled with hypereosinophilic material. The nuclei were basally located and supported by a delicate vascular network. Immunohistochemical studies revealed the tumor cells to express cytokeratin 7, CD10 variably, and carbonic anhydrase IX in an incomplete "cup-like" membranous pattern. The tumor cells did not express AMACR, TFE3, MART-1, or cathepsin K. This report describes a unique presentation of a rare entity and brings attention to an evolving diagnostic field. We discuss problems and controversy surrounding the diagnosis of renal cell carcinoma with (angio)leiomyomatous stroma, its relationship to clear cell papillary renal cell carcinoma and other tumors, and how it correlates with newly discovered genetic mutations.	[Hibbert, Joseph Milo; Janssen, Karmon; Simper, Novae B.] US Army Madigan Army Med Ctr, 9040 Jackson Ave, Tacoma, WA 98431 USA; [Simper, Novae B.] InCyte Pathol, Spokane, WA USA	Hibbert, JM (reprint author), US Army Madigan Army Med Ctr, 9040 Jackson Ave, Tacoma, WA 98431 USA.	joseph.m.hibbert.mil@mail.mil					Crumley Suzanne M, 2013, World J Clin Cases, V1, P262, DOI 10.12998/wjcc.v1.i9.262; Deml KF, 2015, AM J SURG PATHOL, V39, P889, DOI 10.1097/PAS.0000000000000456; Guo J, 2014, AM J SURG PATHOL, V38, P1457, DOI 10.1097/PAS.0000000000000248; Hakimi AA, 2015, MODERN PATHOL, V28, P845, DOI 10.1038/modpathol.2015.6; Hes O, 2016, ANN DIAGN PATHOL, V21, P59, DOI 10.1016/j.anndiagpath.2015.11.003; Kuhn E, 2006, AM J SURG PATHOL, V30, P1372, DOI 10.1097/01.pas.0000213277.45715.82; Michal M, 2009, VIRCHOWS ARCH, V454, P89, DOI 10.1007/s00428-008-0697-3; Petersson F, 2014, VIRCHOWS ARCH, V465, P89, DOI 10.1007/s00428-014-1591-9; Sato Y, 2013, NAT GENET, V45, P860, DOI 10.1038/ng.2699; Ulamec Monika, 2011, Lijec Vjesn, V133, P190; Williamson SR, 2015, MODERN PATHOL, V28, P279, DOI 10.1038/modpathol.2014.105; Yang P, 2014, AM J SURG PATHOL, V38, P895, DOI 10.1097/PAS.0000000000000237; Zhou HJ, 2014, HUM PATHOL, V45, P59, DOI 10.1016/j.humpath.2013.08.004	13	0	0	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1082-9784	1533-4015		AJSP-REV REP	AJSP-Rev. Rep.	NOV-DEC	2018	23	6					284	287		10.1097/PCR.0000000000000274			4	Pathology	Pathology	HK0XW	WOS:000457629000010					2019-10-28	
J	Manucha, V; Azar, A; Roda, M; Lewin, J				Manucha, Varsha; Azar, Azniv; Roda, Manohar; Lewin, Jack			Primary Renal Well-differentiated Neuroendocrine Tumor-Report of a Case With Cytological-Histopathologic Correlation and Review of Literature	AJSP-REVIEWS AND REPORTS			English	Review						kidney; neuroendocrine tumor; renal carcinoid	CARCINOID-TUMORS; KIDNEY	Renal well-differentiated neuroendocrine tumor (WDNET; also known as carcinoid), although considered as a distinct entity in the World Health Organization classification, continues to be an enigma to the pathologists and clinicians because of its rarity. In this case report, we describe a case of primary renal WDNET in a 54-year-old man. The tumor was initially diagnosed as a urothelial carcinoma. After a second review and a broad-spectrum immunopanel, a revised diagnosis of WDNET was rendered.	[Manucha, Varsha; Azar, Azniv; Lewin, Jack] Univ Mississippi, Med Ctr, Dept Pathol, 2500 North State St, Jackson, MS 39216 USA; [Roda, Manohar] Univ Mississippi, Med Ctr, Dept Radiol, Jackson, MS 39216 USA	Manucha, V (reprint author), Univ Mississippi, Med Ctr, Dept Pathol, 2500 North State St, Jackson, MS 39216 USA.	vmanucha@umc.edu					Aung PP, 2013, HUM PATHOL, V44, P873, DOI 10.1016/j.humpath.2012.08.013; Guillou L., 2016, WHO CLASSIFICATION T, P72; Guy L, 1999, PATHOL RES PRACT, V195, P25, DOI 10.1016/S0344-0338(99)80090-9; Hansel DE, 2007, AM J SURG PATHOL, V31, P1539, DOI 10.1097/PAS.0b013e318042d596; Jeung JA, 2011, HUM PATHOL, V42, P1554, DOI 10.1016/j.humpath.2010.12.019; Omiyale AO, 2013, ADV UROL, DOI 10.1155/2013/579396; RASLAN WF, 1993, CANCER, V72, P2660, DOI 10.1002/1097-0142(19931101)72:9<2660::AID-CNCR2820720923>3.0.CO;2-O; Resnick M E, 1966, Med Times, V94, P895; Romero FR, 2006, J UROLOGY, V176, P2359, DOI 10.1016/j.juro.2006.07.129; Sahin A, 1996, SCAND J UROL NEPHROL, V30, P325, DOI 10.3109/00365599609182316; Verma R, 2013, BMJ CASE REP, V2013	11	0	0	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1082-9784	1533-4015		AJSP-REV REP	AJSP-Rev. Rep.	NOV-DEC	2018	23	6					288	290		10.1097/PCR.0000000000000281			3	Pathology	Pathology	HK0XW	WOS:000457629000011					2019-10-28	
J	Saleem, A; Brown, RA; Higgins, JPT; Troxell, ML; Kunder, CA; Pinsky, BA; Zambrano, E; Kao, CS				Saleem, Atif; Brown, Ryanne A.; Higgins, John P. T.; Troxell, Megan L.; Kunder, Christian A.; Pinsky, Benjamin A.; Zambrano, Eduardo; Kao, Chia-Sui			A Case Report of Pediatric Clear Cell Carcinoma of the Urinary Bladder Associated With Polyomavirus	AJSP-REVIEWS AND REPORTS			English	Article						bladder; clear cell carcinoma; pediatric; polyomavirus; SV40	BK-POLYOMAVIRUS; ADENOCARCINOMA; HISTOGENESIS; TRACT	Clear cell carcinoma of the bladder is a rare, aggressive malignancy with fewer than 60 reported cases to date, and it has never been described in a pediatric patient. We describe a urinary bladder tumor in an 8-year-old girl, which demonstrated similar features to clear cell carcinoma of the female genital tract with additional strong expression of SV40 large Tantigen by immunohistochemistry. The patient had a history of severe infantile Crohn's disease refractory to medical therapy, necessitating eventual stem cell transplant, complicated by graft-versus-host disease. Subsequent magnetic resonance enterography showed an incidental mass arising from the bladder dome, for which a partial cystectomy was performed. Histologically, the tumor demonstrated high-grade cytologic features with hobnail morphology, organized in various architectures, including solid, papillary, and tubulocystic, with strong and diffuse expression of PAX8, CK7, p53, and SV40 by immunohistochemistry. Additional stains were performed, and SALL4, GATA3, and napsin A were focally positive, whereas ER, WT1, and p63 were all negative. The overall features were consistent with clear cell carcinoma. The patient is currently alive with no evidence of disease at 1-year follow-up, status post-partial cystectomy without adjunct therapy. Clear cell carcinoma of the bladder is a rare malignancy that may occur in pediatric patients and may be associated with polyomavirus.	[Saleem, Atif; Brown, Ryanne A.; Higgins, John P. T.; Troxell, Megan L.; Kunder, Christian A.; Pinsky, Benjamin A.; Zambrano, Eduardo; Kao, Chia-Sui] Stanford Univ, Sch Med, Dept Pathol, Stanford, CA 94305 USA; [Pinsky, Benjamin A.] Stanford Univ, Sch Med, Div Geog Med & Infect Dis, Dept Med, Stanford, CA 94305 USA	Kao, CS (reprint author), Stanford Univ, Sch Med, 300 Pasteur Dr,Lane Bldg L235, Stanford, CA 94305 USA.	ckao2@stanford.edu					Adeniran AJ, 2009, ARCH PATHOL LAB MED, V133, P987, DOI 10.1043/1543-2165-133.6.987; Alexiev BA, 2015, PATHOL RES PRACT, V211, P697, DOI 10.1016/j.prp.2015.06.006; Dalianis T, 2013, VIROLOGY, V437, P63, DOI 10.1016/j.virol.2012.12.015; Dhaliwal Catharine A, 2012, Curr Urol, V6, P106, DOI 10.1159/000343520; DOW JA, 1968, J UROLOGY, V100, P466, DOI 10.1016/S0022-5347(17)62554-0; Drew PA, 1996, HUM PATHOL, V27, P248, DOI 10.1016/S0046-8177(96)90064-7; Herawi M, 2010, HUM PATHOL, V41, P594, DOI 10.1016/j.humpath.2009.10.011; Hoffman AM, 2011, EPIGENOMICS-UK, V3, P19, DOI 10.2217/EPI.10.64; Kenan DJ, 2015, J PATHOL, V237, P379, DOI 10.1002/path.4584; Kobayashi H, 2009, ONCOL REP, V22, P233, DOI 10.3892/or_00000429; Kosem M, 2005, SCAND J UROL NEPHROL, V39, P89, DOI 10.1080/00365590510007630; Oliva E, 2002, AM J SURG PATHOL, V26, P190, DOI 10.1097/00000478-200202000-00005; Salvatore SP, 2016, CLIN NEPHROL, V85, P179, DOI 10.5414/CN108410; Santos-Juanes J, 2015, BRIT J DERMATOL, V173, P42, DOI 10.1111/bjd.13870; Sung MT, 2008, CLIN CANCER RES, V14, P1947, DOI 10.1158/1078-0432.CCR-07-4147; Toptan T, 2016, JCI INSIGHT, V1, DOI 10.1172/jci.insight.85562; Venyo AK, 2014, INT SCH RES NOTICES, V2014; Yan L, 2016, HUM PATHOL, V48, P122, DOI 10.1016/j.humpath.2015.09.021; YOUNG RH, 1985, AM J SURG PATHOL, V9, P816, DOI 10.1097/00000478-198511000-00005	19	0	0	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1082-9784	1533-4015		AJSP-REV REP	AJSP-Rev. Rep.	NOV-DEC	2018	23	6					291	295		10.1097/PCR.0000000000000284			5	Pathology	Pathology	HK0XW	WOS:000457629000012					2019-10-28	
J	Homlar, K; Sullivan, BT; Sharma, S				Homlar, Kelly; Sullivan, Brian T.; Sharma, Suash			Phosphaturic Mesenchymal Tumor: A Single Case Report Discussing Diagnostic and Therapeutic Challenges of Tumor-Induced Osteomalacia	AJSP-REVIEWS AND REPORTS			English	Article						fibroblast growth factor 23; phosphaturic mesenchymal tumor; tumor-induced osteomalacia		Phosphaturic mesenchymal tumor is a rare neoplasm that produces fibroblast growth factor 23 resulting in the paraneoplastic tumor-induced osteomalacia. Patients are typically diagnosed several years after the first signs of bone pain, fatigue, and weakness; the non-specific character of the symptoms often delays the diagnosis and curative surgical treatment. The following case report details a classic presentation of a phosphaturic mesenchymal tumor of mixed connective tissue type involving the right posterior tibialis muscle with erosion of the adjacent medial fibular cortex. The patient underwent a surgical resection and is currently asymptomatic. This report highlights the need for multidisciplinary diagnostic effort, effectiveness, of early surgical intervention, and emphasizes the importance of including this rare but damaging disease process in the differential diagnosis of osteomalacia.	[Homlar, Kelly] Augusta Univ, Med Coll Georgia, Orthopaed Oncol & Total Joints & Reconstruct Surg, 1120 15th St, Augusta, GA 30912 USA; [Sharma, Suash] Augusta Univ, Med Coll Georgia, Dept Pathol, Sect Anat Pathol, Augusta, GA 30912 USA	Homlar, K (reprint author), Augusta Univ, Med Coll Georgia, Orthopaed Oncol & Total Joints & Reconstruct Surg, 1120 15th St, Augusta, GA 30912 USA.	khomlar@augusta.odu					de Beur SMJ, 2005, JAMA-J AM MED ASSOC, V294, P1260; Duet M, 2008, CLIN NUCL MED, V33, P752, DOI 10.1097/RLU.0b013e31818866bf; Folpe AL, 2004, AM J SURG PATHOL, V28, P1, DOI 10.1097/00000478-200401000-00001; Gore MO, 2009, KIDNEY INT, V76, P342, DOI 10.1038/ki.2008.355; Hautmann AH, 2015, CURR RHEUMATOL REP, V17, DOI 10.1007/s11926-015-0512-5; Ito N, 2010, J INTERN MED, V268, P390, DOI 10.1111/j.1365-2796.2010.02262.x; Ledford CK, 2013, CLIN ORTHOP RELAT R, V471, P3618, DOI 10.1007/s11999-013-3178-1; Lee J, 2016, GEOTECH SP, P1, DOI 10.1061/9780784480090; Saito H, 2003, J BIOL CHEM, V278, P2206, DOI 10.1074/jbc.M207872200; Shustik DA, 2015, INT J CLIN EXP PATHO, V8, P7506; Wang H, 2015, J BONE JOINT SURG AM, V97A, P1084, DOI 10.2106/JBJS.N.01299; Yavropoulou MP, 2015, ENDOCRINOL DIAB META, DOI 10.1530/EDM-15-0025; Zhang JJ, 2015, CLIN NUCL MED, V40, P642, DOI 10.1097/RLU.0000000000000854	13	0	0	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1082-9784	1533-4015		AJSP-REV REP	AJSP-Rev. Rep.	NOV-DEC	2018	23	6					296	300		10.1097/PCR.0000000000000271			5	Pathology	Pathology	HK0XW	WOS:000457629000013					2019-10-28	
J	Morbeck, DL; Batista, PMD; Tregnago, AC; Cabrera, RA; Costa, FD; Kalil, RK				Morbeck, Diogo Lago; Dornelas Batista, Patricia Marquis; Tregnago, Aline Caldart; Cabrera, Rafael Adame; Costa, Felipe D'Almeida; Kalil, Ricardo Karam			Poorly Differentiated/Anaplastic Chordoma in a Child-Case Report and Review of the Literature	AJSP-REVIEWS AND REPORTS			English	Review							DIFFERENTIAL-DIAGNOSIS; CHONDROID CHORDOMA; BASE; CYTOGENETICS; EXPRESSION; BRACHYURY; THERAPY; BENIGN	Chordomas are rare bone tumors, with highest incidence after the age of 40 years. When they occur in infants and toddlers, they usually are poorly differentiated/anaplastic chordomas with characteristic histopathologic presentation and unique molecular changes such as the lack of expression of SMARCB1/INI1. We present the case of a 3-year-old girl with a 5.0-cm sacrococcygeal mass. Magnetic resonance imaging showed a lobulated, heterogeneous mass attached to S5. Chordomas are very rare at this age; therefore, it is very important to distinguish this tumor from other more common neoplasms that occur in this location and age range because when they are identified their immunogenetic profile may suggest a worse prognosis. Histological, immunohistochemical, molecular characteristics, and differential diagnosis of this variant of chordoma are discussed.	[Morbeck, Diogo Lago; Dornelas Batista, Patricia Marquis; Tregnago, Aline Caldart; Cabrera, Rafael Adame; Costa, Felipe D'Almeida; Kalil, Ricardo Karam] AC Camargo Canc Ctr, Santo Andre, Brazil	Morbeck, DL (reprint author), AC Camargo Canc Ctr, Rua Tamandare,753 Liberdade, BR-01511010 Sao Paulo, SP, Brazil.	dlmorbeck@gmail.com	Tregnago, Aline C/L-7239-2018	Tregnago, Aline C/0000-0001-7370-3370			Amichetti M, 2009, NEUROSURG REV, V32, P403, DOI 10.1007/s10143-009-0194-4; Barresi V, 2014, DIS MARKERS, DOI 10.1155/2014/514753; Borba LAB, 1996, J NEUROSURG, V84, P584, DOI 10.3171/jns.1996.84.4.0584; Casali PG, 2007, CURR OPIN ONCOL, V19, P367, DOI 10.1097/CCO.0b013e3281214448; COFFIN CM, 1993, ARCH PATHOL LAB MED, V117, P927; DENORONHA L, 1995, ARQ NEURO-PSIQUIAT, V53, P654, DOI 10.1590/S0004-282X1995000400018; Deshpande V, 2007, AM J SURG PATHOL, V31, P1573, DOI 10.1097/PAS.0b013e31805c9967; DORFMAN HD, 1995, CANCER, V75, P203, DOI 10.1002/1097-0142(19950101)75:1+<203::AID-CNCR2820751308>3.0.CO;2-V; Dorfman HD, 1998, BONE TUMORS; Erdem E, 2003, RADIOGRAPHICS, V23, P995, DOI 10.1148/rg.234025176; Hoch BL, 2006, AM J SURG PATHOL, V30, P811, DOI 10.1097/01.pas.0000209828.39477.ab; JACOB HE, 1994, J NEURO-ONCOL, V20, P327, DOI 10.1007/BF01053047; JEFFREY PB, 1995, AM J CLIN PATHOL, V103, P271, DOI 10.1093/ajcp/103.3.271; Kelley MJ, 2001, AM J HUM GENET, V69, P454, DOI 10.1086/321982; Larizza L, 2005, HERED CANCER CLIN PR, V3, P29, DOI 10.1186/1897-4287-3-1-29; McMaster ML, 2011, J MED GENET, V48, P444, DOI 10.1136/jmg.2010.085092; McMaster ML, 2001, CANCER CAUSE CONTROL, V12, P1, DOI 10.1023/A:1008947301735; MEIS JM, 1988, ARCH PATHOL LAB MED, V112, P553; Mirra JM, 2002, PATHOLOGY GENETICS T, P316; Mobley BC, 2010, ACTA NEUROPATHOL, V120, P745, DOI 10.1007/s00401-010-0767-x; O'Hara BJ, 1998, HUM PATHOL, V29, P119, DOI 10.1016/S0046-8177(98)90220-9; PERRY A, 2007, WHO CLASSIFICATION T, P164; Presneau N, 2011, J PATHOL, V223, P327, DOI 10.1002/path.2816; Ridenour RV, 2010, PEDIATR DEVEL PATHOL, V13, P9, DOI 10.2350/09-01-0584.1; Rombi B, 2013, INT J RADIAT ONCOL, V86, P578, DOI 10.1016/j.ijrobp.2013.02.026; ROSENBERG AE, 1994, AM J CLIN PATHOL, V101, P36, DOI 10.1093/ajcp/101.1.36; Santini-Araujo E., 2015, TUMORS TUMOR LIKE LE; Scheil S, 2001, GENE CHROMOSOME CANC, V32, P203, DOI 10.1002/gcc.1184; Staab A, 2011, INT J RADIAT ONCOL, V81, pE489, DOI 10.1016/j.ijrobp.2011.02.018; Szuhai K, 2012, J PATHOL, V228, P261, DOI 10.1002/path.4102; Tirabosco R, 2008, AM J SURG PATHOL, V32, P572, DOI 10.1097/PAS.0b013e31815b693a; Versteege I, 1998, NATURE, V394, P203, DOI 10.1038/28212; Vujovic S, 2006, J PATHOL, V209, P157, DOI 10.1002/path.1969; Yadav R, 2014, NEURO-ONCOLOGY, V16, P372, DOI 10.1093/neuonc/not228; Yamaguchi T, 2002, SKELETAL RADIOL, V31, P413, DOI 10.1007/s00256-002-0514-z; Yamagushi Y, 2015, TUMORS TUMOR LIKE LE, P116; Yeom KW, 2013, AM J NEURORADIOL, V34, P1056, DOI 10.3174/ajnr.A3333	37	0	0	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1082-9784	1533-4015		AJSP-REV REP	AJSP-Rev. Rep.	NOV-DEC	2018	23	6					301	304		10.1097/PCR.0000000000000279			4	Pathology	Pathology	HK0XW	WOS:000457629000014					2019-10-28	
J	Stoll, AL; Suarez-Bonnet, A; Summers, BA; Priestnall, SL				Stoll, A. L.; Suarez-Bonnet, A.; Summers, B. A.; Priestnall, S. L.			Malignant Cutaneous Peripheral Nerve Sheath Tumour with Rhabdomyosarcomatous Differentiation (Triton Tumour) in a Domestic Cat	JOURNAL OF COMPARATIVE PATHOLOGY			English	Article						cat; peripheral nerve sheath tumour; rhabdomyosarcomatous differentiation; triton tumour	DIVERGENT; DOG	Divergent differentiation is encountered frequently within human malignant peripheral nerve sheath tumours (MPNSTs). The new component is often a rhabdomyosarcoma, but in animals this specific form of divergent differentiation within MPNSTs has only been reported once (in a dog). Incisional wedge biopsy of a locally extensive, ventral abdominal wall mass, which extended from the dermis to the subcutis, from a 12-year-old female domestic shorthaired cat, was performed. The tissue was examined with routine haematoxylin and eosin staining and immunohistochemical methods. A malignant neoplasm with spindle and polygonal cell components and progression towards a rhabdomyosarcomatous phenotype was observed. Both neoplastic cell populations exhibited strong expression of vimentin and there was multifocal expression of S100 and desmin. There was strong cytoplasmic labelling for alpha-sarcomeric actin and muscle actin and weak labelling for myoglobin within the cells positive for desmin. There was multifocal positive nuclear labelling for myogenin. Glial fibrillary acidic protein, alpha-smooth muscle actin, microphthalmia-associated transcription factor and melanoma antigen recognized by T cells were not expressed. Microscopical features, aided by immunohistochemistry, identified a MPNST with progression towards a rhabdomyosarcomatous phenotype, a so-called 'triton tumour'. A Schwann cell component could account for the divergent patterns of growth, given the plasticity of the neural crest. Nerve sheath tumours have been reported in the skin and subcutis of cats and are a differential diagnosis of feline cutaneous spindle cell neoplasms. (C) 2018 Elsevier Ltd. All rights reserved.	[Stoll, A. L.] Univ Surrey, Sch Vet Med, Fac Hlth & Med Sci, Dept Pathol & Infect Dis,Vet Pathol Ctr, Guildford, Surrey, England; [Suarez-Bonnet, A.; Summers, B. A.; Priestnall, S. L.] Royal Vet Coll, Dept Pathobiol & Populat Sci, Hatfield, Herts, England	Suarez-Bonnet, A (reprint author), Royal Vet Coll, Dept Pathobiol & Populat Sci, Hatfield, Herts, England.	asuarezbonnet@rvc.ac.uk		Suarez-Bonnet, Alejandro/0000-0003-0296-5896			BROOKS JSJ, 1985, CANCER-AM CANCER SOC, V55, P2543, DOI 10.1002/1097-0142(19850601)55:11<2543::AID-CNCR2820551105>3.0.CO;2-4; Chijiwa K, 2004, VET PATHOL, V41, P307, DOI 10.1354/vp.41-4-307; Dahme VE, 1987, TIERAERZTL UMSCHAU, V42, P658; DUCATMAN BS, 1984, CANCER, V54, P1049, DOI 10.1002/1097-0142(19840915)54:6<1049::AID-CNCR2820540620>3.0.CO;2-1; Fletcher CDM, 2007, DIAGNOSTIC HISTOPATH, V2, P1733; Gao LJ, 2015, EUR J MED RES, V20, DOI 10.1186/s40001-015-0172-y; Hendrick M. J., 2017, Tumors in domestic animals, P142; Higgins RJ, 2006, VET PATHOL, V43, P50, DOI 10.1354/vp.43-1-50; JONES BR, 1995, NEW ZEAL VET J, V43, P190, DOI 10.1080/00480169.1995.35888; Locatelli P, 1925, C R ASS ANAT, V20, P279; Masson P, 1932, CONTRIBUTIONS MED SC, V2, P793; Ochi A, 2008, VET PATHOL, V45, P685, DOI 10.1354/vp.45-5-685; Patnaik AK, 2002, VET PATHOL, V39, P406, DOI 10.1354/vp.39-3-406; Schoniger S, 2011, VET PATHOL, V48, P433, DOI 10.1177/0300985810377072; Schoniger S, 2009, VET PATHOL, V46, P904, DOI 10.1354/vp.08-VP-0322-S-FL; Schulman FY, 2009, VET PATHOL, V46, P1166, DOI 10.1354/vp.08-VP-0327-S-FL; Stasik CJ, 2006, ARCH PATHOL LAB MED, V130, P1878; Summers BA, 1992, VET PATHOL, V29, P447; Summers BA, 1995, VET NEUROPATHOLOGY, P476	19	0	0	0	1	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0021-9975	1532-3129		J COMP PATHOL	J. Comp. Pathol.	NOV	2018	165						1	5		10.1016/j.jcpa.2018.09.003			5	Pathology; Veterinary Sciences	Pathology; Veterinary Sciences	HG3SY	WOS:000454895900001	30502790				2019-10-28	
J	Leite, RV; Panziera, W; Bandinelli, MB; Pavarini, SP				Leite-Filho, R. V.; Panziera, W.; Bandinelli, M. B.; Pavarini, S. P.			Pathological Characterization of Lymphoma with Pulmonary Involvement in Cats	JOURNAL OF COMPARATIVE PATHOLOGY			English	Article						cat; histological pattern; lung; lymphoma	T-CELL; LUNG; TISSUE; CLASSIFICATION; LYMPHOSARCOMA; PATTERNS	Studies evaluating histological patterns of lung infiltration by lymphoma in cats are lacking. We evaluated retrospectively the histological patterns of 125 necropsy cases of feline lymphoma collected over a 12-year period. Of the 125 cases, 16 showed lung infiltration (12.8%). Nine cats were female, seven cats were male and all were of mixed breed. Gross lesions observed in the lungs consisted of masses (25%) and nodules (18.7%); however, the majority of cases (56.2%) did not show any gross abnormality. Peribronchial-vascular infiltration (93.7%) was the most frequent pattern, followed by pleural (56.2%), interstitial (50%), nodular (37.5%) and alveolar (12.5%) patterns, but 75% of the cases had more than one pulmonary infiltration pattern. There were 14 (87.5%) B-cell and two (12.5%) T-cell lymphomas. Six cats (37.5%) were positive for feline leukaemia virus and three cats (18.7%) were positive for feline immunodeficiency virus. Diffuse large B-cell lymphoma was the most frequent type, accounting for 56% of all cases. (C) 2018 Elsevier Ltd. All rights reserved.	[Leite-Filho, R. V.; Panziera, W.; Bandinelli, M. B.; Pavarini, S. P.] Univ Fed Rio Grande do Sul, Setor Patol Vet, Porto Alegre, RS, Brazil	Leite, RV (reprint author), Univ Fed Rio Grande do Sul, Setor Patol Vet, Porto Alegre, RS, Brazil.	vianaleite@hotmail.com			National Council for Scientific and Technological Development (CNPq)National Council for Scientific and Technological Development (CNPq) [40619/2016-7]; Co-ordination of Improvement in Higher Education Personal (CAPES)	The authors acknowledge the National Council for Scientific and Technological Development for financial support (CNPq Proc. 40619/2016-7) and the Co-ordination of Improvement in Higher Education Personal (CAPES) for awarding a scholarship to R. Viana Leite-Filho.	Al-Tikriti MS, 2012, ANATOMY PHYSL, V2, P100; Bree L, 2017, J FELINE MED SURG OP, V3, P1; Brown AL, 2011, J FELINE MED SURG, V13, P772, DOI 10.1016/j.jfms.2011.05.018; Cadranel J, 2002, EUR RESPIR J, V20, P750, DOI 10.1183/09031936.02.00404102; Costa MBG, 2004, AM J CLIN PATHOL, V121, P718, DOI 10.1309/R4BRRADYF20K49HE; Darbes J, 1998, VET PATHOL, V35, P370, DOI 10.1177/030098589803500506; de Almeida NR, 2012, J FELINE MED SURG, V14, P583, DOI 10.1177/1098612X12444693; Gabor LJ, 1998, AUST VET J, V76, P725, DOI 10.1111/j.1751-0813.1998.tb12300.x; Gabor LJ, 1999, AUST VET J, V77, P436, DOI 10.1111/j.1751-0813.1999.tb12085.x; Geyer NE, 2010, VET RADIOL ULTRASOUN, V51, P386, DOI 10.1111/j.1740-8261.2010.01683.x; King LJ, 2000, EUR RADIOL, V10, P1932, DOI 10.1007/s003300000491; Krecic MR, 2000, J AM VET MED ASSOC, V216, P524, DOI 10.2460/javma.2000.216.524; Lee KS, 1997, AM J ROENTGENOL, V168, P339, DOI 10.2214/ajr.168.2.9016202; LEWIS ER, 1991, AM J ROENTGENOL, V156, P711, DOI 10.2214/ajr.156.4.2003430; Louwerens M, 2005, J VET INTERN MED, V19, P329, DOI 10.1892/0891-6640(2005)19[329:FLITPL]2.0.CO;2; MENTZER SJ, 1993, SURGERY, V113, P507; Moore PF, 2012, VET PATHOL, V49, P658, DOI 10.1177/0300985811404712; PABST R, 1990, AM J RESP CELL MOL, V3, P131, DOI 10.1165/ajrcmb/3.2.131; Pohlman LM, 2009, VET PATHOL, V46, P259, DOI 10.1354/vp.46-2-259; SMINIA T, 1989, CRIT REV IMMUNOL, V9, P119; Taylor SS, 2009, J SMALL ANIM PRACT, V50, P584, DOI 10.1111/j.1748-5827.2009.00813.x; Teixeira BM, 2007, ARQ BRAS MED VET ZOO, V59, P939, DOI 10.1590/S0102-09352007000400019; Vail D, 2007, WITHROW MACEWENS SMA, P733; Vail DM, 2013, SMALL ANIMAL CLIN ON, P638; VALLI V. E., 2016, JUBB KENNEDY PALMERS, P102; Vezzali E, 2010, VET COMP ONCOL, V8, P38, DOI 10.1111/j.1476-5829.2009.00201.x; William J, 2013, ARCH PATHOL LAB MED, V137, P382, DOI 10.5858/arpa.2012-0202-RA; Wislez M, 1999, EUR RESPIR J, V14, P423, DOI 10.1034/j.1399-3003.1999.14b30.x	28	0	0	0	4	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0021-9975	1532-3129		J COMP PATHOL	J. Comp. Pathol.	NOV	2018	165						6	12		10.1016/j.jcpa.2018.09.007			7	Pathology; Veterinary Sciences	Pathology; Veterinary Sciences	HG3SY	WOS:000454895900002	30502798				2019-10-28	
J	Bertram, CA; Muller, K; Klopfleisch, R				Bertram, C. A.; Mueller, K.; Klopfleisch, R.			Genital Tract Pathology in Female Pet Guinea Pigs (Cavia porcellus): a Retrospective Study of 655 Post-mortem and 64 Biopsy Cases	JOURNAL OF COMPARATIVE PATHOLOGY			English	Article						guinea pig; ovarian disorder; uterine disorder; vaginal disorder	CYSTIC RETE OVARII; IMMUNOHISTOCHEMICAL EVALUATION; SEROUS CYSTS; DIAGNOSIS; TERATOMAS; LESIONS	Disorders of the female genital tract are among the most common disorders in pet guinea pigs (Cavia porcellus); however, knowledge of many aspects of these disorders is sparse, especially regarding their incidence and age distribution. Ovarian cysts, as the most common genital tract disorder in guinea pigs, have been investigated in detail; however, information on the nature of these cysts is inconsistent. The present study reviewed genital tract disorders occurring within 655 full post-mortem examinations of intact female pet guinea pigs and 64 female genital tract biopsies examined over a 22.5 year period. Age distribution was determined from 550 post-mortem examinations of animals of known age. Genital tract disorders were found in 295 post-mortem examinations (45.0%) in animals with a median age of 52 months. Additionally, disorders were found in all genital tract biopsy samples from guinea pigs with a median age of 48 months. The incidence of genital tract diseases increased from 1.5% in guinea pigs <= 6 months of age to up to 77.8% in animals >6 years of age. Ovarian cysts were the most common genital tract disorder, found in 245 of the 655 post-mortem cases (37.4%) and 38 of 43 ovarian biopsy samples (88.4%). The incidence of ovarian cysts increased with advancing age, reaching 75.6% in animals >6 years. In 119 cases, histopathology and immunohistochemistry confirmed cystic rete ovarii as the only cyst type. A Fallopian tube adenoma was found in a single case, so disorders of the Fallopian tube should be considered rare. Uterine disorders were diagnosed in 17.4% of the post-mortem examinations and 98.1% of uterine biopsy samples. Uterine neoplasia, hyperplasia and inflammation were common, but occurred at different ages. The incidence of uterine neoplasia and hyperplasia was higher in older animals (>15% in guinea pigs >6 years), while the incidence of uterine inflammation was the highest (17.9%) in animals aged 7-12 months. An association between ovarian cysts and uterine neoplasia or hyperplasia was not evident. Vaginal disorders were rare and included leiomyoma, polyps and vaginitis. (C) 2018 Elsevier Ltd. All rights reserved.	[Bertram, C. A.; Klopfleisch, R.] Free Univ Berlin, Inst Vet Pathol, Robert von Ostertagstr 15, Berlin, Germany; [Mueller, K.] Free Univ Berlin, Small Anim Clin, Oertzenweg 19b, Berlin, Germany	Klopfleisch, R (reprint author), Free Univ Berlin, Inst Vet Pathol, Robert von Ostertagstr 15, Berlin, Germany.	Robert.klopfleisch@fu-berlin.de		Klopfleisch, Robert/0000-0002-6308-0568			Akihara Y, 2007, REPROD DOMEST ANIM, V42, P495, DOI 10.1111/j.1439-0531.2006.00812.x; Akihara Y, 2007, J VET MED SCI, V69, P1033, DOI 10.1292/jvms.69.1033; Arlt SP, 2016, REPROD DOMEST ANIM, V51, P3, DOI 10.1111/rda.12781; Bean Andrew D, 2013, Vet Clin North Am Exot Anim Pract, V16, P757, DOI 10.1016/j.cvex.2013.05.008; Beregi A, 1999, VET RADIOL ULTRASOUN, V40, P74, DOI 10.1111/j.1740-8261.1999.tb01841.x; Beregi A, 2001, J SMALL ANIM PRACT, V42, P459, DOI 10.1111/j.1748-5827.2001.tb02503.x; Bertram CA, 2017, J VET MED SCI, V79, P1994, DOI 10.1292/jvms.17-0358; Burns RP, 2001, J AM VET MED ASSOC, V218, P726, DOI 10.2460/javma.2001.218.726; Chambers JK, 2014, J VET MED SCI, V76, P909, DOI 10.1292/jvms.14-0053; Cooper TK, 2006, VET PATHOL, V43, P377, DOI 10.1354/vp.43-3-377; Dixon D, 2014, J TOXICOL PATHOL, V27, p1S, DOI 10.1293/tox.27.1S; Eatwell K., 2003, Exotic DVM, V5, P37; FIELD KJ, 1989, J COMP PATHOL, V101, P287, DOI 10.1016/0021-9975(89)90038-8; Fuchs-Baumgartinger A, 2009, WIEN TIERARZTL MONAT, V96, P272; GELBERG HB, 1984, VET PATHOL, V21, P304, DOI 10.1177/030098588402100307; HONG CC, 1980, LAB ANIM, V14, P39, DOI 10.1258/002367780780942999; JAIN S K, 1970, Indian Veterinary Journal, V47, P563; KELLER LSF, 1987, VET PATHOL, V24, P335, DOI 10.1177/030098588702400408; Kennedy P, 1998, HISTOLOGICAL CLASSIF, P24; Kohutova S, 2018, J EXOT PET MED, V27, P41, DOI 10.1053/j.jepm.2017.10.001; Kondert Leonie, 2017, Veterinary Clinics of North America Exotic Animal Practice, V20, P609, DOI 10.1016/j.cvex.2016.11.014; Laik-Schandelmaier C, 2017, J COMP PATHOL, V156, P339, DOI 10.1016/j.jcpa.2017.03.002; Lukasova R, 2017, ACTA VET BRNO, V86, P269, DOI 10.2754/avb201786030269; Minarikova A, 2015, VET REC, V177, DOI 10.1136/vr.103053; MITCHELL JA, 1978, BIOL REPROD, V19, P1135, DOI 10.1095/biolreprod19.5.1135; Nielsen TD, 2003, J SMALL ANIM PRACT, V44, P257, DOI 10.1111/j.1748-5827.2003.tb00152.x; OLSON LC, 1980, VET PATHOL, V17, P245, DOI 10.1177/030098588001700215; QUATTROPANI SL, 1977, ANAT REC, V188, P351, DOI 10.1002/ar.1091880308; Ricken A, 2008, KLIN KLEINTIERE; Shi FX, 2002, J VET MED SCI, V64, P129, DOI 10.1292/jvms.64.129; Silva EG, 1998, GYNECOL ONCOL, V71, P240, DOI 10.1006/gyno.1998.5153; Sommerey CC, 2004, TIERARZTL PRAX K H, V32, P377; Veiga-Parga T, 2016, J VET DIAGN INVEST, V28, P656, DOI 10.1177/1040638716665429; VINK HH, 1970, J PATHOL, V102, P180, DOI 10.1002/path.1711020310; WILLIS RA, 1962, J PATHOL BACTERIOL, V84, P237, DOI 10.1002/path.1700840129; Yoshizawa K, 2013, J TOXICOL PATHOL, V26, P61, DOI 10.1293/tox.26.61	36	0	0	1	1	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0021-9975	1532-3129		J COMP PATHOL	J. Comp. Pathol.	NOV	2018	165						13	22		10.1016/j.jcpa.2018.09.001			10	Pathology; Veterinary Sciences	Pathology; Veterinary Sciences	HG3SY	WOS:000454895900003	30502791				2019-10-28	
J	Dagleish, MP; Clark, JJ; Robson, C; Tucker, M; Orton, RJ; Rocchi, MS				Dagleish, M. P.; Clark, J. J.; Robson, C.; Tucker, M.; Orton, R. J.; Rocchi, M. S.			A Fatal Case of Louping-ill in a Dog: Immunolocalization and Full Genome Sequencing of the Virus	JOURNAL OF COMPARATIVE PATHOLOGY			English	Article						dog; genome; immunohistochemistry; louping-ill	TICK-BORNE FEVER; ENVELOPE GLYCOPROTEIN; SHEEP; IDENTIFICATION; ENCEPHALOMYELITIS; NUCLEOTIDE; INFECTION; ALIGNMENT; MAMMALS; DISEASE	Louping-ill (LI), caused by louping-ill virus (LIV), results in a frequently fatal encephalitis primarily affecting sheep and red grouse (Lagopus lagopus scotica), but it does occur in other species. An adult male Border collie dog was definitively diagnosed with fatal LI and the lesion profile, LIV antigen distribution and full genome sequence of the LIV responsible were investigated to determine if this differed significantly from sheep-derived LIV. No gross lesions were present. The histological lesions were confined to the central nervous system and comprised of lymphocytic perivascular cuffs, glial foci, neuronal necrosis and neuronophagia. Immunolocalization of viral antigen showed small amounts present in neurons only. These histological and immunohistochemical findings were similar to those reported in affected sheep. Compared with published full genome sequences of sheep-derived LIV, only very minor differences were present and phylogenetically the virus clustered individually between a subclade containing Scottish strains, LIV 369/T2 and G and another subclade containing an English isolate LIV A. The LIV isolated from the dog shares a common progenitor with LIV A. These findings suggest there is no canine-specific LIV strain, dogs are susceptible to sheep-associated strains of LI and with the increase in tick prevalence, and therefore exposure to LIV, a safe, effective vaccine for dogs may be required. (C) 2018 The Authors. Published by Elsevier Ltd.	[Dagleish, M. P.; Clark, J. J.; Rocchi, M. S.] Moredun Res Inst, Pentlands Sci Pk, Penicuik, Midlothian, Scotland; [Clark, J. J.; Orton, R. J.] Univ Glasgow, MRC, Ctr Virus Res, Glasgow, Lanark, Scotland; [Robson, C.; Tucker, M.] Castle Vet Grp Ltd, Pennygillam Way, Launceston, Scotland	Dagleish, MP (reprint author), Moredun Res Inst, Pentlands Sci Pk, Penicuik, Midlothian, Scotland.	mark.dagleish@moredun.ac.uk			Scottish Government; BBSRCBiotechnology and Biological Sciences Research Council (BBSRC) [BB/J013854/1]; UK Medical Research CouncilMedical Research Council UK (MRC) [MC_UU_12014/12, MC_UU_12014/8]	The authors thank the owners of the dog for allowing access to the tissues, C. Underwood (Moredun Research Institute) for expert histological and immunohistochemical preparations, M. Baird for help with NGS sample preparation, G. Wilkie and A. da Silva Filipe for sequencing, Dr C. McInnes, Dr R. Biek and Professor A. Kohl for their support and Drs H. Reid and D. Buxton for constructive criticism of the manuscript. MR and MPD are funded by the Scottish Government. JC was supported by the BBSRC Doctoral Training Partnership 2012, (grant number BB/J013854/1) as well as the UK Medical Research Council (MC_UU_12014/8). RJO was supported by the UK Medical Research Council (grant number MC_UU_12014/12).	Balseiro A, 2012, EMERG INFECT DIS, V18, P976, DOI 10.3201/eid1806.120220; BANNATYNE CC, 1980, VET REC, V106, P13, DOI 10.1136/vr.106.1.13; Benavides J, 2011, VET PATHOL, V48, pE1, DOI 10.1177/0300985810396515; Buxton D, 2017, J COMP PATHOL, V157, P270, DOI 10.1016/j.jcpa.2017.09.002; Courtney JW, 2004, J CLIN MICROBIOL, V42, P3164, DOI 10.1128/JCM.42.7.3164-3168.2004; Cranwell MP, 2008, VET REC, V162, P28, DOI 10.1136/vr.162.1.28; Dagleish MP, 2010, SMALL RUMINANT RES, V92, P19, DOI 10.1016/j.smallrumres.2010.04.003; Darriba D, 2012, NAT METHODS, V9, P772, DOI 10.1038/nmeth.2109; DOHERTY PC, 1971, J COMP PATHOL, V81, P331, DOI 10.1016/0021-9975(71)90020-X; DOHERTY PC, 1971, J COMP PATHOL, V81, P531, DOI 10.1016/0021-9975(71)90081-8; Edgar RC, 2004, NUCLEIC ACIDS RES, V32, P1792, DOI 10.1093/nar/gkh340; GAO GF, 1993, J GEN VIROL, V74, P109, DOI 10.1099/0022-1317-74-1-109; GAO GF, 1993, VIRUS RES, V30, P129, DOI 10.1016/0168-1702(93)90002-5; GONZALEZ L, 1987, VET REC, V121, P12, DOI 10.1136/vr.121.1.12; GRAY D, 1988, VET REC, V122, P66, DOI 10.1136/vr.122.3.66; GRITSUN TS, 1993, J GEN VIROL, V74, P287, DOI 10.1099/0022-1317-74-2-287; Guindon S, 2003, SYST BIOL, V52, P696, DOI 10.1080/10635150390235520; Jeffries CL, 2014, J GEN VIROL, V95, P1005, DOI 10.1099/vir.0.062356-0; Jensen Per M, 2004, Ugeskr Laeger, V166, P2563; Kearse M, 2012, BIOINFORMATICS, V28, P1647, DOI 10.1093/bioinformatics/bts199; Leonova GN, 2015, ARCH VIROL, V160, P663, DOI 10.1007/s00705-014-2310-1; Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324; Macaldowie C, 2005, VET REC, V156, P420, DOI 10.1136/vr.156.13.420; MACKENZIE CP, 1982, J SMALL ANIM PRACT, V23, P233, DOI 10.1111/j.1748-5827.1982.tb01662.x; MACKENZIE CP, 1973, VET REC, V92, P354, DOI 10.1136/vr.92.14.354; Mansfield KL, 2015, J GEN VIROL, V96, P1676, DOI 10.1099/vir.0.000096; Marriott L, 2006, J VIROL METHODS, V137, P21, DOI 10.1016/j.jviromet.2006.05.025; Martin DP, 2015, VIRUS EVOL, V1, DOI 10.1093/ve/vev003; McGuire K, 1998, J GEN VIROL, V79, P981, DOI 10.1099/0022-1317-79-5-981; Pavlidou V, 2008, VECTOR-BORNE ZOONOT, V8, P351, DOI 10.1089/vbz.2007.0215; Pond SLK, 2005, BIOINFORMATICS, V21, P676, DOI 10.1093/bioinformatics/bti079; REID HW, 1986, RES VET SCI, V41, P56, DOI 10.1016/S0034-5288(18)30572-1; REID HW, 1972, LANCET, V1, P592; REID HW, 1971, J COMP PATHOL, V81, P521, DOI 10.1016/0021-9975(71)90080-6; REID HW, 1976, VET REC, V98, P116, DOI 10.1136/vr.98.6.116; REID HW, 1978, VET REC, V102, P463, DOI 10.1136/vr.102.21.463; REID HW, 1971, J COMP PATHOL, V81, P291, DOI 10.1016/0021-9975(71)90103-4; Reid HW, 2007, DIS SHEEP, P250; Schmieder R, 2011, BIOINFORMATICS, V27, P863, DOI 10.1093/bioinformatics/btr026; SHIU SYW, 1992, J GEN VIROL, V73, P207, DOI 10.1099/0022-1317-73-1-207; SHIU SYW, 1991, VIROLOGY, V180, P411, DOI 10.1016/0042-6822(91)90048-G; SMITH CEG, 1964, NATURE, V203, P992; TIMONEY P J, 1976, Equine Veterinary Journal, V8, P113; VENUGOPAL K, 1992, VIROLOGY, V190, P515, DOI 10.1016/0042-6822(92)91245-P	44	0	0	0	0	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0021-9975	1532-3129		J COMP PATHOL	J. Comp. Pathol.	NOV	2018	165						23	32		10.1016/j.jcpa.2018.09.004			10	Pathology; Veterinary Sciences	Pathology; Veterinary Sciences	HG3SY	WOS:000454895900004	30502792	Green Published, Green Accepted			2019-10-28	
J	Fraser, AR; Bacci, B; le Chevoir, MA; Long, SN				Fraser, A. R.; Bacci, B.; le Chevoir, M. A.; Long, S. N.			Isocitrate Dehydrogenase 1 Expression in Canine Gliomas	JOURNAL OF COMPARATIVE PATHOLOGY			English	Article						dog; gene mutation; glioma; isocitrate dehydrogenase 1	IDH2 MUTATIONS; GENETIC ALTERATIONS; DIFFUSE GLIOMA; NEOPLASIA; IMMUNOHISTOCHEMISTRY; ASTROCYTOMAS; POPULATION; SURVIVAL; ANTIBODY; RATES	Mutation of the isocitrate dehydrogenase 1 (IDH1) gene at codon 132 has been identified in approximately 70% of low-grade (II and III) human gliomas and secondary glioblastomas, with the IDH1 R132H point mutation representing 92.7% of these mutations. In people, the presence of an IDH1 gene mutation is associated with a better prognosis (both progression-free survival time and overall survival time) and a better response to therapy, including chemotherapy and radiation therapy. Furthermore, IDH1 mutations are included in diagnostic panels to improve diagnosis and molecular classification. Canine gliomas resemble their human counterpart both morphologically and immunohistochemically, therefore they are likely to share similar genetic abnormalities. The IDH1 gene is also comparable between man and dogs. If the IDH1 R132H point mutation is demonstrated in canine gliomas, the prognostic significance of this mutation in people may be transferable to the dog. The objective of this study was to investigate canine gliomas for the IDH1 R132H point mutation using immunohistochemistry. Thirty-one formalin-fixed and paraffin wax-embedded canine gliomas were examined for both IDH1 R132H expression and pan-IDH1 (IDH1 wild-type and point mutated IDH1). Glial tumour specimens were recorded to be either positive or negative for expression. Pan-IDH1 expression was identified in all 31 tumours (100%), while the IDH1 R132H point mutation was identified in none of the tumours (0%). Therefore, the IDH1 R132H point mutation was not identified in this population of canine gliomas and may not be a suitable biomarker or treatment target in canine gliomas. Further investigation is required to determine if other point mutations occur in the IDH1 gene of canine gliomas. (C) 2018 Elsevier Ltd. All rights reserved.	[Fraser, A. R.; le Chevoir, M. A.; Long, S. N.] Univ Melbourne, Translat Res & Anim Clin Trial Studies Grp, Sect Vet Neurol & Neurosurg, 250 Princes Hwy, Werribee, Vic, Australia; [Bacci, B.] Univ Melbourne, Dept Anat Pathol, Fac Vet & Agr Sci, 250 Princes Hwy, Werribee, Vic, Australia	Fraser, AR (reprint author), Univ Melbourne, Translat Res & Anim Clin Trial Studies Grp, Sect Vet Neurol & Neurosurg, 250 Princes Hwy, Werribee, Vic, Australia.	anne.fraser@andersonmoores.com		Bacci, Barbara/0000-0002-2206-0384	University of Melbourne Veterinary Hospital Research Grant, Werribee, Victoria, Australia	The authors acknowledge the Anatomical Pathology Department, Melbourne Health, Parkville, Victoria, Australia, for providing the non-identifiable human control tissues, in addition to Professor B. Summers and Dr A. Stent for their contribution in reviewing the histopathological slides. The authors also wish to acknowledge P. Benham for his assistance with the IHC. This work was supported by the University of Melbourne Veterinary Hospital Research Grant, Werribee, Victoria, Australia. The present address for A. R. Fraser is Anderson Moores Veterinary Specialists, Bunstead Barns, Poles Lane, Hursely, Winchester, Hampshire, UK. The present address for B. Bacci is the School of Veterinary Medicine, Faculty of Health and Medical Sciences, University of Surrey, Guildford, UK. The present address for S. N. Long is the Centre for Animal Referral and Emergency, 5 Hood Street, Collingwood, Victoria, Australia.	Bleeker FE, 2010, ACTA NEUROPATHOL, V119, P487, DOI 10.1007/s00401-010-0645-6; BOORMAN GA, 1986, ENVIRON HEALTH PERSP, V68, P155; Capper D, 2010, AM J SURG PATHOL, V34, P1199, DOI 10.1097/PAS.0b013e3181e7740d; Capper D, 2010, BRAIN PATHOL, V20, P245, DOI 10.1111/j.1750-3639.2009.00352.x; Coons SW, 1997, CANCER, V79, P1381, DOI 10.1002/(SICI)1097-0142(19970401)79:7<1381::AID-CNCR16>3.0.CO;2-W; de Robles P, 2015, NEURO-ONCOLOGY, V17, P776, DOI 10.1093/neuonc/nou283; Dobson JM, 2002, J SMALL ANIM PRACT, V43, P240, DOI 10.1111/j.1748-5827.2002.tb00066.x; Hartmann C, 2009, ACTA NEUROPATHOL, V118, P469, DOI 10.1007/s00401-009-0561-9; Higgins RJ, 2010, J NEURO-ONCOL, V98, P49, DOI 10.1007/s11060-009-0072-5; Johnson DR, 2012, J NEURO-ONCOL, V107, P359, DOI 10.1007/s11060-011-0749-4; Kawakami S, 2018, VET RES COMMUN, V42, P49, DOI 10.1007/s11259-017-9707-8; Kleihues P, 2007, WHO CLASSIFICATION T, V10, P11; Koestner A, 1999, WHO INT HISTOLOGICAL, VV, P17; Lipsitz D, 2003, VET PATHOL, V40, P659, DOI 10.1354/vp.40-6-659; Mondesir J, 2016, J BLOOD MED, V7, P171, DOI 10.2147/JBM.S70716; Oevermann A, 2012, VET NEUROPATHOLOGY E, P129; Okamoto Y, 2004, ACTA NEUROPATHOL, V108, P49, DOI 10.1007/s00401-004-0861-z; Preusser M, 2011, CLIN NEUROPATHOL, V30, P217, DOI 10.5414/NP300422; Preusser M, 2011, J NEUROPATH EXP NEUR, V70, P715, DOI 10.1097/NEN.0b013e31822713f0; Reitman ZJ, 2010, INT J CANCER, V127, P245, DOI 10.1002/ijc.25017; Snyder JM, 2006, J VET INTERN MED, V20, P669, DOI 10.1892/0891-6640(2006)20[669:CIPNC]2.0.CO;2; Song RB, 2013, J VET INTERN MED, V27, P1143, DOI 10.1111/jvim.12136; Spitzbarth I, 2017, VET PATHOL, V54, P369, DOI 10.1177/0300985816688745; Stoica G, 2004, VET PATHOL, V41, P10, DOI 10.1354/vp.41-1-10; Stupp R, 2006, ONCOLOGIST, V11, P165, DOI 10.1634/theoncologist.11-2-165; Tanboon J, 2016, J NEUROPATH EXP NEUR, V75, P4, DOI 10.1093/jnen/nlv009; van den Bent MJ, 2013, J NEURO-ONCOL, V112, P173, DOI 10.1007/s11060-013-1056-z; van den Bent MJ, 2010, CLIN CANCER RES, V16, P1597, DOI 10.1158/1078-0432.CCR-09-2902; Waitkus MS, 2016, NEURO-ONCOLOGY, V18, P16, DOI 10.1093/neuonc/nov136; Watanabe T, 2009, AM J PATHOL, V174, P1149, DOI 10.2353/ajpath.2009.080958; Yan H, 2009, NEW ENGL J MED, V360, P765, DOI 10.1056/NEJMoa0808710	31	1	1	0	1	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0021-9975	1532-3129		J COMP PATHOL	J. Comp. Pathol.	NOV	2018	165						33	39		10.1016/j.jcpa.2018.09.005			7	Pathology; Veterinary Sciences	Pathology; Veterinary Sciences	HG3SY	WOS:000454895900005	30502793				2019-10-28	
J	Argenta, FF; de Souza, SO; Meirelles, LS; Snel, GGM; De Lorenzo, C; Ienes-Lima, J; Horn, F; Driemeier, D; Pavarini, SP				Argenta, F. F.; de Souza, S. O.; Meirelles, L. S.; Snel, G. G. M.; De Lorenzo, C.; Ienes-Lima, J.; Horn, F.; Driemeier, D.; Pavarini, S. P.			Histiocytic Ulcerative Colitis in an American Staffordshire Terrier	JOURNAL OF COMPARATIVE PATHOLOGY			English	Article						dog; Escherichia coli; histiocytic ulcerative colitis; immunohistochemistry	INVASIVE ESCHERICHIA-COLI; GRANULOMATOUS COLITIS	A 9-year-old female American Staffordshire terrier was presented to a veterinary hospital with diarrhoea, severe prostration, hypothermia, dehydration and anaemia. The dog died 6 days after the first consultation. At necropsy examination the serosa of the large intestine showed a granular appearance and the mucosa was thickened, ulcerated and red, with prominent folding. Histological examination revealed marked inflammatory infiltration of macrophages into the mucosa and submucosa of the large intestine. These cells stained positively by the periodic acid-Schiff reaction. Immunohistochemistry showed marked presence of intracytoplasmic Escherichia coli in the macrophages. Bacteriological examination of intestinal sections yielded E. coli growth and the isolate displayed atypical characteristics when compared with strains associated with previously published cases of histiocytic ulcerative colitis (HUC). The molecular characterization showed that the isolate harboured none of the genes associated with enterotoxigenic E. coli strains and harboured only a limited number of genes associated with extra-intestinal pathotypes. Adherent and invasive E. coli are unlikely to have been involved in the pathogenesis of HUC in the present case. HUC is a rare disease with a predisposition for boxer dogs; however, sporadic occurrence in other breeds may occur. This is the first reported case of HUC in an American Staffordshire terrier. (C) 2018 Elsevier Ltd. All rights reserved.	[Argenta, F. F.; de Souza, S. O.; Snel, G. G. M.; De Lorenzo, C.; Driemeier, D.; Pavarini, S. P.] Univ Fed Rio Grande do Sul, Dept Vet Pathol, Coll Vet Med, Porto Alegre, RS, Brazil; [Meirelles, L. S.] Univ Fed Rio Grande do Sul, Dept Anim Med, Coll Vet Med, Porto Alegre, RS, Brazil; [Ienes-Lima, J.; Horn, F.] Univ Fed Rio Grande do Sul, Dept Biophys, Porto Alegre, RS, Brazil	Argenta, FF (reprint author), Univ Fed Rio Grande do Sul, Dept Vet Pathol, Coll Vet Med, Porto Alegre, RS, Brazil.	nando.arg83@gmail.com	Driemeier, David/H-3461-2012; Horn, Fabiana/K-9637-2013	Driemeier, David/0000-0003-3766-0654; 	Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq)National Council for Scientific and Technological Development (CNPq); Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)CAPES	Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq) and Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES) supported this study.	Barbieri NL, 2012, AVIAN DIS, V56, P436, DOI 10.1637/9921-090811-Case.1; Carvallo FR, 2015, EXP TOXICOL PATHOL, V67, P219, DOI 10.1016/j.etp.2014.10.004; Clermont O, 2000, APPL ENVIRON MICROB, V66, P4555, DOI 10.1128/AEM.66.10.4555-4558.2000; Clinical and Laboratory Standards Institute, 2009, M02A10 CLSI; Crepin S, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-568; Darfeuille-Michaud A, 2002, INT J MED MICROBIOL, V292, P185, DOI 10.1078/1438-4221-00201; De Lorenzo C, 2018, J VET SCI, V19, P27, DOI 10.4142/jvs.2018.19.1.27; Ewers C, 2007, INT J MED MICROBIOL, V297, P163, DOI 10.1016/j.ijmm.2007.01.003; Johnson TJ, 2008, J CLIN MICROBIOL, V46, P3987, DOI 10.1128/JCM.00816-08; Manchester AC, 2013, J VET INTERN MED, V27, P56, DOI 10.1111/jvim.12020; Mansfield CS, 2009, J VET INTERN MED, V23, P964, DOI 10.1111/j.1939-1676.2009.0363.x; Pedersen Niels C, 2016, Canine Genet Epidemiol, V3, P6, DOI 10.1186/s40575-016-0036-y; Simpson KW, 2006, INFECT IMMUN, V74, P4778, DOI 10.1128/IAI.00067-06; Stokes JE, 2001, J AM ANIM HOSP ASSOC, V37, P461, DOI 10.5326/15473317-37-5-461; Uzal FA, 2016, JUBB KENNEDY PALMERS, V2, P91	15	0	0	1	4	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0021-9975	1532-3129		J COMP PATHOL	J. Comp. Pathol.	NOV	2018	165						40	44		10.1016/j.jcpa.2018.09.006			5	Pathology; Veterinary Sciences	Pathology; Veterinary Sciences	HG3SY	WOS:000454895900006	30502794				2019-10-28	
J	Iglesias, OAS; Wright, C; Duchene, AG; Risso, MA; Risso, P; Zanuzzi, CN; Nishida, F; Lavid, A; Confente, F; Diaz, M; Portiansky, EL; Gimeno, EJ; Barbeito, CG				Iglesias, O. A. Santelices; Wright, C.; Duchene, A. G.; Risso, M. A.; Risso, P.; Zanuzzi, C. N.; Nishida, F.; Lavid, A.; Confente, F.; Diaz, M.; Portiansky, E. L.; Gimeno, E. J.; Barbeito, C. G.			Association between Degree of Anaplasia and Degree of Inflammation with the Expression of COX-2 in Feline Injection Site Sarcomas	JOURNAL OF COMPARATIVE PATHOLOGY			English	Article						cat; cyclo-oxygenase-2; feline injection site sarcoma; immunohistochemistry	VACCINE-ASSOCIATED FIBROSARCOMA; CYCLOOXYGENASE-2 EXPRESSION; POSTVACCINAL SARCOMAS; TECHNICAL ASPECTS; CATS; CANCER; METASTASIS; P53	Feline injection site sarcomas (FISSs) are mesenchymal neoplasms that develop at the sites of delivery of vaccines or other injectable products. Vaccine adjuvants can trigger an intense and persistent inflammatory response that may lead to neoplastic transformation. The proinflammatory role of cyclo-oxygenase (COX)-2 is well known and its overexpression has prognostic value in multiple neoplastic processes. One hundred and seventeen FISSs were evaluated for the degree of inflammation and anaplasia. Immunohistochemistry was used to determine the expression of COX-2 in these sarcomas. There was a significant association between the degree of inflammation and the expression of COX-2 by neoplastic cells. COX-2 expression was lower in tumours with higher degrees of anaplasia. These findings may be useful in predicting the sensitivity of FISSs to treatment with COX-2 inhibitors. The potential therapeutic use of such agents could then be restricted to tumours with lower degrees of anaplasia. (C) 2018 Published by Elsevier Ltd.	[Iglesias, O. A. Santelices; Wright, C.; Zanuzzi, C. N.; Nishida, F.; Portiansky, E. L.; Gimeno, E. J.; Barbeito, C. G.] Natl Univ La Plata, Sch Vet Sci, Image Anal Lab, La Plata, Buenos Aires, Argentina; [Barbeito, C. G.] Natl Univ La Plata, Sch Vet Sci, Lab Descript Expt & Comparat Histol & Embryol, La Plata, Buenos Aires, Argentina; [Duchene, A. G.; Lavid, A.] Natl Univ Buenos Aires, Sch Vet Sci, Buenos Aires, DF, Argentina; [Risso, M. A.; Risso, P.] Natl Univ La Plata, Sch Vet Sci, Dept Epizootiol & Publ Hlth, La Plata, Buenos Aires, Argentina; [Zanuzzi, C. N.; Nishida, F.; Portiansky, E. L.; Gimeno, E. J.; Barbeito, C. G.] Natl Res Council Sci & Technol, Buenos Aires, DF, Argentina	Iglesias, OAS (reprint author), Natl Univ La Plata, Sch Vet Sci, Image Anal Lab, La Plata, Buenos Aires, Argentina.	asantelices@fcv.unlp.edu.ar		Santelices Iglesias, Olga/0000-0003-3863-4116	National Scientific and Technical Research Council (CONICET)Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); National University of La Plata (UNLP)National University of La Plata	This work was supported by grants from the National Scientific and Technical Research Council (CONICET) and National University of La Plata (UNLP).	Araki Y, 2003, CANCER RES, V63, P728; Bardagi M, 2012, J COMP PATHOL, V146, P11, DOI 10.1016/j.jcpa.2011.03.012; Beam SL, 2003, VET PATHOL, V40, P496, DOI 10.1354/vp.40-5-496; Burton G, 1997, AUST VET J, V75, P102, DOI 10.1111/j.1751-0813.1997.tb14167.x; Campbell JID, 2012, BEHAV RES METHODS, V44, P1255, DOI 10.3758/s13428-012-0186-0; Carneiro CS, 2019, J FELINE MED SURG, V21, P314, DOI 10.1177/1098612X18774709; Cha YI, 2007, ANNU REV MED, V58, P239, DOI 10.1146/annurev.med.57.121304.131253; Chang HW, 2006, VET PATHOL, V43, P55, DOI 10.1354/vp.43-1-55; Costa C, 2002, J CLIN PATHOL, V55, P429, DOI 10.1136/jcp.55.6.429; Couto SS, 2002, VET PATHOL, V39, P33, DOI 10.1354/vp.39-1-33; Cullen J. M., 2002, Tumors in domestic animals, P3; De Nardi AB, 2011, PAK VET J, V31, P275; Deim Z, 2008, ACTA VET HUNG, V56, P111, DOI 10.1556/AVet.56.2008.1.11; Doddy FD, 1996, J COMP PATHOL, V114, P165, DOI 10.1016/S0021-9975(96)80005-3; Goldschmidt M. H., 2002, Tumors in domestic animals, P45, DOI 10.1002/9780470376928.ch2; Greenhough A, 2009, CARCINOGENESIS, V30, P377, DOI 10.1093/carcin/bgp014; HENDRICK MJ, 1994, J AM VET MED ASSOC, V205, P1425; HENDRICK MJ, 1991, J AM VET MED ASSOC, V199, P968; HENDRICK MJ, 1991, J AM VET MED ASSOC, V198, P304; HENDRICK MJ, 1992, CANCER RES, V52, P5391; HENDRICK MJ, 1994, VET PATHOL, V31, P126, DOI 10.1177/030098589403100121; Hendrick MJ, 1998, WHO INT CLASSIFICATI, P15; Hershey AE, 2000, J AM VET MED ASSOC, V216, P58, DOI 10.2460/javma.2000.216.58; Hershey AE, 2005, VET PATHOL, V42, P805, DOI 10.1354/vp.42-6-805; KASS PH, 1993, J AM VET MED ASSOC, V203, P396; Khan KNM, 2001, VET PATHOL, V38, P116, DOI 10.1354/vp.38-1-116; Lavalle GE, 2009, VET PATHOL, V46, P1275, DOI 10.1354/vp.08-VP-0226-C-FL; Madewell BR, 2001, VET PATHOL, V38, P196, DOI 10.1354/vp.38-2-196; Magi GE, 2010, J COMP PATHOL, V143, P340, DOI 10.1016/j.jcpa.2010.09.110; Newman SJ, 2006, J VET DIAGN INVEST, V18, P590, DOI 10.1177/104063870601800612; Nieto A, 2003, VET PATHOL, V40, P651, DOI 10.1354/vp.40-6-651; O'Byrne KJ, 2001, BRIT J CANCER, V85, P473, DOI 10.1054/bjoc.2001.1943; Ramos-Vara JA, 2014, VET PATHOL, V51, P42, DOI 10.1177/0300985813505879; Ramos-Vara JA, 2005, VET PATHOL, V42, P405, DOI 10.1354/vp.42-4-405; Risso MA, 2017, INTRO ESTADISTICA BA, P19; Rodriguez NI, 2008, J PEDIAT HEMATOL ONC, V30, P507, DOI 10.1097/MPH.0b013e31816e238c; Sharma-Walia N, 2012, ONCOGENESIS, V1, DOI 10.1038/oncsis.2012.5; SharmaWalia N, 2010, PLOS PATHOG, V6, P1; Shaw SC, 2009, JAVMA-J AM VET MED A, V234, P376, DOI 10.2460/javma.234.3.376; Soni EEC, 2011, ONCOL REP, V26, P1513, DOI 10.3892/or.2011.1431; Wang D, 2010, ONCOGENE, V29, P781, DOI 10.1038/onc.2009.421; Wilcock B, 2012, CAN VET J, V53, P430; Williams CS, 1999, ONCOGENE, V18, P7908, DOI 10.1038/sj.onc.1203286; Woodward Kevin N, 2011, ISRN Vet Sci, V2011, P210982, DOI 10.5402/2011/210982; Xu Z, 2006, CANCER RES, V66, P6657, DOI 10.1158/0008-5472.CAN-05-3624	45	0	0	1	3	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0021-9975	1532-3129		J COMP PATHOL	J. Comp. Pathol.	NOV	2018	165						45	51		10.1016/j.jcpa.2018.09.002			7	Pathology; Veterinary Sciences	Pathology; Veterinary Sciences	HG3SY	WOS:000454895900007	30502795				2019-10-28	
J	Park, CH; Shiwa, N; Sumimoto, J; Kimitsuki, K				Park, C. -H.; Shiwa, N.; Sumimoto, J.; Kimitsuki, K.			Epithelial-Myoepithelial Carcinoma in a Canine Salivary Gland	JOURNAL OF COMPARATIVE PATHOLOGY			English	Article						dog; epithelial-myoepithelial carcinoma; immunohistochemistry; salivary gland	PLEOMORPHIC ADENOMA; ULTRASTRUCTURE	A 7-year-old male cavalier King Charles spaniel was presented with a cervical subcutaneous mass. The mass had a multilobular growth pattern and each individual lobule contained ductal epithelial cells and myoepithelial cells surrounding the ductal cells. Immunohistochemically, the ductal epithelial cells were positive for cytokeratin (CK) 7 and CAM5.2 and the myoepithelial cells were positive for alpha-smooth muscle actin and p63. Both types of cells were positive for CK14, a myoepithelial cell marker. Ultrastructurally, the ductal epithelial cells were attached by desmosomes and contained abundant intracytoplasmic tonofilaments. Some ductal epithelial cells contained myofilaments characteristic of myoepithelial cells. Based on these findings, a diagnosis of epithelial-myoepithelial carcinoma was made. It is presumed that the tumour originated from an intercalated duct in a parotid salivary gland. (C) 2018 Elsevier Ltd. All rights reserved.	[Park, C. -H.; Shiwa, N.; Sumimoto, J.] Kitasato Univ, Sch Vet Med, Dept Vet Pathol, 23-35-1 Higashi, Towada, Aomori, Japan; [Kimitsuki, K.] Oita Univ, Dept Microbiol, Fac Med, 1-1 Idaigaoka,Hasama Machi, Oita, Japan	Park, CH (reprint author), Kitasato Univ, Sch Vet Med, Dept Vet Pathol, 23-35-1 Higashi, Towada, Aomori, Japan.	baku@vmas.kitasato-u.ac.jp					Alos L, 1996, SEMIN DIAGN PATHOL, V13, P138; Ashley DJB, 1990, EVANS HISTOLOGICAL A, P609; Barnes L, 2005, WHO CLASSIFICATION T, P209; CORIO RL, 1982, ORAL SURG ORAL MED O, V53, P280, DOI 10.1016/0030-4220(82)90304-8; DONATH K, 1972, VIRCHOWS ARCH A, V356, P16, DOI 10.1007/BF00543554; Ellis GL, 2008, AFIP ATLAS TUMOR PAT, P309; Faustino AM, 2007, VET J, V173, P223, DOI 10.1016/j.tvjl.2005.08.018; Fonseca I, 2000, AM J SURG PATHOL, V24, P469, DOI 10.1097/00000478-200003000-00018; Hammer A, 2001, J AM ANIM HOSP ASSOC, V37, P478, DOI 10.5326/15473317-37-5-478; Head K, 2002, TUMORS DOMESTIC ANIM, P410; Jones T, 1997, VET PATHOL, P1053; Kishimoto TE, 2015, J COMP PATHOL, V153, P111, DOI 10.1016/j.jcpa.2015.06.006; Misdorp W, 1999, WHO INT HISTOLOGICAL, V7, P18; Shimoyama Y, 2006, J COMP PATHOL, V134, P254, DOI 10.1016/j.jcpa.2005.10.001; Smrkovski OA, 2006, VET PATHOL, V43, P374, DOI 10.1354/vp.43-3-374; TANDLER B, 1970, J MORPHOL, V130, P227, DOI 10.1002/jmor.1051300208; Vazquez A, 2015, OTOLARYNG HEAD NECK, V153, P569, DOI 10.1177/0194599815594788	17	0	0	0	0	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0021-9975	1532-3129		J COMP PATHOL	J. Comp. Pathol.	NOV	2018	165						52	56		10.1016/j.jcpa.2018.09.010			5	Pathology; Veterinary Sciences	Pathology; Veterinary Sciences	HG3SY	WOS:000454895900008	30502796				2019-10-28	
J	Hoon-Hanks, LL; Frank, CB; Edmondson, EF				Hoon-Hanks, L. L.; Frank, C. B.; Edmondson, E. F.			Primary Meningeal Rhabdomyosarcoma of the Spinal Cord of a Young Dog with Neuromelanocytosis and Multiple Cutaneous Neurofibromas	JOURNAL OF COMPARATIVE PATHOLOGY			English	Article						congenital abnormalities; dog; rhabdomyosarcoma; spinal cord	SPINDLE-CELL RHABDOMYOSARCOMA	A 7-week-old male black Labrador retriever puppy was presented for post-mortem examination following progressive hindlimb paralysis and multiple masses within the skin. A highly compressive and infiltrative intradural mass was found within the T9-T11 spinal cord. Microscopical and immunohistochemical analysis revealed features compatible with spindle cell rhabdomyosarcoma (RMS). The adjacent spinal cord had numerous melanin-containing cells, arranged in small nodules, predominantly within the grey matter (proposed term of 'micronodular neuromelanocytosis') and the left lateral thorax had multifocal dermal neurofibromas. In this case, the constellation of proliferative/neoplastic lesions represents a unique case presentation with unclear aetiology. Primary canine meningeal RMS of the spinal cord has not been reported previously and represents a novel differential diagnosis for spinal tumours of young dogs. Moreover, such cases should be assessed for the presence of additional congenital abnormalities. (C) 2018 Elsevier Ltd. All rights reserved.	[Hoon-Hanks, L. L.; Frank, C. B.] Colorado State Univ, Coll Vet Med & Biomed Sci, Dept Microbiol Immunol & Pathol, Ft Collins, CO 80523 USA; [Edmondson, E. F.] NCI, Frederick Natl Lab Canc Res, Frederick, MD 21701 USA	Hoon-Hanks, LL (reprint author), Colorado State Univ, Coll Vet Med & Biomed Sci, Dept Microbiol Immunol & Pathol, Ft Collins, CO 80523 USA.	laura.hoon-hanks@colostate.edu		Edmondson, Elijah/0000-0002-6106-3705			Boyd KP, 2009, J AM ACAD DERMATOL, V61, P1, DOI 10.1016/j.jaad.2008.12.051; Caserto BG, 2013, VET PATHOL, V50, P806, DOI 10.1177/0300985813476069; CAVAZZANA AO, 1992, AM J SURG PATHOL, V16, P229, DOI 10.1097/00000478-199203000-00002; Christman MP, 2014, PEDIATR DERMATOL, V31, P584, DOI 10.1111/pde.12359; da Roza MR, 2010, J VET MED SCI, V72, P1363, DOI 10.1292/jvms.10-0082; Dagher R, 1999, Oncologist, V4, P34; Hettmer S, 2010, NAT MED, V16, P171, DOI 10.1038/nm0210-171; Hope D G, 1981, Adv Neurol, V29, P33; KOBAYASHI S, 1995, ACTA CYTOL, V39, P428; KORINTHENBERG R, 1984, CLIN NEUROL NEUROSUR, V86, P301, DOI 10.1016/0303-8467(84)90294-4; Parham DM, 2013, WHO CLASSIFICATION T, P123; SMITH MT, 1981, CANCER, V47, P2081, DOI 10.1002/1097-0142(19810415)47:8<2081::AID-CNCR2820470829>3.0.CO;2-1; SUMMERS BA, 1988, ACTA NEUROPATHOL, V75, P402, DOI 10.1007/BF00687794; Xu FS, 2000, ARCH PATHOL LAB MED, V124, P762; YANG P, 1995, GENET EPIDEMIOL, V12, P467, DOI 10.1002/gepi.1370120504	15	0	0	0	1	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0021-9975	1532-3129		J COMP PATHOL	J. Comp. Pathol.	NOV	2018	165						57	61		10.1016/j.jcpa.2018.09.008			5	Pathology; Veterinary Sciences	Pathology; Veterinary Sciences	HG3SY	WOS:000454895900009	30502797				2019-10-28	
J	Ros, C; Fernandez-Flores, F; de la Fuente, C; Pi, D; Anor, S; Planellas, M; Pumarola, M				Ros, C.; Fernandez-Flores, F.; de la Fuente, C.; Pi, D.; Anor, S.; Planellas, M.; Pumarola, M.			Tumour-to-Tumour Metastasis Phenomenon: Metastatic Prostatic Adenocarcinoma within an Anaplastic Oligodendroglioma in the Brain of a Dog	JOURNAL OF COMPARATIVE PATHOLOGY			English	Article						dog; oligodendroglioma; prostatic carcinoma; tumour-to-tumour metastasis	INTRACRANIAL NEOPLASIA; MENINGIOMA	A 10-year-old entire male French bulldog was presented following clusters of generalized tonic-clonic epileptic seizures. Neurolocalization was consistent with a lesion in the left forebrain. Magnetic resonance imaging of the brain revealed a large, ill-defined, intra-axial, space-occupying lesion at the level of the left temporal and parietal lobes, causing marked compression of the adjacent parenchyma. Computed tomography of the thorax and abdomen was consistent with disseminated metastatic disease. The dog was humanely destroyed and subjected to necropsy examination. Histological examination of the brain revealed a metastasis of prostatic carcinoma within an anaplastic oligodendroglioma in the left forebrain. To the author's knowledge, this is the first report describing clinical, imaging and histopathological features of an intracranial tumour-to-tumour metastasis in the brain of a dog. (C) 2018 Elsevier Ltd. All rights reserved.	[Ros, C.; de la Fuente, C.; Anor, S.; Planellas, M.] Univ Autonoma Barcelona, Fundacio Hosp Clin Vet, Cerdanyola Del Valles, Spain; [Ros, C.; Fernandez-Flores, F.; de la Fuente, C.; Pi, D.; Planellas, M.; Pumarola, M.] Univ Autonoma Barcelona, Dept Anim Med & Surg, Vet Fac, Cerdanyola Del Valles, Spain; [Fernandez-Flores, F.; Pi, D.; Anor, S.; Pumarola, M.] Univ Autonoma Barcelona, Networking Res Ctr Bioengn Biomat & Nanomed CIBER, Cerdanyola Del Valles, Spain	Ros, C (reprint author), Univ Autonoma Barcelona, Fundacio Hosp Clin Vet, Cerdanyola Del Valles, Spain.; Ros, C (reprint author), Univ Autonoma Barcelona, Dept Anim Med & Surg, Vet Fac, Cerdanyola Del Valles, Spain.	carlos.ros@ucv.es	Fernandez-Flores, Francisco/AAA-5061-2019	Fernandez-Flores, Francisco/0000-0001-6196-8208			Alves A, 2006, J SMALL ANIM PRACT, V47, P607, DOI 10.1111/j.1748-5827.2006.00066.x; CHAMBERS PW, 1980, ARCH PATHOL LAB MED, V104, P350; Erdogan H, 2014, TURK NEUROSURG, V24, P151, DOI 10.5137/1019-5149.JTN.8317-13.1; Espino L, 2009, ACTA VET HUNG, V57, P389, DOI 10.1556/AVet.57.2009.3.5; Fan TM, 2007, WITHROW MACEWENS SMA, P637; MacKillop E, 2007, VET RADIOL ULTRASOUN, V48, P550, DOI 10.1111/j.1740-8261.2007.00294.x; Moody P, 2012, INT J CLIN EXP PATHO, V5, P367; Snyder JM, 2008, J VET INTERN MED, V22, P172, DOI 10.1111/j.1939-1676.2007.0002.x; Snyder JM, 2006, J VET INTERN MED, V20, P669, DOI 10.1892/0891-6640(2006)20[669:CIPNC]2.0.CO;2; Song RB, 2013, J VET INTERN MED, V27, P1143, DOI 10.1111/jvim.12136; Stacy BA, 2003, J VET INTERN MED, V17, P357, DOI 10.1892/0891-6640(2003)17<357:SOOAMI>2.0.CO;2; Takei H, 2009, NEUROPATHOLOGY, V29, P303, DOI 10.1111/j.1440-1789.2008.00952.x	12	0	0	0	1	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0021-9975	1532-3129		J COMP PATHOL	J. Comp. Pathol.	NOV	2018	165						62	66		10.1016/j.jcpa.2018.09.009			5	Pathology; Veterinary Sciences	Pathology; Veterinary Sciences	HG3SY	WOS:000454895900010	30502799				2019-10-28	
J	Schmitz, A; Korbel, R; Rinder, M				Schmitz, A.; Korbel, R.; Rinder, M.			Zygomycosis due to Mucor racemosus Associated with a Circovirus Infection in a Blue Tit (Cyanistes caeruleus)	JOURNAL OF COMPARATIVE PATHOLOGY			English	Article						circovirus; Mucor racemosus; passeriform bird; zygomycosis	CLINICAL-MANIFESTATIONS; PROVENTRICULITIS; IDENTIFICATION; VENTRICULITIS; ASPERGILLOSIS; MUCORMYCOSIS; PHYLOGENIES; MYCOSIS; MUSCLE; BIRDS	In spring 2014, several wild passeriform garden birds were found severely ill or dead, all with severe periocular swellings. A blue tit (Cyanistes caeruleus) showing severe depression was humanely destroyed and sent for necropsy examination. In this bird, the lower eyelids were sagging, red and oedematous. Microscopical examination revealed marked infiltration of the eyelid tissue with fungal hyphae (stained by periodic acid-Schiff) without any inflammatory reaction. Polymerase chain reaction followed by sequencing identified Mucor racemosus and a so far unknown circovirus. The circovirus infection in this bird might have induced immunosuppression and thus facilitated the fungal infection. To our knowledge this is the first report of ocular M. racemosus infection associated with circovirus infection in a bird. (C) 2018 Elsevier Ltd. All rights reserved.	[Schmitz, A.; Korbel, R.; Rinder, M.] Ludwig Maximilians Univ Munchen, Ctr Clin Vet Med, Clin Birds Small Mammals Reptiles & Ornamental Fi, Sonnenstr 18, Oberschleissheim, Germany	Schmitz, A (reprint author), Ludwig Maximilians Univ Munchen, Ctr Clin Vet Med, Clin Birds Small Mammals Reptiles & Ornamental Fi, Sonnenstr 18, Oberschleissheim, Germany.	anna.schmitz@fu-berlin.de					BARROS SS, 1972, SABOURAUD, V10, P189; BIGLAND CH, 1961, AVIAN DIS, V5, P367, DOI 10.2307/1587767; Carrasco L, 1998, MYCOSES, V41, P297, DOI 10.1111/j.1439-0507.1998.tb00342.x; CARRASCO L, 1993, AVIAN DIS, V37, P923, DOI 10.2307/1592056; Chayakulkeeree M, 2006, EUR J CLIN MICROBIOL, V25, P215, DOI 10.1007/s10096-006-0107-1; DAWSON CO, 1976, AVIAN DIS, V20, P593, DOI 10.2307/1589394; DORRESTEIN GM, 1985, AVIAN DIS, V29, P951, DOI 10.2307/1590448; Edgar RC, 2004, NUCLEIC ACIDS RES, V32, P1792, DOI 10.1093/nar/gkh340; FELSENSTEIN J, 1985, EVOLUTION, V39, P783, DOI 10.1111/j.1558-5646.1985.tb00420.x; Gerlach H, 1994, AVIAN MED PRINCIPLES, P894; Gulbahar MY, 2000, AUST VET J, V78, P247, DOI 10.1111/j.1751-0813.2000.tb11744.x; Hagen N, 2007, THESIS; Halami MY, 2008, VIRUS RES, V132, P208, DOI 10.1016/j.virusres.2007.11.001; JEFFREY JS, 1994, AVIAN DIS, V38, P630, DOI 10.2307/1592090; MCCASKEY PC, 1984, AVIAN DIS, V28, P791, DOI 10.2307/1590251; Michels J, 2014, THESIS; MITCHELL G, 1986, VET PATHOL, V23, P625, DOI 10.1177/030098588602300513; Muszewska A, 2014, EUR J CLIN MICROBIOL, V33, P1273, DOI 10.1007/s10096-014-2076-0; PERELMAN B, 1992, AVIAN PATHOL, V21, P675, DOI 10.1080/03079459208418889; Petrikkos G, 2012, CLIN INFECT DIS, V54, pS23, DOI 10.1093/cid/cir866; Quesada O, 2007, AVIAN DIS, V51, P643, DOI 10.1637/0005-2086(2007)51[643:MRAWFL]2.0.CO;2; Rampin T, 2006, AVIAN PATHOL, V35, P277, DOI 10.1080/03079450600817057; Rosario K, 2017, ARCH VIROL, V162, P1447, DOI 10.1007/s00705-017-3247-y; SAITOU N, 1987, MOL BIOL EVOL, V4, P406; Schmitz A, 2017, J ZOO WILDLIFE MED, V48, P18, DOI 10.1638/2014-0126.1; Stein K, 2011, THESIS; Steinlage SJT, 2003, AVIAN DIS, V47, P229, DOI 10.1637/0005-2086(2003)047[0229:DMILCA]2.0.CO;2; Stenkat J, 2013, ECOHEALTH, V10, P352, DOI 10.1007/s10393-013-0868-9; Tamura K, 2004, P NATL ACAD SCI USA, V101, P11030, DOI 10.1073/pnas.0404206101; Tamura K, 2011, MOL BIOL EVOL, V28, P2731, DOI 10.1093/molbev/msr121; Todd D, 2004, VET MICROBIOL, V98, P169, DOI 10.1016/j.vetmic.2003.10.010; Todd D, 2001, AVIAN PATHOL, V30, P321, DOI 10.1080/03079450120066322; Turenne CY, 1999, J CLIN MICROBIOL, V37, P1846; Turenne CY, 2000, J CLIN MICROBIOL, V38, P944; Woods LW, 2000, J AVIAN MED SURG, V14, P154, DOI 10.1647/1082-6742(2000)014[0154:CIONB]2.0.CO;2	35	0	0	0	0	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0021-9975	1532-3129		J COMP PATHOL	J. Comp. Pathol.	NOV	2018	165						67	71		10.1016/j.jcpa.2018.09.011			5	Pathology; Veterinary Sciences	Pathology; Veterinary Sciences	HG3SY	WOS:000454895900011	30502800				2019-10-28	
J	Horta, RD; Lavalle, GE; Monteiro, LN; dos Reis, FBTMA; Costa, MD; Giuliano, A; Cassali, GD; Dobson, J				dos Santos Horta, R.; Eunice Lavalle, G.; Narducci Monteiro, L.; Alves dos Reis, F. B. T. M.; de Padua Costa, M.; Giuliano, A.; Dantas Cassali, G.; Dobson, J.			Evaluation of Histological, Immunohistochemical, Clinical and Genetic Prognostic Factors Associated with the Response of Canine Mast Cell Tumours to Glucocorticotherapy	JOURNAL OF COMPARATIVE PATHOLOGY			English	Article						dog; glucocorticotherapy; mast cell tumour; prognostic factors	MOLECULAR-MECHANISMS; INDUCED APOPTOSIS; MITOTIC INDEX; RESISTANCE; PROLIFERATION; PREDNISOLONE; VINBLASTINE; DIAGNOSIS; EXCISION; LEUKEMIA	Mast cell tumours (MCTs) are one of the most frequent neoplasms in dogs. Glucocorticoids (GCs) are widely used in the management of this disease, although no guidelines for their use have been established. The aim of this study was to evaluate the correlation of MCT prognostic factors with measurable response to GCs. This retrospective study included 60 dogs treated with prednisone or prednisolone prior to surgical biopsy of MCT. Incisional or excisional biopsy was performed 7-14 days after initiation of GC therapy. Histopathology, immunohistochemical labelling for Ki67 and KITr, and polymerase chain reaction for the c-KIT gene were performed. Partial response occurred in 63.3% of cases (38/60), while 36.7% (22/60) did not respond. A response to GCs was correlated with lower stage of the disease, low histological grade, lower pattern of KITr expression and Ki67 score. Response to GCs was positively correlated with well-established favourable prognostic factors. (C) 2018 Elsevier Ltd. All rights reserved.	[dos Santos Horta, R.; Eunice Lavalle, G.; Alves dos Reis, F. B. T. M.; de Padua Costa, M.] Univ Fed Minas Gerais, Dept Vet Med & Surg, Pres Antonio Carlos Ave 6627, Belo Horizonte, MG, Brazil; [Narducci Monteiro, L.; Dantas Cassali, G.] Univ Fed Minas Gerais, Dept Gen Pathol, Pres Antonio Carlos Ave 6627, Belo Horizonte, MG, Brazil; [Giuliano, A.; Dobson, J.] Univ Cambridge, Dept Vet Med, Madingley Rd, Cambridge, England	Horta, RD (reprint author), Univ Fed Minas Gerais, Dept Vet Med & Surg, Pres Antonio Carlos Ave 6627, Belo Horizonte, MG, Brazil.	rodrigohvet@gmail.com					Abadie JJ, 1999, J AM VET MED ASSOC, V215, P1629; Addison T, 1855, CONSTITUTIONAL LOCAL; BARRETT ID, 1981, DIAGN HISTOPATHOL, V4, P189; Blackwood L, 2012, VET COMP ONCOL, V10, pe1, DOI 10.1111/j.1476-5829.2012.00341.x; BLOOM F, 1952, P SOC EXP BIOL MED, V79, P651; BLOOMFIELD CD, 1984, J CLIN ONCOL, V2, P323, DOI 10.1200/JCO.1984.2.4.323; Camps-Palau MA, 2007, VET COMP ONCOL, V5, P156, DOI 10.1111/j.1476-5829.2006.00125.x; Davies DR, 2004, J AM ANIM HOSP ASSOC, V40, P124, DOI 10.5326/0400124; Dobson J, 2004, Vet Comp Oncol, V2, P132, DOI 10.1111/j.1476-5810.2004.00048.x; Dobson JM, 2007, J SMALL ANIM PRACT, V48, P424, DOI 10.1111/j.1748-5827.2007.00366.x; Dohse M, 2010, DRUG METAB DISPOS, V38, P1371, DOI 10.1124/dmd.109.031302; Dougherty TF, 1943, P SOC EXP BIOL MED, V53, P132; HENCH PS, 1950, ARCH INTERN MED, V85, P545, DOI 10.1001/archinte.1950.00230100002001; Horta RS, 2018, VET PATHOL, V55, P212, DOI 10.1177/0300985817747325; Kadmiel M, 2013, TRENDS PHARMACOL SCI, V34, P518, DOI 10.1016/j.tips.2013.07.003; Karmakar S, 2013, J BIOL CHEM, V288, P24020, DOI 10.1074/jbc.M113.473819; Killick DR, 2011, J SMALL ANIM PRACT, V52, P469, DOI [10.1111/j.1748-5827.2011.01093, 10.1111/j.1748-5827.2011.01093.x]; Kiupel M, 2004, VET PATHOL, V41, P371, DOI 10.1354/vp.41-4-371; Kiupel M, 2011, VET PATHOL, V48, P147, DOI 10.1177/0300985810386469; Kojika S, 1996, LEUKEMIA, V10, P994; Lin KT, 2016, STEROIDS, V111, P84, DOI 10.1016/j.steroids.2016.02.019; London CA, 2013, SMALL ANIMAL CLIN ON, P335; Mason HL, 1936, J BIOL CHEM, V114, P613; MCCAW DL, 1994, J VET INTERN MED, V8, P406, DOI 10.1111/j.1939-1676.1994.tb03259.x; Mealey KL, 2015, J VET INTERN MED, V29, P1, DOI [10.1111/jvim.12482, 10.1111/jvim.12525]; Nguyen SM, 2015, VET COMP ONCOL, V13, P176, DOI 10.1111/vco.12032; Obiri DD, 2012, ALLERGY, V67, P175, DOI 10.1111/j.1398-9995.2011.02731.x; OKEEFE DA, 1990, VET CLIN N AM-SMALL, V20, P1105, DOI 10.1016/S0195-5616(90)50087-X; Oppong E, 2013, MOL CELL ENDOCRINOL, V380, P119, DOI 10.1016/j.mce.2013.05.014; PATNAIK A. K., 1984, VET PATHOL, V21, P268; Pratt WB, 1997, ENDOCR REV, V18, P306, DOI 10.1210/er.18.3.306; Rassnick KM, 1999, J VET INTERN MED, V13, P601, DOI 10.1892/0891-6640(1999)013<0601:TOCMCT>2.3.CO;2; Renner K, 2003, CURR MOL MED, V3, P707, DOI 10.2174/1566524033479357; Rogers KS, 1996, VET CLIN N AM-SMALL, V26, P87, DOI 10.1016/S0195-5616(96)50008-2; Romansik EM, 2007, VET PATHOL, V44, P335, DOI 10.1354/vp.44-3-335; Rozanski E., 2010, NAVC Clinician's Brief, P80; Sahu B, 2013, CANCER RES, V73, P1570, DOI 10.1158/0008-5472.CAN-12-2350; Scase TJ, 2006, J VET INTERN MED, V20, P151, DOI 10.1892/0891-6640(2006)20[151:CMCTCO]2.0.CO;2; Schlossmacher G, 2011, J ENDOCRINOL, V211, P17, DOI 10.1530/JOE-11-0135; Schmidt S, 2004, CELL DEATH DIFFER, V11, pS45, DOI 10.1038/sj.cdd.4401456; Shaw T, 2018, VET COMP ONCOL, V16, P214, DOI 10.1111/vco.12346; Song IH, 2006, MOL CELL ENDOCRINOL, V246, P142, DOI 10.1016/j.mce.2005.11.012; Spoelhoef B, 2014, ENCY TOXICOLOGY, V1, P1038; Stanclift RM, 2008, JAVMA-J AM VET MED A, V232, P53, DOI 10.2460/javma.232.1.53; Steiger M, 1937, HELV CHIM ACTA, V20, P1164, DOI 10.1002/hlca.193702001158; STICKNEY JM, 1950, P STAFF M MAYO CLIN, V25, P488; Takahashi T, 1997, J VET MED SCI, V59, P995, DOI 10.1292/jvms.59.995; Taylor F, 2009, J SMALL ANIM PRACT, V50, P284, DOI 10.1111/j.1748-5827.2009.00732.x; van Lelyveld S, 2015, J SMALL ANIM PRACT, V56, P312, DOI 10.1111/jsap.12320; *VET COOP ONC GROU, 2016, VET COMP ONCOL, V14, P417; WALSH D, 1992, CLEV CLIN J MED, V59, P505, DOI 10.3949/ccjm.59.5.505; Warland J, 2015, IN PRACTICE, V37, DOI 10.1136/inp.h3440; Wooldridge JE, 2001, ONCOLOGY-NY, V15, P225; Zen M, 2011, AUTOIMMUN REV, V10, P305, DOI 10.1016/j.autrev.2010.11.009	54	0	0	1	2	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0021-9975	1532-3129		J COMP PATHOL	J. Comp. Pathol.	NOV	2018	165						72	81		10.1016/j.jcpa.2018.10.001			10	Pathology; Veterinary Sciences	Pathology; Veterinary Sciences	HG3SY	WOS:000454895900012	30502801				2019-10-28	
J	Coutant, R; Bouhours-Nouet, N; Donzeau, A; Decrequy, A; Louvigne, M; Rouleau, S				Coutant, R.; Bouhours-Nouet, N.; Donzeau, A.; Decrequy, A.; Louvigne, M.; Rouleau, S.			How to investigate a child with excessive growth?	MEDECINE NUCLEAIRE-IMAGERIE FONCTIONNELLE ET METABOLIQUE			French	Review						Tall stature; Family history; Genetic syndrome; Growth velocity; Constitutional tall stature	ADULT HEIGHT; TALL STATURE; FINAL HEIGHT; GIGANTISM; ESTROGEN	The diagnostic approach to tall stature in children is based on collecting birth data (macrosomia), sizes and family puberty, a family history of constitutional or pathological tall stature, search for a delay of development, dysmorphia, disproportion, analysis of the growth velocity (normal or accelerated), general and pubertal assessment, and bone age. When there is psychomotor retardation, a family history of pathological tall stature, or a disproportion in the clinical examination, the genetic causes of tall stature will be mentioned. The most frequent causes are Marfan syndrome and similar, Sotos syndrome, Beckwith-Wiedemann syndrome, Klinefelter syndrome, and MEN2B. These different genetic syndromes with tall stature justify a consultation with the geneticist. When the speed of growth is accelerated, first of all, it evokes puberty and early pseudopuberty, obesity and acromegaly. Finally, when the speed of growth is regular, and the parents are of tall stature, it evokes constitutional tall stature: this is the most frequent diagnosis to retain after having rejected pathological tall statures. (C) 2017 Elsevier Masson SAS. All rights reserved.	[Coutant, R.; Bouhours-Nouet, N.; Donzeau, A.; Decrequy, A.; Louvigne, M.; Rouleau, S.] CHU Angers, Serv Endocrinol & Diabetol Pediat, Pole Mere Enfant, 4 Rue Larrey, F-49933 Angers, France	Coutant, R (reprint author), CHU Angers, Serv Endocrinol & Diabetol Pediat, Pole Mere Enfant, 4 Rue Larrey, F-49933 Angers, France.	recoutant@chu-angers.fr	Co, Re/Z-5330-2019				BAYLEY N, 1952, J PEDIATR-US, V40, P423, DOI 10.1016/S0022-3476(52)80205-7; Benyi E, 2014, HORM RES PAEDIAT, V82, P89, DOI 10.1159/000360137; Benyi E, 2010, INT J PEDIATR ENDOCR, DOI 10.1155/2010/740629; Binder G, 1997, EUR J PEDIATR, V156, P905, DOI 10.1007/s004310050740; Bouhours-Nouet N, 2007, J CLIN ENDOCR METAB, V92, P629, DOI 10.1210/jc.2005-2631; Bruinsma FJ, 2006, J AFFECT DISORDERS, V91, P145, DOI 10.1016/j.jad.2005.11.019; deWaal WJ, 1996, J CLIN ENDOCR METAB, V81, P1206, DOI 10.1210/jc.81.3.1206; Drop SLS, 1998, ENDOCR REV, V19, P540, DOI 10.1210/er.19.5.540; Erkula G, 2002, AM J MED GENET, V109, P100, DOI 10.1002/ajmg.10312; Goudet P, 2015, J CLIN ENDOCR METAB, V100, P1568, DOI 10.1210/jc.2014-3659; Josefson J, 2011, J PEDIATR-US, V158, P433, DOI 10.1016/j.jpeds.2010.09.013; Korbonits M, 2012, CLIN ENDOCRINOL, V77, P351, DOI 10.1111/j.1365-2265.2012.04445.x; Lecointre C, 1997, J PEDIATR ENDOCR MET, V10, P529; Odink RJ, 2006, EUR J PEDIATR, V165, P50, DOI 10.1007/s00431-005-1722-z; Rostomyan L, 2015, ENDOCR-RELAT CANCER, V22, P745, DOI 10.1530/ERC-15-0320; Trivellin G, 2014, NEW ENGL J MED, V371, P2363, DOI 10.1056/NEJMoa1408028; Venn A, 2004, LANCET, V364, P1513, DOI 10.1016/S0140-6736(04)17274-7; Visser Remco, 2009, Pediatr Endocrinol Rev, V6, P375	18	0	0	0	1	ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER	ISSY-LES-MOULINEAUX	65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY-LES-MOULINEAUX, FRANCE	0928-1258	1878-6820		MED NUCL	Med. Nucl.-Imag. Fonct. Metab.	NOV-DEC	2018	42	6					417	421		10.1016/j.mednuc.2017.11.001			5	Pathology	Pathology	HF8CO	WOS:000454468700001					2019-10-28	
J	Abgral, R; Valette, G; Salaun, PY; Rousset, J				Abgral, R.; Valette, G.; Salaun, P. -Y.; Rousset, J.			Complementary role of FDG PET-CT and conventional imaging in initial assessment and post-therapeutic management of head and neck cancers: Guidelines and perspectives	MEDECINE NUCLEAIRE-IMAGERIE FONCTIONNELLE ET METABOLIQUE			French	Review						(18)FDG PET/CT; Initial assessment; Post-therapeutic management; Head neck cancer	SQUAMOUS-CELL CARCINOMA; POSITRON-EMISSION-TOMOGRAPHY; DETECTING DISTANT METASTASES; PET/CONTRAST-ENHANCED CT; 2ND PRIMARY CANCERS; COMPUTED-TOMOGRAPHY; INDUCTION CHEMOTHERAPY; PROGNOSTIC VALUE; F-18-FDG PET/CT; ORAL-CAVITY	Functional imaging by (18)fluorodesoxyglucose (FDG) positron emission tomography (PET) and morphological imaging by computed tomography (CT) and magnetic resonance imaging (MRI) hold an important and complementary role in characterization of head and neck squamous cell carcinoma (HNSCC). Based on an exhaustive literature, the recommendations and perspectives of their use in the initial assessment and the post-therapeutic management of HNSCC are presented. (C) 2018 Published by Elsevier Masson SAS.	[Abgral, R.; Salaun, P. -Y.] CHRU Morvan, Serv Med Nucl, 2 Ave Foch, F-29200 Brest, France; [Abgral, R.; Salaun, P. -Y.] EA GETBO 3878, IFR 148, F-29200 Brest, France; [Valette, G.] CHRU Morvan, Serv Chirurg Cerv Faciale, 2 Ave Foch, F-29200 Brest, France; [Rousset, J.] HIA Clermont Tonnerre, Serv Radiol, F-29200 Brest, France	Abgral, R (reprint author), CHRU Morvan, Serv Med Nucl, 2 Ave Foch, F-29200 Brest, France.; Abgral, R (reprint author), EA GETBO 3878, IFR 148, F-29200 Brest, France.	ronan.abgral@chu-brest.fr	SALAUN, Pierre-Yves/X-6701-2019	SALAUN, Pierre-Yves/0000-0002-3899-2135			Abgral R, 2016, HEAD NECK-J SCI SPEC, V38, pE600, DOI 10.1002/hed.24048; Abgral R, 2014, EUR J NUCL MED MOL I, V41, P659, DOI 10.1007/s00259-013-2618-1; Abgral R, 2013, NUCL MED COMMUN, V34, P551, DOI 10.1097/MNM.0b013e32836089ab; Abgral R, 2012, EUR J NUCL MED MOL I, V39, P1839, DOI 10.1007/s00259-012-2213-x; Abgral R, 2009, J NUCL MED, V50, P24, DOI 10.2967/jnumed.108.055806; Adkins D, 2014, CANCER MED-US, V3, P1493, DOI 10.1002/cam4.294; Al-Ibraheem A, 2009, J ONCOL, DOI 10.1155/2009/208725; Blanchard D, 2015, EUR ANN OTORHINOLARY, V132, P217, DOI 10.1016/j.anorl.2015.07.001; Castelli J, 2016, CRIT REV ONCOL HEMAT, V108, P40, DOI 10.1016/j.critrevonc.2016.10.009; Ceulemans G, 2011, INT J RADIAT ONCOL, V81, P938, DOI 10.1016/j.ijrobp.2010.07.019; Chaput A, 2018, LARYNGOSCOPE, V128, P378, DOI 10.1002/lary.26729; Chen SW, 2014, LARYNGOSCOPE, V124, P2732, DOI 10.1002/lary.24826; Cheng NM, 2015, EUR J NUCL MED MOL I, V42, P419, DOI 10.1007/s00259-014-2933-1; Cheng NM, 2013, J NUCL MED, V54, P1703, DOI 10.2967/jnumed.112.119289; Connell CA, 2007, HEAD NECK-J SCI SPEC, V29, P986, DOI 10.1002/hed.20629; de Bree R, 2016, RADIOTHER ONCOL, V118, P251, DOI 10.1016/j.radonc.2015.10.010; de Mones E, 2013, EUR ANN OTORHINOLARY, V130, P107, DOI 10.1016/j.anorl.2012.09.003; Farrag A, 2010, NUCL MED COMMUN, V31, P495, DOI 10.1097/MNM.0b013e3283334e2b; Garibaldi C, 2017, INT J RADIAT ONCOL, V98, P555, DOI 10.1016/j.ijrobp.2017.02.217; Gavid M, 2015, EUR ANN OTORHINOLARY, V132, P3, DOI 10.1016/j.anorl.2014.01.009; Gilbert K, 2010, AM J NEURORADIOL, V31, P251, DOI 10.3174/ajnr.A1796; Gupta T, 2011, EUR J NUCL MED MOL I, V38, P2083, DOI 10.1007/s00259-011-1893-y; Haerle SK, 2011, HEAD NECK-J SCI SPEC, V33, P324, DOI 10.1002/hed.21447; Halimi C, 2015, EUR ANN OTORHINOLARY, V132, P287, DOI 10.1016/j.anorl.2015.07.002; Hentschel M, 2011, EUR J NUCL MED MOL I, V38, P1203, DOI 10.1007/s00259-011-1759-3; Isles MG, 2008, CLIN OTOLARYNGOL, V33, P210, DOI 10.1111/j.1749-4486.2008.01688.x; Kikuchi M, 2013, INT J CLIN ONCOL, V18, P402, DOI 10.1007/s10147-012-0393-9; Kim SY, 2007, ANN ONCOL, V18, P1698, DOI 10.1093/annonc/mdm270; Kondo N, 2012, EUR ARCH OTO-RHINO-L, V269, P1503, DOI 10.1007/s00405-011-1784-7; Kostakoglu L, 2013, ONCOLOGIST, V18, P1108, DOI 10.1634/theoncologist.2013-0068; Krabbe CA, 2011, INT J ORAL MAX SURG, V40, P1263, DOI 10.1016/j.ijom.2011.06.023; Kubota K, 2004, EUR J NUCL MED MOL I, V31, P590, DOI 10.1007/s00259-003-1408-6; Kyzas PA, 2008, JNCI-J NATL CANCER I, V100, P712, DOI 10.1093/jnci/djn125; Lee JR, 2015, RADIOLOGY, V274, P764, DOI 10.1148/radiol.14141073; Ng SH, 2008, NEURORADIOLOGY, V50, P969, DOI 10.1007/s00234-008-0426-2; Ng SH, 2011, EUR J NUCL MED MOL I, V38, P996, DOI 10.1007/s00259-011-1740-1; Pak K, 2014, J NUCL MED, V55, P884, DOI 10.2967/jnumed.113.133801; Perie S, 2007, OTOLARYNG HEAD NECK, V137, P647, DOI 10.1016/j.otohns.2007.05.063; Rangaswamy B, 2013, LARYNGOSCOPE, V123, P2664, DOI 10.1002/lary.24077; Robin P, 2015, EUR J NUCL MED MOL I, V42, P72, DOI 10.1007/s00259-014-2889-1; Roh JL, 2009, ORAL ONCOL, V45, P218, DOI 10.1016/j.oraloncology.2008.05.010; Rousset J, 2013, HEAD NECK-J SCI SPEC, V35, pE202, DOI 10.1002/hed.23000; Rusthoven KE, 2004, CANCER-AM CANCER SOC, V101, P2641, DOI 10.1002/cncr.20687; Salaun PY, 2007, HEAD NECK-J SCI SPEC, V29, P1115, DOI 10.1002/hed.20645; Sanghera B, 2005, NUCL MED COMMUN, V26, P859, DOI 10.1097/00006231-200510000-00003; Seve P, 2007, CANCER, V109, P292, DOI 10.1002/cncr.22410; Sheikhbahaei S, 2015, AM J ROENTGENOL, V205, P1102, DOI 10.2214/AJR.15.14647; Sheikhbahaei S, 2015, AM J ROENTGENOL, V205, P629, DOI 10.2214/AJR.14.14166; Suenaga Y, 2016, EUR RADIOL, V26, P1018, DOI 10.1007/s00330-015-3902-1; Vergez S, 2013, EUR ANN OTORHINOLARY, V130, P39, DOI 10.1016/j.anorl.2012.09.004; Wong RJ, 2008, J SURG ONCOL, V97, P649, DOI 10.1002/jso.21018; Xi K, 2015, HEAD NECK-J SCI SPEC, V37, P1680, DOI 10.1002/hed.23774; Xie P, 2011, J CANCER RES CLIN, V137, P1085, DOI 10.1007/s00432-010-0972-y; Xu GZ, 2011, ORAL ONCOL, V47, P560, DOI 10.1016/j.oraloncology.2011.04.021; Xu GZ, 2011, HEAD NECK-J SCI SPEC, V33, P87, DOI 10.1002/hed.21400; Yi JS, 2012, J SURG ONCOL, V106, P708, DOI 10.1002/jso.23185; Yi XL, 2013, J MED IMAG RADIAT ON, V57, P674, DOI 10.1111/1754-9485.12077; Yoon DH, 2011, INT J RADIAT ONCOL, V81, P118, DOI 10.1016/j.ijrobp.2010.04.034; Zhang BT, 2015, ONCOL RES TREAT, V38, P45, DOI 10.1159/000370331; Zhu LH, 2013, SURG ONCOL, V22, P190, DOI 10.1016/j.suronc.2013.06.002	60	0	0	0	0	ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER	ISSY-LES-MOULINEAUX	65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY-LES-MOULINEAUX, FRANCE	0928-1258	1878-6820		MED NUCL	Med. Nucl.-Imag. Fonct. Metab.	NOV-DEC	2018	42	6					422	427		10.1016/j.mednuc.2018.08.001			6	Pathology	Pathology	HF8CO	WOS:000454468700002					2019-10-28	
J	Morgat, C; Vimont, D; Gallerande, HD; Mazere, J; Xuereb, F; Bordenave, L; Hindie, E; Fernandez, P				Morgat, C.; Vimont, D.; Gallerande, H. de Clermont; Mazere, J.; Xuereb, F.; Bordenave, L.; Hindie, E.; Fernandez, P.			Current status of Ga-68-radiolabelled agents used in clinical trials in France. Experience at the Bordeaux PET Research Center	MEDECINE NUCLEAIRE-IMAGERIE FONCTIONNELLE ET METABOLIQUE			French	Article; Proceedings Paper	1st Franco-Mediterranean Days of Molecular and Theranostic Imaging	NOV 03-04, 2017	Marseille, FRANCE			Ga-68; PET; Precursor; Clinical trial; Radiopharmacy		Production of Ga-68-radiopharmaceuticals for Positron Emission Tomography coupled with Computed Tomography (PET/CT) is increasing. These developments are today consolidated by the availability in France of a somatostatin receptor agonist (DOTATOC, Somakit (R)), under marketed authorization, and two Prostate Specific Membrane Antigen (PSMA) inhibitors (PSMA-11 and PSMA-617) under nominative temporary authorization of use. The unquestionable success of these radiopharmaceuticals and their uses within diagnostic strategies represent clinical trials carried out using Ga-68-DOTATOC and Ga-68-PSMA-11 mainly. Today, new indications and new 68Ga-radiopharmaceuticals arise to further promote PET/CT molecular imaging. In this article, we would share our experience to establish such clinical trials. (C) 2018 Elsevier Masson SAS. All rights reserved.	[Morgat, C.; Gallerande, H. de Clermont; Mazere, J.; Bordenave, L.; Hindie, E.; Fernandez, P.] CHU Bordeaux, Serv Med Nucl, F-33000 Bordeaux, France; [Morgat, C.; Vimont, D.; Mazere, J.; Hindie, E.; Fernandez, P.] Univ Bordeaux, INCIA, UMR 5287, F-33000 Bordeaux, France; [Xuereb, F.] Univ Bordeaux, Inserm UMR 1034, Biol Cardiovasc Dis, F-33000 Bordeaux, France; [Xuereb, F.] CHU Bordeaux, Serv Pharm, Pole Prod Sante, F-33600 Pessac, France; [Bordenave, L.] Univ Bordeaux, INSERM, UMR Biotis 1026, F-33000 Bordeaux, France; [Bordenave, L.] CHU Bordeaux, CIC1401, F-33000 Bordeaux, France	Morgat, C (reprint author), CHU Bordeaux, Serv Med Nucl, Hop Pellegrin, Pl Amelie Raba Leon, F-33076 Bordeaux, France.	clement.morgat@u-bordeaux.fr	Morgat, Clement/L-6911-2019	Morgat, Clement/0000-0002-9432-9223			[Anonymous], 2013, MON GALL 68GA ED SOL, P2482; Fragomeni RAS, 2018, J NUCL MED, V59, P871, DOI 10.2967/jnumed.117.203570; Minamimoto R, 2016, J NUCL MED, V57, P557, DOI 10.2967/jnumed.115.168393; Morgat C, 2016, EUR J NUCL MED MOL I, V43, P1258, DOI 10.1007/s00259-016-3319-3; Morgat C, 2014, J NUCL MED, V55, P1650, DOI 10.2967/jnumed.114.142000; Reubi JC, 2017, J NUCL MED, V58, P300, DOI 10.2967/jnumed.116.177733	6	1	1	1	1	ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER	ISSY-LES-MOULINEAUX	65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY-LES-MOULINEAUX, FRANCE	0928-1258	1878-6820		MED NUCL	Med. Nucl.-Imag. Fonct. Metab.	NOV-DEC	2018	42	6					428	431		10.1016/j.mednuc.2018.08.003			4	Pathology	Pathology	HF8CO	WOS:000454468700003					2019-10-28	
J	Homo-Seban, M; Thevenet, HS; Harache, B; Boucheneb, S; Ghazzar-Pierquet, N; Weinmann, P				Homo-Seban, M.; Thevenet, H. Slimani; Harache, B.; Boucheneb, S.; Ghazzar-Pierquet, N.; Weinmann, P.			Focal incidental uptake detected by 18F-FDG-PET-TDM in the parotid gland: Prevalence, diagnostic and impact on patient management	MEDECINE NUCLEAIRE-IMAGERIE FONCTIONNELLE ET METABOLIQUE			French	Article						Parotid gland incidentalomas; PET/CT; FDG	NEEDLE-ASPIRATION-CYTOLOGY; FDG PET; TOMOGRAPHY; BIOPSY; HEAD	Objective. - Parotid gland incidentalomas are unexpected hypermetabolic foci in the parotid region that can be found when scanning the whole-body by PET/CT. The role of SUVmax is controversial to differentiate benign or malignant tumours in this indication. The aim of this study was to determine PET/CT features of malignant parotid incidentaloma, in order to improve medical care. Methods. - We retrospectively reviewed 10,756 PET/CT scans performed during 3 years at our center in search of parotid gland incidentalomas. Twenty-eight patients were included. For each lesion, we have collected the results of parotid MRI, histology and/or subsequent imaging. Logistic regression was used to compare SUVmax, SUVmean, MTV and TLG, and ROC curves were used to assess threshold values. Results. - Prevalence of parotid gland incidentalomas was 1.29% (n = 139). Thirty-seven were included, among them, 46% were malignant. SUVmax, MTV and TLG were significantly higher for malignant tumours (P <= 0.001). MTV > 4 mL and TLG > 7.5 mL were strongly associated with a malignant lesion (MTV and TLG: P' < 0.001; SUVmax: P = 0.005; SUVmean: P = 0.07). According to ROC curves, MTV thresholded at 4 had an AUC of 0.92 (Se 75%, Sp 100%) to differentiate benign and malignant lesions. Conclusions. - MTV and TLG were predictive factors of malignancy, stronger than SUVmax. However, given the high proportion of malignant lesions and the suboptimal sensitivity of the MTV further exploration must be requested for any parotid gland incidentaloma. (C) 2018 Published by Elsevier Masson SAS.	[Homo-Seban, M.; Thevenet, H. Slimani; Harache, B.; Boucheneb, S.; Ghazzar-Pierquet, N.; Weinmann, P.] Hop Europeen Georges Pompidou, Serv Med Nucl, Paris, France	Weinmann, P (reprint author), Hop Europeen Georges Pompidou, Serv Med Nucl, Paris, France.	marie.homo@gmail.com; pierre.weinmann@aphp.fr					Basu S, 2008, NUCL MED COMMUN, V29, P367, DOI 10.1097/MNM.0b013e3282f8147a; Bothe C, 2015, INT ARCH OTORHINOLAR, V19, P112, DOI 10.1055/s-0034-1397334; Hadiprodjo D, 2012, AJR, V198, P185; Keyes JW, 1997, AM J ROENTGENOL, V169, P1663, DOI 10.2214/ajr.169.6.9393187; Kim BS, 2016, ANN NUCL MED, V30, P346, DOI 10.1007/s12149-016-1068-9; Lee SK, 2009, EUR RADIOL, V19, P2268, DOI 10.1007/s00330-009-1407-5; Lim CM, 2007, ANZ J SURG, V77, P742, DOI 10.1111/j.1445-2197.2007.04222.x; Lima RA, 2005, OTOLARYNG HEAD NECK, V133, P702, DOI 10.1016/j.otohns.2005.08.001; Makis W, 2015, CLIN IMAG, V39, P667, DOI 10.1016/j.clinimag.2015.03.011; Matsuda M, 1998, ACTA OTO-LARYNGOL, P214; Mikaszewski B, 2017, J ORAL MAXIL SURG, V75, P2248, DOI 10.1016/j.joms.2017.03.018; Seo YL, 2015, EUR RADIOL, V25, P171, DOI 10.1007/s00330-014-3397-1; Speight PM, 2002, ORAL DIS, V8, P229, DOI 10.1034/j.1601-0825.2002.02870.x; Treglia G, 2015, EUR ARCH OTO-RHINO-L, V272, P3617, DOI 10.1007/s00405-014-3308-8; Uchida Y, 2005, CLIN NUCL MED, V30, P170, DOI 10.1097/00003072-200503000-00005; Wang HF, 2010, J FOOD DRUG ANAL, V18, P24; Wilson AR, 2018, AM J CLIN PATHOL, V2011, P45; Yerli H, 2010, DENTOMAXILLOFAC RAD, V39, P349, DOI 10.1259/dmfr/15047967	18	0	0	0	0	ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER	ISSY-LES-MOULINEAUX	65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY-LES-MOULINEAUX, FRANCE	0928-1258	1878-6820		MED NUCL	Med. Nucl.-Imag. Fonct. Metab.	NOV-DEC	2018	42	6					432	438		10.1016/j.mednuc.2018.09.007			7	Pathology	Pathology	HF8CO	WOS:000454468700004					2019-10-28	
J	Fagart, A; Hubaut, MA; Tonnelet, D				Fagart, A.; Hubaut, M. -A.; Tonnelet, D.			Oncology - "FDG-PET and immunomodulators"	MEDECINE NUCLEAIRE-IMAGERIE FONCTIONNELLE ET METABOLIQUE			French	Editorial Material											davidtonnelet@hotmail.com						0	0	0	0	0	ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER	ISSY-LES-MOULINEAUX	65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY-LES-MOULINEAUX, FRANCE	0928-1258	1878-6820		MED NUCL	Med. Nucl.-Imag. Fonct. Metab.	NOV-DEC	2018	42	6					439	444		10.1016/j.mednuc.2018.09.001			6	Pathology	Pathology	HF8CO	WOS:000454468700005					2019-10-28	
J	Hubaut, MA; Fagart, A; Tonnelet, D				Hubaut, M. -A.; Fagart, A.; Tonnelet, D.			Neurology: "PET and Alzheimer: Current and futures perspectives"	MEDECINE NUCLEAIRE-IMAGERIE FONCTIONNELLE ET METABOLIQUE			French	Editorial Material											ma.hubaut@gmail.com						0	0	0	0	0	ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER	ISSY-LES-MOULINEAUX	65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY-LES-MOULINEAUX, FRANCE	0928-1258	1878-6820		MED NUCL	Med. Nucl.-Imag. Fonct. Metab.	NOV-DEC	2018	42	6					445	449		10.1016/j.mednuc.2018.09.002			5	Pathology	Pathology	HF8CO	WOS:000454468700006					2019-10-28	
J	Tonnelet, D; Hubaut, MA; Fagart, A				Tonnelet, D.; Hubaut, M. -A.; Fagart, A.			Regulatory aspects: "Development and debate on regulatory developments in the field of radiation protection"	MEDECINE NUCLEAIRE-IMAGERIE FONCTIONNELLE ET METABOLIQUE			French	Editorial Material											davidtonnelet@hotmail.com						0	0	0	0	0	ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER	ISSY-LES-MOULINEAUX	65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY-LES-MOULINEAUX, FRANCE	0928-1258	1878-6820		MED NUCL	Med. Nucl.-Imag. Fonct. Metab.	NOV-DEC	2018	42	6					450	451		10.1016/j.mednuc.2018.09.003			2	Pathology	Pathology	HF8CO	WOS:000454468700007					2019-10-28	
J	Hubaut, MA; Tonnelet, D; Fagart, A				Hubaut, M. -A.; Tonnelet, D.; Fagart, A.			Neurology: "Abnormal movements"	MEDECINE NUCLEAIRE-IMAGERIE FONCTIONNELLE ET METABOLIQUE			French	Editorial Material							POSITRON-EMISSION-TOMOGRAPHY; MULTIPLE SYSTEM ATROPHY; FP-CIT SPECT; PARKINSONS-DISEASE; DOPA PET; DOPAMINERGIC FUNCTION; LEWY BODIES; DIAGNOSIS; PROGRESSION; DEMENTIA				ma.hubaut@gmail.com					Benamer HTS, 2000, MOVEMENT DISORD, V15, P503, DOI 10.1002/1531-8257(200005)15:3<503::AID-MDS1013>3.0.CO;2-V; Benskey MJ, 2016, J NEUROCHEM, V137, P331, DOI 10.1111/jnc.13570; Bezard E, 2003, TRENDS NEUROSCI, V26, P215, DOI 10.1016/S0166-2236(03)00038-9; Bonardel G, 2011, MED NUCL, V35, P657, DOI 10.1016/j.mednuc.2011.10.004; Brooks David J, 2004, NeuroRx, V1, P243, DOI 10.1007/BF03206608; BROOKS DJ, 1990, ANN NEUROL, V28, P547, DOI 10.1002/ana.410280412; Brotchie J, 2009, NEUROLOGY, V72, pS32, DOI 10.1212/WNL.0b013e318198e0e9; BURN DJ, 1994, J NEUROL NEUROSUR PS, V57, P278, DOI 10.1136/jnnp.57.3.278; Darcourt J, 2014, Q J NUCL MED MOL IM, V58, P355; Defebvre L., 2007, MED NUCL, V31, P304, DOI 10.1016/j.mednuc.2007.03.013; Dhawan V, 2002, J NUCL MED, V43, P1324; Erlandsson K, 2012, PHYS MED BIOL, V57, pR119, DOI 10.1088/0031-9155/57/21/R119; Eshuis SA, 2009, EUR J NUCL MED MOL I, V36, P454, DOI 10.1007/s00259-008-0989-5; Eshuis SA, 2006, EUR J NUCL MED MOL I, V33, P200, DOI 10.1007/s00259-005-1904-y; Guignard R, 2014, MED NUCL, V38, P91, DOI 10.1016/j.mednuc.2014.01.002; HOFFMAN JM, 1992, J NUCL MED, V33, P1472; Ishikawa T, 1996, J NUCL MED, V37, P1760; Jokinen P, 2009, J NUCL MED, V50, P893, DOI 10.2967/jnumed.108.061572; Khan NL, 2005, NEUROLOGY, V64, P134, DOI 10.1212/01.WNL.0000148725.48740.6D; Klein JC, 2010, NEUROLOGY, V74, P885, DOI 10.1212/WNL.0b013e3181d55f61; Lee CS, 2000, ANN NEUROL, V47, P493, DOI 10.1002/1531-8249(200004)47:4<493::AID-ANA13>3.0.CO;2-4; McKeith IG, 2017, NEUROLOGY, V89, P88, DOI 10.1212/WNL.0000000000004058; MORRISH PK, 1995, J NEUROL NEUROSUR PS, V59, P597, DOI 10.1136/jnnp.59.6.597; Morrish PK, 1996, BRAIN, V119, P585, DOI 10.1093/brain/119.2.585; NAGASAWA H, 1993, J NEUROL SCI, V115, P136, DOI 10.1016/0022-510X(93)90216-L; Nurmi E, 2001, MOVEMENT DISORD, V16, P608, DOI 10.1002/mds.1139; Piccini P, 1997, ANN NEUROL, V41, P222, DOI 10.1002/ana.410410213; Ribeiro MJ, 2002, ARCH NEUROL-CHICAGO, V59, P580, DOI 10.1001/archneur.59.4.580; Rinne JO, 2001, SYNAPSE, V40, P193; SAWLE GV, 1994, ARCH NEUROL-CHICAGO, V51, P237, DOI 10.1001/archneur.1994.00540150027011; SAWLE GV, 1991, BRAIN, V114, P541, DOI 10.1093/brain/114.1.541; Soret M, 2006, EUR J NUCL MED MOL I, V33, P1062, DOI 10.1007/s00259-005-0003-4; Varrone A, 2013, EUR J NUCL MED MOL I, V40, P213, DOI 10.1007/s00259-012-2276-8	33	0	0	0	0	ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER	ISSY-LES-MOULINEAUX	65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY-LES-MOULINEAUX, FRANCE	0928-1258	1878-6820		MED NUCL	Med. Nucl.-Imag. Fonct. Metab.	NOV-DEC	2018	42	6					452	458		10.1016/j.mednuc.2018.09.004			7	Pathology	Pathology	HF8CO	WOS:000454468700008					2019-10-28	
J	Fagart, A; Hubaut, MA; Tonnelet, D				Fagart, A.; Hubaut, M. -A.; Tonnelet, D.			Instrumentation: "Technological evolution"	MEDECINE NUCLEAIRE-IMAGERIE FONCTIONNELLE ET METABOLIQUE			French	Editorial Material							OF-FLIGHT PET; PERFORMANCE				Alexandre.fagart@gmail.com					Chadwick L, 2017, CONSTRAST MEDIA MOL; Goshen E, 2018, EJNMMI PHYS, V5, DOI 10.1186/s40658-018-0205-z; Gregoire B, 2018, CLIN NUCL MED, V43, P389, DOI 10.1097/RLU.0000000000002062; Imbert L, 2012, J NUCL MED, V53, P1897, DOI 10.2967/jnumed.112.107417; Mehranian A, 2015, J NUCL MED, V56, P635, DOI 10.2967/jnumed.114.148817; Nguyen NC, 2015, J NUCL MED, V56, P1378, DOI 10.2967/jnumed.114.148338; Surti S, 2015, J NUCL MED, V56, P98, DOI 10.2967/jnumed.114.145029; Vandenberghe S, 2016, EJNMMI PHYS, V3, DOI 10.1186/s40658-016-0138-3	8	0	0	0	1	ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER	ISSY-LES-MOULINEAUX	65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY-LES-MOULINEAUX, FRANCE	0928-1258	1878-6820		MED NUCL	Med. Nucl.-Imag. Fonct. Metab.	NOV-DEC	2018	42	6					459	462		10.1016/j.mednuc.2018.09.005			4	Pathology	Pathology	HF8CO	WOS:000454468700009					2019-10-28	
J	Hubaut, MA; Fagart, A; Tonnelet, D				Hubaut, M. -A.; Fagart, A.; Tonnelet, D.			Gallium 68	MEDECINE NUCLEAIRE-IMAGERIE FONCTIONNELLE ET METABOLIQUE			French	Editorial Material											ma.hubaut@gmail.com						0	0	0	0	0	ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER	ISSY-LES-MOULINEAUX	65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY-LES-MOULINEAUX, FRANCE	0928-1258	1878-6820		MED NUCL	Med. Nucl.-Imag. Fonct. Metab.	NOV-DEC	2018	42	6					463	465		10.1016/j.mednuc.2018.09.006			3	Pathology	Pathology	HF8CO	WOS:000454468700010					2019-10-28	
J	Bright, FM; Vink, R; Byard, RW				Bright, Fiona M.; Vink, Robert; Byard, Roger W.			Neuropathological Developments in Sudden Infant Death Syndrome	PEDIATRIC AND DEVELOPMENTAL PATHOLOGY			English	Review						sudden infant death syndrome; neuropathology; brain; serotonin; substance P; brainstem; hippocampus; hypothalamus	BRAIN-STEM; MEDULLA-OBLONGATA; RECEPTOR-BINDING; CEREBELLAR CORTEX; UNEXPECTED DEATH; SEROTONERGIC SYSTEM; SYNDROME SIDS; DENDRITIC SPINES; ARCUATE NUCLEUS; DENTATE GYRUS	A wide variety of neuropathological abnormalities have been investigated in infants who have died of sudden infant death syndrome (SIDS). Issues which detracted from early studies included failure to use uniform definitions of SIDS and lack of appropriately matched control populations. Development of the triple risk model focused attention on the concept of an inherent susceptibility to unexpected death in certain infants, with research demonstrating a role for the neurotransmitter serotonin within the brainstem. However, it now appears that neuropathological abnormalities in SIDS infants are more complex than a simple serotonergic deficiency in certain medullary nuclei but instead could involve failure of an integrated network of neurochemical transmitters in a variety of subcortical locations. The following overview examines recent research developments looking particularly at the potential role of the peptide neurotransmitter substance P and its neurokinin-1 receptor in multiple nuclei within the brainstem, asymmetry and microdysgenesis of the hippocampus, and decreased orexin levels within dorsomedial, perifornical, and lateral levels in the hypothalamus. Whether such research will lead to identifiable biomarker for infants at risk of SIDS is yet to be established. Use of standardized and consistent methods of classifying and categorizing infant deaths will be pivotal in generating reproducible research results.	[Bright, Fiona M.; Byard, Roger W.] Univ Adelaide, Sch Med, Adelaide, SA, Australia; [Vink, Robert] Univ South Australia, Sansom Inst Hlth Res, Adelaide, SA, Australia	Bright, FM (reprint author), Univ Adelaide, Sch Med, Fac Hlth & Med Sci, Adelaide, SA 5005, Australia.	fiona.bright@sydney.edu.au	AM, Robert Vink/S-5616-2019	AM, Robert Vink/0000-0002-4885-0667; Bright, Fiona/0000-0002-1255-2350			Anaclet C, 2009, J NEUROSCI, V29, P14423, DOI 10.1523/JNEUROSCI.2604-09.2009; ARMSTRONG DD, 1993, J NEUROPATH EXP NEUR, V52, P433, DOI 10.1097/00005072-199309000-00001; Bright F., 2017, THESIS; Bright FM, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0184958; Bright FM, 2017, J NEUROPATH EXP NEUR, V76, P864, DOI 10.1093/jnen/nlx071; Broadbelt KG, 2012, MOL CELL PROTEOMICS, V11, DOI 10.1074/mcp.M111.009530; Broadbelt KG, 2011, J NEUROPATH EXP NEUR, V70, P799, DOI 10.1097/NEN.0b013e31822c09bc; Burton MD, 2000, RESP PHYSIOL, V122, P111, DOI 10.1016/S0034-5687(00)00153-5; Byard R W, 1995, J Clin Forensic Med, V2, P121, DOI 10.1016/1353-1131(95)90079-9; Byard Roger W, 2007, J Forensic Leg Med, V14, P453, DOI 10.1016/j.jflm.2006.11.003; Byard RW, 2012, J FORENSIC LEG MED, V19, P455, DOI 10.1016/j.jflm.2012.04.004; BYARD RW, 1991, J PAEDIATR CHILD H, V27, P147, DOI 10.1111/j.1440-1754.1991.tb00376.x; Byard RW, 2003, PEDIATR DEVEL PATHOL, V6, P112, DOI 10.1007/s10024-002-0205-8; Byard RW, 2010, SUDDEN DEATH YOUNG; Carpentier V, 1998, NEUROSCIENCE, V86, P159, DOI 10.1016/S0306-4522(98)00002-5; CHIGR F, 1992, NEUROCHEM INT, V20, P113, DOI 10.1016/0197-0186(92)90134-D; CruzSanchez FF, 1997, J NEUROPATH EXP NEUR, V56, P340, DOI 10.1097/00005072-199704000-00002; DELBIGIO MR, 1994, NEUROPATH APPL NEURO, V20, P144, DOI 10.1111/j.1365-2990.1994.tb01173.x; Doi A, 2008, RESP PHYSIOL NEUROBI, V164, P96, DOI 10.1016/j.resp.2008.06.007; Duncan JR, 2010, JAMA-J AM MED ASSOC, V303, P430, DOI 10.1001/jama.2010.45; Duncan JR, 2008, AUTON NEUROSCI-BASIC, V144, P61, DOI 10.1016/j.autneu.2008.09.006; FILIANO JJ, 1994, BIOL NEONATE, V65, P194; Franco P, 1998, J PEDIATR-US, V132, P240, DOI 10.1016/S0022-3476(98)70438-X; Garcia AJ, 2013, RESP PHYSIOL NEUROBI, V189, P288, DOI 10.1016/j.resp.2013.05.032; Goldstein RD, 2016, PEDIATRICS, V137, DOI 10.1542/peds.2015-2298; GUILLEMINAULT C, 1984, PEDIATRICS, V73, P71; Harper RM, 1998, CLIN EXP PHARMACOL P, V25, P483, DOI 10.1111/j.1440-1681.1998.tb02240.x; Harper RM, 2000, BRAIN RES BULL, V53, P125, DOI 10.1016/S0361-9230(00)00317-8; Harper RM, 2010, CURR PEDIATR REV, V6, P39, DOI 10.2174/157339610791317214; Hauck FR, 2008, PEDIATRICS, V122, P660, DOI 10.1542/peds.2007-0135; Hausmann R, 2007, INT J LEGAL MED, V121, P175, DOI 10.1007/s00414-006-0122-x; Haynes RL, 2017, P NATL ACAD SCI USA, V114, P7695, DOI 10.1073/pnas.1617374114; HOUSER CR, 1990, BRAIN RES, V535, P195, DOI 10.1016/0006-8993(90)91601-C; Huggle S, 1996, J CHILD NEUROL, V11, P433, DOI 10.1177/088307389601100603; Hunt NJ, 2016, J PROTEOMICS, V138, P48, DOI 10.1016/j.jprot.2016.02.022; Hunt N, 2015, ACTA NEUROPATHOL, V130, P185, DOI 10.1007/s00401-015-1437-9; Jensen LL, 2014, NEUROPATH APPL NEURO, V40, P385, DOI 10.1111/nan.12109; Kadhim H, 2003, NEUROLOGY, V61, P1256, DOI 10.1212/01.WNL.0000092014.14997.47; Kato I, 2003, AM J RESP CRIT CARE, V168, P1298, DOI 10.1164/rccm.200301-134OC; Kato I, 2001, AM J RESP CRIT CARE, V164, P1464, DOI 10.1164/ajrccm.164.8.2009001; Kiessling MC, 2013, J NEUROPATH EXP NEUR, V72, P861, DOI 10.1097/NEN.0b013e3182a31c31; Kinney HC, 2015, ACTA NEUROPATHOL, V129, P65, DOI 10.1007/s00401-014-1357-0; Kinney HC, 2013, FORENSIC SCI MED PAT, V9, P418, DOI 10.1007/s12024-013-9448-0; Kinney HC, 2012, FORENSIC SCI MED PAT, V8, P414, DOI 10.1007/s12024-012-9376-4; Kinney Hannah C, 2009, Dev Psychobiol, V51, P223, DOI 10.1002/dev.20367; Kinney HC, 2009, NEW ENGL J MED, V361, P795, DOI 10.1056/NEJMra0803836; Kinney H, 2009, ACTA NEUROPATHOL, V117, P247, DOI 10.1007/s00401-009-0490-7; KINNEY HC, 1983, PEDIATRICS, V72, P181; Kinney HC, 2005, PEDIATR DEVEL PATHOL, V8, P507, DOI 10.1007/s10024-005-0067-y; KINNEY HC, 1995, SCIENCE, V269, P1446, DOI 10.1126/science.7660131; Kinney HC, 2002, J NEUROPATH EXP NEUR, V61, P427, DOI 10.1093/jnen/61.5.427; KOPP N, 1992, PROG BRAIN RES, V93, P167; KOPP N, 1993, NEUROPEDIATRICS, V24, P25, DOI 10.1055/s-2008-1071508; Krous HF, 2004, PEDIATRICS, V114, P234, DOI 10.1542/peds.114.1.234; Kubo S, 1998, Nihon Hoigaku Zasshi, V52, P350; Lavezzi AM, 2013, FOLIA NEUROPATHOL, V51, P290, DOI 10.5114/fn.2013.39718; Lavezzi AM, 2007, VIRCHOWS ARCH, V450, P31, DOI 10.1007/s00428-006-0311-5; Lavezzi AM, 2006, INT J DEV NEUROSCI, V24, P365, DOI 10.1016/j.ijdevneu.2006.06.002; Machaalani R, 2003, J NEUROPATH EXP NEUR, V62, P1076, DOI 10.1093/jnen/62.10.1076; Machaalani R, 2014, PAEDIATR RESPIR REV, V15, P293, DOI 10.1016/j.prrv.2014.09.008; Machaalani R, 2011, TOXICOL APPL PHARM, V257, P396, DOI 10.1016/j.taap.2011.09.023; Machaalani R, 2009, ACTA NEUROPATHOL, V117, P257, DOI 10.1007/s00401-008-0468-x; Mallard C, 1999, J NEUROPATH EXP NEUR, V58, P255, DOI 10.1097/00005072-199903000-00005; Mitchell E, 2000, AM J FOREN MED PATH, V21, P395, DOI 10.1097/00000433-200012000-00020; Moon RY, 2012, PEDIATR REV, V33, P314, DOI 10.1542/pir.33-7-314; Muller-Starck J, 2014, J NEUROPATH EXP NEUR, V73, P312, DOI 10.1097/NEN.0000000000000055; Nachmanoff DB, 1998, J NEUROPATH EXP NEUR, V57, P1018, DOI 10.1097/00005072-199811000-00004; NAEYE RL, 1976, AM J CLIN PATHOL, V66, P526; Obonai T, 1998, PEDIATRICS, V101, P285, DOI 10.1542/peds.101.2.285; OEHMICHEN M, 1989, ACTA NEUROPATHOL, V78, P404, DOI 10.1007/BF00688177; Oehmichen M, 2009, ACTA NEUROPATHOL, V117, P267, DOI 10.1007/s00401-008-0459-y; Ozawa Y, 2002, NEUROPEDIATRICS, V33, P142, DOI 10.1055/s-2002-33678; Ozawa Y, 2003, EARLY HUM DEV, V75, P38; Pae EK, 2005, NEUROSCI LETT, V375, P123, DOI 10.1016/j.neulet.2004.10.091; Paine SML, 2014, NEUROPATH APPL NEURO, V40, P364, DOI 10.1111/nan.12095; Panigrahy A, 1997, J NEUROPATH EXP NEUR, V56, P1253, DOI 10.1097/00005072-199711000-00010; Panigrahy A, 2000, J NEUROPATH EXP NEUR, V59, P377, DOI 10.1093/jnen/59.5.377; Paterson DS, 2006, JAMA-J AM MED ASSOC, V296, P2124, DOI 10.1001/jama.296.17.2124; Paterson DS, 2009, RESP PHYSIOL NEUROBI, V168, P133, DOI 10.1016/j.resp.2009.05.010; Poets CF, 1999, PEDIATR RES, V45, P350, DOI 10.1203/00006450-199903000-00010; Poets Christian F, 2004, Paediatr Respir Rev, V5 Suppl A, pS383, DOI 10.1016/S1526-0542(04)90068-1; QUATTROCHI JJ, 1985, BRAIN RES, V325, P39, DOI 10.1016/0006-8993(85)90300-2; QUATTROCHI JJ, 1980, BRAIN RES, V181, P245, DOI 10.1016/0006-8993(80)91280-9; RIEDEL A, 1989, BRAIN RES, V499, P333, DOI 10.1016/0006-8993(89)90782-8; Rodriguez ML, 2012, FORENSIC SCI MED PAT, V8, P441, DOI 10.1007/s12024-012-9367-5; Rognum IJ, 2009, ACTA NEUROPATHOL, V118, P519, DOI 10.1007/s00401-009-0535-y; Sawaguchi T, 2005, FORENSIC SCI INT, V149, P205, DOI 10.1016/j.forsciint.2004.10.015; Sawaguchi T, 2003, EARLY HUM DEV, V75, pS31, DOI 10.1016/j.earlhumdev.2003.08.006; Schechtman VL, 1996, PEDIATR RES, V40, P571, DOI 10.1203/00006450-199610000-00010; Schwartz MD, 2015, PSYCHIAT CLIN N AM, V38, P615, DOI 10.1016/j.psc.2015.07.002; Sparks DL, 1996, J CHILD NEUROL, V11, P101, DOI 10.1177/088307389601100208; SPARKS DL, 1991, J CHILD NEUROL, V6, P335, DOI 10.1177/088307389100600409; SPARKS DL, 1991, J CHILD NEUROL, V6, P123, DOI 10.1177/088307389100600205; Spinelli J, 2017, J PAEDIATR CHILD H, V53, P112, DOI 10.1111/jpc.13429; Srch M, 1992, Soud Lek, V37, P33; Sridhar R, 2003, PEDIATR PULM, V36, P113, DOI 10.1002/ppul.10287; SWAAB DF, 1995, NEUROCHEM RES, V20, P509, DOI 10.1007/BF01694533; TAKASHIMA S, 1991, NEUROPEDIATRICS, V22, P97, DOI 10.1055/s-2008-1071424; TAKASHIMA S, 1985, EXP NEUROL, V90, P580, DOI 10.1016/0014-4886(85)90155-4; Tang S, 2012, RESP PHYSIOL NEUROBI, V180, P25, DOI 10.1016/j.resp.2011.10.004; Waters KA, 1999, PEDIATR RES, V45, P166, DOI 10.1203/00006450-199902000-00002; YAMANOUCHI H, 1993, NEUROPEDIATRICS, V24, P200, DOI 10.1055/s-2008-1071539	102	1	1	3	4	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1093-5266	1615-5742		PEDIATR DEVEL PATHOL	Pediatr. Dev. Pathol.	NOV	2018	21	6					515	521		10.1177/1093526618776439			7	Pathology; Pediatrics	Pathology; Pediatrics	HF1JC	WOS:000453921600001	29759045				2019-10-28	
J	Duncan, VE; Wicker, JA; Kelly, DR; Li, R				Duncan, Virginia E.; Wicker, Jason A.; Kelly, David R.; Li, Rong			TLE1 Expression in Malignant Rhabdoid Tumor and Atypical Teratoid/Rhabdoid Tumor	PEDIATRIC AND DEVELOPMENTAL PATHOLOGY			English	Article						transducer-like enhancer of split 1; malignant rhabdoid tumor; atypical teratoid/rhabdoid tumor; synovial sarcoma; Remmele score; Immunoreactive score	DIAGNOSTIC IMMUNOHISTOCHEMICAL MARKER; DISTINGUISHES SYNOVIAL SARCOMA; SOFT-TISSUE	Malignant rhabdoid tumors (MRT; atypical teratoid/rhabdoid tumor [ATRT] in the central nervous system) are aggressive tumors in infants and children which can overlap with other sarcomas, such as synovial sarcoma (SS). The gold standard for SS diagnosis is characterization of the t(X;18) chromosomal translocation. However, stratification of cases for molecular analysis is not always straightforward or feasible. Recent literature suggests transducer-like enhancer of split 1 (TLE1) protein expression may distinguish SS from certain histologic mimics; however, this has not been investigated in MRT and ATRT. We stained whole-tissue sections of 18 archived cases of MRT and ATRT with TLE1. Nuclear expression was scored using a 4-tiered (0, 1+, 2+, and 3+) scale describing staining intensity, extent, or combination of both. The majority of MRT and ATRT cases showed some TLE1 immunoreactivity (n = 16; 89% for >= 1 + staining); 14 (78%) of total cases showed >= 2 + positivity using any of the 3 scoring systems. Over half (n = 10; 56%) of cases showed >= 2 + staining; 4 (22%) cases showed 3 + strong and diffuse TLE1 staining measured by all scoring systems in agreement. Although still of potential use, we urge caution in the interpretation of TLE1 when the differential diagnosis includes both SS and MRT or ATRT.	[Duncan, Virginia E.] Seattle Childrens Hosp, Dept Pathol, 4800 Sand Point Way NE, Seattle, WA 98105 USA; [Wicker, Jason A.; Kelly, David R.; Li, Rong] Childrens Alabama, Dept Pathol, Birmingham, AL USA; [Wicker, Jason A.; Kelly, David R.] Univ Alabama Birmingham, Dept Pathol, Birmingham, AL 35294 USA	Duncan, VE (reprint author), Seattle Childrens Hosp, Dept Pathol, 4800 Sand Point Way NE, Seattle, WA 98105 USA.	veduncan@bellsouth.net					Arnold MA, 2013, HUM PATHOL, V44, P881, DOI 10.1016/j.humpath.2012.08.014; Atef Aliaa, 2015, Asian Pac J Cancer Prev, V16, P6545; Chuang HC, 2013, PATHOL INT, V63, P573, DOI 10.1111/pin.12113; He X, 2016, INT J CLIN EXP PATHO, V9, P4339; Hollmann TJ, 2011, AM J SURG PATHOL, V35, pE47, DOI 10.1097/PAS.0b013e31822b325b; Jagdis A, 2009, AM J SURG PATHOL, V33, P1743, DOI 10.1097/PAS.0b013e3181b7ed36; Knosel T, 2010, EUR J CANCER, V46, P1170, DOI 10.1016/j.ejca.2010.01.032; Kosemehmetoglu K, 2009, MODERN PATHOL, V22, P872, DOI 10.1038/modpathol.2009.47; Kreiger PA, 2009, MODERN PATHOL, V22, P142, DOI 10.1038/modpathol.2008.185; Poo WC, 2011, AM J CLIN PATHOL, V135, P839, DOI 10.1309/AJCP45SSNAOPXYXU; Rekhi B, 2015, APMIS, V123, P618, DOI 10.1111/apm.12395; REMMELE W, 1987, PATHOLOGE, V8, P138; Terry J, 2007, AM J SURG PATHOL, V31, P240, DOI 10.1097/01.pas.0000213330.71745.39; Thway K, 2014, ANN DIAGN PATHOL, V18, P369, DOI 10.1016/j.anndiagpath.2014.09.002; Zaccarini DJ, 2019, APPL IMMUNOHISTO M M, V27, pE1, DOI 10.1097/PAI.0000000000000479; Zaccarini DJ, APPL IMMUNOHISTOCHEM	16	0	0	0	2	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1093-5266	1615-5742		PEDIATR DEVEL PATHOL	Pediatr. Dev. Pathol.	NOV	2018	21	6					522	527		10.1177/1093526618761720			6	Pathology; Pediatrics	Pathology; Pediatrics	HF1JC	WOS:000453921600002	29490565				2019-10-28	
J	Reyes, JA; Somers, GR; Chiasson, DA				Reyes, Jeanette A.; Somers, Gino R.; Chiasson, David A.			Sudden Unexpected Death in Neonates: A Clinico-pathological Study	PEDIATRIC AND DEVELOPMENTAL PATHOLOGY			English	Article						autopsy; cause of death; neonatal death; neonates; sudden death; sudden unexpected death in infancy	AUTOPSY FINDINGS; BIRTH-DEFECTS; PREVALENCE; DIAGNOSIS; INFANCY; DISEASE; PATHOPHYSIOLOGY; MORTALITY; RISK	Clinico-pathological studies that focus on sudden unexpected death (SUD) in the neonatal period are rare. The objective of this study was to elucidate the frequency and pathological spectrum of anatomical causes of death (CODs), found in the setting of sudden unexpected death in neonates (SUD-N), and to correlate the COD with premortem circumstantial information. We conducted a detailed review of all autopsy reports on SUD-N cases at our institution from 1997 to 2015. Analyzed clinical data included obstetrical history, postpartum/neonatal medical course, and circumstances surrounding death. Evaluated autopsy data included growth parameters, pathological findings, ancillary test results, and COD. Data from decedents in which a COD was established (COD-E) were statistically compared with that from decedents in which the COD was undetermined (COD-U). Of 104 neonates (M: 49; F: 55) who fulfilled our inclusion criteria, a COD was established at autopsy in 46 cases (44%). Infections, congenital abnormalities, and inborn errors of metabolism were the most common CODs. Single variables statistically more likely to be found in COD-E neonates were clinical history of prodromal illness, witnessed loss of vital signs, and evidence of physiological stress in the thymus or the liver. A prodrome was statistically more common in the COD-E group, but the absence of a prodrome does not reliably exclude COD-E cases, since over 50% of these patients were asymptomatic prior to their demise. In COD-U neonates, the statistically significant factors were death during sleep, death during sleep while "bed"-sharing, "heavy" lungs, and petechial hemorrhages on the epicardium or pleura. Given the frequency and wide spectrum of underlying pathologies in COD-E neonates, referral of SUD-N cases to pathologists with specialized pediatric autopsy expertise is recommended.	[Reyes, Jeanette A.; Somers, Gino R.; Chiasson, David A.] Hosp Sick Children, Dept Paediat Lab Med, Div Pathol, 555 Univ Ave, Toronto, ON M5G 1X8, Canada; [Somers, Gino R.; Chiasson, David A.] Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON, Canada	Reyes, JA (reprint author), Hosp Sick Children, Dept Paediat Lab Med, Div Pathol, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	jeanette.reyes@sickkids.ca					[Anonymous], CANSIM1020506; Archie JG, 2006, AM J CLIN PATHOL, V126, P256, DOI 10.1309/FK9D5WBA1UEPT5BB; BENNETT MJ, 1994, HUM PATHOL, V25, P742, DOI 10.1016/0046-8177(94)90241-0; Bird TM, 2006, BIRTH DEFECTS RES A, V76, P762, DOI 10.1002/bdra.20323; Byard R, 2010, SUDDEN DEATH YOUNG, P1; Canfield MA, 2006, BIRTH DEFECTS RES A, V76, P747, DOI 10.1002/bdra.20294; Caviness AC, 2008, J PEDIATR-US, V153, P164, DOI 10.1016/j.jpeds.2008.02.031; Cohen MC, 2015, ACTA PAEDIATR, V104, P883, DOI 10.1111/apa.13046; Corey L, 2009, NEW ENGL J MED, V361, P1376, DOI 10.1056/NEJMra0807633; Cutz E, 2016, JAMA PEDIATR, V170, P315, DOI 10.1001/jamapediatrics.2015.4172; Fleming PJ, 2015, ARCH DIS CHILD, V100, P984, DOI 10.1136/archdischild-2014-306424; Gaschignard J, 2011, PEDIATR INFECT DIS J, V30, P212, DOI 10.1097/INF.0b013e3181fab1e7; Heath PT, 2003, ARCH DIS CHILD, V88, P173; Hunt CE, 2015, FORENSIC SCI MED PAT, V11, P283, DOI 10.1007/s12024-014-9650-8; HUNT CE, 1987, J PEDIATR-US, V110, P669, DOI 10.1016/S0022-3476(87)80001-X; Ishikawa T, 2011, ACTA PAEDIATR, V100, pE55, DOI 10.1111/j.1651-2227.2011.02248.x; Khoshnood B, 2012, HEART, V98, P1667, DOI 10.1136/heartjnl-2012-302543; Kimberlin DW, 2004, CLIN MICROBIOL REV, V17, P1, DOI 10.1128/CMR.17.1.1-13.2004; Kinney HC, 2009, NEW ENGL J MED, V361, P795, DOI 10.1056/NEJMra0803836; Klinger G, 2000, PEDIATRICS, V106, P477, DOI 10.1542/peds.106.3.477; Meyers DE, 2013, TEX HEART I J, V40, P385; Modre-Osprian R, 2009, BMC SYST BIOL, V3, DOI 10.1186/1752-0509-3-2; Moon RY, 2016, PEDIATRICS, V138, DOI 10.1542/peds.2016-2940; Opdal SH, 2004, PEDIATRICS, V114, pE506, DOI 10.1542/peds.2004-0683; Stoll BJ, 2011, PEDIATRICS, V127, P817, DOI 10.1542/peds.2010-2217; The Baroness Helena Kennedy QC, 2016, SUDDEN UNEXPECTED DE; Vennemann M, 2007, ARCH DIS CHILD, V92, P133, DOI 10.1136/adc.2006.101337; Wappner RS, 2006, OSKIS PEDIAT PRINCIP, P2145; Weber MA, 2008, ARCH DIS CHILD, V93, P1048, DOI 10.1136/adc.2007.136739; Weber MA, 2012, J PAEDIATR CHILD H, V48, P335, DOI 10.1111/j.1440-1754.2011.02228.x; Weber MA, 2009, J MATERN-FETAL NEO M, V22, P398, DOI 10.1080/14767050802406677; Weese-Mayer DE, 2007, AM J MED GENET A, V143A, P771, DOI 10.1002/ajmg.a.31722; Weiner DL, 2006, TXB PEDIAT EMERGENCY, P1193; World Health Organization, 2016, INT STAT CLASS DIS R; Wren C, 2008, ARCH DIS CHILD-FETAL, V93, pF33, DOI 10.1136/adc.2007.119032; Wren C, 2012, EUR J PEDIATR, V171, P281, DOI 10.1007/s00431-011-1525-3	36	0	0	0	1	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1093-5266	1615-5742		PEDIATR DEVEL PATHOL	Pediatr. Dev. Pathol.	NOV	2018	21	6					528	536		10.1177/1093526618764054			9	Pathology; Pediatrics	Pathology; Pediatrics	HF1JC	WOS:000453921600003	29642737				2019-10-28	
J	Steinl, GK; Gandelman, JS; Katzman, PJ; Ru, Y; Guillet, R; Pressman, E; Cooper, EM; O'Brien, KO				Steinl, Gabrielle K.; Gandelman, Jocelyn S.; Katzman, Philip J.; Ru, Yuan; Guillet, Ronnie; Pressman, Eva; Cooper, Elizabeth M.; O'Brien, Kimberly O.			Umbilical Cord Coiling in High-risk Pregnancies: Associations With Determinants of Adverse Birth Outcomes and Iron Status	PEDIATRIC AND DEVELOPMENTAL PATHOLOGY			English	Article						adolescents; cord coiling; iron deficiency; multiple gestations	HUMAN PLACENTAL TISSUE; FOR-GESTATIONAL-AGE; DEFICIENCY ANEMIA; MOTOR-ACTIVITY; VITAMIN-D; INDEX; EXPRESSION; MARKER; SERUM; TWIN	Abnormal umbilical cord coiling has been associated with adverse neonatal outcomes, but the etiology of these findings remains poorly characterized. This study was undertaken to examine associations between cord coiling and maternal iron (Fe) status and to identify potential determinants of hypo- and hypercoiling in 2 higher risk obstetric groups: pregnant adolescents (<= 18 years, n = 92) and adult women carrying twins (n = 49), triplets (n = 11), or quadruplets (n = 1). Umbilical cords were classified as hypo-, normo-, or hypercoiled using digital photographs to assess gross appearance. Hypocoiling and hypercoiling were observed in 44% (n = 86/195) and 13% (n = 26/195) of the combined study population. The prevalence of hypocoiling among women carrying multiples was over 3-fold higher than the prevalence in singleton pregnancies based on the published data. Within the entire study population, hypocoiling was associated with a lower gestational age at birth when compared to normocoiling and hypercoiling (36.3 +/- 3.6 weeks [n = 86] vs 37.8 +/- 2.7 [n = 83], P < .01, and 38.2 +/- 2.6 [n = 26], P < .01, respectively), whereas hypercoiling was associated with significantly lower serum ferritin when compared to normocoiling (P < .01) and hypocoiling (P < .001). In the multiples cohort only, hypercoiling was significantly associated with multiparity (P < .01) and lower birth weight (P < .05). Further studies are needed to identify the determinants and consequences of cord coiling.	[Steinl, Gabrielle K.; Gandelman, Jocelyn S.; Ru, Yuan; O'Brien, Kimberly O.] Cornell Univ, Div Nutr Sci, Ithaca, NY 14853 USA; [Katzman, Philip J.; Guillet, Ronnie; Pressman, Eva; Cooper, Elizabeth M.] Univ Rochester, Sch Med, Rochester, NY USA	O'Brien, KO (reprint author), Cornell Univ, 230 Savage Hall, Ithaca, NY 14853 USA.	koo4@cornell.edu			National Research Initiative or Agriculture and Food Research Initiative of the United States Department of Agriculture National Institute of Food and Agriculture [2005-35200, 2008-01857]; Gerber Foundation	The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This research was supported by the National Research Initiative or Agriculture and Food Research Initiative of the United States Department of Agriculture National Institute of Food and Agriculture, award #2005-35200 and award #2008-01857, and by The Gerber Foundation	Adesina K T, 2014, East Afr Med J, V91, P274; Adesina KT, 2018, J PERINAT MED, V46, P341, DOI 10.1515/jpm-2017-0170; Aliyu MH, 2010, J ADOLESCENT HEALTH, V46, P77, DOI 10.1016/j.jadohealth.2009.06.006; Allen LH, 2000, AM J CLIN NUTR, V71, p1280S, DOI 10.1093/ajcn/71.5.1280s; Angulo-Kinzler RM, 2002, EARLY HUM DEV, V66, P67, DOI 10.1016/S0378-3782(01)00238-9; Behrman R. E., 2007, PRETERM BIRTH CAUSES; Benirschke K, 2012, PATHOLOGY HUMAN PLAC, P309; Cao C, 2013, NUTR REV, V71, P35, DOI 10.1111/j.1753-4887.2012.00550.x; Centers for Disease Control and Prevention, 1998, MMWR RECOMM REP, V47, P1; Challis JR, 2009, REPROD SCI, V16, P206, DOI 10.1177/1933719108329095; Chitra T, 2012, OBSTET GYNECOL INT, DOI 10.1155/2012/213689; Cromi A, 2005, PRENATAL DIAG, V25, P851, DOI 10.1002/pd.1273; Dakshayini D, 2012, J OBSTET GYN INDIA, V62, P43, DOI 10.1007/s13224-012-0158-4; De Laat MWM, 2006, ULTRASOUND OBST GYN, V28, P704, DOI 10.1002/uog.2786; de Laat MWM, 2007, EARLY HUM DEV, V83, P571, DOI 10.1016/j.earlhumdev.2006.12.003; de Laat MWM, 2007, EUR J OBSTET GYN R B, V130, P66, DOI 10.1016/j.ejogrb.2006.01.018; de Laat MWM, 2006, OBSTET GYNECOL, V107, P1049, DOI 10.1097/01.AOG.0000209197.84185.15; de Laat MWM, 2005, J MATERN-FETAL NEO M, V17, P93, DOI 10.1080/14767050400028899; Degani S, 2001, J ULTRAS MED, V20, P1183; DUDIAK CM, 1995, RADIOGRAPHICS, V15, P1035, DOI 10.1148/radiographics.15.5.7501849; Durlacher J, 2014, FASEB J, V28; Earl R, 1993, IRON DEFICIENCY ANEM; Ercal T, 1996, BRIT J CLIN PRACT, V50, P254; Essley B, 2011, J DEV ORIG HLTH DIS, V2, P272, DOI 10.1017/S2040174411000511; Ezimokhai M, 2000, AM J PERINAT, V17, P441, DOI 10.1055/s-2000-13452; FRASER AM, 1995, NEW ENGL J MED, V332, P1113, DOI 10.1056/NEJM199504273321701; GARDNER MO, 1995, OBSTET GYNECOL, V85, P553, DOI 10.1016/0029-7844(94)00455-M; Georgieff MK, 2007, AM J CLIN NUTR, V85, p614S; Gupta S, 2006, J OBSTET GYN INDIA, V56, P315; Iannotti LL, 2005, J NUTR, V135, P2572; Jaacks LM, 2011, J NUTR, V141, P1267, DOI 10.3945/jn.110.135798; Jessop FA, 2014, VIRCHOWS ARCH, V464, P105, DOI 10.1007/s00428-013-1513-2; JOHNSONSPEAR MA, 1994, AM J CLIN NUTR, V60, P117; Kalem MN, 2019, J MATERN-FETAL NEO M, V32, P954, DOI 10.1080/14767058.2017.1396311; Kashanian M, 2006, INT J GYNECOL OBSTET, V95, P8, DOI 10.1016/j.ijgo.2006.05.029; Kell DB, 2014, METALLOMICS, V6, P748, DOI 10.1039/c3mt00347g; Kiely JL, 1998, CLIN OBSTET GYNECOL, V41, P3, DOI 10.1097/00003081-199803000-00005; Lackmann GM, 1998, BIOL NEONATE, V74, P208, DOI 10.1159/000014026; LACRO RV, 1987, AM J OBSTET GYNECOL, V157, P833, DOI 10.1016/S0002-9378(87)80067-4; Lee S. M., 2014, ICAN: Infant, Child & Adolescent Nutrition, V6, P152, DOI 10.1177/1941406414525993; Lozoff B, 2006, ARCH PEDIAT ADOL MED, V160, P1108, DOI 10.1001/archpedi.160.11.1108; Ma'ayeh M, 2018, J PERINAT MED, V46, P593, DOI 10.1515/jpm-2017-0034; Machin GA, 2000, PEDIATR DEVEL PATHOL, V3, P462, DOI 10.1007/s100240010103; MALPAS P, 1966, SURG GYNECOL OBSTETR, V123, P746; McCann JC, 2007, AM J CLIN NUTR, V85, P931; Nanes JA, 2014, CHEMOSPHERE, V106, P20, DOI 10.1016/j.chemosphere.2013.12.080; Nishio J, 1999, ULTRASOUND OBST GYN, V13, P171, DOI 10.1046/j.1469-0705.1999.13030171.x; O'Brien KO, 2014, J CLIN ENDOCR METAB, V99, P1348, DOI 10.1210/jc.2013-1366; Ohno Y, 2016, J OBSTET GYNAECOL RE, V42, P1457, DOI 10.1111/jog.13092; Olney DK, 2007, J NUTR, V137, P2756; Patil NS, 2013, J CLIN DIAGN RES, V7, P1675, DOI 10.7860/JCDR/2013/5135.3224; POWERS WF, 1994, AM J OBSTET GYNECOL, V170, P456, DOI 10.1016/S0002-9378(94)70211-X; Predanic M, 2005, AM J OBSTET GYNECOL, V193, P387, DOI 10.1016/j.ajog.2004.12.092; Predanic M, 2005, J ULTRAS MED, V24, P185, DOI 10.7863/jum.2005.24.2.185; Qin Y, 2002, ULTRASOUND OBST GYN, V20, P458, DOI 10.1046/j.1469-0705.2002.00846.x; Raio L, 1999, ULTRASOUND OBST GYN, V13, P176, DOI 10.1046/j.1469-0705.1999.13030176.x; RANA J, 1995, OBSTET GYNECOL, V85, P573, DOI 10.1016/0029-7844(94)00435-G; Ru Y, 2016, AM J CLIN NUTR, V104, P1052, DOI 10.3945/ajcn.115.126284; SCHOLL TO, 1992, AM J CLIN NUTR, V55, P985; Sebire NJ, 2007, ULTRASOUND OBST GYN, V30, P804, DOI 10.1002/uog.5180; Sibai BM, 2000, AM J OBSTET GYNECOL, V182, P938, DOI 10.1016/S0002-9378(00)70350-4; SIIMES ASI, 1986, EARLY HUM DEV, V13, P47, DOI 10.1016/0378-3782(86)90097-6; SINGLA PN, 1985, ACTA PAEDIATR SCAND, V74, P701, DOI 10.1111/j.1651-2227.1985.tb10017.x; Spong CY, 2013, JAMA-J AM MED ASSOC, V309, P2445, DOI 10.1001/jama.2013.6235; Strong T H Jr, 1996, J Matern Fetal Med, V5, P359; STRONG TH, 1994, AM J OBSTET GYNECOL, V170, P1729; STRONG TH, 1994, AM J OBSTET GYNECOL, V170, P29, DOI 10.1016/S0002-9378(94)70378-7; van Diik C C, 2002, J Matern Fetal Neonatal Med, V11, P280, DOI 10.1080/713605510; Whisner CM, 2014, J BONE MINER RES, V29, P2109, DOI 10.1002/jbmr.2233; Young BE, 2012, AM J CLIN NUTR, V95, P1103, DOI 10.3945/ajcn.111.023861; Young BE, 2012, J BONE MINER RES, V27, P177, DOI 10.1002/jbmr.526; Young MF, 2010, PLACENTA, V31, P1010, DOI 10.1016/j.placenta.2010.08.009	72	1	2	1	1	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1093-5266	1615-5742		PEDIATR DEVEL PATHOL	Pediatr. Dev. Pathol.	NOV	2018	21	6					537	547		10.1177/1093526618770318			11	Pathology; Pediatrics	Pathology; Pediatrics	HF1JC	WOS:000453921600004	29652240				2019-10-28	
J	Chisholm, KM; Norton, ME; Penn, AA; Heerema-McKenney, A				Chisholm, Karen M.; Norton, Mary E.; Penn, Anna A.; Heerema-McKenney, Amy			Classification of Preterm Birth With Placental Correlates	PEDIATRIC AND DEVELOPMENTAL PATHOLOGY			English	Article						amniotic fluid infection; chronic inflammation; placenta histology; preeclampsia; preterm birth	PREMATURE RUPTURE; PHYSIOLOGICAL TRANSFORMATION; CHRONIC CHORIOAMNIONITIS; PATHOLOGICAL FEATURES; CLINICAL-SIGNIFICANCE; INTRAUTERINE GROWTH; UNKNOWN ETIOLOGY; SPIRAL ARTERIES; LABOR; INFECTION	Premature birth lacks a widely accepted classification that unites features of the clinical presentation with placental pathology. To further explore associations between the clinical categories of preterm birth and placental histology, 109 infants with gestational age <34 weeks and birth weight <2000 g were selected and, based on electronic records, were classified into preterm birth categories of preterm labor, prelabor premature rupture of membranes, preeclampsia, indicated preterm birth for maternal factors (other than preeclampsia), indicated preterm birth for fetal factors, and the clinical diagnosis of abruption. Corresponding placentas were analyzed for gross and microscopic variables, with findings grouped into categories of amniotic fluid infection, lymphocytic inflammation, maternal vascular malperfusion, and fetal vascular malperfusion. Placental features of maternal vascular malperfusion were pervasive in all preterm birth categories and were commonly associated with amniotic fluid infection and lymphocytic inflammation. Features of maternal vascular malperfusion were significantly associated with preterm birth due to preeclampsia, and amniotic fluid infection was highly associated with prelabor preterm rupture of membranes. Findings of lymphocytic inflammation were significantly increased in cases of abruption. Laminar decidual necrosis was present in all cases of abruption. Placentas from multiple gestations had significantly less histologic findings compared to singletons. Given that 75% of placentas demonstrated at least 1 feature of maternal vascular malperfusion despite different clinical presentations, seemingly different pathologies such as ascending amniotic fluid infection or lymphocytic inflammation may be mechanistically related to processes established early in pregnancy. The concept of "uterine ischemia" may be too simplistic to account for all of the changes attributed to maternal vascular malperfusion in the preterm placenta.	[Chisholm, Karen M.; Heerema-McKenney, Amy] Stanford Univ, Sch Med, Dept Pathol, Stanford, CA 94305 USA; [Norton, Mary E.] Stanford Univ, Sch Med, Dept Obstet & Gynecol, Div Maternal Fetal Med, Stanford, CA 94305 USA; [Penn, Anna A.] Stanford Univ, Sch Med, Dept Pediat, Div Neonatal & Dev Med, Stanford, CA 94305 USA	Chisholm, KM (reprint author), Seattle Childrens Hosp, Dept Labs, Seattle, WA 98105 USA.; Heerema-McKenney, A (reprint author), Cleveland Clin, Pathol & Lab Med Inst, Cleveland, OH 44106 USA.	karen.chisholm@seattlechildrens.org; mckenna@ccf.org		Chisholm, Karen/0000-0002-1898-1252			Ananth CV, 2006, AM J OBSTET GYNECOL, V195, P1557, DOI 10.1016/j.ajog.2006.05.021; ARIAS F, 1993, AM J OBSTET GYNECOL, V168, P585, DOI 10.1016/0002-9378(93)90499-9; Arias F, 1997, OBSTET GYNECOL, V89, P265, DOI 10.1016/S0029-7844(96)00451-6; Bendon RW, 2012, PEDIATR DEVEL PATHOL, V15, P213, DOI 10.2350/11-08-1072-OA.1; Brunton PJ, 2013, REPRODUCTION, V146, pR175, DOI 10.1530/REP-13-0258; Catov JM, 2017, AM J OBSTET GYNECOL, V216, DOI 10.1016/j.ajog.2016.12.022; Chisholm KM, 2016, PLACENTA, V39, P61, DOI 10.1016/j.placenta.2016.01.012; DOMMISSE J, 1992, BRIT J OBSTET GYNAEC, V99, P651, DOI 10.1111/j.1471-0528.1992.tb13848.x; Elsasser DA, 2010, EUR J OBSTET GYN R B, V148, P125, DOI 10.1016/j.ejogrb.2009.10.005; Gargano JW, 2010, BJOG-INT J OBSTET GY, V117, P445, DOI 10.1111/j.1471-0528.2009.02472.x; Goldenberg RL, 2001, JAMA-J AM MED ASSOC, V285, P633, DOI 10.1001/jama.285.5.633; Goldenberg RL, 2008, LANCET, V371, P75, DOI 10.1016/S0140-6736(08)60074-4; HILLIER SL, 1988, NEW ENGL J MED, V319, P972, DOI 10.1056/NEJM198810133191503; Kelly R, 2009, AM J EPIDEMIOL, V170, P148, DOI 10.1093/aje/kwp131; Khong TY, 2016, ARCH PATHOL LAB MED, V140, P698, DOI 10.5858/arpa.2015-0225-CC; Kim CJ, 2015, AM J OBSTET GYNECOL, V213, pS53, DOI 10.1016/j.ajog.2015.08.041; Kim CJ, 2015, AM J OBSTET GYNECOL, V213, pS29, DOI 10.1016/j.ajog.2015.08.040; Kim CJ, 2010, MODERN PATHOL, V23, P1000, DOI 10.1038/modpathol.2010.73; Kim MJ, 2009, J IMMUNOL, V182, P3919, DOI 10.4049/jimmunol.0803834; Kim YM, 2002, AM J OBSTET GYNECOL, V187, P1137, DOI 10.1067/mob.2002.127720; Kim YM, 2003, AM J OBSTET GYNECOL, V189, P1063, DOI 10.1067/S0002-9378(03)00838-X; Kovo M, 2011, J PERINAT MED, V39, P423, DOI 10.1515/JPM.2011.038; Kramer MS, 2012, AM J OBSTET GYNECOL, V206, P108, DOI 10.1016/j.ajog.2011.10.864; Kramer MS, 2000, JAMA-J AM MED ASSOC, V284, P843, DOI 10.1001/jama.284.7.843; Lee J, 2013, PLACENTA, V34, P681, DOI 10.1016/j.placenta.2013.04.014; Lee J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016806; LUBCHENCO LO, 1963, PEDIATRICS, V32, P793; Manuck TA, 2015, AM J OBSTET GYNECOL, V212, DOI 10.1016/j.ajog.2015.02.010; Martin Joyce A, 2017, Natl Vital Stat Rep, V66, P1; Morgan TK, 2016, AM J PERINAT, V33, P258, DOI 10.1055/s-0035-1570379; NAEYE RL, 1989, HUM PATHOL, V20, P441, DOI 10.1016/0046-8177(89)90008-7; Nath CA, 2007, AM J OBSTET GYNECOL, V197, DOI 10.1016/j.ajog.2007.06.012; Nijman TAJ, 2016, PLACENTA, V48, P56, DOI 10.1016/j.placenta.2016.10.006; Pinar H, 1996, PEDIATR PATHOL LAB M, V16, P901, DOI 10.1080/15513819609168713; Redline RW, 2003, PEDIATR DEVEL PATHOL, V6, P435, DOI 10.1007/s10024-003-7070-y; Redline RW, 2004, PEDIATR DEVEL PATHOL, V7, P237, DOI 10.1007/s10024-003-8083-2; Roberts DJ, 2008, J CLIN PATHOL, V61, P1254, DOI 10.1136/jcp.2008.055236; Romero R, 2006, BJOG-INT J OBSTET GY, V113, P17, DOI 10.1111/j.1471-0528.2006.01120.x; ROMERO R, 1988, AM J OBSTET GYNECOL, V159, P661, DOI 10.1016/S0002-9378(88)80030-9; Romero R, 2014, SCIENCE, V345, P760, DOI 10.1126/science.1251816; Romero R, 2011, BEST PRACT RES CL OB, V25, P313, DOI 10.1016/j.bpobgyn.2011.02.006; Saria S, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3001304; Stanek J, 2005, PEDIATR DEVEL PATHOL, V8, P34, DOI 10.1007/s10024-004-8092-9; Tamblyn JA, 2013, PLACENTA, V34, P846, DOI 10.1016/j.placenta.2013.07.002; Verma RP, 2008, FETAL PEDIATR PATHOL, V27, P53, DOI 10.1080/15513810802026559; Villar J, 2012, AM J OBSTET GYNECOL, V206, P119, DOI 10.1016/j.ajog.2011.10.866	46	2	2	1	4	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1093-5266	1615-5742		PEDIATR DEVEL PATHOL	Pediatr. Dev. Pathol.	NOV	2018	21	6					548	560		10.1177/1093526618775958			13	Pathology; Pediatrics	Pathology; Pediatrics	HF1JC	WOS:000453921600005	29759046				2019-10-28	
J	LeBel, DP; Wolff, DJ; Batalis, NI; Ellingham, T; Matics, N; Patwardhan, SC; Znoyko, IY; Schandl, CA				LeBel, David P., II; Wolff, Daynna J.; Batalis, Nicholas I.; Ellingham, Tara; Matics, Natalie; Patwardhan, Sanjay C.; Znoyko, Iya Y.; Schandl, Cynthia A.			First Report of Prenatal Ascertainment of a Fetus With Homozygous Loss of the SOX10 Gene and Phenotypic Correlation by Autopsy Examination	PEDIATRIC AND DEVELOPMENTAL PATHOLOGY			English	Article						forensic science; postmortem examination; prenatal cytogenetics; DNA microarray; SOX10; Waardenburg syndrome	WAARDENBURG SYNDROME; STANDARDS; MUTATION; MOUSE	The SOX10 gene plays a vital role in neural crest cell development and migration. Abnormalities in SOX10 are associated with Waardenburg syndrome Types II and IV, and these patients have recognizable clinical features. This case report highlights the first ever reported homozygous loss of function of the SOX10 gene in a human. This deletion is correlated using family history, prenatal ultrasound, microarray analysis of amniotic fluid, and ultimately, a medical autopsy examination to further elucidate phenotypic effects of this genetic variation. Incorporating the use of molecular pathology into the autopsy examination of fetuses with suspected congenital anomalies is vital for appropriate family counseling, and with the ability to use formalin-fixed and paraffin-embedded tissues, has become a practical approach in autopsy pathology.	[LeBel, David P., II; Wolff, Daynna J.; Batalis, Nicholas I.; Ellingham, Tara; Matics, Natalie; Znoyko, Iya Y.; Schandl, Cynthia A.] Med Univ South Carolina, Dept Pathol & Lab Med, 171 Ashley Ave,MSC 908, Charleston, SC 29425 USA; [Patwardhan, Sanjay C.] Wayne State Univ, Dept Obstet & Gynecol, Detroit, MI USA	Schandl, CA (reprint author), Med Univ South Carolina, Dept Pathol & Lab Med, 171 Ashley Ave,MSC 908, Charleston, SC 29425 USA.	schandlc@musc.edu					Archie JG, 2006, AM J CLIN PATHOL, V126, P256, DOI 10.1309/FK9D5WBA1UEPT5BB; Bondurand N, 1998, FEBS LETT, V432, P168, DOI 10.1016/S0014-5793(98)00843-6; Britsch S, 2001, GENE DEV, V15, P66, DOI 10.1101/gad.186601; De Paepe ME, 2005, PEDIATR PULM, V40, P445, DOI 10.1002/ppul.20218; Erickson CA, 1998, CURR TOP DEV BIOL, V40, P177, DOI 10.1016/S0070-2153(08)60367-1; Herbarth B, 1998, P NATL ACAD SCI USA, V95, P5161, DOI 10.1073/pnas.95.9.5161; Jelena B, 2014, AM J MED GENET A, V164, P1512, DOI 10.1002/ajmg.a.36446; Le Douarin N.M., 1999, NEURAL CREST; Mollaaghababa R, 2003, ONCOGENE, V22, P3024, DOI 10.1038/sj.onc.1206442; Mousty E, 2015, PRENATAL DIAG, V35, P1379, DOI 10.1002/pd.4703; National Library of Medicine (US), 2016, GEN HOM REF; Pingault V, 2010, HUM MUTAT, V31, P391, DOI 10.1002/humu.21211; Siomou E, 2012, EUR J MED GENET, V55, P641, DOI 10.1016/j.ejmg.2012.07.002; Southard-Smith EM, 1999, GENOME RES, V9, P215; WAARDENBURG PJ, 1951, AM J HUM GENET, V3, P195	15	0	0	0	0	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1093-5266	1615-5742		PEDIATR DEVEL PATHOL	Pediatr. Dev. Pathol.	NOV	2018	21	6					561	567		10.1177/1093526617744714			7	Pathology; Pediatrics	Pathology; Pediatrics	HF1JC	WOS:000453921600006	29216801				2019-10-28	
J	Al Badi, MK; Al-Alwan, I; Al-Dubayee, M; Al-Anzi, A; Al Turki, MS; Aloudah, N; Alsaad, KO				Al Badi, Maryam K.; Al-Alwan, Ibrahim; Al-Dubayee, Mohammed; Al-Anzi, Ayed; Al Turki, Maram S.; Aloudah, Noura; Alsaad, Khaled O.			Testosterone- and Cortisol-secreting Oncocytic Adrenocortical Adenoma in the Pediatric Age-group	PEDIATRIC AND DEVELOPMENTAL PATHOLOGY			English	Article						adrenal; oncocytoma; adenoma; virilization; precocious puberty; Cushing syndrome	CUSHINGS-SYNDROME	Oncocytic tumors are epithelial neoplasms that occur in various organs, including adrenal glands. Oncocytic adrenocortical adenomas and carcinomas are uncommon but well-known pathological entities in adults. However, generally oncocytic tumors, particularly in the adrenal glands, are very rare in the pediatric age-group. Most oncocytic adrenal tumors are not functional. We present a rare case of right-sided, functional oncocytic adrenocortical adenoma in a 5-year-old boy, who presented with clinical manifestations of precocious puberty and Cushing syndrome. Laparoscopic adrenalectomy showed a well-defined mass weighing 8.4 g and measuring 3 cm in maximum dimension. Histological examination demonstrated no features suggestive of aggressive biological behavior. The patient showed no evidence of recurrent or metastatic disease and continued to have normal serum hormonal levels 28 months following the surgery. In this report, we discuss the clinicopathological characteristics of this rare pathological entity and briefly review the literature on functional oncocytic adrenal tumors in the pediatric population.	[Al Badi, Maryam K.; Al-Alwan, Ibrahim; Al-Dubayee, Mohammed] King Abdul Aziz Med City, Dept Pediat, Riyadh, Saudi Arabia; [Al Badi, Maryam K.] Royal Hosp, Natl Diabet & Endocrine Ctr, Dept Pediat Endocrinol, Muscat, Oman; [Al-Alwan, Ibrahim; Al-Dubayee, Mohammed; Al Turki, Maram S.; Aloudah, Noura; Alsaad, Khaled O.] King Saud bin Abdulaziz Univ Hlth Sci, Coll Med, Riyadh, Saudi Arabia; [Al-Anzi, Ayed] Al Jahra Hosp, Dept Pediat, Kuwait, Kuwait; [Aloudah, Noura; Alsaad, Khaled O.] King Abdul Aziz Med City, Dept Pathol & Lab Med, POB 22490, Riyadh 11426, Saudi Arabia	Alsaad, KO (reprint author), King Abdul Aziz Med City, Dept Pathol & Lab Med, POB 22490, Riyadh 11426, Saudi Arabia.	saadkh@ngha.med.sa					Ahmed Mooyad A, 2013, Sultan Qaboos Univ Med J, V13, pE334; Bisceglia M, 2004, INT J SURG PATHOL, V12, P231, DOI 10.1177/106689690401200304; CHANG A, 1992, PATHOL ANNU, V27, P263; Chen TS, 2003, INT J SURG PATHOL, V11, P325, DOI 10.1177/106689690301100415; Gumy-Pause F, 2005, PEDIAT BLOOD CANC, V50, P718; Hoang MP, 2002, MODERN PATHOL, V15, P973, DOI 10.1038/modpathol.3880638; Kawahara Y, 2014, EUR J PEDIATR, V173, P1107, DOI 10.1007/s00431-014-2292-8; Lim YJ, 2010, J KOREAN MED SCI, V25, P1077, DOI 10.3346/jkms.2010.25.7.1077; MAGIAKOU MA, 1994, NEW ENGL J MED, V331, P629, DOI 10.1056/NEJM199409083311002; Miller WL, 2001, ENDOCRINOL METAB, P386; Pereira BD, 2014, ENDOCR PATHOL, V25, P397, DOI 10.1007/s12022-014-9325-8; Sharma D, 2012, J CLIN IMAG SCI, V2, DOI 10.4103/2156-7514.104309; Subbiah S, 2013, ANN SAUDI MED, V33, P294, DOI 10.5144/0256-4947.2013.294; Tahar GT, 2008, J PEDIATR SURG, V43, DOI 10.1016/j.jpedsurg.2007.12.067; Wong DD, 2011, HUM PATHOL, V42, P489, DOI 10.1016/j.humpath.2010.08.010; Xiao Guang-Qian, 2005, Ann Diagn Pathol, V9, P295, DOI 10.1016/j.anndiagpath.2005.05.005	16	0	0	0	1	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1093-5266	1615-5742		PEDIATR DEVEL PATHOL	Pediatr. Dev. Pathol.	NOV	2018	21	6					568	573		10.1177/1093526617753045			6	Pathology; Pediatrics	Pathology; Pediatrics	HF1JC	WOS:000453921600007	29426273				2019-10-28	
J	Mok, Y; Pang, YH; Sanjeev, JS; Kuick, CH; Chang, KTE				Mok, Yingting; Pang, Yin Huei; Sanjeev, Jain Sudhanshi; Kuick, Chik Hong; Chang, Kenneth Tou-En			Primary Renal Hybrid Low-grade Fibromyxoid Sarcoma-Sclerosing Epithelioid Fibrosarcoma: An Unusual Pediatric Case With EWSR1-CREB3L1 Fusion	PEDIATRIC AND DEVELOPMENTAL PATHOLOGY			English	Article						pediatric renal tumor; low-grade fibromyxoid sarcoma; sclerosing epithelioid fibrosarcoma; hybrid tumor; Archer FusionPlex anchored multiplex PCR; MUC4 immunohistochemistry; gene fusion discovery	GENE; KIDNEY; MARKER; MUC4	Low-grade fibromyxoid sarcoma (LGFMS) and sclerosing epithelioid fibrosarcoma (SEF) are rare tumors with distinct sets of morphological features, both characterized by MUC4 immunoreactivity. Tumors exhibiting features of both entities are considered hybrid LGFMS-SEF lesions. While the majority of LGFMS cases are characterized by FUS-CREB3L2 gene fusions, most cases of pure SEF show EWSR1 gene rearrangements. In the largest study of hybrid LGFMS-SEF tumors to date, all cases exhibited FUS rearrangements, a similar genetic profile to LGFMS. We herein describe the clinicopathological features and genetic findings of a case of primary renal hybrid LGFMS-SEF occurring in a 10-year-old child, with disseminated metastases. Fusion gene detection using a next-generation sequencing-based anchored multiplex PCR technique (Archer FusionPlex Sarcoma Panel) was performed on both the primary renal tumor that showed the morphology of a LGFMS, and a cervical metastasis that showed the morphology of SEF. An EWSR1-CREB3L1 gene fusion occurring between exon 11 of EWSR1 and exon 6 of CREB3L1 was present in both the LGFMS and SEF components. This unusual case provides evidence that a subset of hybrid LGFMS-SEF harbor EWSR1-CREB3L1 gene fusions. In this case, these features were associated with an aggressive clinical course, with disease-associated mortality occurring within 12 months of diagnosis.	[Mok, Yingting; Pang, Yin Huei] Natl Univ Hlth Syst, Dept Pathol, 5 Lower Kent Ridge Rd, Singapore 119074, Singapore; [Sanjeev, Jain Sudhanshi; Kuick, Chik Hong; Chang, Kenneth Tou-En] KK Womens & Childrens Hosp, Dept Pathol & Lab Med, Singapore, Singapore; [Chang, Kenneth Tou-En] Duke NUS Med Sch, Singapore, Singapore	Mok, Y (reprint author), Natl Univ Hlth Syst, Dept Pathol, 5 Lower Kent Ridge Rd, Singapore 119074, Singapore.	yingting_mok@nuhs.edu.sg			VIVA-KKH Pediatric Brain and Solid Tumor Programme	The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was supported by the VIVA-KKH Pediatric Brain and Solid Tumor Programme.	Alevizopoulos A, 2012, CASE REP NEPHROL DIA, V2, P87, DOI 10.1159/000341191; Antonescu CR, 2001, AM J SURG PATHOL, V25, P699, DOI 10.1097/00000478-200106000-00001; Arbajian E, 2014, AM J SURG PATHOL, V38, P801, DOI 10.1097/PAS.0000000000000158; Argani P, 2015, AM J SURG PATHOL, V39, P365, DOI 10.1097/PAS.0000000000000338; Baydar DE, 2015, DIAGN PATHOL, V10, DOI 10.1186/s13000-015-0420-z; Doyle LA, 2012, AM J SURG PATHOL, V36, P1444, DOI 10.1097/PAS.0b013e3182562bf8; Doyle LA, 2011, AM J SURG PATHOL, V35, P733, DOI 10.1097/PAS.0b013e318210c268; Evans HL, 2011, AM J SURG PATHOL, V35, P1450, DOI 10.1097/PAS.0b013e31822b3687; Guillou L, 2007, AM J SURG PATHOL, V31, P1387, DOI 10.1097/PAS.0b013e3180321959; Lau PPL, 2013, AM J SURG PATHOL, V37, P734, DOI 10.1097/PAS.0b013e31827560f8; MEISKINDBLOM JM, 1995, AM J SURG PATHOL, V19, P979, DOI 10.1097/00000478-199509000-00001; Mertens F, 2005, LAB INVEST, V85, P408, DOI 10.1038/labinvest.3700230; Ohlmann CH, 2015, ANN DIAGN PATHOL, V19, P221, DOI 10.1016/j.anndiagpath.2015.04.005; Panagopoulos L, 2004, GENE CHROMOSOME CANC, V40, P218, DOI 10.1002/gcc.20037; Prieto-Granada C, 2015, GENE CHROMOSOME CANC, V54, P28, DOI 10.1002/gcc.22215; Rekhi B, 2011, PATHOL ONCOL RES, V17, P145, DOI 10.1007/s12253-010-9277-3; Rubinstein JC, 2014, PEDIATR DEVEL PATHOL, V17, P321, DOI 10.2350/14-05-1487-CR.1; Torabi A, 2017, PATHOLOGY, V49, P447, DOI 10.1016/j.pathol.2017.01.010	18	3	3	0	3	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1093-5266	1615-5742		PEDIATR DEVEL PATHOL	Pediatr. Dev. Pathol.	NOV	2018	21	6					574	579		10.1177/1093526617754030			6	Pathology; Pediatrics	Pathology; Pediatrics	HF1JC	WOS:000453921600008	29426275				2019-10-28	
J	Hale, GI; Cohen, MC; Quarrell, OW; McGrath, JOA; Messenger, AG				Hale, Gordon, I; Cohen, Marta C.; Quarrell, Oliver W.; McGrath, J. Ohn A.; Messenger, Andrew G.			Coinheritance of 2 New Potentially Damaging Heterozygous COL7A1 Variants in a Family With Autosomal Dominant Epidermolysis Bullosa Pruriginosa	PEDIATRIC AND DEVELOPMENTAL PATHOLOGY			English	Article						dermatopathology; genodermatoses; dystrophic epidermolysis bullosa; epidermolysis bullosa pruriginosa; pediatric dermatology; pretibial epidermolysis bullosa		Epidermolysis bullosa pruriginosa (EBP) is a rare subtype of EB which is characterized by intense pruritus with blistering and nodular or lichenoid lesions most prominent on the lower extremities. It is caused by variants in COL7A1 which encodes for type VII collagen. There is wide phenotypic and genotypic variability between affected individuals. We report 2 potentially pathogenic variants in COL7A1 occurring on the same allele in a family with EBP and autosomal dominant inheritance. Late-onset EBP and incomplete penetrance may lead to delayed presentation in affected family members with the same variants. The broad phenotypic variability seen in EBP suggests that further genotypic and environmental factors may influence presentation. Genetic and histopathological diagnosis is essential, given the considerable overlap with clinically similar presentations such as hypertrophic lichen planus.	[Hale, Gordon, I; Messenger, Andrew G.] Sheffield Childrens Hosp NHS Fdn Trust, Dept Dermatol, Western Bank, Sheffield, S Yorkshire, England; [Cohen, Marta C.] Sheffield Childrens Hosp NHS Fdn Trust, Dept Histopathol, Western Bank, Sheffield, S Yorkshire, England; [Quarrell, Oliver W.] Sheffield Childrens Hosp NHS Fdn Trust, Dept Genet, Western Bank, Sheffield, S Yorkshire, England; [McGrath, J. Ohn A.] Kings Coll London, St Johns Inst Dermatol, London, England	Hale, GI (reprint author), Sheffield Childrens Hosp NHS Fdn Trust, Western Bank, Sheffield S10 2TH, S Yorkshire, England.	gordon.hale@nhs.net	Cohen, Marta/X-2014-2019; McGrath, John/N-3529-2019; McGrath, John/D-6824-2012	Cohen, Marta/0000-0001-5534-444X; McGrath, John/0000-0002-3708-9964			Banky JP, 2004, ARCH DERMATOL, V140, P794, DOI 10.1001/archderm.140.7.794; Brick K, 2012, PEDIATR DERMATOL, V29, P732, DOI 10.1111/j.1525-1470.2012.01786.x; Bulic SO, 2005, BRIT J DERMATOL, V152, P1332, DOI 10.1111/j.1365-2133.2005.06492.x; Cohen Philip R, 2014, Dermatol Pract Concept, V4, P21, DOI 10.5826/dpc.0404a03; Cunningham L, 2016, J EUR ACAD DERMATOL, V30, pE115, DOI 10.1111/jdv.13385; Hayashi M, 2011, J DERMATOL, V38, P173, DOI 10.1111/j.1346-8138.2010.00953.x; Kim WB, 2015, INT J LOW EXTR WOUND, V14, P196, DOI 10.1177/1534734615572469; MCGRATH JA, 1994, BRIT J DERMATOL, V130, P617, DOI 10.1111/j.1365-2133.1994.tb13109.x; Varki R, 2007, J MED GENET, V44, P181, DOI 10.1136/jmg.2006.045302; Vivehanantha S, 2013, JAMA DERMATOL, V149, P727, DOI 10.1001/jamadermatol.2013.155; Yamasaki H, 1997, BRIT J DERMATOL, V137, P308; Yang CS, 2012, PEDIATR DERMATOL, V29, P725, DOI 10.1111/j.1525-1470.2012.01757.x	12	0	0	0	1	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1093-5266	1615-5742		PEDIATR DEVEL PATHOL	Pediatr. Dev. Pathol.	NOV	2018	21	6					580	584		10.1177/1093526618761497			5	Pathology; Pediatrics	Pathology; Pediatrics	HF1JC	WOS:000453921600009	29504492				2019-10-28	
J	Pacheco, MC; Monroe, EJ; Horslen, SP				Pacheco, M. Cristina; Monroe, Eric J.; Horslen, Simon P.			Hepatic Adenoma Arising in a Patient With Alagille Syndrome: A Case Report	PEDIATRIC AND DEVELOPMENTAL PATHOLOGY			English	Article						Alagille; hepatic adenoma; pathology; pediatric; liver; arteriohepatic dysplasia; gadoxetate disodium; magnetic resonance imaging	HEPATOCELLULAR ADENOMA; LIVER; CLASSIFICATION; CARCINOMA	Alagille syndrome is associated with decreased bile ducts, cardiac abnormalities, vertebral body fusion defects, and a typical facies. While regenerative nodules and hepatocellular carcinoma have been described in these patients, hepatic adenoma has not. Herein, we present a patient with Alagille syndrome caused by a mutation in NOTCH2 with a hepatic adenoma. The clinical, imaging, and histologic features are discussed.	[Pacheco, M. Cristina] Univ Washington, Dept Pathol, Seattle, WA 98195 USA; [Pacheco, M. Cristina] Seattle Childrens Hosp, Dept Labs, 4800 Sand Point Way, Seattle, WA 98155 USA; [Monroe, Eric J.] Univ Washington, Dept Radiol, Seattle, WA 98195 USA; [Monroe, Eric J.] Seattle Childrens Hosp, Dept Radiol, Seattle, WA 98155 USA; [Horslen, Simon P.] Univ Washington, Dept Pediat, Seattle, WA 98195 USA; [Horslen, Simon P.] Seattle Childrens Hosp, Dept Gastroenterol & Hepatol, Seattle, WA 98155 USA	Pacheco, MC (reprint author), Seattle Childrens Hosp, Dept Labs, 4800 Sand Point Way, Seattle, WA 98155 USA.	cristina.pacheco@seattlechildrens.org		Monroe, Eric/0000-0002-5481-8751			ALAGILLE D, 1975, J PEDIATR-US, V86, P63, DOI 10.1016/S0022-3476(75)80706-2; Bhadri VA, 2005, J PEDIATR GASTR NUTR, V41, P676, DOI 10.1097/01.mpg.0000179759.60048.c4; Bioulac-Sage P, 2007, HEPATOLOGY, V46, P740, DOI 10.1002/hep.21743; Bosman F. T., 2010, WHO CLASSIFICATION T, V3, P198; Chiorean L, 2015, WORLD J GASTROENTERO, V21, P8541, DOI 10.3748/wjg.v21.i28.8541; Deutsch GH, 2001, PEDIATR DEVEL PATHOL, V4, P559, DOI 10.1007/s10024001-0102-6; Dhingra S, 2014, ARCH PATHOL LAB MED, V138, P1090, DOI 10.5858/arpa.2013-0183-RA; Grazioli L, 2001, RADIOGRAPHICS, V21, P877, DOI 10.1148/radiographics.21.4.g01jl04877; Hale G, 2016, MODERN PATHOL, V29, P1370, DOI 10.1038/modpathol.2016.122; Jinguji M, 2003, ANN NUCL MED, V17, P693, DOI 10.1007/BF02984977; Kim B, 2005, PATHOL RES PRACT, V201, P55, DOI 10.1016/j.prp.2004.11.007; Leonard LD, 2014, EUR J HUM GENET, V22, DOI 10.1038/ejhg.2013.140; Meyers AB, 2011, PEDIATR RADIOL, V41, P1183, DOI 10.1007/s00247-011-2148-6; Rapp JB, 2017, PEDIATR RADIOL, V47, P197, DOI 10.1007/s00247-016-3728-2; RESNICK MB, 1995, AM J SURG PATHOL, V19, P1181, DOI 10.1097/00000478-199510000-00008; Syed M A, 2008, Br J Radiol, V81, pe79, DOI 10.1259/bjr/63424939; Tajima T, 2001, PEDIATR RADIOL, V31, P584, DOI 10.1007/s002470100510; Zong YW, 2009, DEVELOPMENT, V136, P1727, DOI 10.1242/dev.029140; Zucman-Rossi J, 2006, HEPATOLOGY, V43, P515, DOI 10.1002/hep.21068	19	1	1	0	1	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1093-5266	1615-5742		PEDIATR DEVEL PATHOL	Pediatr. Dev. Pathol.	NOV	2018	21	6					585	589		10.1177/1093526618762550			5	Pathology; Pediatrics	Pathology; Pediatrics	HF1JC	WOS:000453921600010	29516774				2019-10-28	
J	Hung, YP; Sholl, LM				Hung, Yin P.; Sholl, Lynette M.			Diagnostic and Predictive Immunohistochemistry for Non-Small Cell Lung Carcinomas	ADVANCES IN ANATOMIC PATHOLOGY			English	Review						non-small cell lung carcinoma; immunohistochemistry; biomarker; NUT; SMARCA4; ALK; ROS1; PD-L1; BRAF	GROWTH-FACTOR RECEPTOR; MUTATION-SPECIFIC ANTIBODIES; NUT MIDLINE CARCINOMA; BRAF V600E MUTATION; MOLECULAR TESTING GUIDELINE; TYROSINE KINASE INHIBITORS; OPEN-LABEL; EGFR MUTATIONS; SWI/SNF COMPLEX; INTERNATIONAL ASSOCIATION	Non-small cell lung carcinoma (NSCLC) accounts for significant morbidity and mortality worldwide, with most patients diagnosed at advanced stages and managed increasingly with targeted therapies and immunotherapy. In this review, we discuss diagnostic and predictive immunohistochemical markers in NSCLC, one of the most common tumors encountered in surgical pathology. We highlight 2 emerging diagnostic markers: nuclear protein in testis (NUT) for NUT carcinoma; SMARCA4 for SMARCA4-deficient thoracic tumors. Given their highly aggressive behavior, proper recognition facilitates optimal management. For patients with advanced NSCLCs, we discuss the utility and limitations of immunohistochemistry (IHC) for the must-test predictive biomarkers: anaplastic lymphoma kinase, ROS1, programmed cell death protein 1, and epidermal growth factor receptor. IHC using mutant-specific BRAF V600E, RET, pan-TRK, and LKB1 antibodies can be orthogonal tools for screening or confirmation of molecular events. ERBB2 and MET alterations include both activating mutations and gene amplifications, detection of which relies on molecular methods with a minimal role for IHC in NSCLC. IHC sits at the intersection of an integrated surgical pathology and molecular diagnostic practice, serves as a powerful functional surrogate for molecular testing, and is an indispensable tool of precision medicine in the care of lung cancer patients.	[Sholl, Lynette M.] Brigham & Womens Hosp, Dept Pathol, 75 Francis St, Boston, MA 02115 USA; [Hung, Yin P.] Harvard Med Sch, Boston, MA USA; [Hung, Yin P.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA	Sholl, LM (reprint author), Brigham & Womens Hosp, Dept Pathol, 75 Francis St, Boston, MA 02115 USA.	lmsholl@bwh.harvard.edu		Hung, Yin Pun/0000-0002-8568-1591			Achcar RDD, 2009, AM J CLIN PATHOL, V131, P694, DOI 10.1309/AJCPBS85VJEOBPDO; Adackapara CA, 2013, HISTOPATHOLOGY, V63, P187, DOI 10.1111/his.12154; Agaimy A, 2017, VIRCHOWS ARCH, V471, P599, DOI 10.1007/s00428-017-2148-5; Agaimy A, 2017, HEAD NECK PATHOL, V11, P541, DOI 10.1007/s12105-017-0783-4; Agaimy A, 2016, VIRCHOWS ARCH, V469, P321, DOI 10.1007/s00428-016-1977-y; Agaimy A, 2016, AM J SURG PATHOL, V40, P544, DOI 10.1097/PAS.0000000000000554; Aisner DL, 2018, CLIN CANCER RES, V24, P1038, DOI 10.1158/1078-0432.CCR-17-2289; Arcila ME, 2012, CLIN CANCER RES, V18, P4910, DOI 10.1158/1078-0432.CCR-12-0912; Awad MM, 2016, J CLIN ONCOL, V34, P721, DOI 10.1200/JCO.2015.63.4600; Barlesi F, 2016, LANCET, V387, P1415, DOI 10.1016/S0140-6736(16)00004-0; Bauer DE, 2012, CLIN CANCER RES, V18, P5773, DOI 10.1158/1078-0432.CCR-12-1153; Bell DW, 2005, NAT GENET, V37, P1315, DOI 10.1038/ng1671; Bell EH, 2016, CLIN CANCER RES, V22, P2396, DOI 10.1158/1078-0432.CCR-15-1468; Benedettini E, 2010, AM J PATHOL, V177, P415, DOI 10.2353/ajpath.2010.090863; Bergethon K, 2012, J CLIN ONCOL, V30, P863, DOI 10.1200/JCO.2011.35.6345; BIRCHMEIER C, 1987, P NATL ACAD SCI USA, V84, P9270, DOI 10.1073/pnas.84.24.9270; Bisceglia M, 2011, AM J SURG PATHOL, V35, P1087, DOI 10.1097/PAS.0b013e31821c2d47; Bishop JA, 2012, MODERN PATHOL, V25, P405, DOI 10.1038/modpathol.2011.173; Bondgaard AL, 2014, MODERN PATHOL, V27, P1590, DOI 10.1038/modpathol.2014.67; Borghaei H, 2015, NEW ENGL J MED, V373, P1627, DOI 10.1056/NEJMoa1507643; Brahmer J, 2015, NEW ENGL J MED, V373, P123, DOI 10.1056/NEJMoa1504627; Brevet M, 2010, J MOL DIAGN, V12, P169, DOI 10.2353/jmoldx.2010.090140; Buttner R, 2017, J CLIN ONCOL, V35, P3867, DOI 10.1200/JCO.2017.74.7642; Cai W, 2013, ANN ONCOL, V24, P1822, DOI 10.1093/annonc/mdt071; Calles A, 2015, CLIN CANCER RES, V21, P2851, DOI 10.1158/1078-0432.CCR-14-3112; Campbell JD, 2016, NAT GENET, V48, P607, DOI 10.1038/ng.3564; Carbone DP, 2017, NEW ENGL J MED, V376, P2415, DOI 10.1056/NEJMoa1613493; Cardarella S, 2013, CLIN CANCER RES, V19, P4532, DOI 10.1158/1078-0432.CCR-13-0657; Chen YF, 2014, J THORAC ONCOL, V9, P1171, DOI 10.1097/JTO.0000000000000232; Collisson EA, 2014, NATURE, V511, P543, DOI 10.1038/nature13385; Comperat E, 2005, MODERN PATHOL, V18, P1371, DOI 10.1038/modpathol.3800422; Cooper WA, 2017, CLIN CANCER RES, V23, P4569, DOI 10.1158/1078-0432.CCR-17-0151; Ding L, 2008, NATURE, V455, P1069, DOI 10.1038/nature07423; Drilon A, 2018, NEW ENGL J MED, V378, P731, DOI 10.1056/NEJMoa1714448; Drilon A, 2018, NAT REV CLIN ONCOL, V15, P151, DOI [10.1038/nrclinonc.2017.188, 10.1038/nrclinonc.2017.175]; Drilon A, 2016, LANCET ONCOL, V17, P1653, DOI 10.1016/S1470-2045(16)30562-9; Drilon A, 2013, CANCER DISCOV, V3, P630, DOI 10.1158/2159-8290.CD-13-0035; Dugay F, 2017, ONCOTARGET, V8, P53336, DOI 10.18632/oncotarget.18408; Evans AG, 2012, AM J SURG PATHOL, V36, P1222, DOI 10.1097/PAS.0b013e318258f03b; Farago AF, 2015, J THORAC ONCOL, V10, P1670, DOI 10.1097/01.JTO.0000473485.38553.f0; Fillmore CM, 2015, NATURE, V520, P239, DOI 10.1038/nature14122; Forde PM, 2018, NEW ENGL J MED, V378, P1976, DOI 10.1056/NEJMoa1716078; Frampton GM, 2015, CANCER DISCOV, V5, P850, DOI 10.1158/2159-8290.CD-15-0285; French CA, 2008, ONCOGENE, V27, P2237, DOI 10.1038/sj.onc.1210852; French CA, 2004, J CLIN ONCOL, V22, P4135, DOI 10.1200/JCO.2004.02.107; French CA, 2003, CANCER RES, V63, P304; French CA, 2001, AM J PATHOL, V159, P1987, DOI 10.1016/S0002-9440(10)63049-0; French CA, 2014, CANCER DISCOV, V4, P928, DOI 10.1158/2159-8290.CD-14-0014; Gainor JF, 2016, CLIN CANCER RES, V22, P4585, DOI 10.1158/1078-0432.CCR-15-3101; Gainor JF, 2013, CLIN CANCER RES, V19, P4273, DOI 10.1158/1078-0432.CCR-13-0318; Gandhi L, 2018, NEW ENGL J MED, V378, P2078, DOI 10.1056/NEJMoa1801005; Gandhi L, 2014, J CLIN ONCOL, V32, P68, DOI 10.1200/JCO.2012.47.2787; Garon EB, 2015, NEW ENGL J MED, V372, P2018, DOI 10.1056/NEJMoa1501824; Gaule P, 2017, JAMA ONCOL, V3, P256, DOI 10.1001/jamaoncol.2016.3015; Gautschi O, 2017, J CLIN ONCOL, V35, P1403, DOI 10.1200/JCO.2016.70.9352; Gettinger SN, 2012, J CLIN ONCOL, V30; Ghaffar H, 2003, CLIN CANCER RES, V9, P2998; Go H, 2013, J THORAC ONCOL, V8, P1445, DOI 10.1097/JTO.0b013e3182a4dd6e; Go H, 2013, LUNG CANCER, V82, P44, DOI 10.1016/j.lungcan.2013.07.009; Graham RP, 2018, ARCH PATHOL LAB MED, V142, P163, DOI 10.5858/arpa.2016-0579-CP; GRIECO M, 1990, CELL, V60, P557, DOI 10.1016/0092-8674(90)90659-3; Haack H, 2009, AM J SURG PATHOL, V33, P984, DOI 10.1097/PAS.0b013e318198d666; Hammerman PS, 2012, NATURE, V489, P519, DOI 10.1038/nature11404; Hasselblatt M, 2011, AM J SURG PATHOL, V35, P933, DOI 10.1097/PAS.0b013e3182196a39; Hechtman JF, 2017, AM J SURG PATHOL, V41, P1547, DOI 10.1097/PAS.0000000000000911; Herbst RS, 2016, LANCET, V387, P1540, DOI 10.1016/S0140-6736(15)01281-7; Herpel E, 2017, ANN DIAGN PATHOL, V26, P47, DOI 10.1016/j.anndiagpath.2016.10.006; Hida T, 2017, LANCET, V390, P29, DOI 10.1016/S0140-6736(17)30565-2; Hirsch FR, 2017, J THORAC ONCOL, V12, P208, DOI 10.1016/j.jtho.2016.11.2228; Hitij NT, 2017, CLIN LUNG CANCER, V18, pE187, DOI 10.1016/j.cllc.2016.11.021; Hollmann TJ, 2011, AM J SURG PATHOL, V35, pE47, DOI 10.1097/PAS.0b013e31822b325b; Hsu WH, 2018, ANN ONCOL, V29, pI3, DOI 10.1093/annonc/mdx702; Hu YB, 2017, CLIN CANCER RES, V23, P7351, DOI 10.1158/1078-0432.CCR-17-1745; Hung YP, 2018, JAMA ONCOL, V4, P235, DOI 10.1001/jamaoncol.2017.2918; Ilie M, 2013, ANN ONCOL, V24, P742, DOI 10.1093/annonc/mds534; Imielinski M, 2012, CELL, V150, P1107, DOI 10.1016/j.cell.2012.08.029; Inamura K, 2009, MODERN PATHOL, V22, P508, DOI 10.1038/modpathol.2009.2; Jelinic P, 2014, NAT GENET, V46, P424, DOI 10.1038/ng.2922; Ji HB, 2007, NATURE, V448, P807, DOI 10.1038/nature06030; Ju YS, 2012, GENOME RES, V22, P436, DOI 10.1101/gr.133645.111; Kadoch C, 2013, NAT GENET, V45, P592, DOI 10.1038/ng.2628; Kadota K, 2015, AM J SURG PATHOL, V39, P1170, DOI 10.1097/PAS.0000000000000439; Kang SM, 2007, CANCER, V109, P581, DOI 10.1002/cncr.22413; Karanian-Philippe M, 2015, AM J SURG PATHOL, V39, P1197, DOI 10.1097/PAS.0000000000000475; Karlsson A, 2014, CLIN CANCER RES, V20, P6127, DOI 10.1158/1078-0432.CCR-14-1087; Karnezis AN, 2016, MODERN PATHOL, V29, P302, DOI 10.1038/modpathol.2015.155; Kato Y, 2010, J THORAC ONCOL, V5, P1551, DOI 10.1097/JTO.0b013e3181e9da60; Kitamura A, 2010, CLIN CANCER RES, V16, P3349, DOI 10.1158/1078-0432.CCR-10-0129; Klebe S, 2016, J CLIN PATHOL, V69, P136, DOI 10.1136/jclinpath-2015-203184; Kohashi K, 2018, AM J SURG PATHOL, V42, P312, DOI 10.1097/PAS.0000000000001011; Kohno T, 2015, TRANSL LUNG CANCER R, V4, P156, DOI 10.3978/j.issn.2218-6751.2014.11.11; Kohno T, 2012, NAT MED, V18, P375, DOI 10.1038/nm.2644; Koivunen JP, 2008, BRIT J CANCER, V99, P245, DOI 10.1038/sj.bjc.6604469; Kwak EL, 2010, NEW ENGL J MED, V363, P1693, DOI 10.1056/NEJMoa1006448; Le DT, 2017, SCIENCE, V357, P409, DOI 10.1126/science.aan6733; Le Loarer F, 2015, NAT GENET, V47, P1200, DOI 10.1038/ng.3399; Lee CK, 2018, JAMA ONCOL, V4, P210, DOI 10.1001/jamaoncol.2017.4427; Lee JK, 2017, J CLIN ONCOL, V35, P3065, DOI 10.1200/JCO.2016.71.9096; Lee SH, 2017, ANN ONCOL, V28, P292, DOI 10.1093/annonc/mdw559; Lee SE, 2015, MODERN PATHOL, V28, P468, DOI 10.1038/modpathol.2014.107; Lemelle L, 2017, PEDIATR BLOOD CANCER, V64, DOI 10.1002/pbc.26693; Li BT, 2016, J THORAC ONCOL, V11, P414, DOI 10.1016/j.jtho.2015.10.025; Li CG, 2012, J THORAC ONCOL, V7, P85, DOI 10.1097/JTO.0b013e318234f0a2; Lindeman NI, 2018, ARCH PATHOL LAB MED, V142, P321, DOI 10.5858/arpa.2017-0388-CP; Lindeman NI, 2013, ARCH PATHOL LAB MED, V137, P828, DOI 10.5858/arpa.2012-0720-OA; Lipson D, 2012, NAT MED, V18, P382, DOI 10.1038/nm.2673; Litvak AM, 2014, J THORAC ONCOL, V9, P1669, DOI 10.1097/JTO.0000000000000344; Liu XW, 2016, J CLIN ONCOL, V34, P794, DOI 10.1200/JCO.2015.62.0674; Lo Russo G, 2017, ONCOTARGET, V8, P59889, DOI 10.18632/oncotarget.17431; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; Ma PC, 2005, CANCER RES, V65, P1479, DOI 10.1158/0008-5472.CAN-04-2650; Mackinnon AC, 2014, MODERN PATHOL, V27, P1063, DOI 10.1038/modpathol.2013.227; Mahoney KM, 2015, CANCER IMMUNOL RES, V3, P1308, DOI 10.1158/2326-6066.CIR-15-0116; Marchetti A, 2016, J THORAC ONCOL, V11, P487, DOI 10.1016/j.jtho.2015.12.111; Marchetti A, 2011, J CLIN ONCOL, V29, P3574, DOI 10.1200/JCO.2011.35.9638; Martelli MP, 2009, AM J PATHOL, V174, P661, DOI 10.2353/ajpath.2009.080755; Matoso A, 2010, APPL IMMUNOHISTO M M, V18, P142, DOI 10.1097/PAI.0b013e3181bdf4e7; Matsubara D, 2013, CANCER SCI, V104, P266, DOI 10.1111/cas.12065; Mazieres J, 2013, J CLIN ONCOL, V31, P1997, DOI 10.1200/JCO.2012.45.6095; McLaughlin J, 2016, JAMA ONCOL, V2, P46, DOI 10.1001/jamaoncol.2015.3638; Mescam-Mancini L, 2014, LUNG CANCER, V83, P168, DOI 10.1016/j.lungcan.2013.11.019; Mino-Kenudson M, 2010, CLIN CANCER RES, V16, P1561, DOI 10.1158/1078-0432.CCR-09-2845; Mishra R, 2017, ONCOTARGET, V8, P114371, DOI 10.18632/oncotarget.22825; Mok TS, 2009, NEW ENGL J MED, V361, P947, DOI 10.1056/NEJMoa0810699; MORRIS SW, 1994, SCIENCE, V263, P1281, DOI 10.1126/science.8122112; Noh KW, 2017, J PATHOL, V243, P307, DOI 10.1002/path.4950; Nonaka D, 2012, AM J SURG PATHOL, V36, P895, DOI 10.1097/PAS.0b013e3182498f2b; Ohtsuka K, 2007, CANCER, V109, P741, DOI 10.1002/cncr.22476; Ordonez NG, 2012, APPL IMMUNOHISTO M M, V20, P429, DOI 10.1097/PAI.0b013e31825439bc; Ou SHI, 2017, J THORAC ONCOL, V12, P446, DOI 10.1016/j.jtho.2016.11.2224; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; Paik PK, 2015, CANCER DISCOV, V5, P842, DOI 10.1158/2159-8290.CD-14-1467; Paik PK, 2011, J CLIN ONCOL, V29, P2046, DOI 10.1200/JCO.2010.33.1280; Pao W, 2004, P NATL ACAD SCI USA, V101, P13306, DOI 10.1073/pnas.0405220101; Parra ER, 2018, APPL IMMUNOHISTO M M, V26, P83, DOI 10.1097/PAI.0000000000000531; Pelosi G, 2012, J THORAC ONCOL, V7, P281, DOI 10.1097/JTO.0b013e31823815d3; Peters S, 2017, NEW ENGL J MED, V377, P829, DOI 10.1056/NEJMoa1704795; Peters S, 2017, J CLIN ONCOL, V35, P2781, DOI 10.1200/JCO.2016.71.9476; Planchard D, 2016, LANCET ONCOL, V17, P984, DOI 10.1016/S1470-2045(16)30146-2; Planchard D, 2016, LANCET ONCOL, V17, P642, DOI 10.1016/S1470-2045(16)00077-2; Postow MA, 2015, J CLIN ONCOL, V33, P1974, DOI 10.1200/JCO.2014.59.4358; Ragazzi M, 2016, J CLIN PATHOL, V69, P440, DOI 10.1136/jclinpath-2015-203348; Ramalingam SS, 2018, J CLIN ONCOL, V36, P841, DOI 10.1200/JCO.2017.74.7576; Ramos P, 2014, NAT GENET, V46, P427, DOI 10.1038/ng.2928; Reck M, 2016, NEW ENGL J MED, V375, P1823, DOI 10.1056/NEJMoa1606774; Rikova K, 2007, CELL, V131, P1190, DOI 10.1016/j.cell.2007.11.025; Rimkunas VM, 2012, CLIN CANCER RES, V18, P4449, DOI 10.1158/1078-0432.CCR-11-3351; Rimm DL, 2017, JAMA ONCOL, V3, P1051, DOI 10.1001/jamaoncol.2017.0013; Ritterhouse LL, 2015, SEMIN DIAGN PATHOL, V32, P400, DOI 10.1053/j.semdp.2015.02.010; Rittmeyer A, 2017, LANCET, V389, P255, DOI 10.1016/S0140-6736(16)32517-X; Rizvi H, 2018, J CLIN ONCOL, V36, P633, DOI 10.1200/JCO.2017.75.3384; Rizvi NA, 2015, SCIENCE, V348, P124, DOI 10.1126/science.aaa1348; Rodig SJ, 2009, CLIN CANCER RES, V15, P5216, DOI 10.1158/1078-0432.CCR-09-0802; Ross JS, 2017, ONCOLOGIST, V22, P1444, DOI 10.1634/theoncologist.2016-0488; Russell-Goldman E, 2018, CANCER CYTOPATHOL, V126, P253, DOI 10.1002/cncy.21973; Sacher AG, 2016, JAMA ONCOL, V2, P1217, DOI 10.1001/jamaoncol.2016.0639; Sasaki H, 2013, LUNG CANCER, V82, P51, DOI 10.1016/j.lungcan.2013.06.014; Sasaki H, 2012, CANCER MED-US, V1, P68, DOI 10.1002/cam4.13; Sauter JL, 2017, MODERN PATHOL, V30, P1422, DOI 10.1038/modpathol.2017.61; Scarpino S, 2016, LUNG CANCER, V97, P95, DOI 10.1016/j.lungcan.2016.04.022; Schaefer IM, 2017, MODERN PATHOL, V30, P539, DOI 10.1038/modpathol.2016.230; Schneppenheim R, 2010, AM J HUM GENET, V86, P279, DOI 10.1016/j.ajhg.2010.01.013; Schrock AB, 2016, J THORAC ONCOL, V11, P1493, DOI 10.1016/j.jtho.2016.06.004; Selinger CI, 2017, HISTOPATHOLOGY, V70, P402, DOI 10.1111/his.13076; Seo AN, 2014, LUNG CANCER, V83, P316, DOI 10.1016/j.lungcan.2013.12.008; Sequist LV, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002003; Shain AH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055119; Shan L, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0120422; Sharma SV, 2007, NAT REV CANCER, V7, P169, DOI 10.1038/nrc2088; Shaw AT, 2014, NEW ENGL J MED, V371, P1963, DOI 10.1056/NEJMoa1406766; Shaw AT, 2014, NEW ENGL J MED, V370, P1189, DOI 10.1056/NEJMoa1311107; Shi Y, 2014, J THORAC ONCOL, V9, P154, DOI 10.1097/JTO.0000000000000033; Shigematsu H, 2005, CANCER RES, V65, P1642, DOI 10.1158/0008-5472.CAN-04-4235; Shigematsu H, 2005, JNCI-J NATL CANCER I, V97, P339, DOI 10.1093/jnci/dji055; Sholl LM, 2016, JCI INSIGHT, V1, DOI 10.1172/jci.insight.87062; Sholl LM, 2015, J THORAC ONCOL, V10, P951, DOI 10.1097/JTO.0000000000000545; Sholl LM, 2015, J THORAC ONCOL, V10, P768, DOI 10.1097/JTO.0000000000000516; Sholl LM, 2013, AM J SURG PATHOL, V37, P1441, DOI 10.1097/PAS.0b013e3182960fa7; Sholl LM, 2013, J THORAC ONCOL, V8, P322, DOI 10.1097/JTO.0b013e31827db604; Sholl LM, 2010, AM J CLIN PATHOL, V133, P922, DOI 10.1309/AJCPST1CTHZS3PSZ; Soda M, 2007, NATURE, V448, P561, DOI 10.1038/nature05945; Solomon BJ, 2014, NEW ENGL J MED, V371, P2167, DOI [10.1056/NEJMoa1408440, 10.1056/NEJMx150034]; Stathis A, 2018, CANCER DISCOV, V8, P24, DOI 10.1158/2159-8290.CD-17-0605; Stathis A, 2016, CANCER DISCOV, V6, P492, DOI 10.1158/2159-8290.CD-15-1335; Stelow EB, 2008, AM J SURG PATHOL, V32A, P828, DOI 10.1097/PAS.0b013e31815a3900; Stephens P, 2004, NATURE, V431, P525, DOI 10.1038/431525b; Stransky N, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5846; Strehl JD, 2015, ANN DIAGN PATHOL, V19, P198, DOI 10.1016/j.anndiagpath.2015.04.001; Su YH, 2017, AM J CLIN PATHOL, V147, P77, DOI [10.1093/AJCP/AQW201, 10.1093/ajcp/aqw201]; Suehara Y, 2012, CLIN CANCER RES, V18, P6599, DOI 10.1158/1078-0432.CCR-12-0838; Takeuchi K, 2012, NAT MED, V18, P378, DOI 10.1038/nm.2658; Takezawa K, 2012, CANCER DISCOV, V2, P922, DOI 10.1158/2159-8290.CD-12-0108; Tanaka K, 2017, CANCER-AM CANCER SOC, V123, P1731, DOI 10.1002/cncr.30539; Tong JH, 2016, CLIN CANCER RES, V22, P3048, DOI 10.1158/1078-0432.CCR-15-2061; Travis WD, 2015, PATHOLOGY GENETICS T; Travis WD, 2013, ARCH PATHOL LAB MED, V137, P668, DOI 10.5858/arpa.2012-0263-RA; Travis WD, 2011, J THORAC ONCOL, V6, P244, DOI 10.1097/JTO.0b013e318206a221; Tsao MS, 2017, ANN ONCOL, V28, P882, DOI 10.1093/annonc/mdx003; Tsuta K, 2014, BRIT J CANCER, V110, P1571, DOI 10.1038/bjc.2014.36; Vaishnavi A, 2013, NAT MED, V19, P1469, DOI 10.1038/nm.3352; Wang R, 2012, J CLIN ONCOL, V30, P4352, DOI 10.1200/JCO.2012.44.1477; Warth A, 2014, HISTOPATHOLOGY, V65, P187, DOI 10.1111/his.12379; Witkowski L, 2014, NAT GENET, V46, P438, DOI 10.1038/ng.2931; Yarchoan M, 2017, NEW ENGL J MED, V377, P2500, DOI 10.1056/NEJMc1713444; Yatabe Y, 2005, AM J SURG PATHOL, V29, P633, DOI 10.1097/01.pas.0000157935.28066.35; Yoh K, 2017, LANCET RESP MED, V5, P42, DOI 10.1016/S2213-2600(16)30322-8; Yoshida A, 2017, MODERN PATHOL, V30, P797, DOI 10.1038/modpathol.2017.11; Yoshida A, 2014, MODERN PATHOL, V27, P711, DOI 10.1038/modpathol.2013.192; Yoshida A, 2011, AM J SURG PATHOL, V35, P1226, DOI 10.1097/PAS.0b013e3182233e06; Yoshida Y, 2005, LUNG CANCER, V50, P1, DOI 10.1016/j.lungcan.2005.04.012; Yoshimoto T, 2015, PATHOL INT, V65, P595, DOI 10.1111/pin.12350; Yu J, 2009, CLIN CANCER RES, V15, P3023, DOI 10.1158/1078-0432.CCR-08-2739; Zhao J, 2018, HISTOPATHOLOGY, V73, P19, DOI 10.1111/his.13492	213	0	0	1	10	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1072-4109	1533-4031		ADV ANAT PATHOL	Adv. Anat. Pathol.	NOV	2018	25	6					374	386		10.1097/PAP.0000000000000206			13	Pathology	Pathology	GX4IE	WOS:000447692000002	30188361				2019-10-28	
J	Cox, RM; Magi-Galluzzi, C; McKenney, JK				Cox, Roni M.; Magi-Galluzzi, Cristina; McKenney, Jesse K.			Immunohistochemical Pitfalls in Genitourinary Pathology: 2018 Update	ADVANCES IN ANATOMIC PATHOLOGY			English	Review						NKX3.1; SF-1; SALL4; OCT4; AMACR; FH; SDHB; GATA3	RENAL-CELL CARCINOMA; METHYLACYL-COA-RACEMASE; MOLECULAR-WEIGHT CYTOKERATIN; POTENTIAL-DIAGNOSTIC-PITFALL; PROSTATE NEEDLE BIOPSIES; ATYPICAL ADENOMATOUS HYPERPLASIA; TUBEROUS SCLEROSIS COMPLEX; TMPRSS2-ERG GENE FUSION; COENZYME-A RACEMASE; PAX8 EXPRESSION	Immunohistochemistry may be a very useful adjunct to morphologic diagnosis in many areas of surgical pathology, including genitourinary pathology. In this review, we address common diagnostic dilemmas where immunophenotypic analysis may be utilized and we highlight pitfalls specific to each scenario. For prostate, we review the diagnosis of limited prostatic adenocarcinoma and the distinction of high-grade prostatic adenocarcinoma from urothelial carcinoma. We also cover markers of urothelial lineage in the diagnosis of metastatic carcinoma of unknown primary site. In the kidney, distinction of poorly differentiated renal cell carcinoma from urothelial carcinoma and epithelioid angiomyolipoma, adjuncts to the recognition of hereditary renal neoplasia, and the diagnosis of metastatic renal cell carcinoma are discussed. Finally, for testis we address distinction of germ cell tumors from sex cord-stromal tumors, as well as the diagnosis of metastatic germ cell tumors.	[Cox, Roni M.; Magi-Galluzzi, Cristina; McKenney, Jesse K.] Cleveland Clin, Robert J Tomsich Inst Pathol & Lab Med, Cleveland, OH 44106 USA	McKenney, JK (reprint author), Cleveland Clin, Robert J Tomsich Inst Pathol & Lab Med, Anat Pathol, 9500 Euclid Ave,L25, Cleveland, OH 44195 USA.	mckennj@ccf.org					Abrahams NA, 2002, HISTOPATHOLOGY, V41, P35, DOI 10.1046/j.1365-2559.2002.01425.x; Adley BP, 2006, AM J CLIN PATHOL, V126, P849, DOI 10.1309/F3R88U2574Q8G1J3; Albadine R, 2010, AM J SURG PATHOL, V34, P965, DOI 10.1097/PAS.0b013e3181dc5e8a; Alexander RE, 2012, MODERN PATHOL, V25, P1526, DOI 10.1038/modpathol.2012.103; Ali TZ, 2008, AM J SURG PATHOL, V32, P1890, DOI 10.1097/PAS.0b013e31817ce994; Andrews C, 2014, AM J SURG PATHOL, V38, P1007, DOI 10.1097/PAS.0000000000000205; Asch-Kendrick RJ, 2016, HUM PATHOL, V57, P7, DOI 10.1016/j.humpath.2016.06.014; Bardella C, 2011, J PATHOL, V225, P4, DOI 10.1002/path.2932; Barresi V, 2016, APMIS, V124, P188, DOI 10.1111/apm.12483; Bassily NH, 2000, AM J CLIN PATHOL, V113, P383; Beach R, 2002, AM J SURG PATHOL, V26, P1588, DOI 10.1097/00000478-200212000-00006; Bonsib SM, 2016, PATHOL RES PRACT, V212, P972, DOI 10.1016/j.prp.2016.04.005; Bowen NJ, 2007, GYNECOL ONCOL, V104, P331, DOI 10.1016/j.ygyno.2006.08.052; Browne TJ, 2004, HUM PATHOL, V35, P1462, DOI 10.1016/j.humpath.2004.09.009; Buelow B, 2016, AM J SURG PATHOL, V40, P982, DOI 10.1097/PAS.0000000000000626; Chang A, 2013, HUM PATHOL, V44, P1563, DOI 10.1016/j.humpath.2012.12.012; Chapel DB, 2017, AM J SURG PATHOL, V41, P1675, DOI 10.1097/PAS.0000000000000935; Chen YB, 2014, AM J SURG PATHOL, V38, P627, DOI 10.1097/PAS.0000000000000163; Cheng L, 2013, AM J SURG PATHOL, V37, P1550, DOI 10.1097/PAS.0b013e318294e9bc; Chuang AY, 2007, AM J SURG PATHOL, V31, P1246, DOI 10.1097/PAS.0b013e31802f5d33; Emerson RE, 2005, SEMIN DIAGN PATHOL, V22, P33, DOI 10.1053/j.semdp.2005.11.003; Epstein JI, 2014, AM J SURG PATHOL, V38, pE6, DOI 10.1097/PAS.0000000000000238; Fujimoto M, 2014, HISTOPATHOLOGY, V64, P309, DOI 10.1111/his.12241; Gelmann EP, 2003, PROSTATE, V55, P111, DOI 10.1002/pros.10210; Genega EM, 2000, MODERN PATHOL, V13, P1186, DOI 10.1038/modpathol.3880220; Giannico GA, 2013, AM J SURG PATHOL, V37, P1401, DOI 10.1097/PAS.0b013e31828d5c32; Giannico GA, 2017, HUM PATHOL, V67, P152, DOI 10.1016/j.humpath.2017.07.002; Gill AJ, 2014, AM J SURG PATHOL, V38, P1588, DOI 10.1097/PAS.0000000000000292; Gill AJ, 2010, HUM PATHOL, V41, P805, DOI 10.1016/j.humpath.2009.12.005; Goldstein NS, 2002, AM J CLIN PATHOL, V117, P471, DOI 10.1309/G6PR-Y774-X738-FG2K; Gonzalez-Roibon N, 2013, HUM PATHOL, V44, P2651, DOI 10.1016/j.humpath.2013.07.006; Gonzalez-Roibon N, 2013, HUM PATHOL, V44, P1293, DOI 10.1016/j.humpath.2012.10.017; Gordetsky J, 2014, AM J SURG PATHOL, V38, P941, DOI 10.1097/PAS.0000000000000178; Green WM, 2013, HUM PATHOL, V44, P1895, DOI 10.1016/j.humpath.2013.02.019; Guo J, 2014, AM J SURG PATHOL, V38, P1457, DOI 10.1097/PAS.0000000000000248; Gupta A, 2004, AM J SURG PATHOL, V28, P1224, DOI 10.1097/01.pas.0000131544.18266.a4; Gurel B, 2010, AM J SURG PATHOL, V34, P1097, DOI 10.1097/PAS.0b013e3181e6cbf3; Hameed O, 2005, AM J SURG PATHOL, V29, P579, DOI 10.1097/01.pas.0000157936.93999.18; He HY, 2011, AM J SURG PATHOL, V35, P608, DOI 10.1097/PAS.0b013e31820bcd2d; Henske EP, 2016, NAT REV DIS PRIMERS, V2, DOI 10.1038/nrdp.2016.35; Holmes BJ, 2014, INT J GYNECOL PATHOL, V33, P425, DOI 10.1097/PGP.0b013e31829d7705; Howitt Brooke E, 2015, Surg Pathol Clin, V8, P687, DOI 10.1016/j.path.2015.07.007; Jiang Z, 2002, AM J SURG PATHOL, V26, P1169, DOI 10.1097/01.PAS.0000024997.88486.83; Jiang Z, 2001, AM J SURG PATHOL, V25, P1397, DOI 10.1097/00000478-200111000-00007; Jiang Z, 2005, AM J CLIN PATHOL, V123, P231, DOI 10.1309/1G1NK9DBGFNB792L; Jiang Z, 2004, HISTOPATHOLOGY, V45, P218, DOI 10.1111/j.1365-2559.2004.01930.x; Jones TD, 2004, AM J SURG PATHOL, V28, P935, DOI 10.1097/00000478-200407000-00014; Kao CS, 2015, AM J SURG PATHOL, V39, P1159, DOI 10.1097/PAS.0000000000000450; Kaufmann O, 2000, AM J CLIN PATHOL, V113, P683; Kilic E, 2016, VIRCHOWS ARCH, V468, P483, DOI 10.1007/s00428-016-1908-y; Kinoshita S, 2014, PATHOL INT, V64, P581, DOI 10.1111/pin.12211; Kristiansen I, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18061151; Kunju LP, 2006, AM J CLIN PATHOL, V125, P675, DOI 10.1309/V1RY91NKX5ARW2Q5; Kunju LP, 2003, AM J CLIN PATHOL, V120, P737, DOI 10.1309/3T3Y0K0TUMYH3WY2; Laury AR, 2011, AM J SURG PATHOL, V35, P816, DOI 10.1097/PAS.0b013e318216c112; Li W, 2014, AM J CLIN PATHOL, V142, P864, DOI 10.1309/AJCP1J0JPJBPSUXF; Li YJ, 2018, HISTOPATHOLOGY, V72, P588, DOI 10.1111/his.13395; Linehan WM, 2016, NEW ENGL J MED, V374, P135, DOI 10.1056/NEJMoa1505917; Long KB, 2010, AM J SURG PATHOL, V34, P723, DOI 10.1097/PAS.0b013e3181da0a20; Magi-Galluzzi C, 2003, AM J SURG PATHOL, V27, P1128, DOI 10.1097/00000478-200308000-00010; Mantilla JG, 2017, HUM PATHOL, V66, P152, DOI 10.1016/j.humpath.2017.06.016; Martignoni G, 2009, MODERN PATHOL, V22, P1016, DOI 10.1038/modpathol.2009.58; Martignoni G, 2016, WHO CLASSIFICATION T, P62; Martignoni G, 2012, MODERN PATHOL, V25, P100, DOI 10.1038/modpathol.2011.136; McDaniel AS, 2014, AM J SURG PATHOL, V38, P1664, DOI 10.1097/PAS.0000000000000267; Merino MJ, 2007, AM J SURG PATHOL, V31, P1578, DOI 10.1097/PAS.0b013e31804375b8; Mertz KD, 2013, HUM PATHOL, V44, P2727, DOI 10.1016/j.humpath.2013.07.019; Mhawech-Fauceglia P, 2007, HISTOPATHOLOGY, V50, P472, DOI 10.1111/j.1365-2559.2007.02635.x; Miettinen M, 2014, AM J SURG PATHOL, V38, P13, DOI 10.1097/PAS.0b013e3182a0218f; Miettinen M, 2014, AM J SURG PATHOL, V38, P410, DOI 10.1097/PAS.0000000000000116; Miettinen M, 2011, AM J SURG PATHOL, V35, P432, DOI 10.1097/PAS.0b013e318206b67b; Mills AM, 2017, AM J SURG PATHOL, V41, P607, DOI 10.1097/PAS.0000000000000800; Minner S, 2013, MODERN PATHOL, V26, P106, DOI 10.1038/modpathol.2012.130; Molinie V, 2004, MODERN PATHOL, V17, P1180, DOI 10.1038/modpathol.3800197; Morais CL, 2016, HUM PATHOL, V55, P117, DOI 10.1016/j.humpath.2016.04.017; Moretti L, 2012, MODERN PATHOL, V25, P231, DOI 10.1038/modpathol.2011.162; Muller M, 2018, MODERN PATHOL, V31, P974, DOI 10.1038/s41379-018-0017-7; Nonaka D, 2008, MODERN PATHOL, V21, P192, DOI 10.1038/modpathol.3801002; Oliai BR, 2002, AM J SURG PATHOL, V26, P1151, DOI 10.1097/01.PAS.0000024540.83286.D7; Ordonez NG, 2012, ADV ANAT PATHOL, V19, P140, DOI 10.1097/PAP.0b013e318253465d; Ordonez NG, 1998, AM J CLIN PATHOL, V110, P385, DOI 10.1093/ajcp/110.3.385; Osunkoya AO, 2008, AM J SURG PATHOL, V32, P461, DOI 10.1097/PAS.0b013e318157020e; Ozcan A, 2012, ARCH PATHOL LAB MED, V136, P1541, DOI 10.5858/arpa.2012-0072-OA; Ozcan A, 2011, MODERN PATHOL, V24, P751, DOI 10.1038/modpathol.2011.3; Pai R, 2014, APMIS, V122, P1130, DOI 10.1111/apm.12269; Parker DC, 2003, AM J SURG PATHOL, V27, P1, DOI 10.1097/00000478-200301000-00001; Patil PA, 2015, AM J SURG PATHOL, V39, P349, DOI 10.1097/PAS.0000000000000354; Pellizzari L, 2006, ONCOL REP, V16, P1015; Przybycin CG, 2008, AM J SURG PATHOL, V32, P58, DOI 10.1097/PAS.0b013e318093e3f6; Puglisi F, 2000, ANTICANCER RES, V20, P311; Rao P, 2012, AM J SURG PATHOL, V36, P583, DOI 10.1097/PAS.0b013e3182417d78; Rao Q, 2013, MODERN PATHOL, V26, P725, DOI 10.1038/modpathol.2012.229; Reuter VE, 2014, AM J SURG PATHOL, V38, pE35, DOI 10.1097/PAS.0000000000000258; Ricketts C, 2008, J NATL CANCER I, V100, P1260, DOI 10.1093/jnci/djn254; Rivera AL, 2010, NEUROPATHOLOGY, V30, P580, DOI 10.1111/j.1440-1789.2010.01109.x; Rodriguez Erika, 2014, Transl Respir Med, V2, P10, DOI 10.1186/s40247-014-0010-7; Roy S, 2012, DIAGN PATHOL, V7, DOI 10.1186/1746-1596-7-151; Sangoi AR, 2013, APPL IMMUNOHISTO M M, V21, P318, DOI 10.1097/PAI.0b013e318277cf5a; Sangoi AR, 2013, AM J DERMATOPATH, V35, P448, DOI 10.1097/DAD.0b013e318271ce53; Sangoi AR, 2011, MODERN PATHOL, V24, P412, DOI 10.1038/modpathol.2010.176; Sangoi AR, 2011, MODERN PATHOL, V24, P425, DOI 10.1038/modpathol.2010.196; Sangoi AR, 2010, ADV ANAT PATHOL, V17, P377, DOI 10.1097/PAP.0b013e3181f89400; Schwartz LE, 2016, AM J SURG PATHOL, V40, P27, DOI 10.1097/PAS.0000000000000524; Shah RB, 2013, HUM PATHOL, V44, P786, DOI 10.1016/j.humpath.2012.06.024; Shah RB, 2004, AM J CLIN PATHOL, V122, P517, DOI 10.1309/WRM51C70P1NBFE4K; Shah RB, 2002, AM J SURG PATHOL, V26, P1161, DOI 10.1097/01.PAS.0000022568.53433.96; Sheridan T, 2007, AM J SURG PATHOL, V31, P1351, DOI 10.1097/PAS.0b013e3180536678; Skinnider BF, 2004, AM J SURG PATHOL, V28, P701, DOI 10.1097/01.pas.0000126759.43227.d9; Smith SC, 2017, HISTOPATHOLOGY, V71, P42, DOI 10.1111/his.13183; Smith SC, 2016, AM J SURG PATHOL, V40, P1457, DOI 10.1097/PAS.0000000000000719; Smith SC, 2014, HISTOPATHOLOGY, V65, P132, DOI 10.1111/his.12360; Srinivasan M, 2011, DIAGN PATHOL, V6, DOI 10.1186/1746-1596-6-67; Sung MT, 2007, HUM PATHOL, V38, P332, DOI 10.1016/j.humpath.2006.08.016; Tani HL, 2015, MODERN PATHOL, V28, P446, DOI 10.1038/modpathol.2014.115; Teng LH, 2013, UROLOGY, V82, P394, DOI 10.1016/j.urology.2013.03.029; Tian W, 2017, HISTOPATHOLOGY, V71, P150, DOI 10.1111/his.13214; Tomlins SA, 2005, SCIENCE, V310, P644, DOI 10.1126/science.1117679; Tomlins SA, 2012, ARCH PATHOL LAB MED, V136, P935, DOI 10.5858/arpa.2011-0424-OA; Tong GX, 2008, AM J SURG PATHOL, V32, P1380, DOI 10.1097/PAS.0b013e31816b1020; Tong GX, 2009, MODERN PATHOL, V22, P1218, DOI 10.1038/modpathol.2009.88; Toro JR, 2003, AM J HUM GENET, V73, P95, DOI 10.1086/376435; Trpkov K, 2016, AM J SURG PATHOL, V40, P865, DOI 10.1097/PAS.0000000000000617; Trpkov K, 2009, AM J CLIN PATHOL, V132, P211, DOI 10.1309/AJCPGFJP83IXZEUR; Udager AM, 2018, HUM PATHOL, V71, P47, DOI 10.1016/j.humpath.2017.10.013; Ulbright TM, 2014, AM J SURG PATHOL, V38, pE50, DOI 10.1097/PAS.0000000000000233; Varinot J, 2016, VIRCHOWS ARCH, V468, P619, DOI 10.1007/s00428-016-1917-x; Varinot J, 2013, VIRCHOWS ARCH, V463, P803, DOI 10.1007/s00428-013-1495-0; Wang WL, 2008, AM J SURG PATHOL, V32A, P851, DOI 10.1097/PAS.0b013e31815a0508; Weinstein MH, 2002, MODERN PATHOL, V15, P1302, DOI 10.1097/01.MP.0000038460.95912.6E; Williams AS, 2016, AM J SURG PATHOL, V40, P950, DOI 10.1097/PAS.0000000000000648; Williamson SR, 2018, HUM PATHOL, V75, P10, DOI 10.1016/j.humpath.2017.11.013; Williamson SR, 2015, MODERN PATHOL, V28, P80, DOI 10.1038/modpathol.2014.86; Wobker SE, 2017, AM J SURG PATHOL, V41, P557, DOI 10.1097/PAS.0000000000000798; WOJNO KJ, 1995, AM J SURG PATHOL, V19, P251, DOI 10.1097/00000478-199503000-00002; Wu CL, 2004, HUM PATHOL, V35, P1008, DOI 10.1016/j.humpath.2004.03.019; Yang P, 2014, AM J SURG PATHOL, V38, P895, DOI 10.1097/PAS.0000000000000237; Yang XMJ, 1999, AM J SURG PATHOL, V23, P147, DOI 10.1097/00000478-199902000-00002; Yang XMJ, 2002, AM J SURG PATHOL, V26, P921, DOI 10.1097/00000478-200207000-00011; Yaskiv O, 2011, AM J SURG PATHOL, V35, P1062, DOI 10.1097/PAS.0b013e318215cc03; Yemelyanova A, 2014, INT J GYNECOL PATHOL, V33, P492, DOI 10.1097/PGP.0b013e3182a54afa; Yin M, 2007, DIAGN PATHOL, V2, DOI 10.1186/1746-1596-2-41; Zhang G, 2017, HISTOPATHOLOGY, V71, P669, DOI 10.1111/his.13275; Zhang P, 2006, PATHOL INT, V56, P240, DOI 10.1111/j.1440-1827.2006.01959.x; Zhao CQ, 2008, INT J GYNECOL PATHOL, V27, P507, DOI 10.1097/PGP.0b013e31817c1b0a; Zhao CQ, 2009, AM J SURG PATHOL, V33, P354, DOI 10.1097/PAS.0b013e318188373d; Zhou M, 2004, AM J SURG PATHOL, V28, P239, DOI 10.1097/00000478-200402000-00012; Zhou M, 2003, AM J SURG PATHOL, V27, P365, DOI 10.1097/00000478-200303000-00010; Zhou M, 2003, AM J SURG PATHOL, V27, P772, DOI 10.1097/00000478-200306000-00007	148	0	0	1	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1072-4109	1533-4031		ADV ANAT PATHOL	Adv. Anat. Pathol.	NOV	2018	25	6					387	399		10.1097/PAP.0000000000000205			13	Pathology	Pathology	GX4IE	WOS:000447692000003	30157041				2019-10-28	
J	Higgins, SE; Barletta, JA				Higgins, Sara E.; Barletta, Justine A.			Applications of Immunohistochemistry to Endocrine Pathology	ADVANCES IN ANATOMIC PATHOLOGY			English	Review						immunohistochemistry; thyroid; parathyroid; adrenal	PAPILLARY THYROID-CARCINOMA; TRANSCRIPTION FACTOR-I; HYALINIZING TRABECULAR ADENOMA; CRIBRIFORM-MORULAR VARIANT; ANALOG SECRETORY CARCINOMA; SPORADIC PARATHYROID ADENOMAS; ADRENAL-CORTICAL CARCINOMA; SDHD GENE-MUTATIONS; BRAF V600E MUTATION; GERM-LINE MUTATIONS	The role of immunohistochemistry (IHC) in endocrine pathology is similar to that in other organ systems in that it can aid in the subclassification of tumors within an organ, confirm site of primary in metastatic disease, provide prognostic information, identify underlying genetic alterations, and predict response to treatment. Although most endocrine tumors do not require IHC to render a diagnosis, there are certain scenarios in which IHC can be extremely helpful. For example, in thyroid, IHC can be used to support tumor dedifferentiation, in the adrenal it can aid in the diagnosis of low-grade adrenocortical carcinomas, and in paragangliomas it can help identify tumors arising as part of an inherited tumor syndrome. This review will focus on the applications of IHC in tumors of the thyroid, parathyroids, adrenals, and paraganglia in adults.	[Higgins, Sara E.; Barletta, Justine A.] Harvard Med Sch, Brigham & Womens Hosp, Dept Pathol, Boston, MA USA	Barletta, JA (reprint author), Brigham & Womens Hosp, Dept Pathol, 75 Francis St, Boston, MA 02115 USA.	jbarletta@bwh.harvard.edu					Agoff SN, 2000, MODERN PATHOL, V13, P238, DOI 10.1038/modpathol.3880044; Agrawal N, 2014, CELL, V159, P676, DOI 10.1016/j.cell.2014.09.050; ALBORESSAAVEDRA J, 1983, HUM PATHOL, V14, P62, DOI 10.1016/S0046-8177(83)80046-X; Amar L, 2005, J CLIN ONCOL, V23, P8812, DOI 10.1200/JCO.2005.03.1484; Arola J, 2000, ENDOCR RES, V26, P861, DOI 10.3109/07435800009048609; Asioli S, 2013, HUM PATHOL, V44, P320, DOI 10.1016/j.humpath.2012.06.003; Asioli S, 2010, MODERN PATHOL, V23, P1269, DOI 10.1038/modpathol.2010.117; Asioli S, 2010, AM J SURG PATHOL, V34, P44, DOI 10.1097/PAS.0b013e3181c46677; Barletta JA, 2011, AM J SURG PATHOL, V35, P1505, DOI 10.1097/PAS.0b013e31822fbc7d; Bejarano PA, 2000, APPL IMMUNOHISTO M M, V8, P189, DOI 10.1097/00022744-200009000-00004; Bellizzi AM, 2013, ADV ANAT PATHOL, V20, P285, DOI 10.1097/PAP.0b013e3182a2dc67; Benn DE, 2006, J CLIN ENDOCR METAB, V91, P827, DOI 10.1210/jc.2005-1862; Betts G, 2014, HISTOPATHOLOGY, V65, P288, DOI 10.1111/his.12388; Beuschlein F, 2015, J CLIN ENDOCR METAB, V100, P841, DOI 10.1210/jc.2014-3182; Bishop JA, 2011, HUM PATHOL, V42, P1873, DOI 10.1016/j.humpath.2011.02.004; Bullock M, 2012, ENDOCR-RELAT CANCER, V19, P779, DOI 10.1530/ERC-12-0239; Burnichon N, 2012, CLIN CANCER RES, V18, P2828, DOI 10.1158/1078-0432.CCR-12-0160; Burnichon N, 2009, J CLIN ENDOCR METAB, V94, P2817, DOI 10.1210/jc.2008-2504; Cameselle-Teijeiro J, 2001, AM J CLIN PATHOL, V115, P486; Capper D, 2011, ACTA NEUROPATHOL, V122, P11, DOI 10.1007/s00401-011-0841-z; Carney JA, 2008, AM J SURG PATHOL, V32, P1877, DOI 10.1097/PAS.0b013e31817a8f1b; CARNEY JA, 1987, AM J SURG PATHOL, V11, P583, DOI 10.1097/00000478-198708000-00001; Carpten JD, 2002, NAT GENET, V32, P676, DOI 10.1038/ng1048; Casey MB, 2004, AM J CLIN PATHOL, V122, P506, DOI 10.1309/KLJU9LVBLLA6CL76; Casey MB, 2003, ENDOCR PATHOL, V14, P55, DOI 10.1385/EP:14:1:55; Cetani F, 2004, J CLIN ENDOCR METAB, V89, P5583, DOI 10.1210/jc.2004-0294; Cetani F, 2007, EUR J ENDOCRINOL, V156, P547, DOI 10.1530/EJE-06-0720; Cetani F, 2013, ENDOCR CONNECT, V2, P186, DOI 10.1530/EC-13-0046; Chen L, 2005, ARCH PATHOL LAB MED, V129, P531; Chernock RD, 2013, AM J SURG PATHOL, V37, P1215, DOI 10.1097/PAS.0b013e318283b7b2; Cheung CC, 2001, MODERN PATHOL, V14, P338, DOI 10.1038/modpathol.3880312; Cho U, 2017, MODERN PATHOL, V30, P810, DOI 10.1038/modpathol.2017.9; Choi YL, 2005, J KOREAN MED SCI, V20, P853, DOI 10.3346/jkms.2005.20.5.853; Chou A, 2015, AM J SURG PATHOL, V39, P652, DOI 10.1097/PAS.0000000000000368; Christophe D, 2004, MOL CELL ENDOCRINOL, V223, P1, DOI 10.1016/j.mce.2004.06.006; DASOVICKNEZEVIC M, 1989, MODERN PATHOL, V2, P610; Dettloff J, 2017, HEAD NECK PATHOL, V11, P124, DOI 10.1007/s12105-016-0741-6; Dogan S, 2016, MODERN PATHOL, V29, P985, DOI 10.1038/modpathol.2016.115; Duregon E, 2015, HUM PATHOL, V46, P1799, DOI 10.1016/j.humpath.2015.08.012; Erickson LA, 2001, ENDOCR PATHOL, V12, P429, DOI 10.1385/EP:12:4:429; Erickson LA, 2018, ENDOCR PATHOL, V29, P113, DOI 10.1007/s12022-018-9527-6; Fassnacht M, 2013, J CLIN ENDOCR METAB, V98, P4551, DOI 10.1210/jc.2013-3020; Fletcher C, 2013, WHO CLASSIFICATION T; Fujiwara S, 2010, HUM PATHOL, V41, P560, DOI 10.1016/j.humpath.2009.09.010; Ghossein RA, 2013, J CLIN ENDOCR METAB, V98, pE1414, DOI 10.1210/jc.2013-1408; Gill AJ, 2018, AM J SURG PATHOL; Gill AJ, 2006, AM J SURG PATHOL, V30, P1140; Gill AJ, 2010, HUM PATHOL, V41, P805, DOI 10.1016/j.humpath.2009.12.005; Giordano TJ, 2009, CLIN CANCER RES, V15, P668, DOI 10.1158/1078-0432.CCR-08-1067; Gottlieb E, 2005, NAT REV CANCER, V5, P857, DOI 10.1038/nrc1737; Gucer H, 2018, ENDOCR PATHOL, V29, P49, DOI 10.1007/s12022-017-9511-6; Guyetant S, 1999, HUM PATHOL, V30, P957, DOI 10.1016/S0046-8177(99)90250-2; Harach H R, 1999, Ann Diagn Pathol, V3, P331, DOI 10.1016/S1092-9134(99)80011-2; HARACH HR, 1988, HISTOPATHOLOGY, V13, P43, DOI 10.1111/j.1365-2559.1988.tb02002.x; Haugen BR, 2016, THYROID, V26, P1, DOI 10.1089/thy.2015.0020; Hirokawa M, 2000, AM J SURG PATHOL, V24, P575, DOI 10.1097/00000478-200004000-00013; Hirokawa M, 2010, DIAGN CYTOPATHOL, V38, P890, DOI 10.1002/dc.21309; Howitt BE, 2015, HISTOPATHOLOGY, V67, P579, DOI 10.1111/his.12680; Howitt BE, 2013, THYROID, V23, P1256, DOI 10.1089/thy.2013.0018; Hung YP, 2018, HISTOPATHOLOGY, V72, P53, DOI 10.1111/his.13363; Ilie M, 2013, ANN ONCOL, V24, P742, DOI 10.1093/annonc/mds534; Ip JCY, 2015, ONCOLOGIST, V20, P247, DOI 10.1634/theoncologist.2014-0392; Ito Y, 2011, ENDOCR J, V58, P685, DOI 10.1507/endocrj.EJ11-0022; Ji JH, 2015, PLOS GENET, V11, DOI 10.1371/journal.pgen.1005467; Jung CK, 2009, THYROID, V19, P905, DOI 10.1089/thy.2008.0332; Kadivar M, 2013, APPL IMMUNOHISTO M M, V21, P191, DOI 10.1097/PAI.0b013e3182612643; Kelly LM, 2014, P NATL ACAD SCI USA, V111, P4233, DOI 10.1073/pnas.1321937111; Koperek O, 2012, AM J SURG PATHOL, V36, P844, DOI 10.1097/PAS.0b013e318246b527; Korpershoek E, 2016, J CLIN ENDOCR METAB, V101, P453, DOI 10.1210/jc.2015-2592; Korpershoek E, 2011, J CLIN ENDOCR METAB, V96, pE1472, DOI 10.1210/jc.2011-1043; Krabak BJ, 2011, MED SCI SPORT EXER, V43, P2314, DOI 10.1249/MSS.0b013e318221bfe3; Krebs LJ, 2005, J CLIN ENDOCR METAB, V90, P5015, DOI 10.1210/jc.2005-0717; Kruijff S, 2014, ANN SURG ONCOL, V21, P426, DOI 10.1245/s10434-013-3288-8; Kunstman JW, 2015, HUM MOL GENET, V24, P2318, DOI 10.1093/hmg/ddu749; Kurihara K, 2000, JPN J CANCER RES, V91, P1100, DOI 10.1111/j.1349-7006.2000.tb00891.x; Labrousse F, 1999, CLIN NEUROPATHOL, V18, P208; Lancia I, 2016, J CLIN INVEST, V126, P1052, DOI 10.1172/JCI85271; Laury AR, 2011, AM J SURG PATHOL, V35, P816, DOI 10.1097/PAS.0b013e318216c112; Laury AR, 2011, THYROID, V21, P135, DOI 10.1089/thy.2010.0226; Lee JP, 2017, HISTOPATHOLOGY, V71, P503, DOI 10.1111/his.13243; Leonardo E, 2007, APPL IMMUNOHISTO M M, V15, P220, DOI 10.1097/01.pai.0000213122.66096.f0; Liaw D, 1997, NAT GENET, V16, P64, DOI 10.1038/ng0597-64; Lloyd RV, 2018, HUM PATHOL, V74, P1, DOI 10.1016/j.humpath.2017.12.027; LLOYD RV, 1995, ENDOCR PATHOL, V6, P279, DOI 10.1007/BF02738728; Long KB, 2010, AM J SURG PATHOL, V34, P723, DOI 10.1097/PAS.0b013e3181da0a20; Lubitz CC, 2014, THYROID, V24, P958, DOI 10.1089/thy.2013.0573; MAEDA T, 1989, JPN J MED, V28, P640; Mannelli M, 2009, J CLIN ENDOCR METAB, V94, P1541, DOI 10.1210/jc.2008-2419; Mete O, 2018, AM J SURG PATHOL, V42, P201, DOI 10.1097/PAS.0000000000000943; Miettinen M, 2000, HUM PATHOL, V31, P1139, DOI 10.1053/hupa.2000.16667; Miettinen M, 2014, AM J SURG PATHOL, V38, P13, DOI 10.1097/PAS.0b013e3182a0218f; Morandi L, 2017, ENDOCR-RELAT CANCER, V24, P107, DOI 10.1530/ERC-16-0546; Morimoto R, 2008, ENDOCR J, V55, P49, DOI 10.1507/endocrj.K07-079; Neumann HPH, 2002, NEW ENGL J MED, V346, P1459, DOI 10.1056/NEJMoa020152; Neumann HPH, 2004, JAMA-J AM MED ASSOC, V292, P943, DOI 10.1001/jama.292.8.943; Nikiforov YE, 2016, JAMA ONCOL, V2, P1023, DOI 10.1001/jamaoncol.2016.0386; Nikiforova MN, 2003, J CLIN ENDOCR METAB, V88, P5399, DOI 10.1210/jc.2003-030838; Nonaka D, 2008, AM J SURG PATHOL, V32, P1566, DOI 10.1097/PAS.0b013e31816d71ad; Nonaka D, 2008, MODERN PATHOL, V21, P192, DOI 10.1038/modpathol.3801002; Nonaka D, 2011, AM J SURG PATHOL, V35, P145, DOI 10.1097/PAS.0b013e31820371e4; Nozieres C, 2016, EUR J ENDOCRINOL, V174, P335, DOI 10.1530/EJE-15-0917; Ordonez NG, 2014, APPL IMMUNOHISTO M M, V22, P756, DOI 10.1097/PAI.0000000000000007; Ordonez NG, 2000, ADV ANAT PATHOL, V7, P123, DOI 10.1097/00125480-200007020-00007; Ozolins A, 2016, LANGENBECK ARCH SURG, V401, P943, DOI 10.1007/s00423-015-1361-4; Papathomas TG, 2016, HUM PATHOL, V58, P113, DOI 10.1016/j.humpath.2016.08.006; Papathomas TG, 2016, AM J SURG PATHOL, V40, P569, DOI 10.1097/PAS.0000000000000574; Papathomas TG, 2015, MODERN PATHOL, V28, P807, DOI 10.1038/modpathol.2015.41; Pattyn A, 1999, NATURE, V399, P366; POLEEV A, 1992, DEVELOPMENT, V116, P611; Prager GW, 2016, THYROID, V26, P1515, DOI 10.1089/thy.2015.0575; Raymond VM, 2013, J CLIN ONCOL, V31, P3012, DOI 10.1200/JCO.2012.48.0988; Reagh J, 2017, AM J SURG PATHOL, V41, P75, DOI 10.1097/PAS.0000000000000740; Reynolds S, 2016, HEAD NECK PATHOL, V10, P405, DOI 10.1007/s12105-016-0715-8; Ritterhouse LL, 2015, SEMIN DIAGN PATHOL, V32, P400, DOI 10.1053/j.semdp.2015.02.010; Rivera M, 2010, MODERN PATHOL, V23, P1191, DOI 10.1038/modpathol.2010.112; Rosove MH, 2013, NEW ENGL J MED, V368, P684, DOI 10.1056/NEJMc1215697; RYFFDELECHE A, 1986, CANCER, V57, P1145, DOI 10.1002/1097-0142(19860315)57:6<1145::AID-CNCR2820570615>3.0.CO;2-X; SAAD MF, 1984, J CLIN ENDOCR METAB, V59, P850, DOI 10.1210/jcem-59-5-850; Saltman B, 2006, SURGERY, V140, P899, DOI 10.1016/j.surg.2006.07.027; Sangoi AR, 2011, AM J SURG PATHOL, V35, P678, DOI 10.1097/PAS.0b013e3182152629; Sangoi AR, 2011, MODERN PATHOL, V24, P412, DOI 10.1038/modpathol.2010.176; Sbiera S, 2010, J CLIN ENDOCR METAB, V95, pE161, DOI 10.1210/jc.2010-0653; Schmitt A, 2006, HISTOPATHOLOGY, V49, P298, DOI 10.1111/j.1365-2559.2006.02505.x; Shattuck TM, 2003, NEW ENGL J MED, V349, P1722, DOI 10.1056/NEJMoa031237; Siami K, 2007, AM J SURG PATHOL, V31, P1759, DOI 10.1097/PAS.0b013e3181131e21; Soon PSH, 2009, ENDOCR-RELAT CANCER, V16, P573, DOI 10.1677/ERC-08-0237; Srivastava A, 2009, AM J SURG PATHOL, V33, P626, DOI 10.1097/PAS.0b013e31818d7d8b; Stefaneanu L, 1984, Endocrinologie, V22, P55; Stojadinovic A, 2003, HUM PATHOL, V34, P54, DOI 10.1053/hupa.2003.55; Subbiah V, 2018, J CLIN ONCOL, V36, P7, DOI 10.1200/JCO.2017.73.6785; Sun F, 2005, CELL, V121, P1043, DOI 10.1016/j.cell.2005.05.025; Tan MH, 2004, CLIN CANCER RES, V10, P6629, DOI 10.1158/1078-0432.CCR-04-0493; Tan PH, 2013, AM J SURG PATHOL, V37, P1518, DOI 10.1097/PAS.0b013e318299f12e; Thompson LDR, 2002, AM J SURG PATHOL, V26, P551, DOI 10.1097/00000478-200205000-00002; Tomita T, 1999, ENDOCR PATHOL, V10, P145, DOI 10.1007/BF02739826; Trueba SS, 2005, J CLIN ENDOCR METAB, V90, P455, DOI 10.1210/jc.2004-1358; Truran PP, 2014, WORLD J SURG, V38, P2845, DOI 10.1007/s00268-014-2700-2; Tufano RP, 2012, MEDICINE, V91, P274, DOI 10.1097/MD.0b013e31826a9c71; Turchini J, 2018, HISTOPATHOLOGY, V72, P97, DOI 10.1111/his.13402; Uccella S, 2017, ENDOCR PATHOL, V28, P351, DOI 10.1007/s12022-017-9505-4; Udager AM, 2018, HUM PATHOL, V71, P47, DOI 10.1016/j.humpath.2017.10.013; van Nederveen FH, 2009, LANCET ONCOL, V10, P764, DOI 10.1016/S1470-2045(09)70164-0; Vargas MP, 1997, AM J SURG PATHOL, V21, P556, DOI 10.1097/00000478-199705000-00008; Volante M, 2007, AM J SURG PATHOL, V31, P1256, DOI 10.1097/PAS.0b013e3180309e6a; Volante M, 2009, J CLIN ENDOCR METAB, V94, P4735, DOI 10.1210/jc.2009-1233; Wang CP, 2014, HISTOPATHOLOGY, V64, P567, DOI 10.1111/his.12283; Weissferdt A, 2014, APPL IMMUNOHISTO M M, V22, P24, DOI 10.1097/PAI.0b013e31828a96cf; Weissferdt A, 2013, AM J CLIN PATHOL, V139, P780, DOI 10.1309/AJCPCDZLC13RSXRZ; Weissferdt A, 2012, HUM PATHOL, V43, P874, DOI 10.1016/j.humpath.2011.07.015; Wells SA, 2015, THYROID, V25, P567, DOI 10.1089/thy.2014.0335; Wu EY, 2017, HISTOPATHOLOGY, V71, P665, DOI 10.1111/his.13268; Xing MZ, 2013, JAMA-J AM MED ASSOC, V309, P1493, DOI 10.1001/jama.2013.3190; Xu B, 2003, J PATHOL, V199, P58, DOI 10.1002/path.1225; Zhang PJ, 2009, INT J GYNECOL PATHOL, V28, P10, DOI 10.1097/PGP.0b013e3181804bc6; Zhang PJ, 2003, MODERN PATHOL, V16, P591, DOI 10.1097/01.MP.0000073134.60541.E8; Zheng SY, 2016, CANCER CELL, V29, P723, DOI 10.1016/j.ccell.2016.04.002	156	0	0	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1072-4109	1533-4031		ADV ANAT PATHOL	Adv. Anat. Pathol.	NOV	2018	25	6					413	429		10.1097/PAP.0000000000000209			17	Pathology	Pathology	GX4IE	WOS:000447692000005	30157042				2019-10-28	
J	Brandler, TC; Liu, CZ; Cho, M; Zhou, F; Cangiarella, J; Yee-Chang, M; Ski, Y; Simsir, A; Sun, W				Brandler, Tamar C.; Liu, Cheng Z.; Cho, Margaret; Zhou, Fang; Cangiarella, Joan; Yee-Chang, Melissa; Ski, Yan; Simsir, Aylin; Sun, Wei			Does Noninvasive Follicular Thyroid Neoplasm With Papillary-Like Nuclear Features (NIFTP) Have a Unique Molecular Profile?	AMERICAN JOURNAL OF CLINICAL PATHOLOGY			English	Article						NIFTP; Noninvasive follicular thyroid neoplasm with papillary-like nuclear features; Molecular; RAS; BRAF	FINE-NEEDLE-ASPIRATION; YOUNG INVESTIGATOR CHALLENGE; GENE-EXPRESSION CLASSIFIER; CARCINOMA; VARIANT; DIAGNOSIS; CYTOLOGY; DISTINCT; IDENTIFICATION; ADENOMAS	Objectives: Recognizing preoperative characteristics of noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP) is important for clinical management. Therefore, we assessed presurgical NIFTP molecular profiles using fine-needle aspiration ( FNA) material. Methods: Presurgical FNA reports of 39 surgically confirmed NIFTP cases from January 2013 through May 2017 were assessed for Afirma and ThyroSeq results. Results: Twenty-one of 39 NIFTP nodules were preoperatively tested with Afirma with two benign and 19 suspicious results. Twenty-seven of 39 nodules were tested with ThyroSeq (nine of 39 had both Afirma and Thyroseq): 18 (67%) had RAS mutations ( 13 NRAS, four HRAS, one KRAS), and three of 18 had multiple alterations (NRAS + TP53, n = 1; NRAS + PTEN, n = 2). BRAF T599_R603 + EIF1AX mutation (n = 1), PTEN mutation (n = 1 ), MET overexpression (n = 1), PAX8/PPARG fusion (n = 3), and THADA/IGF2BP3 fusion ( n = 3) comprised the remainder. Conclusions: NIFTP cases most commonly displayed suspicious Afirma results and RAS mutations on ThyroSeq, lacking aggressive/BRAF-V600E-like mutations. While NIFTP remains a surgical entity, the lack of aggressive/BRAF-V600E-like mutations can aid in determining the extent of surgery.	[Brandler, Tamar C.; Liu, Cheng Z.; Cho, Margaret; Zhou, Fang; Cangiarella, Joan; Yee-Chang, Melissa; Ski, Yan; Simsir, Aylin; Sun, Wei] NYU, Langone Med Ctr, Dept Pathol, 560 First Ave,Tisch 451, New York, NY 10016 USA	Brandler, TC (reprint author), NYU, Langone Med Ctr, Dept Pathol, 560 First Ave,Tisch 451, New York, NY 10016 USA.	Tamar.brandler@nyumc.org		Shi, Yan/0000-0003-4580-7556; Liu, Cheng/0000-0002-2219-1018; Zhou, Fang/0000-0002-5542-2994			Agrawal N, 2017, ENDOCR PRACT, V23, P451, DOI 10.4158/EP161632.OR; Agrawal N, 2014, CELL, V159, P676, DOI 10.1016/j.cell.2014.09.050; Baloch ZW, 2016, CANCER CYTOPATHOL, V124, P616, DOI 10.1002/cncy.21744; Bizzarro T, 2016, CANCER CYTOPATHOL, V124, P699, DOI 10.1002/cncy.21777; Borrelli N, 2017, MODERN PATHOL, V30, P39, DOI [10.1038/nnodpathol.2016.157, 10.1038/modpathol.2016.157]; Brandler TC, 2018, DIAGN CYTOPATHOL, V46, P139, DOI 10.1002/dc.23863; Brandler TC, 2017, CANCER CYTOPATHOL, V125, P378, DOI 10.1002/cncy.21848; Chandler JB, 2017, CANCER CYTOPATHOL, V125, P865, DOI 10.1002/cncy.21910; Cho U, 2017, MODERN PATHOL, V30, P810, DOI 10.1038/modpathol.2017.9; Fu GD, 2017, EBIOMEDICINE, V18, P50, DOI 10.1016/j.ebiom.2017.03.031; Ganly I, 2015, HUM PATHOL, V46, P657, DOI 10.1016/j.humpath.2015.01.010; Ghossein R, 2009, ARCH PATHOL LAB MED, V133, P683, DOI 10.1043/1543-2165-133.5.683; Giannini R, 2017, THYROID, V27, P1267, DOI 10.1089/thy.2016.0605; Hahn SY, 2017, CLIN ENDOCRINOL, V86, P113, DOI 10.1111/cen.13144; Hang JF, 2017, CANCER CYTOPATHOL, V125, P683, DOI 10.1002/cncy.21879; Howitt BE, 2015, AM J CLIN PATHOL, V144, P850, DOI 10.1309/AJCPEIE12POICULI; Howitt BE, 2015, HISTOPATHOLOGY, V67, P579, DOI 10.1111/his.12680; Ibrahim AA, 2016, AM J CLIN PATHOL, V146, P373, DOI [10.1093/AJCP/AQW126, 10.1093/ajcp/aqw126]; Jaconi M, 2017, CYTOPATHOLOGY, V28, P495, DOI 10.1111/cyt.12459; Jang EK, 2015, CLIN ENDOCRINOL, V83, P968, DOI 10.1111/cen.12674; Jiang XY, 2016, CANCER CYTOPATHOL, V124, P893, DOI 10.1002/cncy.21802; Kakudo K, 2018, PATHOL INT, V68, P327, DOI 10.1111/pin.12673; Kim TH, 2018, HISTOPATHOLOGY, V72, P648, DOI 10.1111/his.13401; Lee SE, 2017, THYROID, V27, P802, DOI 10.1089/thy.2016.0547; Liu J, 2006, CANCER-AM CANCER SOC, V107, P1255, DOI 10.1002/cncr.22138; Maletta F, 2016, HUM PATHOL, V54, P134, DOI 10.1016/j.humpath.2016.03.014; Medici M, 2015, BMC MED, V13, DOI 10.1186/s12916-015-0419-z; Mehrzad R, 2016, SURGERY, V159, P1396, DOI 10.1016/j.surg.2015.11.026; Nikiforov YE, 2017, ENDOCR PRACT, V23, P979, DOI 10.4158/EP171805.RA; Nikiforov YE, 2016, JAMA ONCOL, V2, P1023, DOI 10.1001/jamaoncol.2016.0386; Ohori NP, 2017, CANCER CYTOPATHOL, V125, P692, DOI 10.1002/cncy.21892; Paulson VA, 2017, THYROID, V27, P506, DOI 10.1089/thy.2016.0583; Rivera M, 2010, MODERN PATHOL, V23, P1191, DOI 10.1038/modpathol.2010.112; Rivera M, 2009, THYROID, V19, P119, DOI 10.1089/thy.2008.0303; Rosario PW, 2017, ENDOCR PATHOL, V28, P367, DOI 10.1007/s12022-017-9493-4; Rosario PW, 2015, ARCH ENDOCRIN METAB, V59, P79, DOI 10.1590/2359-3997000000014; Song SJ, 2017, CYTOPATHOLOGY, V28, P488, DOI 10.1111/cyt.12501; Strickland KC, 2016, THYROID, V26, P1466, DOI 10.1089/thy.2016.0280; Thompson LDR, 2016, MODERN PATHOL, V29, P698, DOI 10.1038/modpathol.2016.65; Valderrabano P, 2017, ENDOCR-RELAT CANCER, V24, P127, DOI 10.1530/ERC-16-0512; Vivero M, 2013, THYROID, V23, P273, DOI 10.1089/thy.2012.0369; Xu B, 2017, THYROID, V27, P512, DOI 10.1089/thy.2016.0649; Zhao LN, 2017, CANCER CYTOPATHOL, V125, P323, DOI 10.1002/cncy.21839	43	6	6	0	1	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0002-9173	1943-7722		AM J CLIN PATHOL	Am. J. Clin. Pathol.	NOV	2018	150	5					451	460		10.1093/AJCP/AQY075			10	Pathology	Pathology	GV4PB	WOS:000446081500009	30052723				2019-10-28	
J	Klairmont, MM; Hoskoppal, D; Yadak, N; Choi, JK				Klairmont, Matthew M.; Hoskoppal, Deepthi; Yadak, Nour; Choi, John Kim			The Comparative Sensitivity of Immunohistochemical Markers of Megakaryocytic Differentiation in Acute Megakaryoblastic Leukemia	AMERICAN JOURNAL OF CLINICAL PATHOLOGY			English	Article						Acute megakaryoblastic leukemia; AMKL; CD42b; CD61; von Willebrand factor; vWF; Factor VIII	EXPRESSION; DISTINCT	Objectives: Immunohistochemistry ( IHC) staining of core biopsy sections often plays an essential role in the diagnosis of acute megakaryoblastic leukemia ( AMKL). The goal of this study was to define the relative sensitivities of commonly used stains for markers of megakaryocytic differentiation. Methods: The sensitivities of IHC stains for CD42b, CD61, and von Willebrand factor (vWF) were compared in 32 cases of pediatric AMKL. Results: The sensitivities of CD42b, CD61, and vWF were 90.6%, 78.1% and 62.5%, respectively. When CD42b and CD61 were used together, the combined sensitivity increased to 93.6%. There were no cases in which vWF was positive when both CD42b and CD61 were negative. Conclusions: CD42b can reliably be used as a solitary first-line marker for blasts of megakaryocytic lineage, whereas CD61 may be reserved for infrequent cases that are CD42b negative. There is no role for the routine use of vWF when CD42b and CD61 are available.	[Klairmont, Matthew M.; Hoskoppal, Deepthi; Yadak, Nour] Univ Tennessee, Hlth Sci Ctr, Dept Pathol, Memphis, TN USA; [Choi, John Kim] St Jude Childrens Res Hosp, Dept Pathol, MS 250,262 Danny Thomas Pl, Memphis, TN 38105 USA	Choi, JK (reprint author), St Jude Childrens Res Hosp, Dept Pathol, MS 250,262 Danny Thomas Pl, Memphis, TN 38105 USA.	johnkim.choi@stjude.org		Klairmont, Matthew/0000-0002-4463-0835			Athale UH, 2001, BLOOD, V97, P3727, DOI 10.1182/blood.V97.12.3727; BENNETT JM, 1985, ANN INTERN MED, V103, P460, DOI 10.7326/0003-4819-103-3-460; BETZ SA, 1992, BLOOD, V79, P2399; de Rooij JDE, 2017, NAT GENET, V49, P451, DOI 10.1038/ng.3772; Kafer G, 1999, ANN HEMATOL, V78, P472, DOI 10.1007/s002770050601; Lam G, PEDIAT BLOOD CANC; Metrock LK, PEDIAT BLOOD CANC; Oki Y, 2006, BLOOD, V107, P880, DOI 10.1182/blood-2005-06-2450; Orazi A, 2005, MODERN PATHOL, V18, P603, DOI 10.1038/modpathol.3800348; Schweitzer J, 2015, ANN HEMATOL, V94, P1327, DOI 10.1007/s00277-015-2383-2; Swerdlow SH, 2017, WHO CLASSIFICATION T	11	1	1	0	0	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0002-9173	1943-7722		AM J CLIN PATHOL	Am. J. Clin. Pathol.	NOV	2018	150	5					461	467		10.1093/AJCP/AQY074			7	Pathology	Pathology	GV4PB	WOS:000446081500010	30052718				2019-10-28	
J	Dao, DT; Anez-Bustillos, L; Adam, RM; Puder, M; Bielenberg, DR				Dao, Duy T.; Anez-Bustillos, Lorenzo; Adam, Rosalyn M.; Puder, Mark; Bielenberg, Diane R.			Heparin-Binding Epidermal Growth Factor-Like Growth Factor as a Critical Mediator of Tissue Repair and Regeneration	AMERICAN JOURNAL OF PATHOLOGY			English	Review							SMOOTH-MUSCLE-CELLS; FACTOR HB-EGF; TYMPANIC MEMBRANE PERFORATIONS; CORNEAL EPITHELIAL-CELLS; FOCAL CEREBRAL-ISCHEMIA; INDUCED LIVER-INJURY; FACTOR RECEPTOR; NECROTIZING ENTEROCOLITIS; KERATINOCYTE MIGRATION; IN-VITRO	Heparin-binding epidermal growth factor-like growth factor (HB-EGF) is a member of the EGF family. It contains an EGF-like domain as well as a heparin-binding domain that allows for interactions with heparin and cell-surface heparan sulfate. Soluble mature HB-EGF, a ligand of human epidermal growth factor receptors 1 and 4, is cleaved from the membrane-associated pro-HB-EGF by matrix metalloproteinase or a disintegrin and metalloproteinase in a process called ectodomain shedding. Signaling through human epidermal growth factor receptors 1 and 4 results in a variety of effects, including cellular proliferation, migration, adhesion, and differentiation. HB-EGF levels increase in response to different forms of injuries as well as stimuli, such as lysophosphatidic acid, retinoic acid, and 17 beta-estradiol. Because it is widely expressed in many organs, HB-EGF plays a critical role in tissue repair and regeneration throughout the body. It promotes cutaneous wound healing, hepatocyte proliferation after partial hepatectomy, intestinal anastomosis strength, alveolar regeneration after pneumonectomy, neurogenesis after ischemic injury, bladder wall thickening in response to urinary tract obstruction, and protection against ischemia/reperfusion injury to many cell types. Additionally, innovative strategies to deliver HB-EGF to sites of organ injury or to increase the endogenous levels of shed HB-EGF have been attempted with promising results. Harnessing the reparatory properties of HB-EGF in the clinical setting, therefore, may produce therapies that augment the treatment of various organ injuries.	[Dao, Duy T.; Anez-Bustillos, Lorenzo; Adam, Rosalyn M.; Puder, Mark; Bielenberg, Diane R.] Harvard Med Sch, Boston Childrens Hosp, Dept Surg, Boston, MA USA; [Dao, Duy T.; Anez-Bustillos, Lorenzo; Adam, Rosalyn M.; Puder, Mark; Bielenberg, Diane R.] Harvard Med Sch, Boston Childrens Hosp, Vasc Biol Program, Boston, MA USA; [Adam, Rosalyn M.] Harvard Med Sch, Boston Childrens Hosp, Urol Dis Res Ctr, Boston, MA USA	Bielenberg, DR (reprint author), Boston Childrens Hosp, Vasc Biol Program, 300 Longwood Ave, Boston, MA 02115 USA.	diane.bielenberg@childrens.harvard.edu		Dao, Duy/0000-0001-9915-7080	Boston Children's Hospital Surgical Foundation; Vascular Biology Program at Boston Children's Hospital; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [T32HL007734, R01DK104641]	Supported by the Boston Children's Hospital Surgical Foundation (M.P.), the Vascular Biology Program at Boston Children's Hospital (D.R.B.), and NIH grants T32HL007734 (D.T.D.) and R01DK104641 (R.M.A. and D.R.B.).	Allahverdian S, 2008, AM J RESP CELL MOL, V38, P153, DOI 10.1165/rcmb.2007-0173OC; Borer JG, 1999, LAB INVEST, V79, P1335; Boucher I, 2007, EXP EYE RES, V85, P130, DOI 10.1016/j.exer.2007.03.009; Cribbs RK, 2002, J BURN CARE REHABIL, V23, P116, DOI 10.1097/00004630-200203000-00008; Cribbs RK, 1998, J BURN CARE REHABIL, V19, P95, DOI 10.1097/00004630-199803000-00002; Daher A, 2003, LAB INVEST, V83, P1333, DOI 10.1097/01.LAB.0000086380.23263.52; Dao DT, 2018, PLOS ONE, V13, DOI [10.1371//journal.pone.0198700, 10.1371/journal.pone.0198700]; Ding BS, 2011, CELL, V147, P539, DOI 10.1016/j.cell.2011.10.003; Eguchi S, 1998, J BIOL CHEM, V273, P8890, DOI 10.1074/jbc.273.15.8890; El-Assal ON, 2005, GASTROENTEROLOGY, V129, P609, DOI 10.1053/j.gastro.2005.05.054; Elenius K, 1997, EMBO J, V16, P1268, DOI 10.1093/emboj/16.6.1268; Feng JX, 2007, J PEDIATR SURG, V42, P214, DOI 10.1016/j.jpedsurg.2006.09.055; Feng Jiexiong, 2005, Semin Pediatr Surg, V14, P167, DOI 10.1053/j.sempedsurg.2005.05.005; Freeman MR, 1997, J CLIN INVEST, V99, P1028, DOI 10.1172/JCI119230; Friedman SL, 2008, GASTROENTEROLOGY, V134, P1655, DOI 10.1053/j.gastro.2008.03.003; Gechtman Z, 1999, J BIOL CHEM, V274, P28828, DOI 10.1074/jbc.274.40.28828; Grosfeld JL, 1998, J PEDIATR SURG, V33, P978; Harding PA, 1996, GENE, V169, P291, DOI 10.1016/0378-1119(95)00861-6; HIGASHIYAMA S, 1991, SCIENCE, V251, P936, DOI 10.1126/science.1840698; Hollborn M, 2006, CURR EYE RES, V31, P863, DOI 10.1080/02713680600888807; HOMMA T, 1995, J CLIN INVEST, V96, P1018, DOI 10.1172/JCI118087; Hung KW, 2014, BIOCHEMISTRY-US, V53, P1935, DOI 10.1021/bi5003019; Hyder A, 2012, CELL COMMUN SIGNAL, V10, DOI 10.1186/1478-811X-10-23; Ito J, 2011, BIOCHEM BIOPH RES CO, V412, P109, DOI 10.1016/j.bbrc.2011.07.054; ITO N, 1994, BIOCHEM BIOPH RES CO, V198, P25, DOI 10.1006/bbrc.1994.1004; Iwamoto R, 2003, P NATL ACAD SCI USA, V100, P3221, DOI 10.1073/pnas.0537588100; Izumi Y, 1998, EMBO J, V17, P7260, DOI 10.1093/emboj/17.24.7260; Jin KL, 2004, J CEREBR BLOOD F MET, V24, P399, DOI 10.1097/01.WCB.0000110763.10146.EE; Jin KL, 2003, ANN NEUROL, V53, P405, DOI 10.1002/ana.10506; Johnson NR, 2015, WOUND REPAIR REGEN, V23, P591, DOI 10.1111/wrr.12319; Kajiya M, 2010, J ENDODONT, V36, P1009, DOI 10.1016/j.joen.2010.02.028; Kanda N, 2005, AM J PHYSIOL-CELL PH, V288, pC813, DOI 10.1152/ajpcell.00483.2004; Kaya G, 2006, PLOS MED, V3, P2291, DOI 10.1371/journal.pmed.0030493; Khai NC, 2006, J HEPATOL, V44, P1046, DOI 10.1016/j.jhep.2005.10.027; Kim JM, 2011, ORAL DIS, V17, P785, DOI 10.1111/j.1601-0825.2011.01836.x; Kinugasa Y, 2007, J BIOL CHEM, V282, P14797, DOI 10.1074/jbc.M611036200; Kirkland G, 1998, J AM SOC NEPHROL, V9, P1464; Kiso S, 1996, BIOCHEM BIOPH RES CO, V220, P285, DOI 10.1006/bbrc.1996.0397; Kiso S, 2003, GASTROENTEROLOGY, V124, P701, DOI 10.1053/gast.2003.50097; KISO S, 1995, HEPATOLOGY, V22, P1584, DOI 10.1002/hep.1840220535; Komurasaki T, 2002, GROWTH FACTORS, V20, P61, DOI 10.1080/08977190290024192; Lee JS, 2009, J PERIODONTAL RES, V44, P52, DOI 10.1111/j.1600-0765.2007.01062.x; Li DQ, 2015, J CLIN INVEST, V125, P3008, DOI 10.1172/JCI79052; Liu JH, 2003, AM J PHYSIOL-LUNG C, V285, pL1106, DOI 10.1152/ajplung.00180.2003; Maria PLS, 2017, TISSUE ENG PT A, V23, P436, DOI [10.1089/ten.TEA.2016.0395, 10.1089/ten.tea.2016.0395]; Maria PLS, 2015, OTOL NEUROTOL, V36, P1279, DOI 10.1097/MAO.0000000000000795; Maria PLS, 2015, TISSUE ENG PT A, V21, P1483, DOI [10.1089/ten.TEA.2014.0474, 10.1089/ten.tea.2014.0474]; Marikovsky M, 1996, J INVEST DERMATOL, V106, P616, DOI 10.1111/1523-1747.ep12345413; Mathay C, 2008, J INVEST DERMATOL, V128, P717, DOI 10.1038/sj.jid.5701069; McCarthy DW, 1996, J INVEST DERMATOL, V106, P49, DOI 10.1111/1523-1747.ep12327214; Mitchell C, 2005, J BIOL CHEM, V280, P2562, DOI 10.1074/jbc.M412372200; Miyazaki Y, 2001, GASTROENTEROLOGY, V120, P108, DOI 10.1053/gast.2001.20950; Monslow J, 2009, J INVEST DERMATOL, V129, P2046, DOI 10.1038/jid.2009.9; Murayama Y, 2002, INT J CANCER, V98, P505, DOI 10.1002/ijc.10198; Nanba D, 2003, J CELL BIOL, V163, P489, DOI 10.1083/jcb.200303017; Nishi E, 2004, GROWTH FACTORS, V22, P253, DOI 10.1080/08977190400008448; Okwueze MI, 2007, J INVEST DERMATOL, V127, P1030, DOI 10.1038/sj.jid.5700637; Oyagi A, 2011, NEUROSCIENCE, V185, P116, DOI 10.1016/j.neuroscience.2011.04.034; Oyagi A, 2011, BRAIN RES, V1419, P97, DOI 10.1016/j.brainres.2011.09.003; Paria BC, 1999, DEVELOPMENT, V126, P1997; Park JM, 1999, AM J PHYSIOL-CELL PH, V277, pC294; Park JM, 1998, AM J PHYSIOL-CELL PH, V275, pC1247; Parnia S, 2014, RESP RES, V15, DOI 10.1186/1465-9921-15-22; Piao YS, 2005, NEUROSCI LETT, V390, P21, DOI 10.1016/j.neulet.2005.07.048; Piepkorn M, 2003, ARCH DERMATOL RES, V295, P93, DOI 10.1007/s00403-003-0391-x; Pillai SB, 1998, J PEDIATR SURG, V33, P973, DOI 10.1016/S0022-3468(98)90517-6; Prenzel N, 1999, NATURE, V402, P884; Prince RN, 2010, J CELL SCI, V123, P2308, DOI 10.1242/jcs.058321; Radulescu A, 2011, J SURG RES, V171, P540, DOI 10.1016/j.jss.2010.06.036; Radulescu A, 2010, J PEDIATR SURG, V45, P729, DOI 10.1016/j.jpedsurg.2009.06.035; Sakamoto K, 2016, INT J MOL MED, V38, P1673, DOI 10.3892/ijmm.2016.2784; Sakuma T, 1997, J BIOCHEM-TOKYO, V122, P474; Shiomi T, 2011, WOUND REPAIR REGEN, V19, P229, DOI 10.1111/j.1524-475X.2010.00655.x; Shirakata Y, 2005, J CELL SCI, V118, P2363, DOI 10.1242/jcs.02346; Stoll SW, 2012, J INVEST DERMATOL, V132, P2148, DOI 10.1038/jid.2012.78; Stoll SW, 1998, EXP DERMATOL, V7, P391, DOI 10.1111/j.1600-0625.1998.tb00339.x; Sugiura S, 2005, STROKE, V36, P859, DOI 10.1161/01.STR.0000158905.22871.95; Takemura T, 2013, HEPATOL RES, V43, P384, DOI 10.1111/j.1872-034X.2012.01074.x; Tammi RH, 2009, J INVEST DERMATOL, V129, P1858, DOI 10.1038/jid.2009.91; THOMPSON SA, 1994, J BIOL CHEM, V269, P2541; Tokumaru S, 2000, J CELL BIOL, V151, P209, DOI 10.1083/jcb.151.2.209; Tokumaru S, 2005, J IMMUNOL, V175, P4662, DOI 10.4049/jimmunol.175.7.4662; Tolino MA, 2011, BBA-GEN SUBJECTS, V1810, P875, DOI 10.1016/j.bbagen.2011.05.011; Umata Toshiyuki, 2014, J UOEH, V36, P105; Wei J, 2015, PEDIATR RES, V78, P29, DOI 10.1038/pr.2015.63; Xiao JH, 1999, EMBO J, V18, P1539, DOI 10.1093/emboj/18.6.1539; Xu KP, 2007, INVEST OPHTH VIS SCI, V48, P2242, DOI 10.1167/iovs.06-0560; Xu KP, 2007, INVEST OPHTH VIS SCI, V48, P636, DOI 10.1167/iovs.06-0203; Xu KP, 2006, INVEST OPHTH VIS SCI, V47, P2832, DOI 10.1167/iovs.05-1361; Xu KP, 2009, DIABETES, V58, P1077, DOI 10.2337/db08-0997; Xu KP, 2004, INVEST OPHTH VIS SCI, V45, P813, DOI 10.1167/iovs.03-0851; Yahata Y, 2006, J BIOL CHEM, V281, P13209, DOI 10.1074/jbc.M509771200; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; Yin J, 2009, INVEST OPHTH VIS SCI, V50, P132, DOI 10.1167/iovs.08-2246; Yin J, 2010, INVEST OPHTH VIS SCI, V51, P1891, DOI 10.1167/iovs.09-3904; Yoshioka R, 2010, INVEST OPHTH VIS SCI, V51, P5630, DOI 10.1167/iovs.10-5158; Yu XY, 2009, GASTROENTEROLOGY, V137, P221, DOI 10.1053/j.gastro.2009.03.060; Zhang D, 2014, J GASTROEN HEPATOL, V29, P623, DOI 10.1111/jgh.12412; Zhou B, 2015, J SURG RES, V197, P201, DOI 10.1016/j.jss.2015.03.081; Zhuang S, 2008, AM J PHYSIOL-RENAL, V294, pF459, DOI 10.1152/ajprenal.00473.2007; Zvibel I, 2013, CLIN EXP METASTAS, V30, P189, DOI 10.1007/s10585-012-9527-8	101	4	4	4	9	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	NOV	2018	188	11					2446	2456		10.1016/j.ajpath.2018.07.016			11	Pathology	Pathology	GZ0FK	WOS:000449036900001	30142332	Bronze			2019-10-28	
J	Sharma, S				Sharma, Surendra			Autophagy-Based Diagnosis of Pregnancy Hypertension and Pre-Eclampsia	AMERICAN JOURNAL OF PATHOLOGY			English	Editorial Material							DISEASE; RISK		[Sharma, Surendra] Brown Univ, Women & Infants Hosp, Dept Pediat, Warren Alpert Med Sch, Providence, RI 02908 USA	Sharma, S (reprint author), Women & Infants Hosp Rhode Isl, Dept Pediat, 101 Dudley St, Providence, RI 02905 USA.	ssharma@wihri.org			NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [P20 GM121298]	Supported in part by the NIH Research Grant P20 GM121298.	Aoki A, 2018, AM J PATHOL, V188, P2474, DOI 10.1016/j.ajpath.2018.07.021; Buhimschi IA, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3008808; Burton GJ, 2011, PREGNANCY HYPERTENS, V1, P72, DOI 10.1016/j.preghy.2010.12.002; Cao B, 2017, J EXP MED, V214, P2303, DOI 10.1084/jem.20170957; Cheng SB, 2016, SEMIN IMMUNOPATHOL, V38, P699, DOI 10.1007/s00281-016-0579-8; Delorme-Axford E, 2013, P NATL ACAD SCI USA, V110, P12048, DOI 10.1073/pnas.1304718110; Gao L, 2015, J HYPERTENS, V33, P106, DOI 10.1097/HJH.0000000000000366; Hung TH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0083475; Kalkunte S, 2010, AM J PATHOL, V177, P2387, DOI 10.2353/ajpath.2010.100475; Kalkunte SS, 2013, AM J PATHOL, V183, P1425, DOI 10.1016/j.ajpath.2013.07.022; Komatsu M, 2007, CELL, V131, P1149, DOI 10.1016/j.cell.2007.10.035; Komatsu M, 2007, P NATL ACAD SCI USA, V104, P14489, DOI 10.1073/pnas.0701311104; Levine RJ, 2004, NEW ENGL J MED, V350, P672, DOI 10.1056/NEJMoa031884; McCarthy FP, 2016, AM J OBSTET GYNECOL, V215, DOI 10.1016/j.ajog.2016.04.041; Melland-Smith M, 2015, AUTOPHAGY, V11, P653, DOI 10.1080/15548627.2015.1034414; Mizushima N, 2008, NATURE, V451, P1069, DOI 10.1038/nature06639; Nakatogawa H, 2009, NAT REV MOL CELL BIO, V10, P458, DOI 10.1038/nrm2708; Ohsumi Y, 2014, CELL RES, V24, P9, DOI 10.1038/cr.2013.169; Redman CWG, 1999, AM J OBSTET GYNECOL, V180, P499, DOI 10.1016/S0002-9378(99)70239-5; Roberts JM, 1999, LANCET, V354, P788, DOI 10.1016/S0140-6736(99)80002-6; Sibai B, 2005, LANCET, V365, P785, DOI 10.1016/S0140-6736(05)17987-2; Smith GCS, 2001, LANCET, V357, P2002, DOI 10.1016/S0140-6736(00)05112-6; TONG M, 2017, SCI REP UK, V7; Vikse BE, 2008, NEW ENGL J MED, V359, P800, DOI 10.1056/NEJMoa0706790; Wildman K, 2004, BJOG-INT J OBSTET GY, V111, P164, DOI 10.1046/j.1471-0528.2003.00043.x; Yamaguchi J, 2018, AUTOPHAGY, V14, P764, DOI 10.1080/15548627.2017.1314897	26	0	0	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	NOV	2018	188	11					2457	2460		10.1016/j.ajpath.2018.09.001			4	Pathology	Pathology	GZ0FK	WOS:000449036900002	30240596				2019-10-28	
J	Aoki, A; Nakashima, A; Kusabiraki, T; Ono, Y; Yoshino, O; Muto, M; Kumasawa, K; Yoshimori, T; Ikawa, M; Saito, S				Aoki, Aiko; Nakashima, Akitoshi; Kusabiraki, Tae; Ono, Yosuke; Yoshino, Osamu; Muto, Masanaga; Kumasawa, Keiichi; Yoshimori, Tamotsu; Ikawa, Masahito; Saito, Shigeru			Trophoblast-Specific Conditional Atg7 Knockout Mice Develop Gestational Hypertension	AMERICAN JOURNAL OF PATHOLOGY			English	Article							SOLUBLE ENDOGLIN; AUTOPHAGY REGULATION; PLACENTAL AUTOPHAGY; EXCESSIVE AUTOPHAGY; MOUSE MODEL; PREECLAMPSIA; CELLS; PATHOGENESIS; FETAL; APG7P/CVT2P	Hypertensive disorder of pregnancy (HDP) is a serious pregnancy complication that is life threatening to both the mother and fetus. Understanding HDP pathophysiology is important for developing medical treatments. This study demonstrates the involvement of autophagy deficiency in adverse maternal and fetal outcomes using trophoblast-specific autophagy related (Atg)7, an autophagy-related protein, knockout mice. Atg7 conditional knockout (cKO) placentas were significantly smaller than controls in the spongiotrophoblast layer but not the labyrinth layer, which significantly elevated blood pressure in dams. A marker of autophagy deficiency, sequestosome 1/p62, was accumulated in giant trophoblast cells and in the spongiotrophoblast layer, accompanying increased apoptosis. However, neither proteinuria in dams nor fetal growth restriction was observed. Regarding trophoblast function, the number of trophoblasts migrating into the maternal decidua was significantly reduced, and the wall/lumen ratio of the spiral arteries was significantly increased in cKO placentas, suggesting shallow trophoblast invasion and inadequate vascular remodeling. The relative expression of placental growth factor mRNA was significantly decreased in cKO placentas compared with the control, likely causing poor placentation; however, other factors were unchanged in cKO placentas. This is the first report of autophagy deficiency leading to impaired placentation complicated by maternal HDP attributable to trophoblast dysfunction, and it suggests that placental autophagy is required for normal placentation.	[Aoki, Aiko; Nakashima, Akitoshi; Kusabiraki, Tae; Ono, Yosuke; Yoshino, Osamu; Saito, Shigeru] Univ Toyama, Dept Obstet & Gynecol, Toyama, Japan; [Aoki, Aiko; Muto, Masanaga; Ikawa, Masahito] Osaka Univ, Res Inst Microbial Dis, Suita, Osaka, Japan; [Aoki, Aiko; Yoshimori, Tamotsu] Osaka Univ, Dept Genet, Grad Sch Med, Suita, Osaka, Japan; [Muto, Masanaga] Osaka Univ, Grad Sch Pharmaceut Sci, Suita, Osaka, Japan; [Kumasawa, Keiichi] Osaka Univ, Dept Obstet & Gynecol, Suita, Osaka, Japan	Saito, S (reprint author), 2630 Sugitani, Toyama 9300194, Japan.	s30saito@med.u-toyama.ac.jp	ikawa, masahito/A-5315-2009	ikawa, masahito/0000-0001-9859-6217	Japan Agency for Medical Research and Development (AMED)Japan Agency for Medical Research and Development (AMED) [16gk0110018h0001]; Kanzawa Medical Research Foundation grant; Tamura Science and Technology Foundation grant; Yamaguchi Endocrine Research Foundation grant; First Bank of Toyama Scholarship Foundation grant; Ministry of Education, Culture, Sports, Science and Technology, Japan grant [15H04980, 16K11082, 17K11221]	Supported by the Japan Agency for Medical Research and Development (AMED) grant 16gk0110018h0001, a Kanzawa Medical Research Foundation grant, a Tamura Science and Technology Foundation grant, a Yamaguchi Endocrine Research Foundation grant, a First Bank of Toyama Scholarship Foundation grant, and Ministry of Education, Culture, Sports, Science and Technology, Japan, grants 15H04980, 16K11082, and 17K11221.	Arikawa T, 2016, SCI REP-UK, V6, DOI 10.1038/srep32248; BARKER DJP, 1990, BRIT MED J, V301, P259, DOI 10.1136/bmj.301.6746.259; Benyo DF, 2001, J CLIN ENDOCR METAB, V86, P2505, DOI 10.1210/jc.86.6.2505; BONDS DR, 1984, AM J OBSTET GYNECOL, V149, P195, DOI 10.1016/0002-9378(84)90198-4; Cao B, 2016, JCI INSIGHT, V1, DOI 10.1172/jci.insight.86654; Croy BA, 2011, PREGNANCY HYPERTENS, V1, P87, DOI 10.1016/j.preghy.2010.10.002; Du JH, 2012, AM J PHYSIOL-CELL PH, V302, pC383, DOI 10.1152/ajpcell.00164.2011; FARIA TN, 1991, ENDOCRINOLOGY, V129, P2895, DOI 10.1210/endo-129-6-2895; Fujita N, 2008, MOL BIOL CELL, V19, P4651, DOI 10.1091/mbc.E08-03-0312; Gao L, 2015, J HYPERTENS, V33, P106, DOI 10.1097/HJH.0000000000000366; Guo XL, 2013, J MOL MED, V91, P473, DOI 10.1007/s00109-012-0966-0; Hara T, 2006, NATURE, V441, P885, DOI 10.1038/nature04724; Hung TH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0083475; Kalkat M, 2013, AUTOPHAGY, V9, P2140, DOI 10.4161/auto.26452; Kanasaki K, 2008, NATURE, V453, P1117, DOI 10.1038/nature06951; Kim J, 1999, MOL BIOL CELL, V10, P1337, DOI 10.1091/mbc.10.5.1337; Komatsu M, 2005, J CELL BIOL, V169, P425, DOI 10.1083/jcb.200412022; Komatsu M, 2006, NATURE, V441, P880, DOI 10.1038/nature04723; Kuma A, 2004, NATURE, V432, P1032, DOI 10.1038/nature03029; Kumasawa K, 2011, P NATL ACAD SCI USA, V108, P1451, DOI 10.1073/pnas.1011293108; Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018; Levine RJ, 2006, NEW ENGL J MED, V355, P992, DOI 10.1056/NEJMoa055352; Levine RJ, 2004, NEW ENGL J MED, V350, P672, DOI 10.1056/NEJMoa031884; Maynard SE, 2003, J CLIN INVEST, V111, P649, DOI 10.1172/JCI200317189; Melland-Smith M, 2015, AUTOPHAGY, V11, P653, DOI 10.1080/15548627.2015.1034414; Mizushima N, 2011, CELL, V147, P728, DOI 10.1016/j.cell.2011.10.026; Mizushima N, 2010, CELL, V140, P313, DOI 10.1016/j.cell.2010.01.028; Morioka Y, 2009, GENESIS, V47, P793, DOI 10.1002/dvg.20563; Muralimanoharan S, 2016, AUTOPHAGY, V12, P752, DOI 10.1080/15548627.2016.1156822; Nakagawa I, 2004, SCIENCE, V306, P1037, DOI 10.1126/science.1103966; Nakashima A, 2008, AM J PATHOL, V173, P653, DOI 10.2353/ajpath.2008.071169; Nakashima A, 2017, J REPROD IMMUNOL, V123, P17, DOI 10.1016/j.jri.2017.08.006; Nakashima A, 2017, J OBSTET GYNAECOL RE, V43, P633, DOI 10.1111/jog.13292; Nakashima A, 2013, AUTOPHAGY, V9, P303, DOI 10.4161/auto.22927; Okada Y, 2007, NAT BIOTECHNOL, V25, P233, DOI 10.1038/nbt1280; Pan TY, 2017, ONCOTARGET, V8, P89824, DOI 10.18632/oncotarget.21158; Redman CWG, 2010, AM J REPROD IMMUNOL, V63, P534, DOI 10.1111/j.1600-0897.2010.00831.x; Saito S, 2013, PLACENTA, V34, pS79, DOI 10.1016/j.placenta.2012.11.026; Saito S, 2014, J REPROD IMMUNOL, V101, P80, DOI 10.1016/j.jri.2013.06.002; Selvakumaran M, 2013, CLIN CANCER RES, V19, P2995, DOI 10.1158/1078-0432.CCR-12-1542; Steegers EAP, 2010, LANCET, V376, P631, DOI 10.1016/S0140-6736(10)60279-6; Tanaka S, 2016, HEPATOLOGY, V64, P1994, DOI 10.1002/hep.28820; Tanida I, 1999, MOL BIOL CELL, V10, P1367, DOI 10.1091/mbc.10.5.1367; Venkatesha S, 2006, NAT MED, V12, P642, DOI 10.1038/nm1429; Walker JJ, 1998, SEMIN REPROD ENDOCR, V16, P47, DOI 10.1055/s-2007-1016252; Yamanaka-Tatematsu M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076605; Yoshino O, 2004, AM J REPROD IMMUNOL, V52, P306, DOI 10.1111/j.1600-0897.2004.00231.x; Yoshino O, 2011, FERTIL STERIL, V96, P118, DOI 10.1016/j.fertnstert.2011.05.006; Yosuke O, 2018, SCI REP, V8, P8171	49	6	6	3	7	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	NOV	2018	188	11					2474	2486		10.1016/j.ajpath.2018.07.021			13	Pathology	Pathology	GZ0FK	WOS:000449036900005	30165042				2019-10-28	
J	Feng, Y; Lv, LL; Wu, WJ; Li, ZL; Chen, J; Ni, HF; Zhou, LT; Tang, TT; Wang, FM; Wang, B; Chen, PS; Crowley, SD; Liu, BC				Feng, Ye; Lv, Lin-Li; Wu, Wei-Jun; Li, Zuo-Lin; Chen, Jun; Ni, Hai-Feng; Zhou, Le-Ting; Tang, Tao-Tao; Wang, Feng-Mei; Wang, Bin; Chen, Ping-Sheng; Crowley, Steven D.; Liu, Bi-Cheng			Urinary Exosomes and Exosomal CCL2 mRNA as Biomarkers of Active Histologic Injury in IgA Nephropathy	AMERICAN JOURNAL OF PATHOLOGY			English	Article							CHRONIC KIDNEY-DISEASE; TUBULOINTERSTITIAL INFLAMMATION; RENAL FIBROSIS; ALBUMIN; IDENTIFICATION; PROGRESSION; SEVERITY; CELLS	IgA nephropathy (IgAN) features variable renal pathology and a heterogeneous clinical course. Our aim was to search noninvasive biomarkers from urinary exosomes for IgAN patients; membrane nephropathy and minimal change disease were included as other glomerulopathy controls. Transmission electron microscopy and nanoparticle tracking analysis confirmed the size and morphology characteristic of urinary exosomes. Exosome markers (Alix and CD63) as well as renal cell. markers [aquaporin 2 (AQP2) and nephrin] were detected, which indicate the renal origin of urinary exosomes. Exosome excretion was increased markedly in IgAN patients compared with controls and correlated with levels of proteinuria and tubular injury. More important, urinary exosome excretion correlated with greater histologic activity (mesangial hypercellularity, crescents, and endocapillary hypercellularity). Profiling of the inflammation-related mRNA revealed that exosomal chemokine (C-C motif) ligand 2 (CCL2) was up regulated in IgAN patients. In a validation study, CCL2 was exclusively highly expressed in IgAN patients compared with healthy controls as well as minimal change disease and membrane nephropathy patients. Also, a correlation between exosomal CCL2 and estimated glomerular filtration rate levels was found in IgAN. Exosomal CCL2 was correlated with tubulointerstitial inflammation and C3 deposition. High CCL2 levels at the time of renal biopsy were associated with subsequent deterioration in renal function. Thus, urinary exosomes and exosomal CCL2 mRNA are promising biomarkers reflecting active renal histologic injury and renal function deterioration in IgAN.	[Feng, Ye; Lv, Lin-Li; Wu, Wei-Jun; Li, Zuo-Lin; Chen, Jun; Ni, Hai-Feng; Zhou, Le-Ting; Tang, Tao-Tao; Wang, Feng-Mei; Wang, Bin; Chen, Ping-Sheng; Liu, Bi-Cheng] Southeast Univ, Sch Med, Inst Nephrol, Zhongda Hosp, 87 Ding Jia Qiao Rd, Nanjing, Jiangsu, Peoples R China; [Crowley, Steven D.] Duke Univ, Durham VA Med Ctr, Dept Med, Durham, NC USA	Lv, LL; Liu, BC (reprint author), Southeast Univ, Sch Med, Inst Nephrol, Zhongda Hosp, 87 Ding Jia Qiao Rd, Nanjing, Jiangsu, Peoples R China.	lvlinli@seu.edu.cn; liubc64@163.com			National Natural Scientific FoundationNational Natural Science Foundation of China [81470922, 31671194, 81720108007, 81670696]; Clinic Research Center of Jiangsu Province grant [BL2014080]; Jiangsu Province Medical Youth Talent grant [QNRC2016818]	Supported by National Natural Scientific Foundation grants 81470922 (L.-L.L.), 31671194 (L.-L.L.), 81720108007 (B.-C.L.), and 81670696 (B.-C.L.), Clinic Research Center of Jiangsu Province grant BL2014080 (B.-C.L.), and Jiangsu Province Medical Youth Talent grant QNRC2016818 (L.-L.L.).	Berthelot L, 2015, KIDNEY INT, V88, P815, DOI 10.1038/ki.2015.158; Coppo R, 2017, J AM SOC NEPHROL, V28, P2831, DOI 10.1681/ASN.2017060639; de Jong OG, 2012, J EXTRACELL VESICLES, V1, DOI 10.3402/jev.v1i0.18396; Eardley KS, 2006, KIDNEY INT, V69, P1189, DOI 10.1038/sj.ki.5000212; Eissa S, 2016, J DIABETES COMPLICAT, V30, P1585, DOI 10.1016/j.jdiacomp.2016.07.012; Freese P, 1998, NEPHRON, V79, P420, DOI 10.1159/000045087; Hurley JH, 2012, NAT CELL BIOL, V14, P654, DOI 10.1038/ncb2530; Khurana R, 2017, RNA, V23, P142, DOI 10.1261/rna.058834.116; Li L, 2016, CANCER RES, V76, P1770, DOI 10.1158/0008-5472.CAN-15-1625; Liu D, 2015, J BIOL CHEM, V290, P18018, DOI 10.1074/jbc.M115.662064; Lv LL, 2018, J AM SOC NEPHROL, V29, P919, DOI 10.1681/ASN.2017050523; Lv LL, 2014, CLIN CHIM ACTA, V428, P26, DOI 10.1016/j.cca.2013.10.003; Lv LL, 2013, AM J PHYSIOL-RENAL, V305, pF1220, DOI 10.1152/ajprenal.00148.2013; Mohan A, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0154055; Myllymaki J, 2005, NEPHROL DIAL TRANSPL, V20, P89, DOI 10.1093/ndt/gfh584; Myllymaki JM, 2007, KIDNEY INT, V71, P343, DOI 10.1038/sj.ki.5002046; Pisitkun T, 2004, P NATL ACAD SCI USA, V101, P13368, DOI 10.1073/pnas.0403453101; Roberts ISD, 2014, NAT REV NEPHROL, V10, P445, DOI 10.1038/nrneph.2014.92; Serino G, 2016, KIDNEY INT, V89, P683, DOI 10.1038/ki.2015.333; Sole C, 2015, NEPHROL DIAL TRANSPL, V30, P1488, DOI 10.1093/ndt/gfv128; Thery C, 2002, NAT REV IMMUNOL, V2, P569, DOI 10.1038/nri855; Thomou T, 2017, NATURE, V542, P450, DOI 10.1038/nature21365; Tkach M, 2016, CELL, V164, P1226, DOI 10.1016/j.cell.2016.01.043; Torres DD, 2008, KIDNEY INT, V73, P327, DOI 10.1038/sj.ki.5002621; Trimarchi H, 2017, KIDNEY INT, V91, P1014, DOI 10.1016/j.kint.2017.02.003; Wei PZ, 2018, NEPHROL DIAL TRANSPL, V33, P784, DOI 10.1093/ndt/gfx339; Worawichawong S, 2016, KIDNEY BLOOD PRESS R, V41, P997, DOI 10.1159/000452595; Yeo SC, 2018, PEDIATR NEPHROL, V33, P763, DOI 10.1007/s00467-017-3699-z; Yokoyama H, 1998, J LEUKOCYTE BIOL, V63, P493; Zhao YF, 2016, CLIN J AM SOC NEPHRO, V11, P947, DOI 10.2215/CJN.10150915	30	5	7	5	22	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	NOV	2018	188	11					2542	2552		10.1016/j.ajpath.2018.07.017			11	Pathology	Pathology	GZ0FK	WOS:000449036900010	30142333				2019-10-28	
J	Roh, YS; Kim, JW; Park, S; Shon, C; Kim, S; Eo, SK; Kwon, JK; Lim, CW; Kim, B				Roh, Yoon Seok; Kim, Jong Won; Park, Surim; Shon, Changho; Kim, Sokho; Eo, Seong Kug; Kwon, Jung Kee; Lim, Chae Woong; Kim, Bumseok			Toll-Like Receptor-7 Signaling Promotes Nonalcoholic Steatohepatitis by Inhibiting Regulatory T Cells in Mice	AMERICAN JOURNAL OF PATHOLOGY			English	Article							INCREASED INTESTINAL PERMEABILITY; DEFICIENT DIETARY MODEL; LIVER-DISEASE; PATHOGENESIS; RECOGNITION; APOPTOSIS; DEPLETION; ALPHA; ROLES; TLR7	Toll-like receptor 7 (TLR7) signaling regulates the production of type 1 interferons (IFNs) and proinflammatory cytokines, such as tumor necrosis factor (INF)-alpha, implicated in the control of regulatory T (Treg) cell activity. However, the mechanistic interplay between TLR7 signaling and Treg cells in nonalcoholic steatohepatitis (NASH) has not been elucidated. Our aim was to clarify the role of TLR7 signaling in the pathogenesis of NASH. Steatohepatitis was induced in wild-type (WT), TLR7-deficient, IFN-alpha/beta receptor 1-deficient, and Treg cell-depleted mice. TLR7-deficient and IFN-alpha/beta receptor 1-deficient mice were more protective to steatohepatitis than WT mice. Of interest, both TNF-alpha and type 1 IFN promoted apoptosis of Treg cells involved in the prevention of NASH. Indeed, Treg cell-depleted mice had aggravated steatohepatitis compared with WT mice. Finally, treatment with immunoregulatory sequence 661, an antagonist of TLR7, efficiently ameliorated NASH in vivo. These results demonstrate that TLR7 signaling can induce INF-alpha production in Kupffer cells and type I IFN production in dendritic cells. These cytokines subsequently induce hepatocyte death and inhibit Treg cells activities, leading to the progression of NASH. Thus, manipulating the TLR7-Treg cell axis might be used as a novel therapeutic strategy to treat NASH.	[Roh, Yoon Seok; Shon, Changho] Chungbuk Natl Univ, Coll Pharm, Dept Pharm, Cheongju, Chungbuk, South Korea; [Roh, Yoon Seok; Shon, Changho] Chungbuk Natl Univ, Med Res Ctr, Cheongju, Chungbuk, South Korea; [Kim, Jong Won; Park, Surim; Kim, Sokho; Eo, Seong Kug; Kwon, Jung Kee; Lim, Chae Woong; Kim, Bumseok] Chonbuk Natl Univ, Biosafety Res Inst, Iksan, Jeonbuk, South Korea; [Kim, Jong Won; Park, Surim; Kim, Sokho; Eo, Seong Kug; Kwon, Jung Kee; Lim, Chae Woong; Kim, Bumseok] Chonbuk Natl Univ, Coll Vet Med, Plus Program BK21, Iksan, Jeonbuk, South Korea	Kim, B (reprint author), Chonbuk Natl Univ, Coll Vet Med, Lab Pathol, Iksan 54596, Jeonbuk, South Korea.	bskims@jbnu.ac.kr			Basic Science Research Program grant through the National Research Foundation - Ministry of Education, Republic of Korea [NRF-2017R1D1A3B03030521]; Ministry of Science and Information and Communications Technology grant [MRC 2017R1A5A2015541]; Ministry of Health and Welfare, Republic of KoreaMinistry of Health & Welfare, Republic of Korea [HI17C2262]	Supported by Basic Science Research Program grant NRF-2017R1D1A3B03030521 (B.K.) through the National Research Foundation funded by the Ministry of Education, Republic of Korea; Ministry of Science and Information and Communications Technology grant MRC 2017R1A5A2015541 (Y.S.R.); and Ministry of Health and Welfare, Republic of Korea grant HI17C2262 (Y.S.R.).	Akira S, 2004, NAT REV IMMUNOL, V4, P499, DOI 10.1038/nri1391; Alisi A, 2012, FRONT CELL INFECT MI, V2, DOI 10.3389/fcimb.2012.00132; [Anonymous], 2011, GUIDE CARE USE LAB A; Armstrong D., 1994, FREE RADIC BIOL MED, V366, P43; Barrat FJ, 2005, J EXP MED, V202, P1131, DOI 10.1084/jem.20050914; Bhattacharya A, 2015, IMMUNITY, V43, P974, DOI 10.1016/j.immuni.2015.10.013; Brun P, 2007, AM J PHYSIOL-GASTR L, V292, pG518, DOI 10.1152/ajpgi.00024.2006; Csak T, 2011, AM J PHYSIOL-GASTR L, V300, pG433, DOI 10.1152/ajpgi.00163.2009; Nguyen DX, 2016, J EXP MED, V213, P1241, DOI 10.1084/jem.20151255; Devey L, 2009, MOL THER, V17, P65, DOI 10.1038/mt.2008.237; Diehl AM, 2005, HEPATOL RES, V33, P138, DOI 10.1016/j.hepres.2005.09.022; Eberle F, 2009, EUR J IMMUNOL, V39, P2537, DOI 10.1002/eji.200838978; Farhadi A, 2008, LIVER INT, V28, P1026, DOI 10.1111/j.1478-3231.2008.01723.x; Gabele E, 2008, BIOCHEM BIOPH RES CO, V376, P271, DOI 10.1016/j.bbrc.2008.08.096; George J, 2008, MOL PHARMACEUT, V5, P49, DOI 10.1021/mp700110z; Guiducci C, 2010, J EXP MED, V207, P2931, DOI 10.1084/jem.20101048; Gupte AA, 2010, HEPATOLOGY, V52, P2001, DOI 10.1002/hep.23941; Hackl D, 2011, EUR J IMMUNOL, V41, P1334, DOI 10.1002/eji.201041014; HAN J, 1991, J IMMUNOL, V146, P1843; Hemmi H, 2002, NAT IMMUNOL, V3, P196, DOI 10.1038/ni758; Herrmann JL, 1997, EXP CELL RES, V237, P101, DOI 10.1006/excr.1997.3737; Kariko K, 2004, J BIOL CHEM, V279, P12542, DOI 10.1074/jbc.M310175200; Kawai T, 2009, INT IMMUNOL, V21, P317, DOI 10.1093/intimm/dxp017; Kim S, 2016, SCI REP-UK, V6, DOI 10.1038/srep27849; Kinoshita M, 2010, J HEPATOL, V53, P903, DOI 10.1016/j.jhep.2010.04.037; Kleiner DE, 2005, HEPATOLOGY, V41, P1313, DOI 10.1002/hep.20701; Lahl K, 2007, J EXP MED, V204, P57, DOI 10.1084/jem.20061852; Liu L, 2011, J LIPID RES, V52, P732, DOI 10.1194/jlr.M011395; Mancuso G, 2009, NAT IMMUNOL, V10, P587, DOI 10.1038/ni.1733; Marshak-Rothstein A, 2006, NAT REV IMMUNOL, V6, P823, DOI 10.1038/nri1957; McCuskey RS, 2004, HEPATOLOGY, V40, P386, DOI 10.1002/hep.20302; Miele L, 2009, HEPATOLOGY, V49, P1877, DOI 10.1002/hep.22848; Miura K, 2010, GASTROENTEROLOGY, V139, P323, DOI 10.1053/j.gastro.2010.03.052; Nie H, 2013, NAT MED, V19, P322, DOI 10.1038/nm.3085; POWELL EE, 1990, HEPATOLOGY, V11, P74, DOI 10.1002/hep.1840110114; Rangnekar AS, 2006, LIVER INT, V26, P1000, DOI 10.1111/j.1478-3231.2006.01314.x; Raptis DA, 2014, J HEPATOL, V60, P625, DOI 10.1016/j.jhep.2013.11.006; Rinella ME, 2008, J LIPID RES, V49, P1068, DOI 10.1194/jlr.M800042-JLR200; Rinella ME, 2004, J HEPATOL, V40, P47, DOI 10.1016/j.jhep.2003.09.020; Rivera CA, 2007, J HEPATOL, V47, P571, DOI 10.1016/j.jhep.2007.04.019; Roberts Eve A, 2003, Curr Gastroenterol Rep, V5, P253, DOI 10.1007/s11894-003-0028-4; Roh YS, 2015, DIGEST DIS SCI, V60, P2009, DOI 10.1007/s10620-014-3438-2; Roh YS, 2014, HEPATOLOGY, V60, P237, DOI 10.1002/hep.26981; Seki E, 2008, HEPATOLOGY, V48, P322, DOI 10.1002/hep.22306; Seki E, 2007, NAT MED, V13, P1324, DOI 10.1038/nm1663; Son G, 2010, GASTROENT RES PRACT, DOI 10.1155/2010/453563; Srivastava S, 2014, J EXP MED, V211, P961, DOI 10.1084/jem.20131556; Szabo G, 2006, HEPATOLOGY, V44, P287, DOI 10.1002/hep.21308; Tosello-Trampont AC, 2012, J BIOL CHEM, V287, P40161, DOI 10.1074/jbc.M112.417014; Toubi E, 2005, ANN NY ACAD SCI, V1051, P506, DOI 10.1196/annals.1361.095; Watanabe A, 2007, HEPATOLOGY, V46, P1509, DOI 10.1002/hep.21867; Wu CW, 2010, GENE THER, V17, P790, DOI 10.1038/gt.2010.41; Wu WC, 2008, WORLD J GASTROENTERO, V14, P313, DOI 10.3748/wjg.14.313	53	1	1	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	NOV	2018	188	11					2574	2588		10.1016/j.ajpath.2018.07.011			15	Pathology	Pathology	GZ0FK	WOS:000449036900013	30125542				2019-10-28	
J	Matisz, CE; Geuking, MB; Lopes, F; Petri, B; Wang, A; Sharkey, KA; McKay, DM				Matisz, Chelsea E.; Geuking, Markus B.; Lopes, Fernando; Petri, Bjorn; Wang, Arthur; Sharkey, Keith A.; McKay, Derek M.			Helminth Antigen-Conditioned Dendritic Cells Generate Anti-Inflammatory Cd4 T Cells Independent of Antigen Presentation via Major Histocompatibility Complex Class II	AMERICAN JOURNAL OF PATHOLOGY			English	Article							TAPEWORM HYMENOLEPIS-DIMINUTA; CHEMICALLY-INDUCED COLITIS; ADOPTIVE TRANSFER; IMMUNE-RESPONSES; SECRETED PROTEINS; TH2 RESPONSE; RAT TAPEWORM; BONE-MARROW; TGF-BETA; MICE	A recently identified feature of the host response to infection with helminth parasites is suppression of concomitant disease. Dendritic cells (DCs) exposed to antigens from the tapeworm Hymenolepis diminuta significantly reduce the severity of dinitrobenzene sulfonic acid-induced colitis in mice. Here we elucidate mechanisms underlying this cellular immunotherapy. We show a requirement for Ccr7 expression on transferred H. diminuta antigen-treated (HD)-DCs, suggesting that homing to secondary Lymphoid tissues is important for suppression of colitis. Furthermore, sodium metaperiodate-sensitive helminth-derived glycans are required to drive the anti-colitic response in recipient mice. Induction of Th2-type cytokines and Gata-3(+)Cd4(+) cells in secondary lymphoid tissues is dependent on major histocompatibility complex class II (MHC II) protein expression on transferred DCs, although remarkably, transfer of MHC II-/- HD-DCs still attenuated dinitrobenzene sulfonic acid induced colitis in recipient mice. Moreover, transfer of Cd4(+) splenic T cells retrieved from mice administered MHC II-/- HD-DCs suppressed dinitrobenzene sulfonic acid-induced colitis in recipient mice. Our studies reveal that HD-DCs can suppress colitis via an alternative MHC II-independent pathway that involves, in part, mobilization of T-cell responses. These data support the utility of HD-DCs in blocking colitis, revealing a requirement for Ccr7 and providing for HD-DC autologous immunotherapy for disease in which MHC II expression and/or function is compromised.	[Matisz, Chelsea E.; Lopes, Fernando; Wang, Arthur; Sharkey, Keith A.; McKay, Derek M.] Univ Calgary, Cumming Sch Med, Gastrointestinal Res Grp, Calgary, AB, Canada; [Matisz, Chelsea E.; Lopes, Fernando; Wang, Arthur; Sharkey, Keith A.; McKay, Derek M.] Univ Calgary, Cumming Sch Med, Inflammat Res Network, Calgary, AB, Canada; [Geuking, Markus B.] Univ Calgary, Cumming Sch Med, Dept Physiol & Pharmacol, Dept Microbiol Immunol & Infect Dis, Calgary, AB, Canada; [Petri, Bjorn] Univ Calgary, Cumming Sch Med, Mouse Phen Resource Lab, Calgary, AB, Canada; [Sharkey, Keith A.] Univ Calgary, Cumming Sch Med, Snyder Inst Chron Dis, Dept Microbiol Immunol & Infect Dis, Calgary, AB, Canada	McKay, DM (reprint author), Univ Calgary, Dept Physiol & Pharmacol, 3330 Hosp Dr NW, Calgary, AB T2N 4N1, Canada.	dmckay@ucalgary.ca		Sharkey, Keith/0000-0001-9560-1711	Natural Sciences and Research Council of Canada grant [RGPIN-2017-03826]; Canadian Institutes of Health Research grantsCanadian Institutes of Health Research (CIHR) [PJT 391060, FDN 148380]; Alberta Innovates; University of Calgary	Supported by Natural Sciences and Research Council of Canada grant RGPIN-2017-03826 (D.M.M.), Canadian Institutes of Health Research grants PJT 391060 (M.B.G.) and FDN 148380 (K.A.S.), and a grant from Alberta Innovates (C.E.M. and F.L.). The Flow Cytometry suite and the Snyder Mouse Phenomics Resources Laboratory were supported by the University of Calgary.	Anguille S, 2015, PHARMACOL REV, V67, P731, DOI 10.1124/pr.114.009456; Bager P, 2010, J ALLERGY CLIN IMMUN, V125, P123, DOI 10.1016/j.jaci.2009.08.006; Balic A, 2004, EUR J IMMUNOL, V34, P3047, DOI 10.1002/eji.200425167; Cabezon R, 2013, CLIN DEV IMMUNOL, DOI 10.1155/2013/789814; Carranza F, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040356; Casaravilla C, 2014, INFECT IMMUN, V82, P3164, DOI 10.1128/IAI.01959-14; Connor LM, 2014, J IMMUNOL, V193, P2709, DOI 10.4049/jimmunol.1400374; Correale J, 2012, FRONT CELL INFECT MI, V2, DOI 10.3389/fcimb.2012.00112; Creusot RJ, 2009, BLOOD, V113, P6638, DOI 10.1182/blood-2009-02-204321; Croese J, 2006, GUT, V55, P136, DOI 10.1136/gut.2005.079129; de Jesus ER, 2016, J CLIN CELL IMMUNOL, V7; Duchmann R, 2006, GUT, V55, P604, DOI 10.1136/gut.2005.083592; Everts B, 2012, J EXP MED, V209, P1753, DOI 10.1084/jem.20111381; Falcon C, 2010, VET IMMUNOL IMMUNOP, V137, P36, DOI 10.1016/j.vetimm.2010.04.007; Fleming J, 2019, MULT SCLER J, V25, P81, DOI 10.1177/1352458517736377; Flint HJ, 2012, NAT REV GASTRO HEPAT, V9, P577, DOI 10.1038/nrgastro.2012.156; Garcia F, 2013, HUM VACC IMMUNOTHER, V9, P2445, DOI 10.4161/hv.25876; Garcia F, 2011, J INFECT DIS, V203, P473, DOI 10.1093/infdis/jiq077; Goodridge HS, 2005, J IMMUNOL, V174, P284, DOI 10.4049/jimmunol.174.1.284; Grainger JR, 2010, J EXP MED, V207, P2331, DOI 10.1084/jem.20101074; Hamady ZZR, 2011, INFLAMM BOWEL DIS, V17, P1925, DOI 10.1002/ibd.21565; Hang L, 2013, J IMMUNOL, V191, P1927, DOI 10.4049/jimmunol.1201457; Harn DA, 2009, IMMUNOL REV, V230, P247, DOI 10.1111/j.1600-065X.2009.00799.x; Hartmann W, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068380; Hewitson JP, 2009, MOL BIOCHEM PARASIT, V167, P1, DOI 10.1016/j.molbiopara.2009.04.008; Holland MJ, 2000, EUR J IMMUNOL, V30, P1977, DOI 10.1002/1521-4141(200007)30:7<1977::AID-IMMU1977>3.0.CO;2-3; Hunter MM, 2010, GASTROENTEROLOGY, V138, P1395, DOI 10.1053/j.gastro.2009.12.041; Hunter MM, 2005, J IMMUNOL, V174, P7368, DOI 10.4049/jimmunol.174.11.7368; Jenne CN, 2013, NAT IMMUNOL, V14, P996, DOI 10.1038/ni.2691; Jin Y, 2014, EXP MOL MED, V46, DOI 10.1038/emm.2013.144; Johnston MJG, 2010, INFECT IMMUN, V78, P1364, DOI 10.1128/IAI.01349-08; Junt T, 2004, J IMMUNOL, V173, P6684, DOI 10.4049/jimmunol.173.11.6684; Kim HM, 2018, INT J OBESITY, V42, P270, DOI 10.1038/ijo.2017.200; Leung G, 2015, MOL MED, V21, P924, DOI 10.2119/molmed.2015.00193; Liu J, 2011, PROCEEDINGS OF THE ASME INTERNATIONAL MANUFACTURING SCIENCE AND ENGINEERING CONFERENCE 2011, VOL 2, P525, DOI 10.1111/j.1365-3024.2011.01308.x; Lopes F, 2016, INFLAMM BOWEL DIS, V22, P2499, DOI 10.1097/MIB.0000000000000889; Lutz MB, 1999, J IMMUNOL METHODS, V223, P77, DOI 10.1016/S0022-1759(98)00204-X; MacDonald AS, 2001, J IMMUNOL, V167, P1982, DOI 10.4049/jimmunol.167.4.1982; Martin-Fontecha A, 2003, J EXP MED, V198, P615, DOI 10.1084/jem.20030448; Matisz CE, 2017, SCI REP-UK, V7, DOI 10.1038/srep40631; Matisz CE, 2015, EUR J IMMUNOL, V45, P3126, DOI 10.1002/eji.201545579; Mori S, 2001, J EXP MED, V193, P207, DOI 10.1084/jem.193.2.207; Pedersen AE, 2007, IMMUNOLOGY, V121, P526, DOI 10.1111/j.1365-2567.2007.02600.x; Persaud R, 2007, INT J PARASITOL, V37, P393, DOI 10.1016/j.ijpara.2006.09.012; Ricart BG, 2011, J IMMUNOL, V186, P53, DOI 10.4049/jimmunol.1002358; Riol-Blanco L, 2005, J IMMUNOL, V174, P4070, DOI 10.4049/jimmunol.174.7.4070; Ritter M, 2010, P NATL ACAD SCI USA, V107, P20459, DOI 10.1073/pnas.1010337107; Robinson MW, 2012, FASEB J, V26, P4614, DOI 10.1096/fj.12-213876; Rodriguez E, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0004234; Ruyssers NE, 2009, INFLAMM BOWEL DIS, V15, P491, DOI 10.1002/ibd.20787; Sala E, 2015, GASTROENTEROLOGY, V149, P163, DOI 10.1053/j.gastro.2015.03.013; Scholmerich J, 2017, J CROHNS COLITIS, V11, P390, DOI 10.1093/ecco-jcc/jjw184; Sofronic-Milosavljevic L, 2013, MED MICROBIOL IMMUN, V202, P239, DOI 10.1007/s00430-012-0286-6; Stumptner-Cuvelette P, 2001, P NATL ACAD SCI USA, V98, P12144, DOI 10.1073/pnas.221256498; Tawill S, 2004, INFECT IMMUN, V72, P398, DOI 10.1128/IAI.72.1.398-407.2004; Thomas PG, 2003, J IMMUNOL, V171, P5837, DOI 10.4049/jimmunol.171.11.5837; Thornton AM, 2010, J IMMUNOL, V184, P3433, DOI 10.4049/jimmunol.0904028; van Stijn CMW, 2010, MOL IMMUNOL, V47, P1544, DOI 10.1016/j.molimm.2010.01.014; Walsh JT, 2015, J CLIN INVEST, V125, P699, DOI [10.1172/JCI176210, 10.1172/JCI76210]; Wang A, 2005, PARASITOLOGY, V130, P575, DOI 10.1017/S0031182004006985; Whelan M, 2000, J IMMUNOL, V164, P6453, DOI 10.4049/jimmunol.164.12.6453; Wilson MS, 2005, J EXP MED, V202, P1199, DOI 10.1084/jem.20042572; Yamanishi H, 2012, J IMMUNOL, V188, P2164, DOI 10.4049/jimmunol.1100559; Zuo JM, 2012, VIRUSES-BASEL, V4, P1335, DOI 10.3390/v4081335	64	0	0	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	NOV	2018	188	11					2589	2604		10.1016/j.ajpath.2018.07.008			16	Pathology	Pathology	GZ0FK	WOS:000449036900014	30121255				2019-10-28	
J	Nguyen, DN; Thymann, T; Goericke-Pesch, SK; Ren, SQ; Wei, W; Skovgaard, K; Damborg, P; Brunse, A; van Gorp, C; Kramer, BW; Wolfs, TG; Sangild, PT				Duc Ninh Nguyen; Thymann, Thomas; Goericke-Pesch, Sandra K.; Ren, Shuqiang; Wei, Wei; Skovgaard, Kerstin; Damborg, Peter; Brunse, Anders; van Gorp, Charlotte; Kramer, Boris W.; Wolfs, Tim G.; Sangild, Per T.			Prenatal Intra-Amniotic Endotoxin Induces Fetal Gut and Lung Immune Responses and Postnatal Systemic Inflammation in Preterm Pigs	AMERICAN JOURNAL OF PATHOLOGY			English	Article							PREVENT NECROTIZING ENTEROCOLITIS; RISK-FACTOR; HUMAN-MILK; CHORIOAMNIONITIS; INFECTION; MODEL; MATURATION; INFANTS; INJURY; BIRTH	Prenatal inflammation is a major risk for preterm birth and neonatal morbidity, but its effects on postnatal immunity and organ functions remain unclear. Using preterm pigs as a model for preterm infants, we investigated whether prenatal intra-amniotic (IA) inflammation modulates postnatal systemic immune status and organ functions. Preterm pigs exposed to IA lipopolysaccharide (LPS) for 3 days were compared with controls at birth and postnatal day 5 after formula feeding. IA LPS induced mild chorioamnionitis but extensive intra-amniotic inflammation. There were minor systemic effects at birth (increased blood neutrophil counts), but a few days later, prenatal LPS induced delayed neonatal arousal, systemic inflammation (increased blood leukocytes, plasma cytokines, and splenic bacterial counts), altered serum biochemistry (lower albumin and cholesterol and higher iron and glucose values), and increased urinary protein and sodium excretion. In the gut and lungs, IA LPS-induced inflammatory responses were observed mainly at birth (increased LPS, CXCL8, and IL-1 beta levels and myeloperoxidase-positive cell density, multiple increases in innate immune gene expressions, and reduced villus heights), but not on postnatal day 5 (except elevated lung CXCL8 and diarrhea symptoms). Finally, IA LPS did not affect postnatal gut brush-border enzymes, hexose absorption, permeability, or sensitivity to necrotizing enterocolitis on day 5. Short-term IA LPS exposure predisposes preterm pigs to postnatal systemic inflammation after acute fetal gut and lung inflammatory responses.	[Duc Ninh Nguyen; Thymann, Thomas; Ren, Shuqiang; Wei, Wei; Brunse, Anders; Sangild, Per T.] Univ Copenhagen, Sect Comparat Pediat & Nutr, Dept Vet & Anim Sci, Dyrlaegevej 68, DK-1870 Frederiksberg C, Denmark; [Goericke-Pesch, Sandra K.] Univ Copenhagen, Dept Vet Clin Sci, Sect Vet Reprod & Obstet, Frederiksberg, Denmark; [Skovgaard, Kerstin] Univ Copenhagen, Dept Vet Dis Biol, Frederiksberg, Denmark; [Damborg, Peter] Tech Univ Denmark, Dept Biotechnol & Biomed, Lyngby, Denmark; [van Gorp, Charlotte; Kramer, Boris W.; Wolfs, Tim G.] Maastricht Univ, Sch Oncol & Dev Biol, Dept Pediat, Maastricht, Netherlands; [Sangild, Per T.] Rigshosp, Dept Pediat & Adolescent Med, Copenhagen, Denmark; [Sangild, Per T.] Odense Univ Hosp, Dept Pediat, Odense, Denmark	Sangild, PT (reprint author), Univ Copenhagen, Sect Comparat Pediat & Nutr, Dept Vet & Anim Sci, Dyrlaegevej 68, DK-1870 Frederiksberg C, Denmark.	pts@sund.ku.dk		Brunse, Anders/0000-0002-0199-3417; Damborg, Peter Panduro/0000-0001-9932-5996; Thymann, Thomas/0000-0001-7480-6064; Wolfs, Tim/0000-0003-4417-4144; skovgaard, kerstin/0000-0001-5663-4879; Nguyen, Duc Ninh/0000-0002-4997-555X; Goericke-Pesch, Sandra/0000-0002-4327-9780	Center of Arla Foods for Health STIMMUNE project; Innovation Foundation Denmark NEOCOL project	Supported by the Center of Arla Foods for Health STIMMUNE project (P.T.S. and D.N.N.); and the Innovation Foundation Denmark NEOCOL project (P.T.S.).	Andersen AD, 2016, AM J PHYSIOL-REG I, V310, pR481, DOI 10.1152/ajpregu.00349.2015; Andersen CL, 2004, CANCER RES, V64, P5245, DOI 10.1158/0008-5472.CAN-04-0496; Azizia M, 2012, PEDIATRICS, V129, pE967, DOI 10.1542/peds.2011-1579; Barington K, 2017, FORENSIC SCI MED PAT, V13, P151, DOI 10.1007/s12024-017-9869-2; Been JV, 2009, ARCH DIS CHILD-FETAL, V94, pF218, DOI 10.1136/adc.2008.150458; Been JV, 2013, J PEDIATR-US, V162, P236, DOI 10.1016/j.jpeds.2012.07.012; Birck MM, 2016, AM J PHYSIOL-GASTR L, V310, pG323, DOI 10.1152/ajpgi.00392.2015; Chien JY, 2005, CRIT CARE MED, V33, P1688, DOI 10.1097/01.CCM.0000171183.79525.6B; de Araujo MCK, 1999, EARLY HUM DEV, V56, P1; Dean JM, 2015, DEV NEUROSCI-BASEL, V37, P289, DOI 10.1159/000370309; Nguyen DN, 2016, SCI REP-UK, V6, DOI 10.1038/srep36816; Nguyen DN, 2016, INNATE IMMUN-LONDON, V22, P51, DOI 10.1177/1753425915615195; Gabay C, 1999, NEW ENGL J MED, V340, P448, DOI 10.1056/NEJM199902113400607; Gantert M, 2010, J PERINATOL, V30, pS21, DOI 10.1038/jp.2010.96; Rodrigo FGM, 2014, NEONATOLOGY, V106, P229, DOI 10.1159/000363127; Gisslen T, 2016, ARCH DIS CHILD-FETAL, V101, pF513, DOI 10.1136/archdischild-2015-308518; Goldenberg RL, 2008, LANCET, V371, P75, DOI 10.1016/S0140-6736(08)60074-4; Hanita T, 2017, REPROD SCI, V24, P478, DOI 10.1177/1933719116660846; Jensen ML, 2014, AM J PHYSIOL-GASTR L, V306, pG59, DOI 10.1152/ajpgi.00213.2013; Jobe AH, 2000, AM J RESP CRIT CARE, V162, P1656, DOI 10.1164/ajrccm.162.5.2003044; Kallapur SG, 2001, AM J PHYSIOL-LUNG C, V280, pL527; Kallapur SG, 2005, AM J RESP CRIT CARE, V172, P1315, DOI 10.1164/rccm.200506-1007OC; Kallapur SG, 2014, SEMIN REPROD MED, V32, P56, DOI 10.1055/s-0033-1361823; Kallapur SG, 2013, J IMMUNOL, V191, P1102, DOI 10.4049/jimmunol.1300270; Kemp MW, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063355; Kemp MW, 2010, REPROD SCI, V17, P619, DOI 10.1177/1933719110373148; Kinder JM, 2015, CELL, V162, P505, DOI 10.1016/j.cell.2015.07.006; Kramer BW, 2011, NEONATOLOGY, V99, P320, DOI 10.1159/000326620; Kramer BW, 2005, AM J RESP CRIT CARE, V171, P73, DOI 10.1164/rccm.200406-745OC; Kramer BW, 2001, AM J RESP CRIT CARE, V164, P982, DOI 10.1164/ajrccm.164.6.2103061; Levings MK, 2002, INT ARCH ALLERGY IMM, V129, P263, DOI 10.1159/000067596; LUCAS A, 1990, LANCET, V336, P1519, DOI 10.1016/0140-6736(90)93304-8; Maneenil G, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0119281; MCCANCE RA, 1957, J EMBRYOL EXP MORPH, V5, P43; Nadhazi Z., 2002, Acta Microbiologica et Immunologica Hungarica, V49, P151, DOI 10.1556/AMicr.49.2002.1.15; Nikiforou M, 2016, SCI REP-UK, V6, DOI 10.1038/srep29806; Nikiforou M, 2016, LAB INVEST, V96, P69, DOI 10.1038/labinvest.2015.127; Nikiforou M, 2015, INFLAMM BOWEL DIS, V21, P2026, DOI 10.1097/MIB.0000000000000455; Pagel J, 2016, CLIN EXP IMMUNOL, V185, P219, DOI 10.1111/cei.12810; Redline RW, 2003, PEDIATR DEVEL PATHOL, V6, P435, DOI 10.1007/s10024-003-7070-y; Rueda CM, 2016, J IMMUNOL, V196, P3706, DOI 10.4049/jimmunol.1502613; Sangild PT, 2013, J ANIM SCI, V91, P4713, DOI 10.2527/jas.2013-6359; Schanler RJ, 1999, PEDIATRICS, V103, P1150, DOI 10.1542/peds.103.6.1150; Schmidt AF, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0706-4; Seehase M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047631; Senthamaraikannan P, 2016, J INFECT DIS, V214, P1597, DOI 10.1093/infdis/jiw408; Shen RL, 2015, AM J PHYSIOL-GASTR L, V309, pG310, DOI 10.1152/ajpgi.00163.2015; Snyder CC, 2013, AM J OBSTET GYNECOL, V208, DOI 10.1016/j.ajog.2013.02.018; Splichal I, 2002, PHYSIOL RES, V51, P523; Splichalova A, 2004, FOLIA MICROBIOL, V49, P751, DOI 10.1007/BF02931560; Strunk T, 2014, LANCET INFECT DIS, V14, P751, DOI 10.1016/S1473-3099(14)70710-8; Sweeney EL, 2017, CLIN MICROBIOL REV, V30, P349, DOI 10.1128/CMR.00091-16; TOMODA S, 1985, AM J PHYSIOL, V249, pR133; Trebichavsky I, 2002, VET IMMUNOL IMMUNOP, V87, P11, DOI 10.1016/S0165-2427(02)00025-9; Underwood MA, 2013, PEDIATR CLIN N AM, V60, P189, DOI 10.1016/j.pcl.2012.09.008; Vandesompele J, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-7-research0034; Willems MGM, 2016, AM J PHYSIOL-LUNG C, V310, pL1, DOI 10.1152/ajplung.00289.2015; Wolfs TGA, 2013, MUCOSAL IMMUNOL, V6, P547, DOI 10.1038/mi.2012.97; Wolfs TGAM, 2014, AM J PHYSIOL-GASTR L, V306, pG382, DOI 10.1152/ajpgi.00260.2013; Wolfs TGAM, 2012, J MATERN-FETAL NEO M, V25, P8, DOI 10.3109/14767058.2012.664447; Wolfs TGAM, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005837	61	1	1	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	NOV	2018	188	11					2629	2643		10.1016/j.ajpath.2018.07.020			15	Pathology	Pathology	GZ0FK	WOS:000449036900017	30314768				2019-10-28	
J	Delacroix, C; Hyzewicz, J; Lemaitre, M; Friguet, B; Li, ZL; Klein, A; Furling, D; Agbulut, O; Ferry, A				Delacroix, Clement; Hyzewicz, Janek; Lemaitre, Megane; Friguet, Bertrand; Li, Zhenlin; Klein, Arnaud; Furling, Denis; Agbulut, Onnik; Ferry, Arnaud			Improvement of Dystrophic Muscle Fragility by Short-Term Voluntary Exercise through Activation of Calcineurin Pathway in mdx Mice	AMERICAN JOURNAL OF PATHOLOGY			English	Article							CONTRACTION-INDUCED INJURY; DUCHENNE MUSCULAR-DYSTROPHY; LIMB SKELETAL-MUSCLE; MURINE MODELS; IN-VIVO; EXPRESSION; UTROPHIN; FORCE; STIMULATION; PATHOLOGY	Dystrophin deficiency in mdx mice, a model for Duchenne muscular dystrophy, leads to muscle weakness revealed by a reduced specific maximal force as well as fragility (ie, higher susceptibility to contraction induced injury, as shown by a greater force decrease after lengthening contractions). Both symptoms could be improved with dystrophin restoration-based therapies and long-term (months) voluntary exercise. Herein, we evaluated the effect of short-term (1-week) voluntary wheel running. We found that running improved fragility of tibialis anterior muscle (TA), but not plantaris muscle, independently of utrophin up-regulation, without affecting weakness. Moreover, TA muscle excitability was also preserved by running, as shown by compound muscle action potential measurements after lengthening contractions. Of interest, the calcineurin inhibitor cyclosporin A prevented the effect of running on both muscle fragility and excitability. Cyclosporin also prevented the running-induced changes in expression of genes involved in excitability (Scn4a and Cacna1s) and slower contractile phenotype (Myh2 and Tnni1) in TA muscle. In conclusion, short-term voluntary exercise improves TA muscle fragility in mdx mice, without worsening weakness. Its effect was related to preserved excitability, calcineurin pathway activation, and changes in the program of genes involved in excitability and slower contractile phenotype. Thus, remediation of muscle fragility of Duchenne muscular dystrophy patients through appropriate exercise training deserves to be explored in more detail.	[Delacroix, Clement; Lemaitre, Megane; Klein, Arnaud; Furling, Denis; Ferry, Arnaud] Sorbonne Univ, INSERM, UMRS974, Res Ctr Myol,Assoc Inst Myol, Paris, France; [Hyzewicz, Janek; Friguet, Bertrand; Li, Zhenlin; Agbulut, Onnik] Sorbonne Univ, INSERM, Biol Adaptat & Aging, Inst Biol Paris Seine,UMR CNRS 8256,ERL U1164, Paris, France; [Ferry, Arnaud] Paris Descartes Univ, Sorbonne Paris Cite, Paris, France	Ferry, A (reprint author), GH Pitie Salpetriere, UMRS974, Res Ctr Myol, 47 Bld Hop, F-75651 Paris 13, France.	arnaud.ferry@upmc.fr	ferry, arnaud/D-2816-2019	Friguet, Bertrand/0000-0001-8085-1961; LI, Zhenlin/0000-0002-3706-4505; Klein, Arnaud/0000-0002-3860-7049; Agbulut, Onnik/0000-0003-1923-8871; Furling, Denis/0000-0001-7912-4409; HYZEWICZ, Janek/0000-0002-2333-9336	Pierre and Marie Curie University; INSERMInstitut National de la Sante et de la Recherche Medicale (Inserm); Association Institute of Myology; Paris Descartes University; French Association against Myopathies	Supported by Pierre and Marie Curie University, INSERM, Association Institute of Myology, Paris Descartes University, and French Association against Myopathies.	Al-Rewashdy H, 2015, HUM MOL GENET, V24, P1243, DOI 10.1093/hmg/ddu535; Banks GB, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004431; Blaauw B, 2010, J APPL PHYSIOL, V108, P105, DOI 10.1152/japplphysiol.00803.2009; Booth FW, 2015, PROG MOL BIOL TRANSL, V135, P129, DOI 10.1016/bs.pmbts.2015.07.016; Call JA, 2008, J APPL PHYSIOL, V105, P923, DOI 10.1152/japplphysiol.00028.2008; Call JA, 2013, J PHYSIOL-LONDON, V591, P3765, DOI 10.1113/jphysiol.2013.254656; Call JA, 2010, MUSCLE NERVE, V42, P871, DOI 10.1002/mus.21764; Cannon SC, 2015, COMPR PHYSIOL, V5, P761, DOI 10.1002/cphy.c140062; Capogrosso RF, 2017, J APPL PHYSIOL, V122, P828, DOI 10.1152/japplphysiol.00776.2015; Chakkalakal JV, 2006, HUM MOL GENET, V15, P1423, DOI 10.1093/hmg/ddl065; Chakkalakal JV, 2004, HUM MOL GENET, V13, P379, DOI 10.1093/hmg/ddh037; Chakkalakal JV, 2003, P NATL ACAD SCI USA, V100, P7791, DOI 10.1073/pnas.0932671100; Chan MC, 2014, SKELET MUSCLE, V4, DOI 10.1186/2044-5040-4-2; Chan S, 2011, EXP PHYSIOL, V96, P564, DOI 10.1113/expphysiol.2010.056713; Chin ER, 1998, GENE DEV, V12, P2499, DOI 10.1101/gad.12.16.2499; Deconinck N, 1998, NEUROMUSCULAR DISORD, V8, P362, DOI 10.1016/S0960-8966(98)00048-0; Deconinck N, 1997, NAT MED, V3, P1216, DOI 10.1038/nm1197-1216; Dellorusso C, 2001, J MUSCLE RES CELL M, V22, P467, DOI 10.1023/A:1014587918367; Dumonceaux J, 2010, MOL THER, V18, P881, DOI 10.1038/mt.2009.322; Dunn SE, 1999, J BIOL CHEM, V274, P21908, DOI 10.1074/jbc.274.31.21908; Ferry A, 2015, MUSCLE NERVE, V52, P788, DOI 10.1002/mus.24604; Ferry A, 2015, AM J PATHOL, V185, P2012, DOI 10.1016/j.ajpath.2015.03.027; Ferry A, 2014, NEUROMUSCULAR DISORD, V24, P960, DOI 10.1016/j.nmd.2014.06.001; Frey N, 2008, J CLIN INVEST, V118, P3598, DOI 10.1172/JCI36277; Gordon BS, 2014, MUSCLE NERVE, V49, P915, DOI 10.1002/mus.24151; Goyenvalle A, 2015, NAT MED, V21, P270, DOI 10.1038/nm.3765; Gumerson JD, 2011, J BIOMED BIOTECHNOL, DOI 10.1155/2011/210797; Gundersen K., 2010, BIOL REV CAMB PHILOS, V86, P564; Hayes A, 1996, J APPL PHYSIOL, V80, P670; HEAD SI, 1992, P ROY SOC B-BIOL SCI, V248, P163, DOI 10.1098/rspb.1992.0058; Hoogaars WMH, 2012, HUM GENE THER, V23, P1269, DOI 10.1089/hum.2012.056; Hourde C, 2013, AM J PATHOL, V182, P1509, DOI 10.1016/j.ajpath.2013.01.020; Hyzewicz Janek, 2015, J Neuromuscul Dis, V2, P325; Irwin WA, 2003, NAT GENET, V35, P367, DOI 10.1038/ng1270; Kivela R, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13124; Koo T, 2011, HUM GENE THER, V22, P1379, DOI 10.1089/hum.2011.020; Ljubicic V, 2011, HUM MOL GENET, V20, P3478, DOI 10.1093/hmg/ddr265; Lovering RM, 2014, J APPL PHYSIOL, V116, P1439, DOI 10.1152/japplphysiol.00174.2013; Lucas B, 2014, PHYSIOL GENOMICS, V46, P385, DOI 10.1152/physiolgenomics.00166.2013; Lynch GS, 2004, CLIN EXP PHARMACOL P, V31, P557, DOI 10.1111/j.1440-1681.2004.04026.x; Manttari S, 2013, MOL CELL BIOCHEM, V373, P171, DOI 10.1007/s11010-012-1486-5; Matsakas A, 2013, FASEB J, V27, P4004, DOI 10.1096/fj.13-228296; Miura P, 2009, HUM MOL GENET, V18, P4640, DOI 10.1093/hmg/ddp431; MOENS P, 1993, J MUSCLE RES CELL M, V14, P446, DOI 10.1007/BF00121296; Pandorf CE, 2009, AM J PHYSIOL-REG I, V297, pR1037, DOI 10.1152/ajpregu.00349.2009; Parsons SA, 2004, J BIOL CHEM, V279, P26192, DOI 10.1074/jbc.M313800200; PASTORET C, 1993, J MUSCLE RES CELL M, V14, P423, DOI 10.1007/BF00121294; PETROF BJ, 1993, P NATL ACAD SCI USA, V90, P3710, DOI 10.1073/pnas.90.8.3710; Pratt SJP, 2013, J PHYSIOL-LONDON, V591, P559, DOI 10.1113/jphysiol.2012.241679; Ramamoorthy TG, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms10210; Roy P, 2016, SKELET MUSCLE, V6, DOI 10.1186/s13395-016-0096-4; Sacco A, 2010, CELL, V143, P1059, DOI 10.1016/j.cell.2010.11.039; Schiaffino S, 2007, PHYSIOLOGY, V22, P269, DOI 10.1152/physiol.00009.2007; Selsby JT, 2013, J APPL PHYSIOL, V115, P660, DOI 10.1152/japplphysiol.00252.2013; Squire S, 2002, HUM MOL GENET, V11, P3333, DOI 10.1093/hmg/11.26.3333; Stupka N, 2008, AM J PHYSIOL-REG I, V294, pR983, DOI 10.1152/ajpregu.00375.2007; Stupka N, 2006, J PHYSIOL-LONDON, V575, P645, DOI 10.1113/jphysiol.2006.108472; Talmadge RJ, 2004, BMC CELL BIOL, V5, DOI 10.1186/1471-2121-5-28; Yan Z, 2011, J APPL PHYSIOL, V110, P264, DOI 10.1152/japplphysiol.00993.2010; Zhang YD, 2013, HUM MOL GENET, V22, P3720, DOI 10.1093/hmg/ddt224	60	0	0	0	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	NOV	2018	188	11					2662	2673		10.1016/j.ajpath.2018.07.015			12	Pathology	Pathology	GZ0FK	WOS:000449036900020	30142334				2019-10-28	
J	Noh, BJ; Park, YK				Noh, Byeong-Joo; Park, Yong-Koo			Giant cell tumor of bone: updated molecular pathogenesis and tumor biology	HUMAN PATHOLOGY			English	Article						Giant cell tumor of bone; G34W mutation; H3F3A; Molecular pathogenesis; Tumor microenvironment; RANKLs; Cytokines; Chemokines	DIAGNOSTIC-VALUE; GENE-EXPRESSION; H3F3A MUTATION; STROMAL CELLS; CYCLIN D1; TGF-BETA; DENOSUMAB; PROTEIN; OSTEOCLASTOGENESIS; LOCALIZATION	Giant cell tumor of bone (GCTB) related clonal aberrations occur in a background of epigenetic histone modifications (especially the G34W mutation of H3F3A gene) that induce cytogenetic abnormalities. Clonal aberrations are closely linked to the aggressiveness of GCTB. The "neoplastic" mononuclear stromal cells in GCTB express fundamental RANKLs and various chemokines and cytokines associated with monocyte recruitment and "reactive" multinucleated giant cells (osteoclastogenesis). The reciprocal and orchestrated actions between mononuclear stromal cells and multinucleated giant cells help in the understanding of the molecular pathogenesis and tumor biology of GCTB. In the future, novel targets in the updated tumor biology and molecular pathogenesis of GCTB should be explored and scrutinized for the development of systemic therapy. (C) 2018 Elsevier Inc. All rights reserved.	[Noh, Byeong-Joo] Univ Ulsan, Coll Med, Gangneung Asan Hosp, Dept Pathol, Kangnung 25440, South Korea; [Park, Yong-Koo] Kyung Hee Univ, Sch Med, Dept Pathol, Seoul 02447, South Korea	Park, YK (reprint author), Kyung Hee Univ Hosp, Dept Pathol, 23 Kyungheedaero, Seoul 02447, South Korea.	ykpark0204@gmail.com					Amary F, 2017, AM J SURG PATHOL, V41, P1059, DOI 10.1097/PAS.0000000000000859; Atkins GJ, 2000, J BONE MINER RES, V15, P640, DOI 10.1359/jbmr.2000.15.4.640; Behjati S, 2013, NAT GENET, V45, P1479, DOI 10.1038/ng.2814; Chawla S, 2013, LANCET ONCOL, V14, P901, DOI 10.1016/S1470-2045(13)70277-8; EKRYLANDER B, 1994, J BIOL CHEM, V269, P14853; Girolami I, 2016, J CLIN PATHOL, V69, P240, DOI 10.1136/jclinpath-2015-203248; Gohda J, 2005, EMBO J, V24, P790, DOI 10.1038/sj.emboj.7600564; Gorunova L, 2009, GENE CHROMOSOME CANC, V48, P583, DOI 10.1002/gcc.20667; Hemingway F, 2011, BONE, V48, P938, DOI 10.1016/j.bone.2010.12.023; Herr I, 2017, CANCER LETT, V409, P49, DOI 10.1016/j.canlet.2017.08.029; Kandel R, 2006, J ORTHOP RES, V24, P428, DOI 10.1002/jor.20036; Kato I, 2018, HISTOPATHOLOGY, V72, P914, DOI 10.1111/his.13448; Kauzman A, 2003, MODERN PATHOL, V16, P210, DOI 10.1097/01.MP.0000057235.65327.40; Kervarrec T, 2017, MODERN PATHOL, V30, P393, DOI 10.1038/modpathol.2016.212; Lau CPY, 2013, CONNECT TISSUE RES, V54, P439, DOI 10.3109/03008207.2013.848202; Lee S, 2005, J CELL BIOL, V169, P681, DOI 10.1083/jcb.200409115; Luke J, 2017, HISTOPATHOLOGY, V71, P125, DOI 10.1111/his.13190; Lum L, 1999, J BIOL CHEM, V274, P13613, DOI 10.1074/jbc.274.19.13613; Mak IWY, 2013, BONE, V55, P198, DOI 10.1016/j.bone.2013.02.020; Mancini I, 2017, HISTOPATHOLOGY, V71, P453, DOI 10.1111/his.13249; Matsubayashi S, 2009, PATHOL RES PRACT, V205, P626, DOI 10.1016/j.prp.2009.02.011; Miyamoto H, 2012, J BONE MINER RES, V27, P1289, DOI 10.1002/jbmr.1575; Morgan T, 2005, AM J PATHOL, V167, P117, DOI 10.1016/S0002-9440(10)62959-8; Moskovszky L, 2010, MODERN PATHOL, V23, P359, DOI 10.1038/modpathol.2009.134; Mukaihara K, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0148401; Ng PKS, 2010, J CELL BIOCHEM, V110, P438, DOI 10.1002/jcb.22556; Ng RK, 2008, NAT CELL BIOL, V10, P102, DOI 10.1038/ncb1674; Nohr E, 2017, HUM PATHOL, V68, P119, DOI 10.1016/j.humpath.2017.08.030; Okubo T, 2013, VIRCHOWS ARCH, V463, P67, DOI 10.1007/s00428-013-1435-z; Pilkington MF, 2001, J BONE MINER RES, V16, P1237, DOI 10.1359/jbmr.2001.16.7.1237; Pratap J, 2003, CANCER RES, V63, P5357; Presneau N, 2015, J PATHOL CLIN RES, V1, P113, DOI 10.1002/cjp2.13; Rao UNM, 2005, CANCER GENET CYTOGEN, V158, P126, DOI 10.1016/j.cancergencyto.2004.09.015; Raskin KA, 2013, J AM ACAD ORTHOP SUR, V21, P118, DOI 10.5435/JAAOS-21-02-118; Saada E, 2011, J CLIN ONCOL, V29, pE86, DOI 10.1200/JCO.2010.31.4286; Si AIC, 2003, J CELL BIOCHEM, V89, P1154, DOI 10.1002/jcb.10578; Singh S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046769; Singh S, 2011, J CELL BIOCHEM, V112, P2287, DOI 10.1002/jcb.23149; Tagami H, 2004, CELL, V116, P51, DOI 10.1016/S0092-8674(03)01064-X; Tian BL, 2002, J CLIN PATHOL-MOL PA, V55, P394, DOI 10.1136/mp.55.6.394; van Dam H, 2001, ONCOGENE, V20, P2453, DOI 10.1038/sj.onc.1204239; Wada T, 2006, TRENDS MOL MED, V12, P17, DOI 10.1016/j.molmed.2005.11.007; Wang T, 2017, INT J CANCER, V141, P1630, DOI 10.1002/ijc.30862; Wu MR, 2016, BONE RES, V4, DOI 10.1038/boneres.2016.9; Wuelling M, 2004, VIRCHOWS ARCH, V445, P621, DOI 10.1007/s00428-004-1113-2; Xu JS, 2001, J CELL BIOL, V154, P1069, DOI 10.1083/jcb.200103111; Yamamoto H, 2018, HUM PATHOL, V73, P41, DOI 10.1016/j.humpath.2017.11.020; Yu Q, 2000, GENE DEV, V14, P163; Zhang L, 2013, TRENDS BIOCHEM SCI, V38, P612, DOI 10.1016/j.tibs.2013.10.001; Zheng MH, 1998, J CELL BIOCHEM, V70, P121, DOI 10.1002/(SICI)1097-4644(19980701)70:1<121::AID-JCB12>3.3.CO;2-D	50	3	3	0	4	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	NOV	2018	81						1	8		10.1016/j.humpath.2018.06.017			8	Pathology	Pathology	HB5LM	WOS:000451102300001	29944971				2019-10-28	
J	Jung, CK; Kim, Y; Jeon, S; Jo, K; Lee, S; Bae, JS				Jung, Chan Kwon; Kim, Yourha; Jeon, Sora; Jo, Kwanhoon; Lee, Sohee; Bae, Ja Seong			Clinical utility of EZH1 mutations in the diagnosis A Check for of follicular-patterned thyroid tumors	HUMAN PATHOLOGY			English	Article						Thyroid nodule; RAS genes; EZH1; BRAF; TERT; Molecular diagnostics	TERT PROMOTER MUTATIONS; NUCLEAR FEATURES; VARIANT; METHYLATION; CARCINOMA; CHROMATIN; NEOPLASM; SYSTEM	Follicular-patterned tumors of the thyroid gland are characterized by a predominantly follicular growth pattern. They frequently harbor RAS mutations, not BRAF mutations. Technological advances in molecular testing have discovered novel RAS-type mutations. However, clinical significance of these mutations remains unknown. We investigated the prevalence and clinical impact of mutations ofBRAF, NRAS, HRAS, KRAS, EZH1, EIF1AX, and TERT genes by Sanger sequencing in a series of 201 follicular-patterned thyroid tumors including follicular adenoma (n = 40), Hfirthle cell adenoma (n = 54), noninvasive follicular thyroid neoplasms with papillary-like nuclear features (n = 50), follicular thyroid carcinoma (n = 40), Hiirthle cell carcinoma (n = 10), and poorly differentiated thyroid carcinoma arising in a well-differentiated follicular neoplasm (n = 7), and 120 classic papillary carcinoma. Two hotspots of EZH I mutations were only found in RAS-negative follicular-patterned tumors. EZH1 mutations were detected in 3% of follicular adenoma and in 20% of Hfirthle cell adenoma, and one minimally invasive Hiirthle cell carcinoma. Thyroid tumors with EZH1 mutations reported in the literature were benign in most cases. Otherwise, they were minimally invasive or noninvasive cancer. EIF1AX mutation was found in one follicular adenoma. We confirmed the presence of RAS mutations and BRAF K601E mutation in benign, borderline, and malignant follicular-pattemed tumors. No BRAF V600E was found in all follicular-pattemed tumors. This study also confirmed the occurrence of TERT promoter mutations in high-risk thyroid cancers. These genetic markers can be used for the diagnostic purpose and risk stratification of thyroid nodules. (C) 2018 The Authors. Published by Elsevier Inc.	[Jung, Chan Kwon] Catholic Univ Korea, Dept Hosp Pathol & Canc Res Inst, Coll Med, Seoul 06591, South Korea; [Kim, Yourha; Jeon, Sora] Catholic Univ Korea, Dept Biomed & Hlth Sci, Coll Med, Seoul 06591, South Korea; [Jo, Kwanhoon] Catholic Univ Korea, Dept Internal Med, Coll Med, Div Endocrinol & Metab, Seoul 06591, South Korea; [Lee, Sohee; Bae, Ja Seong] Catholic Univ Korea, Dept Surg, Coll Med, Seoul 06591, South Korea	Jung, CK (reprint author), Catholic Univ Korea, Seoul St Marys Hosp, Coll Med, Dept Hosp Pathol & Canc Res Inst, 222 Banpo Daero, Seoul 06591, South Korea.	ckjung@catholic.ac.kr	Jung, Chan Kwon/C-7578-2014	Jung, Chan Kwon/0000-0001-6843-3708	Korean Health Technology R&D Project, Ministry of Health and Welfare, Republic of Korea [HI16C2013]	This work was supported by a grant (HI16C2013) from the Korean Health Technology R&D Project, Ministry of Health and Welfare, Republic of Korea.	Agrawal N, 2014, CELL, V159, P676, DOI 10.1016/j.cell.2014.09.050; Bae JS, 2016, DIAGN PATHOL, V11, DOI 10.1186/s13000-016-0458-6; Bychkov A, 2018, ENDOCR PATHOL, V29, P276, DOI 10.1007/s12022-018-9519-6; Bychkov A, 2017, J PATHOL TRANSL MED, V51, P517, DOI 10.4132/jptm.2017.09.27; Calebiro D, 2016, J CLIN INVEST, V126, P3383, DOI 10.1172/JCI84894; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Cho U, 2017, MODERN PATHOL, V30, P810, DOI 10.1038/modpathol.2017.9; Choi Y, 2015, BIOINFORMATICS, V31, P2745, DOI 10.1093/bioinformatics/btv195; Choi Y, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046688; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Huang FW, 2013, SCIENCE, V339, P957, DOI 10.1126/science.1229259; Jung SH, 2016, ONCOTARGET, V7, P69638, DOI 10.18632/oncotarget.11922; Kakudo K, 2012, PATHOL INT, V62, P155, DOI 10.1111/j.1440-1827.2011.02773.x; Kim M, 2017, J PATHOL TRANSL MED, V51, P410, DOI 10.4132/jptm.2017.04.05; Liu RY, 2017, JAMA ONCOL, V3, P202, DOI 10.1001/jamaoncol.2016.3288; Liu RY, 2016, ENDOCR-RELAT CANCER, V23, pR143, DOI 10.1530/ERC-15-0533; Lloyd RV, 2004, AM J SURG PATHOL, V28, P1336, DOI 10.1097/01.pas.0000135519.34847.f6; Lloyd RV, 2017, WHO CLASSIFICATION T; Margueron R, 2008, MOL CELL, V32, P503, DOI 10.1016/j.molcel.2008.11.004; Martin M, 2013, NAT GENET, V45, P933, DOI 10.1038/ng.2674; Moritz LE, 2018, J BIOL CHEM, V293, P13805, DOI 10.1074/jbc.R117.800367; Nikiforov YE, 2016, JAMA ONCOL, V2, P1023, DOI 10.1001/jamaoncol.2016.0386; Rice JC, 2003, MOL CELL, V12, P1591, DOI 10.1016/S1097-2765(03)00479-9; Seethala RR, 2018, MODERN PATHOL, V31, P39, DOI 10.1038/modpathol.2017.130; Shen XH, 2008, MOL CELL, V32, P491, DOI 10.1016/j.molcel.2008.10.016; Song YS, 2016, CANCER-AM CANCER SOC, V122, P1370, DOI 10.1002/cncr.29934; Xu B, 2016, ENDOCR PATHOL, V27, P205, DOI 10.1007/s12022-016-9445-4; Ye L, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15533; Yoo KH, 2012, INT J BIOL SCI, V8, P59, DOI 10.7150/ijbs.8.59; Yoo SK, 2016, PLOS GENET, V12, DOI 10.1371/journal.pgen.1006239	30	4	4	0	3	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	NOV	2018	81						9	17		10.1016/j.humpath.2018.04.018			9	Pathology	Pathology	HB5LM	WOS:000451102300002	29723601	Other Gold			2019-10-28	
J	Ryu, HJ; Koh, YW; Yoon, SO				Ryu, Hyang Joo; Koh, Yoon Woo; Yoon, Sun Och			The implications of TrkA and MET aberrations in de novo salivary duct carcinoma	HUMAN PATHOLOGY			English	Article						Salivary duct carcinoma; Trk; MET; Prognosis; Biomarker	GROWTH; OVEREXPRESSION; TRASTUZUMAB	Salivary duct carcinoma (SDC) is an aggressive carcinoma with poor prognosis. Although anti-HER2 therapy is a potential treatment option for HER2-positive SDC, other potential therapeutic targets are not known, in particular for HER2-negative cases. In this study, the recently identified receptors tyrosine kinases MET and tropomyosin-receptor kinase (Trk) were investigated as potential therapeutic targets. A total of 28 consecutive, surgically resected, de novo SDC cases were selected after evaluating histology and immunohistochemical expression of androgen receptor. Immunohistochemical expression of c-erb2, TrkA, TrkB, TrkC, and c-MET was analyzed, and the genetic status of the HER2 and MET genes was investigated through dual-color silver in situ hybridization. High expression of c-MET or Trk was defined as that above the median value. Among the 28 SDC cases, 64.3% (18/28) were HER2-positive. c-MET expression varied, with a median H-score of 65 (range, 0 to 200). Copy number gain and amplification of MET were noted in 57.1% (16/28) and 10.7% (3/28) of cases, respectively. TrkA was variably expressed, with a median H-score of 100 (range, 0 to250). High TrkA expression was significantly related to an inferior overall survival rate in HER2-negative SDC. High expression of TrkA and c-MET and MET copy number gain/amplification were frequent events in SDC, and high expression of TrkA revealed the tendency to be related to poor prognosis in HER2-negative SDC. TrkA and MET may be possible therapeutic targets in SDC, especially in HER2-negative SDC. (C) 2018 Elsevier Inc. All rights reserved.	[Ryu, Hyang Joo; Yoon, Sun Och] Yonsei Univ, Severance Hosp, Dept Pathol, Coll Med, Seoul 03722, South Korea; [Koh, Yoon Woo] Yonsei Univ, Severance Hosp, Dept Otorhinolaryngol, Coll Med, Seoul 03722, South Korea	Yoon, SO (reprint author), Yonsei Univ, Coll Med, Dept Pathol, 50-1 Yonsei Ro, Seoul 120752, South Korea.	soyoon@yuhs.ac		Yoon, Sun Och/0000-0002-5115-1402	Basic Science Research Program through the National Research Foundation of Korea (NFU) - Ministry of Education [NRF-2015R1D1A1A09059399]	The study was supported by the Basic Science Research Program through the National Research Foundation of Korea (NFU), funded by the Ministry of Education (NRF-2015R1D1A1A09059399).	Ardini E, 2016, MOL CANCER THER, V15, P628, DOI 10.1158/1535-7163.MCT-15-0758; BARNES L, 1994, ORAL SURG ORAL MED O, V78, P64, DOI 10.1016/0030-4220(94)90119-8; Barnes L., 2005, PATHOLOGY GENETICS H; Blumenschein GR, 2012, J CLIN ONCOL, V30, P3287, DOI 10.1200/JCO.2011.40.3774; Boon E, 2018, HEAD NECK-J SCI SPEC, V40, P605, DOI 10.1002/hed.25035; Cho YA, 2016, J CANCER, V7, P2197, DOI 10.7150/jca.16686; Choi CH, 2016, J PATHOL TRANSL MED, V50, P96, DOI 10.4132/jptm.2016.01.12; Cornolti G, 2007, ARCH OTOLARYNGOL, V133, P1031, DOI 10.1001/archotol.133.10.1031; Edge SB, 2010, AJCC CANC STAGING MA; El-Naggar A, 2017, WHO CLASSIFICATION H; Glisson B, 2004, CLIN CANCER RES, V10, P944, DOI 10.1158/1078-0432.CCR-03-0253; Hammond MEH, 2010, J CLIN ONCOL, V28, P2784, DOI 10.1200/JCO.2009.25.6529; Herpen CML, 2017, ANN ONCOL, V28; Huang EJ, 2003, ANNU REV BIOCHEM, V72, P609, DOI 10.1146/annurev.biochem.72.121801.161629; Jaehne M, 2005, CANCER, V103, P2526, DOI 10.1002/cncr.21116; Joffre C, 2011, NAT CELL BIOL, V13, P827, DOI 10.1038/ncb2257; Lagadec C, 2009, ONCOGENE, V28, P1960, DOI 10.1038/onc.2009.61; Lee SJ, 2015, ONCOTARGET, V6, P39028, DOI 10.18632/oncotarget.5494; Limaye SA, 2013, ONCOLOGIST, V18, P294, DOI 10.1634/theoncologist.2012-0369; Liu XD, 2010, TRENDS MOL MED, V16, P37, DOI 10.1016/j.molmed.2009.11.005; Maina F, 2001, MOL CELL, V7, P1293, DOI 10.1016/S1097-2765(01)00261-1; Pasini L, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1791-y; Perissinotti AJ, 2013, ANTICANCER RES, V33, P2587; Peters S, 2012, NAT REV CLIN ONCOL, V9, P314, DOI 10.1038/nrclinonc.2012.71; Sierra J Rafael, 2011, Ther Adv Med Oncol, V3, pS21, DOI 10.1177/1758834011422557; Simpson RHW, 2014, VIRCHOWS ARCH, V465, P371, DOI 10.1007/s00428-014-1639-x; Wolff AC, 2013, J CLIN ONCOL, V31, P3997, DOI 10.1200/JCO.2013.50.9984	27	1	1	1	1	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	NOV	2018	81						18	25		10.1016/j.humpath.2018.04.027			8	Pathology	Pathology	HB5LM	WOS:000451102300003	29753009				2019-10-28	
J	Rougemont, AL; Tille, JC				Rougemont, Anne-Laure; Tille, Jean-Christophe			Role of HNF1 beta in the differential diagnosis of yolk sac tumor from other germ cell tumors	HUMAN PATHOLOGY			English	Article						Yolk sac tumor; Germ cell tumor; Embryonal carcinoma; Immunohistochemistry; Hepatocyte nuclear factor 1	HEPATOCYTE NUCLEAR FACTOR-1; HEPATOCELLULAR-CARCINOMA; GASTRIC-CARCINOMA; MARKER; SALL4; EXPRESSION; BIOMARKER; PATTERNS; DISTINCT; ZBTB16	Identification of the yolk sac tumor (YST) component in germ cell tumors (GCT) may prove challenging, and highly sensitive and specific immunohistochemical markers are still lacking. Preliminary data from the literature suggest that HNF10 may represent a sensitive marker of YST. The specificity of HNF1 beta has not been addressed in GCT. A cohort of 49 YST specimens from 45 patients was designed, occurring either as pure tumors, or as a component of a mixed GCT. Immunohistochemistry was conducted on whole tumor sections using HNF1 beta. SALL4, OCT4, CD30, CDX2, Cytokeratin 19, Glypican 3, and GATA3 were used for classification of the GCT components. Patients were mostly male (39/45), aged 14 months to 49 years, with primary testicular tumors (37/39), or primary mediastinal pure YSTs (2/39). All 6 primary tumors occurring in females (6/45) were pure ovarian YSTs; age range was 4 to 72 years. HNF10 nuclear reactivity was seen in the YST component in all 49 tumors, with a moderate to strong nuclear pattern of staining. Embryonal carcinoma (EC, 0/32) and seminoma (0/6) were negative. Choriocarcinoma (6/6) showed faint focal cytoplasmic reactivity to HNF1 beta but no nuclear staining. In teratomas, only enteric-type glands showed nuclear reactivity to HNF1 beta (11/16). Therefore, HNF1 beta sensitivity in YST component identification was 100% and specificity was 80%. Thus, in our experience, HNF1 beta is a sensitive and reliable marker of the YST component in GCT, and allows distinction of YST from intricately admixed EC, especially in the diffuse embryoma pattern. (C) 2018 Elsevier Inc. All rights reserved.	[Rougemont, Anne-Laure; Tille, Jean-Christophe] Geneva Univ Hosp, Div Clin Pathol, CH-1205 Geneva, Switzerland	Rougemont, AL (reprint author), Geneva Univ Hosp, Div Clin Pathol, CH-1205 Geneva, Switzerland.	anne-laure.rougemont@hcuge.ch		Rougemont, Anne-Laure/0000-0002-1785-792X			Cao DF, 2009, CANCER-AM CANCER SOC, V115, P2640, DOI 10.1002/cncr.24308; CEREGHINI S, 1992, DEVELOPMENT, V116, P783; Coffinier C, 1999, DEVELOPMENT, V126, P4785; Fadare O, 2015, PATHOLOGY, V47, P105, DOI 10.1097/PAT.0000000000000223; Gnemmi V, 2013, HISTOPATHOLOGY, V63, P425, DOI 10.1111/his.12187; Gonzalez-Roibon N, 2013, HUM PATHOL, V44, P1293, DOI 10.1016/j.humpath.2012.10.017; Gudmundsson J, 2007, NAT GENET, V39, P977, DOI 10.1038/ng2062; Kao CS, 2014, AM J SURG PATHOL, V38, P689, DOI 10.1097/PAS.0000000000000171; Kim L, 2008, MODERN PATHOL, V21, P1075, DOI 10.1038/modpathol.2008.95; Li JC, 2014, ONCOL REP, V32, P979, DOI 10.3892/or.2014.3297; Mangili G, 2011, INT J GYNECOL CANCER, V21, P1414, DOI 10.1097/IGC.0b013e3182236582; Matsui A, 2016, FEBS LETT, V590, P1211, DOI 10.1002/1873-3468.12147; MATSUNOU H, 1994, CANCER, V73, P534, DOI 10.1002/1097-0142(19940201)73:3<534::AID-CNCR2820730307>3.0.CO;2-X; Meguro S, 2013, ANN DIAGN PATHOL, V17, P140, DOI 10.1016/j.anndiagpath.2011.07.010; Moch H, 2016, WHO CLASSIFICATION T; Nogales FF, 2018, HISTOPATHOLOGY, V72, P634, DOI 10.1111/his.13426; OTT MO, 1991, MECH DEVELOP, V36, P47, DOI 10.1016/0925-4773(91)90071-D; Rougemont AL, 2012, J HEPATOL, V56, P1392, DOI 10.1016/j.jhep.2011.10.028; Shim JH, 2013, LIVER TRANSPLANT, V19, P336, DOI 10.1002/lt.23584; Tsuchiya A, 2003, AM J PATHOL, V163, P2503, DOI 10.1016/S0002-9440(10)63605-X; Tu SM, 2016, CANCER-AM CANCER SOC, V122, P1836, DOI 10.1002/cncr.29996; Ushiku T, 2010, AM J SURG PATHOL, V34, P533, DOI 10.1097/PAS.0b013e3181d1dcdd; Wang JL, 2006, NATURE, V444, P364, DOI 10.1038/nature05284; Xiao GQ, 2017, HISTOPATHOLOGY, V71, P562, DOI 10.1111/his.13276; Xiao GQ, 2016, MODERN PATHOL, V29, P591, DOI 10.1038/modpathol.2016.46; Yu DD, 2015, CELL BIOSCI, V5, DOI 10.1186/s13578-015-0049-3	26	0	0	0	1	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	NOV	2018	81						26	36		10.1016/j.humpath.2018.04.025			11	Pathology	Pathology	HB5LM	WOS:000451102300004	29753846				2019-10-28	
J	Lee, M; Kim, K; Kim, SY; Jung, SH; Yoon, J; Kim, MS; Park, HC; Jung, ES; Chung, YJ; Lee, SH				Lee, Minho; Kim, Kyung; Kim, Shinn Young; Jung, Seung-Hyun; Yoon, Jonghwan; Kim, Min Sung; Park, Hyeon-Chun; Jung, Eun Sun; Chung, Yeun-Jun; Lee, Sug Hyung			Genomic structures of dysplastic nodule and concurrent hepatocellular carcinoma	HUMAN PATHOLOGY			English	Article						Hepatocellular carcinoma; Dysplastic nodule; Preneoplastic lesion; Genomic difference; Whole exome; Copy number alteration; Mutation	MUTATIONS; SIGNATURES; AMPLIFICATION; EXPRESSION; FRAMEWORK; ALIGNMENT; LESIONS; TISSUE; GENES; TUMOR	Although high-grade dysplastic nodule (HGDN) is a preneoplastic lesion that precedes hepatocellular carcinoma (HCC), the genomic structures of HGDN in conjunction with HCC remain elusive. The objective of this study was to identify genomic alterations of HGDN and its difference from HCC that may drive HGDN progression to HCC. We analyzed 16 regions of paired HGDN and HCC from 6 patients using whole-exome sequencing to find somatic mutation and copy number alteration (CNA) profiles of HGDN and HCC. The numbers of mutations, driver mutations, and CNAs of HGDNs were not significantly different from those of HCCs. We identified that the CNA gain of 1q25.3-1q42.13 was predominant in the HCCs compared with that in the HGDNs. Two cases (one nodule-in-nodule case and another case with closely attached HCC and HGDN) showed several overlapped driver mutations (CTNNB1 and CEBPA) and CNAs (losses of CDKN2A, RB1, and TP53) between HGDNs and HCCs, suggesting their roles in the early HCC development. The other 4 cases with spatially separated HCCs and HGDNs showed few overlapped alterations between the paired HCCs and HGDNs. Mutations in ERBB2 and CCND1, and CNAs (gains of CTNNB1, MET, and SMO and losses of PTEN, TP53, and SETD2) were identified as "HCC predominant," suggesting their roles in the progression of HGDN to HCC. Our data show that HCCs are direct descendants of HGDNs in some cases, but there is no direct evidence of such relationship in spatially separated cases. Genomic features of HGDN identified in this study provide a useful resource for dissecting clues for the genetic diagnosis of HGDN and HCC. (C) 2018 Elsevier Inc. All tights reserved.	[Lee, Minho; Yoon, Jonghwan; Chung, Yeun-Jun; Lee, Sug Hyung] Catholic Univ Korea, Coll Med, Catholic Precis Med Res Ctr, Seoul 06591, South Korea; [Kim, Kyung; Jung, Seung-Hyun; Park, Hyeon-Chun; Chung, Yeun-Jun] Catholic Univ Korea, Coll Med, Integrated Res Ctr Genome Polymorphism, 505 Banpo Dong, Seoul 06591, South Korea; [Kim, Shinn Young; Chung, Yeun-Jun] Catholic Univ Korea, Coll Med, Dept Microbiol, Seoul 06591, South Korea; [Kim, Shinn Young] Catholic Univ Korea, Coll Med, Dept Surg, Seoul 06591, South Korea; [Jung, Seung-Hyun; Park, Hyeon-Chun; Lee, Sug Hyung] Catholic Univ Korea, Coll Med, Canc Evolut Res Ctr, Seoul 06591, South Korea; [Kim, Min Sung; Lee, Sug Hyung] Catholic Univ Korea, Coll Med, Dept Pathol, 505 Banpo Dong, Seoul 06591, South Korea; [Jung, Eun Sun] Catholic Univ Korea, Coll Med, Dept Hosp Pathol, Seoul 06591, South Korea	Chung, YJ (reprint author), Catholic Univ Korea, Coll Med, Integrated Res Ctr Genome Polymorphism, 505 Banpo Dong, Seoul 06591, South Korea.; Lee, SH (reprint author), Catholic Univ Korea, Coll Med, Dept Pathol, 505 Banpo Dong, Seoul 06591, South Korea.	yejun@catholic.ac.kr; suhulee@catholic.ac.kr		Lee, Minho/0000-0002-0168-9546	National Research Foundation of KoreaNational Research Foundation of Korea [2012R1A5A2047939, 2017R1A2B2002314, 2017R1E1A1A01074913, 2017M3A9B6061511]	This study was supported by grants from the National Research Foundation of Korea (2012R1A5A2047939, 2017R1A2B2002314, 2017R1E1A1A01074913, and 2017M3A9B6061511).	Chen J, 2009, NUCLEIC ACIDS RES, V37, pW305, DOI 10.1093/nar/gkp427; Chen LL, 2010, ACTA PHARMACOL SIN, V31, P1165, DOI 10.1038/aps.2010.94; Cibulskis K, 2013, NAT BIOTECHNOL, V31, P213, DOI 10.1038/nbt.2514; DePristo MA, 2011, NAT GENET, V43, P491, DOI 10.1038/ng.806; El-Serag HB, 2011, NEW ENGL J MED, V365, P1118, DOI 10.1056/NEJMra1001683; Farazi PA, 2006, NAT REV CANCER, V6, P674, DOI 10.1038/nrc1934; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Felsenstein J, 1989, CLADISTICS, V5, P164, DOI DOI 10.1111/J.1096-0031.1989.TB00562.X; Fujimoto A, 2012, NAT GENET, V44, P760, DOI 10.1038/ng.2291; Futreal PA, 2004, NAT REV CANCER, V4, P177, DOI 10.1038/nrc1299; Garcia-Alcalde F, 2012, BIOINFORMATICS, V28, P2678, DOI 10.1093/bioinformatics/bts503; Guichard C, 2012, NAT GENET, V44, P694, DOI 10.1038/ng.2256; Jiang JH, 2014, HEPATOLOGY, V59, P2216, DOI 10.1002/hep.27012; Joung JG, 2017, ONCOTARGET, V8, P2076, DOI 10.18632/oncotarget.10502; Jung SH, 2016, P NATL ACAD SCI USA, V113, P10672, DOI 10.1073/pnas.1606946113; Kobayashi M, 2006, CANCER-AM CANCER SOC, V106, P636, DOI 10.1002/cncr.21607; Kojiro M, 2005, SEMIN LIVER DIS, V25, P133, DOI 10.1055/s-2005-871193; Kojiro M, 2000, J Hepatobiliary Pancreat Surg, V7, P535, DOI 10.1007/s005340070001; Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324; Maggioni M, 2000, HEPATOLOGY, V32, P942, DOI 10.1053/jhep.2000.18425; Magi A, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-10-r120; McKenna A, 2010, GENOME RES, V20, P1297, DOI 10.1101/gr.107524.110; Midorikawa Y, 2004, CANCER RES, V64, P7263, DOI 10.1158/0008-5472.CAN-04-1275; MORIMITSU Y, 1995, HUM PATHOL, V26, P1126, DOI 10.1016/0046-8177(95)90275-9; Park YN, 2011, ARCH PATHOL LAB MED, V135, P704, DOI 10.1043/2010-0524-RA.1; Raidl M, 2004, J HEPATOL, V40, P660, DOI 10.1016/j.jhep.2003.12.020; Roncalli M, 2011, DIGEST LIVER DIS, V43, pS361, DOI 10.1016/S1590-8658(11)60592-6; Schutte K, 2009, DIGEST DIS, V27, P80, DOI 10.1159/000218339; Schulze K, 2015, NAT GENET, V47, P505, DOI 10.1038/ng.3252; Tornillo L, 2002, LAB INVEST, V82, P547, DOI 10.1038/labinvest.3780449; Utsunomiya T, 2014, CANCER SCI, V105, P749, DOI 10.1111/cas.12431; Wang K, 2010, NUCLEIC ACIDS RES, V38, DOI 10.1093/nar/gkq603; Wang Y, 2002, CANCER-AM CANCER SOC, V95, P2346, DOI 10.1002/cncr.10963; WANLESS IR, 1995, HEPATOLOGY, V22, P983, DOI 10.1002/hep.1840220341	34	0	0	1	4	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	NOV	2018	81						37	46		10.1016/j.humpath.2018.06.026			10	Pathology	Pathology	HB5LM	WOS:000451102300005	29949741				2019-10-28	
J	Huang, SZ; Zhong, WQ; Shi, Z; Wang, K; Jin, HL; Zhang, ZJ; Wang, HY; Wei, YC; Chen, SX; Zhou, Q; He, XS				Huang, Shanzhou; Zhong, Wenqiang; Shi, Zhi; Wang, Kun; Jin, Huilin; Zhang, Zijian; Wang, Huanyu; Wei, Yongcheng; Chen, Sixv; Zhou, Qi; He, Xiaoshun			Overexpression of signal sequence receptor gamma predicts poor survival in patients with hepatocellular carcinoma	HUMAN PATHOLOGY			English	Article						Cancer; Hepatocellular carcinoma; SSR3; Survival analysis; Biomarker	SQUAMOUS-CELL CARCINOMA; GENE-EXPRESSION; PROTEIN; TRANSLOCON; MEMBRANE; CANCER	SSR subunit gamma (SSR3), an SSR family member, is heavily involved in cell growth and differentiation and closely associated with many tumor types. However, the role of this protein in HCC remains unknown. In this study, we used data from public databases to analyze SSR3 expression in HCC. We subjected 20 pairs of fresh-frozen tissues to quantitative real-time polymerase chain reaction to investigate SSR3 expression. We also subjected 95 formalin-fixed, paraffin-embedded HCC tissues to immunohistochemistry to detect SSR3 expression and determine the clinical significance of SSR3 expression in HCC. Bioinformatics analysis and quantitative real-time polymerase chain reaction results showed that compared with that in adjacent normal liver tissues, SSR3 was highly expressed in HCC tissues. High SSR3 expression was positively correlated with tumor size (P <.01), cancer embolus (P =.01), TNM stages (P =.02), and differentiation grades (P <.01). Kaplan-Meier and Cox proportional hazards analyses indicated that high SSR3 expression was significantly associated with poor survival in HCC patients and that SSR3 was an independent prognostic factor for overall survival in HCC patients. In conclusion, SSR3 acts as an oncogene in HCC and can therefore serve as a biomarker for the prognoses of HCC patients. (C) 2018 Published by Elsevier Inc.	[Huang, Shanzhou; Wei, Yongcheng; He, Xiaoshun] Sun Yat Sen Univ, Affiliated Hosp 1, Organ Transplant Ctr, 58 Zhongshan Er Rd, Guangzhou 510080, Guangdong, Peoples R China; [Zhong, Wenqiang; Jin, Huilin; Zhou, Qi] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Liver Surg, Guangzhou 510080, Guangdong, Peoples R China; [Shi, Zhi; Wang, Kun] Jinan Univ, Guangdong Prov Key Lab Bioengn Med, Natl Engn Res Ctr Genet Med, Dept Cell Biol,Coll Life Sci & Technol, Guangzhou 510632, Guangdong, Peoples R China; [Shi, Zhi; Wang, Kun] Jinan Univ, Guangdong Prov Key Lab Bioengn Med, Natl Engn Res Ctr Genet Med, Inst Biomed,Coll Life Sci & Technol, Guangzhou 510632, Guangdong, Peoples R China; [Zhang, Zijian] Sun Yat Sen Univ, Affiliated Hosp 7, Dept Hepatobiliary Surg, Shenzhen 518000, Peoples R China; [Wang, Huanyu] Nanshan Dist Peoples Hosp, Dept Thyroid & Breast Surg, Shenzhen 518000, Peoples R China; [Chen, Sixv] Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Dept Cardiol, Guangzhou 510120, Guangdong, Peoples R China; [Zhou, Qi] Sun Yat Sen Univ, Hui Ya Hosp, Dept Gen Surg, Affiliated Hosp 1, Huizhou 516081, Guangdong, Peoples R China	Zhou, Q; He, XS (reprint author), Sun Yat Sen Univ, Affiliated Hosp 1, Organ Transplant Ctr, 58 Zhongshan Er Rd, Guangzhou 510080, Guangdong, Peoples R China.	hnzhouqi@163.com; gdtrc@163.com			Program Sci-Tech Research Development of Guangdong Province [2014A020212717]; Science and Technology Program of Huizhou [170520181743174]	This work was supported by the Program Sci-Tech Research Development of Guangdong Province (2014A020212717) and the Science and Technology Program of Huizhou (170520181743174).	Barrett T, 2013, NUCLEIC ACIDS RES, V41, pD991, DOI 10.1093/nar/gks1193; Chandrashekar DS, 2017, NEOPLASIA, V19, P649, DOI 10.1016/j.neo.2017.05.002; Chen HZ, 2013, INT J BIOCHEM CELL B, V45, P1600, DOI 10.1016/j.biocel.2013.04.026; Chen Y, 2005, Z GASTROENTEROL, V43, P162, DOI [10.1055/s-2005-919940, DOI 10.1055/S-2005-919940]; Dang H, 2017, CANCER CELL, V32, P101, DOI 10.1016/j.ccell.2017.06.002; Dehm SM, 2006, J CELL BIOCHEM, V99, P333, DOI 10.1002/jcb.20794; Dutertre M, 2010, CANCER RES, V70, P896, DOI 10.1158/0008-5472.CAN-09-2703; Dybkaer K, 2007, BMC GENOMICS, V8, DOI 10.1186/1471-2164-8-230; Ferlay J, 2010, INT J CANCER, V127, P2893, DOI 10.1002/ijc.25516; Fons RD, 2003, J CELL BIOL, V160, P529, DOI 10.1083/jcb.200210095; GORLICH D, 1992, NATURE, V357, P47, DOI 10.1038/357047a0; Li Y, 2016, TUMOR BIOL, V37, P13091, DOI 10.1007/s13277-016-5227-3; Pfeffer S, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14516; Skach WR, 2007, J CELL BIOL, V179, P1333, DOI 10.1083/jcb.200711107; Tang ZF, 2017, NUCLEIC ACIDS RES, V45, pW98, DOI 10.1093/nar/gkx247; Tomczak Katarzyna, 2015, Contemp Oncol (Pozn), V19, pA68, DOI 10.5114/wo.2014.47136; Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262; Van Puyenbroeck V, 2018, CELL MOL LIFE SCI, V75, P1541, DOI 10.1007/s00018-017-2743-2; VOGEL F, 1990, EUR J CELL BIOL, V53, P197; Wang L, 1999, FEBS LETT, V457, P316, DOI 10.1016/S0014-5793(99)01075-3; Yamaguchi YL, 2011, DEV DYNAM, V240, P394, DOI 10.1002/dvdy.22528; Yen CC, 2005, WORLD J GASTROENTERO, V11, P1267, DOI 10.3748/wjg.v11.i9.1267; Zhi JJ, 2018, INT J MOL MED, V41, P1419, DOI 10.3892/ijmm.2018.3359; Zhu YT, 2014, NAT METHODS, V11, P599, DOI 10.1038/nmeth.2956	24	1	1	5	10	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	NOV	2018	81						47	54		10.1016/j.humpath.2018.06.014			8	Pathology	Pathology	HB5LM	WOS:000451102300006	29940286				2019-10-28	
J	Magro, G; Angelico, G; Righi, A; Benini, S; Salvatorelli, L; Palazzo, J				Magro, Gaetano; Angelico, Giuseppe; Righi, Alberto; Benini, Stefania; Salvatorelli, Lucia; Palazzo, Juan			Utility of STAT6 and 13q14 deletion in the classification of the benign spindle cell stromal tumors of the breast	HUMAN PATHOLOGY			English	Article						Breast; Benign spindle cell tumors; Stroma; STAT6; 13q14 deletion	SOLITARY FIBROUS TUMOR; MAMMARY MYOFIBROBLASTOMA; LIPOMA; ANGIOFIBROMA; EMPHASIS; LESIONS	The boundaries of the benign spindle cell stromal tumors of the breast are still confusing. This is the reason why different names are interchangeably used for the same tumor and vice versa the same name for different tumors. Therefore, we studied the immunoexpression of easily available markers, such as CD34, alpha-smooth muscle actin, and desmin, with the addition of STAT6, as well as the chromosome 13q14 region by fluorescence in situ hybridization analysis in a series of 19 cases of benign spindle cell stromal tumors of the breast. Based on the morphologic and immunohistochemical findings, the following histotypes were identified: (i) tumors (10/19 cases) with the characteristic morphology of myofibroblastoma and stained with vimentin, CD34, desmin, and alpha-smooth muscle actin; (ii) fibroblastic benign spindle cell tumors (5/19 cases) composed of fibroblast-like cells stained only with vimentin and CD34; (iii) tumors (2/19 cases) with the typical morphologic features of solitary fibrous tumor and stained with vimentin, CD34, and STAT6; (iv) 1 case of spindle cell lipoma stained with vimentin and CD34; and (v) 1 case of fibroma composed of a paucicellular, diffusely hyalinized stroma with expression of vimentin and CD34. Notably most of the tumors, with the exception of solitary fibrous tumor, showed monoallelic deletion of FOXO1. This finding supports that myofibroblastoma, fibroblastic benign spindle cell tumor, spindle cell lipoma, and fibroma of the breast are histogenetically related lesions which belong to the same tumor entity. (C) 2018 Elsevier Inc. All rights reserved.	[Magro, Gaetano; Salvatorelli, Lucia] Univ Catania, Dept Med & Surg Sci & Adv Technol GF Ingrassia, Azienda Osped Univ Policlin Vittorio Emanuele, Anat Pathol Sect,Sch Med, I-95123 Catania, Italy; [Angelico, Giuseppe] Univ Messina, Sect Anat Pathol, Dept Human Pathol Adult & Dev Age Gaetano Barresi, I-98122 Messina, Italy; [Righi, Alberto; Benini, Stefania] Rizzoli Inst, Dept Pathol, I-40136 Bologna, Italy; [Palazzo, Juan] Thomas Jefferson Univ, Dept Pathol Anat & Cell Biol, Philadelphia, PA 19107 USA	Magro, G (reprint author), Univ Catania, Dept Med & Surg Sci & Adv Technol GF Ingrassia, Azienda Osped Univ Policlin Vittorio Emanuele, Anat Pathol Sect,Sch Med, I-95123 Catania, Italy.	g.magro@unict.it	Righi, Alberto/J-6028-2016	Righi, Alberto/0000-0002-1074-0155; Angelico, Giuseppe/0000-0003-4808-2052	Fondi d'Ateneo (PRA), University of Catania	The research was supported by the funding "Fondi d'Ateneo (PRA), University of Catania-2006-2007."	BEGIN LR, 1991, ULTRASTRUCT PATHOL, V15, P613, DOI 10.3109/01913129109023191; Billings SD, 2007, AM J DERMATOPATH, V29, P437, DOI 10.1097/DAD.0b013e31813735df; BOGER A, 1984, PATHOL RES PRACT, V178, P395; Bombonati Alessandro, 2003, Breast J, V9, P251, DOI 10.1046/j.1524-4741.2003.09315.x; CHAN KW, 1984, PATHOLOGY, V16, P331, DOI 10.3109/00313028409068546; Chmielecki J, 2013, NAT GENET, V45, P131, DOI 10.1038/ng.2522; DAMIANI S, 1994, VIRCHOWS ARCH, V425, P89; Doyle LA, 2014, MODERN PATHOL, V27, P390, DOI 10.1038/modpathol.2013.164; Falconieri Giovanni, 2004, Ann Diagn Pathol, V8, P121, DOI 10.1016/j.anndiagpath.2004.03.002; Flucke U, 2011, MODERN PATHOL, V24, P82, DOI 10.1038/modpathol.2010.170; Fritchie KJ, 2012, AM J CLIN PATHOL, V137, P963, DOI 10.1309/AJCPQEG6YNN6CNAL; Halpert B, 1933, AM J PATHOL, V9, P905; Khalifa MA, 1997, SOUTH MED J, V90, P793, DOI 10.1097/00007611-199708000-00005; LEW WYC, 1993, DIAGN CYTOPATHOL, V9, P434, DOI 10.1002/dc.2840090412; Maggiam F, 2007, HISTOPATHOLOGY, V51, P410, DOI 10.1111/j.1365-2559.2007.02775.x; Magro G, 2002, VIRCHOWS ARCH, V440, P249, DOI 10.1007/s00428-001-0572-y; Magro G, 1998, Ann Diagn Pathol, V2, P306, DOI 10.1016/S1092-9134(98)80023-3; Magro G, 2000, HISTOPATHOLOGY, V37, P189, DOI 10.1046/j.1365-2559.2000.00985-3.x; Magro G, 2001, PATHOL RES PRACT, V197, P453, DOI 10.1078/0344-0338-00112; Magro G, 2008, ARCH PATHOL LAB MED, V132, P1813, DOI 10.1043/1543-2165-132.11.1813; Magro G, 2016, PATHOL RES PRACT, V212, P463, DOI 10.1016/j.prp.2015.12.013; Magro G, 2016, HISTOL HISTOPATHOL, V31, P1, DOI 10:14670; Magro G, 2012, HUM PATHOL, V43, P1887, DOI 10.1016/j.humpath.2012.01.015; Magro G, 2009, AM J SURG PATHOL, V33, P1085, DOI 10.1097/PAS.0b013e31819e642a; Magro M, 2012, WHO CLASSIFICATION T, P130; Meguerditchian AN, 2008, BREAST J, V14, P287, DOI 10.1111/j.1524-4741.2008.00588.x; Mulvany NJ, 1999, PATHOLOGY, V31, P288, DOI 10.1080/003130299105188; Robinson DR, 2013, NAT GENET, V45, P180, DOI 10.1038/ng.2509; Rovera F, 2008, WORLD J SURG ONCOL, V6, DOI 10.1186/1477-7819-6-16; Salomao DR, 2001, BREAST, V10, P49, DOI 10.1054/brst.2000.0188; Smith DN, 1996, ACTA RADIOL, V37, P893; Tavassoli F. A., 2009, TUMORS MAMMARY GLAND; TOKER C, 1981, CANCER, V48, P1615, DOI 10.1002/1097-0142(19811001)48:7<1615::AID-CNCR2820480724>3.0.CO;2-I; WARGOTZ ES, 1987, AM J SURG PATHOL, V11, P493, DOI 10.1097/00000478-198707000-00001; Yang LH, 2014, INT J CLIN EXP PATHO, V7, P4461; Yoshida A, 2014, AM J SURG PATHOL, V38, P552, DOI 10.1097/PAS.0000000000000137	36	0	0	0	0	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	NOV	2018	81						55	64		10.1016/j.humpath.2018.06.015			10	Pathology	Pathology	HB5LM	WOS:000451102300007	29940288				2019-10-28	
J	Zhao, CHLS; Hui, Y; Amin, A				Zhao, Chaohui Lisa; Hui, Yiang; Amin, Ali			Temporal small arterial inflammation is common in patients with giant cell arteritis	HUMAN PATHOLOGY			English	Article						Giant cell arteritis; Temporal artery biopsy; Small arterial inflammation; CD8-Positive; T-lymphocytes; CD4-Positive; T-lymphocytes	POLYMYALGIA-RHEUMATICA; INVOLVEMENT; CLASSIFICATION	Giant cell arteritis (GCA) primarily involves medium-to-large arteries. Small-vessel inflammation is a recognized phenomenon occurring in association with GCA. However, its significance is poorly elucidated. Histologic sections and medical records of 105 temporal artery specimens were retrospectively reviewed between 2008 and 2017 to examine associated clinical manifestations and laboratory data including antinuclear antibody and p-antineutrophilic cytoplasmic antibody titers. Immunohistochemical staining for CD4 and CD8 was performed in select cases to assess the nature of the inflammatory response. Seventy-eight patients meeting the diagnostic criteria of temporal arteritis were included in the analysis. Twenty-eight specimens demonstrated temporal arteritis with small arterial inflammation (SAI), and 50 specimens showed temporal arteritis without SAI. Eight (28.6%) of 28 patients with SAI presented with jaw claudication, whereas 5 (17.9%) were febrile at presentation. In contrast, in 50 patients without SAI, jaw claudication and fever were seen in 11 and 2 cases, respectively (P =.01 and P =.0047, respectively). No statistically significant difference was noted between other symptoms and laboratory indices between the 2 groups. Elevated p-antineutrophilic cytoplasmic antibody titers in GCA may be associated with concomitant polymyalgia rheumatica or treatment-resistant disease. We also identified a higher count of CD4 and CD8 T cells in SAI cases, although the ratio of CD4/CD8 T lymphocytes was within normal limits. In conclusion, simultaneous involvement of arterioles and medium- to large-sized arteries is common in GCA and may be associated with treatment-refractory disease. Documentation of small arterial involvement in GCA will help the clinicians to manage the disease more effectively. (C) 2018 Elsevier Inc. All rights reserved.	[Zhao, Chaohui Lisa; Hui, Yiang; Amin, Ali] Brown Univ, Warren Alpert Med Sch, Rhode Isl Hosp, Dept Pathol & Lab Med,Miriam Hosp, Providence, RI 02903 USA	Zhao, CHLS (reprint author), Brown Univ, Warren Alpert Med Sch, Dept Pathol & Med, 593 Eddy St,APC 12, Providence, RI 02903 USA.; Zhao, CHLS (reprint author), Rhode Isl Hosp, 593 Eddy St,APC 12, Providence, RI 02903 USA.	chaohui_zhao@brown.edu					Belilos E, 2011, J RHEUMATOL, V38, P331, DOI 10.3899/jrheum.100455; Borchers AT, 2012, AUTOIMMUN REV, V11, pA544, DOI 10.1016/j.autrev.2012.01.003; Cavazza A, 2014, AM J SURG PATHOL, V38, P1360, DOI 10.1097/PAS.0000000000000244; Chirinos JA, 2004, CLIN RHEUMATOL, V23, P152, DOI 10.1007/s10067-003-0816-0; Fujii K, 2012, MOD RHEUMATOL, V22, P934, DOI 10.1007/s10165-012-0610-4; Hamidou MA, 2003, J RHEUMATOL, V30, P2165; HUNDER GG, 1990, ARTHRITIS RHEUM, V33, P1122; Kumar V, 2010, BLOOD VESSELS, P488; LIE JT, 1987, PATHOL ANNU, V22, P125; LIE JT, 1994, J RHEUMATOL, V21, P186; Myklebust G, 1996, BRIT J RHEUMATOL, V35, P1161; Restuccia G, 2012, ARTHRITIS RHEUM-US, V64, P549, DOI 10.1002/art.33362; Samson M, 2016, J AUTOIMMUN, V72, P73, DOI 10.1016/j.jaut.2016.05.008; Schmidt J, 2011, DRUG AGING, V28, P651, DOI 10.2165/11592500-000000000-00000; Smetana GW, 2002, JAMA-J AM MED ASSOC, V287, P92, DOI 10.1001/jama.287.1.92; Soriano A, 2012, BEST PRACT RES CL RH, V26, P91, DOI 10.1016/j.berh.2012.01.007; Tanaka A, 2011, INTERNAL MED, V50, P1033, DOI 10.2169/internalmedicine.50.4345	17	0	0	0	0	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	NOV	2018	81						65	70		10.1016/j.humpath.2018.06.020			6	Pathology	Pathology	HB5LM	WOS:000451102300008	29953896				2019-10-28	
J	Larsen, CP; Bonsib, SM; Beggs, ML; Wilson, JD				Larsen, Christopher P.; Bonsib, Stephen M.; Beggs, Marjorie L.; Wilson, Jon D.			Fluorescence in situ hybridization for the diagnosis of NPHP1 deletion-related nephronophthisis on renal biopsy	HUMAN PATHOLOGY			English	Article						Nephronophthisis; NPHP; Chronic kidney disease; Renal biopsy; Genetics; Cystic kidney disease		Nephronophthisis is an autosomal recessive tubulointerstitial nephropathy that is a leading genetic etiology of end-stage renal disease in children and young adults. Approximately 60% of patients with a known genetic etiology of nephronophthisis are due to homozygous deletion of the NPHP1 gene. We identified a total of 45 renal biopsies from young patients with chronic kidney disease of undetermined etiology and analyzed them for the possibility of nephronophthisis due to NPHP1 deletion using interphase fluorescence in situ hybridization and/or polymerase chain reaction. Homozygous NPHP1 deletion was identified in 9 patients (20%). In cases with adequate tissue, both assays were performed and showed 100% agreement. Blinded histopathologic analysis was then performed and identified 6 lesions that were significantly more common in biopsies from patients with NPHP1 deletion proven nephronophthisis than chronic kidney injury of other known etiologies. Many of the classically described nephronophthisis biopsy lesions such as tubular basement membrane duplication, presence of cysts, and mononuclear interstitial inflammation were not significantly associated with this disease when compared with biopsies from patients with chronic kidney injury due to other etiologies. There were, however, morphologic lesions that were strongly associated with NPHP1 deletion including tubular abnormalities such as diverticulum, florets, and macula densa like change as well as interstitial Tamm-Horsfall aggregates, periglomerular fibrosis, and the absence of arteriosclerosis. Awareness of the histopathologic pattern of injury in nephronophthisis combined with testing for NPHP1 deletion enables renal pathologists to provide a definitive pathologic and genetic diagnosis in a subset of patients with this disease. (C) 2018 The Authors. Published by Elsevier Inc.	[Larsen, Christopher P.; Bonsib, Stephen M.; Beggs, Marjorie L.; Wilson, Jon D.] Arkana Labs, 10180 Execut Ctr Dr,Suite 100, Little Rock, AR 72211 USA	Larsen, CP (reprint author), Arkana Labs, 10180 Execut Ctr Dr,Suite 100, Little Rock, AR 72211 USA.	Chris.larsen@arkanalabs.com					Benzing T, 2012, CURR OPIN NEPHROL HY, V21, P272, DOI 10.1097/MNH.0b013e3283520f17; Blowey DL, 1996, PEDIATR NEPHROL, V10, P22, DOI 10.1007/BF00863431; Chaki M, 2011, KIDNEY INT, V80, P1239, DOI 10.1038/ki.2011.284; CHAMBERLIN BC, 1977, MAYO CLIN PROC, V52, P485; Fillastre J P, 1976, Clin Nephrol, V5, P14; Halbritter J, 2013, HUM GENET, V132, P865, DOI 10.1007/s00439-013-1297-0; Halbritter J, 2012, J MED GENET, V49, P756, DOI 10.1136/jmedgenet-2012-100973; Hildebrandt F, 2009, J AM SOC NEPHROL, V20, P23, DOI 10.1681/ASN.2008050456; Larsen CP, 2015, MODERN PATHOL, V28, P95, DOI 10.1038/modpathol.2014.92; MONGEAU JG, 1967, AM J MED, V43, P345, DOI 10.1016/0002-9343(67)90191-X; Otto EA, 2011, J MED GENET, V48, P105, DOI 10.1136/jmg.2010.082552; Racusen LC, 1999, KIDNEY INT, V55, P713, DOI 10.1046/j.1523-1755.1999.00299.x; Simms RJ, 2009, EUR J HUM GENET, V17, P406, DOI 10.1038/ejhg.2008.238; Snoek R, 2018, J AM SOC NEPHROL, V29, P1772, DOI 10.1681/ASN.2017111200; Srivastava S, 2014, J PEDIATR GENET, V3, P103, DOI 10.3233/PGE-14086; Stokman M, 2016, NEPHRONOPHTHISIS GEN; WALDHERR R, 1982, VIRCHOWS ARCH A, V394, P235, DOI 10.1007/BF00430668; Walker PD, 2004, MODERN PATHOL, V17, P1555, DOI 10.1038/modpathol.3800239; Wolf MTF, 2015, CURR OPIN PEDIATR, V27, P201, DOI 10.1097/MOP.0000000000000194; Wolf MTF, 2011, PEDIATR NEPHROL, V26, P181, DOI 10.1007/s00467-010-1585-z	20	0	0	0	0	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	NOV	2018	81						71	77		10.1016/j.humpath.2018.06.021			7	Pathology	Pathology	HB5LM	WOS:000451102300009	29949740	Other Gold			2019-10-28	
J	Acosta, AM; Al Rasheed, MRH; Pins, MR; Borgen, KR; Panchal, D; Rogozinska, M; Wiley, EL; Behm, FG; Mohapatra, G				Acosta, Andres Martin; Al Rasheed, Mohamed R. H.; Pins, Michael R.; Borgen, Kristina R.; Panchal, Dipti; Rogozinska, Magdalena; Wiley, Elizabeth L.; Behm, Frederick G.; Mohapatra, Gayatry			The role of next-generation sequencing in the differential diagnosis of composite neoplasms	HUMAN PATHOLOGY			English	Article						Composite tumor; Tumor-to-tumor metastasis; Collision tumor; Biphenotypic; Next-generation sequencing	PAPILLARY THYROID-CARCINOMA; LUNG ADENOCARCINOMA; GENOMIC ALTERATIONS; BARRETTS-ESOPHAGUS; GENE-EXPRESSION; MUTATIONS; BRAF; TUMOR	Composite neoplasms (CNs) are rare and diagnostically challenging lesions that require differentiating between mixed clonal tumors with divergent phenotypes (MT), collision of 2 independent tumors adjacent to each other (CT), and tumor-to-tumor metastasis (TTM). To that end, pathologists have traditionally used immunohistochemistry and limited molecular studies, such as Sanger sequencing. Herein we evaluate the potential application of NGS in the differential diagnosis of these rare neoplasms. Four CNs were included in the study. Two were diagnosed as MT (mixed adenoneuroendocrine carcinoma of the gallbladder and metastatic papillary thyroid carcinoma with squamous dedifferentiation) and 2 were interpreted as TIM (esophageal adenocarcinoma to lung adenocarcinoma and small cell carcinoma of the lung to meningeal melanoma). Diagnoses were made using clinical, histologic, and immunophenotypic information, with the aid of limited molecular studies in 2 cases. Formalin-fixed, paraffin-embedded tissue was dissected for DNA and RNA extraction, and NGS was performed using the Oncomine Comprehensive Panel. The 2 tumors initially interpreted as MT showed shared genetic aberrations in the different neoplastic components, supporting the pathologic diagnosis. NGS results for the lesion diagnosed as esophageal adenocarcinoma metastatic to lung adenocarcinoma did not support the histopathologic interpretation and were deemed inconclusive. However, the identification of an identical CDKN2A mutation in all components and in the adjacent benign lung parenchyma suggests a possible germ line aberration. Sequencing results in the last case were clearly supportive of TTM. This study illustrates the role of NGS in the diagnostic workup of CNs, as an adjunct to light microscopy and immunohistochemistry. (C) 2018 Elsevier Inc. All rights reserved.	[Acosta, Andres Martin; Al Rasheed, Mohamed R. H.; Panchal, Dipti; Rogozinska, Magdalena; Wiley, Elizabeth L.; Behm, Frederick G.; Mohapatra, Gayatry] Univ Illinois, Dept Pathol, 820 S Wood St,Suite 130 CSN, Chicago, IL 60612 USA; [Pins, Michael R.; Borgen, Kristina R.] Advocate Lutheran Gen Hosp, Dept Pathol, Park Ridge, IL USA	Acosta, AM (reprint author), Univ Illinois, Dept Pathol, 820 S Wood St,Suite 130 CSN, Chicago, IL 60612 USA.; Mohapatra, G (reprint author), Univ Illinois, Dept Pathol, Lab Genom Med, 820 S Wood St,Suite 130 CSN, Chicago, IL 60612 USA.	andresmartinacosta@hotmail.com; gayamoha@uic.edu		Acosta, Andres/0000-0003-0164-5911	Department of Pathology of the University of Illinois at Chicago	This study was performed with intradepartmental research funds of the Department of Pathology of the University of Illinois at Chicago. No external funding was received.	Acosta AM, 2017, APPL IMMUNOHISTO M M, V25, pE58, DOI 10.1097/PAI.0000000000000419; Acosta AM, 2016, VIRCHOWS ARCH, V468, P239, DOI 10.1007/s00428-015-1875-8; Acosta AM, 2015, INT J SURG PATHOL, V23, P414, DOI 10.1177/1066896915580433; Akbani R, 2015, CELL, V161, P1681, DOI 10.1016/j.cell.2015.05.044; Arbour KC, 2018, CLIN CANCER RES, V24, P334, DOI 10.1158/1078-0432.CCR-17-1841; Charles RP, 2014, MOL CANCER RES, V12, P979, DOI 10.1158/1541-7786.MCR-14-0158-T; Collisson EA, 2014, NATURE, V511, P543, DOI 10.1038/nature13385; Facchinetti F, 2017, LUNG CANCER, V112, P62, DOI 10.1016/j.lungcan.2017.08.002; Farshidfar F, 2017, CELL REP, V18, P2780, DOI 10.1016/j.celrep.2017.02.033; Forbes SA, 2015, NUCLEIC ACIDS RES, V43, pD805, DOI 10.1093/nar/gku1075; George J, 2015, NATURE, V524, P47, DOI 10.1038/nature14664; Hovelson DH, 2015, NEOPLASIA, V17, P385, DOI 10.1016/j.neo.2015.03.004; Huang J, 2002, ARCH PATHOL LAB MED, V126, P437; Kanzaki R, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-10873-2; Katsuya Y, 2015, HISTOPATHOLOGY, V67, P262, DOI 10.1111/his.12643; Kim J, 2017, NATURE, V541, P169, DOI 10.1038/nature20805; Lancia I, 2016, J CLIN INVEST, V126, P1052, DOI 10.1172/JCI85271; Nakamura H, 2015, NAT GENET, V47, P1003, DOI 10.1038/ng.3375; Orlow I, 2007, J INVEST DERMATOL, V127, P1234, DOI 10.1038/sj.jid.5700689; Rhodes DR, 2007, NEOPLASIA, V9, P166, DOI 10.1593/neo.07112; Ross-Innes CS, 2015, NAT GENET, V47, P1038, DOI 10.1038/ng.3357; Scardoni M, 2014, NEUROENDOCRINOLOGY, V100, P310, DOI 10.1159/000369071; Schabath MB, 2016, ONCOGENE, V35, P3209, DOI 10.1038/onc.2015.375; Stachler MD, 2015, NAT GENET, V47, P1047, DOI 10.1038/ng.3343; Torenbeek R, 1999, J PATHOL, V189, P338; Yoo KH, 2016, TRANSL ONCOL, V9, P173, DOI 10.1016/j.tranon.2016.01.007; Zhang ZF, 2012, NAT GENET, V44, P852, DOI 10.1038/ng.2330	27	1	1	0	0	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	NOV	2018	81						78	88		10.1016/j.humpath.2018.06.022			11	Pathology	Pathology	HB5LM	WOS:000451102300010	29958927				2019-10-28	
J	Li, Z; Maeda, D; Kudo-Asabe, Y; Tamura, D; Nanjo, H; Hayashi, A; Ikemura, M; Fukayama, M; Goto, A				Li, Zhuo; Maeda, Daichi; Kudo-Asabe, Yukitsugu; Tamura, Daisuke; Nanjo, Hiroshi; Hayashi, Akimasa; Ikemura, Masako; Fukayama, Masashi; Goto, Akiteru			MED12 is frequently mutated in ovarian and other adnexal leiomyomas	HUMAN PATHOLOGY			English	Article						Leiomyoma; Ovary; MED12; Desmin; Smooth muscle actin	UTERINE LEIOMYOMA; MEDIATOR COMPLEX; MUTATIONS; PREVALENCE	In the female genital tract, extrauterine leiomyomas such as those that arise in the ovary and paraovarian/paratubal regions are rare. Currently, little is known about the background genetic changes in such adnexal leiomyomas. Recent studies have found that the MED12 mutation is common in uterine leiomyomas, which suggests that such mutations may play an oncogenic role in smooth muscle neoplasms in females. Herein, we examined a series of ovarian and other adnexal leiomyomas in terms of MED12 mutational status to investigate possible MED12 involvement in the pathogenesis of extrauterine smooth muscle tumors. We evaluated 10 cases of adnexal leiomyomas (5 ovarian, 3 paraovarian, and 2 paratubal) and 49 cases of ovarian sex cord-stromal tumors as controls. We performed polymerase chain reaction followed by direct sequencing of exon 2 of MED12, and immunohistochemical staining for smooth muscle actin and desmin. We identified somatic MED12 mutations in 90% (9/10) of the adnexal leiomyomas. None of the sex cord-stromal tumors in the control group harbored MED12 mutations. Diffuse immunoreactivity for both smooth muscle actin and desmin was characteristic of adnexal leiomyomas only. Thus, we conclude that ovarian leiomyomas are distinct from sex cord-stromal tumors. MED12 mutations are key molecular features of ovarian and other adnexal leiomyomas. We speculate that the pathogenesis of adnexal leiomyoma is similar to that of its uterine counterpart. (C) 2018 Elsevier Inc. All rights reserved.	[Li, Zhuo; Maeda, Daichi; Kudo-Asabe, Yukitsugu; Tamura, Daisuke; Goto, Akiteru] Akita Univ, Grad Sch Med, Dept Cellular & Organ Pathol, 1-1-1 Hondo, Akita, Akita 0108543, Japan; [Li, Zhuo] Xian Med Univ, Dept Lab Med, Affiliated Hosp 1, Xian 710077, Shaanxi, Peoples R China; [Maeda, Daichi] Osaka Univ, Grad Sch Med, Dept Clin Genom, Suita, Osaka 5650871, Japan; [Tamura, Daisuke] Akita Univ, Grad Sch Med, Dept Obstet & Gynecol, Akita 0108543, Japan; [Nanjo, Hiroshi] Akita Univ Hosp, Dept Pathol, Akita 0108543, Japan; [Hayashi, Akimasa; Ikemura, Masako; Fukayama, Masashi] Univ Tokyo, Grad Sch Med, Dept Pathol, Tokyo 1130033, Japan	Maeda, D (reprint author), Akita Univ, Grad Sch Med, Dept Cellular & Organ Pathol, 1-1-1 Hondo, Akita, Akita 0108543, Japan.; Maeda, D (reprint author), Osaka Univ, Grad Sch Med, Dept Clin Genom, Suita, Osaka 5650871, Japan.	maeda-tky@umin.ac.jp		Tamura, Daisuke/0000-0001-9808-1897	JSPS KAKENHIMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI) [JP 26870129]; Takara Bio, Inc.; Japan-China Sasakawa Medical Fellowship	This work was supported by the following grants: JSPS KAKENHI (Grant No. JP 26870129 [D.M.]). The research of D.M. is partly supported by Takara Bio, Inc. This study was supported in part by Japan-China Sasakawa Medical Fellowship.	Bertsch E, 2014, MODERN PATHOL, V27, P1144, DOI 10.1038/modpathol.2013.243; CARABIAS E, 1995, EUR J RADIOL, V20, P28, DOI 10.1016/0720-048X(95)00627-3; Chan SC, 2004, J AM ASSOC GYN LAP, V11, P96, DOI 10.1016/S1074-3804(05)60022-9; Croce S, 2015, EUR J CANCER, V51, P1603, DOI 10.1016/j.ejca.2015.04.023; CZERNOBILSKY B, 1989, VIRCHOWS ARCH B, V57, P55, DOI 10.1007/BF02899065; Doss BJ, 1999, INT J GYNECOL PATHOL, V18, P63, DOI 10.1097/00004347-199901000-00009; Heinonen HR, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-01199-0; Je EM, 2012, INT J CANCER, V131, pE1044, DOI 10.1002/ijc.27610; Kampjarvi K, 2012, BRIT J CANCER, V107, P1761, DOI 10.1038/bjc.2012.428; Kampjarvi K, 2015, ONCOTARGET, V6, P1884; Koo YJ, 2011, FERTIL STERIL, V95, DOI 10.1016/j.fertnstert.2010.09.007; LASTARRIA D, 1990, ARCH PATHOL LAB MED, V114, P502; Lerwill MF, 2004, AM J SURG PATHOL, V28, P1436, DOI 10.1097/01.pas.0000141393.99300.d0; Lim SC, 2004, GYNECOL ONCOL, V95, P733, DOI 10.1016/j.ygyno.2004.07.048; Makinen N, 2011, SCIENCE, V334, P252, DOI 10.1126/science.1208930; Matsubara A, 2013, HISTOPATHOLOGY, V62, P657, DOI 10.1111/his.12039; Mehine M, 2013, NEW ENGL J MED, V369, P43, DOI 10.1056/NEJMoa1302736; Osinovskaya N S, 2013, Genetika, V49, P1426; Rajabi Parvin, 2014, Adv Biomed Res, V3, P88, DOI 10.4103/2277-9175.128001; Roue A, 2007, J Gynecol Obstet Biol Reprod (Paris), V36, P403; Schwetye KE, 2014, HUM PATHOL, V45, P65, DOI 10.1016/j.humpath.2013.08.005; Taatjes DJ, 2010, TRENDS BIOCHEM SCI, V35, P315, DOI 10.1016/j.tibs.2010.02.004; Tomas D, 2009, DIAGN PATHOL, V4, DOI 10.1186/1746-1596-4-25; Turunen M, 2014, CELL REP, V7, P654, DOI 10.1016/j.celrep.2014.03.047; Wang H, 2013, PROTEIN CELL, V4, P643, DOI 10.1007/s13238-013-3048-3; Wu J, 2017, ONCOL LETT, V14, P47, DOI 10.3892/ol.2017.6120	26	0	0	1	3	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	NOV	2018	81						89	95		10.1016/j.humpath.2018.06.013			7	Pathology	Pathology	HB5LM	WOS:000451102300011	29944972				2019-10-28	
J	Neff, JL; Rangan, A; Jevremovic, D; Nguyen, PL; Chiu, A; Go, RS; Chen, D; Morice, WG; Shi, M				Neff, Jadee L.; Rangan, Aruna; Jevremovic, Dragan; Nguyen, Phuong L.; Chiu, April; Go, Ronald S.; Chen, Dong; Morice, William G.; Shi, Min			Mixed-phenotype large granular lymphocytic leukemia: a rare subtype in the large granular lymphocytic leukemia spectrum	HUMAN PATHOLOGY			English	Article						Large granular lymphocytic leukemia; T-LGLL; CLPD-NK; Mixed-phenotype; Flow cytometry	CHRONIC LYMPHOPROLIFERATIVE DISORDER; NATURAL-KILLER-CELLS; T-CELL; LGL LEUKEMIA; NK-CELLS; CLINICAL-FEATURES; STAT3 MUTATIONS; PATHOGENESIS; EXPRESSION; COHORT	Large granular lymphocytic leukemia (LGLL) is a chronic proliferation of cytotoxic lymphocytes in which more than 70% of patients develop cytopenia(s) requiring therapy. LGLL includes T-cell LGLL and chronic lymphoproliferative disorder of natural killer (NK) cells. The neoplastic cells in LGLL usually exhibit a single immunophenotype in a patient, with CD8-positive/alpha beta T-cell type being the most common, followed by NK-cell, gamma delta T-cell, and CD4-positive/alpha beta T-cell types. We investigated a total of 220 LGLL cases and identified 12 mixed-phenotype LGLLs (5%): 7 cases with coexistent alpha beta, T-cell and NK-cell clones and 5 with coexistent alpha beta and gamma delta T-cell clones. With a median follow-up of 48 months, the clinicopathological characteristics of these patients seemed similar to those of typical LGLL patients. Treatment was instituted in 9 patients, and 5 patients (55%) attained complete hematologic response or partial response. The therapeutic response rate of this cohort is comparable to the reported overall response rate of 40% to 60% in typical LGLL patients. Three patients who did not receive any treatment had progressive or persistent cytopenias. Interestingly, inverted proportions of 2 clones at disease recurrence were identified in 4 patients (36%) and stable clonal proportions in 7 patients (64%). Mixed-phenotype LGLL is rare, and this study underscores the importance of recognizing this rare type of LGLL in patients who may benefit from LGLL treatment. (C) 2018 Elsevier Inc. All rights reserved.	[Neff, Jadee L.; Rangan, Aruna; Jevremovic, Dragan; Nguyen, Phuong L.; Chiu, April; Chen, Dong; Morice, William G.; Shi, Min] Mayo Clin, Div Hematopathol, 200 First St SW, Rochester, MN 55905 USA; [Go, Ronald S.] Mayo Clin, Div Hematol, 200 First St SW, Rochester, MN 55905 USA	Shi, M (reprint author), Mayo Clin, Dept Lab Med & Pathol, 200 First St SW, Rochester, MN 55905 USA.	Shi.Min@mayo.edu	Chen, Dong/V-8825-2019	Jevremovic, Dragan/0000-0002-1792-5822			Au WY, 2003, AM J CLIN PATHOL, V120, P626, DOI 10.1309/VA755A0PVRV9XDT; Bareau B, 2010, HAEMATOL-HEMATOL J, V95, P1534, DOI 10.3324/haematol.2009.018481; Bigouret V, 2003, BLOOD, V101, P3198, DOI 10.1182/blood-2002-08-2408; Bourgault-Rouxel AS, 2008, LEUKEMIA RES, V32, P45, DOI 10.1016/j.leukres.2007.04.011; Cady FM, 2007, CLIN LAB MED, V27, P513, DOI 10.1016/j.cll.2007.05.004; Clemente MJ, 2011, BLOOD, V118, P4384, DOI 10.1182/blood-2011-02-338517; Gattazzo C, 2014, HAEMATOLOGICA, V99, P1826, DOI 10.3324/haematol.2014.105726; Jerez A, 2012, BLOOD, V120, P3048, DOI 10.1182/blood-2012-06-435297; Kondo H, 2001, LEUKEMIA LYMPHOMA, V41, P207, DOI 10.3109/10428190109057973; Koskela HLM, 2012, NEW ENGL J MED, V366, P1905, DOI 10.1056/NEJMoa1114885; Lamy T, 2003, SEMIN HEMATOL, V40, P185, DOI 10.1016/S0037-1963(03)00133-1; Lamy T, 2017, BLOOD, V129, P1082, DOI 10.1182/blood-2016-08-692590; Lamy T, 2011, BLOOD, V117, P2764, DOI 10.1182/blood-2010-07-296962; Loughran TP, 2015, LEUKEMIA, V29, P886, DOI 10.1038/leu.2014.298; Morice WG, 2010, LEUKEMIA, V24, P881, DOI 10.1038/leu.2009.304; Morice WG, 2003, BRIT J HAEMATOL, V120, P1026, DOI 10.1046/j.1365-2141.2003.04201.x; Narumi H, 2004, BONE MARROW TRANSPL, V33, P99, DOI 10.1038/sj.bmt.1704298; Poullot E, 2014, ANN ONCOL, V25, P2030, DOI 10.1093/annonc/mdu369; Rajala HLM, 2014, ANN MED, V46, P114, DOI 10.3109/07853890.2014.882105; Sandberg Y, 2006, LEUKEMIA, V20, P2212, DOI 10.1038/sj.leu.2404451; Sanikommu SR, 2018, LEUKEMIA LYMPHOMA, V59, P416, DOI 10.1080/10428194.2017.1339880; Shi M, 2018, HUM PATHOL, V73, P74, DOI 10.1016/j.humpath.2017.12.014; Shi M, 2016, LEUKEMIA LYMPHOMA, V57, P1230, DOI 10.3109/10428194.2015.1081191; Shi M, 2015, CLIN CASE REP, V3, P740, DOI 10.1002/ccr3.333; Sokol L, 2006, ONCOLOGIST, V11, P263, DOI 10.1634/theoncologist.11-3-263; Swerdlow SH, 2016, BLOOD, V127, P2375, DOI 10.1182/blood-2016-01-643569; van Dongen JJM, 2003, LEUKEMIA, V17, P2257, DOI 10.1038/sj.leu.2403202; Wlodarski MW, 2005, BLOOD, V106, P2769, DOI 10.1182/blood-2004-10-4045; Yabe M, 2015, AM J CLIN PATHOL, V144, P607, DOI 10.1309/AJCPJSA1E1YWSZEY; Yan Yiyi, 2015, Leuk Res Rep, V4, P4, DOI 10.1016/j.lrr.2014.12.001; Yang J, 2008, BLOOD, V111, P1610, DOI 10.1182/blood-2007-06-093823; Zambello R, 2003, BLOOD, V102, P1797, DOI 10.1182/blood-2002-12-3898	32	1	1	0	0	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	NOV	2018	81						96	104		10.1016/j.humpath.2018.06.023			9	Pathology	Pathology	HB5LM	WOS:000451102300012	29949739				2019-10-28	
J	Cao, J; Huang, YQ; Jiao-Sun; Lan, XB; Ge, MH				Cao, Jun; Huang, Yu-Qing; Jiao-Sun; Lan, Xia-Bin; Ge, Ming-Hua			Clinicopathological and prognostic significance of SHP2 and Hook1 expression in patients with thyroid carcinoma	HUMAN PATHOLOGY			English	Article						Thyroid carcinoma; SHP2; Hook1; Immunochemistry; Prognosis	TYROSINE-PHOSPHATASE SHP2; EPITHELIAL-MESENCHYMAL TRANSITION; BREAST-CANCER; CLINICAL-SIGNIFICANCE; PTPN11; PROMOTES; MUTATIONS; TUMORIGENESIS; ACTIVATION; CELLS	Some thyroid carcinomas (TCs) have an aggressive biological behavior and poor prognosis, and lacking of effective molecular markers is still the main obstacle for clinical stratified diagnosis and treatment of TC. The aim of the study was to discover the clinicopathological and prognostic implications of Src homology region 2-containing protein tyrosine phosphatase 2 (SHP2) and Hook microtubule tethering protein I (Hook1) expression in TC. The expression of SHP2 and Hook1 was detected by immunohistochemistry on tissue microarrays from 313 primary TCs who underwent surgery in January 2006 and January 2010 in Zhejiang Cancer Hospital. The chi(2) test, Kaplan-Meier method, and Cox proportional-hazards regression models were used to analyze the associations between their expressions and clinicopathological features and prognosis. The expression rates of SHP2 and Hook1 in TC were 57.5% (180/313) and 22.0% (69/313), respectively. SHP2 was positively correlated with Hook1 in TC. SHP2 expression differed significantly by age, histologic variants, maximal tumor diameter, intrathyroidal dissemination, metastases, and disease stage (P < .05). Moreover, patients with high SHP2 expression had reduced risk for death of disease compared with those with low SHP2 expression (hazard ratio, 0.267; 95% confidence interval, 0.105-0.684; P = .006) in univariate analysis, but that multivariate analysis failed to suggest that SHP2 was an independent prognostic factor. Hook1 expression differed significantly by histologic variants, maximal tumor diameter, and intrathyroidal dissemination (P < .05). However, there was no significant correlation between Hook1 expression and outcome in TC (P > .05). Our results suggested that SHP2 may be a favorable indicator of prognosis in TC. (C) 2018 Elsevier Inc. All rights reserved.	[Cao, Jun; Huang, Yu-Qing; Lan, Xia-Bin; Ge, Ming-Hua] Zhejiang Canc Hosp, Dept Head & Neck Surg, 1 Banshan East Rd, Hangzhou 310022, Zhejiang, Peoples R China; [Jiao-Sun] Zhejiang Canc Hosp, Dept Pharm, Hangzhou 310022, Zhejiang, Peoples R China; [Cao, Jun; Huang, Yu-Qing; Lan, Xia-Bin; Ge, Ming-Hua] Key Lab Head & Neck Canc Translat Res Zhejiang Pr, Hangzhou, Zhejiang, Peoples R China	Ge, MH (reprint author), Zhejiang Canc Hosp, Dept Head & Neck Surg, 1 Banshan East Rd, Hangzhou 310022, Zhejiang, Peoples R China.	gemingh@163.com			National Natural Science Foundations of ChinaNational Natural Science Foundation of China [81672642, 81702653, 81702645]; Zhejiang Medical and Health Science and Technology Plan [2018253753]	This study was supported by 3 National Natural Science Foundations of China (Grant Nos. 81672642, 81702653, and 81702645), and a grant from the Zhejiang Medical and Health Science and Technology Plan (Grant No. 2018253753). Leading talents in scientific and technological innovation of "ten thousand people plan" of Zhejiang province; The training target of health leaders of Zhejiang province.	Aceto N, 2012, NAT MED, V18, P529, DOI 10.1038/nm.2645; Aigner K, 2007, ONCOGENE, V26, P6979, DOI 10.1038/sj.onc.1210508; Bard-Chapeau EA, 2011, CANCER CELL, V19, P629, DOI 10.1016/j.ccr.2011.03.023; Bentires-Alj M, 2004, CANCER RES, V64, P8816, DOI 10.1158/0008-5472.CAN-04-1923; Bowen ME, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002050; Cai PF, 2014, BIOMED PHARMACOTHER, V68, P285, DOI 10.1016/j.biopha.2013.10.012; Chan G, 2008, CANCER METAST REV, V27, P179, DOI 10.1007/s10555-008-9126-y; Chan RJ, 2007, BLOOD, V109, P862, DOI 10.1182/blood-2006-07-028829; De Craene B, 2005, CANCER RES, V65, P6237, DOI 10.1158/0008-5472.CAN-04-3545; Dong LB, 2013, GENET MOL RES, V12, P4207, DOI 10.4238/2013.October.7.6; Edge S.B., 2016, AJCC CANC STAGING MA; Furcht CM, 2013, ONCOGENE, V32, P2346, DOI 10.1038/onc.2012.240; Gimm O, 2001, CANCER LETT, V163, P143, DOI 10.1016/S0304-3835(00)00697-2; Grossmann KS, 2010, ADV CANCER RES, V106, P53, DOI 10.1016/S0065-230X(10)06002-1; Hagihara K, 2009, DEV BIOL, V334, P276, DOI 10.1016/j.ydbio.2009.07.029; Hu ZQ, 2015, ONCOL LETT, V10, P1507, DOI 10.3892/ol.2015.3479; Hu ZQ, 2014, ONCOL REP, V32, P205, DOI 10.3892/or.2014.3201; Jiang J, 2013, WORLD J GASTROENTERO, V19, P575, DOI 10.3748/wjg.v19.i4.575; Kurrey NK, 2009, STEM CELLS, V27, P2059, DOI 10.1002/stem.154; Legius E, 2002, J MED GENET, V39, P571, DOI 10.1136/jmg.39.8.571; Li FF, 2012, J IMMUNOL, V189, P3159, DOI 10.4049/jimmunol.1200197; Li SM, 2014, J BIOL CHEM, V289, P34152, DOI 10.1074/jbc.M113.546077; Oh ES, 1999, MOL CELL BIOL, V19, P3205; Qin XJ, 2012, ALLERGY, V67, P1547, DOI 10.1111/all.12048; Sausgruber N, 2015, ONCOGENE, V34, P2272, DOI 10.1038/onc.2014.170; Schneeberger VE, 2014, CARCINOGENESIS, V35, P1717, DOI 10.1093/carcin/bgu025; Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387; Sobreira NLM, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000991; Sun X, 2017, TUMOR BIOL, V39, DOI 10.1177/1010428317711098; Tartaglia M, 2001, NAT GENET, V29, P465, DOI 10.1038/ng772; Taube JH, 2010, P NATL ACAD SCI USA, V107, P15449, DOI 10.1073/pnas.1004900107; Wang HC, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-442; Yang WT, 2013, NATURE, V499, P491, DOI 10.1038/nature12396	33	1	1	0	4	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	NOV	2018	81						105	112		10.1016/j.humpath.2018.06.016			8	Pathology	Pathology	HB5LM	WOS:000451102300013	29953894				2019-10-28	
J	Sun, CJ; Huang, SZ; Ju, WQ; Hou, YC; Wang, ZM; Liu, YJ; Wu, LW; He, XS				Sun, Chengjun; Huang, Shanzhou; Ju, Weiqiang; Hou, Yuchen; Wang, Ziming; Liu, Youjie; Wu, Linwei; He, Xiaoshun			Elevated DSN1 expression is associated with poor survival in patients with hepatocellular carcinoma	HUMAN PATHOLOGY			English	Article						Cancer; Hepatocellular carcinoma; DSN1; Survival analysis; Prognosis	CHROMOSOMAL INSTABILITY; MICROTUBULE-BINDING; CANCER CELL; KINETOCHORE; PROGRESSION; COMPLEX	Dosage suppressor of Nnf1 (DSN1) is a component of the kinetochore protein complex that is required for proper chromosome segregation. Some studies have explored that DSN1 is related to colorectal cancer progression. However, the role of DSN1 in hepatocellular carcinoma (HCC) remains unknown. This study aimed to explore DSN1 expression in HCC tissues. We obtained data from The Cancer Genome Atlas and Gene Expression Omnibus to analyze DSN1 expression in HCC. DSN1 mRNA expression was assessed in 30 pairs of HCC samples via reverse-transcription quantitative polymerase chain reaction. Immunohistochemical analysis of 95 HCC tissue specimens was performed to assess DSN1 expression and examine the clinicopathological characteristics of DSN1 in HCC. Results showed that DSN1 was upregulated in HCC tissues and was strongly associated with sex (P = .031), alpha-fetoprotein (P < .001), tumor size (P = .032), tumor nodule number (P = .028), cancer embolus (P = .011), and differentiation grade (P = .001). Moreover, Kaplan-Meier and Cox proportional-hazards analyses indicated that high DSN1 expression was related to poor HCC patient survival and that DSN1 can serve as an independent prognostic factor for overall survival and disease-free survival. In conclusion, our findings indicate that DSN1 could serve as a novel prognostic biomarker for HCC patients. (C) 2018 Elsevier Inc. All rights reserved.	[Sun, Chengjun; Huang, Shanzhou; Ju, Weiqiang; Hou, Yuchen; Wang, Ziming; Wu, Linwei; He, Xiaoshun] Sun Yat Sen Univ, Affiliated Hosp 1, Organ Transplant Ctr, 58 Zhongshan Er Rd, Guangzhou 510080, Guangdong, Peoples R China; [Liu, Youjie] Jinan Univ, Basic Med Coll, Guangzhou 510632, Guangdong, Peoples R China	Wu, LW; He, XS (reprint author), Sun Yat Sen Univ, Affiliated Hosp 1, Organ Transplant Ctr, 58 Zhongshan Er Rd, Guangzhou 510080, Guangdong, Peoples R China.	lw97002@163.com; gdtrc@163.com			National Natural Science Foundation of ChinaNational Natural Science Foundation of China [81670592]; Natural Science Foundation of Guangdong Province, ChinaNational Natural Science Foundation of Guangdong Province [2016A030313242]; Medical Scientific Research Foundation of Guangdong Province, China [A2016033]; Science and Technology Program of Guangzhou, China [201804020075]; Fundamental Research Funds for the Central UniversitiesFundamental Research Funds for the Central Universities [17ykjc09]; Ke Lin Programme Foundation for Youth Talents [y50181]; Science and Technology Program of Guangzhou [201704020150]	This study was supported by the National Natural Science Foundation of China (grant 81670592); the Natural Science Foundation of Guangdong Province, China (grant 2016A030313242); the Medical Scientific Research Foundation of Guangdong Province, China (grant A2016033); the Science and Technology Program of Guangzhou, China (grant 201804020075); the Fundamental Research Funds for the Central Universities (grant 17ykjc09); the Ke Lin Programme Foundation for Youth Talents (y50181); and the Science and Technology Program of Guangzhou (201704020150).	Akiyoshi B, 2013, GENETICS, V194, P785, DOI 10.1534/genetics.113.150839; Arai T, 2017, CANCER SCI, V108, P2088, DOI 10.1111/cas.13331; Best J, 2017, ANN GASTROENTEROL, V30, P23, DOI 10.20524/aog.2016.0092; Bieniek J, 2014, PROSTATE, V74, P999, DOI 10.1002/pros.22815; Carloni V, 2018, GUT, V67, P348, DOI 10.1136/gutjnl-2016-313114; Cheeseman IM, 2008, NAT REV MOL CELL BIO, V9, P33, DOI 10.1038/nrm2310; Cheeseman IM, 2006, CELL, V127, P983, DOI 10.1016/j.cell.2006.09.039; Chuang TP, 2016, ONCOTARGET, V7, P45803, DOI 10.18632/oncotarget.9960; Forner A, 2012, LANCET, V379, P1245, DOI 10.1016/S0140-6736(11)61347-0; Hamasaki M, 2014, CHEM BIOL, V21, P1707, DOI 10.1016/j.chembiol.2014.11.005; Ji ZJ, 2015, SCIENCE, V348, P1260, DOI 10.1126/science.aaa4029; Kanthaje S, 2018, HEPATOL RES, V48, P5, DOI 10.1111/hepr.12991; Kline SL, 2006, J CELL BIOL, V173, P9, DOI 10.1083/jcb.200509158; Kudo M, 2017, LIVER CANCER, V6, P16, DOI 10.1159/000449343; Lee H, 2014, MOL CELLS, V37, P713, DOI 10.14348/molcells.2014.0233; Lee S, 2018, J HEPATOL, V69, P70, DOI 10.1016/j.jhep.2018.02.026; Ling L, 2018, CELL CYCLE, V17, P550, DOI 10.1080/15384101.2017.1329067; Liu PH, 2016, J HEPATOL, V64, P601, DOI [10.1016/j.jhep.2015.11.040, 10.1016/j.jhep.2015.10.029]; Lu J, 2016, TRANSL RES, V172, P96, DOI 10.1016/j.trsl.2016.03.002; Nishida N, 2003, HISTOL HISTOPATHOL, V18, P897, DOI 10.14670/HH-18.897; Obuse C, 2004, NAT CELL BIOL, V6, P1135, DOI 10.1038/ncb1187; Sia D, 2017, GASTROENTEROLOGY, V152, P745, DOI 10.1053/j.gastro.2016.11.048; Visagie MH, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0176006; Xu JY, 2018, CANCER RES, V78, P2564, DOI 10.1158/0008-5472.CAN-17-2061; Zhang YY, 2016, CANCER LETT, V372, P101, DOI 10.1016/j.canlet.2015.12.029; Zhao YH, 2018, ONCOGENE, V37, P2921, DOI 10.1038/s41388-018-0168-5	26	1	1	2	7	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	NOV	2018	81						113	120		10.1016/j.humpath.2018.06.032			8	Pathology	Pathology	HB5LM	WOS:000451102300014	30136646				2019-10-28	
J	Kobayashi, K; Miki, Y; Saito, R; Adachi, K; Seyama, K; Okada, Y; Sasano, H				Kobayashi, Kazuma; Miki, Yasuhiro; Saito, Ryoko; Adachi, Koko; Seyama, Kuniaki; Okada, Yoshinori; Sasano, Hironobu			Roles of human epidermal growth factor receptor family in pulmonary lymphangioleiomyomatosis	HUMAN PATHOLOGY			English	Article						Lymphangioleiomyomatosis; EGFR; HER2; HER3; HER4	TUBEROUS SCLEROSIS COMPLEX; TYROSINE KINASES; EXPRESSION; CANCER; AGE; MUTATIONS; SIROLIMUS; SURVIVAL; WOMEN; TSC2	Lymphangioleiomyomatosis (LAM) is a rare and refractory disease that affects women of reproductive age. Several target therapies are used to manage LAM, but no curative modes of treatment have been reported yet. Therefore, in this study, we focused on targeting human epidermal growth factor receptor (HER) family proteins as a treatment strategy for LAM. In antibody array analysis, HER signaling was detected in the proteins extracted from LAM tissues. We then evaluated the expression of HER family members in 34 pulmonary LAM specimens using both immunohistochemistry and quantitative reverse transcription polymerase chain reaction. Hierarchical clustering analysis was performed to classify the cases based on the immunohistochemistry results. Both epidermal growth factor receptor (EGFR) and HER4 were expressed in all 34 cases. HER3 was expressed in 25 of 34 cases, but HER2 was not expressed in any case. hi addition, results of quantitative reverse-transcription polymerase chain reaction analysis confirmed the expression of EGFR and HER4 expression in LAM cells. Patients with HER3- or HER4-positive tissues were younger and had a history of pneumothorax. The cases were classified into 4 different clusters based on the results of hierarchical cluster analysis. One of these clusters was associated with EGFR, HER3, and HER4; the patients in this cluster were significantly younger and had a history of pneumothorax. These results indicated that HER family could contribute to the progression of pulmonary LAM, and treatments targeted against HER family might be effective for treating pulmonary LAM. (C) 2018 Elsevier Inc. All rights reserved.	[Kobayashi, Kazuma; Okada, Yoshinori] Tohoku Univ, Inst Dev Aging & Canc, Dept Thorac Surg, Sendai, Miyagi, Japan; [Kobayashi, Kazuma; Miki, Yasuhiro; Saito, Ryoko; Adachi, Koko; Sasano, Hironobu] Tohoku Univ, Dept Pathol, Grad Sch Med, Sendai, Miyagi, Japan; [Miki, Yasuhiro] Tohoku Univ, Int Res Inst Disaster Sci, Dept Disaster Obstet & Gynecol, Sendai, Miyagi, Japan; [Adachi, Koko] Tohoku Univ, Dept Anesthesiol, Grad Sch Med, Sendai, Miyagi, Japan; [Seyama, Kuniaki] Juntendo Univ, Dept Resp Med, Fac Med, Tokyo, Japan	Miki, Y (reprint author), Tohoku Univ, Dept Disaster Obstet & Gynecol, Int Res Inst Disaster Sci, Aoba Ku, 2-1 Seiryo Machi, Sendai, Miyagi 9808575, Japan.; Sasano, H (reprint author), Tohoku Univ, Grad Sch Med, Dept Pathol, Aoba Ku, 2-1 Seiryo Machi, Sendai, Miyagi 9808575, Japan.	miki@patholo2.med.tohoku.ac.jp; hsasano@patholo2.med.tohoku.ac.jp					Aubele M, 2007, BRIT J CANCER, V96, P801, DOI 10.1038/sj.bjc.6603613; Bissler JJ, 2008, NEW ENGL J MED, V358, P140, DOI 10.1056/NEJMoa063564; Braut T, 2014, APPL IMMUNOHISTO M M, V22, P674, DOI 10.1097/PAI.0000000000000014; Carsillo T, 2000, P NATL ACAD SCI USA, V97, P6085, DOI 10.1073/pnas.97.11.6085; Chorianopoulos D, 2008, LUNG, V186, P197, DOI 10.1007/s00408-008-9087-5; Citri A, 2006, NAT REV MOL CELL BIO, V7, P505, DOI 10.1038/nrm1962; Cuenca-Lopez MD, 2015, ONCOTARGET, V6, P27923, DOI 10.18632/oncotarget.4736; Grzegorek I, 2015, ANTICANCER RES, V35, P3353; Han W, 2012, CANCER LETT, V318, P124, DOI 10.1016/j.canlet.2012.01.011; Hayashi M, 2008, CLIN CANCER RES, V14, P7843, DOI 10.1158/1078-0432.CCR-08-1064; Kersting C, 2006, J CLIN PATHOL, V59, P585, DOI 10.1136/jcp.2005.028373; Koleckova M, 2017, ONCOL LETT, V13, P4201, DOI 10.3892/ol.2017.6000; Kumamoto H, 2001, PATHOL INT, V51, P579, DOI 10.1046/j.1440-1827.2001.01255.x; Kumasaka T, 2005, AM J SURG PATHOL, V29, P1356, DOI 10.1097/01.pas.0000172192.25295.45; Laplante M, 2012, CELL, V149, P274, DOI 10.1016/j.cell.2012.03.017; McCormack FX, 2008, CHEST, V133, P507, DOI 10.1378/chest.07-0898; McCormack FX, 2011, NEW ENGL J MED, V364, P1595, DOI 10.1056/NEJMoa1100391; Mukai H, 2016, CANCER SCI, V107, P1465, DOI 10.1111/cas.13017; Ness GO, 1996, INT J CANCER, V65, P161, DOI 10.1002/(SICI)1097-0215(19960117)65:2<161::AID-IJC6>3.0.CO;2-X; Oikawa M, 2013, J ORAL PATHOL MED, V42, P424, DOI 10.1111/jop.12024; Partridge AH, 2013, J CLIN ONCOL, V31, P2692, DOI 10.1200/JCO.2012.44.1956; Phuchareon J, 2015, P NATL ACAD SCI USA, V112, pE3855, DOI 10.1073/pnas.1510733112; Sassen A, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr1843; Smolarek TA, 1998, AM J HUM GENET, V62, P810, DOI 10.1086/301804; Takada T, 2016, ANN AM THORAC SOC, V13, P1912, DOI 10.1513/AnnalsATS.201605-335OC; Taveira-DaSilva Angelo M, 2006, Cancer Control, V13, P276; Taveira-Dasilva AM, 2016, EXPERT OPIN ORPHAN D, V4, P369, DOI 10.1517/21678707.2016.1148597; Ueno T, 2012, LUNG CANCER, V78, P207, DOI 10.1016/j.lungcan.2012.09.006; Lopez-Malpartida AV, 2009, LUNG CANCER, V65, P25, DOI 10.1016/j.lungcan.2008.10.009; Watz H, 2007, THORAX, V62, P559, DOI 10.1136/thx.2006.071811; Witton CJ, 2003, J PATHOL, V200, P290, DOI 10.1002/path.1370; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; Yonesaka K, 2016, ONCOGENE, V35, P878, DOI 10.1038/onc.2015.142; Young LR, 2010, CHEST, V138, P674, DOI 10.1378/chest.10-0573	34	0	0	0	0	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	NOV	2018	81						121	130		10.1016/j.humpath.2018.07.002			10	Pathology	Pathology	HB5LM	WOS:000451102300015	30030119				2019-10-28	
J	Pizzi, M; Brignola, S; Righi, S; Agostinelli, C; Bertuzzi, C; Pillon, M; Semenzato, G; Rugge, M; Sabattini, E				Pizzi, Marco; Brignola, Stefano; Righi, Simona; Agostinelli, Claudio; Bertuzzi, Clara; Pillon, Marta; Semenzato, Gianpietro; Rugge, Massimo; Sabattini, Elena			Benign TdT-positive cells in pediatric and adult lymph nodes: a potential diagnostic pitfall	HUMAN PATHOLOGY			English	Article						TdT; Reactive lymph nodes; Acute lymphoblastic leukemia/lymphoma; Indolent T-lymphoblastic proliferation; Lymphopoiesis; Common lymphoid precursor	TERMINAL DEOXYNUCLEOTIDYL TRANSFERASE; T-LYMPHOBLASTIC PROLIFERATION; ASSOCIATION; EXPRESSION; TUMORS	Benign terminal deoxynucleotidyl transferase (TdT) positive cells have been documented in a variety of nonhematopoietic tissues. Scant data are, however, available on their presence in nonneoplastic lymph nodes. This study is aimed to (1) characterize the presence/distribution of benign TdT-positive cells in pediatric and adult reactive lymph nodes and (2) define the phenotype and nature of such elements. This retrospective study considered 141 reactive lymph nodes from pediatric and adult patients without history of neoplastic disease. TdT-positive cells were characterized by immunohistochemical and morphometric analyses, and their presence was correlated with the clinical-pathological features. The nature of TdT-positive cells was investigated by (1) double immunostaining for early lymphoid cell markers and (2) assessment of TdT expression in fetal lymph nodes. Sparse TdT-positive cells were documented in all pediatric cases and in most (76%) adult lymph nodes. TdT-positive cell density was higher in children than adults (15.9/mm(2) versus 8.6/mm(2); P < .05). TdT positivity did not correlate with any clinical or histological parameter, and double immunostaining disclosed a phenotype compatible with early lymphoid precursors (positivity for CD34 and CD10, and variable expression of CD7). A very high TdT-positive cell density (802.4/mm(2)) was reported in all fetal lymph nodes. In conclusion, TdT-positive cells are a common finding in pediatric and adult lymph nodes. The interstitial distribution and low number of such cells allow for the differential diagnosis with precursor lymphoid neoplasms. The high density in fetal lymph nodes and the phenotype of such cells suggest their belonging to an immature lymphoid subset gradually decreasing with age. (C) 2018 Elsevier Inc. All rights reserved.	[Pizzi, Marco; Brignola, Stefano; Rugge, Massimo] Univ Padua, Dept Med DIMED, Gen Pathol & Cytopathol Unit, I-35121 Padua, Italy; [Righi, Simona; Agostinelli, Claudio; Bertuzzi, Clara; Sabattini, Elena] St Orsola Hosp, Dept Hematol & Oncol, Haematopathol Unit, Dept Expt Diagnost & Specialty Med, I-40138 Bologna, Italy; [Pillon, Marta] Univ Padua, Dept Womens & Childrens Hlth, Clin Paediat Haematooncol, I-35128 Padua, Italy; [Semenzato, Gianpietro] Univ Padua, Dept Med DIMED, Hematol & Clin Immunol Unit, I-35128 Padua, Italy	Pizzi, M (reprint author), Padova Univ Hosp, Gen Pathol & Cytopathol Unit, Dept Med DIMED, Via Gabelli 61, I-35121 Padua, PD, Italy.	marcopizzi2002@yahoo.it		Agostinelli, Claudio/0000-0002-4945-1422			Buscone S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098222; CATTORETTI G, 1989, EUR J IMMUNOL, V19, P493, DOI 10.1002/eji.1830190313; Dunlap JB, 2017, AM J SURG PATHOL, V41, P706, DOI 10.1097/PAS.0000000000000828; Guy-Grand D, 2003, J EXP MED, V197, P333, DOI 10.1084/jem.20021639; Hoebeke I, 2007, LEUKEMIA, V21, P311, DOI 10.1038/sj.leu.2404488; Kansal R, 2015, HUM PATHOL, V46, P1057, DOI 10.1016/j.humpath.2015.03.007; McClory S, 2012, J CLIN INVEST, V122, P1403, DOI 10.1172/JCI46125; Montecino-Rodriguez E, 2012, IMMUNITY, V36, P13, DOI 10.1016/j.immuni.2011.11.017; Nagasawa T, 2006, NAT REV IMMUNOL, V6, P107, DOI 10.1038/nri1780; O'Malley DP, 2006, HAEMATOL-HEMATOL J, V91, P1139; Ohgami RS, 2014, AM J SURG PATHOL, V38, P1298, DOI 10.1097/PAS.0000000000000197; Ohgami RS, 2013, ADV ANAT PATHOL, V20, P137, DOI 10.1097/PAP.0b013e31828d17ec; Ohgami RS, 2012, AM J SURG PATHOL, V36, P1619, DOI 10.1097/PAS.0b013e318264e223; Onciu M, 2002, AM J CLIN PATHOL, V118, P248, DOI 10.1309/L3UW-3AE7-L4LB-3QX3; Pizzi M, 2017, HISTOPATHOLOGY, V71, P769, DOI 10.1111/his.13286; Six EM, 2007, J EXP MED, V204, P3085, DOI 10.1084/jem.20071003; Staal FJT, 2016, ANN NY ACAD SCI, V1370, P36, DOI 10.1111/nyas.12995; Strauchen JA, 2001, AM J CLIN PATHOL, V116, P12; Strauchen JA, 2001, AM J SURG PATHOL, V25, P411, DOI 10.1097/00000478-200103000-00018; Suzuki K, 2000, IMMUNITY, V13, P691, DOI 10.1016/S1074-7613(00)00068-6; Swerdlow SH, 2017, WHO CLASSIFICATION T; Velankar MM, 1999, AM J SURG PATHOL, V23, P977, DOI 10.1097/00000478-199908000-00017; Yang F, 2014, INT J CLIN EXP PATHO, V7, P6350; Yui MA, 2014, NAT REV IMMUNOL, V14, P529, DOI 10.1038/nri3702; Zhang ZX, 2001, ARTHRITIS RHEUM, V44, P2275, DOI 10.1002/1529-0131(200110)44:10<2275::AID-ART390>3.0.CO;2-K	25	0	0	0	0	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	NOV	2018	81						131	137		10.1016/j.humpath.2018.06.027			7	Pathology	Pathology	HB5LM	WOS:000451102300016	29969607				2019-10-28	
J	Song, H; Zheng, GQ; Guo, XZ; Liu, CR; Liang, YF; Yang, DL				Song Hui; Zheng Guo-Qi; Guo Xiao-Zhong; Liu Chun-Rong; Liang Yu-Fei; Yang Dong-Liang			IMP3 as a prognostic biomarker in patients with malignant peritoneal mesothelioma	HUMAN PATHOLOGY			English	Article						Peritoneal mesothelioma; Survival; Immunohistochemistry; IMP3; Fli-1; Ki-67; PCI	HYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPY; LONG-TERM SURVIVAL; CYTOREDUCTIVE SURGERY; FLI-1 EXPRESSION; IMMUNOHISTOCHEMISTRY; DIFFERENTIATION; PROLIFERATION; DIAGNOSIS; ANTIBODY; INDEX	Malignant peritoneal mesothelioma (MPeM) is an incurable cancer with poor prognosis, and several biomarkers have been suggested for screening of MPeM. The aim of our study was to evaluate the prognostic significances of IMP3 and Fli-1 in MPeM. Diagnostic biopsies of 44 MPeM patients were centrally collected and were immunohistochemically analyzed for expression of IMP3, Fli-1, and Ki-67. Labeling was assessed by 2 pathologists. Complete clinical information and follow-up were obtained from patients' records. Carcinomas expressed Fli-1 in 42 (95.5%) of 44 specimens, and IMP3 in 23 (52.3%) of 44 specimens. Spearman rho analysis revealed that Fli-1 expression was related to both histologic type and Ki-67 labeling index (Ki-67LI; r = -0.500, P < .05; r = 0.358, P < .05), and IMP3 expression was related to Ki-67LI (r = 0.401, P < .05). A Kaplan-Meier analysis and univariate Cox regression analysis showed that tumor-directed treatment, a lower peritoneal carcinomatosis index, stage I, lower Ki-67LI, and lower level of IMP3 expression had a statistically significantly positive effect on overall survival; Fli-1 did not affect overall survival in the univariate analysis (hazard ratio [FIR], 1.026; P = .904). A Kaplan-Meier analysis showed the correlation between IMP3 Fli-1 and overall survival, whereas univariate and multivariate Cox regression analyses did not confirm the correlation. Cox regression analysis revealed that IMP3 expression (HR, 2.311 [95% confidence interval, 1.190-4.486]; P = .013) and no tumor-directed treatment (HR, 0.189 [95% confidence interval, 0.086-0.416]; P = .000) retained independent prognostic significance, both with negative effect on OS. IMP3, along with tumor-directed treatment protocols, is a powerful prognosticator in patients with MPeM. (C) 2018 Elsevier Inc. All rights reserved.	[Song Hui; Zheng Guo-Qi; Liang Yu-Fei] Cangzhou Cent Hosp, Dept Gastroenterol, Cangzhou 061001, Hebei, Peoples R China; [Guo Xiao-Zhong; Liu Chun-Rong] Cangzhou Cent Hosp, Dept Pathol, Cangzhou 061001, Hebei, Peoples R China; [Yang Dong-Liang] Cangzhou Med Coll, Cangzhou 061001, Hebei, Peoples R China	Zheng, GQ (reprint author), Cangzhou Cent Hosp, Dept Gastroenterol, Cangzhou 061001, Hebei, Peoples R China.	czzxyyxhk@126.com			Cang Zhou Finance Bureau	The present study was funded by Cang Zhou Finance Bureau.	Alexander HR, 2013, SURGERY, V153, P779, DOI 10.1016/j.surg.2013.01.001; Baratti D, 2013, EUR J CANCER, V49, P3140, DOI 10.1016/j.ejca.2013.05.027; Berney DM, 2009, BRIT J CANCER, V100, P888, DOI 10.1038/sj.bjc.6604951; Chua TC, 2009, PATHOL ONCOL RES, V15, P671, DOI 10.1007/s12253-009-9170-0; Churg A, 2016, ARCH PATHOL LAB MED, V140, P318, DOI 10.5858/arpa.2015-0240-SA; Cui JW, 2009, LEUKEMIA, V23, P1311, DOI 10.1038/leu.2009.20; Damasceno EAM, 2014, J CANCER RES CLIN, V140, P2163, DOI 10.1007/s00432-014-1850-9; Davidson B, 2001, CLIN CANCER RES, V7, P551; Eliazer S, 2003, MOL CELL BIOL, V23, P482, DOI 10.1128/MCB.23.2.482-492.2003; Feldman AL, 2003, J CLIN ONCOL, V21, P4560, DOI 10.1200/JCO.2003.04.150; Findeis-Hosey JJ, 2011, HUM PATHOL, V42, P303, DOI 10.1016/j.humpath.2010.06.003; GERDES J, 1991, AM J PATHOL, V138, P867; Ghanim B, 2015, BRIT J CANCER, V112, P783, DOI 10.1038/bjc.2015.9; Hasteh F, 2010, CANCER CYTOPATHOL, V118, P90, DOI 10.1002/cncy.20071; Henley SJ, 2013, INT J OCCUP ENV HEAL, V19, P1, DOI 10.1179/2049396712Y.0000000016; Hommell-Fontaine J, 2013, ANN SURG ONCOL, V20, P3892, DOI 10.1245/s10434-013-3077-4; Husain AN, 2013, ARCH PATHOL LAB MED, V137, P647, DOI 10.5858/arpa.2012-0214-OA; Ikeda K, 2011, DIAGN CYTOPATHOL, V39, P395, DOI 10.1002/dc.21398; Ikeda K, 2010, HUM PATHOL, V41, P745, DOI 10.1016/j.humpath.2009.04.030; Kushitani K, 2016, PATHOBIOLOGY, V83, P33, DOI 10.1159/000442092; Lee AF, 2013, AM J SURG PATHOL, V37, P421, DOI 10.1097/PAS.0b013e31826ab1c0; LIANG H, 1994, NAT STRUCT BIOL, V1, P871, DOI 10.1038/nsb1294-871; Liang XX, 2014, TRANSL ONCOL, V7, P493, DOI 10.1016/j.tranon.2014.04.015; Magge D, 2014, ANN SURG ONCOL, V21, P1159, DOI 10.1245/s10434-013-3358-y; Minato H, 2014, AM J CLIN PATHOL, V141, P85, DOI 10.1309/AJCP5KNL7QTELLYI; Nagasako Yoshihide, 2003, Gastric Cancer, V6, P168, DOI 10.1007/s10120-003-0246-3; Nielsen J, 1999, MOL CELL BIOL, V19, P1262; Rossi L, 2015, BRIT J CANCER, V113, P996, DOI 10.1038/bjc.2015.239; Schaub NP, 2013, ANN SURG ONCOL, V20, P555, DOI 10.1245/s10434-012-2651-5; Sim SH, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0182107; Torlakovic EE, 2008, HISTOL HISTOPATHOL, V23, P1309, DOI 10.14670/HH-23.1309; Vigneswaran WT, 2017, ANN THORAC SURG, V103, P962, DOI 10.1016/j.athoracsur.2016.08.063; Yan TD, 2011, CANCER-AM CANCER SOC, V117, P1855, DOI 10.1002/cncr.25640; Yan TD, 2009, J CLIN ONCOL, V27, P6237, DOI 10.1200/JCO.2009.23.9640; Zhu Q, 2017, AM J TRANSL RES, V9, P3387	35	0	0	0	1	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	NOV	2018	81						138	147		10.1016/j.humpath.2018.07.003			10	Pathology	Pathology	HB5LM	WOS:000451102300017	30031101				2019-10-28	
J	Yang, ZT; Ni, WD; Cui, CN; Qi, WB; Piao, LZ; Xuan, YH				Yang, Zhaoting; Ni, Weidong; Cui, Chunai; Qi, Wenbo; Piao, Longzhen; Xuan, Yanhua			Identification of LETM1 as a marker of cancer stem-like cells and predictor of poor prognosis in esophageal squamous cell carcinoma	HUMAN PATHOLOGY			English	Article						Leucine zipper-EF-hand containing transmembrane protein 1; Esophageal squamous cell carcinoma; Cancer stem-like cells; Cell cycle progression; Prognosis	MACROPHAGES; ASSOCIATION	Leucine zipper-EF-hand containing transmembrane protein 1 (LETM1) is closely related to the occurrence and development of malignant tumors. This study discusses the expression of LETM1 in esophageal squamous cell carcinoma (ESCC) and its association with cancer stem-like cells (CSC). We used immunohistochemistry in 166 ESCC tissue samples, as well as Western blot and immunofluorescent methods in ESCC cell lines, to study the role of LETM1 and its association with CSC in ESCC. The expression of LETM1 was significantly higher in ESCC, and it was closely related to the primary tumor stage and clinical stage. LETM1 expression was significantly associated with lower overall survival and disease-free survival. In addition, the protein expression of LETM1 and CSC markers was higher in TE11 and ECG10 than in other ESCC cell lines. Moreover, the expression of LETM1 positively correlated with LSD1, CD44, and OCT4. Immunofluorescence revealed that LETM1 costained with CD44 and OCT4 in ECG10. The expression of LETM1 was associated with not only HIF-1 alpha but also higher microvessel density and tumor-associated macrophage infiltration. Furthermore, LETM1 significantly correlated with cyclinD1 and pAkt. High expression of LETM1 indicates poor prognosis and may be a potential CSC marker in ESCC. Moreover, LETM1 may be a novel therapeutic target for the treatment of ESCC. (C) 2018 Elsevier Inc. All rights reserved.	[Yang, Zhaoting; Ni, Weidong; Qi, Wenbo; Xuan, Yanhua] Yanbian Univ, Key Lab Nat Resources Changbai Mt & Funct Mol, Minist Educ, 977 Gongyuan Rd, Yanji 133002, Peoples R China; [Yang, Zhaoting; Ni, Weidong; Qi, Wenbo; Xuan, Yanhua] Yanbian Univ, Dept Pathol, Coll Med, Yanji 133002, Peoples R China; [Cui, Chunai] Yanbian Univ, Dept Anat, Coll Med, Yanji 133002, Peoples R China; [Piao, Longzhen] Yanbian Univ, Dept Oncol, Affiliated Hosp, Yanji 133002, Peoples R China	Xuan, YH (reprint author), Yanbian Univ, Key Lab Nat Resources Changbai Mt & Funct Mol, Minist Educ, 977 Gongyuan Rd, Yanji 133002, Peoples R China.	xuanyh1@ybu.edu.cn			National Natural Science Funds of ChinaNational Natural Science Foundation of China [81460390, 81760531, 81560400, 81660687]	This study was supported by grants from the National Natural Science Funds of China (Nos. 81460390, 81760531, 81560400, and 81660687).	Amin MB, 2017, AJCC CANC STAGING MA; Ando N, 2012, ANN SURG ONCOL, V19, P68, DOI 10.1245/s10434-011-2049-9; Angelo RCD, 2010, PROG MOL BIOL TRANSL, V95, P113, DOI 10.1016/B978-0-12-385071-3.00006-X; Carnero A, 2016, BIOESSAYS, V38, pS65, DOI 10.1002/bies.201670911; Chen LZ, 2014, ADV DIFFER EQU-NY, DOI 10.1186/1687-1847-2014-251; Clarke MF, 2006, CELL, V124, P1111, DOI 10.1016/j.cell.2006.03.011; Corliss BA, 2016, MICROCIRCULATION, V23, P95, DOI 10.1111/micc.12259; Dalerba P, 2007, CELL STEM CELL, V1, P241, DOI 10.1016/j.stem.2007.08.012; Dean M, 2005, NAT REV CANCER, V5, P275, DOI 10.1038/nrc1590; Doonan PJ, 2014, FASEB J, V28, P4936, DOI 10.1096/fj.14-256453; Filatova A, 2013, BBA-GEN SUBJECTS, V1830, P2496, DOI 10.1016/j.bbagen.2012.10.008; Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI 10.3322/caac.20115; Jiang DW, 2013, P NATL ACAD SCI USA, V110, pE2249, DOI 10.1073/pnas.1308558110; Jiang DW, 2009, SCIENCE, V326, P144, DOI 10.1126/science.1175145; Khacho M, 2016, CELL STEM CELL, V19, P232, DOI 10.1016/j.stem.2016.04.015; Lee J, 2016, ONCOTARGET, V7, P66728, DOI 10.18632/oncotarget.11456; Lee S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099452; Ma GZ, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000007600; Piao L, 2009, CANCER RES, V69, P3397, DOI 10.1158/0008-5472.CAN-08-3235; Shimura S, 2000, CANCER RES, V60, P5857; Tan DQ, 2018, ANTIOXID REDOX SIGN, V29, P149, DOI 10.1089/ars.2017.7273; Thallinger CMR, 2011, J CLIN ONCOL, V29, P4709, DOI 10.1200/JCO.2011.36.7599; Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262; Wang CA, 2015, EXP MOL PATHOL, V98, P254, DOI 10.1016/j.yexmp.2014.12.012; Yang ZT, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0145807; Zhong ZQ, 2012, ASIAN PAC J CANCER P, V13, P3781, DOI 10.7314/APJCP.2012.13.8.3781	26	1	1	4	8	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	NOV	2018	81						148	156		10.1016/j.humpath.2018.07.001			9	Pathology	Pathology	HB5LM	WOS:000451102300018	30031102				2019-10-28	
